Clinical	JJ	O
usefulness	NN	O
of	IN	O
serum	NN	Pharmacological
prostate	NN	Pharmacological
specific	JJ	Pharmacological
antigen	NN	Pharmacological
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
is	VBZ	O
preserved	VBN	O
in	IN	O
men	NNS	O
receiving	VBG	O
the	DT	O
dual	JJ	Pharmacological
5alpha-reductase	JJ	Pharmacological
inhibitor	NN	Pharmacological
dutasteride	NN	Pharmacological
.	.	O

PURPOSE	NNP	O
We	PRP	O
determined	VBD	O
whether	IN	O
the	DT	O
decrease	NN	O
in	IN	O
serum	NN	O
PSA	NNP	O
seen	VBN	O
with	IN	O
5alpha-reductase	JJ	Pharmacological
inhibitors	NNS	Pharmacological
affects	VBZ	O
the	DT	O
clinical	JJ	O
usefulness	NN	O
of	IN	O
PSA	NNP	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
using	VBG	O
data	NNS	O
from	IN	O
2	CD	O
dutasteride	JJ	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
studies	NNS	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
2,802	CD	O
men	NNS	O
50	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
a	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
,	,	O
no	DT	O
history	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
,	,	O
PSA	NNP	O
1.5	CD	O
to	TO	O
10	CD	O
ng/ml	NNS	O
,	,	O
prostate	NN	O
volume	NN	O
30	CD	O
cc	NN	O
or	CC	O
greater	JJR	O
,	,	O
an	DT	O
American	NNP	O
Urological	NNP	O
Association	NNP	O
symptom	VBD	O
score	NN	O
of	IN	O
12	CD	O
or	CC	O
greater	JJR	O
and	CC	O
peak	JJ	O
urinary	JJ	O
flow	NN	O
rate	NN	O
15	CD	O
ml	NN	O
per	IN	O
second	NN	O
or	CC	O
less	JJR	O
were	VBD	O
randomized	VBN	O
to	TO	O
0.5	CD	Control
mg	NNS	Control
dutasteride	JJ	Control
daily	RB	Control
or	CC	O
matching	VBG	O
placebo	NN	Control
for	IN	O
24	CD	O
months	NNS	O
.	.	O

Increases	NNS	O
in	IN	O
PSA	NNP	O
from	IN	O
baseline	NN	O
and	CC	O
the	DT	O
maximum	JJ	O
increase	NN	O
from	IN	O
nadir	JJ	O
to	TO	O
month	NN	O
24	CD	O
were	VBD	O
compared	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
and	CC	O
analyzed	VBN	O
by	IN	O
prostate	NN	O
cancer	NN	O
status	NN	O
,	,	O
as	IN	O
determined	VBN	O
by	IN	O
PSA	NNP	O
driven	JJ	O
biopsy	NN	O
and	CC	O
an	DT	O
advised	JJ	O
cutoff	NN	O
of	IN	O
more	JJR	O
than	IN	O
4	CD	O
ng/ml	NNS	O
after	IN	O
doubling	VBG	O
to	TO	O
correct	VB	O
for	IN	O
dutasteride	JJ	Pharmacological
treatment	NN	O
with	IN	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
calculated	VBN	O
for	IN	O
each	DT	O
.	.	O

RESULTS	NNP	O
In	IN	O
placebo	NN	Control
treated	VBN	O
men	NNS	O
without	IN	O
prostate	NN	O
cancer	NN	O
there	EX	O
was	VBD	O
an	DT	O
8.3	CD	O
%	NN	O
median	JJ	O
increase	NN	O
in	IN	O
PSA	NNP	O
at	IN	O
month	NN	O
24	CD	O
compared	VBN	O
with	IN	O
-59.5	CD	O
%	NN	O
in	IN	O
those	DT	O
who	WP	O
received	VBD	O
dutasteride	RB	Pharmacological
,	,	O
using	VBG	O
doubled	VBD	O
values	NNS	O
to	TO	O
correct	VB	O
for	IN	O
dutasteride	JJ	Pharmacological
treatment	NN	O
.	.	O

In	IN	O
those	DT	O
with	IN	O
prostate	JJ	O
cancer	NN	O
these	DT	O
changes	NNS	O
were	VBD	O
23.8	CD	O
%	NN	O
and	CC	O
-37.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

Using	VBG	O
the	DT	O
upper	JJ	O
PSA	NNP	O
limit	NN	O
of	IN	O
4	CD	O
ng/ml	JJ	O
sensitivity	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
in	IN	O
men	NNS	O
receiving	VBG	O
dutasteride	NN	Pharmacological
vs	NN	O
placebo	NN	Control
was	VBD	O
0.737	CD	O
vs	NN	O
0.804	CD	O
,	,	O
while	IN	O
specificity	NN	O
was	VBD	O
0.671	CD	O
vs	JJ	O
0.578	CD	O
.	.	O

Using	VBG	O
a	DT	O
PSA	NNP	O
increase	NN	O
from	IN	O
nadir	NN	O
of	IN	O
0.8	CD	O
ng/ml	IN	O
the	DT	O
sensitivity	NN	O
of	IN	O
dutasteride	NN	Pharmacological
was	VBD	O
0.548	CD	O
and	CC	O
its	PRP$	O
specificity	NN	O
was	VBD	O
0.795	CD	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
doubling	JJ	O
factor	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
maintaining	VBG	O
the	DT	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
of	IN	O
PSA	NNP	O
for	IN	O
prostate	NN	O
cancer	NN	O
detection	NN	O
in	IN	O
men	NNS	O
on	IN	O
dutasteride	NN	Pharmacological
.	.	O

Increases	VBZ	O
in	IN	O
serum	NN	O
PSA	NNP	O
in	IN	O
men	NNS	O
receiving	VBG	O
dutasteride	NN	Pharmacological
should	MD	O
be	VB	O
considered	VBN	O
suspicious	JJ	O
and	CC	O
serial	JJ	O
PSA	NNP	O
measurements	NNS	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
evaluate	VB	O
changes	NNS	O
from	IN	O
nadir	NN	O
.	.	O

Gastrointestinal	NNP	O
safety	NN	O
of	IN	O
NO-aspirin	NNP	Pharmacological
(	(	Pharmacological
NCX-4016	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
:	:	O
a	DT	O
proof	NN	O
of	IN	O
concept	NN	O
endoscopic	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
NCX-4016	NNP	Pharmacological
is	VBZ	O
a	DT	O
nitric	JJ	O
oxide-releasing	JJ	O
derivative	NN	O
of	IN	O
aspirin	NN	O
with	IN	O
antiplatelet	NN	O
activity	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
NCX-4016	NNP	Pharmacological
on	IN	O
gastrointestinal	JJ	O
mucosa	NN	O
and	CC	O
platelet	NN	O
functions	NNS	O
in	IN	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
parallel-group	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Forty	NNP	O
healthy	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
7	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
NCX-4016	NNP	Pharmacological
(	(	Pharmacological
400	CD	Pharmacological
and	CC	Pharmacological
800	CD	Pharmacological
mg	NN	Pharmacological
twice	RB	Pharmacological
daily	RB	Pharmacological
)	)	Pharmacological
,	,	O
equimolar	JJ	Pharmacological
doses	NNS	Pharmacological
of	IN	Pharmacological
aspirin	NN	Pharmacological
(	(	Pharmacological
200	CD	Pharmacological
and	CC	Pharmacological
420	CD	Pharmacological
mg	NN	Pharmacological
twice	RB	Pharmacological
daily	RB	Pharmacological
)	)	O
,	,	O
or	CC	O
placebo	NN	Control
.	.	O

Upper	IN	O
endoscopies	NNS	O
were	VBD	O
performed	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
and	CC	O
gastroduodenal	JJ	O
lesions	NNS	O
were	VBD	O
graded	VBN	O
using	VBG	O
a	DT	O
predefined	VBN	O
scoring	NN	O
system	NN	O
.	.	O

Basal	NNP	O
and	CC	O
posttreatment	JJ	O
platelet	NN	O
aggregation	NN	O
in	IN	O
response	NN	O
to	TO	O
arachidonic	JJ	O
acid	NN	O
(	(	O
AA	NNP	O
)	)	O
and	CC	O
serum	JJ	O
thromboxane	NN	O
(	(	O
TX	NNP	O
)	)	O
B	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
AA-stimulated	JJ	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
production	NN	O
were	VBD	O
investigated	VBN	O
.	.	O

RESULTS	NNP	O
Mucosal	NNP	O
endoscopic	JJ	O
injury	NN	O
score	NN	O
on	IN	O
day	NN	O
7	CD	O
was	VBD	O
0.63	CD	O
+/-	JJ	O
0.16	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
11.0	CD	O
+/-	JJ	O
3.0	CD	O
and	CC	O
16.1	CD	O
+/-	JJ	O
1.6	CD	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
treated	VBD	O
with	IN	O
200	CD	O
and	CC	O
420	CD	O
mg	NN	O
aspirin	JJ	O
twice	RB	O
daily	RB	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	NN	O
was	VBD	O
virtually	RB	O
devoid	JJ	O
of	IN	O
gastric	JJ	O
and	CC	O
duodenal	JJ	O
toxicity	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
total	JJ	O
gastric	NN	O
and	CC	O
duodenal	JJ	O
endoscopic	NN	O
score	NN	O
of	IN	O
1.38	CD	O
+/-	JJ	O
0.3	CD	O
and	CC	O
1.25	CD	O
+/-	JJ	O
0.5	CD	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	NN	O
aspirin	NN	O
,	,	O
not	RB	O
significant	JJ	O
vs.	FW	O
placebo	NN	O
)	)	O
.	.	O

NCX-4016	JJ	O
inhibited	JJ	O
AA-induced	JJ	O
platelet	NN	O
aggregation	NN	O
as	RB	O
well	RB	O
as	IN	O
serum	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
and	CC	O
platelet	NN	O
TXB	NNP	O
(	(	O
2	CD	O
)	)	O
generation	NN	O
induced	VBN	O
by	IN	O
AA	NNP	O
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
as	IN	O
aspirin	NN	Pharmacological
(	(	O
not	RB	O
significant	JJ	O
vs.	FW	O
aspirin	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
have	VBP	O
proven	VBN	O
the	DT	O
concept	NN	O
that	IN	O
addition	NN	O
of	IN	O
an	DT	O
NO-donating	JJ	O
moiety	NN	O
to	TO	O
aspirin	VB	O
results	NNS	O
in	IN	O
a	DT	O
new	JJ	O
chemical	NN	O
entity	NN	O
that	WDT	O
maintains	VBZ	O
cyclooxygenase-1	NN	O
and	CC	O
platelet	VB	O
inhibitory	JJ	O
activity	NN	O
while	IN	O
nearly	RB	O
avoiding	VBG	O
gastrointestinal	JJ	O
damage	NN	O
.	.	O

Weight	NNP	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
change	NN	O
with	IN	O
antiretroviral	JJ	Physical
initiation	NN	Physical
and	CC	O
impact	NN	O
on	IN	O
bone	NN	O
mineral	JJ	O
density	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effect	NN	O
that	IN	O
initiating	VBG	O
different	JJ	O
antiretroviral	JJ	Physical
therapy	NN	Physical
(	(	Physical
ART	NNP	Physical
)	)	Physical
regimens	VBZ	O
has	VBZ	O
on	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
(	(	O
LBM	NNP	O
)	)	O
and	CC	O
explore	VB	O
how	WRB	O
changes	NNS	O
in	IN	O
body	NN	O
composition	NN	O
are	VBP	O
associated	VBN	O
with	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
A5224s	NNP	O
was	VBD	O
a	DT	O
sub-study	NN	O
of	IN	O
A5202	NNP	O
,	,	O
a	DT	O
prospective	JJ	O
trial	NN	O
of	IN	O
1857	CD	O
ART-naive	JJ	O
participants	NNS	O
randomized	VBN	O
to	TO	O
blinded	VBN	O
abacavir-lamivudine	NN	Pharmacological
(	(	Pharmacological
ABC/3TC	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
tenofovir	JJ	Pharmacological
DF-emtricitabine	NNP	Pharmacological
(	(	Pharmacological
TDF/FTC	NNP	Pharmacological
)	)	Pharmacological
with	IN	O
open-label	JJ	O
efavirenz	NN	O
(	(	O
EFV	NNP	O
)	)	O
or	CC	O
atazanavir-ritonavir	JJ	Pharmacological
(	(	Pharmacological
ATV/r	NNP	Pharmacological
)	)	Pharmacological
.	.	O

All	DT	O
participants	NNS	O
underwent	JJ	O
dual-energy	JJ	Physical
absorptiometry	NN	Physical
(	(	Physical
DXA	NNP	Physical
)	)	Physical
and	CC	O
abdominal	JJ	Physical
computed	VBN	Physical
tomography	NN	Physical
for	IN	Physical
body	NN	Physical
composition	NN	Physical
.	.	O

Analyses	NNS	O
used	VBD	O
two-sample	JJ	O
t-tests	NNS	O
and	CC	O
linear	JJ	O
regression	NN	O
.	.	O

RESULTS	NNP	O
A5224s	NNP	O
included	VBD	O
269	CD	O
participants	NNS	O
:	:	O
85	CD	O
%	NN	O
men	NNS	O
,	,	O
47	CD	O
%	NN	O
white	JJ	O
non-Hispanic	JJ	O
,	,	O
median	JJ	O
age	NN	O
38	CD	O
years	NNS	O
,	,	O
HIV-1	NNP	O
RNA	NNP	O
4.6	CD	O
log10	NN	O
copies/ml	NN	O
,	,	O
and	CC	O
CD4	NNP	O
cell	VBP	O
count	NN	O
233	CD	O
cells/?l	NN	O
.	.	O

Overall	JJ	O
,	,	O
significant	JJ	O
gains	NNS	O
occurred	VBD	O
in	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
and	CC	O
LBM	NNP	O
at	IN	O
96	CD	O
weeks	NNS	O
post-randomization	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Assignment	NN	O
to	TO	O
ATV/r	NNP	Pharmacological
(	(	O
vs.	FW	O
EFV	NNP	O
)	)	O
resulted	VBD	O
in	IN	O
significantly	RB	O
greater	JJR	O
weight	NN	O
(	(	O
mean	JJ	O
difference	NN	O
3.35	CD	O
kg	NN	O
)	)	O
and	CC	O
BMI	NNP	O
gain	NN	O
(	(	O
0.88	CD	O
kg/m	NN	O
;	:	O
both	DT	O
P=0.02	NNP	O
)	)	O
,	,	O
but	CC	O
not	RB	O
LBM	NNP	O
(	(	O
0.67	CD	O
kg	NN	O
;	:	O
P=0.15	NNP	O
)	)	O
,	,	O
whereas	JJ	O
ABC/3TC	NNP	O
and	CC	O
TDF/FTC	NNP	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
P?0.10	NNP	O
)	)	O
.	.	O

In	IN	O
multivariable	JJ	O
analysis	NN	O
,	,	O
only	RB	O
lower	JJR	O
baseline	NN	O
CD4	NNP	O
cell	NN	O
count	NN	O
and	CC	O
higher	JJR	O
HIV-1	NNP	O
RNA	NNP	O
were	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
increase	NN	O
in	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
or	CC	O
LBM	NNP	O
.	.	O

In	IN	O
multivariable	JJ	O
analyses	NNS	O
,	,	O
increased	VBD	O
LBM	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
hip	NN	O
BMD	NNP	O
.	.	O

CONCLUSION	NNP	O
ABC/3TC	NNP	O
vs.	IN	O
TDF/FTC	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
change	NN	O
in	IN	O
weight	NN	O
,	,	O
BMI	NNP	O
,	,	O
or	CC	O
LBM	NNP	O
;	:	O
ATV/r	NNP	O
vs.	FW	O
EFV	NNP	O
resulted	VBD	O
in	IN	O
greater	JJR	O
weight	NN	O
and	CC	O
BMI	NNP	O
gain	NN	O
but	CC	O
not	RB	O
LBM	NNP	O
.	.	O

A	NNP	O
positive	JJ	O
association	NN	O
between	IN	O
increased	VBN	O
LBM	NNP	O
and	CC	O
increased	VBD	O
hip	NN	O
BMD	NNP	O
should	MD	O
be	VB	O
further	RB	O
investigated	VBN	O
through	IN	O
prospective	JJ	O
interventional	JJ	O
studies	NNS	O
to	TO	O
verify	VB	O
the	DT	O
impact	NN	O
of	IN	O
increased	JJ	O
LBM	NNP	O
on	IN	O
hip	NN	O
BMD	NNP	O
.	.	O

Single-session	JJ	O
behavioral	JJ	Psychological
treatment	NN	Psychological
of	IN	O
earthquake-related	JJ	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
:	:	O
a	DT	O
randomized	JJ	O
waiting	NN	O
list	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

In	IN	O
an	DT	O
attempt	NN	O
to	TO	O
develop	VB	O
a	DT	O
brief	JJ	O
treatment	NN	O
for	IN	O
disaster	NN	O
survivors	NNS	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
single	JJ	O
session	NN	O
of	IN	O
modified	JJ	Psychological
behavioral	JJ	Psychological
treatment	NN	Psychological
in	IN	O
earthquake-related	JJ	O
posttraumatic	JJ	O
stress	NN	O
disorder	NN	O
.	.	O

Fifty-nine	JJ	O
earthquake	NN	O
survivors	NNS	O
in	IN	O
Turkey	NNP	O
were	VBD	O
randomized	VBN	O
into	IN	O
either	DT	O
single-session	NN	Psychological
modified	VBD	Psychological
behavioral	JJ	Psychological
treatment	NN	Psychological
(	(	Psychological
SSBT	NNP	Psychological
)	)	Psychological
designed	VBN	O
to	TO	O
enhance	VB	O
sense	NN	O
of	IN	O
control	NN	O
over	IN	O
earthquake-related	JJ	O
fears	NNS	O
or	CC	O
waiting	VBG	Educational
list	NN	Educational
control	NN	Educational
condition	NN	Educational
(	(	Educational
WL	NNP	Educational
)	)	Educational
.	.	O

The	DT	O
WL	NNP	O
group	NN	O
received	VBD	O
SSBT	NNP	Pharmacological
after	IN	O
a	DT	O
second	JJ	O
baseline	NN	O
assessment	NN	O
.	.	O

Follow-ups	NNS	O
were	VBD	O
at	IN	O
weeks	NNS	O
6	CD	O
,	,	O
12	CD	O
,	,	O
24	CD	O
,	,	O
and	CC	O
at	IN	O
1-2	JJ	O
years	NNS	O
posttreatment	NN	O
.	.	O

Significant	JJ	O
treatment	NN	O
effects	NNS	O
were	VBD	O
found	VBN	O
on	IN	O
all	DT	O
measures	NNS	O
at	IN	O
posttreatment	NN	O
.	.	O

The	DT	O
improvement	NN	O
rate	NN	O
was	VBD	O
49	CD	O
%	NN	O
at	IN	O
week	NN	O
6	CD	O
;	:	O
it	PRP	O
rose	VBD	O
to	TO	O
80	CD	O
%	NN	O
by	IN	O
week	NN	O
12	CD	O
,	,	O
85	CD	O
%	NN	O
by	IN	O
week	NN	O
24	CD	O
,	,	O
and	CC	O
83	CD	O
%	NN	O
by	IN	O
the	DT	O
1-2-year	JJ	O
follow-up	NN	O
.	.	O

Brief	JJ	O
behavioral	JJ	Psychological
treatment	NN	Psychological
has	VBZ	O
promise	VBN	O
as	IN	O
a	DT	O
cost-effective	JJ	O
intervention	NN	O
for	IN	O
disaster	NN	O
survivors	NNS	O
.	.	O

A	DT	O
pilot	NN	O
randomised	VBN	O
control	NN	O
trial	NN	O
of	IN	O
a	DT	O
parent	NN	Educational
training	NN	Educational
intervention	NN	Educational
for	IN	O
pre-school	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Preliminary	JJ	O
findings	NNS	O
and	CC	O
methodological	JJ	O
challenges	NNS	O
.	.	O

Few	JJ	O
attempts	NNS	O
have	VBP	O
been	VBN	O
made	VBN	O
to	TO	O
conduct	VB	O
randomised	VBN	O
control	NN	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
of	IN	O
interventions	NNS	O
for	IN	O
pre-school	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

We	PRP	O
report	VBP	O
findings	NNS	O
of	IN	O
a	DT	O
pilot	NN	O
RCT	NNP	O
for	IN	O
a	DT	O
parent	NN	Educational
training	NN	Educational
intervention	NN	Educational
with	IN	O
a	DT	O
focus	NN	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
joint	JJ	O
attention	NN	O
skills	NNS	O
and	CC	O
joint	JJ	O
action	NN	O
routines	NNS	O
.	.	O

Twenty-four	CD	O
children	NNS	O
meeting	VBG	O
ICD-10	NNP	O
criteria	NNS	O
for	IN	O
childhood	NN	O
autism	NN	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
23	CD	O
months	NNS	O
)	)	O
were	VBD	O
identified	VBN	O
using	VBG	O
the	DT	O
CHAT	NNP	O
screen	NN	O
and	CC	O
randomised	VBD	O
to	TO	O
the	DT	O
parent	NN	Educational
training	VBG	Educational
group	NN	O
or	CC	O
to	TO	O
local	JJ	Control
services	NNS	Control
only	RB	Control
.	.	O

A	DT	O
follow-up	NN	O
was	VBD	O
conducted	VBN	O
12	CD	O
months	NNS	O
later	RB	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
35	CD	O
months	NNS	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
some	DT	O
evidence	NN	O
that	IN	O
the	DT	O
parent	NN	O
training	NN	O
group	NN	O
made	VBD	O
more	JJR	O
progress	NN	O
in	IN	O
language	NN	O
development	NN	O
than	IN	O
the	DT	O
local	JJ	O
services	NNS	O
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
present	JJ	O
pilot	NN	O
study	NN	O
was	VBD	O
compromised	VBN	O
by	IN	O
several	JJ	O
factors	NNS	O
:	:	O
a	DT	O
reliance	NN	O
on	IN	O
parental	JJ	O
report	NN	O
to	TO	O
measure	VB	O
language	NN	O
,	,	O
non-matching	NN	O
of	IN	O
the	DT	O
groups	NNS	O
on	IN	O
initial	JJ	O
IQ	NNP	O
,	,	O
and	CC	O
a	DT	O
lack	NN	O
of	IN	O
systematic	JJ	O
checking	NN	O
regarding	VBG	O
the	DT	O
implementation	NN	O
of	IN	O
the	DT	O
parent	NN	O
training	NN	O
intervention	NN	O
.	.	O

Furthermore	RB	O
,	,	O
three	CD	O
parents	NNS	O
in	IN	O
the	DT	O
local	JJ	O
services	NNS	O
group	NN	O
commenced	VBD	O
intensive	JJ	O
,	,	O
home-based	JJ	Educational
behavioural	JJ	Educational
intervention	NN	Educational
during	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
difficulties	NNS	O
encountered	VBN	O
in	IN	O
the	DT	O
conduct	NN	O
of	IN	O
RCTs	NNP	O
for	IN	O
pre-school	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Methodological	JJ	O
challenges	NNS	O
and	CC	O
strategies	NNS	O
for	IN	O
future	JJ	O
well-designed	JJ	O
RCTs	NNP	O
for	IN	O
autism	NN	O
interventions	NNS	O
are	VBP	O
highlighted	VBN	O
.	.	O

The	DT	O
benefit	NN	O
of	IN	O
low-dose	JJ	O
dopamine	NN	Pharmacological
during	IN	O
vigorous	JJ	O
diuresis	NN	O
for	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
associated	VBN	O
with	IN	O
renal	JJ	O
insufficiency	NN	O
:	:	O
does	VBZ	O
it	PRP	O
protect	VB	O
renal	JJ	O
function	NN	O
?	.	O
BACKGROUND	NNP	O
Low-dose	NNP	O
dopamine	NN	Pharmacological
,	,	O
a	DT	O
renal	JJ	O
vasodilator	NN	O
,	,	O
has	VBZ	O
been	VBN	O
used	VBN	O
empirically	RB	O
to	TO	O
improve	VB	O
renal	JJ	O
function	NN	O
or	CC	O
outcome	NN	O
in	IN	O
critically	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
oliguria	NNS	O
or	CC	O
acute	JJ	O
renal	JJ	O
failure	NN	O
.	.	O

HYPOTHESIS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
low-dose	JJ	O
dopamine	NN	Pharmacological
(	(	O
2	CD	O
micrograms/kg/min	NN	O
)	)	O
as	IN	O
a	DT	O
renal-protective	JJ	O
agent	NN	O
during	IN	O
vigorous	JJ	O
diuresis	NN	O
for	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
CHF	NNP	O
)	)	O
associated	VBN	O
with	IN	O
mild	NN	O
or	CC	O
moderate	JJ	O
renal	JJ	O
insufficiency	NN	O
.	.	O

METHODS	NNP	O
Of	IN	O
20	CD	O
study	NN	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
74.3	CD	O
+/-	JJ	O
15	CD	O
years	NNS	O
)	)	O
with	IN	O
severe	JJ	O
CHF	NNP	O
,	,	O
10	CD	O
(	(	O
Group	NNP	O
A	NNP	O
)	)	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
treatment	NN	O
strategy	NN	O
of	IN	O
intravenous	JJ	O
bumetanide	NN	Pharmacological
(	(	O
1	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

)	)	O
alone	RB	O
and	CC	O
another	DT	O
10	CD	O
(	(	O
Group	NNP	O
B	NNP	O
)	)	O
to	TO	O
low-dose	JJ	O
dopamine	NN	Pharmacological
and	CC	O
a	DT	O
similar	JJ	O
diuretic	JJ	O
regimen	NNS	O
for	IN	O
a	DT	O
duration	NN	O
of	IN	O
5	CD	O
days	NNS	O
or	CC	O
less	JJR	O
if	IN	O
clinical	JJ	O
edema	NN	O
remitted	VBN	O
.	.	O

RESULTS	NNP	O
Group	NNP	O
B	NNP	O
patients	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
renal	JJ	O
function	NN	O
and	CC	O
urinary	JJ	O
output	NN	O
:	:	O
serum	NN	O
blood	NN	O
urea	JJ	O
nitrogen	RB	O
48.9	CD	O
+/-	JJ	O
10.3	CD	O
to	TO	O
32.1	CD	O
+/-	JJ	O
14.4	CD	O
mg/dl	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
serum	JJ	O
creatinine	NN	O
1.97	CD	O
+/-	JJ	O
0.24	CD	O
to	TO	O
1.49	CD	O
+/-	JJ	O
0.39	CD	O
mg/dl	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
creatinine	JJ	O
clearance	NN	O
35.6	CD	O
+/-	JJ	O
11.6	CD	O
to	TO	O
48.8	CD	O
+/-	JJ	O
12.3	CD	O
ml/min	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
and	CC	O
indexed	JJ	O
urinary	JJ	O
output	NN	O
0.56	CD	O
+/-	JJ	O
0.16	CD	O
to	TO	O
2.02	CD	O
+/-	JJ	O
0.72	CD	O
ml/kg/h	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Group	NNP	O
A	NNP	O
patients	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
urinary	JJ	O
output	NN	O
but	CC	O
nonsignificant	JJ	O
renal	JJ	O
functional	JJ	O
deterioration	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
renal-protective	JJ	O
effect	NN	O
of	IN	O
low-dose	JJ	O
dopamine	NN	Pharmacological
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
CHF	NNP	O
and	CC	O
vigorous	JJ	O
diuresis	NN	O
is	VBZ	O
supported	VBN	O
by	IN	O
this	DT	O
study	NN	O
.	.	O

FDA	NNP	O
review	NN	O
of	IN	O
a	DT	O
panitumumab	NN	Pharmacological
(	(	Pharmacological
Vectibix	NNP	Pharmacological
)	)	Pharmacological
clinical	JJ	O
trial	NN	O
for	IN	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

On	IN	O
September	NNP	O
27	CD	O
,	,	O
2006	CD	O
,	,	O
the	DT	O
U.S.	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
granted	VBD	O
accelerated	VBD	O
approval	NN	O
to	TO	O
panitumumab	VB	Pharmacological
(	(	Pharmacological
Vectibix	NNP	Pharmacological
;	:	Pharmacological
Amgen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Thousand	NNP	O
Oaks	NNP	O
,	,	O
CA	NNP	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor-expressing	NN	O
,	,	O
metastatic	JJ	O
colorectal	NN	O
carcinoma	NN	O
with	IN	O
disease	JJ	O
progression	NN	O
on	IN	O
or	CC	O
following	VBG	O
fluoropyrimidine-	JJ	Pharmacological
,	,	O
oxaliplatin-	JJ	O
,	,	O
and	CC	O
irinotecan-containing	JJ	Pharmacological
chemotherapy	NN	Pharmacological
regimens	NNS	Pharmacological
.	.	O

Accelerated	NNP	O
approval	NN	O
was	VBD	O
based	VBN	O
on	IN	O
demonstration	NN	O
of	IN	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
submission	NN	O
summarizes	VBZ	O
a	DT	O
second	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
to	TO	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
panitumumab	JJ	Pharmacological
package	NN	O
insert	NN	O
in	IN	O
June	NNP	O
2008	CD	O
,	,	O
of	IN	O
chemotherapy	NN	Pharmacological
and	CC	O
bevacizumab	NN	Pharmacological
with	IN	Pharmacological
and	CC	Pharmacological
without	IN	Pharmacological
panitumumab	NN	Pharmacological
in	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
closed	VBN	O
when	WRB	O
inferior	JJ	O
PFS	NNP	O
and	CC	O
greater	JJR	O
toxicity	NN	O
were	VBD	O
demonstrated	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
planned	VBN	O
interim	NN	O
efficacy	NN	O
analysis	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
panitumumab	NN	Pharmacological
in	IN	O
combination	NN	O
with	IN	O
bevacizumab	NN	Pharmacological
and	CC	Pharmacological
chemotherapy	NN	Pharmacological
experienced	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
death	NN	O
(	(	O
9	CD	O
%	NN	O
versus	IN	O
4	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
higher	JJR	O
risk	NN	O
for	IN	O
grade	NN	O
3	CD	O
and	CC	O
4	CD	O
toxicities	NNS	O
than	IN	O
patients	NNS	O
receiving	VBG	O
bevacizumab	NN	Pharmacological
and	CC	O
chemotherapy	NN	Pharmacological
alone	RB	O
.	.	O

The	DT	O
incidences	NNS	O
of	IN	O
any	DT	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNP	O
grade	VBD	O
3	CD	O
and	CC	O
4	CD	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
87	CD	O
%	NN	O
and	CC	O
72	CD	O
%	NN	O
in	IN	O
the	DT	O
panitumumab	NN	Pharmacological
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

Grade	VB	O
3	CD	O
and	CC	O
4	CD	O
AEs	NNP	O
occurring	VBG	O
more	JJR	O
commonly	RB	O
in	IN	O
panitumumab-treated	JJ	Pharmacological
patients	NNS	O
included	VBD	O
rash/acneiform	NN	O
dermatitis	NN	O
,	,	O
diarrhea	NN	O
,	,	O
dehydration	NN	O
,	,	O
primarily	RB	O
resulting	VBG	O
from	IN	O
diarrhea	NN	O
,	,	O
hypokalemia	NN	O
,	,	O
stomatitis/mucositis	NN	O
,	,	O
and	CC	O
pulmonary	JJ	O
embolism	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
panitumumab	NN	Pharmacological
to	TO	Pharmacological
bevacizumab	VB	Pharmacological
and	CC	Pharmacological
chemotherapy	VB	Pharmacological
for	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
colorectal	NN	O
cancer	NN	O
was	VBD	O
harmful	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
bevacizumab	NN	Pharmacological
and	CC	Pharmacological
chemotherapy	NN	Pharmacological
alone	RB	Pharmacological
.	.	O

The	DT	O
use	NN	O
of	IN	O
panitumumab	NN	Pharmacological
in	IN	O
this	DT	O
setting	NN	O
can	MD	O
not	RB	O
be	VB	O
recommended	VBN	O
.	.	O

Clinical	JJ	O
and	CC	O
radiographic	JJ	O
evaluation	NN	O
of	IN	O
guided	JJ	O
tissue	NN	O
regeneration	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
class	NN	O
II	NNP	O
furcation	NN	O
defects	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
treatment	NN	O
outcomes	RB	O
after	IN	O
guided	VBN	Physical
tissue	NN	Physical
regeneration	NN	Physical
(	(	Physical
GTR	NNP	Physical
)	)	Physical
with	IN	O
a	DT	O
bioabsorbable	JJ	O
membrane	NN	O
in	IN	O
Class	NNP	O
II	NNP	O
furcation	NN	O
defects	NNS	O
in	IN	O
mandibular	JJ	O
molars	NNS	O
.	.	O

The	DT	O
open	JJ	O
flap	NN	O
debridement	NN	O
(	(	O
OFD	NNP	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
the	DT	O
control	NN	O
.	.	O

METHODS	NNP	O
Nine	NNP	O
patients	NNS	O
,	,	O
with	IN	O
two	CD	O
comparable	JJ	O
Class	NNP	O
II	NNP	O
furcation	NN	O
defects	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

After	IN	O
initial	JJ	O
preparation	NN	O
,	,	O
the	DT	O
defects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
each	DT	O
patient	NN	O
to	TO	O
either	DT	O
GTR-group	NNP	Physical
or	CC	O
OFD-group	NNP	Physical
.	.	O

Clinical	JJ	O
parameters	NNS	O
and	CC	O
standardized	JJ	O
radiographs	NN	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
the	DT	O
surgeries	NNS	O
.	.	O

The	DT	O
radiographs	NN	Physical
were	VBD	O
analyzed	VBN	O
by	IN	O
subtraction	NN	O
radiography	NN	O
.	.	O

RESULTS	NNP	O
Comparing	NNP	O
baseline	NN	O
to	TO	O
6-month	JJ	O
results	NNS	O
,	,	O
both	DT	O
groups	NNS	O
showed	VBD	O
statistically	RB	O
significant	JJ	O
probing	VBG	O
depth	NN	O
reduction	NN	O
(	(	O
PD	NNP	O
)	)	O
,	,	O
horizontal	JJ	O
clinical	JJ	O
attachment	NN	O
level	NN	O
(	(	O
CAL-h	NNP	O
)	)	O
gain	NN	O
,	,	O
and	CC	O
increase	VB	O
in	IN	O
gingival	JJ	O
recession	NN	O
(	(	O
GR	NNP	O
)	)	O
.	.	O

The	DT	O
vertical	JJ	O
clinical	JJ	O
attachment	NN	O
level	NN	O
(	(	O
CAL-v	NNP	O
)	)	O
gain	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
OFD-group	NNP	O
.	.	O

Comparing	VBG	O
the	DT	O
two	CD	O
treatments	NNS	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
PD	NNP	O
reduction	NN	O
(	(	O
GTR	NNP	O
:	:	O
1.67	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
2.51	CD	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.26	CD	O
)	)	O
,	,	O
CAL-v	JJ	O
gain	NN	O
(	(	O
GTR	NNP	O
:	:	O
0.62	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
1.16	CD	O
mm	NN	O
,	,	O
P=	NNP	O
0.37	CD	O
)	)	O
,	,	O
and	CC	O
GR	NNP	O
increase	NN	O
(	(	O
GTR	NNP	O
:	:	O
1.04	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
1.24	CD	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.31	CD	O
)	)	O
.	.	O

GTR	NNP	Physical
provided	VBD	O
complete	JJ	O
closure	NN	O
of	IN	O
the	DT	O
furcation	NN	O
defect	NN	O
in	IN	O
two	CD	O
sites	NNS	O
and	CC	O
superior	JJ	O
horizontal	JJ	O
clinical	JJ	O
attachment	NN	O
level	NN	O
gain	NN	O
(	(	O
GTR	NNP	O
:	:	O
2.27	CD	O
mm	NN	O
;	:	O
OFD	NNP	O
:	:	O
1.01	CD	O
mm	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

Subtraction	NN	O
radiography	NN	O
showed	VBD	O
significant	JJ	O
difference	NN	O
in	IN	O
bone	NN	O
height	NN	O
change	NN	O
between	IN	O
GTR-group	NNP	O
and	CC	O
OFD-group	NNP	O
(	(	O
-0.14	NNP	O
mm	NN	O
and	CC	O
0.86	CD	O
mm	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.028	CD	O
)	)	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
TOM	NNP	Other
test	NN	Other
:	:	O
a	DT	O
new	JJ	O
instrument	NN	O
for	IN	O
assessing	VBG	O
theory	NN	O
of	IN	O
mind	NN	O
in	IN	O
normal	JJ	O
children	NNS	O
and	CC	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

This	DT	O
article	NN	O
describes	VBZ	O
a	DT	O
first	JJ	O
attempt	NN	O
to	TO	O
investigate	VB	O
the	DT	O
reliability	NN	O
and	CC	O
validity	NN	O
of	IN	O
the	DT	O
TOM	NNP	Other
test	NN	Other
,	,	O
a	DT	O
new	JJ	O
instrument	NN	O
for	IN	O
assessing	VBG	O
theory	NN	O
of	IN	O
mind	NN	O
ability	NN	O
in	IN	O
normal	JJ	O
children	NNS	O
and	CC	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDDs	NNP	O
)	)	O
.	.	O

In	IN	O
Study	NNP	O
1	CD	O
,	,	O
TOM	NNP	Other
test	NN	Other
scores	NNS	O
of	IN	O
normal	JJ	O
children	NNS	O
(	(	O
n	JJ	O
=	NNP	O
70	CD	O
)	)	O
correlated	VBD	O
positively	RB	O
with	IN	O
their	PRP$	O
performance	NN	O
on	IN	O
other	JJ	O
theory	NN	O
of	IN	O
mind	NN	O
tasks	NNS	O
.	.	O

Furthermore	NNP	O
,	,	O
young	JJ	O
children	NNS	O
only	RB	O
succeeded	VBD	O
on	IN	O
TOM	NNP	O
items	NNS	O
that	WDT	O
tap	VBP	O
the	DT	O
basic	JJ	O
domains	NNS	O
of	IN	O
theory	NN	O
of	IN	O
mind	NN	O
(	(	O
e.g.	JJ	O
,	,	O
emotion	JJ	O
recognition	NN	O
)	)	O
,	,	O
whereas	JJ	O
older	JJR	O
children	NNS	O
also	RB	O
passed	VBD	O
items	NNS	O
that	WDT	O
measure	VBP	O
the	DT	O
more	JJR	O
mature	JJ	O
areas	NNS	O
of	IN	O
theory	NN	O
of	IN	O
mind	NN	O
(	(	O
e.g.	JJ	O
,	,	O
understanding	NN	O
of	IN	O
humor	NN	O
,	,	O
understanding	VBG	O
of	IN	O
second-order	JJ	O
beliefs	NNS	O
)	)	O
.	.	O

Taken	VBN	O
together	RB	O
,	,	O
the	DT	O
findings	NNS	O
of	IN	O
Study	NNP	O
1	CD	O
suggest	NN	O
that	IN	O
the	DT	O
TOM	NNP	Other
test	NN	Other
is	VBZ	O
a	DT	O
valid	JJ	O
measure	NN	O
.	.	O

Study	NNP	O
2	CD	O
showed	VBD	O
for	IN	O
a	DT	O
separate	JJ	O
sample	NN	O
of	IN	O
normal	JJ	O
children	NNS	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
that	IN	O
the	DT	O
TOM	NNP	Other
test	NN	Other
possesses	VBZ	O
sufficient	JJ	O
test-retest	JJ	O
stability	NN	O
.	.	O

Study	NNP	O
3	CD	O
demonstrated	VBD	O
for	IN	O
a	DT	O
sample	NN	O
of	IN	O
children	NNS	O
with	IN	O
PDDs	NNP	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
that	IN	O
the	DT	O
interrater	NN	O
reliability	NN	O
of	IN	O
the	DT	O
TOM	NNP	Other
test	NN	Other
is	VBZ	O
good	JJ	O
.	.	O

Study	VB	O
4	CD	O
found	NN	O
that	IN	O
children	NNS	O
with	IN	O
PDDs	NNP	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
had	VBD	O
significantly	RB	O
lower	JJR	O
TOM	NNP	Other
test	NN	Other
scores	NNS	O
than	IN	O
children	NNS	O
with	IN	O
other	JJ	O
psychiatric	JJ	O
disorders	NNS	O
(	(	O
e.g.	NN	O
,	,	O
children	NNS	O
with	IN	O
Attention-deficit	NNP	O
Hyperactivity	NNP	O
Disorder	NNP	O
;	:	O
n	CC	O
=	VB	O
32	CD	O
)	)	O
,	,	O
a	DT	O
finding	NN	O
that	WDT	O
underlines	VBZ	O
the	DT	O
discriminant	JJ	O
validity	NN	O
of	IN	O
the	DT	O
TOM	NNP	Other
test	NN	Other
.	.	O

Furthermore	RB	O
,	,	O
Study	NNP	O
4	CD	O
showed	VBD	O
that	DT	O
intelligence	NN	O
as	IN	O
indexed	VBN	O
by	IN	O
the	DT	O
Wechsler	NNP	O
Intelligence	NNP	O
Scale	NNP	O
for	IN	O
Children	NNP	O
was	VBD	O
positively	RB	O
associated	VBN	O
with	IN	O
TOM	NNP	Other
test	NN	Other
scores	NNS	O
.	.	O

Finally	RB	O
,	,	O
in	IN	O
all	DT	O
studies	NNS	O
,	,	O
the	DT	O
TOM	NNP	Other
test	NN	Other
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
reliable	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
internal	JJ	O
consistency	NN	O
.	.	O

Altogether	RB	O
,	,	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
TOM	NNP	Other
test	NN	Other
is	VBZ	O
a	DT	O
reliable	JJ	O
and	CC	O
valid	JJ	O
instrument	NN	O
that	WDT	O
can	MD	O
be	VB	O
employed	VBN	O
to	TO	O
measure	VB	O
various	JJ	O
aspects	NNS	O
of	IN	O
theory	NN	O
of	IN	O
mind	NN	O
.	.	O

Chemoradiotherapy	NN	O
with	IN	O
concurrent	JJ	Pharmacological
gemcitabine	NN	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
with	IN	Pharmacological
or	CC	Pharmacological
without	IN	Pharmacological
sequential	JJ	Pharmacological
chemotherapy	NN	Pharmacological
with	IN	Pharmacological
gemcitabine/cisplatin	JJ	Pharmacological
vs	NNS	O
chemoradiotherapy	NN	Pharmacological
with	IN	Pharmacological
concurrent	JJ	Pharmacological
5-fluorouracil	JJ	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
pancreatic	JJ	O
cancer	NN	O
--	:	O
a	DT	O
multi-centre	JJ	O
randomised	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
No	NNP	O
standard	NN	O
treatment	NN	O
for	IN	O
locally	RB	O
advanced	JJ	O
pancreatic	JJ	O
cancer	NN	O
(	(	O
LAPC	NNP	O
)	)	O
is	VBZ	O
defined	VBN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Within	NNP	O
a	DT	O
multi-centre	JJ	O
,	,	O
randomised	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
,	,	O
95	CD	O
patients	NNS	O
with	IN	O
LAPC	NNP	O
were	VBD	O
assigned	VBN	O
to	TO	O
three	CD	O
different	JJ	O
chemoradiotherapy	NN	O
(	(	O
CRT	NNP	O
)	)	O
regimens	VBZ	O
:	:	O
patients	NNS	O
received	VBD	O
conventionally	RB	O
fractionated	VBN	O
radiotherapy	NN	Pharmacological
of	IN	O
50	CD	O
Gy	NNP	O
and	CC	O
were	VBD	O
randomised	VBN	O
to	TO	O
concurrent	VB	O
5-fluorouracil	NNP	Pharmacological
(	(	O
350	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
per	IN	O
day	NN	O
on	IN	O
each	DT	O
day	NN	O
of	IN	O
radiotherapy	NN	Pharmacological
,	,	O
RT-5-FU	NNP	O
arm	NN	O
)	)	O
,	,	O
concurrent	JJ	Pharmacological
gemcitabine	NN	Pharmacological
(	(	O
300	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
,	,	O
and	CC	O
cisplatin	NN	Pharmacological
(	(	O
30	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
22	CD	O
,	,	O
and	CC	O
29	CD	O
(	(	O
RT-GC	NNP	O
arm	NN	O
)	)	O
,	,	O
or	CC	O
the	DT	O
same	JJ	Pharmacological
concurrent	NN	Pharmacological
treatment	NN	Pharmacological
followed	VBN	Pharmacological
by	IN	Pharmacological
sequential	JJ	Pharmacological
full-dose	JJ	Pharmacological
gemcitabine	NN	Pharmacological
(	(	O
1000	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
and	CC	O
cisplatin	NN	Pharmacological
(	(	O
50	CD	O
mg	NN	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
every	DT	O
2	CD	O
weeks	NNS	O
(	(	O
RT-GC+GC	NNP	O
arm	NN	O
)	)	O
.	.	O

Primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
rate	NN	O
after	IN	O
9	CD	O
months	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
9-month	JJ	O
OS	NNP	O
rate	NN	O
was	VBD	O
58	CD	O
%	NN	O
in	IN	O
the	DT	O
RT-5-FU	NNP	O
arm	NN	O
,	,	O
52	CD	O
%	NN	O
in	IN	O
the	DT	O
RT-GC	NNP	O
arm	NN	O
,	,	O
and	CC	O
45	CD	O
%	NN	O
in	IN	O
the	DT	O
RT-GC+GC	JJ	O
arm	NN	O
.	.	O

Corresponding	VBG	O
median	JJ	O
survival	NN	O
times	NNS	O
were	VBD	O
9.6	CD	O
,	,	O
9.3	CD	O
,	,	O
and	CC	O
7.3	CD	O
months	NNS	O
(	(	O
P=0.61	NNP	O
)	)	O
respectively	RB	O
.	.	O

The	DT	O
intent-to-treat	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
19	CD	O
,	,	O
22	CD	O
,	,	O
and	CC	O
13	CD	O
%	NN	O
respectively	RB	O
.	.	O

Median	JJ	O
progression-free	JJ	O
survival	NN	O
was	VBD	O
estimated	VBN	O
with	IN	O
4.0	CD	O
,	,	O
5.6	CD	O
,	,	O
and	CC	O
6.0	CD	O
months	NNS	O
(	(	O
P=0.21	NNP	O
)	)	O
.	.	O

Grade	$	O
3/4	CD	O
haematological	JJ	O
toxicities	NNS	O
were	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
two	CD	O
GC-containing	JJ	O
arms	NNS	O
,	,	O
no	DT	O
grade	NN	O
3/4	CD	O
febrile	NN	O
neutropaenia	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSION	NNP	O
None	NN	O
of	IN	O
the	DT	O
three	CD	O
CRT	NNP	O
regimens	NNS	O
tested	VBD	O
met	VBD	O
the	DT	O
investigators	NNS	O
'	POS	O
definition	NN	O
for	IN	O
efficacy	NN	O
;	:	O
the	DT	O
median	JJ	O
OS	NNP	O
was	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
previously	RB	O
reported	VBN	O
with	IN	O
gemcitabine	NN	O
alone	RB	O
in	IN	O
LAPC	NNP	O
.	.	O

Marimastat	NNP	Pharmacological
as	IN	O
maintenance	NN	O
therapy	NN	O
for	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
gastric	JJ	O
cancer	NN	O
:	:	O
a	DT	O
randomised	JJ	O
trial	NN	O
.	.	O

This	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
orally	RB	O
administered	VBN	O
matrix	JJ	O
metalloproteinase	NN	O
inhibitor	NN	O
,	,	O
marimastat	NN	Pharmacological
,	,	O
to	TO	O
prolong	VB	O
survival	NN	O
in	IN	O
patients	NNS	O
with	IN	O
non-resectable	JJ	O
gastric	JJ	O
and	CC	O
gastro-oesophageal	JJ	O
adenocarcinoma	NN	O
.	.	O

Three	CD	O
hundred	VBD	O
and	CC	O
sixty-nine	JJ	O
patients	NNS	O
with	IN	O
histological	JJ	O
proof	NN	O
of	IN	O
adenocarcinoma	NN	O
,	,	O
who	WP	O
had	VBD	O
received	VBN	O
no	RB	O
more	RBR	O
than	IN	O
a	DT	O
single	JJ	O
regimen	NN	O
of	IN	O
5-fluorouracil-based	JJ	O
chemotherapy	NN	O
,	,	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
marimastat	NN	Pharmacological
(	(	O
10	CD	O
mg	NN	O
b.d	NN	O
.	.	O

)	)	O
or	CC	O
placebo	NN	Control
.	.	O

Patients	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
was	VBD	O
tolerable	JJ	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
overall	JJ	O
survival	NN	O
with	IN	O
secondary	JJ	O
endpoints	NNS	O
of	IN	O
time	NN	O
to	TO	O
disease	VB	O
progression	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

At	IN	O
the	DT	O
point	NN	O
of	IN	O
protocol-defined	JJ	O
study	NN	O
completion	NN	O
(	(	O
85	CD	O
%	NN	O
mortality	NN	O
in	IN	O
the	DT	O
placebo	NN	O
arm	NN	O
)	)	O
there	EX	O
was	VBD	O
a	DT	O
modest	JJ	O
difference	NN	O
in	IN	O
survival	NN	O
in	IN	O
the	DT	O
intention-to-treat	JJ	O
population	NN	O
in	IN	O
favour	NN	O
of	IN	O
marimastat	NN	Pharmacological
(	(	O
P=0.07	NNP	O
log-rank	JJ	O
test	NN	O
,	,	O
hazard	NN	O
ratio=1.23	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.98-1.55	NNP	O
)	)	O
)	)	O
.	.	O

This	DT	O
survival	JJ	O
benefit	NN	O
was	VBD	O
maintained	VBN	O
over	IN	O
a	DT	O
further	JJ	O
2	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
(	(	O
P=0.024	NNP	O
,	,	O
hazard	NN	O
ratio=1.27	NN	O
(	(	O
1.03-1.57	JJ	O
)	)	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
138	CD	O
days	NNS	O
for	IN	O
placebo	NN	Control
and	CC	O
160	CD	O
days	NNS	O
for	IN	O
marimastat	NN	Pharmacological
,	,	O
with	IN	O
2-year	JJ	O
survival	NN	O
of	IN	O
3	CD	O
%	NN	O
and	CC	O
9	CD	O
%	NN	O
respectively	RB	O
.	.	O

A	DT	O
significant	JJ	O
survival	JJ	O
benefit	NN	O
was	VBD	O
identified	VBN	O
at	IN	O
study	NN	O
completion	NN	O
in	IN	O
the	DT	O
pre-defined	JJ	O
sub-group	NN	O
of	IN	O
123	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
prior	RB	O
chemotherapy	NN	O
(	(	O
P=0.045	NNP	O
,	,	O
hazard	NN	O
ratio=1.53	NN	O
(	(	O
1.00-2.34	JJ	O
)	)	O
)	)	O
.	.	O

This	DT	O
benefit	NN	O
increased	VBD	O
with	IN	O
2	CD	O
years	NNS	O
additional	JJ	O
follow-up	NN	O
(	(	O
P=0.006	NNP	O
,	,	O
hazard	NN	O
ratio=1.68	NN	O
(	(	O
1.16-2.44	JJ	O
)	)	O
)	)	O
,	,	O
with	IN	O
2-year	JJ	O
survival	NN	O
of	IN	O
5	CD	O
%	NN	O
and	CC	O
18	CD	O
%	NN	O
respectively	RB	O
.	.	O

Progression-free	JJ	O
survival	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
longer	RBR	O
for	IN	O
patients	NNS	O
receiving	VBG	O
marimastat	NNS	Pharmacological
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
P=0.009	NNP	O
,	,	O
hazard	NN	O
ratio=1.32	NN	O
(	(	O
1.07-1.63	JJ	O
)	)	O
)	)	O
.	.	O

Marimastat	NNP	Pharmacological
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
musculoskeletal	JJ	O
pain	NN	O
and	CC	O
inflammation	NN	O
.	.	O

Events	NNS	O
of	IN	O
anaemia	NN	O
,	,	O
abdominal	JJ	O
pain	NN	O
,	,	O
jaundice	NN	O
and	CC	O
weight	JJ	O
loss	NN	O
were	VBD	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
placebo	NN	O
arm	NN	O
.	.	O

This	DT	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
first	JJ	O
demonstrations	NNS	O
of	IN	O
a	DT	O
therapeutic	JJ	O
benefit	NN	O
for	IN	O
a	DT	O
matrix	JJ	O
metalloproteinase	NN	O
inhibitor	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

The	DT	O
greatest	JJS	O
benefit	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
received	VBN	O
chemotherapy	NN	O
.	.	O

A	DT	O
further	RB	O
randomised	VBN	O
study	NN	O
of	IN	O
marimastat	NN	Pharmacological
in	IN	O
these	DT	O
patients	NNS	O
is	VBZ	O
warranted	VBN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
pentoxifylline	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
recurrent	NN	O
aphthous	JJ	O
stomatitis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
pentoxifylline	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
recurrent	NN	O
aphthous	JJ	O
stomatitis	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
60-day	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
with	IN	O
a	DT	O
60-day	JJ	O
no	DT	O
treatment	NN	O
follow-up	RB	O
.	.	O

SETTING	VBG	O
An	DT	O
oral	JJ	O
medicine	NN	O
specialist	NN	O
referral	JJ	O
center	NN	O
in	IN	O
Manchester	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Forty-nine	JJ	O
volunteers	NNS	O
who	WP	O
passed	VBD	O
the	DT	O
initial	JJ	O
assessment	NN	O
for	IN	O
recurrent	NN	O
aphthous	JJ	O
stomatitis	NN	O
entered	VBD	O
a	DT	O
pretrial	JJ	O
phase	NN	O
in	IN	O
which	WDT	O
their	PRP$	O
eligibility	NN	O
for	IN	O
the	DT	O
trial	NN	O
phase	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

Sixteen	JJ	O
subjects	NNS	O
were	VBD	O
deemed	VBN	O
ineligible	JJ	O
,	,	O
and	CC	O
7	CD	O
failed	VBD	O
to	TO	O
attend	VB	O
or	CC	O
withdrew	VB	O
.	.	O

The	DT	O
remaining	VBG	O
26	CD	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
placebo	VB	O
or	CC	O
treatment	NN	O
.	.	O

Six	NNP	O
subjects	VBZ	O
withdrew	JJ	O
because	IN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
,	,	O
and	CC	O
1	CD	O
was	VBD	O
unavailable	JJ	O
for	IN	O
follow-up	NN	O
.	.	O

INTERVENTION	NNP	O
Pentoxifylline	NNP	Pharmacological
(	(	O
also	RB	O
called	VBN	O
oxpentifylline	NN	O
)	)	O
,	,	O
400	CD	O
mg	NN	O
3	CD	O
times	NNS	O
daily	RB	O
,	,	O
or	CC	O
matching	VBG	O
placebo	NN	Control
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
A	NNP	O
reduction	NN	O
in	IN	O
the	DT	O
median	JJ	O
pain	NN	O
score	NN	O
,	,	O
ulcer	JJ	O
size	NN	O
,	,	O
number	NN	O
of	IN	O
ulcers	NNS	O
,	,	O
or	CC	O
total	JJ	O
number	NN	O
of	IN	O
ulcer	JJ	O
episodes	NNS	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
taking	VBG	O
pentoxifylline	NN	Pharmacological
had	VBD	O
less	JJR	O
pain	NN	O
and	CC	O
reported	VBD	O
smaller	JJR	O
and	CC	O
fewer	JJR	O
ulcers	NNS	O
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

Patients	NNS	O
taking	VBG	O
placebo	NN	Control
reported	VBD	O
no	DT	O
improvement	NN	O
in	IN	O
these	DT	O
variables	NNS	O
.	.	O

Patients	NNS	O
taking	VBG	O
pentoxifylline	NN	Pharmacological
also	RB	O
reported	VBD	O
more	RBR	O
ulcer-free	JJ	O
days	NNS	O
than	IN	O
those	DT	O
taking	VBG	O
placebo	NN	Control
.	.	O

However	RB	O
,	,	O
the	DT	O
differences	NNS	O
were	VBD	O
small	JJ	O
and	CC	O
,	,	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
median	JJ	O
ulcer	NN	O
size	NN	O
(	(	O
P	NNP	O
=	NNP	O
.05	NNP	O
)	)	O
,	,	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
.	.	O

Adverse	JJ	O
effects	NNS	O
were	VBD	O
common	JJ	O
with	IN	O
pentoxifylline	NN	Pharmacological
,	,	O
but	CC	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
those	DT	O
experienced	VBN	O
by	IN	O
patients	NNS	O
taking	VBG	O
placebo	NN	Control
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
pentoxifylline	NN	Pharmacological
may	MD	O
have	VB	O
some	DT	O
benefit	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
recurrent	NN	O
aphthous	JJ	O
stomatitis	NN	O
,	,	O
the	DT	O
benefit	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

It	PRP	O
may	MD	O
have	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
unresponsive	JJ	O
to	TO	O
other	JJ	O
treatments	NNS	O
,	,	O
but	CC	O
can	MD	O
not	RB	O
yet	RB	O
be	VB	O
recommended	VBN	O
as	IN	O
a	DT	O
first-line	JJ	O
treatment	NN	O
.	.	O

Open	JJ	Surgical
flap	NN	Surgical
debridement	NN	Surgical
with	IN	Surgical
or	CC	Surgical
without	IN	Surgical
intentional	JJ	Surgical
cementum	NN	Surgical
removal	NN	Surgical
:	:	Surgical
a	DT	O
4-month	JJ	O
follow-up	NN	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
cementum	NN	Surgical
removal	NN	Surgical
on	IN	Surgical
periodontal	JJ	Surgical
repair	NN	Surgical
.	.	Surgical

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Forty	NNP	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
periodontitis	NN	O
and	CC	O
presenting	NN	O
,	,	O
at	IN	O
least	JJS	O
,	,	O
two	CD	O
proximal	JJ	O
sites	NNS	O
in	IN	O
anterior	JJ	O
teeth	NNS	O
(	(	O
upper	JJ	O
or	CC	O
lower	JJR	O
)	)	O
with	IN	O
probing	VBG	O
depth	JJ	O
>	NN	O
or	CC	O
=5	JJ	O
mm	NNS	O
were	VBD	O
selected	VBN	O
.	.	O

After	IN	O
oral	JJ	O
hygiene	NN	O
instructions	NNS	O
and	CC	O
ultrasonic	JJ	O
supragingival	NN	O
instrumentation	NN	O
,	,	O
the	DT	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
groups	NNS	O
:	:	O
CIC	NNP	Surgical
,	,	Surgical
scaled	VBD	Surgical
with	IN	Surgical
Gracey	NNP	Surgical
curettes	NNS	Surgical
;	:	Surgical
CIUS	NNP	Surgical
,	,	Surgical
scaled	VBD	Surgical
with	IN	Surgical
ultrasonic	JJ	Surgical
device	NN	Surgical
;	:	O
CDC	NNP	Surgical
,	,	Surgical
calculus	JJ	Surgical
deattachment	NN	Surgical
with	IN	Surgical
Gracey	NNP	Surgical
curettes	NNS	Surgical
and	CC	Surgical
brushing	VBG	Surgical
with	IN	Surgical
saline	JJ	Surgical
solution	NN	Surgical
;	:	O
and	CC	O
CDUS	NNP	Surgical
,	,	Surgical
calculus	JJ	Surgical
deattachment	NN	Surgical
with	IN	Surgical
ultrasonic	JJ	Surgical
device	NN	Surgical
and	CC	Surgical
brushing	VBG	Surgical
with	IN	Surgical
saline	JJ	Surgical
solution	NN	Surgical
.	.	O

Full-thickness	JJ	O
flaps	NNS	O
were	VBD	O
reflected	VBN	O
and	CC	O
the	DT	O
instrumentation	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
a	DT	O
clinical	JJ	O
microscope	NN	O
.	.	O

Probing	VBG	O
depth	NN	O
(	(	O
PD	NNP	O
)	)	O
,	,	O
relative	JJ	O
gingival	NN	O
margin	NN	O
level	NN	O
(	(	O
RGML	NNP	O
)	)	O
and	CC	O
relative	JJ	O
attachment	NN	O
level	NN	O
(	(	O
RAL	NNP	O
)	)	O
were	VBD	O
registered	VBN	O
at	IN	O
five	CD	O
experimental	JJ	O
periods	NNS	O
:	:	O
baseline	NN	O
and	CC	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
and	CC	O
120	CD	O
days	NNS	O
postoperative	JJ	O
.	.	O

RESULTS	VB	O
All	PDT	O
the	DT	O
approaches	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
markedly	RB	O
reduce	VB	O
the	DT	O
PD	NNP	O
values	NNS	O
from	IN	O
the	DT	O
baseline	NN	O
to	TO	O
the	DT	O
other	JJ	O
evaluation	NN	O
periods	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

The	DT	O
increase	NN	O
in	IN	O
RGML	NNP	O
values	NNS	O
was	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
the	DT	O
CDUS	NNP	Surgical
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
baseline	NN	O
and	CC	O
postoperative	JJ	O
values	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
for	IN	O
the	DT	O
RAL	NNP	O
changes	NNS	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
RAL	NNP	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
among	IN	O
the	DT	O
groups	NNS	O
CDC	NNP	Surgical
and	CC	O
CDUS	NNP	Surgical
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
conventional	JJ	Surgical
scaling	NN	Surgical
and	CC	Surgical
root	NN	Surgical
planing	NN	Surgical
and	CC	Surgical
the	DT	Surgical
calculus	JJ	Surgical
deattachment	NN	Surgical
were	VBD	O
effective	JJ	O
in	IN	O
reducing	VBG	O
the	DT	O
probing	VBG	O
depth	NN	O
values	NNS	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
instrumentation	NN	O
method	NN	O
.	.	O

Randomized	VBN	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
crossover	NN	O
study	NN	O
of	IN	O
methylphenidate	NN	Pharmacological
for	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
symptoms	NNS	O
in	IN	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
short-term	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
methylphenidate	NN	Pharmacological
(	(	Pharmacological
MPH	NNP	Pharmacological
)	)	Pharmacological
to	TO	O
treat	VB	O
attention-deficit/hyperactivity	JJ	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
symptoms	NNS	O
in	IN	O
an	DT	O
understudied	JJ	O
population	NN	O
of	IN	O
preschoolers	NNS	O
with	IN	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
or	CC	O
intellectual	JJ	O
disability	NN	O
(	(	O
ID	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Fourteen	NNP	O
preschoolers	NNS	O
with	IN	O
developmental	JJ	O
disorders	NNS	O
(	(	O
DD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
14	CD	O
;	:	O
PDD	NNP	O
,	,	O
n	JJ	O
=	VBP	O
12	CD	O
;	:	O
ID	NNP	O
,	,	O
n	JJ	O
=	NNP	O
2	CD	O
)	)	O
underwent	NN	O
MPH	NNP	Pharmacological
titration	NN	Pharmacological
in	IN	O
a	DT	O
single-blind	JJ	O
manner	NN	O
followed	VBN	O
by	IN	O
a	DT	O
4-week	JJ	O
double-blind	NN	O
crossover	NN	O
phase	NN	O
.	.	O

Each	DT	O
child	NN	O
was	VBD	O
administered	VBN	O
placebo	NN	Control
for	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
optimal	JJ	Pharmacological
dose	NN	Pharmacological
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
4	CD	O
(	(	O
th	NN	O
)	)	O
edition	NN	O
(	(	O
DSM-IV	NNP	O
)	)	O
ADHD	NNP	O
subscale	NN	O
of	IN	O
the	DT	O
Conners	NNP	O
'	POS	O
Parent	NN	O
Rating	VBG	O
Scale-Revised	JJ	O
(	(	O
CPRS-R-DSM-IV-ADHD	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
MPH	NNP	Pharmacological
improved	VBD	O
parent-rated	JJ	O
ADHD	NNP	O
symptoms	NNS	O
of	IN	O
the	DT	O
preschoolers	NNS	O
;	:	O
50	CD	O
%	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
responders	NNS	O
.	.	O

The	DT	O
CPRS-R-DSM-IV-ADHD	JJ	O
subscale	NN	O
was	VBD	O
significant	JJ	O
for	IN	O
the	DT	O
PDD	NNP	O
subgroup	NN	O
(	(	O
p	JJ	O
=	NN	O
0.005	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.97	CD	O
)	)	O
and	CC	O
marginally	RB	O
significant	JJ	O
for	IN	O
the	DT	O
entire	JJ	O
DD	NNP	O
sample	NN	O
(	(	O
p	JJ	O
=	NN	O
0.08	CD	O
,	,	O
Cohen	NNP	O
d	VBZ	O
=	NNP	O
0.50	CD	O
)	)	O
.	.	O

Half	NN	O
of	IN	O
the	DT	O
preschoolers	NNS	O
experienced	VBD	O
side	JJ	O
effects	NNS	O
with	IN	O
MPH	NNP	Pharmacological
,	,	O
including	VBG	O
reports	NNS	O
of	IN	O
increased	VBN	O
stereotypic	NN	O
behavior	NN	O
,	,	O
upset	JJ	O
stomach	NN	O
,	,	O
sleep-related	JJ	O
difficulties	NNS	O
,	,	O
and	CC	O
emotional	JJ	O
lability	NN	O
.	.	O

One	CD	O
child	NN	O
discontinued	VBN	O
during	IN	O
titration	NN	O
due	JJ	O
to	TO	O
side	VB	O
effects	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
predominant	JJ	O
direction	NN	O
of	IN	O
response	NN	O
in	IN	O
these	DT	O
preschoolers	NNS	O
with	IN	O
both	DT	O
ADHD	NNP	O
and	CC	O
PDD/ID	NNP	O
favored	VBD	O
MPH	NNP	Pharmacological
,	,	O
even	RB	O
though	IN	O
the	DT	O
response	NN	O
was	VBD	O
more	RBR	O
subtle	JJ	O
and	CC	O
variable	JJ	O
than	IN	O
in	IN	O
older	JJR	O
and	CC	O
typically	RB	O
developing	VBG	O
children	NNS	O
.	.	O

Due	NNP	O
to	TO	O
high	JJ	O
rates	NNS	O
of	IN	O
adverse	JJ	O
effects	NNS	O
,	,	O
preschoolers	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
.	.	O

Hysteroscopic	NNP	Surgical
transcervical	JJ	Surgical
endometrial	JJ	Surgical
resection	NN	Surgical
versus	IN	O
thermal	JJ	Surgical
destruction	NN	Surgical
for	IN	O
menorrhagia	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
on	IN	O
satisfaction	NN	O
rate	NN	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
satisfaction	NN	O
rate	NN	O
and	CC	O
the	DT	O
effectiveness	NN	O
of	IN	O
transcervical	JJ	Surgical
hysteroscopic	NN	Surgical
endometrial	JJ	Surgical
resection	NN	Surgical
and	CC	O
thermal	JJ	Surgical
destruction	NN	Surgical
of	IN	O
the	DT	O
endometrium	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
with	IN	O
2	CD	O
years	NNS	O
of	IN	O
follow-up	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
the	DT	O
Department	NNP	O
of	IN	O
Gynecology	NNP	O
of	IN	O
the	DT	O
University	NNP	O
of	IN	O
Naples	NNP	O
.	.	O

Eighty-two	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
affected	VBN	O
by	IN	O
menorrhagia	NN	O
that	WDT	O
was	VBD	O
unresponsive	JJ	O
to	TO	O
medical	JJ	O
treatment	NN	O
were	VBD	O
respectively	RB	O
randomized	VBN	O
to	TO	O
transcervical	JJ	Surgical
hysteroscopic	NN	Surgical
endometrial	JJ	Surgical
resection	NN	Surgical
or	CC	O
to	TO	O
thermal	JJ	Surgical
destruction	NN	Surgical
of	IN	Surgical
the	DT	Surgical
endometrium	NN	Surgical
.	.	O

Satisfaction	NN	O
rate	NN	O
,	,	O
operative	JJ	O
time	NN	O
,	,	O
discharge	NN	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
,	,	O
reintervention	NN	O
rate	NN	O
,	,	O
and	CC	O
resumption	NN	O
of	IN	O
normal	JJ	O
activity	NN	O
were	VBD	O
evaluated	VBN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
satisfaction	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
thermal	JJ	Surgical
destruction	NN	Surgical
group	NN	O
.	.	O

Operative	JJ	O
time	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
24	CD	O
+/-	JJ	O
4	CD	O
minutes	NNS	O
vs	JJ	O
37	CD	O
+/-	JJ	O
6	CD	O
minutes	NNS	O
)	)	O
.	.	O

Intraoperative	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
thermal	JJ	O
destruction	NN	O
group	NN	O
(	(	O
7.2	CD	O
+/-	JJ	O
2.8	CD	O
mL	NN	O
vs	NN	O
89	CD	O
+/-	JJ	O
38	CD	O
mL	NN	O
)	)	O
.	.	O

Reintervention	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
transcervical	JJ	Surgical
hysteroscopic	NN	Surgical
endometrial	JJ	Surgical
resection	NN	Surgical
group	NN	O
,	,	O
although	IN	O
postoperative	JJ	O
pain	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Discharge	NNP	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
,	,	O
and	CC	O
resumption	NN	O
of	IN	O
normal	JJ	O
activity	NN	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Thermal	NNP	Surgical
destruction	NN	Surgical
of	IN	Surgical
the	DT	Surgical
endometrium	NN	Surgical
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
menorrhagia	NN	O
should	MD	O
be	VB	O
considered	VBN	O
an	DT	O
effective	JJ	O
therapeutic	JJ	O
option	NN	O
because	IN	O
of	IN	O
its	PRP$	O
acceptability	NN	O
among	IN	O
patients	NNS	O
,	,	O
shorter	RB	O
operative	JJ	O
time	NN	O
,	,	O
and	CC	O
lower	JJR	O
blood	NN	O
loss	NN	O
.	.	O

Randomized	VBN	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
high-dose	JJ	O
4'-epi-doxorubicin	JJ	Pharmacological
+	NNP	O
cyclophosphamide	NN	Pharmacological
versus	IN	O
high-dose	JJ	O
4'-epi-doxorubicin	JJ	Pharmacological
+	NN	O
cisplatin	NN	Pharmacological
in	IN	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
extensive	JJ	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eleven	RB	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
extensive	JJ	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
with	IN	O
the	DT	O
aim	NN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerance	NN	O
of	IN	O
high-dose	JJ	Pharmacological
epirubicin	NN	Pharmacological
(	(	O
120	CD	O
mg/m2	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
either	DT	O
cyclophosphamide	NN	Pharmacological
(	(	O
800	CD	O
mg/m2	NN	O
;	:	O
arm	CC	O
1	CD	O
)	)	O
or	CC	O
cisplatin	NN	Pharmacological
(	(	O
60	CD	O
mg/m2	NN	O
;	:	O
arm	CC	O
2	CD	O
)	)	O
.	.	O

Ninety-six	JJ	O
patients	NNS	O
were	VBD	O
evaluable	JJ	O
for	IN	O
response	NN	O
and	CC	O
toxicity	NN	O
and	CC	O
additional	JJ	O
12	CD	O
patients	NNS	O
for	IN	O
toxicity	NN	O
only	RB	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
(	(	O
CR+PR	NNP	O
)	)	O
in	IN	O
arm	NN	O
1	CD	O
and	CC	O
2	CD	O
were	VBD	O
61.4	CD	O
(	(	O
27/44	CD	O
)	)	O
and	CC	O
67.3	CD	O
%	NN	O
(	(	O
35/52	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	O
duration	NN	O
of	IN	O
remission	NN	O
was	VBD	O
4.4	CD	O
months	NNS	O
(	(	O
arm	JJ	O
1	CD	O
)	)	O
and	CC	O
4.9	CD	O
months	NNS	O
(	(	O
arm	JJ	O
2	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
survival	NN	O
time	NN	O
was	VBD	O
6.6	CD	O
months	NNS	O
in	IN	O
arm	NN	O
1	CD	O
and	CC	O
7.7	CD	O
months	NNS	O
in	IN	O
arm	NN	O
2.	CD	O
WHO	NNP	O
grade	VBD	O
4	CD	O
toxicity	NN	O
was	VBD	O
encountered	VBN	O
in	IN	O
25.5	CD	O
and	CC	O
15.8	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
arm	JJ	O
1	CD	O
and	CC	O
2	CD	O
,	,	O
respectively	RB	O
.	.	O

One	CD	O
case	NN	O
of	IN	O
cardiotoxicity	NN	O
resulting	VBG	O
in	IN	O
the	DT	O
patient	NN	O
's	POS	O
death	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
arm	NN	O
1	CD	O
.	.	O

Both	DT	O
combinations	NNS	O
showed	VBD	O
considerable	JJ	O
antitumor	NN	O
activity	NN	O
.	.	O

Toxicity	NN	O
was	VBD	O
acceptable	JJ	O
.	.	O

Dalteparin	NNP	Pharmacological
low	JJ	O
molecular	JJ	O
weight	NN	O
heparin	NN	Pharmacological
(	(	O
LMWH	NNP	O
)	)	O
in	IN	O
ovarian	JJ	O
cancer	NN	O
:	:	O
a	DT	O
phase	NN	O
II	NNP	O
randomized	VBD	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
Low	NNP	O
molecular	JJ	O
weight	NN	O
heparin	NN	O
reduces	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
(	(	O
VTE	NNP	O
)	)	O
and	CC	O
may	MD	O
have	VB	O
antineoplastic	JJ	O
effects	NNS	O
by	IN	O
interfering	VBG	O
with	IN	O
angiogenesis	NN	O
and	CC	O
with	IN	O
tumor	NN	O
growth	NN	O
and	CC	O
metastasis	NN	O
.	.	O

A	DT	O
multicentre	JJ	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
was	VBD	O
done	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
antineoplastic	JJ	O
potential	NN	O
of	IN	O
dalteparin	NN	Pharmacological
in	IN	O
ovarian	JJ	O
cancer	NN	O
(	(	O
OC	NNP	O
)	)	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Women	NNP	O
with	IN	O
newly-diagnosed	JJ	O
epithelial	JJ	O
OC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
standard	JJ	Pharmacological
chemotherapy	NN	Pharmacological
(	(	Pharmacological
CT	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
one	CD	O
of	IN	O
3	CD	O
doses	NNS	O
of	IN	O
dalteparin	NN	Pharmacological
(	(	O
50	CD	O
IU/kg	NNP	O
,	,	O
100	CD	O
IU/kg	NNP	O
,	,	O
or	CC	O
150	CD	O
IU/kg	NNP	O
)	)	O
subcutaneously	RB	O
once	RB	O
daily	JJ	O
during	IN	O
the	DT	O
first	JJ	O
3	CD	O
of	IN	O
6	CD	O
cycles	NNS	O
of	IN	O
3-weekly	JJ	O
CT	NNP	O
.	.	O

Blood	NNP	O
was	VBD	O
drawn	VBN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
cycle	NN	O
for	IN	O
CA125	NNP	O
and	CC	O
,	,	O
in	IN	O
a	DT	O
substudy	NN	O
of	IN	O
randomized	JJ	O
patients	NNS	O
,	,	O
for	IN	O
markers	NNS	O
of	IN	O
coagulation	NN	O
activation	NN	O
and	CC	O
angiogenesis	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
tumor	JJ	O
response	NN	O
defined	VBN	O
by	IN	O
?	.	O
50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
serum	NN	O
CA125	NNP	O
from	IN	O
baseline	NN	O
sustained	VBN	O
for	IN	O
at	IN	O
least	JJS	O
28	CD	O
days	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
until	IN	O
the	DT	O
end	NN	O
of	IN	O
CT	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
study	NN	O
was	VBD	O
terminated	VBN	O
early	RB	O
due	JJ	O
to	TO	O
poor	JJ	O
recruitment	NN	O
.	.	O

Seventy-seven	JJ	O
women	NNS	O
were	VBD	O
evaluable	JJ	O
for	IN	O
the	DT	O
primary	JJ	O
outcome	NN	O
.	.	O

A	DT	O
50	CD	O
%	NN	O
drop	NN	O
in	IN	O
CA125	NNP	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
cycle	NN	O
3	CD	O
was	VBD	O
seen	VBN	O
in	IN	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
50	CD	O
IU/kg	NNP	O
group	NN	O
,	,	O
92	CD	O
%	NN	O
of	IN	O
the	DT	O
100	CD	O
IU/kg	NNP	O
group	NN	O
,	,	O
and	CC	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
150	CD	O
IU/kg	NNP	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
symptomatic	JJ	O
VTE	NNP	O
or	CC	O
major	JJ	O
bleeding	VBG	O
events	NNS	O
while	IN	O
on	IN	O
dalteparin	NN	O
.	.	O

Two	CD	O
patients	NNS	O
experienced	VBD	O
VTE	NNP	O
several	JJ	O
days	NNS	O
after	IN	O
discontinuing	VBG	O
study	JJ	O
drug	NN	O
.	.	O

Women	NNS	O
on	IN	O
dalteparin	NN	O
had	VBD	O
lower	JJR	O
levels	NNS	O
of	IN	O
D-dimer	NNP	O
and	CC	O
thrombin-antithrombin	NN	O
,	,	O
and	CC	O
higher	JJR	O
levels	NNS	O
of	IN	O
tissue	NN	O
factor	NN	O
pathway	NN	O
inhibitor	NN	O
,	,	O
relative	JJ	O
to	TO	O
baseline	VB	O
.	.	O

CONCLUSION	NNP	O
Dalteparin	NNP	O
is	VBZ	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
women	NNS	O
receiving	VBG	O
CT	NNP	O
for	IN	O
newly-diagnosed	JJ	O
epithelial	JJ	O
OC	NNP	O
.	.	O

A	DT	O
dose-response	JJ	O
effect	NN	O
was	VBD	O
not	RB	O
identified	VBN	O
.	.	O

The	DT	O
lack	NN	O
of	IN	O
control	NN	O
group	NN	O
precluded	VBD	O
any	DT	O
inference	NN	O
on	IN	O
the	DT	O
antineoplastic	JJ	O
effect	NN	O
of	IN	O
dalteparin	NN	O
.	.	O

Treatment	NN	O
of	IN	O
Wilms	NNP	O
'	POS	O
tumor	NN	O
.	.	O

Results	NNS	O
of	IN	O
the	DT	O
Third	NNP	O
National	NNP	O
Wilms	NNP	O
'	POS	O
Tumor	NNP	O
Study	NNP	O
.	.	O

The	DT	O
Third	NNP	O
National	NNP	O
Wilms	NNP	O
'	POS	O
Tumor	NNP	O
Study	NNP	O
sought	VBD	O
to	TO	O
reduce	VB	O
treatment	NN	O
for	IN	O
low-risk	JJ	O
patients	NNS	O
and	CC	O
find	VB	O
better	JJR	O
chemotherapy	NN	Pharmacological
for	IN	O
those	DT	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
relapse	NN	O
.	.	O

Eligible	JJ	O
patients	NNS	O
(	(	O
1439	CD	O
)	)	O
were	VBD	O
randomized	VBN	O
according	VBG	O
to	TO	O
stage	NN	O
(	(	O
I-IV	NNP	O
)	)	O
and	CC	O
histology	NN	O
(	(	O
favorable	JJ	O
[	NN	O
FH	NNP	O
]	NNP	O
or	CC	O
unfavorable	JJ	O
[	JJ	O
UH	NNP	O
]	NNP	O
)	)	O
,	,	O
and	CC	O
contributed	VBD	O
data	NNS	O
to	TO	O
survival	VB	O
and	CC	O
relapse-free	JJ	O
survival	NN	O
(	(	O
RFS	NNP	O
)	)	O
analyses	VBZ	O
.	.	O

Four-year	JJ	O
(	(	O
postnephrectomy	NN	O
)	)	O
survival	NN	O
percentages	NNS	O
and	CC	O
randomized	VBN	O
treatment	NN	O
regimens	NNS	O
for	IN	O
low-risk	JJ	O
patients	NNS	O
were	VBD	O
96.5	CD	O
%	NN	O
for	IN	O
607	CD	O
Stage	NNP	O
I/FH	NNP	O
patients	NNS	O
who	WP	O
received	VBD	O
dactinomycin	NN	Pharmacological
(	(	Pharmacological
Actinomycin	NNP	Pharmacological
D	NNP	Pharmacological
[	NNP	Pharmacological
AMD	NNP	Pharmacological
]	NNP	Pharmacological
,	,	O
Merck	NNP	O
Sharp	NNP	O
&	CC	O
Dohme	NNP	O
,	,	O
West	NNP	O
Point	NNP	O
,	,	O
PA	NNP	O
)	)	O
and	CC	O
vincristine	NN	Pharmacological
(	(	Pharmacological
VCR	NNP	Pharmacological
)	)	Pharmacological
for	IN	O
10	CD	O
weeks	NNS	O
versus	RB	O
6	CD	O
months	NNS	O
;	:	O
92.2	CD	O
%	NN	O
for	IN	O
278	CD	O
Stage	NNP	O
II/FH	NNP	O
patients	NNS	O
;	:	O
and	CC	O
86.9	CD	O
%	NN	O
for	IN	O
275	CD	O
Stage	NNP	O
III/FH	NNP	O
patients	NNS	O
who	WP	O
received	VBD	O
AMD	NNP	Pharmacological
+	NNP	Pharmacological
VCR	NNP	Pharmacological
+/-	JJ	Pharmacological
Adriamycin	NNP	Pharmacological
(	(	Pharmacological
ADR	NNP	Pharmacological
,	,	O
Adria	NNP	O
Laboratories	NNPS	O
,	,	O
Columbus	NNP	O
,	,	O
OH	NNP	O
)	)	O
for	IN	O
15	CD	O
months	NNS	O
.	.	O

Stage	NNP	O
II/FH	NNP	O
patients	NNS	O
also	RB	O
had	VBD	O
either	CC	O
zero	CD	O
or	CC	O
2000	CD	O
cGy	NN	O
irradiation	NN	O
(	(	O
RT	NNP	O
)	)	O
postoperatively	RB	O
and	CC	O
Stage	NNP	O
III/FH	NNP	O
patients	NNS	O
either	RB	O
1000	CD	O
or	CC	O
2000	CD	O
cGy	NN	O
.	.	O

Four-year	JJ	O
survival	NN	O
was	VBD	O
73.0	CD	O
%	NN	O
for	IN	O
279	CD	O
high-risk	JJ	O
patients	NNS	O
(	(	O
any	DT	O
Stage	NNP	O
IV	NNP	O
,	,	O
all	DT	O
UH	NNP	O
)	)	O
who	WP	O
received	VBD	O
postoperative	JJ	Physical
radiation	NN	Physical
therapy	NN	Physical
(	(	Physical
RT	NNP	Physical
)	)	Physical
and	CC	O
AMD	NNP	Pharmacological
+	NNP	Pharmacological
VCR	NNP	Pharmacological
+	NNP	Pharmacological
ADR	NNP	Pharmacological
+/-	JJ	Pharmacological
cyclophosphamide	NN	Pharmacological
(	(	Pharmacological
CPM	NNP	Pharmacological
)	)	Pharmacological
.	.	O

Statistical	JJ	O
analysis	NN	O
of	IN	O
survival	NN	O
and	CC	O
RFS	NNP	O
experience	NN	O
shows	VBZ	O
that	IN	O
the	DT	O
less	RBR	O
intensive	JJ	O
therapy	NN	O
does	VBZ	O
not	RB	O
worsen	VB	O
results	NNS	O
for	IN	O
low-risk	JJ	O
patients	NNS	O
and	CC	O
CPM	NNP	Pharmacological
does	VBZ	O
not	RB	O
benefit	VB	O
those	DT	O
at	IN	O
high	JJ	O
risk	NN	O
.	.	O

Can	MD	O
incentives	VB	Educational
undermine	JJ	O
intrinsic	JJ	O
motivation	NN	O
to	TO	O
participate	VB	O
in	IN	O
epidemiologic	JJ	O
surveys	NNS	O
?	.	O
Response	JJ	O
rates	NNS	O
to	TO	O
surveys	NNS	O
are	VBP	O
decreasing	VBG	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
use	NN	Educational
of	IN	Educational
lottery	JJ	Educational
tickets	NNS	Educational
as	IN	Educational
incentives	NNS	Educational
in	IN	O
an	DT	O
epidemiologic	JJ	O
control	NN	O
group	NN	O
.	.	O

A	DT	O
self-administered	JJ	O
questionnaire	NN	O
was	VBD	O
sent	VBN	O
to	TO	O
parents	NNS	O
in	IN	O
the	DT	O
municipality	NN	O
of	IN	O
Stockholm	NNP	O
,	,	O
Sweden	NNP	O
,	,	O
who	WP	O
were	VBD	O
to	TO	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
control	NN	O
group	NN	O
in	IN	O
a	DT	O
study	NN	O
addressing	VBG	O
stress	NN	O
in	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
cancer	NN	O
.	.	O

A	DT	O
stratified	JJ	O
random	JJ	O
sample	NN	O
of	IN	O
450	CD	O
parents	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
three	CD	O
incentive	JJ	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
no	DT	Control
incentive	NN	Control
;	:	O
(	(	O
b	NN	O
)	)	O
a	DT	O
promised	JJ	Educational
incentive	NN	Educational
of	IN	Educational
one	CD	Educational
lottery	NN	Educational
ticket	NN	Educational
to	TO	Educational
be	VB	Educational
received	VBN	Educational
upon	IN	Educational
reply	NN	Educational
;	:	O
(	(	O
c	NN	O
)	)	O
a	DT	O
promised	JJ	Educational
incentive	NN	Educational
of	IN	Educational
one	CD	Educational
lottery	NN	Educational
ticket	NN	Educational
to	TO	Educational
be	VB	Educational
received	VBN	Educational
upon	IN	Educational
reply	NN	Educational
and	CC	Educational
an	DT	Educational
additional	JJ	Educational
lottery	NN	Educational
ticket	NN	Educational
upon	IN	Educational
reply	NN	Educational
within	IN	Educational
1	CD	Educational
week	NN	Educational
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
across	IN	O
the	DT	O
three	CD	O
groups	NNS	O
was	VBD	O
65.3	CD	O
%	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
was	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
no	DT	Control
incentive	NN	Control
group	NN	Control
(	(	O
69.3	CD	O
%	NN	O
)	)	O
and	CC	O
lowest	JJS	O
in	IN	O
the	DT	O
one	CD	Educational
plus	CC	Educational
one	CD	Educational
lottery	NN	Educational
ticket	NN	Educational
group	NN	Educational
(	(	O
62.0	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
a	DT	O
survival	JJ	O
analysis	NN	O
,	,	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
response	NN	O
curves	NNS	O
was	VBD	O
significant	JJ	O
by	IN	O
the	DT	O
log-rank	JJ	O
test	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
with	IN	O
the	DT	O
no	DT	O
incentive	NN	O
group	NN	O
having	VBG	O
a	DT	O
shorter	JJR	O
time	NN	O
to	TO	O
response	NN	O
than	IN	O
the	DT	O
incentive	NN	Educational
group	NN	Educational
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
lottery	JJ	Educational
tickets	NNS	Educational
as	IN	O
incentives	NNS	O
to	TO	O
increase	VB	O
participation	NN	O
in	IN	O
a	DT	O
mail	NN	O
questionnaire	NN	O
among	IN	O
parents	NNS	O
may	MD	O
be	VB	O
less	RBR	O
valuable	JJ	O
or	CC	O
even	RB	O
harmful	JJ	O
.	.	O

Incentives	NNS	Educational
may	MD	O
undermine	VB	O
motivation	NN	O
in	IN	O
studies	NNS	O
in	IN	O
which	WDT	O
the	DT	O
intrinsic	JJ	O
motivation	NN	O
of	IN	O
the	DT	O
respondents	NNS	O
is	VBZ	O
already	RB	O
high	JJ	O
.	.	O

[	JJ	O
Long-term	JJ	O
effects	NNS	O
of	IN	O
7-year	JJ	O
growth	NN	Pharmacological
hormone	CD	Pharmacological
substitution	NN	Pharmacological
on	IN	O
bone	NN	O
metabolism	NN	O
,	,	O
bone	NN	O
density	NN	O
,	,	O
and	CC	O
bone	NN	O
quality	NN	O
in	IN	O
growth	NN	O
hormone-deficient	JJ	O
adults	NNS	O
]	FW	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
PURPOSE	NNP	O
Subnormal	NNP	O
bone	NN	O
mineral	NN	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
and	CC	O
increased	JJ	O
fracture	NN	O
risk	NN	O
are	VBP	O
described	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
growth	NN	O
hormone	NN	O
deficiency	NN	O
(	(	O
GHD	NNP	O
)	)	O
.	.	O

Growth	NNP	Pharmacological
hormone	NN	Pharmacological
(	(	Pharmacological
GH	NNP	Pharmacological
)	)	Pharmacological
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
have	VB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
bone	NN	O
in	IN	O
GHD	NNP	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
long-term	JJ	O
effects	NNS	O
of	IN	O
GH	NNP	Pharmacological
replacement	NN	Pharmacological
therapy	NN	Pharmacological
on	IN	O
bone	NN	O
metabolism	NN	O
,	,	O
BMD	NNP	O
,	,	O
and	CC	O
bone	NN	O
quality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
GHD	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
20	CD	O
adult	NN	O
patients	NNS	O
with	IN	O
GHD	NNP	O
(	(	O
eleven	JJ	O
male	NN	O
,	,	O
nine	CD	O
female	NN	O
,	,	O
mean	JJ	O
age	NN	O
42.5	CD	O
years	NNS	O
)	)	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
either	DT	O
GH	NNP	Pharmacological
or	CC	O
placebo	NN	Control
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.25	CD	O
U/kg	NNP	O
body	NN	O
weight/week	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
all	DT	O
patients	NNS	O
received	VBD	O
GH	NNP	Pharmacological
.	.	O

After	IN	O
a	DT	O
1-year	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
study	NN	O
the	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
another	DT	O
72	CD	O
months	NNS	O
in	IN	O
an	DT	O
open	JJ	O
study	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
compared	VBN	O
to	TO	O
20	CD	O
age-	JJ	O
und	JJ	O
sex-matched	JJ	O
healthy	JJ	O
controls	NNS	O
.	.	O

Bone	NNP	O
turnover	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
ICTP	NNP	O
(	(	O
type	NN	O
I	PRP	O
collagen	VBP	O
carboxyterminal	JJ	O
cross-linked	JJ	O
telopeptide	NN	O
)	)	O
as	IN	O
parameter	NN	O
of	IN	O
bone	NN	O
resorption	NN	O
and	CC	O
PICP	NNP	O
(	(	O
carboxyterminal	JJ	O
propeptide	NN	O
of	IN	O
type	NN	O
I	PRP	O
procollagen	VBP	O
)	)	O
as	IN	O
marker	NN	O
of	IN	O
bone	NN	O
formation	NN	O
.	.	O

BMD	NNP	O
was	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
lumbar	NN	O
spine	NN	O
by	IN	O
dual-photon	JJ	O
absorptiometry	NN	O
(	(	O
DPA	NNP	O
)	)	O
and	CC	O
at	IN	O
the	DT	O
forearm	NN	O
by	IN	O
single-photon	JJ	O
absorptiometry	NN	O
(	(	O
SPA	NNP	O
)	)	O
.	.	O

Apparent	JJ	O
phalangeal	NN	O
ultrasound	JJ	O
transmission	NN	O
velocity	NN	O
(	(	O
APU	NNP	O
)	)	O
was	VBD	O
assessed	VBN	O
as	IN	O
parameter	NN	O
of	IN	O
bone	NN	O
quality	NN	O
independent	JJ	O
of	IN	O
BMD	NNP	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
BMD	NNP	O
at	IN	O
both	DT	O
measuring	VBG	O
sites	NNS	O
was	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
GHD	NNP	O
than	IN	O
in	IN	O
healthy	JJ	O
controls	NNS	O
.	.	O

During	IN	O
the	DT	O
1st	CD	O
year	NN	O
of	IN	O
GH	NNP	O
replacement	NN	O
therapy	NN	O
BMD	NNP	O
decreased	VBD	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
increase	NN	O
in	IN	O
BMD	NNP	O
(	(	O
about	IN	O
12	CD	O
%	NN	O
)	)	O
up	RB	O
to	TO	O
60	CD	O
months	NNS	O
which	WDT	O
remained	VBD	O
unchanged	JJ	O
thereafter	RB	O
,	,	O
building	VBG	O
up	RP	O
a	DT	O
plateau	NN	O
.	.	O

After	IN	O
72	CD	O
months	NNS	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
patients	NNS	O
and	CC	O
the	DT	O
healthy	JJ	O
controls	NNS	O
could	MD	O
be	VB	O
detected	VBN	O
.	.	O

Concerning	VBG	O
parameters	NNS	O
of	IN	O
bone	NN	O
turnover	NN	O
,	,	O
first	RB	O
ICTP	NNP	O
as	IN	O
marker	NN	O
of	IN	O
bone	NN	O
resorption	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
,	,	O
later	RB	O
on	IN	O
the	DT	O
marker	NN	O
of	IN	O
bone	NN	O
formation	NN	O
increased	VBD	O
as	RB	O
well	RB	O
.	.	O

APU	NNP	O
decreased	VBD	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
,	,	O
but	CC	O
had	VBD	O
returned	VBN	O
to	TO	O
its	PRP$	O
baseline	NN	O
value	NN	O
after	IN	O
24	CD	O
months	NNS	O
and	CC	O
remained	VBD	O
unchanged	JJ	O
throughout	IN	O
the	DT	O
rest	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSION	NNP	O
BMD	NNP	O
is	VBZ	O
subnormal	JJ	O
in	IN	O
adults	NNS	O
with	IN	O
GHD	NNP	O
.	.	O

GH	NNP	Pharmacological
replacement	NN	O
therapy	NN	O
stimulates	VBZ	O
bone	CD	O
turnover	NN	O
in	IN	O
patients	NNS	O
with	IN	O
GHD	NNP	O
and	CC	O
in	IN	O
the	DT	O
long	JJ	O
term	NN	O
such	JJ	O
stimulation	NN	O
results	NNS	O
in	IN	O
an	DT	O
increased	JJ	O
BMD	NNP	O
.	.	O

Thereby	NNP	O
,	,	O
GH	NNP	Pharmacological
shows	VBZ	O
a	DT	O
triphasic	JJ	O
action	NN	O
on	IN	O
BMD	NNP	O
:	:	O
an	DT	O
initial	JJ	O
decrease	NN	O
in	IN	O
BMD	NNP	O
during	IN	O
the	DT	O
1st	CD	O
year	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
increase	NN	O
in	IN	O
BMD	NNP	O
with	IN	O
buildup	NN	O
of	IN	O
a	DT	O
stable	JJ	O
plateau	NN	O
after	IN	O
60	CD	O
months	NNS	O
.	.	O

The	DT	O
newly	RB	O
formed	VBN	O
bone	NN	O
seems	VBZ	O
to	TO	O
have	VB	O
normal	JJ	O
bone	NN	O
elasticity	NN	O
.	.	O

Prospective	JJ	O
randomized	VBN	O
evaluation	NN	O
of	IN	O
diode-laser	NN	O
and	CC	O
cryotherapy	NN	O
in	IN	O
prethreshold	JJ	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
study	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
indirect	JJ	O
diode	NN	O
laser	NN	O
photocoagulation	NN	O
and	CC	O
cryotherapy	NN	O
in	IN	O
prethreshold	JJ	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
(	(	O
ROP	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Thirty-six	JJ	O
eyes	NNS	O
of	IN	O
18	CD	O
premature	NN	O
infants	NNS	O
less	RBR	O
than	IN	O
34	CD	O
weeks	NNS	O
gestational	JJ	O
age	NN	O
and/or	NN	O
less	JJR	O
than	IN	O
1600	CD	O
g	JJ	O
birth	NN	O
weight	NN	O
with	IN	O
prethreshold	JJ	O
ROP	NNP	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
either	DT	O
indirect	JJ	Physical
laser	NN	Physical
photocoagulation	NN	Physical
or	CC	O
cryotherapy	NN	Physical
.	.	O

Prethreshold	NNP	O
ROP	NNP	O
was	VBD	O
defined	VBN	O
as	IN	O
any	DT	O
stage	NN	O
of	IN	O
ROP	NNP	O
in	IN	O
zone	NN	O
I	PRP	O
with	IN	O
plus	JJ	O
disease	NN	O
;	:	O
or	CC	O
stage	VB	O
3	CD	O
with	IN	O
three	CD	O
or	CC	O
more	JJR	O
contiguous	JJ	O
clock	NN	O
hours	NNS	O
or	CC	O
five	CD	O
or	CC	O
more	JJR	O
total	JJ	O
clock	NN	O
hours	NNS	O
of	IN	O
involvement	NN	O
of	IN	O
retina	NN	O
in	IN	O
zone	NN	O
II	NNP	O
with	IN	O
plus	JJ	O
disease	NN	O
but	CC	O
less	JJR	O
than	IN	O
threshold	JJ	O
disease	NN	O
.	.	O

Regression	NN	O
of	IN	O
the	DT	O
ROP	NNP	O
was	VBD	O
assessed	VBN	O
for	IN	O
a	DT	O
minimum	JJ	O
period	NN	O
of	IN	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Regression	NNP	O
of	IN	O
ROP	NNP	O
occurred	VBD	O
in	IN	O
all	DT	O
36	CD	O
eyes	NNS	O
(	(	O
100	CD	O
%	NN	O
)	)	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Excellent	JJ	O
results	NNS	O
are	VBP	O
achieved	VBN	O
if	IN	O
ROP	NNP	O
is	VBZ	O
treated	VBN	O
at	IN	O
the	DT	O
prethreshold	JJ	O
stage	NN	O
with	IN	O
both	DT	O
indirect	JJ	O
laser	NN	O
photocoagulation	NN	O
and	CC	O
cryotherapy	NN	O
.	.	O

Although	IN	O
laser	NN	O
has	VBZ	O
definite	VBN	O
advantages	NNS	O
,	,	O
cryotherapy	NN	O
can	MD	O
be	VB	O
considered	VBN	O
as	IN	O
an	DT	O
alternative	JJ	O
modality	NN	O
of	IN	O
treatment	NN	O
in	IN	O
developing	VBG	O
countries	NNS	O
due	JJ	O
to	TO	O
economic	JJ	O
reasons	NNS	O
.	.	O

Intraperitoneal	NNP	O
application	NN	O
of	IN	O
bupivacaine	NN	Pharmacological
plus	CC	O
morphine	NN	Pharmacological
for	IN	O
pain	NN	O
relief	NN	O
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Intraperitoneal	NNP	O
administration	NN	O
of	IN	O
a	DT	O
local	JJ	O
anaesthetic	NN	O
in	IN	O
combination	NN	O
with	IN	O
an	DT	O
opioid	NN	O
,	,	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
postoperative	JJ	O
pain	NN	O
,	,	O
has	VBZ	O
already	RB	O
been	VBN	O
reported	VBN	O
except	IN	O
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
at	IN	O
assessing	VBG	O
the	DT	O
analgesic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
intraperitoneal	JJ	O
administration	NN	O
of	IN	O
bupivacaine	NN	Pharmacological
and	CC	O
morphine	NN	Pharmacological
in	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

METHODS	NNP	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
,	,	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	JJ	O
manner	NN	O
,	,	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
injections	NNS	O
was	VBD	O
given	VBN	O
intraperitoneally	RB	O
.	.	O

There	EX	O
were	VBD	O
30	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
:	:	O
Group	NNP	O
1	CD	O
,	,	O
physiological	JJ	Pharmacological
saline	NN	Pharmacological
30	CD	O
mL	NN	O
;	:	O
Group	NNP	O
2	CD	O
,	,	O
bupivacaine	VBP	Pharmacological
0.25	CD	O
%	NN	O
30	CD	O
mL	NN	O
;	:	O
Group	NNP	O
3	CD	O
,	,	O
bupivacaine	VBP	Pharmacological
0.25	CD	O
%	NN	O
30	CD	O
mL	NN	O
plus	CC	Pharmacological
morphine	JJ	Pharmacological
2	CD	O
mg	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
Group	NNP	O
2	CD	O
received	VBD	O
2	CD	O
mg	NNS	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
morphine	NN	Pharmacological
in	IN	O
2	CD	O
mL	NNS	O
saline	NN	Pharmacological
,	,	O
and	CC	O
Groups	NNP	O
1	CD	O
and	CC	O
3	CD	O
,	,	O
2	CD	O
mL	NN	O
saline	NN	Pharmacological
intravenously	RB	O
.	.	O

Patients	NNS	O
'	POS	O
postoperative	JJ	O
pain	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
and	CC	O
a	DT	O
verbal	JJ	O
rating	NN	O
score	NN	O
.	.	O

The	DT	O
postoperative	JJ	O
analgesic	JJ	O
requirement	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
total	JJ	O
dose	NN	O
of	IN	O
metamizol	NN	O
administered	VBN	O
by	IN	O
an	DT	O
i.v	NN	O
.	.	O

patient-controlled	JJ	O
analgesia	NN	O
(	(	O
PCA	NNP	O
)	)	O
device	NN	O
.	.	O

Pain	NNP	O
,	,	O
vital	JJ	O
signs	NNS	O
,	,	O
supplemental	JJ	O
analgesic	JJ	O
consumption	NN	O
and	CC	O
side-effects	NNS	O
were	VBD	O
recorded	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
for	IN	O
24	CD	O
h.	JJ	O
RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
regarding	VBG	O
pain	NN	O
scores	NNS	O
(	(	O
at	IN	O
rest	NN	O
and	CC	O
coughing	VBG	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
except	IN	O
in	IN	O
the	DT	O
first	JJ	O
2	CD	O
h	NN	O
,	,	O
when	WRB	O
scores	NNS	O
were	VBD	O
lower	JJR	O
for	IN	O
patients	NNS	O
receiving	VBG	O
intraperitoneal	JJ	O
bupivacaine	NN	Pharmacological
plus	CC	O
i.v	NN	O
.	.	O

morphine	NN	Pharmacological
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Supplemental	JJ	O
consumption	NN	O
of	IN	O
metamizol	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
Group	NNP	O
3	CD	O
than	IN	O
in	IN	O
Group	NNP	O
1	CD	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
h	NN	O
after	IN	O
surgery	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
cumulative	JJ	O
doses	NNS	O
of	IN	O
metamizol	NN	O
were	VBD	O
also	RB	O
lower	JJR	O
in	IN	O
Group	NNP	O
2	CD	O
than	IN	O
in	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
3	CD	O
over	IN	O
the	DT	O
entire	JJ	O
study	NN	O
(	(	O
2025	CD	O
+/-	NN	O
1044	CD	O
mg	NN	O
vs.	FW	O
4925	CD	O
+/-	JJ	O
1238	CD	O
and	CC	O
4125	CD	O
+/-	JJ	O
1276mg	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
cholecystectomy	NN	O
,	,	O
the	DT	O
intraperitoneal	JJ	O
administration	NN	O
of	IN	O
morphine	JJ	Pharmacological
plus	CC	O
bupivacaine	JJ	Pharmacological
0.25	CD	O
%	NN	O
reduced	VBD	O
the	DT	O
analgesic	JJ	O
requirements	NNS	O
during	IN	O
the	DT	O
first	JJ	O
6	CD	O
postoperative	JJ	O
hours	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
intraperitoneal	JJ	O
bupivacaine	JJ	Pharmacological
0.25	CD	O
%	NN	O
and	CC	O
i.v	NN	O
.	.	O

morphine	NN	Pharmacological
was	VBD	O
more	RBR	O
effective	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
pain	NN	O
after	IN	O
laparoscopic	JJ	O
cholecystectomy	NN	O
.	.	O

Oxytocin	NNP	Pharmacological
increases	VBZ	O
retention	NN	O
of	IN	O
social	JJ	O
cognition	NN	O
in	IN	O
autism	NN	O
.	.	O

BACKGROUND	NNP	O
Oxytocin	NNP	Pharmacological
dysfunction	NN	O
might	MD	O
contribute	VB	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
social	JJ	O
deficits	NNS	O
in	IN	O
autism	NN	O
,	,	O
a	DT	O
core	NN	O
symptom	NN	O
domain	NN	O
and	CC	O
potential	JJ	O
target	NN	O
for	IN	O
intervention	NN	O
.	.	O

This	DT	O
study	NN	O
explored	VBD	O
the	DT	O
effect	NN	O
of	IN	O
intravenous	JJ	O
oxytocin	JJ	Pharmacological
administration	NN	O
on	IN	O
the	DT	O
retention	NN	O
of	IN	O
social	JJ	O
information	NN	O
in	IN	O
autism	NN	O
.	.	O

METHODS	NNP	O
Oxytocin	NNP	Pharmacological
and	CC	O
placebo	NN	Control
challenges	NNS	O
were	VBD	O
administered	VBN	O
to	TO	O
15	CD	O
adult	NN	O
subjects	NNS	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
's	POS	O
disorder	NN	O
,	,	O
and	CC	O
comprehension	NN	O
of	IN	O
affective	JJ	O
speech	NN	O
(	(	O
happy	JJ	O
,	,	O
indifferent	JJ	O
,	,	O
angry	JJ	O
,	,	O
and	CC	O
sad	NN	O
)	)	O
in	IN	O
neutral	JJ	O
content	NN	O
sentences	NNS	O
was	VBD	O
tested	VBN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
subjects	VBZ	O
showed	VBD	O
improvements	NNS	O
in	IN	O
affective	JJ	O
speech	NN	O
comprehension	NN	O
from	IN	O
pre-	JJ	O
to	TO	O
post-infusion	NN	O
;	:	O
however	RB	O
,	,	O
whereas	NNS	O
those	DT	O
who	WP	O
received	VBD	O
placebo	NN	Control
first	RB	O
tended	VBD	O
to	TO	O
revert	VB	O
to	TO	O
baseline	VB	O
after	IN	O
a	DT	O
delay	NN	O
,	,	O
those	DT	O
who	WP	O
received	VBD	O
oxytocin	PRP	O
first	RB	O
retained	VBD	O
the	DT	O
ability	NN	O
to	TO	O
accurately	RB	O
assign	VB	O
emotional	JJ	O
significance	NN	O
to	TO	O
speech	VB	O
intonation	NN	O
on	IN	O
the	DT	O
speech	NN	O
comprehension	NN	O
task	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
studies	NNS	O
linking	VBG	O
oxytocin	NN	Pharmacological
to	TO	O
social	JJ	O
recognition	NN	O
in	IN	O
rodents	NNS	O
as	RB	O
well	RB	O
as	IN	O
studies	NNS	O
linking	VBG	O
oxytocin	NN	O
to	TO	O
prosocial	JJ	O
behavior	NN	O
in	IN	O
humans	NNS	O
and	CC	O
suggest	VBP	O
that	IN	O
oxytocin	NN	O
might	MD	O
facilitate	VB	O
social	JJ	O
information	NN	O
processing	NN	O
in	IN	O
those	DT	O
with	IN	O
autism	NN	O
.	.	O

These	DT	O
findings	NNS	O
also	RB	O
provide	VBP	O
preliminary	JJ	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
oxytocin	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

Effects	NNS	O
of	IN	O
insufficient	JJ	Physical
sleep	NN	Physical
on	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
:	:	O
a	DT	O
24-h	JJ	O
study	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
acute	JJ	O
sleep	JJ	O
deprivation	NN	O
during	IN	O
the	DT	O
first	JJ	O
part	NN	O
of	IN	O
the	DT	O
night	NN	O
on	IN	O
24-h	JJ	Physical
blood	NN	Physical
pressure	NN	Physical
monitoring	NN	Physical
(	(	O
ABPM	NNP	O
)	)	O
was	VBD	O
studied	VBN	O
in	IN	O
36	CD	O
never-treated	JJ	O
mild	NN	O
to	TO	O
moderate	VB	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

According	VBG	O
to	TO	O
a	DT	O
crossover	NN	O
design	NN	O
,	,	O
they	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
have	VB	O
either	DT	O
sleep	JJ	Physical
deprivation	NN	Physical
or	CC	O
a	DT	O
full	JJ	Physical
night	NN	Physical
's	POS	Physical
sleep	NN	Physical
1	CD	O
week	NN	O
apart	RB	O
,	,	O
during	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
monitored	VBN	O
with	IN	O
ABPM	NNP	O
.	.	O

Urine	NNP	O
samples	NNS	O
for	IN	O
analysis	NN	O
of	IN	O
nocturnal	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
norepinephrine	NN	O
were	VBD	O
collected	VBN	O
.	.	O

During	IN	O
the	DT	O
sleep-deprivation	JJ	Physical
day	NN	O
,	,	O
both	DT	O
mean	JJ	O
24-h	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
mean	JJ	O
24-h	JJ	O
heart	NN	O
rate	NN	O
were	VBD	O
higher	JJR	O
in	IN	O
comparison	NN	O
with	IN	O
those	DT	O
recorded	VBN	O
during	IN	O
the	DT	O
routine	JJ	O
workday	NN	O
,	,	O
the	DT	O
difference	NN	O
being	VBG	O
more	RBR	O
pronounced	JJ	O
during	IN	O
the	DT	O
nighttime	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Urinary	JJ	O
excretion	NN	O
of	IN	O
norepinephrine	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
at	IN	O
night	NN	O
during	IN	O
sleep	JJ	Physical
deprivation	NN	Physical
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Blood	NNP	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
significantly	RB	O
increased	VBN	O
in	IN	O
the	DT	O
morning	NN	O
after	IN	O
a	DT	O
sleep-insufficient	JJ	Physical
night	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
lack	NN	O
of	IN	O
sleep	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
may	MD	O
increase	VB	O
sympathetic	JJ	O
nervous	JJ	O
activity	NN	O
during	IN	O
the	DT	O
night	NN	O
and	CC	O
the	DT	O
following	JJ	O
morning	NN	O
,	,	O
leading	VBG	O
to	TO	O
increased	VBN	O
blood	NN	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
.	.	O

This	DT	O
situation	NN	O
might	MD	O
represent	VB	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
both	DT	O
target	NN	O
organ	JJ	O
damage	NN	O
and	CC	O
acute	JJ	O
cardiovascular	JJ	O
diseases	NNS	O
.	.	O

Randomized	VBN	O
comparative	JJ	O
study	NN	O
of	IN	O
tegafur/uracil	NN	Pharmacological
and	CC	Pharmacological
oral	JJ	Pharmacological
leucovorin	NN	Pharmacological
versus	IN	Pharmacological
parenteral	JJ	Pharmacological
fluorouracil	NN	Pharmacological
and	CC	Pharmacological
leucovorin	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
metastatic	JJ	O
colorectal	NN	O
cancer	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
phase	NN	O
III	NNP	O
study	NN	O
compared	VBN	O
the	DT	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TTP	NNP	O
)	)	O
of	IN	O
an	DT	O
oral	JJ	O
regimen	NNS	O
of	IN	O
dihydropyrimidine	JJ	Pharmacological
dehydrogenase	NN	Pharmacological
inhibitory	NN	Pharmacological
fluoropyrimidine	NN	Pharmacological
composed	VBN	O
of	IN	O
a	DT	O
fixed	JJ	O
combination	NN	O
of	IN	O
tegafur	NN	Pharmacological
and	CC	Pharmacological
uracil	NN	Pharmacological
in	IN	O
a	DT	O
1:4	CD	O
molar	JJ	O
ratio	NN	O
(	(	O
UFT	NNP	O
)	)	O
and	CC	O
leucovorin	$	Pharmacological
(	(	O
LV	NNP	O
)	)	O
to	TO	O
intravenous	JJ	Pharmacological
(	(	Pharmacological
IV	NNP	Pharmacological
)	)	Pharmacological
fluorouracil	NN	Pharmacological
(	(	O
5-FU	JJ	O
)	)	O
and	CC	Pharmacological
LV	NNP	Pharmacological
in	IN	O
previously	RB	O
untreated	VBN	O
metastatic	JJ	O
colorectal	NN	O
carcinoma	NN	O
(	(	O
CRC	NNP	O
)	)	O
patients	NNS	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
survival	JJ	O
,	,	O
tumor	JJ	O
response	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
May	NNP	O
1996	CD	O
and	CC	O
July	NNP	O
1997	CD	O
,	,	O
380	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
UFT	NNP	Pharmacological
(	(	O
300	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
and	CC	O
LV	NNP	Pharmacological
(	(	O
90	CD	O
mg/d	NN	O
)	)	O
,	,	O
administered	VBN	O
for	IN	O
28	CD	O
days	NNS	O
every	DT	O
35	CD	O
days	NNS	O
,	,	O
or	CC	O
5-FU	JJ	Pharmacological
(	(	O
425	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
and	CC	O
LV	NNP	Pharmacological
(	(	O
20	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
,	,	O
given	VBN	O
IV	NNP	O
for	IN	O
5	CD	O
days	NNS	O
every	DT	O
35	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
TTP	NNP	O
was	VBD	O
observed	VBN	O
between	IN	O
treatments	NNS	O
.	.	O

With	IN	O
320	CD	O
events	NNS	O
assessed	VBN	O
,	,	O
the	DT	O
median	JJ	O
TTP	NNP	O
was	VBD	O
3.4	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
Confidence	NNP	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
2.6	CD	O
to	TO	O
3.8	CD	O
)	)	O
on	IN	O
UFT/LV	NNP	O
and	CC	O
3.3	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
2.5	CD	O
to	TO	O
3.7	CD	O
)	)	O
on	IN	O
5-FU/LV	JJ	O
(	(	O
P	NNP	O
=.591	NNP	O
,	,	O
stratified	VBD	O
log-rank	JJ	O
test	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
survival	NN	O
,	,	O
tumor	NN	O
response	NN	O
,	,	O
duration	NN	O
of	IN	O
response	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
response	NN	O
.	.	O

Substantial	NNP	O
safety	NN	O
benefits	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
UFT/LV	NNP	O
.	.	O

They	PRP	O
experienced	VBD	O
significantly	RB	O
less	JJR	O
stomatitis/mucositis	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
myelosuppression	NN	O
,	,	O
resulting	VBG	O
in	IN	O
fewer	JJR	O
episodes	NNS	O
of	IN	O
febrile	JJ	O
neutropenia	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
and	CC	O
less	RBR	O
documented	JJ	O
infection	NN	O
(	(	O
P	NNP	O
=.04	NNP	O
)	)	O
.	.	O

Concomitant	JJ	O
medication	NN	O
usage	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
on	IN	O
5-FU/LV	JJ	O
(	(	O
P	NNP	O
=.010	NNP	O
)	)	O
.	.	O

With	IN	O
respect	NN	O
to	TO	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
after	IN	O
correcting	VBG	O
for	IN	O
baseline	NN	O
imbalances	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatments	NNS	O
for	IN	O
any	DT	O
scale	NN	O
,	,	O
except	IN	O
diarrhea	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
oral	JJ	O
UFT/LV	NNP	O
regimen	NNS	O
failed	VBD	O
to	TO	O
achieve	VB	O
improved	JJ	O
TTP	NNP	O
;	:	O
however	RB	O
,	,	O
the	DT	O
study	NN	O
confirms	VBZ	O
significant	JJ	O
safety	NN	O
improvements	NNS	O
compared	VBN	O
with	IN	O
bolus	JJ	O
IV	NNP	O
5-FU/LV	NN	O
for	IN	O
the	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
metastatic	JJ	O
CRC	NNP	O
.	.	O

Interferential	JJ	Physical
therapy	NN	Physical
electrode	NN	Physical
placement	NN	Physical
technique	NN	Physical
in	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
a	DT	O
preliminary	JJ	O
investigation	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
interferential	JJ	Physical
therapy	NN	Physical
(	(	Physical
IFT	NNP	Physical
)	)	Physical
electrode	VBP	Physical
placement	NN	Physical
technique	NN	Physical
compared	VBN	O
with	IN	O
a	DT	O
control	NN	Control
treatment	NN	Control
in	IN	O
subjects	NNS	O
with	IN	O
acute	NN	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
LBP	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single-blind	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
with	IN	O
a	DT	O
3-month	JJ	O
follow-up	NN	O
.	.	O

SETTING	NN	O
Outpatient	NNP	O
physiotherapy	NN	O
departments	NNS	O
in	IN	O
hospital	NN	O
and	CC	O
university	NN	O
settings	NNS	O
.	.	O

PATIENTS	VB	O
A	DT	O
random	JJ	O
sample	NN	O
of	IN	O
60	CD	O
eligible	JJ	O
patients	NNS	O
with	IN	O
back	JJ	O
pain	NN	O
(	(	O
28	CD	O
men	NNS	O
,	,	O
32	CD	O
women	NNS	O
)	)	O
were	VBD	O
recruited	VBN	O
by	IN	O
general	JJ	O
practitioners	NNS	O
and	CC	O
self-referral	JJ	O
for	IN	O
physiotherapy	NN	O
treatment	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
.	.	O

INTERVENTIONS	NNP	O
(	(	O
1	CD	O
)	)	O
IFT	NNP	Pharmacological
painful	JJ	Pharmacological
area	NN	Pharmacological
and	CC	Pharmacological
The	DT	Pharmacological
Back	NNP	Pharmacological
Book	NNP	Pharmacological
,	,	O
(	(	O
2	CD	O
)	)	O
IFT	NNP	Physical
spinal	JJ	Physical
nerve	NN	Physical
and	CC	Pharmacological
The	DT	Physical
Back	NNP	Physical
Book	NNP	Physical
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
Control	NN	Control
,	,	Control
The	DT	Control
Back	NNP	Control
Book	NNP	Control
only	RB	O
.	.	O

Standardized	VBN	O
IFT	NNP	Pharmacological
stimulation	NN	O
parameters	NNS	O
were	VBD	O
used	VBN	O
:	:	O
carrier	NN	O
frequency	NN	O
3.85	CD	O
kHz	NN	O
;	:	O
140	CD	O
Hz	NNP	O
constant	NN	O
;	:	O
pulse	JJ	O
duration	NN	O
130	CD	O
micros	NN	O
;	:	O
30	CD	O
minutes	NNS	O
'	POS	O
duration	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Pain	NNP	O
Rating	NNP	O
Index	NNP	O
,	,	O
Roland-Morris	NNP	O
Disability	NNP	O
Questionnaire	NNP	O
(	(	O
RMDQ	NNP	O
)	)	O
,	,	O
and	CC	O
EuroQol	NNP	O
were	VBD	O
completed	VBN	O
by	IN	O
subjects	NNS	O
pretreatment	JJ	O
,	,	O
at	IN	O
discharge	NN	O
,	,	O
and	CC	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
All	NNP	O
groups	NNS	O
had	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
all	DT	O
outcomes	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

Subjects	NNS	O
managed	VBN	O
by	IN	O
IFT	NNP	O
spinal	JJ	O
nerve	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
displayed	VBD	O
both	DT	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
.030	NNP	O
)	)	O
and	CC	O
clinically	RB	O
meaningful	JJ	O
reduction	NN	O
in	IN	O
functional	JJ	O
disability	NN	O
(	(	O
RMDQ	NNP	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
management	NN	O
via	IN	O
IFT	NNP	O
painful	JJ	O
area	NN	O
and	CC	O
The	DT	O
Back	NNP	O
Book	NNP	O
combined	VBD	O
or	CC	O
The	DT	O
Back	JJ	O
Book	NNP	O
alone	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
showed	VBD	O
that	IN	O
IFT	NNP	Physical
electrode	FW	Physical
placement	NN	Physical
technique	NN	Physical
affects	VBZ	O
LBP-specific	JJ	O
functional	JJ	O
disability	NN	O
,	,	O
providing	VBG	O
preliminary	JJ	O
implications	NNS	O
for	IN	O
future	JJ	O
clinical	JJ	O
studies	NNS	O
.	.	O

Ganitumab	NNP	Pharmacological
with	IN	O
either	DT	O
exemestane	NN	Pharmacological
or	CC	O
fulvestrant	NN	Pharmacological
for	IN	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
advanced	JJ	O
,	,	O
hormone-receptor-positive	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomised	JJ	O
,	,	O
controlled	VBN	O
,	,	O
double-blind	NN	O
,	,	O
phase	NN	O
2	CD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Insulin-like	JJ	O
growth	NN	O
factors	NNS	O
(	(	O
IGF-1	JJ	O
and	CC	O
IGF-2	NNP	O
)	)	O
bind	NN	O
to	TO	O
the	DT	O
IGF-1	NNP	O
receptor	NN	O
(	(	O
IGF-1R	NNP	O
)	)	O
,	,	O
increasing	VBG	O
cell	NN	O
proliferation	NN	O
and	CC	O
survival	NN	O
.	.	O

Ganitumab	NNP	Pharmacological
is	VBZ	O
a	DT	O
monoclonal	JJ	O
IgG1	NNP	O
antibody	NN	O
that	WDT	O
blocks	VBZ	O
IGF-1R	NNP	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
adding	VBG	O
ganitumab	NN	O
to	TO	O
endocrine	VB	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
hormone-receptor-positive	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
did	VBD	O
this	DT	O
phase	NN	O
2	CD	O
trial	NN	O
in	IN	O
outpatient	JJ	O
clinics	NNS	O
and	CC	O
hospitals	NNS	O
.	.	O

We	PRP	O
enrolled	VBD	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
hormone-receptor-positive	JJ	O
,	,	O
locally	RB	O
advanced	VBD	O
or	CC	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
previously	RB	O
treated	VBN	O
with	IN	O
endocrine	JJ	O
treatment	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
(	(	O
2:1	CD	O
)	)	O
with	IN	O
a	DT	O
central	JJ	O
randomisation	NN	O
schedule	NN	O
to	TO	O
receive	VB	O
intravenous	JJ	Pharmacological
ganitumab	NNS	Pharmacological
12	CD	O
mg	NNS	O
per	IN	O
kg	NN	O
bodyweight	NN	O
or	CC	O
placebo	NN	Control
in	IN	O
combination	NN	O
with	IN	O
open-label	JJ	Physical
intramuscular	JJ	Physical
fulvestrant	NN	Pharmacological
(	(	O
500	CD	O
mg	NN	O
on	IN	O
day	NN	O
1	CD	O
,	,	O
then	RB	O
250	CD	O
mg	NNS	O
on	IN	O
days	NNS	O
15	CD	O
,	,	O
29	CD	O
,	,	O
and	CC	O
every	DT	O
28	CD	O
days	NNS	O
)	)	O
or	CC	O
oral	JJ	O
exemestane	NN	Pharmacological
(	(	O
25	CD	O
mg	NN	O
once	RB	O
daily	RB	O
)	)	O
on	IN	O
a	DT	O
28-day	JJ	O
cycle	NN	O
.	.	O

Patients	NNS	O
,	,	O
investigators	NNS	O
,	,	O
study	NN	O
monitors	NNS	O
,	,	O
and	CC	O
the	DT	O
sponsor	JJ	O
staff	NN	O
were	VBD	O
masked	VBN	O
to	TO	O
treatment	NN	O
allocation	NN	O
.	.	O

Response	NNP	O
was	VBD	O
assessed	VBN	O
every	DT	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
median	JJ	O
progression-free	JJ	O
survival	NN	O
in	IN	O
the	DT	O
intention-to-treat	JJ	O
population	NN	O
.	.	O

We	PRP	O
analysed	VBD	O
overall	JJ	O
survival	NN	O
as	IN	O
one	CD	O
of	IN	O
our	PRP$	O
secondary	JJ	O
endpoints	NNS	O
.	.	O

The	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00626106	NNP	O
.	.	O

FINDINGS	NNP	O
We	PRP	O
screened	VBD	O
189	CD	O
patients	NNS	O
and	CC	O
enrolled	VBD	O
156	CD	O
(	(	O
106	CD	O
in	IN	O
the	DT	O
ganitumab	NN	Pharmacological
group	NN	O
and	CC	O
50	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
)	)	O
.	.	O

Median	JJ	O
progression-free	JJ	O
survival	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
ganitumab	NN	Pharmacological
and	CC	O
placebo	NN	O
groups	NNS	O
(	(	O
3?9	CD	O
months	NNS	O
,	,	O
80	CD	O
%	NN	O
CI	NNP	O
3?6-5?3	CD	O
vs	NN	O
5?7	CD	O
months	NNS	O
,	,	O
4?4-7?4	JJ	O
;	:	O
hazard	PRP$	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
1?17	CD	O
,	,	O
80	CD	O
%	NN	O
CI	NNP	O
0?91-1?50	CD	O
;	:	O
p=0?44	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
overall	JJ	O
survival	NN	O
was	VBD	O
worse	RBR	O
in	IN	O
the	DT	O
the	DT	O
ganitumab	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
HR	NNP	O
1?78	CD	O
,	,	O
80	CD	O
%	NN	O
CI	NNP	O
1?27-2?50	CD	O
;	:	O
p=0?025	NN	O
)	)	O
.	.	O

With	IN	O
the	DT	O
exception	NN	O
of	IN	O
hyperglycaemia	NN	O
,	,	O
adverse	JJ	O
events	NNS	O
were	VBD	O
generally	RB	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
grade	NN	O
3	CD	O
or	CC	O
higher	JJR	O
adverse	JJ	O
event	NN	O
was	VBD	O
neutropenia-reported	JJ	O
by	IN	O
six	CD	O
of	IN	O
106	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
ganitumab	NN	O
group	NN	O
and	CC	O
one	CD	O
of	IN	O
49	CD	O
(	(	O
2	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Hyperglycaemia	NNP	O
was	VBD	O
reported	VBN	O
by	IN	O
12	CD	O
of	IN	O
106	CD	O
(	(	O
11	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
ganitumab	NN	O
group	NN	O
(	(	O
with	IN	O
six	CD	O
patients	NNS	O
having	VBG	O
grade	JJ	O
3	CD	O
or	CC	O
4	CD	O
hyperglycaemia	NN	O
)	)	O
and	CC	O
none	NN	O
of	IN	O
49	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Serious	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
by	IN	O
27	CD	O
of	IN	O
106	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
ganitumab	NN	O
group	NN	O
and	CC	O
nine	CD	O
of	IN	O
49	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

INTERPRETATION	NNP	O
Addition	NNP	O
of	IN	O
ganitumab	NN	O
to	TO	O
endocrine	VB	O
treatment	NN	O
in	IN	O
women	NNS	O
with	IN	O
previously	RB	O
treated	VBN	O
hormone-receptor-positive	JJ	O
locally	RB	O
advanced	VBD	O
or	CC	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
did	VBD	O
not	RB	O
improve	VB	O
outcomes	RB	O
.	.	O

Our	PRP$	O
results	NNS	O
do	VBP	O
not	RB	O
support	VB	O
further	RBR	O
study	NN	O
of	IN	O
ganitumab	NN	O
in	IN	O
this	DT	O
subgroup	NN	O
of	IN	O
patients	NNS	O
.	.	O

FUNDING	NN	O
Amgen	NNP	O
.	.	O

Bradykinin-induced	JJ	O
cough	NN	O
reflex	NN	O
markedly	RB	O
increases	VBZ	O
in	IN	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
captopril	NN	O
and	CC	O
enalapril	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
angiotensin	NN	Pharmacological
converting	VBG	Pharmacological
enzyme	NN	Pharmacological
(	(	Pharmacological
ACE	NNP	Pharmacological
)	)	Pharmacological
inhibitors	NNS	Pharmacological
on	IN	O
cough	NN	Pharmacological
responses	NNS	Pharmacological
to	TO	Pharmacological
bradykinin	VB	Pharmacological
(	(	Pharmacological
BK	NNP	Pharmacological
)	)	Pharmacological
,	,	O
substance	NN	Pharmacological
P	NNP	Pharmacological
(	(	Pharmacological
SP	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
citric	JJ	Pharmacological
acid	NN	Pharmacological
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
random	NN	O
study	NN	O
on	IN	O
10	CD	O
hypertensive	JJ	O
patients	NNS	O
receiving	VBG	O
ACE	NNP	Pharmacological
inhibitors	NNS	Pharmacological
.	.	O

Of	IN	O
these	DT	O
patients	NNS	O
,	,	O
five	CD	O
had	VBD	O
reported	VBN	O
cough	NN	O
with	IN	O
ACE	NNP	Pharmacological
inhibitors	NNS	Pharmacological
.	.	O

Cough	NNP	O
responses	VBZ	O
to	TO	O
citric	VB	O
acid	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
cough	NN	O
,	,	O
and	CC	O
SP	NNP	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

BK	NNP	Pharmacological
caused	VBD	O
cough	NN	O
at	IN	O
13.4	CD	O
+/-	JJ	O
1.2	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
5	CD	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	Pharmacological
inhibitors	NNS	Pharmacological
,	,	O
but	CC	O
it	PRP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
at	IN	O
concentrations	NNS	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
other	JJ	O
5	CD	O
patients	NNS	O
.	.	O

One	CD	O
month	NN	O
after	IN	O
the	DT	O
withdrawal	NN	O
of	IN	O
ACE	NNP	O
inhibitors	NNS	O
,	,	O
5	CD	O
patients	NNS	O
were	VBD	O
free	JJ	O
from	IN	O
cough	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
BK	NNP	O
did	VBD	O
not	RB	O
cause	VB	O
cough	NN	O
up	RB	O
to	TO	O
10	CD	O
(	(	O
-5	NN	O
)	)	O
M	NNP	O
in	IN	O
these	DT	O
patients	NNS	O
,	,	O
except	IN	O
for	IN	O
one	CD	O
who	WP	O
coughed	VBD	O
at	IN	O
10	CD	O
(	(	O
-9	NN	O
)	)	O
M	NNP	O
,	,	O
without	IN	O
changes	NNS	O
in	IN	O
responses	NNS	O
to	TO	O
citric	VB	O
acid	NN	O
.	.	O

BK	NNP	O
caused	VBD	O
cough	NN	O
at	IN	O
14.3	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
although	IN	O
BK1-7	NNP	O
,	,	O
a	DT	O
major	JJ	O
metabolite	NN	O
of	IN	O
BK	NNP	O
by	IN	O
ACE	NNP	O
,	,	O
caused	VBD	O
cough	NN	O
at	IN	O
5.7	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
-log	NNP	O
M	NNP	O
)	)	O
in	IN	O
another	DT	O
3	CD	O
patients	NNS	O
with	IN	O
cough	NN	O
associated	VBN	O
with	IN	O
ACE	NNP	O
inhibitor	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
impaired	JJ	O
metabolism	NN	O
of	IN	O
BK	NNP	O
induced	VBN	O
by	IN	O
ACE	NNP	O
inhibitors	NNS	O
may	MD	O
relate	VB	O
to	TO	O
the	DT	O
manifestation	NN	O
of	IN	O
cough	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
receiving	VBG	O
ACE	NNP	O
inhibitors	NNS	O
.	.	O

Long-term	JJ	O
follow-up	NN	O
of	IN	O
a	DT	O
phase	NN	O
I/II	NNP	O
randomized	VBD	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
palifermin	NN	Pharmacological
to	TO	O
prevent	VB	O
graft-versus-host	JJ	O
disease	NN	O
(	(	O
GVHD	NNP	O
)	)	O
after	IN	O
related	VBN	O
donor	NN	O
allogeneic	NN	O
hematopoietic	JJ	O
cell	NN	O
transplantation	NN	O
(	(	O
HCT	NNP	O
)	)	O
.	.	O

We	PRP	O
previously	RB	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
conducted	VBN	O
from	IN	O
2000	CD	O
to	TO	O
2003	CD	O
of	IN	O
palifermin	NN	Pharmacological
,	,	O
a	DT	O
recombinant	JJ	O
human	JJ	O
keratinocyte	NN	O
growth	NN	O
factor	NN	O
,	,	O
dosed	VBN	O
from	IN	O
240	CD	O
microg/kg	NNS	O
to	TO	O
720	CD	O
microg/kg	NN	O
,	,	O
in	IN	O
100	CD	O
allogeneic	JJ	O
hematopoietic	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
HCT	NNP	O
)	)	O
recipients	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
palifermin	NN	Pharmacological
showed	VBD	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
mucositis	NN	O
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
engraftment	NN	O
,	,	O
acute	JJ	O
graft-versus-host	JJ	O
disease	NN	O
(	(	O
GVHD	NNP	O
)	)	O
,	,	O
or	CC	O
early	JJ	O
survival	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
effect	NN	O
of	IN	O
palifermin	NN	Pharmacological
on	IN	O
mucosa	NN	O
,	,	O
other	JJ	O
pleotrophic	JJ	O
effects	NNS	O
,	,	O
including	VBG	O
more	RBR	O
rapid	JJ	O
immune	JJ	O
reconstitution	NN	O
,	,	O
have	VBP	O
been	VBN	O
seen	VBN	O
in	IN	O
experimental	JJ	O
transplant	NN	O
models	NNS	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
whether	IN	O
with	IN	O
longer	JJR	O
follow-up	NN	O
we	PRP	O
could	MD	O
detect	VB	O
additional	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
palifermin-treated	JJ	Pharmacological
and	CC	O
placebo	JJ	Control
cohorts	NNS	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
CMV	NNP	O
or	CC	O
invasive	JJ	O
fungal	JJ	O
infections	NNS	O
,	,	O
chronic	JJ	O
GVHD	NNP	O
,	,	O
or	CC	O
long-term	JJ	O
survival	NN	O
between	IN	O
cohorts	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
palifermin	NN	Pharmacological
appear	VBP	O
primarily	RB	O
to	TO	O
be	VB	O
limited	VBN	O
to	TO	O
ameliorating	VBG	O
mucotoxicity	NN	O
when	WRB	O
given	VBN	O
to	TO	O
allogeneic	VB	O
HCT	NNP	O
recipients	NNS	O
.	.	O

Improved	VBN	O
fibrinolysis	NN	O
after	IN	O
1-year	JJ	O
treatment	NN	O
with	IN	O
HMG	NNP	Pharmacological
CoA	NNP	Pharmacological
reductase	NN	Pharmacological
inhibitors	NNS	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
different	JJ	O
statins	NNS	Pharmacological
on	IN	O
the	DT	O
levels	NNS	O
of	IN	O
haemostatic	JJ	O
variables	NNS	O
reflecting	VBG	O
procoagulant	NN	O
and	CC	O
fibrinolytic	JJ	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
,	,	O
with	IN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
statins	VBZ	Pharmacological
might	MD	O
beneficially	RB	O
modify	VB	O
these	DT	O
levels	NNS	O
.	.	O

Fifty-eight	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
atorvastatin	NN	Pharmacological
(	(	O
n=28	JJ	O
)	)	O
or	CC	O
simvastatin	NN	Pharmacological
(	(	O
n=30	JJ	O
)	)	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
starting	VBG	O
dose	NN	O
in	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
20	CD	O
mg/day	NN	O
.	.	O

Fasting	VBG	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
before	IN	O
and	CC	O
after	IN	O
12-month	JJ	O
treatment	NN	O
for	IN	O
determinations	NNS	O
of	IN	O
fibrinogen	NN	O
,	,	O
prothrombin	JJ	O
fragment	NN	O
1+2	CD	O
(	(	O
F1+2	NNP	O
)	)	O
,	,	O
plasma	JJ	O
D-dimer	NNP	O
,	,	O
soluble	JJ	O
tissue	NN	O
factor	NN	O
,	,	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
(	(	O
tPA	NN	O
)	)	O
antigen	NN	O
,	,	O
tPA	NN	O
activity	NN	O
,	,	O
plasminogen	NN	O
activator	NN	O
inhibitor	JJ	O
type-1	JJ	O
activity	NN	O
(	(	O
PAI-1	NNP	O
activity	NN	O
)	)	O
and	CC	O
serum	JJ	O
D-dimer	NNP	O
as	IN	O
a	DT	O
global	JJ	O
test	NN	O
of	IN	O
fibrinolytic	JJ	O
activity	NN	O
.	.	O

In	IN	O
the	DT	O
total	JJ	O
population	NN	O
,	,	O
improved	VBN	O
fibrinolytic	JJ	O
activity	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
1	CD	O
year	NN	O
with	IN	O
increased	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
D-dimer	NNP	O
(	(	O
P=.001	NNP	O
)	)	O
and	CC	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.024	NNP	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.048	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
measured	JJ	O
coagulation	NN	O
variables	NNS	O
.	.	O

Separately	RB	O
examined	VBD	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
atorvastatin	NN	Pharmacological
group	NN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
serum	JJ	O
D-dimer	NNP	O
(	(	O
P=.005	NNP	O
)	)	O
,	,	O
a	DT	O
borderline	JJ	O
increase	NN	O
in	IN	O
tPA	JJ	O
activity	NN	O
(	(	O
P=.083	NNP	O
)	)	O
and	CC	O
a	DT	O
borderline	NN	O
reduction	NN	O
in	IN	O
tPA	NN	O
antigen	NN	O
(	(	O
P=.069	NNP	O
)	)	O
.	.	O

Within	IN	O
the	DT	O
simvastatin	NN	Pharmacological
group	NN	O
,	,	O
a	DT	O
reduction	NN	O
in	IN	O
prothrombin	NN	O
F1+2	NNP	O
was	VBD	O
observed	VBN	O
(	(	O
P=.038	NNP	O
)	)	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
changes	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
only	RB	O
for	IN	O
global	JJ	O
fibrinolysis	NN	O
(	(	O
serum	JJ	O
D-dimer	NNP	O
,	,	O
P=.046	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
an	DT	O
improved	JJ	O
fibrinolytic	JJ	O
profile	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
statin	NN	Pharmacological
treatment	NN	O
,	,	O
most	RBS	O
pronounced	JJ	O
with	IN	O
atorvastatin	NN	Pharmacological
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
drugs	NNS	O
promote	VBP	O
a	DT	O
profibrinolytic	JJ	O
profile	NN	O
,	,	O
and	CC	O
may	MD	O
in	IN	O
part	NN	O
explain	VBP	O
the	DT	O
benefit	NN	O
of	IN	O
statin	NN	Pharmacological
treatment	NN	O
rendered	VBN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
CHD	NNP	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
amiloride	NN	Pharmacological
on	IN	O
the	DT	O
therapeutic	JJ	O
and	CC	O
metabolic	JJ	O
effects	NNS	O
of	IN	O
carbenoxolone	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
gastric	JJ	O
ulcer	NN	O
.	.	O

A	DT	O
double-blind	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Patients	NNS	O
with	IN	O
benign	JJ	O
gastric	JJ	O
ulcer	NN	O
were	VBD	O
treated	VBN	O
for	IN	O
four	CD	O
weeks	NNS	O
with	IN	O
carbenoxolone	NN	Pharmacological
sodium	NN	Pharmacological
as	IN	Pharmacological
Biogastrone	NNP	Pharmacological
tablets	VBZ	Pharmacological
100	CD	Pharmacological
mg	NN	Pharmacological
three	CD	Pharmacological
times	NNS	Pharmacological
a	DT	Pharmacological
day	NN	Pharmacological
,	,	O
and	CC	O
if	IN	O
the	DT	O
ulcers	NNS	O
were	VBD	O
not	RB	O
healed	VBN	O
at	IN	O
4	CD	O
weeks	NNS	O
treatment	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
a	DT	O
further	JJ	O
4	CD	O
weeks	NNS	O
.	.	O

Fifty	NNP	O
two	CD	O
patients	NNS	O
entered	VBD	O
the	DT	O
trial	NN	O
,	,	O
and	CC	O
12	CD	O
were	VBD	O
withdrawn	VBN	O
.	.	O

In	IN	O
17	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
randomly	RB	O
allotted	VBN	O
double-blind	JJ	O
additional	JJ	O
dummy	NN	Control
tablets	NNS	Control
16	CD	O
of	IN	O
their	PRP$	O
ulcer	NN	O
healed	VBD	O
completely	RB	O
endoscopically	RB	O
,	,	O
whereas	NNS	O
of	IN	O
the	DT	O
23	CD	O
patients	NNS	O
given	VBN	O
additional	JJ	O
amiloride	NN	Pharmacological
5	CD	O
mg	NN	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
only	RB	O
14	CD	O
ulcers	NNS	O
healed	VBD	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
ulcer	JJ	O
healing	NN	O
.	.	O

The	DT	O
clinical	JJ	O
(	(	O
weight	JJ	O
gain	NN	O
and	CC	O
oedema	NN	O
)	)	O
and	CC	O
metabolic	JJ	O
(	(	O
hypertension	NN	O
,	,	O
hypokalaemia	NN	O
and	CC	O
hypernatraemia	NN	O
)	)	O
side-effects	NNS	O
were	VBD	O
reduced	VBN	O
by	IN	O
the	DT	O
active	JJ	O
amiloride	NN	Pharmacological
therapy	NN	O
,	,	O
but	CC	O
serum	VBP	O
carbenoxolone	NN	Pharmacological
levels	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
.	.	O

Thus	VB	O
the	DT	O
potassium-retaining	JJ	O
diuretic	JJ	O
amiloride	NN	Pharmacological
,	,	O
like	IN	O
the	DT	O
aldosterone	NN	O
antagonist	NN	O
spironolactone	NN	Pharmacological
,	,	O
markedly	RB	O
reduces	VBZ	O
both	CC	O
the	DT	O
ulcer-healing	JJ	O
and	CC	O
the	DT	O
metabolic	JJ	O
side-effects	NNS	O
of	IN	O
carbenoxolone	NN	O
sodium	NN	O
,	,	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
together	RB	O
with	IN	O
it	PRP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
peptic	JJ	O
ulcer	NN	O
.	.	O

The	DT	O
low-dose	JJ	O
monoethylglycinexylidide	JJ	O
test	NN	O
:	:	O
assessment	NN	O
of	IN	O
liver	NN	O
function	NN	O
with	IN	O
fewer	JJR	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
hepatic	JJ	O
metabolism	NN	O
of	IN	O
lidocaine	NN	Pharmacological
(	(	O
1	CD	O
mg/kg	RB	O
intravenously	RB	O
)	)	O
to	TO	O
its	PRP$	O
metabolite	JJ	O
monoethylglycinexylidide	NN	Pharmacological
(	(	Pharmacological
MEG-X	NNP	Pharmacological
)	)	Pharmacological
is	VBZ	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
standard	JJ	O
MEG-X	NNP	Pharmacological
test	NN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
lidocaine-induced	JJ	Pharmacological
side	NN	O
effects	NNS	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
MEG-X	NNP	Pharmacological
formation	NN	O
after	IN	O
0.5	CD	O
and	CC	O
1	CD	O
mg/kg	NNS	O
lidocaine	JJ	O
intravenously	RB	O
in	IN	O
subjects	NNS	O
with	IN	O
normal	JJ	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
and	CC	O
severely	RB	O
impaired	JJ	O
liver	NN	O
function	NN	O
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
(	(	O
study	NN	O
I	PRP	O
)	)	O
.	.	O

From	IN	O
this	DT	O
study	NN	O
,	,	O
a	DT	O
low-dose	JJ	O
test	NN	O
(	(	O
MEG-X	NNP	Pharmacological
concentration	NN	O
30	CD	O
minutes	NNS	O
after	IN	O
50	CD	O
mg	JJ	O
lidocaine	NN	Pharmacological
intravenously	RB	O
[	JJ	O
MEG-X30min	NNP	Pharmacological
]	NNP	O
normalized	VBD	O
to	TO	O
standard	VB	O
MEG-X	NNP	Pharmacological
test	NN	O
results	NNS	O
)	)	O
was	VBD	O
developed	VBN	O
.	.	O

Sensory	JJ	O
side	NN	O
effects	NNS	O
from	IN	O
this	DT	O
low	JJ	O
dose	NN	O
and	CC	O
from	IN	O
the	DT	O
standard	JJ	O
MEG-X	NNP	O
test	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
cross-over	JJ	O
study	NN	O
(	(	O
study	VB	O
II	NNP	O
)	)	O
comprising	VBG	O
15	CD	O
individuals	NNS	O
with	IN	O
normal	JJ	O
liver	NN	O
function	NN	O
and	CC	O
45	CD	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
(	(	O
15	CD	O
Child	NNP	O
A	NNP	O
,	,	O
15	CD	O
Child	NNP	O
B	NNP	O
,	,	O
and	CC	O
15	CD	O
Child	NNP	O
C	NNP	O
)	)	O
.	.	O

In	IN	O
study	NN	O
I	PRP	O
,	,	O
MEG-X	JJ	Pharmacological
formation	NN	O
rate	NN	O
was	VBD	O
dose-independent	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
severely	RB	O
impaired	JJ	O
liver	NN	O
function	NN	O
.	.	O

In	IN	O
study	NN	O
II	NNP	O
,	,	O
normalized	VBD	O
MEG-X	JJ	O
test	NN	O
results	NNS	O
(	(	O
ranging	VBG	O
from	IN	O
<	NN	O
or	CC	O
=	$	O
4	CD	O
to	TO	O
120	CD	O
microg/L	NNS	O
)	)	O
were	VBD	O
virtually	RB	O
identical	JJ	O
to	TO	O
the	DT	O
standard	JJ	O
test	NN	O
results	NNS	O
(	(	O
mean	JJ	O
difference	NN	O
:	:	O
-1.9	JJ	O
microg/L	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NN	O
:	:	O
-5.3	NN	O
;	:	O
1.5	CD	O
microg/L	NN	O
)	)	O
.	.	O

Fewer	JJR	O
individuals	NNS	O
experienced	VBD	O
side	NN	O
effects	NNS	O
(	(	O
30	CD	O
%	NN	O
vs.	FW	O
53	CD	O
%	NN	O
)	)	O
with	IN	O
the	DT	O
low-dose	JJ	O
test	NN	O
(	(	O
P	NNP	O
=	NNP	O
.0013	NNP	O
)	)	O
.	.	O

In	IN	O
a	DT	O
multivariate	NN	O
analysis	NN	O
,	,	O
the	DT	O
Child-Pugh	NNP	O
score	NN	O
was	VBD	O
inversely	RB	O
related	VBN	O
to	TO	O
the	DT	O
occurrence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
low-dose	JJ	O
MEG-X	JJ	O
test	NN	O
gives	VBZ	O
almost	RB	O
identical	JJ	O
results	NNS	O
to	TO	O
the	DT	O
standard	JJ	O
MEG-X	NNP	O
test	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
fewer	JJR	O
side	NN	O
effects	NNS	O
,	,	O
which	WDT	O
occur	VBP	O
less	RBR	O
often	RB	O
in	IN	O
individuals	NNS	O
with	IN	O
more	RBR	O
severely	RB	O
compromised	VBN	O
liver	NN	O
function	NN	O
.	.	O

Local	JJ	O
delivery	NN	O
of	IN	O
a	DT	O
recombinant	NN	Pharmacological
adenoassociated	VBN	Pharmacological
vector	NN	Pharmacological
containing	VBG	Pharmacological
a	DT	Pharmacological
tumour	JJ	Pharmacological
necrosis	NN	Pharmacological
factor	NN	Pharmacological
alpha	IN	Pharmacological
antagonist	JJ	Pharmacological
gene	NN	Pharmacological
in	IN	O
inflammatory	JJ	O
arthritis	NN	O
:	:	O
a	DT	O
phase	NN	O
1	CD	O
dose-escalation	NN	O
safety	NN	O
and	CC	O
tolerability	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	Pharmacological
:	:	Pharmacological
Fc	NNP	Pharmacological
,	,	Pharmacological
an	DT	Pharmacological
adenoassociated	JJ	Pharmacological
virus	NN	Pharmacological
serotype	NN	Pharmacological
2	CD	Pharmacological
vector	NN	Pharmacological
containing	VBG	Pharmacological
the	DT	Pharmacological
cDNA	NN	Pharmacological
for	IN	O
the	DT	O
human	JJ	O
tumour	JJ	O
necrosis	NN	O
factor-immunoglobulin	JJ	O
Fc	NNP	O
fusion	NN	O
gene	NN	O
(	(	O
tgAAC94	NN	O
)	)	O
,	,	O
in	IN	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
phase	JJ	O
1	CD	O
,	,	O
dose-escalation	NN	O
study	NN	O
,	,	O
15	CD	O
subjects	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
(	(	O
14	CD	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
and	CC	O
1	CD	O
with	IN	O
ankylosing	VBG	O
spondylitis	NN	O
)	)	O
not	RB	O
receiving	VBG	O
tumour	JJ	O
necrosis	NN	O
factor	NN	O
alpha	NN	O
(	(	O
TNFalpha	NNP	O
)	)	O
inhibitors	NNS	O
with	IN	O
persistent	JJ	O
moderate	NN	O
(	(	O
grade	JJ	O
2	CD	O
)	)	O
or	CC	O
severe	JJ	O
(	(	O
grade	JJ	O
3	CD	O
)	)	O
swelling	NN	O
in	IN	O
a	DT	O
target	NN	O
joint	NN	O
due	JJ	O
to	TO	O
inflammatory	JJ	O
arthritis	NN	O
received	VBD	O
a	DT	O
single	JJ	O
intra-articular	JJ	O
injection	NN	O
of	IN	O
rAAV2-TNFR	NN	Pharmacological
:	:	Pharmacological
Fc	NN	Pharmacological
at	IN	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
5	CD	O
)	)	O
or	CC	O
1	CD	O
x	JJ	O
10	CD	O
(	(	O
11	CD	O
)	)	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
DNase	NNP	O
resistant	JJ	O
particles	NNS	O
per	IN	O
ml	NN	O
joint	NN	O
volume	NN	O
or	CC	Control
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
4	CD	O
)	)	O
into	IN	O
a	DT	O
knee	NN	O
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
or	CC	O
ankle	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
.	.	O

Safety	NN	O
was	VBD	O
assessed	VBN	O
through	IN	O
adverse	JJ	O
event	NN	O
monitoring	NN	O
.	.	O

As	IN	O
a	DT	O
secondary	JJ	O
objective	NN	O
,	,	O
changes	NNS	O
in	IN	O
injected	JJ	O
joint	NN	O
tenderness	NN	O
and	CC	O
swelling	VBG	O
scores	NNS	O
,	,	O
each	DT	O
measured	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
,	,	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Intra-articular	JJ	O
injections	NNS	O
of	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NN	O
were	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
no	DT	O
major	JJ	O
safety	NN	O
issues	NNS	O
.	.	O

One	CD	O
event	NN	O
,	,	O
mild	JJ	O
knee	NN	O
pruritus	NN	O
,	,	O
was	VBD	O
considered	VBN	O
probably	RB	O
related	VBN	O
.	.	O

Synovial	JJ	O
fluid	NN	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
protein	NN	O
was	VBD	O
not	RB	O
detected	VBN	O
(	(	O
nor	CC	O
expected	VBN	O
)	)	O
at	IN	O
the	DT	O
doses	NNS	O
used	VBN	O
.	.	O

At	IN	O
12	CD	O
weeks	NNS	O
after	IN	O
injection	NN	O
,	,	O
a	DT	O
two-point	JJ	O
decrease	NN	O
in	IN	O
swelling	VBG	O
was	VBD	O
noted	VBN	O
in	IN	O
2/11	CD	O
and	CC	O
2/4	CD	O
subjects	NNS	O
injected	VBN	O
with	IN	O
rAAV2-TNFR	NN	O
:	:	O
Fc	NNP	O
and	CC	O
placebo	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intra-articular	JJ	O
rAAV2-TNFR	NN	O
:	:	O
Fc	CD	O
appears	VBZ	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
subjects	NNS	O
without	IN	O
concurrent	JJ	O
systemic	JJ	O
TNFalpha	NNP	O
antagonist	NN	O
use	NN	O
.	.	O

It	PRP	O
is	VBZ	O
thus	RB	O
feasible	JJ	O
to	TO	O
proceed	VB	O
with	IN	O
larger	JJR	O
trials	NNS	O
to	TO	O
further	JJ	O
test	NN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
local	JJ	O
TNFR	NNP	O
:	:	O
Fc	NNP	O
gene	NN	O
transfer	NN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
modality	NN	O
for	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
arthritis	NN	O
.	.	O

Increasing	VBG	O
verbal	JJ	O
responsiveness	NN	O
in	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

Correlational	NNP	O
studies	NNS	O
have	VBP	O
revealed	VBN	O
a	DT	O
positive	JJ	O
relationship	NN	O
between	IN	O
parent	NN	O
verbal	JJ	O
responsiveness	NN	O
and	CC	O
language	NN	O
outcomes	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
parents	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
on	IN	O
the	DT	O
autism	NN	O
spectrum	NN	O
could	MD	O
learn	VB	O
and	CC	O
implement	VB	O
the	DT	O
specific	JJ	O
categories	NNS	O
of	IN	O
verbal	JJ	O
responsiveness	NN	O
that	WDT	O
have	VBP	O
been	VBN	O
suggested	VBN	O
to	TO	O
facilitate	VB	O
language	NN	O
development	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
taught	VBN	O
to	TO	O
increase	VB	Educational
their	PRP$	Educational
verbal	JJ	Educational
responsiveness	NN	Educational
in	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
short-term	JJ	Educational
language	NN	Educational
intervention	NN	Educational
that	WDT	O
included	VBD	O
group	NN	Educational
parent	NN	Educational
education	NN	Educational
sessions	NNS	Educational
,	,	O
as	RB	O
well	RB	O
as	IN	O
individual	JJ	Educational
and	CC	Educational
small-group	JJ	Educational
coaching	NN	Educational
sessions	NNS	Educational
of	IN	Educational
parent-child	JJ	Educational
play	NN	Educational
interactions	NNS	Educational
.	.	O

Parents	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
increased	VBD	O
their	PRP$	O
use	NN	O
of	IN	O
comments	NNS	O
that	WDT	O
:	:	O
described	VBD	O
their	PRP$	O
child	NN	O
's	POS	O
focus	NN	O
of	IN	O
attention	NN	O
;	:	O
interpreted	VBN	O
or	CC	O
expanded	VBN	O
child	JJ	O
communication	NN	O
acts	NNS	O
;	:	O
and	CC	O
prompted	VBD	O
child	JJ	O
communication	NN	O
.	.	O

Preliminary	JJ	O
treatment	NN	O
effects	NNS	O
were	VBD	O
also	RB	O
noted	VBN	O
in	IN	O
children	NNS	O
's	POS	O
prompted	VBN	O
and	CC	O
spontaneous	JJ	O
communication	NN	O
.	.	O

These	DT	O
results	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
parent-mediated	JJ	Educational
interventions	NNS	Educational
targeting	VBG	O
verbal	JJ	O
responsiveness	NN	O
to	TO	O
facilitate	VB	O
language	NN	O
development	NN	O
and	CC	O
communication	NN	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Milk	NN	O
production	NN	O
in	IN	O
cows	NNS	O
with	IN	O
endotoxin-induced	JJ	Pharmacological
mastitis	NN	Pharmacological
treated	VBN	O
with	IN	O
isotonic	JJ	Pharmacological
or	CC	Pharmacological
hypertonic	JJ	Pharmacological
sodium	NN	Pharmacological
chloride	NN	Pharmacological
solution	NN	Pharmacological
.	.	O

Milk	NNP	O
production	NN	O
was	VBD	O
monitored	VBN	O
in	IN	O
16	CD	O
cows	NNS	O
for	IN	O
6	CD	O
milkings	NNS	O
after	IN	O
intramammary	JJ	O
infusion	NN	O
of	IN	O
1	CD	O
mg	NN	O
of	IN	O
endotoxin	NN	Pharmacological
in	IN	O
a	DT	O
single	JJ	O
forequarter	NN	O
.	.	O

The	DT	O
cows	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
2	CD	O
treatment	NN	O
groups	NNS	O
;	:	O
8	CD	O
cows	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
isotonic	JJ	Pharmacological
saline	NN	Pharmacological
solution	NN	Pharmacological
and	CC	O
8	CD	O
cows	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
hypertonic	JJ	Pharmacological
saline	JJ	Pharmacological
solution	NN	Pharmacological
.	.	O

Saline	JJ	Pharmacological
solutions	NNS	O
were	VBD	O
administered	VBN	O
IV	NNP	O
(	(	O
5	CD	O
ml/kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
)	)	O
4	CD	O
hours	NNS	O
after	IN	O
infusion	NN	O
of	IN	O
endotoxin	NN	Pharmacological
.	.	O

Mean	NNP	O
cumulative	JJ	O
change	NN	O
in	IN	O
milk	NN	O
yield	NN	O
and	CC	O
interval	JJ	O
change	NN	O
in	IN	O
milk	NN	O
yield	NN	O
were	VBD	O
greater	JJR	O
in	IN	O
cows	NNS	O
treated	VBN	O
with	IN	O
isotonic	JJ	O
saline	NN	O
solution	NN	O
than	IN	O
in	IN	O
cows	NNS	O
treated	VBN	O
with	IN	O
hypertonic	JJ	Pharmacological
saline	JJ	Pharmacological
solution	NN	Pharmacological
.	.	O

Significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
were	VBD	O
not	RB	O
detected	VBN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
vitamin	JJ	Pharmacological
A-fortified	NNP	Pharmacological
coconut	NN	Pharmacological
cooking	VBG	Pharmacological
oil	NN	Pharmacological
on	IN	O
the	DT	O
serum	NN	O
retinol	JJ	O
concentration	NN	O
of	IN	O
Filipino	NNP	O
children	NNS	O
4-7	CD	O
years	NNS	O
old	JJ	O
.	.	O

A	DT	O
6-month	JJ	O
intervention	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
542	CD	O
Filipino	NNP	O
children	NNS	O
aged	VBD	O
4	CD	O
to	TO	O
7	CD	O
years	NNS	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
vitamin	JJ	Pharmacological
A-fortified	NNP	Pharmacological
coconut	NN	Pharmacological
cooking	VBG	Pharmacological
oil	NN	Pharmacological
intake	NN	O
on	IN	O
their	PRP$	O
vitamin	NN	O
A	DT	O
status	NN	O
and	CC	O
to	TO	O
identify	VB	O
factors	NNS	O
that	WDT	O
influence	NN	O
this	DT	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
Experimental	NNP	O
group	NN	O
,	,	O
with	IN	O
vitamin	JJ	Pharmacological
A-fortified	JJ	Pharmacological
cooking	NN	Pharmacological
oil	NN	Pharmacological
ration	NN	O
;	:	O
to	TO	O
Control-1	NNP	O
group	NN	O
with	IN	O
unfortified	JJ	Pharmacological
cooking	NN	Pharmacological
oil	NN	Pharmacological
ration	NN	Pharmacological
;	:	O
and	CC	O
to	TO	O
Control-2	NNP	O
group	NN	O
without	IN	Control
cooking	VBG	Control
oil	NN	Control
ration	NN	Control
.	.	O

In	IN	O
all	DT	O
groups	NNS	O
,	,	O
children	NNS	O
's	POS	O
serum	NN	O
retinol	NN	O
concentration	NN	O
improved	VBN	O
.	.	O

Relative	JJ	O
change	NN	O
in	IN	O
serum	NN	O
retinol	NN	O
concentration	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
among	IN	O
the	DT	O
Experimental	NNP	O
group	NN	O
,	,	O
with	IN	O
one-third	NN	O
of	IN	O
total	JJ	O
vitamin	FW	O
A	DT	O
intake	NN	O
coming	VBG	O
from	IN	O
vitamin	JJ	Pharmacological
A-fortified	JJ	Pharmacological
cooking	NN	Pharmacological
oil	NN	Pharmacological
intake	NN	O
,	,	O
than	IN	O
in	IN	O
the	DT	O
Control	NNP	O
groups	NNS	O
,	,	O
with	IN	O
more	JJR	O
than	IN	O
half	NN	O
of	IN	O
intake	NN	O
from	IN	O
other	JJ	O
vitamin	JJ	O
A-rich	JJ	O
foods	NNS	O
.	.	O

Determinants	NNS	O
of	IN	O
post-intervention	NN	O
serum	NN	O
retinol	NN	O
concentration	NN	O
included	VBD	O
baseline	JJ	O
serum	NN	O
retinol	NN	O
concentration	NN	O
,	,	O
caregiver	NN	O
's	POS	O
education	NN	O
,	,	O
receipt	NN	O
of	IN	O
high-dose	JJ	O
vitamin	NN	O
A	NNP	O
capsule	NN	O
,	,	O
interaction	NN	O
between	IN	O
consumption	NN	O
of	IN	O
vitamin	JJ	O
A-fortified	JJ	O
cooking	NN	O
oil	NN	O
and	CC	O
of	IN	O
other	JJ	O
vitamin	JJ	O
A-rich	NNP	O
foods	NNS	O
,	,	O
and	CC	O
between	IN	O
households	NNS	O
purchasing	VBG	O
cooking	JJ	O
oil	NN	O
and	CC	O
food	NN	O
expenditure	NN	O
.	.	O

Intake	NNP	O
of	IN	O
vitamin	JJ	Pharmacological
A-fortified	JJ	Pharmacological
cooking	NN	Pharmacological
oil	NN	Pharmacological
combined	VBN	O
with	IN	O
vitamin	JJ	O
A-rich	NNP	O
foods	NNS	O
was	VBD	O
necessary	JJ	O
to	TO	O
increase	VB	O
serum	NN	O
retinol	JJ	O
concentration	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
to	TO	O
vigorously	RB	O
promote	VB	O
the	DT	O
consumption	NN	O
of	IN	O
vitamin	JJ	Pharmacological
A-fortified	JJ	Pharmacological
cooking	NN	Pharmacological
oil	NN	Pharmacological
together	RB	O
with	IN	O
other	JJ	O
vitamin	JJ	O
A-rich	JJ	O
sources	NNS	O
to	TO	O
sustain	VB	O
the	DT	O
prevention	NN	O
and	CC	O
control	NN	O
of	IN	O
vitamin	FW	O
A	DT	O
deficiency	NN	O
.	.	O

Postoperative	JJ	Pharmacological
fondaparinux	NN	Pharmacological
versus	NN	O
postoperative	JJ	Pharmacological
enoxaparin	NN	Pharmacological
for	IN	O
prevention	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
elective	JJ	O
hip-replacement	JJ	O
surgery	NN	O
:	:	O
a	DT	O
randomised	JJ	O
double-blind	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Elective	NNP	O
hip-replacement	NN	O
surgery	NN	O
carries	VBZ	O
significant	JJ	O
risk	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
,	,	O
despite	IN	O
use	NN	O
of	IN	O
thromboprophylaxis	NN	Pharmacological
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
see	VB	O
whether	IN	O
the	DT	O
pentasaccharide	NN	Pharmacological
fondaparinux	NN	Pharmacological
,	,	O
the	DT	O
first	JJ	O
drug	NN	O
of	IN	O
a	DT	O
new	JJ	O
class	NN	O
of	IN	O
synthetic	JJ	Pharmacological
antithrombotic	JJ	Pharmacological
agents	NNS	Pharmacological
,	,	O
could	MD	O
reduce	VB	O
this	DT	O
risk	NN	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
other	JJ	O
available	JJ	O
treatments	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	NN	O
study	NN	O
,	,	O
we	PRP	O
randomly	VBP	O
assigned	JJ	O
2275	CD	O
consecutive	JJ	O
patients	NNS	O
aged	VBN	O
18	CD	O
years	NNS	O
or	CC	O
older	JJR	O
who	WP	O
were	VBD	O
undergoing	VBG	O
elective	JJ	O
hip-replacement	JJ	O
surgery	NN	O
to	TO	O
receive	VB	O
postoperative	JJ	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
either	DT	O
2.5	CD	Pharmacological
mg	NN	Pharmacological
fondaparinux	NN	Pharmacological
once	RB	Pharmacological
daily	JJ	Pharmacological
or	CC	O
30	CD	Pharmacological
mg	NNS	Pharmacological
enoxaparin	JJ	Pharmacological
twice	RB	O
daily	RB	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
outcome	NN	O
was	VBD	O
venous	JJ	O
thromboembolism	NN	O
to	TO	O
day	NN	O
11	CD	O
.	.	O

The	DT	O
main	JJ	O
safety	NN	O
outcomes	NNS	O
were	VBD	O
bleeding	VBG	O
and	CC	O
death	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

FINDINGS	IN	O
We	PRP	O
assessed	VBD	O
venous	JJ	O
thromboembolism	NN	O
to	TO	O
day	NN	O
11	CD	O
in	IN	O
1584	CD	O
(	(	O
70	CD	O
%	NN	O
)	)	O
of	IN	O
2275	CD	O
patients	NNS	O
.	.	O

By	IN	O
day	NN	O
11	CD	O
,	,	O
venous	JJ	O
thromboembolisms	NNS	O
were	VBD	O
recorded	VBN	O
in	IN	O
48	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
of	IN	O
787	CD	O
patients	NNS	O
on	IN	O
fondaparinux	NN	Pharmacological
and	CC	O
in	IN	O
66	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
of	IN	O
797	CD	O
patients	NNS	O
on	IN	O
enoxaparin	NN	Pharmacological
.	.	O

The	DT	O
relative	JJ	O
reduction	NN	O
in	IN	O
risk	NN	O
was	VBD	O
26.3	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-10.8	NNP	O
to	TO	O
52.8	CD	O
,	,	O
p=0.099	NN	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
died	VBD	O
or	CC	O
in	IN	O
the	DT	O
number	NN	O
who	WP	O
had	VBD	O
clinically	RB	O
relevant	JJ	O
bleeding	NN	O
.	.	O

INTERPRETATION	NNP	O
In	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
hip-replacement	JJ	O
surgery	NN	O
,	,	O
2.5	CD	O
mg	NN	O
fondaparinux	NN	Pharmacological
once	RB	O
daily	RB	O
was	VBD	O
not	RB	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
30	CD	O
mg	JJ	O
enoxaparin	JJ	Pharmacological
twice	RB	O
daily	RB	O
in	IN	O
reducing	VBG	O
risk	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
lower	JJR	O
risk	NN	O
recorded	VBN	O
with	IN	O
fondaparinux	NN	Pharmacological
than	IN	O
enoxaparin	NN	Pharmacological
was	VBD	O
clinically	RB	O
important	JJ	O
,	,	O
with	IN	O
no	DT	O
increase	NN	O
in	IN	O
clinically	RB	O
relevant	JJ	O
bleeding	NN	O
.	.	O

Polydioxanone	NNP	Surgical
sternal	JJ	Surgical
sutures	NNS	Surgical
for	IN	O
prevention	NN	O
of	IN	O
sternal	JJ	O
dehiscence	NN	O
.	.	O

BACKGROUND	NNP	O
Sternal	NNP	O
dehiscence	NN	O
and	CC	O
wound	NN	O
instability	NN	O
are	VBP	O
troublesome	JJ	O
complications	NNS	O
following	VBG	O
median	JJ	O
sternotomy	NN	O
.	.	O

Classic	JJ	O
sternal	JJ	O
approximation	NN	O
with	IN	O
stainless	JJ	O
steel	NN	O
wires	NNS	O
may	MD	O
not	RB	O
be	VB	O
the	DT	O
ideal	JJ	O
approach	NN	O
in	IN	O
patients	NNS	O
predisposed	VBN	O
to	TO	O
these	DT	O
complications	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
polydioxanone	NN	Surgical
(	(	Surgical
PDS	NNP	Surgical
)	)	Surgical
suture	NN	Surgical
in	IN	O
sternal	JJ	O
closure	NN	O
and	CC	O
in	IN	O
prevention	NN	O
of	IN	O
complications	NNS	O
in	IN	O
comparison	NN	O
to	TO	O
steel	NN	O
wires	NNS	O
in	IN	O
high-risk	JJ	O
individuals	NNS	O
.	.	O

METHODS	NNP	O
Three	CD	O
hundred	VBD	O
sixty-six	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
cardiac	JJ	O
surgery	NN	O
with	IN	O
full	JJ	O
median	JJ	O
sternotomy	NN	O
and	CC	O
having	VBG	O
body	NN	O
surface	JJ	O
area	NN	O
(	(	O
BSA	NNP	O
)	)	O
less	JJR	O
than	IN	O
1.5	CD	O
m	NN	O
(	(	O
2	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
PDS	NNP	Surgical
(	(	O
n	JJ	O
=	NNP	O
181	CD	O
)	)	O
or	CC	O
stainless	JJ	Other
steel	NN	Other
(	(	O
SS	NNP	O
,	,	O
n	JJ	O
=	NNP	O
185	CD	O
)	)	O
sternal	JJ	O
approximation	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
focused	VBN	O
on	IN	O
aseptic	JJ	O
sternal	JJ	O
complications	NNS	O
,	,	O
namely	RB	O
bone	JJ	O
dehiscence	NN	O
and	CC	O
superficial	JJ	O
wound	NN	O
instability	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
bone	VBD	O
dehiscence	NN	O
and	CC	O
superficial	JJ	O
wound	NN	O
instability	NN	O
were	VBD	O
less	JJR	O
frequent	JJ	O
in	IN	O
the	DT	O
PDS	NNP	Surgical
Group	NNP	O
(	(	O
4	CD	O
and	CC	O
3	CD	O
cases	NNS	O
in	IN	O
the	DT	O
SS	NNP	O
Group	NNP	O
,	,	O
respectively	RB	O
,	,	O
vs.	IN	O
no	DT	O
cases	NNS	O
in	IN	O
the	DT	O
PDS	NNP	O
Group	NNP	O
)	)	O
.	.	O

Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
model	NN	O
in	IN	O
the	DT	O
whole	NN	O
study	NN	O
population	NN	O
identified	VBN	O
female	JJ	O
sex	NN	O
,	,	O
chronic	JJ	O
renal	JJ	O
insufficiency	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
advanced	JJ	O
age	NN	O
,	,	O
lower	JJR	O
sternal	JJ	O
thickness	NN	O
,	,	O
osteoporosis	NN	O
,	,	O
corticosteroid	JJ	O
therapy	NN	O
,	,	O
and	CC	O
prolonged	VBD	O
CPB	NNP	O
or	CC	O
ventilation	NN	O
times	NNS	O
as	IN	O
predisposing	VBG	O
factors	NNS	O
to	TO	O
any	DT	O
of	IN	O
the	DT	O
two	CD	O
studied	VBD	O
sternal	JJ	O
complications	NNS	O
.	.	O

DISCUSSION	NNP	O
Data	NNP	O
suggest	NN	O
that	IN	O
PDS	NNP	Surgical
suture	NN	O
can	MD	O
protect	VB	O
against	IN	O
development	NN	O
of	IN	O
aseptic	JJ	O
sternal	JJ	O
complications	NNS	O
following	VBG	O
median	JJ	O
sternotomy	NN	O
in	IN	O
high-risk	JJ	O
patients	NNS	O
with	IN	O
little	JJ	O
body	NN	O
mass	NN	O
.	.	O

The	DT	O
adoption	NN	O
of	IN	O
PDS	NNP	Surgical
in	IN	O
other	JJ	O
subsets	NNS	O
of	IN	O
patients	NNS	O
,	,	O
i.e.	FW	O
,	,	O
obese	JJ	O
individuals	NNS	O
,	,	O
is	VBZ	O
to	TO	O
be	VB	O
questioned	VBN	O
.	.	O

[	RB	O
Clinical	JJ	O
benefits	NNS	O
of	IN	O
normothermic	JJ	Surgical
cardiopulmonary	JJ	Surgical
bypass	NN	Surgical
on	IN	O
postoperative	JJ	O
systemic	JJ	O
metabolism	NN	O
]	NNP	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
influence	NN	O
of	IN	O
body	NN	O
temperature	NN	O
during	IN	O
cardiopulmonary	JJ	Surgical
bypass	NN	Surgical
(	(	Surgical
CPB	NNP	Surgical
)	)	Surgical
on	IN	O
postoperative	JJ	O
systemic	JJ	O
metabolism	NN	O
,	,	O
32	CD	O
patients	NNS	O
undergoing	JJ	O
elective	JJ	O
cardiac	NN	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	DT	O
hypothermia	NN	Surgical
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
or	CC	O
normothermia	NN	Surgical
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
.	.	O

Serial	JJ	O
hemodynamic	JJ	O
parameters	NNS	O
and	CC	O
blood	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
after	IN	O
surgery	NN	O
.	.	O

CPB	NNP	O
and	CC	O
operation	NN	O
times	NNS	O
were	VBD	O
significantly	RB	O
shorter	JJR	O
and	CC	O
the	DT	O
platelet	NN	O
reduction	NN	O
ratio	NN	O
during	IN	O
CPB	NNP	Surgical
[	NNP	O
=	NNP	O
(	(	O
platelets	NNS	O
before	IN	O
CPB-platelets	NNS	O
after	IN	O
CPB	NNP	O
)	)	O
/platelets	VBZ	O
before	IN	O
CPB	NNP	O
]	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
normothermic	JJ	O
patients	NNS	O
than	IN	O
in	IN	O
hypothermic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
platelet	NN	O
reduction	NN	O
ratio	NN	O
was	VBD	O
dependent	JJ	O
on	IN	O
the	DT	O
minimum	JJ	O
rectal	JJ	O
temperature	NN	O
during	IN	O
CPB	NNP	Surgical
,	,	O
the	DT	O
operation	NN	O
time	NN	O
,	,	O
and	CC	O
the	DT	O
CPB	NNP	O
time	NN	O
.	.	O

In	IN	O
the	DT	O
early	JJ	O
postoperative	JJ	O
period	NN	O
,	,	O
hypothermic	JJ	O
patients	NNS	O
had	VBD	O
abnormally	RB	O
high	JJ	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
and	CC	O
a	DT	O
reduced	JJ	O
cardiac	JJ	O
index	NN	O
compared	VBN	O
with	IN	O
the	DT	O
normothermic	JJ	O
patients	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
2	CD	O
groups	NNS	O
in	IN	O
postoperative	JJ	O
hepatic	JJ	O
and	CC	O
renal	JJ	O
functions	NNS	O
,	,	O
changes	NNS	O
in	IN	O
oxygen	NN	O
consumption	NN	O
,	,	O
arterial-venous	JJ	O
PCO2	NNP	O
or	CC	O
arterial-venous	JJ	O
pH	JJ	O
gradient	NN	O
.	.	O

This	DT	O
study	NN	O
suggested	VBD	O
a	DT	O
beneficial	JJ	O
influence	NN	O
of	IN	O
normothermic	JJ	Surgical
CPB	NNP	Surgical
on	IN	O
postoperative	JJ	O
hemodynamics	NNS	O
.	.	O

Normothermic	NNP	Surgical
CPB	NNP	Surgical
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
adverse	JJ	O
effects	NNS	O
on	IN	O
postoperative	JJ	O
metabolic	JJ	O
recovery	NN	O
.	.	O

Breathlessness	NNP	O
and	CC	O
psychiatric	JJ	O
morbidity	NN	O
in	IN	O
chronic	JJ	O
bronchitis	NN	O
and	CC	O
emphysema	NN	O
:	:	O
a	DT	O
study	NN	O
of	IN	O
psychotherapeutic	JJ	Educational
management	NN	Educational
.	.	O

This	DT	O
paper	NN	O
describes	VBZ	O
a	DT	O
study	NN	O
of	IN	O
the	DT	O
outcome	NN	O
of	IN	O
psychotherapy	NN	Psychological
with	IN	O
patients	NNS	O
disabled	VBN	O
by	IN	O
chronic	JJ	O
obstructive	JJ	O
airways	NNS	O
disease	NN	O
giving	VBG	O
rise	NN	O
to	TO	O
dyspnoea	VB	O
.	.	O

Forty-three	JJ	O
men	NNS	O
and	CC	O
22	CD	O
women	NNS	O
with	IN	O
severe	JJ	O
COAD	NNP	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
for	IN	O
8	CD	O
weeks	NNS	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
types	NNS	O
of	IN	O
psychotherapy	NN	Educational
or	CC	O
to	TO	O
an	DT	O
untreated	JJ	Control
control	NN	Control
group	NN	O
,	,	O
and	CC	O
were	VBD	O
followed	VBN	O
up	RP	O
six	CD	O
months	NNS	O
later	RB	O
.	.	O

The	DT	O
group	NN	O
treated	VBN	O
by	IN	O
a	DT	O
medical	JJ	O
nurse	NN	O
without	IN	O
training	NN	O
in	IN	O
psychotherapy	NN	Psychological
experienced	VBD	O
sustained	JJ	O
relief	NN	O
of	IN	O
dyspnoea	NN	O
but	CC	O
tended	VBD	O
to	TO	O
undergo	VB	O
less	JJR	O
psychodynamic	JJ	O
change	NN	O
;	:	O
psychiatric	JJ	O
symptoms	NNS	O
were	VBD	O
reduced	VBN	O
in	IN	O
those	DT	O
receiving	VBG	O
supportive	JJ	O
,	,	O
but	CC	O
not	RB	O
analytical	JJ	O
,	,	O
psychotherapy	NN	Psychological
.	.	O

The	DT	O
psychosomatic	JJ	O
mechanisms	NNS	O
involved	VBN	O
and	CC	O
the	DT	O
implications	NNS	O
for	IN	O
medical	JJ	O
and	CC	O
nursing	JJ	O
practice	NN	O
and	CC	O
for	IN	O
liaison	JJ	O
psychotherapy	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Effects	NNS	O
of	IN	O
two	CD	O
combined	JJ	O
hormonal	JJ	Pharmacological
contraceptives	NNS	Pharmacological
with	IN	O
the	DT	O
same	JJ	O
composition	NN	O
and	CC	O
different	JJ	O
doses	NNS	O
on	IN	O
female	JJ	O
sexual	JJ	O
function	NN	O
and	CC	O
plasma	NN	O
androgen	NN	O
levels	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
two	CD	O
contraceptive	JJ	Pharmacological
pills	NNS	Pharmacological
with	IN	O
different	JJ	O
doses	NNS	O
of	IN	O
the	DT	O
same	JJ	O
components	NNS	O
,	,	O
on	IN	O
plasma	JJ	O
androgen	NN	O
levels	NNS	O
and	CC	O
female	JJ	O
sexual	JJ	O
function	NN	O
among	IN	O
women	NNS	O
without	IN	O
previous	JJ	O
sexual	JJ	O
dysfunction	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
The	DT	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
to	TO	O
receive	VB	O
pills	NNS	O
containing	VBG	O
ethynylestradiol	NN	Pharmacological
(	(	Pharmacological
EE	NNP	Pharmacological
)	)	Pharmacological
30	CD	Pharmacological
mcg	NN	Pharmacological
and	CC	Pharmacological
levonorgestrel	NN	Pharmacological
(	(	Pharmacological
LNG	NNP	Pharmacological
)	)	Pharmacological
150	CD	Pharmacological
mcg	NN	Pharmacological
or	CC	Pharmacological
EE	NNP	Pharmacological
20	CD	Pharmacological
mcg	NN	Pharmacological
and	CC	Pharmacological
LNG	NNP	Pharmacological
100	CD	Pharmacological
mcg	NN	Pharmacological
,	,	O
for	IN	O
six	CD	O
cycles	NNS	O
.	.	O

Sexual	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
a	DT	O
standardized	JJ	O
questionnaire	NN	O
[	NNP	O
Female	NNP	O
Sexual	NNP	O
Function	NNP	O
Index	NNP	O
(	(	O
FSFI	NNP	O
)	)	O
]	NN	O
.	.	O

Hormone	NNP	O
assays	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
the	DT	O
sixth	JJ	O
cycle	NN	O
.	.	O

RESULTS	NNP	O
Forty-nine	JJ	O
women	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
EE30/LNG150	NNP	Pharmacological
group	NN	O
and	CC	O
48	CD	O
in	IN	O
the	DT	O
EE20/LNG100	NNP	Pharmacological
group	NN	O
.	.	O

EE30/LNG150	NNP	Pharmacological
group	NN	O
presented	VBD	O
54	CD	O
%	NN	O
and	CC	O
67	CD	O
%	NN	O
decreases	NNS	O
of	IN	O
total	JJ	O
testosterone	NN	O
and	CC	O
free	JJ	O
androgen	NN	O
index	NN	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
statistical	JJ	O
significance	NN	O
.	.	O

EE20/LNG100	NNP	Pharmacological
presented	VBD	O
reductions	NNS	O
of	IN	O
20	CD	O
%	NN	O
and	CC	O
42	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
but	CC	O
without	IN	O
statistical	JJ	O
significance	NN	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
improvements	NNS	O
in	IN	O
the	DT	O
FSFI	NNP	O
desire	NN	O
score	NN	O
,	,	O
but	CC	O
with	IN	O
statistical	JJ	O
significance	NN	O
only	RB	O
for	IN	O
EE20/LNG100	NNP	Pharmacological
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
EE30/LNG150	NNP	Pharmacological
decreased	VBD	O
plasma	JJ	O
androgen	NN	O
levels	NNS	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
impairment	NN	O
in	IN	O
sexual	JJ	O
desire	NN	O
,	,	O
on	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
sexual	JJ	O
desire	NN	O
score	NN	O
increased	VBD	O
with	IN	O
EE20/LNG100	NNP	Pharmacological
formulation	NN	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
(	(	O
gamma	NN	Pharmacological
linolenic	RB	Pharmacological
acid	NN	Pharmacological
)	)	O
and	CC	O
fish	JJ	O
oil	NN	O
(	(	O
eicosapentaenoic	JJ	Pharmacological
+	NNP	Pharmacological
docahexaenoic	NN	Pharmacological
acid	NN	Pharmacological
)	)	O
versus	NN	O
magnesium	NN	Pharmacological
,	,	O
and	CC	O
versus	NN	O
placebo	NN	Control
in	IN	O
preventing	VBG	O
pre-eclampsia	NN	O
.	.	O

In	IN	O
a	DT	O
placebo	NN	Control
controlled	VBN	O
,	,	O
partially	RB	O
double-blinded	JJ	O
,	,	O
clinical	JJ	O
trial	NN	O
,	,	O
a	DT	O
combination	NN	O
of	IN	O
evening	VBG	O
primrose	JJ	O
oil	NN	O
and	CC	O
fish	JJ	O
oil	NN	O
was	VBD	O
compared	VBN	O
to	TO	O
Magnesium	NNP	Pharmacological
Oxide	NNP	Pharmacological
,	,	O
and	CC	O
to	TO	O
a	DT	O
Placebo	NNP	Control
in	IN	O
preventing	VBG	O
Pre-Eclampsia	NNP	O
of	IN	O
Pregnancy	NNP	O
.	.	O

All	DT	O
were	VBD	O
given	VBN	O
as	IN	O
nutritional	JJ	O
supplements	NNS	O
for	IN	O
six	CD	O
months	NNS	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
primiparous	JJ	O
and	CC	O
multiparous	JJ	O
pregnant	JJ	O
women	NNS	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
women	NNS	O
had	VBD	O
personal	JJ	O
or	CC	O
family	NN	O
histories	NNS	O
of	IN	O
hypertension	NN	O
(	(	O
21	CD	O
%	NN	O
)	)	O
.	.	O

Only	RB	O
those	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
prenatal	JJ	O
care	NN	O
at	IN	O
the	DT	O
Central	NNP	O
Maternity	NNP	O
Hospital	NNP	O
for	IN	O
Luanda	NNP	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
Placebo	NNP	Control
group	NN	O
(	(	O
29	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
group	NN	O
receiving	VBG	O
the	DT	O
mixture	NN	O
of	IN	O
evening	VBG	Pharmacological
primrose	JJ	Pharmacological
oil	NN	Pharmacological
and	CC	O
fish	JJ	Pharmacological
oil	NN	Pharmacological
containing	VBG	O
Gamma-linolenic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
GLA	NNP	Pharmacological
)	)	Pharmacological
,	,	O
Eicosapentaenoic	NNP	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
EPA	NNP	Pharmacological
)	)	Pharmacological
,	,	O
and	CC	O
Docosahexaenoic	NNP	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
DHA	NNP	Pharmacological
)	)	Pharmacological
had	VBD	O
a	DT	O
significantly	RB	O
lower	JJR	O
incidence	NN	O
of	IN	O
edema	NN	O
(	(	O
13	CD	O
%	NN	O
,	,	O
p	NN	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
group	NN	O
receiving	VBG	O
Magnesium	NNP	Pharmacological
Oxide	NNP	Pharmacological
had	VBD	O
statistically	RB	O
significant	JJ	O
fewer	JJR	O
subjects	NNS	O
who	WP	O
developed	VBD	O
hypertension	NN	O
of	IN	O
pregnancy	NN	O
.	.	O

There	EX	O
were	VBD	O
3	CD	O
cases	NNS	O
of	IN	O
eclampsia	NN	O
,	,	O
all	DT	O
in	IN	O
the	DT	O
Placebo	NNP	Control
group	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	O
parallel	NN	O
study	NN	O
of	IN	O
loteprednol	JJ	Pharmacological
etabonate	JJ	Pharmacological
0.2	CD	O
%	NN	O
in	IN	O
patients	NNS	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
conjunctivitis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
loteprednol	JJ	Pharmacological
etabonate	NN	Pharmacological
(	(	Pharmacological
LE	NNP	Pharmacological
)	)	Pharmacological
0.2	CD	O
%	NN	O
in	IN	O
reducing	VBG	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
seasonal	JJ	O
allergic	JJ	O
conjunctivitis	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-masked	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
parallel	JJ	O
group	NN	O
multicenter	RBR	O
study	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
duration	NN	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
135	CD	O
patients	NNS	O
with	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
seasonal	JJ	O
allergic	JJ	O
conjunctivitis	NN	O
participated	VBD	O
.	.	O

INTERVENTION	NNP	O
All	NNP	O
patients	NNS	O
received	VBD	O
either	RB	O
LE	NNP	Pharmacological
0.2	CD	Pharmacological
%	NN	Pharmacological
or	CC	O
placebo	NN	Control
(	(	O
vehicle	NN	O
)	)	O
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
in	IN	O
both	DT	O
eyes	NNS	O
for	IN	O
42	CD	O
days	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Bulbar	NNP	O
conjunctival	NN	O
injection	NN	O
(	(	O
primary	JJ	O
sign	NN	O
)	)	O
and	CC	O
itching	VBG	O
(	(	O
primary	JJ	O
symptom	NN	O
)	)	O
over	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	VB	O
A	DT	O
reduction	NN	O
in	IN	O
severity	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
both	DT	O
LE	NNP	O
and	CC	O
placebo	NN	O
groups	NNS	O
for	IN	O
bulbar	NN	O
conjunctival	NN	O
injection	NN	O
(	(	O
1.5	CD	O
vs.	FW	O
1.0	CD	O
units	NNS	O
on	IN	O
a	DT	O
0-3	JJ	O
scale	NN	O
)	)	O
and	CC	O
itching	VBG	O
(	(	O
3.4	CD	O
vs.	FW	O
3.0	CD	O
units	NNS	O
on	IN	O
a	DT	O
0-4	JJ	O
scale	NN	O
)	)	O
over	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
by	IN	O
these	DT	O
measures	NNS	O
was	VBD	O
-0.5	NNP	O
and	CC	O
-0.4	NNP	O
units	NNS	O
in	IN	O
favor	NN	O
of	IN	O
LE	NNP	O
(	(	O
P	NNP	O
<	NNP	O
or	CC	O
=	VB	O
0.008	CD	O
)	)	O
.	.	O

Resolution	NNP	O
(	(	O
i.e.	NN	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
signs	NNS	O
or	CC	O
symptoms	VBZ	O
no	DT	O
longer	RBR	O
present	JJ	O
)	)	O
at	IN	O
day	NN	O
14	CD	O
strongly	RB	O
favored	VBN	O
LE-treated	JJ	O
patients	NNS	O
(	(	O
36	CD	O
%	NN	O
and	CC	O
15	CD	O
%	NN	O
;	:	O
58	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
,	,	O
for	IN	O
injection	NN	O
and	CC	O
itching	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

One	CD	O
patient	NN	O
in	IN	O
each	DT	O
treatment	NN	O
group	NN	O
(	(	O
1	CD	O
of	IN	O
67	CD	O
and	CC	O
1	CD	O
of	IN	O
68	CD	O
,	,	O
respectively	RB	O
)	)	O
had	VBD	O
an	DT	O
elevation	NN	O
of	IN	O
intraocular	JJ	O
pressure	NN	O
of	IN	O
10	CD	O
mmHg	NN	O
or	CC	O
greater	JJR	O
during	IN	O
the	DT	O
6	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Loteprednol	NNP	O
etabonate	VB	O
0.2	CD	O
%	NN	O
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
seasonal	JJ	O
allergic	JJ	O
conjunctivitis	NN	O
.	.	O

Loteprednol	NNP	O
etabonate	VBP	O
0.2	CD	O
%	NN	O
had	VBD	O
a	DT	O
safety	NN	O
profile	NN	O
comparable	JJ	O
to	TO	O
placebo	VB	O
.	.	O

Epileptogenic	JJ	O
activity	NN	O
of	IN	O
folic	JJ	O
acid	NN	O
after	IN	O
drug	NN	O
induces	NNS	O
SLE	NNP	O
(	(	O
folic	JJ	O
acid	NN	O
and	CC	O
epilepsy	NN	O
)	)	O
OBJECTIVE	NN	O
To	TO	O
study	VB	O
the	DT	O
effect	NN	O
of	IN	O
folic	JJ	Pharmacological
acid-containing	JJ	Pharmacological
multivitamin	NN	Pharmacological
supplementation	NN	Pharmacological
in	IN	O
epileptic	JJ	O
women	NNS	O
before	IN	O
and	CC	O
during	IN	O
pregnancy	NN	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
the	DT	O
rate	NN	O
of	IN	O
structural	JJ	O
birth	NN	O
defects	NNS	O
and	CC	O
epilepsy-related	JJ	O
side	NN	O
effects	NNS	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
First	NNP	O
a	DT	O
randomised	JJ	O
trial	NN	O
,	,	O
later	RB	O
periconception	NN	O
care	NN	O
including	VBG	O
in	IN	O
total	JJ	O
12225	CD	O
females	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
60	CD	O
epileptic	JJ	O
women	NNS	O
with	IN	O
periconceptional	JJ	Pharmacological
folic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	O
0.8	CD	O
mg	NN	O
)	)	O
-containing	VBG	Pharmacological
multivitamin	JJ	Pharmacological
supplementation	NN	Pharmacological
,	,	O
no	DT	O
one	NN	O
developed	VBD	O
epilepsy-related	JJ	O
side	NN	O
effects	NNS	O
during	IN	O
the	DT	O
periconception	NN	O
period	NN	O
.	.	O

One	CD	O
epileptic	JJ	O
woman	NN	O
delivered	VBD	O
a	DT	O
newborn	JJ	O
with	IN	O
cleft	NN	O
lip	NN	O
and	CC	O
palate	NN	O
.	.	O

Another	DT	O
patient	NN	O
exhibited	VBN	O
with	IN	O
a	DT	O
cluster	NN	O
of	IN	O
seizures	NNS	O
after	IN	O
the	DT	O
periconception	NN	O
period	NN	O
using	VBG	O
another	DT	O
multivitamin	NN	O
.	.	O

This	DT	O
22-year-old	JJ	O
epileptic	JJ	O
woman	NN	O
was	VBD	O
treated	VBN	O
continuously	RB	O
by	IN	O
carbamazepine	NN	Pharmacological
and	CC	Pharmacological
a	DT	Pharmacological
folic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	O
1	CD	O
mg	NN	O
)	)	O
-containing	VBG	Pharmacological
multivitamin	NN	Pharmacological
from	IN	O
the	DT	O
20th	JJ	O
week	NN	O
of	IN	O
gestation	NN	O
.	.	O

She	PRP	O
developed	VBD	O
status	NN	O
epilepticus	NN	O
and	CC	O
later	RB	O
symptoms	NNS	O
of	IN	O
systemic	JJ	O
lupus	NN	O
erythematodes	NNS	O
.	.	O

Her	PRP$	O
pregnancy	NN	O
ended	VBN	O
with	IN	O
stillbirth	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
epileptic	JJ	O
pregnant	JJ	O
patient	NN	O
's	POS	O
autoimmune	JJ	O
disease	NN	O
(	(	O
probably	RB	O
drug-induced	JJ	O
lupus	NN	O
)	)	O
could	MD	O
damage	VB	O
the	DT	O
blood-brain	JJ	O
barrier	NN	O
,	,	O
therefore	IN	O
the	DT	O
therapeutic	JJ	O
dose	NN	O
(	(	O
>	CD	O
or	CC	O
=1	VB	O
mg	NN	O
)	)	O
of	IN	O
folic	JJ	O
acid	NN	O
triggered	VBD	O
a	DT	O
cluster	NN	O
of	IN	O
seizures	NNS	O
.	.	O

Physiological	NNP	O
dose	NN	O
(	(	O
<	JJ	O
1	CD	O
mg	NN	O
)	)	O
of	IN	O
folic	JJ	O
acid	NNS	O
both	DT	O
in	IN	O
healthy	JJ	O
and	CC	O
60	CD	O
epileptic	JJ	O
women	NNS	O
,	,	O
all	DT	O
without	IN	O
any	DT	O
autoimmune	JJ	O
disease	NN	O
,	,	O
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	O
for	IN	O
epileptic	JJ	O
seizures	NNS	O
.	.	O

Mending	VBG	O
the	DT	O
rhythm	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
prognosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
persistent	JJ	O
atrial	JJ	O
fibrillation	NN	O
:	:	O
a	DT	O
subanalysis	NN	O
of	IN	O
the	DT	O
RACE	NNP	O
study	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
compare	VB	O
outcome	NN	O
of	IN	O
AF	NNP	O
patients	NNS	O
with	IN	O
effective	JJ	O
rhythm	NNS	O
control	NN	O
with	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
rate	NN	O
control	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Out	NNP	O
of	IN	O
the	DT	O
266	CD	O
AF	NNP	O
patients	NNS	O
randomized	VBD	O
to	TO	O
rhythm	VB	Physical
control	NN	Physical
in	IN	O
the	DT	O
RACE	NNP	O
study	NN	O
,	,	O
49	CD	O
patients	NNS	O
turned	VBD	O
to	TO	O
long-term	JJ	Physical
sinus	NN	Physical
rhythm	NN	Physical
and	CC	O
were	VBD	O
continuously	RB	O
treated	VBN	O
with	IN	O
oral	JJ	Pharmacological
anticoagulation	NN	Pharmacological
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
in	IN	O
these	DT	O
patients	NNS	O
was	VBD	O
compared	VBN	O
to	TO	O
that	DT	O
in	IN	O
178	CD	O
patients	NNS	O
out	IN	O
of	IN	O
the	DT	O
initial	JJ	O
256	CD	O
rate-control	JJ	O
patients	NNS	O
of	IN	O
RACE	NNP	O
who	WP	O
were	VBD	O
in	IN	O
AF	NNP	O
and	CC	O
using	VBG	O
oral	JJ	O
anticoagulation	NN	O
continuously	RB	O
.	.	O

Baseline	NNP	O
characteristics	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
not	RB	O
different	JJ	O
.	.	O

After	IN	O
a	DT	O
mean	JJ	O
follow-up	NN	O
of	IN	O
2.3+/-0.6	CD	O
years	NNS	O
,	,	O
the	DT	O
primary	JJ	O
endpoint	NN	O
(	(	O
a	DT	O
composite	NN	O
of	IN	O
cardiovascular	JJ	O
mortality	NN	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
thrombo-embolic	JJ	O
complications	NNS	O
(	(	O
TECs	NNP	O
)	)	O
,	,	O
bleeding	VBG	O
,	,	O
serious	JJ	O
adverse	JJ	O
effects	NNS	O
of	IN	O
antiarrhythmic	JJ	O
drugs	NNS	O
and	CC	O
pacemaker	NN	O
implants	NNS	O
)	)	O
was	VBD	O
22.4	CD	O
%	NN	O
in	IN	O
the	DT	O
rhythm-control	NN	O
group	NN	O
vs.	FW	O
15.2	CD	O
%	NN	O
in	IN	O
the	DT	O
rate-control	NN	O
group	NN	O
.	.	O

Multivariable	JJ	O
regression	NN	O
analysis	NN	O
indicated	VBD	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
and	CC	O
digitalis	RB	O
as	IN	O
independent	JJ	O
risk	NN	O
indicators	NNS	O
of	IN	O
cardiovascular	JJ	O
morbidity	NN	O
and	CC	O
mortality	NN	O
.	.	O

Chronic	NNP	O
sinus	NN	O
rhythm	NN	O
did	VBD	O
not	RB	O
matter	NN	O
.	.	O

CONCLUSION	NNP	O
Among	IN	O
patients	NNS	O
who	WP	O
remained	VBD	O
on	IN	O
warfarin	NN	Pharmacological
,	,	O
those	DT	O
who	WP	O
mostly	RB	O
were	VBD	O
maintained	VBN	O
in	IN	O
sinus	NN	O
rhythm	NN	O
under	IN	O
a	DT	O
rhythm-control	JJ	O
strategy	NN	O
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
superior	JJ	O
prognosis	NN	O
compared	VBN	O
to	TO	O
those	DT	O
who	WP	O
remained	VBD	O
in	IN	O
AF	NNP	O
under	IN	O
a	DT	O
rate-control	JJ	O
strategy	NN	O
.	.	O

Bizzy	NNP	O
Break	NNP	O
!	.	O
The	DT	O
effect	NN	O
of	IN	O
a	DT	O
classroom-based	JJ	Educational
activity	NN	Educational
break	NN	Educational
on	IN	O
in-school	JJ	O
physical	JJ	O
activity	NN	O
levels	NNS	O
of	IN	O
primary	JJ	O
school	NN	O
children	NNS	O
.	.	O

The	DT	O
school	NN	O
has	VBZ	O
been	VBN	O
identified	VBN	O
as	IN	O
a	DT	O
key	JJ	O
setting	NN	O
to	TO	O
promote	VB	O
physical	JJ	O
activity	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
classroom-based	JJ	Educational
activity	NN	Educational
break	NN	Educational
on	IN	O
in-school	JJ	O
step	NN	O
counts	NNS	O
of	IN	O
primary	JJ	O
school	NN	O
children	NNS	O
.	.	O

Data	NNP	O
for	IN	O
90	CD	O
children	NNS	O
(	(	O
49	CD	O
boys	NNS	O
,	,	O
41	CD	O
girls	NNS	O
,	,	O
9.3	CD	O
?	.	O
1.4	CD	O
years	NNS	O
)	)	O
from	IN	O
three	CD	O
Irish	JJ	O
primary	NN	O
schools	NNS	O
is	VBZ	O
presented	VBN	O
.	.	O

In	IN	O
each	DT	O
school	NN	O
one	CD	O
class	NN	O
was	VBD	O
randomly	RB	O
assigned	VBN	O
as	IN	O
the	DT	O
intervention	NN	O
group	NN	O
and	CC	O
another	DT	O
as	IN	O
controls	NNS	O
.	.	O

Children	NNP	O
's	POS	O
step	NN	O
counts	NNS	O
were	VBD	O
measured	VBN	O
for	IN	O
five	CD	O
consecutive	JJ	O
days	NNS	O
during	IN	O
school	NN	O
hours	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
follow-up	NN	O
.	.	O

Teachers	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
classes	VBZ	O
led	VBD	O
a	DT	O
10	CD	O
min	NN	O
activity	NN	O
break	NN	O
in	IN	O
the	DT	O
classroom	NN	O
each	DT	O
day	NN	O
(	(	O
Bizzy	NNP	O
Break	NNP	O
!	.	O
)	)	O
.	.	O

Mean	JJ	O
daily	JJ	O
in-school	JJ	O
steps	NNS	O
for	IN	O
the	DT	O
intervention	NN	O
at	IN	O
baseline	NN	O
and	CC	O
follow-up	NN	O
were	VBD	O
5351	CD	O
and	CC	O
5054	CD	O
.	.	O

Corresponding	VBG	O
values	NNS	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
5469	CD	O
and	CC	O
4246	CD	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
change	NN	O
in	IN	O
daily	JJ	O
steps	NNS	O
from	IN	O
baseline	NN	O
to	TO	O
follow-up	NN	O
between	IN	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
girls	NNS	O
and	CC	O
boys	NNS	O
responded	VBD	O
differently	RB	O
to	TO	O
the	DT	O
intervention	NN	O
(	(	O
p	JJ	O
>	NNP	O
.05	NNP	O
)	)	O
.	.	O

Children	NNP	O
participating	VBG	O
in	IN	O
a	DT	O
daily	JJ	O
10	CD	O
min	JJ	O
classroom-based	JJ	O
activity	NN	O
break	VB	O
undertake	JJ	O
more	JJR	O
physical	JJ	O
activity	NN	O
during	IN	O
school	NN	O
hours	NNS	O
than	IN	O
controls	NNS	O
.	.	O

Pilot	NNP	O
study	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
weighted	JJ	Physical
vests	NNS	Physical
.	.	O

OBJECTIVE	NN	O
In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
we	PRP	O
determined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
weighted	JJ	Physical
vest	NN	Physical
on	IN	O
attention	NN	O
to	TO	O
task	VB	O
for	IN	O
second-grade	JJ	O
general	JJ	O
education	NN	O
students	NNS	O
with	IN	O
difficulty	NN	O
attending	VBG	O
.	.	O

METHOD	NNP	O
We	PRP	O
used	VBD	O
an	DT	O
intervention	NN	Physical
and	CC	O
a	DT	O
control	NN	Control
group	NN	O
and	CC	O
an	DT	O
ABA	NNP	O
design	NN	O
to	TO	O
compare	VB	O
participants	NNS	O
'	POS	O
percentage	NN	O
of	IN	O
time	NN	O
on	IN	O
task	NN	O
with	IN	Other
and	CC	Other
without	IN	Other
a	DT	Other
vest	NN	Other
.	.	O

Ten	CD	O
participants	NNS	O
from	IN	O
nine	CD	O
elementary	JJ	O
schools	NNS	O
in	IN	O
a	DT	O
suburban	JJ	O
Texas	NNP	O
school	NN	O
district	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	Physical
or	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

Control	NNP	O
group	NN	O
participants	NNS	O
wore	VBD	O
a	DT	O
nonweighted	JJ	Other
vest	NN	Other
.	.	O

Participants	NNS	O
,	,	O
classroom	NN	O
teachers	NNS	O
,	,	O
and	CC	O
research	NN	O
assistants	NNS	O
who	WP	O
coded	VBD	O
the	DT	O
data	NNS	O
were	VBD	O
blind	RB	O
as	IN	O
to	TO	O
the	DT	O
group	NN	O
to	TO	O
which	WDT	O
the	DT	O
participants	NNS	O
were	VBD	O
assigned	VBN	O
.	.	O

RESULTS	VB	O
A	NNP	O
repeated	JJ	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
indicated	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
or	CC	O
between	IN	O
baseline	NN	O
,	,	O
intervention	NN	O
,	,	O
and	CC	O
withdrawal	NN	O
conditions	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
weighted	JJ	Physical
vests	NNS	Physical
were	VBD	O
not	RB	O
effective	JJ	O
in	IN	O
increasing	VBG	O
time	NN	O
on	IN	O
task	NN	O
.	.	O

These	DT	O
results	NNS	O
should	MD	O
be	VB	O
generalized	VBN	O
cautiously	RB	O
owing	VBG	O
to	TO	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
and	CC	O
participant	JJ	O
selection	NN	O
process	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
aging	VBG	O
on	IN	O
circulating	VBG	O
levels	NNS	O
of	IN	O
proinflammatory	NN	O
cytokines	NNS	O
during	IN	O
septic	JJ	O
shock	NN	O
.	.	O

Norasept	NNP	Pharmacological
II	NNP	Pharmacological
Study	NNP	O
Investigators	NNP	O
.	.	O

BACKGROUND	NNP	O
As	IN	O
the	DT	O
proportion	NN	O
of	IN	O
the	DT	O
population	NN	O
that	WDT	O
is	VBZ	O
older	JJR	O
continues	VBZ	O
to	TO	O
rise	VB	O
,	,	O
infection	NN	O
in	IN	O
older	JJR	O
people	NNS	O
has	VBZ	O
become	VBN	O
an	DT	O
important	JJ	O
healthcare	NN	O
problem	NN	O
.	.	O

Although	IN	O
aging	VBG	O
is	VBZ	O
associated	VBN	O
with	IN	O
multiple	JJ	O
abnormalities	NNS	O
in	IN	O
immune	JJ	O
function	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
aging	VBG	O
on	IN	O
the	DT	O
production	NN	O
of	IN	O
proinflammatory	NN	O
cytokines	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
well	RB	O
studied	VBN	O
under	IN	O
conditions	NNS	O
of	IN	O
clinical	JJ	O
stress	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
aging	VBG	O
on	IN	O
circulating	VBG	O
levels	NNS	O
of	IN	O
the	DT	O
proinflammatory	NN	O
cytokines	NNS	O
in	IN	O
a	DT	O
large	JJ	O
cohort	NN	O
of	IN	O
septic	JJ	O
shock	NN	O
patients	NNS	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
aging	VBG	O
would	MD	O
be	VB	O
associated	VBN	O
with	IN	O
a	DT	O
diminished	JJ	O
proinflammatory	NN	O
cytokine	NN	O
response	NN	O
to	TO	O
sepsis	NN	O
.	.	O

DESIGN	NNP	O
Patients	NNPS	O
with	IN	O
septic	JJ	O
shock	NN	O
who	WP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
placebo	NN	Control
limb	NN	O
of	IN	O
the	DT	O
North	JJ	Other
American	JJ	Other
Sepsis	NNP	Other
Trial	NNP	Other
(	(	Other
NORASEPT	NNP	Other
II	NNP	Other
)	)	Other
study	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

SETTING	VBG	O
The	DT	O
intensive	JJ	O
care	NN	O
units	NNS	O
of	IN	O
105	CD	O
hospitals	NNS	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
and	CC	O
Canada	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Nine	NNP	O
hundred	VBD	O
and	CC	O
thirty	JJ	O
patients	NNS	O
presenting	VBG	O
to	TO	O
hospital	VB	O
within	IN	O
12	CD	O
hours	NNS	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
septic	JJ	O
shock	NN	O
.	.	O

MEASUREMENTS	NNP	O
Interleukin-6	NNP	O
(	(	O
IL-6	NNP	O
)	)	O
,	,	O
tumor	JJ	O
necrosis	NN	O
factor-alpha	NN	O
(	(	O
TNF-alpha	NNP	O
)	)	O
,	,	O
soluble	JJ	O
tumor	NN	O
necrosis	NN	O
factor-receptor-55	JJ	O
(	(	O
sTNF-R55	JJ	O
)	)	O
,	,	O
and	CC	O
soluble	JJ	O
tumor	NN	O
necrosis	NN	O
factor-receptor-75	JJ	O
(	(	O
sTNF-R75	JJ	O
)	)	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
enrollment	NN	O
.	.	O

The	DT	O
study	NN	O
population	NN	O
was	VBD	O
broken	VBN	O
down	RP	O
into	IN	O
five	CD	O
age	NN	O
groups	NNS	O
as	IN	O
follows	VBZ	O
:	:	O
less	JJR	O
than	IN	O
50	CD	O
years	NNS	O
(	(	O
group	NN	O
one	CD	O
)	)	O
,	,	O
50	CD	O
to	TO	O
64	CD	O
years	NNS	O
(	(	O
group	NN	O
two	CD	O
)	)	O
,	,	O
65	CD	O
to	TO	O
74	CD	O
years	NNS	O
(	(	O
group	NN	O
three	CD	O
)	)	O
,	,	O
75	CD	O
to	TO	O
84	CD	O
years	NNS	O
(	(	O
group	NN	O
four	CD	O
)	)	O
,	,	O
and	CC	O
85	CD	O
or	CC	O
older	JJR	O
(	(	O
group	NN	O
five	CD	O
)	)	O
.	.	O

Clinical	JJ	O
,	,	O
demographic	JJ	O
,	,	O
and	CC	O
cytokine	NN	O
data	NNS	O
were	VBD	O
extracted	VBN	O
to	TO	O
describe	VB	O
each	DT	O
age	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
were	VBD	O
available	JJ	O
for	IN	O
930	CD	O
patients	NNS	O
.	.	O

The	DT	O
patients	NNS	O
'	POS	O
mean	JJ	O
age	NN	O
(	(	O
+/-	JJ	O
SD	NNP	O
)	)	O
was	VBD	O
59	CD	O
+/-	JJ	O
17	CD	O
years	NNS	O
(	(	O
range	NN	O
,	,	O
18	CD	O
to	TO	O
102	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
280	CD	O
patients	NNS	O
in	IN	O
group	NN	O
one	CD	O
,	,	O
242	CD	O
in	IN	O
group	NN	O
two	CD	O
,	,	O
210	CD	O
in	IN	O
group	NN	O
three	CD	O
,	,	O
150	CD	O
in	IN	O
group	NN	O
four	CD	O
,	,	O
and	CC	O
48	CD	O
in	IN	O
group	NN	O
five	CD	O
.	.	O

The	DT	O
primary	JJ	O
diagnoses	NNS	O
;	:	O
clinical	JJ	O
characteristics	NNS	O
;	:	O
and	CC	O
IL-6	NNP	O
,	,	O
sTNF-R55	NN	O
,	,	O
and	CC	O
sTNF-R75	JJ	O
levels	NNS	O
were	VBD	O
similar	JJ	O
among	IN	O
the	DT	O
five	CD	O
age	NN	O
groups	NNS	O
.	.	O

The	DT	O
TNF-alpha	JJ	O
levels	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
,	,	O
however	RB	O
,	,	O
in	IN	O
the	DT	O
oldest	JJS	O
group	NN	O
of	IN	O
patients	NNS	O
(	(	O
group	NN	O
five	CD	O
)	)	O
.	.	O

The	DT	O
28-day	JJ	O
survival	NN	O
was	VBD	O
49	CD	O
%	NN	O
in	IN	O
patients	NNS	O
over	IN	O
the	DT	O
age	NN	O
of	IN	O
75	CD	O
and	CC	O
58	CD	O
%	NN	O
in	IN	O
those	DT	O
under	IN	O
75	CD	O
years	NNS	O
(	(	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
gender	NN	O
difference	NN	O
in	IN	O
survival	NN	O
or	CC	O
cytokine	NN	O
levels	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Contrary	NNP	O
to	TO	O
our	PRP$	O
expectations	NNS	O
,	,	O
we	PRP	O
found	VBD	O
that	IN	O
aging	VBG	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
a	DT	O
decline	NN	O
in	IN	O
the	DT	O
circulating	NN	O
levels	NNS	O
of	IN	O
proinflammatory	NN	O
cytokines	NNS	O
.	.	O

Pars	NNS	Surgical
plana	VBP	Surgical
vitrectomy	NN	Surgical
for	IN	O
diabetic	JJ	O
macular	JJ	O
edema	NN	O
.	.	O

Internal	NNP	Surgical
limiting	VBG	Surgical
membrane	NN	Surgical
delamination	NN	Surgical
vs	FW	O
posterior	JJ	Surgical
hyaloid	NN	Surgical
removal	NN	Surgical
.	.	O

A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Diabetes	VBZ	O
mellitus	RB	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
subsequent	JJ	O
ocular	JJ	O
complications	NNS	O
such	JJ	O
as	IN	O
cystoid	JJ	O
macular	JJ	O
edema	NN	O
(	(	O
CME	NNP	O
)	)	O
,	,	O
are	VBP	O
of	IN	O
fundametal	JJ	O
socio-economic	JJ	O
relevance	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
evaluated	VBD	O
the	DT	O
influence	NN	O
of	IN	O
internal	JJ	Surgical
limiting	VBG	Surgical
membrane	NN	Surgical
(	(	Surgical
ILM	NNP	Surgical
)	)	Surgical
removal	NN	Surgical
on	IN	O
longterm	JJ	O
morphological	JJ	O
and	CC	O
functional	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
mellitus	NNS	O
(	(	O
DM	NNP	O
)	)	O
type	NN	O
2	CD	O
and	CC	O
chronic	JJ	O
CME	NNP	O
without	IN	O
evident	JJ	O
vitreomacular	JJ	O
traction	NN	O
.	.	O

METHOD	NNP	O
Forty	NNP	O
eyes	NNS	O
with	IN	O
attached	JJ	O
posterior	JJ	O
hyaloid	NN	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
prospective	JJ	O
trial	NN	O
and	CC	O
randomized	VBN	O
intraoperatively	RB	O
.	.	O

Prior	NNP	O
focal	JJ	O
(	(	O
n	JJ	O
=	NNP	O
31	CD	O
)	)	O
or	CC	O
panretinal	JJ	O
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
laser	JJR	O
coagulation	NN	O
was	VBD	O
permitted	VBN	O
.	.	O

Group	NNP	O
I	PRP	O
(	(	O
n	JJ	O
=	$	O
19	CD	O
patients	NNS	O
)	)	O
underwent	JJ	O
surgical	JJ	O
induction	NN	O
of	IN	O
posterior	JJ	O
vitreous	JJ	O
detachment	NN	O
(	(	O
PVD	NNP	O
)	)	O
,	,	O
group	NN	O
II	NNP	O
(	(	O
n	JJ	O
=	$	O
20	CD	O
patients	NNS	O
)	)	O
PVD	NNP	O
and	CC	O
removal	NN	O
of	IN	O
the	DT	O
ILM	NNP	O
.	.	O

Eleven	NNP	O
patients	NNS	O
with	IN	O
detached	JJ	O
posterior	JJ	O
hyaloid	NN	O
(	(	O
group	NN	O
III	NNP	O
)	)	O
were	VBD	O
not	RB	O
randomized	VBN	O
,	,	O
and	CC	O
ILM	NNP	O
removal	NN	O
was	VBD	O
performed	VBN	O
.	.	O

One	CD	O
eye	NN	O
had	VBD	O
to	TO	O
be	VB	O
excluded	VBN	O
from	IN	O
further	JJ	O
analysis	NN	O
.	.	O

Examinations	NNS	O
included	VBD	O
ETDRS	NNP	O
best-corrected	JJ	O
visual	JJ	O
acuity	NN	O
(	(	O
BCVA	NNP	O
)	)	O
,	,	O
fluorescein	JJ	O
angiography	NN	O
(	(	O
FLA	NNP	O
)	)	O
and	CC	O
OCT	NNP	O
at	IN	O
baseline	NN	O
,	,	O
3	CD	O
and	CC	O
6	CD	O
months	NNS	O
postoperatively	RB	O
.	.	O

Main	NNP	O
outcome	JJ	O
measure	NN	O
was	VBD	O
BCVA	NNP	O
at	IN	O
6	CD	O
months	NNS	O
,	,	O
secondary	JJ	O
was	VBD	O
foveal	JJ	O
thickness	NN	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
BCVA	NNP	O
over	IN	O
6	CD	O
months	NNS	O
remained	VBD	O
unchanged	JJ	O
in	IN	O
85	CD	O
%	NN	O
of	IN	O
patients	NNS	O
of	IN	O
group	NN	O
II	NNP	O
,	,	O
and	CC	O
decreased	VBD	O
in	IN	O
53	CD	O
%	NN	O
of	IN	O
patients	NNS	O
of	IN	O
group	NN	O
I	PRP	O
.	.	O

Results	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
different	JJ	O
[	NNP	O
group	NN	O
I	PRP	O
:	:	O
mean	JJ	O
decrease	NN	O
log	NN	O
MAR	NNP	O
95	CD	O
%	NN	O
CI	NNP	O
(	(	O
0.06	CD	O
;	:	O
0.32	CD	O
)	)	O
,	,	O
group	NN	O
II	NNP	O
:	:	O
(	(	O
-0.02	VBP	O
;	:	O
0.11	CD	O
)	)	O
]	NN	O
.	.	O

OCT	NNP	O
revealed	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
reduction	NN	O
of	IN	O
foveal	JJ	O
thickness	NN	O
following	VBG	O
PVD	NNP	O
with	IN	O
ILM	NNP	O
removal	NN	O
[	NNP	O
group	NN	O
I	PRP	O
:	:	O
mean	JJ	O
change	NN	O
:	:	O
95	CD	O
%	NN	O
CI	NNP	O
(	(	O
-208.95	NNP	O
?m	NNP	O
;	:	O
-78.05	NNP	O
?m	NNP	O
)	)	O
,	,	O
group	NN	O
II	NNP	O
:	:	O
(	(	O
-80.90	JJ	O
?m	NN	O
:	:	O
+59.17	JJ	O
?m	NN	O
)	)	O
]	NN	O
.	.	O

CONCLUSION	NNP	O
Vitrectomy	NNP	O
,	,	O
PVD	NNP	O
with	IN	O
or	CC	O
without	IN	O
ILM	NNP	O
removal	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
vision	NN	O
in	IN	O
patients	NNS	O
with	IN	O
DM	NNP	O
type	NN	O
2	CD	O
and	CC	O
cystoid	JJ	O
diabetic	JJ	O
macular	NN	O
edema	NN	O
without	IN	O
evident	JJ	O
vitreoretinal	JJ	O
traction	NN	O
.	.	O

ILM	NNP	O
delamination	NN	O
shows	VBZ	O
improved	JJ	O
morphological	JJ	O
results	NNS	O
,	,	O
and	CC	O
appears	VBZ	O
to	TO	O
be	VB	O
beneficial	JJ	O
in	IN	O
eyes	NNS	O
with	IN	O
preexisting	VBG	O
PVD	NNP	O
.	.	O

Mandibular	JJ	O
overdentures	NNS	O
supported	VBN	O
by	IN	O
two	CD	O
Br?nemark	NNP	O
,	,	O
IMZ	NNP	O
or	CC	O
ITI	NNP	O
implants	NNS	O
:	:	O
a	DT	O
5-year	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
comparative	NN	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
survival	NN	O
rate	NN	O
and	CC	O
the	DT	O
condition	NN	O
of	IN	O
the	DT	O
peri-implant	JJ	O
tissues	NNS	O
of	IN	O
the	DT	O
IMZ	NNP	O
implant	NN	O
system	NN	O
(	(	O
two-stage	JJ	O
cylindertype	NN	O
)	)	O
,	,	O
the	DT	O
Br?nemark	NNP	O
implant	NN	O
system	NN	O
(	(	O
two-stage	JJ	O
screwtype	NN	O
)	)	O
and	CC	O
the	DT	O
ITI	NNP	O
implant	NN	O
system	NN	O
(	(	O
one-stage	JJ	O
screwtype	NN	O
)	)	O
supporting	VBG	O
a	DT	O
mandibular	JJ	O
overdenture	NN	O
during	IN	O
a	DT	O
5-year	JJ	O
follow-up	JJ	O
period	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
Three	NNP	O
groups	NNS	O
of	IN	O
30	CD	O
edentulous	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
two	CD	O
endosseous	JJ	O
implants	NNS	O
in	IN	O
the	DT	O
interforaminal	JJ	O
region	NN	O
of	IN	O
the	DT	O
mandible	JJ	O
.	.	O

Clinical	JJ	O
and	CC	O
radiographic	JJ	O
parameters	NNS	O
were	VBD	O
evaluated	VBN	O
immediately	RB	O
after	IN	O
completion	NN	O
of	IN	O
the	DT	O
prosthetic	JJ	O
treatment	NN	O
and	CC	O
after	IN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
and	CC	O
5	CD	O
years	NNS	O
of	IN	O
functional	JJ	O
loading	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
five-year	JJ	O
survival	NN	O
rate	NN	O
is	VBZ	O
98.3	CD	O
%	NN	O
for	IN	O
the	DT	O
IMZ	NNP	O
group	NN	O
,	,	O
98.3	CD	O
%	NN	O
for	IN	O
the	DT	O
Br?	NNP	O
group	NN	O
and	CC	O
100	CD	O
%	NN	O
for	IN	O
the	DT	O
ITI	NNP	O
group	NN	O
.	.	O

Mean	NNP	O
scores	VBZ	O
on	IN	O
indices	NNS	O
for	IN	O
plaque	NN	O
,	,	O
calculus	NN	O
,	,	O
gingiva	NN	O
and	CC	O
bleeding	NN	O
were	VBD	O
very	RB	O
low	JJ	O
at	IN	O
all	DT	O
evaluation	NN	O
periods	NNS	O
.	.	O

Mean	NNP	O
marginal	JJ	O
bone	NN	O
loss	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
5	CD	O
years	NNS	O
,	,	O
was	VBD	O
1.4	CD	O
mm	NN	O
for	IN	O
the	DT	O
IMZ	NNP	O
group	NN	O
,	,	O
0.7	CD	O
mm	NN	O
for	IN	O
the	DT	O
Br?	NNP	O
group	NN	O
and	CC	O
0.9	CD	O
mm	NN	O
for	IN	O
the	DT	O
ITI	NNP	O
group	NN	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
two	CD	O
implants	NNS	O
placed	VBN	O
in	IN	O
the	DT	O
interforaminal	JJ	O
region	NN	O
,	,	O
connected	VBN	O
with	IN	O
a	DT	O
bar	NN	O
,	,	O
supply	VB	O
a	DT	O
proper	JJ	O
base	NN	O
for	IN	O
the	DT	O
support	NN	O
of	IN	O
a	DT	O
mandibular	JJ	O
overdenture	NN	O
in	IN	O
the	DT	O
edentulous	JJ	O
patient	NN	O
.	.	O

After	IN	O
5	CD	O
years	NNS	O
no	DT	O
clinically	RB	O
relevant	JJ	O
and	CC	O
statistically	RB	O
significant	JJ	O
radiographic	JJ	O
changes	NNS	O
had	VBD	O
developed	VBN	O
between	IN	O
the	DT	O
three	CD	O
implant	JJ	O
systems	NNS	O
.	.	O

Perioperative	JJ	O
enteral	JJ	O
nutrition	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
severely	RB	O
malnourished	VBN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
use	NN	O
of	IN	O
perioperative	JJ	Physical
nutritional	JJ	Physical
support	NN	Physical
on	IN	O
Quality	NN	O
of	IN	O
Life	NNP	O
(	(	O
QOL	NNP	O
)	)	O
in	IN	O
malnourished	VBN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
undergoing	VBG	O
surgery	NN	O
.	.	O

METHODS	NNP	O
49	CD	O
Malnourished	NNP	O
(	(	O
weight	JJ	O
loss	NN	O
>	VBZ	O
10	CD	O
%	NN	O
)	)	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
who	WP	O
were	VBD	O
included	VBN	O
in	IN	O
a	DT	O
nutrition	NN	O
intervention	NN	O
trial	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
no	DT	Physical
preoperative	JJ	Physical
and	CC	Physical
standard	JJ	Physical
postoperative	JJ	Physical
tube-feeding	NN	Physical
(	(	Physical
group	NN	Physical
I	PRP	Physical
)	)	Physical
,	,	Physical
standard	JJ	Physical
preoperative	NN	Physical
and	CC	Physical
postoperative	JJ	Physical
tube-feeding	NN	Physical
(	(	Physical
group	NN	Physical
II	NNP	Physical
)	)	Physical
or	CC	O
arginine-supplemented	JJ	Physical
preoperative	NN	Physical
and	CC	O
postoperative	JJ	Physical
tube-feeding	NN	Physical
(	(	O
group	NN	O
III	NNP	O
)	)	O
.	.	O

Of	IN	O
these	DT	O
patients	NNS	O
,	,	O
31	CD	O
completed	VBD	O
a	DT	O
full	JJ	O
QOL	NNP	O
assessment	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
preoperative	JJ	O
nutritional	JJ	O
support	NN	O
,	,	O
one	CD	O
day	NN	O
before	IN	O
surgery	NN	O
,	,	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Both	CC	O
a	DT	O
disease-specific	NN	O
(	(	O
EORTC	NNP	O
QLQ-C30	NNP	O
)	)	O
and	CC	O
a	DT	O
generic	JJ	O
questionnaire	NN	O
(	(	O
COOP-WONCA	NNP	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O

One	CD	O
way	NN	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
and	CC	O
the	DT	O
Kruskal-Wallis	NNP	O
test	NN	O
were	VBD	O
applied	VBN	O
for	IN	O
testing	VBG	O
differences	NNS	O
in	IN	O
scores	NNS	O
between	IN	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
baseline	NN	O
and	CC	O
the	DT	O
day	NN	O
before	IN	O
surgery	NN	O
,	,	O
both	DT	O
preoperatively	RB	Physical
fed	VBN	Physical
groups	NNS	O
revealed	VBD	O
a	DT	O
positive	JJ	O
change	NN	O
for	IN	O
the	DT	O
dimensions	NNS	O
physical	JJ	O
and	CC	O
emotional	JJ	O
functioning	NN	O
and	CC	O
dyspnea	NN	O
(	(	O
with	IN	O
significance	NN	O
in	IN	O
group	NN	O
II	NNP	O
,	,	O
P=0.050,0.031,0.045	NNP	O
respectively	RB	O
)	)	O
.	.	O

Group	NNP	O
III	NNP	O
showed	VBD	O
a	DT	O
negative	JJ	O
change	NN	O
in	IN	O
appetite	NN	O
(	(	O
P=0.049	NNP	O
)	)	O
.	.	O

Between	NNP	O
baseline	NN	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
group	NN	O
I	PRP	O
and	CC	O
both	DT	Physical
pre-fed	JJ	Physical
groups	NNS	Physical
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
favour	NN	O
of	IN	O
group	NN	O
III	NNP	O
compared	VBN	O
to	TO	O
group	NN	O
II	NNP	O
.	.	O

CONCLUSION	NNP	O
Enteral	NNP	Physical
nutrition	NN	Physical
improves	VBZ	O
QOL	NNP	O
of	IN	O
severely	RB	O
malnourished	VBN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
patients	NNS	O
in	IN	O
the	DT	O
period	NN	O
preceding	VBG	O
surgery	NN	O
.	.	O

No	DT	O
benefit	NN	O
of	IN	O
preoperative	JJ	Physical
enteral	JJ	Physical
feeding	NN	Physical
on	IN	O
QOL	NNP	O
could	MD	O
be	VB	O
demonstrated	VBN	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

Lack	NN	O
of	IN	O
benefit	NN	O
of	IN	O
intravenous	JJ	Pharmacological
synthetic	JJ	Pharmacological
human	NN	Pharmacological
secretin	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
an	DT	O
intravenous	JJ	Pharmacological
infusion	NN	Pharmacological
of	IN	Pharmacological
synthetic	JJ	Pharmacological
human	JJ	Pharmacological
secretin	NN	Pharmacological
improves	VBZ	O
language	NN	O
and	CC	O
behavioral	JJ	O
symptoms	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Forty-two	JJ	O
children	NNS	O
with	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
autism	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
in	IN	O
this	DT	O
double-blind	JJ	O
cross-over	JJ	O
trial	NN	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
2	CD	Pharmacological
IU/kg	NNP	Pharmacological
of	IN	Pharmacological
intravenous	JJ	Pharmacological
synthetic	JJ	Pharmacological
human	NN	Pharmacological
secretin	NN	Pharmacological
at	IN	O
the	DT	O
first	JJ	O
visit	NN	O
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
intravenous	JJ	Control
saline	NN	Control
placebo	NN	Control
at	IN	O
week	NN	O
6	CD	O
.	.	O

The	DT	O
other	JJ	O
group	NN	O
received	VBD	O
treatments	NNS	O
in	IN	O
the	DT	O
reverse	NN	O
order	NN	O
.	.	O

All	DT	O
children	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
weeks	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
with	IN	O
standardized	JJ	O
assessments	NNS	O
of	IN	O
language	NN	O
,	,	O
behavior	NN	O
,	,	O
and	CC	O
autism	NN	O
symptomatology	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
mean	JJ	O
scores	NNS	O
on	IN	O
any	DT	O
measure	NN	O
of	IN	O
language	NN	O
,	,	O
behavior	NN	O
,	,	O
or	CC	O
autism	NN	O
symptom	JJ	O
severity	NN	O
after	IN	O
treatment	NN	O
with	IN	O
secretin	NN	O
compared	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
placebo	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
do	VBP	O
not	RB	O
support	VB	O
secretin	NN	O
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
autism	NN	O
.	.	O

Predicting	VBG	O
completion	NN	O
of	IN	O
treatment	NN	O
among	IN	O
foreign-born	JJ	O
adolescents	NNS	O
treated	VBN	O
for	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O
in	IN	O
Los	NNP	O
Angeles	NNP	O
.	.	O

SETTING	NNP	O
Two	CD	O
health	NN	O
clinics	NNS	O
in	IN	O
Los	NNP	O
Angeles	NNP	O
County	NNP	O
,	,	O
California	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
among	IN	O
foreign-born	JJ	O
adolescents	NNS	O
treated	VBN	O
for	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O
(	(	O
LTBI	NNP	O
)	)	O
.	.	O

DESIGN	VB	O
A	DT	O
total	NN	O
of	IN	O
766	CD	O
low-income	JJ	O
adolescents	NNS	O
(	(	O
79	CD	O
%	NN	O
participation	NN	O
rate	NN	O
)	)	O
,	,	O
including	VBG	O
610	CD	O
foreign-born	JJ	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

In	IN	O
prospective	JJ	O
face-to-face	NN	Educational
interviews	NNS	Educational
,	,	O
data	NNS	O
were	VBD	O
obtained	VBN	O
on	IN	O
socio-demographic	JJ	O
and	CC	O
lifestyle	JJ	O
characteristics	NNS	O
,	,	O
psychosocial	JJ	O
factors	NNS	O
and	CC	O
clinic-related	JJ	O
variables	NNS	O
.	.	O

Medical	JJ	Educational
chart	NN	Educational
data	NNS	Educational
were	VBD	Educational
abstracted	VBN	Educational
regarding	VBG	O
clinic	JJ	O
appointment	NN	O
keeping	VBG	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
.	.	O

Univariate	NNP	Physical
and	CC	Physical
multivariate	VB	Physical
logistic	JJ	Physical
regression	NN	Physical
analyses	NNS	Physical
were	VBD	O
performed	VBN	O
to	TO	O
identify	VB	O
factors	NNS	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

RESULTS	NNP	O
Foreign-born	JJ	O
adolescents	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
complete	VB	O
care	NN	O
than	IN	O
US-born	JJ	O
adolescents	NNS	O
,	,	O
with	IN	O
82	CD	O
%	NN	O
completion	NN	O
of	IN	O
care	NN	O
rate	NN	O
.	.	O

In	IN	O
logistic	JJ	O
regression	NN	O
analyses	NNS	O
after	IN	O
controlling	VBG	O
for	IN	O
age	NN	O
,	,	O
medication	NN	O
taking	VBG	O
behavior	NN	O
(	(	O
OR	CC	O
1.26	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.15-1.39	CD	O
)	)	O
,	,	O
living	VBG	O
with	IN	O
both	DT	O
parents	NNS	O
(	(	O
OR	NNP	O
1.74	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.02-2.97	CD	O
)	)	O
,	,	O
sexual	JJ	O
intercourse	NN	O
(	(	O
OR	CC	O
0.66	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.36-1.19	NN	O
)	)	O
and	CC	O
speaking	VBG	O
mostly	RB	O
or	CC	O
only	RB	O
English	JJ	O
with	IN	O
parents	NNS	O
(	(	O
OR	NNP	O
0.39	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.15-1.03	NN	O
)	)	O
were	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
completion	NN	O
of	IN	O
care	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
contribute	VBP	O
to	TO	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
factors	NNS	O
that	WDT	O
may	MD	O
explain	VB	O
why	WRB	O
some	DT	O
adolescents	NNS	O
complete	JJ	O
care	NN	O
whereas	IN	O
others	NNS	O
do	VBP	O
not	RB	O
.	.	O

They	PRP	O
provide	VBP	O
supportive	JJ	O
evidence	NN	O
that	WDT	O
tailored	VBD	O
intervention	NN	O
programs	NNS	O
should	MD	O
be	VB	O
developed	VBN	O
to	TO	O
support	VB	O
the	DT	O
screening	NN	O
and	CC	O
completion	NN	O
of	IN	O
treatment	NN	O
of	IN	O
foreign-born	JJ	O
adolescents	NNS	O
.	.	O

Intermittent	JJ	Physical
theta-burst	JJ	Physical
transcranial	JJ	Physical
magnetic	JJ	Physical
stimulation	NN	Physical
for	IN	O
treatment	NN	O
of	IN	O
Parkinson	NNP	O
disease	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
intermittent	JJ	Physical
theta-burst	JJ	Physical
stimulation	NN	Physical
(	(	Physical
iTBS	NN	Physical
)	)	Physical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
motor	NN	O
symptoms	NNS	O
in	IN	O
Parkinson	NNP	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Progression	NNP	O
of	IN	O
PD	NNP	O
is	VBZ	O
characterized	VBN	O
by	IN	O
the	DT	O
emergence	NN	O
of	IN	O
motor	NN	O
deficits	NNS	O
,	,	O
which	WDT	O
eventually	RB	O
respond	VBZ	O
less	JJR	O
to	TO	O
dopaminergic	VB	O
therapy	NN	O
and	CC	O
pose	VB	O
a	DT	O
therapeutic	JJ	O
challenge	NN	O
.	.	O

Repetitive	JJ	Physical
transcranial	JJ	Physical
magnetic	JJ	Physical
stimulation	NN	Physical
(	(	Physical
rTMS	NN	Physical
)	)	Physical
has	VBZ	O
shown	VBN	O
promising	JJ	O
results	NNS	O
in	IN	O
improving	VBG	O
gait	NN	O
,	,	O
a	DT	O
major	JJ	O
cause	NN	O
of	IN	O
disability	NN	O
,	,	O
and	CC	O
may	MD	O
provide	VB	O
a	DT	O
therapeutic	JJ	O
alternative	NN	O
.	.	O

iTBS	NN	Physical
is	VBZ	O
a	DT	O
novel	JJ	O
type	NN	O
of	IN	O
rTMS	NN	Physical
that	WDT	O
may	MD	O
be	VB	O
more	RBR	O
efficacious	JJ	O
than	IN	O
conventional	JJ	O
rTMS	NN	Physical
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
sham-controlled	JJ	O
study	NN	O
,	,	O
we	PRP	O
investigated	VBD	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
iTBS	NN	Physical
of	IN	O
the	DT	O
motor	NN	O
and	CC	O
dorsolateral	JJ	O
prefrontal	NN	O
cortices	NNS	O
in	IN	O
8	CD	O
sessions	NNS	O
over	IN	O
2	CD	O
weeks	NNS	O
(	(	O
evidence	NN	O
Class	NNP	O
I	PRP	O
)	)	O
.	.	O

Assessment	NN	O
of	IN	O
safety	NN	O
and	CC	O
clinical	JJ	O
efficacy	NN	O
over	IN	O
a	DT	O
1-month	JJ	O
period	NN	O
included	VBD	O
timed	JJ	O
tests	NNS	O
of	IN	O
gait	NN	O
and	CC	O
bradykinesia	NN	O
,	,	O
Unified	NNP	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
UPDRS	NNP	O
)	)	O
,	,	O
and	CC	O
additional	JJ	O
clinical	NN	O
,	,	O
neuropsychological	JJ	O
,	,	O
and	CC	O
neurophysiologic	JJ	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
investigated	VBD	O
26	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
PD	NNP	O
:	:	O
13	CD	O
received	VBD	O
iTBS	NN	Physical
and	CC	O
13	CD	O
sham	JJ	Physical
stimulation	NN	Physical
.	.	O

We	PRP	O
found	VBD	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
iTBS	NN	Physical
on	IN	O
mood	NN	O
,	,	O
but	CC	O
no	DT	O
improvement	NN	O
of	IN	O
gait	NN	O
,	,	O
bradykinesia	NN	O
,	,	O
UPDRS	NNP	O
,	,	O
and	CC	O
other	JJ	O
measures	NNS	O
.	.	O

EEG/EMG	NNP	O
monitoring	NN	O
recorded	VBD	O
no	DT	O
pathologic	JJ	O
increase	NN	O
of	IN	O
cortical	JJ	O
excitability	NN	O
or	CC	O
epileptic	JJ	O
activity	NN	O
.	.	O

Few	JJ	O
reported	VBD	O
discomfort	NN	O
or	CC	O
pain	NN	O
and	CC	O
one	CD	O
experienced	JJ	O
tinnitus	NN	O
during	IN	O
real	JJ	O
stimulation	NN	O
.	.	O

CONCLUSION	NNP	O
iTBS	NN	Physical
of	IN	O
the	DT	O
motor	NN	O
and	CC	O
prefrontal	JJ	O
cortices	NNS	O
appears	VBZ	O
safe	JJ	O
and	CC	O
improves	VBZ	O
mood	NN	O
,	,	O
but	CC	O
failed	VBD	O
to	TO	O
improve	VB	O
motor	NN	O
performance	NN	O
and	CC	O
functional	JJ	O
status	NN	O
in	IN	O
PD	NNP	O
.	.	O

CLASSIFICATION	NNP	O
OF	IN	O
EVIDENCE	NNP	O
This	DT	O
study	NN	O
provides	VBZ	O
Class	NNP	O
I	PRP	O
evidence	NN	O
that	IN	O
iTBS	NN	Physical
was	VBD	O
not	RB	O
effective	JJ	O
for	IN	O
gait	NN	O
,	,	O
upper	JJ	O
extremity	NN	O
bradykinesia	NN	O
,	,	O
or	CC	O
other	JJ	O
motor	NN	O
symptoms	NNS	O
in	IN	O
PD	NNP	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
chiropractic	JJ	Pharmacological
and	CC	O
medical	JJ	Educational
care	NN	Educational
for	IN	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
eighteen-month	JJ	O
follow-up	JJ	O
outcomes	NNS	O
from	IN	O
the	DT	O
UCLA	NNP	O
low	JJ	O
back	RB	O
pain	NN	O
study	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
compare	VB	O
the	DT	O
long-term	JJ	O
effectiveness	NN	O
of	IN	O
medical	JJ	Educational
and	CC	Educational
chiropractic	JJ	Educational
care	NN	Educational
for	IN	Educational
low	JJ	Educational
back	RB	Educational
pain	NN	Educational
in	IN	O
managed	VBN	O
care	NN	O
and	CC	O
to	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
physical	JJ	Physical
therapy	NN	Physical
and	CC	O
modalities	NNS	O
among	IN	O
patients	NNS	O
receiving	VBG	O
medical	JJ	Educational
or	CC	Educational
chiropractic	JJ	Educational
care	NN	Educational
.	.	O

SUMMARY	NNP	O
OF	IN	O
BACKGROUND	NNP	O
DATA	NNP	O
Evidence	NNP	O
comparing	VBG	O
the	DT	O
long-term	JJ	O
relative	JJ	O
effectiveness	NN	O
of	IN	O
common	JJ	O
treatment	NN	O
strategies	NNS	O
offered	VBD	O
to	TO	O
low	VB	O
back	RB	O
pain	NN	O
patients	NNS	O
in	IN	O
managed	VBN	O
care	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
681	CD	O
low	JJ	O
back	RB	O
pain	NN	O
patients	NNS	O
presenting	VBG	O
to	TO	O
a	DT	O
managed-care	JJ	O
facility	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
chiropractic	VB	Physical
with	IN	Physical
or	CC	Physical
without	IN	Physical
physical	JJ	Physical
modalities	NNS	Physical
,	,	O
or	CC	O
medical	JJ	Physical
care	NN	Physical
with	IN	Physical
or	CC	Physical
without	IN	Physical
physical	JJ	Physical
therapy	NN	Physical
,	,	O
and	CC	O
followed	VBD	O
for	IN	O
18	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
variables	NNS	O
are	VBP	O
low	JJ	O
back	RB	O
pain	NN	O
intensity	NN	O
,	,	O
disability	NN	O
,	,	O
and	CC	O
complete	JJ	O
remission	NN	O
.	.	O

The	DT	O
secondary	JJ	O
outcome	NN	O
is	VBZ	O
participants	NNS	O
'	POS	O
perception	NN	O
of	IN	O
improvement	NN	O
in	IN	O
low	JJ	O
back	RB	O
symptoms	NNS	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
681	CD	O
patients	NNS	O
,	,	O
610	CD	O
(	(	O
89.6	CD	O
%	NN	O
)	)	O
were	VBD	O
followed	VBN	O
through	IN	O
18	CD	O
months	NNS	O
.	.	O

Among	IN	O
participants	NNS	O
not	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
physical	JJ	O
therapy	NN	O
or	CC	O
modalities	NNS	O
,	,	O
the	DT	O
estimated	JJ	O
improvements	NNS	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
and	CC	O
18-month	JJ	O
risk	NN	O
of	IN	O
complete	JJ	O
remission	NN	O
were	VBD	O
a	DT	O
little	JJ	O
greater	JJR	O
in	IN	O
the	DT	O
chiropractic	JJ	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
medical	JJ	O
group	NN	O
(	(	O
adjusted	VBN	O
RR	NNP	O
of	IN	O
remission	NN	O
=	NNP	O
1.29	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.80-2.07	NN	O
)	)	O
.	.	O

Among	IN	O
participants	NNS	O
assigned	VBN	O
to	TO	O
medical	JJ	O
care	NN	O
,	,	O
mean	JJ	O
changes	NNS	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
and	CC	O
risk	NN	O
of	IN	O
remission	NN	O
were	VBD	O
larger	JJR	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
receive	VB	O
physical	JJ	Physical
therapy	NN	Physical
(	(	O
adjusted	VBN	O
RR	NNP	O
=	NNP	O
1.69	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.08-2.66	JJ	O
)	)	O
.	.	O

Among	IN	O
those	DT	O
assigned	VBN	O
to	TO	O
chiropractic	JJ	Educational
care	NN	Educational
,	,	O
however	RB	O
,	,	O
assignment	NN	O
to	TO	O
methods	NNS	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
improvement	NN	O
or	CC	O
remission	NN	O
(	(	O
adjusted	VBN	O
RR	NNP	O
=	NNP	O
0.98	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.62-1.55	NN	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
medical	JJ	O
care	NN	O
only	RB	O
patients	NNS	O
,	,	O
chiropractic	JJ	Educational
and	CC	O
physical	JJ	O
therapy	NN	O
patients	NNS	O
were	VBD	O
much	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
perceive	VB	O
improvement	NN	O
in	IN	O
their	PRP$	O
low	JJ	O
back	RB	O
symptoms	NNS	O
.	.	O

However	RB	O
,	,	O
less	JJR	O
than	IN	O
20	CD	O
%	NN	O
of	IN	O
all	DT	O
patients	NNS	O
were	VBD	O
pain-free	JJ	O
at	IN	O
18	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Differences	NNPS	O
in	IN	O
outcomes	NNS	O
between	IN	O
medical	JJ	Educational
and	CC	Educational
chiropractic	JJ	Educational
care	NN	Educational
without	IN	O
physical	JJ	O
therapy	NN	O
or	CC	O
modalities	NNS	O
are	VBP	O
not	RB	O
clinically	RB	O
meaningful	JJ	O
,	,	O
although	IN	O
chiropractic	JJ	O
may	MD	O
result	VB	O
in	IN	O
a	DT	O
greater	JJR	O
likelihood	NN	O
of	IN	O
perceived	JJ	O
improvement	NN	O
,	,	O
perhaps	RB	O
reflecting	VBG	O
satisfaction	NN	O
or	CC	O
lack	NN	O
of	IN	O
blinding	NN	O
.	.	O

Physical	JJ	Physical
therapy	NN	Physical
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
medical	JJ	O
care	NN	O
alone	RB	O
for	IN	O
some	DT	O
patients	NNS	O
,	,	O
while	IN	O
physical	JJ	O
modalities	NNS	O
appear	VBP	O
to	TO	O
have	VB	O
no	DT	O
benefit	NN	O
in	IN	O
chiropractic	JJ	O
care	NN	O
.	.	O

Denosumab	NNP	Pharmacological
compared	VBN	O
with	IN	O
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bone	NN	O
metastases	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
randomized	VBN	O
study	NN	O
compared	VBN	O
denosumab	NN	Pharmacological
,	,	O
a	DT	O
fully	RB	O
human	JJ	O
monoclonal	JJ	O
antibody	NN	O
against	IN	O
receptor	NN	O
activator	NN	O
of	IN	O
nuclear	JJ	O
factor	NN	O
?	.	O
B	NNP	O
(	(	O
RANK	NNP	O
)	)	O
ligand	NN	O
,	,	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
or	CC	O
preventing	VBG	O
skeletal-related	JJ	O
events	NNS	O
(	(	O
SREs	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
with	IN	O
bone	NN	O
metastases	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
subcutaneous	JJ	O
denosumab	NN	O
120	CD	O
mg	NN	O
and	CC	O
intravenous	JJ	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
1,026	CD	O
)	)	O
or	CC	O
intravenous	JJ	O
zoledronic	JJ	O
acid	NN	O
4	CD	O
mg	NN	O
adjusted	VBN	O
for	IN	O
creatinine	JJ	O
clearance	NN	O
and	CC	O
subcutaneous	JJ	O
placebo	NN	O
(	(	O
n	JJ	O
=	NNP	O
1,020	CD	O
)	)	O
every	DT	O
4	CD	O
weeks	NNS	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
strongly	RB	O
recommended	VBN	O
to	TO	O
take	VB	O
daily	JJ	O
calcium	NN	O
and	CC	O
vitamin	NN	O
D	NNP	O
supplements	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
time	NN	O
to	TO	O
first	VB	O
on-study	JJ	O
SRE	NNP	O
(	(	O
defined	VBN	O
as	IN	O
pathologic	JJ	O
fracture	NN	O
,	,	O
radiation	NN	O
or	CC	O
surgery	NN	O
to	TO	O
bone	VB	O
,	,	O
or	CC	O
spinal	JJ	O
cord	NN	O
compression	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Denosumab	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
time	NN	O
to	TO	O
first	VB	O
on-study	JJ	O
SRE	NNP	O
(	(	O
hazard	NN	O
ratio	NN	O
,	,	O
0.82	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.71	CD	O
to	TO	O
0.95	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
superiority	NN	O
)	)	O
and	CC	O
time	NN	O
to	TO	O
first	RB	O
and	CC	O
subsequent	JJ	O
(	(	O
multiple	JJ	O
)	)	O
on-study	NN	O
SREs	NNP	O
(	(	O
rate	NN	O
ratio	NN	O
,	,	O
0.77	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.66	CD	O
to	TO	O
0.89	CD	O
;	:	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Reduction	NN	O
in	IN	O
bone	NN	O
turnover	NN	O
markers	NNS	O
was	VBD	O
greater	JJR	O
with	IN	O
denosumab	NN	O
.	.	O

Overall	JJ	O
survival	NN	O
,	,	O
disease	NN	O
progression	NN	O
,	,	O
and	CC	O
rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
and	CC	O
serious	JJ	O
AEs	NNP	O
were	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

An	DT	O
excess	NN	O
of	IN	O
renal	JJ	O
AEs	NNP	O
and	CC	O
acute-phase	JJ	O
reactions	NNS	O
occurred	VBD	O
with	IN	O
zoledronic	JJ	O
acid	NN	O
;	:	O
hypocalcemia	NN	O
occurred	VBD	O
more	RBR	O
frequently	RB	O
with	IN	O
denosumab	NN	O
.	.	O

Osteonecrosis	NN	O
of	IN	O
the	DT	O
jaw	NN	O
occurred	VBD	O
infrequently	RB	O
(	(	O
2.0	CD	O
%	NN	O
,	,	O
denosumab	NN	O
;	:	O
1.4	CD	O
%	NN	O
,	,	O
zoledronic	JJ	O
acid	NN	O
;	:	O
P	NNP	O
=	NNP	O
.39	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Denosumab	NNP	O
was	VBD	O
superior	JJ	O
to	TO	O
zoledronic	JJ	O
acid	NN	O
in	IN	O
delaying	VBG	O
or	CC	O
preventing	VBG	O
SREs	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
metastatic	NN	O
to	TO	O
bone	NN	O
and	CC	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

With	IN	O
the	DT	O
convenience	NN	O
of	IN	O
a	DT	O
subcutaneous	JJ	O
injection	NN	O
and	CC	O
no	DT	O
requirement	NN	O
for	IN	O
renal	JJ	O
monitoring	NN	O
,	,	O
denosumab	JJ	O
represents	VBZ	O
a	DT	O
potential	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
patients	NNS	O
with	IN	O
bone	NN	O
metastases	NNS	O
.	.	O

Stapled	JJ	O
mucosectomy	NN	O
for	IN	O
acute	NN	O
thrombosed	VBN	O
circumferentially	RB	O
prolapsed	JJ	O
piles	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
with	IN	O
conventional	JJ	O
haemorrhoidectomy	NN	O
.	.	O

OBJECTIVE	NNP	O
Stapled	NNP	Surgical
mucosectomy	NN	Surgical
has	VBZ	O
been	VBN	O
developed	VBN	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
conventional	JJ	Physical
haemorrhoidectomy	NN	Physical
for	IN	O
the	DT	O
elective	JJ	O
treatment	NN	O
of	IN	O
haemorrhoids	NNS	O
,	,	O
but	CC	O
has	VBZ	O
not	RB	O
been	VBN	O
assessed	VBN	O
in	IN	O
the	DT	O
emergency	NN	O
setting	VBG	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
this	DT	O
technique	NN	O
with	IN	O
a	DT	O
conventional	JJ	Surgical
procedure	NN	Surgical
for	IN	O
acute	NN	O
thrombosed	VBN	O
circumferential	JJ	O
prolapsed	JJ	O
haemorrhoids	NNS	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
of	IN	O
conventional	JJ	Physical
Milligan-Morgan	JJ	Physical
haemorrhoidectomy	NN	Physical
and	CC	Physical
stapled	VBD	Physical
mucosectomy	NN	Physical
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
35	CD	O
consecutive	JJ	O
patients	NNS	O
presenting	VBG	O
with	IN	O
acute	NN	O
thrombosed	VBN	O
circumferential	JJ	O
prolapsed	JJ	O
haemorrhoids	NNS	O
.	.	O

Operative	NNP	O
data	NN	O
,	,	O
postoperative	JJ	O
stay	NN	O
,	,	O
pain	NN	O
assessment	NN	O
and	CC	O
persistent	NN	O
symptoms	NNS	O
were	VBD	O
compared	VBN	O
at	IN	O
discharge	NN	O
and	CC	O
at	IN	O
2	CD	O
week	NN	O
and	CC	O
6	CD	O
week	NN	O
review	NN	O
.	.	O

Additionally	RB	O
at	IN	O
6	CD	O
week	NN	O
review	VB	O
the	DT	O
time	NN	O
to	TO	O
return	VB	O
to	TO	O
work	VB	O
was	VBD	O
recorded	VBN	O
and	CC	O
an	DT	O
endoanal	JJ	Physical
ultrasound	NN	Physical
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O

RESULTS	NNP	O
Thirty	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
and	CC	O
followed	VBN	O
up	RP	O
for	IN	O
six	CD	O
weeks	NNS	O
.	.	O

Although	IN	O
postoperative	JJ	O
stay	NN	O
and	CC	O
in-hospital	JJ	O
analgesia	NN	O
were	VBD	O
the	DT	O
same	JJ	O
,	,	O
patients	NNS	O
from	IN	O
the	DT	O
stapled	VBN	Educational
group	NN	Educational
reported	VBD	O
significantly	RB	O
more	RBR	O
pain	NN	O
at	IN	O
discharge	NN	O
.	.	O

However	RB	O
,	,	O
by	IN	O
2	CD	O
weeks	NNS	O
the	DT	O
conventional	JJ	Educational
group	NN	Educational
reported	VBD	O
significantly	RB	O
higher	JJR	O
pain	NN	O
scores	NNS	O
particularly	RB	O
on	IN	O
passing	VBG	O
stool	NN	O
.	.	O

By	IN	O
this	DT	O
stage	NN	O
over	IN	O
half	PDT	O
the	DT	O
stapled	JJ	O
group	NN	O
patients	NNS	O
reported	VBD	O
no	DT	O
pain	NN	O
at	IN	O
all	DT	O
.	.	O

More	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
complained	VBD	O
of	IN	O
persistent	JJ	O
symptoms	NNS	O
of	IN	O
pain	NN	O
,	,	O
bleeding	NN	O
and	CC	O
discharge	NN	O
at	IN	O
2	CD	O
week	NN	O
and	CC	O
6	CD	O
week	NN	O
review	NN	O
with	IN	O
20	CD	O
%	NN	O
requiring	VBG	O
readmission	NN	O
compared	VBN	O
with	IN	O
none	NN	O
in	IN	O
the	DT	O
stapled	JJ	O
group	NN	O
.	.	O

The	DT	O
median	JJ	O
return	NN	O
to	TO	O
work	VB	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
for	IN	O
the	DT	O
stapled	VBN	O
group	NN	O
(	(	O
14	CD	O
days	NNS	O
vs	RB	O
28	CD	O
days	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Although	IN	O
all	DT	O
patients	NNS	O
claimed	VBD	O
to	TO	O
be	VB	O
continent	JJ	O
,	,	O
two	CD	O
patients	NNS	O
from	IN	O
each	DT	O
group	NN	O
had	VBD	O
ultrasonic	JJ	O
evidence	NN	O
of	IN	O
internal	JJ	O
sphincter	NN	O
damage	NN	O
.	.	O

CONCLUSION	NNP	O
Stapled	VBD	O
mucosectomy	NN	O
for	IN	O
acute	NN	O
thrombosed	VBN	O
circumferential	JJ	O
piles	NNS	O
is	VBZ	O
feasible	JJ	O
and	CC	O
may	MD	O
result	VB	O
in	IN	O
less	JJR	O
pain	NN	O
,	,	O
a	DT	O
more	RBR	O
rapid	JJ	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
an	DT	O
earlier	JJR	O
return	NN	O
to	TO	O
work	VB	O
compared	VBN	O
with	IN	O
a	DT	O
conventional	JJ	O
procedure	NN	O
.	.	O

Delayed	VBN	O
alloimmunization	NN	O
using	VBG	O
random	JJ	Physical
single	JJ	Physical
donor	NN	Physical
platelet	NN	Physical
transfusions	NNS	Physical
:	:	O
a	DT	O
prospective	JJ	O
study	NN	O
in	IN	O
thrombocytopenic	JJ	O
patients	NNS	O
with	IN	O
acute	JJ	O
leukemia	NN	O
.	.	O

A	DT	O
randomized	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
54	CD	O
thrombocytopenic	JJ	O
patients	NNS	O
with	IN	O
acute	JJ	O
leukemia	NN	O
.	.	O

Alloimmunization	NN	O
of	IN	O
recipients	NNS	O
of	IN	O
random	JJ	O
multiple-donor	JJ	Pharmacological
platelet	NN	Pharmacological
concentrates	NNS	Pharmacological
(	(	O
MD	NNP	O
group	NN	O
)	)	O
was	VBD	O
compared	VBN	O
to	TO	O
that	DT	O
of	IN	O
patients	NNS	O
receiving	VBG	O
random	JJ	Physical
single-donor	JJ	Physical
platelets	NNS	Physical
(	(	O
SD	NNP	O
group	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
SD	NNP	O
patients	NNS	O
,	,	O
formation	NN	O
of	IN	O
alloantibodies	NNS	O
(	(	O
mostly	RB	O
anti-HLA	RB	O
)	)	O
occurred	VBD	O
less	RBR	O
frequently	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.002	CD	O
)	)	O
,	,	O
after	IN	O
a	DT	O
longer	JJR	O
time	NN	O
period	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.002	CD	O
)	)	O
,	,	O
and	CC	O
after	IN	O
a	DT	O
higher	JJR	O
number	NN	O
of	IN	O
transfusions	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
as	IN	O
compared	VBN	O
to	TO	O
MD	NNP	O
patients	NNS	O
.	.	O

SD	NNP	O
patients	NNS	O
also	RB	O
became	VBD	O
refractory	JJ	O
to	TO	O
random	VB	O
platelets	NNS	O
less	RBR	O
frequently	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
,	,	O
after	IN	O
a	DT	O
longer	JJR	O
time	NN	O
period	NN	O
,	,	O
and	CC	O
after	IN	O
a	DT	O
higher	JJR	O
number	NN	O
of	IN	O
transfusions	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

In	IN	O
SD	NNP	O
patients	NNS	O
,	,	O
the	DT	O
increments	NNS	O
after	IN	O
the	DT	O
first	JJ	O
and	CC	O
the	DT	O
last	JJ	O
transfusion	NN	O
were	VBD	O
in	IN	O
the	DT	O
same	JJ	O
range	NN	O
,	,	O
whereas	NNS	O
in	IN	O
MD	NNP	O
patients	NNS	O
,	,	O
the	DT	O
1-hr	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
the	DT	O
24-hr	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.025	CD	O
)	)	O
increments	NNS	O
decreased	VBN	O
from	IN	O
the	DT	O
first	JJ	O
to	TO	O
the	DT	O
last	JJ	O
transfusion	NN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
random	NN	Physical
SD	NNP	Physical
platelet	NN	Physical
transfusions	NNS	Physical
postponed	VBD	O
alloimmunization	NN	O
.	.	O

Fibrin	NNP	Pharmacological
application	NN	Pharmacological
for	IN	O
preventing	VBG	O
lymphocysts	NNS	O
after	IN	O
retroperitoneal	JJ	O
lymphadenectomy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
gynecologic	JJ	O
malignancies	NNS	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
performed	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
fibrin	JJ	Pharmacological
glue	NN	Pharmacological
on	IN	O
the	DT	O
incidence	NN	O
of	IN	O
lymphocysts	NNS	O
after	IN	O
systematic	JJ	O
pelvic	NN	O
or	CC	O
pelvic	NN	O
and	CC	O
paraaortic	JJ	O
lymphadenectomy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
gynecologic	JJ	O
malignancies	NNS	O
.	.	O

METHODS	NNP	O
Ninety-three	JJ	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
gynecologic	JJ	O
pelvic	JJ	O
malignancies	NNS	O
who	WP	O
underwent	VBP	O
surgery	NN	O
including	VBG	O
pelvic	NN	O
or	CC	O
pelvic	NN	O
and	CC	O
paraaortic	JJ	O
lymphadenectomy	NN	O
were	VBD	O
randomized	VBN	O
during	IN	O
surgery	NN	O
to	TO	O
be	VB	O
treated	VBN	Pharmacological
with	IN	Pharmacological
fibrin	JJ	Pharmacological
glue	NN	Pharmacological
or	CC	O
not	RB	Control
.	.	O

Serial	JJ	Physical
computed	JJ	Physical
tomography	NN	Physical
(	(	Physical
CT	NNP	Physical
)	)	Physical
scans	NNS	Physical
were	VBD	O
performed	VBN	O
during	IN	O
follow-up	JJ	O
.	.	O

CT	NNP	O
findings	NNS	O
of	IN	O
a	DT	O
smooth	JJ	O
and	CC	O
thin-walled	JJ	O
cavity	NN	O
filled	VBN	O
with	IN	O
a	DT	O
water-equivalent	JJ	O
fluid	NN	O
,	,	O
sharply	RB	O
demarcated	VBN	O
from	IN	O
its	PRP$	O
surroundings	NNS	O
and	CC	O
without	IN	O
signs	NNS	O
of	IN	O
infiltration	NN	O
were	VBD	O
interpreted	VBN	O
as	IN	O
lymphocysts	NNS	O
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
patients	NNS	O
(	(	O
51	CD	O
%	NN	O
)	)	O
were	VBD	O
treated	VBN	O
with	IN	O
fibrin	JJ	Pharmacological
glue	NN	Pharmacological
and	CC	O
46	CD	O
(	(	O
49	CD	O
%	NN	O
)	)	O
were	VBD	O
not	RB	O
.	.	O

All	DT	O
93	CD	O
patients	NNS	O
underwent	JJ	O
pelvic	JJ	O
lymphadenectomy	NN	O
;	:	O
15	CD	O
patients	NNS	O
(	(	O
32	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
fibrin	NN	O
group	NN	O
and	CC	O
12	CD	O
(	(	O
26	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
controls	NNS	O
also	RB	O
underwent	JJ	O
paraaortic	JJ	O
lymphadenectomy	NN	O
.	.	O

We	PRP	O
found	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
fibrin	JJ	O
glue	NN	O
and	CC	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

CONCLUSION	NNP	O
Intraoperative	NNP	O
application	NN	O
of	IN	O
fibrin	JJ	O
glue	NN	O
did	VBD	O
not	RB	O
reduce	VB	O
the	DT	O
rate	NN	O
of	IN	O
postoperative	JJ	O
lymphocysts	NNS	O
after	IN	O
lymphadenectomy	NN	O
and	CC	O
had	VBD	O
no	DT	O
impact	NN	O
on	IN	O
any	DT	O
follow-up	JJ	O
parameter	NN	O
.	.	O

Its	PRP$	O
use	NN	O
seems	VBZ	O
not	RB	O
to	TO	O
be	VB	O
indicated	VBN	O
in	IN	O
systematic	JJ	O
gynecologic	NN	O
pelvic	NN	O
or	CC	O
pelvic	NN	O
and	CC	O
paraaortic	JJ	O
lymphadenectomy	NN	O
.	.	O

Veterans	NNS	O
Administration	NNP	O
Cooperative	NNP	O
Study	NNP	O
on	IN	O
antiplatelet	NN	Pharmacological
agents	NNS	Pharmacological
in	IN	O
diabetic	JJ	O
patients	NNS	O
after	IN	O
amputation	NN	O
for	IN	O
gangrene	NN	O
:	:	O
II	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
aspirin	NN	Pharmacological
and	CC	O
dipyridamole	NN	Pharmacological
on	IN	O
atherosclerotic	JJ	O
vascular	JJ	O
disease	NN	O
rates	NNS	O
.	.	O

We	PRP	O
report	VBP	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
multicenter	NN	O
clinical	JJ	O
trial	NN	O
on	IN	O
the	DT	O
effects	NNS	O
of	IN	O
aspirin	JJ	Pharmacological
plus	CC	Pharmacological
dipyridamole	JJ	Pharmacological
versus	NN	O
placebo	NN	Control
on	IN	O
major	JJ	O
vascular	JJ	O
end	NN	O
points	NNS	O
in	IN	O
231	CD	O
non-insulin-dependent	JJ	O
diabetic	JJ	O
men	NNS	O
with	IN	O
either	DT	O
a	DT	O
recent	JJ	O
amputation	NN	O
for	IN	O
gangrene	NN	O
or	CC	O
active	JJ	O
gangrene	NN	O
.	.	O

Primary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
death	NN	O
from	IN	O
atherosclerotic	JJ	O
vascular	JJ	O
disease	NN	O
plus	CC	O
amputation	NN	O
of	IN	O
the	DT	O
opposite	JJ	O
extremity	NN	O
for	IN	O
gangrene	NN	O
.	.	O

There	EX	O
were	VBD	O
24	CD	O
atherosclerotic	JJ	O
deaths	NNS	O
in	IN	O
the	DT	O
drug	NN	O
treatment	NN	O
group	NN	O
(	(	O
21.8	CD	O
%	NN	O
)	)	O
and	CC	O
23	CD	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
19.0	CD	O
%	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
22	CD	O
patients	NNS	O
in	IN	O
the	DT	O
drug	NN	O
treatment	NN	O
group	NN	O
(	(	O
20.0	CD	O
%	NN	O
)	)	O
and	CC	O
29	CD	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
24.0	CD	O
%	NN	O
)	)	O
with	IN	O
opposite-side	JJ	O
amputations	NNS	O
.	.	O

Survival	NNP	O
curve	NN	O
analyses	NNS	O
revealed	VBD	O
little	JJ	O
difference	NN	O
between	IN	O
these	DT	O
groups	NNS	O
for	IN	O
major	JJ	O
vascular	JJ	O
end	NN	O
points	NNS	O
,	,	O
total	JJ	O
mortality	NN	O
,	,	O
all	DT	O
amputations	NNS	O
,	,	O
or	CC	O
myocardial	JJ	O
infarctions	NNS	O
.	.	O

The	DT	O
most	RBS	O
noteworthy	JJ	O
group	NN	O
difference	NN	O
was	VBD	O
observed	VBN	O
for	IN	O
cerebrovascular	JJ	O
end	NN	O
points	NNS	O
(	(	O
strokes	NNS	O
and	CC	O
transient	JJ	O
ischemic	JJ	O
attacks	NNS	O
)	)	O
,	,	O
with	IN	O
an	DT	O
incidence	NN	O
of	IN	O
8.2	CD	O
%	NN	O
(	(	O
9	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
drug	NN	O
treatment	NN	O
group	NN	O
and	CC	O
19.0	CD	O
%	NN	O
(	(	O
23	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
from	IN	O
this	DT	O
study	NN	O
that	WDT	O
antiplatelet	NN	O
agents	NNS	O
have	VBP	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
primary	JJ	O
vascular	JJ	O
end	NN	O
points	NNS	O
,	,	O
vascular	JJ	O
deaths	NNS	O
and/or	IN	O
amputation	NN	O
of	IN	O
the	DT	O
opposite	JJ	O
extremity	NN	O
,	,	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Similarly	RB	O
,	,	O
no	DT	O
effects	NNS	O
were	VBD	O
seen	VBN	O
on	IN	O
secondary	JJ	O
vascular	JJ	O
end	NN	O
points	NNS	O
,	,	O
except	IN	O
for	IN	O
a	DT	O
suggestion	NN	O
of	IN	O
protection	NN	O
versus	NN	O
strokes	NNS	O
and	CC	O
transient	JJ	O
ischemic	JJ	O
attacks	NNS	O
.	.	O

However	RB	O
,	,	O
this	DT	O
finding	NN	O
must	MD	O
be	VB	O
interpreted	VBN	O
with	IN	O
caution	NN	O
,	,	O
since	IN	O
it	PRP	O
is	VBZ	O
a	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
and	CC	O
was	VBD	O
found	VBN	O
only	RB	O
after	IN	O
multiple	JJ	O
analyses	NNS	O
of	IN	O
the	DT	O
data	NNS	O
.	.	O

A	DT	O
training	NN	O
study	NN	O
of	IN	O
theory	NN	O
of	IN	O
mind	NN	O
and	CC	O
executive	NN	O
function	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
theory	NN	O
of	IN	O
mind	NN	O
and	CC	O
executive	NN	O
functioning	NN	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
through	IN	O
a	DT	O
training	NN	O
study	NN	O
.	.	O

Ten	CD	O
children	NNS	O
were	VBD	O
trained	VBN	O
on	IN	O
theory	NN	Educational
of	IN	Educational
mind	NN	Educational
,	,	O
whilst	WP	O
ten	EX	O
were	VBD	O
trained	VBN	Educational
in	IN	Educational
executive	JJ	Educational
function	NN	Educational
.	.	O

Seven	JJ	O
children	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
,	,	O
receiving	VBG	O
no	DT	Other
intervention	NN	Other
.	.	O

Training	VBG	O
programmes	NNS	O
were	VBD	O
administered	VBN	O
individually	RB	O
,	,	O
lasting	VBG	O
for	IN	O
25	CD	O
minutes	NNS	O
per	IN	O
day	NN	O
for	IN	O
5-10	JJ	O
days	NNS	O
.	.	O

Children	NNP	O
were	VBD	O
tested	VBN	O
before	IN	O
training	NN	O
,	,	O
after	IN	O
training	NN	O
and	CC	O
at	IN	O
a	DT	O
two-month	JJ	O
follow-up	NN	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
performance	NN	O
on	IN	O
theory	NN	O
of	IN	O
mind	NN	O
tasks	NNS	O
in	IN	O
both	DT	O
trained	JJ	O
groups	NNS	O
,	,	O
whilst	IN	O
the	DT	O
control	NN	O
group	NN	O
showed	VBD	O
no	DT	O
improvement	NN	O
.	.	O

No	DT	O
improvement	NN	O
on	IN	O
the	DT	O
executive	NN	O
function	NN	O
tasks	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O

The	DT	O
implications	NNS	O
of	IN	O
these	DT	O
findings	NNS	O
are	VBP	O
discussed	VBN	O
.	.	O

CD4+FOXP3+	NNP	O
regulatory	JJ	O
T	NNP	O
cell	NN	O
depletion	NN	O
by	IN	O
low-dose	JJ	O
cyclophosphamide	NN	Pharmacological
prevents	NNS	O
recurrence	NN	O
in	IN	O
patients	NNS	O
with	IN	O
large	JJ	O
condylomata	NNS	O
acuminata	NNS	O
after	IN	O
laser	NN	Physical
therapy	NN	Physical
.	.	Physical

Condylomata	NNP	O
acuminata	NN	O
(	(	O
CA	NNP	O
)	)	O
caused	VBN	O
by	IN	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
sexually	RB	O
transmitted	JJ	O
disease	NN	O
with	IN	O
half	PDT	O
a	DT	O
million	CD	O
new	JJ	O
cases	NNS	O
diagnosed	VBN	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
per	IN	O
year	NN	O
and	CC	O
the	DT	O
annual	JJ	O
increase	NN	O
in	IN	O
incidence	NN	O
in	IN	O
China	NNP	O
.	.	O

Recurrence	NNP	O
is	VBZ	O
a	DT	O
major	JJ	O
challenge	NN	O
for	IN	O
CA	NNP	O
treatment	NN	O
.	.	O

Recently	RB	O
,	,	O
we	PRP	O
demonstrated	VBD	O
that	IN	O
FOXP3	NNP	O
(	(	O
+	NNP	O
)	)	O
regulatory	JJ	O
T	NNP	O
(	(	O
Treg	NNP	O
)	)	O
cells	NNS	O
mediate	VBP	O
the	DT	O
immunosuppression	NN	O
in	IN	O
large	JJ	O
genital	JJ	O
warts	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
further	VBP	O
report	VB	O
that	IN	O
low-dose	JJ	Pharmacological
cyclophosphamide	NN	Pharmacological
(	(	Pharmacological
CY	NNP	Pharmacological
)	)	Pharmacological
,	,	O
a	DT	O
conventional	JJ	O
chemotherapy	JJ	O
drug	NN	O
,	,	O
can	MD	O
effectively	RB	O
prevent	VB	O
the	DT	O
recurrence	NN	O
of	IN	O
large	JJ	O
CA	NNP	O
in	IN	O
clinical	JJ	O
patients	NNS	O
after	IN	O
laser	NN	Physical
therapy	NN	Physical
.	.	Physical

Surprisingly	RB	O
,	,	O
although	IN	O
9	CD	O
out	IN	O
of	IN	O
52	CD	O
patients	NNS	O
recur	JJ	O
six	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
combination	NN	O
treatment	NN	O
,	,	O
the	DT	O
re-administration	NN	O
of	IN	O
low-dose	JJ	O
CY	NNP	Pharmacological
alone	RB	O
completely	RB	O
eliminates	VBZ	O
most	JJS	O
recurred	JJ	O
lesions	NNS	O
.	.	O

We	PRP	O
provide	VBP	O
evidence	NN	O
that	IN	O
low-dose	JJ	O
CY	NNP	Pharmacological
not	RB	O
only	RB	O
depletes	VBZ	O
patients	NNS	O
'	POS	O
Treg	NNP	O
cells	NNS	O
and	CC	O
enhances	NNS	O
function	NN	O
of	IN	O
HPV-specific	NNP	O
T	NNP	O
cells	NNS	O
and	CC	O
NK	NNP	O
cells	NNS	O
in	IN	O
the	DT	O
periphery	NN	O
,	,	O
but	CC	O
also	RB	O
ameliorates	VBZ	O
the	DT	O
immune	JJ	O
milieu	NN	O
of	IN	O
the	DT	O
lesion	NN	O
site	NN	O
,	,	O
leading	VBG	O
to	TO	O
the	DT	O
elimination	NN	O
of	IN	O
remnant	JJ	O
viruses	NNS	O
.	.	O

These	DT	O
findings	NNS	O
have	VBP	O
important	JJ	O
clinical	JJ	O
significance	NN	O
,	,	O
and	CC	O
potentially	RB	O
lead	JJ	O
to	TO	O
a	DT	O
therapeutic	JJ	O
breakthrough	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
CA	NNP	O
.	.	O

T	NNP	O
lymphocyte	JJ	O
subsets	NNS	O
and	CC	O
NK	NNP	O
cell	VBP	O
cytotoxicity	NN	O
in	IN	O
chronic	JJ	O
hemodialysis	NN	O
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
erythropoietin	NN	Pharmacological
(	(	Pharmacological
rHu-EPO	JJ	Pharmacological
)	)	Pharmacological
treatment	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
subpopulations	NNS	O
of	IN	O
T	NNP	O
lymphocytes	NNS	O
,	,	O
NK	NNP	O
cell	NN	O
number	NN	O
and	CC	O
cytotoxic	JJ	O
activity	NN	O
in	IN	O
14	CD	O
chronic	JJ	O
uremic	JJ	O
patients	NNS	O
on	IN	O
regular	JJ	Control
hemodialysis	NN	Control
treatment	NN	Control
.	.	O

We	PRP	O
observed	VBD	O
a	DT	O
significantly	RB	O
decreased	VBN	O
absolute	NN	O
lymphocyte	NN	O
number	NN	O
and	CC	O
percentage	NN	O
of	IN	O
CD3	NNP	O
cells	NNS	O
.	.	O

Relative	JJ	O
numbers	NNS	O
of	IN	O
CD16	NNP	O
cells	NNS	O
were	VBD	O
significantly	RB	O
elevated	VBN	O
,	,	O
but	CC	O
NK	NNP	O
cell	VBP	O
cytotoxic	JJ	O
activity	NN	O
was	VBD	O
within	IN	O
a	DT	O
normal	JJ	O
range	NN	O
.	.	O

Nine	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
renal	JJ	O
anemia	NN	O
on	IN	O
maintenance	NN	O
hemodialysis	NN	O
were	VBD	O
enrolled	VBN	O
in	IN	O
rHu-EPO	JJ	Pharmacological
treatment	NN	O
trial	NN	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
continued	VBN	O
till	IN	O
the	DT	O
hematocrit	NN	O
level	NN	O
reached	VBD	O
30	CD	O
%	NN	O
.	.	O

Each	DT	O
of	IN	O
the	DT	O
patients	NNS	O
had	VBD	O
corrected	VBN	O
anemia	NN	O
and	CC	O
well-being	NN	O
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
treatment	NN	O
we	PRP	O
observed	VBD	O
in	IN	O
these	DT	O
patients	NNS	O
decreases	NNS	O
in	IN	O
CD3	NNP	O
,	,	O
CD4	NNP	O
,	,	O
CD8	NNP	O
and	CC	O
CD16	NNP	O
cell	NN	O
numbers	NNS	O
and	CC	O
elevation	NN	O
of	IN	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Cytotoxic	NNP	O
activity	NN	O
of	IN	O
NK	NNP	O
cells	NNS	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
.	.	O

Presented	VBN	O
results	NNS	O
indicate	VBP	O
that	IN	O
chronic	JJ	O
hemodialysis	NN	O
patients	NNS	O
have	VBP	O
significantly	RB	O
diminished	VBN	O
lymphocyte	JJ	O
number	NN	O
.	.	O

rHu	JJ	Pharmacological
EPO	NNP	Pharmacological
treatment	NN	O
affects	VBZ	O
the	DT	O
T	NNP	O
lymphocyte	NN	O
subsets	NNS	O
inducing	VBG	O
a	DT	O
deep	JJ	O
decrease	NN	O
of	IN	O
CD8	NNP	O
and	CC	O
CD16	NNP	O
cell	NN	O
percentage	NN	O
leading	VBG	O
to	TO	O
normalisation	NN	O
of	IN	O
the	DT	O
CD4/CD8	NNP	O
ratio	NN	O
.	.	O

Standard	NNP	Physical
versus	NN	O
extended	VBD	Surgical
lymphadenectomy	NN	Surgical
in	IN	O
radical	JJ	O
pancreatoduodenectomy	NN	O
for	IN	O
ductal	JJ	O
adenocarcinoma	NN	O
of	IN	O
the	DT	O
head	NN	O
of	IN	O
the	DT	O
pancreas	NNS	O
:	:	O
long-term	JJ	O
results	NNS	O
of	IN	O
a	DT	O
Japanese	JJ	O
multicenter	NN	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
value	NN	O
of	IN	O
pancreatoduodenectomy	NN	O
(	(	O
PD	NNP	O
)	)	O
with	IN	O
extended	VBN	O
lymphadenectomy	NN	O
for	IN	O
pancreatic	JJ	O
cancer	NN	O
has	VBZ	O
been	VBN	O
evaluated	VBN	O
by	IN	O
many	JJ	O
retrospective	JJ	O
studies	NNS	O
and	CC	O
3	CD	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
(	(	O
RCT	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
protocols	NNS	O
used	VBN	O
and	CC	O
the	DT	O
results	NNS	O
found	VBD	O
in	IN	O
the	DT	O
3	CD	O
RCTs	NNP	O
were	VBD	O
diverse	JJ	O
.	.	O

Therefore	RB	O
,	,	O
a	DT	O
multicenter	NN	O
RCT	NNP	O
was	VBD	O
proposed	VBN	O
in	IN	O
1998	CD	O
to	TO	O
evaluate	VB	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
of	IN	O
long-term	JJ	O
survival	NN	O
and	CC	O
the	DT	O
secondary	JJ	O
end	NN	O
points	NNS	O
of	IN	O
morbidity	NN	O
,	,	O
mortality	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
standard	JJ	O
versus	NN	O
extended	VBD	Surgical
lymphadenectomy	NN	Surgical
in	IN	O
radical	JJ	O
PD	NNP	O
for	IN	O
pancreatic	JJ	O
cancer	NN	O
.	.	O

METHODS	NNP	O
From	IN	O
March	NNP	O
2000	CD	O
to	TO	O
May	NNP	O
2003	CD	O
,	,	O
112	CD	O
patients	NNS	O
with	IN	O
potentially	RB	O
curable	JJ	O
pancreatic	JJ	O
head	NN	O
cancer	NN	O
were	VBD	O
enrolled	VBN	O
and	CC	O
intraoperatively	RB	O
randomized	VBN	O
to	TO	O
a	DT	O
standard	NN	Surgical
or	CC	Surgical
extended	JJ	Surgical
lymphadenectomy	NN	Surgical
group	NN	O
.	.	O

No	RB	O
resected	JJ	O
patients	NNS	O
received	VBD	O
any	DT	O
adjuvant	JJ	O
treatments	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
hundred	CD	O
and	CC	O
one	CD	O
eligible	JJ	O
patients	NNS	O
were	VBD	O
analyzed	VBN	O
.	.	O

Demographic	NNP	O
and	CC	O
histopathological	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

The	DT	O
mean	NN	O
operating	NN	O
time	NN	O
,	,	O
intraoperative	JJ	O
blood	NN	O
loss	NN	O
and	CC	O
number	NN	O
of	IN	O
retrieved	JJ	O
lymph	NN	O
nodes	NNS	O
were	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
extended	JJ	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
other	JJ	O
operative	JJ	O
results	NNS	O
were	VBD	O
comparable	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Although	IN	O
this	DT	O
multicenter	NN	O
RCT	NNP	O
was	VBD	O
conducted	VBN	O
in	IN	O
a	DT	O
strict	JJ	O
setting	NN	O
,	,	O
extended	VBD	Surgical
lymphadenectomy	NN	Surgical
in	IN	O
radical	JJ	O
PD	NNP	O
did	VBD	O
not	RB	O
benefit	VB	O
long-term	JJ	O
survival	NN	O
in	IN	O
patients	NNS	O
with	IN	O
resectable	JJ	O
pancreatic	JJ	O
head	NN	O
cancer	NN	O
and	CC	O
led	VBD	O
to	TO	O
levels	NNS	O
of	IN	O
morbidity	NN	O
,	,	O
mortality	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
comparable	JJ	O
to	TO	O
those	DT	O
found	VBN	O
after	IN	O
standard	JJ	Surgical
lymphadenectomy	NN	Surgical
.	.	Surgical

Neuromuscular	JJ	O
excitability	NN	O
changes	NNS	O
in	IN	O
the	DT	O
vastus	NN	O
medialis	NN	O
following	VBG	O
anterior	JJ	Surgical
cruciate	JJ	Surgical
ligament	NN	Surgical
reconstruction	NN	Surgical
.	.	O

PURPOSE	NNP	O
Quadriceps	NNP	O
weakness	NN	O
following	VBG	O
anterior	JJ	O
cruciate	JJ	Surgical
ligament	NN	Surgical
reconstruction	NN	Surgical
(	(	Surgical
ACLR	NNP	Surgical
)	)	Surgical
is	VBZ	O
prevalent	JJ	O
despite	IN	O
intensive	JJ	O
rehabilitation	NN	O
.	.	O

Diminished	NNP	O
neuromuscular	JJ	O
excitability	NN	O
is	VBZ	O
one	CD	O
potential	JJ	O
factor	NN	O
that	WDT	O
may	MD	O
limit	VB	O
muscular	JJ	O
recovery	NN	O
following	VBG	O
injury	NN	O
or	CC	O
surgery	NN	O
.	.	O

The	DT	O
H-reflex	NNP	O
provides	VBZ	O
a	DT	O
measure	NN	O
of	IN	O
alpha	NN	O
motorneuron	NN	O
(	(	O
neuromuscular	JJ	O
)	)	O
excitability	NN	O
in	IN	O
the	DT	O
sensory-motor	JJ	O
pathway	NN	O
of	IN	O
the	DT	O
respective	JJ	O
muscle	NN	O
and	CC	O
nerve	NN	O
.	.	O

To	TO	O
date	NN	O
the	DT	O
vastus	NN	O
medialis	NN	O
(	(	O
VM	NNP	O
)	)	O
and	CC	O
soleus	NN	O
(	(	O
SOL	NNP	O
)	)	O
H-reflexes	NNP	O
have	VBP	O
been	VBN	O
examined	VBN	O
primarily	RB	O
in	IN	O
control	NN	O
subjects	NNS	O
with	IN	O
induced	JJ	O
knee	NNS	O
joint	JJ	O
effusion	NN	O
.	.	O

This	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
evaluated	VBD	O
the	DT	O
affect	NN	O
of	IN	O
ACLR	NNP	Surgical
,	,	O
utilizing	VBG	O
hamsting	NN	Surgical
(	(	Surgical
HS	NNP	Surgical
)	)	Surgical
or	CC	Surgical
bone-patellar	JJ	Surgical
tendon-bone	NN	Surgical
(	(	Surgical
BTB	NNP	Surgical
)	)	Surgical
autograft	NN	Surgical
,	,	O
on	IN	O
VM	NNP	O
and	CC	O
SOL	NNP	O
H-reflex	NNP	O
latency	NN	O
and	CC	O
amplitude	NN	O
in	IN	O
twenty	JJ	O
subjects	NNS	O
.	.	O

METHODS	NNP	O
Preoperatively	RB	O
bilateral	JJ	O
VM	NNP	O
and	CC	O
SOL	NNP	O
H-reflex	NNP	O
tests	NNS	O
were	VBD	O
conducted	VBN	O
.	.	O

VM	NNP	O
and	CC	O
SOL	NNP	O
H-reflexes	NNP	O
were	VBD	O
subsequently	RB	O
conducted	VBN	O
on	IN	O
the	DT	O
involved	VBN	O
lower	JJR	O
extremity	NN	O
at	IN	O
1	CD	O
and	CC	O
3	CD	O
months	NNS	O
post	VBN	O
surgery	NN	O
.	.	O

At	IN	O
each	DT	O
test	NN	O
session	NN	O
subjects	NNS	O
completed	VBN	O
visual	JJ	O
analog	NN	O
scales	NNS	O
and	CC	O
knee	VB	O
girth	NN	O
was	VBD	O
measured	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
VM	NNP	O
H-reflex	NNP	O
amplitude	NN	O
increased	VBD	O
in	IN	O
the	DT	O
HS	NNP	O
group	NN	O
at	IN	O
3	CD	O
months	NNS	O
compared	VBN	O
to	TO	O
1-month	JJ	O
post	NN	O
surgery	NN	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Significant	JJ	O
changes	NNS	O
over	IN	O
time	NN	O
were	VBD	O
also	RB	O
noted	VBN	O
in	IN	O
the	DT	O
visual	JJ	O
analog	NN	O
pain	NN	O
and	CC	O
functional	JJ	O
scales	NNS	O
and	CC	O
the	DT	O
mid-patella	JJ	O
girth	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
increased	JJ	O
VM	NNP	O
H-reflex	NNP	O
amplitude	NN	O
at	IN	O
3	CD	O
months	NNS	O
following	VBG	O
HS	NNP	O
autograft	NN	O
ACLR	NNP	Surgical
demonstrates	VBZ	O
an	DT	O
increase	NN	O
in	IN	O
VM	NNP	O
neuromuscular	JJ	O
excitability	NN	O
.	.	O

Increased	VBN	O
VM	NNP	O
neuromuscular	JJ	O
excitability	NN	O
was	VBD	O
not	RB	O
evident	JJ	O
in	IN	O
patients	NNS	O
following	VBG	O
BTB	NNP	O
reconstruction	NN	O
.	.	O

The	DT	O
increased	JJ	O
neuromuscular	JJ	O
excitability	NN	O
,	,	O
observed	VBD	O
only	RB	O
in	IN	O
the	DT	O
HS	NNP	O
group	NN	O
,	,	O
warrants	NNS	O
consideration	NN	O
when	WRB	O
selecting	VBG	O
graft	NN	O
type	NN	O
for	IN	O
patients	NNS	O
with	IN	O
extensive	JJ	O
preoperative	JJ	O
quadriceps	NNS	O
dysfunction	NN	O
.	.	O

An	DT	O
allopurinol-controlled	JJ	Pharmacological
,	,	O
randomized	VBN	O
,	,	O
double-dummy	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
parallel	JJ	O
between-group	NN	O
,	,	O
comparative	JJ	O
study	NN	O
of	IN	O
febuxostat	NN	Pharmacological
(	(	Pharmacological
TMX-67	NNP	Pharmacological
)	)	Pharmacological
,	,	O
a	DT	O
non-purine-selective	JJ	Pharmacological
inhibitor	NN	Pharmacological
of	IN	Pharmacological
xanthine	JJ	Pharmacological
oxidase	NN	Pharmacological
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
hyperuricemia	JJ	O
including	VBG	O
those	DT	O
with	IN	O
gout	NN	O
in	IN	O
Japan	NNP	O
:	:	O
phase	NN	O
3	CD	O
clinical	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Allopurinol	NNP	Pharmacological
has	VBZ	O
been	VBN	O
widely	RB	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
hyperuricemia	NN	O
,	,	O
however	RB	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
various	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

Febuxostat	NNP	O
is	VBZ	O
potentially	RB	O
a	DT	O
safe	JJ	O
and	CC	O
efficacious	JJ	O
alternative	NN	O
.	.	O

OBJECTIVES	NNP	O
Febuxostat	NNP	Pharmacological
or	CC	O
allopurinol	NN	Pharmacological
was	VBD	O
administered	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
hyperuricemia	JJ	O
including	VBG	O
gout	NN	O
for	IN	O
8	CD	O
weeks	NNS	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
these	DT	O
drugs	NNS	O
.	.	O

METHODS	NNP	O
Doses	NNP	O
of	IN	O
febuxostat	NN	Pharmacological
and	CC	O
allopurinol	NN	Pharmacological
were	VBD	O
10	CD	O
and	CC	O
100	CD	O
mg/d	NN	O
,	,	O
respectively	RB	O
,	,	O
during	IN	O
a	DT	O
12-day	JJ	O
introduction	NN	O
period	NN	O
and	CC	O
were	VBD	O
increased	VBN	O
to	TO	O
40	CD	O
and	CC	O
200	CD	O
mg/d	NN	O
for	IN	O
the	DT	O
subsequent	JJ	O
treatment	NN	O
period	NN	O
of	IN	O
44	CD	O
days	NNS	O
.	.	O

RESULTS	NN	O
:	:	O
The	DT	O
percent	NN	O
changes	NNS	O
in	IN	O
serum	NN	O
uric	JJ	O
acid	NN	O
levels	NNS	O
after	IN	O
8	CD	O
weeks	NNS	O
were	VBD	O
-40.75	CD	O
%	NN	O
for	IN	O
the	DT	O
febuxostat	NN	Pharmacological
group	NN	O
and	CC	O
-34.41	CD	O
%	NN	O
for	IN	O
the	DT	O
allopurinol	NN	Pharmacological
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
,	,	O
analysis	NN	O
of	IN	O
variance	NN	O
,	,	O
closing	VBG	O
testing	VBG	O
procedure	NN	O
)	)	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
achieving	VBG	O
serum	JJ	O
uric	JJ	O
acid	NN	O
levels	NNS	O
6.0	CD	O
mg/dL	NN	O
or	CC	O
less	JJR	O
after	IN	O
8	CD	O
weeks	NNS	O
was	VBD	O
82.0	CD	O
%	NN	O
for	IN	O
the	DT	O
febuxostat	NN	O
group	NN	O
and	CC	O
70.0	CD	O
%	NN	O
for	IN	O
the	DT	O
allopurinol	NN	Pharmacological
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.019	CD	O
,	,	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
)	)	O
.	.	O

Regarding	VBG	O
safety	NN	O
,	,	O
213	CD	O
adverse	JJ	O
events	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
febuxostat	NN	Pharmacological
group	NN	O
and	CC	O
220	CD	O
events	NNS	O
in	IN	O
the	DT	O
allopurinol	NN	O
group	NN	O
.	.	O

For	IN	O
10	CD	O
patients	NNS	O
(	(	O
8.2	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
febuxostat	NN	Pharmacological
group	NN	O
and	CC	O
14	CD	O
patients	NNS	O
(	(	O
11.6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
allopurinol	NN	Pharmacological
group	NN	O
,	,	O
association	NN	O
with	IN	O
the	DT	O
study	NN	O
drugs	NNS	O
could	MD	O
not	RB	O
be	VB	O
ruled	VBN	O
out	RP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
severe	JJ	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
in	IN	O
the	DT	O
febuxostat	NN	Pharmacological
group	NN	O
other	JJ	O
than	IN	O
a	DT	O
high	JJ	O
frequency	NN	O
of	IN	O
gout	NN	O
attacks	NNS	O
induced	VBN	O
by	IN	O
the	DT	O
sudden	JJ	O
reduction	NN	O
in	IN	O
blood	NN	O
uric	JJ	O
acid	NN	O
levels	NNS	O
during	IN	O
the	DT	O
early	JJ	O
treatment	NN	O
period	NN	O
.	.	O

CONCLUSIONS	NNP	O
Febuxostat	NNP	Pharmacological
at	IN	O
40	CD	O
mg/d	NN	O
demonstrated	VBD	O
more	RBR	O
potent	JJ	O
hypouricemic	JJ	O
effects	NNS	O
than	IN	O
allopurinol	NN	Pharmacological
at	IN	O
200	CD	O
mg/d	NN	O
,	,	O
was	VBD	O
efficacious	JJ	O
regardless	NN	O
of	IN	O
medical	JJ	O
history	NN	O
of	IN	O
gout	NN	O
,	,	O
and	CC	O
is	VBZ	O
considered	VBN	O
safe	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
hyperuricemia	NN	O
.	.	O

The	DT	O
ADDITION-Cambridge	NNP	O
trial	NN	O
protocol	NN	O
:	:	O
a	DT	O
cluster	NN	O
--	:	O
randomised	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
screening	VBG	O
for	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
and	CC	O
intensive	JJ	O
treatment	NN	O
for	IN	O
screen-detected	JJ	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
increasing	VBG	O
prevalence	NN	O
of	IN	O
type	NN	O
2	CD	O
diabetes	VBZ	O
poses	NNS	O
a	DT	O
major	JJ	O
public	JJ	O
health	NN	O
challenge	NN	O
.	.	O

Population-based	JJ	O
screening	NN	O
and	CC	O
early	JJ	O
treatment	NN	O
for	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
could	MD	O
reduce	VB	O
this	DT	O
growing	VBG	O
burden	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
benefits	NNS	O
of	IN	O
such	JJ	O
a	DT	O
strategy	NN	O
remain	NN	O
uncertain	JJ	O
.	.	O

METHODS	NNP	O
AND	CC	O
DESIGN	NNP	O
The	DT	O
ADDITION-Cambridge	NNP	O
study	NN	O
aims	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
cost-effectiveness	NN	O
of	IN	O
(	(	O
i	NN	O
)	)	O
a	DT	O
stepwise	NN	O
screening	NN	O
strategy	NN	O
for	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
;	:	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
intensive	JJ	Educational
multifactorial	JJ	Educational
treatment	NN	Educational
for	IN	O
people	NNS	O
with	IN	O
screen-detected	JJ	O
diabetes	NNS	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

63	CD	O
practices	NNS	O
in	IN	O
the	DT	O
East	NNP	O
Anglia	NNP	O
region	NN	O
participated	VBD	O
.	.	O

Three	CD	O
undertook	IN	O
the	DT	O
pilot	NN	O
study	NN	O
,	,	O
33	CD	O
were	VBD	O
allocated	VBN	O
to	TO	O
three	CD	O
groups	NNS	O
:	:	O
no	DT	Control
screening	NN	Control
(	(	Control
control	NN	Control
)	)	Control
,	,	O
screening	VBG	Educational
followed	VBN	Educational
by	IN	Educational
intensive	JJ	Educational
treatment	NN	Educational
(	(	Educational
IT	NNP	Educational
)	)	Educational
and	CC	O
screening	VBG	O
plus	CC	O
routine	JJ	O
care	NN	O
(	(	O
RC	NNP	O
)	)	O
in	IN	O
an	DT	O
unbalanced	JJ	O
(	(	O
1:3:3	CD	O
)	)	O
randomisation	NN	O
.	.	O

The	DT	O
remaining	VBG	O
27	CD	O
practices	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
IT	NNP	O
and	CC	O
RC	NNP	O
.	.	O

A	NNP	O
risk	NN	O
score	NN	O
incorporating	VBG	O
routine	JJ	O
practice	NN	O
data	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
identify	VB	O
people	NNS	O
aged	VBN	O
40-69	JJ	O
years	NNS	O
at	IN	O
high-risk	NN	O
of	IN	O
undiagnosed	JJ	O
diabetes	NNS	O
.	.	O

In	IN	O
the	DT	O
screening	NN	O
practices	NNS	O
,	,	O
high-risk	JJ	O
individuals	NNS	O
were	VBD	O
invited	VBN	O
to	TO	O
take	VB	O
part	NN	O
in	IN	O
a	DT	O
stepwise	NN	O
screening	VBG	O
programme	NN	O
.	.	O

In	IN	O
the	DT	O
IT	NNP	O
group	NN	O
,	,	O
diabetes	VBZ	O
treatment	NN	O
is	VBZ	O
optimised	VBN	O
through	IN	O
guidelines	NNS	O
,	,	O
target-led	JJ	O
multifactorial	JJ	O
treatment	NN	O
,	,	O
audit	NN	O
,	,	O
feedback	NN	O
,	,	O
and	CC	O
academic	JJ	O
detailing	NN	O
for	IN	O
practice	NN	O
teams	NNS	O
,	,	O
alongside	JJ	O
provision	NN	O
of	IN	O
educational	JJ	O
materials	NNS	O
for	IN	O
newly	RB	O
diagnosed	VBN	O
participants	NNS	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
are	VBP	O
modelled	VBN	O
cardiovascular	JJ	O
risk	NN	O
at	IN	O
one	CD	O
year	NN	O
,	,	O
and	CC	O
cardiovascular	JJ	O
mortality	NN	O
and	CC	O
morbidity	NN	O
at	IN	O
five	CD	O
years	NNS	O
after	IN	O
diagnosis	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
include	VBP	O
all-cause	JJ	O
mortality	NN	O
,	,	O
development	NN	O
of	IN	O
renal	JJ	O
and	CC	O
visual	JJ	O
impairment	NN	O
,	,	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
health	NN	O
service	NN	O
costs	NNS	O
,	,	O
self-reported	JJ	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
functional	JJ	O
status	NN	O
and	CC	O
health	NN	O
utility	NN	O
.	.	O

Impact	NN	O
of	IN	O
the	DT	O
screening	NN	O
programme	NN	O
at	IN	O
the	DT	O
population	NN	O
level	NN	O
is	VBZ	O
also	RB	O
assessed	VBN	O
through	IN	O
measures	NNS	O
of	IN	O
mortality	NN	O
,	,	O
cardiovascular	JJ	O
morbidity	NN	O
,	,	O
health	NN	O
status	NN	O
and	CC	O
health	NN	O
service	NN	O
use	NN	O
among	IN	O
high-risk	JJ	O
individuals	NNS	O
.	.	O

DISCUSSION	NNP	O
ADDITION-Cambridge	NNP	O
is	VBZ	O
conducted	VBN	O
in	IN	O
a	DT	O
defined	JJ	O
high-risk	JJ	O
group	NN	O
accessible	JJ	O
through	IN	O
primary	JJ	O
care	NN	O
.	.	O

It	PRP	O
addresses	VBZ	O
the	DT	O
feasibility	NN	O
of	IN	O
population-based	JJ	O
screening	NN	O
for	IN	O
diabetes	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
benefits	NNS	O
and	CC	O
costs	NNS	O
of	IN	O
screening	VBG	O
and	CC	O
intensive	JJ	O
multifactorial	JJ	O
treatment	NN	O
early	RB	O
in	IN	O
the	DT	O
disease	NN	O
trajectory	NN	O
.	.	O

The	DT	O
intensive	JJ	O
treatment	NN	O
algorithm	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
evidence	NN	O
from	IN	O
studies	NNS	O
including	VBG	O
individuals	NNS	O
with	IN	O
clinically	RB	O
diagnosed	VBN	O
diabetes	NNS	O
and	CC	O
the	DT	O
education	NN	O
materials	NNS	O
are	VBP	O
informed	VBN	O
by	IN	O
psychological	JJ	O
theory	NN	O
.	.	O

ADDITION-Cambridge	NNP	O
will	MD	O
provide	VB	O
timely	RB	O
evidence	NN	O
concerning	VBG	O
the	DT	O
benefits	NNS	O
of	IN	O
early	JJ	O
intensive	JJ	O
treatment	NN	O
and	CC	O
will	MD	O
inform	VB	O
policy	NN	O
decisions	NNS	O
concerning	VBG	O
screening	NN	O
for	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
trials	NNS	O
ISRCTN86769081	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
hypotensive	JJ	O
effects	NNS	O
of	IN	O
bendrofluazide	NN	Pharmacological
,	,	O
bumetanide	NN	Pharmacological
and	CC	O
xipamide	NNP	Pharmacological
.	.	O

A	NNP	O
randomized	JJ	O
,	,	O
triple	JJ	O
crossover	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
24	CD	O
elderly	JJ	O
patients	NNS	O
requiring	VBG	O
chronic	JJ	Pharmacological
diuretic	JJ	Pharmacological
therapy	NN	Pharmacological
to	TO	O
assess	VB	O
the	DT	O
different	JJ	O
hypotensive	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
fixed	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
5	CD	Pharmacological
mg	NNS	Pharmacological
bendrofluazide	RB	Pharmacological
,	,	O
1	CD	Pharmacological
mg	NN	Pharmacological
bumetanide	NN	Pharmacological
and	CC	O
40	CD	Pharmacological
mg	NN	Pharmacological
xipamide	NN	Pharmacological
.	.	O

Each	DT	O
treatment	NN	O
was	VBD	O
given	VBN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
no	DT	O
significant	JJ	O
weight	NN	O
change	NN	O
took	VBD	O
place	NN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

There	EX	O
was	VBD	O
,	,	O
however	RB	O
,	,	O
a	DT	O
significant	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
decrease	NN	O
compared	VBN	O
to	TO	O
baseline	VB	O
values	NNS	O
both	DT	O
in	IN	O
systolic	NN	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
during	IN	O
the	DT	O
xipamide	JJ	O
period	NN	O
and	CC	O
a	DT	O
decrease	NN	O
in	IN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
when	WRB	O
taking	VBG	O
bumetanide	NN	Pharmacological
.	.	O

Only	RB	O
minor	JJ	O
side-effects	NNS	O
were	VBD	O
reported	VBN	O
.	.	O

Treatment	NN	O
of	IN	O
sperm	NN	O
with	IN	O
platelet-activating	JJ	Pharmacological
factor	NN	Pharmacological
does	VBZ	O
not	RB	O
improve	VB	O
intrauterine	JJ	Physical
insemination	NN	Physical
outcome	NN	O
in	IN	O
unselected	JJ	O
cases	NNS	O
of	IN	O
mild	JJ	O
male	JJ	O
factor	NN	O
infertility	NN	O
:	:	O
a	DT	O
prospective	JJ	O
double-blind	NN	O
randomized	VBN	O
crossover	NN	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
sperm	JJ	O
treatment	NN	O
with	IN	O
exogenous	JJ	Pharmacological
platelet-activating	JJ	Pharmacological
factor	NN	Pharmacological
(	(	Pharmacological
PAF	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
intrauterine	JJ	Physical
insemination	NN	Physical
(	(	Physical
IUI	NNP	Physical
)	)	Physical
clinical	JJ	O
pregnancy	NN	O
rate	NN	O
in	IN	O
cases	NNS	O
of	IN	O
mild	JJ	O
male	JJ	O
factor	NN	O
infertility	NN	O
.	.	O

PAF	NNP	O
is	VBZ	O
a	DT	O
phospholipid	JJ	O
mediator	NN	O
,	,	O
which	WDT	O
is	VBZ	O
present	JJ	O
in	IN	O
human	JJ	O
sperm	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
Assisted	NNP	O
Reproduction	NNP	O
Unit	NNP	O
of	IN	O
the	DT	O
2nd	CD	O
Department	NNP	O
of	IN	O
Obstetrics	NNP	O
and	CC	O
Gynecology	NNP	O
,	,	O
University	NNP	O
of	IN	O
Athens	NNP	O
,	,	O
Aretaieion	NNP	O
Hospital	NNP	O
,	,	O
Athens	NNP	O
,	,	O
Greece	NNP	O
,	,	O
and	CC	O
included	VBD	O
92	CD	O
couples	NNS	O
who	WP	O
presented	VBD	O
with	IN	O
mild	JJ	O
male	JJ	O
factor	NN	O
infertility-all	JJ	O
candidates	NNS	O
for	IN	O
IUI	NNP	O
.	.	O

A	NNP	O
maximum	NN	O
of	IN	O
4	CD	O
IUI	NNP	Physical
cycles	NNS	O
per	IN	O
couple	NN	O
with	IN	O
or	CC	O
without	IN	O
exogenous	JJ	Pharmacological
PAF	NNP	Pharmacological
treatment	NN	Pharmacological
were	VBD	O
performed	VBN	O
and	CC	O
the	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
clinical	JJ	O
pregnancy	NN	O
rate	NN	O
(	(	O
pregnancies	NNS	O
confirmed	VBN	O
by	IN	O
ultrasonography	NN	O
per	IN	O
100	CD	O
cycles	NNS	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
overall	JJ	O
clinical	JJ	O
pregnancy	NN	O
rate	NN	O
after	IN	O
a	DT	O
maximum	NN	O
of	IN	O
4	CD	O
IUI	NNP	Physical
cycles	NNS	O
was	VBD	O
comparable	JJ	O
in	IN	O
cases	NNS	O
with	IN	O
and	CC	O
without	IN	O
sperm	JJ	Pharmacological
treatment	NN	Pharmacological
with	IN	Pharmacological
PAF	NNP	Pharmacological
(	(	O
12.24	CD	O
%	NN	O
vs	JJ	O
11.11	CD	O
%	NN	O
)	)	O
.	.	O

Addition	NN	O
or	CC	O
exclusion	NN	O
of	IN	O
PAF	NNP	Pharmacological
sperm	FW	Pharmacological
treatment	NN	Pharmacological
in	IN	O
the	DT	O
same	JJ	O
patients	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
alter	VB	O
the	DT	O
outcome	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
generalized	JJ	O
use	NN	O
of	IN	O
exogenous	JJ	Pharmacological
PAF	NNP	Pharmacological
for	IN	O
the	DT	O
preparation	NN	O
of	IN	O
sperm	NN	O
in	IN	O
unselected	JJ	O
cases	NNS	O
of	IN	O
mild	JJ	O
male	JJ	O
infertility	NN	O
does	VBZ	O
not	RB	O
improve	VB	O
the	DT	O
clinical	JJ	O
outcome	NN	O
of	IN	O
IUI	NNP	O
.	.	O

Omega-3/omega-6	NNP	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
for	IN	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
:	:	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	O
trial	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
omega	JJ	Pharmacological
3/6	CD	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
(	(	O
eye	NN	O
q	NN	O
)	)	O
in	IN	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
.	.	O

METHOD	PDT	O
The	DT	O
study	NN	O
included	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
3-month	JJ	O
,	,	O
omega	JJ	Pharmacological
3/6	CD	Pharmacological
placebo-controlled	JJ	Control
,	,	O
one-way	JJ	O
crossover	NN	O
trial	NN	O
with	IN	O
75	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
8-18	CD	O
years	NNS	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	Pharmacological
months	NNS	Pharmacological
with	IN	Pharmacological
omega	JJ	Pharmacological
3/6	CD	Pharmacological
for	IN	Pharmacological
all	DT	Pharmacological
.	.	O

Investigator-rated	JJ	O
ADHD	NNP	O
Rating	NNP	O
Scale-IV	NNP	O
and	CC	O
Clinical	NNP	O
Global	NNP	O
Impression	NNP	O
(	(	O
CGI	NNP	O
)	)	O
scale	NN	O
were	VBD	O
outcome	JJ	O
measures	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
majority	NN	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
omega	VB	O
3/6	CD	O
treatment	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
subgroup	NN	O
of	IN	O
26	CD	O
%	NN	O
responded	VBD	O
with	IN	O
more	JJR	O
than	IN	O
25	CD	O
%	NN	O
reduction	NN	O
of	IN	O
ADHD	NNP	O
symptoms	NNS	O
and	CC	O
a	DT	O
drop	NN	O
of	IN	O
CGI	NNP	O
scores	NNS	O
to	TO	O
the	DT	O
near-normal	JJ	O
range	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
47	CD	O
%	NN	O
of	IN	O
all	DT	O
showed	VBD	O
such	JJ	O
improvement	NN	O
.	.	O

Responders	NNS	O
tended	VBD	O
to	TO	O
have	VB	O
ADHD	NNP	O
inattentive	JJ	O
subtype	NN	O
and	CC	O
comorbid	NN	O
neurodevelopmental	JJ	O
disorders	NNS	O
.	.	O

CONCLUSION	VB	O
A	DT	O
subgroup	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ADHD	NNP	O
,	,	O
characterized	VBN	O
by	IN	O
inattention	NN	O
and	CC	O
associated	VBN	O
neurodevelopmental	JJ	O
disorders	NNS	O
,	,	O
treated	VBN	O
with	IN	O
omega	JJ	Pharmacological
3/6	CD	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
for	IN	O
6	CD	O
months	NNS	O
responded	VBN	O
with	IN	O
meaningful	JJ	O
reduction	NN	O
of	IN	O
ADHD	NNP	O
symptoms	NNS	O
.	.	O

Science	NN	O
to	TO	O
practice	NN	O
in	IN	O
underserved	JJ	O
communities	NNS	O
:	:	O
the	DT	O
effectiveness	NN	O
of	IN	O
school	NN	Educational
mental	JJ	Educational
health	NN	Educational
programming	NN	Educational
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
treatment	NN	Educational
program	NN	Educational
comprised	VBN	O
of	IN	O
several	JJ	O
components	NNS	O
based	VBN	O
on	IN	O
evidence-based	JJ	Educational
treatments	NNS	Educational
(	(	Educational
EBTs	NNP	Educational
)	)	Educational
for	IN	Educational
disruptive	JJ	Educational
behavior	NN	Educational
problems	NNS	Educational
delivered	VBN	O
to	TO	O
youth	VB	O
participating	VBG	O
in	IN	O
a	DT	O
school	NN	O
mental	JJ	O
health	NN	O
program	NN	O
in	IN	O
an	DT	O
underserved	JJ	O
community	NN	O
in	IN	O
the	DT	O
Appalachian	JJ	O
region	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
117	CD	O
children	NNS	O
in	IN	O
kindergarten	VBN	O
through	IN	O
6th	CD	O
grade	NN	O
including	VBG	O
91	CD	O
children	NNS	O
(	(	O
78	CD	O
%	NN	O
male	NN	O
)	)	O
from	IN	O
5	CD	O
schools	NNS	O
who	WP	O
were	VBD	O
consecutively	RB	O
referred	VBN	O
to	TO	O
the	DT	O
intervention	NN	Educational
program	NN	Educational
and	CC	O
26	CD	O
children	NNS	O
(	(	O
73	CD	O
%	NN	O
male	NN	O
)	)	O
from	IN	O
3	CD	O
schools	NNS	O
in	IN	O
which	WDT	O
program	NN	O
implementation	NN	O
was	VBD	O
delayed	VBN	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

Treatment	NNP	O
outcome	NN	O
was	VBD	O
measured	VBN	O
via	IN	O
parent	NN	O
and	CC	O
teacher	JJ	O
ratings	NNS	O
of	IN	O
child	NN	O
symptoms	NNS	O
and	CC	O
functioning	VBG	O
.	.	O

The	DT	O
treatment	NN	O
condition	NN	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reduction	NN	O
in	IN	O
hyperactivity/impulsivity	NN	O
and	CC	O
early	JJ	O
aggressive	JJ	O
and	CC	O
delinquent	JJ	O
behavior	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
significant	JJ	O
improvement	NN	O
in	IN	O
several	JJ	O
other	JJ	O
functional	JJ	O
domains	NNS	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
EBTs	NNP	Educational
can	MD	O
retain	VB	O
their	PRP$	O
effectiveness	NN	O
when	WRB	O
transported	VBN	O
to	TO	O
a	DT	O
community	NN	O
context	NN	O
.	.	O

Effect	NN	O
of	IN	O
a	DT	O
synthetic	JJ	Pharmacological
appeasing	VBG	Pharmacological
pheromone	NN	Pharmacological
on	IN	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
synthetic	JJ	Pharmacological
,	,	Pharmacological
dog-appeasing	JJ	Pharmacological
pheromone	NN	Pharmacological
(	(	Pharmacological
sDAP	NN	Pharmacological
)	)	Pharmacological
on	IN	O
the	DT	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
in	IN	O
dogs	NNS	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

ANIMALS	$	O
46	CD	O
dogs	NNS	O
housed	VBN	O
in	IN	O
animal	NN	O
shelters	NNS	O
and	CC	O
undergoing	VBG	O
elective	JJ	O
orchiectomy	NN	O
or	CC	O
ovariohysterectomy	NN	O
.	.	O

PROCEDURES	NNP	O
Intensive	NNP	O
care	NN	O
unit	NN	O
cages	NNS	O
were	VBD	O
sprayed	VBN	O
with	IN	O
sDAP	JJ	Physical
solution	NN	Physical
or	CC	O
sham	NN	Control
treated	VBN	Control
with	IN	Control
the	DT	Control
carrier	NN	Control
used	VBN	O
in	IN	O
the	DT	O
solution	NN	O
20	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

Dogs	NNS	O
(	(	O
n	JJ	O
=	NN	O
24	CD	O
and	CC	O
22	CD	O
in	IN	O
the	DT	O
sDAP	NN	Physical
and	CC	O
sham	JJ	Control
treatment	NN	Control
exposure	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
were	VBD	O
placed	VBN	O
in	IN	O
treated	JJ	O
cages	NNS	O
for	IN	O
30	CD	O
minutes	NNS	O
before	IN	O
and	CC	O
after	IN	O
surgery	NN	O
.	.	O

Indicators	NNS	O
of	IN	O
stress	NN	O
(	(	O
ie	NN	O
,	,	O
alterations	NNS	O
in	IN	O
behavioral	JJ	O
,	,	O
neuroendocrine	JJ	O
,	,	O
immune	JJ	O
,	,	O
and	CC	O
acute-phase	JJ	O
responses	NNS	O
)	)	O
were	VBD	O
evaluated	VBN	O
perioperatively	RB	O
.	.	O

Behavioral	JJ	O
response	NN	O
variables	NNS	O
,	,	O
salivary	JJ	O
cortisol	NN	O
concentration	NN	O
,	,	O
WBC	NNP	O
count	NN	O
,	,	O
and	CC	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
glucose	NN	O
,	,	O
prolactin	NN	O
,	,	O
haptoglobin	NN	O
,	,	O
and	CC	O
C-reactive	JJ	O
protein	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

RESULTS	NNP	O
Behavioral	NNP	O
response	NN	O
variables	NNS	O
and	CC	O
serum	NN	O
prolactin	NN	O
concentration	NN	O
were	VBD	O
influenced	VBN	O
by	IN	O
sDAP	NN	O
exposure	NN	O
.	.	O

Dogs	NNS	O
exposed	VBD	O
to	TO	O
sDAP	VB	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
alertness	NN	O
and	CC	O
visual	JJ	O
exploration	NN	O
behaviors	NNS	O
after	IN	O
surgery	NN	O
than	IN	O
were	VBD	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sham	VB	O
treatment	NN	O
.	.	O

Decreases	VBZ	O
in	IN	O
serum	NN	O
prolactin	NN	O
concentrations	NNS	O
in	IN	O
response	NN	O
to	TO	O
perioperative	JJ	O
stress	NN	O
were	VBD	O
significantly	RB	O
smaller	JJR	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
sDAP	VB	O
,	,	O
compared	VBN	O
with	IN	O
findings	NNS	O
in	IN	O
dogs	NNS	O
exposed	VBN	O
to	TO	O
the	DT	O
sham	NN	O
treatment	NN	O
.	.	O

Variables	NNS	O
examined	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
hypothalamic-pituitary-adrenal	JJ	O
axis	NN	O
,	,	O
immune	JJ	O
system	NN	O
,	,	O
and	CC	O
acute-phase	JJ	O
responses	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
CLINICAL	NNP	O
RELEVANCE	NNP	O
sDAP	NN	O
appeared	VBD	O
to	TO	O
affect	VB	O
behavioral	JJ	O
and	CC	O
neuroendocrine	JJ	O
perioperative	JJ	O
stress	NN	O
responses	NNS	O
by	IN	O
modification	NN	O
of	IN	O
lactotropic	JJ	O
axis	NN	O
activity	NN	O
.	.	O

Use	NN	O
of	IN	O
sDAP	NN	Pharmacological
in	IN	O
a	DT	O
clinical	JJ	O
setting	NN	O
may	MD	O
improve	VB	O
the	DT	O
recovery	NN	O
and	CC	O
welfare	NN	O
of	IN	O
dogs	NNS	O
undergoing	VBG	O
surgery	NN	O
.	.	O

Teaching	VBG	Psychological
emotion	NN	Psychological
recognition	NN	Psychological
skills	NNS	Psychological
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	JJ	O
trial	NN	O
of	IN	O
an	DT	O
emotion	NN	Psychological
training	NN	Psychological
programme	NN	Psychological
.	.	Educational

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
autism	NN	O
have	VBP	O
difficulties	NNS	O
in	IN	O
emotion	NN	O
recognition	NN	O
and	CC	O
a	DT	O
number	NN	O
of	IN	O
interventions	NNS	O
have	VBP	O
been	VBN	O
designed	VBN	O
to	TO	O
target	VB	O
these	DT	O
problems	NNS	O
.	.	O

However	RB	O
,	,	O
few	JJ	O
emotion	NN	Psychological
training	NN	Psychological
interventions	NNS	Psychological
have	VBP	O
been	VBN	O
trialled	VBN	O
with	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
co-morbid	JJ	O
ID	NNP	O
.	.	O

This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
an	DT	O
emotion	NN	Educational
training	NN	Educational
programme	NN	Educational
for	IN	O
a	DT	O
group	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
range	NN	O
of	IN	O
intellectual	JJ	O
ability	NN	O
.	.	O

METHODS	NNP	O
Participants	NNPS	O
were	VBD	O
55	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBN	O
4-7	CD	O
years	NNS	O
(	(	O
FSIQ	NNP	O
42-107	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
or	CC	O
control	VB	Control
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
watched	VBD	O
a	DT	O
DVD	NNP	Psychological
designed	VBN	Psychological
to	TO	Psychological
teach	VB	Psychological
emotion	NN	Psychological
recognition	NN	Psychological
skills	NNS	Psychological
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
(	(	O
the	DT	O
Transporters	NNPS	Educational
)	)	O
,	,	O
whereas	IN	O
the	DT	O
control	NN	O
group	NN	O
watched	VBD	Control
a	DT	Control
DVD	NNP	Control
of	IN	Control
Thomas	NNP	Control
the	DT	Control
Tank	NNP	Control
Engine	NNP	Control
.	.	O

Participants	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
complete	VB	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
tasks	NNS	O
,	,	O
mindreading	VBG	O
and	CC	O
theory	NN	O
of	IN	O
mind	NN	O
(	(	O
TOM	NNP	O
)	)	O
tasks	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
4-week	JJ	O
intervention	NN	O
period	NN	O
,	,	O
and	CC	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
Analyses	NNP	O
controlled	VBD	O
for	IN	O
the	DT	O
effect	NN	O
of	IN	O
chronological	JJ	O
age	NN	O
,	,	O
verbal	JJ	O
intelligence	NN	O
,	,	O
gender	NN	O
and	CC	O
DVD	NNP	O
viewing	VBG	O
time	NN	O
on	IN	O
outcomes	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
showed	VBD	O
improved	JJ	O
performance	NN	O
in	IN	O
the	DT	O
recognition	NN	O
of	IN	O
anger	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
with	IN	O
few	JJ	O
improvements	NNS	O
maintained	VBD	O
at	IN	O
3-month	JJ	O
follow-up	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
generalisation	NN	O
of	IN	O
skills	NNS	O
to	TO	O
TOM	NNP	O
or	CC	O
social	JJ	O
skills	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	Educational
Transporters	NNP	Psychological
programme	NN	Psychological
showed	VBD	O
limited	JJ	O
efficacy	NN	O
in	IN	O
teaching	VBG	O
basic	JJ	O
emotion	NN	O
recognition	NN	O
skills	NNS	O
to	TO	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
with	IN	O
a	DT	O
lower	JJR	O
range	NN	O
of	IN	O
cognitive	JJ	O
ability	NN	O
.	.	O

Improvements	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
recognition	NN	O
of	IN	O
expressions	NNS	O
of	IN	O
anger	NN	O
,	,	O
with	IN	O
poor	JJ	O
maintenance	NN	O
of	IN	O
these	DT	O
skills	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

These	DT	O
findings	NNS	O
provide	VBP	O
limited	JJ	O
support	NN	O
for	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
Transporters	NNP	Psychological
programme	NN	Psychological
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
of	IN	O
a	DT	O
lower	JJR	O
cognitive	JJ	O
range	NN	O
.	.	O

Small-diameter	JJ	Physical
hysteroscopy	NN	Physical
with	IN	Physical
Versapoint	NNP	Physical
versus	NN	O
resectoscopy	NN	Physical
with	IN	Physical
a	DT	Physical
unipolar	JJ	Physical
knife	NN	Physical
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
septate	JJ	O
uterus	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
2	CD	O
procedures	NNS	O
for	IN	O
metroplasty	NN	O
:	:	O
resectoscopy	NN	Physical
with	IN	Physical
monopolar	JJ	Physical
knife	NNS	Physical
versus	IN	O
small-diameter	JJ	Physical
hysteroscopy	NN	Physical
fitted	VBN	Physical
with	IN	Physical
a	DT	Physical
Versapoint	NNP	Physical
device	NN	Physical
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
randomized	VBN	O
study	NN	O
(	(	O
Canadian	JJ	O
Task	NNP	O
Force	NNP	O
classification	NN	O
I	PRP	O
)	)	O
.	.	O

SETTING	NN	O
Endoscopic	NNP	O
gynecology	NN	O
units	NNS	O
at	IN	O
tertiary	JJ	O
care	NN	O
university	NN	O
hospitals	NNS	O
.	.	O

PATIENTS	VB	O
One	CD	O
hundred-sixty	JJ	O
patients	NNS	O
with	IN	O
septate	JJ	O
uterus	NNS	O
and	CC	O
a	DT	O
history	NN	O
of	IN	O
recurrent	JJ	O
abortion	NN	O
or	CC	O
primary	JJ	O
infertility	NN	O
undergoing	VBG	O
hysteroscopic	NN	O
metroplasty	NN	O
from	IN	O
2001	CD	O
to	TO	O
2005	CD	O
.	.	O

INTERVENTIONS	NNP	O
Hysteroscopic	NNP	Physical
resection	NN	O
of	IN	O
the	DT	O
uterine	JJ	O
septum	NN	O
performed	VBN	O
with	IN	O
either	CC	O
a	DT	O
26F	CD	Physical
resectoscope	NN	Physical
with	IN	Physical
unipolar	JJ	Physical
knife	NN	Physical
(	(	O
80	CD	O
women	NNS	O
,	,	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
a	DT	O
5-mm	JJ	Physical
diameter	NN	Physical
hysteroscope	NN	Physical
with	IN	Physical
Versapoint	NNP	Physical
device	NN	Physical
(	(	O
80	CD	O
women	NNS	O
,	,	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
managed	VBN	O
expectantly	RB	O
,	,	O
with	IN	O
follow-up	JJ	O
lasting	VBG	O
1	CD	O
year	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Operative	NNP	O
parameters	NNS	O
(	(	O
operative	JJ	O
time	NN	O
,	,	O
fluid	JJ	O
absorption	NN	O
,	,	O
complications	NNS	O
,	,	O
need	VBP	O
for	IN	O
second	JJ	O
intervention	NN	O
)	)	O
and	CC	O
reproductive	JJ	O
outcome	NN	O
parameters	NNS	O
(	(	O
pregnancy	NN	O
,	,	O
abortion	NN	O
,	,	O
term	NN	O
and	CC	O
preterm	JJ	O
delivery	NN	O
,	,	O
modality	NN	O
of	IN	O
delivery	NN	O
,	,	O
cervical	JJ	O
cerclage	NN	O
)	)	O
were	VBD	O
measured	VBN	O
.	.	O

Operative	JJ	O
time	NN	O
and	CC	O
fluid	JJ	O
absorption	NN	O
were	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
group	NN	O
A	NNP	O
than	IN	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
23.4	CD	O
+/-	JJ	O
5.7	CD	O
vs	JJ	O
16.9	CD	O
+/-	JJ	O
4.7	CD	O
minutes	NNS	O
and	CC	O
486.4	CD	O
+/-	JJ	O
170.0	CD	O
vs	JJ	O
222.1	CD	O
+/-	JJ	O
104.9	CD	O
mL	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	O
complication	NN	O
rate	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
group	NN	O
B	NNP	O
than	IN	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
reproductive	JJ	O
parameters	NNS	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
:	:	O
pregnancy	NN	O
and	CC	O
delivery	NN	O
rates	NNS	O
were	VBD	O
70	CD	O
%	NN	O
and	CC	O
81.6	CD	O
%	NN	O
in	IN	O
group	NN	O
A	NNP	O
vs	RB	O
76.9	CD	O
%	NN	O
and	CC	O
84	CD	O
%	NN	O
in	IN	O
group	NN	O
B	NNP	O
.	.	O

Nine	NNP	O
women	NNS	O
(	(	O
18.4	CD	O
%	NN	O
)	)	O
from	IN	O
group	NN	O
B	NNP	O
and	CC	O
8	CD	O
women	NNS	O
(	(	O
16	CD	O
%	NN	O
)	)	O
from	IN	O
group	NN	O
B	NNP	O
experienced	VBD	O
spontaneous	JJ	O
abortions	NNS	O
.	.	O

Most	JJS	O
patients	NNS	O
(	(	O
54/82	CD	O
)	)	O
delivered	VBN	O
by	IN	O
cesarean	JJ	O
section	NN	O
without	IN	O
differences	NNS	O
according	VBG	O
to	TO	O
the	DT	O
hysteroscopic	NN	O
technique	NN	O
used	VBN	O
for	IN	O
metroplasty	NN	O
(	(	O
65	CD	O
%	NN	O
in	IN	O
group	NN	O
A	NNP	O
vs	RB	O
67.7	CD	O
%	NN	O
in	IN	O
group	NN	O
B	NNP	O
)	)	O
or	CC	O
to	TO	O
the	DT	O
gestational	JJ	O
age	NN	O
(	(	O
65.1	CD	O
%	NN	O
of	IN	O
term	NN	O
and	CC	O
68.7	CD	O
%	NN	O
of	IN	O
preterm	JJ	O
deliveries	NNS	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Small-diameter	NNP	O
hysteroscopy	NN	Physical
with	IN	O
bipolar	JJ	O
electrode	NN	O
for	IN	O
the	DT	O
incision	NN	O
of	IN	O
uterine	JJ	O
septum	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
resectoscopy	NN	Physical
with	IN	O
unipolar	JJ	O
electrode	NN	O
regarding	VBG	O
reproductive	JJ	O
outcome	NN	O
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
shorter	JJR	O
operating	NN	O
time	NN	O
and	CC	O
lower	JJR	O
complication	NN	O
rate	NN	O
.	.	O

Expectancies	NNS	O
,	,	O
not	RB	O
aroma	RB	O
,	,	O
explain	JJ	O
impact	NN	O
of	IN	O
lavender	NN	Pharmacological
aromatherapy	NN	Pharmacological
on	IN	O
psychophysiological	JJ	O
indices	NNS	O
of	IN	O
relaxation	NN	O
in	IN	O
young	JJ	O
healthy	JJ	O
women	NNS	O
.	.	O

OBJECTIVES	NNP	O
In	IN	O
aromatherapy	NN	Pharmacological
,	,	Pharmacological
lavender	JJR	Pharmacological
aroma	NN	Pharmacological
is	VBZ	O
reputed	VBN	O
to	TO	O
assist	VB	O
with	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
while	IN	O
there	EX	O
is	VBZ	O
much	JJ	O
anecdotal	JJ	O
evidence	NN	O
to	TO	O
that	DT	O
effect	NN	O
,	,	O
the	DT	O
empirical	JJ	O
literature	NN	O
is	VBZ	O
very	RB	O
inconsistent	JJ	O
.	.	O

Failure	NN	O
to	TO	O
employ	VB	O
adequate	JJ	O
placebos	NNS	Control
,	,	O
proper	JJ	O
blinding	NN	O
,	,	O
objective	JJ	O
measures	NNS	O
,	,	O
or	CC	O
screening	NN	O
of	IN	O
prior	JJ	O
beliefs	NNS	O
about	IN	O
aromatherapy	NN	O
means	NNS	O
that	IN	O
many	JJ	O
previous	JJ	O
findings	NNS	O
could	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
sought	VBD	O
to	TO	O
establish	VB	O
whether	IN	O
lavender	NN	Pharmacological
aroma	NN	Pharmacological
and/or	JJ	O
expectancies	NNS	O
affect	VBP	O
post-stress	JJ	O
relaxation	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
double-blind	NN	O
,	,	O
3	CD	O
(	(	O
aroma	NN	O
)	)	O
x	VBZ	O
3	CD	O
(	(	O
instruction	NN	O
)	)	O
x	VBZ	O
10	CD	O
(	(	O
time	NN	O
in	IN	O
minutes	NNS	O
)	)	O
mixed-factorial	JJ	Control
placebo-controlled	JJ	Control
trial	NN	O
.	.	O

METHOD	NNP	O
In	IN	O
a	DT	O
laboratory	NN	O
,	,	O
96	CD	O
healthy	JJ	O
undergraduate	JJ	O
women	NNS	O
were	VBD	O
exposed	VBN	Pharmacological
to	TO	Pharmacological
lavender	VB	Pharmacological
,	,	O
placebo	NN	Control
,	,	O
or	CC	O
no	DT	Other
aroma	NN	Other
during	IN	O
physiologically	RB	O
assessed	VBN	O
relaxation	NN	O
after	IN	O
an	DT	O
arousing	VBG	O
cognitive	JJ	O
task	NN	O
.	.	O

Where	WRB	O
an	DT	O
aroma	NN	O
was	VBD	O
presented	VBN	O
,	,	O
an	DT	O
instructional	JJ	O
priming	NN	O
procedure	NN	O
was	VBD	O
used	VBN	O
to	TO	O
manipulate	VB	O
participants	NNS	O
'	POS	O
expectancies	NNS	O
about	IN	O
the	DT	O
aroma	NN	O
's	POS	O
likely	JJ	O
impact	NN	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
relax	VB	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
showed	VBD	O
no	DT	O
effect	NN	O
of	IN	O
aroma	NN	O
on	IN	O
galvanic	JJ	O
skin	NN	O
response	NN	O
during	IN	O
relaxation	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
nature	NN	O
of	IN	O
instructional	JJ	O
prime	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
relaxation	NN	O
patterns	NNS	O
:	:	O
when	WRB	O
expecting	VBG	O
the	DT	O
aroma	NN	O
to	TO	O
inhibit	VB	O
them	PRP	O
,	,	O
participants	NNS	O
relaxed	VBD	O
more	RBR	O
;	:	O
when	WRB	O
expecting	VBG	O
facilitation	NN	O
,	,	O
participants	NNS	O
relaxed	VBD	O
less	RBR	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
not	RB	O
seen	VBN	O
with	IN	O
regard	NN	O
to	TO	O
self-reported	JJ	O
relaxation	NN	O
(	(	O
as	IN	O
represented	VBN	O
by	IN	O
changes	NNS	O
in	IN	O
state	NN	O
anxiety	NN	O
)	)	O
and	CC	O
was	VBD	O
independent	JJ	O
of	IN	O
ratings	NNS	O
of	IN	O
attitudes	NNS	O
towards	NNS	O
aromatherapy	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
imply	VBP	O
that	IN	O
the	DT	O
previous	JJ	O
associations	NNS	O
of	IN	O
lavender	NN	Control
aroma	NN	Control
with	IN	O
assisted	JJ	O
relaxation	NN	O
may	MD	O
have	VB	O
been	VBN	O
influenced	VBN	O
by	IN	O
expectancy	NN	O
biases	NNS	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
relevant	JJ	O
expectancies	NNS	O
are	VBP	O
easily	RB	O
manipulable	JJ	O
.	.	O

Prospective	JJ	O
trial	NN	O
of	IN	O
intraoperative	JJ	Pharmacological
mitomycin	NN	Pharmacological
C	NNP	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
primary	JJ	O
pterygium	NN	O
.	.	O

AIMS	VB	O
A	NNP	O
prospective	JJ	O
,	,	O
randomised	VBD	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo	NN	Control
controlled	VBD	O
study	NN	O
of	IN	O
intraoperative	JJ	Pharmacological
mitomycin	NN	Pharmacological
C	NNP	Pharmacological
as	IN	O
adjunctive	JJ	O
treatment	NN	O
of	IN	O
primary	JJ	O
pterygium	NN	O
was	VBD	O
conducted	VBN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
66	CD	O
eyes	NNS	O
of	IN	O
54	CD	O
patients	NNS	O
with	IN	O
primary	JJ	O
pterygium	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
excision	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
single	JJ	O
intraoperative	JJ	Pharmacological
application	NN	Pharmacological
of	IN	Pharmacological
mitomycin	NN	Pharmacological
C	NNP	Pharmacological
(	(	O
0.1	CD	O
mg/ml	NN	O
for	IN	O
5	CD	O
minutes	NNS	O
)	)	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
toxicity	NN	O
of	IN	O
this	DT	O
adjunctive	JJ	O
treatment	NN	O
.	.	O

The	DT	O
mean	NN	O
follow	VBP	O
up	RB	O
was	VBD	O
14.1	CD	O
months	NNS	O
(	(	O
range	VB	O
12-23	JJ	O
months	NNS	O
)	)	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
36	CD	O
eyes	NNS	O
that	WDT	O
underwent	JJ	O
simple	JJ	O
excision	NN	O
,	,	O
14	CD	O
(	(	O
38.8	CD	O
%	NN	O
)	)	O
exhibited	VBD	O
recurrences	NNS	O
whereas	IN	O
only	RB	O
one	CD	O
of	IN	O
30	CD	O
eyes	NNS	O
(	(	O
3.33	CD	O
%	NN	O
)	)	O
treated	VBD	O
with	IN	O
excision	NN	O
and	CC	O
intraoperative	JJ	O
application	NN	O
of	IN	O
mitomycin	NN	Pharmacological
C	NNP	Pharmacological
had	VBD	O
recurrence	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.0006	CD	O
)	)	O
.	.	O

Neither	CC	O
serious	JJ	O
ocular	JJ	O
complications	NNS	O
nor	CC	O
systemic	JJ	O
toxicity	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
mitomycin	NN	Pharmacological
C	NNP	Pharmacological
treated	VBD	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Intraoperative	NNP	O
mitomycin	NN	Pharmacological
C	NNP	Pharmacological
appears	VBZ	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
adjunctive	JJ	O
treatment	NN	O
of	IN	O
primary	JJ	O
pterygium	NN	O
.	.	O

Effects	NNS	O
of	IN	O
Positive	NNP	Educational
Action	NNP	Educational
on	IN	O
the	DT	O
emotional	JJ	O
health	NN	O
of	IN	O
urban	JJ	O
youth	NN	O
:	:	O
a	DT	O
cluster-randomized	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
Positive	JJ	Educational
Action	NNP	Educational
(	(	Educational
PA	NNP	Educational
)	)	Educational
,	,	O
a	DT	O
school-based	JJ	Educational
social-emotional	JJ	Educational
learning	NN	Educational
and	CC	Educational
health	NN	Educational
promotion	NN	Educational
program	NN	Educational
,	,	O
on	IN	O
the	DT	O
emotional	JJ	O
health	NN	O
of	IN	O
predominately	RB	O
low-income	JJ	O
and	CC	O
ethnic	JJ	O
minority	NN	O
urban	JJ	O
youth	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
matched-pair	JJ	O
,	,	O
cluster-randomized	JJ	O
controlled	VBN	O
trial	NN	O
involving	VBG	O
14	CD	O
Chicago	NNP	O
public	JJ	O
schools	NNS	O
.	.	O

Outcomes	NNS	O
were	VBD	O
assessed	VBN	O
over	IN	O
a	DT	O
6-year	JJ	O
period	NN	O
of	IN	O
program	NN	O
implementation	NN	O
for	IN	O
a	DT	O
cohort	NN	O
of	IN	O
youth	NN	O
in	IN	O
each	DT	O
school	NN	O
,	,	O
followed	VBD	O
from	IN	O
grades	NNS	O
3	CD	O
to	TO	O
8	CD	O
.	.	O

Youth	NN	O
reported	VBD	O
on	IN	O
their	PRP$	O
emotional	JJ	O
health	NN	O
(	(	O
positive	JJ	O
affect	NN	O
,	,	O
life	NN	O
satisfaction	NN	O
,	,	O
depression	NN	O
,	,	O
anxiety	NN	O
)	)	O
and	CC	O
social-emotional	JJ	O
and	CC	O
character	NN	O
development	NN	O
.	.	O

Growth-curve	NNP	O
and	CC	O
structural-equation	NN	O
modeling	NN	O
analyses	NNS	O
assessed	VBD	O
overall	JJ	O
program	NN	O
effects	NNS	O
on	IN	O
the	DT	O
emotional	JJ	O
health	NN	O
outcomes	NNS	O
as	RB	O
well	RB	O
as	IN	O
mediation	NN	O
of	IN	O
these	DT	O
effects	NNS	O
via	IN	O
the	DT	O
program	NN	O
's	POS	O
impact	NN	O
on	IN	O
youths	NNS	O
'	POS	O
social-emotional	JJ	O
and	CC	O
character	NN	O
development	NN	O
.	.	O

RESULTS	JJ	O
Students	NNS	O
in	IN	O
PA	NNP	Educational
schools	NNS	O
,	,	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
control	NN	O
schools	NNS	O
,	,	O
had	VBD	O
more	RBR	O
favorable	JJ	O
change	NN	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
in	IN	O
positive	JJ	O
affect	NN	O
(	(	O
standardized	JJ	O
mean	NN	O
difference	NN	O
effect	NN	O
size	NN	O
[	NNP	O
ES	NNP	O
]	NNP	O
=	NNP	O
.17	NNP	O
)	)	O
and	CC	O
life	NN	O
satisfaction	NN	O
(	(	O
ES	NNP	O
=	NNP	O
.13	NNP	O
)	)	O
as	RB	O
well	RB	O
as	IN	O
significantly	RB	O
lower	JJR	O
depression	NN	O
(	(	O
ES	NNP	O
=	NNP	O
-.14	NNP	O
)	)	O
and	CC	O
anxiety	NN	O
(	(	O
ES	NNP	O
=	NNP	O
-.26	NNP	O
)	)	O
at	IN	O
study	JJ	O
end	NN	O
point	NN	O
.	.	O

Program	NNP	O
effects	NNS	O
for	IN	O
positive	JJ	O
affect	NN	O
,	,	O
depression	NN	O
,	,	O
and	CC	O
anxiety	NN	O
were	VBD	O
mediated	VBN	O
by	IN	O
more	RBR	O
favorable	JJ	O
change	NN	O
over	IN	O
time	NN	O
in	IN	O
social-emotional	JJ	O
and	CC	O
character	NN	O
development	NN	O
for	IN	O
students	NNS	O
in	IN	O
PA	NNP	O
schools	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Results	NNP	O
suggest	VBP	O
that	IN	O
universal	JJ	O
,	,	O
school-based	JJ	O
programs	NNS	O
can	MD	O
benefit	VB	O
the	DT	O
emotional	JJ	O
health	NN	O
of	IN	O
youth	NN	O
in	IN	O
low-income	JJ	O
,	,	O
urban	JJ	O
settings	NNS	O
.	.	O

The	DT	O
modest	JJ	O
magnitude	NN	O
of	IN	O
effects	NNS	O
over	IN	O
an	DT	O
extended	JJ	O
period	NN	O
of	IN	O
program	NN	O
implementation	NN	O
,	,	O
however	RB	O
,	,	O
reflects	VBZ	O
the	DT	O
challenges	NNS	O
of	IN	O
both	DT	O
mounting	VBG	O
interventions	NNS	O
and	CC	O
offsetting	VBG	O
formidable	JJ	O
risks	NNS	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
in	IN	O
such	JJ	O
environments	NNS	O
.	.	O

Safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
an	DT	O
oral	JJ	Pharmacological
,	,	Pharmacological
inactivated	JJ	Pharmacological
,	,	Pharmacological
whole-cell	JJ	Pharmacological
vaccine	NN	Pharmacological
for	IN	Pharmacological
Shigella	NNP	Pharmacological
sonnei	NN	Pharmacological
:	:	O
preclinical	JJ	O
studies	NNS	O
and	CC	O
a	DT	O
Phase	NNP	O
I	PRP	O
trial	NN	O
.	.	O

Orally	RB	O
delivered	VBN	O
,	,	O
inactivated	VBN	O
whole-cell	NN	O
vaccines	NNS	Pharmacological
are	VBP	O
safe	JJ	O
methods	NNS	O
of	IN	O
inducing	VBG	O
local	JJ	O
and	CC	O
systemic	JJ	O
immunity	NN	O
.	.	O

To	TO	O
increase	VB	O
surface	NN	O
proteins	NNS	O
associated	VBN	O
with	IN	O
adherence	NN	O
and	CC	O
invasion	NN	O
,	,	O
Shigella	NNP	O
sonnei	NN	O
were	VBD	O
grown	VBN	O
in	IN	O
BHI	NNP	O
broth	CC	O
containing	VBG	O
deoxycholate	NN	O
.	.	O

A	DT	O
whole-cell	JJ	Pharmacological
vaccine	NN	Pharmacological
(	(	Pharmacological
SsWC	NNP	Pharmacological
)	)	Pharmacological
was	VBD	O
then	RB	O
produced	VBN	O
by	IN	O
formalin	JJ	O
inactivation	NN	O
.	.	O

In	IN	O
pre-clinical	JJ	O
studies	NNS	O
,	,	O
the	DT	O
SsWC	NNP	Pharmacological
vaccine	NN	Pharmacological
was	VBD	O
immunogenic	JJ	O
and	CC	O
protected	VBN	O
against	IN	O
S.	NNP	O
sonnei-induced	JJ	O
keratoconjunctivitis	NN	O
in	IN	O
the	DT	O
guinea	NN	O
pig	NN	O
model	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
Phase	NNP	O
I	PRP	O
study	VBP	O
,	,	O
10	CD	O
evaluable	JJ	O
subjects	NNS	O
received	VBD	O
either	DT	O
three	CD	O
doses	NNS	O
of	IN	O
SsWC	NNP	Pharmacological
on	IN	O
Days	NNP	O
0	CD	O
,	,	O
14	CD	O
,	,	O
and	CC	O
28	CD	O
(	(	O
N	NNP	O
=	NNP	O
3	CD	O
)	)	O
;	:	O
five	CD	O
doses	NNS	O
of	IN	O
SsWC	NNP	Pharmacological
on	IN	O
Days	NNP	O
0	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
28	CD	O
(	(	O
N	NNP	O
=	NNP	O
4	CD	O
)	)	O
;	:	O
or	CC	O
placebo	VB	Control
(	(	O
N	NNP	O
=	NNP	O
3	CD	O
)	)	O
.	.	O

Each	DT	O
dose	NN	O
contained	VBD	O
2.0	CD	O
x	JJ	O
10	CD	O
(	(	O
10	CD	O
)	)	O
inactivated	VBN	O
cells	NNS	O
.	.	O

Serum	NNP	O
and	CC	O
fecal	JJ	O
antibodies	NNS	O
against	IN	O
SsWC	NNP	O
,	,	O
LPS	NNP	O
,	,	O
and	CC	O
IpaC	NNP	O
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O

A	NNP	O
>	NN	O
or	CC	O
=	VB	O
4-fold	JJ	O
increase	NN	O
in	IN	O
titer	NN	O
was	VBD	O
considered	VBN	O
significant	JJ	O
.	.	O

Both	DT	O
SsWC	NNP	Pharmacological
dosing	NN	O
regimens	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

No	DT	O
fever	NN	O
or	CC	O
severe	JJ	O
gastrointestinal	JJ	O
symptoms	NNS	O
were	VBD	O
noted	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
vaccinated	JJ	O
subjects	NNS	O
.	.	O

Antibody	NN	O
responses	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
dosing	VBG	O
groups	NNS	O
.	.	O

Serum	NNP	O
IgG	NNP	O
or	CC	O
IgA	NNP	O
responses	NNS	O
to	TO	O
SsWC	NNP	Pharmacological
were	VBD	O
seen	VBN	O
in	IN	O
six	CD	O
of	IN	O
seven	CD	O
vaccinees	NNS	O
(	(	O
86	CD	O
%	NN	O
)	)	O
,	,	O
to	TO	O
LPS	NNP	O
in	IN	O
four	CD	O
of	IN	O
seven	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
to	TO	O
IpaC	NNP	O
in	IN	O
five	CD	O
of	IN	O
seven	CD	O
(	(	O
61	CD	O
%	NN	O
)	)	O
.	.	O

Fecal	JJ	O
IgA	NNP	O
responses	NNS	O
to	TO	O
these	DT	O
three	CD	O
antigens	NNS	O
developed	VBN	O
in	IN	O
five	CD	O
of	IN	O
five	CD	O
,	,	O
three	CD	O
of	IN	O
five	CD	O
,	,	O
and	CC	O
three	CD	O
of	IN	O
five	CD	O
subjects	NNS	O
,	,	O
respectively	RB	O
.	.	O

Among	IN	O
the	DT	O
seven	CD	O
vaccinees	NNS	O
,	,	O
geometric	JJ	O
mean	NN	O
rises	NNS	O
in	IN	O
serum	JJ	O
IgA	NNP	O
levels	NNS	O
to	TO	O
all	DT	O
three	CD	O
immunogens	NNS	O
were	VBD	O
significant	JJ	O
;	:	O
IgG	NNP	O
increases	VBZ	O
trended	VBD	O
toward	IN	O
significance	NN	O
(	(	O
paired	JJ	O
one-tailed	JJ	O
t-test	NN	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
SsWC	NNP	Pharmacological
was	VBD	O
immunogenic	JJ	O
and	CC	O
protective	JJ	O
in	IN	O
animal	JJ	O
studies	NNS	O
and	CC	O
well	RB	O
tolerated	VBN	O
and	CC	O
immunogenic	JJ	O
in	IN	O
a	DT	O
Phase	NNP	O
I	PRP	O
trial	NN	O
.	.	O

Potentiation	NN	O
of	IN	O
bradykinin-induced	JJ	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
release	NN	O
by	IN	O
angiotensin-converting	JJ	O
enzyme	JJ	O
inhibition	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
angiotensin-converting	JJ	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
inhibition	NN	O
on	IN	O
the	DT	O
local	JJ	O
stimulated	VBD	O
release	NN	O
of	IN	O
tissue	NN	O
plasminogen	NN	O
activator	NN	O
(	(	O
t-PA	JJ	O
)	)	O
from	IN	O
the	DT	O
endothelium	NN	O
.	.	O

BACKGROUND	NNP	O
Angiotensin-converting	NNP	Physical
enzyme	NN	Physical
inhibitor	NN	Physical
therapy	NN	Physical
may	MD	O
exert	VB	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
endogenous	JJ	O
fibrinolytic	JJ	O
balance	NN	O
.	.	O

METHODS	NNP	O
Blood	NNP	O
flow	NN	O
and	CC	O
plasma	JJ	O
fibrinolytic	JJ	O
factors	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
both	DT	O
forearms	NNS	O
of	IN	O
eight	CD	O
healthy	JJ	O
males	NNS	O
who	WP	O
received	VBD	O
unilateral	JJ	O
brachial	JJ	O
artery	NN	O
infusions	NNS	O
of	IN	O
the	DT	O
endothelium-dependent	JJ	Pharmacological
vasodilators	NNS	Pharmacological
substance	NN	Pharmacological
P	NNP	Pharmacological
(	(	O
2	CD	O
to	TO	O
8	CD	O
pmol/min	NN	O
)	)	O
and	CC	O
bradykinin	NN	Pharmacological
(	(	O
100	CD	O
to	TO	O
1,000	CD	O
pmol/min	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
endothelium-independent	JJ	Pharmacological
vasodilator	NN	Pharmacological
sodium	NN	Pharmacological
nitroprusside	NN	Pharmacological
(	(	O
2	CD	O
to	TO	O
8	CD	O
microg/min	NN	O
)	)	O
.	.	O

These	DT	O
measurements	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
of	IN	O
three	CD	O
occasions	NNS	O
following	VBG	O
one	CD	O
week	NN	O
of	IN	O
matched	JJ	O
placebo	NN	Pharmacological
,	,	O
quinapril	RB	Pharmacological
40	CD	O
mg	NN	O
or	CC	O
losartan	JJ	Pharmacological
50	CD	O
mg	JJ	O
daily	RB	O
administered	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
crossover	NN	O
design	NN	O
.	.	O

RESULTS	NNP	O
Sodium	NNP	O
nitroprusside	RB	O
,	,	O
substance	NN	O
P	NNP	O
and	CC	O
bradykinin	NN	O
produced	VBD	O
dose-dependent	JJ	O
increases	NNS	O
in	IN	O
the	DT	O
blood	NN	O
flow	NN	O
of	IN	O
infused	JJ	O
forearm	NN	O
(	(	O
analysis	NN	O
of	IN	O
variance	NN	O
[	NNP	O
ANOVA	NNP	O
]	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
for	IN	O
all	DT	O
)	)	O
.	.	O

Although	IN	O
sodium	JJ	O
nitroprusside	RB	O
did	VBD	O
not	RB	O
affect	VB	O
plasma	JJ	O
t-PA	JJ	O
concentrations	NNS	O
,	,	O
they	PRP	O
were	VBD	O
increased	VBN	O
dose-dependently	RB	O
in	IN	O
the	DT	O
infused	JJ	O
forearm	NN	O
by	IN	O
substance	NN	O
P	NNP	O
and	CC	O
bradykinin	JJ	O
infusion	NN	O
(	(	O
ANOVA	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

Bradykinin-induced	JJ	O
release	NN	O
of	IN	O
active	JJ	O
t-PA	NN	O
was	VBD	O
more	RBR	O
than	IN	O
doubled	VBD	O
during	IN	O
treatment	NN	O
with	IN	O
quinapril	NN	Pharmacological
in	IN	O
comparison	NN	O
to	TO	O
placebo	VB	Control
or	CC	O
losartan	VB	Pharmacological
(	(	O
two-way	JJ	O
ANOVA	NNP	O
:	:	O
p	NN	O
<	VBZ	O
0.003	CD	O
for	IN	O
treatment	NN	O
group	NN	O
,	,	O
p	VBP	O
<	$	O
0.001	CD	O
for	IN	O
t-PA	JJ	O
response	NN	O
and	CC	O
p	NN	O
=	NNP	O
ns	NN	O
for	IN	O
interaction	NN	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
substance	NN	O
P	NNP	O
response	NN	O
was	VBD	O
unaffected	JJ	O
.	.	O

CONCLUSIONS	NN	O
We	PRP	O
have	VBP	O
shown	VBN	O
a	DT	O
selective	JJ	O
and	CC	O
marked	JJ	O
augmentation	NN	O
of	IN	O
bradykinin-induced	JJ	O
t-PA	JJ	O
release	NN	O
during	IN	O
ACE	NNP	O
inhibition	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
beneficial	JJ	O
clinical	JJ	O
and	CC	O
vascular	JJ	O
effects	NNS	O
of	IN	O
ACE	NNP	O
inhibition	NN	O
may	MD	O
,	,	O
in	IN	O
part	NN	O
,	,	O
be	VB	O
mediated	VBN	O
through	IN	O
local	JJ	O
augmentation	NN	O
of	IN	O
bradykinin-induced	JJ	O
t-PA	JJ	O
release	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
sildenafil	NN	Pharmacological
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
and	CC	O
cardiovascular	JJ	O
risk	NN	O
.	.	O

OBJECTIVE	NNP	O
Assess	NNP	O
the	DT	O
effectiveness	NN	O
of	IN	O
sildenafil	NN	Pharmacological
in	IN	O
Asian	JJ	O
males	NNS	O
with	IN	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
co-morbidities	NNS	O
,	,	O
mild-to-moderate	JJ	O
hypertension	NN	O
,	,	O
dyslipidemia	NN	O
,	,	O
and	CC	O
diabetes	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHOD	NNP	O
A	NNP	O
six-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
multicenter	NN	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
Thailand	NNP	O
,	,	O
Malaysia	NNP	O
and	CC	O
Singapore	NNP	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
fifty	VB	O
five	CD	O
male	JJ	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
2:1	CD	O
)	)	O
to	TO	O
sildenafil	VB	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
104	CD	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
51	CD	O
)	)	O
.	.	O

Sildenafil	NNP	Pharmacological
was	VBD	O
started	VBN	O
at	IN	O
50	CD	O
mg	NN	O
and	CC	O
increased	VBD	O
(	(	O
100	CD	O
mg	NN	O
)	)	O
or	CC	O
decreased	VBN	O
(	(	O
25	CD	O
mg	NN	O
)	)	O
at	IN	O
week	NN	O
2	CD	O
if	IN	O
necessary	JJ	O
.	.	O

RESULTS	VB	O
On	IN	O
the	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
,	,	O
sildenafil-treated	JJ	Pharmacological
subjects	NNS	O
had	VBD	O
significantly	RB	O
better	JJR	O
scores	NNS	O
on	IN	O
the	DT	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function	NNP	O
(	(	O
IIEF	NNP	O
)	)	O
questions	NNS	O
3	CD	O
and	CC	O
4	CD	O
than	IN	O
placebo	NN	O
(	(	O
p	JJ	O
<	NN	O
0.001	CD	O
,	,	O
both	DT	O
questions	NNS	O
)	)	O
.	.	O

When	WRB	O
accumulated	VBN	O
into	IN	O
IIEF	NNP	O
domains	NNS	O
,	,	O
all	DT	O
five	CD	O
domains	NNS	O
were	VBD	O
significant	JJ	O
in	IN	O
favor	NN	O
of	IN	O
sildenafil	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
sildenafil-treated	JJ	Pharmacological
subjects	NNS	O
were	VBD	O
more	RBR	O
satisfied	JJ	O
with	IN	O
treatment	NN	O
and	CC	O
had	VBD	O
a	DT	O
higher	JJR	O
intercourse	JJ	O
success	NN	O
rate	NN	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
were	VBD	O
mild	VBN	O
in	IN	O
severity	NN	O
;	:	O
the	DT	O
most	RBS	O
commonly	RB	O
reported	VBD	O
treatment-related	JJ	O
events	NNS	O
were	VBD	O
dizziness	NN	O
(	(	O
7.7	CD	O
%	NN	O
)	)	O
and	CC	O
tinnitus	NN	O
(	(	O
2.9	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Sildenafil	NNP	O
(	(	O
25	CD	O
,	,	O
50	CD	O
,	,	O
and	CC	O
100	CD	O
mg	NN	O
)	)	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
,	,	O
safe	JJ	O
,	,	O
and	CC	O
well-tolerated	JJ	O
treatment	NN	O
for	IN	O
ED	NNP	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
population	NN	O
of	IN	O
Thai	NNP	O
,	,	O
Malaysian	NNP	O
,	,	O
and	CC	O
Singaporean	NNP	O
males	NNS	O
who	WP	O
also	RB	O
had	VBD	O
increased	VBN	O
cardiovascular	JJ	O
risk	NN	O
Does	VBZ	O
short-term	JJ	O
treatment	NN	O
with	IN	O
proton	NN	Pharmacological
pump	NN	Pharmacological
inhibitors	NNS	Pharmacological
cause	VBP	O
rebound	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
?	.	O
BACKGROUND	NNP	O
Rebound	NNP	O
acid	VBZ	O
hypersecretion	NN	O
might	MD	O
occur	VB	O
after	IN	O
treatment	NN	O
with	IN	O
proton	NN	Pharmacological
pump	NN	Pharmacological
inhibitors	NNS	Pharmacological
.	.	O

This	DT	O
study	NN	O
looks	VBZ	O
for	IN	O
a	DT	O
rebound	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
after	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
lansoprazole	NN	Pharmacological
.	.	Pharmacological

STUDY	NNP	O
Sixty-two	JJ	O
patients	NNS	O
(	(	O
19	CD	O
men	NNS	O
and	CC	O
43	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
54	CD	O
years	NNS	O
;	:	O
range	NN	O
,	,	O
32-77	CD	O
years	NNS	O
)	)	O
with	IN	O
heartburn	NN	O
and	CC	O
regurgitation	NN	O
and	CC	O
normal	JJ	O
upper	JJ	O
endoscopy	NN	O
findings	NNS	O
were	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
with	IN	O
a	DT	O
crossover	NN	O
design	NN	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
5-day	JJ	O
treatment	NN	O
periods	NNS	O
with	IN	O
lansoprazole	JJ	Pharmacological
60	CD	Pharmacological
mg	NN	Pharmacological
once	RB	Pharmacological
daily	JJ	Pharmacological
or	CC	O
placebo	NN	Control
in	IN	O
random	JJ	O
order	NN	O
,	,	O
separated	VBN	O
by	IN	O
a	DT	O
9-day	JJ	O
washout	NN	O
period	NN	O
.	.	O

Reflux	NNP	O
,	,	O
total	JJ	O
,	,	O
and	CC	O
antacid	JJ	O
scores	NNS	O
were	VBD	O
calculated	VBN	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
treatment	NN	O
periods	NNS	O
.	.	O

Higher	JJR	O
scores	NNS	O
during	IN	O
the	DT	O
placebo	JJ	Control
period	NN	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
lansoprazole	VBZ	Pharmacological
first	RB	O
than	IN	O
in	IN	O
the	DT	O
group	NN	O
given	VBN	O
placebo	VBP	O
first	RB	O
indicated	VBN	O
a	DT	O
rebound	NN	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
symptom	NN	O
scores	NNS	O
during	IN	O
the	DT	O
placebo	JJ	Control
period	NN	O
in	IN	O
the	DT	O
groups	NNS	O
given	VBN	O
lansoprazole	VBP	O
first	JJ	O
and	CC	O
placebo	NN	O
first	RB	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
reflux	NN	O
score	NN	O
,	,	O
21.5	CD	O
and	CC	O
17.6	CD	O
,	,	O
respectively	RB	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
;	:	O
total	JJ	O
score	NN	O
,	,	O
11.2	CD	O
and	CC	O
10.3	CD	O
,	,	O
respectively	RB	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
;	:	O
and	CC	O
antacid	VB	O
score	NN	O
,	,	O
8.2	CD	O
and	CC	O
7.2	CD	O
,	,	O
respectively	RB	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
no	DT	O
indication	NN	O
of	IN	O
a	DT	O
rebound	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
12	CD	O
to	TO	O
14	CD	O
days	NNS	O
after	IN	O
a	DT	O
5-day	JJ	O
treatment	NN	O
with	IN	O
lansoprazole	JJ	Pharmacological
60	CD	O
mg	NN	O
once	RB	O
daily	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
reflux	NN	O
symptoms	NNS	O
.	.	O

Intravesical	JJ	Physical
seeding	NN	Physical
of	IN	Physical
upper	JJ	Physical
urinary	JJ	Physical
tract	NN	Physical
urothelial	JJ	Physical
carcinoma	NN	Physical
cells	NNS	Physical
during	IN	O
nephroureterectomy	NN	Physical
:	:	O
an	DT	O
exploratory	JJ	O
analysis	NN	O
from	IN	O
the	DT	O
THPMG	NNP	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
trial	NN	O
was	VBD	O
a	DT	O
randomized	JJ	O
Phase	NNP	O
II	NNP	O
study	NN	O
that	WDT	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
intravesical	JJ	O
instillation	NN	O
of	IN	O
pirarubicin	NN	Pharmacological
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
bladder	NN	O
recurrence	NN	O
after	IN	O
nephroureterectomy	NN	O
for	IN	O
upper	JJ	O
urinary	JJ	O
tract	NN	O
urothelial	JJ	O
carcinoma	NN	O
.	.	O

This	DT	O
study	NN	O
conducted	VBD	O
further	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
cohort	NN	O
,	,	O
focusing	VBG	O
on	IN	O
intravesical	JJ	Physical
seeding	NN	Physical
of	IN	Physical
cancer	NN	Physical
cells	NNS	Physical
.	.	O

METHODS	NNP	O
Using	VBG	O
the	DT	O
data	NN	O
from	IN	O
the	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
trial	NN	O
,	,	O
bladder	VB	O
recurrence-free	JJ	O
survival	NN	O
rates	NNS	O
and	CC	O
factors	NNS	O
associated	VBN	O
with	IN	O
bladder	NN	O
recurrence	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
36	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	Control
group	NN	O
,	,	O
14	CD	O
with	IN	O
positive	JJ	O
urine	JJ	O
cytology	NN	O
had	VBD	O
more	RBR	O
frequent	JJ	O
recurrence	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
22	CD	O
patients	NNS	O
with	IN	O
negative	JJ	O
cytology	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
multivariate	NN	O
analysis	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
voided	VBD	O
urine	JJ	O
cytology	NN	O
was	VBD	O
an	DT	O
independent	JJ	O
predictive	JJ	O
factor	NN	O
of	IN	O
bladder	NN	O
recurrence	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
5.54	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
1.12-27.5	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.036	CD	O
)	)	O
.	.	O

Of	IN	O
72	CD	O
patients	NNS	O
in	IN	O
the	DT	O
Pirarubicin	NNP	O
Monotherapy	NNP	O
Study	NNP	O
Group	NNP	O
trial	NN	O
,	,	O
31	CD	O
had	VBD	O
positive	JJ	O
urine	JJ	O
cytology	NN	O
.	.	O

Among	IN	O
the	DT	O
31	CD	O
patients	NNS	O
,	,	O
17	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
pirarubicin	JJ	Pharmacological
instillation	NN	Pharmacological
had	VBD	O
fewer	JJR	O
recurrences	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
14	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
control	NN	O
treatment	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

On	IN	O
multivariate	NN	O
analysis	NN	O
,	,	O
pirarubicin	JJ	O
instillation	NN	O
was	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
better	JJR	O
recurrence-free	JJ	O
survival	NN	O
rates	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
with	IN	O
positive	JJ	O
urine	JJ	O
cytology	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.02	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.00-0.53	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.018	CD	O
)	)	O
.	.	O

Of	IN	O
21	CD	O
patients	NNS	O
with	IN	O
bladder	NN	O
recurrence	NN	O
,	,	O
17	CD	O
had	VBD	O
recurrent	JJ	O
tumor	NN	O
around	IN	O
cystotomy	NN	O
or	CC	O
in	IN	O
the	DT	O
bladder	NN	O
neck	NN	O
compromised	VBN	O
by	IN	O
the	DT	O
urethral	JJ	O
catheter	NN	O
,	,	O
supporting	VBG	O
the	DT	O
notion	NN	O
that	IN	O
tumor	NN	O
cells	NNS	O
seeded	VBN	O
in	IN	O
the	DT	O
injured	JJ	O
urothelium	NN	O
.	.	O

CONCLUSIONS	NNP	O
Intravesical	NNP	Pharmacological
instillation	NN	Pharmacological
of	IN	Pharmacological
pirarubicin	NN	Pharmacological
immediately	RB	O
after	IN	O
nephroureterectomy	NN	Pharmacological
significantly	RB	O
reduced	VBD	O
the	DT	O
bladder	NN	O
recurrence	NN	O
rate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
positive	JJ	O
voided	JJ	O
urine	JJ	O
cytology	NN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
intravesical	JJ	O
seeding	NN	O
of	IN	O
upper	JJ	O
urinary	JJ	O
tract	NN	O
urothelial	JJ	O
carcinoma	NN	O
occurs	VBZ	O
during	IN	O
nephroureterectomy	NN	O
.	.	O

Automatic	JJ	O
detection	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
in	IN	O
digital	JJ	O
color	NN	O
fundus	NN	O
photographs	NN	O
.	.	O

The	DT	O
robust	JJ	O
detection	NN	Physical
of	IN	Physical
red	JJ	Physical
lesions	NNS	Physical
in	IN	Physical
digital	JJ	Other
color	NN	Other
fundus	NN	Other
photographs	NN	Other
is	VBZ	O
a	DT	O
critical	JJ	O
step	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
automated	JJ	O
screening	VBG	O
systems	NNS	O
for	IN	O
diabetic	JJ	O
retinopathy	NN	O
.	.	O

In	IN	O
this	DT	O
paper	NN	O
,	,	O
a	DT	O
novel	NN	Other
red	JJ	Other
lesion	NN	Other
detection	NN	Other
method	NN	Other
is	VBZ	O
presented	VBN	O
based	VBN	O
on	IN	O
a	DT	O
hybrid	JJ	O
approach	NN	O
,	,	O
combining	VBG	O
prior	JJ	O
works	NNS	O
by	IN	O
Spencer	NNP	O
et	CC	O
al	NN	O
.	.	O

(	(	O
1996	CD	O
)	)	O
and	CC	O
Frame	NNP	O
et	NNP	O
al	NN	O
.	.	O

(	(	O
1998	CD	O
)	)	O
with	IN	O
two	CD	O
important	JJ	O
new	JJ	O
contributions	NNS	O
.	.	O

The	DT	O
first	JJ	O
contribution	NN	O
is	VBZ	O
a	DT	O
new	JJ	O
red	JJ	Other
lesion	NN	Other
candidate	NN	Other
detection	NN	Other
system	NN	Other
based	VBN	O
on	IN	O
pixel	JJ	O
classification	NN	O
.	.	O

Using	VBG	O
this	DT	O
technique	NN	O
,	,	O
vasculature	NN	O
and	CC	O
red	JJ	O
lesions	NNS	O
are	VBP	O
separated	VBN	O
from	IN	O
the	DT	O
background	NN	O
of	IN	O
the	DT	O
image	NN	O
.	.	O

After	IN	O
removal	NN	O
of	IN	O
the	DT	O
connected	JJ	O
vasculature	NN	O
the	DT	O
remaining	VBG	O
objects	NNS	O
are	VBP	O
considered	VBN	O
possible	JJ	O
red	JJ	O
lesions	NNS	O
.	.	O

Second	NNP	O
,	,	O
an	DT	O
extensive	JJ	O
number	NN	O
of	IN	O
new	JJ	O
features	NNS	O
are	VBP	O
added	VBN	O
to	TO	O
those	DT	O
proposed	VBN	O
by	IN	O
Spencer-Frame	NNP	O
.	.	O

The	DT	O
detected	JJ	O
candidate	NN	O
objects	NNS	O
are	VBP	O
classified	VBN	O
using	VBG	O
all	DT	O
features	NNS	O
and	CC	O
a	DT	O
k-nearest	JJ	O
neighbor	NN	O
classifier	NN	O
.	.	O

An	DT	O
extensive	JJ	O
evaluation	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
test	NN	O
set	NN	O
composed	VBN	O
of	IN	O
images	NNS	O
representative	NN	O
of	IN	O
those	DT	O
normally	RB	O
found	VBN	O
in	IN	O
a	DT	O
screening	NN	O
set	NN	O
.	.	O

When	WRB	O
determining	VBG	O
whether	IN	O
an	DT	O
image	NN	O
contains	VBZ	O
red	JJ	O
lesions	NNS	O
the	DT	O
system	NN	O
achieves	VBZ	O
a	DT	O
sensitivity	NN	O
of	IN	O
100	CD	O
%	NN	O
at	IN	O
a	DT	O
specificity	NN	O
of	IN	O
87	CD	O
%	NN	O
.	.	O

The	DT	O
method	NN	O
is	VBZ	O
compared	VBN	O
with	IN	O
several	JJ	O
different	JJ	O
automatic	JJ	O
systems	NNS	O
and	CC	O
is	VBZ	O
shown	VBN	O
to	TO	O
outperform	VB	O
them	PRP	O
all	DT	O
.	.	O

Performance	NNP	O
is	VBZ	O
close	RB	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
human	JJ	O
expert	NN	O
examining	VBG	O
the	DT	O
images	NNS	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
red	JJ	O
lesions	NNS	O
.	.	O

Improving	VBG	O
emotion	NN	O
regulation	NN	O
with	IN	O
CBT	NNP	Pharmacological
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
This	DT	O
pilot	NN	O
study	NN	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
developmentally	RB	O
modified	VBN	O
CBT	NNP	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
to	TO	O
teach	VB	O
emotion	NN	O
regulation	NN	O
strategies	NNS	O
for	IN	O
reducing	VBG	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
commonly	RB	O
noted	VBD	O
problems	NNS	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

METHOD	NNP	O
Eleven	NNP	O
5-7	JJ	O
year-old	JJ	O
children	NNS	O
participated	VBN	O
in	IN	O
a	DT	O
CBT-group	NNP	Pharmacological
while	IN	O
parents	NNS	O
participated	VBN	Educational
in	IN	Educational
psychoeducation	NN	Educational
.	.	O

Children	NNP	Control
were	VBD	Control
randomly	RB	Control
assigned	VBN	Control
to	TO	Control
an	DT	Control
experimental	JJ	Control
or	CC	Control
delayed-treatment	JJ	Control
control	NN	Control
group	NN	Control
.	.	O

RESULTS	CC	O
From	IN	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
,	,	O
all	DT	O
children	NNS	O
had	VBD	O
less	RBR	O
parent	NN	O
reported	VBD	O
negativity/lability	NN	O
,	,	O
better	JJR	O
parent	NN	O
reported	VBD	O
emotion	NN	O
regulation	NN	O
,	,	O
and	CC	O
shorter	JJR	O
outbursts	NNS	O
,	,	O
and	CC	O
also	RB	O
generated	VBD	O
more	RBR	O
coping	JJ	O
strategies	NNS	O
in	IN	O
response	NN	O
to	TO	O
vignettes	NNS	O
.	.	O

Parents	NNS	O
also	RB	O
reported	VBD	O
increases	NNS	O
in	IN	O
their	PRP$	O
own	JJ	O
confidence	NN	O
and	CC	O
their	PRP$	O
child	NN	O
's	POS	O
ability	NN	O
to	TO	O
deal	VB	O
with	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
young	JJ	O
children	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
ASD	NNP	O
may	MD	O
benefit	VB	O
from	IN	O
CBT	NNP	Pharmacological
to	TO	O
improve	VB	O
regulation	NN	O
of	IN	O
anger	NN	O
and	CC	O
anxiety	NN	O
,	,	O
and	CC	O
parent	NN	O
training	NN	O
may	MD	O
improve	VB	O
parental	JJ	O
self-efficacy	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
make	VB	O
conclusions	NNS	O
about	IN	O
its	PRP$	O
efficacy	NN	O
.	.	O

Reaching	VBG	O
out	RP	O
,	,	O
inviting	VBG	O
back	RB	O
:	:	O
using	VBG	O
Interactive	NNP	Educational
voice	NN	Educational
response	NN	Educational
(	(	Educational
IVR	NNP	Educational
)	)	Educational
technology	NN	Educational
to	TO	O
recycle	VB	O
relapsed	JJ	O
smokers	NNS	O
back	RB	O
to	TO	O
Quitline	NNP	Educational
treatment	NN	Educational
--	:	Educational
a	DT	Educational
randomized	JJ	O
controlled	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Tobacco	NNP	O
dependence	NN	O
is	VBZ	O
a	DT	O
chronic	JJ	O
,	,	O
relapsing	VBG	O
condition	NN	O
that	WDT	O
typically	RB	O
requires	VBZ	O
multiple	JJ	O
quit	NN	O
attempts	NNS	O
and	CC	O
extended	VBD	O
treatment	NN	O
.	.	O

When	WRB	O
offered	VBD	O
the	DT	O
opportunity	NN	O
,	,	O
relapsed	VBN	O
smokers	NNS	O
are	VBP	O
interested	JJ	O
in	IN	O
recycling	VBG	O
back	RB	O
into	IN	O
treatment	NN	O
for	IN	O
a	DT	O
new	JJ	O
,	,	O
assisted	VBN	O
quit	NN	O
attempt	NN	O
.	.	O

This	DT	O
manuscript	NN	O
presents	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
testing	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
interactive	JJ	Educational
voice	NN	Educational
response	NN	Educational
(	(	Educational
IVR	NNP	Educational
)	)	Educational
in	IN	O
recycling	VBG	O
low	JJ	O
income	NN	O
smokers	NNS	O
who	WP	O
had	VBD	O
previously	RB	O
used	VBN	O
quitline	NN	O
(	(	O
QL	NNP	O
)	)	O
support	NN	O
back	RB	O
to	TO	O
QL	NNP	O
support	NN	O
for	IN	O
a	DT	O
new	JJ	O
quit	NN	O
attempt	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
sample	NN	O
of	IN	O
2985	CD	O
previous	JJ	O
QL	NNP	O
callers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
receive	JJ	O
IVR	NNP	Control
screening	NN	Control
for	IN	Control
current	JJ	Control
smoking	NN	Control
(	(	Control
control	VB	Control
group	NN	Control
)	)	Control
or	CC	O
IVR	NNP	Educational
screening	VBG	Educational
plus	CC	Educational
an	DT	Educational
IVR	NNP	Educational
intervention	NN	Educational
.	.	Educational

The	DT	O
IVR	NNP	Educational
intervention	NN	Educational
consists	VBZ	O
of	IN	O
automated	JJ	O
questions	NNS	O
to	TO	O
identify	VB	O
and	CC	O
address	VB	O
barriers	NNS	O
to	TO	O
re-cycling	NN	O
in	IN	O
QL	NNP	O
support	NN	O
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
offer	NN	O
to	TO	O
be	VB	O
transferred	VBN	O
to	TO	O
the	DT	O
QL	NNP	O
and	CC	O
reinitiate	VB	O
treatment	NN	O
.	.	O

Re-enrollment	JJ	O
in	IN	O
QL	NNP	O
services	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
was	VBD	O
documented	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
IVR	NNP	Educational
system	NN	Educational
successfully	RB	O
reached	VBD	O
715	CD	O
(	(	O
23.9	CD	O
%	NN	O
)	)	O
former	JJ	O
QL	NNP	O
participants	NNS	O
.	.	O

Of	IN	O
those	DT	O
,	,	O
27	CD	O
%	NN	O
(	(	O
194/715	CD	O
)	)	O
reported	VBD	O
to	TO	O
the	DT	O
IVR	NNP	Educational
system	NN	Educational
that	IN	O
they	PRP	O
had	VBD	O
quit	NN	O
smoking	NN	O
and	CC	O
were	VBD	O
therefore	RB	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
and	CC	O
analysis	NN	O
.	.	O

The	DT	O
trial	NN	O
's	POS	O
final	JJ	O
sample	NN	O
was	VBD	O
composed	VBN	O
of	IN	O
521	CD	O
current	JJ	O
smokers	NNS	O
.	.	O

The	DT	O
re-enrollment	JJ	O
rate	NN	O
was	VBD	O
3.3	CD	O
%	NN	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
28.2	CD	O
%	NN	O
for	IN	O
the	DT	O
intervention	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Logistic	JJ	O
regression	NN	O
results	NNS	O
indicated	VBD	O
an	DT	O
11.2	CD	O
times	NNS	O
higher	JJR	O
odds	NNS	O
for	IN	O
re-enrollment	NN	O
of	IN	O
the	DT	O
intervention	NN	O
group	NN	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Results	NNS	O
did	VBD	O
not	RB	O
vary	JJ	O
by	IN	O
gender	NN	O
,	,	O
race	NN	O
,	,	O
ethnicity	NN	O
,	,	O
or	CC	O
level	NN	O
of	IN	O
education	NN	O
,	,	O
however	RB	O
recycled	JJ	O
smokers	NNS	O
were	VBD	O
older	JJR	O
(	(	O
Mean	NNP	O
=	NNP	O
45.2	CD	O
;	:	O
SD	NNP	O
=	NNP	O
11.7	CD	O
)	)	O
than	IN	O
smokers	NNS	O
who	WP	O
declined	VBD	O
a	DT	O
new	JJ	O
treatment	NN	O
cycle	NN	O
(	(	O
Mean	NNP	O
=	NNP	O
41.8	CD	O
;	:	O
SD	NNP	O
=	NNP	O
13.2	CD	O
)	)	O
;	:	O
(	(	O
p	VB	O
=	RB	O
0.013	CD	O
)	)	O
.	.	O

The	DT	O
main	JJ	O
barriers	NNS	O
reported	VBD	O
for	IN	O
not	RB	O
engaging	VBG	O
in	IN	O
a	DT	O
new	JJ	O
treatment	NN	O
cycle	NN	O
were	VBD	O
low	JJ	O
self-efficacy	NN	O
and	CC	O
lack	NN	O
of	IN	O
interest	NN	O
in	IN	O
quitting	VBG	O
.	.	O

After	IN	O
delivering	VBG	O
IVR	NNP	Educational
messages	NNS	Educational
targeting	VBG	O
these	DT	O
reported	VBN	O
barriers	NNS	O
,	,	O
32	CD	O
%	NN	O
of	IN	O
the	DT	O
smokers	NNS	O
reporting	VBG	O
low	JJ	O
self-efficacy	NN	O
and	CC	O
4.8	CD	O
%	NN	O
of	IN	O
those	DT	O
reporting	VBG	O
lack	NN	O
of	IN	O
interest	NN	O
in	IN	O
quitting	VBG	O
re-engaged	JJ	O
in	IN	O
a	DT	O
new	JJ	O
QL	NNP	O
treatment	NN	O
cycle	NN	O
.	.	O

CONCLUSION	NNP	O
Proactive	NNP	Educational
IVR	NNP	Educational
outreach	NN	Educational
is	VBZ	O
a	DT	O
promising	JJ	O
tool	NN	O
to	TO	O
engage	VB	O
low	JJ	O
income	NN	O
,	,	O
relapsed	VBD	O
smokers	NNS	O
back	RB	O
into	IN	O
a	DT	O
new	JJ	O
cycle	NN	O
of	IN	O
treatment	NN	O
.	.	O

Integration	NN	O
of	IN	O
IVR	NNP	Educational
intervention	NN	O
for	IN	O
recycling	VBG	O
smokers	NNS	O
with	IN	O
previous	JJ	O
QL	NNP	O
treatment	NN	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
decrease	VB	O
tobacco-related	JJ	O
disparities	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT01260597	NN	O
.	.	O

Effects	NNS	O
of	IN	O
pindolol	NN	Pharmacological
and	CC	O
clopamide	NN	Pharmacological
on	IN	O
blood	NN	O
lipids	NNS	O
in	IN	O
arterial	JJ	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
clopamide	NN	Pharmacological
,	,	O
pindolol	NN	Pharmacological
and	CC	O
its	PRP$	O
combination	NN	Pharmacological
on	IN	Pharmacological
plasma	JJ	Pharmacological
lipids	NNS	Pharmacological
in	IN	O
49	CD	O
hypertensive	JJ	O
patients	NNS	O
(	(	O
WHO	NNP	O
I-II	NNP	O
)	)	O
,	,	O
divided	VBD	O
into	IN	O
three	CD	O
parallel	JJ	O
randomized	VBN	O
groups	NNS	O
,	,	O
were	VBD	O
studied	VBN	O
over	IN	O
a	DT	O
6	CD	O
months	NNS	O
period	NN	O
.	.	O

Total	JJ	O
cholesterol	NN	O
,	,	O
triglycerides	NNS	O
,	,	O
HDL	NNP	O
and	CC	O
LDL	NNP	O
cholesterol	NN	O
fractions	NNS	O
were	VBD	O
determined	VBN	O
twice	RB	O
during	IN	O
an	DT	O
initial	JJ	O
4-week	JJ	O
washout	NN	O
phase	NN	O
,	,	O
and	CC	O
after	IN	O
a	DT	O
1-	JJ	O
,	,	O
3-	JJ	O
and	CC	O
6-month	JJ	O
active	JJ	O
hypotensive	JJ	O
drug	NN	O
phase	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
maintain	VB	O
their	PRP$	O
usual	JJ	O
dietary	JJ	O
habits	NNS	O
.	.	O

Daily	JJ	O
drug	NN	O
doses	NNS	O
were	VBD	O
adjusted	VBN	O
progressively	RB	O
to	TO	O
attain	VB	O
optimal	JJ	O
hypotensive	JJ	O
effects	NNS	O
.	.	O

In	IN	O
the	DT	O
clopamide	NN	O
monotherapy	NN	O
group	NN	O
,	,	O
total	JJ	O
cholesterol	NN	O
increased	VBD	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
;	:	O
triglycerides	NNS	O
and	CC	O
LDL	NNP	O
showed	VBD	O
a	DT	O
tendency	NN	O
to	TO	O
increase	VB	O
while	IN	O
for	IN	O
HDL	NNP	O
a	DT	O
tendency	NN	O
to	TO	O
decrease	VB	O
was	VBD	O
observed	VBN	O
.	.	O

In	IN	O
the	DT	O
pindolol	NN	O
monotherapy	NN	O
group	NN	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
triglycerides	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
and	CC	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
HDL	NNP	O
cholesterol	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
were	VBD	O
recorded	VBN	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
total	JJ	O
cholesterol	NN	O
or	CC	O
LDL	NNP	O
fraction	NN	O
were	VBD	O
observed	VBN	O
.	.	O

Combined	VBN	O
pindolol-clopamide	JJ	O
therapy	NN	O
decreased	VBD	O
total	JJ	O
triglycerides	NNS	O
(	(	O
NS	NNP	O
)	)	O
,	,	O
increased	VBD	O
HDL	NNP	O
significantly	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
and	CC	O
did	VBD	O
not	RB	O
influence	VB	O
total	JJ	O
cholesterol	NN	O
and	CC	O
LDL	NNP	O
fraction	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
pindolol	NN	O
does	VBZ	O
not	RB	O
negatively	RB	O
influence	VB	O
blood	NN	O
lipids	NNS	O
as	IN	O
the	DT	O
thiazide-type	JJ	O
diuretic	JJ	O
clopamide	NN	O
does	VBZ	O
,	,	O
and	CC	O
that	IN	O
when	WRB	O
both	DT	O
drugs	NNS	O
are	VBP	O
used	VBN	O
together	RB	O
,	,	O
the	DT	O
beta-blocker	NN	O
can	MD	O
probably	RB	O
counterbalance	VB	O
the	DT	O
diuretic-induced	JJ	O
negative	JJ	O
effects	NNS	O
on	IN	O
blood	NN	O
lipids	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
pindolol	NN	O
could	MD	O
be	VB	O
a	DT	O
more	RBR	O
favorable	JJ	O
beta-blocker	JJ	O
drug	NN	O
to	TO	O
be	VB	O
used	VBN	O
on	IN	O
hypertensive	JJ	O
subjects	NNS	O
with	IN	O
metabolic	JJ	O
coronary	JJ	O
risk	NN	O
factors	NNS	O
.	.	O

Group	NNP	Educational
cognitive	JJ	Educational
behavior	NN	Educational
therapy	NN	Educational
for	IN	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
anxiety	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Children	NNP	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
are	VBP	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
developing	VBG	O
significant	JJ	O
anxiety	NN	O
.	.	O

Anxiety	NN	O
can	MD	O
adversely	RB	O
impact	VB	O
functioning	VBG	O
across	IN	O
school	NN	O
,	,	O
home	NN	O
and	CC	O
community	NN	O
environments	NNS	O
.	.	O

Cognitive	JJ	Educational
behavioral	JJ	Educational
therapies	NNS	Educational
(	(	Educational
CBT	NNP	Educational
)	)	Educational
are	VBP	O
frequently	RB	O
used	VBN	O
with	IN	O
success	NN	O
for	IN	O
children	NNS	O
with	IN	O
anxiety	NN	O
symptoms	NNS	O
.	.	O

Modified	NNP	Educational
CBT	NNP	Educational
interventions	NNS	Educational
for	IN	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
have	VBP	O
also	RB	O
yielded	VBN	O
promising	JJ	O
results	NNS	O
.	.	O

METHODS	NNP	O
Fifty	NNP	O
children	NNS	O
with	IN	O
high-functioning	JJ	O
ASD	NNP	O
and	CC	O
anxiety	NN	O
were	VBD	O
randomizedto	JJ	O
group	NN	Educational
CBT	NNP	Educational
or	CC	O
treatment-as-usual	JJ	Educational
(	(	Educational
TAU	NNP	Educational
)	)	Educational
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Independent	NNP	O
clinical	JJ	O
evaluators	NNS	O
,	,	O
blind	NN	O
to	TO	O
condition	NN	O
,	,	O
completed	VBN	O
structured	JJ	O
interviews	NNS	O
(	(	O
Anxiety	NNP	O
Disorders	NNP	O
Interview	NNP	O
Schedule	NNP	O
?	.	O
Parent	NNP	O
Version	NNP	O
;	:	O
ADIS-P	NNP	O
)	)	O
pre-	NN	O
and	CC	O
post-intervention	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Forty-seven	JJ	O
children	NNS	O
completed	VBN	O
either	CC	O
the	DT	O
CBT	NNP	Educational
or	CC	O
TAU	NNP	Educational
condition	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
markedly	RB	O
better	RBR	O
outcomes	NNS	O
for	IN	O
the	DT	O
CBT	NNP	Educational
group	NN	O
.	.	O

Significant	JJ	O
differences	NNS	O
by	IN	O
group	NN	O
were	VBD	O
noted	VBN	O
in	IN	O
Clinician	JJ	O
Severity	NNP	O
Ratings	NNP	O
,	,	O
diagnostic	JJ	O
status	NN	O
,	,	O
and	CC	O
clinician	JJ	O
ratings	NNS	O
of	IN	O
global	JJ	O
improvement	NN	O
.	.	O

In	IN	O
the	DT	O
intent-to-treat	JJ	O
sample	NN	O
,	,	O
10	CD	O
of	IN	O
20	CD	O
children	NNS	O
(	(	O
50	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
CBT	NNP	O
group	NN	O
had	VBD	O
a	DT	O
clinically	RB	O
meaningful	JJ	O
positive	JJ	O
treatment	NN	O
response	NN	O
,	,	O
compared	VBN	O
to	TO	O
2	CD	O
of	IN	O
23	CD	O
children	NNS	O
(	(	O
8.7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
TAU	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Initial	JJ	O
results	NNS	O
from	IN	O
this	DT	O
randomized	VBN	O
,	,	O
designed	VBN	O
treatment	NN	O
study	NN	O
suggest	VBP	O
that	IN	O
agroup	NN	O
CBT	NNP	O
intervention	NN	O
specifically	RB	O
developed	VBD	O
for	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
may	MD	O
be	VB	O
effective	JJ	O
in	IN	O
decreasing	VBG	O
anxiety	NN	O
.	.	O

Limitations	NNS	O
of	IN	O
this	DT	O
study	NN	O
include	VBP	O
small	JJ	O
sample	JJ	O
size	NN	O
,	,	O
lack	NN	O
of	IN	O
an	DT	O
attention	NN	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
use	NN	O
of	IN	O
outcome	NN	O
measures	NNS	O
normed	VBN	O
with	IN	O
typically	RB	O
developing	VBG	O
children	NNS	O
Torasemide	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
and	CC	O
ascites	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
torasemide	NN	Pharmacological
(	(	Pharmacological
20	CD	Pharmacological
mg/day	NN	Pharmacological
)	)	Pharmacological
and	CC	O
furosemide	JJ	Pharmacological
(	(	Pharmacological
50	CD	Pharmacological
mg/day	NN	Pharmacological
)	)	Pharmacological
,	,	O
each	DT	O
given	VBN	O
over	IN	O
4	CD	O
days	NNS	O
,	,	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
and	CC	O
crossover	NN	O
study	NN	O
carried	VBD	O
out	RP	O
in	IN	O
seven	CD	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
and	CC	O
tense	NN	O
ascites	NNS	O
.	.	O

Patients	NNS	O
also	RB	O
received	VBD	O
a	DT	O
low-sodium	NN	Pharmacological
(	(	Pharmacological
40	CD	Pharmacological
mmol/day	NN	Pharmacological
)	)	Pharmacological
diet	NN	Pharmacological
and	CC	O
the	DT	O
aldosterone	NN	Pharmacological
antagonist	NN	Pharmacological
,	,	O
potassium	NN	Pharmacological
canrenoate	NN	Pharmacological
(	(	O
100	CD	O
mg	RB	O
b.i.d.	NN	O
)	)	O
.	.	O

Torasemide	NNP	Pharmacological
induced	VBD	O
a	DT	O
remarkably	RB	O
higher	RBR	O
natriuretic	JJ	O
(	(	O
120	CD	O
+/-	JJ	O
15	CD	O
vs.	FW	O
33	CD	O
+/-	JJ	O
6	CD	O
mmol/day	NN	O
,	,	O
p	NN	O
<	NNP	O
0.02	CD	O
)	)	O
and	CC	O
diuretic	JJ	O
(	(	O
1450	CD	O
+/-	NN	O
63	CD	O
vs.	IN	O
900	CD	O
+/-	JJ	O
58	CD	O
ml	NN	O
,	,	O
p	NN	O
<	NNP	O
0.005	CD	O
)	)	O
effect	NN	O
than	IN	O
furosemide	NN	Pharmacological
.	.	O

Body	NNP	O
weight	JJ	O
loss	NN	O
was	VBD	O
also	RB	O
significantly	RB	O
higher	JJR	O
(	(	O
2.5	CD	O
+/-	JJ	O
1.6	CD	O
vs.	FW	O
0.2	CD	O
+/-	JJ	O
1.3	CD	O
kg	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
during	IN	O
the	DT	O
torasemide	JJ	Pharmacological
period	NN	O
.	.	O

Kaliuresis	NNP	O
was	VBD	O
similar	JJ	O
during	IN	O
the	DT	O
two	CD	O
treatment	NN	O
periods	NNS	O
,	,	O
despite	IN	O
the	DT	O
striking	JJ	O
differences	NNS	O
observed	VBN	O
in	IN	O
natriuresis	NN	O
.	.	O

Neither	CC	O
torasemide	JJ	Pharmacological
nor	CC	O
furosemide	JJ	Pharmacological
induced	VBD	O
any	DT	O
significant	JJ	O
change	NN	O
in	IN	O
serum	NN	O
electrolyte	NN	O
or	CC	O
creatinine	NN	O
concentrations	NNS	O
,	,	O
or	CC	O
in	IN	O
ammonia	JJ	O
levels	NNS	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
torasemide	NN	Pharmacological
is	VBZ	O
suitable	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
sodium	NN	O
retention	NN	O
in	IN	O
patients	NNS	O
with	IN	O
cirrhosis	NN	O
and	CC	O
ascites	NNS	O
.	.	O

[	NN	O
Pilot	NNP	O
results	NNS	O
of	IN	O
using	VBG	O
tamsulone-FS	JJ	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
prostatic	JJ	O
adenoma	NN	O
according	VBG	O
to	TO	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
multicenter	NN	O
comparative	JJ	O
trial	NN	O
]	NN	O
.	.	O

Tamsulone-FS	NNP	Pharmacological
--	:	Pharmacological
a	DT	O
novel	JJ	O
Russian	JJ	O
alpha1A/D-adrenoblocker	NN	O
(	(	O
Farm-Syntez	NNP	O
)	)	O
--	:	O
was	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
multicenter	NN	O
comparative	JJ	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
prostatic	JJ	O
adenoma	NN	O
.	.	O

Pilot	NNP	O
results	NNS	O
agreed	VBD	O
with	IN	O
other	JJ	O
trials	NNS	O
published	VBN	O
in	IN	O
the	DT	O
literature	NN	O
and	CC	O
demonstrated	VBD	O
tamsulone-FS	JJ	Pharmacological
efficacy	NN	O
and	CC	O
safety	NN	O
for	IN	O
management	NN	O
of	IN	O
lower	JJR	O
urinary	JJ	O
tract	NN	O
symptoms	NNS	O
caused	VBN	O
by	IN	O
prostatic	JJ	O
adenoma	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
tamsulone-FS	NN	Pharmacological
was	VBD	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
omnik	FW	O
.	.	O

This	DT	O
drug	NN	O
can	MD	O
be	VB	O
recommended	VBN	O
for	IN	O
wide	JJ	O
clinical	JJ	O
practice	NN	O
in	IN	O
prostatic	JJ	O
adenoma	NN	O
.	.	O

It	PRP	O
is	VBZ	O
registered	VBN	O
by	IN	O
Roszdravnadzor	NNP	O
(	(	O
certificate	JJ	O
N	NNP	O
LC-000859	NNP	O
of	IN	O
03.11.2005	CD	O
)	)	O
and	CC	O
allowed	VBN	O
for	IN	O
production	NN	O
and	CC	O
sale	NN	O
.	.	O

Propranolol	NNP	Pharmacological
in	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
:	:	O
the	DT	O
MILIS	NNP	O
experience	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
propranolol	NN	Pharmacological
limb	NN	O
of	IN	O
the	DT	O
Multicenter	NNP	O
Investigation	NNP	O
of	IN	O
the	DT	O
Limitation	NNP	O
of	IN	O
Infarct	NNP	O
Size	NNP	O
are	VBP	O
reviewed	VBN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
269	CD	O
patients	NNS	O
,	,	O
who	WP	O
presented	VBD	O
with	IN	O
symptoms	NNS	O
and	CC	O
electrocardiographic	JJ	O
signs	NNS	O
suggesting	VBG	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
acute	VB	O
intravenous	JJ	O
and	CC	O
subsequent	JJ	O
oral	JJ	O
therapy	NN	O
with	IN	O
propranolol	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
134	CD	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
135	CD	O
)	)	O
.	.	O

Eligibility	NN	O
for	IN	O
acute	JJ	O
beta-blocker	NN	O
therapy	NN	O
was	VBD	O
determined	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
readily	RB	O
available	JJ	O
,	,	O
noninvasive	JJ	O
tests	NNS	O
.	.	O

Therapy	NN	O
was	VBD	O
started	VBN	O
at	IN	O
an	DT	O
average	JJ	O
time	NN	O
of	IN	O
8.5	CD	O
hours	NNS	O
after	IN	O
onset	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

The	DT	O
full	JJ	O
induction	NN	O
dose	NN	O
of	IN	O
intravenous	JJ	O
propranolol	NN	Pharmacological
(	(	O
0.1	CD	O
mg/kg	NN	O
)	)	O
was	VBD	O
tolerated	VBN	O
by	IN	O
90	CD	O
%	NN	O
of	IN	O
treated	JJ	O
patients	NNS	O
,	,	O
and	CC	O
oral	JJ	O
maintenance	NN	O
therapy	NN	O
was	VBD	O
being	VBG	O
continued	VBN	O
in	IN	O
82	CD	O
%	NN	O
of	IN	O
treated	JJ	O
patients	NNS	O
on	IN	O
the	DT	O
second	JJ	O
hospital	NN	O
day	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
heart	NN	O
rate	NN	O
throughout	IN	O
maintenance	NN	O
therapy	NN	O
with	IN	O
propranolol	NN	O
,	,	O
which	WDT	O
continued	VBD	O
through	IN	O
the	DT	O
tenth	JJ	O
hospital	NN	O
day	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
between	IN	O
propranolol-	JJ	Pharmacological
and	CC	O
placebo-treated	JJ	Control
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
in	IN	O
infarct	JJ	O
size	NN	O
estimated	VBN	O
by	IN	O
measurement	NN	O
of	IN	O
serum	JJ	O
CK-MB	NNP	O
,	,	O
planimetry	NN	O
of	IN	O
infarct	JJ	O
area	NN	O
on	IN	O
technetium	NN	O
pyrophosphate	NN	O
myocardial	JJ	O
scintigrams	NNS	O
or	CC	O
R-wave	JJ	O
measurements	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
transmural	JJ	O
anterior	NNS	O
and	CC	O
inferior	JJ	O
infarcts	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
mortality	NN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
during	IN	O
an	DT	O
average	NN	O
of	IN	O
36	CD	O
months	NNS	O
'	POS	O
follow-up	NN	O
.	.	O

Although	IN	O
propranolol	NN	Pharmacological
can	MD	O
be	VB	O
administered	VBN	O
safely	RB	O
to	TO	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
who	WP	O
are	VBP	O
selected	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
simple	JJ	O
clinical	JJ	O
criteria	NNS	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
evidence	NN	O
of	IN	O
reduction	NN	O
of	IN	O
infarct	NN	O
size	NN	O
when	WRB	O
beta	NN	O
blockade	NN	O
is	VBZ	O
begun	VBN	O
8.5	CD	O
hours	NNS	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
crossover	NN	O
study	NN	O
of	IN	O
Cappra?	NNP	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
mild	NN	O
or	CC	O
mild	NN	O
to	TO	O
moderate	VB	O
erectile	JJ	O
dysfunction	NN	O
in	IN	O
Thai	NNP	O
male	NN	O
.	.	O

Erectile	JJ	O
dysfunction	NN	O
(	(	O
ED	NNP	O
)	)	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
major	JJ	O
health	NN	O
concerns	NNS	O
affects	VBZ	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
among	IN	O
Thai	NNP	O
male	NN	O
.	.	O

The	DT	O
treatment	NN	O
of	IN	O
ED	NNP	O
by	IN	O
the	DT	O
first-line	JJ	O
drugs	NNS	O
is	VBZ	O
limited	VBN	O
to	TO	O
a	DT	O
certain	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
due	JJ	O
to	TO	O
their	PRP$	O
side	NN	O
effects	NNS	O
and	CC	O
costs	NNS	O
.	.	O

Alternative	JJ	O
medicine	NN	O
can	MD	O
be	VB	O
beneficial	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ED	NNP	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
crossover	NN	O
study	NN	O
aimed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
Cappra	NNP	Pharmacological
(	(	O
?	.	O
)	)	O
,	,	O
a	DT	O
traditional	JJ	O
herbal	NN	O
medicine	NN	O
which	WDT	O
was	VBD	O
used	VBN	O
in	IN	O
Thailand	NNP	O
for	IN	O
decades	NNS	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
mild	NN	O
and	CC	O
mild	NN	O
to	TO	O
moderate	VB	O
ED	NNP	O
in	IN	O
Thai	NNP	O
patients	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
63	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
or	CC	O
mild	JJ	O
to	TO	O
moderate	VB	O
ED	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
Cappra	NNP	Pharmacological
(	(	O
?	.	O
)	)	O
or	CC	O
placebo	NN	Control
for	IN	O
two	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
first	JJ	O
period	NN	O
,	,	O
followed	VBN	O
by	IN	O
one	CD	O
week	NN	O
washout	NN	O
period	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
switched	VBN	O
to	TO	O
the	DT	O
alternative	JJ	O
treatment	NN	O
in	IN	O
the	DT	O
second	JJ	O
period	NN	O
.	.	O

The	DT	O
efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function	NNP	O
(	(	O
IIEF	NNP	O
)	)	O
questionnaire	NN	O
and	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

Sixty	NNP	O
one	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

There	EX	O
was	VBD	O
an	DT	O
improvement	NN	O
of	IN	O
IIEF	NNP	O
score	NN	O
for	IN	O
all	DT	O
domains	NNS	O
in	IN	O
Cappra	NNP	O
(	(	O
?	.	O
)	)	O
group	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
group	NN	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
of	IN	O
IIEF	NNP	O
score	NN	O
from	IN	O
baseline	NN	O
for	IN	O
erectile	JJ	O
function	NN	O
domain	NN	O
of	IN	O
Cappra	NNP	O
(	(	O
?	.	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
placebo	NN	O
(	(	O
4.87	CD	O
vs	NN	O
3.44	CD	O
,	,	O
p	NN	O
=	NNP	O
0.032	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
dizziness	NN	O
(	(	O
13.3	CD	O
%	NN	O
Cappra	NNP	O
(	(	O
?	.	O
)	)	O
,	,	O
9.6	CD	O
%	NN	O
placebo	NN	O
)	)	O
,	,	O
face	NN	O
numbness	NN	O
(	(	O
1.6	CD	O
%	NN	O
Cappra	NNP	O
(	(	O
?	.	O
)	)	O
,	,	O
0	CD	O
%	NN	O
placebo	NN	O
)	)	O
,	,	O
and	CC	O
tachycardia	NN	O
(	(	O
1.6	CD	O
%	NN	O
Cappra	NNP	O
(	(	O
?	.	O
)	)	O
,	,	O
0	CD	O
%	NN	O
placebo	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
from	IN	O
this	DT	O
study	NN	O
demonstrated	VBD	O
that	IN	O
Cappra	NNP	O
(	(	O
?	.	O
)	)	O
is	VBZ	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
alternative	JJ	O
therapy	NN	O
for	IN	O
mild	NN	O
and	CC	O
mild	NN	O
to	TO	O
moderate	VB	O
ED	NNP	O
.	.	O

Videotaped	NNP	Educational
training	NN	Educational
in	IN	Educational
alcohol	NN	Educational
counseling	NN	Educational
for	IN	O
obstetric	JJ	O
care	NN	O
practitioners	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
videotaped	JJ	Educational
training	NN	Educational
for	IN	Educational
obstetric	JJ	Educational
care	NN	Educational
practitioners	NNS	Educational
in	IN	Educational
motivational	JJ	Educational
interviewing	NN	Educational
skills	NNS	Educational
that	WDT	O
could	MD	O
be	VB	O
used	VBN	O
in	IN	O
brief	JJ	O
patient	JJ	O
consultations	NNS	O
on	IN	O
problem	NN	O
drinking	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
health	NN	O
care	NN	O
practitioners	NNS	O
participated	VBD	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
using	VBG	O
a	DT	O
20-minute	JJ	Educational
videotape	NN	Educational
to	TO	O
instruct	VB	O
them	PRP	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
.	.	O

Participants	NNS	O
engaged	VBN	O
in	IN	O
a	DT	O
pretest	JJ	O
roleplay	NN	O
with	IN	O
an	DT	O
actress	NN	O
playing	VBG	O
a	DT	O
drinking	NN	O
pregnant	JJ	O
woman	NN	O
.	.	O

Those	DT	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
experimental	JJ	O
condition	NN	O
watched	VBD	O
the	DT	O
motivational	JJ	Educational
interviewing	NN	Educational
videotape	NN	Educational
.	.	O

Control	NNP	Pharmacological
condition	NN	O
participants	NNS	O
watched	VBD	O
a	DT	O
20-minute	JJ	Pharmacological
docudrama	NN	Pharmacological
of	IN	O
a	DT	O
pregnant	JJ	O
problem	NN	O
drinker	NN	O
.	.	O

Both	DT	O
groups	NNS	O
then	RB	O
engaged	VBD	O
in	IN	O
a	DT	O
post-test	JJ	O
roleplay	NN	O
similar	JJ	O
to	TO	O
the	DT	O
pretest	NN	O
.	.	O

Behavioral	JJ	O
ratings	NNS	O
of	IN	O
the	DT	O
roleplays	NNS	O
and	CC	O
participant	JJ	O
evaluations	NNS	O
of	IN	O
the	DT	O
motivational	JJ	O
interviewing	NN	O
video	NN	O
constituted	VBD	O
the	DT	O
outcome	NN	O
measures	NNS	O
.	.	O

RESULTS	NNP	O
Participant	NNP	O
evaluations	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
training	NN	Educational
video	NN	Educational
was	VBD	O
clear	JJ	O
in	IN	O
explaining	VBG	O
and	CC	O
demonstrating	VBG	O
the	DT	O
principles	NNS	O
and	CC	O
skills	NNS	O
of	IN	O
motivational	JJ	O
interviewing	NN	O
.	.	O

Change	NN	O
in	IN	O
behavioral	JJ	O
ratings	NNS	O
from	IN	O
pretest	NN	O
to	TO	O
post-test	NN	O
showed	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
skills	NNS	O
between	IN	O
the	DT	O
experimental	JJ	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Obstetric	NNP	O
care	NN	O
practitioners	NNS	O
who	WP	O
viewed	VBD	O
the	DT	O
training	NN	O
video	NN	O
were	VBD	O
rated	VBN	O
as	IN	O
showing	VBG	O
greater	JJR	O
empathy	NN	O
,	,	O
minimizing	VBG	O
patient	JJ	O
defensiveness	NN	O
,	,	O
and	CC	O
supporting	VBG	O
women	NNS	O
's	POS	O
beliefs	NNS	O
in	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
change	VB	O
.	.	O

CONCLUSION	NNP	O
Obstetric	NNP	O
care	NN	O
practitioners	NNS	O
can	MD	O
improve	VB	O
their	PRP$	O
alcohol	NN	O
intervention	NN	O
skills	NNS	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
20-minute	JJ	O
videotaped	JJ	Educational
instruction	NN	Educational
in	IN	Educational
motivational	JJ	Educational
interviewing	NN	Educational
.	.	Educational

Clinicians	NNPS	O
who	WP	O
improve	VBP	O
their	PRP$	O
skills	NNS	O
in	IN	O
motivational	JJ	O
interviewing	NN	O
can	MD	O
intervene	VB	O
more	RBR	O
effectively	RB	O
with	IN	O
their	PRP$	O
drinking	NN	O
pregnant	JJ	O
patients	NNS	O
.	.	O

Using	VBG	O
motivational	JJ	Educational
interviewing	NN	Educational
with	IN	O
this	DT	O
population	NN	O
holds	VBZ	O
promise	RB	O
for	IN	O
helping	VBG	O
prevent	JJ	O
alcohol-related	JJ	O
health	NN	O
problems	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
oral	JJ	O
DMSA	NNP	Pharmacological
therapy	NN	Pharmacological
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
part	NN	O
B	NNP	O
-	:	O
behavioral	JJ	O
results	NNS	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	Pharmacological
dimercapto	NN	Pharmacological
succinic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
DMSA	NNP	Pharmacological
)	)	Pharmacological
therapy	NN	Pharmacological
on	IN	O
the	DT	O
behavioural	JJ	O
symptoms	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
ages	VBZ	O
3-8	JJ	O
years	NNS	O
.	.	O

METHODS	NNP	O
Phase	NNP	O
1	CD	O
involved	VBD	O
65	CD	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
received	VBD	O
one	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
(	(	O
3	CD	O
days	NNS	O
)	)	O
.	.	O

Participants	NNS	O
who	WP	O
had	VBD	O
high	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
were	VBD	O
selected	VBN	O
to	TO	O
continue	VB	O
on	IN	O
to	TO	O
phase	VB	O
2	CD	O
.	.	O

In	IN	O
phase	NN	O
2	CD	O
,	,	O
49	CD	O
participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
design	NN	O
to	TO	O
receive	VB	O
an	DT	O
additional	JJ	O
6	CD	Pharmacological
rounds	NNS	Pharmacological
of	IN	Pharmacological
either	DT	Pharmacological
DMSA	NNP	Pharmacological
or	CC	O
placebo	NN	Control
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
receiving	VBG	O
one	CD	O
round	NN	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	Pharmacological
had	VBD	O
significant	JJ	O
improvements	NNS	O
on	IN	O
all	PDT	O
the	DT	O
assessment	JJ	O
measures	NNS	O
.	.	O

For	IN	O
the	DT	O
seven	CD	O
round	NN	O
group	NN	O
,	,	O
the	DT	O
degree	NN	O
of	IN	O
improvement	NN	O
on	IN	O
the	DT	O
assessment	NN	O
measures	NNS	O
could	MD	O
be	VB	O
partially	RB	O
explained	VBN	O
by	IN	O
a	DT	O
regression	NN	O
analysis	NN	O
based	VBN	O
on	IN	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
and	CC	O
changes	NNS	O
in	IN	O
glutathione	NN	O
(	(	O
adjusted	VBN	O
R2	NNP	O
of	IN	O
0.28-0.75	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.02	CD	O
in	IN	O
all	DT	O
cases	NNS	O
)	)	O
.	.	O

One	CD	O
round	NN	O
of	IN	O
DMSA	NNP	O
had	VBD	O
nearly	RB	O
the	DT	O
same	JJ	O
benefit	NN	O
as	IN	O
seven	CD	O
rounds	NNS	O
.	.	O

The	DT	O
assessment	JJ	O
measures	NNS	O
correlated	VBN	O
reasonably	RB	O
with	IN	O
one	CD	O
another	DT	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.60-0.87	NN	O
)	)	O
and	CC	O
even	RB	O
better	JJR	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.63-0.94	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
both	DT	O
one	CD	O
and	CC	O
seven	CD	O
rounds	NNS	O
of	IN	O
DMSA	NNP	Pharmacological
therapy	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
reasonably	RB	O
safe	JJ	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
have	VBP	O
high	JJ	O
urinary	JJ	O
excretion	NN	O
of	IN	O
toxic	JJ	O
metals	NNS	O
,	,	O
and	CC	O
possibly	RB	O
helpful	JJ	O
in	IN	O
reducing	VBG	O
some	DT	O
of	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
autism	NN	O
in	IN	O
those	DT	O
children	NNS	O
.	.	O

Patterning	VBG	O
of	IN	O
pain	NN	O
and	CC	O
power	NN	O
with	IN	O
guided	JJ	Physical
imagery	NN	Physical
.	.	O

Using	VBG	O
Martha	NNP	O
Rogers	NNP	O
'	POS	O
science	NN	O
of	IN	O
unitary	JJ	O
human	JJ	O
beings	NNS	O
,	,	O
changes	NNS	O
in	IN	O
pain	NN	O
and	CC	O
power	NN	O
among	IN	O
42	CD	O
patients	NNS	O
were	VBD	O
examined	VBN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
guided	JJ	Other
imagery	NN	Other
modality	NN	Other
.	.	Educational

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
and	CC	O
control	NN	Control
groups	NNS	Control
and	CC	O
repeated	VBD	O
measures	NNS	O
MANCOVA	NNP	O
was	VBD	O
used	VBN	O
to	TO	O
detect	VB	O
differences	NNS	O
in	IN	O
pain	NN	O
and	CC	O
power	NN	O
over	IN	O
a	DT	O
4-day	JJ	O
period	NN	O
of	IN	O
time	NN	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
's	POS	O
pain	NN	O
decreased	VBD	O
during	IN	O
the	DT	O
last	JJ	O
2	CD	O
days	NNS	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

No	DT	O
differences	NNS	O
in	IN	O
power	NN	O
emerged	VBN	O
.	.	O

Guided	VBN	Physical
imagery	NN	Physical
appeared	VBD	O
to	TO	O
have	VB	O
potential	JJ	O
as	IN	O
a	DT	O
useful	JJ	O
nursing	NN	O
modality	NN	O
for	IN	O
chronic	JJ	O
pain	NN	O
sufferers	NNS	O
.	.	O

[	JJ	O
Usage	NN	O
of	IN	O
titanoreine	NN	Pharmacological
after	IN	O
procedure	NN	O
for	IN	O
prolapse	NN	O
and	CC	O
hemorrhoids	NNS	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
titanoreine	NN	Pharmacological
on	IN	O
early	JJ	O
postoperative	NN	O
symptoms	NNS	O
after	IN	O
procedure	NN	O
for	IN	O
prolapse	NN	O
and	CC	O
hemorrhoids	NNS	O
(	(	O
PPH	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
From	IN	O
November	NNP	O
2002	CD	O
to	TO	O
July	NNP	O
2003	CD	O
,	,	O
80	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
PPH	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
in	IN	O
to	TO	O
titanoreine	VB	Pharmacological
group	NN	O
(	(	O
n=42	CC	O
)	)	O
and	CC	O
control	VB	Control
group	NN	Control
without	IN	Control
titanoreine	NN	Control
(	(	O
n=38	JJ	O
)	)	O
.	.	O

Symptom	JJ	O
relief	NN	O
was	VBD	O
recorded	VBN	O
24	CD	O
hours	NNS	O
,	,	O
6	CD	O
days	NNS	O
and	CC	O
12	CD	O
days	NNS	O
after	IN	O
PPH	NNP	O
,	,	O
urine	JJ	O
retention	NN	O
24h	CD	O
after	IN	O
PPH	NNP	O
,	,	O
first	RB	O
stool	JJ	O
time	NN	O
,	,	O
wound	IN	O
healing	VBG	O
time	NN	O
,	,	O
mean	JJ	O
hospital	NN	O
stay	NN	O
were	VBD	O
also	RB	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
score	NN	O
of	IN	O
symptom	NN	O
was	VBD	O
lower	JJR	O
in	IN	O
titanoreine	NN	Pharmacological
group	NN	O
(	(	O
4.4	CD	O
)	)	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
6.1	CD	O
)	)	O
24	CD	O
hours	NNS	O
after	IN	O
PPH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
symptom	NN	O
grade	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
6	CD	O
days	NNS	O
and	CC	O
12	CD	O
days	NNS	O
after	IN	O
PPH	NNP	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Decrements	NNS	O
of	IN	O
symptom	NN	O
grade	NN	O
were	VBD	O
lower	JJR	O
in	IN	O
titanoreine	NN	Pharmacological
group	NN	O
than	IN	O
those	DT	O
of	IN	O
control	NN	O
group	NN	O
at	IN	O
any	DT	O
point	NN	O
after	IN	O
PPH	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
urine	JJ	O
retention	NN	O
rate	NN	O
and	CC	O
mean	JJ	O
hospital	NN	O
stay	NN	O
between	IN	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Titanoreine	NNP	Pharmacological
can	MD	O
effectively	RB	O
relieve	VB	O
the	DT	O
early	JJ	O
postoperative	NN	O
symptoms	NNS	O
after	IN	O
PPH	NNP	O
.	.	O

Public	NNP	O
and	CC	O
private	JJ	O
heart	NN	O
rate	NN	O
feedback	NN	O
in	IN	O
social	JJ	Educational
phobia	NN	Educational
:	:	Physical
a	DT	O
manipulation	NN	O
of	IN	O
anxiety	NN	O
visibility	NN	O
.	.	O

According	VBG	O
to	TO	O
cognitive	JJ	O
behavioural	JJ	O
models	NNS	O
of	IN	O
social	JJ	Educational
phobia	NN	Educational
,	,	O
bodily	RB	O
symptoms	NNS	O
are	VBP	O
the	DT	O
main	JJ	O
source	NN	O
of	IN	O
information	NN	O
concerning	VBG	O
social	JJ	O
evaluation	NN	O
for	IN	O
social	JJ	Psychological
phobics	NNS	Psychological
.	.	O

Experience	NN	O
and	CC	O
perception	NN	O
of	IN	O
bodily	RB	O
symptoms	NNS	O
therefore	RB	O
play	VBP	O
an	DT	O
important	JJ	O
role	NN	O
in	IN	O
social	JJ	O
anxiety	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
anxiety	NN	O
visibility	NN	O
on	IN	O
patients	NNS	O
and	CC	O
controls	NNS	O
using	VBG	O
feedback	NN	O
of	IN	O
veridical	JJ	O
heart	NN	O
sounds	VBZ	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
32	CD	O
social	JJ	Educational
phobics	NNS	Educational
and	CC	O
32	CD	O
controls	NNS	O
were	VBD	O
asked	VBN	O
twice	RB	O
to	TO	O
sit	VB	O
in	IN	O
a	DT	O
chair	NN	O
and	CC	O
appear	VB	O
relaxed	VBN	O
while	IN	O
being	VBG	O
evaluated	VBN	O
.	.	O

Half	NN	O
of	IN	O
the	DT	O
participants	NNS	Psychological
heard	VBP	Psychological
their	PRP$	Psychological
heart	NN	Psychological
sounds	VBZ	Psychological
first	JJ	Psychological
via	IN	Psychological
headphones	NNS	Psychological
and	CC	O
then	RB	O
via	IN	O
loudspeakers	NNS	O
which	WDT	O
were	VBD	O
also	RB	O
audible	JJ	O
to	TO	O
observers	NNS	O
.	.	O

The	DT	O
presentation	NN	O
order	NN	O
of	IN	O
the	DT	O
heart	NN	O
sound	NN	O
was	VBD	O
reversed	VBN	O
for	IN	O
the	DT	O
other	JJ	O
half	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
.	.	O

Social	NNP	Psychological
phobics	NNS	Psychological
reported	VBD	O
substantially	RB	O
more	JJR	O
anxiety	NN	O
than	IN	O
controls	NNS	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
habituation	NN	O
in	IN	O
heart	NN	O
rate	NN	O
from	IN	O
the	DT	O
first	JJ	O
to	TO	O
the	DT	O
second	JJ	O
presentation	NN	O
,	,	O
and	CC	O
both	DT	O
groups	NNS	O
reported	VBD	O
perception	NN	O
of	IN	O
a	DT	O
higher	JJR	O
heart	NN	O
rate	NN	O
,	,	O
but	CC	O
only	RB	O
social	JJ	O
phobics	NNS	O
reported	VBD	O
significantly	RB	O
more	JJR	O
anxiety	NN	O
and	CC	O
were	VBD	O
more	JJR	O
worried	JJ	O
about	IN	O
their	PRP$	O
heart	NN	O
rates	NNS	O
in	IN	O
the	DT	O
public	NN	O
than	IN	O
in	IN	O
the	DT	O
private	JJ	O
condition	NN	O
.	.	O

These	DT	O
effects	NNS	O
were	VBD	O
in	IN	O
excess	NN	O
of	IN	O
actual	JJ	O
heart	NN	O
rate	NN	O
differences	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
social	JJ	Educational
phobics	NNS	Educational
worried	VBD	O
about	IN	O
the	DT	O
broadcast	NN	O
of	IN	O
a	DT	O
bodily	JJ	O
anxiety	NN	O
symptom	NN	O
,	,	O
whereas	JJ	O
controls	NNS	Control
did	VBD	O
not	RB	O
.	.	O

Information	NN	O
about	IN	O
arousal	NN	O
made	VBN	O
public	NN	O
has	VBZ	O
a	DT	O
strong	JJ	O
potential	NN	O
to	TO	O
increase	VB	O
anxiety	NN	O
levels	NNS	O
in	IN	O
social	JJ	O
phobics	NNS	O
.	.	O

Comparative	JJ	O
evaluation	NN	O
of	IN	O
calcium	NN	Pharmacological
hydroxide	NN	Pharmacological
and	CC	O
zinc	NN	Pharmacological
oxide	RB	Pharmacological
eugenol	RB	Pharmacological
as	IN	O
root	JJ	Physical
canal	JJ	Physical
filling	NN	Physical
materials	NNS	O
for	IN	O
primary	JJ	O
molars	NNS	O
:	:	O
a	DT	O
clinical	JJ	O
and	CC	O
radiographic	JJ	O
study	NN	O
.	.	O

Calcium	NNP	Pharmacological
hydroxide	NN	Pharmacological
,	,	O
a	DT	O
material	NN	O
widely	RB	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
permanent	JJ	O
teeth	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
used	VBN	O
frequently	RB	O
for	IN	O
pulpectomy	NN	O
in	IN	O
primary	JJ	O
teeth	NNS	O
.	.	O

A	DT	O
comparative	JJ	O
evaluation	NN	O
of	IN	O
calcium	NN	Pharmacological
hydroxide	NN	Pharmacological
and	CC	O
zinc	NN	Pharmacological
oxide	NN	Pharmacological
eugenol	NN	Pharmacological
used	VBN	O
as	IN	O
root	JJ	Physical
canal	JJ	Physical
filling	NN	Physical
materials	NNS	Physical
in	IN	O
primary	JJ	O
molars	NNS	O
is	VBZ	O
presented	VBN	O
.	.	O

[	JJ	O
Antiinflammatory	NNP	O
potential	NN	O
of	IN	O
seven	CD	Pharmacological
plant	NN	Pharmacological
extracts	NNS	Pharmacological
in	IN	O
the	DT	O
ultraviolet	NN	O
erythema	JJ	O
test	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	Control
study	NN	O
]	NNP	O
.	.	O

BACKGROUND	NNP	O
Phytotherapeutics	NNPS	O
are	VBP	O
widely	RB	O
used	VBN	O
in	IN	O
medicine	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
the	DT	O
evaluation	NN	O
of	IN	O
the	DT	O
antiinflammatory	JJ	O
potential	NN	O
of	IN	O
seven	CD	Pharmacological
medical	JJ	Pharmacological
plant	NN	Pharmacological
extracts	NNS	Pharmacological
using	VBG	O
the	DT	O
ultraviolet-	JJ	O
(	(	O
UV	NNP	O
)	)	O
-erythema	VBP	O
test	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Randomized	NNP	O
,	,	O
placebo-controlled	JJ	Control
study	NN	O
on	IN	O
40	CD	O
healthy	JJ	O
subjects	NNS	O
.	.	O

Test	NNP	O
areas	NNS	O
on	IN	O
the	DT	O
upper	JJ	O
back	NN	O
were	VBD	O
irradiated	VBN	O
with	IN	O
the	DT	O
1.5	CD	Pharmacological
fold	JJ	Pharmacological
UV-B	NNP	Pharmacological
minimal	NN	Pharmacological
erythema	NN	Pharmacological
dose	NN	Pharmacological
(	(	O
MED	NNP	O
)	)	O
.	.	O

Formulations	NNS	O
of	IN	O
Aloe	NNP	Pharmacological
vera	NN	Pharmacological
,	,	O
Chamomilla	NNP	Pharmacological
recutita	NN	Pharmacological
,	,	O
Hamamelis	NNP	Pharmacological
virginiana	NN	Pharmacological
,	,	O
Melissa	NNP	Pharmacological
officinalis	NN	Pharmacological
,	,	O
Mentha	NNP	Pharmacological
arvensis	NN	Pharmacological
,	,	O
Melaleuca	NNP	Pharmacological
alternifolia	NN	Pharmacological
,	,	O
Coriandrum	NNP	Pharmacological
sativum	NN	Pharmacological
as	RB	O
well	RB	O
as	IN	O
1	CD	Pharmacological
%	NN	Pharmacological
hydrocortisone	NN	Pharmacological
acetate	NN	Pharmacological
and	CC	O
0.1	CD	Pharmacological
%	NN	Pharmacological
betamethasone	NN	Pharmacological
valerate	NN	Pharmacological
as	IN	O
positive	JJ	O
controls	NNS	O
and	CC	O
unguentum	JJ	Pharmacological
leniens	NNS	Pharmacological
as	IN	O
vehicle	NN	O
control	NN	O
were	VBD	O
applied	VBN	O
under	IN	O
occlusion	NN	O
on	IN	O
the	DT	O
irradiated	JJ	O
areas	NNS	O
and	CC	O
on	IN	O
non-irradiated	JJ	O
area	NN	O
on	IN	O
the	DT	O
contralateral	JJ	O
side	NN	O
.	.	O

Photometric	NNP	O
assessment	NN	O
of	IN	O
the	DT	O
erythema	NN	O
was	VBD	O
performed	VBN	O
before	IN	O
the	DT	O
application	NN	O
of	IN	O
the	DT	O
substances	NNS	O
(	(	O
t0	NN	O
)	)	O
,	,	O
at	IN	O
24	CD	O
h	NN	O
(	(	O
t1	NN	O
)	)	O
and	CC	O
at	IN	O
48	CD	O
h	NN	O
(	(	O
t2	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
Aloe	NNP	O
vera	NN	O
,	,	O
Chamomilla	NNP	O
recutita	NN	O
,	,	O
Melissa	NNP	O
officinalis	NN	O
,	,	O
Melaleuca	NNP	O
alternifolia	NN	O
and	CC	O
Coriandrum	NNP	O
sativum	NN	O
showed	VBD	O
an	DT	O
antiinflammatory	JJ	O
effect	NN	O
compared	VBN	O
to	TO	O
UV-control	NNP	O
and	CC	O
unguentum	JJ	O
leniens	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
results	NNS	O
were	VBD	O
only	RB	O
statistically	RB	O
significant	JJ	O
for	IN	O
Aloe	NNP	O
vera	NN	O
.	.	O

All	DT	O
tested	VBD	O
plant	NN	O
extracts	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	NNP	O
Aloe	NNP	O
vera	NN	O
possesses	VBZ	O
an	DT	O
antiinflammatory	JJ	O
effect	NN	O
on	IN	O
UV-induced	NNP	O
erythemas	NN	O
.	.	O

Pilot	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
of	IN	O
Reciprocal	NNP	Educational
Imitation	NNP	Educational
Training	NNP	Educational
for	IN	O
teaching	VBG	O
elicited	VBN	O
and	CC	O
spontaneous	JJ	O
imitation	NN	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Children	NNP	O
with	IN	O
autism	NN	O
exhibit	NN	O
significant	JJ	O
deficits	NNS	O
in	IN	O
imitation	NN	O
skills	NNS	O
.	.	O

Reciprocal	JJ	Educational
Imitation	NNP	Educational
Training	NNP	Educational
(	(	Educational
RIT	NNP	Educational
)	)	Educational
,	,	O
a	DT	O
naturalistic	JJ	O
imitation	NN	O
intervention	NN	O
,	,	O
was	VBD	O
developed	VBN	O
to	TO	O
teach	VB	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
to	TO	O
imitate	VB	O
during	IN	O
play	NN	O
.	.	O

This	DT	O
study	NN	O
used	VBD	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
RIT	NNP	O
on	IN	O
elicited	VBN	O
and	CC	O
spontaneous	JJ	O
imitation	NN	O
skills	NNS	O
in	IN	O
21	CD	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Results	NNP	O
found	VBD	O
that	IN	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
made	VBD	O
significantly	RB	O
more	RBR	O
gains	NNS	O
in	IN	O
elicited	JJ	O
and	CC	O
spontaneous	JJ	O
imitation	NN	O
,	,	O
replicating	VBG	O
previous	JJ	O
single-subject	JJ	O
design	NN	O
studies	NNS	O
.	.	O

Number	NNP	O
of	IN	O
spontaneous	JJ	O
play	NN	O
acts	NNS	O
at	IN	O
pre-treatment	NN	O
was	VBD	O
related	VBN	O
to	TO	O
improvements	NNS	O
in	IN	O
imitation	NN	O
during	IN	O
the	DT	O
intervention	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
children	NNS	O
with	IN	O
a	DT	O
greater	JJR	O
play	NN	O
repertoire	NN	O
make	VBP	O
greater	JJR	O
gains	NNS	O
during	IN	O
RIT	NNP	O
.	.	O

Improved	VBN	O
intraoperative	JJ	O
management	NN	O
of	IN	O
anastomotic	JJ	O
bleeding	NN	O
during	IN	O
aortic	JJ	O
reconstruction	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
,	,	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
polymeric	JJ	Surgical
surgical	JJ	Surgical
sealant	NN	Surgical
(	(	Surgical
CoSeal	NNP	Surgical
)	)	Surgical
was	VBD	O
compared	VBN	O
to	TO	O
Gelfoam/thrombin	NNP	Surgical
for	IN	O
managing	VBG	O
anastomotic	JJ	O
bleeding	NN	O
after	IN	O
implantation	NN	Physical
of	IN	Surgical
Dacron	NNP	Surgical
grafts	NNS	Surgical
during	IN	Surgical
aortic	JJ	Surgical
reconstruction	NN	Surgical
for	IN	Surgical
nonruptured	JJ	Surgical
aneurysms	NNS	Surgical
.	.	O

Each	DT	Surgical
treatment	NN	Surgical
was	VBD	Surgical
directly	RB	Surgical
applied	VBN	Surgical
to	TO	Surgical
the	DT	Surgical
suture	NN	Surgical
line	NN	Surgical
after	IN	Surgical
confirmation	NN	Surgical
of	IN	Surgical
anastomotic	JJ	Surgical
bleeding	NN	Surgical
.	.	Surgical

The	DT	O
proportion	NN	O
of	IN	O
suture	NN	O
line	NN	O
sites	VBZ	O
that	IN	O
achieved	VBD	O
immediate	JJ	O
sealing	NN	O
and	CC	O
the	DT	O
proportion	NN	O
sealed	VBD	O
within	IN	O
5	CD	O
minutes	NNS	O
were	VBD	O
determined	VBN	O
among	IN	O
37	CD	O
experimental	JJ	O
(	(	O
59	CD	O
sites	NNS	O
)	)	O
and	CC	O
17	CD	O
control	NN	O
subjects	NNS	O
(	(	O
27	CD	O
sites	NNS	O
)	)	O
.	.	O

A	DT	O
significantly	RB	O
greater	JJR	O
proportion	NN	O
of	IN	O
bleeding	VBG	O
suture	NN	O
line	NN	O
sites	NNS	O
treated	VBD	O
with	IN	O
the	DT	O
polymeric	JJ	Surgical
sealant	NN	Surgical
achieved	VBN	O
immediate	JJ	O
sealing	NN	O
following	VBG	O
reestablishment	NN	O
of	IN	O
blood	NN	O
flow	NN	O
compared	VBN	O
with	IN	O
control-treated	JJ	O
sites	NNS	O
[	VBP	O
48	CD	O
of	IN	O
59	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
vs	VBZ	O
10	CD	O
of	IN	O
27	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
;	:	O
P	NNP	O
=	VBD	O
0.002	CD	O
]	NN	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
was	VBD	O
maintained	VBN	O
after	IN	O
5	CD	O
minutes	NNS	O
with	IN	O
approximately	RB	O
85	CD	O
per	IN	O
cent	NN	O
(	(	O
50	CD	O
of	IN	O
59	CD	O
)	)	O
of	IN	O
CoSeal	NNP	Surgical
sites	NNS	O
compared	VBN	O
to	TO	O
just	RB	O
over	IN	O
one-half	JJ	O
(	(	O
14	CD	O
of	IN	O
27	CD	O
)	)	O
of	IN	O
control	NN	O
sites	VBZ	O
demonstrating	VBG	O
ultimate	JJ	O
sealing	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
adverse	JJ	O
events	NNS	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
polymeric	JJ	Surgical
sealant	NN	Surgical
in	IN	O
this	DT	O
study	NN	O
.	.	O

These	DT	O
results	NNS	O
support	VBP	O
the	DT	O
use	NN	O
of	IN	O
this	DT	O
novel	JJ	O
sealant	NN	O
for	IN	O
the	DT	O
intraoperative	JJ	O
management	NN	O
of	IN	O
anastomotic	JJ	O
bleeding	NN	O
during	IN	O
aortic	JJ	O
reconstruction	NN	O
procedures	NNS	O
.	.	O

Perispinal	JJ	O
analgesia	NN	O
for	IN	O
labour	NN	O
followed	VBN	O
by	IN	O
patient-controlled	JJ	O
infusion	NN	O
with	IN	O
bupivacaine	NN	Pharmacological
and	CC	O
sufentanil	NN	Pharmacological
:	:	O
combined	VBN	O
spinal-epidural	JJ	Pharmacological
vs.	FW	Pharmacological
epidural	JJ	Pharmacological
analgesia	NN	O
alone	RB	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Combined	NNP	O
spinal-epidural	JJ	O
is	VBZ	O
an	DT	O
alternative	JJ	O
technique	NN	O
to	TO	O
epidural	JJ	O
analgesia	NN	O
for	IN	O
labour	NN	O
,	,	O
but	CC	O
its	PRP$	O
benefits	NNS	O
are	VBP	O
not	RB	O
clearly	RB	O
identified	VBN	O
.	.	O

METHODS	VB	O
A	DT	O
prospective	JJ	O
,	,	O
blinded	VBD	O
,	,	O
randomized	VBD	O
study	NN	O
was	VBD	O
undertaken	JJ	O
involving	VBG	O
113	CD	O
women	NNS	O
attending	VBG	O
a	DT	O
university	NN	O
hospital	NN	O
obstetric	JJ	O
department	NN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
initiated	VBN	O
with	IN	O
intrathecal	JJ	O
bupivacaine	NN	Pharmacological
0.25	CD	Pharmacological
%	NN	Pharmacological
1	CD	Pharmacological
mL	NN	Pharmacological
+	NNP	O
sufentanil	VBD	Pharmacological
5	CD	Pharmacological
microg	NN	Pharmacological
in	IN	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
,	,	O
and	CC	O
with	IN	O
bupivacaine	JJ	Pharmacological
0.125	CD	Pharmacological
%	NN	Pharmacological
+	JJ	O
epinephrine	NN	Pharmacological
2.5	CD	Pharmacological
microg	NN	Pharmacological
mL	NN	Pharmacological
(	(	Pharmacological
-1	NNP	Pharmacological
)	)	Pharmacological
+	VBD	O
sufentanil	$	Pharmacological
7.5	CD	Pharmacological
microg	NN	Pharmacological
in	IN	O
the	DT	O
epidural	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
59	CD	O
)	)	O
.	.	O

In	IN	Pharmacological
both	DT	Pharmacological
cases	NNS	Pharmacological
this	DT	Pharmacological
was	VBD	Pharmacological
followed	VBN	Pharmacological
by	IN	Pharmacological
patient-controlled	JJ	Pharmacological
epidural	JJ	Pharmacological
analgesia	NN	Pharmacological
with	IN	Pharmacological
bupivacaine	JJ	Pharmacological
0.125	CD	Pharmacological
%	NN	Pharmacological
(	(	O
+	JJ	O
sufentanil	NN	Pharmacological
0.25	CD	Pharmacological
microg	NN	Pharmacological
mL	NN	Pharmacological
(	(	Pharmacological
-1	NNP	Pharmacological
)	)	Pharmacological
)	)	Pharmacological
.	.	O

Duration	NN	O
of	IN	O
labour	NN	O
,	,	O
quality	NN	O
of	IN	O
analgesia	NN	O
and	CC	O
side-effects	NNS	O
were	VBD	O
compared	VBN	O
between	IN	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
group	NN	O
,	,	O
the	DT	O
onset	NN	O
of	IN	O
analgesia	NN	O
was	VBD	O
faster	RBR	O
(	(	O
5	CD	O
vs.	FW	O
15	CD	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
the	DT	O
consumption	NN	O
of	IN	O
bupivacaine	NN	Pharmacological
was	VBD	O
lower	JJR	O
(	(	O
7.5	CD	O
vs.	FW	O
11.3	CD	O
mg	NN	O
h	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
there	EX	O
was	VBD	O
less	JJR	O
unilateral	JJ	O
analgesia	NN	O
(	(	O
14.8	CD	O
%	NN	O
vs.	FW	O
40.7	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
epidural	JJ	O
group	NN	O
.	.	O

The	DT	O
characteristics	NNS	O
of	IN	O
labour	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
in	IN	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
group	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
posterior	JJ	O
presentation	NN	O
(	(	O
25.9	CD	O
%	NN	O
vs.	FW	O
10	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
,	,	O
pruritus	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
hypotension	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
,	,	O
somnolence	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
nausea	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
and	CC	O
one	CD	O
case	NN	O
of	IN	O
meningitis	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
combined	JJ	O
spinal-epidural	JJ	O
technique	NN	O
provided	VBD	O
more	RBR	O
effective	JJ	O
analgesia	NN	O
during	IN	O
labour	JJR	O
than	IN	O
epidural	JJ	O
analgesia	NN	O
alone	RB	O
but	CC	O
offered	VBN	O
no	DT	O
other	JJ	O
advantage	NN	O
.	.	O

It	PRP	O
induced	VBD	O
more	RBR	O
adverse	JJ	O
effects	NNS	O
and	CC	O
this	DT	O
should	MD	O
be	VB	O
considered	VBN	O
before	IN	O
routinely	RB	O
using	VBG	O
the	DT	O
combined	JJ	O
spinal-epidural	JJ	O
technique	NN	O
.	.	O

Safety	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
amyloid	JJ	O
beta	NN	O
concentrations	NNS	O
after	IN	O
administration	NN	O
of	IN	O
a	DT	O
gamma-secretase	JJ	Pharmacological
inhibitor	NN	Pharmacological
in	IN	O
volunteers	NNS	O
.	.	O

Amyloid	NNP	O
beta	NN	O
(	(	O
Abeta	NNP	O
)	)	O
may	MD	O
play	VB	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
Alzheimer	NNP	O
disease	NN	O
.	.	O

A	DT	O
functional	JJ	O
gamma-secretase	NN	O
inhibitor	NN	O
,	,	O
LY450139	NNP	Pharmacological
,	,	O
was	VBD	O
developed	VBN	O
that	IN	O
inhibits	NNS	O
Abeta	NNP	O
formation	NN	O
in	IN	O
whole	JJ	O
cell	NN	O
assays	NNS	O
,	,	O
transgenic	JJ	O
mice	NN	O
,	,	O
and	CC	O
beagle	JJ	O
dogs	NNS	O
.	.	O

The	DT	O
authors	NNS	O
wished	VBD	O
to	TO	O
determine	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
this	DT	O
drug	NN	O
,	,	O
and	CC	O
the	DT	O
reduction	NN	O
of	IN	O
Abeta	NNP	O
in	IN	O
plasma	NN	O
and	CC	O
cerebrospinal	JJ	O
fluid	NN	O
(	(	O
CSF	NNP	O
)	)	O
after	IN	O
multiple	JJ	O
doses	NNS	O
.	.	O

Volunteer	NNP	O
subjects	NNS	O
(	(	O
N	NNP	O
=	NNP	O
37	CD	O
)	)	O
were	VBD	O
studied	VBN	O
using	VBG	Pharmacological
doses	NNS	Pharmacological
from	IN	Pharmacological
5	CD	Pharmacological
to	TO	Pharmacological
50	CD	Pharmacological
mg/day	NN	Pharmacological
given	VBN	Pharmacological
for	IN	Pharmacological
14	CD	Pharmacological
days	NNS	Pharmacological
.	.	Pharmacological

Plasma	NNP	Pharmacological
and	CC	Pharmacological
CSF	NNP	Pharmacological
concentrations	NNS	Pharmacological
of	IN	Pharmacological
LY450139	NNP	Pharmacological
,	,	Pharmacological
Abeta	NNP	Pharmacological
(	(	Pharmacological
1-40	JJ	Pharmacological
)	)	Pharmacological
and	CC	Pharmacological
Abeta	NNP	Pharmacological
(	(	Pharmacological
1-X	JJ	Pharmacological
)	)	Pharmacological
(	(	Pharmacological
Abeta	NNP	Pharmacological
(	(	Pharmacological
total	JJ	Pharmacological
)	)	Pharmacological
)	)	Pharmacological
were	VBD	O
determined	VBN	O
,	,	O
and	CC	O
safety	NN	O
and	CC	O
tolerability	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

The	DT	O
plasma	JJ	O
half-life	NN	O
of	IN	O
LY450139	NNP	O
was	VBD	O
approximately	RB	O
2.5	CD	O
hours	NNS	O
.	.	O

Pharmacokinetic	JJ	O
analyses	NNS	O
showed	VBD	O
a	DT	O
linear	JJ	O
relationship	NN	O
between	IN	O
dose	NN	O
and	CC	O
plasma	JJ	O
concentrations	NNS	O
,	,	O
with	IN	O
a	DT	O
Cmax	NNP	O
of	IN	O
828	CD	O
+/-	JJ	O
19.2	CD	O
ng/mL	NN	O
after	IN	O
a	DT	O
50-mg	JJ	O
dose	NN	O
.	.	O

Plasma	NNP	O
Abeta	NNP	O
concentrations	NNS	O
decreased	VBD	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
over	IN	O
a	DT	O
6-hour	JJ	O
interval	NN	O
following	VBG	O
drug	NN	O
administration	NN	O
,	,	O
with	IN	O
a	DT	O
maximum	JJ	O
decrease	NN	O
of	IN	O
approximately	RB	O
40	CD	O
%	NN	O
relative	JJ	O
to	TO	O
baseline	VB	O
.	.	O

After	IN	O
returning	VBG	O
to	TO	O
baseline	VB	O
,	,	O
Abeta	NNP	O
concentrations	NNS	O
were	VBD	O
transiently	RB	O
increased	VBN	O
.	.	O

CSF	NNP	O
Abeta	NNP	O
concentrations	NNS	O
were	VBD	O
unchanged	JJ	O
.	.	O

Adverse	JJ	O
events	NNS	O
reported	VBN	O
by	IN	O
subjects	NNS	O
taking	VBG	O
5-mg	JJ	O
,	,	O
20-mg	JJ	O
,	,	O
or	CC	O
40-mg	JJ	O
doses	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
reported	VBN	O
by	IN	O
subjects	NNS	O
taking	VBG	O
placebo	NN	O
.	.	O

Two	CD	O
of	IN	O
7	CD	O
subjects	NNS	O
taking	VBG	O
50	CD	O
mg/day	NN	O
experienced	VBD	O
adverse	JJ	O
events	NNS	O
that	WDT	O
may	MD	O
have	VB	O
been	VBN	O
drug	NN	O
related	VBN	O
.	.	O

In	IN	O
this	DT	O
phase	NN	O
1	CD	O
volunteer	NN	O
study	NN	O
,	,	O
reported	VBD	O
adverse	JJ	O
events	NNS	O
after	IN	O
taking	VBG	O
LY450139	NNP	Pharmacological
were	VBD	O
manageable	JJ	O
.	.	O

A	DT	O
dose-dependent	JJ	O
reduction	NN	O
in	IN	O
plasma	NN	O
Abeta	NNP	O
was	VBD	O
demonstrated	VBN	O
,	,	O
and	CC	O
changes	NNS	O
in	IN	O
plasma	NN	O
Abeta	NNP	O
concentrations	NNS	O
were	VBD	O
temporally	RB	O
related	VBN	O
to	TO	O
the	DT	O
pharmacokinetic	JJ	O
characteristics	NNS	O
of	IN	O
LY450139	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
iron	NN	Pharmacological
in	IN	O
formula	NN	O
milk	NN	O
after	IN	O
6	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Ninety	NNP	O
two	CD	O
normal	JJ	O
birthweight	JJ	O
infants	NNS	O
aged	VBD	O
6	CD	O
months	NNS	O
entered	VBD	O
a	DT	O
double	JJ	O
blind	NN	O
controlled	VBD	O
trial	NN	O
which	WDT	O
compared	VBN	O
a	DT	O
follow	NN	O
on	IN	O
formula	NN	Control
milk	NN	Control
with	IN	Control
no	DT	Control
added	JJ	Control
iron	NN	Control
against	IN	O
the	DT	O
same	JJ	Pharmacological
formula	NN	Pharmacological
milk	NN	Pharmacological
containing	VBG	Pharmacological
1.2	CD	Pharmacological
mg	NN	Pharmacological
of	IN	Pharmacological
iron	NN	Pharmacological
per	IN	Pharmacological
100	CD	Pharmacological
ml	NN	Pharmacological
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
social	JJ	O
class	NN	O
or	CC	O
demographic	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
or	CC	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
each	DT	O
group	NN	O
completing	VBG	O
the	DT	O
trial	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
the	DT	O
quantity	NN	O
of	IN	O
milk	NN	O
taken	VBN	O
but	CC	O
the	DT	O
amounts	NNS	O
taken	VBN	O
lessened	VBD	O
between	IN	O
6	CD	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
with	IN	O
respect	NN	O
to	TO	O
mean	VB	O
haemoglobin	NN	O
and	CC	O
median	JJ	O
serum	NN	O
ferritin	NN	O
at	IN	O
6	CD	O
,	,	O
9	CD	O
,	,	O
12	CD	O
,	,	O
15	CD	O
,	,	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Very	RB	O
few	JJ	O
infants	NNS	O
developed	VBD	O
iron	NN	O
deficiency	NN	O
anaemia	NN	O
in	IN	O
either	CC	O
group	NN	O
but	CC	O
there	EX	O
was	VBD	O
a	DT	O
tendency	NN	O
for	IN	O
serum	NN	O
ferritin	NN	O
levels	NNS	O
to	TO	O
fall	VB	O
between	IN	O
6	CD	O
and	CC	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
iron	NN	Pharmacological
added	VBD	O
to	TO	O
follow	VB	O
on	IN	O
milk	NN	O
was	VBD	O
not	RB	O
an	DT	O
important	JJ	O
source	NN	O
of	IN	O
dietary	JJ	O
iron	NN	Pharmacological
in	IN	O
the	DT	O
infants	NNS	O
studied	VBN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
comparative	JJ	O
trial	NN	O
of	IN	O
a	DT	O
COX-2	NNP	Pharmacological
selective	JJ	Pharmacological
nonsteroidal	JJ	Pharmacological
anti-inflammatory	JJ	Pharmacological
drug	NN	Pharmacological
versus	NN	O
placebo	NN	Control
in	IN	O
inguinal	JJ	O
herniorrhaphy	NN	O
patients	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
standard	JJ	O
opioid	NN	O
treatment	NN	O
for	IN	O
postoperative	JJ	O
pain	NN	O
can	MD	O
be	VB	O
associated	VBN	O
with	IN	O
nausea	NN	O
,	,	O
vomiting	NN	O
,	,	O
and	CC	O
constipation	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
opioids	NNS	O
often	RB	O
provide	VBP	O
insufficient	JJ	O
pain	NN	O
relief	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
postoperative	JJ	O
pain	NN	O
and	CC	O
functional	JJ	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
inguinal	JJ	O
herniorrhaphy	NN	O
who	WP	O
receive	VBP	O
a	DT	O
COX-2	NNP	O
selective	JJ	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	O
(	(	O
COX-2	NNP	O
)	)	O
or	CC	O
placebo	VB	O
preoperatively	RB	O
and	CC	O
for	IN	O
4	CD	O
days	NNS	O
postoperatively	RB	O
.	.	O

METHODS	VB	O
A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
blinded	VBN	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
adults	NNS	O
undergoing	VBG	O
elective	JJ	O
,	,	O
outpatient	JJ	O
,	,	O
unilateral	JJ	O
inguinal	JJ	O
herniorrhaphy	NN	O
.	.	O

Patients	NNS	O
received	VBD	O
rofecoxib	JJ	Pharmacological
(	(	O
50	CD	O
mg	NN	O
,	,	O
1	CD	O
h	NN	O
prior	RB	O
to	TO	O
incision	NN	O
)	)	O
or	CC	O
placebo	NN	Control
.	.	O

Doses	NNS	O
were	VBD	O
re-administered	JJ	O
once	RB	O
daily	JJ	O
on	IN	O
postoperative	JJ	O
days	NNS	O
1-4	JJ	O
.	.	O

Patients	NNS	O
were	VBD	O
also	RB	O
given	VBN	O
hydrocodone	NN	Pharmacological
bitartrate	NN	Pharmacological
for	IN	O
use	NN	O
as	IN	O
needed	VBN	O
in	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

Pain	VB	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
,	,	O
including	VBG	O
pain	NN	O
intensity	NN	O
(	(	O
1-10	JJ	O
visual-analogue	JJ	O
scale	NN	O
)	)	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
hydrocodone	NN	O
bitartrate	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
functional	JJ	O
outcomes	NNS	O
such	JJ	O
as	IN	O
activity	NN	O
and	CC	O
return	NN	O
of	IN	O
bowel	NN	O
function	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
5	CD	O
postoperative	JJ	O
days	NNS	O
.	.	O

Incidence	NN	O
and	CC	O
severity	NN	O
of	IN	O
side	NN	O
effects	NNS	O
were	VBD	O
examined	VBN	O
.	.	O

Statistics	NNS	O
are	VBP	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
deviation	NN	O
.	.	O

RESULTS	NNP	O
Fifty-five	JJ	O
subjects	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Twenty-six	JJ	O
patients	NNS	O
received	VBN	O
rofecoxib	JJ	O
and	CC	O
29	CD	O
patients	NNS	O
received	VBD	O
placebo	JJ	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
COX-2	NNP	O
demonstrated	VBD	O
improved	JJ	O
bowel	NN	O
function	NN	O
as	IN	O
reflected	VBN	O
by	IN	O
more	JJR	O
bowel	NN	O
movements	NNS	O
on	IN	O
postoperative	JJ	O
day	NN	O
2	CD	O
and	CC	O
postoperative	JJ	O
day	NN	O
3	CD	O
.	.	O

COX-2-treated	JJ	O
patients	NNS	O
also	RB	O
reported	VBD	O
better	RBR	O
oral	JJ	O
intake	NN	O
on	IN	O
these	DT	O
same	JJ	O
days	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
COX-2-treated	JJ	O
patients	NNS	O
had	VBD	O
less	RBR	O
difficulty	NN	O
coughing	VBG	O
on	IN	O
postoperative	JJ	O
day	NN	O
1	CD	O
.	.	O

Overall	JJ	O
satisfaction	NN	O
with	IN	O
pain	NN	O
management	NN	O
was	VBD	O
better	RBR	O
in	IN	O
COX-2-treated	JJ	O
patients	NNS	O
(	(	O
very	RB	O
satisfied	VBN	O
vs.	FW	O
satisfied	VBN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
hydrocodone	NN	O
bitartrate	NN	O
consumption	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
complications	NNS	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
.	.	O

CONCLUSIONS	NNP	O
Administration	NNP	O
of	IN	O
a	DT	O
COX-2	NNP	O
selective	JJ	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	O
prior	RB	O
to	TO	O
and	CC	O
following	VBG	O
outpatient	JJ	O
inguinal	JJ	O
herniorrhaphy	NN	O
improves	VBZ	O
functional	JJ	O
outcomes	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	O
and	CC	O
increases	VBZ	O
patient	JJ	O
satisfaction	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
multimodal	NN	O
pain	NN	O
therapy	NN	O
with	IN	O
COX-2	NNP	O
inhibitors	NNS	O
may	MD	O
have	VB	O
a	DT	O
role	NN	O
in	IN	O
outpatient	JJ	O
inguinal	JJ	O
hernia	NN	O
repair	NN	O
.	.	O

[	JJ	O
New	NNP	O
approaches	NNS	O
to	TO	O
evaluation	NN	O
of	IN	O
nonspecific	JJ	Pharmacological
inhalation	NN	Pharmacological
provocation	NN	Pharmacological
(	(	O
dose-response	JJ	O
relationship	NN	O
)	)	O
in	IN	O
the	DT	O
comparative	JJ	O
evaluation	NN	O
of	IN	O
bronchial	JJ	O
hyperreactivity	NN	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
clinical	JJ	O
trials	NNS	O
]	VBP	O
.	.	O

For	IN	O
the	DT	O
performance	NN	O
of	IN	O
clinical	JJ	O
drug	NN	O
trials	NNS	O
in	IN	O
the	DT	O
therapy	NN	O
for	IN	O
bronchial	JJ	O
hyperresponsiveness	NN	O
,	,	O
unspecific	JJ	O
inhalatory	JJ	O
provocation	NN	O
tests	NNS	O
are	VBP	O
generally	RB	O
employed	VBN	O
to	TO	O
judge	VB	O
therapeutic	JJ	O
success	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
parameter-specific	JJ	O
provocation	NN	O
doses	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
the	DT	O
main	JJ	O
target	NN	O
values	NNS	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
must	MD	O
be	VB	O
considered	VBN	O
that	IN	O
these	DT	O
provocation	NN	O
doses	NNS	O
are	VBP	O
not	RB	O
equally	RB	O
calculable	JJ	O
for	IN	O
every	DT	O
patient	NN	O
in	IN	O
the	DT	O
same	JJ	O
way	NN	O
and	CC	O
at	IN	O
any	DT	O
examination	NN	O
time	NN	O
.	.	O

This	DT	O
leads	VBZ	O
to	TO	O
the	DT	O
fact	NN	O
that	IN	O
the	DT	O
number	NN	O
of	IN	O
evaluable	JJ	O
case	NN	O
studies	NNS	O
is	VBZ	O
often	RB	O
appreciably	RB	O
lower	JJR	O
than	IN	O
the	DT	O
number	NN	O
of	IN	O
test	NN	O
participants	NNS	O
and	CC	O
that	IN	O
a	DT	O
meaningful	JJ	O
therapy	NN	O
group	NN	O
comparison	NN	O
may	MD	O
even	RB	O
not	RB	O
be	VB	O
possible	JJ	O
under	IN	O
certain	JJ	O
circumstances	NNS	O
.	.	O

An	DT	O
evaluation	NN	O
model	NN	O
is	VBZ	O
presented	VBN	O
here	RB	O
in	IN	O
order	NN	O
to	TO	O
fully	RB	O
exploit	VB	O
the	DT	O
obtained	VBN	O
data	NNS	O
;	:	O
in	IN	O
this	DT	O
the	DT	O
percentile	JJ	O
changes	NNS	O
of	IN	O
the	DT	O
function	NN	O
parameters	NNS	O
(	(	O
estimated	VBN	O
by	IN	O
linear	JJ	O
regression	NN	O
)	)	O
at	IN	O
a	DT	O
defined	JJ	O
dose	NN	O
of	IN	O
the	DT	O
provocation	NN	O
substance	NN	O
are	VBP	O
analyzed	VBN	O
.	.	O

In	IN	O
analogy	NN	O
,	,	O
a	DT	O
survival	JJ	O
time	NN	O
model	NN	O
and	CC	O
,	,	O
as	IN	O
a	DT	O
supplement	NN	O
,	,	O
a	DT	O
best	JJS	O
case/worst	JJ	O
case	NN	O
analysis	NN	O
are	VBP	O
performed	VBN	O
for	IN	O
further	JJ	O
statistical	JJ	O
evaluation	NN	O
.	.	O

With	IN	O
the	DT	O
present	JJ	O
procedure	NN	O
,	,	O
an	DT	O
evaluation	NN	O
with	IN	O
inclusion	NN	O
of	IN	O
all	DT	O
test	NN	O
participants	NNS	O
is	VBZ	O
possible	JJ	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
the	DT	O
previously	RB	O
used	VBN	O
evaluation	NN	O
procedures	NNS	O
,	,	O
this	DT	O
allows	VBZ	O
a	DT	O
reliable	JJ	O
statistical	JJ	O
confirmation	NN	O
of	IN	O
the	DT	O
results	NNS	O
of	IN	O
clinical	JJ	O
tests	NNS	O
in	IN	O
the	DT	O
therapy	NN	O
for	IN	O
bronchial	JJ	O
hyperresponsiveness	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	Educational
computer	NN	Educational
intervention	NN	Educational
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
to	TO	O
recognize	VB	O
and	CC	O
predict	VB	O
emotions	NNS	O
in	IN	O
others	NNS	O
.	.	O

This	DT	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
looked	VBD	O
at	IN	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
new	JJ	Educational
computer	NN	Educational
program	NN	Educational
designed	VBN	O
to	TO	O
teach	VB	O
people	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
to	TO	O
better	JJR	O
recognize	VB	O
and	CC	O
predict	VBP	O
emotional	JJ	O
responses	NNS	O
in	IN	O
others	NNS	O
.	.	O

Two	CD	O
groups	NNS	O
of	IN	O
11	CD	O
children	NNS	O
(	(	O
age	NN	O
12-18	CD	O
)	)	O
with	IN	O
autism	NN	O
or	CC	O
Asperger	NNP	O
syndrome	VBP	O
at	IN	O
two	CD	O
special	JJ	O
schools	NNS	O
participated	VBD	O
:	:	O
one	CD	Educational
group	NN	Educational
used	VBD	Educational
the	DT	Educational
computer	NN	Educational
program	NN	Educational
for	IN	Educational
10	CD	Educational
half-hour	JJ	Educational
sessions	NNS	Educational
over	IN	Educational
2	CD	Educational
weeks	NNS	Educational
.	.	O

Within-program	NNP	O
data	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
errors	NNS	O
made	VBN	O
from	IN	O
first	JJ	O
to	TO	O
last	JJ	O
use	NN	O
.	.	O

Students	NNS	O
were	VBD	O
assessed	VBN	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
using	VBG	O
facial	JJ	O
expression	NN	O
photographs	NN	O
,	,	O
cartoons	NNS	O
depicting	VBG	O
emotion-laden	JJ	O
situations	NNS	O
,	,	O
and	CC	O
non-literal	JJ	O
stories	NNS	O
.	.	O

Scores	NNS	O
were	VBD	O
not	RB	O
related	VBN	O
to	TO	O
age	NN	O
or	CC	O
verbal	JJ	O
ability	NN	O
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
made	VBD	O
gains	NNS	O
relative	JJ	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
on	IN	O
all	DT	O
three	CD	O
measures	NNS	O
.	.	O

Gains	NNP	O
correlated	VBD	O
significantly	RB	O
with	IN	O
the	DT	O
number	NN	O
of	IN	O
times	NNS	O
the	DT	O
computer	NN	Educational
program	NN	Educational
was	VBD	O
used	VBN	O
and	CC	O
results	NNS	O
suggest	VBP	O
positive	JJ	O
effects	NNS	O
.	.	O

Further	NNP	O
research	NN	O
could	MD	O
assess	VB	O
whether	IN	O
these	DT	O
gains	NNS	O
generalized	VBD	O
into	IN	O
real	JJ	O
life	NN	O
or	CC	O
improved	VBN	O
performance	NN	O
on	IN	O
theory	NN	O
of	IN	O
mind	NN	O
measures	NNS	O
.	.	O

A	DT	O
program	NN	O
of	IN	O
screening	VBG	O
and	CC	O
prompting	VBG	O
improves	NNS	O
short-term	JJ	O
physician	JJ	O
counseling	NN	O
of	IN	O
dependent	NN	O
and	CC	O
nondependent	JJ	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

BACKGROUND	NNP	O
Physicians	NNPS	O
in	IN	O
the	DT	O
general	JJ	O
medical	JJ	O
setting	VBG	O
commonly	RB	O
encounter	RB	O
but	CC	O
rarely	RB	O
counsel	NN	O
patients	NNS	O
with	IN	O
dependent	JJ	O
or	CC	O
harmful	JJ	O
drinking	NN	O
behaviors	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
whether	IN	O
providing	VBG	O
physicians	NNS	O
with	IN	O
their	PRP$	O
patients	NNS	O
'	POS	O
results	NNS	O
on	IN	O
the	DT	O
alcohol	NN	O
module	NN	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
would	MD	O
prompt	VB	O
them	PRP	O
to	TO	O
counsel	NN	O
these	DT	O
patients	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
83	CD	O
first-	JJ	O
,	,	O
second-	JJ	O
,	,	O
and	CC	O
third-year	JJ	O
medical	JJ	O
residents	NNS	O
to	TO	O
receive	VB	Educational
or	CC	Educational
not	RB	Educational
to	TO	Educational
receive	VB	Educational
diagnostic	JJ	Educational
information	NN	Educational
and	CC	Educational
counseling	VBG	Educational
directives	NNS	Educational
on	IN	Educational
214	CD	O
patients	NNS	O
who	WP	O
reported	VBD	O
at	IN	O
least	JJS	O
one	CD	O
symptom	NN	O
of	IN	O
alcohol	NN	O
impairment	NN	O
as	IN	O
defined	VBN	O
in	IN	O
the	DT	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Third	NNP	O
Edition	NNP	O
.	.	O

Using	VBG	O
binary	JJ	Educational
logistic	JJ	Educational
regression	NN	Educational
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
specific	JJ	O
covariables	NNS	O
on	IN	O
rates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
.	.	O

These	DT	O
variables	NNS	O
included	VBD	O
physician	JJ	O
information	NN	O
status	NN	O
,	,	O
patient	JJ	O
gender	NN	O
,	,	O
and	CC	O
drinking	VBG	O
disorder	NN	O
severity	NN	O
and	CC	O
recency	NN	O
.	.	O

We	PRP	O
also	RB	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
physician	JJ	O
prompting	VBG	O
on	IN	O
counseling	NN	O
of	IN	O
female	JJ	O
patients	NNS	O
,	,	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinkers	NNS	O
.	.	O

We	PRP	O
determined	VBD	O
counseling	VBG	O
by	IN	O
post-visit	JJ	O
patient	JJ	O
interviews	NNS	O
.	.	O

RESULTS	NNP	O
Physician	JJ	O
prompting	NN	O
,	,	O
dependent	JJ	O
drinking	NN	O
,	,	O
and	CC	O
recent	JJ	O
disorder	NN	O
activity	NN	O
were	VBD	O
significant	JJ	O
correlates	NNS	O
of	IN	O
physician	JJ	O
counseling	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
,	,	O
while	IN	O
male	JJ	O
gender	NN	O
was	VBD	O
a	DT	O
marginally	RB	O
significant	JJ	O
correlate	NN	O
(	(	O
P	NNP	O
=	NNP	O
.08	NNP	O
)	)	O
.	.	O

Informed	VBN	O
physicians	NNS	O
counseled	VBD	O
female	JJ	O
patients	NNS	O
,	,	O
harmful	JJ	O
but	CC	O
nondependent	JJ	O
drinkers	NNS	O
,	,	O
and	CC	O
patients	NNS	O
with	IN	O
inactive	JJ	O
disorders	NNS	O
more	RBR	O
often	RB	O
than	IN	O
their	PRP$	O
uninformed	JJ	O
colleagues	NNS	O
,	,	O
although	IN	O
only	RB	O
the	DT	O
last	JJ	O
variable	JJ	O
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Providing	VBG	O
physicians	NNS	O
with	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
Diagnostic	NNP	O
Interview	NNP	O
Schedule	NNP	O
and	CC	O
counseling	VBG	O
directives	NNS	O
resulted	VBD	O
in	IN	O
short-term	JJ	O
improvement	NN	O
in	IN	O
their	PRP$	O
rates	NNS	O
of	IN	O
counseling	VBG	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
dependent	NN	O
or	CC	O
nondependent	NN	O
but	CC	O
harmful	JJ	O
drinking	NN	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
determine	VB	O
long-term	JJ	O
gains	NNS	O
in	IN	O
rates	NNS	O
of	IN	O
physician	JJ	Educational
counseling	NN	Educational
and	CC	Educational
improvements	NNS	Educational
in	IN	O
the	DT	O
course	NN	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
comparing	VBG	O
radiotherapy	NN	Physical
with	IN	O
concurrent	JJ	O
weekly	JJ	O
cisplatin	NN	Pharmacological
or	CC	O
weekly	JJ	O
paclitaxel	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
cervical	JJ	O
cancer	NN	O
.	.	O

PURPOSE/OBJECTIVE	VB	O
This	DT	O
is	VBZ	O
a	DT	O
prospective	JJ	O
comparison	NN	O
of	IN	O
weekly	JJ	O
cisplatin	NN	Pharmacological
to	TO	O
weekly	VB	O
paclitaxel	NN	Pharmacological
as	IN	O
concurrent	JJ	O
chemotherapy	NN	O
with	IN	O
standard	JJ	Physical
radiotherapy	NN	Physical
for	IN	O
locally	RB	O
advanced	JJ	O
cervical	JJ	O
carcinoma	NN	O
.	.	O

MATERIALS/METHODS	NNP	O
Between	NNP	O
May	NNP	O
2000	CD	O
and	CC	O
May	NNP	O
2004	CD	O
,	,	O
31	CD	O
women	NNS	O
with	IN	O
FIGO	NNP	O
stage	NN	O
IB2-IVA	NNP	O
cervical	JJ	O
cancer	NN	O
or	CC	O
with	IN	O
postsurgical	JJ	O
pelvic	JJ	O
recurrence	NN	O
were	VBD	O
enrolled	VBN	O
into	IN	O
this	DT	O
phase	NN	O
II	NNP	O
study	NN	O
and	CC	O
randomized	VBN	O
to	TO	O
receive	VB	O
on	IN	O
a	DT	O
weekly	JJ	O
basis	NN	O
either	CC	O
40	CD	O
mg/m?	NN	O
Cisplatin	NNP	O
(	(	O
group	NN	O
I	PRP	O
;	:	O
16	CD	O
patients	NNS	O
)	)	O
or	CC	O
50	CD	O
mg/m?	NNS	O
paclitaxel	NN	O
(	(	O
group	NN	O
II	NNP	O
;	:	O
15	CD	O
patients	NNS	O
)	)	O
concurrently	RB	O
with	IN	O
radiotherapy	NN	O
.	.	O

Median	JJ	O
total	NN	O
dose	NN	O
to	TO	O
point	VB	O
A	NNP	O
was	VBD	O
74	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
66-92	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
66	CD	O
Gy	NNP	O
(	(	O
range	NN	O
:	:	O
40-98	JJ	O
Gy	NNP	O
)	)	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

Median	JJ	O
follow-up	JJ	O
time	NN	O
was	VBD	O
46	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patient	NNP	O
and	CC	O
tumor	NN	O
characteristics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
chemotherapy	NN	O
cycles	NNS	O
was	VBD	O
also	RB	O
comparable	JJ	O
with	IN	O
87	CD	O
%	NN	O
and	CC	O
80	CD	O
%	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
at	IN	O
least	JJS	O
4	CD	O
doses	NNS	O
in	IN	O
groups	NNS	O
I	PRP	O
and	CC	O
II	NNP	O
,	,	O
respectively	RB	O
.	.	O

Seven	JJ	O
patients	NNS	O
(	(	O
44	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
I	PRP	O
and	CC	O
8	CD	O
patients	NNS	O
(	(	O
53	CD	O
%	NN	O
)	)	O
of	IN	O
group	NN	O
II	NNP	O
developed	VBD	O
tumor	NN	O
recurrence	NN	O
.	.	O

The	DT	O
Median	JJ	O
Survival	NNP	O
time	NN	O
was	VBD	O
not	RB	O
reached	VBN	O
for	IN	O
Group	NNP	O
I	PRP	O
and	CC	O
53	CD	O
months	NNS	O
for	IN	O
group	NN	O
II	NNP	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
surviving	VBG	O
at	IN	O
2	CD	O
and	CC	O
5	CD	O
years	NNS	O
was	VBD	O
78	CD	O
%	NN	O
and	CC	O
54	CD	O
%	NN	O
for	IN	O
group	NN	O
I	PRP	O
and	CC	O
73	CD	O
%	NN	O
and	CC	O
43	CD	O
%	NN	O
for	IN	O
group	NN	O
II	NNP	O
respectively	RB	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
small	JJ	O
prospective	JJ	O
study	NN	O
shows	NNS	O
that	WDT	O
weekly	VBP	O
paclitaxel	NN	O
does	VBZ	O
not	RB	O
provide	VB	O
any	DT	O
clinical	JJ	O
advantage	NN	O
over	IN	O
weekly	JJ	O
cisplatin	NN	O
for	IN	O
concurrent	JJ	O
chemoradiation	NN	O
for	IN	O
advanced	JJ	O
carcinoma	NN	O
of	IN	O
the	DT	O
cervix	NN	O
.	.	O

Anxiety	NN	O
disorders	NNS	O
in	IN	O
typically	RB	O
developing	VBG	O
youth	NN	O
:	:	O
autism	NN	O
spectrum	NN	O
symptoms	NNS	O
as	IN	O
a	DT	O
predictor	NN	O
of	IN	O
cognitive-behavioral	JJ	Educational
treatment	NN	Educational
.	.	O

Symptoms	NNS	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
were	VBD	O
assessed	VBN	O
(	(	O
Social	NNP	O
Responsiveness	NNP	O
Scale-Parent	NNP	O
(	(	O
SRS-P	NNP	O
)	)	O
;	:	O
coded	VBN	O
in-session	NN	O
behavior	NN	O
)	)	O
in	IN	O
typically-developing	NN	O
,	,	O
anxiety-disordered	JJ	O
children	NNS	O
(	(	O
N	NNP	O
=	NNP	O
50	CD	O
)	)	O
treated	VBN	O
with	IN	O
cognitive-behavioral	JJ	O
therapy	NN	O
(	(	O
CBT	NNP	O
)	)	O
.	.	O

Study	$	O
1	CD	O
:	:	O
children	NNS	O
with	IN	O
moderate	JJ	O
autistic	JJ	O
symptomology	NN	O
(	(	O
per	IN	O
SRS-P	NNP	O
)	)	O
were	VBD	O
significantly	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
improve	VB	O
from	IN	O
family	NN	O
CBT	NNP	O
(	(	O
FCBT	NNP	O
)	)	O
than	IN	O
individual	JJ	O
CBT	NNP	O
(	(	O
ICBT	NNP	O
;	:	O
OR	NNP	O
=	VBZ	O
8.67	CD	O
)	)	O
.	.	O

Coded	VBN	O
behavior	NN	O
did	VBD	O
not	RB	O
predict	JJ	O
outcome	NN	O
.	.	O

Study	CC	O
2	CD	O
:	:	O
CBT	JJ	O
components	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
treatment	NN	O
and	CC	O
ASD	NNP	O
symptom	NN	O
status	NN	O
.	.	O

At-home	JJ	O
exposure	NN	O
completion	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
FCBT	NNP	O
and	CC	O
there	EX	O
was	VBD	O
an	DT	O
interaction	NN	O
in	IN	O
child	JJ	O
involvement	NN	O
for	IN	O
treatment	NN	O
and	CC	O
ASD	NNP	O
status	NN	O
.	.	O

Though	IN	O
both	DT	O
treatments	NNS	O
reduced	VBD	O
anxiety	NN	O
,	,	O
FCBT	NNP	O
outperformed	VBD	O
ICBT	NNP	O
for	IN	O
children	NNS	O
with	IN	O
moderate	JJ	O
ASD	NNP	O
symptoms	NNS	O
,	,	O
a	DT	O
benefit	NN	O
potentially	RB	O
linked	VBN	O
to	TO	O
more	RBR	O
at-home	JJ	O
exposures	NNS	O
and	CC	O
greater	JJR	O
child	NN	O
involvement	NN	O
in	IN	O
FCBT	NNP	O
.	.	O

Controlled	VBN	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
partial	JJ	Physical
ceramic	JJ	Physical
crowns	NNS	Physical
inserted	VBN	O
with	IN	O
RelyX	NNP	Physical
Unicem	NNP	Physical
with	IN	Physical
or	CC	Physical
without	IN	Physical
selective	JJ	Physical
enamel	NN	Physical
etching	VBG	Physical
.	.	O

1-year	JJ	O
results	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
performance	NN	O
of	IN	O
partial	JJ	Physical
ceramic	JJ	Physical
crowns	NNS	Physical
(	(	Physical
PCCs	NNP	Physical
)	)	Physical
inserted	VBD	Physical
with	IN	Physical
RelyX	NNP	Physical
Unicem	NNP	Physical
(	(	Physical
RXU	NNP	Physical
)	)	Physical
either	CC	O
with	IN	Physical
(	(	Physical
RXU+E	NNP	Physical
)	)	Physical
or	CC	Physical
without	IN	Physical
(	(	Physical
RXU	NNP	Physical
)	)	Physical
selective	VBP	Physical
enamel	JJ	Physical
etching	NN	Physical
.	.	O

METHODS	NNP	O
34	CD	O
patients	NNS	O
(	(	O
15	CD	O
male	NN	O
,	,	O
19	CD	O
female	NN	O
)	)	O
participated	VBD	O
in	IN	O
the	DT	O
investigation	NN	O
,	,	O
with	IN	O
a	DT	O
total	NN	O
of	IN	O
68	CD	O
PCC	NNP	O
restorations	NNS	O
.	.	O

In	IN	O
each	DT	O
patient	NN	O
,	,	O
one	CD	O
PCC	NNP	Physical
was	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
insertion	NN	O
with	IN	O
RXU	NNP	Physical
,	,	O
the	DT	O
second	JJ	O
PCC	NNP	Physical
was	VBD	O
assigned	VBN	O
to	TO	O
insertion	NN	O
with	IN	O
RXU+E	NNP	Physical
.	.	O

The	DT	O
PCCs	NNPS	O
were	VBD	O
CAD/CAM	NNP	O
fabricated	VBD	O
using	VBG	O
the	DT	O
Cerec	NNP	Physical
3	CD	Physical
system	NN	Physical
.	.	O

RXU	NN	Physical
:	:	O
25	CD	O
PCCs	NNP	O
were	VBD	O
placed	VBN	O
in	IN	O
molars	NNS	O
,	,	O
nine	CD	O
in	IN	O
premolars	NNS	O
.	.	O

RXU+E	NN	Physical
:	:	O
26	CD	O
PCCs	NNP	O
were	VBD	O
placed	VBN	O
in	IN	O
molars	NNS	O
,	,	O
eight	CD	O
in	IN	O
premolars	NNS	O
.	.	O

The	DT	O
restorations	NNS	O
were	VBD	O
clinically	RB	O
rated	VBN	O
using	VBG	O
modified	VBN	O
United	NNP	O
States	NNPS	O
Public	NNP	O
Health	NNP	O
Service	NNP	O
(	(	O
USPHS	NNP	O
)	)	O
criteria	NNS	O
at	IN	O
baseline	NN	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
placement	NN	O
.	.	O

The	DT	O
median	JJ	O
patient	NN	O
age	NN	O
was	VBD	O
41	CD	O
years	NNS	O
(	(	O
24-59	CD	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
(	(	O
25-75	CD	O
%	NN	O
)	)	O
PBI	NNP	O
was	VBD	O
6	CD	O
%	NN	O
(	(	O
3-9	CD	O
%	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
All	DT	O
patients	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
the	DT	O
three	CD	O
recall	NN	O
appointments	NNS	O
.	.	O

One	CD	O
PCC	NNP	O
(	(	O
RXU	NNP	Physical
)	)	O
debonded	VBD	O
after	IN	O
11	CD	O
months	NNS	O
in	IN	O
situ	NN	O
,	,	O
one	CD	O
PCC	NNP	O
(	(	O
RXU+E	NNP	Physical
)	)	O
fractured	VBD	O
after	IN	O
12	CD	O
months	NNS	O
in	IN	O
situ	NN	O
.	.	O

Both	DT	O
restorations	NNS	O
had	VBD	O
to	TO	O
be	VB	O
replaced	VBN	O
.	.	O

At	IN	O
the	DT	O
12	CD	O
months	NNS	O
recall	RB	O
,	,	O
66	CD	O
of	IN	O
68	CD	O
controlled	JJ	O
restorations	NNS	O
were	VBD	O
functional	JJ	O
without	IN	O
need	NN	O
of	IN	O
replacement	NN	O
.	.	O

The	DT	O
evaluation	NN	O
using	VBG	O
USHPS	NNP	O
criteria	NNS	O
revealed	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
of	IN	O
alfa	JJ	O
ratings	NNS	O
over	IN	O
time	NN	O
with	IN	O
respect	NN	O
to	TO	O
criteria	VB	O
marginal	JJ	O
adaptation	NN	O
and	CC	O
marginal	JJ	O
discoloration	NN	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
luting	VBG	O
techniques	NNS	O
,	,	O
RXU	NNP	Physical
and	CC	O
RXU+E	NNP	Physical
,	,	O
we	PRP	O
reobserved	VBD	O
during	IN	O
the	DT	O
observation	NN	O
period	NN	O
of	IN	O
1	CD	O
year	NN	O
.	.	O

Within	IN	O
the	DT	O
limitations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
,	,	O
adhesive	JJ	O
luting	NN	O
with	IN	O
RXU	NNP	Physical
with	IN	O
or	CC	O
without	IN	O
selective	JJ	O
enamel	NN	O
etching	NN	O
can	MD	O
be	VB	O
recommended	VBN	O
.	.	O

Pre-medication	NN	O
with	IN	O
pronase	NN	Pharmacological
reduces	NNS	O
artefacts	VBZ	O
during	IN	O
endoscopic	NN	O
ultrasonography	NN	Physical
.	.	O

BACKGROUND	NNP	O
Gastric	NNP	O
mucus	NN	O
usually	RB	O
induces	VBZ	O
artefacts	NNS	O
during	IN	O
endoscopic	JJ	O
ultrasonography	NN	O
.	.	O

AIM	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
pre-medication	NN	O
with	IN	O
the	DT	O
proteolytic	JJ	Pharmacological
enzyme	NN	Pharmacological
,	,	O
pronase	NN	Pharmacological
,	,	O
before	IN	O
endoscopic	JJ	Physical
ultrasonography	NN	Physical
.	.	O

METHODS	NNP	O
Out-patients	NNS	O
scheduled	VBN	O
for	IN	O
endoscopic	NN	O
ultrasonography	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
oral	JJ	O
pre-medication	NN	O
with	IN	O
the	DT	O
anti-foam	JJ	Pharmacological
agent	NN	Pharmacological
,	,	O
dimethylpolysiloxane	NN	Pharmacological
,	,	Pharmacological
alone	RB	Pharmacological
(	(	O
treatment	NN	O
A	NNP	O
;	:	O
n	JJ	O
=	NNP	O
29	CD	O
)	)	O
,	,	O
with	IN	O
dimethylpolysiloxane	JJ	Pharmacological
plus	CC	Pharmacological
sodium	JJ	Pharmacological
bicarbonate	NN	Pharmacological
(	(	O
treatment	NN	O
B	NNP	O
;	:	O
n	CC	O
=	VB	O
29	CD	O
)	)	O
or	CC	O
with	IN	O
dimethylpolysiloxane	NN	O
,	,	O
sodium	NN	O
bicarbonate	NN	O
and	CC	O
pronase	NN	O
(	(	O
treatment	NN	O
C	NNP	O
;	:	O
n	CC	O
=	VB	O
29	CD	O
)	)	O
.	.	O

All	DT	O
drinks	NNS	O
were	VBD	O
given	VBN	O
about	IN	O
10	CD	O
min	NN	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
procedure	NN	O
.	.	O

After	IN	O
insertion	NN	O
of	IN	O
the	DT	O
endoscope	NN	O
,	,	O
endoscopists	VBZ	O
recorded	JJ	O
visibility	NN	O
scores	NNS	O
before	IN	O
the	DT	O
procedure	NN	O
,	,	O
imaging	VBG	O
scores	NNS	O
at	IN	O
endoscopic	NN	O
ultrasonography	NN	O
and	CC	O
the	DT	O
numbers	NNS	O
of	IN	O
high-echo	JJ	O
spots	NNS	O
in	IN	O
the	DT	O
gastric	JJ	O
cavity	NN	O
and	CC	O
on	IN	O
the	DT	O
gastric	NN	O
wall	NN	O
surface	NN	O
after	IN	O
the	DT	O
procedure	NN	O
.	.	O

RESULTS	VB	O
Pre-medication	JJ	O
with	IN	O
pronase	NN	Pharmacological
(	(	O
treatment	NN	O
C	NNP	O
)	)	O
significantly	RB	O
reduced	VBN	O
(	(	O
both	DT	O
at	IN	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
the	DT	O
visibility	NN	O
score	NN	O
(	(	O
score	RB	O
4	CD	O
,	,	O
46	CD	O
%	NN	O
)	)	O
in	IN	O
comparison	NN	O
with	IN	O
that	DT	O
obtained	VBN	O
for	IN	O
pre-medication	NN	O
without	IN	O
pronase	NN	Pharmacological
(	(	O
10	CD	O
%	NN	O
for	IN	O
both	DT	O
treatments	NNS	O
A	DT	O
and	CC	O
B	NNP	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
pronase	NN	Pharmacological
significantly	RB	O
reduced	VBN	O
(	(	O
both	DT	O
at	IN	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
the	DT	O
endoscopic	NN	O
ultrasonography	NN	O
score	NN	O
in	IN	O
the	DT	O
gastric	JJ	O
cavity	NN	O
(	(	O
score	RB	O
4	CD	O
,	,	O
34	CD	O
%	NN	O
)	)	O
in	IN	O
comparison	NN	O
with	IN	O
that	DT	O
found	NN	O
for	IN	O
treatments	NNS	O
A	NNP	O
(	(	O
7	CD	O
%	NN	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
0	CD	O
%	NN	O
)	)	O
.	.	O

It	PRP	O
also	RB	O
significantly	RB	O
reduced	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
the	DT	O
endoscopic	NN	O
ultrasonography	NN	O
score	NN	O
on	IN	O
the	DT	O
gastric	NN	O
wall	NN	O
surface	NN	O
(	(	O
score	RB	O
4	CD	O
,	,	O
14	CD	O
%	NN	O
)	)	O
in	IN	O
comparison	NN	O
with	IN	O
that	DT	O
observed	VBD	O
for	IN	O
treatment	NN	O
A	NNP	O
(	(	O
3	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
numbers	NNS	O
of	IN	O
high-echo	JJ	O
spots	NNS	O
in	IN	O
the	DT	O
gastric	JJ	O
cavity	NN	O
and	CC	O
on	IN	O
the	DT	O
gastric	NN	O
wall	NN	O
surface	NN	O
were	VBD	O
significantly	RB	O
less	JJR	O
(	(	O
both	DT	O
at	IN	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
for	IN	O
pre-medication	NN	O
with	IN	O
pronase	NN	Pharmacological
(	(	O
treatment	NN	O
C	NNP	O
)	)	O
than	IN	O
for	IN	O
pre-medication	NN	O
with	IN	O
treatments	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
complications	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
solutions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Pre-treatment	JJ	O
with	IN	O
pronase	NN	Pharmacological
reduced	VBD	O
the	DT	O
artefacts	NNS	O
during	IN	O
endoscopic	JJ	O
ultrasonography	NN	O
.	.	O

Acute	NNP	O
reduction	NN	O
of	IN	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
reduces	VBZ	O
urinary	JJ	O
albumin	NN	O
excretion	NN	O
in	IN	O
type	NN	O
1	CD	O
(	(	O
insulin-dependent	NN	O
)	)	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
incipient	JJ	O
nephropathy	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
an	DT	O
acute	JJ	O
reduction	NN	O
in	IN	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
upon	IN	O
kidney	NN	O
function	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
Type	NNP	O
1	CD	O
(	(	O
insulin-dependent	NN	O
)	)	O
diabetes	VBZ	O
and	CC	O
incipient	JJ	O
nephropathy	NN	O
(	(	O
persistent	JJ	O
microalbuminuria	NN	O
)	)	O
.	.	O

Renal	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
measurement	NN	O
of	IN	O
the	DT	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
single	JJ	O
bolus	IN	O
51Cr-EDTA	JJ	O
technique	NN	O
)	)	O
and	CC	O
by	IN	O
the	DT	O
urinary	JJ	O
albumin	JJ	O
excretion	NN	O
rate	NN	O
(	(	O
radioimmunoassay	NN	O
)	)	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
twice	RB	O
within	IN	O
2	CD	O
weeks	NNS	O
,	,	O
with	IN	O
the	DT	O
patients	NNS	O
receiving	VBG	O
a	DT	O
slow	JJ	O
intravenous	JJ	O
injection	NN	O
of	IN	O
either	DT	O
clonidine	NN	Pharmacological
(	(	O
225	CD	O
micrograms	NNS	O
)	)	O
or	CC	O
saline	NN	Pharmacological
(	(	O
154	CD	O
mmol/l	NN	O
)	)	O
in	IN	O
random	NN	O
order	NN	O
.	.	O

Clonidine	NNP	Pharmacological
reduced	VBD	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
from	IN	O
125/79	CD	O
+/-	JJ	O
13/8	CD	O
to	TO	O
104/68	CD	O
+/-	JJ	O
9/7	CD	O
mmHg	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
,	,	O
urinary	JJ	O
albumin	JJ	O
excretion	NN	O
rate	NN	O
from	IN	O
68	CD	O
(	(	O
31-369	JJ	O
)	)	O
to	TO	O
46	CD	O
(	(	O
6-200	CD	O
)	)	O
micrograms/min	NN	O
(	(	O
median	JJ	O
and	CC	O
range	NN	O
)	)	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
fractional	JJ	O
clearance	NN	O
of	IN	O
albumin	NN	O
in	IN	O
all	DT	O
patients	NNS	O
(	(	O
median	JJ	O
29	CD	O
%	NN	O
)	)	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Glomerular	JJ	O
filtration	NN	O
rate	NN	O
was	VBD	O
110	CD	O
+/-	JJ	O
11	CD	O
before	IN	O
and	CC	O
106	CD	O
+/-	JJ	O
13	CD	O
ml/min/1.73	NN	O
m2	NN	O
after	IN	O
clonidine	JJ	Pharmacological
injection	NN	O
.	.	O

The	DT	O
blood	NN	O
glucose	JJ	O
concentration	NN	O
was	VBD	O
15	CD	O
+/-	JJ	O
4	CD	O
mmol/l	NN	O
before	IN	O
and	CC	O
14	CD	O
+/-	JJ	O
5	CD	O
mmol/l	NN	O
after	IN	O
clonidine	JJ	Pharmacological
injection	NN	O
.	.	O

In	IN	O
agreement	NN	O
with	IN	O
findings	NNS	O
in	IN	O
animal	JJ	O
studies	NNS	O
,	,	O
our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
microalbuminuria	NN	O
is	VBZ	O
to	TO	O
a	DT	O
large	JJ	O
extent	NN	O
pressure-dependent	NN	O
,	,	O
probably	RB	O
because	IN	O
of	IN	O
glomerular	JJ	O
hypertension	NN	O
,	,	O
and	CC	O
that	DT	O
autoregulation	NN	O
of	IN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
is	VBZ	O
normal	JJ	O
in	IN	O
most	JJS	O
patients	NNS	O
with	IN	O
incipient	JJ	O
diabetic	JJ	O
nephropathy	NN	O
.	.	O

Milk	NNP	O
production	NN	O
of	IN	O
dairy	NN	O
cows	NNS	O
fed	VBP	O
wet	JJ	O
corn	NN	O
gluten	NNS	O
feed	VBP	O
during	IN	O
the	DT	O
dry	JJ	O
period	NN	O
and	CC	O
lactation	NN	O
.	.	O

An	DT	O
experiment	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
36	CD	O
primiparous	JJ	O
and	CC	O
40	CD	O
multiparous	JJ	O
Holstein	NNP	O
cows	NNS	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
feeding	VBG	O
wet	JJ	Other
corn	NN	Other
gluten	NNS	Other
feed	VBP	Other
(	(	Other
WCGF	NNP	Other
)	)	Other
on	IN	O
305-d	JJ	O
milk	NN	O
production	NN	O
,	,	O
dry	JJ	O
matter	NN	O
(	(	O
DM	NNP	O
)	)	O
intake	NN	O
,	,	O
body	NN	O
condition	NN	O
score	NN	O
(	(	O
BCS	NNP	O
)	)	O
,	,	O
and	CC	O
health	NN	O
.	.	O

The	DT	O
experimental	JJ	O
treatments	NNS	O
included	VBD	O
:	:	O
1	CD	O
)	)	O
control	NN	Physical
--	:	Physical
WCGF	NNP	Physical
not	RB	Physical
fed	RB	Physical
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
;	:	O
2	CD	O
)	)	O
WCGF-L-cows	NNP	O
received	VBD	O
diets	NNS	Other
containing	VBG	Other
WCGF	NNP	Other
(	(	O
38	CD	O
%	NN	O
DM	NNP	O
basis	NN	O
)	)	O
during	IN	O
lactation	NN	O
(	(	O
n	JJ	O
=	NNP	O
23	CD	O
)	)	O
;	:	O
and	CC	O
3	CD	O
)	)	O
WCGF-DL	NNP	O
--	:	O
cows	VBZ	O
received	VBN	O
diets	NNS	Other
containing	VBG	Other
WCGF	NNP	Other
(	(	O
38	CD	O
%	NN	O
DM	NNP	O
basis	NN	O
)	)	O
during	IN	O
the	DT	O
dry	JJ	O
period	NN	O
and	CC	O
lactation	NN	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
.	.	O

During	IN	O
the	DT	O
dry	JJ	O
period	NN	O
,	,	O
cows	VBZ	O
consuming	VBG	O
WCGF	NNP	O
were	VBD	O
observed	VBN	O
to	TO	O
have	VB	O
a	DT	O
significant	JJ	O
gain	NN	O
in	IN	O
BCS	NNP	O
(	(	O
0.07	CD	O
+/-	JJ	O
0.06	CD	O
)	)	O
compared	VBN	O
with	IN	O
a	DT	O
loss	NN	O
in	IN	O
BCS	NNP	O
in	IN	O
cows	NNS	O
fed	VBP	O
the	DT	O
control	NN	O
diet	JJ	O
(	(	O
control	VB	O
=	NNP	O
-0.11	NNP	O
+/-	JJ	O
0.06	CD	O
and	CC	O
WCGF-L	NNP	O
=	NNP	O
-0.04	NNP	O
+/-	JJ	O
0.06	CD	O
)	)	O
.	.	O

During	IN	O
lactation	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
by	IN	O
treatment	NN	O
on	IN	O
BCS	NNP	O
.	.	O

Cows	NNP	O
consuming	VBG	O
WCGF	NNP	O
during	IN	O
lactation	NN	O
consumed	VBN	O
more	RBR	O
feed	JJ	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
:	:	O
25.4	CD	O
,	,	O
23.8	CD	O
,	,	O
and	CC	O
21.2	CD	O
+/-	JJ	O
0.76	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

Milk	NNP	O
production	NN	O
was	VBD	O
higher	JJR	O
for	IN	O
cows	NNS	O
consuming	VBG	O
WCGF	NNP	O
:	:	O
35.0	CD	O
,	,	O
34.7	CD	O
,	,	O
and	CC	O
31.1	CD	O
+/-	JJ	O
2.1	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

No	UH	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
either	DT	O
DM	NNP	O
intake	NN	O
or	CC	O
actual	JJ	O
milk	NN	O
yield	NN	O
between	IN	O
the	DT	O
WCGF-L	NNP	O
and	CC	O
WCGF-DL	NNP	O
treatments	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
prepartum	JJ	O
diets	NNS	O
did	VBD	O
not	RB	O
influence	VB	O
lactational	JJ	O
performance	NN	O
.	.	O

The	DT	O
WCGF	NNP	O
diets	NNS	O
resulted	VBD	O
in	IN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
concentration	NN	O
of	IN	O
milk	NN	O
fat	NN	O
(	(	O
3.94	CD	O
,	,	O
3.74	CD	O
,	,	O
and	CC	O
4.15	CD	O
+/-	JJ	O
0.08	CD	O
%	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
but	CC	O
because	IN	O
total	JJ	O
milk	NN	O
yield	NN	O
was	VBD	O
increased	VBN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
total	JJ	O
milk	NN	O
fat	JJ	O
yield	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
3.5	CD	O
%	NN	O
of	IN	O
fat-corrected	JJ	O
milk	NN	O
tended	VBN	O
to	TO	O
be	VB	O
affected	VBN	O
by	IN	O
diet	JJ	O
:	:	O
38.9	CD	O
,	,	O
36.3	CD	O
,	,	O
and	CC	O
34.7	CD	O
+/-	JJ	O
1.93	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
increasing	VBG	O
effect	NN	O
of	IN	O
DM	NNP	O
intake	NN	O
and	CC	O
milk	NN	O
yield	NN	O
in	IN	O
cows	NNS	O
consuming	VBG	O
WCGF	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
similar	JJ	O
efficiency	NN	O
of	IN	O
3.5	CD	O
%	NN	O
fat-corrected	JJ	O
milk	NN	O
production	NN	O
for	IN	O
all	DT	O
treatments	NNS	O
,	,	O
averaging	VBG	O
1.5	CD	O
+/-	JJ	O
0.09	CD	O
.	.	O

Total	JJ	O
protein	JJ	O
yields	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
for	IN	O
cows	NNS	O
consuming	VBG	O
WCGF	NNP	O
diets	NNS	O
during	IN	O
lactation	NN	O
:	:	O
1.15	CD	O
,	,	O
1.10	CD	O
,	,	O
1.00	CD	O
+/-	JJ	O
0.06	CD	O
kg/d	NN	O
for	IN	O
WCGF-L	NNP	O
,	,	O
WCGF-DL	NNP	O
,	,	O
and	CC	O
the	DT	O
control	NN	O
,	,	O
respectively	RB	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
diets	NNS	O
may	MD	O
be	VB	O
formulated	VBN	O
to	TO	O
contain	VB	O
as	RB	O
much	JJ	O
as	IN	O
37.5	CD	O
%	NN	O
WCGF	NNP	O
(	(	O
DM	NNP	O
basis	NN	O
)	)	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	Pharmacological
conivaptan	NN	Pharmacological
:	:	O
a	DT	O
V1A/V2	NNP	Pharmacological
vasopressin	NN	Pharmacological
receptor	NN	Pharmacological
antagonist	NN	Pharmacological
,	,	O
assessed	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
euvolemic	JJ	O
or	CC	O
hypervolemic	JJ	O
hyponatremia	NN	O
.	.	O

CONTEXT	NNP	O
Hyponatremia	NNP	O
[	NNP	O
serum	NN	O
sodium	NN	O
concentration	NN	O
(	(	O
[	JJ	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	NN	O
)	)	O
,	,	O
<	$	O
135	CD	O
mEq/liter	NN	O
]	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
common	JJ	O
fluid	NN	O
and	CC	O
electrolyte	JJ	O
abnormality	NN	O
among	IN	O
hospitalized	JJ	O
patients	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
frequently	RB	O
caused	VBN	O
by	IN	O
the	DT	O
inappropriate	JJ	O
release	NN	O
of	IN	O
arginine	JJ	O
vasopressin	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
oral	JJ	O
conivaptan	NN	Pharmacological
,	,	O
a	DT	O
vasopressin	NN	Pharmacological
V	NNP	Pharmacological
(	(	Pharmacological
1A	CD	Pharmacological
)	)	Pharmacological
/V	NN	Pharmacological
(	(	Pharmacological
2	CD	Pharmacological
)	)	Pharmacological
receptor	NN	Pharmacological
antagonist	NN	Pharmacological
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
euvolemic	JJ	O
or	CC	O
hypervolemic	JJ	O
hyponatremia	NN	O
.	.	O

DESIGN	VB	O
The	DT	O
study	NN	O
design	NN	O
was	VBD	O
a	DT	O
5-d	JJ	O
placebo-controlled	JJ	Control
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

SETTING	CC	O
The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
a	DT	O
hospital	NN	O
.	.	O

INTERVENTION	NNP	O
Oral	NNP	Pharmacological
conivaptan	NN	Pharmacological
(	(	O
40	CD	O
or	CC	O
80	CD	O
mg/d	NN	O
)	)	O
or	CC	O
placebo	NN	Control
was	VBD	O
given	VBN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
.	.	O

PATIENTS	VB	O
Seventy-four	JJ	O
patients	NNS	O
(	(	O
average	JJ	O
baseline	NN	O
serum	NN	O
[	NNP	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	NN	O
,	,	O
115	CD	O
to	TO	O
<	VB	O
130	CD	O
mEq/liter	NN	O
)	)	O
were	VBD	O
studied	VBN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
serum	NN	O
[	NN	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	VBP	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
least-squares	JJ	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
the	DT	O
serum	NN	O
[	NNP	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	VBP	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
with	IN	O
conivaptan	NN	Pharmacological
(	(	O
40	CD	O
and	CC	O
80	CD	O
mg/d	NN	O
)	)	O
was	VBD	O
2.0-fold	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
2.5-fold	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
greater	JJR	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
that	DT	O
with	IN	O
placebo	NN	Control
.	.	O

The	DT	O
median	JJ	O
time	NN	O
to	TO	O
achieve	VB	O
a	DT	O
confirmed	JJ	O
increase	NN	O
in	IN	O
serum	JJ	O
[	NNP	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	NN	O
of	IN	O
4	CD	O
mEq/liter	NN	O
or	CC	O
more	JJR	O
from	IN	O
baseline	NN	O
was	VBD	O
71.7	CD	O
h	NN	O
for	IN	O
placebo	NN	Control
,	,	O
27.5	CD	O
h	NN	O
for	IN	O
40	CD	O
mg/d	NNS	O
conivaptan	NN	Pharmacological
(	(	O
P	NNP	O
=	NNP	O
0.044	CD	O
)	)	O
,	,	O
and	CC	O
12.1	CD	O
h	NN	O
for	IN	O
80	CD	O
mg/d	NNS	O
conivaptan	NN	Pharmacological
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
total	JJ	O
times	NNS	O
during	IN	O
which	WDT	O
patients	NNS	O
had	VBD	O
a	DT	O
serum	NN	O
[	NN	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	VBP	O
level	NN	O
of	IN	O
4	CD	O
mEq/liter	NN	O
or	CC	O
more	JJR	O
above	IN	O
baseline	NN	O
were	VBD	O
46.5	CD	O
,	,	O
69.8	CD	O
,	,	O
and	CC	O
88.8	CD	O
h	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
least-squares	JJ	O
mean	NN	O
change	NN	O
in	IN	O
serum	NN	O
[	NN	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	VBP	O
from	IN	O
baseline	NN	O
to	TO	O
end	VB	O
of	IN	O
treatment	NN	O
was	VBD	O
3.4	CD	O
mEq/liter	NN	O
for	IN	O
placebo	NN	Control
,	,	O
6.4	CD	O
mEq/liter	NN	O
for	IN	O
40	CD	O
mg/d	NN	O
conivaptan	NN	Pharmacological
,	,	O
and	CC	O
8.2	CD	O
mEq/liter	NN	O
for	IN	O
80	CD	O
mg/d	NNS	O
conivaptan	NN	Pharmacological
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

A	DT	O
confirmed	JJ	O
normal	JJ	O
serum	NN	O
[	NNP	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	NN	O
(	(	O
>	JJ	O
/=135	NNP	O
mEq/liter	NN	O
)	)	O
or	CC	O
increase	NN	O
of	IN	O
6	CD	O
mEq/liter	NN	O
or	CC	O
more	JJR	O
was	VBD	O
observed	VBN	O
in	IN	O
48	CD	O
%	NN	O
of	IN	O
patients	NNS	O
given	VBN	O
placebo	NNS	Control
,	,	O
71	CD	O
%	NN	O
given	VBN	O
40	CD	O
mg/d	JJ	O
conivaptan	NN	Pharmacological
,	,	O
and	CC	O
82	CD	O
%	NN	O
given	VBN	O
80	CD	O
mg/d	JJ	O
conivaptan	NN	Pharmacological
(	(	O
P	NNP	O
=	NNP	O
0.014	CD	O
)	)	O
.	.	O

Headache	NNP	O
,	,	O
hypotension	NN	O
,	,	O
nausea	NN	O
,	,	O
constipation	NN	O
,	,	O
and	CC	O
postural	JJ	O
hypotension	NN	O
were	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

CONCLUSION	NNP	O
Oral	NNP	O
conivaptan	NN	Pharmacological
(	(	O
40	CD	O
and	CC	O
80	CD	O
mg/d	NN	O
)	)	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
efficacious	JJ	O
in	IN	O
correcting	VBG	O
serum	NN	O
[	NNP	O
Na	NNP	O
(	(	O
+	NNP	O
)	)	O
]	NN	O
in	IN	O
hyponatremia	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
knee	NN	Physical
position	NN	Physical
on	IN	O
blood	NN	O
loss	NN	O
and	CC	O
range	NN	O
of	IN	O
motion	NN	O
following	VBG	O
total	JJ	O
knee	JJ	O
arthroplasty	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
prospectively	RB	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
knee	JJ	Physical
position	NN	Physical
on	IN	O
blood	NN	O
loss	NN	O
and	CC	O
range	NN	O
of	IN	O
motion	NN	O
after	IN	O
primary	JJ	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
(	(	O
TKA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
ten	VB	O
consecutive	JJ	O
TKA	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
flexion	NN	O
group	NN	O
and	CC	O
extension	NN	O
group	NN	O
.	.	O

Both	DT	O
groups	NNS	O
had	VBD	O
the	DT	O
leg	NN	O
elevated	VBD	O
30?	CD	O
at	IN	O
the	DT	O
hip	NN	O
over	IN	O
an	DT	O
inactive	JJ	O
CPM	NNP	O
for	IN	O
72	CD	O
h	NN	O
postoperatively	RB	O
.	.	O

The	DT	O
flexion	NN	O
group	NN	O
had	VBD	O
the	DT	O
knee	NN	O
flexed	VBD	O
to	TO	O
30?	CD	O
during	IN	O
this	DT	O
period	NN	O
.	.	O

The	DT	O
extension	NN	O
group	NN	O
had	VBD	O
the	DT	O
knee	NN	O
extended	VBD	O
fully	RB	O
.	.	O

Perioperative	JJ	O
blood	NN	O
loss	NN	O
,	,	O
hidden	JJ	O
blood	NN	O
loss	NN	O
,	,	O
knee	NN	O
swelling	NN	O
,	,	O
ecchymosis	NN	O
,	,	O
analgesia	NN	O
requirements	NNS	O
,	,	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
,	,	O
fixed	VBN	O
flexion	NN	O
deformity	NN	O
(	(	O
FFD	NNP	O
)	)	O
,	,	O
straight-leg	JJ	O
raising	VBG	O
action	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
complications	NNS	O
within	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
surgery	NN	O
were	VBD	O
measured	VBN	O
for	IN	O
evaluation	NN	O
and	CC	O
comparison	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
postoperative	JJ	O
hidden	JJ	O
blood	NN	O
loss	NN	O
,	,	O
knee	NN	O
swelling	NN	O
,	,	O
and	CC	O
scope	NN	O
of	IN	O
ecchymosis	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
flexion	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
extension	NN	O
group	NN	O
,	,	O
and	CC	O
ROM	NNP	O
and	CC	O
straight-leg	JJ	O
raising	VBG	O
action	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
during	IN	O
the	DT	O
early	JJ	O
period	NN	O
after	IN	O
operation	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
perioperative	JJ	O
blood	NN	O
loss	NN	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
morphine	NN	O
used	VBN	O
,	,	O
or	CC	O
FFD	NNP	O
in	IN	O
the	DT	O
early	JJ	O
postoperative	JJ	O
period	NN	O
or	CC	O
in	IN	O
ROM	NNP	O
and	CC	O
FFD	NNP	O
at	IN	O
6	CD	O
weeks	NNS	O
postoperatively	RB	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
findings	NNS	O
of	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
flexion	NN	O
of	IN	O
the	DT	O
knee	NN	O
to	TO	O
30?	CD	O
with	IN	O
the	DT	O
leg	NN	O
elevated	VBD	O
30?	CD	O
at	IN	O
the	DT	O
hip	NN	O
after	IN	O
total	JJ	O
knee	NN	O
arthroplasty	NN	O
may	MD	O
mitigate	VB	O
knee	NN	O
swelling	VBG	O
and	CC	O
provide	VB	O
other	JJ	O
beneficial	JJ	O
results	NNS	O
during	IN	O
the	DT	O
early	JJ	O
rehabilitation	NN	O
following	VBG	O
TKA	NNP	O
.	.	O

LEVEL	NNP	O
OF	IN	O
EVIDENCE	NNP	O
Prospective	NNP	O
comparative	NN	O
study	NN	O
,	,	O
Level	NNP	O
I	PRP	O
.	.	O

A	DT	O
home	NN	Educational
visiting	NN	Educational
asthma	JJ	Educational
education	NN	Educational
program	NN	Educational
:	:	O
challenges	NNS	O
to	TO	O
program	NN	O
implementation	NN	O
.	.	O

This	DT	O
study	NN	O
describes	VBZ	O
the	DT	O
implementation	NN	O
of	IN	O
a	DT	O
nurse	JJ	Educational
home	NN	Educational
visiting	NN	Educational
asthma	JJ	Educational
education	NN	Educational
program	NN	Educational
for	IN	O
low-income	JJ	O
African	JJ	O
American	JJ	O
families	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
asthma	NN	O
.	.	O

Of	IN	O
55	CD	O
families	NNS	O
,	,	O
71	CD	O
%	NN	O
completed	VBD	O
the	DT	O
program	NN	O
consisting	NN	O
of	IN	O
eight	CD	O
lessons	NNS	O
.	.	O

The	DT	O
achievement	NN	O
of	IN	O
learning	VBG	O
objectives	NNS	O
was	VBD	O
predicted	VBN	O
by	IN	O
caregiver	NN	O
factors	NNS	O
,	,	O
such	JJ	O
as	IN	O
education	NN	O
,	,	O
presence	NN	O
of	IN	O
father	NN	O
or	CC	O
surrogate	VB	O
father	NN	O
in	IN	O
the	DT	O
household	NN	O
,	,	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
neighborhood	NN	O
,	,	O
but	CC	O
not	RB	O
by	IN	O
child	JJ	O
factors	NNS	O
,	,	O
such	JJ	O
as	IN	O
age	NN	O
or	CC	O
severity	NN	O
of	IN	O
asthma	NN	O
as	IN	O
implied	VBN	O
by	IN	O
the	DT	O
prescribed	JJ	O
asthma	JJ	O
medication	NN	O
regimen	NNS	O
.	.	O

Incompatibility	NN	O
between	IN	O
the	DT	O
scheduling	VBG	O
needs	NNS	O
of	IN	O
the	DT	O
families	NNS	O
and	CC	O
the	DT	O
nurse	JJ	O
home	NN	O
visitors	NNS	O
was	VBD	O
a	DT	O
major	JJ	O
obstacle	NN	O
in	IN	O
delivering	VBG	O
the	DT	O
program	NN	O
on	IN	O
time	NN	O
,	,	O
despite	IN	O
the	DT	O
flexibility	NN	O
of	IN	O
the	DT	O
nurse	JJ	O
home	NN	O
visitors	NNS	O
.	.	O

The	DT	O
authors	NNS	O
suggest	VBP	O
that	IN	O
future	JJ	O
home-based	JJ	Educational
asthma	NN	Educational
education	NN	Educational
programs	NNS	Educational
contain	VBP	O
a	DT	O
more	RBR	O
limited	JJ	O
number	NN	O
of	IN	O
home	NN	O
visits	NNS	O
but	CC	O
add	VBP	O
telephone	NN	O
follow-ups	NNS	O
and	CC	O
address	VB	O
the	DT	O
broader	JJR	O
needs	NNS	O
of	IN	O
low-income	JJ	O
families	NNS	O
that	IN	O
most	JJS	O
likely	JJ	O
function	NN	O
as	IN	O
barriers	NNS	O
to	TO	O
program	NN	O
success	NN	O
.	.	O

Effect	NN	O
of	IN	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
,	,	O
cardiopulmonary	JJ	Surgical
bypass	NN	Surgical
and	CC	O
myocardial	JJ	Surgical
ischaemic/reperfusion	NN	Surgical
on	IN	O
free	JJ	O
radical	JJ	O
generation	NN	O
in	IN	O
CABG	NNP	O
patients	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
free	JJ	O
radicals	NNS	O
(	(	O
FR	NNP	O
)	)	O
generation	NN	O
after	IN	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
and	CC	O
cardiopulmonary	JJ	Surgical
bypass	NN	Surgical
and	CC	O
during	IN	O
reperfusion	NN	O
in	IN	O
CABG	NNP	O
patients	NNS	O
,	,	O
and	CC	O
the	DT	O
role	NN	O
of	IN	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
.	.	Surgical

METHODS	NNP	O
Forty-three	JJ	O
CABG	NNP	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
into	IN	O
an	DT	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
and	CC	O
a	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
protocol	NN	O
for	IN	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
was	VBD	O
two	CD	O
cycles	NNS	O
of	IN	O
2-min	JJ	O
ischaemia	NN	Physical
followed	VBN	O
by	IN	O
3-min	JJ	O
reperfusion	NN	Physical
.	.	O

Free	JJ	O
radicals	NNS	O
were	VBD	O
measured	VBN	O
using	VBG	O
electron	NN	O
spin	NN	O
resonance	NN	O
spectroscopy	NN	O
.	.	O

Global	NNP	O
and	CC	O
right	JJ	O
heart	NN	O
functions	NNS	O
were	VBD	O
collected	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
free	JJ	O
radicals	NNS	O
generation	NN	O
in	IN	O
coronary	JJ	O
sinus	NN	O
blood	NN	O
in	IN	O
the	DT	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
group	NN	O
was	VBD	O
9.7	CD	O
and	CC	O
16.6	CD	O
%	NN	O
after	IN	O
the	DT	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
protocol	NN	O
and	CC	O
10	CD	O
min	NN	O
after	IN	O
declamping	VBG	O
,	,	O
6.8	CD	O
and	CC	O
13.3	CD	O
%	NN	O
in	IN	O
the	DT	O
controls	NNS	O
.	.	O

The	DT	O
free	JJ	O
radicals	NNS	O
in	IN	O
arterial	JJ	O
samples	NNS	O
were	VBD	O
,	,	O
respectively	RB	O
,	,	O
21	CD	O
,	,	O
14	CD	O
,	,	O
10	CD	O
and	CC	O
9	CD	O
%	NN	O
at	IN	O
10	CD	O
min	NN	O
,	,	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
reperfusion	NN	O
.	.	O

Cardiac	NNP	O
index	NN	O
(	(	O
CI	NNP	O
)	)	O
and	CC	O
right	JJ	O
ventricular	NN	O
ejection	NN	O
fraction	NN	O
(	(	O
RVEF	NNP	O
)	)	O
were	VBD	O
improved	VBN	O
by	IN	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
.	.	Surgical

CONCLUSION	NNP	O
Both	NNP	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
and	CC	O
cardiopulmonary	JJ	Surgical
bypass	NN	Surgical
induced	VBD	O
free	JJ	O
radicals	NNS	O
generation	NN	O
.	.	O

Although	IN	O
ischaemic	JJ	Physical
preconditioning	NN	Physical
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
free	JJ	O
radicals	NNS	O
generation	NN	O
after	IN	O
the	DT	O
operation	NN	O
,	,	O
it	PRP	O
protected	VBD	O
against	IN	O
postoperative	JJ	O
stunning	NN	O
.	.	O

Effect	NN	O
of	IN	O
total	JJ	Pharmacological
androgen	NN	Pharmacological
ablation	NN	Pharmacological
on	IN	O
pathologic	JJ	O
stage	NN	O
and	CC	O
resection	NN	O
limit	NN	O
status	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
.	.	O

Initial	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Italian	JJ	O
PROSIT	NNP	O
study	NN	O
.	.	O

The	DT	O
likelihood	NN	O
of	IN	O
finding	VBG	O
organ-confined	JJ	O
untreated	JJ	O
prostate	NN	O
cancer	NN	O
(	(	O
PCa	NNP	O
)	)	O
by	IN	O
pathological	JJ	O
examination	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
radical	JJ	Surgical
prostatectomy	NN	Surgical
(	(	Surgical
RP	NNP	Surgical
)	)	Surgical
is	VBZ	O
only	RB	O
50	CD	O
%	NN	O
in	IN	O
patients	NNS	O
with	IN	O
clinically	RB	O
organ-confined	JJ	O
disease	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
tumour	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
the	DT	O
resection	NN	O
margin	NN	O
in	IN	O
approximately	RB	O
30	CD	O
%	NN	O
of	IN	O
clinical	JJ	O
T2	NNP	O
(	(	O
clinical	JJ	O
stage	NN	O
B	NNP	O
)	)	O
cases	NNS	O
.	.	O

The	DT	O
issue	NN	O
of	IN	O
clinical	JJ	O
understaging	NN	O
and	CC	O
of	IN	O
resection	NN	O
limit	NN	O
positivity	NN	O
have	VBP	O
led	VBN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
novel	JJ	O
management	NN	O
practices	NNS	O
,	,	O
including	VBG	O
neoadjuvant	JJ	Pharmacological
hormonal	JJ	Pharmacological
therapy	NN	Pharmacological
(	(	Pharmacological
NHT	NNP	Pharmacological
)	)	Pharmacological
.	.	O

The	DT	O
optimal	JJ	O
duration	NN	O
of	IN	O
NHT	NNP	O
is	VBZ	O
unknown	JJ	O
.	.	O

We	PRP	O
undertook	VBD	O
the	DT	O
present	JJ	O
analysis	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
NHT	NNP	O
on	IN	O
pathologic	JJ	O
stage	NN	O
of	IN	O
PCa	NNP	O
and	CC	O
resection	NN	O
limit	NN	O
status	NN	O
in	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
and	CC	O
treated	VBN	O
with	IN	O
total	JJ	Pharmacological
androgen	NN	Pharmacological
ablation	NN	Pharmacological
either	DT	O
for	IN	O
three	CD	O
or	CC	O
six	CD	O
months	NNS	O
before	IN	O
RP	NNP	O
.	.	O

Between	NNP	O
January	NNP	O
1996	CD	O
and	CC	O
February	NNP	O
1998	CD	O
,	,	O
259	CD	O
men	NNS	O
with	IN	O
prostate	NN	O
cancer	NN	O
underwent	JJ	O
radical	JJ	Surgical
retropubic	NN	Surgical
prostatectomy	NN	Surgical
and	CC	Surgical
bilateral	JJ	Surgical
pelvic	JJ	Surgical
node	NN	Surgical
dissection	NN	Surgical
in	IN	O
the	DT	O
26	CD	O
centres	NNS	O
participating	VBG	O
in	IN	O
the	DT	O
Italian	JJ	O
randomised	VBD	O
prospective	JJ	O
PROSIT	NNP	O
study	NN	O
.	.	O

Whole	NNP	O
mount	NN	O
sectioning	NN	O
of	IN	O
the	DT	O
complete	JJ	O
RP	NNP	O
specimens	NNS	O
was	VBD	O
adopted	VBN	O
in	IN	O
each	DT	O
centre	NN	O
for	IN	O
accurately	RB	O
evaluating	VBG	O
the	DT	O
pathologic	JJ	O
stage	NN	O
and	CC	O
resection	NN	O
limit	NN	O
status	NN	O
.	.	O

By	IN	O
February	NNP	O
1998	CD	O
,	,	O
haematoxylin	NN	O
and	CC	O
eosin	NN	O
stained	VBD	O
sections	NNS	O
from	IN	O
155	CD	O
RP	NNP	O
specimens	NNS	O
had	VBD	O
been	VBN	O
received	VBN	O
and	CC	O
evaluated	VBN	O
by	IN	O
the	DT	O
reviewing	VBG	O
pathologist	NN	O
(	(	O
RM	NNP	O
)	)	O
.	.	O

64	CD	O
cases	NNS	O
had	VBD	O
not	RB	O
been	VBN	O
treated	VBN	O
with	IN	O
total	JJ	Pharmacological
androgen	NN	Pharmacological
ablation	NN	Pharmacological
(	(	O
e.g	JJ	O
.	.	O

NHT	NNP	Pharmacological
)	)	O
before	IN	O
RP	NNP	O
was	VBD	O
performed	VBN	O
,	,	O
whereas	JJ	O
58	CD	O
and	CC	O
33	CD	O
had	VBD	O
been	VBN	O
treated	VBN	O
for	IN	O
three	CD	O
and	CC	O
six	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

114	CD	O
patients	NNS	O
were	VBD	O
clinical	JJ	O
stage	NN	O
B	NNP	O
whereas	IN	O
41	CD	O
were	VBD	O
clinical	JJ	O
stage	NN	O
C.	NNP	O
After	IN	O
three	CD	O
months	NNS	O
of	IN	O
total	JJ	Pharmacological
androgen	NN	Pharmacological
ablation	NN	Pharmacological
,	,	O
pathological	JJ	O
stage	NN	O
B	NNP	O
was	VBD	O
more	RBR	O
prevalent	JJ	O
among	IN	O
patients	NNS	O
with	IN	O
clinical	JJ	O
B	NNP	O
tumours	NN	O
,	,	O
compared	VBN	O
with	IN	O
untreated	JJ	O
patients	NNS	O
(	(	O
57	CD	O
%	NN	O
in	IN	O
treated	JJ	O
patients	NNS	O
vs.	FW	O
36	CD	O
%	NN	O
in	IN	O
untreated	JJ	O
)	)	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
cancers	NNS	O
with	IN	O
negative	JJ	O
margins	NNS	O
was	VBD	O
statistically	RB	O
significantly	RB	O
greater	JJR	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
neoadjuvant	JJ	Pharmacological
therapy	NN	Pharmacological
than	IN	O
those	DT	O
treated	VBN	O
with	IN	O
immediate	JJ	Pharmacological
surgery	NN	Pharmacological
alone	RB	Pharmacological
(	(	O
69	CD	O
%	NN	O
vs.	FW	O
42	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
of	IN	O
NHT	NNP	O
therapy	VBP	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
pathological	JJ	O
stage	NN	O
B	NNP	O
(	(	O
67	CD	O
%	NN	O
vs.	FW	O
36	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
negative	JJ	O
margins	NNS	O
was	VBD	O
greater	JJR	O
than	IN	O
after	IN	O
3	CD	O
months	NNS	O
(	(	O
92	CD	O
%	NN	O
vs.	FW	O
42	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

For	IN	O
clinical	JJ	O
C	NNP	O
tumours	NN	O
,	,	O
the	DT	O
prevalence	NN	O
of	IN	O
pathological	JJ	O
stage	NN	O
B	NNP	O
and	CC	O
negative	JJ	O
margins	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
treated	VBD	O
for	IN	O
either	DT	O
3	CD	O
or	CC	O
6	CD	O
months	NNS	O
was	VBD	O
not	RB	O
as	RB	O
high	JJ	O
as	IN	O
in	IN	O
the	DT	O
clinical	JJ	O
B	NNP	O
tumours	NN	O
,	,	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
untreated	JJ	O
group	NN	O
(	(	O
pathological	JJ	O
stage	NN	O
B	NNP	O
:	:	O
31	CD	O
%	NN	O
and	CC	O
33	CD	O
%	NN	O
vs.	FW	O
6	CD	O
%	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
C	NNP	O
cases	NNS	O
,	,	O
respectively	RB	O
.	.	O

Negative	JJ	O
margins	NNS	O
:	:	O
56	CD	O
%	NN	O
and	CC	O
67	CD	O
%	NN	O
vs.	FW	O
31	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
initial	JJ	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggest	VBP	O
that	IN	O
total	JJ	Pharmacological
androgen	NN	Pharmacological
ablation	NN	Pharmacological
before	IN	O
RP	NNP	Surgical
is	VBZ	O
beneficial	JJ	O
in	IN	O
men	NNS	O
with	IN	O
clinical	JJ	O
stage	NN	O
B	NNP	O
because	IN	O
of	IN	O
the	DT	O
significant	JJ	O
pathological	JJ	O
downstaging	NN	O
and	CC	O
decrease	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
positive	JJ	O
margins	NNS	O
in	IN	O
the	DT	O
RP	NNP	O
specimens	NNS	O
.	.	O

These	DT	O
two	CD	O
effects	NNS	O
are	VBP	O
more	RBR	O
pronounced	JJ	O
after	IN	O
six	CD	O
months	NNS	O
of	IN	O
NHT	NNP	Pharmacological
than	IN	O
after	IN	O
three	CD	O
months	NNS	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
same	JJ	O
degree	NN	O
of	IN	O
beneficial	JJ	O
effects	NNS	O
are	VBP	O
not	RB	O
observed	VBN	O
in	IN	O
clinical	JJ	O
C	NNP	O
tumours	NN	O
.	.	O

Resisting	VBG	O
good	JJ	O
news	NN	O
:	:	O
reactions	NNS	O
to	TO	O
breast	VB	O
cancer	NN	O
risk	NN	O
communication	NN	O
.	.	O

Many	JJ	O
women	NNS	O
overestimate	VBP	O
their	PRP$	O
percentage	NN	O
risk	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
,	,	O
even	RB	O
after	IN	O
they	PRP	O
have	VBP	O
received	VBN	O
careful	JJ	Educational
estimates	NNS	Educational
from	IN	O
health	NN	O
professionals	NNS	O
.	.	O

In	IN	O
2	CD	O
experiments	NNS	O
with	IN	O
134	CD	O
young	JJ	O
adult	NN	O
women	NNS	O
,	,	O
6	CD	O
variables	NNS	O
were	VBD	O
explored	VBN	O
that	IN	O
might	MD	O
influence	VB	O
such	JJ	O
risk	NN	O
perception	NN	O
persistence	NN	O
.	.	O

In	IN	O
Study	NNP	O
1	CD	O
,	,	O
each	DT	O
of	IN	O
the	DT	O
following	JJ	O
explanations	NNS	O
was	VBD	O
unrelated	JJ	O
to	TO	O
persistence	VB	O
:	:	O
public	JJ	Educational
commitment	NN	Educational
,	,	O
self-consistency	NN	Educational
,	,	O
and	CC	O
unique	JJ	Educational
causal	NN	Educational
risk	NN	Educational
models	NNS	Educational
.	.	O

In	IN	O
Study	NNP	O
2	CD	O
,	,	O
two	CD	O
individual	JJ	O
difference	NN	O
measures	NNS	O
,	,	O
pessimism	NN	O
and	CC	O
differences	NNS	O
in	IN	O
understanding	JJ	O
percentages	NNS	O
,	,	O
were	VBD	O
unrelated	JJ	O
to	TO	O
risk	VB	O
perception	NN	O
persistence	NN	O
.	.	O

However	RB	O
,	,	O
providing	VBG	O
a	DT	O
risk	NN	Educational
anchor	NN	Educational
based	VBN	Educational
on	IN	Educational
downward	JJ	Educational
social	JJ	Educational
comparison	NN	Educational
processes	NNS	Educational
resulted	VBD	O
in	IN	O
better	JJR	O
risk	NN	O
acceptance	NN	O
at	IN	O
posttest	JJS	O
that	IN	O
persisted	VBD	O
at	IN	O
a	DT	O
2-week	JJ	O
follow-up	JJ	O
assessment	NN	O
.	.	O

This	DT	O
article	NN	O
discusses	VBZ	O
why	WRB	O
comparison	NN	Educational
anchors	NNS	Educational
might	MD	O
be	VB	O
important	JJ	O
in	IN	O
risk	NN	O
feedback	NN	O
situations	NNS	O
and	CC	O
concludes	NNS	O
with	IN	O
recommendations	NNS	O
for	IN	O
professionals	NNS	O
who	WP	O
wish	VBP	O
to	TO	O
provide	VB	O
accurate	NN	O
risk	NN	O
information	NN	O
and	CC	O
have	VBP	O
patients	NNS	O
adopt	VB	O
that	DT	O
information	NN	O
.	.	O

Epidural	JJ	Pharmacological
morphine	NN	Pharmacological
in	IN	O
the	DT	O
elderly	JJ	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
after	IN	O
upper	JJ	O
abdominal	JJ	O
surgery	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
epidurally	RB	Pharmacological
administered	VBN	Pharmacological
morphine	NN	Pharmacological
in	IN	O
the	DT	O
relief	NN	O
of	IN	O
pain	NN	O
after	IN	O
upper	JJ	O
abdominal	JJ	O
surgery	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
controlled	VBN	O
study	NN	O
involving	VBG	O
20	CD	O
patients	NNS	O
aged	VBD	O
61	CD	O
to	TO	O
78	CD	O
years	NNS	O
.	.	O

Analgesia	NNP	O
provided	VBN	O
by	IN	O
epidural	JJ	Pharmacological
morphine	NN	Pharmacological
was	VBD	O
comparable	JJ	O
to	TO	O
that	DT	O
obtained	VBN	O
in	IN	O
matched	JJ	O
patients	NNS	O
given	VBN	O
an	DT	O
intramuscular	JJ	Pharmacological
regime	NN	Pharmacological
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
required	VBN	O
by	IN	O
the	DT	O
epidural	JJ	O
route	NN	O
was	VBD	O
less	JJR	O
than	IN	O
one-fifth	JJ	O
that	IN	O
required	VBD	O
intramuscularly	RB	O
,	,	O
and	CC	O
sedation	NN	O
was	VBD	O
correspondingly	RB	O
reduced	VBN	O
.	.	O

Postoperative	JJ	O
respiratory	NN	O
mechanics	NNS	O
,	,	O
however	RB	O
,	,	O
were	VBD	O
not	RB	O
significantly	RB	O
improved	VBN	O
and	CC	O
delayed	VBN	O
respiratory	NN	O
depression	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
one	CD	O
patient	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
undergoing	VBG	O
upper	JJ	O
abdominal	JJ	O
surgery	NN	O
the	DT	O
risks	NNS	O
related	VBN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
morphine	NN	Pharmacological
by	IN	O
the	DT	O
epidural	JJ	O
route	NN	O
outweigh	VBP	O
the	DT	O
marginal	JJ	O
advantages	NNS	O
it	PRP	O
may	MD	O
offer	VB	O
over	IN	O
conventional	JJ	O
analgesic	JJ	O
techniques	NNS	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
dopexamine	NN	Pharmacological
in	IN	O
splanchnic	JJ	O
perfusion	NN	O
during	IN	O
surgery	NN	O
of	IN	O
the	DT	O
abdominal	JJ	O
aorta	NN	O
]	NNP	O
.	.	O

Abdominal	NNP	O
aortic	JJ	O
surgery	NN	O
has	VBZ	O
significant	JJ	O
effects	NNS	O
on	IN	O
cardiac	NN	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
dopexamine	NN	O
,	,	O
an	DT	O
inodilator	JJ	O
drug	NN	O
,	,	O
on	IN	O
hemodynamic	JJ	O
and	CC	O
splanchnic	JJ	O
perfusion	NN	O
with	IN	O
measurement	NN	O
of	IN	O
gastric	JJ	O
intramucosal	NN	O
pH	NN	O
,	,	O
by	IN	O
the	DT	O
method	NN	O
of	IN	O
gastric	JJ	O
tonometry	NN	O
,	,	O
during	IN	O
abdominal	JJ	O
aneurysm	JJ	O
resection	NN	O
.	.	O

Twenty-five	JJ	O
patients	NNS	O
undergoing	VBG	O
excision	NN	O
of	IN	O
an	DT	O
aortic	JJ	O
abdominal	JJ	O
aneurysm	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
Group	NNP	O
II	NNP	O
patients	NNS	O
received	VBD	O
dopexamine	JJ	Pharmacological
infusion	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
microgram/kg/m	NN	O
,	,	O
and	CC	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	O
micrograms/kg/m	NN	O
from	IN	O
declamping	VBG	O
to	TO	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
surgery	NN	O
.	.	O

Whereas	NNP	O
Group	NNP	O
I	PRP	O
patients	NNS	O
did	VBD	Control
not	RB	Control
receive	VB	Control
a	DT	Control
dopexamine	JJ	Control
infusion	NN	Control
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	VBG	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
decreased	VBN	O
in	IN	O
Group	NNP	O
I	PRP	O
patients	NNS	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
change	VB	O
in	IN	O
Group	NNP	O
II	NNP	O
patients	NNS	O
.	.	O

Heart	NNP	O
rate	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
,	,	O
and	CC	O
mixed	JJ	O
venous	JJ	O
oxygen	NN	O
saturation	NN	O
increased	VBD	O
significantly	RB	O
during	IN	O
dopexamine	JJ	O
infusion	NN	O
,	,	O
whereas	JJ	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
was	VBD	O
reduced	VBN	O
.	.	O

During	IN	O
aortic	JJ	O
cross-clamping	JJ	O
dopexamine	NN	Pharmacological
was	VBD	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
improving	VBG	O
splanchnic	JJ	O
blood	NN	O
flow	NN	O
,	,	O
cardiac	JJ	O
index	NN	O
venous	JJ	O
saturation	NN	O
.	.	O

Also	RB	O
,	,	O
since	IN	O
the	DT	O
drug	NN	O
produces	VBZ	O
dose	RB	O
related	JJ	O
hemodynamic	JJ	O
changes	NNS	O
of	IN	O
rapid	JJ	O
onset	NN	O
and	CC	O
reversibility	NN	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
interrupt	VB	O
the	DT	O
infusion	NN	O
before	IN	O
aortic	JJ	O
declamping	NN	O
to	TO	O
avoid	VB	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
intramucosal	NN	O
pH	VBZ	O
value	NN	O
.	.	O

Metabolic	JJ	O
responses	NNS	O
to	TO	O
oral	JJ	Surgical
surgery	NN	Surgical
under	IN	O
local	JJ	Pharmacological
anesthesia	NN	Pharmacological
and	CC	O
sedation	NN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	Pharmacological
:	:	O
the	DT	O
effects	NNS	O
of	IN	O
two	CD	O
different	JJ	O
local	JJ	Pharmacological
anesthetics	NNS	Pharmacological
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
epinephrine-free	JJ	Pharmacological
and	CC	Pharmacological
epinephrine-containing	JJ	Pharmacological
local	JJ	Pharmacological
anesthetic	JJ	Pharmacological
solutions	NNS	O
on	IN	O
plasma	NN	O
potassium	NN	O
and	CC	O
blood	NN	O
glucose	JJ	O
concentrations	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
20	CD	O
patients	NNS	O
undergoing	JJ	O
oral	JJ	O
surgery	NN	O
with	IN	O
intravenous	JJ	O
midazolam	NNS	Pharmacological
sedation	NN	O
.	.	O

Ten	CD	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
4.4	CD	Pharmacological
mL	NN	Pharmacological
of	IN	Pharmacological
2	CD	Pharmacological
%	NN	Pharmacological
lidocaine	NN	Pharmacological
with	IN	Pharmacological
1:80,000	CD	Pharmacological
epinephrine	NN	Pharmacological
as	IN	Pharmacological
a	DT	Pharmacological
local	JJ	Pharmacological
anesthetic	NN	Pharmacological
and	CC	O
10	CD	O
were	VBD	O
given	VBN	O
4.4	CD	Pharmacological
mL	NN	Pharmacological
of	IN	Pharmacological
3	CD	Pharmacological
%	NN	Pharmacological
prilocaine	NN	Pharmacological
with	IN	Pharmacological
0.03	CD	Pharmacological
IU/mL	NNP	Pharmacological
felypressin	NN	Pharmacological
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
potassium	NN	O
and	CC	O
glucose	JJ	O
concentrations	NNS	O
both	DT	O
within	IN	O
and	CC	O
between	IN	O
treatments	NNS	O
in	IN	O
the	DT	O
early	JJ	O
postinjection	NN	O
period	NN	O
.	.	O

The	DT	O
epinephrine-containing	JJ	O
local	JJ	O
anesthetic	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
plasma	NN	O
potassium	NN	O
concentration	NN	O
10	CD	O
min	NN	O
after	IN	O
injection	NN	O
,	,	O
by	IN	O
0.16	CD	O
+/-	JJ	O
0.20	CD	O
mmol/L	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
,	,	O
and	CC	O
increased	VBD	O
the	DT	O
blood	NN	O
glucose	JJ	O
concentration	NN	O
at	IN	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
(	(	O
by	IN	O
0.46	CD	O
+/-	JJ	O
0.37	CD	O
,	,	O
0.63	CD	O
+/-	JJ	O
0.45	CD	O
,	,	O
and	CC	O
0.56	CD	O
+/-	JJ	O
0.28	CD	O
mmol/L	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Conversely	RB	O
,	,	O
plasma	JJ	O
potassium	NN	O
increased	VBD	O
and	CC	O
blood	NN	O
glucose	NN	O
decreased	VBD	O
10	CD	O
,	,	O
20	CD	O
,	,	O
and	CC	O
30	CD	O
min	NN	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
epinephrine-free	JJ	Pharmacological
solution	NN	Pharmacological
.	.	O

At	IN	O
30	CD	O
min	NN	O
potassium	NN	O
was	VBD	O
increased	VBN	O
by	IN	O
0.24	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
,	,	O
and	CC	O
glucose	NN	O
was	VBD	O
decreased	VBN	O
by	IN	O
0.23	CD	O
+/-	JJ	O
0.16	CD	O
mmol/L	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
epinephrine-free	JJ	Pharmacological
and	CC	O
epinephrine-containing	JJ	Pharmacological
local	JJ	Pharmacological
anesthetics	NNS	Pharmacological
differ	VBP	O
in	IN	O
their	PRP$	O
metabolic	JJ	O
effects	NNS	O
during	IN	O
oral	JJ	O
surgery	NN	O
with	IN	O
midazolam	JJ	Pharmacological
sedation	NN	Pharmacological
.	.	O

A	DT	O
comparative	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
fixed	JJ	O
combination	NN	Pharmacological
of	IN	Pharmacological
timolol	NN	Pharmacological
and	CC	Pharmacological
dorzolamide	VB	Pharmacological
versus	NN	O
latanoprost	NN	O
plus	CC	O
timolol	NN	O
on	IN	O
ocular	JJ	O
hemodynamics	NNS	O
and	CC	O
visual	JJ	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
.	.	O

AIMS	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
fixed	JJ	O
combination	NN	O
of	IN	O
timolol	NN	Pharmacological
and	CC	Pharmacological
dorzolamide	NN	Pharmacological
and	CC	Pharmacological
latanoprost	NN	Pharmacological
plus	CC	Pharmacological
timolol	NN	Pharmacological
on	IN	O
retinal	JJ	O
,	,	O
choroidal	JJ	O
,	,	O
and	CC	O
retrobulbar	NN	O
hemodynamics	NNS	O
and	CC	O
visual	JJ	O
function	NN	O
in	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
(	(	O
OAG	NNP	O
)	)	O
subjects	VBZ	O
.	.	O

METHODS	NNP	O
Sixteen	NNP	O
(	(	O
16	CD	O
)	)	O
OAG	NN	O
patients	NNS	O
(	(	O
age	NN	O
,	,	O
63.5	CD	O
+/-	JJ	O
10.8	CD	O
years	NNS	O
;	:	O
9	CD	O
male	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
crossover	RB	O
,	,	O
double-blind	JJ	O
study	NN	O
design	NN	O
after	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
of	IN	O
latanoprost	NN	Pharmacological
with	IN	Pharmacological
timolol	NN	Pharmacological
and	CC	O
fixed	JJ	O
combination	NN	O
of	IN	O
timolol	NN	Pharmacological
and	CC	Pharmacological
dorzolamide	NN	Pharmacological
.	.	Pharmacological

After	IN	O
randomization	NN	O
,	,	O
9	CD	O
right	JJ	O
eyes	NNS	O
and	CC	O
7	CD	O
left	JJ	O
eyes	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
hemodynamic	JJ	O
portion	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Measurements	NNS	O
included	VBD	O
:	:	O
adverse	JJ	O
events	NNS	O
check	NN	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
contrast	NN	O
sensitivity	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
intraocular	JJ	O
pressure	NN	O
(	(	O
IOP	NNP	O
)	)	O
,	,	O
and	CC	O
fundus	JJ	O
examination	NN	O
.	.	O

Ocular	JJ	O
blood	NN	O
flow	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
confocal	JJ	O
scanning	VBG	O
laser	NN	O
Doppler	NNP	O
flowmetry	NN	O
,	,	O
color	NN	O
Doppler	NNP	O
imaging	NN	O
,	,	O
and	CC	O
scanning	VBG	O
laser	NN	O
ophthalmoscopy	NN	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
therapies	NNS	O
were	VBD	O
effective	JJ	O
at	IN	O
lowering	VBG	O
IOP	NNP	O
,	,	O
whereas	IN	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
latanoprost	NN	O
plus	CC	O
timolol	NN	O
and	CC	O
the	DT	O
fixed	JJ	O
combination	NN	O
of	IN	O
timolol	NN	O
and	CC	O
dorzolamide	NN	O
(	(	O
13.9	CD	O
%	NN	O
and	CC	O
12.2	CD	O
%	NN	O
reduction	NN	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	NNP	O
0.5533	CD	O
)	)	O
.	.	O

Fixed	VBN	O
combination	NN	Pharmacological
of	IN	Pharmacological
timolol	NN	Pharmacological
and	CC	Pharmacological
dorzolamide	VB	Pharmacological
significantly	RB	O
increased	JJ	O
central	JJ	O
retinal	JJ	O
artery	NN	O
end	NN	O
diastolic	NN	O
blood	NN	O
flow	NN	O
velocity	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0168	CD	O
)	)	O
and	CC	O
lowered	VBD	O
resistance	NN	O
to	TO	O
flow	VB	O
(	(	O
P	NNP	O
=	NNP	O
0.0279	CD	O
)	)	O
.	.	O

Temporal	JJ	O
posterior	JJ	O
ciliary	JJ	O
artery	NN	O
peak	NN	O
systolic	NN	O
and	CC	O
end	VB	O
diastolic	JJ	O
velocities	NNS	O
were	VBD	O
significantly	RB	O
increased	VBN	O
with	IN	O
the	DT	O
fixed	JJ	O
combination	NN	O
of	IN	O
timolol	NN	O
and	CC	O
dorzolamide	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0125	CD	O
and	CC	O
0.0238	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Latanoprost	NNP	Pharmacological
plus	CC	Pharmacological
timolol	NN	Pharmacological
had	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
ocular	JJ	O
blood	NN	O
flow	NN	O
during	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
contrast	NN	O
sensitivity	NN	O
scanning	VBG	O
laser	NN	O
ophthalmoscopy	NN	O
,	,	O
or	CC	O
Heidelberg	NNP	O
Retinal	NNP	O
Flowmeter	NNP	O
for	IN	O
any	DT	O
treatment	NN	O
period	NN	O
.	.	O

CONCLUSIONS	NNP	O
Fixed	NNP	O
combination	NN	O
of	IN	O
timolol	NN	O
and	CC	O
dorzolamide	JJ	O
therapy	NN	O
might	MD	O
increase	VB	O
blood	NN	O
flow	NN	O
in	IN	O
OAG	NNP	O
patients	NNS	O
while	IN	O
attaining	VBG	O
a	DT	O
similar	JJ	O
IOP	NNP	O
reduction	NN	O
compared	VBN	O
to	TO	O
latanoprost	VB	O
plus	JJ	O
timolol	NN	O
.	.	O

Visual	JJ	O
function	NN	O
,	,	O
however	RB	O
,	,	O
was	VBD	O
not	RB	O
different	JJ	O
in	IN	O
this	DT	O
short-term	JJ	O
comparison	NN	O
between	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
.	.	O

Effect	NN	O
of	IN	O
esmolol	JJ	Pharmacological
pretreatment	NN	O
on	IN	O
EEG	NNP	O
seizure	NN	O
morphology	NN	O
in	IN	O
RUL	NNP	O
ECT	NNP	O
.	.	O

Intravenous	JJ	O
beta-blockers	NNS	O
are	VBP	O
an	DT	O
effective	JJ	O
means	NNS	O
of	IN	O
controlling	VBG	O
heart	NN	O
rate	NN	O
and	CC	O
blood	NN	O
pressure	NN	O
during	IN	O
electroconvulsive	JJ	Physical
therapy	NN	Physical
(	(	Physical
ECT	NNP	Physical
)	)	Physical
,	,	O
but	CC	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
decrease	VB	O
seizure	NN	O
duration	NN	O
.	.	O

While	IN	O
the	DT	O
importance	NN	O
of	IN	O
seizure	NN	O
duration	NN	O
to	TO	O
the	DT	O
antidepressant	JJ	O
response	NN	O
of	IN	O
ECT	NNP	O
grows	VBZ	O
less	JJR	O
certain	JJ	O
,	,	O
there	EX	O
is	VBZ	O
growing	VBG	O
evidence	NN	O
that	IN	O
seizure	NN	O
morphology	NN	O
predicts	VBZ	O
the	DT	O
antidepressant	JJ	O
effect	NN	O
of	IN	O
ECT	NNP	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
impact	NN	O
of	IN	O
esmolol	JJ	Pharmacological
pretreatment	NN	O
on	IN	O
seizure	NN	O
morphology	NN	O
.	.	O

Eighteen	NNP	O
depressed	VBD	O
patients	NNS	O
(	(	O
6	CD	O
men	NNS	O
,	,	O
12	CD	O
women	NNS	O
;	:	O
69	CD	O
+/-	JJ	O
12.8	CD	O
years	NNS	O
old	JJ	O
)	)	O
received	VBD	O
ECT	NNP	Surgical
with	IN	Pharmacological
and	CC	Pharmacological
without	IN	Pharmacological
esmolol	JJ	Pharmacological
pretreatment	NN	Pharmacological
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
blinded	VBD	O
crossover	NN	O
design	NN	O
.	.	O

The	DT	O
seizures	NNS	O
were	VBD	O
blindly	RB	O
rated	VBN	O
for	IN	O
duration	NN	O
of	IN	O
motor	NN	O
convulsion	NN	O
,	,	O
duration	NN	O
of	IN	O
electroencephalogram	NN	O
(	(	O
EEG	NNP	O
)	)	O
seizure	NN	O
,	,	O
degree	NN	O
of	IN	O
seizure	NN	O
regularity	NN	O
,	,	O
and	CC	O
degree	NN	O
of	IN	O
postictal	JJ	O
EEG	NNP	O
suppression	NN	O
.	.	O

Esmolol	NNP	O
shortened	VBD	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
motor	NN	O
convulsion	NN	O
and	CC	O
degraded	VBD	O
the	DT	O
quality	NN	O
of	IN	O
the	DT	O
ictal	JJ	O
regularity	NN	O
.	.	O

Routine	JJ	O
administration	NN	O
of	IN	O
intravenous	JJ	O
esmolol	NN	O
before	IN	O
ECT	NNP	O
may	MD	O
cause	VB	O
a	DT	O
decrease	NN	O
in	IN	O
ictal	JJ	O
regularity	NN	O
.	.	O

Careful	JJ	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
the	DT	O
potential	JJ	O
benefits	NNS	O
of	IN	O
esmolol	NN	O
versus	IN	O
the	DT	O
deleterious	JJ	O
effect	NN	O
on	IN	O
the	DT	O
electrophysiologic	JJ	O
process	NN	O
.	.	O

Esmolol	NN	O
may	MD	O
still	RB	O
be	VB	O
indicated	VBN	O
on	IN	O
a	DT	O
case-by-case	JJ	O
basis	NN	O
for	IN	O
extreme	JJ	O
tachycardia	NN	O
or	CC	O
hypertension	NN	O
associated	VBN	O
with	IN	O
ECT	NNP	O
,	,	O
and	CC	O
presumably	RB	O
poses	VBZ	O
no	DT	O
problem	NN	O
for	IN	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
ECT	NNP	O
if	IN	O
given	VBN	O
after	IN	O
the	DT	O
seizure	NN	O
is	VBZ	O
over	IN	O
.	.	O

The	DT	O
utility	NN	O
of	IN	O
laparoscopy	NN	O
in	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
appendicitis	NN	O
in	IN	O
women	NNS	O
of	IN	O
reproductive	JJ	O
age	NN	O
.	.	O

AIM	NNP	O
To	TO	O
see	VB	O
whether	IN	O
laparoscopy	NN	Physical
improves	VBZ	O
the	DT	O
accuracy	NN	O
of	IN	O
a	DT	O
clinical	JJ	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
appendicitis	NN	O
in	IN	O
women	NNS	O
of	IN	O
reproductive	JJ	O
age	NN	O
,	,	O
and	CC	O
to	TO	O
determine	VB	O
what	WP	O
the	DT	O
long-term	JJ	O
sequelae	NN	O
are	VBP	O
of	IN	O
not	RB	O
removing	VBG	O
an	DT	O
appendix	NN	O
deemed	VBN	O
at	IN	O
laparoscopy	NN	O
to	TO	O
be	VB	O
normal	JJ	O
.	.	O

METHOD	NNP	O
The	DT	O
initial	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
during	IN	O
1991-1992	JJ	O
.	.	O

Female	JJ	O
patients	NNS	O
between	IN	O
16	CD	O
and	CC	O
45	CD	O
years	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
once	RB	O
a	DT	O
clinical	JJ	O
decision	NN	O
had	VBD	O
been	VBN	O
made	VBN	O
to	TO	O
perform	VB	O
an	DT	O
appendicectomy	NN	O
for	IN	O
suspected	JJ	O
acute	JJ	O
appendicitis	NN	O
.	.	O

Following	VBG	O
consent	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
had	VBD	O
open	JJ	Surgical
appendicectomy	NN	Surgical
,	,	O
as	IN	O
planned	VBN	O
.	.	O

The	DT	O
other	JJ	O
group	NN	O
had	VBD	O
laparoscopy	VBN	Physical
,	,	O
followed	VBN	O
by	IN	O
open	JJ	Surgical
appendicectomy	NN	Surgical
only	RB	O
if	IN	O
the	DT	O
appendix	NN	O
was	VBD	O
seen	VBN	O
to	TO	O
be	VB	O
inflamed	VBN	O
or	CC	O
was	VBD	O
not	RB	O
visualized	VBN	O
.	.	O

The	DT	O
end	NN	O
points	NNS	O
for	IN	O
the	DT	O
study	NN	O
were	VBD	O
the	DT	O
clinical	JJ	O
outcomes	NNS	O
of	IN	O
all	DT	O
patients	NNS	O
,	,	O
and	CC	O
the	DT	O
results	NNS	O
of	IN	O
histology	NN	O
,	,	O
where	WRB	O
appropriate	NN	O
.	.	O

An	DT	O
attempt	NN	O
was	VBD	O
made	VBN	O
to	TO	O
contact	VB	O
all	DT	O
patients	NNS	O
at	IN	O
10	CD	O
years	NNS	O
to	TO	O
determine	VB	O
whether	IN	O
they	PRP	O
had	VBD	O
had	VBN	O
a	DT	O
subsequent	JJ	O
appendicectomy	NN	O
,	,	O
or	CC	O
had	VBD	O
been	VBN	O
diagnosed	VBN	O
with	IN	O
another	DT	O
abdominal	JJ	O
condition	NN	O
that	WDT	O
might	MD	O
be	VB	O
relevant	JJ	O
to	TO	O
the	DT	O
initial	JJ	O
presentation	NN	O
in	IN	O
1991-1992	JJ	O
.	.	O

RESULTS	NNP	O
Laparoscopic	NNP	O
assessment	NN	O
was	VBD	O
correct	JJ	O
in	IN	O
all	DT	O
cases	NNS	O
in	IN	O
which	WDT	O
the	DT	O
appendix	NN	O
was	VBD	O
visualized	VBN	O
.	.	O

Diagnostic	JJ	O
accuracy	NN	O
was	VBD	O
improved	VBN	O
from	IN	O
75	CD	O
%	NN	O
to	TO	O
97	CD	O
%	NN	O
.	.	O

Laparoscopy	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
no	DT	O
added	JJ	O
complications	NNS	O
,	,	O
no	DT	O
increase	NN	O
in	IN	O
hospital	JJ	O
stay	NN	O
in	IN	O
patients	NNS	O
who	WP	O
went	VBD	O
on	IN	O
to	TO	O
appendicectomy	VB	O
,	,	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
hospital	NN	O
stay	NN	O
for	IN	O
those	DT	O
who	WP	O
underwent	JJ	O
laparoscopy	NN	O
alone	RB	O
.	.	O

No	UH	O
patients	NNS	O
developed	VBD	O
a	DT	O
problem	NN	O
over	IN	O
the	DT	O
10-year	JJ	O
follow-up	JJ	O
period	NN	O
from	IN	O
having	VBG	O
a	DT	O
normal-looking	JJ	O
appendix	NN	O
not	RB	O
removed	VBN	O
at	IN	O
laparoscopy	NN	O
.	.	O

CONCLUSION	NNP	O
Laparoscopic	NNP	O
assessment	NN	O
of	IN	O
the	DT	O
appendix	NN	O
is	VBZ	O
reliable	JJ	O
,	,	O
and	CC	O
to	TO	O
leave	VB	O
a	DT	O
normal-looking	JJ	O
appendix	NN	O
at	IN	O
laparoscopy	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
cause	VB	O
any	DT	O
long-term	JJ	O
problems	NNS	O
.	.	O

[	JJ	O
Observation	NNP	O
on	IN	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
electroacupuncture	NN	Physical
plus	CC	Physical
blood-letting	JJ	Physical
puncture	NN	Physical
and	CC	Physical
cupping	NN	Physical
combined	VBN	Physical
with	IN	Physical
diet	JJ	Educational
intervention	NN	Educational
for	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
gouty	NN	O
arthritis	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
explore	VB	O
a	DT	O
more	RBR	O
effective	JJ	O
therapy	NN	O
for	IN	O
acute	JJ	O
gouty	NN	O
arthritis	NN	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
cases	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
an	DT	O
observation	NN	O
group	NN	O
and	CC	O
a	DT	O
control	NN	O
group	NN	O
,	,	O
30	CD	O
cases	NNS	O
in	IN	O
eachgroup	NN	O
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
diet	JJ	Educational
intervention	NN	Educational
,	,	O
the	DT	O
observation	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
electroacupuncture	NN	Physical
at	IN	Physical
local	JJ	Physical
points	NNS	Physical
combined	VBN	Physical
with	IN	Physical
blood-letting	JJ	Physical
puncture	NN	Physical
and	CC	Physical
cupping	NN	Physical
,	,	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
with	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
Probenecid	NNP	Pharmacological
.	.	O

Their	PRP$	O
therapeutic	JJ	O
effects	NNS	O
were	VBD	O
ob	JJ	O
served	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
effective	JJ	O
rate	NN	O
was	VBD	O
96.7	CD	O
%	NN	O
in	IN	O
the	DT	O
observation	NN	O
group	NN	O
which	WDT	O
was	VBD	O
better	JJR	O
than	IN	O
86.7	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
blood	NN	O
uric	JJ	O
acid	NN	O
decreased	VBN	O
significantly	RB	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
both	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
the	DT	O
observed	JJ	O
group	NN	O
being	VBG	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NN	O
On	IN	O
the	DT	O
basis	NN	O
of	IN	O
diet	JJ	Physical
intervention	NN	Physical
,	,	O
electroacupuncture	JJ	Physical
plus	CC	Physical
blood-letting	JJ	Physical
puncture	NN	Physical
and	CC	Physical
cupping	NN	Physical
is	VBZ	O
a	DT	O
better	JJR	O
therapy	NN	O
for	IN	O
acute	JJ	O
gouty	NN	O
arthritis	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
Naftidrofuryl	NNP	Pharmacological
on	IN	O
ethanol-induced	JJ	O
liver	NN	O
damage	NN	O
in	IN	O
chronic	JJ	O
alcoholic	JJ	O
patients	NNS	O
.	.	O

A	DT	O
prospective	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
intramuscular	JJ	O
Naftidrofuryl	NNP	Pharmacological
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
32	CD	O
randomly	RB	O
selected	VBN	O
hospitalized	VBN	O
male	JJ	O
alcoholic	JJ	O
patients	NNS	O
with	IN	O
clinical	JJ	O
,	,	O
biochemical	JJ	O
and	CC	O
histological	JJ	O
evidence	NN	O
of	IN	O
hepatic	JJ	O
damage	NN	O
.	.	O

Seventeen	JJ	O
patients	NNS	O
received	VBD	O
the	DT	O
drug	NN	O
(	(	O
40	CD	O
mg	NN	O
in	IN	O
5	CD	O
ml	NN	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
and	CC	O
15	CD	O
patients	NNS	O
received	VBD	O
a	DT	O
placebo	NN	Pharmacological
(	(	O
5	CD	O
ml	NN	O
in	IN	O
normal	JJ	O
saline	JJ	O
i.m	NN	O
.	.	O

three	CD	O
times	NNS	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
drug	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
and	CC	O
there	EX	O
were	VBD	O
no	DT	O
adverse	JJ	O
side-effects	NNS	O
.	.	O

Naftidrofuryl	NNP	O
significantly	RB	O
improved	VBD	O
the	DT	O
physiological	JJ	O
function	NN	O
of	IN	O
the	DT	O
liver	NN	O
cells	NNS	O
as	IN	O
reflected	VBN	O
by	IN	O
indocyanine	NN	O
green	NN	O
(	(	O
ICG	NNP	O
)	)	O
clearance	NN	O
by	IN	O
the	DT	O
liver	NN	O
(	(	O
t	JJ	O
=	VBZ	O
2.61	CD	O
;	:	O
p	NN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
0.02	CD	O
)	)	O
and	CC	O
also	RB	O
caused	VBD	O
a	DT	O
larger	JJR	O
fall	NN	O
in	IN	O
raised	VBN	O
serum	NN	O
levels	NNS	O
of	IN	O
gamma	NN	O
glutamyl	NN	O
transpeptidase	NN	O
(	(	O
GGT	NNP	O
)	)	O
than	IN	O
did	VBD	O
the	DT	O
placebo	NN	O
injections	NNS	O
.	.	O

Overall	JJ	O
clinical	JJ	O
improvement	NN	O
(	(	O
e.g	NN	O
.	.	O

appetite	NN	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
reduced	VBD	O
liver	JJ	O
size	NN	O
,	,	O
general	JJ	O
sense	NN	O
of	IN	O
well-being	NN	O
)	)	O
was	VBD	O
more	RBR	O
clearly	RB	O
evident	JJ	O
in	IN	O
patients	NNS	O
of	IN	O
the	DT	O
treated	VBN	O
group	NN	O
than	IN	O
in	IN	O
those	DT	O
of	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Naftidrofuryl	NNP	Pharmacological
,	,	O
therefore	RB	O
,	,	O
appears	VBZ	O
to	TO	O
be	VB	O
of	IN	O
benefit	NN	O
in	IN	O
ethanol-induced	JJ	O
liver	NN	O
damage	NN	O
and	CC	O
more	RBR	O
extensive	JJ	O
long-term	JJ	O
trials	NNS	O
are	VBP	O
suggested	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
alcoholic	JJ	O
liver	NN	O
disease	NN	O
(	(	O
ALD	NNP	O
)	)	O
.	.	O

Prognostic	JJ	O
value	NN	O
of	IN	O
clinical	JJ	O
,	,	O
laboratory	NN	O
,	,	O
and	CC	O
histological	JJ	O
characteristics	NNS	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
:	:	O
improved	JJ	O
definition	NN	O
of	IN	O
risk	NN	O
groups	NNS	O
.	.	O

Follow-up	NNP	O
data	NN	O
of	IN	O
320	CD	O
multiple	JJ	O
myeloma	NN	O
(	(	O
MM	NNP	O
)	)	O
patients	NNS	O
entering	VBG	O
the	DT	Pharmacological
German	JJ	Pharmacological
Myeloma	NNP	Pharmacological
Treatment	NNP	Pharmacological
Group	NNP	Pharmacological
(	(	Pharmacological
GMTG	NNP	Pharmacological
)	)	Pharmacological
trial	NN	O
MM01	NNP	O
were	VBD	O
analysed	VBN	O
for	IN	O
factors	NNS	O
predicting	VBG	O
overall	JJ	O
(	(	O
OAS	NNP	O
)	)	O
and	CC	O
tumour	$	O
related	VBN	O
survival	NN	O
(	(	O
TRS	NNP	O
)	)	O
.	.	O

Response	NN	O
to	TO	O
primary	JJ	Pharmacological
induction	NN	Pharmacological
chemotherapy	NN	Pharmacological
was	VBD	O
relevant	JJ	O
for	IN	O
prognosis	NN	O
if	IN	O
a	DT	O
limit	NN	O
of	IN	O
25	CD	O
%	NN	O
tumour	NN	O
cell	NN	O
mass	NN	O
(	(	O
TCM	NNP	O
)	)	O
reduction	NN	O
was	VBD	O
used	VBN	O
to	TO	O
separate	JJ	O
responders	NNS	O
from	IN	O
non-responders	NNS	O
.	.	O

Furthermore	NNP	O
,	,	O
TCM	NNP	O
,	,	O
histological	JJ	O
grading	NN	O
of	IN	O
myeloma	NN	O
cells	NNS	O
,	,	O
degree	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
infiltration	NN	O
,	,	O
haemoglobin	NN	O
,	,	O
platelet	NN	O
counts	NNS	O
,	,	O
calcium	NN	O
,	,	O
creatinine	NN	O
,	,	O
albumin	NN	O
,	,	O
beta	NN	O
2M	CD	O
,	,	O
and	CC	O
Bence	NNP	O
Jones	NNP	O
proteinuria	NNS	O
correlated	VBD	O
to	TO	O
both	DT	O
OAS	NNP	O
and	CC	O
TRS	NNP	O
.	.	O

Age	NNP	O
was	VBD	O
relevant	JJ	O
for	IN	O
OAS	NNP	O
only	RB	O
.	.	O

The	DT	O
multivariate	NN	O
analysis	NN	O
revealed	VBD	O
histological	JJ	O
grading	NN	O
,	,	O
TCM	NNP	O
and	CC	O
platelets	NNS	O
as	IN	O
the	DT	O
most	RBS	O
reliable	JJ	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
data	NNS	O
the	DT	O
Durie/Salmon	NNP	O
classification	NN	O
could	MD	O
be	VB	O
improved	VBN	O
by	IN	O
defining	VBG	O
poor	JJ	Educational
prognosis	NN	Educational
patients	NNS	O
(	(	O
50	CD	O
%	NN	O
TRS	NNP	O
:	:	O
16	CD	O
months	NNS	O
)	)	O
characterised	VBN	O
by	IN	O
pretreatment	JJ	O
platelets	NNS	O
of	IN	O
<	NN	O
or	CC	O
=	$	O
150,000	CD	O
and/or	JJ	O
poorly	RB	O
differentiated	VBN	O
myeloma	NN	O
cell	NN	O
morphology	NN	O
.	.	O

Patients	NNS	O
lacking	VBG	O
both	DT	O
risk	NN	O
factors	NNS	O
displayed	VBD	O
50	CD	O
%	NN	O
survival	JJ	O
times	NNS	O
of	IN	O
46	CD	O
months	NNS	O
in	IN	O
stage	NN	O
III	NNP	O
and	CC	O
88	CD	O
months	NNS	O
in	IN	O
stage	NN	O
II	NNP	O
.	.	O

Efficacy	NN	O
of	IN	O
amantadine	NN	Pharmacological
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
treated	VBD	O
with	IN	O
interferon-alpha	JJ	Pharmacological
and	CC	Pharmacological
ribavirin	NN	Pharmacological
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

AIM	VB	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
whether	IN	O
amantadine	JJ	O
reduces	NNS	O
deterioration	NN	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
during	IN	O
and	CC	O
after	IN	O
treatment	NN	O
with	IN	O
interferon-alpha	JJ	O
(	(	O
IFN-alpha	NNP	O
)	)	O
and	CC	O
ribavirin	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
multicenter	JJ	O
trial	NN	O
,	,	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
IFN-alpha	NNP	Pharmacological
plus	CC	Pharmacological
ribavirin	JJ	Pharmacological
[	NN	Pharmacological
17	CD	Pharmacological
]	NN	Pharmacological
and	CC	O
randomized	VBN	O
for	IN	O
treatment	NN	O
with	IN	O
amantadine	NN	Pharmacological
(	(	O
200	CD	O
mg/day	NN	O
,	,	O
orally	RB	O
,	,	O
n=136	NN	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n=131	JJ	O
)	)	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
'Profile	NN	O
of	IN	O
Mood	NNP	O
States	NNPS	O
'	POS	O
scale	NN	O
and	CC	O
the	DT	O
'Everyday	JJ	O
Life	NNP	O
'	POS	O
questionnaire	NN	O
at	IN	O
baseline	NN	O
,	,	O
treatment	NN	O
week	NN	O
(	(	O
TW	NNP	O
)	)	O
8	CD	O
,	,	O
TW24	NNP	O
,	,	O
TW48	NNP	O
,	,	O
and	CC	O
at	IN	O
follow-up	JJ	O
.	.	O

RESULTS	VB	O
Early	JJ	O
during	IN	O
treatment	NN	O
at	IN	O
TW8	NNP	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
amantadine	NN	O
group	NN	O
.	.	O

At	IN	O
TW24	NNP	O
,	,	O
the	DT	O
control	NN	O
group	NN	O
but	CC	O
not	RB	O
the	DT	O
amantadine	NN	Pharmacological
group	NN	O
,	,	O
however	RB	O
,	,	O
showed	VBD	O
significant	JJ	O
deterioration	NN	O
of	IN	O
the	DT	O
modalities	NNS	O
depression	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
vigor	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
.	.	O

Especially	RB	O
,	,	O
nonresponders	NNS	O
in	IN	O
the	DT	O
amantadine	NN	O
group	NN	O
showed	VBD	O
significantly	RB	O
lower	JJR	O
deterioration	NN	O
of	IN	O
depression	NN	O
,	,	O
anger	NN	O
,	,	O
mind	NN	O
function	NN	O
,	,	O
everyday	JJ	O
life	NN	O
,	,	O
and	CC	O
zest	JJS	O
for	IN	O
life	NN	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
amantadine	NN	O
disappeared	VBN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
addition	NN	O
of	IN	O
amantadine	NN	Pharmacological
to	TO	O
IFN-alpha	NNP	Pharmacological
plus	CC	Pharmacological
ribavirin	JJ	Pharmacological
combination	NN	O
therapy	NN	O
may	MD	O
reduce	VB	O
deterioration	NN	O
of	IN	O
depression	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
vigor	NN	O
during	IN	O
treatment	NN	O
but	CC	O
does	VBZ	O
not	RB	O
affect	JJ	O
quality	NN	O
of	IN	O
life	NN	O
after	IN	O
treatment	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
cyclosporin	NN	Pharmacological
administered	VBN	O
during	IN	O
a	DT	O
third-party	JJ	O
blood	NN	O
transfusion	NN	O
protocol	NN	O
on	IN	O
humoral	JJ	O
immune	JJ	O
responses	NNS	O
.	.	O

Antigen	NNP	Physical
pre-treatment	NN	Physical
in	IN	O
animals	NNS	O
undoubtedly	RB	O
prolongs	NNS	O
graft	NN	O
survival	NN	O
.	.	O

In	IN	O
man	NN	O
,	,	O
however	RB	O
,	,	O
routine	JJ	O
pre-transplantation	NN	O
blood	NN	O
transfusions	NNS	O
have	VBP	O
recently	RB	O
become	VBN	O
controversial	JJ	O
,	,	O
principally	RB	O
because	IN	O
of	IN	O
the	DT	O
adverse	JJ	O
effect	NN	O
of	IN	O
transfusion-induced	JJ	O
sensitisation	NN	O
on	IN	O
graft	NN	O
survival	NN	O
rates	NNS	O
.	.	O

We	PRP	O
have	VBP	O
monitored	VBN	O
the	DT	O
effect	NN	O
of	IN	O
cyclosporin	NN	Pharmacological
administered	VBN	O
during	IN	O
a	DT	O
planned	JJ	O
programme	NN	O
of	IN	O
third-party	JJ	O
blood	NN	O
transfusions	NNS	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
both	DT	O
cytotoxic	JJ	O
and	CC	O
anti-idiotypic	JJ	O
antibodies	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
24	CD	O
patients	NNS	O
were	VBD	O
recruited	VBN	O
to	TO	O
the	DT	O
study	NN	O
;	:	O
ten	CC	O
received	VBD	O
cyclosporin	NNS	Pharmacological
with	IN	Pharmacological
blood	NN	Pharmacological
transfusions	NNS	Pharmacological
(	(	Pharmacological
BT	NNP	Pharmacological
)	)	Pharmacological
(	(	O
group	NN	O
1	CD	O
)	)	O
,	,	O
14	CD	O
received	VBD	O
BT	NNP	Pharmacological
alone	RB	Pharmacological
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

Anti-HLA	JJ	O
antibodies	NNS	O
developed	VBN	O
in	IN	O
3	CD	O
of	IN	O
9	CD	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
8	CD	O
of	IN	O
12	CD	O
patients	NNS	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Anti-idiotypic	JJ	O
antibody	NN	O
activity	NN	O
was	VBD	O
detectable	JJ	O
in	IN	O
9	CD	O
of	IN	O
9	CD	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
7	CD	O
of	IN	O
12	CD	O
patients	NNS	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.006	CD	O
)	)	O
.	.	O

The	DT	O
mechanism	NN	O
by	IN	O
which	WDT	O
cyclosporin	NN	O
can	MD	O
prevent	VB	O
an	DT	O
anti-HLA	JJ	O
antibody	NN	O
response	NN	O
and	CC	O
promote	VB	O
an	DT	O
anti-idiotypic	JJ	O
response	NN	O
is	VBZ	O
unclear	JJ	O
.	.	O

Feasibility	NN	O
of	IN	O
two	CD	O
dose-dense	JJ	O
FEC	NNP	Pharmacological
regimens	VBZ	O
with	IN	O
growth	NN	Physical
factor	NN	Physical
support	NN	Physical
for	IN	O
adjuvant	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
results	NNS	O
from	IN	O
a	DT	O
randomised	JJ	O
study	NN	O
of	IN	O
the	DT	O
Central	NNP	O
European	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
CECOG	NNP	O
)	)	O
.	.	O

Addition	NN	O
of	IN	O
epirubicin	NN	Pharmacological
to	TO	O
adjuvant	VB	O
chemotherapy	NN	O
can	MD	O
provide	VB	O
important	JJ	O
benefits	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
but	CC	O
the	DT	O
optimal	JJ	O
dose	NN	O
remains	VBZ	O
unclear	JJ	O
.	.	O

Further	JJ	O
improvements	NNS	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
dose-dense	JJ	O
regimens	NNS	O
,	,	O
but	CC	O
densification	NN	O
of	IN	O
fluorouracil/epirubicin/cyclophosphamide	NN	Pharmacological
(	(	Pharmacological
FEC	NNP	Pharmacological
)	)	Pharmacological
has	VBZ	O
proved	VBN	O
difficult	JJ	O
,	,	O
with	IN	O
FEC	NNP	O
(	(	O
60	CD	O
)	)	O
providing	VBG	O
little	JJ	O
benefit	NN	O
over	IN	O
standard	JJ	O
chemotherapy	NN	O
and	CC	O
FEC	NNP	Pharmacological
(	(	Pharmacological
100	CD	Pharmacological
)	)	Pharmacological
associated	VBN	O
with	IN	O
toxicity	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
two	CD	O
intermediate	JJ	O
dose-dense	JJ	Physical
FEC	NNP	Physical
regimens	NNS	Physical
.	.	O

Patients	NNS	O
were	VBD	O
randomised	VBN	O
to	TO	O
six	CD	O
cycles	NNS	O
of	IN	O
FEC	NNP	Pharmacological
(	(	Pharmacological
75	CD	Pharmacological
)	)	Pharmacological
or	CC	O
FEC	NNP	Pharmacological
(	(	Pharmacological
90	CD	Pharmacological
)	)	Pharmacological
,	,	O
with	IN	O
all	DT	O
three	CD	O
drugs	NNS	O
given	VBN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
14-day	JJ	O
cycle	NN	O
.	.	O

Patients	NNS	O
also	RB	O
received	VBD	O
pegfilgrastim	JJ	Pharmacological
6	CD	O
mg	NN	O
as	IN	O
a	DT	O
single	JJ	O
subcutaneous	JJ	O
injection	NN	O
on	IN	O
day	NN	O
2	CD	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
subjects	NNS	O
receiving	VBG	O
>	NN	O
or	CC	O
=85	CD	O
%	NN	O
relative	JJ	O
dose	JJ	O
intensity	NN	O
and	CC	O
was	VBD	O
achieved	VBN	O
by	IN	O
96	CD	O
%	NN	O
and	CC	O
88	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	O
(	(	O
75	CD	O
)	)	O
and	CC	O
FEC	NNP	O
(	(	O
90	CD	O
)	)	O
arms	NNS	O
,	,	O
respectively	RB	O
.	.	O

Of	IN	O
147	CD	O
FEC	NNP	Pharmacological
(	(	Pharmacological
75	CD	Pharmacological
)	)	Pharmacological
infusions	NNS	O
,	,	O
4.1	CD	O
%	NN	O
were	VBD	O
delayed	VBN	O
,	,	O
while	IN	O
9.8	CD	O
%	NN	O
of	IN	O
143	CD	O
FEC	NNP	Pharmacological
(	(	Pharmacological
90	CD	Pharmacological
)	)	Pharmacological
infusions	NNS	O
were	VBD	O
delayed	VBN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
reasons	NNS	O
for	IN	O
delay	NN	O
were	VBD	O
adverse	JJ	O
events	NNS	O
and	CC	O
personal/logistical	JJ	O
reasons	NNS	O
.	.	O

One	CD	O
dose	JJ	O
reduction	NN	O
occurred	VBD	O
during	IN	O
the	DT	O
study	NN	O
(	(	Pharmacological
FEC	NNP	Pharmacological
(	(	Pharmacological
90	CD	Pharmacological
)	)	Pharmacological
)	)	Pharmacological
,	,	O
related	VBN	O
to	TO	O
diarrhoea	VB	O
.	.	O

Grade	VB	O
3-4	JJ	O
haematological	JJ	O
toxicities	NNS	O
were	VBD	O
reported	VBN	O
in	IN	O
two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
FEC	NNP	Pharmacological
(	(	Pharmacological
90	CD	Pharmacological
)	)	Pharmacological
arm	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
incidences	NNS	O
of	IN	O
febrile	JJ	O
neutropenia	NN	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
increases	NNS	O
in	IN	O
liver	NN	O
enzymes	NNS	O
and	CC	O
gastrointestinal	JJ	O
events	NNS	O
;	:	O
no	DT	O
event	NN	O
resulted	VBD	O
in	IN	O
discontinuation	NN	O
.	.	O

Only	RB	O
one	CD	O
patient	NN	O
(	(	Pharmacological
FEC	NNP	Pharmacological
(	(	Pharmacological
90	CD	Pharmacological
)	)	Pharmacological
)	)	Pharmacological
experienced	VBD	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
vomiting	VBG	O
and	CC	O
throat	VB	O
oedema	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
dose-dense	JJ	O
FEC	NNP	Pharmacological
(	(	Pharmacological
75	CD	Pharmacological
)	)	O
and	CC	O
FEC	NNP	Pharmacological
(	(	Pharmacological
90	CD	Pharmacological
)	)	Pharmacological
are	VBP	O
feasible	JJ	O
with	IN	O
pegfilgrastim	JJ	O
support	NN	O
.	.	O

These	DT	O
regimens	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
a	DT	O
very	RB	O
low	JJ	O
risk	NN	O
of	IN	O
Grade	NNP	O
3-4	JJ	O
toxicity	NN	O
.	.	O

In	IN	O
school-aged	JJ	O
children	NNS	O
a	DT	O
combination	NN	O
of	IN	O
galacto-oligosaccharides	NNS	Pharmacological
and	CC	O
Lactobacillus	NNP	Pharmacological
GG	NNP	Pharmacological
increases	VBZ	O
bifidobacteria	RB	O
more	JJR	O
than	IN	O
Lactobacillus	NNP	Pharmacological
GG	NNP	Pharmacological
on	IN	O
its	PRP$	O
own	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
a	DT	O
combination	NN	O
of	IN	O
Lactobacillus	NNP	Pharmacological
GG	NNP	Pharmacological
(	(	Pharmacological
LGG	NNP	Pharmacological
)	)	Pharmacological
and	CC	Pharmacological
galacto-oligosaccharides	NNS	Pharmacological
(	(	Pharmacological
GOS	NNP	Pharmacological
)	)	Pharmacological
with	IN	Pharmacological
LGG	NNP	Pharmacological
on	IN	Pharmacological
its	PRP$	Pharmacological
own	JJ	Pharmacological
,	,	O
and	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
the	DT	O
intestinal	JJ	O
microbiota	NN	O
in	IN	O
school-aged	JJ	O
children	NNS	O
.	.	O

The	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
crossover	NN	O
study	NN	O
comprised	VBD	O
30	CD	O
healthy	JJ	O
children	NNS	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
3-week	JJ	O
study	NN	O
periods	NNS	O
with	IN	O
a	DT	O
4-week	JJ	O
wash-out	JJ	O
period	NN	O
in	IN	O
between	IN	O
.	.	O

The	DT	O
children	NNS	O
ingested	VBD	O
daily	RB	O
65	CD	O
ml	NN	O
of	IN	O
milk-based	JJ	Pharmacological
fruit	NN	Pharmacological
juice	NN	Pharmacological
containing	VBG	Pharmacological
either	CC	Pharmacological
LGG	NNP	Pharmacological
alone	RB	Pharmacological
(	(	O
6.5	CD	O
x	RB	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU	NNP	O
)	)	O
or	CC	O
LGG	NNP	Pharmacological
plus	CC	Pharmacological
2	CD	Pharmacological
g	NN	Pharmacological
of	IN	Pharmacological
GOS	NNP	Pharmacological
.	.	O

Symptom	NNP	O
diaries	NNS	O
were	VBD	O
filled	VBN	O
during	IN	O
the	DT	O
study	NN	O
periods	NNS	O
.	.	O

Fecal	JJ	O
samples	NNS	O
were	VBD	O
collected	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
both	DT	O
study	NN	O
periods	NNS	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
bifidobacteria	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
after	IN	O
the	DT	O
ingestion	NN	O
of	IN	O
LGG	NNP	Pharmacological
+	NNP	Pharmacological
GOS	NNP	Pharmacological
compared	VBN	O
with	IN	O
LGG	NNP	Pharmacological
alone	RB	Pharmacological
(	(	O
geometric	JJ	O
mean	VBP	O
9.33	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
vs.	FW	O
4.28	CD	O
x	$	O
10	CD	O
(	(	O
9	CD	O
)	)	O
CFU/g	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
lactobacilli	NN	O
or	CC	O
LGG	NNP	Pharmacological
,	,	O
nor	CC	O
did	VBD	O
gastrointestinal	JJ	O
symptoms	NNS	O
,	,	O
defecation	NN	O
frequency	NN	O
,	,	O
consistency	NN	O
of	IN	O
stools	NNS	O
or	CC	O
ease	NN	O
of	IN	O
defecation	NN	O
differ	NN	O
between	IN	O
the	DT	O
two	CD	O
study	NN	O
periods	NNS	O
.	.	O

Ingestion	NN	O
of	IN	O
LGG	NNP	Pharmacological
combined	VBD	Pharmacological
with	IN	Pharmacological
2	CD	Pharmacological
g	NN	Pharmacological
of	IN	Pharmacological
GOS	NNP	Pharmacological
increased	VBD	O
the	DT	O
bifidobacteria	NN	O
more	JJR	O
than	IN	O
LGG	NNP	Pharmacological
on	IN	Pharmacological
its	PRP$	Pharmacological
own	JJ	Pharmacological
and	CC	O
thus	RB	O
GOS	NNP	Pharmacological
clearly	RB	O
has	VBZ	O
a	DT	O
prebiotic	JJ	O
effect	NN	O
in	IN	O
children	NNS	O
.	.	O

The	DT	O
children	NNS	O
tolerated	VBN	O
well	RB	O
a	DT	O
daily	JJ	O
intake	NN	O
of	IN	O
2	CD	O
g	NN	O
of	IN	O
GOS	NNP	Pharmacological
.	.	O

Local	JJ	O
contextual	JJ	O
processing	NN	O
in	IN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
study	NN	O
investigated	VBD	O
local	JJ	O
contextual	JJ	O
processing	NN	O
in	IN	O
patients	NNS	O
with	IN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
(	(	O
MDD	NNP	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
ability	NN	O
to	TO	O
utilize	VB	O
predictive	JJ	O
contextual	JJ	O
information	NN	O
to	TO	O
facilitate	VB	O
detection	NN	O
of	IN	O
predictable	JJ	O
versus	NN	O
random	JJ	O
targets	NNS	O
.	.	O

METHOD	NNP	O
We	PRP	O
recorded	VBD	O
EEG	NNP	Physical
in	IN	O
15	CD	O
MDD	NNP	O
patients	NNS	O
and	CC	O
14	CD	O
age-matched	JJ	O
controls	NNS	O
.	.	O

Recording	VBG	Physical
blocks	NNS	Physical
consisted	VBN	Physical
of	IN	Physical
targets	NNS	Physical
preceded	VBN	Physical
by	IN	Physical
randomized	JJ	Physical
sequences	NNS	Physical
of	IN	Physical
standards	NNS	Physical
and	CC	Physical
by	IN	Physical
sequences	NNS	Physical
of	IN	Physical
standards	NNS	Physical
that	WDT	Physical
included	VBD	Physical
a	DT	Physical
predictive	JJ	Physical
sequence	NN	Physical
signaling	VBG	Physical
the	DT	Physical
occurrence	NN	Physical
of	IN	Physical
a	DT	Physical
subsequent	JJ	Physical
target	NN	Physical
event	NN	Physical
.	.	O

RESULTS	NNP	O
Both	NNP	O
MDD	NNP	O
patients	NNS	O
and	CC	O
age-matched	JJ	O
controls	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
reaction	NN	O
time	NN	O
(	(	O
RT	NNP	O
)	)	O
and	CC	O
P3b	NNP	O
latency	NN	O
differences	NNS	O
between	IN	O
predicted	VBN	O
and	CC	O
random	JJ	O
targets	NNS	O
.	.	O

However	RB	O
,	,	O
patients	NNS	O
demonstrated	VBD	O
a	DT	O
specific	JJ	O
prolongation	NN	O
of	IN	O
these	DT	O
measures	NNS	O
during	IN	O
processing	NN	O
of	IN	O
predicted	JJ	O
targets	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
an	DT	O
attenuation	NN	O
of	IN	O
P3b	NNP	O
amplitudes	NNS	O
for	IN	O
the	DT	O
predictive	JJ	O
sequence	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
patients	NNS	O
target	VBP	O
N1	NNP	O
amplitudes	NNS	O
were	VBD	O
attenuated	VBN	O
compared	VBN	O
with	IN	O
controls	NNS	Physical
.	.	O

CONCLUSION	NNP	O
MDD	NNP	O
patients	NNS	O
were	VBD	O
able	JJ	O
to	TO	O
utilize	VB	O
predictive	JJ	O
context	NN	O
in	IN	O
order	NN	O
to	TO	O
facilitate	VB	O
processing	NN	O
of	IN	O
deterministic	JJ	O
targets	NNS	O
,	,	O
however	RB	O
,	,	O
this	DT	O
ability	NN	O
was	VBD	O
limited	VBN	O
compared	VBN	O
to	TO	O
controls	NNS	O
,	,	O
as	IN	O
demonstrated	VBN	O
by	IN	O
context-dependent	JJ	O
P3b	NNP	O
deficits	NNS	O
.	.	O

SIGNIFICANCE	NNP	O
These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
patients	NNS	O
with	IN	O
major	JJ	O
depression	NN	O
have	VBP	O
altered	VBN	O
processing	NN	O
of	IN	O
local	JJ	O
contextual	JJ	O
processing	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
crossover	NN	O
study	NN	O
investigating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
porcine	NN	Pharmacological
secretin	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

OBJECTIVES	CC	O
A	DT	O
recent	JJ	O
patient	NN	O
series	NN	O
reported	VBD	O
the	DT	O
incidental	JJ	O
findings	NNS	O
of	IN	O
improved	VBN	O
social	JJ	O
and	CC	O
language	NN	O
skills	NNS	O
in	IN	O
3	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
secretin	NN	Pharmacological
,	,	O
a	DT	O
peptide	NN	O
hormone	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
subsequent	JJ	O
study	NN	O
did	VBD	O
not	RB	O
find	VB	O
evidence	NN	O
for	IN	O
a	DT	O
drug	NN	O
effect	NN	O
.	.	O

Parents	NNS	O
are	VBP	O
seeking	VBG	O
treatment	NN	O
with	IN	O
secretin	JJ	Pharmacological
despite	IN	O
the	DT	O
absence	NN	O
of	IN	O
empirical	JJ	O
investigations	NNS	O
demonstrating	VBG	O
amelioration	NN	O
in	IN	O
autism	NN	O
symptomology	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
more	RBR	O
precisely	RB	O
measure	VB	O
the	DT	O
effects	NNS	O
of	IN	O
secretin	NN	Pharmacological
,	,	O
this	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	Pharmacological
dose	NN	Pharmacological
of	IN	Pharmacological
porcine	NN	Pharmacological
secretin	NN	Pharmacological
on	IN	O
12	CD	O
autistic	JJ	O
children	NNS	O
through	IN	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
crossover	NN	O
study	NN	O
.	.	O

Children	NNP	O
were	VBD	O
assessed	VBN	O
on	IN	O
objective	JJ	O
language	NN	O
and	CC	O
on	IN	O
social	JJ	O
,	,	O
neuropsychological	JJ	O
,	,	O
and	CC	O
gastrointestinal	JJ	O
measures	NNS	O
to	TO	O
evaluate	VB	O
drug	NN	O
effects	NNS	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
over	IN	O
a	DT	O
16-week	JJ	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
significant	JJ	O
differences	NNS	O
were	VBD	O
not	RB	O
observed	VBN	O
on	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
dependent	JJ	O
variables	NNS	O
.	.	O

Statistically	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
on	IN	O
measures	NNS	O
of	IN	O
positive	JJ	O
affect	NN	O
and	CC	O
activity	NN	O
level	NN	O
following	VBG	O
secretin	JJ	Pharmacological
infusion	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
autistic	JJ	O
children	NNS	O
did	VBD	O
not	RB	O
demonstrate	VB	O
the	DT	O
improvements	NNS	O
described	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
retrospective	JJ	O
report	NN	O
.	.	O

Albendazole	JJ	Pharmacological
trial	NN	O
at	IN	O
15	CD	O
or	CC	O
30	CD	O
mg/kg/day	NN	O
for	IN	O
subarachnoid	NN	O
and	CC	O
intraventricular	JJ	O
cysticercosis	NN	O
.	.	O

Thirty-six	JJ	O
patients	NNS	O
with	IN	O
subarachnoid	JJ	O
and	CC	O
intraventricular	JJ	O
cysticercosis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
albendazole	NN	Pharmacological
at	IN	O
15	CD	O
or	CC	O
30	CD	O
mg/kg/day	JJ	O
plus	CC	O
dexamethasone	NN	Pharmacological
for	IN	O
8	CD	O
days	NNS	O
.	.	O

Results	NNS	O
favored	VBD	O
a	DT	O
higher	JJR	O
dose	NN	O
,	,	O
with	IN	O
larger	JJR	O
cyst	NN	O
reduction	NN	O
on	IN	O
MRI	NNP	O
at	IN	O
90	CD	O
and	CC	O
180	CD	O
days	NNS	O
and	CC	O
higher	JJR	O
albendazole	JJ	O
sulfoxide	NN	O
levels	NNS	O
in	IN	O
plasma	NN	O
.	.	O

An	DT	O
albendazole	JJ	Pharmacological
course	NN	O
at	IN	O
30	CD	O
mg/kg/day	NN	O
combined	VBN	O
with	IN	O
corticosteroids	NNS	Pharmacological
is	VBZ	O
safe	JJ	O
and	CC	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
usual	JJ	O
dose	NN	O
.	.	O

A	DT	O
single	JJ	O
treatment	NN	O
was	VBD	O
insufficient	JJ	O
in	IN	O
intraventricular	JJ	O
and	CC	O
giant	JJ	O
cysts	NNS	O
.	.	O

[	JJ	O
Validity	NNP	O
of	IN	O
cardiotocography	NN	Physical
in	IN	O
the	DT	O
detection	NN	O
of	IN	O
umbilical	JJ	O
cord	NN	O
complications	NNS	O
]	VBP	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
validity	NN	O
of	IN	O
cardiotocography	NN	Physical
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
cord	NN	O
complications	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
low-risk	JJ	O
population	NN	O
of	IN	O
4196	CD	O
cases	NNS	O
was	VBD	O
selected	VBN	O
in	IN	O
which	WDT	O
cord	NN	O
complications	NNS	O
have	VBP	O
been	VBN	O
recognized	VBN	O
in	IN	O
34.3	CD	O
%	NN	O
.	.	O

Cases	VBZ	O
with	IN	O
cord	NN	O
complications	NNS	O
and	CC	O
controls	NNS	O
were	VBD	O
paired	VBN	O
by	IN	O
parity	NN	O
,	,	O
gestational	JJ	O
age	NN	O
,	,	O
maternal	JJ	O
age	NN	O
and	CC	O
mode	NN	O
of	IN	O
delivery	NN	O
.	.	O

25	CD	O
pairs	NNS	O
were	VBD	O
randomly	RB	O
selected	VBN	O
.	.	O

50	CD	O
tracings	NNS	O
were	VBD	O
presented	VBN	O
twice	RB	O
to	TO	O
4	CD	O
obstetricians	NNS	O
in	IN	O
a	DT	O
double-blind	JJ	O
manner	NN	O
.	.	O

As	IN	O
parameters	NNS	O
for	IN	O
the	DT	O
determination	NN	O
of	IN	O
the	DT	O
validity	NN	O
of	IN	O
fetal	JJ	O
monitoring	VBG	O
the	DT	O
reliability	NN	O
,	,	O
positive	JJ	O
(	(	O
ppv	NN	O
)	)	O
and	CC	O
negative	JJ	O
predictive	JJ	O
value	NN	O
(	(	O
npv	JJ	O
)	)	O
,	,	O
sensitivity	NN	O
and	CC	O
specificity	NN	O
were	VBD	O
used	VBN	O
.	.	O

Inter-	JJ	O
and	CC	O
intra-observer	JJ	O
variability	NN	O
were	VBD	O
also	RB	O
examined	VBN	O
.	.	O

RESULTS	NNP	O
Reliability	NNP	O
52	CD	O
%	NN	O
,	,	O
ppv	RB	O
52	CD	O
%	NN	O
,	,	O
npv	RB	O
52	CD	O
%	NN	O
,	,	O
sensitivity	NN	O
46	CD	O
%	NN	O
,	,	O
specificity	NN	O
58	CD	O
%	NN	O
.	.	O

Interobserver	NNP	O
variability	NN	O
:	:	O
All	DT	O
4	CD	O
obstetricians	NNS	O
agreed	VBD	O
in	IN	O
47	CD	O
of	IN	O
100	CD	O
evaluations	NNS	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
agreement	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
controls	NNS	O
(	(	O
63	CD	O
%	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
cord	NN	O
complication	NN	O
group	NN	O
(	(	O
56	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
intraobserver	NN	O
variability	NN	O
was	VBD	O
25	CD	O
%	NN	O
.	.	O

CONCLUSIONS	NNP	O
Cardiotocography	NNP	Physical
is	VBZ	O
not	RB	O
useful	JJ	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
cord	NN	O
complications	NNS	O
.	.	O

The	DT	O
range	NN	O
of	IN	O
possibilities	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
exploited	VBN	O
yet	RB	O
,	,	O
even	RB	O
for	IN	O
the	DT	O
evaluation	NN	O
of	IN	O
the	DT	O
fetal	JJ	O
state	NN	O
.	.	O

Changes	NNS	O
in	IN	O
beta-carotene	NN	O
levels	NNS	O
by	IN	O
long-term	JJ	O
administration	NN	O
of	IN	O
natural	JJ	Pharmacological
beta-carotene	JJ	Pharmacological
derived	VBN	O
from	IN	O
Dunaliella	NNP	O
bardawil	NN	O
in	IN	O
humans	NNS	O
.	.	O

Long-term	JJ	O
administration	NN	O
of	IN	O
a	DT	O
beta-carotene	JJ	Pharmacological
preparation	NN	Pharmacological
derived	VBN	O
from	IN	O
Dunaliella	NNP	O
bardawil	NN	O
,	,	O
a	DT	O
beta-carotene-rich	JJ	Pharmacological
algae	NN	Pharmacological
,	,	O
was	VBD	O
studied	VBN	O
in	IN	O
healthy	JJ	O
young	JJ	O
male	NN	O
volunteers	NNS	O
.	.	O

The	DT	O
daily	JJ	O
administration	NN	O
of	IN	O
60	CD	Pharmacological
mg	NN	Pharmacological
of	IN	Pharmacological
the	DT	Pharmacological
beta-carotene	JJ	Pharmacological
preparation	NN	Pharmacological
(	(	O
30	CD	O
mg	NN	O
of	IN	O
all-trans	JJ	O
beta-carotene	NN	O
and	CC	O
30	CD	O
mg	NN	O
of	IN	O
9-cis	JJ	O
beta-carotene	NN	O
)	)	O
was	VBD	O
performed	VBN	O
and	CC	O
beta-carotene	JJ	O
concentrations	NNS	O
were	VBD	O
determined	VBN	O
in	IN	O
the	DT	O
plasma	NN	O
,	,	O
red	JJ	O
blood	NN	O
cells	NNS	O
(	(	O
RBC	NNP	O
)	)	O
,	,	O
platelets	NNS	O
(	(	O
PLT	NNP	O
)	)	O
,	,	O
and	CC	O
mononuclear	JJ	O
cells	NNS	O
(	(	O
MN	NNP	O
)	)	O
.	.	O

The	DT	O
all-trans	JJ	O
beta-carotene	JJ	O
level	NN	O
increased	VBD	O
four-	JJ	O
,	,	O
two-	JJ	O
,	,	O
and	CC	O
threefold	VBD	O
the	DT	O
baseline	NN	O
in	IN	O
plasma	NN	O
,	,	O
PLT	NNP	O
,	,	O
and	CC	O
MN	NNP	O
,	,	O
respectively	RB	O
.	.	O

Basal	NNP	O
levels	NNS	O
of	IN	O
9-cis	CD	O
beta-carotene	NN	O
in	IN	O
plasma	NN	O
,	,	O
PLT	NNP	O
,	,	O
and	CC	O
MN	NNP	O
were	VBD	O
low	JJ	O
and	CC	O
found	VBN	O
as	IN	O
one-tenth	JJ	O
,	,	O
one-fifth	JJ	O
,	,	O
and	CC	O
one-fifth	JJ	O
of	IN	O
all-trans	JJ	O
beta-carotene	NN	O
,	,	O
which	WDT	O
increased	VBD	O
three-	NN	O
,	,	O
two-	JJ	O
,	,	O
and	CC	O
1.5-fold	JJ	O
the	DT	O
baseline	NN	O
,	,	O
respectively	RB	O
.	.	O

Plasma	NNP	O
and	CC	O
RBC	NNP	O
alpha-tocopherol	NN	O
levels	NNS	O
were	VBD	O
not	RB	O
changed	VBN	O
by	IN	O
the	DT	O
intake	NN	O
of	IN	O
beta-carotene	NN	O
.	.	O

No	DT	O
side	NN	O
effects	NNS	O
or	CC	O
toxicities	NNS	O
were	VBD	O
documented	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
subjects	NNS	O
during	IN	O
the	DT	O
administration	NN	O
period	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
bioavailability	NN	O
of	IN	O
beta-carotene	JJ	O
derived	VBN	O
from	IN	O
Dunaliella	NNP	O
bardawil	NN	O
was	VBD	O
preferential	JJ	O
for	IN	O
all-trans	JJ	O
beta-carotene	NN	O
,	,	O
although	IN	O
a	DT	O
small	JJ	O
amount	NN	O
of	IN	O
the	DT	O
9-cis	JJ	O
form	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
plasma	NN	O
and	CC	O
blood	NN	O
cells	NNS	O
.	.	O

Humoral	NNP	O
immune	JJ	O
response	NN	O
to	TO	O
tetanus-diphtheria	JJ	Pharmacological
vaccine	NN	Pharmacological
given	VBN	O
during	IN	O
extended	VBN	O
use	NN	O
of	IN	O
chloroquine	NN	Pharmacological
or	CC	O
primaquine	NN	Pharmacological
malaria	NNS	Pharmacological
chemoprophylaxis	NN	Pharmacological
.	.	O

Immune	NNP	O
suppression	NN	O
resulting	VBG	O
from	IN	O
prolonged	VBN	O
chemoprophylaxis	NN	O
and	CC	O
potential	JJ	O
drug-vaccine	JJ	O
interaction	NN	O
were	VBD	O
investigated	VBN	O
within	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
placebo-controlled	JJ	Control
trial	NN	O
that	WDT	O
compared	VBN	O
daily	RB	O
primaquine	NN	Pharmacological
or	CC	O
weekly	JJ	O
chloroquine	NN	Pharmacological
administration	NN	O
for	IN	O
malaria	JJ	O
prevention	NN	O
.	.	O

After	IN	O
11	CD	O
months	NNS	O
of	IN	O
prophylaxis	NN	O
,	,	O
adult	VB	O
male	JJ	O
subjects	NNS	O
received	VBD	O
a	DT	O
tetanus-diphtheria	NN	Pharmacological
(	(	Pharmacological
Td	NNP	Pharmacological
)	)	Pharmacological
vaccination	NN	Pharmacological
.	.	Pharmacological

Prophylaxis	NNP	O
continued	VBD	O
4	CD	O
weeks	NNS	O
longer	RBR	O
.	.	O

Anti-tetanus	JJ	O
and	CC	O
anti-diphtheria	JJ	O
antibody	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
ELISA	NNP	Pharmacological
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
and	CC	O
14	CD	O
months	NNS	O
after	IN	O
Td	NNP	O
vaccination	NN	O
.	.	O

All	DT	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
at	IN	O
baseline	NN	O
.	.	O

Immunization	NN	O
triggered	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
anti-tetanus	JJ	O
and	CC	O
anti-diphtheria	JJ	O
IgG	NNP	O
levels	NNS	O
over	IN	O
each	DT	O
group	NN	O
's	POS	O
pre-Td	JJ	O
baseline	NN	O
levels	NNS	O
and	CC	O
those	DT	O
of	IN	O
an	DT	O
unvaccinated	JJ	O
control	NN	O
group	NN	O
.	.	O

Geometric	JJ	O
mean	JJ	O
anti-tetanus	JJ	O
titers	NNS	O
(	(	O
GMTs	NNP	O
)	)	O
in	IN	O
the	DT	O
primaquine	NN	O
group	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
the	DT	O
placebo	NN	Pharmacological
group	NN	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
14	CD	O
months	NNS	O
.	.	O

Anti-tetanus	NNP	O
GMTs	NNP	O
in	IN	O
placebo	NN	Control
and	CC	O
chloroquine	NN	O
groups	NNS	O
declined	VBD	O
over	IN	O
14	CD	O
months	NNS	O
to	TO	O
levels	NNS	O
comparable	JJ	O
to	TO	O
those	DT	O
of	IN	O
unvaccinated	JJ	O
controls	NNS	O
,	,	O
but	CC	O
levels	NNS	O
in	IN	O
the	DT	O
primaquine	NN	O
group	NN	O
remained	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
in	IN	O
controls	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
ezetimibe/simvastatin	JJ	Pharmacological
versus	NN	O
simvastatin	NN	Pharmacological
monotherapy	NN	Pharmacological
on	IN	O
platelet	NN	O
and	CC	O
inflammatory	JJ	O
biomarkers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	NN	O
study	NN	O
of	IN	O
15	CD	O
aspirin-naive	JJ	Pharmacological
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
48.8	CD	O
?	.	O
10.2	CD	O
years	NNS	O
)	)	O
with	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
,	,	O
statin	NN	O
monotherapy	NN	O
(	(	O
simvastatin	JJ	O
40	CD	O
mg	JJ	O
daily	RB	O
)	)	O
was	VBD	O
compared	VBN	O
to	TO	O
combination	VB	O
therapy	NN	O
(	(	O
simvastatin	JJ	O
40	CD	O
mg	NN	O
and	CC	O
ezetimibe	$	O
10	CD	O
mg	JJ	O
daily	RB	O
)	)	O
on	IN	O
biomarkers	NNS	O
of	IN	O
inflammation	NN	O
and	CC	O
platelet	NN	O
activity	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
ezetimibe	NN	O
to	TO	O
simvastatin	VB	O
over	RP	O
a	DT	O
4-week	JJ	O
period	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reduced	JJ	O
expression	NN	O
of	IN	O
CD141	NNP	O
(	(	O
thrombomodulin	NN	O
;	:	O
p	CC	O
=	VB	O
0.02	CD	O
)	)	O
,	,	O
platelet	VBP	O
endothelial	JJ	O
cell	NN	O
adhesion	NN	O
molecule	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
CD51/61	NNP	O
(	(	O
vitronectin	JJ	O
receptor	NN	O
;	:	O
p	CC	O
=	VB	O
0.048	CD	O
)	)	O
compared	VBN	O
to	TO	O
statin	VB	O
monotherapy	NN	O
.	.	O

Ezetimibe	NNP	O
added	VBD	O
to	TO	O
simvastatin	VB	O
improves	NNS	O
several	JJ	O
indices	NNS	O
of	IN	O
platelet	NN	O
reactivity	NN	O
beyond	IN	O
statin	JJ	O
monotherapy	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
clinical	JJ	O
relevance	NN	O
of	IN	O
these	DT	O
findings	NNS	O
await	VBP	O
results	NNS	O
of	IN	O
the	DT	O
IMPROVE-IT	NNP	O
trial	NN	O
(	(	O
Improved	NNP	O
Reduction	NNP	O
of	IN	O
Outcomes	NNP	O
:	:	O
Vytorin	NNP	O
Efficacy	NNP	O
International	NNP	O
Trial	NNP	O
)	)	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	Pharmacological
infusion	NN	O
and	CC	O
intensive	JJ	O
injection	NN	O
therapy	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
long-standing	JJ	O
poor	JJ	O
glycemic	JJ	O
control	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
in	IN	O
a	DT	O
randomized	JJ	O
crossover	NN	O
trial	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
infusion	NN	O
in	IN	O
improving	VBG	O
glycemic	JJ	O
control	NN	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
type	JJ	O
1	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
long-standing	JJ	O
poor	JJ	O
glycemic	JJ	O
control	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
79	CD	O
patients	NNS	O
in	IN	O
11	CD	O
Dutch	NN	O
centers	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
16	CD	O
weeks	NNS	O
of	IN	O
continuous	JJ	Pharmacological
subcutaneous	JJ	Pharmacological
insulin	NN	Pharmacological
infusion	NN	Pharmacological
followed	VBN	O
by	IN	O
16	CD	O
weeks	NNS	O
intensive	JJ	Pharmacological
injection	NN	Pharmacological
therapy	NN	Pharmacological
or	CC	O
the	DT	O
reverse	JJ	Pharmacological
order	NN	Pharmacological
.	.	O

Glycemic	NNP	O
control	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
,	,	O
self-reported	JJ	O
hypoglycemic	JJ	O
events	NNS	O
,	,	O
and	CC	O
blood	NN	O
glucose	JJ	O
memory	NN	O
meter	NN	O
read	VBD	O
outs	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
were	VBD	O
assessed	VBN	O
by	IN	O
self-report	JJ	O
questionnaires	NNS	O
administered	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
16	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
As	IN	O
the	DT	O
drop-out	NN	O
rate	NN	O
after	IN	O
crossover	NN	O
was	VBD	O
high	JJ	O
(	(	O
17	CD	O
of	IN	O
79	CD	O
patients	NNS	O
[	JJ	O
22	CD	O
%	NN	O
]	NN	O
)	)	O
,	,	O
we	PRP	O
analyzed	VBD	O
the	DT	O
trial	NN	O
as	IN	O
a	DT	O
parallel	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
using	VBG	O
data	NNS	O
of	IN	O
the	DT	O
first	JJ	O
half	NN	O
of	IN	O
the	DT	O
crossover	NN	O
phase	NN	O
only	RB	O
.	.	O

At	IN	O
16	CD	O
weeks	NNS	O
,	,	O
mean	JJ	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
was	VBD	O
0.84	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-1.31	NNP	O
to	TO	O
-0.36	VB	O
)	)	O
lower	JJR	O
in	IN	O
the	DT	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
infusion	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
insulin	NN	Pharmacological
injection	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Stability	NN	O
of	IN	O
blood	NN	O
glucose	JJ	O
self-measurement	JJ	O
values	NNS	O
,	,	O
expressed	VBD	O
as	IN	O
SD	NNP	O
of	IN	O
the	DT	O
nine-point	JJ	O
blood	NN	O
glucose	NN	O
profiles	NNS	O
,	,	O
improved	VBN	O
in	IN	O
the	DT	O
insulin	NN	O
pump	NN	O
group	NN	O
by	IN	O
29.3	CD	O
+/-	JJ	O
41.1	CD	O
vs.	FW	O
8.2	CD	O
+/-	JJ	O
36.5	CD	O
%	NN	O
in	IN	O
the	DT	O
injection	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.039	CD	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
mild	JJ	O
hypoglycemic	JJ	O
episodes	NNS	O
per	IN	O
patient-week	NN	O
was	VBD	O
0.99	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
0.11-1.87	NN	O
)	)	O
higher	JJR	O
in	IN	O
the	DT	O
insulin	NN	O
pump	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.028	CD	O
)	)	O
.	.	O

Weight	NNP	O
gain	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Scores	NNS	O
on	IN	O
the	DT	O
Short-Form	JJ	O
36-Item	JJ	O
subscales	NNS	O
'general	POS	O
health	NN	O
'	''	O
and	CC	O
'mental	JJ	O
health	NN	O
'	''	O
improved	VBN	O
in	IN	O
the	DT	O
continuous	JJ	O
subcutaneous	JJ	O
insulin	NN	O
infusion	NN	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
stable	JJ	O
values	NNS	O
in	IN	O
the	DT	O
injection	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.048	CD	O
and	CC	O
0.050	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Continuous	NNP	O
subcutaneous	JJ	O
insulin	NN	Pharmacological
infusion	NN	O
improves	VBZ	O
glycemic	JJ	O
control	NN	O
and	CC	O
some	DT	O
aspects	NNS	O
of	IN	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
long-term	JJ	O
poor	JJ	O
glycemic	JJ	O
control	NN	O
.	.	O

Short-course	JJ	O
nitrofurantoin	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	NN	O
uncomplicated	JJ	O
cystitis	NN	O
in	IN	O
women	NNS	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
a	DT	O
paucity	NN	O
of	IN	O
data	NNS	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
nitrofurantoin	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	NN	O
uncomplicated	JJ	O
cystitis	NN	O
in	IN	O
regimens	NNS	O
shorter	JJR	O
than	IN	O
7	CD	O
days	NNS	O
.	.	O

Evidence-based	JJ	O
use	NN	O
of	IN	O
this	DT	O
drug	NN	O
is	VBZ	O
increasingly	RB	O
important	JJ	O
as	IN	O
trimethoprim-sulfamethoxazole	JJ	Pharmacological
resistance	NN	O
among	IN	O
uropathogens	JJ	O
increases	NNS	O
.	.	O

METHODS	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
nitrofurantoin	JJ	Pharmacological
vs	JJ	O
trimethoprim-sulfamethoxazole	NN	Pharmacological
,	,	O
338	CD	O
women	NNS	O
aged	VBD	O
18	CD	O
to	TO	O
45	CD	O
years	NNS	O
with	IN	O
acute	NN	O
uncomplicated	JJ	O
cystitis	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
open-label	JJ	O
treatment	NN	O
with	IN	O
either	DT	O
trimethoprim-sulfamethoxazole	JJ	Pharmacological
,	,	O
1	CD	O
double-strength	JJ	O
tablet	NN	O
twice	RB	O
daily	RB	O
for	IN	O
3	CD	O
days	NNS	O
,	,	O
or	CC	O
nitrofurantoin	RB	Pharmacological
,	,	O
100	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
5	CD	O
days	NNS	O
.	.	O

Clinical	JJ	O
cure	NN	O
30	CD	O
days	NNS	O
after	IN	O
therapy	NN	O
was	VBD	O
the	DT	O
main	JJ	O
outcome	NN	O
measure	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
clinical	JJ	O
and	CC	O
microbiological	JJ	O
cure	NN	O
rates	NNS	O
5	CD	O
to	TO	O
9	CD	O
days	NNS	O
after	IN	O
therapy	NN	O
and	CC	O
,	,	O
for	IN	O
trimethoprim-sulfamethoxazole-treated	JJ	Pharmacological
women	NNS	O
,	,	O
clinical	JJ	O
cure	NN	O
stratified	VBN	O
by	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	Pharmacological
susceptibility	NN	O
of	IN	O
the	DT	O
uropathogen	NN	O
.	.	O

RESULTS	NNP	O
Clinical	JJ	O
cure	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
79	CD	O
%	NN	O
of	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	O
group	NN	O
and	CC	O
in	IN	O
84	CD	O
%	NN	O
of	IN	O
the	DT	O
nitrofurantoin	NN	O
group	NN	O
,	,	O
for	IN	O
a	DT	O
difference	NN	O
of	IN	O
-5	NN	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-13	CD	O
%	NN	O
to	TO	O
4	CD	O
%	NN	O
)	)	O
.	.	O

Clinical	JJ	O
and	CC	O
microbiological	JJ	O
cure	NN	O
rates	NNS	O
at	IN	O
the	DT	O
first	JJ	O
follow-up	JJ	O
visit	NN	O
were	VBD	O
also	RB	O
equivalent	JJ	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

In	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	Pharmacological
arm	NN	O
,	,	O
7	CD	O
of	IN	O
17	CD	O
women	NNS	O
(	(	O
41	CD	O
%	NN	O
)	)	O
with	IN	O
a	DT	O
trimethoprim-sulfamethoxazole-nonsusceptible	JJ	O
isolate	NN	O
had	VBD	O
a	DT	O
clinical	JJ	O
cure	NN	O
compared	VBN	O
with	IN	O
84	CD	O
%	NN	O
of	IN	O
women	NNS	O
with	IN	O
a	DT	O
trimethoprim-sulfamethoxazole-susceptible	JJ	O
isolate	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	DT	O
5-day	JJ	O
course	NN	O
of	IN	O
nitrofurantoin	NN	O
is	VBZ	O
equivalent	JJ	O
clinically	RB	O
and	CC	O
microbiologically	RB	O
to	TO	O
a	DT	O
3-day	JJ	O
course	NN	O
of	IN	O
trimethoprim-sulfamethoxazole	JJ	O
and	CC	O
should	MD	O
be	VB	O
considered	VBN	O
an	DT	O
effective	JJ	O
fluoroquinolone-sparing	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
cystitis	NN	O
in	IN	O
women	NNS	O
.	.	O

Intensive	JJ	Educational
case	NN	Educational
management	NN	Educational
before	IN	O
and	CC	O
after	IN	O
prison	NN	O
release	NN	O
is	VBZ	O
no	DT	O
more	RBR	O
effective	JJ	O
than	IN	O
comprehensive	JJ	Physical
pre-release	JJ	Physical
discharge	NN	Physical
planning	NN	Physical
in	IN	O
linking	VBG	O
HIV-infected	JJ	O
prisoners	NNS	O
to	TO	O
care	VB	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

Imprisonment	NNP	O
provides	VBZ	O
opportunities	NNS	O
for	IN	O
the	DT	O
diagnosis	NN	O
and	CC	O
successful	JJ	O
treatment	NN	O
of	IN	O
HIV	NNP	O
,	,	O
however	RB	O
,	,	O
the	DT	O
benefits	NNS	O
of	IN	O
antiretroviral	JJ	Physical
therapy	NN	Physical
are	VBP	O
frequently	RB	O
lost	VBN	O
following	VBG	O
release	NN	O
due	JJ	O
to	TO	O
suboptimal	JJ	O
access	NN	O
and	CC	O
utilization	NN	O
of	IN	O
health	NN	O
care	NN	O
and	CC	O
services	NNS	O
.	.	O

In	IN	O
response	NN	O
,	,	O
some	DT	O
have	VBP	O
advocated	VBN	O
for	IN	O
development	NN	O
of	IN	O
intensive	JJ	O
case-management	JJ	O
interventions	NNS	O
spanning	VBG	O
incarceration	NN	O
and	CC	O
release	NN	O
to	TO	O
support	VB	O
treatment	NN	O
adherence	NN	O
and	CC	O
community	NN	O
re-entry	NN	O
for	IN	O
HIV-infected	JJ	O
releasees	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
a	DT	O
motivational	JJ	Educational
Strengths	NNP	Educational
Model	NNP	Educational
bridging	VBG	Educational
case	NN	Educational
management	NN	Educational
intervention	NN	Educational
(	(	Educational
BCM	NNP	Educational
)	)	Educational
beginning	VBG	O
approximately	RB	O
3	CD	O
months	NNS	O
prior	RB	O
to	TO	O
and	CC	O
continuing	VBG	O
6	CD	O
months	NNS	O
after	IN	O
release	NN	O
versus	IN	O
a	DT	O
standard	NN	O
of	IN	O
care	NN	O
prison-administered	JJ	O
discharge	NN	O
planning	VBG	O
program	NN	O
(	(	O
SOC	NNP	O
)	)	O
for	IN	O
HIV-infected	JJ	O
state	NN	O
prison	NN	O
inmates	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
variable	NN	O
was	VBD	O
self-reported	JJ	O
access	NN	O
to	TO	O
post-release	VB	O
medical	JJ	O
care	NN	O
.	.	O

Of	IN	O
the	DT	O
104	CD	O
inmates	NNS	O
enrolled	VBD	O
,	,	O
89	CD	O
had	VBD	O
at	IN	O
least	JJS	O
1	CD	O
post-release	JJ	O
study	NN	O
visit	NN	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
65.1	CD	O
%	NN	O
of	IN	O
BCM	NNP	O
and	CC	O
54.4	CD	O
%	NN	O
of	IN	O
SOC	NNP	O
assigned	VBD	O
participants	NNS	O
attended	VBD	O
a	DT	O
routine	JJ	O
medical	JJ	O
appointment	NN	O
within	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
release	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.3	CD	O
)	)	O
.	.	O

By	IN	O
week	NN	O
12	CD	O
post-release	NN	O
,	,	O
88.4	CD	O
%	NN	O
of	IN	O
the	DT	O
BCM	NNP	O
arm	NN	O
and	CC	O
78.3	CD	O
%	NN	O
of	IN	O
the	DT	O
SOC	NNP	O
arm	NN	O
had	VBD	O
at	IN	O
attended	VBN	O
at	IN	O
least	JJS	O
one	CD	O
medical	JJ	O
appointment	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.2	CD	O
)	)	O
,	,	O
increasing	VBG	O
in	IN	O
both	DT	O
arms	NNS	O
at	IN	O
week	NN	O
24-90.7	CD	O
%	NN	O
with	IN	O
BCM	NNP	O
and	CC	O
89.1	CD	O
%	NN	O
with	IN	O
SOC	NNP	O
(	(	O
P	NNP	O
>	NNP	O
0.5	CD	O
)	)	O
.	.	O

No	DT	O
participant	NN	O
without	IN	O
a	DT	O
routine	JJ	O
medical	JJ	O
visit	NN	O
by	IN	O
week	NN	O
24	CD	O
attended	VBD	O
an	DT	O
appointment	NN	O
from	IN	O
weeks	NNS	O
24	CD	O
to	TO	O
48	CD	O
.	.	O

The	DT	O
mean	JJ	O
number	NN	O
of	IN	O
clinic	JJ	O
visits	NNS	O
during	IN	O
the	DT	O
48	CD	O
weeks	NNS	O
post	NN	O
release	NN	O
was	VBD	O
5.23	CD	O
(	(	O
SD	NNP	O
=	NNP	O
3.14	CD	O
)	)	O
for	IN	O
BCM	NNP	O
and	CC	O
4.07	CD	O
(	(	O
SD	NNP	O
=	NNP	O
3.20	CD	O
)	)	O
for	IN	O
SOC	NNP	O
(	(	O
P	NNP	O
>	NNP	O
0.5	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
arms	NNS	O
in	IN	O
social	JJ	O
service	NN	O
utilization	NN	O
and	CC	O
re-incarceration	NN	O
rates	NNS	O
were	VBD	O
also	RB	O
similar	JJ	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
a	DT	O
case	NN	O
management	NN	O
intervention	NN	O
bridging	VBG	O
incarceration	NN	O
and	CC	O
release	NN	O
was	VBD	O
no	DT	O
more	RBR	O
effective	JJ	O
than	IN	O
a	DT	O
less	RBR	O
intensive	JJ	O
pre-release	JJ	O
discharge	NN	O
planning	VBG	O
program	NN	O
in	IN	O
supporting	VBG	O
health	NN	O
and	CC	O
social	JJ	O
service	NN	O
utilization	NN	O
for	IN	O
HIV-infected	JJ	O
individuals	NNS	O
released	VBN	O
from	IN	O
prison	NN	O
.	.	O

Position	NN	O
of	IN	O
anterior	JJ	O
capsulorhexis	NN	O
and	CC	O
posterior	JJ	O
capsule	NN	O
opacification	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
whether	IN	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
anterior	JJ	O
continuous	JJ	O
curvilinear	NN	O
capsulorhexis	NN	O
influences	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
posterior	JJ	O
capsule	NN	O
opacification	NN	O
(	(	O
PCO	NNP	O
)	)	O
.	.	O

METHODS	CC	O
A	DT	O
total	NN	O
of	IN	O
119	CD	O
patients	NNS	O
,	,	O
aged	VBN	O
61-86	CD	O
years	NNS	O
,	,	O
underwent	JJ	O
cataract	NN	O
surgery	NN	O
with	IN	O
phacoemulsification	NN	O
performed	VBN	O
by	IN	O
a	DT	O
single	JJ	O
surgeon	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
implantation	NN	O
with	IN	O
either	CC	O
a	DT	O
silicone	NN	Physical
intraocular	NN	Physical
lens	NNS	Physical
(	(	Physical
IOL	NNP	Physical
)	)	Physical
(	(	O
SI40NB	NNP	Physical
,	,	Physical
Allergan	NNP	Physical
)	)	O
or	CC	O
an	DT	O
AcrySof	NNP	Physical
IOL	NNP	Physical
(	(	O
MA60BM	NNP	O
,	,	O
Alcon	NNP	O
)	)	O
.	.	O

Three	CD	O
years	NNS	O
after	IN	O
surgery	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
PCO	NNP	O
was	VBD	O
analysed	VBN	O
using	VBG	O
the	DT	O
evaluation	NN	O
of	IN	O
posterior	JJ	O
capsule	NN	O
opacification	NN	O
computer	NN	O
software	NN	O
(	(	O
EPCO	NNP	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
related	VBN	O
to	TO	O
the	DT	O
capsulorhexis	NN	O
position	NN	O
,	,	O
which	WDT	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
retroillumination	NN	O
photograph	NN	O
.	.	O

RESULTS	VB	O
If	IN	O
the	DT	O
capsulorhexis	NN	O
was	VBD	O
located	VBN	O
partially	RB	O
or	CC	O
completely	RB	O
off	IN	O
the	DT	O
optics	NNS	O
of	IN	O
the	DT	O
IOL	NNP	O
,	,	O
compared	VBN	O
to	TO	O
totally	RB	O
on	IN	O
the	DT	O
IOL	NNP	O
,	,	O
significantly	RB	O
more	JJR	O
PCO	NNP	O
was	VBD	O
found	VBN	O
(	(	O
p	JJ	O
=	NNP	O
0.0014	CD	O
)	)	O
.	.	O

When	WRB	O
comparing	VBG	O
within	IN	O
each	DT	O
IOL	NNP	O
type	NN	O
,	,	O
patients	NNS	O
with	IN	O
AcrySof	NNP	O
IOLs	NNP	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
significantly	RB	O
less	JJR	O
PCO	NNP	O
when	WRB	O
the	DT	O
capsulorhexis	NN	O
was	VBD	O
totally	RB	O
on	IN	O
the	DT	O
optic	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.0048	CD	O
)	)	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
also	RB	O
significant	JJ	O
in	IN	O
the	DT	O
silicone	NN	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.041	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
A	NNP	O
relatively	RB	O
small	JJ	O
and	CC	O
central	JJ	O
capsulorhexis	NN	O
allowing	VBG	O
for	IN	O
the	DT	O
complete	JJ	O
covering	NN	O
of	IN	O
the	DT	O
IOL	NNP	Physical
optics	NNS	Physical
by	IN	O
the	DT	O
rhexis	NN	O
edges	VBZ	O
seems	VBZ	O
to	TO	O
protect	VB	O
against	IN	O
PCO	NNP	O
in	IN	O
cataract	NN	O
surgery	NN	O
,	,	O
with	IN	O
both	DT	O
round-edged	JJ	O
silicone	NN	O
IOLs	NNP	O
and	CC	O
sharp-edged	JJ	O
hydrophobic	JJ	O
acrylic	JJ	Physical
IOLs	NNP	Physical
.	.	O

Maternal	NNP	Educational
dietary	JJ	Educational
counseling	NN	Educational
in	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
healthy	JJ	O
eating	VBG	O
index	NN	O
in	IN	O
childhood	NN	O
.	.	O

Food	NNP	O
preferences	NNS	O
are	VBP	O
established	VBN	O
in	IN	O
early	JJ	O
childhood	NN	O
and	CC	O
track	NN	O
later	RB	O
in	IN	O
life	NN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
promote	VB	O
healthy	JJ	O
feeding	NN	O
practices	NNS	O
as	RB	O
early	RB	O
as	IN	O
possible	JJ	O
.	.	O

A	DT	O
randomized	JJ	O
field	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
500	CD	O
mother-child	JJ	O
pairs	NNS	O
from	IN	O
a	DT	O
low-income	JJ	O
area	NN	O
of	IN	O
S?o	NNP	O
Leopoldo	NNP	O
,	,	O
State	NNP	O
of	IN	O
Rio	NNP	O
Grande	NNP	O
do	VBP	O
Sul	NNP	O
,	,	O
Brazil	NNP	O
,	,	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
nutritional	JJ	O
intervention	NN	O
in	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
on	IN	O
the	DT	O
dietary	JJ	O
quality	NN	O
of	IN	O
3-	JJ	O
to	TO	O
4-y-old	JJ	O
children	NNS	O
.	.	O

Mother-child	JJ	O
pairs	NNS	O
were	VBD	O
randomized	VBN	O
either	RB	O
to	TO	O
intervention	NN	O
and	CC	O
control	NN	O
groups	NNS	O
and	CC	O
dietary	JJ	O
counseling	NN	O
was	VBD	O
provided	VBN	O
for	IN	O
mothers	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
during	IN	O
10	CD	O
home	NN	O
visits	NNS	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
.	.	O

These	DT	O
visits	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
by	IN	O
fieldworkers	NNS	O
who	WP	O
counseled	VBD	O
the	DT	O
mothers	NNS	O
about	IN	O
the	DT	O
Ten	NNP	O
Steps	NNP	O
for	IN	O
Healthy	NNP	O
Feeding	VBG	O
from	IN	O
Birth	NNP	O
to	TO	O
Two	CD	O
Years	NNS	O
of	IN	O
Age	NNP	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
WHO	NNP	O
guidelines	NNS	O
.	.	O

Dietary	JJ	O
intake	NN	O
was	VBD	O
assessed	VBN	O
at	IN	O
3-4	JJ	O
y	NN	O
of	IN	O
age	NN	O
for	IN	O
345	CD	O
children	NNS	O
using	VBG	O
two	CD	O
24-h	JJ	O
food	NN	O
recalls	NNS	O
.	.	O

Overall	JJ	O
diet	JJ	O
quality	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
Healthy	NNP	O
Eating	NNP	O
Index	NNP	O
.	.	O

The	DT	O
prevalence	NN	O
of	IN	O
poor	JJ	O
diet	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
was	VBD	O
lower	JJR	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
[	NNP	O
relative	NN	O
risk	NN	O
(	(	O
RR	NNP	O
)	)	O
=	VBZ	O
0.30	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
0.13-0.71	NN	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
children	NNS	O
who	WP	O
achieved	VBD	O
the	DT	O
75th	CD	O
percentile	NN	O
for	IN	O
the	DT	O
vegetable	JJ	O
and	CC	O
fruit	JJ	O
component	NN	O
score	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
intervention	NN	O
than	IN	O
in	IN	O
control	NN	O
group	NN	O
(	(	O
RR	NNP	O
=	NNP	O
1.95	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.31-2.89	JJ	O
and	CC	O
RR	NNP	O
=	NNP	O
1.49	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
=	NNP	O
1.07-2.07	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Such	JJ	O
data	NNS	O
provide	VBP	O
evidence	NN	O
that	IN	O
dietary	JJ	O
counseling	NN	O
for	IN	O
mothers	NNS	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
life	NN	O
improves	VBZ	O
the	DT	O
overall	JJ	O
dietary	JJ	O
quality	NN	O
of	IN	O
children	NNS	O
in	IN	O
a	DT	O
low-income	JJ	O
population	NN	O
.	.	O

Sustained	JJ	O
benefit	NN	O
of	IN	O
continuous	JJ	O
glucose	JJ	O
monitoring	NN	O
on	IN	O
A1C	NNP	O
,	,	O
glucose	JJ	O
profiles	NNS	O
,	,	O
and	CC	O
hypoglycemia	NN	O
in	IN	O
adults	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
long-term	JJ	O
effects	NNS	O
of	IN	O
continuous	JJ	Physical
glucose	JJ	Physical
monitoring	NN	Physical
(	(	Physical
CGM	NNP	Physical
)	)	Physical
in	IN	O
intensively	RB	O
treated	VBN	O
adults	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
We	PRP	O
studied	VBD	O
83	CD	O
of	IN	O
86	CD	O
individuals	NNS	O
>	JJ	O
or=25	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
who	WP	O
used	VBD	O
CGM	NNP	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
6-month	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
in	IN	O
a	DT	O
subsequent	JJ	O
6-month	JJ	O
extension	NN	O
study	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
12	CD	O
months	NNS	O
,	,	O
median	JJ	O
CGM	NNP	O
use	NN	O
was	VBD	O
6.8	CD	O
days	NNS	O
per	IN	O
week	NN	O
.	.	O

Mean	JJ	O
change	NN	O
in	IN	O
A1C	NNP	O
level	NN	O
from	IN	O
baseline	NN	O
to	TO	O
12	CD	O
months	NNS	O
was	VBD	O
-0.4	JJ	O
+/-	JJ	O
0.6	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
subjects	NNS	O
with	IN	O
baseline	NN	O
A1C	NNP	O
>	NNP	O
or=7.0	MD	O
%	NN	O
.	.	O

A1C	NNP	O
remained	VBD	O
stable	JJ	O
at	IN	O
6.4	CD	O
%	NN	O
in	IN	O
those	DT	O
with	IN	O
baseline	JJ	O
A1C	NNP	O
<	NNP	O
7.0	CD	O
%	NN	O
.	.	O

The	DT	O
incidence	NN	O
rate	NN	O
of	IN	O
severe	JJ	O
hypoglycemia	NN	O
was	VBD	O
21.8	CD	O
and	CC	O
7.1	CD	O
events	NNS	O
per	IN	O
100	CD	O
person-years	NNS	O
in	IN	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
6	CD	O
months	NNS	O
,	,	O
respectively	RB	O
.	.	O

Time	NNP	O
per	IN	O
day	NN	O
with	IN	O
glucose	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
71-180	JJ	O
mg/dl	NN	O
increased	VBN	O
significantly	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
from	IN	O
baseline	NN	O
to	TO	O
12	CD	O
months	NNS	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
intensively	RB	O
treated	VBN	O
adults	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
,	,	O
CGM	NNP	O
use	NN	O
and	CC	O
benefit	NN	O
can	MD	O
be	VB	O
sustained	VBN	O
for	IN	O
12	CD	O
months	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
a	DT	O
spiritually	RB	Educational
based	VBN	Educational
and	CC	Educational
non-spiritually	RB	Educational
based	VBN	Educational
educational	JJ	Educational
intervention	NN	Educational
for	IN	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
church-attending	JJ	O
African-American	JJ	O
men	NNS	O
.	.	O

INTRODUCTION	NNP	O
Health	NNP	Educational
communication	NN	Educational
interventions	NNS	Educational
have	VBP	O
been	VBN	O
modestly	RB	O
effective	JJ	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
among	IN	O
African-American	JJ	O
men	NNS	O
;	:	O
however	RB	O
,	,	O
knowledge	NN	O
and	CC	O
informed	JJ	O
decision	NN	O
making	NN	O
is	VBZ	O
still	RB	O
questionable	JJ	O
even	RB	O
with	IN	O
screening	VBG	O
.	.	O

Church-based	JJ	O
programs	NNS	O
may	MD	O
be	VB	O
more	RBR	O
effective	JJ	O
if	IN	O
they	PRP	O
are	VBP	O
spiritually	RB	O
based	VBN	O
in	IN	O
nature	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aims	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
were	VBD	O
to	TO	O
implement	VB	O
and	CC	O
provide	VB	O
an	DT	O
initial	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
spiritually	RB	O
based	VBN	O
prostate	NN	O
cancer	NN	O
screening	VBG	O
informed	JJ	O
decision	NN	O
making	VBG	O
intervention	NN	O
for	IN	O
African-American	JJ	O
men	NNS	O
who	WP	O
attend	VBP	O
church	NN	O
,	,	O
and	CC	O
determine	VB	O
its	PRP$	O
efficacy	NN	O
for	IN	O
increasing	VBG	O
informed	JJ	O
decision	NN	O
making	NN	O
.	.	O

DESIGN	NNP	O
AND	CC	O
METHOD	NNP	O
Churches	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	CC	O
the	DT	O
spiritually	RB	Educational
based	VBN	Educational
or	CC	Educational
the	DT	Educational
non-spiritual	JJ	Educational
intervention	NN	Educational
.	.	O

Trained	NNP	O
community	NN	O
health	NN	O
advisors	NNS	O
,	,	O
who	WP	O
were	VBD	O
African-American	JJ	O
male	JJ	O
church	NN	O
members	NNS	O
,	,	O
led	VBD	O
an	DT	O
educational	JJ	Educational
session	NN	Educational
and	CC	O
distributed	VBD	Educational
educational	JJ	Educational
print	NN	Educational
materials	NNS	Educational
.	.	Educational

Participants	NNS	O
completed	VBD	O
baseline	NN	O
and	CC	O
immediate	JJ	O
follow-up	JJ	O
surveys	NNS	O
to	TO	O
assess	VB	O
the	DT	O
intervention	NN	O
impact	NN	O
on	IN	O
study	NN	O
outcomes	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
spiritually	RB	O
based	VBN	O
intervention	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
areas	NNS	O
such	JJ	O
as	IN	O
knowledge	NN	O
,	,	O
and	CC	O
men	NNS	O
read	VBP	O
more	JJR	O
of	IN	O
their	PRP$	O
materials	NNS	O
in	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
non-spiritual	JJ	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Further	NNP	O
examination	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
spiritually	RB	O
based	VBN	O
approach	NN	O
to	TO	O
health	NN	O
communication	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Sorafenib	NNP	Pharmacological
dose	JJ	O
escalation	NN	O
is	VBZ	O
not	RB	O
uniformly	RB	O
associated	VBN	O
with	IN	O
blood	NN	O
pressure	NN	O
elevations	NNS	O
in	IN	O
normotensive	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
malignancies	NNS	O
.	.	O

Hypertension	NN	O
after	IN	O
treatment	NN	O
with	IN	O
vascular	JJ	Physical
endothelial	JJ	Physical
growth	NN	Physical
factor	NN	Physical
(	(	Physical
VEGF	NNP	Physical
)	)	Physical
receptor	NN	O
inhibitors	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
superior	JJ	O
treatment	NN	O
outcomes	NNS	O
for	IN	O
advanced	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

To	TO	O
determine	VB	O
whether	IN	O
increased	JJ	O
sorafenib	NN	Pharmacological
doses	NNS	O
cause	VBP	O
incremental	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
we	PRP	O
measured	VBD	O
12-h	JJ	O
ambulatory	NN	O
BP	NNP	O
in	IN	O
41	CD	O
normotensive	JJ	O
advanced	VBD	O
solid	JJ	O
tumor	NN	O
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
dose-escalation	NN	O
study	NN	O
.	.	O

After	IN	O
7	CD	O
days	NNS	O
'	POS	O
treatment	NN	O
(	(	O
400	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

)	)	O
,	,	O
mean	JJ	O
diastolic	JJ	O
BP	NNP	O
(	(	O
DBP	NNP	O
)	)	O
increased	VBD	O
in	IN	O
both	DT	O
study	NN	O
groups	NNS	O
.	.	O

After	IN	O
dose	JJ	O
escalation	NN	O
,	,	O
group	NN	O
A	NNP	O
(	(	O
400	CD	O
mg	NN	O
t.i.d	NN	O
.	.	O

)	)	O
had	VBD	O
marginally	RB	O
significant	JJ	O
further	JJ	O
increase	NN	O
in	IN	O
12-h	JJ	O
mean	NN	O
DBP	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.053	CD	O
)	)	O
,	,	O
but	CC	O
group	NN	O
B	NNP	O
(	(	O
600	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

)	)	O
did	VBD	O
not	RB	O
achieve	VB	O
statistically	RB	O
significant	JJ	O
increases	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.25	CD	O
)	)	O
.	.	O

Within	IN	O
groups	NNS	O
,	,	O
individuals	NNS	O
varied	VBD	O
in	IN	O
BP	NNP	O
response	NN	O
to	TO	O
sorafenib	VB	O
dose	JJ	O
escalation	NN	O
,	,	O
but	CC	O
these	DT	O
differences	NNS	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
changes	NNS	O
in	IN	O
steady-state	JJ	O
plasma	NN	O
sorafenib	NN	O
concentrations	NNS	O
.	.	O

These	DT	O
findings	NNS	O
in	IN	O
normotensive	JJ	O
patients	NNS	O
suggest	VBP	O
BP	NNP	O
is	VBZ	O
a	DT	O
complex	JJ	O
pharmacodynamic	JJ	O
biomarker	NN	O
of	IN	O
VEGF	NNP	O
inhibition	NN	O
.	.	O

Patients	NNS	O
have	VBP	O
intrinsic	JJ	O
differences	NNS	O
in	IN	O
sensitivity	NN	O
to	TO	O
sorafenib	VB	O
's	POS	O
BP-elevating	JJ	O
effects	NNS	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
treatment	NN	O
of	IN	O
non-nephrotic	JJ	O
syndrome	JJ	O
IgA	NNP	O
nephropathy	NN	O
with	IN	O
Shenyanning	NNP	Pharmacological
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
curative	JJ	O
effect	NN	O
of	IN	O
Shenyanning	NNP	Pharmacological
(	(	Pharmacological
SYN	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
non-nephrotic	JJ	O
syndrome	NN	O
IgA	NNP	O
nephropathy	NN	O
(	(	O
IgAN	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Seventy	NNP	O
primary	JJ	O
IgAN	NNP	O
patients	NNS	O
were	VBD	O
equally	RB	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
the	DT	O
treatment	NN	O
group	NN	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
they	PRP	O
were	VBD	O
orally	RB	O
treated	VBN	O
with	IN	O
SYN	NNP	Pharmacological
Decoction	NNP	Pharmacological
(	(	O
one	CD	O
dose	NN	O
per	IN	O
day	NN	O
)	)	O
and	CC	O
Losartan	NNP	Pharmacological
(	(	O
50	CD	O
mg	NNS	O
per	IN	O
day	NN	O
)	)	O
respectively	RB	O
for	IN	O
1	CD	O
year	NN	O
.	.	O

Efficacy	NNP	O
of	IN	O
treatment	NN	O
,	,	O
Chinese	JJ	O
medicine	JJ	O
syndrome	NN	O
scores	NNS	O
,	,	O
end-point	JJ	O
events	NNS	O
occurrence	NN	O
as	RB	O
well	RB	O
as	IN	O
changes	NNS	O
of	IN	O
related	JJ	O
laboratory	NN	O
indices	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
obviously	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
77.1	CD	O
%	NN	O
vs.	FW	O
54.3	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

After	IN	O
treatment	NN	O
,	,	O
the	DT	O
Chinese	JJ	O
medicine	JJ	O
syndrome	NN	O
scores	NNS	O
,	,	O
urinary	JJ	O
protein	NN	O
and	CC	O
urinary	JJ	O
red-cell	NN	O
count	NN	O
reduced	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
or	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
showed	VBD	O
significant	JJ	O
difference	NN	O
as	IN	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
or	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
while	IN	O
the	DT	O
endogenous	JJ	O
creatinine	NN	O
clearance	NN	O
was	VBD	O
changed	VBN	O
insignificantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Beside	NNP	O
,	,	O
the	DT	O
occurrence	NN	O
of	IN	O
end-point	JJ	O
events	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
slightly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
though	IN	O
showed	VBN	O
no	DT	O
statistical	JJ	O
difference	NN	O
between	IN	O
them	PRP	O
.	.	O

CONCLUSION	VB	O
The	DT	O
curative	JJ	O
effect	NN	O
of	IN	O
SYN	NNP	Pharmacological
in	IN	O
treating	VBG	O
IgAN	NNP	O
was	VBD	O
obviously	RB	O
better	JJR	O
than	IN	O
that	DT	O
of	IN	O
simple	JJ	O
Western	JJ	O
medicine	NN	O
.	.	O

Protective	JJ	O
effect	NN	O
of	IN	O
high-dose	JJ	Pharmacological
medroxyprogesterone	NN	Pharmacological
acetate	NN	Pharmacological
(	(	Pharmacological
HD-MPA	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
hematological	JJ	O
toxicity	NN	O
induced	VBN	O
by	IN	O
chemotherapy	NN	Physical
for	IN	O
advanced	JJ	O
solid	JJ	O
tumors	NNS	O
:	:	O
a	DT	O
multicentric	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

MPA-Hematology	NNP	O
Italian	JJ	O
Cooperative	NNP	O
Group	NNP	O
.	.	O

A	NNP	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
comparing	VBG	O
active	JJ	O
treatment	NN	O
with	IN	O
placebo	NN	Control
in	IN	O
227	CD	O
patients	NNS	O
with	IN	O
breast	NN	O
,	,	O
colorectal	NN	O
,	,	O
lung	NN	O
and	CC	O
other	JJ	O
solid	JJ	O
forms	NNS	O
of	IN	O
cancer	NN	O
.	.	O

Combination	NNP	Physical
therapy	NN	Physical
,	,	Physical
(	(	Physical
CT	NNP	Physical
)	)	Physical
conventionally	RB	O
employed	VBN	O
for	IN	O
the	DT	O
various	JJ	O
types	NNS	O
of	IN	O
tumor	NN	O
involved	VBN	O
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
MPA	NNP	Pharmacological
(	(	O
117	CD	O
patients	NNS	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
110	CD	O
patients	NNS	O
)	)	O
.	.	O

MPA	NNP	O
was	VBD	O
given	VBN	O
orally	RB	O
as	IN	O
tablets	NNS	O
,	,	O
as	IN	O
a	DT	O
dose	NN	O
of	IN	O
500	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
,	,	O
briefly	NN	O
,	,	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
incidence	NN	O
of	IN	O
leukopenia	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
MPA	NNP	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
breast	NN	O
and	CC	O
colorectal	JJ	O
cancer	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

Tumors	NNS	O
of	IN	O
the	DT	O
lung	NN	O
and	CC	O
other	JJ	O
solid	JJ	O
forms	NNS	O
showed	VBD	O
no	DT	O
such	JJ	O
difference	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
thrombocytopenia	NN	O
was	VBD	O
the	DT	O
same	JJ	O
in	IN	O
all	DT	O
disease	NN	O
groups	NNS	O
.	.	O

Objective	JJ	O
responses	NNS	O
(	(	O
CR	NNP	O
+	NNP	O
PR	NNP	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
23/46	CD	O
(	(	O
50	CD	O
%	NN	O
)	)	O
of	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
CT	NNP	Physical
+	NNP	Physical
MPA	NNP	Physical
,	,	O
and	CC	O
in	IN	O
13/47	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
of	IN	O
those	DT	O
given	VBN	O
CT	NNP	Control
+	NNP	Control
placebo	NN	Control
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

Subjective	JJ	O
parameters	NNS	O
also	RB	O
showed	VBD	O
more	RBR	O
improvement	NN	O
in	IN	O
the	DT	O
MPA	NNP	Physical
group	NN	O
than	IN	O
in	IN	O
the	DT	O
patients	NNS	O
given	VBN	O
CT	NNP	O
alone	RB	O
.	.	O

No	UH	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
other	JJ	O
types	NNS	O
of	IN	O
tumor	NN	O
,	,	O
but	CC	O
the	DT	O
numbers	NNS	O
in	IN	O
this	DT	O
population	NN	O
were	VBD	O
very	RB	O
limited	JJ	O
.	.	O

In	IN	O
a	DT	O
group	NN	O
of	IN	O
45	CD	O
patients	NNS	O
,	,	O
antithrombin	JJ	O
III	NNP	O
a	DT	O
(	(	O
%	NN	O
)	)	O
,	,	O
antithrombin	JJ	O
III	NNP	O
R	NNP	O
:	:	O
Ag	NNP	O
(	(	O
%	NN	O
)	)	O
,	,	O
plasminogen	NN	O
(	(	O
mg/dl	NN	O
)	)	O
,	,	O
alpha-2	JJ	O
macroglobulin	NN	O
(	(	O
%	NN	O
)	)	O
,	,	O
factor	NN	O
VIII	NNP	O
C	NNP	O
(	(	O
%	NN	O
)	)	O
,	,	O
factor	NN	O
VIII	NNP	O
R	NNP	O
:	:	O
Ag	NNP	O
(	(	O
%	NN	O
)	)	O
and	CC	O
factor	NN	O
IX	NNP	O
C	NNP	O
(	(	O
%	NN	O
)	)	O
were	VBD	O
determined	VBN	O
.	.	O

The	DT	O
most	RBS	O
interesting	JJ	O
post-treatment	JJ	O
findings	NNS	O
were	VBD	O
an	DT	O
increase	NN	O
in	IN	O
anti-thrombin	JJ	O
III	NNP	O
(	(	O
activity	NN	O
and	CC	O
antigen	NN	O
level	NN	O
)	)	O
and	CC	O
in	IN	O
plasminogen	NN	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
MPA	NNP	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
thrombosis	NN	O
,	,	O
and	CC	O
might	MD	O
even	RB	O
,	,	O
to	TO	O
some	DT	O
extent	NN	O
,	,	O
impede	VB	O
tumor-induced	JJ	O
thrombophilia	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
The	DT	O
relationship	NN	O
between	IN	O
histology	NN	O
and	CC	O
outcome	NN	O
in	IN	O
advanced	JJ	O
and	CC	O
recurrent	JJ	O
endometrial	JJ	O
cancer	NN	O
patients	NNS	O
participating	VBG	O
in	IN	O
first-line	JJ	O
chemotherapy	NN	Pharmacological
trials	NNS	O
:	:	O
a	DT	O
Gynecologic	NNP	O
Oncology	NNP	O
Group	NNP	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
explore	VB	O
associations	NNS	O
between	IN	O
histology	NN	O
and	CC	O
outcome	NN	O
in	IN	O
advanced	JJ	O
or	CC	O
recurrent	JJ	O
endometrial	JJ	O
cancer	NN	O
patients	NNS	O
participating	VBG	O
in	IN	O
Gynecologic	NNP	O
Oncology	NNP	O
Group	NNP	O
chemotherapy	NN	O
trials	NNS	O
.	.	O

METHODS	NNP	O
Age	NNP	O
,	,	O
race	NN	O
,	,	O
performance	NN	O
status	NN	O
,	,	O
histologic	JJ	O
type	NN	O
(	(	O
serous=S	JJ	O
;	:	O
clear	JJ	O
cell=CC	NN	O
;	:	O
endometrioid=E	CC	O
)	)	O
,	,	O
disease	JJ	O
stage	NN	O
,	,	O
and	CC	O
prior	JJ	O
radiation	NN	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
various	JJ	Physical
analytic	JJ	Physical
methods	NNS	Physical
to	TO	Physical
evaluate	VB	Physical
the	DT	Physical
probability	NN	Physical
of	IN	Physical
response	NN	Physical
and	CC	Physical
identify	VB	Physical
independent	JJ	Physical
predictors	NNS	Physical
of	IN	Physical
progression-free	JJ	Physical
survival	NN	Physical
(	(	Physical
PFS	NNP	Physical
)	)	Physical
and	CC	Physical
overall	JJ	Physical
survival	NN	Physical
(	(	Physical
OS	NNP	Physical
)	)	Physical
.	.	O

RESULTS	NNP	O
Single	NNP	Pharmacological
agent	NN	Pharmacological
or	CC	O
combination	NN	Pharmacological
chemotherapy	NN	Pharmacological
regimens	VBZ	Pharmacological
including	VBG	O
doxorubicin	NN	Pharmacological
(	(	Pharmacological
A	DT	Pharmacological
)	)	Pharmacological
(	(	O
12	CD	O
%	NN	O
)	)	O
,	,	O
doxorubicin/cisplatin	NN	Pharmacological
(	(	O
AP	NNP	O
)	)	O
(	(	O
63	CD	O
%	NN	O
)	)	O
,	,	O
doxorubicin/paclitaxel	FW	Pharmacological
(	(	O
AT	NNP	O
)	)	O
(	(	O
13	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
paclitaxel/doxorubicin/cisplatin	NN	Pharmacological
(	(	O
TAP	NNP	O
)	)	O
(	(	O
11	CD	O
%	NN	O
)	)	O
were	VBD	O
used	VBN	O
among	IN	O
1203	CD	O
patients	NNS	O
treated	VBN	O
on	IN	O
4	CD	O
randomized	JJ	O
clinical	JJ	O
trials	NNS	O
.	.	O

Breakdown	NNP	O
of	IN	O
disease	NN	O
stage	NN	O
was	VBD	O
7.8	CD	O
%	NN	O
stage	NN	O
III	NNP	O
,	,	O
22.8	CD	O
%	NN	O
stage	NN	O
IV	NNP	O
,	,	O
and	CC	O
69.4	CD	O
%	NN	O
recurrent	JJ	O
disease	NN	O
.	.	O

Histologic	NNP	O
distribution	NN	O
was	VBD	O
18	CD	O
%	NN	O
S	NNP	O
,	,	O
3.7	CD	O
%	NN	O
CC	NNP	O
,	,	O
8.5	CD	O
%	NN	O
mixed	JJ	O
,	,	O
51.7	CD	O
%	NN	O
E	NNP	O
and	CC	O
18.1	CD	O
%	NN	O
other	JJ	O
.	.	O

More	JJR	O
S/CC	JJ	O
patients	NNS	O
enrolled	VBN	O
on	IN	O
trials	NNS	O
with	IN	O
advanced	JJ	O
stage	NN	O
(	(	O
III-IV	NNP	O
)	)	O
disease	NN	O
(	(	O
as	IN	O
opposed	VBN	O
to	TO	O
recurrent	VB	O
disease	NN	O
)	)	O
compared	VBN	O
to	TO	O
E	VB	O
patients	NNS	O
(	(	O
45	CD	O
%	NN	O
vs.	FW	O
24	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Overall	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
42	CD	O
%	NN	O
(	(	O
E=44	NNP	O
%	NN	O
,	,	O
S=44	NNP	O
%	NN	O
,	,	O
CC=32	NNP	O
%	NN	O
)	)	O
.	.	O

Histologic	NNP	O
type	NN	O
was	VBD	O
not	RB	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
response	NN	O
.	.	O

Independent	JJ	O
predictors	NNS	O
of	IN	O
PFS	NNP	O
included	VBD	O
race	NN	O
,	,	O
performance	NN	O
status	NN	O
,	,	O
disease	NN	O
stage	NN	O
,	,	O
and	CC	O
CC	NNP	O
histology	NN	O
.	.	O

Histology	NNP	O
was	VBD	O
also	RB	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
OS	NNP	O
;	:	O
the	DT	O
relative	JJ	O
hazard	NN	O
ratio	NN	O
for	IN	O
S	NNP	O
histology	NN	O
was	VBD	O
1.2	CD	O
(	(	O
1.02-1.4	CD	O
;	:	O
p=0.03	NN	O
)	)	O
,	,	O
and	CC	O
for	IN	O
CC	NNP	O
was	VBD	O
1.51	CD	O
(	(	O
1.1-2.07	CD	O
;	:	O
p=0.01	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
advanced/recurrent	JJ	O
endometrial	JJ	O
cancer	NN	O
treated	VBN	O
with	IN	O
A	NNP	O
,	,	O
P	NNP	O
and/or	VBZ	O
T	NNP	O
,	,	O
response	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
histology	NN	O
.	.	O

This	DT	O
exploratory	JJ	O
analysis	NN	O
does	VBZ	O
not	RB	O
support	VB	O
exclusion	NN	O
of	IN	O
S	NNP	O
tumors	NNS	O
in	IN	O
future	JJ	O
trials	NNS	O
.	.	O

Poorer	NNP	O
PFS	NNP	O
and	CC	O
OS	NNP	O
were	VBD	O
observed	VBN	O
in	IN	O
CC	NNP	O
compared	VBN	O
to	TO	O
other	JJ	O
types	NNS	O
,	,	O
but	CC	O
a	DT	O
lack	NN	O
of	IN	O
benefit	NN	O
from	IN	O
chemotherapy	NN	O
was	VBD	O
not	RB	O
shown	VBN	O
,	,	O
and	CC	O
as	IN	O
this	DT	O
histology	NN	O
represents	VBZ	O
such	PDT	O
a	DT	O
small	JJ	O
fraction	NN	O
,	,	O
it	PRP	O
does	VBZ	O
not	RB	O
seem	VB	O
feasible	JJ	O
to	TO	O
have	VB	O
separate	JJ	O
chemotherapy	NN	O
trials	NNS	O
for	IN	O
CC	NNP	O
.	.	O

5-fluorouracil	JJ	Pharmacological
plus	CC	Pharmacological
folinic	JJ	Pharmacological
acid	NN	Pharmacological
with	IN	O
or	CC	O
without	IN	O
ifosfamide	NN	Pharmacological
in	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
:	:	O
a	DT	O
phase	NN	O
II	NNP	O
randomized	VBD	O
trial	NN	O
.	.	O

AIM	VB	O
This	DT	O
phase	NN	O
II	NNP	O
trial	NN	O
evaluated	VBD	O
the	DT	O
biomodulation	NN	O
of	IN	O
5-fluorouracil	JJ	Pharmacological
(	(	Pharmacological
5-FU	JJ	Pharmacological
)	)	Pharmacological
plus	CC	O
folinic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
FA	NNP	Pharmacological
)	)	Pharmacological
with	IN	O
or	CC	O
without	IN	O
ifosfamide	JJ	Pharmacological
(	(	Pharmacological
IFO	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
chemotherapy-naive	JJ	O
patients	NNS	O
with	IN	O
colorectal	JJ	O
cancer	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Forty-eight	NNP	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
:	:	O
FA	NNP	Pharmacological
(	(	O
25	CD	O
mg/m2	NN	O
iv	NN	O
bolus	JJ	O
days	NNS	O
1	CD	O
to	TO	O
3	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
5-FU	JJ	Pharmacological
(	(	O
750	CD	O
mg/m2	NN	O
iv	NN	O
bolus	JJ	O
days	NNS	O
1	CD	O
to	TO	O
3	CD	O
)	)	O
,	,	O
arm	VBZ	O
A	NNP	O
;	:	O
or	CC	O
FA	NNP	Pharmacological
(	(	O
25	CD	O
mg/m2	NN	O
iv	NN	O
bolus	JJ	O
days	NNS	O
1	CD	O
to	TO	O
3	CD	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
5-FU	JJ	Pharmacological
(	(	O
750	CD	O
mg/m2	NN	O
iv	NN	O
bolus	JJ	O
days	NNS	O
1	CD	O
to	TO	O
3	CD	O
)	)	O
plus	CC	O
IFO	NNP	Pharmacological
(	(	O
2,000	CD	O
mg/m2	NN	O
in	IN	O
1000	CD	O
mL	JJ	O
5	CD	O
%	NN	O
dextrose	NN	O
in	IN	O
a	DT	O
2-hr	JJ	O
infusion	NN	O
,	,	O
days	NNS	O
1	CD	O
to	TO	O
3	CD	O
)	)	O
,	,	O
arm	JJ	O
B.	NNP	O
Mesna	NNP	O
was	VBD	O
added	VBN	O
during	IN	O
and	CC	O
after	IN	O
IFO	NNP	O
to	TO	O
prevent	VB	O
hemorrhagic	JJ	O
cystitis	NN	O
.	.	O

Treatment	NNP	O
was	VBD	O
repeated	VBN	O
every	DT	O
21	CD	O
days	NNS	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

RESULTS	JJ	O
Forty-five	JJ	O
patients	NNS	O
were	VBD	O
assessable	JJ	O
for	IN	O
response	NN	O
:	:	O
in	IN	O
arm	NN	O
A	NNP	O
,	,	O
5	CD	O
patients	NNS	O
achieved	VBD	O
a	DT	O
partial	JJ	O
response	NN	O
(	(	O
overall	JJ	O
response	NN	O
,	,	O
25	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
in	IN	O
arm	NN	O
B	NNP	O
,	,	O
2	CD	O
patients	NNS	O
achieved	VBD	O
a	DT	O
complete	JJ	O
and	CC	O
1	CD	O
a	DT	O
partial	JJ	O
response	NN	O
(	(	O
overall	JJ	O
response	NN	O
,	,	O
12	CD	O
%	NN	O
)	)	O
.	.	O

Time	NN	O
to	TO	O
failure	NN	O
was	VBD	O
3.5	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
1-38	JJ	O
)	)	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
5-FU	JJ	O
plus	CC	O
FA	NNP	O
,	,	O
and	CC	O
3	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
1-21	JJ	O
)	)	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
IFO	NNP	O
combination	NN	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
time	NN	O
was	VBD	O
13.5	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
1-49	JJ	O
months	NNS	O
)	)	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
16	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
1-43	JJ	O
months	NNS	O
)	)	O
in	IN	O
arm	NN	O
B	NNP	O
.	.	O

Diarrhea	NNP	O
,	,	O
stomatitis	NN	O
and	CC	O
vomiting	NN	O
were	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
nonhematologic	JJ	O
toxicities	NNS	O
in	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
most	RBS	O
notable	JJ	O
hematologic	JJ	O
toxicity	NN	O
was	VBD	O
leukopenia	VBN	O
;	:	O
15	CD	O
%	NN	O
and	CC	O
20	CD	O
%	NN	O
of	IN	O
patients	NNS	O
experienced	JJ	O
grade	VBD	O
4	CD	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
arm	NN	O
B	NNP	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NNP	O
IFO	NNP	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
5-FU	JJ	O
plus	CC	O
FA	JJ	O
combination	NN	O
in	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

Examining	VBG	O
the	DT	O
temperature	NN	O
of	IN	O
embryo	JJ	O
culture	NN	O
in	IN	O
in	IN	O
vitro	JJ	O
fertilization	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
comparing	VBG	O
traditional	JJ	O
core	NN	O
temperature	NN	O
(	(	O
37?C	CD	O
)	)	O
to	TO	O
a	DT	O
more	RBR	O
physiologic	JJ	O
,	,	O
cooler	JJ	O
temperature	NN	O
(	(	O
36?C	CD	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
determine	VB	O
whether	IN	O
culture	NN	O
at	IN	O
a	DT	O
more	RBR	O
physiologically	RB	O
cooler	JJ	O
temperature	NN	O
,	,	O
as	IN	O
suggested	VBN	O
by	IN	O
limited	JJ	O
human	NN	O
and	CC	O
animal	NN	O
data	NNS	O
,	,	O
would	MD	O
improve	VB	O
blastulation	NN	O
and	CC	O
pregnancy	NN	O
rates	NNS	O
in	IN	O
human	JJ	O
clinical	JJ	O
IVF	NNP	O
.	.	O

DESIGN	NNP	O
Paired	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
Academic	NNP	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
Infertile	NNP	O
couples	NNS	O
(	(	O
n=52	NN	O
)	)	O
with	IN	O
a	DT	O
female	JJ	O
partner	NN	O
less	JJR	O
than	IN	O
42	CD	O
years	NNS	O
old	JJ	O
with	IN	O
eight	CD	O
or	CC	O
more	JJR	O
mature	JJ	O
oocytes	VBZ	O
retrieved	VBN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
Mature	NNP	O
oocytes	VBZ	O
obtained	VBN	O
from	IN	O
a	DT	O
single	JJ	O
cohort	NN	O
of	IN	O
oocytes	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
;	:	O
one	CD	O
was	VBD	O
cultured	VBN	O
at	IN	O
37?C	CD	O
and	CC	O
the	DT	O
other	JJ	O
at	IN	O
36?C	CD	O
from	IN	O
the	DT	O
time	NN	O
of	IN	O
ICSI	NNP	O
to	TO	O
the	DT	O
time	NN	O
of	IN	O
embryo	NN	O
transfer	NN	O
or	CC	O
vitrification	NN	O
.	.	O

Paired	NNP	O
embryo	JJ	O
transfers	NNS	O
were	VBD	O
accomplished	VBN	O
by	IN	O
transferring	VBG	O
one	CD	O
euploid	JJ	O
embryo	NN	O
from	IN	O
each	DT	O
group	NN	O
.	.	O

DNA	NN	O
fingerprinting	NN	O
was	VBD	O
used	VBN	O
as	IN	O
needed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
outcome	NN	O
for	IN	O
each	DT	O
embryo	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Rate	NNP	O
of	IN	O
development	NN	O
of	IN	O
expanded	JJ	O
blastocysts	NNS	O
suitable	JJ	O
for	IN	O
transfer	NN	O
or	CC	O
vitrification	NN	O
(	(	O
primary	JJ	O
outcome	NN	O
)	)	O
,	,	O
fertilization	NN	O
,	,	O
aneuploidy	NN	O
,	,	O
and	CC	O
sustained	VBD	O
implantation	NN	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
total	NN	O
of	IN	O
805	CD	O
mature	NN	O
oocytes	NNS	O
were	VBD	O
cultured	VBN	O
;	:	O
399	CD	O
at	IN	O
36?C	CD	O
and	CC	O
406	CD	O
at	IN	O
37?C	CD	O
.	.	O

Paired	VBN	O
analysis	NN	O
demonstrated	VBD	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
usable	JJ	O
blastocyst	NN	O
formation	NN	O
per	IN	O
zygote	NN	O
at	IN	O
37?C	CD	O
(	(	O
48.4	CD	O
%	NN	O
)	)	O
vs.	NN	O
at	IN	O
36?C	CD	O
(	(	O
41.2	CD	O
%	NN	O
)	)	O
.	.	O

Rates	NNS	O
of	IN	O
fertilization	NN	O
,	,	O
aneuploidy	NN	O
,	,	O
and	CC	O
sustained	JJ	O
implantation	NN	O
were	VBD	O
equivalent	JJ	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
IVF	NNP	O
culture	NN	O
at	IN	O
36?C	CD	O
does	VBZ	O
not	RB	O
improve	VB	O
clinically	RB	O
relevant	JJ	O
parameters	NNS	O
of	IN	O
embryo	NN	O
development	NN	O
or	CC	O
sustained	VBN	O
implantation	NN	O
rates	NNS	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
NUMBER	NNP	O
NCT01506089	NNP	O
.	.	O

Motion	NN	O
aftereffects	NNS	O
with	IN	O
horizontally	RB	O
moving	VBG	O
sound	NN	O
sources	NNS	O
in	IN	O
the	DT	O
free	JJ	O
field	NN	O
.	.	O

A	DT	O
horizontally	RB	Other
moving	VBG	Other
sound	NN	Other
was	VBD	O
presented	VBN	O
to	TO	O
an	DT	O
observer	NN	O
seated	VBN	O
in	IN	O
the	DT	O
center	NN	O
of	IN	O
an	DT	O
anechoic	JJ	O
chamber	NN	O
.	.	O

The	DT	O
sound	NN	O
,	,	O
either	CC	O
a	DT	O
500-Hz	JJ	Other
low-pass	JJ	Other
noise	NN	Other
or	CC	O
a	DT	O
6300-Hz	JJ	Other
high-pass	NN	Other
noise	NN	Other
,	,	O
repeatedly	RB	O
traversed	VBD	O
a	DT	O
semicircular	JJ	O
arc	NN	O
in	IN	O
the	DT	O
observer	NN	O
's	POS	O
front	JJ	O
hemifield	NN	O
at	IN	O
ear	JJ	O
level	NN	O
(	(	O
distance	NN	O
:	:	O
1.5	CD	O
m	NN	O
)	)	O
.	.	O

At	IN	O
10-sec	JJ	O
intervals	NNS	O
this	DT	O
adaptor	NN	O
was	VBD	O
interrupted	VBN	O
,	,	O
and	CC	O
a	DT	O
750-msec	JJ	O
moving	NN	Other
probe	NN	Other
(	(	O
a	DT	O
500-Hz	JJ	O
low-pass	JJ	O
noise	NN	O
)	)	O
was	VBD	O
presented	VBN	O
from	IN	O
a	DT	O
horizontal	JJ	O
arc	NN	O
1.6	CD	O
m	NN	O
in	IN	O
front	NN	O
of	IN	O
the	DT	O
observer	NN	O
.	.	O

During	IN	O
a	DT	O
run	NN	O
,	,	O
the	DT	O
adaptor	NN	O
was	VBD	O
presented	VBN	O
at	IN	O
a	DT	O
constant	JJ	O
velocity	NN	O
(	(	O
-200	JJ	O
degrees	NNS	O
to	TO	O
+200	VB	O
degrees/sec	NN	O
)	)	O
,	,	O
while	IN	O
probes	NNS	O
with	IN	O
velocities	NNS	O
varying	VBG	O
from	IN	O
-10	JJ	O
degrees	NNS	O
to	TO	O
+10	VB	O
degrees/sec	NN	O
were	VBD	O
presented	VBN	O
in	IN	O
a	DT	O
random	JJ	O
order	NN	O
.	.	O

Observers	NNS	O
judged	VBD	O
the	DT	O
direction	NN	O
of	IN	O
motion	NN	O
(	(	O
left	VBD	O
or	CC	O
right	JJ	O
)	)	O
of	IN	O
each	DT	O
probe	NN	O
.	.	O

As	IN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
stimuli	NNS	O
presented	VBN	O
over	IN	O
headphones	NNS	O
(	(	O
Grantham	NNP	O
&	CC	O
Wightman	NNP	O
,	,	O
1979	CD	O
)	)	O
,	,	O
an	DT	O
auditory	JJ	O
motion	NN	O
aftereffect	NN	O
(	(	O
MAE	NNP	O
)	)	O
occurred	VBD	O
:	:	O
subjects	NNS	O
responded	VBD	O
left	VBN	O
to	TO	O
probes	VB	O
more	RBR	O
often	RB	O
when	WRB	O
the	DT	O
adaptor	NN	O
moved	VBD	O
right	RB	O
than	IN	O
when	WRB	O
it	PRP	O
moved	VBD	O
left	RB	O
.	.	O

When	WRB	O
the	DT	O
adaptor	NN	O
and	CC	O
probe	NN	O
were	VBD	O
spectrally	RB	O
the	DT	O
same	JJ	O
,	,	O
the	DT	O
MAE	NNP	O
was	VBD	O
greater	JJR	O
than	IN	O
when	WRB	O
they	PRP	O
were	VBD	O
from	IN	O
different	JJ	O
spectral	JJ	O
regions	NNS	O
;	:	O
the	DT	O
magnitude	NN	O
of	IN	O
this	DT	O
difference	NN	O
depended	VBD	O
on	IN	O
adaptor	NN	O
speed	NN	O
and	CC	O
was	VBD	O
subject-dependent	NN	O
.	.	O

It	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
there	EX	O
are	VBP	O
two	CD	O
components	NNS	O
underlying	VBG	O
the	DT	O
auditory	JJ	O
MAE	NNP	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
generalized	JJ	O
bias	NN	O
to	TO	O
respond	VB	O
that	DT	O
probes	NNS	O
move	VBP	O
in	IN	O
the	DT	O
direction	NN	O
opposite	NN	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
adaptor	NN	O
,	,	O
independent	JJ	O
of	IN	O
their	PRP$	O
spectra	NN	O
;	:	O
and	CC	O
(	(	O
2	CD	O
)	)	O
a	DT	O
loss	NN	O
of	IN	O
sensitivity	NN	O
to	TO	O
the	DT	O
velocity	NN	O
of	IN	O
moving	VBG	O
sounds	NNS	O
after	IN	O
prolonged	JJ	O
exposure	NN	O
to	TO	O
moving	VBG	O
sounds	NNS	O
having	VBG	O
the	DT	O
same	JJ	O
spectral	JJ	O
content	NN	O
.	.	O

Preschoolers	NNS	O
acquire	VB	O
general	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	Educational
in	IN	Educational
pretense	NN	Educational
.	.	O

Children	NNP	O
acquire	VB	O
general	JJ	O
knowledge	NN	O
about	IN	O
many	JJ	O
kinds	NNS	O
of	IN	O
things	NNS	O
,	,	O
but	CC	O
there	EX	O
are	VBP	O
few	JJ	O
known	VBN	O
means	NNS	O
by	IN	O
which	WDT	O
this	DT	O
knowledge	NN	O
is	VBZ	O
acquired	VBN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
,	,	O
it	PRP	O
is	VBZ	O
proposed	VBN	O
that	IN	O
children	NNS	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
by	IN	O
sharing	VBG	O
in	IN	O
pretend	JJ	Educational
play	NN	Educational
.	.	O

In	IN	O
Experiment	JJ	O
1	CD	O
,	,	O
twenty-two	JJ	O
3-	JJ	O
to	TO	O
4-year-olds	NNS	O
watched	VBN	Educational
pretense	NN	Educational
in	IN	Educational
which	WDT	Educational
a	DT	Educational
puppet	NN	Educational
represented	VBD	Educational
a	DT	Educational
nerp	NN	Educational
(	(	O
an	DT	O
unfamiliar	JJ	O
kind	NN	O
of	IN	O
animal	NN	O
)	)	O
.	.	O

For	IN	O
instance	NN	O
,	,	O
in	IN	O
one	CD	O
scenario	NN	O
,	,	O
the	DT	O
nerp	JJ	O
ate	NN	O
and	CC	O
disliked	VBD	O
a	DT	O
carrot	NN	O
.	.	O

When	WRB	O
subsequently	RB	O
asked	VBD	O
generic	JJ	O
questions	NNS	O
about	IN	O
real	JJ	O
nerps	NNS	O
,	,	O
children	NNS	O
's	POS	O
responses	NNS	O
suggested	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
learned	VBN	O
general	JJ	O
facts	NNS	O
(	(	O
e.g.	NN	O
,	,	O
nerps	RB	O
dislike	JJ	O
carrots	NNS	O
)	)	O
.	.	O

In	IN	O
Experiment	JJ	O
2	CD	O
,	,	O
thirty-two	JJ	O
4-	JJ	O
to	TO	O
5-year-olds	NNS	O
learned	VBN	O
from	IN	O
scenarios	NNS	Educational
lacking	VBG	Educational
pretend	JJ	Educational
speech	NN	Educational
or	CC	Educational
sound	JJ	Educational
effects	NNS	Educational
.	.	O

The	DT	O
findings	NNS	O
reveal	VBP	O
a	DT	O
long	JJ	O
overlooked	JJ	O
means	NNS	O
by	IN	O
which	WDT	O
children	NNS	O
can	MD	O
acquire	VB	O
generic	JJ	O
knowledge	NN	O
.	.	O

Goal	NNP	O
attainment	NN	O
scaling	NN	O
as	IN	O
an	DT	O
outcome	NN	O
measure	NN	O
in	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
of	IN	O
psychosocial	JJ	Psychological
interventions	NNS	Psychological
in	IN	O
autism	NN	O
.	.	O

Goal	NNP	Educational
attainment	JJ	Educational
scaling	NN	Educational
(	(	Educational
GAS	NNP	Educational
)	)	Educational
holds	VBZ	O
promise	NN	O
as	IN	O
an	DT	O
idiographic	JJ	O
approach	NN	O
for	IN	O
measuring	VBG	O
outcomes	NNS	O
of	IN	O
psychosocial	JJ	Educational
interventions	NNS	Educational
in	IN	O
community	NN	O
settings	NNS	O
.	.	O

GAS	NNP	O
has	VBZ	O
been	VBN	O
criticized	VBN	O
for	IN	O
untested	JJ	O
assumptions	NNS	O
of	IN	O
scaling	VBG	O
level	NN	O
(	(	O
i.e.	JJ	O
,	,	O
interval	JJ	O
or	CC	O
ordinal	JJ	O
)	)	O
,	,	O
inter-individual	JJ	O
equivalence	NN	O
and	CC	O
comparability	NN	O
,	,	O
and	CC	O
reliability	NN	O
of	IN	O
coding	VBG	O
across	IN	O
different	JJ	O
behavioral	JJ	O
observation	NN	O
methods	NNS	O
.	.	O

We	PRP	O
tested	VBD	O
assumptions	NNS	O
of	IN	O
equality	NN	O
between	IN	O
GAS	NNP	O
descriptions	NNS	O
for	IN	O
outcome	JJ	O
measurement	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
(	(	O
i.e.	FW	O
,	,	O
measurability	NN	O
,	,	O
equidistance	NN	O
,	,	O
level	NN	O
of	IN	O
difficulty	NN	O
,	,	O
comparability	NN	O
of	IN	O
behavior	NN	O
samples	NNS	O
collected	VBN	O
from	IN	O
teachers	NNS	Educational
vs.	FW	O
researchers	NNS	Educational
and	CC	O
live	JJ	O
vs.	FW	O
videotape	NN	O
)	)	O
.	.	O

Results	NNP	O
suggest	VBP	O
GAS	NNP	O
descriptions	NNS	O
can	MD	O
be	VB	O
evaluated	VBN	O
for	IN	O
equivalency	NN	O
,	,	O
that	IN	O
teacher	RB	Educational
collected	VBN	O
behavior	NN	O
samples	NNS	O
are	VBP	O
representative	JJ	O
,	,	O
and	CC	O
that	IN	O
varied	JJ	O
sources	NNS	O
of	IN	O
behavior	NN	O
samples	NNS	O
can	MD	O
be	VB	O
reliably	RB	O
coded	VBN	O
.	.	O

GAS	NNP	O
is	VBZ	O
a	DT	O
promising	JJ	O
measurement	NN	O
approach	NN	O
.	.	O

Recommendations	NNS	O
are	VBP	O
provided	VBN	O
to	TO	O
ensure	VB	O
methodological	JJ	O
quality	NN	O
.	.	O

Pazopanib	NNP	Pharmacological
in	IN	O
locally	RB	O
advanced	JJ	O
or	CC	O
metastatic	JJ	O
renal	NN	O
cell	NN	O
carcinoma	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Pazopanib	NNP	Pharmacological
is	VBZ	O
an	DT	O
oral	JJ	Pharmacological
angiogenesis	NN	Pharmacological
inhibitor	NN	Pharmacological
targeting	VBG	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
platelet-derived	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
and	CC	O
c-Kit	NN	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
phase	NN	O
III	NNP	O
study	NN	O
evaluated	VBD	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
pazopanib	JJ	Pharmacological
monotherapy	NN	Pharmacological
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	Pharmacological
patients	NNS	O
with	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
(	(	O
RCC	NNP	O
)	)	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Adult	NNP	O
patients	NNS	O
with	IN	O
measurable	JJ	O
,	,	O
locally	RB	O
advanced	JJ	O
,	,	O
and/or	JJ	O
metastatic	JJ	O
RCC	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
2:1	CD	O
to	TO	O
receive	VB	O
oral	JJ	Pharmacological
pazopanib	NN	Pharmacological
or	CC	O
placebo	NN	Control
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
overall	JJ	O
survival	NN	O
,	,	O
tumor	NN	O
response	NN	O
rate	NN	O
(	(	O
Response	NNP	O
Evaluation	NNP	O
Criteria	NNP	O
in	IN	O
Solid	NNP	O
Tumors	NNP	O
)	)	O
,	,	O
and	CC	O
safety	NN	O
.	.	O

Radiographic	JJ	O
assessments	NNS	O
of	IN	O
tumors	NNS	O
were	VBD	O
independently	RB	O
reviewed	VBN	O
.	.	O

Results	NNS	O
Of	IN	O
435	CD	O
patients	NNS	O
enrolled	VBD	O
,	,	O
233	CD	O
were	VBD	O
treatment	NN	O
naive	JJ	O
(	(	O
54	CD	O
%	NN	O
)	)	O
and	CC	O
202	CD	O
were	VBD	O
cytokine	NN	O
pretreated	VBN	O
(	(	O
46	CD	O
%	NN	O
)	)	O
.	.	O

PFS	NNP	O
was	VBD	O
significantly	RB	O
prolonged	VBN	O
with	IN	O
pazopanib	NNS	Pharmacological
compared	VBN	O
with	IN	O
placebo	NN	Control
in	IN	O
the	DT	O
overall	JJ	O
study	NN	O
population	NN	O
(	(	O
median	JJ	O
,	,	O
PFS	NNP	O
9.2	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
hazard	PRP$	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.34	CD	O
to	TO	O
0.62	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
the	DT	O
treatment-naive	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
11.1	CD	O
v	NN	O
2.8	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.40	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.27	CD	O
to	TO	O
0.60	CD	O
;	:	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
cytokine-pretreated	JJ	O
subpopulation	NN	O
(	(	O
median	JJ	O
PFS	NNP	O
,	,	O
7.4	CD	O
v	NN	O
4.2	CD	O
months	NNS	O
;	:	O
HR	NNP	O
,	,	O
0.54	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.35	CD	O
to	TO	O
0.84	CD	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
objective	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
30	CD	O
%	NN	O
with	IN	O
pazopanib	NN	Pharmacological
compared	VBN	O
with	IN	O
3	CD	O
%	NN	O
with	IN	O
placebo	NN	Control
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
duration	NN	O
of	IN	O
response	NN	O
was	VBD	O
longer	JJR	O
than	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
diarrhea	RB	O
,	,	O
hypertension	NN	O
,	,	O
hair	NN	O
color	NN	O
changes	NNS	O
,	,	O
nausea	NN	O
,	,	O
anorexia	NN	O
,	,	O
and	CC	O
vomiting	VBG	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
differences	NNS	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
for	IN	O
pazopanib	JJ	Pharmacological
versus	NN	O
placebo	NN	Control
.	.	O

CONCLUSION	NNP	O
Pazopanib	NNP	Pharmacological
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
PFS	NNP	O
and	CC	O
tumor	NN	O
response	NN	O
compared	VBN	O
with	IN	O
placebo	NN	Control
in	IN	O
treatment-naive	JJ	O
and	CC	O
cytokine-pretreated	JJ	Pharmacological
patients	NNS	O
with	IN	O
advanced	JJ	O
and/or	NNS	O
metastatic	JJ	O
RCC	NNP	O
.	.	O

Psychiatric	NNP	Psychological
treatment	NN	Psychological
of	IN	O
eczema	NN	O
:	:	O
a	DT	O
controlled	JJ	O
trial	NN	O
.	.	O

Seventy-two	JJ	O
patients	NNS	O
with	IN	O
eczema	NNS	O
were	VBD	O
randomly	RB	O
allotted	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
treatment	NN	O
groups	NNS	O
:	:	O
A	DT	O
,	,	O
those	DT	O
receiving	VBG	O
dermatological	JJ	Physical
treatment	NN	Physical
only	RB	Physical
,	,	O
and	CC	O
B	NNP	O
,	,	O
those	DT	O
receiving	VBG	O
the	DT	O
same	JJ	Educational
dermatological	JJ	Psychological
treatment	NN	Psychological
plus	CC	Psychological
psychiatric	JJ	Psychological
treatment	NN	Psychological
,	,	O
limited	VBN	O
where	WRB	O
possible	JJ	O
to	TO	O
four	CD	O
months	NNS	O
.	.	O

Cases	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
at	IN	O
six-monthly	JJ	O
dermatological	JJ	O
assessments	NNS	O
,	,	O
57	CD	O
(	(	O
79	CD	O
%	NN	O
)	)	O
for	IN	O
18	CD	O
months	NNS	O
.	.	O

The	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
overt	JJ	O
emotional	JJ	O
disturbance	NN	O
,	,	O
of	IN	O
new	JJ	O
psychological	JJ	O
or	CC	O
psychophysiological	JJ	O
symptoms	NNS	O
preceding	VBG	O
the	DT	O
rash	NN	O
by	IN	O
up	IN	O
to	TO	O
a	DT	O
year	NN	O
,	,	O
and	CC	O
of	IN	O
high	JJ	O
motivation	NN	O
for	IN	O
it	PRP	O
,	,	O
brief	JJ	O
psychiatric	JJ	Psychological
treatment	NN	Psychological
improves	VBZ	O
the	DT	O
outcome	NN	O
in	IN	O
eczema	NN	O
(	(	O
the	DT	O
proportion	NN	O
clear	JJ	O
at	IN	O
18	CD	O
months	NNS	O
was	VBD	O
about	IN	O
doubled	VBN	O
)	)	O
,	,	O
whereas	NNS	O
in	IN	O
their	PRP$	O
absence	NN	O
such	JJ	O
treatment	NN	O
may	MD	O
worsen	VB	O
it	PRP	O
,	,	O
especially	RB	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
.	.	O

Treatment	NN	O
of	IN	O
posterior	JJ	O
uveitis	NN	O
with	IN	O
a	DT	O
fluocinolone	NN	Pharmacological
acetonide	NN	Pharmacological
implant	NN	Pharmacological
:	:	O
three-year	JJ	O
clinical	JJ	O
trial	NN	O
results	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
0.59-mg	JJ	O
and	CC	O
2.1-mg	JJ	O
fluocinolone	NN	Pharmacological
acetonide	NN	Pharmacological
(	(	O
FA	NNP	O
)	)	O
intravitreous	JJ	O
implants	NNS	O
in	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
3-year	JJ	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
historically	RB	O
controlled	VBN	O
trial	NN	O
of	IN	O
the	DT	O
0.59-mg	JJ	Pharmacological
FA	NNP	Pharmacological
intravitreous	JJ	Pharmacological
implant	NN	Pharmacological
in	IN	O
110	CD	O
patients	NNS	O
and	CC	O
the	DT	O
2.1-mg	JJ	O
FA	NNP	O
intravitreous	JJ	O
implant	NN	O
in	IN	O
168	CD	O
patients	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Recurrence	NNP	O
rate	NN	O
,	,	O
vision	NN	O
,	,	O
and	CC	O
complications	NNS	O
.	.	O

RESULTS	NNP	O
Uveitis	NNP	O
recurrence	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
implanted	JJ	O
eyes	NNS	O
from	IN	O
62	CD	O
%	NN	O
(	(	O
during	IN	O
the	DT	O
1-year	JJ	O
preimplantation	NN	O
period	NN	O
)	)	O
to	TO	O
4	CD	O
%	NN	O
,	,	O
10	CD	O
%	NN	O
,	,	O
and	CC	O
20	CD	O
%	NN	O
during	IN	O
the	DT	O
1-	JJ	O
,	,	O
2-	JJ	O
,	,	O
and	CC	O
3-year	JJ	O
postimplantation	NN	O
periods	NNS	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
0.59-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
and	CC	O
from	IN	O
58	CD	O
%	NN	O
to	TO	O
7	CD	O
%	NN	O
,	,	O
17	CD	O
%	NN	O
,	,	O
and	CC	O
41	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
the	DT	O
2.1-mg	JJ	O
dose	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

More	RBR	O
implanted	JJ	O
eyes	NNS	O
than	IN	O
nonimplanted	JJ	O
eyes	NNS	O
had	VBD	O
improved	VBN	O
visual	JJ	O
acuity	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Implanted	VBN	O
eyes	NNS	O
had	VBD	O
higher	JJR	O
incidences	NNS	O
of	IN	O
intraocular	JJ	O
pressure	NN	O
elevation	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
10	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
than	IN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
and	CC	O
glaucoma	NN	O
surgery	NN	O
was	VBD	O
required	VBN	O
in	IN	O
40	CD	O
%	NN	O
of	IN	O
implanted	JJ	O
eyes	NNS	O
vs	VBP	O
2	CD	O
%	NN	O
of	IN	O
nonimplanted	JJ	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Cataracts	NNPS	O
were	VBD	O
extracted	VBN	O
in	IN	O
93	CD	O
%	NN	O
of	IN	O
phakic	NN	O
implanted	VBN	O
eyes	NNS	O
vs	VBP	O
20	CD	O
%	NN	O
of	IN	O
phakic	NN	O
nonimplanted	VBN	O
eyes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
FA	NNP	O
implant	NN	O
significantly	RB	O
reduced	VBN	O
uveitis	JJ	O
recurrence	NN	O
and	CC	O
improved	VBD	O
or	CC	O
stabilized	VBN	O
visual	JJ	O
acuity	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

Most	JJS	O
subjects	NNS	O
required	VBN	O
cataract	JJ	O
extraction	NN	O
,	,	O
and	CC	O
a	DT	O
significant	JJ	O
proportion	NN	O
required	VBN	O
intraocular	JJ	O
pressure-lowering	JJ	O
surgery	NN	O
.	.	O

APPLICATION	NNP	O
TO	NNP	O
CLINICAL	NNP	O
PRACTICE	NNP	O
The	DT	O
FA	NNP	O
implant	NN	O
provides	VBZ	O
an	DT	O
alternative	JJ	O
therapy	NN	O
for	IN	O
prolonged	JJ	O
control	NN	O
of	IN	O
inflammation	NN	O
in	IN	O
noninfectious	JJ	O
posterior	JJ	O
uveitis	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT00407082	NN	O
.	.	O

The	DT	O
relationship	NN	O
of	IN	O
changes	NNS	O
in	IN	O
EORTC	NNP	O
QLQ-C30	NNP	O
scores	NNS	O
to	TO	O
ratings	NNS	O
on	IN	O
the	DT	O
Subjective	JJ	O
Significance	NNP	O
Questionnaire	NNP	Educational
in	IN	O
men	NNS	O
with	IN	O
localized	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
relationship	NN	O
between	IN	O
changes	NNS	O
in	IN	O
health-related	JJ	O
quality-of-life	NN	O
(	(	O
HRQOL	NNP	O
)	)	O
on	IN	O
the	DT	O
EORTC	NNP	Educational
Quality	NNP	Educational
of	IN	Educational
Life	NNP	Educational
Questionnaire	NNP	Educational
(	(	Educational
QLQ-C30	NNP	Educational
)	)	O
,	,	O
and	CC	O
patients	NNS	O
'	POS	O
perceptions	NNS	O
of	IN	O
HRQOL	NNP	O
changes	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Subjective	NNP	Educational
Significance	NNP	Educational
Questionnaire	NNP	Educational
(	(	Educational
SSQ	NNP	Educational
)	)	Educational
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
101	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
QLQ-C30	NNP	Educational
on	IN	O
weeks	NNS	O
1	CD	O
,	,	O
4	CD	O
and	CC	O
7	CD	O
of	IN	O
radical	JJ	O
external-beam	NN	Physical
radiation	NN	Physical
therapy	NN	Physical
(	(	Physical
RT	NNP	Physical
)	)	Physical
for	IN	O
localized	JJ	O
cancer	NN	O
of	IN	O
the	DT	O
prostate	NN	O
.	.	O

Patients	NNS	O
rated	VBD	O
their	PRP$	O
change	NN	O
in	IN	O
physical	JJ	O
functioning	NN	O
,	,	O
emotional	JJ	O
functioning	NN	O
,	,	O
social	JJ	O
functioning	NN	O
,	,	O
and	CC	O
overall/global	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
by	IN	O
completing	VBG	O
a	DT	O
seven-category	JJ	O
SSQ	NNP	Educational
at	IN	O
weeks	NNS	O
4	CD	O
and	CC	O
7	CD	O
.	.	O

The	DT	O
association	NN	O
between	IN	O
changes	NNS	O
in	IN	O
the	DT	O
QLQ-C30	JJ	O
change	NN	O
and	CC	O
the	DT	O
corresponding	JJ	O
SSQ	NNP	Educational
ratings	NNS	O
were	VBD	O
determined	VBN	O
by	IN	O
calculation	NN	O
of	IN	O
mean	JJ	O
change	NN	O
scores	NNS	O
for	IN	O
each	DT	O
SSQ	NNP	Educational
category	NN	O
and	CC	O
by	IN	O
Spearman	NNP	O
rank	NN	O
correlation	NN	O
coefficient	NN	O
analysis	NN	O
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
'	POS	O
completion	NN	O
of	IN	O
the	DT	O
QLQ-C30	NNP	O
and	CC	O
SSQ	NNP	Educational
exceeded	VBD	O
95	CD	O
%	NN	O
.	.	O

Statistically	NNP	O
significant	JJ	O
changes	NNS	O
in	IN	O
fatigue	NN	O
,	,	O
pain	NN	O
,	,	O
appetite	NN	O
,	,	O
diarrhea	NN	O
,	,	O
and	CC	O
global	JJ	O
QOL	NNP	O
scores	NNS	O
were	VBD	O
detected	VBN	O
during	IN	O
RT	NNP	O
.	.	O

For	IN	O
patients	NNS	O
reporting	VBG	O
'a	JJ	O
little	JJ	O
'	POS	O
change	NN	O
in	IN	O
global	JJ	O
QOL	NNP	O
on	IN	O
the	DT	O
SSQ	NNP	Educational
,	,	O
absolute	JJ	O
mean	JJ	O
QLQ-C30	JJ	O
change	NN	O
scores	NNS	O
ranged	VBD	O
between	IN	O
0	CD	O
to	TO	O
15	CD	O
points	NNS	O
with	IN	O
12/16	CD	O
mean	JJ	O
change	NN	O
scores	NNS	O
between	IN	O
2.5	CD	O
and	CC	O
8.5	CD	O
points	NNS	O
.	.	O

In	IN	O
the	DT	O
entire	JJ	O
study	NN	O
sample	NN	O
,	,	O
correlations	NNS	O
between	IN	O
SSQ	NNP	Educational
patient	JJ	O
ratings	NNS	O
and	CC	O
QLQ-C30	JJ	O
change	NN	O
scores	NNS	O
were	VBD	O
lower	JJR	O
than	IN	O
previously	RB	O
reported	VBN	O
,	,	O
ranging	VBG	O
between	IN	O
0.15	CD	O
and	CC	O
0.24	CD	O
for	IN	O
the	DT	O
four	CD	O
different	JJ	O
domains	NNS	O
,	,	O
but	CC	O
were	VBD	O
higher	JJR	O
when	WRB	O
QOL	NNP	O
scores	VBZ	O
producing	VBG	O
ceiling	NN	O
effects	NNS	O
were	VBD	O
omitted	VBN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
SSQ	NNP	Educational
and	CC	O
QLQ-C30	NNP	Educational
may	MD	O
measure	VB	O
related	JJ	O
concepts	NNS	O
that	WDT	O
could	MD	O
assist	VB	O
in	IN	O
the	DT	O
interpretation	NN	O
of	IN	O
changes	NNS	O
in	IN	O
scores	NNS	O
and	CC	O
in	IN	O
the	DT	O
calibration	NN	O
of	IN	O
the	DT	O
QLQ-C30	NNP	Educational
.	.	O

However	RB	O
,	,	O
the	DT	O
nature	NN	O
of	IN	O
this	DT	O
relationship	NN	O
could	MD	O
not	RB	O
be	VB	O
elucidated	VBN	O
in	IN	O
this	DT	O
data	NN	O
set	NN	O
because	IN	O
of	IN	O
a	DT	O
lack	NN	O
of	IN	O
variance	NN	O
in	IN	O
HRQOL	NNP	O
scores	NNS	O
in	IN	O
the	DT	O
study	NN	O
sample	NN	O
.	.	O

Further	JJ	O
investigation	NN	O
should	MD	O
be	VB	O
carried	VBN	O
out	RP	O
in	IN	O
study	NN	O
samples	NNS	O
with	IN	O
sufficient	JJ	O
variance	NN	O
to	TO	O
allow	VB	O
more	JJR	O
robust	JJ	O
conclusions	NNS	O
.	.	O

Multiple	JJ	O
courses	NNS	O
of	IN	O
rituximab	NN	Pharmacological
produce	NN	O
sustained	VBD	O
clinical	JJ	O
and	CC	O
radiographic	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
and	CC	O
an	DT	O
inadequate	JJ	O
response	NN	O
to	TO	O
1	CD	O
or	CC	O
more	JJR	O
tumor	JJ	Physical
necrosis	NN	Physical
factor	NN	Physical
inhibitors	NNS	Physical
:	:	O
5-year	JJ	O
data	NNS	O
from	IN	O
the	DT	O
REFLEX	NNP	O
study	NN	O
.	.	O

OBJECTIVE	VB	O
This	DT	O
5-year	JJ	O
observational	JJ	O
posthoc	NN	O
analysis	NN	O
of	IN	O
the	DT	O
REFLEX	NNP	O
study	NN	O
and	CC	O
its	PRP$	O
open-label	JJ	O
extension	NN	O
assessed	VBD	O
clinical	JJ	O
efficacy	NN	O
,	,	O
radiographic	JJ	O
response	NN	O
,	,	O
and	CC	O
safety	NN	O
of	IN	O
rituximab	NN	Pharmacological
(	(	Pharmacological
RTX	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
who	WP	O
had	VBD	O
an	DT	O
inadequate	JJ	O
response	NN	O
to	TO	O
tumor	VB	Physical
necrosis	NN	Physical
factor	NN	Physical
(	(	Physical
TNF	NNP	Physical
)	)	Physical
inhibitors	NNS	Physical
.	.	O

METHODS	NNP	O
Patients	NNPS	O
in	IN	O
REFLEX	NNP	O
were	VBD	O
originally	RB	O
randomized	VBN	O
to	TO	O
placebo	VB	Control
(	(	O
PBO	NNP	O
)	)	O
+	NN	Pharmacological
methotrexate	NN	Pharmacological
(	(	Pharmacological
MTX	NNP	Pharmacological
;	:	Pharmacological
PBO-randomized	NNP	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
RTX	NNP	Pharmacological
+	NNP	Pharmacological
MTX	NNP	Pharmacological
(	(	Pharmacological
RTX-randomized	NNP	Pharmacological
)	)	Pharmacological
.	.	O

PBO-randomized	JJ	O
patients	NNS	O
were	VBD	O
rescued	VBN	O
with	IN	O
RTX	NNP	O
as	IN	O
appropriate	JJ	O
.	.	O

Patients	NNS	O
responding	VBG	O
to	TO	O
initial	JJ	O
RTX	NNP	Pharmacological
treatment	NN	O
could	MD	O
receive	VB	O
further	JJ	O
RTX	NNP	Pharmacological
courses	NNS	O
.	.	O

For	IN	O
clinical	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
analyses	NNS	O
,	,	O
PBO-randomized	JJ	O
patients	NNS	O
were	VBD	O
re-baselined	JJ	O
prior	NN	O
to	TO	O
first	JJ	O
RTX	NNP	Pharmacological
treatment	NN	O
and	CC	O
the	DT	O
data	NNS	O
were	VBD	O
pooled	VBN	O
with	IN	O
RTX-randomized	JJ	Pharmacological
patient	NN	O
data	NNS	O
.	.	O

Efficacy	NNP	O
outcomes	RB	O
24	CD	O
weeks	NNS	O
after	IN	O
each	DT	O
course	NN	O
were	VBD	O
calculated	VBN	O
relative	JJ	O
to	TO	O
first	JJ	O
RTX	NNP	Pharmacological
pretreatment	NN	O
baseline	NN	O
.	.	O

Radiographic	JJ	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
relative	JJ	O
to	TO	O
randomization	VB	O
baseline	NN	O
for	IN	O
both	DT	O
PBO-randomized	NNP	O
and	CC	O
RTX-randomized	NNP	Pharmacological
groups	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
480	CD	O
patients	NNS	O
received	VBN	O
?	.	O
1	CD	O
RTX	NNP	O
course	NN	O
.	.	O

At	IN	O
24	CD	O
weeks	NNS	O
,	,	O
American	NNP	O
College	NNP	O
of	IN	O
Rheumatology	NNP	O
20/50/70	CD	O
responses	NNS	O
were	VBD	O
62.0	CD	O
%	NN	O
,	,	O
30.8	CD	O
%	NN	O
,	,	O
and	CC	O
13.0	CD	O
%	NN	O
,	,	O
respectively	RB	O
at	IN	O
course	NN	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
400	CD	O
)	)	O
and	CC	O
70.3	CD	O
%	NN	O
,	,	O
41.8	CD	O
%	NN	O
,	,	O
and	CC	O
22.0	CD	O
%	NN	O
at	IN	O
course	NN	O
5	CD	O
(	(	O
n	JJ	O
=	NNP	O
91	CD	O
)	)	O
.	.	O

European	JJ	O
League	NNP	O
Against	NNP	O
Rheumatism	NNP	O
good/moderate	NN	O
responses	NNS	O
were	VBD	O
77.2	CD	O
%	NN	O
and	CC	O
84.4	CD	O
%	NN	O
at	IN	O
courses	NNS	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
390	CD	O
)	)	O
and	CC	O
5	CD	O
(	(	O
n	JJ	O
=	NNP	O
90	CD	O
)	)	O
.	.	O

Rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
,	,	O
serious	JJ	O
AE	NNP	O
,	,	O
and	CC	O
infections	NNS	O
generally	RB	O
remained	VBD	O
stable	JJ	O
.	.	O

Rate	NNP	O
of	IN	O
progressive	JJ	O
joint	JJ	O
damage	NN	O
(	(	O
PJD	NNP	O
;	:	O
change	NN	O
in	IN	O
mean	JJ	O
Total	NNP	O
Sharp	NNP	O
Score	NNP	O
)	)	O
decreased	VBD	O
over	RP	O
time	NN	O
in	IN	O
both	DT	O
PBO-randomized	NNP	O
(	(	O
n	JJ	O
=	NNP	O
79	CD	O
)	)	O
and	CC	O
RTX-randomized	NNP	O
(	(	O
n	JJ	O
=	NNP	O
105	CD	O
)	)	O
groups	NNS	O
.	.	O

Mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
PJD	NNP	O
over	IN	O
5	CD	O
years	NNS	O
was	VBD	O
greater	JJR	O
in	IN	O
PBO-randomized	NNP	O
versus	NN	O
RTX-randomized	JJ	O
patients	NNS	O
(	(	O
5.51	CD	O
vs	RB	O
3.21	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
RTX	NNP	O
re-treatment	NN	O
over	IN	O
5	CD	O
years	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
maintained	VBN	O
or	CC	O
improved	VBN	O
efficacy	NN	O
,	,	O
continued	VBD	O
inhibition	NN	O
of	IN	O
PJD	NNP	O
,	,	O
and	CC	O
a	DT	O
safety	NN	O
profile	NN	O
consistent	JJ	O
with	IN	O
that	DT	O
previously	RB	O
reported	VBN	O
.	.	O

A	DT	O
delay	NN	O
in	IN	O
initiating	VBG	O
RTX	NNP	O
treatment	NN	O
may	MD	O
result	VB	O
in	IN	O
increased	JJ	O
PJD	NNP	O
.	.	O

Yohimbine	NN	Pharmacological
in	IN	O
neurally	RB	O
mediated	VBN	O
syncope	NN	O
.	.	O

Pathophysiological	JJ	O
implications	NNS	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
evaluated	VBD	O
if	IN	O
increased	VBN	O
sympathetic	JJ	O
stimulation	NN	O
is	VBZ	O
an	DT	O
essential	JJ	O
requirement	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
neurally	RB	O
mediated	VBN	O
syncope	NN	O
(	(	O
NMS	NNP	O
)	)	O
by	IN	O
manipulating	VBG	O
overall	JJ	O
sympathetic	JJ	O
outflow	NN	O
in	IN	O
subjects	NNS	O
susceptible	JJ	O
to	TO	O
tilt-induced	JJ	O
syncope	NN	O
.	.	O

Eight	NNP	O
previously	RB	O
characterized	VBD	O
patients	NNS	O
with	IN	O
recurrent	JJ	O
NMS	NNP	O
(	(	O
five	CD	O
females	NNS	O
and	CC	O
three	CD	O
males	NNS	O
;	:	O
34+/-2	JJ	O
yr	NN	O
)	)	O
were	VBD	O
recruited	VBN	O
from	IN	O
the	DT	O
Vanderbilt	NNP	O
Syncope	NNP	O
Unit	NNP	O
and	CC	O
eight	CD	O
age-matched	JJ	O
controls	NNS	O
underwent	JJ	O
initial	JJ	O
administration	NN	O
of	IN	O
clonidine	NN	Pharmacological
(	(	Pharmacological
CLO	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
yohimbine	NN	Pharmacological
(	(	O
YHO	NNP	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
done	VBN	O
,	,	O
prospectively	RB	O
,	,	O
to	TO	O
determine	VB	O
doses	NNS	O
of	IN	O
these	DT	O
agents	NNS	O
that	WDT	O
would	MD	O
increase	VB	O
or	CC	O
decrease	VB	O
plasma	JJ	O
norepinephrine	NN	O
levels	NNS	O
by	IN	O
>	NNP	O
/=	NNP	O
30	CD	O
%	NN	O
.	.	O

On	IN	O
a	DT	O
different	JJ	O
day	NN	O
,	,	O
in	IN	O
all	DT	O
subjects	NNS	O
we	PRP	O
determined	VBD	O
intraarterial	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
EKG	NNP	O
and	CC	O
muscle	NN	O
sympathetic	JJ	O
nerve	NN	O
activity	NN	O
(	(	O
MSNA	NNP	O
)	)	O
both	DT	O
supine	JJ	O
and	CC	O
during	IN	O
upright	JJ	O
tilt	NN	O
.	.	O

After	IN	O
this	DT	O
,	,	O
subjects	VBZ	O
randomly	RB	O
received	VBN	O
either	CC	O
CLO	NNP	Pharmacological
or	CC	O
YHO	NNP	Pharmacological
,	,	O
and	CC	O
3	CD	O
h	NN	O
later	RB	O
another	DT	O
tilt	NN	O
was	VBD	O
performed	VBN	O
.	.	O

After	IN	O
1	CD	O
wk	NN	O
,	,	O
a	DT	O
similar	JJ	O
procedure	NN	O
with	IN	O
the	DT	O
other	JJ	O
drug	NN	O
was	VBD	O
performed	VBN	O
.	.	O

During	IN	O
the	DT	O
two	CD	O
basal	NN	O
tilts	NNS	O
,	,	O
all	PDT	O
the	DT	O
control	NN	O
subjects	VBZ	O
completed	VBN	O
the	DT	O
study	NN	O
,	,	O
whereas	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
developed	VBD	O
syncope	NN	O
.	.	O

Reduction	NN	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
by	IN	O
CLO	NNP	Pharmacological
resulted	VBD	O
in	IN	O
a	DT	O
decreased	JJ	O
tolerance	NN	O
to	TO	O
tilt	VB	O
in	IN	O
three	CD	O
out	IN	O
of	IN	O
eight	CD	O
controls	NNS	O
and	CC	O
in	IN	O
all	PDT	O
the	DT	O
NMS	NNP	O
patients	NNS	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
YHO	NNP	O
not	RB	O
only	RB	O
increased	VBD	O
basal	NN	O
plasma	NN	O
NorEpi	NNP	O
levels	NNS	O
and	CC	O
MSNA	NNP	O
,	,	O
but	CC	O
also	RB	O
prevented	VBD	O
syncope	NN	O
in	IN	O
seven	CD	O
out	IN	O
of	IN	O
eight	CD	O
patients	NNS	O
.	.	O

In	IN	O
a	DT	O
selected	JJ	O
population	NN	O
of	IN	O
patients	NNS	O
,	,	O
increased	VBD	O
sympathetic	JJ	O
activity	NN	O
is	VBZ	O
not	RB	O
a	DT	O
prerequisite	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
syncope	NN	O
.	.	O

Yohimbine-induced	JJ	O
enhancement	NN	O
of	IN	O
sympathetic	JJ	O
tone	NN	O
in	IN	O
patients	NNS	O
with	IN	O
NMS	NNP	O
improves	VBZ	O
orthostatic	JJ	O
tolerance	NN	O
and	CC	O
raises	VBZ	O
the	DT	O
possibility	NN	O
that	IN	O
this	DT	O
drug	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
NMS	NNP	O
.	.	O

Aspirin	NNP	Pharmacological
in	IN	O
patients	NNS	O
undergoing	JJ	O
noncardiac	JJ	O
surgery	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
substantial	JJ	O
variability	NN	O
in	IN	O
the	DT	O
perioperative	JJ	O
administration	NN	O
of	IN	O
aspirin	NNS	Pharmacological
in	IN	O
patients	NNS	O
undergoing	JJ	O
noncardiac	JJ	O
surgery	NN	O
,	,	O
both	DT	O
among	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
already	RB	O
on	IN	O
an	DT	O
aspirin	JJ	Pharmacological
regimen	NNS	O
and	CC	O
among	IN	O
those	DT	O
who	WP	O
are	VBP	O
not	RB	O
.	.	O

METHODS	NNP	O
Using	VBG	O
a	DT	O
2-by-2	JJ	O
factorial	JJ	O
trial	NN	O
design	NN	O
,	,	O
we	PRP	O
randomly	VBP	O
assigned	VBD	O
10,010	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
preparing	VBG	O
to	TO	O
undergo	VB	O
noncardiac	JJ	O
surgery	NN	O
and	CC	O
were	VBD	O
at	IN	O
risk	NN	O
for	IN	O
vascular	JJ	O
complications	NNS	O
to	TO	O
receive	VB	O
aspirin	NN	Pharmacological
or	CC	O
placebo	NN	Control
and	CC	O
clonidine	NN	O
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
the	DT	O
aspirin	JJ	Pharmacological
trial	NN	O
are	VBP	O
reported	VBN	O
here	RB	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
according	VBG	O
to	TO	O
whether	IN	O
they	PRP	O
had	VBD	O
not	RB	O
been	VBN	O
taking	VBG	O
aspirin	NN	Pharmacological
before	IN	O
the	DT	O
study	NN	O
(	(	O
initiation	NN	O
stratum	NN	O
,	,	O
with	IN	O
5628	CD	O
patients	NNS	O
)	)	O
or	CC	O
they	PRP	O
were	VBD	O
already	RB	O
on	IN	O
an	DT	O
aspirin	JJ	Pharmacological
regimen	NNS	O
(	(	O
continuation	NN	O
stratum	NN	O
,	,	O
with	IN	O
4382	CD	O
patients	NNS	O
)	)	O
.	.	O

Patients	NNS	O
started	VBD	O
taking	VBG	O
aspirin	NN	Pharmacological
(	(	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
200	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	VB	Control
just	RB	O
before	RB	O
surgery	NN	O
and	CC	O
continued	VBD	O
it	PRP	O
daily	RB	O
(	(	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
100	CD	O
mg	NNS	O
)	)	O
for	IN	O
30	CD	O
days	NNS	O
in	IN	O
the	DT	O
initiation	NN	O
stratum	NN	O
and	CC	O
for	IN	O
7	CD	O
days	NNS	O
in	IN	O
the	DT	O
continuation	NN	O
stratum	NN	O
,	,	O
after	IN	O
which	WDT	O
patients	NNS	O
resumed	VBD	O
their	PRP$	O
regular	JJ	O
aspirin	JJ	Pharmacological
regimen	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
a	DT	O
composite	JJ	O
of	IN	O
death	NN	O
or	CC	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
at	IN	O
30	CD	O
days	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
primary	JJ	O
outcome	NN	O
occurred	VBD	O
in	IN	O
351	CD	O
of	IN	O
4998	CD	O
patients	NNS	O
(	(	O
7.0	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
aspirin	NN	Pharmacological
group	NN	O
and	CC	O
in	IN	O
355	CD	O
of	IN	O
5012	CD	O
patients	NNS	O
(	(	O
7.1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
,	,	O
0.99	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
0.86	CD	O
to	TO	O
1.15	CD	O
;	:	O
P=0.92	NNP	O
)	)	O
.	.	O

Major	JJ	O
bleeding	NN	O
was	VBD	O
more	RBR	O
common	JJ	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
230	CD	O
patients	NNS	O
[	JJ	O
4.6	CD	O
%	NN	O
]	NNP	O
vs.	IN	O
188	CD	O
patients	NNS	O
[	JJ	O
3.8	CD	O
%	NN	O
]	NN	O
;	:	O
hazard	CC	O
ratio	NN	O
,	,	O
1.23	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.01	CD	O
,	,	O
to	TO	O
1.49	CD	O
;	:	O
P=0.04	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcome	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
aspirin	NN	Pharmacological
strata	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Administration	NNP	O
of	IN	O
aspirin	NN	Pharmacological
before	IN	O
surgery	NN	O
and	CC	O
throughout	IN	O
the	DT	O
early	JJ	O
postsurgical	JJ	O
period	NN	O
had	VBD	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
rate	NN	O
of	IN	O
a	DT	O
composite	NN	O
of	IN	O
death	NN	O
or	CC	O
nonfatal	JJ	O
myocardial	JJ	O
infarction	NN	O
but	CC	O
increased	VBD	O
the	DT	O
risk	NN	O
of	IN	O
major	JJ	O
bleeding	NN	O
.	.	O

(	(	O
Funded	VBN	O
by	IN	O
the	DT	O
Canadian	NNP	O
Institutes	NNPS	O
of	IN	O
Health	NNP	O
Research	NNP	O
and	CC	O
others	NNS	O
;	:	O
POISE-2	NNP	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT01082874	NNP	O
.	.	O

)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
regimens	NNS	O
of	IN	O
amphotericin	NN	Pharmacological
B	NNP	Pharmacological
deoxycholate	NN	Pharmacological
in	IN	O
kala-azar	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
288	CD	O
parasitologically	RB	O
proved	JJ	O
patients	NNS	O
of	IN	O
kala-azar	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
three	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
received	VBD	O
amphotericin	JJ	Pharmacological
B	NNP	Pharmacological
(	(	Pharmacological
AMB	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	O
mg/kg	NNS	O
body	NN	O
weight	NN	O
(	(	O
bw	NN	O
)	)	O
/day	NN	O
,	,	O
0.75	CD	O
mg/kg	NN	O
bw/day	NN	O
and	CC	O
0.5	CD	O
mg/kg	NNS	O
bw/day	NN	O
for	IN	O
20	CD	O
days	NNS	O
respectively	RB	O
.	.	O

Apparent	JJ	O
cure	NN	O
(	(	O
afebrile	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
therapy	NN	O
)	)	O
occurred	VBD	O
in	IN	O
all	DT	O
patients	NNS	O
and	CC	O
parasitological	JJ	O
cure	NN	O
in	IN	O
96	CD	O
(	(	O
100	CD	O
%	NN	O
)	)	O
,	,	O
92	CD	O
(	(	O
96	CD	O
%	NN	O
)	)	O
and	CC	O
84	CD	O
(	(	O
88	CD	O
%	NN	O
)	)	O
patients	NNS	O
respectively	RB	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C.	NNP	O
Ultimate	NNP	O
cure	NN	O
(	(	O
no	DT	O
relapse	NN	O
in	IN	O
six	CD	O
months	NNS	O
of	IN	O
follow	VBP	O
up	RP	O
)	)	O
occurred	VBD	O
in	IN	O
95	CD	O
(	(	O
99	CD	O
%	NN	O
)	)	O
,	,	O
87	CD	O
(	(	O
91	CD	O
%	NN	O
)	)	O
and	CC	O
79	CD	O
(	(	O
82	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
groups	NNS	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O
respectively	RB	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
the	DT	O
ultimate	JJ	O
cure	NN	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
was	VBD	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
(	(	O
rise	NN	O
in	IN	O
serum	JJ	O
creatinine	NN	O
and	CC	O
fall	NN	O
in	IN	O
serum	JJ	O
potassium	NN	O
,	,	O
loss	NN	O
of	IN	O
appetite	NN	O
and	CC	O
shivering	NN	O
,	,	O
rigor	NN	O
and	CC	O
fever	NN	O
during	IN	O
infusion	NN	O
indicative	NN	O
of	IN	O
renal	JJ	O
,	,	O
GIT	NNP	O
and	CC	O
infusion	NN	O
related	JJ	O
toxicities	NNS	O
respectively	RB	O
)	)	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
amphotericin	NN	Pharmacological
B	NNP	Pharmacological
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
1	CD	O
mg/kg	NNS	O
bw/day	NN	O
for	IN	O
20	CD	O
days	NNS	O
for	IN	O
Indian	JJ	O
kala-azar	JJ	O
patients	NNS	O
to	TO	O
minimise	VB	O
relapses	NNS	O
and	CC	O
prevent	NN	O
development	NN	O
of	IN	O
drug	NN	O
unresponsiveness	NN	O
.	.	O

Comparative	JJ	O
effectiveness	NN	O
of	IN	O
exercise	NN	O
electrocardiography	NN	O
with	IN	O
or	CC	O
without	IN	O
myocardial	JJ	O
perfusion	NN	O
single	JJ	O
photon	NN	O
emission	NN	O
computed	VBD	O
tomography	NN	O
in	IN	O
women	NNS	O
with	IN	O
suspected	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
What	WP	O
Is	VBZ	O
the	DT	O
Optimal	NNP	O
Method	NNP	O
for	IN	O
Ischemia	NNP	O
Evaluation	NNP	O
in	IN	O
Women	NNP	O
(	(	O
WOMEN	NNP	O
)	)	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
a	DT	O
paucity	NN	O
of	IN	O
randomized	JJ	O
trials	NNS	O
regarding	VBG	O
diagnostic	JJ	O
testing	NN	O
in	IN	O
women	NNS	O
with	IN	O
suspected	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
(	(	O
CAD	NNP	O
)	)	O
.	.	O

It	PRP	O
remains	VBZ	O
unclear	JJ	O
whether	IN	O
the	DT	O
addition	NN	O
of	IN	O
myocardial	JJ	O
perfusion	NN	O
imaging	NN	O
(	(	O
MPI	NNP	O
)	)	O
to	TO	O
the	DT	O
standard	JJ	O
ECG	NNP	O
exercise	NN	O
treadmill	NN	O
test	NN	O
(	(	O
ETT	NNP	O
)	)	O
provides	VBZ	O
incremental	JJ	O
information	NN	O
to	TO	O
improve	VB	O
clinical	JJ	O
decision	NN	O
making	NN	O
in	IN	O
women	NNS	O
with	IN	O
suspected	JJ	O
CAD	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
randomized	VBD	O
symptomatic	JJ	O
women	NNS	O
with	IN	O
suspected	JJ	O
CAD	NNP	O
,	,	O
an	DT	O
interpretable	JJ	O
ECG	NNP	O
,	,	O
and	CC	O
?5	NNP	O
metabolic	JJ	O
equivalents	NNS	O
on	IN	O
the	DT	O
Duke	NNP	O
Activity	NNP	O
Status	NNP	O
Index	NNP	O
to	TO	O
1	CD	O
of	IN	O
2	CD	O
diagnostic	JJ	O
strategies	NNS	O
:	:	O
ETT	NNP	O
or	CC	O
exercise	NN	O
MPI	NNP	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
2-year	JJ	O
incidence	NN	O
of	IN	O
major	JJ	O
adverse	JJ	O
cardiac	NN	O
events	NNS	O
,	,	O
defined	VBN	O
as	IN	O
CAD	NNP	O
death	NN	O
or	CC	O
hospitalization	NN	O
for	IN	O
an	DT	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
or	CC	O
heart	NN	O
failure	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
824	CD	O
women	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
ETT	NNP	O
or	CC	O
exercise	NN	O
MPI	NNP	O
.	.	O

For	IN	O
women	NNS	O
randomized	VBN	O
to	TO	O
ETT	NNP	O
,	,	O
ECG	NNP	O
results	NNS	O
were	VBD	O
normal	JJ	O
in	IN	O
64	CD	O
%	NN	O
,	,	O
indeterminate	NN	O
in	IN	O
16	CD	O
%	NN	O
,	,	O
and	CC	O
abnormal	JJ	O
in	IN	O
20	CD	O
%	NN	O
.	.	O

By	IN	O
comparison	NN	O
,	,	O
the	DT	O
exercise	NN	O
MPI	NNP	O
results	NNS	O
were	VBD	O
normal	JJ	O
in	IN	O
91	CD	O
%	NN	O
,	,	O
mildly	RB	O
abnormal	JJ	O
in	IN	O
3	CD	O
%	NN	O
,	,	O
and	CC	O
moderate	VB	O
to	TO	O
severely	RB	O
abnormal	JJ	O
in	IN	O
6	CD	O
%	NN	O
.	.	O

At	IN	O
2	CD	O
years	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
major	JJ	O
adverse	JJ	O
cardiac	NN	O
events	NNS	O
(	(	O
98.0	CD	O
%	NN	O
for	IN	O
ETT	NNP	O
and	CC	O
97.7	CD	O
%	NN	O
for	IN	O
MPI	NNP	O
;	:	O
P=0.59	NNP	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
ETT	NNP	O
,	,	O
index	NN	O
testing	VBG	O
costs	NNS	O
were	VBD	O
higher	JJR	O
for	IN	O
exercise	NN	O
MPI	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
whereas	JJ	O
downstream	NN	O
procedural	NN	O
costs	NNS	O
were	VBD	O
slightly	RB	O
lower	JJR	O
(	(	O
P=0.0008	NNP	O
)	)	O
.	.	O

Overall	UH	O
,	,	O
the	DT	O
cumulative	JJ	O
diagnostic	JJ	O
cost	NN	O
savings	NNS	O
was	VBD	O
48	CD	O
%	NN	O
for	IN	O
ETT	NNP	O
compared	VBN	O
with	IN	O
exercise	NN	O
MPI	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
low-risk	JJ	O
,	,	O
exercising	VBG	O
women	NNS	O
,	,	O
a	DT	O
diagnostic	JJ	O
strategy	NN	O
that	WDT	O
uses	VBZ	O
ETT	NNP	O
versus	NN	O
exercise	NN	O
MPI	NNP	O
yields	NNS	O
similar	JJ	O
2-year	JJ	O
posttest	NN	O
outcomes	NNS	O
while	IN	O
providing	VBG	O
significant	JJ	O
diagnostic	JJ	O
cost	NN	O
savings	NNS	O
.	.	O

The	DT	O
ETT	NNP	O
with	IN	O
selective	JJ	O
follow-up	JJ	O
testing	NN	O
should	MD	O
be	VB	O
considered	VBN	O
as	IN	O
the	DT	O
initial	JJ	O
diagnostic	JJ	O
strategy	NN	O
in	IN	O
symptomatic	JJ	O
women	NNS	O
with	IN	O
suspected	JJ	O
CAD	NNP	O
.	.	O

CLINICAL	NNP	O
TRIAL	NNP	O
REGISTRATION	NNP	O
http	NN	O
:	:	O
//www.clinicaltrials.gov	NN	O
.	.	O

Unique	NNP	O
identifier	NN	O
:	:	O
NCT00282711	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
water	NN	Pharmacological
extracts	NNS	Pharmacological
of	IN	Pharmacological
Graptopetalum	NNP	Pharmacological
paraguayense	NN	Pharmacological
on	IN	O
blood	NN	O
pressure	NN	O
,	,	O
fasting	VBG	O
glucose	NN	O
,	,	O
and	CC	O
lipid	JJ	O
profiles	NNS	O
of	IN	O
subjects	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
aimed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
water	NN	Pharmacological
extracts	NNS	Pharmacological
of	IN	Pharmacological
Graptopetalum	NNP	Pharmacological
paraguayense	NN	Pharmacological
(	(	Pharmacological
WGP	NNP	Pharmacological
,	,	Pharmacological
4	CD	Pharmacological
g/d	NN	Pharmacological
)	)	Pharmacological
on	IN	O
blood	NN	O
pressure	NN	O
,	,	O
blood	NN	O
glucose	JJ	O
level	NN	O
,	,	O
and	CC	O
lipid	JJ	O
profiles	NNS	O
in	IN	O
subjects	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	NN	O
(	(	O
MS	NNP	O
)	)	O
.	.	O

Participants	NNS	O
with	IN	O
MS	NNP	O
(	(	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
and	CC	O
WGP	NNP	Pharmacological
groups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
26	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
intervention	NN	O
was	VBD	O
administered	VBN	O
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Systolic	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
SBP	NNP	O
)	)	O
,	,	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
DBP	NNP	O
)	)	O
,	,	O
fasting	VBG	O
glucose	NN	O
(	(	O
FG	NNP	O
)	)	O
,	,	O
lipid	JJ	O
profiles	NNS	O
(	(	O
total	JJ	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
,	,	O
triglyceride	RB	O
(	(	O
TG	NNP	O
)	)	O
,	,	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
LDL-C	NNP	O
)	)	O
,	,	O
and	CC	O
high	JJ	O
density	NN	O
lipoprotein	NN	O
(	(	O
HDL-C	NNP	O
)	)	O
)	)	O
,	,	O
and	CC	O
antioxidant	JJ	O
enzymes	NNS	O
activities	NNS	O
(	(	O
catalase	NN	O
(	(	O
CAT	NNP	O
)	)	O
,	,	O
superoxide	JJ	O
dismutase	NN	O
(	(	O
SOD	NNP	O
)	)	O
,	,	O
and	CC	O
glutathione	NN	O
peroxidase	NN	O
(	(	O
GPx	NNP	O
)	)	O
)	)	O
were	VBD	O
measured	VBN	O
.	.	O

Forty-two	JJ	O
subjects	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
placebo	NN	Control
,	,	O
n	JJ	O
=	VBP	O
19	CD	O
;	:	O
WGP	NNP	Pharmacological
,	,	O
n	JJ	O
=	NNP	O
23	CD	O
)	)	O
.	.	O

FG	NNP	O
,	,	O
SBP	NNP	O
,	,	O
and	CC	O
LDL-C	JJ	O
levels	NNS	O
were	VBD	O
significantly	RB	O
lower	JJR	O
and	CC	O
HDL-C	NNP	O
level	NN	O
and	CC	O
antioxidant	JJ	O
enzymes	NNS	O
activities	NNS	O
(	(	O
CAT	NNP	O
and	CC	O
SOD	NNP	O
)	)	O
were	VBD	O
significantly	RB	O
higher	JJR	O
after	IN	O
WGP	NNP	O
supplementation	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
,	,	O
FG	NNP	O
,	,	O
and	CC	O
lipid	JJ	O
profiles	NNS	O
were	VBD	O
significantly	RB	O
correlated	VBN	O
with	IN	O
antioxidant	JJ	O
enzymes	NNS	O
activities	NNS	O
after	IN	O
supplementation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
,	,	O
blood	NN	O
glucose	NN	O
,	,	O
and	CC	O
lipid	JJ	O
profiles	NNS	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
antioxidant	JJ	O
enzymes	NNS	O
activities	NNS	O
in	IN	O
subjects	NNS	O
with	IN	O
MS	NNP	O
after	IN	O
WGP	NNP	Pharmacological
supplementation	NN	O
.	.	O

Taken	VB	O
together	RB	O
,	,	O
the	DT	O
antioxidative	JJ	O
capacity	NN	O
of	IN	O
WGP	NNP	Control
might	MD	O
exert	VB	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
MS	NNP	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
NCT01463748	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
saxagliptin	NN	Pharmacological
added	VBN	O
to	TO	O
sub-maximal	JJ	O
doses	NNS	O
of	IN	O
metformin	NNS	Pharmacological
compared	VBN	O
with	IN	O
uptitration	NN	O
of	IN	O
metformin	NN	Pharmacological
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
:	:	O
the	DT	O
PROMPT	NNP	O
study	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
PROMPT	NNP	O
study	NN	O
compared	VBN	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
two	CD	O
treatment	NN	O
intensification	NN	O
strategies	NNS	O
:	:	O
adding	VBG	O
saxagliptin	NN	Pharmacological
or	CC	O
uptitrating	JJ	O
metformin	NN	Pharmacological
monotherapy	NN	Pharmacological
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
(	(	O
T2D	NNP	O
)	)	O
and	CC	O
inadequate	JJ	O
glycaemic	NNS	O
control	NN	O
on	IN	O
a	DT	O
sub-maximal	JJ	O
metformin	NN	O
dose	NN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
In	IN	O
this	DT	O
double-blind	NN	O
,	,	O
24-week	JJ	O
study	NN	O
,	,	O
metformin-tolerant	JJ	O
patients	NNS	O
with	IN	O
T2D	NNP	O
on	IN	O
metformin	NN	Pharmacological
monotherapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
fixed-dose	JJ	O
metformin	NN	O
1500	CD	O
mg/day	NN	O
,	,	O
plus	CC	O
either	DT	O
add-on	JJ	O
saxagliptin	NN	O
5	CD	O
mg/day	NN	O
(	(	O
SAXA-MET	NNP	O
)	)	O
or	CC	O
a	DT	O
two-step	JJ	O
metformin	NN	O
uptitration	NN	O
(	(	O
MET-UP	NNP	O
)	)	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
(	(	O
2500	CD	O
mg/day	NN	O
)	)	O
.	.	O

CLINICAL	JJ	O
TRIAL	NNP	O
REGISTRATION	NNP	O
NCT01006590	NNP	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Primary	NNP	O
:	:	O
absolute	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
glycated	JJ	O
haemoglobin	NN	O
A	NNP	O
(	(	O
1c	CD	O
)	)	O
(	(	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
)	)	O
(	(	O
Week	$	O
24	CD	O
)	)	O
.	.	O

Secondary	JJ	O
:	:	O
proportion	NN	O
of	IN	O
patients	NNS	O
achieving	VBG	O
a	DT	O
therapeutic	JJ	O
glycaemic	JJ	O
response	NN	O
(	(	O
Week	NNP	O
24	CD	O
)	)	O
;	:	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
(	(	O
Week	NNP	O
24	CD	O
)	)	O
;	:	O
safety	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Exploratory	JJ	O
analyses	NNS	O
comprised	VBD	O
three	CD	O
patient-related	JJ	O
questionnaires	NNS	O
,	,	O
including	VBG	O
the	DT	O
validated	JJ	O
5-dimension	JJ	O
Digestive	NNP	O
Health	NNP	O
Status	NNP	O
Index	NNP	O
(	(	O
DHSI	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
286	CD	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
:	:	O
(	(	O
SAXA-MET	JJ	O
:	:	O
147	CD	O
;	:	O
MET-UP	JJ	O
:	:	O
139	CD	O
)	)	O
.	.	O

Baseline	JJ	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
:	:	O
7.71	CD	O
(	(	O
0.85	CD	O
;	:	O
SAXA-MET	NNP	O
)	)	O
;	:	O
7.80	CD	O
(	(	O
0.82	CD	O
;	:	O
MET-UP	NNP	O
)	)	O
.	.	O

Adjusted	VBN	O
mean	JJ	O
reductions	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
(	(	O
Week	$	O
24	CD	O
)	)	O
:	:	O
-0.47	CD	O
%	NN	O
(	(	O
SAXA-MET	NNP	O
)	)	O
;	:	O
-0.38	CD	O
%	NN	O
(	(	O
MET-UP	NNP	O
)	)	O
;	:	O
mean	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
difference	NN	O
in	IN	O
treatment	NN	O
effect	NN	O
,	,	O
-0.10	CD	O
%	NN	O
(	(	O
-0.26	NNP	O
,	,	O
0.07	CD	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.260	CD	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
achieving	VBG	O
a	DT	O
therapeutic	JJ	O
glycaemic	JJ	O
response	NN	O
(	(	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
<	VBD	O
7	CD	O
%	NN	O
)	)	O
:	:	O
43.8	CD	O
%	NN	O
(	(	O
34.8	CD	O
,	,	O
49.6	CD	O
)	)	O
(	(	O
SAXA-MET	NNP	O
)	)	O
vs.	FW	O
35.0	CD	O
%	NN	O
(	(	O
29.0	CD	O
,	,	O
43.8	CD	O
)	)	O
(	(	O
MET-UP	NNP	O
)	)	O
.	.	O

Of	IN	O
the	DT	O
five	CD	O
DHSI	NNP	O
domains	NNS	O
,	,	O
mean	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
differences	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
diarrhoea-predominant	JJ	O
score	NN	O
(	(	O
+0.8	JJ	O
[	NNP	O
-2.5	NNP	O
,	,	O
4.0	CD	O
]	NN	O
vs.	FW	O
+7.9	NNP	O
[	NNP	O
4.6	CD	O
,	,	O
11.2	CD	O
]	NN	O
)	)	O
and	CC	O
dysmotility	NN	O
score	NN	O
(	(	O
-0.5	JJ	O
[	NNP	O
-2.0	NNP	O
,	,	O
1.0	CD	O
]	NN	O
vs.	FW	O
+1.9	NNP	O
[	NNP	O
0.3	CD	O
,	,	O
3.4	CD	O
]	NN	O
)	)	O
,	,	O
(	(	O
SAXA-MET	JJ	O
and	CC	O
MET-UP	NNP	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
event	NN	O
was	VBD	O
diarrhoea	NN	O
:	:	O
6.1	CD	O
%	NN	O
(	(	O
SAXA-MET	NNP	O
)	)	O
vs.	FW	O
12.2	CD	O
%	NN	O
(	(	O
MET-UP	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
metformin-tolerant	JJ	O
patients	NNS	O
with	IN	O
T2D	NNP	O
(	(	O
inadequately	RB	O
controlled	VBN	O
on	IN	O
sub-maximal	JJ	O
metformin	NN	O
monotherapy	NN	O
)	)	O
,	,	O
saxagliptin	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Although	IN	O
HbA	NNP	O
(	(	O
1c	CD	O
)	)	O
reduction	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
treatment	NN	O
groups	NNS	O
,	,	O
the	DT	O
lower	JJR	O
occurrence	NN	O
of	IN	O
gastrointestinal	JJ	O
symptoms	NNS	O
in	IN	O
the	DT	O
SAXA-MET	NNP	O
group	NN	O
suggests	VBZ	O
that	IN	O
saxagliptin	JJ	O
add-on	JJ	O
treatment	NN	O
may	MD	O
be	VB	O
a	DT	O
suitable	JJ	O
alternative	JJ	O
treatment	NN	O
strategy	NN	O
to	TO	O
metformin	VB	O
uptitration	NN	O
.	.	O

Not	RB	O
Now	RB	O
!	.	O
Supporting	VBG	O
interruption	NN	O
management	NN	O
by	IN	O
indicating	VBG	O
the	DT	O
modality	NN	O
and	CC	O
urgency	NN	O
of	IN	O
pending	VBG	O
tasks	NNS	O
.	.	O

Operators	NNS	O
in	IN	O
complex	JJ	O
event-driven	JJ	O
domains	NNS	O
must	MD	O
coordinate	VB	O
competing	VBG	O
attentional	JJ	O
demands	NNS	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
multiple	JJ	O
tasks	NNS	O
and	CC	O
interactions	NNS	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
this	DT	O
requirement	NN	O
can	MD	O
be	VB	O
supported	VBN	O
more	RBR	O
effectively	RB	O
through	IN	O
informative	JJ	O
interruption	NN	O
cueing	NN	O
(	(	O
in	IN	O
this	DT	O
case	NN	O
,	,	O
partial	JJ	O
information	NN	O
about	IN	O
the	DT	O
nature	NN	O
of	IN	O
pending	VBG	O
tasks	NNS	O
)	)	O
.	.	O

The	DT	O
48	CD	O
participants	NNS	O
performed	VBD	O
a	DT	O
visually	RB	Other
demanding	VBG	Other
air	NN	Other
traffic	NN	Other
control	NN	Other
(	(	Other
ATC	NNP	Other
)	)	Other
task	NN	Other
.	.	Educational

They	PRP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
1	CD	O
of	IN	O
3	CD	O
experimental	JJ	O
groups	NNS	O
that	WDT	O
differed	VBD	O
in	IN	O
the	DT	O
availability	NN	Educational
of	IN	Educational
information	NN	Educational
(	(	Educational
not	RB	Educational
available	JJ	Educational
,	,	Educational
available	JJ	Educational
upon	IN	Educational
request	NN	Educational
,	,	Educational
available	JJ	Educational
automatically	RB	Educational
)	)	O
about	IN	O
the	DT	O
urgency	NN	O
and	CC	O
modality	NN	O
of	IN	O
pending	VBG	O
interruption	NN	O
tasks	NNS	O
.	.	O

Within-subject	JJ	O
variables	NNS	O
included	VBD	O
ATC-related	JJ	Other
workload	NN	Other
and	CC	O
the	DT	O
modality	NN	Other
,	,	Other
frequency	NN	Other
,	,	Other
and	CC	Other
priority	NN	Other
of	IN	Other
interruption	NN	Other
tasks	NNS	Other
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
that	IN	O
advance	NN	O
knowledge	NN	O
about	IN	O
the	DT	O
nature	NN	O
of	IN	O
pending	VBG	O
tasks	NNS	O
led	VBD	O
participants	NNS	O
to	TO	O
delay	VB	O
visual	JJ	O
interruption	NN	O
tasks	VBZ	O
the	DT	O
longest	JJS	O
,	,	O
which	WDT	O
allowed	VBD	O
them	PRP	O
to	TO	O
avoid	VB	O
intramodal	JJ	O
interference	NN	O
and	CC	O
scanning	NN	O
costs	NNS	O
associated	VBN	O
with	IN	O
performing	VBG	O
these	DT	O
tasks	NNS	O
concurrently	RB	O
with	IN	O
ATC	NNP	O
tasks	NNS	O
.	.	O

The	DT	O
3	CD	O
experimental	JJ	O
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
in	IN	O
terms	NNS	O
of	IN	O
their	PRP$	O
interruption	NN	O
task	NN	O
performance	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
group	NN	O
that	WDT	O
automatically	RB	O
received	VBD	O
task-related	JJ	O
information	NN	O
showed	VBD	O
better	JJR	O
ATC	NNP	O
performance	NN	O
,	,	O
thus	RB	O
experiencing	VBG	O
a	DT	O
net	JJ	O
performance	NN	O
gain	NN	O
.	.	O

Actual	NNP	O
or	CC	O
potential	JJ	O
applications	NNS	O
of	IN	O
this	DT	O
research	NN	O
include	VBP	O
the	DT	O
design	NN	O
of	IN	O
interfaces	NNS	O
in	IN	O
support	NN	O
of	IN	O
attention	NN	O
and	CC	O
interruption	NN	O
management	NN	O
in	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
event-driven	JJ	O
environments	NNS	O
.	.	O

A	DT	O
hybrid	NN	Physical
technique	NN	Physical
using	VBG	O
bipolar	JJ	Surgical
energy	NN	Surgical
in	IN	Surgical
transurethral	JJ	Surgical
prostate	NN	Surgical
surgery	NN	Surgical
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
comparison	NN	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
assessed	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
transurethral	JJ	Surgical
resection	NN	Surgical
and	CC	O
vaporization	NN	Surgical
with	IN	Surgical
bipolar	JJ	Surgical
PlasmaKinetic	NNP	Surgical
energy	NN	Surgical
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
During	IN	O
a	DT	O
2-year	JJ	O
period	NN	O
101	CD	O
men	NNS	O
with	IN	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
PlasmaKinetic	NNP	Surgical
surgery	NN	Surgical
or	CC	O
standard	JJ	Surgical
transurethral	JJ	Surgical
prostate	NN	Surgical
resection	NN	Surgical
(	(	Surgical
TURP	NNP	Surgical
)	)	Surgical
.	.	O

Patient	JJ	O
demographics	NNS	O
,	,	O
indications	NNS	O
for	IN	O
surgery	NN	O
,	,	O
preoperative	JJ	O
and	CC	O
postoperative	JJ	O
International	NNP	O
Prostate	NNP	O
Symptom	NNP	O
Score	NNP	O
,	,	O
uroflowmetry	NN	O
scores	NNS	O
,	,	O
operative	JJ	O
time	NN	O
,	,	O
catheterization	NN	O
duration	NN	O
,	,	O
hospital	NN	O
stay	NN	O
and	CC	O
complication	NN	O
rates	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
Complete	NNP	O
data	NNS	O
on	IN	O
96	CD	O
patients	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
age	NN	O
+/-	JJ	O
SD	NNP	O
of	IN	O
69.1	CD	O
+/-	JJ	O
6.1	CD	O
years	NNS	O
was	VBD	O
available	JJ	O
at	IN	O
a	DT	O
mean	JJ	O
followup	NN	O
of	IN	O
18.3	CD	O
+/-	JJ	O
6.7	CD	O
months	NNS	O
(	(	O
range	VB	O
12	CD	O
to	TO	O
23	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
PlasmaKinetic	NNP	O
and	CC	O
TURP	NNP	O
groups	NNS	O
mean	VBP	O
operative	JJ	O
time	NN	O
was	VBD	O
40.3	CD	O
+/-	JJ	O
11.4	CD	O
(	(	O
range	NN	O
30	CD	O
to	TO	O
60	CD	O
)	)	O
and	CC	O
57.8	CD	O
+/-	JJ	O
13.4	CD	O
minutes	NNS	O
(	(	O
range	VB	O
45	CD	O
to	TO	O
75	CD	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
volume	NN	O
of	IN	O
saline	JJ	O
irrigation	NN	O
during	IN	O
the	DT	O
PlasmaKinetic	JJ	O
procedure	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
of	IN	O
hyperosmolar	JJ	O
solution	NN	O
irrigation	NN	O
during	IN	O
TURP	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
PlasmaKinetic	NNP	O
and	CC	O
TURP	NNP	O
groups	NNS	O
were	VBD	O
catheterized	VBN	O
a	DT	O
mean	NN	O
of	IN	O
2.3	CD	O
+/-	JJ	O
0.7	CD	O
(	(	O
range	NN	O
2	CD	O
to	TO	O
4	CD	O
)	)	O
and	CC	O
3.8	CD	O
+/-	JJ	O
0.7	CD	O
days	NNS	O
(	(	O
range	VB	O
3	CD	O
to	TO	O
5	CD	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
improvement	NN	O
rate	NN	O
from	IN	O
baseline	NN	O
at	IN	O
month	NN	O
12	CD	O
in	IN	O
International	NNP	O
Prostate	NNP	O
Symptom	NNP	O
Score	NNP	O
and	CC	O
the	DT	O
maximal	JJ	O
urinary	JJ	O
flow	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Severe	NNP	O
irritative	JJ	O
symptoms	NNS	O
were	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
complaints	NNS	O
after	IN	O
PlasmaKinetic	JJ	O
surgery	NN	O
,	,	O
as	IN	O
observed	VBN	O
in	IN	O
6	CD	O
cases	NNS	O
(	(	O
12.2	CD	O
%	NN	O
)	)	O
.	.	O

Recatheterization	NN	O
was	VBD	O
necessary	JJ	O
in	IN	O
3	CD	O
cases	NNS	O
(	(	O
6.1	CD	O
%	NN	O
)	)	O
cases	NNS	O
in	IN	O
the	DT	O
PlasmaKinetic	NNP	O
group	NN	O
and	CC	O
in	IN	O
1	CD	O
(	(	O
2.1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
TURP	NNP	O
group	NN	O
.	.	O

During	IN	O
followup	JJ	O
urethral	JJ	O
stricture	NN	O
formation	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
3	CD	O
patients	NNS	O
(	(	O
6.1	CD	O
%	NN	O
)	)	O
cases	NNS	O
in	IN	O
the	DT	O
former	JJ	O
group	NN	O
and	CC	O
in	IN	O
1	CD	O
(	(	O
2.1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
latter	JJ	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
.	.	O

Reoperation	NN	O
was	VBD	O
required	VBN	O
in	IN	O
2	CD	O
(	(	O
4.1	CD	O
%	NN	O
)	)	O
and	CC	O
1	CD	O
(	(	O
2.1	CD	O
%	NN	O
)	)	O
cases	NNS	O
in	IN	O
the	DT	O
PlasmaKinetic	NNP	O
and	CC	O
TURP	NNP	O
groups	NNS	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSIONS	NN	O
:	:	O
Transurethral	JJ	O
surgery	NN	O
with	IN	O
PlasmaKinetic	NNP	O
bipolar	NN	O
energy	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
promising	JJ	O
alternative	NN	O
to	TO	O
prostatic	JJ	O
tissue	NN	O
removal	NN	O
with	IN	O
shorter	RBR	O
operative	JJ	O
,	,	O
catheterization	NN	O
and	CC	O
hospitalization	NN	O
times	NNS	O
,	,	O
although	IN	O
increased	VBN	O
rates	NNS	O
of	IN	O
postoperative	JJ	O
irritative	NN	O
symptoms	NNS	O
and	CC	O
urethral	JJ	O
stricture	NN	O
formation	NN	O
must	MD	O
be	VB	O
further	RB	O
evaluated	VBN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
body	NN	O
weight	JJ	O
changes	NNS	O
and	CC	O
endurance	NN	O
training	NN	O
on	IN	O
24h	CD	O
substrate	JJ	O
oxidation	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
exercise	NN	Other
training	NN	Other
and	CC	Physical
dietary	JJ	Educational
macronutrient	NN	Educational
composition	NN	Educational
on	IN	O
24	CD	O
h	NN	O
substrate	JJ	O
oxidation	NN	O
in	IN	O
male	NN	O
,	,	O
obese	JJ	O
subjects	NNS	O
.	.	O

DESIGN	VB	O
A	DT	O
16	CD	O
month	NN	O
exercise	NN	Other
intervention	NN	Other
study	NN	O
was	VBD	O
executed	VBN	O
,	,	O
including	VBG	O
a	DT	O
weight	JJ	O
loss	NN	O
period	NN	O
with	IN	O
a	DT	O
very	RB	Other
low	JJ	Other
energy	NN	Other
diet	NN	Other
(	(	Other
VLED	NNP	Other
)	)	Pharmacological
for	IN	O
2	CD	O
months	NNS	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

SUBJECTS	NNP	O
Twelve	NNP	O
male	NN	O
,	,	O
obese	JJ	O
subjects	NNS	O
(	(	O
age	NN	O
36.3+/-5.1	CD	O
y	NN	O
;	:	O
body	NN	O
weight	VBD	O
94.6+/-13.9	CD	O
kg	NN	O
;	:	O
body	NN	O
mass	NN	O
index	NN	O
,	,	O
BMI	NNP	O
30.8+/-3.0	NNP	O
kg/m2	NN	O
)	)	O
and	CC	O
in	IN	O
an	DT	O
additional	JJ	O
study	NN	O
15	CD	O
lean	JJ	O
,	,	O
well-trained	JJ	O
subjects	NNS	O
(	(	O
age	NN	O
36.2+/-7.2	CD	O
y	NN	O
;	:	O
body	NN	O
weight	VBD	O
72.2+/-5.9	JJ	O
kg	NN	O
;	:	O
BMI	NNP	O
22.3+/-1.7	CD	O
kg/m2	NN	O
)	)	O
participated	VBD	O
.	.	O

MEASUREMENTS	NNP	O
Substrate	NNP	O
oxidation	NN	O
was	VBD	O
measured	VBN	O
during	IN	O
a	DT	O
standardized	JJ	O
36	CD	O
h	NN	O
stay	NN	O
in	IN	O
the	DT	O
respiration	NN	O
chamber	NN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
(	(	O
0	CD	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
at	IN	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
16	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
respiration	NN	O
chamber	NN	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
high-fat	NN	Other
(	(	Other
Hi.F	NNP	Other
)	)	Other
diet	NN	Other
(	(	Pharmacological
60	CD	Pharmacological
%	NN	Pharmacological
of	IN	Pharmacological
energy	NN	Pharmacological
(	(	Pharmacological
En	NNP	Pharmacological
%	NN	Pharmacological
)	)	Pharmacological
fat	NN	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
a	DT	Pharmacological
reduced-fat	JJ	Other
(	(	Other
Red.F	NNP	Other
)	)	Other
diet	NN	Other
(	(	Pharmacological
30	CD	Pharmacological
En	NNP	Pharmacological
%	NN	Pharmacological
fat	NN	Pharmacological
)	)	O
.	.	O

The	DT	O
well-trained	JJ	O
group	NN	O
was	VBD	O
measured	VBN	O
once	RB	O
in	IN	O
the	DT	O
respiration	NN	O
chamber	NN	O
for	IN	O
36	CD	O
h	NN	O
according	VBG	O
to	TO	O
the	DT	O
same	JJ	O
protocol	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
any	DT	O
time	NN	O
point	NN	O
,	,	O
independent	JJ	O
of	IN	O
the	DT	O
diet	NN	O
consumed	VBD	O
,	,	O
the	DT	O
24	CD	O
h	NN	O
carbohydrate	NN	O
(	(	O
CHO	NNP	O
)	)	O
balances	NNS	O
in	IN	O
the	DT	O
chamber	NN	O
were	VBD	O
mostly	RB	O
negative	JJ	O
(	(	O
means	NNS	O
ranging	VBG	O
from	IN	O
+31	NN	O
to	TO	O
-98	VB	O
g/d	NN	O
)	)	O
and	CC	O
the	DT	O
fat	JJ	O
balances	NNS	O
mostly	RB	O
positive	JJ	O
(	(	O
means	NNS	O
ranging	VBG	O
from	IN	O
-26	NN	O
to	TO	O
+38	VB	O
g/d	NN	O
)	)	O
for	IN	O
the	DT	O
obese	NN	O
a	DT	O
well	RB	O
as	IN	O
for	IN	O
the	DT	O
lean	JJ	O
,	,	O
well-trained	JJ	O
group	NN	O
.	.	O

For	IN	O
both	DT	O
diets	NNS	O
an	DT	O
increased	JJ	O
shortage	NN	O
of	IN	O
70	CD	O
g	NN	O
of	IN	O
CHO	NNP	O
was	VBD	O
found	VBN	O
at	IN	O
16	CD	O
months	NNS	O
compared	VBN	O
with	IN	O
4	CD	O
months	NNS	O
,	,	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
fat	JJ	O
balance	NN	O
of	IN	O
33	CD	O
g	NN	O
during	IN	O
the	DT	O
same	JJ	O
time	NN	O
period	NN	O
in	IN	O
the	DT	O
obese	JJ	O
subjects	NNS	O
,	,	O
indicating	VBG	O
that	IN	O
CHO	NNP	O
oxidation	NN	O
had	VBD	O
increased	VBN	O
with	IN	O
12	CD	O
months	NNS	O
endurance	RB	O
training	VBG	O
.	.	O

In	IN	O
the	DT	O
well-trained	JJ	O
group	NN	O
the	DT	O
24h	CD	O
CHO	NNP	O
balance	NN	O
was	VBD	O
even	RB	O
more	RBR	O
negative	JJ	O
for	IN	O
both	DT	O
types	NNS	O
of	IN	O
diet	NN	O
(	(	O
-103	UH	O
to	TO	O
-185	VB	O
g/d	NN	O
for	IN	O
the	DT	O
Red.F	NNP	O
and	CC	O
Hi.F	NNP	O
diet	NN	O
,	,	O
respectively	RB	O
)	)	O
under	IN	O
similar	JJ	O
conditions	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
trained	JJ	O
obese	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
changes	NNS	O
in	IN	O
24	CD	O
h	NN	O
substrate	JJ	O
utilization	NN	O
in	IN	O
the	DT	O
obese	JJ	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
the	DT	O
well-trained	JJ	O
group	NN	O
,	,	O
suggest	VBP	O
that	IN	O
endurance	NN	O
training	NN	O
increased	VBD	O
the	DT	O
reliance	NN	O
on	IN	O
carbohydrate	NN	O
oxidation	NN	O
and	CC	O
therefore	RB	O
did	VBD	O
not	RB	O
increase	VB	O
24	CD	O
fat	JJ	O
oxidation	NN	O
.	.	O

Alendronate	NNP	Pharmacological
daily	RB	O
,	,	O
weekly	JJ	O
in	IN	O
conventional	JJ	O
tablets	NNS	O
and	CC	O
weekly	JJ	O
in	IN	O
enteric	JJ	O
tablets	NNS	O
:	:	O
preliminary	JJ	O
study	NN	O
on	IN	O
the	DT	O
effects	NNS	O
in	IN	O
bone	NN	O
turnover	NN	O
markers	NNS	O
and	CC	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Bisphosphonates	NNS	Pharmacological
are	VBP	O
now	RB	O
in	IN	O
the	DT	O
vanguard	NN	O
of	IN	O
osteoporosis	NN	O
treatment	NN	O
.	.	O

Frequently	RB	O
,	,	O
gastro-oesophageal	JJ	O
symptoms	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
these	DT	O
drugs	NNS	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
side	JJ	O
effects	NNS	O
and	CC	O
bone	NN	O
turnover	NN	O
markers	NNS	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
alendronate	JJ	Pharmacological
daily	JJ	O
or	CC	O
weekly	JJ	O
in	IN	O
tablets	NNS	O
with	IN	O
or	CC	O
without	IN	O
enteric	JJ	O
coating	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
3-month	JJ	O
trial	NN	O
.	.	O

The	DT	O
trial	NN	O
involved	VBD	O
75	CD	O
volunteers	NNS	O
,	,	O
aged	VBD	O
45-58	JJ	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
osteopenia	NN	O
(	(	O
T-score	NNP	O
lower	JJR	O
than	IN	O
-2	JJR	O
SD	NNP	O
)	)	O
assessed	VBN	O
by	IN	O
quantitative	JJ	O
ultrasound	NN	O
.	.	O

Women	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
:	:	O
(	(	O
a	DT	O
)	)	O
alendronate	NN	Pharmacological
10mg/day	CD	Pharmacological
:	:	O
(	(	O
b	NN	O
)	)	O
alendronate	NN	Pharmacological
70	CD	Pharmacological
mg	NN	Pharmacological
once	RB	Pharmacological
a	DT	Pharmacological
week	NN	Pharmacological
:	:	Pharmacological
or	CC	O
(	(	O
c	NN	O
)	)	O
enteric	JJ	Pharmacological
alendronate	NN	Pharmacological
70	CD	Pharmacological
mg	NN	Pharmacological
per	IN	Pharmacological
week	NN	Pharmacological
.	.	O

We	PRP	O
recorded	VBD	O
side	JJ	O
effects	NNS	O
,	,	O
C-telopeptide	NNP	O
,	,	O
osteocalcin	NN	O
and	CC	O
urine	JJ	O
hydroxyproline	NN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
study	NN	O
and	CC	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
,	,	O
pyrosis	NN	O
(	(	O
heartburn	NN	O
)	)	O
was	VBD	O
noted	VBN	O
by	IN	O
seven	CD	O
women	NNS	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
28	CD	O
%	NN	O
)	)	O
,	,	O
three	CD	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
12	CD	O
%	NN	O
)	)	O
and	CC	O
two	CD	O
in	IN	O
group	NN	O
C	NNP	O
(	(	O
8	CD	O
%	NN	O
)	)	O
;	:	O
nausea	NN	O
:	:	O
by	IN	O
one	CD	O
woman	NN	O
in	IN	O
group	NN	O
B	NNP	O
;	:	O
and	CC	O
headache	NN	O
by	IN	O
one	CD	O
patient	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

C-telopeptide	NNP	O
(	(	O
A	DT	O
:	:	O
40.7	CD	O
%	NN	O
;	:	O
B	NNP	O
:	:	O
34.1	CD	O
%	NN	O
and	CC	O
C	NNP	O
:	:	O
38.5	CD	O
%	NN	O
)	)	O
;	:	O
hydroxyproline	NN	O
(	(	O
A	DT	O
:	:	O
31.1	CD	O
%	NN	O
;	:	O
B	NNP	O
:	:	O
25.3	CD	O
%	NN	O
and	CC	O
C	NNP	O
:	:	O
31.5	CD	O
%	NN	O
)	)	O
and	CC	O
osteocalcin	$	O
(	(	O
A	DT	O
:	:	O
27.0	CD	O
%	NN	O
;	:	O
B	NNP	O
:	:	O
25.4	CD	O
%	NN	O
and	CC	O
C	NNP	O
:	:	O
25.1	CD	O
%	NN	O
)	)	O
decreased	VBD	O
similarly	RB	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Weekly	JJ	O
intake	NN	O
of	IN	O
alendronate	NN	Pharmacological
,	,	O
whether	IN	O
conventional	JJ	O
or	CC	O
enteric-coated	JJ	O
;	:	O
is	VBZ	O
associated	VBN	O
with	IN	O
less	JJR	O
heartburn	NN	O
and	CC	O
nausea	NN	O
.	.	O

Enteric	JJ	Pharmacological
alendronate	NN	Pharmacological
has	VBZ	O
a	DT	O
similar	JJ	O
action	NN	O
to	TO	O
the	DT	O
conventional	JJ	O
tablets	NNS	O
on	IN	O
biochemical	JJ	O
markers	NNS	O
.	.	O

A	DT	O
pilot	NN	O
study	NN	O
of	IN	O
the	DT	O
Tele-Airway	NNP	Educational
Management	NNP	Educational
System	NNP	Educational
in	IN	O
a	DT	O
hospital	NN	O
emergency	NN	O
department	NN	O
.	.	O

We	PRP	O
developed	VBD	O
a	DT	O
telemedicine	NN	O
system	NN	O
for	IN	O
remote	JJ	O
guidance	NN	O
of	IN	O
emergency	NN	O
airway	NN	O
management	NN	O
called	VBD	O
the	DT	O
Tele-Airway	NNP	Educational
Management	NNP	Educational
System	NNP	Educational
(	(	O
TAMS	NNP	O
)	)	O
.	.	O

In	IN	O
a	DT	O
pilot	NN	O
study	NN	O
we	PRP	O
examined	VBD	O
the	DT	O
usefulness	NN	O
of	IN	O
the	DT	O
TAMS	NNP	Educational
for	IN	O
intubations	NNS	O
of	IN	O
actual	JJ	O
patients	NNS	O
in	IN	O
a	DT	O
hospital	NN	O
emergency	NN	O
department	NN	O
.	.	O

Twenty-five	JJ	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
randomly	RB	O
either	DT	O
to	TO	O
a	DT	O
TAMS	NNP	Educational
group	NN	Educational
or	CC	O
to	TO	O
an	DT	O
on-scene	JJ	Educational
directed	NN	Educational
(	(	Educational
OSD	NNP	Educational
)	)	Educational
group	NN	Educational
.	.	O

A	DT	O
total	NN	O
of	IN	O
12	CD	O
were	VBD	O
intubated	VBN	O
using	VBG	O
the	DT	O
TAMS	NNP	Educational
.	.	O

The	DT	O
mean	JJ	O
time	NN	O
to	TO	O
intubation	NN	O
(	(	O
TAMS	NNP	Other
62	CD	O
s	NN	O
vs.	FW	O
OSD	NNP	Educational
56	CD	O
s	NN	O
)	)	O
and	CC	O
the	DT	O
success	NN	O
rate	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
two	CD	O
oesophageal	JJ	O
intubations	NNS	O
in	IN	O
the	DT	O
TAMS	NNP	Educational
group	NN	O
and	CC	O
four	CD	O
in	IN	O
the	DT	O
OSD	NNP	Other
group	NN	O
,	,	O
but	CC	O
this	DT	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.36	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
mechanical	JJ	O
or	CC	O
technical	JJ	O
errors	NNS	O
such	JJ	O
as	IN	O
disconnection	NN	O
during	IN	O
use	NN	O
of	IN	O
the	DT	O
TAMS	NNP	Educational
.	.	O

The	DT	O
pilot	NN	O
study	NN	O
demonstrated	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
the	DT	O
TAMS	NNP	O
as	IN	O
an	DT	O
alternative	NN	O
to	TO	O
OSD	NNP	Educational
.	.	O

However	RB	O
,	,	O
a	DT	O
larger	JJR	O
study	NN	O
will	MD	O
be	VB	O
required	VBN	O
to	TO	O
determine	VB	O
non-superiority	NN	O
or	CC	O
equivalence	NN	O
.	.	O

Analysis	NN	O
of	IN	O
prevention	NN	O
program	NN	O
effectiveness	NN	O
with	IN	O
clustered	VBN	O
data	NNS	O
using	VBG	O
generalized	JJ	O
estimating	NN	O
equations	NNS	O
.	.	O

Experimental	JJ	O
studies	NNS	O
of	IN	O
prevention	NN	O
programs	NNS	O
often	RB	O
randomize	VBP	O
clusters	NNS	O
of	IN	O
individuals	NNS	O
rather	RB	O
than	IN	O
individuals	NNS	O
to	TO	O
treatment	NN	O
conditions	NNS	O
.	.	O

When	WRB	O
the	DT	O
correlation	NN	O
among	IN	O
individuals	NNS	O
within	IN	O
clusters	NNS	O
is	VBZ	O
not	RB	O
accounted	VBN	O
for	IN	O
in	IN	O
statistical	JJ	O
analysis	NN	O
,	,	O
the	DT	O
standard	JJ	O
errors	NNS	O
are	VBP	O
biased	VBN	O
,	,	O
potentially	RB	O
resulting	VBG	O
in	IN	O
misleading	VBG	O
conclusions	NNS	O
about	IN	O
the	DT	O
significance	NN	O
of	IN	O
treatment	NN	O
effects	NNS	O
.	.	O

This	DT	O
study	NN	O
demonstrates	VBZ	O
the	DT	O
generalized	JJ	Other
estimating	NN	Other
equations	NNS	Other
(	(	Other
GEE	NNP	Other
)	)	Other
method	NN	O
,	,	O
focusing	VBG	O
specifically	RB	O
on	IN	O
the	DT	O
GEE-independent	NNP	Physical
method	NN	Physical
,	,	O
to	TO	O
control	VB	O
for	IN	O
within-cluster	JJ	O
correlation	NN	O
in	IN	O
regression	NN	O
models	NNS	O
with	IN	O
either	DT	O
continuous	JJ	O
or	CC	O
binary	JJ	O
outcomes	NNS	O
.	.	O

The	DT	O
GEE-independent	JJ	Physical
method	NN	Physical
yields	NNS	O
consistent	JJ	O
and	CC	O
robust	JJ	O
variance	NN	O
estimates	NNS	O
.	.	O

Data	NNS	O
from	IN	O
project	NN	O
DARE	NNP	O
,	,	O
a	DT	O
youth	NN	O
substance	NN	O
abuse	NN	O
prevention	NN	O
program	NN	O
,	,	O
are	VBP	O
used	VBN	O
for	IN	O
illustration	NN	O
.	.	O

Effects	NNS	O
of	IN	O
short-term	JJ	O
isotonic	JJ	Educational
&	CC	Educational
isometric	JJ	Educational
training	NN	Educational
on	IN	O
cardiovascular	JJ	O
&	CC	O
pulmonary	JJ	O
function	NN	O
.	.	O

A	DT	O
randomised	JJ	O
control	NN	O
trial	NN	O
of	IN	O
short-term	JJ	Physical
exercises	NNS	Physical
on	IN	O
specific	JJ	O
cardiovascular	JJ	O
and	CC	O
respiratory	JJ	O
parameters	NNS	O
was	VBD	O
undertaken	VBN	O
in	IN	O
normal	JJ	O
male	JJ	O
college	NN	O
students	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
isotonic	JJ	Physical
training	NN	Physical
(	(	Physical
5BX	CD	Physical
programme	NN	Physical
)	)	Physical
and	CC	Educational
isometric	JJ	Physical
training	NN	Physical
(	(	Educational
a	DT	Educational
programme	NN	Educational
of	IN	Educational
isometric	JJ	Educational
exercises	NNS	Educational
working	VBG	Educational
all	DT	Educational
major	JJ	Educational
groups	NNS	Educational
of	IN	Educational
muscles	NNS	Educational
)	)	Educational
were	VBD	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	Control
group	NN	O
with	IN	O
no	DT	O
specific	JJ	O
workout	NN	O
.	.	O

Both	DT	O
isotonic	JJ	Educational
and	CC	Educational
isometric	JJ	Physical
training	NN	Physical
resulted	VBD	O
in	IN	O
significant	JJ	O
cardiovascular	JJ	O
improvement	NN	O
but	CC	O
seemed	VBD	O
inadequate	JJ	O
to	TO	O
improve	VB	O
vital	JJ	O
capacity	NN	O
and	CC	O
flow	NN	O
rates	NNS	O
.	.	O

Isotonic	JJ	Physical
training	NN	Physical
in	IN	O
addition	NN	O
,	,	O
improved	JJ	O
ventilatory	NN	O
efficiency	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
such	JJ	O
isotonic	JJ	Educational
or	CC	Educational
isometric	JJ	Educational
training	NN	Educational
of	IN	O
thrice	NN	O
a	DT	O
week	NN	O
for	IN	O
ten	JJ	O
weeks	NNS	O
,	,	O
requiring	VBG	O
no	DT	O
equipment	NN	O
,	,	O
less	JJR	O
time	NN	O
and	CC	O
space	NN	O
can	MD	O
be	VB	O
promoted	VBN	O
to	TO	O
improve	VB	O
physical	JJ	O
fitness	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
different	JJ	O
long-term	JJ	O
asthma	NN	O
treatments	NNS	O
in	IN	O
subjects	NNS	O
with	IN	O
mild-to-moderate	JJ	O
asthma	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
different	JJ	O
asthma	NN	O
treatment	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
mild-to-moderate	JJ	O
asthma	NN	O
,	,	O
three	CD	O
groups	NNS	O
of	IN	O
11	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
nedocromil	JJ	Pharmacological
sodium	NN	Pharmacological
(	(	Pharmacological
NS	NNP	Pharmacological
)	)	Pharmacological
,	,	O
beclomethasone	JJ	Pharmacological
dipropionate	NN	Pharmacological
(	(	Pharmacological
BDP	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
beclomethasone	NN	Pharmacological
dipropionate	NN	Pharmacological
plus	CC	Pharmacological
salmeterol	NN	Pharmacological
(	(	Pharmacological
BDP	NNP	Pharmacological
+	NNP	Pharmacological
S	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
an	DT	O
open	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

Symptom	NNP	O
score	NN	O
,	,	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
(	(	O
PEF	NNP	O
)	)	O
maximal	JJ	O
amplitude	NN	O
,	,	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV1	NNP	O
)	)	O
,	,	O
and	CC	O
methacholine	JJ	O
reactivity	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
baseline	NN	O
and	CC	O
at	IN	O
intervals	NNS	O
of	IN	O
3	CD	O
months	NNS	O
up	RB	O
to	TO	O
12	CD	O
months	NNS	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
,	,	O
symptoms	NNS	O
reduced	VBD	O
significantly	RB	O
in	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
,	,	O
while	IN	O
PEF	NNP	O
variability	NN	O
improved	VBN	O
in	IN	O
BDP	NNP	O
and	CC	O
BDP	NNP	O
+	NNP	O
S	NNP	O
groups	NNS	O
;	:	O
FEV1	NNP	O
and	CC	O
bronchial	JJ	O
responsiveness	NN	O
to	TO	O
methacholine	VB	O
were	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
comparison	NN	O
with	IN	O
baseline	JJ	O
value	NN	O
in	IN	O
the	DT	O
BDP	NNP	O
+	NNP	O
S	NNP	O
group	NN	O
only	RB	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
in	IN	O
PEF	NNP	O
variability	NN	O
,	,	O
FEV1	NNP	O
or	CC	O
bronchial	JJ	O
hyperreactivity	NN	O
in	IN	O
the	DT	O
NS	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
baseline	NN	O
values	NNS	O
,	,	O
while	IN	O
a	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
symptom	NN	O
score	NN	O
.	.	O

BDP	NNP	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
FEV1	NNP	O
and	CC	O
bronchial	JJ	O
reactivity	NN	O
to	TO	O
methacholine	VB	O
after	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

In	IN	O
the	DT	O
BDP	NNP	O
+	NNP	O
S	NNP	O
group	NN	O
,	,	O
the	DT	O
improvement	NN	O
in	IN	O
symptoms	NNS	O
and	CC	O
pulmonary	JJ	O
function	NN	O
persisted	VBN	O
until	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
beclomethasone	NN	O
dipropionate	NN	O
and	CC	O
salmeterol	NN	O
improved	VBD	O
pulmonary	JJ	O
function	NN	O
and	CC	O
bronchial	JJ	O
reactivity	NN	O
earlier	RBR	O
than	IN	O
beclomethasone	CD	O
dipropionate	NN	O
alone	RB	O
,	,	O
while	IN	O
nedocromil	JJ	O
sodium	NN	O
improved	VBD	O
symptoms	NNS	O
but	CC	O
not	RB	O
pulmonary	JJ	O
function	NN	O
.	.	O

Assuming	VBG	O
that	IN	O
bronchial	JJ	O
reactivity	NN	O
could	MD	O
be	VB	O
an	DT	O
indirect	JJ	O
measurement	NN	O
of	IN	O
airway	JJ	O
inflammation	NN	O
,	,	O
overtreatment	NN	O
of	IN	O
asthma	NN	O
in	IN	O
relationship	NN	O
with	IN	O
the	DT	O
classification	NN	O
of	IN	O
asthma	JJ	O
severity	NN	O
of	IN	O
the	DT	O
International	NNP	O
Guidelines	NNP	O
could	MD	O
improve	VB	O
both	DT	O
airway	JJ	O
inflammation	NN	O
and	CC	O
the	DT	O
prognosis	NN	O
of	IN	O
airway	JJ	O
obstruction	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
warfarin	NN	Pharmacological
and	CC	O
aspirin	NN	Pharmacological
for	IN	O
symptomatic	JJ	O
intracranial	JJ	O
arterial	JJ	O
stenosis	NN	O
.	.	O

BACKGROUND	NNP	O
Atherosclerotic	NNP	O
intracranial	JJ	O
arterial	JJ	O
stenosis	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
cause	NN	O
of	IN	O
stroke	NN	O
.	.	O

Warfarin	NNP	O
is	VBZ	O
commonly	RB	O
used	VBN	O
in	IN	O
preference	NN	O
to	TO	O
aspirin	VB	O
for	IN	O
this	DT	O
disorder	NN	O
,	,	O
but	CC	O
these	DT	O
therapies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBN	O
patients	NNS	O
with	IN	O
transient	JJ	O
ischemic	JJ	O
attack	NN	O
or	CC	O
stroke	NN	O
caused	VBN	O
by	IN	O
angiographically	RB	O
verified	VBN	O
50	CD	O
to	TO	O
99	CD	O
percent	NN	O
stenosis	NN	O
of	IN	O
a	DT	O
major	JJ	O
intracranial	JJ	O
artery	NN	O
to	TO	O
receive	VB	O
warfarin	NN	Pharmacological
(	(	O
target	VB	O
international	JJ	O
normalized	JJ	O
ratio	NN	O
,	,	O
2.0	CD	O
to	TO	O
3.0	CD	O
)	)	O
or	CC	O
aspirin	NN	Pharmacological
(	(	O
1300	CD	O
mg	NN	O
per	IN	O
day	NN	O
)	)	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
multicenter	RB	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
ischemic	JJ	O
stroke	NN	O
,	,	O
brain	NN	O
hemorrhage	NN	O
,	,	O
or	CC	O
death	NN	O
from	IN	O
vascular	JJ	O
causes	NNS	O
other	JJ	O
than	IN	O
stroke	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
569	CD	O
patients	NNS	O
had	VBD	O
undergone	JJ	O
randomization	NN	O
,	,	O
enrollment	NN	O
was	VBD	O
stopped	VBN	O
because	IN	O
of	IN	O
concerns	NNS	O
about	IN	O
the	DT	O
safety	NN	O
of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
been	VBN	O
assigned	VBN	O
to	TO	O
receive	VB	O
warfarin	NN	Pharmacological
.	.	Pharmacological

During	IN	O
a	DT	O
mean	JJ	O
follow-up	JJ	O
period	NN	O
of	IN	O
1.8	CD	O
years	NNS	O
,	,	O
adverse	JJ	O
events	NNS	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
included	VBD	O
death	NN	O
(	(	O
4.3	CD	O
percent	NN	O
in	IN	O
the	DT	O
aspirin	NN	Pharmacological
group	NN	O
vs.	FW	O
9.7	CD	O
percent	NN	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
;	:	O
hazard	CC	O
ratio	NN	O
for	IN	O
aspirin	JJ	Pharmacological
relative	JJ	O
to	TO	O
warfarin	VB	Pharmacological
,	,	O
0.46	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.23	CD	O
to	TO	O
0.90	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
,	,	O
major	JJ	O
hemorrhage	NN	O
(	(	O
3.2	CD	O
percent	NN	O
vs.	FW	O
8.3	CD	O
percent	NN	O
,	,	O
respectively	RB	O
;	:	O
hazard	NN	O
ratio	NN	O
,	,	O
0.39	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.18	CD	O
to	TO	O
0.84	CD	O
;	:	O
P=0.01	NNP	O
)	)	O
,	,	O
and	CC	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
sudden	JJ	O
death	NN	O
(	(	O
2.9	CD	O
percent	NN	O
vs.	FW	O
7.3	CD	O
percent	NN	O
,	,	O
respectively	RB	O
;	:	O
hazard	NN	O
ratio	NN	O
,	,	O
0.40	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.18	CD	O
to	TO	O
0.91	CD	O
;	:	O
P=0.02	NNP	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
death	NN	O
from	IN	O
vascular	JJ	O
causes	NNS	O
was	VBD	O
3.2	CD	O
percent	NN	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
and	CC	O
5.9	CD	O
percent	NN	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
(	(	O
P=0.16	NNP	O
)	)	O
;	:	O
the	DT	O
rate	NN	O
of	IN	O
death	NN	O
from	IN	O
nonvascular	JJ	O
causes	NNS	O
was	VBD	O
1.1	CD	O
percent	NN	O
and	CC	O
3.8	CD	O
percent	NN	O
,	,	O
respectively	RB	O
(	(	O
P=0.05	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
occurred	VBD	O
in	IN	O
22.1	CD	O
percent	NN	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
aspirin	NN	O
group	NN	O
and	CC	O
21.8	CD	O
percent	NN	O
of	IN	O
those	DT	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
1.04	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.73	CD	O
to	TO	O
1.48	CD	O
;	:	O
P=0.83	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Warfarin	NNP	Pharmacological
was	VBD	O
associated	VBN	O
with	IN	O
significantly	RB	O
higher	JJR	O
rates	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
provided	VBD	O
no	DT	O
benefit	NN	O
over	IN	O
aspirin	NN	O
in	IN	O
this	DT	O
trial	NN	O
.	.	O

Aspirin	NNP	Pharmacological
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
preference	NN	O
to	TO	O
warfarin	VB	O
for	IN	O
patients	NNS	O
with	IN	O
intracranial	JJ	O
arterial	JJ	O
stenosis	NN	O
.	.	O

Efficiency	NN	O
of	IN	O
slush	NN	Pharmacological
nitrogen	NN	Pharmacological
vitrification	NN	Pharmacological
of	IN	O
human	JJ	O
oocytes	NNS	O
vitrified	VBN	Physical
with	IN	Physical
or	CC	Physical
without	IN	Physical
cumulus	JJ	Physical
cells	NNS	Physical
in	IN	O
relation	NN	O
to	TO	O
survival	VB	O
rate	NN	O
and	CC	O
meiotic	JJ	O
spindle	NN	O
competence	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
slush	NN	Pharmacological
nitrogen	NN	Pharmacological
vitrification	NN	Pharmacological
of	IN	O
human	JJ	O
oocytes	NNS	O
with	IN	Physical
or	CC	Physical
without	IN	Physical
cumulus	JJ	Physical
cells	NNS	Physical
in	IN	O
terms	NNS	O
of	IN	O
survival	NN	O
rate	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
meiotic	JJ	O
spindle	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
comparative	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Medical	NNP	O
center	NN	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
total	NN	O
of	IN	O
274	CD	O
oocytes	NNS	O
obtained	VBN	O
from	IN	O
46	CD	O
couples	NNS	O
undergoing	JJ	O
infertility	NN	O
treatment	NN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
Metaphase	NNP	O
II	NNP	O
oocytes	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
groups	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
vitrified	VBD	Physical
with	IN	Physical
and	CC	Physical
without	IN	Physical
cumulus	JJ	Physical
cells	NNS	Physical
,	,	O
respectively	RB	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Survival	NNP	O
rates	NNS	O
and	CC	O
maintenance	NN	O
of	IN	O
meiotic	JJ	O
spindle	NN	O
observed	VBD	O
immediately	RB	O
after	IN	O
warming	VBG	O
and	CC	O
3	CD	O
hours	NNS	O
after	IN	O
incubation	NN	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
No	NNP	O
statistically	RB	O
significant	JJ	O
difference	NN	O
was	VBD	O
detected	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
survival	NN	O
rate	NN	O
,	,	O
but	CC	O
a	DT	O
significantly	RB	O
higher	JJR	O
percentage	NN	O
of	IN	O
detectable	JJ	O
spindle	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
completely	RB	O
denuded	VBN	O
oocytes	NNS	O
)	)	O
,	,	O
either	RB	O
immediately	RB	O
after	IN	O
warming	VBG	O
or	CC	O
3	CD	O
hours	NNS	O
after	IN	O
incubation	NN	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
Complete	NNP	O
denudation	NN	O
of	IN	O
oocytes	NNS	O
before	IN	O
slush	JJ	O
nitrogen	NN	O
vitrification	NN	O
does	VBZ	O
not	RB	O
influence	VB	O
survival	JJ	O
rates	NNS	O
but	CC	O
positively	RB	O
affects	VBZ	O
oocyte	JJ	O
meiotic	JJ	O
spindle	NN	O
competence	NN	O
.	.	O

These	DT	O
data	NNS	O
support	NN	O
the	DT	O
hypothesis	NN	O
that	WDT	O
cumulus	VBZ	O
cells	NNS	O
during	IN	O
vitrification	NN	O
represent	VBP	O
an	DT	O
obstacle	NN	O
to	TO	O
cryoprotectant	VB	O
penetration	NN	O
more	JJR	O
than	IN	O
having	VBG	O
a	DT	O
protective	JJ	O
role	NN	O
for	IN	O
the	DT	O
oocyte	NN	O
.	.	O

Effects	NNS	O
of	IN	O
fish	JJ	Pharmacological
oil	NN	Pharmacological
supplementation	NN	Pharmacological
on	IN	O
markers	NNS	O
of	IN	O
the	DT	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
whether	IN	O
fish	JJ	Pharmacological
oil	NN	Pharmacological
affects	NNS	O
cardiovascular	JJ	O
risk	NN	O
factors	NNS	O
during	IN	O
the	DT	O
adolescent	JJ	O
growth	NN	O
spurt	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
total	NN	O
of	IN	O
78	CD	O
boys	NNS	O
age	NN	O
13-15	CD	O
years	NNS	O
with	IN	O
a	DT	O
mean	JJ	O
body	NN	O
fat	JJ	O
percentage	NN	O
of	IN	O
30	CD	O
%	NN	O
+/-9	JJ	O
%	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
consume	VB	O
fish	JJ	Pharmacological
oil	NN	Pharmacological
(	(	O
providing	VBG	O
1.5	CD	O
g	NN	O
of	IN	O
n-3	JJ	O
long-chain	NN	Pharmacological
polyunsaturated	VBD	Pharmacological
fatty	JJ	Pharmacological
acid/day	NN	Pharmacological
)	)	Pharmacological
or	CC	O
vegetable	JJ	Pharmacological
oil	NN	Pharmacological
(	(	O
control	NN	O
)	)	O
for	IN	O
16	CD	O
weeks	NNS	O
.	.	O

The	DT	O
oils	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
bread	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
the	DT	O
intervention	NN	O
,	,	O
the	DT	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
content	NN	O
of	IN	O
eicosapentaenoic	JJ	O
acid	NN	O
(	(	O
EPA	NNP	O
)	)	O
and	CC	O
docosahexaenoic	JJ	O
acid	NN	O
(	(	O
DHA	NNP	O
)	)	O
were	VBD	O
1.2	CD	O
%	NN	O
+/-0.5	JJ	O
%	NN	O
and	CC	O
6.7	CD	O
%	NN	O
+/-1.6	JJ	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
those	DT	O
receiving	VBG	O
fish	JJ	Pharmacological
oil	NN	Pharmacological
(	(	Pharmacological
FO	NNP	Pharmacological
group	NN	Pharmacological
)	)	Pharmacological
,	,	O
compared	VBN	O
with	IN	O
0.6	CD	O
%	NN	O
+/-0.3	JJ	O
%	NN	O
and	CC	O
4.1	CD	O
%	NN	O
+/-0.9	JJ	O
%	NN	O
in	IN	O
the	DT	O
control	NN	Control
group	NN	O
.	.	O

Systolic	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
SBP	NNP	O
)	)	O
was	VBD	O
3.8+/-1.4	JJ	O
mm	NN	O
Hg	NNP	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.006	NNP	O
)	)	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
DBP	NNP	O
)	)	O
was	VBD	O
2.6+/-1.1	JJ	O
mm	NN	O
Hg	NNP	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
in	IN	O
the	DT	O
FO	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Plasma	NNP	O
triacylglycerol	NN	O
(	(	O
TAG	NNP	O
)	)	O
concentration	NN	O
and	CC	O
insulin	JJ	O
sensitivity	NN	O
were	VBD	O
unaffected	VBN	O
by	IN	O
either	DT	O
of	IN	O
the	DT	O
treatments	NNS	O
.	.	O

Plasma	NNP	O
high-density	NN	O
lipoprotein	NN	O
(	(	O
HDL	NNP	O
)	)	O
and	CC	O
non-HDL	JJ	O
cholesterol	NN	O
were	VBD	O
increased	VBN	O
by	IN	O
5	CD	O
%	NN	O
and	CC	O
7	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
the	DT	O
FO	NNP	Pharmacological
group	NN	O
,	,	O
and	CC	O
by	IN	O
2	CD	O
%	NN	O
and	CC	O
0	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	Control
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.01-.02	NN	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
RBC	NNP	O
EPA	NNP	O
content	NN	O
were	VBD	O
inversely	RB	O
correlated	VBN	O
with	IN	O
the	DT	O
changes	NNS	O
in	IN	O
SBP	NNP	O
and	CC	O
DBP	NNP	O
and	CC	O
directly	RB	O
correlated	VBN	O
with	IN	O
the	DT	O
increases	NNS	O
in	IN	O
HDL	NNP	O
cholesterol	NN	O
and	CC	O
non-HDL	JJ	O
cholesterol	NN	O
concentrations	NNS	O
.	.	O

No	DT	O
association	NN	O
was	VBD	O
seen	VBN	O
between	IN	O
RBC	NNP	O
EPA	NNP	O
and	CC	O
plasma	VB	O
TAG	NNP	O
concentration	NN	O
or	CC	O
insulin	JJ	O
sensitivity	NN	O
.	.	O

CONCLUSION	NNP	O
Fish	NNP	Pharmacological
oil	NN	Pharmacological
improves	VBZ	O
BP	NNP	O
in	IN	O
normotensive	JJ	O
and	CC	O
normolipidemic	JJ	O
slightly	RB	O
overweight	JJ	O
adolescent	NN	O
boys	NNS	O
.	.	O

Relaxation	NN	Educational
and	CC	Educational
imagery	NN	Educational
and	CC	Educational
cognitive-behavioral	JJ	Educational
training	NN	Educational
reduce	VB	O
pain	NN	O
during	IN	O
cancer	NN	O
treatment	NN	O
:	:	O
a	DT	O
controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Few	NNP	O
controlled	VBD	O
clinical	JJ	O
trials	NNS	O
of	IN	O
psychological	JJ	O
interventions	NNS	O
for	IN	O
cancer	NN	O
pain	NN	O
relief	NN	O
exist	NN	O
in	IN	O
spite	NN	O
of	IN	O
frequent	JJ	O
support	NN	O
for	IN	O
their	PRP$	O
importance	NN	O
as	IN	O
adjuncts	NNS	O
to	TO	O
medical	JJ	O
treatment	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
oral	JJ	O
mucositis	NN	O
pain	NN	O
levels	NNS	O
in	IN	O
4	CD	O
groups	NNS	O
of	IN	O
cancer	NN	O
patients	NNS	O
receiving	VBG	O
bone	NN	O
marrow	NN	O
transplants	NNS	O
(	(	O
BMT	NNP	O
)	)	O
:	:	O
(	(	O
1	CD	O
)	)	O
treatment	NN	Control
as	IN	Control
usual	JJ	Control
control	NN	Control
,	,	O
(	(	O
2	CD	O
)	)	O
therapist	NN	Educational
support	NN	Educational
,	,	Educational
(	(	Educational
3	CD	Educational
)	)	Educational
relaxation	NN	Educational
and	CC	Educational
imagery	NN	Educational
training	NN	Educational
,	,	Educational
and	CC	Educational
(	(	Educational
4	CD	Educational
)	)	Educational
training	NN	Educational
in	IN	Educational
a	DT	Educational
package	NN	Educational
of	IN	Educational
cognitive-behavioral	JJ	Educational
coping	NN	Educational
skills	NNS	Educational
which	WDT	Educational
included	VBD	Educational
relaxation	NN	Educational
and	CC	Educational
imagery	NN	Educational
.	.	O

A	DT	O
total	NN	O
of	IN	O
94	CD	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
which	WDT	O
involved	VBD	O
two	CD	O
training	NN	O
sessions	NNS	O
prior	RB	O
to	TO	O
treatment	NN	O
and	CC	O
twice	RB	O
a	DT	O
week	NN	O
'booster	POS	O
'	POS	O
sessions	NNS	O
during	IN	O
the	DT	O
first	JJ	O
5	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Results	NNS	O
confirmed	VBD	O
our	PRP$	O
hypothesis	NN	O
that	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
either	DT	O
relaxation	NN	O
and	CC	O
imagery	VB	O
alone	RB	O
or	CC	O
patients	NNS	O
who	WP	O
received	VBD	O
the	DT	O
package	NN	O
of	IN	O
cognitive-behavioral	JJ	O
coping	NN	O
skills	NNS	O
would	MD	O
report	VB	O
less	JJR	O
pain	NN	O
than	IN	O
patients	NNS	O
in	IN	O
the	DT	O
other	JJ	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
cognitive-behavioral	JJ	O
skills	NNS	O
package	NN	O
would	MD	O
have	VB	O
an	DT	O
additive	JJ	O
effect	NN	O
beyond	IN	O
relaxation	NN	O
and	CC	O
imagery	NN	O
alone	RB	O
was	VBD	O
not	RB	O
confirmed	VBN	O
.	.	O

Average	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
report	NN	O
of	IN	O
pain	NN	O
within	IN	O
the	DT	O
therapist	JJ	O
support	NN	O
group	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.103	CD	O
)	)	O
nor	CC	O
significantly	RB	O
higher	JJR	O
than	IN	O
the	DT	O
training	NN	O
groups	NNS	O
.	.	O

Patient	JJ	O
reports	NNS	O
of	IN	O
relative	JJ	O
helpfulness	NN	O
of	IN	O
the	DT	O
interventions	NNS	O
for	IN	O
managing	VBG	O
pain	NN	O
and	CC	O
nausea	NN	O
matched	VBD	O
the	DT	O
results	NNS	O
of	IN	O
VAS	NNP	O
reports	NNS	O
.	.	O

From	IN	O
these	DT	O
results	NNS	O
,	,	O
we	PRP	O
conclude	VBP	O
that	DT	O
relaxation	NN	O
and	CC	O
imagery	NN	O
training	NN	O
reduces	NNS	O
cancer	NN	O
treatment-related	JJ	O
pain	NN	O
;	:	O
adding	VBG	O
cognitive-behavioral	JJ	O
skills	NNS	O
to	TO	O
the	DT	O
relaxation	NN	O
with	IN	O
imagery	NN	O
does	VBZ	O
not	RB	O
,	,	O
on	IN	O
average	NN	O
,	,	O
further	JJ	O
improve	VB	O
pain	NN	O
relief	NN	O
.	.	O

Competitive	JJ	O
employment	NN	O
for	IN	O
youth	NN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
early	JJ	O
results	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

For	IN	O
most	JJS	O
youth	NN	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
,	,	O
employment	NN	O
upon	IN	O
graduation	NN	O
from	IN	O
high	JJ	O
school	NN	O
or	CC	O
college	NN	O
is	VBZ	O
elusive	JJ	O
.	.	O

Employment	JJ	O
rates	NNS	O
are	VBP	O
reported	VBN	O
in	IN	O
many	JJ	O
studies	NNS	O
to	TO	O
be	VB	O
very	RB	O
low	JJ	O
despite	IN	O
many	JJ	O
years	NNS	O
of	IN	O
intensive	JJ	O
special	JJ	O
education	NN	O
services	NNS	O
.	.	O

This	DT	O
paper	NN	O
presented	VBD	O
the	DT	O
preliminary	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
Project	NNP	Physical
SEARCH	NNP	Physical
plus	CC	Physical
ASD	NNP	Physical
Supports	NNP	Physical
on	IN	O
the	DT	O
employment	NN	O
outcomes	NNS	O
for	IN	O
youth	NN	O
with	IN	O
ASD	NNP	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
18-21	JJ	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

This	DT	O
model	NN	O
provides	VBZ	O
very	RB	O
promising	JJ	O
results	NNS	O
in	IN	O
that	DT	O
the	DT	O
employment	NN	O
outcomes	NNS	O
for	IN	O
youth	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
were	VBD	O
much	RB	O
higher	JJR	O
in	IN	O
non-traditional	JJ	O
jobs	NNS	O
with	IN	O
higher	JJR	O
than	IN	O
minimum	JJ	O
wage	NN	O
incomes	NNS	O
than	IN	O
for	IN	O
youth	NN	O
in	IN	O
the	DT	O
control	NN	Control
condition	NN	O
.	.	O

Specifically	RB	O
,	,	O
21	CD	O
out	IN	O
of	IN	O
24	CD	O
(	(	O
87.5	CD	O
%	NN	O
)	)	O
treatment	NN	O
group	NN	O
participants	NNS	O
acquired	VBD	O
employment	NN	O
while	IN	O
1	CD	O
of	IN	O
16	CD	O
(	(	O
6.25	CD	O
%	NN	O
)	)	O
of	IN	O
control	NN	O
group	NN	O
participants	NNS	O
acquired	VBD	O
employment	NN	O
.	.	O

Levels	NNS	O
of	IN	O
opioid	JJ	O
physical	JJ	O
dependence	NN	O
in	IN	O
heroin	NN	O
addicts	NNS	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
opioid	JJ	O
physical	JJ	O
dependence	NN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
long-term	JJ	O
heroin	NN	O
addicts	NNS	O
were	VBD	O
ascertained	VBN	O
by	IN	O
measuring	VBG	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
opioid	JJ	O
withdrawal	NN	O
syndrome	NN	O
before	IN	O
and	CC	O
after	IN	O
pharmacological	JJ	O
challenge	NN	O
with	IN	O
either	DT	O
0.4	CD	O
mg	NN	O
naloxone	NN	Pharmacological
or	CC	O
placebo	NN	Control
.	.	O

Prior	NNP	O
to	TO	O
challenge	VB	O
,	,	O
patients	NNS	O
manifested	VBD	O
some	DT	O
subjective	JJ	O
symptoms	NNS	O
but	CC	O
few	JJ	O
objective	JJ	O
signs	NNS	O
of	IN	O
opioid	JJ	O
withdrawal	NN	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
showed	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
mean	NN	O
score	NN	O
on	IN	O
one	CD	O
of	IN	O
three	CD	O
rating	NN	O
scales	NNS	O
used	VBN	O
to	TO	O
assess	VB	O
opioid	JJ	O
withdrawal	NN	O
.	.	O

Patients	NNS	O
who	WP	O
received	VBD	O
naloxone	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
58	CD	O
)	)	O
showed	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
mean	JJ	O
scores	NNS	O
on	IN	O
all	DT	O
three	CD	O
rating	NN	O
scales	NNS	O
,	,	O
but	CC	O
this	DT	O
was	VBD	O
due	JJ	O
primarily	RB	O
to	TO	O
increases	NNS	O
observed	VBN	O
in	IN	O
a	DT	O
minority	NN	O
of	IN	O
patients	NNS	O
.	.	O

Sixty-one	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
failed	VBD	O
to	TO	O
manifest	VB	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
subjective	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
74	CD	O
%	NN	O
of	IN	O
patients	NNS	O
failed	VBD	O
to	TO	O
manifest	VB	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
objective	JJ	O
signs	NNS	O
of	IN	O
opioid	JJ	O
withdrawal	NN	O
following	VBG	O
naloxone	JJ	Pharmacological
administration	NN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
substantial	JJ	O
subgroup	NN	O
of	IN	O
heroin	NN	O
addicts	NNS	O
are	VBP	O
able	JJ	O
to	TO	O
use	VB	O
opioids	NNS	O
regularly	RB	O
while	IN	O
maintaining	VBG	O
relatively	RB	O
low	JJ	O
levels	NNS	O
of	IN	O
physical	JJ	O
dependence	NN	O
.	.	O

Circulating	VBG	Physical
blood	NN	Physical
B	NNP	Physical
cells	NNS	Physical
in	IN	O
multiple	JJ	O
myeloma	NN	O
:	:	O
analysis	NN	O
and	CC	O
relationship	NN	O
to	TO	O
circulating	VBG	O
clonal	JJ	O
cells	NNS	O
and	CC	O
clinical	JJ	O
parameters	NNS	O
in	IN	O
a	DT	O
cohort	NN	O
of	IN	O
patients	NNS	O
entered	VBN	O
on	IN	O
the	DT	O
Eastern	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
phase	VBD	O
III	NNP	O
E9486	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

Recent	JJ	O
analyses	NNS	O
of	IN	O
circulating	VBG	O
blood	NN	O
B	NNP	O
cells	NNS	O
in	IN	O
myeloma	NN	O
have	VBP	O
generated	VBN	O
controversy	NN	O
concerning	VBG	O
the	DT	O
exact	JJ	O
levels	NNS	O
of	IN	O
these	DT	O
cells	NNS	O
and	CC	O
whether	IN	O
they	PRP	O
may	MD	O
represent	VB	O
circulating	VBG	O
clonal	JJ	O
tumor	NN	O
B	NNP	O
cells	NNS	O
.	.	O

Previous	JJ	O
reports	NNS	O
suggested	VBD	O
that	IN	O
CD19+	NNP	O
B	NNP	O
cells	NNS	O
are	VBP	O
markedly	RB	O
increased	VBN	O
in	IN	O
myeloma	NN	O
patients	NNS	O
and	CC	O
that	IN	O
this	DT	O
population	NN	O
shares	NNS	O
clonotypic	VBD	O
rearrangements	NNS	O
with	IN	O
the	DT	O
malignant	JJ	O
plasma	NN	O
cell	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
numbers	NNS	O
of	IN	O
CD19+	NNP	Physical
B	NNP	Physical
cells	NNS	Physical
by	IN	O
flow	JJ	O
cytometry	NN	O
in	IN	O
previously	RB	O
untreated	JJ	O
newly	RB	O
diagnosed	VBN	O
myeloma	NN	O
patients	NNS	O
in	IN	O
Eastern	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
(	(	O
ECOG	NNP	O
)	)	O
phase	NN	O
III	NNP	O
trial	NN	O
E9486	NNP	O
.	.	O

There	EX	O
were	VBD	O
628	CD	O
patients	NNS	O
who	WP	O
were	VBD	O
eligible	JJ	O
for	IN	O
the	DT	O
clinical	JJ	O
protocol	NN	O
E9486	NNP	O
,	,	O
but	CC	O
of	IN	O
these	DT	O
521	CD	O
were	VBD	O
also	RB	O
entered	VBN	O
on	IN	O
the	DT	O
companion	NN	O
laboratory	NN	O
study	NN	O
(	(	O
E9487	NNP	O
)	)	O
and	CC	O
had	VBD	O
CD19	NNP	O
data	NNS	O
.	.	O

In	IN	O
comparison	NN	O
with	IN	O
normal	JJ	O
controls	NNS	O
,	,	O
the	DT	O
myeloma	NN	O
patients	NNS	O
exhibited	VBD	O
a	DT	O
marked	JJ	O
heterogeneity	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
circulating	VBG	O
CD19+	NNP	O
B	NNP	O
cells	NNS	O
as	IN	O
detected	VBN	O
by	IN	O
flow	JJ	Physical
cytometry	NN	Physical
.	.	O

Approximately	RB	O
20	CD	O
%	NN	O
of	IN	O
patients	NNS	O
had	VBD	O
significantly	RB	O
increased	VBN	O
levels	NNS	O
of	IN	O
circulating	VBG	O
CD19+	NNP	O
B	NNP	O
cells	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
total	JJ	O
CD19+	NNP	O
blood	NN	O
population	NN	O
from	IN	O
myeloma	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
the	DT	O
median	NN	O
of	IN	O
age-matched	JJ	O
,	,	O
normal	JJ	O
controls	NNS	O
.	.	O

Analysis	NN	O
of	IN	O
CD19+	NNP	O
blood	NN	O
cells	NNS	O
in	IN	O
relationship	NN	O
to	TO	O
circulating	VBG	O
clonal	JJ	O
cells	NNS	O
was	VBD	O
done	VBN	O
in	IN	O
13	CD	O
myeloma	NN	O
patients	NNS	O
using	VBG	O
a	DT	O
clonotypic	NN	O
,	,	O
quantitative	JJ	O
allele-specific	JJ	O
oligonucleotide-polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
assay	VBP	O
.	.	O

No	DT	O
correlation	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
numbers	NNS	O
of	IN	O
CD19+	NNP	O
B	NNP	O
cells	NNS	O
(	(	O
range	NN	O
,	,	O
5	CD	O
%	NN	O
to	TO	O
51	CD	O
%	NN	O
)	)	O
and	CC	O
PCR	NNP	Physical
estimates	NNS	O
of	IN	O
the	DT	O
number	NN	O
of	IN	O
clonal	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
peripheral	JJ	O
blood	NN	O
(	(	O
range	NN	O
,	,	O
.009	CD	O
%	NN	O
to	TO	O
3.6	CD	O
%	NN	O
)	)	O
.	.	O

Low	JJ	O
CD19+	NNP	O
B-cell	NNP	O
level	NN	O
(	(	O
<	JJ	O
125	CD	O
microL	NN	O
)	)	O
was	VBD	O
associated	VBN	O
with	IN	O
clinical	JJ	O
stage	NN	O
III	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.033	NNP	O
)	)	O
.	.	O

A	DT	O
significant	JJ	O
relationship	NN	O
exists	VBZ	O
between	IN	O
higher	JJR	O
levels	NNS	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
125/microL	CD	O
)	)	O
of	IN	O
CD19	NNP	O
cells	NNS	O
and	CC	O
longer	JJR	O
overall	JJ	O
survival	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
high	JJ	O
CD19	NNP	O
levels	NNS	O
also	RB	O
predicted	VBD	O
a	DT	O
clinical	JJ	O
response	NN	O
and	CC	O
longer	JJR	O
event-free	JJ	O
survival	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
inverse	NN	O
association	NN	O
between	IN	O
the	DT	O
level	NN	O
of	IN	O
CD19	NNP	Physical
values	NNS	Physical
at	IN	O
diagnosis	NN	O
and	CC	O
infections	NNS	O
within	IN	O
the	DT	O
first	JJ	O
2	CD	O
months	NNS	O
of	IN	O
diagnosis	NN	O
.	.	O

Importantly	RB	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
deaths	NNS	O
related	VBN	O
to	TO	O
infections	NNS	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
low	JJ	O
versus	NN	O
high	JJ	O
CD19	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0202	NNP	O
)	)	O
.	.	O

Also	RB	O
,	,	O
CD19	NNP	O
is	VBZ	O
an	DT	O
independent	JJ	O
prognostic	JJ	O
factor	NN	O
in	IN	O
addition	NN	O
to	TO	O
plasma	VB	O
cell	NN	O
labeling	VBG	O
indices	NNS	O
,	,	O
beta2-microglobulin	NN	O
,	,	O
hemoglobin	NN	O
,	,	O
and	CC	O
plasmablastic	JJ	O
morphology	NN	O
.	.	O

Patients	NNS	O
with	IN	O
infections	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
low	JJ	O
levels	NNS	O
of	IN	O
CD19+	NNP	O
cells	NNS	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
higher	JJR	O
CD19+	NNP	O
cell	NN	O
levels	NNS	O
are	VBP	O
a	DT	O
favorable	JJ	O
prognostic	JJ	O
sign	NN	O
with	IN	O
no	DT	O
apparent	JJ	O
relationship	NN	O
to	TO	O
circulating	VBG	O
tumor	NN	O
cells	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
this	DT	O
analysis	NN	O
strongly	RB	O
suggests	VBZ	O
that	IN	O
low	JJ	O
peripheral	JJ	O
blood	NN	O
levels	NNS	O
of	IN	O
CD19+	NNP	O
cells	NNS	O
are	VBP	O
an	DT	O
adverse	JJ	O
prognostic	JJ	O
sign	NN	O
in	IN	O
myeloma	NN	O
.	.	O

The	DT	O
CD19+	NNP	Physical
cell	NN	O
levels	NNS	O
in	IN	O
myeloma	NN	O
patients	NNS	O
is	VBZ	O
an	DT	O
important	JJ	O
parameter	NN	O
in	IN	O
the	DT	O
overall	JJ	O
assessment	NN	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

[	JJ	O
Dose-effect	NNP	O
relationship	NN	O
of	IN	O
isosorbide	NN	Pharmacological
dinitrate	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
angina	JJ	O
pectoris	NN	O
(	(	O
author	NN	O
's	POS	O
transl	NN	O
)	)	O
]	NN	O
.	.	O

Fifteen	JJ	O
males	NNS	O
with	IN	O
angiographic	JJ	O
evidence	NN	O
of	IN	O
coronary	JJ	O
heart	NN	O
disease	NN	O
and	CC	O
stable	JJ	O
,	,	O
exercise-induced	JJ	O
angina	NN	O
pectoris	NN	O
were	VBD	O
given	VBN	O
placebo	NNS	Control
or	CC	O
isosorbide	VB	Pharmacological
dinitrate	NN	Pharmacological
(	(	Pharmacological
ISDN	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
a	DT	O
dialy	NN	O
dose	NN	O
of	IN	O
30	CD	O
mg	NNS	O
,	,	O
120	CD	O
mg	NN	O
,	,	O
240	CD	O
mg	NN	O
and	CC	O
480	CD	O
mg	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
single-blind	JJ	O
trial	NN	O
.	.	O

The	DT	O
daily	JJ	O
doses	NNS	O
were	VBD	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
5	CD	O
mg	NNS	O
,	,	O
20	CD	O
mg	NN	O
,	,	O
40	CD	O
mg	NN	O
and	CC	O
80	CD	O
mg	JJ	O
tablets	NNS	O
.	.	O

Each	DT	O
dose	NN	O
and	CC	O
placebo	NN	O
was	VBD	O
given	VBN	O
for	IN	O
seven	CD	O
days	NNS	O
.	.	O

On	IN	O
the	DT	O
seventh	JJ	O
day	NN	O
an	DT	O
exercise	NN	O
ECG	NNP	O
of	IN	O
standardized	JJ	O
level	NN	O
and	CC	O
duration	NN	O
of	IN	O
exercise	NN	O
was	VBD	O
recorded	VBN	O
.	.	O

The	DT	O
ischaemia	NN	O
response	NN	O
in	IN	O
the	DT	O
ECG	NNP	O
revealed	VBD	O
a	DT	O
dose-dependent	JJ	O
reduction	NN	O
by	IN	O
28	CD	O
%	NN	O
(	(	O
5	CD	O
mg	RB	O
ISDN	NNP	O
)	)	O
,	,	O
43	CD	O
%	NN	O
(	(	O
20	CD	O
mg	NN	O
)	)	O
,	,	O
60	CD	O
%	NN	O
(	(	O
40	CD	O
mg	NN	O
)	)	O
and	CC	O
73	CD	O
%	NN	O
(	(	O
80	CD	O
mg	NN	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
anginal	JJ	O
attacks	NNS	O
similarly	RB	O
fell	VBD	O
parallel	RB	O
to	TO	O
dose	VB	O
.	.	O

Plasma	NNP	O
level	NN	O
of	IN	O
ISDN	NNP	O
and	CC	O
the	DT	O
mononitrates	NNS	O
,	,	O
measured	VBD	O
one	CD	O
and	CC	O
four	CD	O
hours	NNS	O
after	IN	O
drug	NN	O
intake	NN	O
,	,	O
rose	VBD	O
almost	RB	O
linearly	JJ	O
in	IN	O
relation	NN	O
to	TO	O
dose	VB	O
.	.	O

Oral	NNP	O
ISDN	NNP	O
thus	RB	O
has	VBZ	O
a	DT	O
dose-dependent	JJ	O
effect	NN	O
on	IN	O
the	DT	O
frequency	NN	O
of	IN	O
angina	NN	O
and	CC	O
ischaemia	NN	O
parameters	NNS	O
during	IN	O
ergometric	JJ	O
exercise	NN	O
.	.	O

The	DT	O
protracted	JJ	O
anti-anginal	JJ	O
effect	NN	O
of	IN	O
ISDN	NNP	O
is	VBZ	O
largely	RB	O
due	JJ	O
to	TO	O
its	PRP$	O
metabolites	NNS	O
.	.	O

At	IN	O
high	JJ	O
doses	NNS	O
there	EX	O
is	VBZ	O
presumably	RB	O
an	DT	O
added	JJ	O
effect	NN	O
of	IN	O
the	DT	O
high	JJ	O
blood	NN	O
level	NN	O
of	IN	O
the	DT	O
basic	JJ	O
substance.U	NN	O
A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
levofloxacin	NN	Pharmacological
,	,	Pharmacological
omeprazole	NN	Pharmacological
,	,	Pharmacological
nitazoxanide	RB	Pharmacological
,	,	O
and	CC	O
doxycycline	VB	Pharmacological
versus	NN	O
triple	JJ	Pharmacological
therapy	NN	Pharmacological
for	IN	O
the	DT	O
eradication	NN	O
of	IN	O
Helicobacter	NNP	O
pylori	NN	O
.	.	O

OBJECTIVES	NNP	O
Resistance	NNP	O
to	TO	O
standard	VB	O
Helicobacter	NNP	O
pylori	NN	O
(	(	O
HP	NNP	O
)	)	O
treatment	NN	O
regimens	VBZ	O
has	VBZ	O
led	VBN	O
to	TO	O
unsatisfactory	JJ	O
cure	NN	O
rates	NNS	O
in	IN	O
HP-infected	JJ	O
patients	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
a	DT	O
novel	JJ	O
four-drug	JJ	Pharmacological
regimen	NNS	Pharmacological
(	(	O
three	CD	O
antibiotics	NNS	O
and	CC	O
a	DT	O
proton	NN	O
pump	NN	O
inhibitor	NN	O
(	(	O
PPI	NNP	O
)	)	O
)	)	O
for	IN	O
eradication	NN	O
of	IN	O
HP	NNP	O
infection	NN	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
HP	NNP	O
gastritis	NN	O
or	CC	O
peptic	JJ	O
ulcer	JJ	O
disease	NN	O
confirmed	VBD	O
using	VBG	O
endoscopy	NN	O
and	CC	O
stool	NN	O
antigen	NN	O
testing	VBG	O
were	VBD	O
eligible	JJ	O
for	IN	O
inclusion	NN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
underwent	VBD	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
from	IN	O
any	DT	O
prior	JJ	O
antibiotic	JJ	O
or	CC	O
PPI	JJ	O
usage	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
then	RB	O
randomized	VBN	O
to	TO	O
either	DT	O
levofloxacin	NN	Pharmacological
,	,	Pharmacological
omeprazole	NN	Pharmacological
,	,	Pharmacological
nitazoxanide	RB	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
doxycycline	NN	Pharmacological
(	(	Pharmacological
LOAD	NNP	Pharmacological
)	)	Pharmacological
therapy	NN	O
for	IN	O
7	CD	O
days	NNS	O
(	(	O
LOAD-7	NNP	O
)	)	O
or	CC	O
10	CD	O
days	NNS	O
(	(	O
LOAD-10	NNP	O
)	)	O
,	,	O
including	VBG	O
levofloxacin	JJ	Pharmacological
250	CD	Pharmacological
mg	NN	Pharmacological
with	IN	Pharmacological
breakfast	NN	Pharmacological
,	,	Pharmacological
omeprazole	JJ	Pharmacological
40	CD	Pharmacological
mg	NN	Pharmacological
before	IN	Pharmacological
breakfast	NN	Pharmacological
,	,	Pharmacological
nitazoxanide	RB	Pharmacological
(	(	Pharmacological
Alina	NNP	Pharmacological
)	)	Pharmacological
500	CD	Pharmacological
mg	JJ	Pharmacological
twice	RB	Pharmacological
daily	RB	Pharmacological
with	IN	O
meals	NNS	O
and	CC	O
doxycycline	VB	Pharmacological
100	CD	Pharmacological
mg	NN	Pharmacological
at	IN	O
dinner	NN	O
,	,	O
or	CC	O
lansoprozole	NN	Pharmacological
,	,	Pharmacological
amoxicillin	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
clarithromycin	NN	Pharmacological
(	(	Pharmacological
LAC	NNP	Pharmacological
)	)	Pharmacological
therapy	NN	Pharmacological
for	IN	O
10	CD	O
days	NNS	O
,	,	O
which	WDT	O
included	VBD	O
lansoprozole	JJ	Pharmacological
30	CD	Pharmacological
mg	NN	Pharmacological
,	,	Pharmacological
amoxicillin	VBZ	Pharmacological
1	CD	Pharmacological
g	NN	Pharmacological
with	IN	Pharmacological
breakfast	NN	Pharmacological
and	CC	Pharmacological
dinner	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
clarithromycin	VBZ	Pharmacological
500	CD	Pharmacological
mg	NN	Pharmacological
with	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
.	.	O

HP	NNP	O
eradication	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
stool	NN	O
antigen	NN	O
testing	VBG	O
at	IN	O
least	JJS	O
4	CD	O
weeks	NNS	O
after	IN	O
cessation	NN	O
of	IN	O
therapy	NN	O
.	.	O

RESULTS	NNP	O
Intention-to-treat	JJ	O
analysis	NN	O
revealed	VBD	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
respective	JJ	O
eradication	NN	O
rates	NNS	O
of	IN	O
the	DT	O
LOAD	NNP	O
therapies	NNS	O
(	(	O
88.9	CD	O
%	NN	O
(	(	O
80/90	CD	O
)	)	O
LOAD-10	NNP	O
,	,	O
90	CD	O
%	NN	O
(	(	O
81/90	CD	O
)	)	O
LOAD-7	NNP	O
,	,	O
89.4	CD	O
%	NN	O
(	(	O
161/180	CD	O
)	)	O
for	IN	O
combined	VBN	O
LOAD	NNP	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
receiving	VBG	O
LAC	NNP	O
,	,	O
73.3	CD	O
%	NN	O
(	(	O
66/90	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
adverse	JJ	O
effects	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
open-label	JJ	O
,	,	O
prospective	JJ	O
trial	NN	O
demonstrates	VBZ	O
that	IN	O
LOAD	NNP	Pharmacological
is	VBZ	O
a	DT	O
highly	RB	O
active	JJ	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HP	NNP	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
.	.	O

A	DT	O
large	JJ	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
is	VBZ	O
warranted	VBN	O
to	TO	O
further	RBR	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
this	DT	O
regimen	NNS	O
.	.	O

[	JJ	O
Profiles	NNP	O
of	IN	O
irregular	JJ	O
bleeding	NN	O
induced	VBN	O
by	IN	O
low-dose	JJ	Physical
hormone	NN	Physical
therapy	NN	Physical
and	CC	O
Chinese	JJ	Pharmacological
formulated	VBN	Pharmacological
herbs	NN	Pharmacological
products	NNS	Pharmacological
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
profiles	NNS	O
and	CC	O
related	JJ	O
factors	NNS	O
of	IN	O
irregular	JJ	O
bleeding	NN	O
induced	VBN	O
by	IN	O
different	JJ	O
types	NNS	O
of	IN	O
low-dose	JJ	Physical
hormone	NN	Physical
therapy	NN	Physical
(	(	Physical
HT	NNP	Physical
)	)	Physical
and	CC	O
a	DT	O
Chinese	JJ	Pharmacological
formulated	VBN	Pharmacological
herbs	NN	Pharmacological
products	NNS	Pharmacological
.	.	O

METHODS	NNP	O
Applied	NNP	O
with	IN	O
open-labeled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
and	CC	O
clinical	JJ	O
trial	NN	O
design	NN	O
,	,	O
136	CD	O
postmenopausal	JJ	O
women	NNS	O
were	VBD	O
assigned	VBN	O
into	IN	O
four	CD	O
groups	NNS	O
:	:	O
group	NN	O
A	DT	O
:	:	O
estradiol	NN	Pharmacological
valerate	NN	Pharmacological
(	(	Pharmacological
E2	NNP	Pharmacological
V	NNP	Pharmacological
)	)	Pharmacological
1	CD	Pharmacological
mg/d	NN	Pharmacological
+	NNP	O
medroxyprogesterone	NN	Pharmacological
acetate	NN	Pharmacological
(	(	Pharmacological
MPA	NNP	Pharmacological
)	)	Pharmacological
2	CD	Pharmacological
mg/d	NN	Pharmacological
;	:	O
group	NN	O
B	NNP	O
:	:	O
conjugated	JJ	Pharmacological
equine	NN	Pharmacological
estrogen	NN	Pharmacological
0.45	CD	Pharmacological
mg/d	NN	Pharmacological
+	NNP	O
MPA	NNP	Pharmacological
2	CD	Pharmacological
mg/d	NN	O
;	:	O
group	NN	O
C	NNP	O
:	:	O
tibolone	NN	Pharmacological
1.25	CD	O
mg/d	NN	O
;	:	O
group	NN	O
D	NNP	O
:	:	O
a	DT	Pharmacological
Chinese	JJ	Pharmacological
formulated	VBN	Pharmacological
herbs	JJ	Pharmacological
product	NN	Pharmacological
(	(	Pharmacological
Kuntai	NNP	Pharmacological
)	)	Pharmacological
4	CD	O
#	#	O
tid	NN	O
.	.	O

Each	DT	O
subject	NN	O
took	VBD	O
element	NN	O
calcium	NN	Pharmacological
400	CD	O
mg/d	NN	O
and	CC	O
vitamin	NN	Pharmacological
D	NNP	Pharmacological
200	CD	O
IU/d	NNP	O
concomitantly	RB	O
.	.	O

Modified	NNP	O
Kupperman	NNP	O
scores	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
baseline	NN	O
and	CC	O
every	DT	O
3	CD	O
months	NNS	O
thereafter	RB	O
and	CC	O
irregular	JJ	O
bleeding	NN	O
was	VBD	O
recorded	VBN	O
on	IN	O
menopausal	NN	O
diary	JJ	O
every	DT	O
day	NN	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
1	CD	O
year	NN	O
.	.	O

Results	VB	O
The	DT	O
efficacies	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
three	CD	O
HT-managed	JJ	O
groups	NNS	O
,	,	O
but	CC	O
was	VBD	O
better	JJR	O
than	IN	O
in	IN	O
group	NN	O
D	NNP	O
,	,	O
although	IN	O
the	DT	O
latter	NN	O
was	VBD	O
also	RB	O
effective	JJ	O
in	IN	O
alleviating	VBG	O
menopausal	NN	O
symptoms	NNS	O
.	.	O

Hazard	NNP	O
ratio	NN	O
(	(	O
HR	NNP	O
)	)	O
of	IN	O
irregular	JJ	O
bleeding	NN	O
was	VBD	O
1.00	CD	O
in	IN	O
group	NN	O
C	NNP	O
,	,	O
2.43	CD	O
in	IN	O
group	NN	O
A	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.08-5.46	JJ	O
)	)	O
,	,	O
3.12	CD	O
in	IN	O
group	NN	O
B	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
1.42-6.88	JJ	O
)	)	O
,	,	O
and	CC	O
0.73	CD	O
in	IN	O
group	NN	O
D	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.26-2.04	NN	O
)	)	O
.	.	O

Most	JJS	O
cases	NNS	O
initially	RB	O
experienced	VBD	O
bleeding	NN	O
in	IN	O
the	DT	O
first	JJ	O
3	CD	O
months	NNS	O
but	CC	O
such	JJ	O
initiation	NN	O
was	VBD	O
a	DT	O
bit	NN	O
later	RB	O
in	IN	O
group	NN	O
C.	NNP	O
Endometrium	NNP	O
,	,	O
as	IN	O
detected	VBN	O
by	IN	O
B-mode	NNP	O
ultrasound	NN	O
,	,	O
increased	VBD	O
approximately	RB	O
1	CD	O
mm	NNS	O
in	IN	O
HT	NNP	O
groups	NNS	O
,	,	O
while	IN	O
it	PRP	O
was	VBD	O
a	DT	O
bit	NN	O
thicker	NN	O
in	IN	O
group	NN	O
C.	NNP	O
Long	NNP	O
periods	NNS	O
in	IN	O
reproductive	JJ	O
age	NN	O
and	CC	O
short	JJ	O
time	NN	O
since	IN	O
menopause	NN	O
were	VBD	O
high	JJ	O
risk	NN	O
factors	NNS	O
for	IN	O
irregular	JJ	O
bleeding	NN	O
.	.	O

CONCLUSION	NNP	O
Profiles	NNP	O
of	IN	O
irregular	JJ	O
bleeding	NN	O
in	IN	O
3	CD	O
commonly	RB	O
used	JJ	O
types	NNS	O
of	IN	O
low-dose	JJ	Pharmacological
HT	NNP	Pharmacological
are	VBP	O
different	JJ	O
and	CC	O
some	DT	O
factors	NNS	O
such	JJ	O
as	IN	O
long	JJ	O
period	NN	O
in	IN	O
reproductive	JJ	O
age	NN	O
and	CC	O
short	JJ	O
time	NN	O
since	IN	O
menopause	NN	O
may	MD	O
contribute	VB	O
to	TO	O
bleeding	VBG	O
initiation	NN	O
.	.	O

Healthcare	NN	O
costs	NNS	O
around	IN	O
the	DT	O
time	NN	O
of	IN	O
smoking	VBG	O
cessation	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
Affordable	NNP	O
Care	NNP	O
Act	NNP	O
mandates	VBZ	O
that	IN	O
new	JJ	O
insurance	NN	O
plans	NNS	O
cover	VBP	O
smoking-cessation	NN	Educational
therapy	NN	Educational
without	IN	O
cost-sharing	NN	O
.	.	O

Previous	JJ	O
cost	NN	O
difference	NN	O
estimates	NNS	O
,	,	O
which	WDT	O
show	VBP	O
a	DT	O
spike	NN	O
around	IN	O
the	DT	O
time	NN	O
of	IN	O
cessation	NN	O
,	,	O
suggest	VBP	O
premiums	NNS	O
might	MD	O
rise	VB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
covering	VBG	O
these	DT	O
services	NNS	O
.	.	O

PURPOSE	VB	O
The	DT	O
goal	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
test	VB	O
(	(	O
1	CD	O
)	)	O
whether	IN	O
individuals	NNS	O
in	IN	O
an	DT	O
RCT	NNP	O
of	IN	O
pharmacotherapy	NN	Pharmacological
and	CC	O
counseling	VBG	Educational
for	IN	O
smoking	VBG	O
cessation	NN	O
differed	VBN	O
in	IN	O
their	PRP$	O
healthcare	NN	O
costs	VBZ	O
around	IN	O
the	DT	O
cessation	NN	O
period	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
whether	IN	O
the	DT	O
healthcare	NN	O
costs	NNS	O
of	IN	O
those	DT	O
in	IN	O
the	DT	O
trial	NN	O
who	WP	O
successfully	RB	O
quit	VBP	O
were	VBD	O
different	JJ	O
from	IN	O
a	DT	O
matched	JJ	O
sample	NN	O
of	IN	O
smokers	NNS	O
in	IN	O
the	DT	O
community	NN	O
.	.	O

METHODS	NNP	O
Generalized	NNP	O
linear	JJ	O
regression	NN	O
models	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
analyze	VB	O
healthcare	NN	O
cost	NN	O
data	NNS	O
on	IN	O
individuals	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
comparative	JJ	O
effectiveness	NN	O
trial	NN	O
of	IN	O
cessation	NN	O
therapies	NNS	O
between	IN	O
October	NNP	O
2005	CD	O
and	CC	O
May	NNP	O
2007	CD	O
(	(	O
1346	CD	O
total	NN	O
participants	NNS	O
;	:	O
1338	CD	O
with	IN	O
requisite	JJ	O
data	NNS	O
for	IN	O
further	JJ	O
analysis	NN	O
)	)	O
.	.	O

Cost	NN	O
differences	NNS	O
for	IN	O
the	DT	O
period	NN	O
preceding	NN	O
and	CC	O
subsequent	JJ	O
to	TO	O
the	DT	O
cessation	NN	O
attempt	NN	O
were	VBD	O
assessed	VBN	O
by	IN	O
trial	NN	O
participants	NNS	O
'	POS	O
12-month	JJ	O
sustained	VBD	O
quit	NN	O
status	NN	O
.	.	O

Healthcare	NNP	O
cost	NN	O
differences	NNS	O
between	IN	O
sustained	VBN	O
quitters	NNS	O
and	CC	O
a	DT	O
sample	NN	O
of	IN	O
community-dwelling	JJ	O
smokers	NNS	O
,	,	O
matched	VBD	O
to	TO	O
these	DT	O
quitters	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
health	NN	O
services	NNS	O
use	VBP	O
around	IN	O
the	DT	O
time	NN	O
trial	NN	O
participant	NN	O
enrolled	VBN	O
and	CC	O
by	IN	O
demographics	NNS	O
,	,	O
were	VBD	O
also	RB	O
examined	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
in	IN	O
2011	CD	O
.	.	O

RESULTS	VB	O
All	DT	O
three	CD	O
groups	NNS	O
had	VBD	O
a	DT	O
spike	NN	O
in	IN	O
cost	NN	O
associated	VBN	O
with	IN	O
the	DT	O
index	NN	O
clinic	JJ	O
visit	NN	O
.	.	O

Regression	NNP	O
results	NNS	O
revealed	VBD	O
little	JJ	O
difference	NN	O
in	IN	O
healthcare	NN	O
costs	NNS	O
by	IN	O
quit	NN	O
status	NN	O
for	IN	O
trial	NN	O
participants	NNS	O
until	IN	O
the	DT	O
sixth	JJ	O
quarter	NN	O
post-quit	NN	O
.	.	O

By	IN	O
that	DT	O
quarter	NN	O
,	,	O
continuous	JJ	O
sustained	VBD	O
quitters	NNS	O
cost	VBD	O
$	$	O
541	CD	O
(	(	O
p	NN	O
<	RB	O
0.001	CD	O
)	)	O
less	JJR	O
than	IN	O
continuing	VBG	O
smokers	NNS	O
.	.	O

Continuous	JJ	O
sustained	VBD	O
quitters	NNS	O
cost	NN	O
less	JJR	O
than	IN	O
their	PRP$	O
matched	JJ	O
community-	JJ	O
dwelling	VBG	O
smokers	NNS	O
in	IN	O
almost	RB	O
every	DT	O
quarter	NN	O
observed	VBN	O
.	.	O

The	DT	O
cost	NN	O
difference	NN	O
ranged	VBD	O
from	IN	O
$	$	O
270	CD	O
(	(	O
p=0.01	NN	O
)	)	O
during	IN	O
the	DT	O
quarter	NN	O
of	IN	O
quit	NN	O
,	,	O
to	TO	O
$	$	O
490	CD	O
(	(	O
p	NN	O
<	RB	O
0.01	CD	O
)	)	O
in	IN	O
the	DT	O
6th	CD	O
quarter	NN	O
after	IN	O
quitting	VBG	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
inclusion	NN	O
of	IN	O
smoking-cessation	JJ	Educational
therapy	NN	Educational
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
raise	VB	O
short-term	JJ	O
healthcare	NN	O
costs	NNS	O
.	.	O

By	IN	O
the	DT	O
sixth	JJ	O
quarter	NN	O
post-quit	NN	O
,	,	O
sustained	VBN	O
quitters	NNS	O
were	VBD	O
less	RBR	O
costly	JJ	O
than	IN	O
trial	NN	O
participants	NNS	O
who	WP	O
continued	VBD	O
smoking	NN	O
.	.	O

Clinical	JJ	O
trial	NN	O
:	:	O
exposure	NN	O
to	TO	O
ribavirin	VB	O
predicts	NNS	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
HCV	NNP	O
genotype	NN	O
1	CD	O
infection	NN	O
treated	VBN	O
with	IN	O
peginterferon	NN	O
alpha-2a	JJ	O
plus	CC	O
ribavirin	JJ	O
.	.	O

BACKGROUND	VB	O
The	DT	O
impact	NN	O
of	IN	O
reduced	JJ	O
drug	NN	O
exposure	NN	O
on	IN	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
determined	VBN	O
in	IN	O
routine	JJ	O
clinical	JJ	O
practice	NN	O
.	.	O

AIM	NNP	O
To	TO	O
examine	VB	O
the	DT	O
impact	NN	O
of	IN	O
exposure	NN	O
to	TO	O
peginterferon	VB	O
alpha-2a	JJ	O
and	CC	O
ribavirin	VB	O
on	IN	O
early	JJ	O
virological	JJ	O
response	NN	O
(	(	O
EVR	NNP	O
)	)	O
and	CC	O
sustained	VBD	O
virological	JJ	O
response	NN	O
(	(	O
SVR	NNP	O
)	)	O
in	IN	O
treatment-naive	JJ	O
patients	NNS	O
with	IN	O
HCV	NNP	O
genotype	NN	O
1	CD	O
infection	NN	O
enrolled	VBN	O
in	IN	O
a	DT	O
large	JJ	O
expanded	JJ	O
access	NN	O
programme	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	O
hundred	VBD	O
and	CC	O
ninety-one	JJ	O
patients	NNS	O
treated	VBD	O
for	IN	O
48	CD	O
weeks	NNS	O
with	IN	O
an	DT	O
initial	JJ	O
ribavirin	NN	Pharmacological
dose	NN	Pharmacological
of	IN	Pharmacological
800	CD	Pharmacological
or	CC	Pharmacological
1000/1200	CD	Pharmacological
mg/day	NNS	Pharmacological
were	VBD	O
evaluated	VBN	O
.	.	O

Ribavirin	JJ	Pharmacological
1000	CD	O
mg/day	NN	O
(	(	O
<	JJ	O
75	CD	O
kg	NN	O
)	)	O
or	CC	O
1200	CD	O
mg/day	NN	O
(	(	O
>	JJ	O
or=75	RB	O
kg	NN	O
)	)	O
and	CC	O
peginterferon	VB	Pharmacological
alpha-2a	JJ	Pharmacological
180	CD	Pharmacological
microg/week	NN	O
were	VBD	O
considered	VBN	O
optimal	JJ	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
reduced	JJ	O
drug	NN	O
exposure	NN	O
(	(	O
expressed	VBN	O
as	IN	O
a	DT	O
percentage	NN	O
of	IN	O
optimal	NN	O
)	)	O
on	IN	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
was	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	JJ	O
Mean	NNP	O
ribavirin	NN	O
exposure	NN	O
in	IN	O
week	NN	O
0-12	NN	O
was	VBD	O
70	CD	O
%	NN	O
and	CC	O
96	CD	O
%	NN	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
ribavirin	VB	O
800	CD	O
and	CC	O
1000/1200	CD	O
mg/day	NN	O
,	,	O
respectively	RB	O
.	.	O

EVR	NNP	O
and	CC	O
SVR	NNP	O
rates	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
assigned	VBN	O
to	TO	O
ribavirin	VB	O
800	CD	O
than	IN	O
1000/1200	CD	O
mg/day	NN	O
(	(	O
EVR	NNP	O
,	,	O
75	CD	O
%	NN	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
;	:	O
SVR	NNP	O
,	,	O
45	CD	O
%	NN	O
vs.	FW	O
54	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

Furthermore	RB	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
achievement	NN	O
of	IN	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
and	CC	O
ribavirin	VB	O
dose	NN	O
over	IN	O
the	DT	O
first	JJ	O
12	CD	O
weeks	NNS	O
expressed	VBD	O
either	CC	O
as	IN	O
absolute	JJ	O
dose	NN	O
or	CC	O
proportion	NN	O
of	IN	O
optimal	JJ	O
dose	NN	O
received	VBD	O
(	(	O
P	NNP	O
<	VBZ	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Ribavirin	NNP	O
exposure	NN	O
to	TO	O
week	NN	O
12	CD	O
is	VBZ	O
significantly	RB	O
associated	VBN	O
with	IN	O
EVR	NNP	O
and	CC	O
SVR	NNP	O
in	IN	O
genotype	JJ	O
1	CD	O
patients	NNS	O
.	.	O

Maintenance	NNP	O
of	IN	O
an	DT	O
optimal	JJ	O
ribavirin	NN	O
dose	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
important	JJ	O
modifiable	JJ	O
factor	NN	O
during	IN	O
combination	NN	O
therapy	NN	O
for	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
.	.	O

[	RB	O
Comparative	NNP	O
study	NN	O
between	IN	O
5	CD	Pharmacological
%	NN	Pharmacological
prilocaine	NN	Pharmacological
and	CC	O
2	CD	Pharmacological
%	NN	Pharmacological
mepivacaine	NN	Pharmacological
by	IN	O
the	DT	O
subarachnoid	JJ	O
route	NN	O
in	IN	O
transurethral	JJ	O
resections	NNS	O
]	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
duration	NN	O
of	IN	O
spinal	JJ	O
block	NN	O
with	IN	O
5	CD	Pharmacological
%	NN	Pharmacological
prilocaine	NN	Pharmacological
and	CC	O
2	CD	Pharmacological
%	NN	Pharmacological
mepivacaine	NN	Pharmacological
in	IN	O
short	JJ	O
procedures	NNS	O
for	IN	O
transurethral	JJ	O
resection	NN	O
and	CC	O
to	TO	O
assess	VB	O
possible	JJ	O
complications	NNS	O
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
Fifty-seven	NNP	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
transurethral	JJ	O
resection	NN	O
of	IN	O
the	DT	O
prostate	NN	O
or	CC	O
a	DT	O
vesical	JJ	O
tumor	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
ASA	NNP	O
I-III	NNP	O
,	,	O
over	IN	O
55	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	Pharmacological
groups	NNS	Pharmacological
to	TO	Pharmacological
receive	VB	Pharmacological
5	CD	Pharmacological
%	NN	Pharmacological
prilocaine	NN	Pharmacological
(	(	Pharmacological
1	CD	Pharmacological
mg/kg	NN	Pharmacological
,	,	Pharmacological
n	JJ	Pharmacological
=	NNP	Pharmacological
27	CD	Pharmacological
)	)	Pharmacological
or	CC	O
2	CD	Pharmacological
%	NN	Pharmacological
mepivacaine	NN	Pharmacological
(	(	Pharmacological
0.8	CD	Pharmacological
mg/kg	NN	Pharmacological
,	,	Pharmacological
n	JJ	Pharmacological
=	NNP	Pharmacological
30	CD	Pharmacological
)	)	Pharmacological
.	.	O

We	PRP	Surgical
collected	VBD	Surgical
data	NNS	Surgical
on	IN	Surgical
anesthetic	JJ	Surgical
technique	NN	Surgical
,	,	Surgical
levels	NNS	Surgical
of	IN	Surgical
extension	NN	Surgical
of	IN	Surgical
motor	NN	Surgical
and	CC	Surgical
sensory	JJ	Surgical
blockades	NNS	Surgical
,	,	Surgical
duration	NN	Surgical
of	IN	Surgical
blockades	NNS	Surgical
and	CC	Surgical
complications	NNS	Surgical
within	IN	Surgical
the	DT	Surgical
first	JJ	Surgical
24	CD	Surgical
hours	NNS	Surgical
after	IN	Surgical
surgery	NN	Surgical
.	.	O

RESULTS	NNP	O
Demographic	NNP	O
data	NNS	O
,	,	O
ASA	NNP	O
classification	NN	O
and	CC	O
duration	NN	O
of	IN	O
surgery	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

We	PRP	O
found	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
duration	NN	O
of	IN	O
sensory	JJ	O
blockade	NN	O
(	(	O
120.92	CD	O
+/-	JJ	O
36.21	CD	O
min	NN	O
with	IN	O
prilocaine	NN	Pharmacological
and	CC	O
145.83	CD	O
+/-	JJ	O
35.81	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	Pharmacological
)	)	O
and	CC	O
in	IN	O
motor	NN	O
blockade	NN	O
(	(	O
106.29	CD	O
+/-	JJ	O
38.16	CD	O
min	NN	O
with	IN	O
prilocaine	NN	O
and	CC	O
133.16	CD	O
+/-	JJ	O
42.21	CD	O
min	NN	O
with	IN	O
mepivacaine	NN	O
)	)	O
.	.	O

Five	JJ	O
cases	NNS	O
of	IN	O
hypotension	NN	O
and	CC	O
4	CD	O
of	IN	O
bradycardia	NN	O
occurred	VBN	O
in	IN	O
each	DT	O
group	NN	O
and	CC	O
one	CD	O
patient	NN	O
in	IN	O
the	DT	O
mepivacaine	NN	O
group	NN	O
suffered	VBD	O
slight	JJ	O
postoperative	JJ	O
cephalea	NN	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
local	JJ	O
anesthetics	NNS	O
offer	VBP	O
good	JJ	O
surgical	JJ	O
conditions	NNS	O
with	IN	O
hemodynamic	JJ	O
stability	NN	O
and	CC	O
few	JJ	O
complications	NNS	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
sensory	NN	O
and	CC	O
motor	NN	O
blockade	NN	O
is	VBZ	O
shorter	JJR	O
with	IN	O
prilocaine	NN	O
than	IN	O
with	IN	O
mepivacaine	NN	O
,	,	O
making	VBG	O
prilocaine	NN	O
more	JJR	O
appropriate	JJ	O
for	IN	O
short	JJ	O
interventions	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
hypertensive	JJ	O
and	CC	O
hypercholesterolaemic	JJ	O
patients	NNS	O
in	IN	O
general	JJ	O
practice	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
captopril	NN	Pharmacological
,	,	O
atenolol	NN	Pharmacological
and	CC	O
pravastatin	NN	Pharmacological
combined	VBN	Pharmacological
with	IN	Pharmacological
life	NN	Pharmacological
style	NN	Pharmacological
intervention	NN	Pharmacological
.	.	O

OBJECTIVE	UH	O
To	TO	O
elucidate	VB	O
the	DT	O
effect	NN	O
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
blood	NN	O
lipids	NNS	O
of	IN	O
an	DT	O
angiotensin	NN	Pharmacological
converting	VBG	Pharmacological
enzyme	JJ	Pharmacological
inhibitor	NN	Pharmacological
(	(	Pharmacological
captopril	NN	Pharmacological
)	)	Pharmacological
,	,	O
and	CC	O
a	DT	O
beta-receptor	NN	Pharmacological
blocking	NN	Pharmacological
agent	NN	Pharmacological
(	(	Pharmacological
atenolol	NN	Pharmacological
)	)	Pharmacological
,	,	O
given	VBN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
cholesterol	NN	Pharmacological
reducing	VBG	Pharmacological
drug	NN	Pharmacological
,	,	O
the	DT	O
beta-hydroxy-methylglutaryl-coenzyme	NN	Pharmacological
A	DT	Pharmacological
reductase	NN	Pharmacological
inhibitor	NN	Pharmacological
pravastatin	NN	Pharmacological
,	,	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	Educational
also	RB	Educational
encouraged	VBN	Educational
to	TO	Educational
improve	VB	Educational
their	PRP$	Educational
lifestyle	NN	Educational
.	.	O

DESIGN	VB	O
A	DT	O
longitudinal	JJ	O
study	NN	O
consisting	VBG	O
of	IN	O
three	CD	O
phases	NNS	O
.	.	O

I	PRP	O
:	:	O
Lifestyle	JJ	Educational
intervention	NN	Educational
alone	RB	Educational
.	.	O

II	NN	O
:	:	O
Continued	JJ	Pharmacological
lifestyle	JJ	Pharmacological
intervention	NN	Pharmacological
combined	VBN	Pharmacological
with	IN	Pharmacological
captopril	NN	Pharmacological
or	CC	Pharmacological
atenolol	NN	Pharmacological
.	.	O

III	NN	O
:	:	O
Continued	JJ	Pharmacological
lifestyle	JJ	Other
intervention	NN	Other
combined	VBN	Other
with	IN	Other
the	DT	Other
same	JJ	Other
drugs	NNS	Other
as	IN	Other
in	IN	Other
phase	NN	Other
II	NNP	Other
and	CC	O
in	IN	O
addition	NN	O
pravastatin	NN	Pharmacological
or	CC	O
placebo	NN	Other
.	.	O

SETTING	CC	O
Fifty-four	JJ	O
general	JJ	O
practice	NN	O
surgeries	NNS	O
in	IN	O
Norway	NNP	O
.	.	O

PARTICIPANTS	NNP	O
Hypertensive	JJ	O
patients	NNS	O
,	,	O
210	CD	O
females	NNS	O
and	CC	O
160	CD	O
males	NNS	O
,	,	O
treated	VBD	O
or	CC	O
untreated	JJ	O
with	IN	O
antihypertensive	JJ	O
drugs	NNS	O
with	IN	O
a	DT	O
sitting	VBG	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
between	IN	O
95	CD	O
and	CC	O
115	CD	O
mmHg	NN	O
and	CC	O
a	DT	O
serum	JJ	O
total	NN	O
cholesterol	NN	O
between	IN	O
6.5	CD	O
mmol/l	NNS	O
(	(	O
7.0	CD	O
for	IN	O
those	DT	O
age	NN	O
60-67	JJ	O
years	NNS	O
)	)	O
and	CC	O
9.0	CD	O
mmol/l	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
captopril	NN	Pharmacological
and	CC	O
atenolol	NN	Pharmacological
was	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
concurrent	JJ	O
administration	NN	O
of	IN	O
pravastatin	NN	Pharmacological
.	.	O

The	DT	O
effect	NN	O
of	IN	O
pravastatin	NN	Pharmacological
was	VBD	O
not	RB	O
limited	VBN	O
by	IN	O
concurrent	JJ	O
medication	NN	O
with	IN	O
captopril	NN	Pharmacological
or	CC	O
atenolol	NN	Pharmacological
.	.	O

Improvement	NN	O
in	IN	O
lifestyle	NN	O
seemed	VBD	O
to	TO	O
reduce	VB	O
the	DT	O
need	NN	O
for	IN	O
supplementary	JJ	O
treatment	NN	O
with	IN	O
diuretics	NNS	Pharmacological
.	.	O

CONCLUSION	NNP	O
Pravastatin	NNP	Pharmacological
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
captopril	NN	Pharmacological
or	CC	O
atenolol	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertensive	JJ	O
and	CC	O
hypercholesterolaemic	JJ	O
patients	NNS	O
.	.	O

[	JJ	O
Intra-uterine	JJ	O
insemination	NN	O
with	IN	O
controlled	JJ	Physical
ovarian	JJ	Physical
hyperstimulation	NN	Physical
compared	VBN	O
to	TO	O
an	DT	O
expectant	JJ	O
management	NN	O
in	IN	O
couples	NNS	O
with	IN	O
unexplained	JJ	O
subfertility	NN	O
and	CC	O
an	DT	O
intermediate	JJ	O
prognosis	NN	O
:	:	O
a	DT	O
randomised	JJ	O
study	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
Intrauterine	NNP	Surgical
insemination	NN	Surgical
(	(	Surgical
IUI	NNP	Surgical
)	)	Surgical
with	IN	O
controlled	JJ	Surgical
ovarian	JJ	Surgical
hyperstimulation	NN	Surgical
(	(	Surgical
COH	NNP	Surgical
)	)	Surgical
is	VBZ	O
commonly	RB	O
used	VBN	O
as	IN	O
treatment	NN	O
of	IN	O
first	JJ	O
choice	NN	O
in	IN	O
couples	NNS	O
with	IN	O
unexplained	JJ	O
subfertility	NN	O
.	.	O

This	DT	O
treatment	NN	O
should	MD	O
only	RB	O
be	VB	O
applied	VBN	O
when	WRB	O
there	EX	O
is	VBZ	O
a	DT	O
realistic	JJ	O
increase	NN	O
in	IN	O
chance	NN	O
of	IN	O
pregnancy	NN	O
,	,	O
particularly	RB	O
because	IN	O
it	PRP	O
carries	VBZ	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
multiple	JJ	O
pregnancies	NNS	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
IUI	NNP	Surgical
with	IN	Physical
COH	NNP	Surgical
relative	VBP	O
to	TO	O
expectant	VB	Educational
management	NN	Educational
in	IN	O
couples	NNS	O
with	IN	O
unexplained	JJ	O
subfertility	NN	O
and	CC	O
an	DT	O
intermediate	JJ	O
prognosis	NN	O
of	IN	O
a	DT	O
spontaneous	JJ	O
ongoing	JJ	O
pregnancy	NN	O
.	.	O

DESIGN	NNP	O
Multicentre	NNP	O
randomised	VBD	O
clinical	JJ	O
study	NN	O
.	.	O

METHOD	NNP	O
253	CD	O
couples	NNS	O
with	IN	O
unexplained	JJ	O
subfertility	NN	O
and	CC	O
a	DT	O
probability	NN	O
of	IN	O
a	DT	O
spontaneous	JJ	O
ongoing	JJ	O
pregnancy	NN	O
of	IN	O
30	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
within	IN	O
12	CD	O
months	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
IUI	NNP	Surgical
with	IN	Physical
COH	NNP	Surgical
for	IN	O
6	CD	O
months	NNS	O
or	CC	O
expectant	JJ	O
management	NN	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
of	IN	O
our	PRP$	O
study	NN	O
was	VBD	O
ongoing	JJ	O
pregnancy	NN	O
within	IN	O
6	CD	O
months	NNS	O
.	.	O

Analysis	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
according	VBG	O
to	TO	O
the	DT	O
intention	NN	O
to	TO	O
treat	VB	O
principle	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
registered	VBN	O
with	IN	O
the	DT	O
Dutch	JJ	O
Trial	NNP	O
Register	NNP	O
and	CC	O
has	VBZ	O
the	DT	O
International	NNP	O
Standard	NNP	O
Randomised	VBD	O
Clinical	JJ	O
Trial	NNP	O
number	NN	O
ISRCTN72675518	NNP	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
253	CD	O
couples	NNS	O
included	VBD	O
,	,	O
127	CD	O
couples	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
IUI	NNP	Surgical
with	IN	O
COH	NNP	Surgical
and	CC	O
126	CD	O
to	TO	O
expectant	VB	Physical
management	NN	Physical
.	.	Educational

In	IN	O
the	DT	O
intervention	NN	O
group	NN	O
,	,	O
42	CD	O
women	NNS	O
(	(	O
33	CD	O
%	NN	O
)	)	O
conceived	VBD	O
,	,	O
of	IN	O
which	WDT	O
29	CD	O
pregnancies	NNS	O
were	VBD	O
ongoing	VBG	O
(	(	O
23	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
expectant	JJ	O
management	NN	O
group	NN	O
,	,	O
40	CD	O
women	NNS	O
(	(	O
32	CD	O
%	NN	O
)	)	O
conceived	VBD	O
,	,	O
of	IN	O
which	WDT	O
34	CD	O
pregnancies	NNS	O
were	VBD	O
ongoing	VBG	O
(	(	O
27	CD	O
%	NN	O
)	)	O
(	(	O
relative	JJ	O
risk	NN	O
:	:	O
0.85	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
0.63-1.1	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
expectant	JJ	Physical
management	NN	Physical
group	NN	O
one	CD	O
twin	NN	O
pregnancy	NN	O
occurred	VBD	O
and	CC	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
one	CD	O
woman	NN	O
conceived	VBD	O
twins	NNS	O
and	CC	O
one	CD	O
a	DT	O
triplet	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
substantial	JJ	O
beneficial	JJ	O
effect	NN	O
of	IN	O
IUI	NNP	Surgical
with	IN	Physical
COH	NNP	Surgical
in	IN	O
couples	NNS	O
with	IN	O
unexplained	JJ	O
subfertility	NN	O
and	CC	O
an	DT	O
intermediate	JJ	O
prognosis	NN	O
can	MD	O
be	VB	O
excluded	VBN	O
.	.	O

Expectant	JJ	O
management	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
6	CD	O
months	NNS	O
therefore	RB	O
appears	VBZ	O
justified	JJ	O
in	IN	O
these	DT	O
couples	NNS	O
.	.	O

Outcomes	NNS	O
of	IN	O
Japanese	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
pre-operative	JJ	Pharmacological
and	CC	Pharmacological
post-operative	JJ	Pharmacological
anastrozole	NN	Pharmacological
or	CC	Pharmacological
tamoxifen	NN	Pharmacological
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
long-term	JJ	O
efficacy	NN	O
outcomes	NNS	O
in	IN	O
a	DT	O
subgroup	NN	O
of	IN	O
postmenopausal	NN	O
,	,	O
estrogen	VBP	O
receptor-positive	JJ	O
Japanese	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
from	IN	O
the	DT	O
Pre-Operative	JJ	O
Arimidex	NNP	Pharmacological
Compared	NNP	O
with	IN	O
Tamoxifen	NNP	Pharmacological
trial	NN	O
,	,	O
following	VBG	O
pre-operative	JJ	Pharmacological
(	(	Pharmacological
3	CD	Pharmacological
months	NNS	Pharmacological
)	)	Pharmacological
and	CC	Pharmacological
post-operative	JJ	Pharmacological
(	(	Pharmacological
5	CD	Pharmacological
years	NNS	Pharmacological
)	)	Pharmacological
adjuvant	VBP	Pharmacological
treatment	NN	Pharmacological
with	IN	O
either	DT	O
anastrozole	NN	Pharmacological
or	CC	O
tamoxifen	NN	Pharmacological
.	.	O

Patients	NNS	O
with	IN	O
large	JJ	O
,	,	O
potentially	RB	O
operable	JJ	O
,	,	O
locally-advanced	JJ	O
breast	NN	O
cancer	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
anastrozole	NN	Pharmacological
(	(	O
1	CD	O
mg/day	NN	O
)	)	O
plus	CC	O
tamoxifen	JJ	Control
placebo	NN	Control
or	CC	O
tamoxifen	NN	Pharmacological
(	(	O
20	CD	O
mg/day	NN	O
)	)	O
plus	CC	O
anastrozole	JJ	Control
placebo	NN	Control
pre-operatively	RB	O
.	.	O

After	IN	O
surgery	NN	O
at	IN	O
3	CD	O
months	NNS	O
,	,	O
patients	NNS	O
continued	VBD	O
on	IN	O
the	DT	O
same	JJ	O
study	NN	O
medication	NN	O
as	IN	O
adjuvant	JJ	Pharmacological
therapy	NN	Pharmacological
for	IN	O
up	IN	O
to	TO	O
5	CD	O
years	NNS	O
or	CC	O
until	IN	O
recurrence	NN	O
,	,	O
intolerable	JJ	O
toxicity	NN	O
or	CC	O
withdrawal	NN	O
of	IN	O
patient	JJ	O
consent	NN	O
.	.	O

Recurrence-free	JJ	O
survival	NN	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
measured	VBN	O
from	IN	O
the	DT	O
date	NN	O
of	IN	O
randomization	NN	O
to	TO	O
the	DT	O
date	NN	O
of	IN	O
recurrence	NN	O
or	CC	O
death	NN	O
,	,	O
whichever	WDT	O
occurred	VBD	O
first	RB	O
.	.	O

Patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
events	NNS	O
throughout	IN	O
the	DT	O
study	NN	O
period	NN	O
and	CC	O
up	RB	O
to	TO	O
30	CD	O
days	NNS	O
following	VBG	O
administration	NN	O
of	IN	O
the	DT	O
last	JJ	O
study	NN	O
medication	NN	O
.	.	O

During	IN	O
post-operative	JJ	O
adjuvant	JJ	O
therapy	NN	O
,	,	O
4/48	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
anastrozole	NN	Pharmacological
and	CC	O
25/49	CD	O
(	(	O
51	CD	O
%	NN	O
)	)	O
tamoxifen	NN	Pharmacological
patients	NNS	O
experienced	VBD	O
recurrence	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
recurrence-free	JJ	O
survival	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
hazard	JJ	O
ratio	NN	O
0.14	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.05-0.41	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
overall	JJ	O
survival	NN	O
with	IN	O
anastrozole	NN	Pharmacological
(	(	O
0.21	CD	O
;	:	O
0.05-0.96	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.0436	CD	O
)	)	O
and	CC	O
there	EX	O
were	VBD	O
2/48	CD	O
(	(	O
4	CD	O
%	NN	O
)	)	O
and	CC	O
10/49	CD	O
(	(	O
20	CD	O
%	NN	O
)	)	O
deaths	NNS	O
with	IN	O
anastrozole	JJ	Pharmacological
and	CC	O
tamoxifen	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

Most	JJS	O
patients	NNS	O
responding	VBG	O
to	TO	O
pre-operative	JJ	O
therapy	NN	O
remained	VBD	O
recurrence-free	JJ	O
.	.	O

Sequential	JJ	O
pre-operative/post-operative	JJ	O
treatment	NN	O
with	IN	O
anastrozole	JJ	Pharmacological
resulted	VBN	O
in	IN	O
lower	JJR	O
recurrence	NN	O
and	CC	O
death	NN	O
rates	NNS	O
,	,	O
compared	VBN	O
with	IN	O
tamoxifen	NN	Pharmacological
.	.	O

National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
's	POS	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
.	.	O

The	DT	O
Breast	NNP	O
Cancer	NNP	O
Prevention	NNP	O
Trial	NNP	O
is	VBZ	O
the	DT	O
largest	JJS	O
breast	NN	O
cancer	NN	O
prevention	NN	O
study	NN	O
ever	RB	O
undertaken	RB	O
.	.	O

Administered	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Surgical	NNP	O
Adjuvant	NNP	O
Breast	NNP	O
and	CC	O
Bowel	NNP	O
Project	NNP	O
,	,	O
it	PRP	O
is	VBZ	O
the	DT	O
first	JJ	O
trial	NN	O
seeking	VBG	O
to	TO	O
demonstrate	VB	O
whether	IN	O
a	DT	O
drug	NN	O
,	,	O
tamoxifen	NN	Pharmacological
,	,	O
can	MD	O
prevent	VB	O
breast	NN	O
cancer	NN	O
in	IN	O
high-risk	JJ	O
women	NNS	O
.	.	O

The	DT	O
objectives	NNS	O
of	IN	O
this	DT	O
trial	NN	O
are	VBP	O
to	TO	O
determine	VB	O
whether	IN	O
tamoxifen	NN	Pharmacological
is	VBZ	O
effective	JJ	O
in	IN	O
1	CD	O
)	)	O
reducing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
invasive	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
2	CD	O
)	)	O
reducing	VBG	O
breast	NN	O
cancer	NN	O
mortality	NN	O
,	,	O
3	CD	O
)	)	O
reducing	VBG	O
deaths	NNS	O
from	IN	O
cardiovascular	JJ	O
disease	NN	O
,	,	O
and	CC	O
4	CD	O
)	)	O
reducing	VBG	O
bone	NN	O
fractures	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
study	NN	O
will	MD	O
evaluate	VB	O
side	NN	O
effects	NNS	O
,	,	O
toxicity	NN	O
,	,	O
and	CC	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
all	DT	O
study	NN	O
participants	NNS	O
.	.	O

Clinical	JJ	Physical
massage	NN	Physical
and	CC	O
modified	VBD	Physical
Proprioceptive	NNP	Physical
Neuromuscular	NNP	Physical
Facilitation	NNP	Physical
stretching	VBG	Physical
in	IN	O
males	NNS	O
with	IN	O
latent	JJ	O
myofascial	JJ	O
trigger	NN	O
points	NNS	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
determine	VB	O
the	DT	O
immediate	JJ	O
effects	NNS	O
of	IN	O
modified	JJ	Physical
Proprioceptive	NNP	Physical
Neuromuscular	NNP	Physical
Facilitation	NNP	Physical
(	(	Physical
PNF	NNP	Physical
)	)	Physical
stretching	NN	Physical
(	(	O
group	NN	O
I	PRP	O
)	)	O
versus	VBP	O
Myofascial	JJ	Physical
Trigger	NNP	Physical
Point	NNP	Physical
(	(	Physical
MTrP	NNP	Physical
)	)	Physical
therapy	NN	Physical
plus	CC	Physical
modified	JJ	Physical
PNF	NNP	Physical
stretching	NN	Physical
(	(	O
group	NN	O
II	NNP	O
)	)	O
in	IN	O
comparison	NN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
receiving	VBG	O
no	DT	Other
treatment	NN	Other
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
assessor-blind	NN	O
,	,	O
(	(	O
3	CD	O
x	RB	O
4	CD	O
)	)	O
mixed-model	NN	O
repeated	VBN	O
measures	NNS	O
.	.	O

SETTING	NNP	O
University	NNP	O
laboratory	NN	O
.	.	O

PARTICIPANTS	NNP	O
Thirty	NNP	O
physically	RB	O
active	JJ	O
males	NNS	O
with	IN	O
tight	JJ	O
hamstrings	NNS	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
latent	NN	O
MTrP	NNP	O
on	IN	O
muscles	NNS	O
innervated	VBN	O
by	IN	O
the	DT	O
lumbosacral	JJ	O
,	,	O
sciatic	JJ	O
,	,	O
tibial	JJ	O
and	CC	O
common	JJ	O
peroneal	JJ	O
nerves	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Knee	NNP	O
range	NN	O
of	IN	O
motion	NN	O
(	(	O
ROM	NNP	O
)	)	O
,	,	O
stretch	JJ	O
perception	NN	O
,	,	O
pressure	NN	O
pain	NN	O
threshold	NN	O
(	(	O
PPT	NNP	O
)	)	O
and	CC	O
subjective	JJ	O
pain	NN	O
intensity	NN	O
.	.	O

Outcomes	CC	O
were	VBD	O
evaluated	VBN	O
at	IN	O
baseline	NN	O
,	,	O
immediately	RB	O
after	IN	O
treatment	NN	O
,	,	O
at	IN	O
10	CD	O
and	CC	O
30	CD	O
min	NN	O
.	.	O

RESULTS	NNP	O
Significant	NNP	O
changes	VBZ	O
over	IN	O
time	NN	O
occurred	VBD	O
for	IN	O
group	NN	O
II	NNP	O
in	IN	O
all	DT	O
outcomes	NNS	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.001	CD	O
)	)	O
.	.	O

Group	NNP	O
II	NNP	O
also	RB	O
showed	VBD	O
lower	JJR	O
pain	NN	O
intensity	NN	O
scores	NNS	O
than	IN	O
group	NN	O
I	PRP	O
immediately	RB	O
post-treatment	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.045	CD	O
)	)	O
and	CC	O
a	DT	O
strong	JJ	O
clinical	JJ	O
effect	NN	O
over	IN	O
group	NN	O
I	PRP	O
in	IN	O
ROM	NNP	O
at	IN	O
all	DT	O
follow-ups	NNS	O
(	(	O
effect	NN	O
sizes	VBZ	O
=	JJ	O
0.9-1.0	JJ	O
,	,	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.05	CD	O
)	)	O
.	.	O

Other	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
between	IN	O
both	DT	O
stretching	VBG	O
groups	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
indicate	VBP	O
immediate	JJ	O
pre-	JJ	O
to	TO	O
post-treatment	JJ	O
benefits	NNS	O
from	IN	O
MTrP	NNP	Physical
therapy	NN	Physical
combined	VBN	O
with	IN	O
modified	JJ	Physical
PNF	NNP	Physical
stretching	NN	Physical
in	IN	O
young	JJ	O
and	CC	O
physically	RB	O
active	JJ	O
males	NNS	O
with	IN	O
latent	JJ	O
MTrPs	NNP	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
an	DT	O
interim	JJ	O
methadone	NN	Pharmacological
maintenance	NN	O
clinic	NN	O
.	.	O

BACKGROUND	NNP	O
Interim	NNP	O
methadone	NN	Pharmacological
maintenance	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
method	NN	O
of	IN	O
providing	VBG	O
clinically	RB	O
effective	JJ	O
services	NNS	O
to	TO	O
heroin	VB	O
addicts	NNS	O
waiting	VBG	O
for	IN	O
treatment	NN	O
in	IN	O
standard	JJ	O
comprehensive	JJ	O
methadone	NN	O
maintenance	NN	O
programs	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
clinic	NN	O
that	WDT	O
provided	VBD	O
initial	JJ	O
medical	JJ	O
evaluation	NN	O
,	,	O
methadone	NN	O
medication	NN	O
,	,	O
and	CC	O
AIDS	NNP	O
education	NN	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
include	VB	O
formal	JJ	O
drug	NN	O
abuse	NN	O
counseling	NN	O
or	CC	O
other	JJ	O
social	JJ	O
support	NN	O
services	NNS	O
was	VBD	O
established	VBN	O
in	IN	O
New	NNP	O
York	NNP	O
City	NNP	O
.	.	O

A	NNP	O
sample	NN	O
of	IN	O
301	CD	O
volunteer	NN	O
subjects	NNS	O
recruited	VBN	O
from	IN	O
the	DT	O
waiting	VBG	O
list	NN	O
for	IN	O
treatment	NN	O
in	IN	O
the	DT	O
Beth	NNP	O
Israel	NNP	O
methadone	NN	Pharmacological
program	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
immediate	VB	O
entry	NN	O
into	IN	O
the	DT	O
interim	JJ	O
clinic	NN	O
or	CC	O
a	DT	O
control	NN	Control
group	NN	Control
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
initial	JJ	O
levels	NNS	O
of	IN	O
illicit	JJ	O
drug	NN	O
use	NN	O
across	IN	O
the	DT	O
experimental	JJ	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

One-month	JJ	O
urinalysis	JJ	O
follow-up	NN	O
data	NNS	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
heroin	NN	O
use	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
from	IN	O
63	CD	O
%	NN	O
positive	JJ	O
at	IN	O
intake	NN	O
to	TO	O
29	CD	O
%	NN	O
positive	JJ	O
)	)	O
with	IN	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
62	CD	O
%	NN	O
to	TO	O
60	CD	O
%	NN	O
positive	JJ	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
change	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
cocaine	NN	O
urinalyses	NNS	O
(	(	O
approximately	RB	O
70	CD	O
%	NN	O
positive	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
at	IN	O
intake	NN	O
and	CC	O
follow-up	NN	O
)	)	O
.	.	O

A	DT	O
higher	JJR	O
percentage	NN	O
of	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
in	IN	O
treatment	NN	O
at	IN	O
16-month	JJ	O
follow-up	NN	O
(	(	O
72	CD	O
%	NN	O
vs	JJ	O
56	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Limited	NNP	O
services	NNS	O
interim	VBP	O
methadone	JJ	O
maintenance	NN	O
can	MD	O
reduce	VB	O
heroin	NNS	O
use	VBP	O
among	IN	O
persons	NNS	O
awaiting	VBG	O
entry	NN	O
into	IN	O
comprehensive	JJ	O
treatment	NN	O
and	CC	O
increase	VB	O
the	DT	O
percentage	NN	O
entering	VBG	O
treatment	NN	O
.	.	O

Clonidine	NNP	Pharmacological
treatment	NN	O
of	IN	O
hyperactive	JJ	O
and	CC	O
impulsive	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Many	JJ	O
autistic	JJ	O
children	NNS	O
have	VBP	O
associated	VBN	O
problems	NNS	O
of	IN	O
inattention	NN	O
,	,	O
impulsivity	NN	O
,	,	O
and	CC	O
hyperactivity	NN	O
that	WDT	O
limit	VBZ	O
the	DT	O
effectiveness	NN	O
of	IN	O
educational	JJ	O
and	CC	O
behavioral	JJ	O
interventions	NNS	O
.	.	O

Few	NNP	O
controlled	VBD	O
psychopharmacologic	JJ	O
trials	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
in	IN	O
autistic	JJ	O
children	NNS	O
to	TO	O
determine	VB	O
which	WDT	O
agents	NNS	O
may	MD	O
be	VB	O
effective	JJ	O
for	IN	O
these	DT	O
associated	VBN	O
features	NNS	O
.	.	O

Eight	NNP	O
male	NN	O
children	NNS	O
(	(	O
8.1	CD	O
+/-	JJ	O
2.8	CD	O
years	NNS	O
)	)	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
diagnosed	VBN	O
by	IN	O
DSM-III-R	NNP	O
criteria	NNS	O
,	,	O
completed	VBD	O
a	DT	O
placebo-controlled	JJ	Control
,	,	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
of	IN	O
clonidine	NN	Pharmacological
.	.	Pharmacological

Subjects	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
if	IN	O
they	PRP	O
had	VBD	O
inattention	NN	O
,	,	O
impulsivity	NN	O
,	,	O
and	CC	O
hyperactivity	NN	O
that	WDT	O
was	VBD	O
excessive	JJ	O
for	IN	O
their	PRP$	O
developmental	JJ	O
level	NN	O
.	.	O

Subjects	NNS	O
had	VBD	O
not	RB	O
tolerated	VBN	O
or	CC	O
responded	VBN	O
to	TO	O
other	JJ	O
psychopharmacologic	JJ	O
treatments	NNS	O
(	(	O
neuroleptics	NNS	Pharmacological
,	,	O
methylphenidate	NN	Pharmacological
,	,	O
or	CC	O
desipramine	NN	Pharmacological
)	)	O
.	.	O

Teacher	PRP$	O
ratings	NNS	O
on	IN	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
irritability	NN	O
,	,	O
stereotypy	NN	O
,	,	O
hyperactivity	NN	O
,	,	O
and	CC	O
inappropriate	JJ	O
speech	NN	O
factors	NNS	O
were	VBD	O
lower	JJR	O
during	IN	O
treatment	NN	O
with	IN	O
clonidine	NN	Pharmacological
than	IN	O
during	IN	O
treatment	NN	O
with	IN	O
placebo	NN	Control
.	.	O

Attention	NNP	O
deficit	NN	O
disorder	NN	O
with	IN	O
hyperactivity	NN	O
:	:	O
Comprehensive	NNP	O
Teacher	NNP	O
's	POS	O
Rating	NNP	O
Scale	NNP	O
ratings	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
improved	VBN	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
except	IN	O
for	IN	O
oppositional	JJ	O
behavior	NN	O
.	.	O

Parent	NN	O
Conners	NNPS	O
Abbreviated	NNP	O
Parent-Teacher	NNP	O
Questionnaire	NNP	O
ratings	NNS	O
significantly	RB	O
improved	VBN	O
during	IN	O
clonidine	JJ	Pharmacological
treatment	NN	O
.	.	O

Clonidine	NNP	O
led	VBD	O
to	TO	O
increased	VBN	O
ratings	NNS	O
of	IN	O
the	DT	O
side	NN	O
effects	NNS	O
of	IN	O
drowsiness	NN	O
and	CC	O
decreased	JJ	O
activity	NN	O
.	.	O

Clinician	JJ	O
ratings	NNS	O
(	(	O
Children	NNP	O
's	POS	O
Psychiatric	NNP	O
Rating	NNP	O
Scale	NNP	O
Autism	NNP	O
,	,	O
Hyperactivity	NNP	O
,	,	O
Anger	NNP	O
and	CC	O
Speech	NNP	O
Deviance	NNP	O
factors	NNS	O
;	:	O
Children	NNP	O
's	POS	O
Global	NNP	O
Assessment	NNP	O
Scale	NNP	O
;	:	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
efficacy	NN	O
)	)	O
of	IN	O
videotaped	JJ	O
sessions	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
clonidine	NN	Pharmacological
and	CC	O
placebo	NN	Control
.	.	O

Clonidine	NNP	Pharmacological
was	VBD	O
modestly	RB	O
effective	JJ	O
in	IN	O
the	DT	O
short-term	JJ	O
treatment	NN	O
of	IN	O
irritability	NN	O
and	CC	O
hyperactivity	NN	O
in	IN	O
some	DT	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

Sustained	VBN	O
ventricular	JJ	O
arrhythmias	NNS	O
and	CC	O
mortality	NN	O
among	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
GUSTO-III	NNP	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
many	JJ	O
patients	NNS	O
,	,	O
ventricular	JJ	O
arrhythmias	NN	O
will	MD	O
develop	VB	O
early	JJ	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
incidence	NN	O
,	,	O
timing	NN	O
,	,	O
and	CC	O
outcomes	NNS	O
of	IN	O
such	JJ	O
arrhythmias	NNS	O
in	IN	O
the	DT	O
international	JJ	O
Global	NNP	O
Utilization	NNP	O
of	IN	O
Streptokinase	NNP	O
and	CC	O
TPA	NNP	O
(	(	O
alteplase	NN	O
)	)	O
for	IN	O
Occluded	NNP	O
Coronary	NNP	O
Arteries	NNP	O
(	(	O
GUSTO	NNP	O
)	)	O
-III	VBP	O
trial	NN	O
.	.	O

METHODS	NNP	O
We	PRP	Educational
identified	VBD	Educational
independent	JJ	Educational
predictors	NNS	Educational
of	IN	Educational
inhospital	JJ	Educational
ventricular	JJ	Educational
fibrillation	NN	Educational
(	(	Educational
VF	NNP	Educational
)	)	Educational
and	CC	Educational
ventricular	JJ	Educational
tachycardia	NN	Educational
(	(	Educational
VT	NNP	Educational
)	)	Educational
and	CC	Educational
compared	VBN	Educational
30-day	JJ	Educational
and	CC	Educational
1-year	JJ	Educational
mortality	NN	Educational
rates	NNS	Educational
of	IN	Educational
patients	NNS	Educational
who	WP	Educational
did	VBD	Educational
(	(	Educational
n	VB	Educational
=	NNP	Educational
1121	CD	Educational
)	)	Educational
and	CC	Educational
did	VBD	Educational
not	RB	Educational
(	(	Educational
n	JJ	Educational
=	NNP	Educational
13,921	CD	Educational
)	)	Educational
have	VBP	Educational
these	DT	Educational
arrhythmias	NNS	Educational
during	IN	Educational
the	DT	Educational
index	NN	Educational
hospitalization	NN	Educational
.	.	Educational

RESULTS	NNP	O
Significant	NNP	O
independent	JJ	O
predictors	NNS	O
of	IN	O
inhospital	JJ	O
VF	NNP	O
were	VBD	O
higher	JJR	O
Killip	NNP	O
class	NN	O
,	,	O
lower	JJR	O
baseline	NN	O
systolic	JJ	O
pressure	NN	O
,	,	O
intravenous	JJ	O
preenrollment	NN	O
lidocaine	NN	Pharmacological
use	NN	Pharmacological
,	,	O
shorter	JJR	O
time	NN	O
to	TO	O
thrombolysis	VB	O
,	,	O
and	CC	O
beta-blocker	NN	O
use	NN	O
<	VBZ	O
2	CD	O
weeks	NNS	O
before	IN	O
enrollment	NN	O
;	:	O
independent	JJ	O
predictors	NNS	O
of	IN	O
inhospital	JJ	O
VT	NNP	O
were	VBD	O
lower	JJR	O
baseline	NN	O
systolic	JJ	O
pressure	NN	O
,	,	O
intravenous	JJ	O
lidocaine	NN	O
use	NN	O
before	IN	O
enrollment	NN	O
,	,	O
higher	JJR	O
Killip	NNP	O
class	NN	O
,	,	O
faster	JJR	O
baseline	JJ	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
advanced	JJ	O
age	NN	O
.	.	O

The	DT	O
30-day	JJ	O
mortality	NN	O
rate	NN	O
was	VBD	O
31	CD	O
%	NN	O
in	IN	O
patients	NNS	O
with	IN	O
VF	NNP	O
,	,	O
24	CD	O
%	NN	O
in	IN	O
those	DT	O
with	IN	O
VT	NNP	O
,	,	O
44	CD	O
%	NN	O
in	IN	O
those	DT	O
with	IN	O
both	DT	O
,	,	O
and	CC	O
6	CD	O
%	NN	O
in	IN	O
those	DT	O
with	IN	O
neither	DT	O
(	(	O
P	NNP	O
=.001	NNP	O
)	)	O
.	.	O

The	DT	O
corresponding	JJ	O
1-year	JJ	O
mortality	NN	O
rates	NNS	O
were	VBD	O
34	CD	O
%	NN	O
,	,	O
29	CD	O
%	NN	O
,	,	O
49	CD	O
%	NN	O
,	,	O
and	CC	O
9	CD	O
%	NN	O
(	(	O
P	NNP	O
=.001	NNP	O
)	)	O
.	.	O

The	DT	O
30-day	JJ	O
and	CC	O
1-year	JJ	O
mortality	NN	O
rates	NNS	O
were	VBD	O
higher	JJR	O
for	IN	O
patients	NNS	O
with	IN	O
late	JJ	O
(	(	O
>	JJ	O
48	CD	O
hours	NNS	O
after	IN	O
enrollment	NN	O
)	)	O
versus	FW	O
early	JJ	O
arrhythmias	NN	O
(	(	O
<	CD	O
or	CC	O
=48	VB	O
hours	NNS	O
after	IN	O
enrollment	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
thrombolysis	NN	O
,	,	O
inhospital	JJ	O
ventricular	NN	O
arrhythmias	NNS	O
are	VBP	O
associated	VBN	O
with	IN	O
higher	JJR	O
30-day	JJ	O
and	CC	O
1-year	JJ	O
mortality	NN	O
rates	NNS	O
after	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
particularly	RB	O
when	WRB	O
occurring	VBG	O
later	RB	O
during	IN	O
the	DT	O
initial	JJ	O
hospitalization	NN	O
.	.	O

Better	JJR	O
therapies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
improve	VB	O
outcomes	NNS	O
of	IN	O
these	DT	O
arrhythmias	NNS	O
.	.	O

A	DT	O
cognitive-behavioral	JJ	Educational
intervention	NN	Educational
for	IN	O
emotion	NN	O
regulation	NN	O
in	IN	O
adults	NNS	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
study	NN	O
protocol	NN	O
for	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Adults	NNP	O
with	IN	O
high-functioning	JJ	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
have	VBP	O
difficulties	NNS	O
in	IN	O
social	JJ	O
communication	NN	O
;	:	O
thus	RB	O
,	,	O
these	DT	O
individuals	NNS	O
have	VBP	O
trouble	NN	O
understanding	VBG	O
the	DT	O
mental	JJ	O
states	NNS	O
of	IN	O
others	NNS	O
.	.	O

Recent	JJ	O
research	NN	O
also	RB	O
suggests	VBZ	O
that	IN	O
adults	NNS	O
with	IN	O
ASD	NNP	O
are	VBP	O
unable	JJ	O
to	TO	O
understand	VB	O
their	PRP$	O
own	JJ	O
mental	JJ	O
states	NNS	O
,	,	O
which	WDT	O
could	MD	O
lead	VB	O
to	TO	O
difficulties	NNS	O
in	IN	O
emotion-regulation	NN	O
.	.	O

Some	DT	O
studies	NNS	O
have	VBP	O
reported	VBN	O
the	DT	O
efficacy	NN	O
of	IN	O
cognitive-behavioral	JJ	Psychological
therapy	NN	Psychological
(	(	Psychological
CBT	NNP	Psychological
)	)	Psychological
in	IN	O
improving	VBG	O
emotion-regulation	NN	O
among	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
will	MD	O
investigate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
group-based	JJ	O
CBT	NNP	O
for	IN	O
adults	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

METHODS/DESIGN	NNP	O
The	DT	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
,	,	O
waitlist	NN	O
controlled	VBD	O
,	,	O
single-blinded	JJ	O
trial	NN	O
.	.	O

The	DT	O
participants	NNS	O
will	MD	O
be	VB	O
60	CD	O
adults	NNS	O
with	IN	O
ASD	NNP	O
;	:	O
30	CD	O
will	MD	O
be	VB	O
assigned	VBN	O
to	TO	O
a	DT	O
CBT	NNP	Educational
group	NN	O
and	CC	O
30	CD	O
to	TO	O
a	DT	O
waitlist	NN	Control
control	NN	Control
group	NN	Control
.	.	O

Primary	NNP	O
outcome	JJ	O
measures	NNS	O
are	VBP	O
the	DT	O
20-item	JJ	O
Toronto	NNP	O
Alexithymia	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
Coping	NNP	O
Inventory	NNP	O
for	IN	O
Stressful	NNP	O
Situations	NNP	O
,	,	O
the	DT	O
Motion	NNP	O
Picture	NNP	O
Mind-Reading	NNP	O
task	NN	O
,	,	O
and	CC	O
an	DT	O
ASD	NNP	O
questionnaire	NN	O
.	.	O

The	DT	O
secondary	JJ	O
outcome	NN	O
measures	NNS	O
are	VBP	O
the	DT	O
Center	NNP	O
for	IN	O
Epidemiological	NNP	O
Studies	NNPS	O
Depression	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
Scale	NNP	O
26-item	JJ	O
version	NN	O
,	,	O
the	DT	O
Global	NNP	O
Assessment	NNP	O
of	IN	O
Functioning	NNP	O
,	,	O
State-trait	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
,	,	O
Social	NNP	O
Phobia	NNP	O
and	CC	O
Anxiety	NNP	O
Inventory	NNP	O
,	,	O
and	CC	O
Liebowitz	NNP	O
Social	NNP	O
Anxiety	NNP	O
Scale	NNP	O
.	.	O

All	DT	O
will	MD	O
be	VB	O
administered	VBN	O
during	IN	O
the	DT	O
pre-	JJ	O
and	CC	O
post-intervention	NN	O
,	,	O
and	CC	O
12	CD	O
week	NN	O
follow-up	JJ	O
periods	NNS	O
.	.	O

The	DT	O
CBT	NNP	O
group	NN	O
will	MD	O
receive	VB	O
group	NN	O
therapy	NN	O
over	IN	O
an	DT	O
8	CD	O
week	NN	O
period	NN	O
(	(	O
one	CD	O
session	NN	O
per	IN	O
week	NN	O
)	)	O
with	IN	O
each	DT	O
session	NN	O
lasting	VBG	O
approximately	RB	O
100	CD	O
minutes	NNS	O
.	.	O

Group	NNP	O
therapy	NN	O
will	MD	O
consist	VB	O
of	IN	O
four	CD	O
or	CC	O
five	CD	O
adults	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
two	CD	O
psychologists	NNS	O
.	.	O

We	PRP	O
will	MD	O
be	VB	O
using	VBG	O
visual	JJ	O
materials	NNS	O
for	IN	O
this	DT	O
program	NN	O
,	,	O
mainly	RB	O
the	DT	O
Cognitive	NNP	O
Affective	NNP	O
Training	NNP	O
kit	NN	O
.	.	O

DISCUSSION	NNP	O
This	DT	O
trial	NN	O
will	MD	O
hopefully	RB	O
indicate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
group-based	JJ	O
CBT	NNP	O
for	IN	O
adults	NNS	O
with	IN	O
high-	JJ	O
functioning	NN	O
ASD	NNP	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
This	DT	O
trial	NN	O
was	VBD	O
registered	VBN	O
in	IN	O
The	DT	O
University	NNP	O
Hospital	NNP	O
Medical	NNP	O
Information	NNP	O
Network	NNP	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
No	NNP	O
.	.	O

UMIN000006236	NNP	O
.	.	O

A	DT	O
randomized	VBN	O
,	,	O
phase	VB	O
II	NNP	O
trial	NN	O
of	IN	O
two	CD	O
dose	JJ	O
schedules	NNS	O
of	IN	O
carboplatin/paclitaxel/cetuximab	NN	Pharmacological
in	IN	O
stage	NN	O
IIIB/IV	NNP	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

BACKGROUND	VB	O
This	DT	O
trial	NN	O
investigated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
weekly	JJ	O
cetuximab	NN	Pharmacological
combined	VBN	Pharmacological
with	IN	Pharmacological
two	CD	Pharmacological
different	JJ	Pharmacological
schedules	NNS	Pharmacological
of	IN	Pharmacological
paclitaxel/carboplatin	NN	Pharmacological
for	IN	O
stage	NN	O
IIIB/IV	NNP	O
non-small-cell	JJ	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
.	.	O

METHODS	CC	O
A	DT	O
total	NN	O
of	IN	O
168	CD	O
patients	NNS	O
with	IN	O
previously	RB	O
untreated	VBN	O
stage	NN	O
IIIB/IV	NNP	O
NSCLC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
arm	VB	O
A	NNP	O
,	,	O
cetuximab	NN	Pharmacological
(	(	O
400	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
day	NN	O
1	CD	O
followed	VBN	O
by	IN	O
weekly	JJ	O
250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
+	FW	O
paclitaxel	NN	Pharmacological
(	(	O
Taxol	NNP	O
)	)	O
(	(	O
225	CD	O
mg/m	NN	Pharmacological
(	(	Pharmacological
2	CD	Pharmacological
)	)	Pharmacological
)	)	Pharmacological
/carboplatin	NN	Pharmacological
(	(	Pharmacological
AUC6	NNP	Pharmacological
)	)	Pharmacological
day	NN	O
1	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
or	CC	O
arm	NN	O
B	NNP	O
,	,	O
same	JJ	O
cetuximab	NN	Pharmacological
regimen	NNS	Pharmacological
plus	CC	Pharmacological
paclitaxel	NN	Pharmacological
(	(	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
days	NNS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
every	DT	O
3	CD	O
weeks	NNS	O
and	CC	Pharmacological
carboplatin	NN	Pharmacological
(	(	O
AUC6	NNP	O
)	)	O
day	NN	O
1	CD	O
every	DT	O
4	CD	O
weeks	NNS	O
.	.	O

Treatment	NNP	O
continued	VBD	O
for	IN	O
a	DT	O
four-cycle	JJ	O
maximum	NN	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
complete	JJ	O
response	NN	O
,	,	O
partial	JJ	O
response	NN	O
,	,	O
or	CC	O
stable	JJ	O
disease	NN	O
after	IN	O
four	CD	O
cycles	NNS	O
could	MD	O
receive	VB	O
cetuximab	NN	Pharmacological
250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/week	NN	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
progression-free	JJ	O
survival	NN	O
(	(	O
PFS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Median	JJ	O
PFS	NNP	O
was	VBD	O
4.7	CD	O
and	CC	O
4.3	CD	O
months	NNS	O
for	IN	O
arms	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
(	(	O
6-month	JJ	O
PFS	NNP	O
,	,	O
27.3	CD	O
%	NN	O
versus	IN	O
30.9	CD	O
%	NN	O
)	)	O
.	.	O

Median	JJ	O
overall	JJ	O
survival	NN	O
was	VBD	O
11.4	CD	O
versus	NN	O
9.8	CD	O
months	NNS	O
for	IN	O
arms	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
,	,	O
respectively	RB	O
;	:	O
estimated	VBN	O
1-year	JJ	O
survival	NN	O
,	,	O
47.7	CD	O
%	NN	O
versus	IN	O
39.3	CD	O
%	NN	O
;	:	O
and	CC	O
objective	JJ	O
response	NN	O
rate	NN	O
,	,	O
29.6	CD	O
%	NN	O
versus	IN	O
25	CD	O
%	NN	O
.	.	O

The	DT	O
regimen	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
rash	NN	O
and	CC	O
hematologic	JJ	O
toxicity	NN	O
being	VBG	O
most	RBS	O
common	JJ	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
did	VBD	O
not	RB	O
meet	VB	O
the	DT	O
prespecified	JJ	O
benchmark	NN	O
of	IN	O
35	CD	O
%	NN	O
6-month	JJ	O
PFS	NNP	O
rate	NN	O
;	:	O
both	DT	O
combination	NN	O
schedules	NNS	O
of	IN	O
cetuximab	NN	Pharmacological
plus	CC	Pharmacological
paclitaxel/carboplatin	NN	Pharmacological
were	VBD	O
feasible	JJ	O
and	CC	O
equivalent	JJ	O
for	IN	O
treating	VBG	O
advanced	JJ	O
NSCLC	NNP	O
.	.	O

Double-blind	NNP	O
comparison	NN	O
of	IN	O
ketazolam	NN	Pharmacological
,	,	O
diazepam	NN	Pharmacological
and	CC	O
placebo	NN	Control
in	IN	O
once-a-day	JJ	O
vs	NN	O
t.i.d	NN	O
.	.	O

dosing	VBG	O
.	.	O

Comparison	NNP	O
of	IN	O
ketazolam	NNP	Pharmacological
given	VBN	O
once-a-day	JJ	O
with	IN	O
diazepam	NN	Pharmacological
given	VBN	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
and	CC	O
placebo	VB	Control
given	VBN	O
either	DT	O
once	RB	O
or	CC	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
in	IN	O
101	CD	O
anxious	JJ	O
outpatients	NNS	O
showed	VBD	O
ketazolam	NNS	O
to	TO	O
be	VB	O
significantly	RB	O
better	JJR	O
than	IN	O
placebo	NN	O
in	IN	O
alleviating	VBG	O
the	DT	O
symptoms	NNS	O
of	IN	O
anxiety	NN	O
and	CC	O
,	,	O
on	IN	O
several	JJ	O
measures	NNS	O
of	IN	O
efficacy	NN	O
,	,	O
better	JJR	O
than	IN	O
diazepam	NN	O
as	IN	O
well	RB	O
.	.	O

Significantly	RB	O
fewer	JJR	O
patients	NNS	O
on	IN	O
ketazolam	NN	Pharmacological
dropped	VBD	O
out	IN	O
of	IN	O
the	DT	O
study	NN	O
due	JJ	O
to	TO	O
ineffective	JJ	O
medication	NN	O
than	IN	O
on	IN	O
the	DT	O
other	JJ	O
3	CD	O
treatments	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
was	VBD	O
lowest	JJS	O
in	IN	O
the	DT	O
ketazolam	NN	O
group	NN	O
.	.	O

Of	IN	O
particular	JJ	O
note	NN	O
,	,	O
drowsiness	NN	O
was	VBD	O
reported	VBN	O
twice	RB	O
as	RB	O
often	RB	O
by	IN	O
diazepam	JJ	Pharmacological
patients	NNS	O
as	IN	O
by	IN	O
ketazolam	NN	Pharmacological
patients	NNS	O
.	.	O

Oral	NNP	O
amoxicillin	NN	Pharmacological
vs.	FW	O
oral	JJ	O
erythromycin	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pyoderma	NN	O
in	IN	O
Bamako	NNP	O
,	,	O
Mali	NNP	O
:	:	O
an	DT	O
open	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Pyoderma	NNP	O
(	(	O
bacterial	JJ	O
superficial	NN	O
skin	NN	O
infection	NN	O
)	)	O
is	VBZ	O
an	DT	O
extremely	RB	O
common	JJ	O
disorder	NN	O
in	IN	O
tropical	JJ	O
developing	VBG	O
countries	NNS	O
.	.	O

In	IN	O
these	DT	O
settings	NNS	O
,	,	O
Streptococcus	NNP	O
pyogenes	NNS	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
the	DT	O
main	JJ	O
etiological	JJ	O
agent	NN	O
.	.	O

Apart	RB	O
from	IN	O
epidemics	NNS	O
of	IN	O
poststreptococcal	JJ	O
glomerulonephritis	NN	O
where	WRB	O
mass	NN	O
treatment	NN	O
with	IN	O
intramuscular	JJ	O
benzathine-penicillin	NN	Pharmacological
is	VBZ	O
recommended	VBN	O
,	,	O
no	DT	O
recommendation	NN	O
exists	VBZ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pyoderma	NN	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
oral	JJ	O
amoxicillin	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
pyoderma	NN	O
in	IN	O
Mali	NNP	O
,	,	O
by	IN	O
comparison	NN	O
with	IN	O
oral	JJ	O
erythromycin	NN	Pharmacological
.	.	Pharmacological

METHODS	NNP	O
In	IN	O
Bamako	NNP	O
,	,	O
132	CD	O
patients	NNS	O
with	IN	O
pyoderma	NN	O
,	,	O
diagnosed	VBN	O
and	CC	O
graded	VBN	O
as	IN	O
severe	JJ	O
on	IN	O
clinical	JJ	O
grounds	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
oral	JJ	O
treatment	NN	O
by	IN	O
either	DT	O
amoxicillin	NN	Pharmacological
(	(	O
50	CD	O
mg/kg	NNS	O
per	IN	O
day	NN	O
)	)	O
or	CC	O
erythromycin	$	Pharmacological
;	:	Pharmacological
infections	NNS	O
of	IN	O
the	DT	O
follicular	JJ	O
appendage	NN	O
were	VBD	O
excluded	VBN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
topical	JJ	O
application	NN	O
of	IN	O
povidone	NN	O
iodine	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
openly	RB	O
at	IN	O
the	DT	O
seventh	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
for	IN	O
cure	NN	O
or	CC	O
marked	JJ	O
improvement	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
features	NNS	O
,	,	O
indicating	VBG	O
successful	JJ	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Three	CD	O
patients	NNS	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	JJ	O
.	.	O

Treatment	NN	O
was	VBD	O
successful	JJ	O
in	IN	O
57	CD	O
of	IN	O
64	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
amoxicillin	NN	O
vs.	FW	O
58	CD	O
of	IN	O
65	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
erythromycin	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.00	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Amoxicillin	NNP	O
was	VBD	O
as	RB	O
efficacious	JJ	O
as	IN	O
erythromycin	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
severe	JJ	O
pyoderma	NN	O
in	IN	O
Mali	NNP	O
.	.	O

Owing	VBG	O
to	TO	O
its	PRP$	O
efficacy	NN	O
,	,	O
added	VBD	O
to	TO	O
high	JJ	O
availability	NN	O
and	CC	O
low	JJ	O
cost	NN	O
,	,	O
this	DT	O
compound	NN	O
should	MD	O
be	VB	O
considered	VBN	O
a	DT	O
first-line	JJ	O
treatment	NN	O
of	IN	O
this	DT	O
disorder	NN	O
in	IN	O
this	DT	O
country	NN	O
,	,	O
and	CC	O
perhaps	RB	O
in	IN	O
other	JJ	O
countries	NNS	O
where	WRB	O
this	DT	O
condition	NN	O
presents	VBZ	O
in	IN	O
a	DT	O
similar	JJ	O
way	NN	O
.	.	O

The	DT	O
course	NN	O
of	IN	O
depression	NN	O
in	IN	O
recent	JJ	O
onset	NN	O
rheumatoid	NN	O
arthritis	NN	O
:	:	O
the	DT	O
predictive	JJ	O
role	NN	O
of	IN	O
disability	NN	O
,	,	O
illness	JJ	O
perceptions	NNS	O
,	,	O
pain	NN	O
and	CC	O
coping	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
course	NN	O
of	IN	O
depression	NN	O
for	IN	O
patients	NNS	O
with	IN	O
recently	RB	O
diagnosed	VBN	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
and	CC	O
to	TO	O
investigate	VB	O
predictors	NNS	O
of	IN	O
depression	NN	O
.	.	O

METHODS	NNP	O
Twenty-two	JJ	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
recently	RB	O
diagnosed	VBN	O
RA	NNP	O
of	IN	O
less	JJR	O
than	IN	O
2	CD	O
years	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
a	DT	O
variety	NN	O
of	IN	O
clinical	JJ	O
outcome	NN	O
and	CC	O
process	NN	O
measures	NNS	O
on	IN	O
six	CD	O
assessment	JJ	O
occasions	NNS	O
over	IN	O
a	DT	O
21-month	JJ	O
period	NN	O
.	.	O

These	DT	O
22	CD	O
patients	NNS	O
constituted	VBD	O
the	DT	O
control	NN	Control
group	NN	Control
of	IN	O
a	DT	O
controlled	VBN	O
trial	NN	O
and	CC	O
received	VBN	O
standard	JJ	Control
outpatient	NN	Control
clinic	JJ	Control
treatment	NN	Control
during	IN	Control
follow-up	JJ	Control
.	.	O

RESULTS	JJ	O
Patients	NNPS	O
became	VBD	O
significantly	RB	O
more	RBR	O
depressed	JJ	O
over	IN	O
time	NN	O
.	.	O

A	DT	O
set	NN	O
of	IN	O
five	CD	O
factors	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
consistently	RB	O
predict	VB	O
depression	NN	O
at	IN	O
the	DT	O
following	JJ	O
assessment	NN	O
.	.	O

These	DT	O
were	VBD	O
initial	JJ	O
level	NN	O
of	IN	O
depression	NN	O
,	,	O
disability	NN	O
,	,	O
pain	NN	O
,	,	O
beliefs	VB	O
about	IN	O
the	DT	O
consequences	NNS	O
of	IN	O
arthritis	NN	O
and	CC	O
coping	VBG	O
strategies	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
confirm	VBP	O
the	DT	O
importance	NN	O
of	IN	O
psychological	JJ	O
factors	NNS	O
in	IN	O
early	JJ	O
RA	NNP	O
and	CC	O
their	PRP$	O
relative	JJ	O
independence	NN	O
from	IN	O
physical	JJ	O
findings	NNS	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
study	NN	O
to	TO	O
document	VB	O
the	DT	O
importance	NN	O
of	IN	O
illness	JJ	O
perceptions	NNS	O
in	IN	O
recent	JJ	O
onset	NN	O
RA	NNP	O
.	.	O

Home	NN	Educational
based	VBN	Educational
management	NN	Educational
in	IN	O
multiple	JJ	O
sclerosis	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Home	NNP	Educational
based	VBN	Educational
medical	JJ	Educational
care	NN	Educational
is	VBZ	O
a	DT	O
popular	JJ	O
alternative	NN	O
to	TO	O
standard	VB	O
hospital	NN	O
care	NN	O
but	CC	O
there	EX	O
is	VBZ	O
uncertainty	NN	O
about	IN	O
its	PRP$	O
cost-effectiveness	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
the	DT	O
costs	NNS	O
of	IN	O
multidisciplinary	JJ	Educational
home	NN	Educational
based	VBN	Educational
care	NN	Educational
in	IN	O
multiple	JJ	O
sclerosis	NN	O
with	IN	O
hospital	NN	O
care	NN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
with	IN	O
a	DT	O
one	CD	O
year	NN	O
follow	VB	O
up	RP	O
.	.	O

METHODS	NNP	O
201	CD	O
patients	NNS	O
with	IN	O
clinically	RB	O
definite	JJ	O
multiple	JJ	O
sclerosis	NN	O
were	VBD	O
studied	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomised	VBN	O
in	IN	O
a	DT	O
ratio	NN	O
2:1	CD	O
to	TO	O
an	DT	O
intervention	NN	O
group	NN	O
(	(	O
133	CD	O
)	)	O
or	CC	O
a	DT	O
control	NN	O
group	NN	O
(	(	O
68	CD	O
)	)	O
.	.	O

They	PRP	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
one	CD	O
year	NN	O
after	IN	O
randomisation	NN	O
with	IN	O
validated	JJ	O
measures	NNS	O
of	IN	O
physical	JJ	O
and	CC	O
psychological	JJ	O
impairment	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
SF-36	NNP	O
health	NN	O
survey	NN	O
)	)	O
.	.	O

The	DT	O
costs	NNS	O
to	TO	O
the	DT	O
National	NNP	O
Health	NNP	O
Service	NNP	O
over	IN	O
the	DT	O
one	CD	O
year	NN	O
follow	VBP	O
up	RP	O
were	VBD	O
calculated	VBN	O
by	IN	O
a	DT	O
cost	NN	O
minimisation	NN	O
analysis	NN	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
functional	JJ	O
status	NN	O
between	IN	O
the	DT	O
home	NN	O
based	VBN	O
care	NN	O
group	NN	O
and	CC	O
the	DT	O
hospital	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
favouring	VBG	O
home	NN	O
based	VBN	O
management	NN	O
in	IN	O
four	CD	O
SF-36	JJ	O
health	NN	O
dimensions-general	JJ	O
health	NN	O
,	,	O
bodily	RB	O
pain	NN	O
,	,	O
role-emotional	JJ	O
,	,	O
and	CC	O
social	JJ	O
functioning	NN	O
(	(	O
all	DT	O
p	VBP	O
<	CD	O
or	CC	O
=	VB	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
cost	NN	O
of	IN	O
home	NN	O
based	VBN	O
care	NN	O
was	VBD	O
slightly	RB	O
less	JJR	O
(	(	O
822	CD	O
euros/patient/year	NN	O
)	)	O
than	IN	O
hospital	NN	O
care	NN	O
,	,	O
mainly	RB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
a	DT	O
reduction	NN	O
in	IN	O
hospital	JJ	O
admissions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Comprehensive	NNP	Educational
planning	NN	Educational
of	IN	Educational
home	NN	Educational
based	VBN	Educational
intervention	NN	Educational
implemented	VBN	O
by	IN	O
an	DT	O
interdisciplinary	JJ	O
team	NN	O
and	CC	O
designed	VBN	O
specifically	RB	O
for	IN	O
people	NNS	O
with	IN	O
multiple	JJ	O
sclerosis	NN	O
may	MD	O
provide	VB	O
a	DT	O
cost-effective	JJ	O
approach	NN	O
to	TO	O
management	NN	O
and	CC	O
improve	VB	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

Modest	NNP	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
epanolol	NN	Pharmacological
,	,	O
a	DT	O
beta	NN	O
1-selective	JJ	O
receptor	NN	O
blocker	NN	O
with	IN	O
beta	NN	O
1	CD	O
agonist	NN	O
activity	NN	O
:	:	O
an	DT	O
acute	NN	O
and	CC	O
long-term	JJ	O
hemodynamic	NN	O
study	NN	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
and	CC	O
double	JJ	O
crossover	NN	O
comparison	NN	O
with	IN	O
atenolol	NN	O
on	IN	O
ambulatory	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Beta-blockers	NNS	O
with	IN	O
less	JJR	O
cardiodepressive	JJ	O
effect	NN	O
than	IN	O
traditional	JJ	O
nonselective	JJ	O
beta	NN	O
(	(	O
1+2	CD	O
)	)	O
-blocking	VBG	O
agents	NNS	O
could	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
,	,	O
provided	VBD	O
the	DT	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
was	VBD	O
satisfactory	JJ	O
.	.	O

Epanolol	NNP	Pharmacological
,	,	O
a	DT	O
selective	JJ	O
beta	NN	O
1-receptor	JJ	O
blocker	NN	O
with	IN	O
intrinsic	JJ	O
sympathomimetic	JJ	O
activity	NN	O
,	,	O
induced	VBD	O
a	DT	O
fall	NN	O
in	IN	O
intraarterial	JJ	O
pressure	NN	O
of	IN	O
8	CD	O
%	NN	O
at	IN	O
rest	NN	O
sitting	VBG	O
and	CC	O
11	CD	O
%	NN	O
during	IN	O
100	CD	O
W	NNP	O
bicycle	NN	O
exercise	NN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
,	,	O
stroke	VBD	O
index	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
index	NN	O
initially	RB	O
fell	VBD	O
by	IN	O
14	CD	O
%	NN	O
,	,	O
11	CD	O
%	NN	O
,	,	O
and	CC	O
23	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
total	JJ	O
peripheral	JJ	O
resistance	NN	O
index	NN	O
increased	VBD	O
by	IN	O
21	CD	O
%	NN	O
after	IN	O
2	CD	O
hours	NNS	O
,	,	O
and	CC	O
then	RB	O
reverted	VBD	O
towards	IN	O
the	DT	O
pretreatment	NN	O
level	NN	O
.	.	O

After	IN	O
10	CD	O
months	NNS	O
of	IN	O
epanolol	JJ	Pharmacological
treatment	NN	O
(	(	O
mean	JJ	O
300	CD	O
mg/day	NN	O
)	)	O
,	,	O
the	DT	O
reduction	NN	O
in	IN	O
arterial	JJ	O
pressure	NN	O
was	VBD	O
5	CD	O
%	NN	O
at	IN	O
rest	NN	O
and	CC	O
10	CD	O
%	NN	O
during	IN	O
exercise	NN	O
.	.	O

Cardiac	NNP	O
index	NN	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
still	RB	O
reduced	VBN	O
14-21	CD	O
%	NN	O
,	,	O
while	IN	O
total	JJ	O
peripheral	JJ	O
resistance	NN	O
was	VBD	O
unchanged	JJ	O
or	CC	O
slightly	RB	O
increased	VBN	O
(	(	O
2-10	CD	O
%	NN	O
)	)	O
.	.	O

Twenty-four	JJ	O
hour	NN	O
ambulatory	NN	O
blood	NN	O
pressure	NN	O
was	VBD	O
higher	JJR	O
on	IN	O
epanolol	NN	Pharmacological
(	(	O
300	CD	O
mg/day	NN	O
)	)	O
than	IN	O
on	IN	O
atenolol	NN	Pharmacological
(	(	O
150	CD	O
mg/day	NN	O
)	)	O
treatment	NN	O
(	(	O
137/97	CD	O
vs.	FW	O
128/91	CD	O
mmHg	NN	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
achieved	VBN	O
blood	NN	O
pressure	NN	O
reduction	NN	O
induced	VBN	O
by	IN	O
epanolol	NN	Pharmacological
was	VBD	O
moderate	JJ	O
,	,	O
while	IN	O
other	JJ	O
characteristics	NNS	O
of	IN	O
beta-receptor	NN	O
blockade	NN	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
heart	NN	O
rate	NN	O
and	CC	O
cardiac	JJ	O
output	NN	O
,	,	O
were	VBD	O
maintained	VBN	O
.	.	O

This	DT	O
suggests	VBZ	O
that	IN	O
the	DT	O
compound	NN	O
may	MD	O
be	VB	O
useful	JJ	O
for	IN	O
other	JJ	O
cardiovascular	JJ	O
disorders	NNS	O
,	,	O
e.g.	NN	O
,	,	O
angina	JJ	O
pectoris	NN	O
in	IN	O
patients	NNS	O
without	IN	O
hypertension	NN	O
or	CC	O
cardiac	JJ	O
arrhythmia	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
nonhandicapped	JJ	Educational
peers	NNS	Educational
on	IN	O
the	DT	O
social	JJ	O
interactions	NNS	O
of	IN	O
children	NNS	O
with	IN	O
a	DT	O
pervasive	JJ	O
development	NN	O
disorder	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
whether	IN	O
or	CC	O
not	RB	O
children	NNS	O
with	IN	O
autism	NN	O
or	CC	O
a	DT	O
related	JJ	O
pervasive	JJ	O
developmental	NN	O
disorder	NN	O
(	(	O
PDD	NNP	O
)	)	O
can	MD	O
benefit	VB	O
from	IN	O
regular	JJ	Educational
opportunities	NNS	Educational
to	TO	Educational
interact	VB	Educational
with	IN	Educational
a	DT	Educational
normally	RB	Educational
developing	VBG	Educational
peer	NN	Educational
,	,	O
matched	VBD	O
as	IN	O
to	TO	O
sex	NN	O
and	CC	O
age	NN	O
.	.	O

An	DT	O
experimental	JJ	O
design	NN	O
with	IN	O
random	JJ	O
assignment	NN	O
of	IN	O
subjects	NNS	O
to	TO	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
demonstrate	VB	O
the	DT	O
impact	NN	O
of	IN	O
this	DT	O
peer-mediated	JJ	Educational
intervention	NN	Educational
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
group	NN	O
,	,	O
we	PRP	O
found	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
social	JJ	O
behavior	NN	O
of	IN	O
the	DT	O
children	NNS	O
with	IN	O
PDD	NNP	O
.	.	O

Several	JJ	O
gains	NNS	O
were	VBD	O
also	RB	O
generalized	VBN	O
to	TO	O
interactions	NNS	O
with	IN	O
an	DT	O
unfamiliar	JJ	O
nonhandicapped	JJ	O
peer	NN	O
,	,	O
to	TO	O
interactions	NNS	O
with	IN	O
another	DT	O
child	NN	O
with	IN	O
PDD	NNP	O
,	,	O
and	CC	O
to	TO	O
the	DT	O
large	JJ	O
school	NN	O
setting	VBG	O
.	.	O

In	IN	O
the	DT	O
untreated	JJ	O
control	NN	O
group	NN	O
,	,	O
no	DT	O
positive	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Results	VB	O
suggest	JJS	O
that	IN	O
children	NNS	O
with	IN	O
PDD	NNP	O
can	MD	O
develop	VB	O
peer	JJ	O
relations	NNS	O
if	IN	O
appropriate	JJ	O
social	JJ	O
contexts	NN	O
are	VBP	O
made	VBN	O
available	JJ	O
for	IN	O
them	PRP	O
.	.	O

Phase	NNP	O
II	NNP	O
trial	NN	O
of	IN	O
nab-paclitaxel	JJ	O
compared	VBN	O
with	IN	O
docetaxel	NN	Pharmacological
as	IN	O
first-line	JJ	O
chemotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
final	JJ	O
analysis	NN	O
of	IN	O
overall	JJ	O
survival	NN	O
.	.	O

BACKGROUND	VB	O
A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
in	IN	O
first-line	JJ	O
MBC	NNP	O
demonstrated	VBD	O
superior	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
weekly	JJ	O
nab-paclitaxel	NNS	O
compared	VBN	O
with	IN	O
docetaxel	NN	Pharmacological
.	.	Physical

Final	NNP	O
survival	NN	O
analyses	NNS	O
and	CC	O
updated	JJ	O
safety	NN	O
results	NNS	O
are	VBP	O
reported	VBN	O
.	.	O

PATIENTS	NNS	O
AND	CC	O
METHODS	NNP	O
Three	NNP	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
no	DT	O
previous	JJ	O
chemotherapy	NN	O
for	IN	O
MBC	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
nab-paclitaxel	JJ	Pharmacological
300	CD	Pharmacological
mg/m	NN	Pharmacological
(	(	Pharmacological
2	CD	Pharmacological
)	)	Pharmacological
q3w	NN	O
,	,	O
nab-paclitaxel	JJ	Pharmacological
100	CD	Pharmacological
mg/m	NN	Pharmacological
(	(	Pharmacological
2	CD	Pharmacological
)	)	Pharmacological
or	CC	O
150	CD	Pharmacological
mg/m	NN	Pharmacological
(	(	Pharmacological
2	CD	Pharmacological
)	)	Pharmacological
the	DT	O
first	JJ	O
3	CD	O
of	IN	O
4	CD	O
weeks	NNS	O
(	(	O
qw	VB	O
3/4	CD	O
)	)	O
,	,	O
or	CC	O
docetaxel	VB	Pharmacological
100	CD	Pharmacological
mg/m	NN	Pharmacological
(	(	Pharmacological
2	CD	Pharmacological
)	)	Pharmacological
q3w	NN	O
.	.	O

The	DT	O
trial	NN	O
was	VBD	O
powered	VBN	O
for	IN	O
analyses	NNS	O
of	IN	O
antitumor	NN	O
activity	NN	O
and	CC	O
safety	NN	O
.	.	O

RESULTS	NNP	O
Treatment	NNP	O
with	IN	O
nab-paclitaxel	JJ	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
qw	NN	O
3/4	CD	O
resulted	VBD	O
in	IN	O
a	DT	O
median	JJ	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
of	IN	O
33.8	CD	O
months	NNS	O
compared	VBN	O
with	IN	O
22.2	CD	O
,	,	O
27.7	CD	O
,	,	O
and	CC	O
26.6	CD	O
months	NNS	O
for	IN	O
nab-paclitaxel	JJ	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
qw	NN	O
3/4	CD	O
,	,	O
nab-paclitaxel	JJ	O
300	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
q3w	NN	O
,	,	O
and	CC	O
docetaxel	NN	Pharmacological
,	,	O
respectively	RB	O
(	(	O
overall	JJ	O
P	NNP	O
=	NNP	O
.047	NNP	O
)	)	O
.	.	O

Patients	NNPS	O
receiving	VBG	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
nab-paclitaxel	NN	O
had	VBD	O
prolonged	VBN	O
median	JJ	O
OS	NNP	O
compared	VBN	O
with	IN	O
those	DT	O
in	IN	O
the	DT	O
100	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
nab-paclitaxel	JJ	O
arm	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.575	CD	O
;	:	O
P	NNP	O
=	NNP	O
.008	NNP	O
)	)	O
.	.	O

A	DT	O
trend	NN	O
toward	IN	O
a	DT	O
longer	JJR	O
OS	NNP	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
nab-paclitaxel	JJ	O
arm	NN	O
versus	NN	O
docetaxel	NN	O
arm	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
,	,	O
0.688	CD	O
)	)	O
.	.	O

Grade	$	O
3	CD	O
or	CC	O
4	CD	O
fatigue	NN	O
,	,	O
neutropenia	NN	O
,	,	O
and	CC	O
febrile	JJ	O
neutropenia	NN	O
were	VBD	O
less	JJR	O
frequent	JJ	O
in	IN	O
all	DT	O
nab-paclitaxel	JJ	O
arms	NNS	O
compared	VBN	O
with	IN	O
docetaxel	NN	Pharmacological
.	.	O

CONCLUSIONS	NNP	O
Consistent	NNP	O
with	IN	O
previously	RB	O
published	VBN	O
efficacy	NN	O
results	NNS	O
,	,	O
these	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
qw	NN	O
3/4	CD	O
may	MD	O
represent	VB	O
the	DT	O
most	RBS	O
clinically	RB	O
efficacious	JJ	O
nab-paclitaxel	JJ	O
dosing	VBG	O
regimen	NNS	O
for	IN	O
patients	NNS	O
with	IN	O
no	DT	O
previous	JJ	O
chemotherapy	NN	O
for	IN	O
MBC	NNP	O
.	.	O

A	DT	O
phase	NN	O
III	NNP	O
trial	NN	O
confirming	VBG	O
these	DT	O
results	NNS	O
would	MD	O
be	VB	O
necessary	JJ	O
and	CC	O
prudent	JJ	O
before	RB	O
widespread	JJ	O
adoption	NN	O
of	IN	O
the	DT	O
150	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
dose	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

Ten-year	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomised	JJ	O
trial	NN	O
comparing	VBG	O
cisplatin	NN	Pharmacological
with	IN	Pharmacological
cisplatin	NN	Pharmacological
and	CC	Pharmacological
cyclophosphamide	NN	Pharmacological
in	IN	O
advanced	JJ	O
,	,	O
suboptimally	RB	O
debulked	JJ	O
ovarian	JJ	O
cancer	NN	O
.	.	O

176	CD	O
eligible	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
suboptimally	RB	O
operated	JJ	O
ovarian	JJ	O
carcinoma	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
either	DT	O
cisplatin	NN	Pharmacological
75	CD	Pharmacological
mg/m2	NN	Pharmacological
or	CC	Pharmacological
cisplatin	NN	Pharmacological
50	CD	Pharmacological
mg/m2	NN	Pharmacological
and	CC	Pharmacological
cyclophosphamide	VB	Pharmacological
500	CD	Pharmacological
mg/m2	NN	Pharmacological
(	(	O
CP	NNP	O
)	)	O
every	DT	O
28	CD	O
days	NNS	O
for	IN	O
six	CD	O
courses	NNS	O
.	.	O

The	DT	O
overall	JJ	O
clinical	JJ	O
response	NN	O
rates	NNS	O
(	(	O
complete	JJ	O
response	NN	O
plus	CC	O
partial	JJ	O
response	NN	O
)	)	O
were	VBD	O
52	CD	O
and	CC	O
63	CD	O
%	NN	O
for	IN	O
CP	NNP	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
,	,	O
respectively	RB	O
(	(	O
non-significant	JJ	O
)	)	O
.	.	O

Including	VBG	O
results	NNS	O
obtained	VBN	O
by	IN	O
second-look	JJ	O
laparotomy	NN	O
,	,	O
we	PRP	O
did	VBD	O
not	RB	O
observe	VB	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
response	NN	O
rates	NNS	O
in	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

Median	JJ	O
progression-free	JJ	O
survival	NN	O
was	VBD	O
10	CD	O
and	CC	O
11.9	CD	O
months	NNS	O
for	IN	O
CP	NNP	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
,	,	O
respectively	RB	O
(	(	O
non-significant	JJ	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
overall	JJ	O
survival	NN	O
,	,	O
with	IN	O
a	DT	O
median	NN	O
of	IN	O
19.4	CD	O
and	CC	O
21.5	CD	O
months	NNS	O
for	IN	O
CP	NNP	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

Thirty-seven	JJ	O
platinum-resistant	JJ	O
and	CC	O
27	CD	O
platinum-sensitive	JJ	O
tumours	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
carboplatin	NN	Pharmacological
or	CC	Pharmacological
cisplatin	NN	Pharmacological
as	IN	O
second-line	JJ	O
therapy	NN	O
.	.	O

Response	JJ	O
rates	NNS	O
to	TO	O
platinum	VB	O
second-line	JJ	O
therapy	NN	O
were	VBD	O
6	CD	O
and	CC	O
50	CD	O
%	NN	O
for	IN	O
resistant	NN	O
and	CC	O
sensitive	JJ	O
tumours	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

This	DT	O
difference	NN	O
in	IN	O
response	NN	O
rate	NN	O
was	VBD	O
also	RB	O
confirmed	VBN	O
by	IN	O
survival	NN	O
analysis	NN	O
.	.	O

Patients	NNS	O
with	IN	O
platinum-sensitive	JJ	O
tumours	NNS	O
survived	VBD	O
longer	RBR	O
when	WRB	O
they	PRP	O
were	VBD	O
treated	VBN	O
with	IN	O
platinum-containing	JJ	Pharmacological
chemotherapy	NN	Pharmacological
(	(	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Median	JJ	O
survival	NN	O
was	VBD	O
22.8	CD	O
and	CC	O
8.5	CD	O
months	NNS	O
after	IN	O
initiation	NN	O
of	IN	O
second-line	JJ	O
treatment	NN	O
for	IN	O
the	DT	O
platinum-containing	JJ	Pharmacological
and	CC	O
platinum-free	JJ	Pharmacological
regimens	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
summary	JJ	O
,	,	O
we	PRP	O
observed	VBD	O
in	IN	O
suboptimally	RB	O
operated	JJ	O
ovarian	JJ	O
carcinoma	NN	O
patients	NNS	O
similar	JJ	O
response	NN	O
rates	NNS	O
,	,	O
progression-free	JJ	O
interval	NN	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
for	IN	O
equitoxic	JJ	O
cisplatin	NN	Pharmacological
and	CC	Pharmacological
CP	NNP	Pharmacological
.	.	Pharmacological

However	RB	O
,	,	O
the	DT	O
doses	NNS	O
of	IN	O
cisplatin	NN	Pharmacological
and	CC	Pharmacological
cyclophosphamide	NN	Pharmacological
chosen	NNS	O
were	VBD	O
substantially	RB	O
lower	JJR	O
than	IN	O
current	JJ	O
standard	JJ	O
doses	NNS	O
of	IN	O
CP	NNP	O
.	.	O

Our	PRP$	O
study	NN	O
demonstrates	VBZ	O
,	,	O
therefore	RB	O
,	,	O
that	IN	O
a	DT	O
suboptimal	JJ	O
dose	NN	O
of	IN	O
CP	NNP	Pharmacological
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
optimal	JJ	O
dose	JJ	O
monotherapy	NN	O
cisplatin	NN	Pharmacological
.	.	Pharmacological

Patients	NNS	O
with	IN	O
recurrences	NNS	O
considered	VBN	O
as	IN	O
platinum-sensitive	JJ	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
response	NN	O
rate	NN	O
and	CC	O
improved	VBN	O
survival	NN	O
when	WRB	O
retreated	VBN	O
with	IN	O
platinum-containing	JJ	Physical
therapy	NN	Physical
.	.	O

Involvement	NN	O
of	IN	O
cholecystokininA	NN	O
receptors	NNS	O
in	IN	O
transient	NN	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
relaxations	NNS	O
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

OBJECTIVE	CC	O
Transient	NNP	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
relaxations	NNS	O
(	(	O
TLESRs	NNP	O
)	)	O
are	VBP	O
the	DT	O
main	JJ	O
mechanism	NN	O
underlying	VBG	O
gastroesophageal	JJ	O
reflux	NN	O
.	.	O

In	IN	O
the	DT	O
present	JJ	O
study	NN	O
we	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
loxiglumide	NN	O
,	,	O
a	DT	O
specific	JJ	O
cholecystokininA	NN	O
(	(	O
CCKA	NNP	O
)	)	O
-receptor	NN	O
antagonist	NN	O
,	,	O
on	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
TLESRs	NNP	O
evoked	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
.	.	O

METHODS	NNP	O
Eight	NNP	O
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
esophageal	JJ	O
manometry	NN	O
using	VBG	O
a	DT	O
10-lumen	JJ	Physical
sleeve	NN	Physical
assembly	NN	Physical
during	IN	Physical
placebo	NN	Physical
or	CC	O
loxiglumide	NN	Pharmacological
(	(	O
10	CD	O
mg/kg/h	NN	O
)	)	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
order	NN	O
.	.	O

Gastric	NNP	O
distension	NN	O
was	VBD	O
induced	VBN	O
by	IN	O
inflation	NN	O
of	IN	O
400	CD	O
ml	NN	O
of	IN	O
air	NN	O
.	.	O

RESULTS	VB	O
Basal	NNP	O
lower	JJR	O
esophageal	NN	O
pressure	NN	O
(	(	O
LESP	NNP	O
)	)	O
and	CC	O
swallow-induced	JJ	O
relaxation	NN	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
loxiglumide	NN	O
.	.	O

Loxiglumide	NNP	O
significantly	RB	O
reduced	VBD	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	O
,	,	O
from	IN	O
11.5	CD	O
(	(	O
5.8-18.3	JJ	O
)	)	O
to	TO	O
6.0	CD	O
(	(	O
3.3-14.3	JJ	O
)	)	O
during	IN	O
the	DT	O
total	JJ	O
recording	JJ	O
period	NN	O
of	IN	O
1	CD	O
h	NN	O
,	,	O
and	CC	O
from	IN	O
5.5	CD	O
(	(	O
4.25-7.5	JJ	O
)	)	O
to	TO	O
2.0	CD	O
(	(	O
0.5-6.8	JJ	O
)	)	O
during	IN	O
the	DT	O
first	JJ	O
15	CD	O
min	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
common	JJ	O
cavities	NNS	O
was	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
loxiglumide	NN	O
,	,	O
from	IN	O
8.0	CD	O
(	(	O
4.0-20.0	JJ	O
)	)	O
to	TO	O
5.0	CD	O
(	(	O
2.0-7.8	JJ	O
)	)	O
.	.	O

TLESRs	NNP	O
represented	VBD	O
the	DT	O
main	JJ	O
mechanism	NN	O
(	(	O
60	CD	O
%	NN	O
during	IN	O
placebo	NN	O
,	,	O
74	CD	O
%	NN	O
during	IN	O
loxiglumide	NN	O
)	)	O
underlying	VBG	O
common	JJ	O
cavities	NNS	O
,	,	O
followed	VBN	O
by	IN	O
swallow-induced	JJ	O
relaxation	NN	O
.	.	O

CONCLUSIONS	NNP	O
Loxiglumide	NNP	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
number	NN	O
of	IN	O
TLESRs	NNP	O
triggered	VBN	O
by	IN	O
gastric	JJ	O
distension	NN	O
without	IN	O
interfering	VBG	O
with	IN	O
swallow-related	JJ	O
relaxation	NN	O
of	IN	O
the	DT	O
lower	JJR	O
esophageal	NN	O
sphincter	NN	O
,	,	O
suggesting	VBG	O
the	DT	O
involvement	NN	O
of	IN	O
CCKA	NNP	O
receptors	NNS	O
in	IN	O
the	DT	O
reflex	JJ	O
pathway	NN	O
mediating	VBG	O
TLESRs	NNP	O
.	.	O

Dose	NNP	O
dependent	JJ	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	Pharmacological
:	:	Pharmacological
Michaelis-Menten	JJ	O
parameters	NNS	O
for	IN	O
its	PRP$	O
major	JJ	O
metabolic	JJ	O
pathways	NNS	O
.	.	O

Dose	NNP	O
Dependency	NNP	O
for	IN	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	Pharmacological
and	CC	O
the	DT	O
formation	NN	O
of	IN	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
,	,	O
3-methylxanthine	JJ	O
(	(	O
3-MX	JJ	O
)	)	O
;	:	O
1-methyluric	JJ	O
acid	NN	O
(	(	O
1-MU	JJ	O
)	)	O
;	:	O
1,3-dimethyluric	JJ	O
acid	NN	O
(	(	O
DMU	NNP	O
)	)	O
,	,	O
were	VBD	O
examined	VBN	O
by	IN	O
administering	VBG	O
three	CD	O
single	JJ	O
oral	JJ	O
doses	NNS	O
(	(	O
250	CD	O
,	,	O
375	CD	O
,	,	O
500	CD	O
mg	NN	O
)	)	O
of	IN	O
theophylline	NN	O
to	TO	O
six	CD	O
healthy	JJ	O
adult	NN	O
volunteers	NNS	O
.	.	O

The	DT	O
serum	NN	O
and	CC	O
urine	JJ	O
concentrations	NNS	O
of	IN	O
theophylline	NN	Pharmacological
and	CC	O
the	DT	O
metabolites	NNS	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
were	VBD	O
determined	VBN	O
by	IN	O
high-performance	NN	O
liquid	NN	O
chromatography	NN	O
.	.	O

Total	JJ	O
clearance	NN	O
of	IN	O
theophylline	NN	Pharmacological
decreased	VBN	O
and	CC	O
its	PRP$	O
half	JJ	O
life	NN	O
increased	VBD	O
over	IN	O
the	DT	O
range	NN	O
of	IN	O
doses	NNS	O
administered	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
dose	NN	O
related	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
fractional	JJ	O
recovery	NN	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
a	DT	O
dose	NN	O
related	JJ	O
increase	NN	O
in	IN	O
fractional	JJ	O
excretion	NN	O
of	IN	O
DMU	NNP	O
and	CC	O
unchanged	JJ	O
theophylline	NN	O
(	(	O
p	JJ	O
<	NN	O
0.01	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.001	CD	O
respectively	RB	O
)	)	O
.	.	O

No	DT	O
significant	JJ	O
dose	NN	O
related	VBN	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
renal	JJ	O
clearance	NN	O
of	IN	O
3-MX	JJ	O
,	,	O
1-MU	JJ	O
and	CC	O
DMU	NNP	O
,	,	O
indicating	VBG	O
linear	JJ	O
urinary	JJ	O
excretion	NN	O
kinetics	NNS	O
of	IN	O
the	DT	O
metabolites	NNS	O
.	.	O

Theophylline	NNP	Pharmacological
metabolic	JJ	O
clearance	NN	O
to	TO	O
3-MX	JJ	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
1-MU	CD	O
decreased	VBN	O
with	IN	O
increasing	VBG	O
dose	NN	O
but	CC	O
clearance	NN	O
to	TO	O
DMU	NNP	O
remained	VBD	O
unnaffected	JJ	O
by	IN	O
the	DT	O
size	NN	O
of	IN	O
dose	NN	O
.	.	O

The	DT	O
individual	JJ	O
Michaelis-Menten	NNP	O
parameters	NNS	O
Km	NNP	O
and	CC	O
Vmax	NNP	O
were	VBD	O
estimated	VBN	O
for	IN	O
six	CD	O
subjects	NNS	O
receiving	VBG	O
three	CD	O
different	JJ	O
single	JJ	O
doses	NNS	O
.	.	O

The	DT	O
Km	NNP	O
values	NNS	O
for	IN	O
theophylline	JJ	Pharmacological
metabolism	NN	O
to	TO	O
3-MX	JJ	O
,	,	O
1-MU	JJ	O
and	CC	O
DMU	NNP	O
were	VBD	O
2.4+/-0.6	JJ	O
,	,	O
5.1+/-1.8+/-	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/L	NN	O
respectively	RB	O
and	CC	O
the	DT	O
Vmax	NNP	O
values	NNS	O
were	VBD	O
3.5+/-0.7	JJ	O
,	,	O
7.5+/-2.6	JJ	O
and	CC	O
112.3+/-36.8	JJ	O
mg/hr	NN	O
respectively	RB	O
.	.	O

The	DT	O
Km	NNP	O
values	NNS	O
for	IN	O
the	DT	O
N-demethylation	NNP	O
pathways	NNS	O
(	(	O
3MX	CD	O
and	CC	O
1-MU	JJ	O
)	)	O
were	VBD	O
lower	JJR	O
corresponding	VBG	O
to	TO	O
therapeutic	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
drug	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
elimination	NN	O
kinetics	NNS	O
of	IN	O
theophylline	NN	Pharmacological
is	VBZ	O
nonlinear	JJ	O
in	IN	O
the	DT	O
human	NN	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
of	IN	O
serum	JJ	O
concenntrations	NNS	O
and	CC	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
saturable	JJ	O
formation	NN	O
kinetics	NNS	O
of	IN	O
3-MX	JJ	O
and	CC	O
1-MU	JJ	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
previous	JJ	O
studies	NNS	O
we	PRP	O
did	VBD	O
n't	RB	O
find	VB	O
obvious	JJ	O
indication	NN	O
for	IN	O
nonlinear	JJ	O
formation	NN	O
of	IN	O
DMU	NNP	O
at	IN	O
therapeutic	JJ	O
concentration	NN	O
range	NN	O
.	.	O

Prospective	JJ	O
trial	NN	O
of	IN	O
timing	NN	O
of	IN	O
bacillus	NN	O
Calmette-Gu?rin	NNP	O
vaccination	NN	O
in	IN	O
Canadian	JJ	O
Cree	NNP	O
infants	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
184	CD	O
Cree	NNP	O
Indian	JJ	O
infants	NNS	O
in	IN	O
randomized	VBN	O
,	,	O
prospective	JJ	O
fashion	NN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
age	NN	O
on	IN	O
lymphocyte	JJ	O
sensitization	NN	O
to	TO	O
purified	VB	O
protein	JJ	O
derivative	JJ	O
(	(	O
PPD	NNP	O
)	)	O
before	IN	O
and	CC	O
after	IN	O
and	CC	O
without	IN	O
bacillus	JJ	O
Calmette-Gu?rin	NNP	O
(	(	O
BCG	NNP	O
)	)	O
vaccination	NN	O
.	.	O

Lymphocyte	JJ	O
responses	NNS	O
to	TO	O
PPD	NNP	O
,	,	O
Candida	NNP	O
,	,	O
and	CC	O
streptokinase	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
birth	NN	O
and	CC	O
at	IN	O
intervals	NNS	O
later	RB	O
.	.	O

The	DT	O
mean	JJ	O
response	NN	O
of	IN	O
paired	JJ	O
values	NNS	O
from	IN	O
26	CD	O
infants	NNS	O
without	IN	O
BCG	NNP	O
vaccination	NN	O
rose	VBD	O
for	IN	O
the	DT	O
PPD	NNP	O
stimulation	NN	O
index	NN	O
(	(	O
SI	NNP	O
)	)	O
from	IN	O
2.7	CD	O
at	IN	O
birth	NN	O
to	TO	O
3.9	CD	O
before	IN	O
2	CD	O
yr	NN	O
of	IN	O
age	NN	O
.	.	O

The	DT	O
SI	NNP	O
for	IN	O
both	DT	O
Candida	NNP	O
and	CC	O
streptokinase	VB	O
for	IN	O
this	DT	O
group	NN	O
of	IN	O
infants	NNS	O
rose	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
first	JJ	O
2	CD	O
yr	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
66	CD	O
infants	NNS	O
who	WP	O
received	VBD	O
BCG	NNP	O
in	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
of	IN	O
life	NN	O
,	,	O
the	DT	O
PPD-SI	NNP	O
rose	VBD	O
from	IN	O
3.1	CD	O
to	TO	O
35.3	CD	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
17	CD	O
infants	NNS	O
who	WP	O
received	VBD	O
the	DT	O
vaccine	NN	O
later	RB	O
but	CC	O
before	IN	O
9	CD	O
months	NNS	O
,	,	O
it	PRP	O
rose	VBD	O
from	IN	O
3.1	CD	O
at	IN	O
birth	NN	O
to	TO	O
24.9	CD	O
,	,	O
and	CC	O
in	IN	O
14	CD	O
who	WP	O
received	VBD	O
it	PRP	O
between	IN	O
9	CD	O
months	NNS	O
and	CC	O
2	CD	O
yr	NN	O
,	,	O
it	PRP	O
rose	VBD	O
from	IN	O
2.2	CD	O
to	TO	O
52.9	CD	O
.	.	O

The	DT	O
lymphocyte	JJ	O
responses	NNS	O
to	TO	O
PPD	NNP	O
after	IN	O
BCG	NNP	O
in	IN	O
these	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
significantly	RB	O
different	JJ	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
in	IN	O
the	DT	O
older	JJR	O
infants	NNS	O
that	IN	O
a	DT	O
raised	VBN	O
PPD-SI	NN	O
before	IN	O
BCG	NNP	O
vaccination	NN	O
affected	VBD	O
lymphocyte	JJ	O
sensitization	NN	O
by	IN	O
the	DT	O
vaccine	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
increasing	VBG	O
the	DT	O
age	NN	O
at	IN	O
vaccination	NN	O
with	IN	O
BCG	NNP	O
from	IN	O
birth	NN	O
to	TO	O
more	JJR	O
than	IN	O
9	CD	O
months	NNS	O
enhances	NNS	O
immunologic	JJ	O
sensitization	NN	O
to	TO	O
PPD	NNP	O
significantly	RB	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Modulation	NN	O
of	IN	O
the	DT	O
intestinal	JJ	O
environment	NN	O
,	,	O
innate	VB	O
immune	JJ	O
response	NN	O
,	,	O
and	CC	O
barrier	JJR	O
function	NN	O
by	IN	O
dietary	JJ	Pharmacological
threonine	NN	Pharmacological
and	CC	O
purified	JJ	Pharmacological
fiber	NN	Pharmacological
during	IN	O
a	DT	O
coccidiosis	NN	O
challenge	NN	O
in	IN	O
broiler	NN	O
chicks	NNS	O
.	.	O

Coccidiosis	NN	O
is	VBZ	O
a	DT	O
major	JJ	O
contributor	NN	O
to	TO	O
economic	JJ	O
losses	NNS	O
in	IN	O
the	DT	O
poultry	NN	O
industry	NN	O
due	JJ	O
to	TO	O
its	PRP$	O
detrimental	JJ	O
effects	NNS	O
on	IN	O
growth	NN	O
performance	NN	O
and	CC	O
nutrient	JJ	O
utilization	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
combined	JJ	O
effects	NNS	O
of	IN	O
supplemental	JJ	Pharmacological
dietary	JJ	Pharmacological
Thr	NNP	Pharmacological
and	CC	O
purified	VBD	Pharmacological
fiber	NN	Pharmacological
may	MD	O
modulate	VB	O
the	DT	O
intestinal	JJ	O
environment	NN	O
and	CC	O
positively	RB	O
affect	JJ	O
intestinal	JJ	O
immune	NN	O
responses	NNS	O
and	CC	O
barrier	JJR	O
function	NN	O
in	IN	O
broiler	NN	O
chicks	NNS	O
infected	VBN	O
with	IN	O
Eimeria	NNP	O
maxima	NN	O
.	.	O

A	DT	O
Thr-deficient	JJ	Pharmacological
basal	NN	Pharmacological
diet	NN	O
(	(	O
3.1	CD	O
g	NN	O
of	IN	O
Thr/kg	NNP	O
of	IN	O
diet	NN	O
)	)	O
was	VBD	O
supplemented	VBN	O
with	IN	O
70	CD	Control
g/kg	NN	Control
of	IN	Control
silica	NN	Control
sand	NN	Control
(	(	Control
control	NN	Control
)	)	Control
or	CC	O
high-methoxy	JJ	Pharmacological
pectin	NN	Pharmacological
and	CC	Pharmacological
1	CD	Pharmacological
of	IN	Pharmacological
2	CD	Pharmacological
concentrations	NNS	Pharmacological
of	IN	Pharmacological
Thr	NNP	Pharmacological
(	(	O
1.8	CD	O
or	CC	O
5.3	CD	O
g/kg	NN	O
of	IN	O
diet	JJ	O
;	:	O
4	CD	O
diets	NNS	O
total	JJ	O
)	)	O
,	,	O
and	CC	O
fed	VBD	O
to	TO	O
chicks	NNS	O
from	IN	O
hatch	NN	O
to	TO	O
d	VB	O
16	CD	O
posthatch	NN	O
.	.	O

On	IN	O
d	NN	O
10	CD	O
posthatch	NN	O
,	,	O
chicks	NNS	O
received	VBD	O
0.5	CD	Pharmacological
mL	NN	Pharmacological
of	IN	Pharmacological
distilled	JJ	Pharmacological
water	NN	Pharmacological
or	CC	O
an	DT	O
acute	JJ	Pharmacological
dose	NN	Pharmacological
of	IN	Pharmacological
Eimeria	NNP	Pharmacological
maxima	NNP	Pharmacological
(	(	O
1.5	CD	O
?	.	O
10	CD	O
(	(	O
3	CD	O
)	)	O
sporulated	VBN	O
oocytes	NNS	O
)	)	O
with	IN	O
6	CD	O
replicate	NN	O
pens	NNS	O
of	IN	O
6	CD	O
chicks	NNS	O
per	IN	O
each	DT	O
of	IN	O
8	CD	O
treatment	NN	O
combinations	NNS	O
(	(	O
4	CD	O
diets	NNS	O
and	CC	O
2	CD	O
inoculation	NN	O
states	NNS	O
)	)	O
.	.	O

Body	NNP	O
weight	VBD	O
gain	NN	O
,	,	O
feed	JJ	O
intake	NN	O
,	,	O
and	CC	O
G	NNP	O
:	:	O
F	NN	O
increased	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
with	IN	O
addition	NN	O
of	IN	O
5.3	CD	O
g	NN	O
of	IN	O
Thr/kg	NNP	O
of	IN	O
diet	JJ	O
.	.	O

Eimeria	NNP	O
maxima	JJ	O
schizonts	NNS	O
were	VBD	O
present	JJ	O
only	RB	O
in	IN	O
intestinal	JJ	O
tissue	NN	O
sampled	VBN	O
from	IN	O
infected	VBN	O
birds	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Weights	NNS	O
of	IN	O
cecal	JJ	O
digesta	NN	O
were	VBD	O
highest	JJS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
in	IN	O
pectin-fed	JJ	O
birds	NNS	O
,	,	O
and	CC	O
ceca	NN	O
with	IN	O
the	DT	O
heaviest	JJS	O
weights	NNS	O
also	RB	O
had	VBD	O
the	DT	O
highest	JJS	O
concentrations	NNS	O
of	IN	O
total	JJ	O
short-chain	JJ	O
fatty	JJ	O
acids	NNS	O
.	.	O

Expression	NN	O
of	IN	O
interleukin-12	NN	O
in	IN	O
ileal	JJ	O
mucosa	NN	O
was	VBD	O
highest	JJS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
in	IN	O
infected	JJ	O
birds	NNS	O
receiving	VBG	O
the	DT	O
control	NN	O
diet	JJ	O
with	IN	O
5.3	CD	O
g	NN	O
of	IN	O
supplemental	JJ	O
Thr/kg	NNP	O
.	.	O

In	IN	O
cecal	JJ	O
tonsils	NNS	O
,	,	O
interferon-?	JJ	O
expression	NN	O
was	VBD	O
highest	JJS	O
in	IN	O
infected	JJ	O
birds	NNS	O
receiving	VBG	O
the	DT	O
control	NN	O
diet	NN	O
(	(	O
fiber	VB	O
?	.	O
infection	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
;	:	O
interferon-?	JJ	O
expression	NN	O
was	VBD	O
lowest	JJS	O
in	IN	O
infected	JJ	O
birds	NNS	O
fed	VBD	O
the	DT	O
high	JJ	O
Thr	NNP	O
diet	NN	O
(	(	O
Thr	NNP	O
?	.	O
infection	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
due	RB	O
to	TO	O
infection	NN	O
or	CC	O
Thr	NNP	O
supplementation	NN	O
for	IN	O
cytokine	JJ	O
expression	NN	O
in	IN	O
birds	NNS	O
fed	VBN	O
pectin-containing	JJ	O
treatments	NNS	O
.	.	O

Overall	JJ	O
,	,	O
we	PRP	O
conclude	VBP	O
that	IN	O
although	IN	O
pectin	NN	O
has	VBZ	O
some	DT	O
protective	JJ	O
function	NN	O
against	IN	O
coccidiosis	NN	O
,	,	O
Thr	NNP	O
supplementation	NN	O
had	VBD	O
the	DT	O
greatest	JJS	O
effect	NN	O
on	IN	O
intestinal	JJ	O
immune	JJ	O
response	NN	O
and	CC	O
maintenance	NN	O
of	IN	O
near	IN	O
normal	JJ	O
growth	NN	O
in	IN	O
young	JJ	O
broiler	NN	O
chicks	NNS	O
infected	VBN	O
with	IN	O
E.	NNP	O
maxima	NNS	O
.	.	O

Hepatobiliary	JJ	O
response	NN	O
in	IN	O
postoperative	JJ	O
lipid	JJ	Pharmacological
therapy	NN	Pharmacological
in	IN	O
gastrointestinal	JJ	O
surgery	NN	O
.	.	O

BACKGROUND/AIMS	NNP	O
Intravenous	NNP	O
lipid	JJ	Pharmacological
emulsions	NNS	Pharmacological
may	MD	O
contribute	VB	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
(	(	O
TPN	NNP	O
)	)	O
--	:	O
induced	VBD	O
hepatobiliary	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
setting	VBG	O
the	DT	O
authors	NNS	O
compared	VBN	O
the	DT	O
short-term	JJ	O
hepatic	JJ	O
effects	NNS	O
of	IN	O
medium-chain	JJ	Pharmacological
triglycerides/short-chain	JJ	Pharmacological
triglycerides	NNS	Pharmacological
(	(	Pharmacological
MCT/LCT	NNP	Pharmacological
)	)	Pharmacological
physical	JJ	Pharmacological
mixture	NN	Pharmacological
with	IN	Pharmacological
a	DT	Pharmacological
four-component	JJ	Pharmacological
intravenous	JJ	Pharmacological
(	(	Pharmacological
i.v	JJ	Pharmacological
.	.	Pharmacological

)	)	Pharmacological
lipid	JJ	Pharmacological
emulsion	NN	Pharmacological
(	(	Pharmacological
LCT	NNP	Pharmacological
,	,	Pharmacological
MCT	NNP	Pharmacological
,	,	Pharmacological
Olive-oil	NNP	Pharmacological
and	CC	Pharmacological
Fish-oil	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
gastrointestial	JJ	O
surgery	NN	O
during	IN	O
the	DT	O
early	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
authors	NNS	O
demonstrated	VBD	O
that	IN	O
total	JJ	O
and	CC	O
conjugated	VBD	O
bilirubin	NN	O
,	,	O
alkaline	JJ	O
phosphatase	NN	O
,	,	O
alanine	JJ	O
aminotransferase	NN	O
,	,	O
aspartate	VBP	O
amino	JJ	O
transferase	NN	O
and	CC	O
cholinesterase	NN	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
during	IN	O
the	DT	O
5-days	JJ	O
observation	NN	O
period	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
this	DT	O
,	,	O
gamma-glutamyl	JJ	O
transferase	NN	O
(	(	O
GGT	NNP	O
)	)	O
activity	NN	O
increased	VBN	O
by	IN	O
2,4	CD	O
times	NNS	O
during	IN	O
5-days	JJ	O
therapy	NN	Pharmacological
with	IN	Pharmacological
the	DT	Pharmacological
lipid	JJ	Pharmacological
emulsions	NNS	Pharmacological
mentioned	VBN	O
above	IN	O
(	(	O
SMOF	NNP	O
lipid	VBZ	O
:	:	O
21,9	CD	O
to	TO	O
52,9	CD	O
U/L	NNP	O
,	,	O
Lipofundin	NNP	O
:	:	O
from	IN	O
32,5	CD	O
to	TO	O
79,6	CD	O
U/L	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
during	IN	O
a	DT	O
4-days	JJ	O
administration	NN	O
hepatic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
intravenous	JJ	O
lipid	JJ	Pharmacological
emulsions	NNS	Pharmacological
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
.	.	O

The	DT	O
changes	NNS	O
in	IN	O
enzyme	NN	O
levels	NNS	O
confirm	VBP	O
the	DT	O
cholestatic	JJ	O
type	NN	O
of	IN	O
hepatobiliary	JJ	O
deviations	NNS	O
without	IN	O
clinical	JJ	O
impact	NN	O
on	IN	O
short-term	JJ	O
TPN	NNP	Pharmacological
therapy	NN	Pharmacological
.	.	O

Simvastatin	NNP	Pharmacological
reduces	VBZ	O
sympathetic	JJ	O
outflow	NN	O
and	CC	O
augments	NNS	O
endothelium-independent	JJ	O
dilation	NN	O
in	IN	O
non-hyperlipidaemic	JJ	O
primary	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVES	NNP	O
Previous	JJ	O
reports	NNS	O
,	,	O
involving	VBG	O
hypercholesterolaemic	JJ	O
hypertensive	JJ	O
subjects	NNS	O
,	,	O
that	IN	O
statins	VBZ	O
reduce	VB	O
muscle	NN	O
sympathetic	JJ	O
nerve	NN	O
activity	NN	O
(	(	O
MSNA	NNP	O
)	)	O
did	VBD	O
not	RB	O
investigate	VB	O
potential	JJ	O
neural	JJ	O
sites	NNS	O
of	IN	O
such	JJ	O
sympathoinhibition	NN	O
or	CC	O
determine	VB	O
its	PRP$	O
consequences	NNS	O
for	IN	O
endothelial	JJ	O
function	NN	O
or	CC	O
insulin	NN	O
resistance	NN	O
.	.	O

This	DT	O
study	NN	O
of	IN	O
hypertensive	JJ	O
subjects	NNS	O
with	IN	O
lower	JJR	O
plasma	NN	O
cholesterol	NN	O
tested	VBD	O
the	DT	O
hypotheses	NNS	O
that	WDT	O
lipophilic	JJ	O
simvastatin	NN	Pharmacological
would	MD	O
attenuate	VB	O
resting	VBG	O
sympathoexcitation	NN	O
and	CC	O
augment	NN	O
baroreflex	JJ	O
modulation	NN	O
of	IN	O
MSNA	NNP	O
and	CC	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
,	,	O
flow-mediated	JJ	O
vasodilation	NN	O
and	CC	O
insulin	NN	O
sensitivity	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomised	VBD	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
crossover	NN	O
study	NN	O
.	.	O

SETTING	NNP	O
Academic	NNP	O
hospital-based	JJ	O
study	NN	O
.	.	O

PATIENTS	NNP	O
Fourteen	JJ	O
non-hyperlipidaemic	JJ	O
primary	JJ	O
hypertensive	JJ	O
subjects	NNS	O
(	(	O
10	CD	O
men	NNS	O
;	:	O
overall	JJ	O
mean?SD	NN	O
age	NN	O
58?12	CD	O
years	NNS	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
Four	NNP	O
weeks	NNS	O
of	IN	O
simvastatin	NN	O
(	(	O
80	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Resting	NNP	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
HR	NNP	O
,	,	O
MSNA	NNP	O
,	,	O
spontaneous	JJ	O
arterial	JJ	O
baroreflex	NN	O
MSNA	NNP	O
and	CC	O
HR	NNP	O
modulation	NN	O
,	,	O
endothelium-dependent	JJ	O
and	CC	O
endothelium-independent	JJ	O
vasodilation	NN	O
,	,	O
and	CC	O
the	DT	O
homoeostatic	JJ	O
model	NN	O
assessment	NN	O
of	IN	O
insulin	NN	O
resistance	NN	O
(	(	O
HOMA-IR	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Simvastatin	NNP	O
lowered	VBD	O
MSNA	NNP	O
burst	JJ	O
frequency	NN	O
(	(	O
from	IN	O
32?12	CD	O
to	TO	O
25?9	CD	O
bursts/min	NN	O
)	)	O
and	CC	O
MSNA	NNP	O
burst	NN	O
incidence	NN	O
(	(	O
from	IN	O
55?23	CD	O
%	NN	O
to	TO	O
43?17	CD	O
%	NN	O
;	:	O
all	DT	O
p	VBP	O
<	$	O
0.01	CD	O
)	)	O
without	IN	O
affecting	VBG	O
BP	NNP	O
,	,	O
HR	NNP	O
,	,	O
baroreflex	JJ	O
modulation	NN	O
of	IN	O
either	DT	O
MSNA	NNP	O
or	CC	O
HR	NNP	O
,	,	O
or	CC	O
HR	NNP	O
variability	NN	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.05	CD	O
)	)	O
.	.	O

Plasma	NNP	O
glucose	NN	O
,	,	O
insulin	NN	O
,	,	O
HOMA-IR	NNP	O
and	CC	O
endothelium-dependent	JJ	O
vasodilation	NN	O
(	(	O
all	DT	O
p	VBP	O
>	$	O
0.05	CD	O
)	)	O
were	VBD	O
unchanged	JJ	O
,	,	O
whereas	JJ	O
endothelium-independent	JJ	O
vasodilation	NN	O
increased	VBD	O
(	(	O
7.1?3.8	CD	O
%	NN	O
to	TO	O
9.7?3.9	CD	O
%	NN	O
,	,	O
n=13	RB	O
;	:	O
p	VB	O
<	$	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
fall	NN	O
in	IN	O
MSNA	NNP	O
was	VBD	O
unrelated	JJ	O
to	TO	O
the	DT	O
decrease	NN	O
in	IN	O
low-density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
(	(	O
r=0.41	NN	O
,	,	O
p=0.14	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
the	DT	O
concept	NN	O
that	IN	O
,	,	O
in	IN	O
non-hyperlipidaemic	JJ	O
subjects	NNS	O
with	IN	O
primary	JJ	O
hypertension	NN	O
,	,	O
simvastatin	JJ	O
causes	VBZ	O
a	DT	O
cholesterol-independent	JJ	O
reduction	NN	O
in	IN	O
an	DT	O
elevated	JJ	O
central	JJ	O
set-point	NN	O
for	IN	O
MSNA	NNP	O
,	,	O
without	IN	O
affecting	VBG	O
arterial	JJ	O
baroreflex	JJ	O
modulation	NN	O
of	IN	O
either	DT	O
MSNA	NNP	O
or	CC	O
HR	NNP	O
.	.	O

There	EX	O
may	MD	O
be	VB	O
less	JJR	O
neurogenic	JJ	O
constraint	NN	O
on	IN	O
endothelium-independent	JJ	O
vasodilation	NN	O
as	IN	O
a	DT	O
consequence	NN	O
.	.	O

Tetrahydrobiopterin	NNP	Pharmacological
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
if	IN	O
tetrahydrobiopterin	NN	Pharmacological
(	(	Pharmacological
BH4	NNP	Pharmacological
)	)	Pharmacological
reduced	VBD	O
core	NN	O
symptoms	NNS	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHOD	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
46	CD	O
children	NNS	O
,	,	O
3-7	CD	O
years	NNS	O
of	IN	O
age	NN	O
diagnosed	VBN	O
with	IN	O
an	DT	O
ASD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
20	CD	O
mg/kg/day	JJ	O
BH4	NNP	O
or	CC	O
placebo	NN	O
for	IN	O
16	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impressions	NNP	O
Improvement	NNP	O
and	CC	O
Severity	NNP	O
Scales	NNP	O
(	(	O
CGI-I	NNP	O
and	CC	O
CGI-S	NNP	O
)	)	O
;	:	O
secondary	JJ	O
outcomes	NNS	O
were	VBD	O
the	DT	O
Preschool	NNP	O
Language	NNP	O
Scale-4	NNP	O
(	(	O
PLS-4	NNP	O
)	)	O
,	,	O
Social	NNP	O
Responsiveness	NNP	O
Scale	NNP	O
(	(	O
SRS	NNP	O
)	)	O
,	,	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
,	,	O
and	CC	O
Vineland	NNP	O
Adaptive	NNP	O
Behavior	NNP	O
Scales	NNP	O
(	(	O
Vineland	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Overall	NNP	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
on	IN	O
global	JJ	O
improvement	NN	O
as	IN	O
measured	VBN	O
with	IN	O
the	DT	O
CGI-I	NNP	O
or	CC	O
CGI-S	NNP	O
.	.	O

Secondary	JJ	O
measures	NNS	O
indicated	VBD	O
significant	JJ	O
improvements	NNS	O
for	IN	O
BH4	NNP	O
relative	NN	O
to	TO	O
placebo	VB	O
with	IN	O
regard	NN	O
to	TO	O
social	JJ	O
awareness	NN	O
,	,	O
autism	NN	O
mannerisms	NNS	O
,	,	O
hyperactivity	NN	O
,	,	O
and	CC	O
inappropriate	JJ	O
speech	NN	O
.	.	O

Side	JJ	O
effects	NNS	O
were	VBD	O
minimal	JJ	O
and	CC	O
similar	JJ	O
between	IN	O
both	DT	O
active	JJ	O
medication	NN	O
and	CC	O
placebo	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
BH4	NNP	O
offers	VBZ	O
promise	NN	O
in	IN	O
reducing	VBG	O
symptoms	NNS	O
of	IN	O
ASD	NNP	O
.	.	O

Clinical	NNP	O
Trials.gov	NNP	O
Identifier	NNP	O
:	:	O
NCT00850070	NN	O
.	.	O

Effect	NN	O
of	IN	O
shearing	VBG	Physical
on	IN	O
water	NN	O
turnover	NN	O
and	CC	O
thermobiological	JJ	O
variables	NNS	O
in	IN	O
German	JJ	O
Blackhead	NNP	O
mutton	NN	O
sheep	NN	O
.	.	O

Current	JJ	O
equations	NNS	O
for	IN	O
estimating	VBG	O
water	NN	O
requirements	NNS	O
in	IN	O
sheep	JJ	O
do	VBP	O
not	RB	O
differentiate	VB	O
between	IN	O
shorn	JJ	O
and	CC	O
unshorn	JJ	O
sheep	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
shearing	VBG	O
on	IN	O
thermoregulative	JJ	O
responses	NNS	O
in	IN	O
sheep	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
adequately	RB	O
studied	VBN	O
under	IN	O
temperate	JJ	O
environmental	JJ	O
conditions	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
wool	NN	O
coverage	NN	O
on	IN	O
water	NN	O
turnover	NN	O
in	IN	O
relation	NN	O
to	TO	O
thermoregulation	NN	O
in	IN	O
sheep	NN	O
by	IN	O
using	VBG	O
the	DT	O
deuterium	NN	O
dilution	NN	O
technique	NN	O
to	TO	O
predict	VB	O
total	JJ	O
water	NN	O
intake	NN	O
before	IN	O
and	CC	O
after	IN	O
shearing	VBG	Physical
.	.	O

Physiological	JJ	O
responses	NNS	O
,	,	O
such	JJ	O
as	IN	O
water	NN	O
turnover	NN	O
,	,	O
surface	NN	O
temperature	NN	O
,	,	O
and	CC	O
rectal	JJ	O
temperature	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
drinking	VBG	O
behavior	NN	O
of	IN	O
sheep	NN	O
were	VBD	O
also	RB	O
evaluated	VBN	O
.	.	O

Fourteen	NNP	O
nonlactating	JJ	O
German	JJ	O
Blackhead	NNP	O
mutton	NN	O
ewes	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
:	:	O
a	DT	Control
control	NN	Control
group	NN	Control
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
that	WDT	O
was	VBD	O
already	RB	Physical
shorn	VBN	Physical
,	,	O
and	CC	O
a	DT	O
treatment	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
that	WDT	O
was	VBD	O
left	VBN	Control
unshorn	JJ	Control
(	(	O
wool	JJ	O
length	NN	O
:	:	O
10.6	CD	O
?	.	O
1.2	CD	O
cm	NN	O
)	)	O
.	.	O

Individual	NNP	O
feed	NN	O
and	CC	O
water	NN	O
intakes	NNS	O
were	VBD	O
recorded	VBN	O
throughout	IN	O
the	DT	O
experiment	NN	O
(	(	O
d	JJ	O
1	CD	O
to	TO	O
71	CD	O
)	)	O
.	.	O

Two	CD	O
weeks	NNS	O
after	IN	O
measurements	NNS	O
commenced	VBD	O
(	(	O
d	JJ	O
15	CD	O
)	)	O
,	,	O
treatment	NN	O
sheep	NN	O
were	VBD	O
shorn	VBN	O
.	.	O

Water	NNP	O
intake	NN	O
was	VBD	O
estimated	VBN	O
twice	RB	O
for	IN	O
2	CD	O
consecutive	JJ	O
weeks	NNS	O
by	IN	O
using	VBG	O
deuterium	JJ	O
dilution	NN	O
techniques	NNS	O
(	(	O
d	VB	O
1	CD	O
to	TO	O
15	CD	O
and	CC	O
d	VB	O
57	CD	O
to	TO	O
71	CD	O
)	)	O
.	.	O

Ambient	JJ	O
temperature	NN	O
(	(	O
T	NNP	O
(	(	O
a	DT	O
)	)	O
)	)	O
,	,	O
relative	JJ	O
humidity	NN	O
,	,	O
and	CC	O
respiratory	JJ	O
rate	NN	O
were	VBD	O
measured	VBN	O
daily	RB	O
,	,	O
whereas	JJ	O
BW	NNP	O
,	,	O
rectal	NN	O
and	CC	O
animal	JJ	O
surface	NN	O
temperatures	NNS	O
(	(	O
using	VBG	O
infrared	VBN	O
thermography	NN	O
)	)	O
,	,	O
and	CC	O
wool	JJ	O
length	NN	O
were	VBD	O
measured	VBN	O
weekly	RB	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
2	CD	O
wk	NN	O
,	,	O
when	WRB	O
treatment	NN	O
sheep	NN	O
were	VBD	O
unshorn	JJ	O
,	,	O
treatment	NN	O
and	CC	O
control	NN	O
ewes	NN	O
differed	VBN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
DMI	NNP	O
(	(	O
52	CD	O
?	.	O
4	CD	O
vs.	IN	O
59	CD	O
?	.	O
4	CD	O
g?kg	NN	O
(	(	O
-0.75	NNP	O
)	)	O
?d	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
,	,	O
water	NN	O
intake	NN	O
(	(	O
165	CD	O
?	.	O
17	CD	O
vs.	IN	O
134	CD	O
?	.	O
18	CD	O
g?kg	NN	O
(	(	O
-0.75	NNP	O
)	)	O
?d	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
,	,	O
respiratory	JJ	O
rate	NN	O
(	(	O
66	CD	O
?	.	O
5	CD	O
vs.	IN	O
31	CD	O
?	.	O
4	CD	O
breath/min	NN	O
)	)	O
,	,	O
rectal	JJ	O
temperature	NN	O
(	(	O
39.3	CD	O
?	.	O
0.2	CD	O
vs.	IN	O
38.8	CD	O
?	.	O
0.1?C	CD	O
)	)	O
,	,	O
and	CC	O
surface	NN	O
temperatures	NNS	O
(	(	O
body	JJ	O
side	NN	O
:	:	O
19.3	CD	O
?	.	O
0.3	CD	O
vs.	IN	O
24.5	CD	O
?	.	O
0.6?C	CD	O
;	:	O
leg	NN	O
:	:	O
25.8	CD	O
?	.	O
2.4	CD	O
vs.	IN	O
27.4	CD	O
?	.	O
1.6?C	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
after	IN	O
shearing	VBG	O
,	,	O
these	DT	O
differences	NNS	O
partly	RB	O
disappeared	VBD	O
.	.	O

The	DT	O
same	JJ	O
trend	NN	O
in	IN	O
water	NN	O
intake	NN	O
between	IN	O
groups	NNS	O
was	VBD	O
confirmed	VBN	O
using	VBG	O
the	DT	O
isotope	NN	O
dilution	NN	O
technique	NN	O
.	.	O

We	PRP	O
found	VBD	O
a	DT	O
significant	JJ	O
relationship	NN	O
between	IN	O
T	NNP	O
(	(	O
a	DT	O
)	)	O
and	CC	O
water	NN	O
intake	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
,	,	O
and	CC	O
body	NN	O
surface	NN	O
temperatures	NNS	O
.	.	O

Even	RB	O
under	IN	O
temperate	NN	O
conditions	NNS	O
(	(	O
T	NNP	O
(	(	O
a	DT	O
)	)	O
<	$	O
28?C	CD	O
)	)	O
,	,	O
shearing	VBG	O
significantly	RB	O
reduced	VBN	O
core	NN	O
body	NN	O
temperature	NN	O
,	,	O
water	NN	O
intake	NN	O
,	,	O
and	CC	O
respiratory	NN	O
rate	NN	O
in	IN	O
German	JJ	O
Blackhead	NNP	O
mutton	NN	O
sheep	NN	O
,	,	O
thus	RB	O
indicating	VBG	O
heat	NN	O
stress	NN	O
in	IN	O
fleeced	JJ	O
animals	NNS	O
,	,	O
which	WDT	O
should	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
determining	VBG	O
the	DT	O
optimal	JJ	O
shearing	NN	O
time	NN	O
in	IN	O
sheep	NN	O
as	RB	O
well	RB	O
as	IN	O
when	WRB	O
estimating	VBG	O
water	NN	O
requirements	NNS	O
.	.	O

Group-based	JJ	O
HIV	NNP	O
risk	NN	O
reduction	NN	O
intervention	NN	O
for	IN	O
adolescent	JJ	O
girls	NNS	O
:	:	O
evidence	NN	O
of	IN	O
feasibility	NN	O
and	CC	O
efficacy	NN	O
.	.	O

The	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
pilot	NN	O
study	NN	O
were	VBD	O
(	(	O
a	DT	O
)	)	O
to	TO	O
assess	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
a	DT	O
community-based	JJ	O
,	,	O
small	JJ	O
group	NN	O
HIV	NNP	O
risk	NN	O
reduction	NN	O
intervention	NN	O
with	IN	O
adolescent	JJ	O
girls	NNS	O
,	,	O
and	CC	O
(	(	O
b	NN	O
)	)	O
to	TO	O
obtain	VB	O
preliminary	JJ	O
evidence	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
this	DT	O
theoretically-guided	JJ	Educational
intervention	NN	Educational
using	VBG	O
a	DT	O
controlled	JJ	O
design	NN	O
.	.	O

The	DT	O
feasibility	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
demonstrated	VBN	O
by	IN	O
successfully	RB	O
implementing	VBG	O
it	PRP	O
with	IN	O
33	CD	O
sexually-active	JJ	O
,	,	O
single	JJ	O
girls	NNS	O
.	.	O

Preliminary	JJ	O
evidence	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
obtained	VBN	O
using	VBG	O
a	DT	O
randomized	JJ	O
trial	NN	O
with	IN	O
62	CD	O
sexually-active	JJ	O
,	,	O
single	JJ	O
girls	NNS	O
.	.	O

Data	NNS	O
obtained	VBD	O
at	IN	O
a	DT	O
3-month	JJ	O
follow-up	JJ	O
assessment	NN	O
showed	VBD	O
that	IN	O
girls	NNS	O
who	WP	O
received	VBD	O
the	DT	O
HIV-related	JJ	O
intervention	NN	O
improved	VBD	O
their	PRP$	O
HIV-related	JJ	O
knowledge	NN	O
and	CC	O
enhanced	VBD	O
their	PRP$	O
motivation	NN	O
for	IN	O
risk	NN	O
reduction	NN	O
compared	VBN	O
to	TO	O
girls	NNS	O
who	WP	O
received	VBD	O
a	DT	O
control	NN	Control
(	(	Control
health	NN	Control
promotion	NN	Control
)	)	Control
intervention	NN	Control
.	.	O

Effect	JJ	O
sizes	VBZ	O
suggest	VBP	O
that	IN	O
the	DT	O
HIV	NNP	O
intervention	NN	O
also	RB	O
reduced	VBD	O
several	JJ	O
risk	NN	O
behaviors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
vaginal	JJ	O
sex	NN	O
without	IN	O
a	DT	O
condom	NN	O
,	,	O
giving	VBG	O
oral	JJ	O
sex	NN	O
,	,	O
and	CC	O
alcohol	NN	O
and	CC	O
drug	NN	O
use	NN	O
before	IN	O
sex	NN	O
)	)	O
.	.	O

Challenges	VBZ	O
to	TO	O
implementation	NN	O
and	CC	O
suggestions	NNS	O
for	IN	O
intervention	NN	O
enhancement	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
rectal	JJ	Physical
distension	NN	Physical
on	IN	O
bladder	NN	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
overactive	JJ	O
bladder	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
rectal	JJ	Physical
distension	NN	Physical
on	IN	O
bladder	NN	O
sensation	NN	O
volumes	NNS	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
detrusor	NN	O
contractions	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
overactive	JJ	O
bladder	NN	O
(	(	O
OAB	NNP	O
)	)	O
symptoms	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
prospective	JJ	O
randomized	VBN	O
study	NN	O
included	VBD	O
patients	NNS	O
with	IN	O
OAB	NNP	O
symptoms	NNS	O
.	.	O

Multichannel	NNP	O
urodynamic	JJ	O
studies	NNS	O
were	VBD	O
completed	VBN	O
with	IN	Physical
and	CC	Physical
without	IN	Physical
rectal	JJ	Physical
balloon	NN	Physical
distension	NN	Physical
.	.	Physical

Bladder	NNP	O
sensation	NN	O
volumes	NNS	O
and	CC	O
detrusor	NN	O
contractions	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
Twenty-six	JJ	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
mean	JJ	O
age	NN	O
was	VBD	O
67	CD	O
years	NNS	O
and	CC	O
mean	JJ	O
BMI	NNP	O
was	VBD	O
28.3	CD	O
kg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Bladder	NNP	O
sensation	NN	O
volumes	NNS	O
were	VBD	O
lower	JJR	O
with	IN	O
rectal	JJ	O
distention	NN	O
as	IN	O
follows	VBZ	O
:	:	O
normal	JJ	O
desire	NN	O
to	TO	O
void	VB	O
(	(	O
139	CD	O
ml	NN	O
SD	NNP	O
,	,	O
?114	NNP	O
vs.	FW	O
197	CD	O
ml	NN	O
SD	NNP	O
?150	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
strong	JJ	O
desire	NN	O
to	TO	O
void	VB	O
(	(	O
260	CD	O
ml	NN	O
SD	NNP	O
?171	NNP	O
vs.	IN	O
330	CD	O
ml	NNS	O
SD	NNP	O
?172	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
maximum	JJ	O
cystometric	JJ	O
capacity	NN	O
(	(	O
326	CD	O
ml	NN	O
SD	NNP	O
?183	NNP	O
vs.	IN	O
403	CD	O
ml	NNS	O
SD	NNP	O
?180	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
detrusor	JJ	O
contractions	NNS	O
or	CC	O
the	DT	O
bladder	NN	O
volume	NN	O
at	IN	O
which	WDT	O
the	DT	O
first	JJ	O
detrusor	NN	O
contraction	NN	O
had	VBD	O
occurred	VBN	O
with	IN	O
and	CC	O
without	IN	O
rectal	JJ	O
distension	NN	O
.	.	O

CONCLUSION	NNP	O
Rectal	NNP	O
distention	NN	O
in	IN	O
patients	NNS	O
with	IN	O
OAB	NNP	O
symptoms	NNS	O
significantly	RB	O
lowered	VBD	O
bladder	JJR	O
sensation	NN	O
volumes	NNS	O
(	(	O
normal	JJ	O
desire	NN	O
,	,	O
strong	JJ	O
desire	NN	O
,	,	O
and	CC	O
maximal	JJ	O
capacity	NN	O
)	)	O
.	.	O

Methylphenidate	NNP	Pharmacological
and	CC	O
baseball	NN	O
playing	NN	O
in	IN	O
ADHD	NNP	O
children	NNS	O
:	:	O
who	WP	O
's	VBZ	O
on	IN	O
first	JJ	O
?	.	O
The	DT	O
effects	NNS	O
of	IN	O
0.3	CD	Pharmacological
and	CC	Pharmacological
0.6	CD	Pharmacological
mg/kg	NN	Pharmacological
methylphenidate	NN	Pharmacological
were	VBD	O
analyzed	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
cross-over	JJ	O
study	NN	O
in	IN	O
which	WDT	O
17	CD	O
boys	NNS	O
(	(	O
ages	IN	O
7.8-9.9	CD	O
years	NNS	O
)	)	O
with	IN	O
attention	NN	O
deficit	NN	O
hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
played	VBD	O
in	IN	O
baseball	NN	O
games	NNS	O
.	.	O

Drug	JJ	O
effects	NNS	O
were	VBD	O
evaluated	VBN	O
on	IN	O
children	NNS	O
's	POS	O
attention	NN	O
during	IN	O
the	DT	O
game	NN	O
,	,	O
as	IN	O
indicated	VBN	O
by	IN	O
their	PRP$	O
on-task	JJ	O
behavior	NN	O
on	IN	O
the	DT	O
field	NN	O
and	CC	O
their	PRP$	O
ability	NN	O
to	TO	O
answer	VB	O
questions	NNS	O
about	IN	O
the	DT	O
status	NN	O
of	IN	O
the	DT	O
game	NN	O
at	IN	O
all	DT	O
times	NNS	O
.	.	O

Judgment	NN	O
during	IN	O
batting	NN	O
,	,	O
batting	VBG	O
skill	NN	O
during	IN	O
the	DT	O
game	NN	O
,	,	O
and	CC	O
performance	NN	O
on	IN	O
skill	NN	O
drills	NNS	O
prior	RB	O
to	TO	O
the	DT	O
game	NN	O
were	VBD	O
also	RB	O
assessed	VBN	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
medication	NN	O
.	.	O

Results	NNS	O
revealed	VBD	O
that	IN	O
methylphenidate	NN	Pharmacological
had	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
attending	VBG	O
during	IN	O
the	DT	O
game	NN	O
.	.	O

A	DT	O
multifactorial	JJ	O
strategy	NN	O
of	IN	O
pain	NN	O
management	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
less	JJR	O
pain	NN	O
in	IN	O
scheduled	JJ	O
vaccination	NN	O
of	IN	O
children	NNS	O
.	.	O

A	DT	O
study	NN	O
realized	VBN	O
by	IN	O
family	NN	O
practitioners	NNS	O
in	IN	O
239	CD	O
children	NNS	O
aged	VBN	O
4-12	CD	O
years	NNS	O
old	JJ	O
.	.	O

BACKGROUND	NNP	O
AND	CC	O
AIMS	NNP	O
The	DT	O
multiplicity	NN	O
of	IN	O
vaccine	JJ	O
injections	NNS	O
during	IN	O
childhood	NN	O
leads	NNS	O
to	TO	O
iterative	VB	O
painful	JJ	O
and	CC	O
stressful	JJ	O
experiences	NNS	O
which	WDT	O
may	MD	O
lead	VB	O
in	IN	O
turn	NN	O
to	TO	O
anticipated	VBN	O
pain	NN	O
and	CC	O
then	RB	O
possibly	RB	O
to	TO	O
a	DT	O
true	JJ	O
needle	JJ	O
phobia	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
at	IN	O
evaluating	VBG	O
a	DT	O
multifactorial	JJ	O
strategy	NN	O
of	IN	O
pain	NN	O
management	NN	O
combining	VBG	O
pharmacological	JJ	O
and	CC	O
non-pharmacological	JJ	O
approaches	NNS	O
during	IN	O
vaccination	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
usual	JJ	O
care	NN	O
,	,	O
in	IN	O
4-	JJ	O
to	TO	O
12-year-old	JJ	O
children	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
all	DT	O
,	,	O
239	CD	O
children	NNS	O
were	VBD	O
enrolled	VBN	O
by	IN	O
25	CD	O
family	NN	O
practitioners	NNS	O
in	IN	O
an	DT	O
open-label	JJ	O
study	NN	O
.	.	O

After	IN	O
a	DT	O
pseudo-randomization	NN	O
,	,	O
usual	JJ	Physical
pain	NN	Physical
management	NN	Physical
(	(	Physical
n	JJ	Physical
=	NNP	Physical
132	CD	Physical
)	)	Physical
was	VBD	Physical
compared	VBN	Physical
to	TO	Physical
a	DT	Physical
multifactorial	JJ	Physical
strategy	NN	Physical
(	(	Physical
n	JJ	Physical
=	NNP	Physical
107	CD	Physical
)	)	Physical
associating	VBG	Physical
preliminary	JJ	Physical
application	NN	Physical
of	IN	Physical
an	DT	Physical
anesthesic	JJ	Physical
patch	NN	Physical
,	,	Physical
preferential	JJ	Physical
use	NN	Physical
of	IN	Physical
specified	JJ	Physical
vaccines	NNS	Physical
,	,	O
child	JJ	Educational
education	NN	Educational
by	IN	Educational
the	DT	Educational
parents	NNS	Educational
and	CC	Educational
the	DT	Educational
doctor	NN	Educational
,	,	Educational
parental	JJ	Educational
accompaniment	NN	Educational
and	CC	Educational
child	JJ	Educational
distraction	NN	Educational
with	IN	Educational
soap	NN	Educational
bubbles	NNS	Educational
during	IN	Educational
the	DT	Educational
procedure	NN	Educational
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
(	(	O
i.e	JJ	O
.	.	O

child	VB	O
pain	NN	O
)	)	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
self-report	JJ	O
scale	NN	O
named	VBN	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
of	IN	O
pain	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
pain	NN	O
was	VBD	O
obtained	VBN	O
using	VBG	O
the	DT	O
multifactorial	JJ	O
strategy	NN	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
self-reported	JJ	O
VAS	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

This	DT	O
was	VBD	O
confirmed	VBN	O
by	IN	O
another	DT	O
self-report	JJ	O
scale	NN	O
(	(	O
the	DT	O
facial	NN	O
pain	NN	O
scale	NN	O
revised	VBN	O
:	:	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
with	IN	O
hetero-evaluations	NNS	O
by	IN	O
GPs	NNP	O
and	CC	O
parents	NNS	O
[	VBP	O
Children	NNP	O
's	POS	O
Hospital	NNP	O
of	IN	O
Eastern	NNP	O
Ontario	NNP	O
Pain	NNP	O
Scale	NNP	O
:	:	O
P	NNP	O
=	VBZ	O
0.0007	CD	O
;	:	O
GPs	NNP	O
VAS	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
parents	NNS	O
VAS	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
]	NN	O
,	,	O
which	WDT	O
were	VBD	O
secondary	JJ	O
outcome	NN	O
criteria	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
multifactorial	JJ	O
method	NN	O
significantly	RB	O
decreases	VBZ	O
vaccination	NN	O
pain	NN	O
in	IN	O
4-	JJ	O
to	TO	O
12-year-old	JJ	O
children	NNS	O
.	.	O

This	DT	O
strategy	NN	O
could	MD	O
make	VB	O
vaccines	NNS	O
more	RBR	O
acceptable	JJ	O
to	TO	O
children	NNS	O
and	CC	O
may	MD	O
improve	VB	O
child-doctor	NN	O
relationships	NNS	O
and	CC	O
contribute	NN	O
to	TO	O
a	DT	O
decrease	NN	O
in	IN	O
child	JJ	O
fear	VBP	O
about	IN	O
health	NN	O
care	NN	O
.	.	O

Pethidine	NNP	Pharmacological
versus	NN	Pharmacological
tramadol	NN	Pharmacological
for	IN	O
pain	NN	O
relief	NN	O
during	IN	O
labor	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
and	CC	O
compare	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
and	CC	O
adverse	JJ	O
effects	NNS	O
of	IN	O
tramadol	NN	Pharmacological
and	CC	O
pethidine	NN	Pharmacological
in	IN	O
labor	NN	O
.	.	O

METHOD	NNP	O
Fifty-nine	NNP	O
full	JJ	O
term	NN	O
parturients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
in	IN	O
active	JJ	O
labor	NN	O
.	.	O

Group	NNP	O
1	CD	O
received	VBD	O
100	CD	O
mg	NNS	O
pethidine	VBP	Pharmacological
;	:	Pharmacological
group	NN	O
2	CD	O
,	,	O
100	CD	O
mg	NN	O
tramadol	NN	Pharmacological
,	,	O
intramuscularly	RB	O
.	.	O

Analgesic	JJ	O
efficacy	NN	O
,	,	O
maternal	JJ	O
side	NN	O
effects	NNS	O
,	,	O
changes	NNS	O
in	IN	O
the	DT	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
duration	NN	O
of	IN	O
labor	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULT	NNP	O
At	IN	O
30	CD	O
and	CC	O
60	CD	O
min	NNS	O
after	IN	O
drug	NN	O
administration	NN	O
,	,	O
pain	VBP	O
relief	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
pethidine	NN	Pharmacological
group	NN	O
than	IN	O
in	IN	O
tramadol	JJ	Pharmacological
group	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
and	CC	O
fatigue	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
tramadol	NN	Pharmacological
group	NN	O
.	.	O

Following	VBG	O
drug	NN	O
administration	NN	O
the	DT	O
decrease	NN	O
in	IN	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
heart	NN	O
rate	NN	O
were	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
when	WRB	O
compared	VBN	O
for	IN	O
duration	NN	O
of	IN	O
labor	NN	O
and	CC	O
Apgar	NNP	O
scores	NNS	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
neonates	NNS	O
developed	VBD	O
respiratory	JJ	O
depression	NN	O
.	.	O

CONCLUSION	NNP	O
Pethidine	NNP	Pharmacological
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
better	RBR	O
alternative	JJ	O
than	IN	O
tramadol	NN	Pharmacological
in	IN	O
obstetric	JJ	O
analgesia	NN	O
because	IN	O
of	IN	O
its	PRP$	O
superiority	NN	O
in	IN	O
analgesic	JJ	O
efficacy	NN	O
and	CC	O
low	JJ	O
incidence	NN	O
of	IN	O
maternal	JJ	O
side	NN	O
effects	NNS	O
.	.	O

A	DT	O
double-blind	JJ	O
crossover	NN	O
comparison	NN	O
of	IN	O
pindolol	NN	Pharmacological
,	,	O
metoprolol	NN	Pharmacological
,	,	O
atenolol	NN	Pharmacological
and	CC	O
labetalol	NN	Pharmacological
in	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
hypertension	NN	O
.	.	O

1	CD	O
This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
compare	VB	O
in	IN	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
crossover	NN	O
trial	NN	O
,	,	O
atenolol	NN	Pharmacological
,	,	O
labetalol	NN	Pharmacological
,	,	O
metoprolol	NN	Pharmacological
and	CC	O
pindolol	NN	Pharmacological
.	.	O

Considerable	JJ	O
differences	NNS	O
in	IN	O
dose	NN	O
(	(	O
atenolol	JJ	Pharmacological
138	CD	O
+/-	JJ	O
13	CD	O
mg	JJ	O
daily	RB	O
;	:	O
labetalol	VBZ	Pharmacological
308	CD	O
+/-	JJ	O
34	CD	O
mg	JJ	O
daily	RB	O
;	:	O
metoprolol	PRP	Pharmacological
234	CD	O
+/-	JJ	O
22	CD	O
mg	JJ	O
daily	RB	O
;	:	O
and	CC	O
pindolol	VB	Pharmacological
24	CD	O
+/-2	JJ	O
mg	NNS	O
daily	JJ	O
were	VBD	O
required	VBN	O
to	TO	O
produce	VB	O
similar	JJ	O
antihypertensive	JJ	O
effects	NNS	O
.	.	O

3	CD	O
The	DT	O
overall	JJ	O
incidence	NN	O
of	IN	O
side-effects	NNS	O
was	VBD	O
similar	JJ	O
with	IN	O
atenolol	NN	Pharmacological
,	,	O
metoprolol	NN	Pharmacological
and	CC	O
pindolol	NN	Pharmacological
but	CC	O
was	VBD	O
slightly	RB	O
less	JJR	O
with	IN	O
labetalol	NN	Pharmacological
.	.	O

Sleep	JJ	O
disturbances	NNS	O
and	CC	O
abnormal	JJ	O
dreaming	NN	O
patterns	NNS	O
were	VBD	O
most	RBS	O
frequent	JJ	O
with	IN	O
pindolol	NN	Pharmacological
.	.	O

4	CD	O
There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
greater	JJR	O
fall	NN	O
in	IN	O
pulse	JJ	O
rate	NN	O
during	IN	O
atenolol	NN	Pharmacological
and	CC	O
metoprolol	NN	Pharmacological
treatment	NN	O
periods	NNS	O
.	.	O

[	IN	O
The	DT	O
effects	NNS	O
of	IN	O
early	JJ	Pharmacological
enteral	JJ	Pharmacological
nutrition	NN	Pharmacological
with	IN	Pharmacological
addition	NN	Pharmacological
of	IN	Pharmacological
probiotics	NNS	Pharmacological
on	IN	O
the	DT	O
prognosis	NN	O
of	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
severe	JJ	O
acute	NN	O
pancreatitis	NN	O
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
curative	JJ	O
effect	NN	O
of	IN	O
early	JJ	Pharmacological
enteral	JJ	Pharmacological
nutrition	NN	Pharmacological
(	(	Pharmacological
EN	NNP	Pharmacological
)	)	Pharmacological
supplemented	VBD	Pharmacological
with	IN	Pharmacological
probiotics	NNS	Pharmacological
(	(	Pharmacological
bifidobacterium	NN	Pharmacological
)	)	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
acute	NN	O
pancreatitis	NN	O
(	(	O
ASP	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Seventy	NNP	O
SAP	NNP	O
cases	NNS	O
admitted	VBD	O
from	IN	O
January	NNP	O
2005	CD	O
to	TO	O
October	NNP	O
2012	CD	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
parenteral	JJ	Pharmacological
nutrition	NN	Pharmacological
(	(	Pharmacological
PN	NNP	Pharmacological
)	)	Pharmacological
group	NN	O
(	(	O
n=22	NN	O
)	)	O
,	,	O
EN	NNP	Pharmacological
group	NN	O
(	(	O
n=25	CC	O
)	)	O
and	CC	O
bifidobacterium	NN	Pharmacological
added	VBD	Pharmacological
EN	NNP	Pharmacological
(	(	Pharmacological
P+EN	NNP	Pharmacological
)	)	Pharmacological
group	NN	O
(	(	O
n=23	RB	O
)	)	O
.	.	O

In	IN	O
P+EN	NNP	Pharmacological
group	NN	O
,	,	O
patients	NNS	O
were	VBD	O
given	VBN	O
their	PRP$	O
nutrition	NN	O
the	DT	O
same	JJ	O
as	IN	O
that	DT	O
of	IN	O
EN	NNP	Pharmacological
,	,	O
and	CC	O
also	RB	O
probiotics	NNS	Pharmacological
(	(	Pharmacological
bifidobacterium	NN	Pharmacological
,	,	O
4	CD	O
capsules	NNS	O
every	DT	O
12	CD	O
hours	NNS	O
,	,	O
given	VBN	O
through	IN	O
nasal	JJ	O
gastric	JJ	O
tube	NN	O
,	,	O
each	DT	O
capsule	NN	O
weighing	VBG	O
210	CD	O
mg	NN	O
)	)	O
.	.	O

The	DT	O
routine	JJ	O
treatment	NN	O
including	VBG	O
anti-infection	NN	Pharmacological
and	CC	Pharmacological
anti-acid	JJ	Pharmacological
agents	NNS	Pharmacological
,	,	O
and	CC	O
that	IN	O
of	IN	O
inhibition	NN	O
of	IN	O
pancreatic	JJ	O
secretion	NN	O
were	VBD	O
given	VBN	O
,	,	O
except	IN	O
for	IN	O
the	DT	O
different	JJ	O
nutritional	JJ	O
interventions	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

The	DT	O
blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
for	IN	O
e	NN	O
same	JJ	O
measurements	NNS	O
of	IN	O
interleukin-8	JJ	O
(	(	O
IL-8	NNP	O
)	)	O
and	CC	O
tumor	JJ	O
necrosis	NN	O
factor	NN	O
(	(	O
TNF-?	NNP	O
)	)	O
by	IN	O
enzyme	NN	O
linked	VBN	O
immunosorbent	JJ	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
,	,	O
and	CC	O
for	IN	O
the	DT	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
,	,	O
lactic	JJ	O
acid	NN	O
dehydrogenase	NN	O
(	(	O
LDH	NNP	O
)	)	O
,	,	O
white	JJ	O
blood	NN	O
cell	NN	O
(	(	O
WBC	NNP	O
)	)	O
count	NN	O
,	,	O
amylase	NN	O
and	CC	O
lipase	NN	O
by	IN	O
biochemistry	NN	O
assay	VBP	O
1	CD	O
day	NN	O
before	IN	O
intervention	NN	O
of	IN	O
nutrition	NN	O
,	,	O
and	CC	O
7	CD	O
days	NNS	O
and	CC	O
14	CD	O
days	NNS	O
after	IN	O
intervention	NN	O
.	.	O

Changes	NNS	O
in	IN	O
organ	JJ	O
function	NN	O
and	CC	O
outcome	NN	O
were	VBD	O
also	RB	O
recorded	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
points	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
plasma	JJ	O
levels	NNS	O
of	IN	O
IL-8	NNP	O
,	,	O
TNF-?	NNP	O
,	,	O
CRP	NNP	O
,	,	O
LDH	NNP	O
,	,	O
WBC	NNP	O
count	NN	O
,	,	O
amylase	NN	O
and	CC	O
lipase	NN	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
nutritional	JJ	O
intervention	NN	O
compared	VBN	O
with	IN	O
their	PRP$	O
levels	NNS	O
on	IN	O
day	NN	O
1	CD	O
before	IN	O
intervention	NN	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
.	.	O

The	DT	O
plasma	JJ	O
IL-8	NNP	O
,	,	O
TNF-?	NNP	O
,	,	O
CRP	NNP	O
,	,	O
lipase	NN	O
,	,	O
LDH	NNP	O
at	IN	O
14	CD	O
days	NNS	O
after	IN	O
intervention	NN	O
of	IN	O
nutrition	NN	O
in	IN	O
P+EN	NNP	O
group	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
those	DT	O
in	IN	O
PN	NNP	O
group	NN	O
and	CC	O
EN	NNP	O
group	NN	O
(	(	O
IL-8	NNP	O
:	:	O
21.00	CD	O
?	.	O
7.07	CD	O
?g/L	NN	O
vs.	FW	O
48.00	CD	O
?	.	O
10.32	CD	O
?g/L	NN	O
,	,	O
32.00	CD	O
?	.	O
9.30	CD	O
?g/L	NN	O
;	:	O
TNF-?	JJ	O
:	:	O
44.3	CD	O
?	.	O
10.9	CD	O
ng/L	JJ	O
vs.	FW	O
132.1	CD	O
?	.	O
34.1	CD	O
ng/L	NN	O
,	,	O
67.8	CD	O
?	.	O
22.3	CD	O
ng/L	NN	O
;	:	O
CRP	NNP	O
:	:	O
35.0	CD	O
?	.	O
12.4	CD	O
mg/L	NN	O
vs.	FW	O
103.2	CD	O
?	.	O
49.2	CD	O
mg/L	NN	O
,	,	O
63.0	CD	O
?	.	O
29.2	CD	O
mg/L	NN	O
;	:	O
lipase	NN	O
:	:	O
269	CD	O
?	.	O
79	CD	O
U/L	NNP	O
vs.	FW	O
670	CD	O
?	.	O
145	CD	O
U/L	NNP	O
,	,	O
310	CD	O
?	.	O
78	CD	O
U/L	NNP	O
;	:	O
LDH	NNP	O
:	:	O
21.8	CD	O
?	.	O
10.3	CD	O
U/L	NNP	O
vs.	FW	O
78.1	CD	O
?	.	O
37.4	CD	O
U/L	NNP	O
,	,	O
37.9	CD	O
?	.	O
25.1	CD	O
U/L	NNP	O
,	,	O
P	NNP	O
<	VBZ	O
0.05	CD	O
or	CC	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
WBC	NNP	O
count	NN	O
in	IN	O
P+EN	NNP	O
group	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
PN	NNP	O
group	NN	O
(	(	O
5.9	CD	O
?	.	O
3.0	CD	O
?	.	O
10?/L	CD	O
,	,	O
6.3	CD	O
?	.	O
3.2	CD	O
?	.	O
10?/L	CD	O
vs.	IN	O
9.6	CD	O
?	.	O
3.0	CD	O
?10?/L	NN	O
,	,	O
both	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
amylase	NN	O
between	IN	O
P+EN	NNP	O
group	NN	O
and	CC	O
PN	NNP	O
group	NN	O
(	(	O
211	CD	O
?	.	O
49	CD	O
U/L	NNP	O
,	,	O
236	CD	O
?	.	O
52	CD	O
U/L	NNP	O
vs.	FW	O
298	CD	O
?	.	O
71	CD	O
U/L	NNP	O
,	,	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
gastrointestinal	JJ	O
dysfunction	NN	O
score	NN	O
in	IN	O
P+EN	NNP	O
,	,	O
EN	NNP	O
,	,	O
PN	NNP	O
groups	NNS	O
14	CD	O
days	NNS	O
after	IN	O
nutritional	JJ	O
intervention	NN	O
was	VBD	O
0.28	CD	O
?	.	O
0.05	CD	O
,	,	O
0.43	CD	O
?	.	O
0.09	CD	O
,	,	O
0.71	CD	O
?	.	O
0.11	CD	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
PN	NNP	O
and	CC	O
EN	NNP	O
groups	NNS	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
upper	JJ	O
gastrointestinal	JJ	O
bleeding	NN	O
(	(	O
1	CD	O
vs.	FW	O
9	CD	O
,	,	O
2	CD	O
)	)	O
,	,	O
infection	NN	O
and	CC	O
abscess	NN	O
(	(	O
2	CD	O
vs.	FW	O
12	CD	O
,	,	O
5	CD	O
)	)	O
was	VBD	O
lower	JJR	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
hospital	JJ	O
day	NN	O
was	VBD	O
significantly	RB	O
shortened	VBN	O
in	IN	O
P+EN	NNP	O
group	NN	O
(	(	O
10.4	CD	O
?	.	O
3.9	CD	O
days	NNS	O
vs.	FW	O
25.8	CD	O
?	.	O
6.4	CD	O
days	NNS	O
,	,	O
13.4	CD	O
?	.	O
5.2	CD	O
days	NNS	O
,	,	O
both	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
statistical	JJ	O
difference	NN	O
in	IN	O
mortality	NN	O
rate	NN	O
among	IN	O
three	CD	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
indicated	VBD	O
that	IN	O
early	JJ	O
EN	NNP	O
with	IN	O
addition	NN	O
of	IN	O
probiotics	NNS	O
(	(	O
bifidobacterium	NN	O
)	)	O
resulted	VBD	O
in	IN	O
significant	JJ	O
lowering	NN	O
of	IN	O
the	DT	O
level	NN	O
of	IN	O
pro-inflammatory	JJ	O
cytokines	NNS	O
,	,	O
earlier	JJR	O
restoration	NN	O
of	IN	O
gastrointestinal	JJ	O
function	NN	O
,	,	O
decrease	NN	O
of	IN	O
complications	NNS	O
such	JJ	O
as	IN	O
infection	NN	O
,	,	O
and	CC	O
shortening	NN	O
of	IN	O
hospital	JJ	O
day	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SAP	NNP	O
.	.	O

[	NN	O
Specific	NNP	O
T	NNP	O
cell	NN	O
immune	NN	O
response	NN	O
in	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
different	JJ	O
doses	NNS	O
of	IN	O
recombinant	JJ	Pharmacological
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
]	NN	Pharmacological
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
specific	JJ	O
cellular	JJ	O
immunoresponse	NN	O
of	IN	O
peripheral	JJ	O
blood	NN	O
lymphocytes	NNS	O
in	IN	O
the	DT	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
different	JJ	O
doses	NNS	O
of	IN	O
recombinant	JJ	Pharmacological
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
.	.	O

METHODS	NNP	O
Seventy-two	NNP	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
use	VB	O
any	DT	O
anti-HBV	JJ	O
drugs	NNS	O
within	IN	O
6	CD	O
months	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
3	CD	O
groups	NNS	O
(	(	O
90	CD	O
micrograms	NNS	O
,	,	O
60	CD	O
micrograms	NNS	O
,	,	O
and	CC	O
placebo	NN	Control
)	)	Control
in	IN	O
a	DT	O
ratio	NN	O
of	IN	O
1:1:1	CD	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
different	JJ	O
groups	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
different	JJ	Pharmacological
doses	NNS	Pharmacological
of	IN	Pharmacological
recombinant	JJ	Pharmacological
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
in	IN	Pharmacological
combination	NN	Pharmacological
with	IN	Pharmacological
IFN	NNP	Pharmacological
alpha	VBP	Pharmacological
1b	CD	Pharmacological
50	CD	Pharmacological
micrograms	NNS	Pharmacological
with	IN	Pharmacological
3	CD	Pharmacological
times	NNS	Pharmacological
a	DT	Pharmacological
week	NN	Pharmacological
for	IN	Pharmacological
24	CD	Pharmacological
weeks	NNS	Pharmacological
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
24	CD	O
weeks	NNS	O
(	(	O
W24	NNP	O
)	)	O
.	.	O

HBV	NNP	O
DNA	NNP	O
,	,	O
HBeAg	NNP	O
and	CC	O
liver	JJ	O
functions	NNS	O
were	VBD	O
detected	VBN	O
at	IN	O
different	JJ	O
time	NN	O
points	NNS	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
cells	NNS	O
that	WDT	O
secrete	VBP	O
IFN-gamma	NNP	O
were	VBD	O
detected	VBN	O
by	IN	O
ELISPOT	NNP	O
.	.	O

RESULTS	NNP	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
ELISPOT	NNP	O
positive	JJ	O
ratio	NN	O
among	IN	O
the	DT	O
3	CD	O
groups	NNS	O
on	IN	O
baseline	JJ	O
detection	NN	O
.	.	O

At	IN	O
W24	NNP	O
,	,	O
12	CD	O
cases	NNS	O
,	,	O
12	CD	O
cases	NNS	O
,	,	O
and	CC	O
7	CD	O
cases	NNS	O
showed	VBD	O
ELISPOT	NNP	O
positive	JJ	O
in	IN	O
the	DT	O
group	NN	O
of	IN	O
90	CD	O
micrograms	NNS	O
,	,	O
60	CD	O
micrograms	NNS	O
,	,	O
and	CC	O
placebo	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
ELISPOT	NNP	O
positive	JJ	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
groups	NNS	O
treated	VBD	O
with	IN	O
recombinant	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
(	(	O
including	VBG	O
the	DT	O
dose	NN	O
of	IN	O
90	CD	O
micrograms	NNS	O
and	CC	O
60	CD	O
micrograms	NNS	O
)	)	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
P=0.0446	NNP	O
)	)	O
.	.	O

HBV	NNP	O
DNA	NNP	O
turned	VBD	O
negative	JJ	O
in	IN	O
6/24	CD	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBD	O
with	IN	O
recombinant	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
(	(	O
at	IN	O
both	DT	O
the	DT	O
doses	NNS	O
of	IN	O
90	CD	O
micrograms	NNS	O
and	CC	O
60	CD	O
micrograms	NNS	O
)	)	O
,	,	O
and	CC	O
HBeAg/Anti-HBe	NNP	O
seroconversion	NN	O
or	CC	O
HBeAg	NNP	O
became	VBD	O
negative	JJ	O
in	IN	O
7/24	CD	O
of	IN	O
them	PRP	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
patients	NNS	O
showed	VBD	O
undetectable	JJ	O
HBV	NNP	O
DNA	NNP	O
,	,	O
HBeAg/Anti-HBe	NNP	O
seroconversion	NN	O
or	CC	O
HBeAg	NNP	O
disappearance	NN	O
.	.	O

At	IN	O
the	DT	O
24W	CD	O
of	IN	O
follow	NN	O
up	RB	O
,	,	O
in	IN	O
the	DT	O
patients	NNS	O
who	WP	O
were	VBD	O
ELISPOT	NNP	O
positive	JJ	O
,	,	O
HBV	NNP	O
DNA	NNP	O
became	VBD	O
undetectable	JJ	O
in	IN	O
4	CD	O
of	IN	O
the	DT	O
patients	NNS	O
treated	VBD	O
with	IN	O
recombinant	JJ	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
(	(	O
at	IN	O
doses	NNS	O
of	IN	O
90	CD	O
micrograms	NNS	O
and	CC	O
60	CD	O
micrograms	NNS	O
)	)	O
,	,	O
and	CC	O
HBeAg/Anti-HBe	NNP	O
seroconversion	NN	O
or	CC	O
HBeAg	NNP	O
disappearance	NN	O
were	VBD	O
found	VBN	O
in	IN	O
9	CD	O
of	IN	O
the	DT	O
cases	NNS	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
cases	NNS	O
showed	VBD	O
undetectable	JJ	O
HBV	NNP	O
DNA	NNP	O
,	,	O
and	CC	O
only	RB	O
1	CD	O
case	NN	O
had	VBD	O
HBeAg/Anti-HBe	NNP	O
seroconversion	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
recombinant	JJ	Pharmacological
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
may	MD	O
increase	VB	O
the	DT	O
function	NN	O
of	IN	O
specific	JJ	O
T	NNP	O
lymphocytes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
dose	NN	O
of	IN	O
90	CD	O
micrograms	NNS	O
and	CC	O
60	CD	O
micrograms	NNS	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
.	.	O

Preoperative	JJ	O
lanreotide	NN	Pharmacological
treatment	NN	O
in	IN	O
acromegalic	JJ	O
patients	NNS	O
with	IN	O
macroadenomas	JJ	O
increases	NNS	O
short-term	JJ	O
postoperative	JJ	O
cure	NN	O
rates	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
investigate	VB	O
whether	IN	O
4-month	JJ	O
preoperative	JJ	O
lanreotide	NN	O
treatment	NN	O
would	MD	O
improve	VB	O
the	DT	O
surgical	JJ	O
cure	NN	O
rate	NN	O
of	IN	O
newly	RB	O
diagnosed	VBN	O
acromegalic	JJ	O
patients	NNS	O
with	IN	O
macroadenomas	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
a	DT	O
baseline	NN	O
evaluation	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
4-month	JJ	O
preoperative	JJ	O
treatment	NN	O
with	IN	O
lanreotide	NN	Pharmacological
(	(	O
starting	VBG	O
with	IN	O
30	CD	O
mg/2	JJ	O
weeks	NNS	O
i.m	NN	O
.	.	O

and	CC	O
increasing	VBG	O
to	TO	O
30	CD	O
mg/week	NN	O
i.m	NN	O
.	.	O

at	IN	O
week	NN	O
8	CD	O
if	IN	O
mean	JJ	O
GH	NNP	O
>	NNP	O
2.5	CD	O
microg/l	NN	O
on	IN	O
GH	NNP	O
day	NN	O
curves	VBZ	O
;	:	O
pretreatment	NN	O
group	NN	O
,	,	O
Group	NNP	O
1	CD	O
)	)	O
or	CC	O
to	TO	O
transsphenoidal	VB	Surgical
surgery	NN	Surgical
(	(	O
direct	JJ	O
surgery	NN	O
group	NN	O
,	,	O
Group	NNP	O
2	CD	O
)	)	O
.	.	O

Cure	NN	O
was	VBD	O
evaluated	VBN	O
4	CD	O
months	NNS	O
postoperatively	RB	O
primarily	RB	O
by	IN	O
fasting	VBG	O
IGF1	NNP	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
age-adjusted	JJ	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
.	.	O

RESULTS	VB	O
A	DT	O
pool	NN	O
of	IN	O
108	CD	O
patients	NNS	O
was	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Five	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
lost	VBN	O
to	TO	O
follow-up	NN	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
so	RB	O
49	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
were	VBD	O
analysed	VBN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
no	DT	O
difference	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Cure	NN	O
was	VBD	O
established	VBN	O
in	IN	O
24	CD	O
of	IN	O
49	CD	O
(	(	O
49.0	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
,	,	O
35.0-63.0	JJ	O
%	NN	O
)	)	O
pretreated	VBD	O
patients	NNS	O
(	(	O
Group	NNP	O
1	CD	O
)	)	O
versus	NN	O
9	CD	O
of	IN	O
49	CD	O
(	(	O
18.4	CD	O
%	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
7.6-29.2	CD	O
%	NN	O
)	)	O
direct	JJ	O
surgery	NN	O
patients	NNS	O
(	(	O
Group	NNP	O
2	CD	O
;	:	O
P=0.001	NNP	O
)	)	O
.	.	O

Surgical	JJ	O
morbidity	NN	O
was	VBD	O
recorded	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
(	(	O
12.2	CD	O
%	NN	O
)	)	O
and	CC	O
was	VBD	O
similar	JJ	O
in	IN	O
Group	NNP	O
1	CD	O
and	CC	O
2	CD	O
patients	NNS	O
(	(	O
14.3	CD	O
and	CC	O
10.2	CD	O
%	NN	O
respectively	RB	O
;	:	O
P=0.538	NNP	O
)	)	O
.	.	O

The	DT	O
postoperative	JJ	O
hospital	NN	O
stay	NN	O
was	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
:	:	O
being	VBG	O
4.5+/-1.6	JJ	O
days	NNS	O
in	IN	O
Group	NNP	O
1	CD	O
vs	IN	O
4.8+/-1.9	JJ	O
days	NNS	O
in	IN	O
Group	NNP	O
2	CD	O
(	(	O
P=0.328	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Pretreatment	NNP	O
with	IN	O
lanreotide	NN	Pharmacological
before	IN	O
transsphenoidal	JJ	O
surgery	NN	O
improves	VBZ	O
surgical	JJ	O
cure	NN	O
rates	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
GH-secreting	NNP	O
pituitary	JJ	O
macroadenomas	NN	O
.	.	O

Pretreatment	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
surgical	JJ	O
complications	NNS	O
or	CC	O
duration	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
(	(	O
ClinicalTrials.gov	NNP	O
number	NN	O
,	,	O
NCT00993356	NNP	O
)	)	O
.	.	O

A	DT	O
selective	JJ	Physical
angiotensin	NN	Physical
receptor	NN	Physical
antagonist	NN	Physical
,	,	O
Valsartan	NNP	Pharmacological
,	,	O
produced	VBD	O
regression	NN	O
of	IN	O
left	JJ	O
ventricular	JJ	O
hypertrophy	NN	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
of	IN	O
arterial	JJ	O
stiffness	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
a	DT	O
selective	JJ	Pharmacological
angiotensin	NN	Pharmacological
II	NNP	Pharmacological
receptor	NN	Pharmacological
blocker	NN	Pharmacological
(	(	Pharmacological
ARB	NNP	Pharmacological
)	)	Pharmacological
would	MD	O
have	VB	O
a	DT	O
regressive	JJ	O
effect	NN	O
on	IN	O
left	NN	O
ventricular	JJ	O
hypertrophy	NN	O
(	(	O
LVH	NNP	O
)	)	O
in	IN	O
patients	NNS	O
on	IN	O
continuous	JJ	O
ambulatory	JJ	O
peritoneal	JJ	O
dialysis	NN	O
(	(	O
CAPD	NNP	O
)	)	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
study	NN	O
,	,	O
24	CD	O
CAPD	NNP	O
patients	NNS	O
with	IN	O
LVH	NNP	O
[	NNP	O
left	VBD	O
ventricular	JJ	O
mass	NN	O
index	NN	O
(	(	O
LVMi	NNP	O
)	)	O
>	VBD	O
110	CD	O
g/m2	NN	O
for	IN	O
women	NNS	O
and	CC	O
LVMi	NNP	O
>	NNP	O
137	CD	O
g/m2	NN	O
for	IN	O
men	NNS	O
]	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
12	CD	O
months	NNS	O
'	POS	O
administration	NN	O
of	IN	O
either	CC	O
the	DT	O
ARB	NNP	Pharmacological
valsartan	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
or	CC	Control
a	DT	Control
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

The	DT	O
target	NN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
was	VBD	O
140/90	CD	O
mmHg	NN	O
or	CC	O
lower	JJR	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
following	JJ	O
parameters	NNS	O
were	VBD	O
measured	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
:	:	O
aortic	JJ	O
and	CC	O
large-artery	JJ	O
compliance	NN	O
and	CC	O
arterial	JJ	O
wave	NN	O
reflections	NNS	O
[	VBP	O
pulse	JJ	O
wave	VBP	O
velocity	NN	O
(	(	O
PWV	NNP	O
)	)	O
and	CC	O
augmentation	NN	O
index	NN	O
(	(	O
AI	NNP	O
)	)	O
application	NN	O
tonometry	NN	O
]	NNP	O
and	CC	O
cardiac	JJ	O
echocardiography	NN	O
.	.	O

Periodically	RB	O
recorded	VBN	O
were	VBD	O
body	JJ	O
weight	NN	O
,	,	O
BP	NNP	O
(	(	O
mercury	NN	O
sphygmomanometer	NN	O
)	)	O
,	,	O
serum	JJ	O
creatinine	NN	O
,	,	O
electrolytes	VBZ	O
,	,	O
complete	JJ	O
blood	NN	O
cell	NN	O
counts	NNS	O
,	,	O
urine	JJ	O
volume	NN	O
,	,	O
drainage	NN	O
volume	NN	O
,	,	O
and	CC	O
weekly	JJ	O
creatinine	NN	O
clearance	NN	O
.	.	O

Two-way	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
for	IN	O
repeated	JJ	O
measurements	NNS	O
was	VBD	O
used	VBN	O
for	IN	O
statistical	JJ	O
analysis	NN	O
.	.	O

Systolic	NNP	O
and	CC	O
diastolic	JJ	O
BP	NNP	O
were	VBD	O
both	DT	O
reduced	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
ARB	NNP	O
.	.	O

The	DT	O
LVMi	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
ARB	NNP	O
(	(	O
to	TO	O
121	CD	O
+/-	JJ	O
4	CD	O
from	IN	O
145	CD	O
+/-	JJ	O
5	CD	O
)	)	O
but	CC	O
not	RB	O
in	IN	O
those	DT	O
receiving	VBG	O
placebo	NN	O
(	(	O
to	TO	O
137	CD	O
+/-	JJ	O
3	CD	O
from	IN	O
152	CD	O
+/-	JJ	O
3	CD	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
LVMi	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
PWV	NNP	O
and	CC	O
AI	NNP	O
.	.	O

In	IN	O
CAPD	NNP	O
patients	NNS	O
with	IN	O
LVH	NNP	O
,	,	O
ARB	NNP	O
reduced	VBD	O
LVMi	NNP	O
in	IN	O
association	NN	O
with	IN	O
alterations	NNS	O
in	IN	O
arterial	JJ	O
hemodynamics	NNS	O
.	.	O

Transthoracic	NNP	Physical
versus	NN	O
transesophageal	NN	Surgical
cardioversion	NN	Surgical
of	IN	Surgical
atrial	JJ	Surgical
fibrillation	NN	Surgical
under	IN	O
light	JJ	O
sedation	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Electrical	JJ	O
cardioversion	NN	O
(	(	O
ECV	NNP	O
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
limited	VBN	O
by	IN	O
a	DT	O
5-10	JJ	O
%	NN	O
failure	NN	O
rate	NN	O
and	CC	O
by	IN	O
the	DT	O
expense	NN	O
arising	VBG	O
from	IN	O
a	DT	O
perceived	JJ	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

A	DT	O
transesophageal	JJ	O
approach	NN	O
using	VBG	O
light	JJ	O
sedation	NN	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
as	IN	O
a	DT	O
means	NN	O
of	IN	O
augmenting	VBG	O
the	DT	O
success	NN	O
rate	NN	O
and	CC	O
avoiding	VBG	O
the	DT	O
need	NN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
the	DT	O
high	JJ	O
rate	NN	O
of	IN	O
success	NN	O
and	CC	O
the	DT	O
lower	JJR	O
energy	NN	O
requirement	NN	O
associated	VBN	O
with	IN	O
biphasic	JJ	O
cardioversion	NN	O
might	MD	O
eliminate	VB	O
any	DT	O
advantage	NN	O
of	IN	O
the	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
randomly	VBP	O
assigned	VBD	O
60	CD	O
patients	NNS	O
attending	VBG	O
for	IN	O
ECV	NNP	O
of	IN	O
persistent	JJ	O
AF	NNP	O
to	TO	O
a	DT	O
transesophageal	NN	Surgical
or	CC	O
a	DT	O
transthoracic	JJ	Physical
approach	NN	Physical
.	.	O

Sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
was	VBD	O
achieved	VBN	O
with	IN	O
intravenous	JJ	Pharmacological
midazolam	NNS	Pharmacological
.	.	O

The	DT	O
dose	NN	O
of	IN	O
midazolam	NN	O
was	VBD	O
titrated	VBN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Sinus	NNP	O
rhythm	NN	O
was	VBD	O
restored	VBN	O
in	IN	O
29/30	CD	O
patients	NNS	O
(	(	O
97	CD	O
%	NN	O
)	)	O
in	IN	O
each	DT	O
group	NN	O
using	VBG	O
a	DT	O
similar	JJ	O
number	NN	O
of	IN	O
shocks	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
1.3	CD	O
+/-	JJ	O
0.6	CD	O
transesophageal	NN	O
vs	NN	O
1.4	CD	O
+/-	JJ	O
0.7	CD	O
transthoracic	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
with	IN	O
a	DT	O
similar	JJ	O
procedure	NN	O
duration	NN	O
(	(	O
14.1	CD	O
+/-	JJ	O
8.2	CD	O
minutes	NNS	O
vs	JJ	O
13.8	CD	O
+/-	JJ	O
7.5	CD	O
minutes	NNS	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
similar	JJ	O
doses	NNS	O
of	IN	O
midazolam	NN	O
(	(	O
4.2	CD	O
+/-	JJ	O
2.7	CD	O
mg	NN	O
vs	NN	O
4.4	CD	O
+/-	JJ	O
2.8	CD	O
mg	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
and	CC	O
both	DT	O
reported	VBD	O
a	DT	O
similar	JJ	O
discomfort	NN	O
score	NN	O
in	IN	O
(	(	O
0.9	CD	O
+/-	JJ	O
1.3	CD	O
vs	JJ	O
1.1	CD	O
+/-	JJ	O
1.8	CD	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

No	DT	O
complication	NN	O
occurred	VBD	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
AF	NNP	O
may	MD	O
be	VB	O
cardioverted	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
by	IN	O
either	CC	O
a	DT	O
transthoracic	NN	O
or	CC	O
a	DT	O
transesophageal	JJ	O
approach	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
sedation	NN	O
of	IN	O
moderate	JJ	O
depth	NN	O
renders	NNS	O
cardioversion	NN	O
by	IN	O
either	DT	O
approach	NN	O
acceptable	JJ	O
.	.	O

As	IN	O
transesophageal	NN	O
ECV	NNP	O
shows	VBZ	O
no	DT	O
clear	JJ	O
advantage	NN	O
,	,	O
transthoracic	JJ	O
cardioversion	NN	O
should	MD	O
remain	VB	O
the	DT	O
approach	NN	O
of	IN	O
first	JJ	O
choice	NN	O
.	.	O

Histopathologic	NNP	O
changes	NNS	O
of	IN	O
the	DT	O
eyelid	JJ	O
skin	NN	O
following	VBG	O
trichloroacetic	JJ	Physical
acid	JJ	Physical
chemical	NN	Physical
peel	NN	Physical
.	.	O

The	DT	O
use	NN	O
of	IN	O
trichloroacetic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
TCA	NNP	Pharmacological
)	)	Pharmacological
as	IN	O
a	DT	O
periorbital	NN	O
and	CC	O
eyelid	JJ	O
peel	NN	O
for	IN	O
skin	JJ	O
rejuvenation	NN	O
is	VBZ	O
gaining	VBG	O
significant	JJ	O
acceptance	NN	O
among	IN	O
oculoplastic	JJ	O
surgeons	NNS	O
,	,	O
dermatologists	NNS	O
,	,	O
and	CC	O
other	JJ	O
surgery	NN	O
groups	NNS	O
.	.	O

In	IN	O
spite	NN	O
of	IN	O
the	DT	O
current	JJ	O
enthusiasm	NN	O
,	,	O
there	EX	O
remain	VBP	O
potentially	RB	O
serious	JJ	O
complications	NNS	O
resulting	VBG	O
from	IN	O
any	DT	O
periorbital	JJ	O
peel	NN	O
.	.	O

Cases	NNS	O
of	IN	O
cicatricial	JJ	O
ectropion	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
phenol-peeled	JJ	O
patients	NNS	O
,	,	O
and	CC	O
lower	JJR	O
eyelid	JJ	O
ectropion	NN	O
has	VBZ	O
reportedly	RB	O
occurred	VBN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
deep	JJ	O
eyelid	NN	O
peel	NN	O
in	IN	O
conjunction	NN	O
with	IN	O
a	DT	O
blepharoplasty	NN	Surgical
(	(	O
1,2	CD	O
)	)	O
.	.	O

To	TO	O
avoid	VB	O
this	DT	O
complication	NN	O
,	,	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
better	RBR	O
understand	VB	O
the	DT	O
depth	NN	O
of	IN	O
the	DT	O
wound	NN	O
produced	VBN	O
by	IN	O
different	JJ	O
strengths	NNS	O
and	CC	O
combinations	NNS	O
of	IN	O
peeling	VBG	O
agents	NNS	O
applied	VBN	O
to	TO	O
living	VBG	O
eyelid	JJ	O
tissue	NN	O
and	CC	O
,	,	O
more	RBR	O
important	JJ	O
,	,	O
to	TO	O
determine	VB	O
the	DT	O
concentrations	NNS	O
of	IN	O
TCA	NNP	Pharmacological
that	WDT	O
are	VBP	O
likely	JJ	O
to	TO	O
lead	VB	O
to	TO	O
cicatricial	JJ	O
ectropion	NN	O
when	WRB	O
applied	VBN	O
in	IN	O
a	DT	O
consistent	JJ	O
fashion	NN	O
.	.	O

We	PRP	O
chose	VBD	O
upper-eyelid	JJ	O
skin	NN	O
because	IN	O
it	PRP	O
is	VBZ	O
easier	JJR	O
to	TO	O
obtain	VB	O
for	IN	O
histopathologic	NN	O
study	NN	O
than	IN	O
lower-eyelid	JJ	O
skin	NN	O
and	CC	O
,	,	O
in	IN	O
our	PRP$	O
experience	NN	O
,	,	O
is	VBZ	O
more	RBR	O
sensitive	JJ	O
to	TO	O
hypertrophic	JJ	O
changes	NNS	O
after	IN	O
chemical	NN	O
peeling	NN	O
or	CC	O
carbon	NN	O
dioxide	IN	O
laser	NN	O
resurfacing	NN	O
.	.	O

We	PRP	O
applied	VBD	O
TCA	NNP	Pharmacological
to	TO	O
the	DT	O
preseptal	JJ	O
skin	NN	O
of	IN	O
10	CD	O
patients	NNS	O
48	CD	O
h	NN	O
before	IN	O
standard	JJ	O
upper-eyelid	JJ	O
blepharoplasty	NN	O
.	.	O

The	DT	O
acid	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
produce	VB	O
a	DT	O
frost	NN	O
,	,	O
using	VBG	O
varying	VBG	O
concentrations	NNS	O
of	IN	O
acid	NN	O
,	,	O
ranging	VBG	O
from	IN	O
20	CD	O
to	TO	O
50	CD	O
%	NN	O
.	.	O

The	DT	O
treated	JJ	O
skin	NN	O
removed	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
blepharoplasty	NN	O
was	VBD	O
reviewed	VBN	O
in	IN	O
a	DT	O
masked	JJ	O
fashion	NN	O
by	IN	O
a	DT	O
dermatopathologist	NN	O
to	TO	O
determine	VB	O
the	DT	O
depth	NN	O
of	IN	O
necrosis	NN	O
.	.	O

We	PRP	O
found	VBD	O
that	IN	O
superficial	JJ	O
peels	NNS	O
with	IN	O
necrosis	NN	O
involving	VBG	O
30	CD	O
%	NN	O
of	IN	O
the	DT	O
epidermis	NN	O
were	VBD	O
produced	VBN	O
by	IN	O
the	DT	O
lowest-concentration	JJ	O
combination	NN	O
of	IN	O
TCA	NNP	Pharmacological
applied	VBD	O
(	(	O
20	CD	O
%	NN	O
followed	VBN	O
by	IN	O
0	CD	O
%	NN	O
)	)	O
.	.	O

As	IN	O
the	DT	O
strength	NN	O
increased	VBD	O
,	,	O
so	RB	O
did	VBD	O
the	DT	O
depth	NN	O
of	IN	O
peel	NN	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
50	CD	O
%	NN	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
application	NN	O
of	IN	O
50	CD	O
%	NN	O
produced	VBD	O
the	DT	O
deepest	JJS	O
peel	NN	O
,	,	O
with	IN	O
necrosis	NN	O
into	IN	O
the	DT	O
papillary	JJ	O
dermis	NN	O
.	.	O

This	DT	O
finding	NN	O
would	MD	O
indicate	VB	O
that	IN	O
the	DT	O
chance	NN	O
of	IN	O
developing	VBG	O
cicatricial	JJ	O
ectropion	NN	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
tested	JJ	O
combinations	NNS	O
of	IN	O
TCA	NNP	Pharmacological
should	MD	O
be	VB	O
very	RB	O
remote	JJ	O
.	.	O

Psoriasis	NN	O
of	IN	O
the	DT	O
scalp	NN	O
treated	VBD	O
with	IN	O
Grenz	NNP	Physical
rays	NNS	Physical
or	CC	O
topical	JJ	Physical
corticosteroid	NN	Physical
combined	VBN	Physical
with	IN	Physical
Grenz	NNP	Physical
rays	NNS	Physical
.	.	Physical

A	DT	O
comparative	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
Grenz	NNP	Physical
ray	NN	Physical
therapy	NN	Physical
alone	RB	O
compared	VBN	O
with	IN	O
Grenz	NNP	Pharmacological
rays	NNS	Pharmacological
combined	VBN	Pharmacological
with	IN	Pharmacological
a	DT	Pharmacological
topical	JJ	Pharmacological
corticosteroid	NN	Pharmacological
(	(	Pharmacological
betamethasone	JJ	Pharmacological
dipropionate	NN	Pharmacological
)	)	Physical
in	IN	O
psoriasis	NN	O
of	IN	O
the	DT	O
scalp	NN	O
,	,	O
40	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

One	CD	O
group	NN	O
received	VBD	O
4	CD	O
Gy	NNP	Physical
of	IN	Physical
Grenz	NNP	Physical
rays	NNS	Physical
administered	VBD	O
on	IN	O
six	CD	O
occasions	NNS	O
at	IN	O
intervals	NNS	O
of	IN	O
1	CD	O
week	NN	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
was	VBD	O
given	VBN	O
the	DT	O
same	JJ	O
Grenz	NNP	Physical
ray	NN	Physical
treatment	NN	Physical
plus	CC	Physical
topical	JJ	Physical
corticosteroid	NN	Physical
.	.	Physical

The	DT	O
patients	NNS	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
Grenz	NNP	O
ray	NN	O
therapy	NN	O
and	CC	O
were	VBD	O
followed-up	NNS	O
for	IN	O
6	CD	O
months	NNS	O
.	.	O

Of	IN	O
the	DT	O
37	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
trial	NN	O
16	CD	O
out	IN	O
of	IN	O
19	CD	O
(	(	O
84	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
Grenz	NNP	Physical
ray	NN	Physical
group	NN	O
,	,	O
and	CC	O
13	CD	O
out	IN	O
of	IN	O
18	CD	O
(	(	O
72	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
combination	NN	O
group	NN	O
healed	VBD	O
.	.	O

The	DT	O
remission	NN	O
time	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Of	IN	O
the	DT	O
patients	NNS	O
who	WP	O
healed	VBD	O
,	,	O
5	CD	O
of	IN	O
16	CD	O
patients	NNS	O
in	IN	O
the	DT	O
Grenz	NNP	Physical
ray	NN	Physical
only	RB	O
group	NN	O
and	CC	O
4	CD	O
of	IN	O
13	CD	O
patients	NNS	O
in	IN	O
the	DT	O
combination	NN	O
group	NN	O
remained	VBD	O
healed	VBN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
Grenz	NNP	Physical
ray	NN	Physical
therapy	NN	Physical
is	VBZ	O
a	DT	O
useful	JJ	O
treatment	NN	O
modality	NN	O
for	IN	O
scalp	JJ	O
psoriasis	NN	O
,	,	O
but	CC	O
that	IN	O
the	DT	O
addition	NN	O
of	IN	O
a	DT	O
topical	JJ	O
corticosteroid	NN	Physical
has	VBZ	O
only	RB	O
a	DT	O
minor	JJ	O
effect	NN	O
.	.	O

Lack	NN	O
of	IN	O
benefit	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	Physical
human	JJ	Physical
secretin	NN	Physical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
and	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

BACKGROUND	NNP	O
Secretin	NNP	Physical
is	VBZ	O
a	DT	O
peptide	JJ	O
hormone	NN	O
that	WDT	O
stimulates	VBZ	O
pancreatic	JJ	O
secretion	NN	O
.	.	O

After	IN	O
recent	JJ	O
publicity	NN	O
about	IN	O
a	DT	O
child	NN	O
with	IN	O
autism	NN	O
whose	WP$	O
condition	NN	O
markedly	RB	O
improved	VBN	O
after	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
secretin	NN	Physical
,	,	O
thousands	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
may	MD	O
have	VB	O
received	VBN	O
secretin	JJ	Physical
injections	NNS	Physical
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	Physical
human	JJ	Physical
secretin	NN	Physical
in	IN	O
60	CD	O
children	NNS	O
(	(	O
age	NN	O
,	,	O
3	CD	O
to	TO	O
14	CD	O
years	NNS	O
)	)	O
with	IN	O
autism	NN	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	O
secretin	NN	O
(	(	O
0.4	CD	O
microg	NN	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
)	)	O
or	CC	O
saline	JJ	Control
placebo	NN	Control
.	.	Control

We	PRP	O
used	VBD	O
standardized	JJ	O
behavioral	JJ	O
measures	NNS	O
of	IN	O
the	DT	O
primary	JJ	O
and	CC	O
secondary	JJ	O
features	NNS	O
of	IN	O
autism	NN	O
,	,	O
including	VBG	O
the	DT	O
Autism	NNP	O
Behavior	NNP	O
Checklist	NNP	O
,	,	O
to	TO	O
assess	VB	O
the	DT	O
degree	NN	O
of	IN	O
impairment	NN	O
at	IN	O
base	NN	O
line	NN	O
and	CC	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
a	DT	O
four-week	JJ	O
period	NN	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
60	CD	O
children	NNS	O
,	,	O
4	CD	O
could	MD	O
not	RB	O
be	VB	O
evaluated	VBN	O
-	:	O
2	CD	O
received	VBD	O
secretin	NN	Physical
outside	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
2	CD	O
did	VBD	O
not	RB	O
return	VB	O
for	IN	O
follow-up	JJ	O
.	.	O

Thus	NNP	O
,	,	O
56	CD	O
children	NNS	O
(	(	O
28	CD	O
in	IN	O
each	DT	O
group	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

As	IN	O
compared	VBN	O
with	IN	O
placebo	NN	Control
,	,	O
secretin	FW	Physical
treatment	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
significant	JJ	O
improvements	NNS	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
outcome	NN	O
measures	NNS	O
.	.	O

Among	IN	O
the	DT	O
children	NNS	O
in	IN	O
the	DT	O
secretin	NN	Physical
group	NN	O
,	,	O
the	DT	O
mean	JJ	O
total	NN	O
score	NN	O
on	IN	O
the	DT	O
Autism	NNP	O
Behavior	NNP	O
Checklist	NNP	O
at	IN	O
base	NN	O
line	NN	O
was	VBD	O
59.0	CD	O
(	(	O
range	NN	O
of	IN	O
possible	JJ	O
values	NNS	O
,	,	O
0	CD	O
to	TO	O
158	CD	O
,	,	O
with	IN	O
a	DT	O
larger	JJR	O
value	NN	O
corresponding	VBG	O
to	TO	O
greater	JJR	O
impairment	NN	O
)	)	O
,	,	O
and	CC	O
among	IN	O
those	DT	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
it	PRP	O
was	VBD	O
63.2	CD	O
.	.	O

The	DT	O
mean	JJ	O
decreases	NNS	O
in	IN	O
scores	NNS	O
over	IN	O
the	DT	O
four-week	JJ	O
period	NN	O
were	VBD	O
8.9	CD	O
in	IN	O
the	DT	O
secretin	NN	Physical
group	NN	O
and	CC	O
17.8	CD	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
mean	JJ	O
difference	NN	O
,	,	O
-8.9	NNP	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
-19.4	VBP	O
to	TO	O
1.6	CD	O
;	:	O
P=0.11	NNP	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
children	NNS	O
had	VBD	O
treatment-limiting	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

After	IN	O
they	PRP	O
were	VBD	O
told	VBN	O
the	DT	O
results	NNS	O
,	,	O
69	CD	O
percent	NN	O
of	IN	O
the	DT	O
parents	NNS	O
of	IN	O
the	DT	O
children	NNS	O
in	IN	O
this	DT	O
study	NN	O
said	VBD	O
they	PRP	O
remained	VBD	O
interested	JJ	O
in	IN	O
secretin	NN	Physical
as	IN	O
a	DT	O
treatment	NN	O
for	IN	O
their	PRP$	O
children	NNS	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
synthetic	JJ	O
human	JJ	Physical
secretin	NN	Physical
is	VBZ	O
not	RB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
autism	NN	O
or	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
three	CD	Pharmacological
dosage-prediction	NN	Pharmacological
methods	NNS	O
for	IN	O
initial	JJ	O
in-hospital	JJ	O
stabilization	NN	O
of	IN	O
warfarin	JJ	O
therapy	NN	O
.	.	O

Three	CD	Pharmacological
dosage-prediction	NN	Pharmacological
methods	NNS	Pharmacological
for	IN	O
initial	JJ	O
in-hospital	JJ	O
stabilization	NN	O
of	IN	O
warfarin	JJ	Pharmacological
therapy	NN	Pharmacological
were	VBD	O
evaluated	VBN	O
.	.	O

Adult	NNP	O
inpatients	NNS	O
who	WP	O
had	VBD	O
received	VBN	O
warfarin	JJ	Pharmacological
sodium	NN	Pharmacological
10	CD	Pharmacological
mg	JJ	Pharmacological
daily	RB	Pharmacological
for	IN	O
less	JJR	O
than	IN	O
three	CD	O
days	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

After	IN	O
receiving	VBG	O
their	PRP$	O
third	JJ	O
warfarin	NN	Pharmacological
dose	NN	O
,	,	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
their	PRP$	O
warfarin	NNS	Pharmacological
dosages	NNS	O
adjusted	VBD	O
using	VBG	O
one	CD	O
of	IN	O
three	CD	O
dosage-prediction	NN	O
methods	NNS	O
:	:	O
by	IN	O
analog	NN	Physical
computer	NN	Physical
(	(	O
n	JJ	O
=	NNP	O
31	CD	O
)	)	O
,	,	O
linear	JJ	Physical
regression	NN	Physical
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
,	,	O
or	CC	O
empiric	JJ	Physical
dosing	NN	Physical
by	IN	Physical
the	DT	Physical
physician	NN	Physical
(	(	O
n	JJ	O
=	NNP	O
34	CD	O
)	)	O
.	.	O

A	DT	O
prothrombin	JJ	O
time	NN	O
(	(	O
PT	NNP	O
)	)	O
ratio	NN	O
(	(	O
patient	JJ	O
PT	NNP	O
divided	VBN	O
by	IN	O
control	NN	O
PT	NNP	O
)	)	O
between	IN	O
1.3	CD	O
and	CC	O
2.5	CD	O
was	VBD	O
considered	VBN	O
to	TO	O
be	VB	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
.	.	O

For	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
a	DT	O
stable	JJ	O
PT	NNP	O
ratio	NN	O
(	(	O
defined	VBN	O
as	IN	O
a	DT	O
PT	NNP	O
ratio	NN	O
between	IN	O
1.3	CD	O
and	CC	O
2.5	CD	O
that	WDT	O
varied	VBN	O
by	IN	O
less	JJR	O
than	IN	O
0.05	CD	O
on	IN	O
two	CD	O
consecutive	JJ	O
days	NNS	O
or	CC	O
by	IN	O
less	JJR	O
than	IN	O
0.1	CD	O
on	IN	O
three	CD	O
consecutive	JJ	O
days	NNS	O
without	IN	O
a	DT	O
dosage	NN	O
change	NN	O
)	)	O
before	IN	O
discharge	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
days	NNS	O
(	(	O
time	NN	O
to	TO	O
stabilization	NN	O
)	)	O
from	IN	O
administration	NN	O
of	IN	O
the	DT	O
first	JJ	O
warfarin	NN	O
dose	NN	O
to	TO	O
achievement	NN	O
of	IN	O
the	DT	O
warfarin	NN	O
dosage	NN	O
that	WDT	O
produced	VBD	O
a	DT	O
stable	JJ	O
PT	NNP	O
ratio	NN	O
(	(	O
stabilization	JJ	O
dosage	NN	O
)	)	O
was	VBD	O
compared	VBN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
54	CD	O
patients	NNS	O
met	VBD	O
the	DT	O
study	NN	O
criteria	NNS	O
for	IN	O
a	DT	O
stable	JJ	O
PT	NNP	O
ratio	NN	O
before	IN	O
hospital	JJ	O
discharge	NN	O
(	(	O
analog	JJ	O
computer	NN	O
,	,	O
n	JJ	O
=	VBP	O
20	CD	O
;	:	O
linear	JJ	O
regression	NN	O
,	,	O
n	JJ	O
=	VBP	O
15	CD	O
;	:	O
empiric	JJ	O
dosing	NN	O
,	,	O
n	JJ	O
=	NNP	O
19	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
times	NNS	O
to	TO	O
stabilization	NN	O
were	VBD	O
6.8	CD	O
days	NNS	O
in	IN	O
the	DT	O
analog-computer	JJ	O
group	NN	O
,	,	O
7.3	CD	O
days	NNS	O
in	IN	O
the	DT	O
linear-regression	NN	O
group	NN	O
,	,	O
and	CC	O
8.4	CD	O
days	NNS	O
in	IN	O
the	DT	O
empiric-dosing	JJ	O
group	NN	O
;	:	O
these	DT	O
times	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

All	DT	O
20	CD	O
stabilized	VBD	O
patients	NNS	O
in	IN	O
the	DT	O
analog-computer	JJ	O
group	NN	O
achieved	VBD	O
a	DT	O
stable	JJ	O
PT	NNP	O
ratio	NN	O
by	IN	O
the	DT	O
fourth	JJ	O
dosage	NN	O
prediction	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Effects	NNS	O
of	IN	O
strontium	NN	Pharmacological
on	IN	O
the	DT	O
quality	NN	O
of	IN	O
bone	NN	O
apatite	JJ	O
crystals	NNS	O
:	:	O
a	DT	O
paired	JJ	O
biopsy	NN	O
study	NN	O
in	IN	O
postmenopausal	JJ	O
osteoporotic	JJ	O
women	NNS	O
.	.	O

UNLABELLED	NN	O
In	IN	O
paired	JJ	O
biopsies	NNS	O
of	IN	O
osteoporotic	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
either	DT	O
strontium	NN	Pharmacological
ranelate	NN	Pharmacological
or	CC	O
a	DT	O
placebo	NN	Control
for	IN	O
36	CD	O
months	NNS	O
,	,	O
characteristics	NNS	O
of	IN	O
bone	NN	O
apatite	JJ	O
crystals	NNS	O
were	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
strontium	NN	Pharmacological
.	.	O

The	DT	O
mean	JJ	O
rate	NN	O
of	IN	O
substitutions	NNS	O
of	IN	O
calcium	NN	O
by	IN	O
strontium	NN	O
ions	NNS	O
was	VBD	O
4.5	CD	O
%	NN	O
.	.	O

INTRODUCTION	NNP	O
The	DT	O
potential	JJ	O
effect	NN	O
of	IN	O
strontium	NN	Pharmacological
(	(	O
Sr	NNP	O
)	)	O
on	IN	O
bone	NN	O
apatite	JJ	O
crystals	NNS	O
was	VBD	O
investigated	VBN	O
in	IN	O
paired	JJ	O
biopsies	NNS	O
of	IN	O
osteoporotic	JJ	O
women	NNS	O
treated	VBN	O
with	IN	O
either	DT	O
strontium	NN	Pharmacological
ranelate	NN	Pharmacological
(	(	Pharmacological
SrRan	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
a	DT	O
placebo	NN	Control
for	IN	O
36	CD	O
months	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
ten	NN	O
paired	JJ	O
biopsies	NNS	O
,	,	O
crystallinity	NN	O
,	,	O
apparent	JJ	O
length	NN	O
and	CC	O
width/thickness	NN	O
of	IN	O
crystals	NNS	O
,	,	O
interplanar	NN	O
distances	NNS	O
,	,	O
and	CC	O
lattice	JJ	O
parameters	NNS	O
of	IN	O
unit	NN	O
cells	NNS	O
were	VBD	O
assessed	VBN	O
by	IN	O
X-ray	JJ	O
diffraction	NN	O
and	CC	O
selected	VBN	O
area	NN	O
electron	NN	O
diffraction	NN	O
.	.	O

RESULTS	VB	O
All	PDT	O
these	DT	O
parameters	NNS	O
,	,	O
reflecting	VBG	O
crystal	NN	O
and	CC	O
unit	NN	O
cell	NN	O
characteristics	NNS	O
,	,	O
were	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
Sr	NNP	O
and	CC	O
were	VBD	O
similar	JJ	O
in	IN	O
SrRan	NNP	Pharmacological
and	CC	O
placebo	NN	Control
groups	NNS	O
after	IN	O
36	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
mean	JJ	O
rate	NN	O
of	IN	O
substitutions	NNS	O
of	IN	O
calcium	NN	O
by	IN	O
Sr	NNP	O
ions	NNS	O
was	VBD	O
4.5	CD	O
%	NN	O
.	.	O

CONCLUSION	NNP	O
Overall	NNP	O
,	,	O
the	DT	O
quality	NN	O
of	IN	O
bone	NN	O
apatite	JJ	O
crystals	NNS	O
was	VBD	O
maintained	VBN	O
after	IN	O
36	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
SrRan	NNP	Pharmacological
.	.	O

A	DT	O
phase	NN	O
II	NNP	O
study	NN	O
of	IN	O
cetuximab	NN	Pharmacological
,	,	O
capecitabine	NN	Pharmacological
and	CC	O
radiotherapy	NN	Pharmacological
in	IN	O
neoadjuvant	JJ	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	VBN	O
resectable	JJ	O
rectal	JJ	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Neoadjuvant	NNP	O
chemoradiotherapy	NN	Pharmacological
(	(	Pharmacological
CRT	NNP	Pharmacological
)	)	Pharmacological
reduces	VBZ	O
local	JJ	O
tumor	NN	O
recurrence	NN	O
in	IN	O
locally	RB	O
advanced	JJ	O
rectal	JJ	O
cancer	NN	O
(	(	O
LARC	NNP	O
)	)	O
.	.	O

This	DT	O
phase	NN	O
II	NNP	O
study	NN	O
assessed	VBD	O
neoadjuvant	JJ	O
cetuximab	NN	O
with	IN	O
capecitabine-based	JJ	O
CRT	NNP	O
in	IN	O
LARC	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
stage	NN	O
II/III	NNP	O
LARC	NNP	O
received	VBD	O
capecitabine	JJ	Pharmacological
1250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
intravenous	JJ	Pharmacological
cetuximab	NNS	Pharmacological
400	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
at	IN	O
week	NN	O
3	CD	O
,	,	O
then	RB	O
weekly	RB	O
intravenous	JJ	O
250	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
cetuximab	NN	Pharmacological
plus	CC	Pharmacological
CRT	NNP	Pharmacological
including	VBG	O
capecitabine	NN	Pharmacological
825	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
(	(	O
including	VBG	O
weekends	NNS	O
during	IN	O
radiotherapy	NN	O
)	)	O
with	IN	O
radiotherapy	NN	Pharmacological
of	IN	O
45	CD	O
Gy	NNP	O
(	(	O
25	CD	O
x	RB	O
1.8	CD	O
Gy	NNP	O
)	)	O
,	,	O
5	CD	O
days	NNS	O
a	DT	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O

Total	JJ	O
mesorectal	JJ	O
excision	NN	O
was	VBD	O
scheduled	VBN	O
4-6	JJ	O
weeks	NNS	O
following	VBG	O
completion	NN	O
of	IN	O
CRT	NNP	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
pathological	JJ	O
complete	JJ	O
response	NN	O
(	(	O
pCR	NN	O
)	)	O
.	.	O

RESULTS	JJ	O
Thirty-seven	JJ	O
patients	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
.	.	O

TMN	NNP	O
staging	VBG	O
at	IN	O
baseline	NN	O
was	VBD	O
:	:	O
T4N2	NNP	O
,	,	O
11	CD	O
%	NN	O
;	:	O
T3N2	NNP	O
,	,	O
40	CD	O
%	NN	O
;	:	O
T2N2	NNP	O
,	,	O
3	CD	O
%	NN	O
;	:	O
T3N1	NNP	O
,	,	O
35	CD	O
%	NN	O
;	:	O
T2N1	NNP	O
,	,	O
3	CD	O
%	NN	O
and	CC	O
T3N0	NNP	O
8	CD	O
%	NN	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
included	VBD	O
,	,	O
grade	VBD	O
1/2	CD	O
acneiform	NN	O
skin	NN	O
rash	NN	O
(	(	O
86	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
grade	VBD	O
3	CD	O
radiodermatitis	NN	O
,	,	O
(	(	O
16	CD	O
%	NN	O
)	)	O
,	,	O
diarrhea	NN	O
(	(	O
11	CD	O
%	NN	O
)	)	O
and	CC	O
hypersensitivity	NN	O
(	(	O
5	CD	O
%	NN	O
)	)	O
.	.	O

pCR	NN	O
was	VBD	O
achieved	VBN	O
in	IN	O
3	CD	O
patients	NNS	O
(	(	O
8	CD	O
%	NN	O
)	)	O
.	.	O

Overall-	JJ	O
,	,	O
T-	JJ	O
and	CC	O
N-downstaging	JJ	O
rates	NNS	O
were	VBD	O
73	CD	O
%	NN	O
,	,	O
57	CD	O
%	NN	O
and	CC	O
81	CD	O
%	NN	O
respectively	RB	O
.	.	O

Total	JJ	O
sphincter	JJ	O
preservation	NN	O
rate	NN	O
was	VBD	O
76	CD	O
%	NN	O
,	,	O
and	CC	O
53	CD	O
%	NN	O
in	IN	O
17	CD	O
patients	NNS	O
whose	WP$	O
tumors	NNS	O
were	VBD	O
located	VBN	O
within	IN	O
5	CD	O
cm	NN	O
from	IN	O
the	DT	O
anal	JJ	O
verge	NN	O
.	.	O

Non-fatal	JJ	O
perioperative	JJ	O
complications	NNS	O
occurred	VBD	O
in	IN	O
13	CD	O
patients	NNS	O
(	(	O
35	CD	O
%	NN	O
)	)	O
with	IN	O
delayed	VBN	O
wound	NN	O
healing	VBG	O
occurring	VBG	O
in	IN	O
6	CD	O
patients	NNS	O
(	(	O
16	CD	O
%	NN	O
)	)	O
.	.	O

One	CD	O
death	NN	O
was	VBD	O
recorded	VBN	O
due	JJ	O
to	TO	O
sepsis	VB	O
following	VBG	O
colonic	JJ	O
necrosis	NN	O
.	.	O

CONCLUSION	NNP	O
Neoadjuvant	NNP	O
cetuximab	NN	Pharmacological
with	IN	Pharmacological
capecitabine-based	JJ	Pharmacological
CRT	NNP	Pharmacological
is	VBZ	O
tolerable	JJ	O
in	IN	O
patients	NNS	O
with	IN	O
resectable	JJ	O
LARC	NNP	O
.	.	O

Whilst	NNP	O
the	DT	O
pCR	NN	O
rate	NN	O
was	VBD	O
similar	JJ	O
to	TO	O
recent	JJ	O
reports	NNS	O
,	,	O
a	DT	O
high	JJ	O
pathological	JJ	O
downstaging	VBG	O
rate	NN	O
was	VBD	O
achieved	VBN	O
.	.	O

Ropinirole	NNP	Pharmacological
as	IN	O
a	DT	O
treatment	NN	O
of	IN	O
restless	JJ	O
legs	JJ	O
syndrome	NN	O
in	IN	O
patients	NNS	O
on	IN	O
chronic	JJ	O
hemodialysis	NN	O
:	:	O
an	DT	O
open	JJ	O
randomized	VBN	O
crossover	NN	O
trial	NN	O
versus	NN	O
levodopa	NN	Pharmacological
sustained	VBD	Pharmacological
release	NN	Pharmacological
.	.	O

OBJECTIVE	NNP	O
Restless	NNP	O
legs	VBZ	O
syndrome	NN	O
(	(	O
RLS	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
neurologic	JJ	O
condition	NN	O
characterized	VBN	O
by	IN	O
uncomfortable	JJ	O
and	CC	O
unpleasant	JJ	O
sensations	NNS	O
in	IN	O
the	DT	O
legs	NN	O
,	,	O
occurring	VBG	O
primarily	RB	O
at	IN	O
rest	NN	O
,	,	O
which	WDT	O
are	VBP	O
usually	RB	O
worse	JJR	O
in	IN	O
the	DT	O
evening	NN	O
and	CC	O
are	VBP	O
alleviated	VBN	O
by	IN	O
movement	NN	O
.	.	O

RLS	NNP	O
is	VBZ	O
present	JJ	O
in	IN	O
20-40	JJ	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
renal	JJ	O
failure	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
a	DT	O
14-week	JJ	O
open	JJ	O
,	,	O
randomized	VBN	O
,	,	O
crossover	JJ	O
trial	NN	O
of	IN	O
ropinirole	NN	Pharmacological
vs.	FW	O
levodopa	NN	Pharmacological
sustained	VBN	Pharmacological
release	NN	Pharmacological
(	(	Pharmacological
SR	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
11	CD	O
patients	NNS	O
with	IN	O
RLS	NNP	O
on	IN	O
chronic	JJ	O
hemodialysis	NN	O
.	.	O

METHODS	NNP	O
Eleven	NNP	O
patients	NNS	O
(	(	O
7	CD	O
men	NNS	O
,	,	O
4	CD	O
women	NNS	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

They	PRP	O
received	VBD	O
either	CC	O
levodopa	JJ	Pharmacological
SR	NNP	Pharmacological
or	CC	O
ropinirole	VB	Pharmacological
for	IN	O
6	CD	O
weeks	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
washout	NN	O
week	NN	O
,	,	O
then	RB	O
the	DT	O
alternate	NN	Pharmacological
treatment	NN	Pharmacological
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
rated	VBD	O
the	DT	O
severity	NN	O
of	IN	O
RLS	NNP	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
6-item	JJ	O
questionnaire	NN	O
developed	VBN	O
by	IN	O
the	DT	O
International	NNP	O
Restless	NNP	O
Legs	NNP	O
Study	NNP	O
Group	NNP	O
(	(	O
6-item	JJ	O
IRLS	NNP	O
)	)	O
,	,	O
by	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impression	NNP	O
(	(	O
CGI	NNP	O
)	)	O
scale	NN	O
,	,	O
and	CC	O
by	IN	O
sleep	JJ	O
diaries	NNS	O
.	.	O

RESULTS	NNP	O
Under	IN	O
treatment	NN	O
with	IN	O
levodopa	JJ	O
SR	NNP	O
,	,	O
1	CD	O
patient	NN	O
presented	VBN	O
severe	JJ	O
vomiting	NN	O
,	,	O
leading	VBG	O
to	TO	O
study	VB	O
discontinuation	NN	O
.	.	O

The	DT	O
10	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
reported	VBD	O
a	DT	O
33.5	CD	O
%	NN	O
improvement	NN	O
(	(	O
from	IN	O
16.7	CD	O
+/-	JJ	O
3.2	CD	O
to	TO	O
11.1	CD	O
+/-	JJ	O
4	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
of	IN	O
the	DT	O
6-item	JJ	O
IRLS	NNP	O
scores	NNS	O
during	IN	O
levodopa	JJ	O
SR	NNP	O
treatment	NN	O
and	CC	O
a	DT	O
73.5	CD	O
%	NN	O
improvement	NN	O
(	(	O
from	IN	O
16.6	CD	O
+/-	JJ	O
2.8	CD	O
to	TO	O
4.4	CD	O
+/-	JJ	O
3.8	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
during	IN	O
ropinirole	JJ	O
treatment	NN	O
.	.	O

By	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
the	DT	O
mean	JJ	O
levodopa	NN	O
SR	NNP	O
dosage	NN	O
was	VBD	O
190	CD	O
mg/d	NN	O
and	CC	O
the	DT	O
mean	JJ	O
ropinirole	NN	O
dosage	NN	O
was	VBD	O
1.45	CD	O
mg/d	NN	O
.	.	O

Ropinirole	NNP	Pharmacological
was	VBD	O
superior	JJ	O
to	TO	O
levodopa	VB	Pharmacological
SR	NNP	Pharmacological
in	IN	O
reducing	VBG	O
6-item	JJ	O
IRLS	NNP	O
scores	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
in	IN	O
increasing	VBG	O
sleep	JJ	O
time	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
patient	NN	O
CGI	NNP	O
scale	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
favoring	VBG	O
ropinirole	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
carryover	NN	O
or	CC	O
period	NN	O
effect	NN	O
for	IN	O
any	DT	O
outcome	JJ	O
measure	NN	O
.	.	O

Four	CD	O
patients	NNS	O
reported	VBD	O
a	DT	O
complete	JJ	O
reversion	NN	O
of	IN	O
RLS	NNP	O
symptoms	NNS	O
during	IN	O
ropinirole	JJ	O
treatment	NN	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
0.25-2	JJ	O
mg/d	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
ropinirole	NN	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
levodopa	JJS	O
SR	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
RLS	NNP	O
in	IN	O
patients	NNS	O
on	IN	O
chronic	JJ	O
hemodialysis	NN	O
.	.	O

Probiotics	NNS	Pharmacological
in	IN	O
the	DT	O
management	NN	O
of	IN	O
atopic	NN	O
eczema	NN	O
.	.	O

BACKGROUND	NNP	O
Over	IN	O
the	DT	O
last	JJ	O
two	CD	O
decades	IN	O
the	DT	O
incidence	NN	O
of	IN	O
allergic	JJ	O
diseases	NNS	O
has	VBZ	O
increased	VBN	O
in	IN	O
industrialized	JJ	O
countries	NNS	O
,	,	O
and	CC	O
consequently	RB	O
new	JJ	O
approaches	NNS	O
have	VBP	O
to	TO	O
be	VB	O
explored	VBN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
potential	NN	O
of	IN	O
probiotics	NNS	O
to	TO	O
control	VB	O
allergic	JJ	O
inflammation	NN	O
at	IN	O
an	DT	O
early	JJ	O
age	NN	O
was	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
double-blind	JJ	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
27	CD	O
infants	NNS	O
,	,	O
mean	JJ	O
age	NN	O
4.6	CD	O
months	NNS	O
,	,	O
who	WP	O
manifested	VBD	O
atopic	JJ	O
eczema	NN	O
during	IN	O
exclusive	JJ	O
breast-feeding	NN	O
and	CC	O
who	WP	O
have	VBP	O
had	VBN	O
no	DT	O
exposure	NN	O
to	TO	O
any	DT	O
infant	NN	O
or	CC	O
substitute	NN	O
formula	NN	O
were	VBD	O
weaned	VBN	O
to	TO	O
probiotic-supplemented	JJ	Pharmacological
,	,	O
Bifidobacterium	NNP	Pharmacological
lactis	VBZ	Pharmacological
Bb-12	NNP	Pharmacological
or	CC	O
Lactobacillus	NNP	Pharmacological
strain	VBP	Pharmacological
GG	NNP	Pharmacological
(	(	Pharmacological
ATCC	NNP	Pharmacological
53103	CD	Pharmacological
)	)	Pharmacological
,	,	Pharmacological
extensively	RB	Pharmacological
hydrolysed	VBD	Pharmacological
whey	JJ	Pharmacological
formulas	NNS	Pharmacological
or	CC	O
to	TO	O
the	DT	O
same	JJ	Control
formula	NN	Control
without	IN	Control
probiotics	NNS	Control
.	.	O

The	DT	O
extent	NN	O
and	CC	O
severity	NN	O
of	IN	O
atopic	NN	O
eczema	NN	O
,	,	O
the	DT	O
growth	NN	O
and	CC	O
nutrition	NN	O
of	IN	O
infants	NNS	O
,	,	O
and	CC	O
concentrations	NNS	O
of	IN	O
circulating	VBG	O
cytokines/chemokines	NNS	O
and	CC	O
soluble	JJ	O
cell	NN	O
surface	NN	O
adhesion	NN	O
molecules	NNS	O
in	IN	O
serum	NN	O
and	CC	O
methyl-histamine	NN	O
and	CC	O
eosinophilic	JJ	O
protein	NN	O
X	NN	O
in	IN	O
urine	JJ	O
were	VBD	O
determined	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
SCORAD	NNP	O
score	NN	O
reflecting	VBG	O
the	DT	O
extent	NN	O
and	CC	O
severity	NN	O
of	IN	O
atopic	NN	O
eczema	NN	O
was	VBD	O
16	CD	O
(	(	O
7-25	JJ	O
)	)	O
during	IN	O
breast-feeding	NN	O
,	,	O
median	JJ	O
(	(	O
interquartile	JJ	O
range	NN	O
)	)	O
.	.	O

After	IN	O
2	CD	O
months	NNS	O
,	,	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
skin	JJ	O
condition	NN	O
occurred	VBD	O
in	IN	O
patients	NNS	O
given	VBN	O
probiotic-supplemented	JJ	O
formulas	NNS	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
unsupplemented	JJ	O
group	NN	O
;	:	O
chi	NNS	O
(	(	O
2	CD	O
)	)	O
=	NN	O
12.27	CD	O
,	,	O
P	NNP	O
=	VBZ	O
0.002	CD	O
.	.	O

SCORAD	NNP	O
decreased	VBD	O
in	IN	O
the	DT	O
Bifidobacterium	NNP	O
lactis	VBZ	O
Bb-12	NNP	O
group	NN	O
to	TO	O
0	CD	O
(	(	O
0-3.8	NN	O
)	)	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
Lactobacillus	NNP	O
GG	NNP	O
group	NN	O
to	TO	O
1	CD	O
(	(	O
0.1-8.7	NN	O
)	)	O
,	,	O
vs	RB	O
unsupplemented	JJ	O
13.4	CD	O
(	(	O
4.5-18.2	JJ	O
)	)	O
,	,	O
median	JJ	O
(	(	O
interquartile	JJ	O
range	NN	O
)	)	O
,	,	O
in	IN	O
parallel	NN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
concentration	NN	O
of	IN	O
soluble	JJ	O
CD4	NNP	O
in	IN	O
serum	NN	O
and	CC	O
eosinophilic	JJ	O
protein	NN	O
X	NN	O
in	IN	O
urine	JJ	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
provide	VBP	O
the	DT	O
first	JJ	O
clinical	JJ	O
demonstration	NN	O
of	IN	O
specific	JJ	O
probiotic	JJ	O
strains	NNS	O
modifying	VBG	O
the	DT	O
changes	NNS	O
related	VBN	O
to	TO	O
allergic	JJ	O
inflammation	NN	O
.	.	O

The	DT	O
data	NN	O
further	RB	O
indicate	VBP	O
that	IN	O
probiotics	NNS	O
may	MD	O
counteract	VB	O
inflammatory	JJ	O
responses	NNS	O
beyond	IN	O
the	DT	O
intestinal	JJ	O
milieu	NN	O
.	.	O

The	DT	O
combined	JJ	O
effects	NNS	O
of	IN	O
these	DT	O
probiotic	JJ	O
strains	NNS	O
will	MD	O
guide	VB	O
infants	NNS	O
through	IN	O
the	DT	O
weaning	JJ	O
period	NN	O
,	,	O
when	WRB	O
sensitization	NN	O
to	TO	O
newly	RB	O
encountered	VBN	O
antigens	NNS	O
is	VBZ	O
initiated	VBN	O
.	.	O

The	DT	O
probiotic	JJ	O
approach	NN	O
may	MD	O
thus	RB	O
offer	VB	O
a	DT	O
new	JJ	O
direction	NN	O
in	IN	O
the	DT	O
search	NN	O
for	IN	O
future	JJ	O
foods	NNS	O
for	IN	O
allergy	JJ	O
treatment	NN	O
and	CC	O
prevention	NN	O
strategies	NNS	O
.	.	O

[	JJ	O
Effect	NNP	O
of	IN	O
branch	NN	O
chain	NN	O
amino	NN	Pharmacological
acid	NN	Pharmacological
enriched	VBD	Pharmacological
formula	NN	Pharmacological
on	IN	O
postoperative	JJ	O
fatigue	NN	O
and	CC	O
nutritional	JJ	O
status	NN	O
after	IN	O
digestive	JJ	O
surgery	NN	O
]	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
branch	NN	Physical
chain	NN	Physical
amino	NN	Physical
acid	NN	Physical
(	(	Physical
BCAA	NNP	Physical
)	)	Physical
enriched	VBD	Physical
formula	NN	Physical
on	IN	O
nutritional	JJ	O
status	NN	O
and	CC	O
postoperative	JJ	O
fatigue	NN	O
for	IN	O
digestive	JJ	O
surgery	NN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
patients	NNS	O
who	WP	O
underwent	VBP	O
digestive	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
received	VBN	O
parenteral	JJ	O
nutrition	NN	O
with	IN	O
either	DT	Pharmacological
BCAA	NNP	Pharmacological
enriched	VBD	Pharmacological
(	(	Pharmacological
study	NN	Pharmacological
group	NN	Pharmacological
,	,	Pharmacological
n=20	RB	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
routine	JJ	Control
amino	NN	Control
acid	NN	Control
(	(	Control
control	NN	Control
group	NN	Control
,	,	Pharmacological
n=20	RB	Pharmacological
)	)	Pharmacological
for	IN	Pharmacological
seven	CD	Pharmacological
consecutive	JJ	Pharmacological
days	NNS	Pharmacological
.	.	Pharmacological

Nitrogen	NNP	Pharmacological
balance	NN	Pharmacological
,	,	Pharmacological
serum	JJ	Pharmacological
total	NN	Pharmacological
protein	NN	Pharmacological
,	,	Pharmacological
albumin	NN	Pharmacological
,	,	Pharmacological
prealbumin	NN	Pharmacological
,	,	Pharmacological
transferrin	NN	Pharmacological
,	,	Pharmacological
retinol	NN	Pharmacological
binding	NN	Pharmacological
protein	NN	Pharmacological
and	CC	Pharmacological
postoperative	JJ	Pharmacological
fatigue	NN	Pharmacological
score	NN	Pharmacological
were	VBD	Pharmacological
monitored	VBN	Pharmacological
during	IN	Pharmacological
the	DT	Pharmacological
postoperative	JJ	Pharmacological
period	NN	Pharmacological
.	.	Pharmacological

RESULTS	VB	O
The	DT	O
cumulative	JJ	O
postoperative	JJ	O
fatigue	NN	O
scores	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
BCAA	NNP	O
group	NN	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
at	IN	O
the	DT	O
4th	CD	O
,	,	O
5th	CD	O
and	CC	O
7th	CD	O
day	NN	O
after	IN	O
operation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Patients	NNS	O
achieved	VBD	O
positive	JJ	O
nitrogen	NN	O
balance	NN	O
2	CD	O
days	NNS	O
earlier	RBR	O
in	IN	O
the	DT	O
study	NN	O
group	NN	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
cumulative	JJ	O
nitrogen	NN	O
balance	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
elevation	NN	O
of	IN	O
serum	JJ	O
total	JJ	O
protein	NN	O
,	,	O
albumin	NN	O
,	,	O
prealbumin	NN	O
,	,	O
transferrin	NN	O
at	IN	O
the	DT	O
7th	CD	O
day	NN	O
after	IN	O
operation	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
those	DT	O
at	IN	O
the	DT	O
first	JJ	O
day	NN	O
after	IN	O
operation	NN	O
.	.	O

The	DT	O
serum	JJ	O
level	NN	O
of	IN	O
retinol	NN	O
binding	VBG	O
protein	NN	O
was	VBD	O
higher	JJR	O
in	IN	O
BCAA-enriched	NNP	Pharmacological
group	NN	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P=0.004	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
TPN	NNP	O
with	IN	O
BCAA	NNP	Pharmacological
enriched	VBD	Pharmacological
formula	NN	Pharmacological
can	MD	O
reduce	VB	O
postoperative	JJ	O
fatigue	NN	O
score	NN	O
and	CC	O
improve	VB	O
the	DT	O
nutritional	JJ	O
status	NN	O
for	IN	O
digestive	JJ	O
surgery	NN	O
patients	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
two	CD	O
regimens	NNS	O
of	IN	O
moderate	JJ	O
dose	JJ	O
chemoradiation	NN	Physical
therapy	NN	Physical
for	IN	O
patients	NNS	O
with	IN	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
not	RB	O
suitable	JJ	O
for	IN	O
curative	JJ	O
therapy	NN	O
:	:	O
Trans	NNPS	O
Tasman	NNP	O
Radiation	NNP	O
Oncology	NNP	O
Study	NNP	O
TROG	NNP	O
03.07	CD	O
.	.	O

BACKGROUND	VB	O
There	EX	O
are	VBP	O
patients	NNS	O
with	IN	O
stage	JJ	O
I-III	JJ	O
non-small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
(	(	O
NSCLC	NNP	O
)	)	O
who	WP	O
are	VBP	O
not	RB	O
suitable	JJ	O
for	IN	O
curative	JJ	Pharmacological
radical	JJ	Pharmacological
chemoradiation	NN	Pharmacological
therapy	NN	Pharmacological
.	.	O

There	EX	O
are	VBP	O
patients	NNS	O
with	IN	O
an	DT	O
isolated	JJ	O
solitary	JJ	O
extracranial	JJ	O
metastasis	NN	O
who	WP	O
have	VBP	O
improved	VBN	O
outcomes	NNS	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
cranial	JJ	O
or	CC	O
multiple	JJ	O
metastases	NNS	O
.	.	O

Patients	NNS	O
of	IN	O
good	JJ	O
performance	NN	O
status	NN	O
receiving	VBG	O
moderate	JJ	O
dose	NN	O
radiation	NN	Physical
therapy	NN	Physical
have	VBP	O
improved	VBN	O
survival	JJ	O
.	.	O

Two	CD	O
regimens	NNS	O
of	IN	O
moderate	JJ	Pharmacological
dose	JJ	Pharmacological
chemoradiation	NN	Pharmacological
therapy	NN	Pharmacological
for	IN	O
such	JJ	O
patients	NNS	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
.	.	O

METHODS	JJ	O
Patients	NNPS	O
were	VBD	O
eligible	JJ	O
if	IN	O
they	PRP	O
had	VBD	O
stage	VBN	O
I-IIIB	NNP	O
NSCLC	NNP	O
,	,	O
unsuitable	JJ	O
for	IN	O
curative	JJ	O
therapy	NN	O
,	,	O
or	CC	O
stage	NN	O
IV	NNP	O
with	IN	O
a	DT	O
PET-detected	JJ	O
extracranial	JJ	O
solitary	JJ	O
metastasis	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
the	DT	O
following	JJ	O
groups-arm	NN	O
A	DT	O
:	:	O
40	CD	O
Gy/20	NNP	Pharmacological
fractions/4	JJ	O
weeks	NNS	O
with	IN	O
concurrent	JJ	O
weekly	JJ	Pharmacological
vinorelbine	NN	Pharmacological
25	CD	Pharmacological
mg/m	NN	Pharmacological
+	NNP	Pharmacological
cisplatin	VBZ	Pharmacological
20	CD	O
mg/m	NN	O
or	CC	O
arm	NN	O
B	NN	O
:	:	O
30	CD	O
Gy/15	NNP	Pharmacological
fractions/3	JJ	O
weeks	NNS	O
with	IN	O
concurrent	JJ	O
weekly	JJ	Pharmacological
gemcitabine	NN	Pharmacological
200	CD	Pharmacological
mg.	NN	Pharmacological
Primary	NNP	O
end	NN	O
points	NNS	O
were	VBD	O
feasibility	NN	O
,	,	O
response	NN	O
rates	NNS	O
,	,	O
and	CC	O
toxicity	NN	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
progression-free	JJ	O
survival	NN	O
,	,	O
overall	JJ	O
survival	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

RESULTS	NNP	O
Eighty-four	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

Compliance	NN	O
was	VBD	O
above	IN	O
90	CD	O
%	NN	O
for	IN	O
both	DT	O
arms	NNS	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
51	CD	O
%	NN	O
in	IN	O
arm	NN	O
A	NN	O
and	CC	O
38	CD	O
%	NN	O
in	IN	O
arm	NN	O
B	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.147	CD	O
)	)	O
.	.	O

Grade	$	O
3/4	CD	O
toxicity	NN	O
in	IN	O
both	DT	O
arms	NNS	O
was	VBD	O
acceptable	JJ	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
median	JJ	O
progression-free	JJ	O
survival	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
(	(	O
5.5	CD	O
versus	NN	O
5.0	CD	O
months	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.19	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
arm	NN	O
A	NN	O
had	VBD	O
longer	RBR	O
median	JJ	O
survival	NN	O
but	CC	O
this	DT	O
did	VBD	O
not	RB	O
reach	VB	O
statistical	JJ	O
significance	NN	O
(	(	O
13.1	CD	O
versus	NN	O
8.3	CD	O
months	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.25	CD	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Arm	NNP	O
A	NNP	O
was	VBD	O
chosen	VBN	O
for	IN	O
a	DT	O
future	JJ	O
phase	NN	O
II	NNP	O
comparison	NN	O
with	IN	O
radiation	NN	Pharmacological
therapy	NN	Pharmacological
alone	RB	O
as	IN	O
it	PRP	O
demonstrated	VBD	O
a	DT	O
response	NN	O
rate	NN	O
greater	JJR	O
than	IN	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
data	NNS	O
suggested	VBD	O
that	IN	O
arm	NN	O
A	NNP	O
had	VBD	O
superior	JJ	O
survival	NN	O
to	TO	O
arm	NN	O
B	NNP	O
.	.	O

Heart	NNP	O
rate	NN	O
variability	NN	O
and	CC	O
QT	NNP	O
dispersion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
subclinical	JJ	O
hypothyroidism	NN	O
.	.	O

UNLABELLED	IN	O
The	DT	O
effect	NN	O
of	IN	O
subclinical	JJ	O
hypothyroidism	NN	O
(	(	O
SH	NNP	O
)	)	O
on	IN	O
cardiovascular	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
yet	RB	O
elucidated	VBN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
dispersion	NN	O
of	IN	O
QT	NNP	O
interval	NN	O
,	,	O
i.e	NN	O
.	.	O

an	DT	O
index	NN	O
of	IN	O
inhomogeneity	NN	O
of	IN	O
repolarization	NN	O
,	,	O
and	CC	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
,	,	O
i.e	RB	O
.	.	O

a	DT	O
measure	NN	O
of	IN	O
cardiac	JJ	O
autonomic	JJ	O
modulation	NN	O
,	,	O
in	IN	O
SH	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
42	CD	O
patients	NNS	O
(	(	O
29	CD	O
women	NNS	O
and	CC	O
13	CD	O
men	NNS	O
;	:	O
mean	JJ	O
age	NN	O
53.2+/-14.2	JJ	O
years	NNS	O
;	:	O
body	NN	O
surface	JJ	O
area	NN	O
1.76+/-0.14	JJ	O
m2	NN	O
)	)	O
with	IN	O
SH	NNP	O
,	,	O
as	IN	O
judged	VBN	O
by	IN	O
elevated	JJ	O
serum	NN	O
TSH	NNP	O
levels	NNS	O
(	(	O
>	$	O
3.6	CD	O
mIU/l	NN	O
;	:	O
range	NN	O
,	,	O
3.8-12.0	JJ	O
)	)	O
and	CC	O
normal	JJ	O
free	JJ	O
thyroid	NN	O
hormones	NNS	O
(	(	O
FT4	NNP	O
and	CC	O
FT3	NNP	O
)	)	O
and	CC	O
30	CD	O
euthyroid	JJ	O
volunteer	NN	O
.	.	O

Subjects	NNS	O
with	IN	O
cardiac	NN	O
,	,	O
metabolic	NN	O
,	,	O
neurological	JJ	O
disease	NN	O
or	CC	O
any	DT	O
other	JJ	O
systemic	JJ	O
disease	NN	O
that	WDT	O
could	MD	O
affect	VB	O
autonomic	JJ	O
activity	NN	O
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
with	IN	O
SH	NNP	O
and	CC	O
control	VB	O
subjects	NNS	O
underwent	VB	O
a	DT	O
full	JJ	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
standard	JJ	O
12-lead	JJ	Physical
ECG	NNP	Physical
,	,	Physical
and	CC	Physical
24-h	JJ	Physical
ambulatory	NN	Physical
ECG	NNP	Physical
monitoring	NN	Physical
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
with	IN	O
L-thyroxine	NNP	Pharmacological
on	IN	O
QT	NNP	O
dispersion	NN	O
and	CC	O
HRV	NNP	O
,	,	O
15	CD	O
patients	NNS	O
with	IN	O
SH	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
therapy	NN	O
with	IN	O
L-thyroxine	NNP	Pharmacological
.	.	O

All	PDT	O
the	DT	O
subjects	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
enrolment	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Patients	NNPS	O
with	IN	O
SH	NNP	O
showed	VBD	O
higher	JJR	O
QT	NNP	O
dispersion	NN	O
and	CC	O
lower	JJR	O
HRV	NNP	O
measures	NNS	O
than	IN	O
healthy	JJ	O
controls	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.01	CD	O
for	IN	O
all	DT	O
)	)	O
.	.	O

In	IN	O
SH	NNP	O
patients	NNS	O
,	,	O
the	DT	O
standard	JJ	O
deviation	NN	O
of	IN	O
N-Ns	NNP	O
(	(	O
SDNN	NNP	O
)	)	O
was	VBD	O
negatively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=-0.42	JJ	O
,	,	O
P=0.006	NNP	O
)	)	O
,	,	O
while	IN	O
low	JJ	O
frequency	NN	O
(	(	O
LF	NNP	O
)	)	O
/high	VBP	O
frequency	NN	O
(	(	O
HF	NNP	O
)	)	O
ratio	NN	O
was	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.42	NN	O
,	,	O
P=0.006	NNP	O
)	)	O
.	.	O

Moreover	RB	O
,	,	O
in	IN	O
SH	NNP	O
patients	NNS	O
both	DT	O
QT	NNP	O
dispersion	NN	O
and	CC	O
QTc	NNP	O
dispersion	NN	O
were	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
TSH	NNP	O
(	(	O
r=0.64	NN	O
and	CC	O
r=0.63	NN	O
,	,	O
P	NNP	O
<	VBZ	O
0.001	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
the	DT	O
patients	NNS	O
treated	VBN	O
with	IN	O
L-tiroxine	NNP	Pharmacological
exhibited	VBD	O
a	DT	O
reduction	NN	O
of	IN	O
QT	NNP	O
dispersion	NN	O
and	CC	O
an	DT	O
increase	NN	O
of	IN	O
HRV	NNP	O
parameters	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
demonstrated	VBD	O
that	IN	O
SH	NNP	O
can	MD	O
alter	VB	O
autonomic	JJ	O
modulation	NN	O
of	IN	O
heart	NN	O
rate	NN	O
and	CC	O
cause	NN	O
increased	VBD	O
inhomogeneity	NN	O
of	IN	O
ventricular	JJ	O
recovery	NN	O
times	NNS	O
.	.	O

Accordingly	RB	O
,	,	O
early	JJ	O
L-thyroxine	JJ	Pharmacological
treatment	NN	O
may	MD	O
be	VB	O
advised	VBN	O
not	RB	O
only	RB	O
to	TO	O
prevent	VB	O
progression	NN	O
to	TO	O
overt	VB	O
hypothyroidism	NN	O
but	CC	O
also	RB	O
to	TO	O
improve	VB	O
abnormal	JJ	O
cardiac	JJ	O
autonomic	JJ	O
function	NN	O
and	CC	O
ventricular	JJ	O
repolarization	NN	O
inhomogeneity	NN	O
.	.	O

Effect	NN	O
of	IN	O
facial	JJ	Educational
sensory	JJ	Educational
re-training	NN	Educational
on	IN	O
sensory	JJ	O
thresholds	NNS	O
.	.	O

Nearly	RB	O
100	CD	O
%	NN	O
of	IN	O
patients	NNS	O
experience	JJ	O
trauma	NN	O
to	TO	O
the	DT	O
trigeminal	JJ	O
nerve	NN	O
during	IN	O
orthognathic	JJ	Surgical
surgery	NN	Surgical
,	,	O
impairing	VBG	O
sensation	NN	O
and	CC	O
sensory	JJ	O
function	NN	O
on	IN	O
the	DT	O
face	NN	O
.	.	O

In	IN	O
a	DT	O
recent	JJ	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
people	NNS	O
who	WP	O
performed	VBD	O
sensory	JJ	Physical
re-training	JJ	Physical
exercises	NNS	Physical
reported	VBD	O
less	RBR	O
difficulty	NN	O
related	VBN	O
to	TO	O
residual	JJ	O
numbness	NN	O
and	CC	O
decreased	VBD	O
lip	JJR	O
sensitivity	NN	O
than	IN	O
those	DT	O
who	WP	O
performed	VBD	O
standard	JJ	Educational
opening	NN	Educational
exercises	VBZ	Educational
only	RB	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
re-training	JJ	Educational
reduces	NNS	O
the	DT	O
impaired	JJ	O
performance	NN	O
on	IN	O
neurosensory	JJ	O
tests	NNS	O
of	IN	O
tactile	JJ	O
function	NN	O
that	WDT	O
is	VBZ	O
commonly	RB	O
observed	JJ	O
post-surgically	RB	O
.	.	O

We	PRP	O
analyzed	VBD	O
thresholds	NNS	O
for	IN	O
contact	NN	O
detection	NN	O
,	,	O
two-point	JJ	O
discrimination	NN	O
,	,	O
and	CC	O
two-point	JJ	O
perception	NN	O
,	,	O
obtained	VBN	O
during	IN	O
the	DT	O
clinical	JJ	O
trial	NN	O
before	IN	O
and	CC	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
6	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
,	,	O
to	TO	O
assess	VB	O
tactile	JJ	O
detection	NN	O
and	CC	O
discriminative	JJ	O
sensitivities	NNS	O
,	,	O
and	CC	O
subjective	JJ	O
interpretation	NN	O
of	IN	O
tactile	JJ	O
stimulation	NN	O
,	,	O
respectively	RB	O
.	.	O

Post-surgery	NN	O
,	,	O
the	DT	O
retrained	JJ	O
persons	NNS	O
exhibited	VBD	O
less	RBR	O
impairment	JJ	O
,	,	O
on	IN	O
average	NN	O
,	,	O
than	IN	O
non-retrained	JJ	O
persons	NNS	O
only	RB	O
in	IN	O
two-point	JJ	O
perception	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.025	CD	O
)	)	O
,	,	O
suggesting	VBG	O
that	IN	O
retrained	VBD	O
persons	NNS	O
experienced	VBD	O
or	CC	O
interpreted	VBD	O
the	DT	O
tactile	NN	O
stimuli	VBZ	O
differently	RB	O
than	IN	O
did	VBD	O
non-retrained	JJ	O
persons	NNS	O
.	.	O

Phase	NNP	O
II	NNP	O
study	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
ginger	NN	Pharmacological
root	NN	Pharmacological
extract	NN	Pharmacological
on	IN	O
eicosanoids	NNS	O
in	IN	O
colon	NN	O
mucosa	NN	O
in	IN	O
people	NNS	O
at	IN	O
normal	JJ	O
risk	NN	O
for	IN	O
colorectal	JJ	O
cancer	NN	O
.	.	O

Inhibitors	NNS	O
of	IN	O
COX	NNP	O
indicate	VBP	O
that	IN	O
upregulation	NN	O
of	IN	O
inflammatory	JJ	O
eicosanoids	NNS	O
produced	VBN	O
by	IN	O
COX	NNP	O
,	,	O
and	CC	O
in	IN	O
particular	JJ	O
prostaglandin	NN	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
PGE	NNP	O
(	(	O
2	CD	O
)	)	O
)	)	O
,	,	O
are	VBP	O
early	JJ	O
events	NNS	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
colorectal	JJ	O
cancer	NN	O
(	(	O
CRC	NNP	O
)	)	O
.	.	O

Ginger	NNP	O
has	VBZ	O
shown	VBN	O
downregulation	NN	O
of	IN	O
COX	NNP	O
in	IN	O
vitro	NN	O
and	CC	O
decreased	JJ	O
incidence/multiplicity	NN	O
of	IN	O
adenomas	NN	O
in	IN	O
rats	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
if	IN	O
2.0	CD	O
g/d	NN	O
of	IN	O
ginger	NN	Pharmacological
could	MD	O
decrease	VB	O
the	DT	O
levels	NNS	O
of	IN	O
PGE	NNP	O
(	(	O
2	CD	O
)	)	O
,	,	O
13-hydroxy-octadecadienoic	JJ	O
acids	NNS	O
,	,	O
and	CC	O
5-	JJ	O
,	,	O
12-	JJ	O
,	,	O
and	CC	O
15-hydroxyeicosatetraenoic	JJ	O
acid	NN	O
(	(	O
5-	JJ	O
,	,	O
12-	JJ	O
,	,	O
and	CC	O
15-HETE	JJ	O
)	)	O
,	,	O
in	IN	O
the	DT	O
colon	NN	O
mucosa	NN	O
of	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

To	TO	O
investigate	VB	O
this	DT	O
aim	NN	O
,	,	O
we	PRP	O
randomized	VBD	O
30	CD	O
subjects	NNS	O
to	TO	O
2.0	CD	Pharmacological
g/d	NN	Pharmacological
ginger	NN	Pharmacological
or	CC	Pharmacological
placebo	NN	Control
for	IN	O
28	CD	O
days	NNS	O
.	.	O

Flexible	JJ	Physical
sigmoidoscopy	NN	Physical
at	IN	O
baseline	NN	O
and	CC	O
day	NN	O
28	CD	O
was	VBD	O
used	VBN	O
to	TO	O
obtain	VB	O
colon	NN	O
biopsies	NNS	O
.	.	O

A	DT	O
liquid	JJ	Physical
chromatography	NN	Physical
mass	NN	Physical
spectrometry	NN	Physical
method	NN	Physical
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
eicosanoid	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
biopsies	NNS	O
,	,	O
and	CC	O
levels	NNS	O
were	VBD	O
expressed	VBN	O
per	IN	O
protein	NN	O
or	CC	O
per	IN	O
free	JJ	O
arachidonic	JJ	O
acid	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
mean	JJ	O
percent	NN	O
change	NN	O
between	IN	O
baseline	NN	O
and	CC	O
day	NN	O
28	CD	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
eicosanoids	NNS	O
,	,	O
when	WRB	O
normalized	VBN	O
to	TO	O
protein	VB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
mean	JJ	O
percent	NN	O
change	NN	O
in	IN	O
PGE	NNP	O
(	(	O
2	CD	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
and	CC	O
5-HETE	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
,	,	O
and	CC	O
a	DT	O
trend	NN	O
toward	IN	O
significant	JJ	O
decreases	NNS	O
in	IN	O
12-HETE	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.09	CD	O
)	)	O
and	CC	O
15-HETE	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.06	CD	O
)	)	O
normalized	VBN	O
to	TO	O
free	VB	O
arachidonic	JJ	O
acid	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
total	JJ	O
adverse	JJ	O
events	NNS	O
P	NNP	O
=	NNP	O
0.55	CD	O
)	)	O
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
these	DT	O
results	NNS	O
,	,	O
it	PRP	O
seems	VBZ	O
that	IN	O
ginger	NN	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
decrease	VB	O
eicosanoid	JJ	O
levels	NNS	O
,	,	O
perhaps	RB	O
by	IN	O
inhibiting	VBG	O
their	PRP$	O
synthesis	NN	O
from	IN	O
arachidonic	JJ	O
acid	NN	O
.	.	O

Ginger	NNP	Pharmacological
also	RB	O
seemed	VBD	O
to	TO	O
be	VB	O
tolerable	JJ	O
and	CC	O
safe	JJ	O
.	.	O

Further	JJ	O
investigation	NN	O
in	IN	O
people	NNS	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
CRC	NNP	O
seems	VBZ	O
warranted	VBN	O
.	.	O

Interactions	NNS	O
of	IN	O
morphine	NN	Pharmacological
and	CC	O
methotrimeprazine	NN	Pharmacological
in	IN	O
mouse	NN	O
and	CC	O
man	NN	O
with	IN	O
respect	NN	O
to	TO	O
analgesia	VB	O
,	,	O
respiration	NN	O
and	CC	O
sedation	NN	O
.	.	O

Interactions	NNS	O
between	IN	O
morphine	NN	Pharmacological
and	CC	O
methotrimeprazine	NN	Pharmacological
have	VBP	O
been	VBN	O
studied	VBN	O
in	IN	O
mice	NN	O
and	CC	O
man	NN	O
with	IN	O
respect	NN	O
to	TO	O
analgesia	VB	O
or	CC	O
antinociceptive	JJ	O
activity	NN	O
,	,	O
respiratory	NN	O
effects	NNS	O
and	CC	O
sedation	NN	O
.	.	O

The	DT	O
volunteer	NN	O
study	NN	O
was	VBD	O
a	DT	O
double-blind	JJ	O
cross-over	JJ	O
trial	NN	O
with	IN	O
10	CD	O
volunteers	NNS	O
.	.	O

In	IN	O
mice	NN	O
,	,	O
methotrimeprazine	VBZ	Pharmacological
only	RB	O
possessed	JJ	O
antinociceptive	JJ	O
activity	NN	O
in	IN	O
doses	NNS	O
which	WDT	O
caused	VBD	O
marked	JJ	O
sedation	NN	O
.	.	O

However	RB	O
,	,	O
small	JJ	O
non-sedative	JJ	O
doses	NNS	O
of	IN	O
methotrimeprazine	NN	O
potentiated	VBN	O
the	DT	O
analgesic	JJ	O
action	NN	O
of	IN	O
morphine	NN	O
.	.	O

The	DT	O
volunteer	NN	O
study	NN	O
did	VBD	O
not	RB	O
confirm	VB	O
this	DT	O
finding	NN	O
in	IN	O
man	NN	O
.	.	O

Methotrimeprazine	NNP	Pharmacological
7.5	CD	O
mg	NN	O
i.m	NN	O
.	.	O

caused	VBN	O
significant	JJ	O
sedation	NN	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
effects	NNS	O
of	IN	O
morphine	NN	Pharmacological
5	CD	O
mg	NN	O
on	IN	O
pain	NN	O
threshold	NN	O
or	CC	O
ventilatory	NN	O
response	NN	O
to	TO	O
carbon	VB	O
dioxide	NN	O
.	.	O

[	NN	O
Study	NNP	O
on	IN	O
treatment	NN	O
of	IN	O
iron-deficiency	NN	O
anemia	NN	O
by	IN	O
shengxuening	VBG	Pharmacological
]	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
observe	VB	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
shengxuening	VBG	Pharmacological
(	(	Pharmacological
SXN	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
treating	VBG	O
iron-deficiency	NN	O
anemia	NN	O
(	(	O
IDA	NNP	O
)	)	O
and	CC	O
to	TO	O
explore	VB	O
its	PRP$	O
molecular	JJ	O
mechanism	NN	O
on	IN	O
iron	NN	O
metabolism	NN	O
balance	NN	O
regulation	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
IDA	NNP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
the	DT	O
treated	VBN	O
group	NN	O
and	CC	O
the	DT	O
control	NN	Control
group	NN	O
,	,	O
50	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

They	PRP	O
were	VBD	O
treated	VBN	O
with	IN	O
SXN	NNP	Pharmacological
(	(	Pharmacological
0.1	CD	Pharmacological
g	NN	Pharmacological
,	,	Pharmacological
three	CD	Pharmacological
times	NNS	Pharmacological
per	IN	Pharmacological
day	NN	Pharmacological
)	)	Pharmacological
and	CC	O
ferrous	JJ	Pharmacological
gluconate	NN	Pharmacological
(	(	Pharmacological
0.1	CD	Pharmacological
g	NN	Pharmacological
,	,	Pharmacological
three	CD	Pharmacological
times	NNS	Pharmacological
per	IN	Pharmacological
day	NN	Pharmacological
)	)	Pharmacological
respectively	RB	O
,	,	O
for	IN	O
30	CD	O
days	NNS	O
.	.	O

Levels	NNS	O
of	IN	O
serum	NN	O
iron	NN	O
(	(	O
Fe	NNP	O
)	)	O
,	,	O
total	JJ	O
iron	NN	O
binding	NN	O
capacity	NN	O
(	(	O
TIBC	NNP	O
)	)	O
,	,	O
transferrin	JJ	O
saturation	NN	O
(	(	O
TS	NNP	O
)	)	O
,	,	O
serum	JJ	O
ferritin	NN	O
(	(	O
SF	NNP	O
)	)	O
,	,	O
transferrin	NN	O
(	(	O
Tf	NNP	O
)	)	O
,	,	O
soluble	JJ	O
transferrin	NN	O
receptor	NN	O
(	(	O
sTfR	NN	O
)	)	O
and	CC	O
blood	NN	O
routine	JJ	O
test	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
scoring	NN	O
of	IN	O
TCM	NNP	O
qi-blood	JJ	O
deficiency	NN	O
Syndrome	NNP	O
were	VBD	O
conducted	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
reached	VBD	O
92	CD	O
%	NN	O
,	,	O
it	PRP	O
was	VBD	O
shown	VBN	O
that	IN	O
SXN	NNP	O
could	MD	O
improve	VB	O
the	DT	O
iron	NN	O
metabolism	NN	O
,	,	O
increase	NN	O
levels	NNS	O
of	IN	O
Fe	NNP	O
,	,	O
TS	NNP	O
,	,	O
SF	NNP	O
and	CC	O
reduce	VB	O
levels	NNS	O
of	IN	O
TIBC	NNP	O
,	,	O
Tf	NNP	O
,	,	O
sTfR	NN	O
,	,	O
it	PRP	O
has	VBZ	O
obvious	JJ	O
effect	NN	O
in	IN	O
promoting	VBG	O
erythrocyte	JJ	O
generation	NN	O
and	CC	O
could	MD	O
promote	VB	O
formation	NN	O
of	IN	O
leucocytes	NNS	O
and	CC	O
platelets	NNS	O
.	.	O

The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
was	VBD	O
32	CD	O
%	NN	O
,	,	O
which	WDT	O
was	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
effect	NN	O
of	IN	O
SXN	NNP	Pharmacological
in	IN	O
treating	VBG	O
IDA	NNP	O
and	CC	O
qi-blood	JJ	O
deficiency	NN	O
Syndrome	NNP	O
is	VBZ	O
evident	JJ	O
,	,	O
it	PRP	O
could	MD	O
improve	VB	O
the	DT	O
iron	NN	O
metabolism	NN	O
,	,	O
increase	NN	O
levels	NNS	O
of	IN	O
Fe	NNP	O
,	,	O
TS	NNP	O
,	,	O
SF	NNP	O
and	CC	O
lower	JJR	O
levels	NNS	O
of	IN	O
TIBC	NNP	O
,	,	O
Tf	NNP	O
,	,	O
sTfR	NN	O
.	.	O

Sedation	NNP	O
depth	NN	O
during	IN	O
spinal	JJ	Pharmacological
anesthesia	NN	Pharmacological
and	CC	O
survival	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
undergoing	VBG	O
hip	JJ	O
fracture	NN	O
repair	NN	O
.	.	O

Low	JJ	O
intraoperative	JJ	O
Bispectral	NNP	O
Index	NNP	O
(	(	O
BIS	NNP	O
)	)	O
values	NNS	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
increased	JJ	O
mortality	NN	O
.	.	O

In	IN	O
a	DT	O
previously	RB	O
reported	VBN	O
trial	NN	O
to	TO	O
prevent	VB	O
delirium	NN	O
,	,	O
we	PRP	O
randomized	VBD	O
patients	NNS	O
undergoing	VBG	O
hip	JJ	O
fracture	NN	O
repair	NN	O
under	IN	O
spinal	JJ	Pharmacological
anesthesia	NN	Pharmacological
to	TO	O
light	NN	Pharmacological
(	(	Pharmacological
BIS	NNP	Pharmacological
>	NNP	Pharmacological
80	CD	Pharmacological
)	)	Pharmacological
or	CC	O
deep	JJ	Pharmacological
(	(	Pharmacological
BIS	NNP	Pharmacological
approximately	RB	Pharmacological
50	CD	Pharmacological
)	)	Pharmacological
sedation	NN	O
.	.	O

We	PRP	O
analyzed	VBD	O
survival	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
original	JJ	O
trial	NN	O
.	.	O

Among	IN	O
all	DT	O
patients	NNS	O
,	,	O
mortality	NN	O
was	VBD	O
equivalent	JJ	O
across	IN	O
sedation	NN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
among	IN	O
patients	NNS	O
with	IN	O
serious	JJ	O
comorbidities	NNS	O
(	(	O
Charlson	NNP	O
score	RB	O
>	VBZ	O
4	CD	O
)	)	O
,	,	O
1-year	JJ	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
light	NN	Other
(	(	O
22.2	CD	O
%	NN	O
)	)	O
vs	NN	O
deep	JJ	Other
(	(	O
43.6	CD	O
%	NN	O
)	)	O
sedation	NN	Pharmacological
group	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
,	,	O
0.43	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.19-0.97	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
during	IN	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

Similarly	RB	O
,	,	O
among	IN	O
patients	NNS	O
with	IN	O
Charlson	NNP	O
score	VBD	O
>	JJ	O
6	CD	O
,	,	O
1-year	JJ	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
light	NN	Pharmacological
(	(	O
28.6	CD	O
%	NN	O
)	)	O
vs	NN	O
deep	JJ	Pharmacological
(	(	O
52.6	CD	O
%	NN	O
)	)	O
sedation	NN	Pharmacological
group	NN	O
(	(	O
HR	NNP	O
0.33	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.12-0.94	JJ	O
;	:	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
during	IN	O
spinal	JJ	Pharmacological
anesthesia	NN	Pharmacological
.	.	O

Further	NNP	O
research	NN	O
on	IN	O
reduced	JJ	O
mortality	NN	O
after	IN	O
light	JJ	Pharmacological
sedation	NN	Pharmacological
during	IN	O
spinal	JJ	Pharmacological
anesthesia	NN	Pharmacological
is	VBZ	O
needed	VBN	O
.	.	O

Allopurinol	NNP	Pharmacological
improves	VBZ	O
endothelial	JJ	O
function	NN	O
and	CC	O
reduces	VBZ	O
oxidant-inflammatory	JJ	O
enzyme	NN	O
of	IN	O
myeloperoxidase	NN	O
in	IN	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

OBJECTIVE	NN	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
tested	VBD	O
in	IN	O
patients	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	VBP	O
whether	IN	O
allopurinol	NNS	O
through	IN	O
decreasing	VBG	O
oxidative	JJ	O
stress	NN	O
improves	VBZ	O
endothelial	JJ	O
function	NN	O
,	,	O
and	CC	O
ameliorates	VBZ	O
inflammatory	JJ	O
state	NN	O
represented	VBN	O
by	IN	O
markers	NNS	O
of	IN	O
myeloperoxidase	NN	O
,	,	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
and	CC	O
fibrinogen	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
fashion	NN	O
;	:	O
subjects	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
allopurinol	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
28	CD	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
for	IN	O
one	CD	O
month	NN	O
.	.	O

Before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
,	,	O
blood	NN	Physical
samples	NNS	Physical
were	VBD	O
collected	VBN	O
and	CC	O
the	DT	O
flow-mediated	JJ	O
dilation	NN	O
(	(	O
FMD	NNP	O
)	)	O
and	CC	O
isosorbide	JJ	O
dinitrate	NN	O
(	(	O
ISDN	NNP	O
)	)	O
-mediated	VBD	O
dilation	NN	O
of	IN	O
the	DT	O
brachial	JJ	O
artery	NN	O
were	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
clinical	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
allopurinol	NN	Pharmacological
and	CC	O
placebo	NN	O
groups	NNS	O
demonstrated	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
clinical	JJ	O
characteristics	NNS	O
,	,	O
endothelial	JJ	O
function	NN	O
and	CC	O
inflammatory	JJ	O
markers	NNS	O
.	.	O

After	IN	O
the	DT	O
treatment	NN	O
with	IN	O
allopurinol	NN	O
,	,	O
FMD	NNP	O
was	VBD	O
increased	VBN	O
from	IN	O
8.0	CD	O
+/-	JJ	O
0.5	CD	O
%	NN	O
to	TO	O
11.8	CD	O
+/-	JJ	O
0.6	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
ISDN-mediated	JJ	O
dilation	NN	O
is	VBZ	O
unaffected	VBN	O
by	IN	O
the	DT	O
treatment	NN	O
.	.	O

As	IN	O
a	DT	O
marker	NN	O
of	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
allopurinol	VBP	O
significantly	RB	O
reduced	VBN	O
malondialdehyde	NN	O
.	.	O

Moreover	RB	O
,	,	O
myeloperoxidase	NN	O
levels	NNS	O
were	VBD	O
reduced	VBN	O
by	IN	O
the	DT	O
treatment	NN	O
with	IN	O
allopurinol	NN	O
(	(	O
56.1	CD	O
+/-	JJ	O
3.4	CD	O
ng/ml	JJ	O
vs.	FW	O
44.4	CD	O
+/-	JJ	O
2.4	CD	O
ng/ml	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
but	CC	O
there	EX	O
were	VBD	O
no	DT	O
change	NN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

Surprisingly	RB	O
,	,	O
neither	DT	O
CRP	NNP	O
nor	CC	O
fibrinogen	NN	O
levels	NNS	O
were	VBD	O
affected	VBN	O
by	IN	O
the	DT	O
treatment	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Xanthine	NNP	O
oxidoreductase	NN	O
inhibition	NN	O
by	IN	O
allopurinol	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	NN	O
reduces	NNS	O
oxidative	JJ	O
stress	NN	O
,	,	O
improves	VBZ	O
endothelial	JJ	O
function	NN	O
,	,	O
ameliorates	VBZ	O
myeloperoxidase	NN	O
levels	NNS	O
and	CC	O
does	VBZ	O
not	RB	O
have	VB	O
any	DT	O
effect	NN	O
on	IN	O
CRP	NNP	O
and	CC	O
fibrinogen	NN	O
levels	NNS	O
.	.	O

Theory	NN	O
of	IN	O
Mind	NNP	Educational
training	NN	Educational
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Many	JJ	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
participate	NN	O
in	IN	O
social	JJ	O
skills	NNS	O
or	CC	O
Theory	NN	Educational
of	IN	Educational
Mind	NNP	Educational
(	(	Educational
ToM	NNP	Educational
)	)	Educational
treatments	NNS	Educational
.	.	O

However	RB	O
,	,	O
few	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
evidence	NN	O
for	IN	O
their	PRP$	O
effectiveness	NN	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
used	VBD	O
a	DT	O
randomized	JJ	O
controlled	JJ	O
design	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
16-week	JJ	O
ToM	NNP	Educational
treatment	NN	Educational
in	IN	O
8-13	JJ	O
year	NN	O
old	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
normal	JJ	O
IQs	NNP	O
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
,	,	O
compared	VBN	O
to	TO	O
controls	NNS	O
,	,	O
the	DT	O
treated	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
improved	VBN	O
in	IN	O
their	PRP$	O
conceptual	JJ	O
ToM	NNP	O
skills	NNS	O
,	,	O
but	CC	O
their	PRP$	O
elementary	JJ	O
understanding	NN	O
,	,	O
self	PRP	O
reported	VBD	O
empathic	JJ	O
skills	NNS	O
or	CC	O
parent	NN	O
reported	VBN	O
social	JJ	O
behaviour	NN	O
did	VBD	O
not	RB	O
improve	VB	O
.	.	O

Despite	IN	O
the	DT	O
effects	NNS	O
on	IN	O
conceptual	JJ	O
understanding	NN	O
,	,	O
the	DT	O
current	JJ	O
study	NN	O
does	VBZ	O
not	RB	O
indicate	VB	O
strong	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
ToM	NNP	O
treatment	NN	O
on	IN	O
the	DT	O
daily	JJ	O
life	NN	O
mindreading	VBG	O
skills	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
enflurane	NN	Pharmacological
and	CC	O
isoflurane	NN	Pharmacological
on	IN	O
splanchnic	JJ	O
oxygenation	NN	O
in	IN	O
humans	NNS	O
.	.	O

STUDY	NNP	O
OBJECTIVES	NNP	O
To	TO	O
determine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
enflurane	NN	Pharmacological
and	CC	O
isoflurane	NN	Pharmacological
on	IN	O
hepatic	JJ	O
venous	JJ	O
oxygen	NN	O
saturation	NN	O
(	(	O
ShvO2	NNP	O
)	)	O
and	CC	O
splanchnic	JJ	O
oxygen	NN	O
(	(	O
O2	NNP	O
)	)	O
extraction	NN	O
.	.	O

To	TO	O
measure	VB	O
hemodynamic	JJ	O
parameters	NNS	O
and	CC	O
ShvO2	NNP	O
,	,	O
mixed	JJ	O
venous	JJ	O
,	,	O
and	CC	O
arterial	JJ	O
lactate	NN	O
concentrations	NNS	O
during	IN	O
enflurane	NN	Pharmacological
and	CC	O
isoflurane	NN	Pharmacological
anesthesia	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
prospective	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
University	NNP	O
hospital	NN	O
.	.	O

PATIENTS	CC	O
20	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I	PRP	O
,	,	O
II	NNP	O
,	,	O
and	CC	O
III	NNP	O
adults	NNS	O
,	,	O
who	WP	O
underwent	VBD	O
major	JJ	O
abdominal	JJ	O
surgery	NN	O
requiring	VBG	O
mechanical	JJ	O
ventilation	NN	O
a	DT	O
few	JJ	O
hours	NNS	O
postoperatively	RB	O
.	.	O

INTERVENTIONS	NNP	O
After	IN	O
placement	NN	O
of	IN	O
catheters	NNS	O
in	IN	O
the	DT	O
pulmonary	JJ	O
artery	NN	O
,	,	O
radial	JJ	O
artery	NN	O
,	,	O
peripheral	JJ	O
and	CC	O
right	JJ	O
hepatic	JJ	O
vein	NN	O
,	,	O
one	CD	O
hour	NN	O
postoperatively	RB	O
either	CC	O
enflurane	NN	Pharmacological
or	CC	O
isoflurane	NN	Pharmacological
was	VBD	O
applied	VBN	O
at	IN	O
different	JJ	O
minimum	JJ	O
alveolar	JJ	O
concentration	NN	O
(	(	O
MAC	NNP	O
)	)	O
of	IN	O
0.5	CD	O
,	,	O
1.0	CD	O
,	,	O
and	CC	O
1.5	CD	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Before	NNP	O
and	CC	O
10	CD	O
minutes	NNS	O
after	IN	O
administration	NN	O
of	IN	O
each	DT	O
desired	VBN	O
end-expiratory	JJ	O
anesthetic	JJ	O
concentration	NN	O
,	,	O
the	DT	O
following	JJ	O
parameters	NNS	O
were	VBD	O
determined	VBN	O
:	:	O
hemodynamic	JJ	O
parameters	NNS	O
,	,	O
arterial	JJ	O
(	(	O
SaO2	NNP	O
)	)	O
,	,	O
mixed	JJ	O
venous	JJ	O
(	(	O
SvO2	NNP	O
)	)	O
,	,	O
and	CC	O
hepatic	JJ	O
venous	JJ	O
oxygen	NN	O
saturations	NNS	O
,	,	O
systemic	JJ	O
and	CC	O
splanchnic	JJ	O
O2	NNP	O
extraction	NN	O
,	,	O
arterial	JJ	O
,	,	O
mixed	JJ	O
venous	JJ	O
,	,	O
and	CC	O
hepatic	JJ	O
venous	JJ	O
lactate	NN	O
concentrations	NNS	O
.	.	O

Cardiac	NNP	O
output	NN	O
(	(	O
CO	NNP	O
)	)	O
and	CC	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
(	(	O
MAP	NNP	O
)	)	O
decreased	VBD	O
in	IN	O
a	DT	O
dose	JJ	O
dependent	JJ	O
manner	NN	O
.	.	O

SaO2	NNP	O
,	,	O
SvO2	NNP	O
,	,	O
and	CC	O
systemic	JJ	O
O2	NNP	O
extraction	NN	O
remained	VBD	O
unchanged	JJ	O
with	IN	O
enflurane	NN	O
and	CC	O
isoflurane	NN	O
anesthesia	NN	O
.	.	O

In	IN	O
the	DT	O
enflurane	NN	Pharmacological
group	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
isoflurane	NN	O
group	NN	O
,	,	O
ShvO2	NNP	O
decreased	VBD	O
with	IN	O
increasing	VBG	O
inhalational	JJ	O
concentrations	NNS	O
.	.	O

This	DT	O
decrease	NN	O
in	IN	O
ShvO2	NNP	O
reflected	VBD	O
an	DT	O
increase	NN	O
in	IN	O
splanchnic	JJ	O
O2	NNP	O
extraction	NN	O
with	IN	O
enflurane	NN	Pharmacological
;	:	O
in	IN	O
contrast	NN	O
to	TO	O
isoflurane	VB	Pharmacological
.	.	O

CONCLUSIONS	NNP	O
Enflurane	NNP	Pharmacological
causes	VBZ	O
a	DT	O
decrease	NN	O
in	IN	O
ShvO2	NNP	O
,	,	O
which	WDT	O
indicates	VBZ	O
an	DT	O
impairment	NN	O
of	IN	O
splanchnic	JJ	O
perfusion	NN	O
corresponding	VBG	O
to	TO	O
the	DT	O
reduction	NN	O
in	IN	O
CO	NNP	O
and	CC	O
MAP	NNP	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
.	.	O

Isoflurane	NNP	Pharmacological
maintains	VBZ	O
splanchnic	JJ	O
perfusion	NN	O
in	IN	O
contrast	NN	O
to	TO	O
enflurane	VB	Pharmacological
.	.	O

A	DT	O
30-month	JJ	O
longitudinal	JJ	O
study	NN	O
of	IN	O
the	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	Physical
hygiene	NN	Physical
measures	NNS	Physical
on	IN	O
Streptococcus	NNP	O
mutans	NNS	O
and	CC	O
approximal	JJ	O
dental	JJ	O
caries	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
some	DT	O
oral	JJ	Physical
hygiene	NN	Physical
measures	NNS	Physical
on	IN	O
Streptococcus	NNP	O
mutants	NNS	O
and	CC	O
approximal	JJ	O
dental	JJ	O
caries	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
eighty-seven	JJ	O
13-year-old	JJ	O
individuals	NNS	O
with	IN	O
high	JJ	O
levels	NNS	O
of	IN	O
salivary	JJ	O
S.	NNP	O
mutans	NNS	O
(	(	O
greater	JJR	O
than	IN	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/mL	NN	O
)	)	O
were	VBD	O
selected	VBN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
distributed	VBN	O
into	IN	O
three	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
initially	RB	O
received	VBD	O
professional	JJ	Physical
mechanical	JJ	Physical
tooth-cleaning	NN	Physical
,	,	Educational
tongue-scraping	NN	Physical
,	,	Educational
chlorhexidine	NN	Control
treatment	NN	Control
,	,	Educational
and	CC	Educational
oral	JJ	Educational
hygiene	NN	Educational
instructions	NNS	Educational
concentrated	VBD	O
on	IN	O
the	DT	O
approximal	JJ	O
surfaces	NNS	O
most	RBS	O
colonized	VBN	O
by	IN	O
S.	NNP	O
mutans	NNS	O
.	.	O

The	DT	O
treatment	NN	O
was	VBD	O
given	VBN	O
four	CD	O
times	NNS	O
with	IN	O
intervals	NNS	O
of	IN	O
two	CD	O
days	NNS	O
,	,	O
followed	VBN	O
by	IN	O
one	CD	O
single	JJ	O
treatment	NN	O
every	DT	O
six	CD	O
months	NNS	O
throughout	IN	O
the	DT	O
experimental	JJ	O
period	NN	O
.	.	O

The	DT	O
initial	JJ	O
treatment	NN	O
period	NN	O
for	IN	O
group	NN	O
II	NNP	O
,	,	O
also	RB	O
consisting	VBG	O
of	IN	O
four	CD	O
visits	NNS	O
,	,	O
included	VBD	O
the	DT	O
same	JJ	O
oral	JJ	Educational
hygiene	NN	Educational
instructions	NNS	Educational
as	IN	O
for	IN	O
group	NN	O
I	PRP	O
.	.	O

The	DT	O
instructions	NNS	O
were	VBD	O
repeated	VBN	O
every	DT	O
six	CD	O
months	NNS	O
.	.	O

Group	NNP	O
III	NNP	O
was	VBD	O
maintained	VBN	O
in	IN	O
the	DT	O
preventive	JJ	Educational
program	NN	Educational
provided	VBN	Educational
by	IN	Educational
the	DT	Educational
local	JJ	Educational
Dental	NNP	Educational
Health	NNP	Educational
Office	NNP	Educational
,	,	O
based	VBN	O
on	IN	O
mechanical	JJ	Physical
plaque	NN	Physical
control	NN	Physical
and	CC	O
topical	JJ	Pharmacological
use	NN	Pharmacological
of	IN	Pharmacological
fluorides	NNS	Pharmacological
and	CC	Pharmacological
chlorhexidine	NN	Pharmacological
at	IN	O
individualized	JJ	O
intervals	NNS	O
.	.	O

Group	NNP	O
I	PRP	O
showed	VBD	O
a	DT	O
significant	JJ	O
immediate	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
saliva	NN	O
as	RB	O
well	RB	O
as	IN	O
an	DT	O
approximal	JJ	O
tooth	NN	O
surfaces	NNS	O
.	.	O

After	IN	O
six	CD	O
months	NNS	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
regarding	VBG	O
these	DT	O
variables	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
baseline	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
S.	NNP	O
mutans	NNS	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
caries	NNS	O
progression	NN	O
among	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
selected	VBN	O
high-risk	JJ	O
individuals	NNS	O
in	IN	O
group	NN	O
I	PRP	O
developed	VBD	O
0.25	CD	O
new	JJ	O
manifest	NN	O
caries	NNS	O
lesions	NNS	O
approximally/year	VBP	O
,	,	O
compared	VBN	O
with	IN	O
0.27	CD	O
for	IN	O
all	DT	O
children	NNS	O
of	IN	O
the	DT	O
same	JJ	O
age	NN	O
group	NN	O
in	IN	O
the	DT	O
area	NN	O
.	.	O

Seventeen	JJ	O
individuals	NNS	O
had	VBD	O
approximal	JJ	O
surfaces	NNS	O
with	IN	O
consistently	RB	O
high	JJ	O
or	CC	O
consistently	RB	O
low	JJ	O
S.	NNP	O
mutans	NN	O
levels	NNS	O
.	.	O

Forty-six	CD	O
percent	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
high	JJ	O
values	NNS	O
developed	VBD	O
new	JJ	O
or	CC	O
progressive	JJ	O
caries	NNS	O
,	,	O
compared	VBN	O
with	IN	O
2	CD	O
%	NN	O
of	IN	O
the	DT	O
surfaces	NNS	O
with	IN	O
low	JJ	O
values	NNS	O
.	.	O

Inhibition	NN	O
of	IN	O
spontaneous	JJ	O
platelet	NN	O
aggregation	NN	O
and	CC	O
adhesion	NN	O
by	IN	O
indobufen	NN	Pharmacological
(	(	Pharmacological
K	NNP	Pharmacological
3920	CD	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
crossover	NN	O
study	NN	O
on	IN	O
platelet	NN	O
,	,	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
function	NN	O
tests	NNS	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
double-blind	NN	O
crossover	NN	O
study	NN	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
atherosclerotic	JJ	O
disease	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
2	CD	O
dosages	NNS	O
(	(	O
100	CD	O
and	CC	O
200	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
of	IN	O
indobufen	NN	Pharmacological
,	,	O
a	DT	O
new	JJ	O
synthetic	JJ	O
inhibition	NN	O
of	IN	O
platelet	NN	O
aggregation	NN	O
,	,	O
on	IN	O
some	DT	O
platelet	NN	O
functions	NNS	O
,	,	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
tests	NNS	O
was	VBD	O
investigated	VBN	O
.	.	O

Regardless	NNP	O
of	IN	O
the	DT	O
dosage	NN	O
used	VBN	O
,	,	O
indobufen	NN	Pharmacological
was	VBD	O
shown	VBN	O
to	TO	O
induce	VB	O
a	DT	O
prompt	JJ	O
normalization	NN	O
of	IN	O
the	DT	O
enhanced	JJ	O
platelet	NN	O
aggregation	NN	O
of	IN	O
these	DT	O
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
lasted	VBD	O
for	IN	O
the	DT	O
entire	JJ	O
period	NN	O
of	IN	O
drug	NN	O
administration	NN	O
and	CC	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
a	DT	O
normal	JJ	O
platelet	NN	O
aggregation	NN	O
was	VBD	O
maintained	VBN	O
until	IN	O
the	DT	O
fourth	JJ	O
day	NN	O
after	IN	O
discontinuation	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

Indobufen	NNP	Pharmacological
was	VBD	O
also	RB	O
able	JJ	O
to	TO	O
reduce	VB	O
platelet	NN	O
adhesiveness	NN	O
and	CC	O
to	TO	O
lengthen	VB	O
bleeding	NN	O
time	NN	O
,	,	O
especially	RB	O
when	WRB	O
the	DT	O
higher	JJR	O
dosage	NN	O
was	VBD	O
used	VBN	O
.	.	O

Thrombin-activatable	JJ	Physical
fibrinolysis	NN	Physical
inhibitor	NN	Physical
in	IN	O
hypothyroidism	NN	O
and	CC	O
hyperthyroxinaemia	NN	O
.	.	O

Endocrine	JJ	O
disorders	NNS	O
affect	VBP	O
both	DT	O
the	DT	O
coagulation	NN	O
and	CC	O
fibrinolytic	JJ	O
systems	NNS	O
,	,	O
and	CC	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
the	DT	O
development	NN	O
of	IN	O
cardiovascular	JJ	O
diseases	NNS	O
.	.	O

Thrombin-activatable	JJ	Physical
fibrinolysis	NN	Physical
inhibitor	NN	Physical
(	(	Physical
TAFI	NNP	Physical
)	)	Physical
is	VBZ	O
a	DT	O
link	NN	O
between	IN	O
coagulation	NN	O
and	CC	O
the	DT	O
fibrinolytic	JJ	O
system	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
thyroid	NN	O
hormone	NN	O
excess	NN	O
and	CC	O
deficiency	NN	O
on	IN	O
TAFI	NNP	Physical
levels	NNS	O
and	CC	O
function	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hyperthyroxinemia	NN	O
on	IN	O
TAFI	NNP	Pharmacological
was	VBD	O
studied	VBN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
levothyroxine	NN	Pharmacological
or	CC	O
no	DT	Control
medication	NN	Control
for	IN	O
14	CD	O
days	NNS	O
in	IN	O
a	DT	O
crossover	NN	O
design	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
hypothyroidism	NN	O
on	IN	O
TAFI	NNP	Pharmacological
was	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
multicentre	JJ	O
observational	JJ	O
cohort	NN	O
study	NN	O
.	.	O

Blood	NNP	O
was	VBD	O
drawn	VBN	O
before	IN	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
hypothyroidism	NN	O
and	CC	O
when	WRB	O
euthyroidism	NN	O
was	VBD	O
achieved	VBN	O
.	.	O

Plasma	NNP	O
clot-lysis	NN	O
times	NNS	O
,	,	O
activated	VBD	O
TAFI	NNP	Physical
(	(	Physical
TAFIa	NNP	Physical
)	)	Physical
-dependent	NN	Physical
prolongation	NN	O
of	IN	O
clot-lysis	NN	O
and	CC	O
TAFI	NNP	O
levels	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Thyroid	NNP	O
hormone	NN	O
excess	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
hypofibrinolytic	JJ	O
condition	NN	O
and	CC	O
in	IN	O
an	DT	O
enhanced	JJ	O
TAFIa-dependent	JJ	O
prolongation	NN	O
of	IN	O
clot	NN	O
lysis	NN	O
.	.	O

A	DT	O
trend	NN	O
towards	NNS	O
decreased	VBD	O
plasma	JJ	O
TAFI	NNP	Pharmacological
levels	NNS	O
was	VBD	O
observed	VBN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
used	VBD	O
levothyroxine	NN	Pharmacological
.	.	O

Hypothyroidism	NNP	O
resulted	VBD	O
in	IN	O
hyperfibrinolysis	NN	O
and	CC	O
a	DT	O
reduced	JJ	O
TAFIa-dependent	JJ	O
prolongation	NN	O
of	IN	O
clot	NN	O
lysis	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
alterations	NNS	O
of	IN	O
TAFIa-dependent	JJ	Pharmacological
prolongation	NN	O
of	IN	O
clot	NN	O
lysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
thyroid	JJ	O
disorders	NNS	O
may	MD	O
cause	VB	O
an	DT	O
impaired	JJ	O
haemostatic	JJ	O
balance	NN	O
.	.	O

The	DT	O
disturbed	JJ	O
haemostatic	JJ	O
balance	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hyperthyroidism	NN	O
might	MD	O
make	VB	O
them	PRP	O
prone	VB	O
to	TO	O
thrombosis	VB	O
,	,	O
while	IN	O
the	DT	O
risk	NN	O
for	IN	O
bleeding	VBG	O
may	MD	O
increase	VB	O
in	IN	O
patients	NNS	O
with	IN	O
hypothyroidism	NN	O
.	.	O

Hodgkin	NNP	O
's	POS	O
disease	NN	O
in	IN	O
childhood	NN	O
and	CC	O
adolescence	NN	O
:	:	O
results	NNS	O
of	IN	O
chemotherapy-radiotherapy	NN	O
in	IN	O
clinical	JJ	O
stages	NNS	O
IA-IIB	NNP	O
.	.	O

From	IN	O
April	NNP	O
1972	CD	O
to	TO	O
May	NNP	O
1980	CD	O
,	,	O
72	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
(	(	O
aged	VBN	O
5	CD	O
to	TO	O
19	CD	O
years	NNS	O
old	JJ	O
,	,	O
median	JJ	O
16	CD	O
)	)	O
with	IN	O
Hodgkin	NNP	O
's	POS	O
disease	NN	O
,	,	O
clinical	JJ	O
stages	NNS	O
IA-IIB	NNP	O
(	(	O
IA	NNP	O
,	,	O
18	CD	O
;	:	O
II2A	NNP	O
,	,	O
two	CD	O
areas	NNS	O
involved	VBN	O
on	IN	O
the	DT	O
same	JJ	O
side	NN	O
of	IN	O
the	DT	O
diaphragm	NN	O
,	,	O
23	CD	O
;	:	O
II3+A	NNP	O
,	,	O
three	CD	O
areas	NNS	O
or	CC	O
more	JJR	O
,	,	O
16	CD	O
;	:	O
IIB	NNP	O
,	,	O
15	CD	O
)	)	O
were	VBD	O
prospectively	RB	O
treated	VBN	O
in	IN	O
two	CD	O
successive	JJ	O
clinical	JJ	O
trials	NNS	O
(	(	O
H	NNP	O
72	CD	O
and	CC	O
H	NNP	O
77	CD	O
)	)	O
.	.	O

Clinical	JJ	O
stages	NNS	O
IA	NNP	O
and	CC	O
II2A	NNP	O
received	VBD	O
three	CD	O
courses	NNS	O
of	IN	O
mechlorethamine	NN	Physical
,	,	Physical
Oncovin	NNP	Physical
,	,	Physical
procarbazine	NN	Physical
,	,	Physical
and	CC	Physical
prednisone	NN	Physical
(	(	Physical
MOPP	NNP	Physical
)	)	Physical
and	CC	O
supradiaphragmatic	JJ	Physical
radiotherapy	NN	Physical
(	(	Physical
40	CD	Physical
Gy	NNP	Physical
)	)	Physical
,	,	O
and	CC	O
no	DT	Physical
laparotomy	NN	Physical
was	VBD	O
performed	VBN	O
.	.	O

Clinical	JJ	O
stages	NNS	O
II3+A	NNP	O
and	CC	O
IIB	NNP	O
received	VBD	O
either	DT	O
six	CD	O
cycles	NNS	O
of	IN	O
MOPP	NNP	Pharmacological
(	(	O
H	NNP	O
72	CD	O
)	)	O
,	,	O
three	CD	O
cycles	NNS	O
of	IN	O
MOPP	NNP	O
,	,	O
or	CC	O
three	CD	O
cycles	NNS	O
of	IN	O
CCNU	NNP	Pharmacological
,	,	Pharmacological
vinblastine	NN	Pharmacological
,	,	Pharmacological
procarbazine	NN	Pharmacological
,	,	O
and	CC	O
prednisone	NN	Pharmacological
(	(	O
CVPP	NNP	O
)	)	O
(	(	O
H	$	O
77	CD	O
)	)	O
and	CC	O
subsequently	RB	O
had	VBD	O
a	DT	O
laparotomy	NN	Surgical
followed	VBN	O
by	IN	O
supradiaphragmatic	JJ	Physical
radiotherapy	NN	Physical
and	CC	O
a	DT	O
lumboaortic	JJ	O
field	NN	O
if	IN	O
results	NNS	O
of	IN	O
laparotomy	NN	O
were	VBD	O
positive	JJ	O
.	.	O

Patients	NNS	O
without	IN	O
evidence	NN	O
of	IN	O
mediastinal	JJ	O
involvement	NN	O
did	VBD	O
not	RB	O
have	VB	O
mediastinal	JJ	O
radiotherapy	NN	O
.	.	O

At	IN	O
the	DT	O
completion	NN	O
of	IN	O
therapy	NN	O
,	,	O
the	DT	O
disease	NN	O
in	IN	O
70	CD	O
of	IN	O
72	CD	O
patients	NNS	O
was	VBD	O
in	IN	O
complete	JJ	O
remission	NN	O
(	(	O
one	CD	O
failure	NN	O
,	,	O
one	CD	O
death	NN	O
during	IN	O
treatment	NN	O
)	)	O
.	.	O

Eight	CD	O
patients	NNS	O
relapsed	VBN	O
(	(	O
in	IN	O
situ	NN	O
,	,	O
1	CD	O
;	:	O
marginal	JJ	O
,	,	O
1	CD	O
;	:	O
nonirradiated	VBN	O
subdiaphragmatic	JJ	O
area	NN	O
,	,	O
6	CD	O
)	)	O
after	IN	O
three	CD	O
to	TO	O
57	CD	O
months	NNS	O
of	IN	O
complete	JJ	O
remission	NN	O
(	(	O
median	JJ	O
20	CD	O
months	NNS	O
)	)	O
;	:	O
one	CD	O
patient	NN	O
died	VBD	O
after	IN	O
relapse	NN	O
.	.	O

There	EX	O
were	VBD	O
three	CD	O
deaths	NNS	O
after	IN	O
complete	JJ	O
remission	NN	O
of	IN	O
the	DT	O
disease	NN	O
(	(	O
infection	NN	O
,	,	O
two	CD	O
;	:	O
acute	CC	O
nonlymphocytic	JJ	O
leukemia	NN	O
[	NNP	O
ANLL	NNP	O
]	NNP	O
,	,	O
one	CD	O
)	)	O
.	.	O

As	IN	O
of	IN	O
June	NNP	O
1984	CD	O
the	DT	O
median	JJ	O
follow-up	NN	O
was	VBD	O
82	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
49	CD	O
to	TO	O
145	CD	O
months	NNS	O
)	)	O
,	,	O
the	DT	O
actuarial	JJ	O
probabilities	NNS	O
for	IN	O
survival	NN	O
and	CC	O
freedom	NN	O
from	IN	O
relapse	NN	O
for	IN	O
all	DT	O
patients	NNS	O
being	VBG	O
91.6	CD	O
%	NN	O
and	CC	O
87.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
statistical	JJ	O
difference	NN	O
according	VBG	O
to	TO	O
clinical	JJ	O
stage	NN	O
,	,	O
age	NN	O
(	(	O
greater	JJR	O
than	IN	O
15	CD	O
or	CC	O
less	JJR	O
than	IN	O
15	CD	O
years	NNS	O
)	)	O
,	,	O
sex	NN	O
,	,	O
or	CC	O
number	NN	O
of	IN	O
cycles	NNS	O
of	IN	O
chemotherapy	NN	O
(	(	O
six	CD	O
or	CC	O
three	CD	O
)	)	O
.	.	O

Bone	NNP	O
growth	NN	O
defects	NNS	O
related	VBN	O
to	TO	O
radiotherapy	VB	O
were	VBD	O
reduced	VBN	O
particularly	RB	O
in	IN	O
the	DT	O
29	CD	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
mediastinal	JJ	O
radiotherapy	NN	O
.	.	O

None	NN	O
of	IN	O
these	DT	O
patients	NNS	O
had	VBD	O
a	DT	O
mediastinal	JJ	O
relapse	NN	O
.	.	O

Azoospermia	NNP	O
was	VBD	O
the	DT	O
rule	NN	O
for	IN	O
the	DT	O
male	NN	O
patients	NNS	O
studied	VBN	O
,	,	O
but	CC	O
young	JJ	O
girls	NNS	O
and	CC	O
young	JJ	O
women	NNS	O
retained	VBD	O
reproductive	JJ	O
integrity	NN	O
.	.	O

Object	JJ	O
interest	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
treatment	NN	O
comparison	NN	O
.	.	O

A	DT	O
randomized	JJ	O
control	NN	O
trial	NN	O
comparing	VBG	O
two	CD	O
social	JJ	Educational
communication	NN	Educational
treatments	NNS	Educational
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
treatment	NN	O
on	IN	O
object	JJ	O
interest	NN	O
.	.	O

Thirty-two	JJ	O
children	NNS	O
,	,	O
18-60	JJ	O
months	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
Picture	NNP	Educational
Exchange	NNP	Educational
Communication	NNP	Educational
System	NNP	Educational
(	(	Educational
PECS	NNP	Educational
)	)	Educational
or	CC	Educational
Responsive	JJ	Educational
Education	NN	Educational
and	CC	Educational
Prelinguistic	NNP	Educational
Milieu	NNP	Educational
Teaching	NNP	Educational
(	(	Educational
RPMT	NNP	Educational
)	)	Educational
condition	NN	Educational
.	.	Educational

Assessment	NN	O
of	IN	O
object	JJ	O
interest	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
an	DT	O
unstructured	JJ	O
play	NN	O
session	NN	O
with	IN	O
different	JJ	O
toys	NNS	O
,	,	O
activities	NNS	O
,	,	O
adult	NN	O
,	,	O
and	CC	O
location	NN	O
than	IN	O
experienced	VBN	O
in	IN	O
treatment	NN	O
.	.	O

Results	NNS	O
indicated	VBD	O
children	NNS	O
in	IN	O
the	DT	O
RPMT	NNP	Educational
condition	NN	O
showed	VBD	O
greater	JJR	O
increases	NNS	O
in	IN	O
object	JJ	O
interest	NN	O
as	IN	O
compared	VBN	O
to	TO	O
children	NNS	O
in	IN	O
the	DT	O
PECS	NNP	Educational
condition	NN	O
.	.	O

Because	IN	O
child	JJ	O
characteristics	NNS	O
such	JJ	O
as	IN	O
interest	NN	O
in	IN	O
objects	NNS	O
may	MD	O
influence	VB	O
response	NN	O
to	TO	O
interventions	NNS	O
using	VBG	O
object	JJ	O
play	NN	O
as	IN	O
contexts	NN	O
for	IN	O
treatment	NN	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
improve	VB	O
our	PRP$	O
understanding	NN	O
of	IN	O
whether	IN	O
intervention	NN	O
can	MD	O
affect	VB	O
object	JJ	O
interest	NN	O
.	.	O

[	JJ	O
Treatment	NNP	O
of	IN	O
autism	NN	O
children	NNS	O
:	:	O
observation	NN	O
on	IN	O
efficacy	NN	O
of	IN	O
behavior	JJ	Educational
training	NN	Educational
with	IN	O
retention	NN	Physical
of	IN	Physical
needles	NNS	Physical
on	IN	Physical
head	NN	Physical
]	NN	Physical
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
the	DT	O
effect	NN	O
difference	NN	O
of	IN	O
behavior	JJ	Educational
training	NN	Educational
with	IN	Educational
head	NN	Educational
needling	VBG	Educational
retention	NN	Educational
and	CC	Educational
behavior	NN	Educational
training	NN	Educational
after	IN	Educational
acupuncture	NN	Educational
for	IN	O
autism	NN	O
children	NNS	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
qualified	VBD	O
autism	NN	O
children	NNS	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
simultaneous	JJ	O
head	NN	Educational
needling	VBG	Educational
retention	NN	Educational
and	CC	Educational
behavior	JJ	Educational
training	NN	Educational
group	NN	Educational
(	(	O
trial	NN	O
group	NN	O
)	)	O
and	CC	O
behavior	JJ	Educational
training	NN	Educational
after	IN	Educational
acupuncture	NN	Educational
treatment	NN	Educational
group	NN	Educational
(	(	O
control	VB	O
group	NN	O
)	)	O
with	IN	O
30	CD	O
case	NN	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Retention	NNP	Physical
needles	NNS	Physical
on	IN	O
the	DT	O
head	NN	O
with	IN	O
simultaneous	JJ	O
behavior	NN	O
training	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
the	DT	O
trial	NN	O
group	NN	O
.	.	O

The	DT	O
main	JJ	O
acupoints	NNS	O
included	VBD	O
Sishen	NNP	O
Xue	NNP	O
,	,	O
Dingshen	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
tranquilization	NN	O
)	)	O
,	,	O
Nao	NNP	O
Sanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
the	DT	O
function	NN	O
of	IN	O
brain	NN	O
)	)	O
,	,	O
Shou	NNP	O
Zhisanxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
hand	NN	O
)	)	O
and	CC	O
Zozhi	NNP	O
Sonxue	NNP	O
(	(	O
3	CD	O
points	NNS	O
for	IN	O
mental	JJ	O
activities	NNS	O
on	IN	O
foot	NN	O
)	)	O
.	.	O

Other	JJ	O
points	NNS	O
were	VBD	O
combined	VBN	O
according	VBG	O
to	TO	O
conditions	NNS	O
of	IN	O
patients	NNS	O
.	.	O

Needles	NNS	O
on	IN	O
the	DT	O
4	CD	O
extremities	NNS	O
were	VBD	O
withdrawn	VBN	O
first	RB	O
after	IN	O
30	CD	O
minutes	NNS	O
,	,	O
needles	NNS	O
on	IN	O
head	NN	O
were	VBD	O
remained	VBN	O
during	IN	O
behavior	JJ	Educational
training	NN	Educational
.	.	Educational

While	IN	O
behavior	JJ	Educational
training	NN	Educational
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
when	WRB	O
acupuncture	NN	O
treatment	NN	O
was	VBD	O
completely	RB	O
accomplished	VBN	O
.	.	O

Treatments	NNS	O
were	VBD	O
applied	VBN	O
once	RB	O
a	DT	O
day	NN	O
to	TO	O
both	DT	O
groups	NNS	O
.	.	O

And	CC	O
3	CD	O
months	NNS	O
was	VBD	O
taken	VBN	O
as	IN	O
one	CD	O
observation	NN	O
cycle	NN	O
.	.	O

Estimation	NN	O
was	VBD	O
made	VBN	O
on	IN	O
therapeutic	JJ	O
effect	NN	O
and	CC	O
developing	VBG	O
level	NN	O
of	IN	O
autism	NN	O
children	NNS	O
with	IN	O
CARS	NNP	O
and	CC	O
PEP	NNP	O
.	.	O

RESULTS	VB	O
The	DT	O
total	JJ	O
effective	JJ	O
rate	NN	O
of	IN	O
the	DT	O
trial	NN	O
group	NN	O
was	VBD	O
83.3	CD	O
%	NN	O
(	(	O
25/30	CD	O
)	)	O
,	,	O
better	JJR	O
than	IN	O
66.7	CD	O
%	NN	O
(	(	O
20/30	CD	O
)	)	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
CARS	NNPS	O
scores	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
declined	VBD	O
after	IN	O
the	DT	O
treatment	NN	O
.	.	O

And	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
lower	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

While	IN	O
the	DT	O
PEP	NNP	O
scores	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
increased	VBD	O
,	,	O
and	CC	O
the	DT	O
score	NN	O
of	IN	O
trail	NN	O
group	NN	O
was	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
increasing	VBG	O
level	NN	O
of	IN	O
scores	NNS	O
of	IN	O
cognitive	JJ	O
understanding	NN	O
and	CC	O
cognitive	JJ	O
expression	NN	O
were	VBD	O
all	DT	O
better	JJR	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
effect	NN	O
of	IN	O
behavior	JJ	Educational
training	NN	Educational
with	IN	O
head	NN	O
needle	JJ	O
retention	NN	O
on	IN	O
autism	NN	O
children	NNS	O
is	VBZ	O
better	JJR	O
than	IN	O
behavior	JJ	O
training	NN	O
after	IN	O
acupuncture	NN	O
treatment	NN	O
,	,	O
especially	RB	O
in	IN	O
enhancing	VBG	O
cognition	NN	O
understanding	NN	O
and	CC	O
cognition	NN	O
expression	NN	O
.	.	O

Comparing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
copper	NN	Physical
intrauterine	NN	Physical
devices	NNS	Physical
available	JJ	O
in	IN	O
Canada	NNP	O
.	.	O

Is	VBZ	O
FlexiT	JJ	Physical
non-inferior	JJ	O
to	TO	O
NovaT	VB	Physical
when	WRB	O
inserted	VBN	O
immediately	RB	O
after	IN	O
first-trimester	JJ	O
abortion	NN	O
?	.	O
Study	NNP	O
protocol	NN	O
for	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	IN	O
We	PRP	O
describe	VBP	O
the	DT	O
rationale	NN	O
and	CC	O
protocol	NN	O
for	IN	O
a	DT	O
randomized	JJ	O
noninferiority	NN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
Flexi-T380	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
copper	NN	Physical
intrauterine	JJ	Physical
contraceptive	JJ	Physical
device	NN	Physical
(	(	Physical
IUD	NNP	Physical
)	)	Physical
is	VBZ	O
comparable	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
effectiveness	NN	O
and	CC	O
expulsion	NN	O
rates	NNS	O
to	TO	O
the	DT	O
most	RBS	O
common	JJ	O
Canadian	JJ	O
IUD	NNP	O
currently	RB	O
in	IN	O
use	NN	O
,	,	O
NovaT-200	NNP	O
,	,	O
when	WRB	O
placed	VBN	O
immediately	RB	O
after	IN	O
a	DT	O
first-trimester	JJ	O
abortion	NN	O
.	.	O

METHODS/DESIGN	NNP	O
Consenting	NNP	O
women	NNS	O
choosing	VBG	O
to	TO	O
use	VB	O
an	DT	O
IUD	NNP	O
after	IN	O
an	DT	O
abortion	NN	O
for	IN	O
a	DT	O
pregnancy	NN	O
of	IN	O
less	JJR	O
than	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
gestation	NN	O
will	MD	O
be	VB	O
randomized	VBN	O
to	TO	O
device-type	JJ	O
groups	NNS	O
to	TO	O
receive	VB	O
immediate	JJ	O
post-abortion	JJ	O
placement	NN	O
of	IN	O
either	CC	O
a	DT	O
Flexi-T380	NNP	Physical
(	(	Physical
+	NNP	Physical
)	)	Physical
IUD	NNP	Physical
,	,	O
a	DT	O
device	NN	O
for	IN	O
which	WDT	O
no	DT	O
current	JJ	O
evidence	NN	O
on	IN	O
expulsion	NN	O
or	CC	O
effectiveness	NN	O
rates	NNS	O
is	VBZ	O
available	JJ	O
,	,	O
or	CC	O
the	DT	O
Nova-T200	JJ	Physical
IUD	NNP	Physical
,	,	O
the	DT	O
only	RB	O
other	JJ	O
brand	NN	O
of	IN	O
copper	NN	O
IUD	NNP	O
available	JJ	O
in	IN	O
Canada	NNP	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
study	NN	O
initiation	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	JJ	O
measure	NN	O
is	VBZ	O
IUD	NNP	O
expulsion	NN	O
rate	NN	O
at	IN	O
1	CD	O
year	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
include	VBP	O
:	:	O
pregnancy	NN	O
rate	NN	O
,	,	O
method	CC	O
continuation	NN	O
rate	NN	O
,	,	O
complication	NN	O
rates	NNS	O
(	(	O
infection	NN	O
,	,	O
perforation	NN	O
)	)	O
,	,	O
and	CC	O
satisfaction	NN	O
with	IN	O
contraceptive	JJ	O
method	NN	O
.	.	O

A	DT	O
non-intervention	JJ	O
group	NN	O
of	IN	O
consenting	VBG	O
women	NNS	O
choosing	VBG	O
a	DT	O
range	NN	O
of	IN	O
other	JJ	O
post-abortion	JJ	O
contraception	NN	O
methods	NNS	O
,	,	O
including	VBG	O
no	DT	O
contraception	NN	O
,	,	O
will	MD	O
be	VB	O
included	VBN	O
for	IN	O
comparison	NN	O
of	IN	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Web-based	JJ	O
contraception	NN	O
satisfaction	NN	O
questionnaires	NNS	O
,	,	O
clinical	JJ	O
records	NNS	O
,	,	O
and	CC	O
government-linked	JJ	O
health	NN	O
administrative	JJ	O
databases	NNS	O
will	MD	O
be	VB	O
used	VBN	O
to	TO	O
assess	VB	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

DISCUSSION	NNP	O
The	DT	O
RCT	NNP	O
design	NN	O
,	,	O
combined	VBN	O
with	IN	O
access	NN	O
to	TO	O
clinical	JJ	O
records	NNS	O
at	IN	O
all	DT	O
provincial	JJ	O
abortion	NN	O
clinics	NNS	O
,	,	O
and	CC	O
to	TO	O
information	NN	O
in	IN	O
provincial	JJ	O
single-payer	NN	O
linked	VBD	O
administrative	JJ	O
health	NN	O
databases	NNS	O
,	,	O
birth	NN	O
registry	NN	O
,	,	O
and	CC	O
hospital	NN	O
records	NNS	O
,	,	O
offers	VBZ	O
a	DT	O
unique	JJ	O
opportunity	NN	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
novel	NN	O
IUD	NNP	O
has	VBZ	O
a	DT	O
comparable	JJ	O
expulsion	NN	O
rate	NN	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
current	JJ	O
standard	NN	O
IUD	NNP	O
in	IN	O
Canada	NNP	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
first	JJ	O
opportunity	NN	O
to	TO	O
determine	VB	O
pregnancy	NN	O
rate	NN	O
and	CC	O
method	NN	O
satisfaction	NN	O
at	IN	O
1	CD	O
year	NN	O
post-abortion	NN	O
for	IN	O
women	NNS	O
choosing	VBG	O
a	DT	O
range	NN	O
of	IN	O
post-abortion	NN	O
contraceptive	NN	O
options	NNS	O
.	.	O

We	PRP	O
highlight	VBD	O
considerations	NNS	O
of	IN	O
design	NN	O
,	,	O
implementation	NN	O
,	,	O
and	CC	O
evaluation	NN	O
of	IN	O
the	DT	O
first	JJ	O
trial	NN	O
to	TO	O
provide	VB	O
rigorous	JJ	O
evidence	NN	O
for	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
current	JJ	O
Canadian	JJ	O
IUDs	NNP	O
when	WRB	O
inserted	VBN	O
after	IN	O
first-trimester	JJ	O
abortion	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
Identifier	NNP	O
NCT01174225	NNP	O
.	.	O

An	DT	O
open-label	JJ	O
extension	NN	O
study	NN	O
of	IN	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
risperidone	NN	Pharmacological
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
long-term	JJ	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
risperidone	NN	Pharmacological
in	IN	O
treating	VBG	O
irritability	NN	O
and	CC	O
related	JJ	O
behaviors	NNS	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
6	CD	O
month	NN	O
(	(	O
26	CD	O
week	NN	O
)	)	O
open-label	NN	O
extension	NN	O
(	(	O
OLE	NNP	O
)	)	O
study	NN	O
,	,	O
patients	NNS	O
(	(	O
5-17	JJ	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
who	WP	O
completed	VBD	O
the	DT	O
previous	JJ	O
fixed-dose	JJ	O
,	,	O
6	CD	O
week	NN	O
,	,	O
double-blind	JJ	O
[	NNP	O
DB	NNP	O
]	NNP	O
phase	NN	O
)	)	O
were	VBD	O
flexibly	RB	O
dosed	VBN	O
with	IN	O
risperidone	NN	Pharmacological
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
maximum	JJ	O
allowed	VBD	O
dose	NN	O
was	VBD	O
1.25	CD	O
mg/day	NN	O
for	IN	O
those	DT	O
weighing	VBG	O
20	CD	O
to	TO	O
<	VB	O
45	CD	O
kg	NN	O
,	,	O
and	CC	O
1.75	CD	O
mg/day	NN	O
for	IN	O
those	DT	O
weighing	VBG	O
?	.	O
45	CD	O
kg	NN	O
.	.	O

The	DT	O
study	NN	O
primarily	RB	O
assessed	VBD	O
risperidone	NN	O
's	POS	O
safety	NN	O
;	:	O
efficacy	NN	O
was	VBD	O
assessed	VBN	O
as	IN	O
a	DT	O
secondary	JJ	O
end-point	NN	O
.	.	O

RESULTS	VB	O
Fifty-six	NNP	O
(	(	O
71	CD	O
%	NN	O
)	)	O
out	IN	O
of	IN	O
79	CD	O
enrolled	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
OLE	NNP	O
;	:	O
the	DT	O
most	RBS	O
common	JJ	O
discontinuations	NNS	O
were	VBD	O
for	IN	O
insufficient	JJ	O
response	NN	O
(	(	O
7	CD	O
[	RB	O
9	CD	O
%	NN	O
]	NN	O
)	)	O
or	CC	O
adverse	JJ	O
events	NNS	O
(	(	O
AE	NNP	O
)	)	O
(	(	O
5	CD	O
[	RB	O
6	CD	O
%	NN	O
]	NN	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
(	(	O
?	.	O
5	CD	O
%	NN	O
frequency	NN	O
in	IN	O
the	DT	O
total	JJ	O
group	NN	O
)	)	O
AEs	NNP	O
were	VBD	O
increased	VBN	O
appetite	RB	O
(	(	O
11	CD	O
%	NN	O
[	JJ	O
n=9	JJ	O
]	NN	O
)	)	O
;	:	O
increased	VBN	O
weight	NN	O
and	CC	O
vomiting	NN	O
(	(	O
9	CD	O
%	NN	O
[	JJ	O
n=7	JJ	O
]	NNP	O
each	DT	O
)	)	O
;	:	O
sedation	NN	O
,	,	O
pyrexia	NN	O
,	,	O
and	CC	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
infection	NN	O
(	(	O
8	CD	O
%	NN	O
[	JJ	O
n=6	JJ	O
]	NNP	O
each	DT	O
)	)	O
;	:	O
nasopharyngitis	NN	O
(	(	O
6	CD	O
%	NN	O
[	JJ	O
n=5	JJ	O
]	NN	O
)	)	O
;	:	O
and	CC	O
somnolence	NN	O
and	CC	O
fatigue	NN	O
(	(	O
5	CD	O
%	NN	O
[	JJ	O
n=4	JJ	O
]	NNP	O
each	DT	O
)	)	O
.	.	O

Extrapyramidal	JJ	O
AEs	NNP	O
were	VBD	O
reported	VBN	O
in	IN	O
6	CD	O
(	(	O
8	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Increase	NNP	O
in	IN	O
mean	JJ	O
weight	NN	O
(	(	O
11-15	CD	O
%	NN	O
)	)	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
5-10	CD	O
%	NN	O
)	)	O
occurred	VBD	O
;	:	O
one	CD	O
patient	NN	O
discontinued	VBN	O
because	IN	O
of	IN	O
weight	JJ	O
increase	NN	O
.	.	O

One	CD	O
potentially	RB	O
prolactin-related	JJ	O
AE	NNP	O
(	(	O
irregular	JJ	O
menstruation	NN	O
)	)	O
was	VBD	O
reported	VBN	O
.	.	O

The	DT	O
risperidone	NN	O
high-dose	JJ	O
group	NN	O
had	VBD	O
the	DT	O
greatest	JJS	O
mean	JJ	O
improvement	NN	O
in	IN	O
sleep	JJ	O
visual	JJ	O
analog	NN	O
scale	NN	O
(	(	O
24.6	CD	O
)	)	O
.	.	O

All	DT	O
groups	NNS	O
showed	VBD	O
additional	JJ	O
improvement	NN	O
in	IN	O
efficacy	NN	O
scale	JJ	O
scores	NNS	O
during	IN	O
the	DT	O
OLE	NNP	O
.	.	O

CONCLUSIONS	NNP	O
During	IN	O
this	DT	O
OLE	NNP	O
,	,	O
safety	NN	O
findings	NNS	O
with	IN	O
risperidone	NN	O
treatment	NN	O
(	(	O
maximum	JJ	O
weight-based	JJ	O
dose	NN	O
of	IN	O
1.25	CD	O
mg/day	NN	O
or	CC	O
1.75	CD	O
mg/day	NN	O
)	)	O
were	VBD	O
consistent	JJ	O
with	IN	O
those	DT	O
observed	VBN	O
in	IN	O
the	DT	O
DB	NNP	O
phase	NN	O
,	,	O
and	CC	O
with	IN	O
the	DT	O
current	JJ	O
safety	NN	O
information	NN	O
for	IN	O
risperidone	NN	O
in	IN	O
autistic	JJ	O
,	,	O
psychiatric	JJ	O
,	,	O
and	CC	O
behavioral	JJ	O
disorders	NNS	O
.	.	O

Patients	NNS	O
experienced	VBD	O
some	DT	O
additional	JJ	O
improvement	NN	O
in	IN	O
irritability	NN	O
and	CC	O
related	JJ	O
behaviors	NNS	O
.	.	O

CLINICAL	JJ	O
TRIALS	NNP	O
REGISTRY	NNP	O
This	DT	O
phase-4	JJ	O
study	NN	O
is	VBZ	O
registered	VBN	O
at	IN	O
ClinicalTrials.gov	NNP	O
(	(	O
NCT00576732	NNP	O
)	)	O
.	.	O

Effect	NN	O
of	IN	O
low-intensity	NN	Physical
back	RB	Physical
exercise	NN	Physical
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
back	RB	O
extensor	JJ	O
strength	NN	O
in	IN	O
patients	NNS	O
with	IN	O
osteoporosis	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

UNLABELLED	NNP	O
Randomized	NNP	O
controlled	VBD	O
study	NN	O
in	IN	O
80	CD	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
osteoporosis	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
home-based	JJ	Physical
,	,	Physical
simple	JJ	Physical
,	,	Physical
low-intensity	JJ	Physical
exercise	NN	Physical
.	.	O

Low-intensity	JJ	Physical
back-strengthening	JJ	Physical
exercise	NN	Physical
was	VBD	O
effective	JJ	O
in	IN	O
improving	VBG	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
back	RB	O
extensor	JJ	O
strength	NN	O
.	.	O

INTRODUCTION	NNP	O
AND	CC	O
HYPOTHESIS	NNP	O
Back-strengthening	NNP	O
exercise	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
increasing	VBG	O
back	RB	O
extensor	NN	O
strength	NN	O
and	CC	O
decreasing	VBG	O
risk	NN	O
of	IN	O
vertebral	JJ	O
fractures	NNS	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
a	DT	O
home-based	JJ	O
,	,	O
simple	JJ	O
,	,	O
low-intensity	JJ	O
exercise	NN	O
could	MD	O
enhance	VB	O
back	RB	O
extensor	JJ	O
strength	NN	O
and	CC	O
improve	VB	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
and/or	IN	O
spinal	JJ	O
range	NN	O
of	IN	O
motion	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
in	IN	O
a	DT	O
short-term	JJ	O
follow-up	NN	O
.	.	O

METHODS	NNP	O
Eighty	NNP	O
postmenopausal	JJ	O
women	NNS	O
with	IN	O
osteoporosis	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
control	NN	Control
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
38	CD	O
)	)	O
or	CC	O
an	DT	O
exercise	NN	Physical
group	NN	Physical
(	(	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
instructed	VBN	O
to	TO	O
lift	VB	O
their	PRP$	O
upper	JJ	O
trunk	NN	O
from	IN	O
a	DT	O
prone	NN	O
position	NN	O
antigravity	NN	O
and	CC	O
maintain	VB	O
the	DT	O
neutral	JJ	O
position	NN	O
.	.	O

Isometric	NNP	O
back	RB	O
extensor	NN	O
strength	NN	O
,	,	O
spinal	JJ	O
range	NN	O
of	IN	O
motion	NN	O
,	,	O
and	CC	O
scores	NNS	O
for	IN	O
quality	NN	O
of	IN	O
life	NN	O
were	VBD	O
evaluated	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
4	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
Back	NNP	O
extensor	NN	O
strength	NN	O
significantly	RB	O
increased	VBD	O
both	DT	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
26	CD	O
%	NN	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
11	CD	O
%	NN	O
)	)	O
.	.	O

Scores	NNS	O
for	IN	O
quality	NN	O
of	IN	O
life	NN	O
increased	VBN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
7	CD	O
%	NN	O
)	)	O
,	,	O
whereas	IN	O
it	PRP	O
remained	VBD	O
unchanged	JJ	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
0	CD	O
%	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
quality	NN	O
of	IN	O
life	NN	O
score	NN	O
between	IN	O
the	DT	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.012	CD	O
)	)	O
.	.	O

CONCLUSIONS	JJ	O
Low-intensity	JJ	O
back-strengthening	NN	O
exercise	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
improving	VBG	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
back	RB	O
extensor	JJ	O
strength	NN	O
in	IN	O
patients	NNS	O
with	IN	O
osteoporosis	NN	O
.	.	O

Treatment	JJ	O
effects	NNS	O
of	IN	O
eptifibatide	NN	Pharmacological
in	IN	O
planned	JJ	O
coronary	JJ	O
stent	NN	O
implantation	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
(	(	O
ESPRIT	NNP	O
Trial	NNP	O
)	)	O
.	.	O

The	DT	O
role	NN	O
of	IN	O
platelet	NN	Pharmacological
glycoprotein	NN	Pharmacological
IIb/IIIa	NNP	Pharmacological
inhibitor	NN	Pharmacological
therapy	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
renal	JJ	O
impairment	NN	O
is	VBZ	O
not	RB	O
well	RB	O
characterized	VBN	O
.	.	O

Our	PRP$	O
objective	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
associations	NNS	O
of	IN	O
creatinine	JJ	O
clearance	NN	O
(	(	O
CrCl	NNP	O
)	)	O
with	IN	O
outcomes	NNS	O
in	IN	O
a	DT	O
trial	NN	O
of	IN	O
eptifibatide	JJ	Pharmacological
therapy	NN	Pharmacological
in	IN	O
patients	NNS	O
who	WP	O
underwent	VBP	O
percutaneous	JJ	O
coronary	JJ	O
intervention	NN	O
(	(	O
PCI	NNP	O
)	)	O
.	.	O

We	PRP	O
analyzed	VBD	O
48-hour	CD	O
and	CC	O
30-day	JJ	O
outcomes	NNS	O
of	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Enhanced	NNP	O
Suppression	NNP	O
of	IN	O
the	DT	O
Platelet	NNP	O
IIb/IIIa	NNP	O
Receptor	NNP	O
with	IN	O
Integrilin	NNP	Physical
Therapy	NNP	Physical
(	(	Physical
ESPRIT	NNP	Physical
)	)	Physical
trial	NN	Physical
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
placebo	VB	Control
or	CC	O
eptifibatide	VB	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
stent	VB	O
implantation	NN	O
(	(	O
1,755	CD	O
with	IN	O
CrCl	NNP	O
>	NNP	O
or	CC	O
=60	NNP	O
ml/min	NN	O
and	CC	O
289	CD	O
with	IN	O
CrCl	NNP	O
<	NNP	O
60	CD	O
ml/min	NN	O
)	)	O
.	.	O

CrCl	NNP	O
was	VBD	O
calculated	VBN	O
using	VBG	O
the	DT	O
Cockcroft	NNP	O
and	CC	O
Gault	NNP	O
formula	NN	O
,	,	O
and	CC	O
the	DT	O
associations	NNS	O
of	IN	O
CrCl	NNP	O
with	IN	O
outcomes	NNS	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
logistic	JJ	O
regression	NN	O
models	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
CrCl	NNP	O
<	NNP	O
60	CD	O
ml/min	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
older	JJR	O
,	,	O
women	NNS	O
,	,	O
hypertensive	JJ	O
,	,	O
and	CC	O
have	VBP	O
a	DT	O
history	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
,	,	O
stroke	NN	O
,	,	O
or	CC	O
peripheral	JJ	O
vascular	JJ	O
disease	NN	O
.	.	O

The	DT	O
interaction	NN	O
of	IN	O
eptifibatide	NN	Pharmacological
with	IN	O
CrCl	NNP	O
had	VBD	O
borderline	JJ	O
significance	NN	O
for	IN	O
the	DT	O
30-day	JJ	O
outcome	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.109	CD	O
)	)	O
.	.	O

Treatment	JJ	O
effect	NN	O
trended	VBD	O
toward	IN	O
a	DT	O
greater	JJR	O
magnitude	NN	O
in	IN	O
patients	NNS	O
with	IN	O
lower	JJR	O
CrCl	NNP	O
(	(	O
60	CD	O
ml/min	NN	O
)	)	O
(	(	O
odds	NNS	O
ratio	VBP	O
0.53	CD	O
,	,	O
confidence	NN	O
interval	NN	O
0.34	CD	O
to	TO	O
0.83	CD	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
higher	JJR	O
CrCl	NNP	O
(	(	O
90	CD	O
ml/min	NN	O
)	)	O
(	(	O
odds	NNS	O
ratio	VBP	O
0.68	CD	O
,	,	O
confidence	NN	O
interval	NN	O
0.49	CD	O
to	TO	O
0.94	CD	O
)	)	O
.	.	O

An	DT	O
accompanying	VBG	O
increase	NN	O
in	IN	O
bleeding	VBG	O
risk	NN	O
also	RB	O
was	VBD	O
not	RB	O
apparent	JJ	O
with	IN	O
lower	JJR	O
CrCl	NNP	O
.	.	O

The	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
eptifibatide	NN	Pharmacological
is	VBZ	O
realized	VBN	O
regardless	RB	O
of	IN	O
renal	JJ	O
function	NN	O
and	CC	O
trends	VBZ	O
toward	IN	O
being	VBG	O
greater	JJR	O
in	IN	O
patients	NNS	O
with	IN	O
mild	JJ	O
renal	JJ	O
impairment	NN	O
.	.	O

Effect	NN	O
of	IN	O
marine	NN	Pharmacological
oils	NNS	Pharmacological
supplementation	NN	Pharmacological
on	IN	O
coagulation	NN	O
and	CC	O
cellular	JJ	O
activation	NN	O
in	IN	O
whole	JJ	O
blood	NN	O
.	.	O

A	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
explore	VB	O
the	DT	O
effects	NNS	O
of	IN	O
supplemental	JJ	O
intake	NN	O
of	IN	O
various	JJ	O
marine	NN	O
oils	NNS	O
known	VBN	O
to	TO	O
be	VB	O
part	NN	O
of	IN	O
the	DT	O
Eskimo	NNP	O
diet	NN	O
.	.	O

Healthy	JJ	O
men	NNS	O
and	CC	O
women	NNS	O
(	(	O
134	CD	O
)	)	O
were	VBD	O
randomly	RB	O
selected	VBN	O
to	TO	O
consume	VB	O
15	CD	O
mL/d	NN	O
of	IN	O
oil	NN	Pharmacological
from	IN	Pharmacological
blubber	NN	Pharmacological
of	IN	Pharmacological
seal	NN	Pharmacological
,	,	Pharmacological
cod	NN	Pharmacological
liver	NN	Pharmacological
,	,	Pharmacological
seal/cod	NN	Pharmacological
liver	NN	Pharmacological
,	,	Physical
blubber	NN	Pharmacological
of	IN	Pharmacological
Minke	NNP	Pharmacological
whale	NN	Pharmacological
,	,	O
or	CC	O
no	DT	Control
oil	NN	Control
for	IN	O
ten	JJ	O
weeks	NNS	O
.	.	O

Total	JJ	O
cholesterol	NN	O
was	VBD	O
unchanged	JJ	O
in	IN	O
the	DT	O
oil	NN	O
groups	NNS	O
,	,	O
whereas	RB	O
high	JJ	O
density	NN	O
lipoprotein	VBP	O
cholesterol	NN	O
increased	VBD	O
7	CD	O
%	NN	O
in	IN	O
the	DT	O
seal/cod	NN	Pharmacological
liver	NN	Pharmacological
oil	NN	Pharmacological
(	(	O
CLO	NNP	O
)	)	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
11	CD	O
%	NN	O
in	IN	O
the	DT	O
whale	JJ	Pharmacological
oil	NN	Pharmacological
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

Triacylglycerol	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
CLO	NNP	O
group	NN	O
only	RB	O
.	.	O

The	DT	O
concentration	NN	O
of	IN	O
prothrombin	JJ	O
fragment	JJ	O
1	CD	O
+	JJ	O
2	CD	O
was	VBD	O
reduced	VBN	O
25	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
after	IN	O
whale	JJ	O
oil	NN	O
supplementation	NN	O
.	.	O

No	DT	O
change	NN	O
in	IN	O
fibrinogen	NN	O
or	CC	O
factor	NN	O
VIIc	NNP	O
was	VBD	O
detected	VBN	O
.	.	O

Tumor	NNP	O
necrosis	NN	O
factor	NN	O
generation	NN	O
in	IN	O
lipopolysaccharide	NN	O
(	(	O
LPS	NNP	O
)	)	O
-stimulated	VBD	O
blood	NN	O
was	VBD	O
30	CD	O
%	NN	O
reduced	VBN	O
after	IN	O
whale	JJ	O
oil	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
unaffected	VBN	O
by	IN	O
intake	NN	O
of	IN	O
seal	NN	O
or	CC	O
CLO	NNP	O
.	.	O

The	DT	O
LPS-induced	JJ	O
tissue	NN	O
factor	NN	O
activity	NN	O
in	IN	O
monocytes	NNS	O
was	VBD	O
reduced	VBN	O
to	TO	O
a	DT	O
significant	JJ	O
degree	NN	O
only	RB	O
in	IN	O
the	DT	O
seal/CLO	NN	O
group	NN	O
(	(	O
34	CD	O
%	NN	O
)	)	O
and	CC	O
whale	JJ	O
oil	NN	O
group	NN	O
(	(	O
35	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
dramatic	JJ	O
change	NN	O
in	IN	O
thromboxane	NN	O
B2	NNP	O
in	IN	O
LPS-stimulated	NNP	O
blood	NN	O
was	VBD	O
seen	VBN	O
after	IN	O
whale	JJ	O
oil	NN	O
intake	NN	O
with	IN	O
44	CD	O
%	NN	O
reduction	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

Supplementation	NN	O
of	IN	O
a	DT	O
regular	JJ	O
diet	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
seal	JJ	O
oil	NN	O
and	CC	O
CLO	NNP	O
and	CC	O
especially	RB	O
with	IN	O
whale	JJ	O
oil	NN	O
seems	VBZ	O
to	TO	O
have	VB	O
beneficial	JJ	O
effects	NNS	O
on	IN	O
several	JJ	O
products	NNS	O
thought	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
cardiovascular	JJ	O
and	CC	O
thrombotic	JJ	O
diseases	NNS	O
.	.	O

Effectiveness	NN	O
of	IN	O
N	NNP	O
,	,	O
N-dimethylglycine	NNP	O
in	IN	O
autism	NN	O
and	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

N	NNP	Pharmacological
,	,	Pharmacological
N-dimethylglycine	NNP	Pharmacological
,	,	O
a	DT	O
dietary	JJ	O
supplement	NN	O
,	,	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
beneficial	JJ	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
pervasive	JJ	O
developmental	JJ	O
disorder	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
dimethylglycine	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
pervasive	JJ	O
developmental	NN	O
disorder	NN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

Thirty-seven	JJ	O
children	NNS	O
between	IN	O
3	CD	O
and	CC	O
11	CD	O
years	NNS	O
of	IN	O
age	NN	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
autism	NN	O
and/or	JJ	O
pervasive	JJ	O
developmental	NN	O
disorder	NN	O
were	VBD	O
gender	JJR	O
and	CC	O
age	NN	O
matched	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	Control
or	CC	O
dimethylglycine	NN	Pharmacological
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

All	DT	O
children	NNS	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
on	IN	O
two	CD	Educational
behavioral	JJ	Educational
measures	NNS	Educational
,	,	Educational
the	DT	Educational
Vineland	NNP	Educational
Maladaptive	NNP	Educational
Behavior	NNP	Educational
Domain	NNP	Educational
and	CC	Educational
the	DT	Educational
Aberrant	NNP	Educational
Behavior	NNP	Educational
Checklist	NNP	Educational
.	.	O

Standardized	NNP	O
neurologic	JJ	O
examinations	NNS	O
before	IN	O
and	CC	O
after	IN	O
treatment	NN	O
on	IN	O
33	CD	O
children	NNS	O
showed	VBD	O
no	DT	O
change	NN	O
.	.	O

An	DT	O
overall	JJ	O
improvement	NN	O
on	IN	O
all	DT	O
behavioral	JJ	O
measures	NNS	O
was	VBD	O
observed	VBN	O
for	IN	O
both	DT	O
the	DT	O
placebo	NN	O
and	CC	O
the	DT	O
dimethylglycine	NN	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
improvement	NN	O
among	IN	O
the	DT	O
children	NNS	O
who	WP	O
received	VBD	O
dimethylglycine	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
from	IN	O
the	DT	O
improvement	NN	O
observed	VBD	O
among	IN	O
the	DT	O
children	NNS	O
who	WP	O
received	VBD	O
the	DT	O
placebo	NN	O
.	.	O

The	DT	O
children	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
a	DT	O
heterogeneous	JJ	O
group	NN	O
,	,	O
and	CC	O
their	PRP$	O
apparent	JJ	O
responses	NNS	O
to	TO	O
the	DT	O
dimethylglycine	NN	O
varied	VBN	O
.	.	O

Some	DT	O
children	NNS	O
appeared	VBD	O
to	TO	O
respond	VB	O
positively	RB	O
to	TO	O
the	DT	O
dimethylglycine	NN	O
,	,	O
and	CC	O
there	RB	O
was	VBD	O
a	DT	O
smaller	JJR	O
proportion	NN	O
of	IN	O
negative	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
dimethylglycine	NN	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
quantitative	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
dimethylglycine	JJ	O
behavioral	JJ	O
assessments	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
what	WP	O
was	VBD	O
observed	VBN	O
among	IN	O
children	NNS	O
who	WP	O
received	VBD	O
placebo	NN	O
.	.	O

Antibiotic	JJ	O
therapy	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

A	DT	O
controlled	VBN	O
study	NN	O
using	VBG	O
tetracycline	NN	Pharmacological
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
in	IN	O
40	CD	O
patients	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
need	NN	O
for	IN	O
antibiotics	NNS	O
in	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
sufficiently	RB	O
ill	VBN	O
to	TO	O
require	VB	O
hospitalization	NN	O
although	IN	O
none	NN	O
needed	VBD	O
ventilatory	JJ	O
support	NN	O
;	:	O
the	DT	O
presence	NN	O
of	IN	O
pneumonia	NN	O
was	VBD	O
excluded	VBN	O
.	.	O

Treatment	NNP	O
consisted	VBD	O
of	IN	O
bronchodilators	NNS	Pharmacological
,	,	O
corticosteroids	NNS	Pharmacological
,	,	O
and	CC	O
either	DT	O
tetracycline	NN	Pharmacological
,	,	O
500	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	NN	Control
by	IN	O
mouth	NN	O
every	DT	O
6	CD	O
hours	NNS	O
for	IN	O
1	CD	O
week	NN	O
.	.	O

Arterial	JJ	O
blood	NN	O
gases	NNS	O
,	,	O
spirometric	JJ	O
tests	NNS	O
,	,	O
bacteriologic	JJ	O
evaluation	NN	O
of	IN	O
sputum	NN	O
,	,	O
and	CC	O
patient	NN	O
and	CC	O
physician	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
illness	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
and	CC	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
improved	VBN	O
both	DT	O
symptomatically	RB	O
and	CC	O
by	IN	O
objective	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
period	NN	O
there	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
those	DT	O
patients	NNS	O
receiving	VBG	O
tetracycline	NN	O
and	CC	O
those	DT	O
receiving	VBG	O
placebo	NN	Control
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
antibiotic	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
needed	VBN	O
in	IN	O
moderately	RB	O
ill	JJ	O
patients	NNS	O
with	IN	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
the	DT	O
monoamine	NN	Pharmacological
oxidase	NN	Pharmacological
B	NNP	Pharmacological
inhibitor	NN	Pharmacological
mofegiline	NN	Pharmacological
assessed	VBN	O
during	IN	O
a	DT	O
phase	NN	O
I	PRP	O
dose	VBP	O
tolerance	JJ	O
trial	NN	O
.	.	O

The	DT	O
safety	NN	O
,	,	O
pharmacokinetics	NNS	O
,	,	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
single	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
up	IN	O
to	TO	O
48	CD	O
mg	NNS	O
and	CC	O
daily	JJ	O
(	(	O
for	IN	O
28	CD	O
days	NNS	O
)	)	O
doses	NNS	O
of	IN	O
up	IN	O
24	CD	O
mg	NNS	O
mofegiline	NN	Pharmacological
were	VBD	O
investigated	VBN	O
in	IN	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
.	.	O

Plasma	NNP	O
pharmacokinetics	NNS	O
indicated	VBD	O
rapid	JJ	O
absorption	NN	O
and	CC	O
elimination	NN	O
:	:	O
time	NN	O
to	TO	O
reach	VB	O
maximum	JJ	O
concentration	NN	O
occurred	VBD	O
at	IN	O
about	IN	O
1	CD	O
hour	NN	O
;	:	O
half-life	JJ	O
ranged	VBD	O
from	IN	O
1	CD	O
to	TO	O
3	CD	O
hours	NNS	O
.	.	O

Maximal	NNP	O
plasma	JJ	O
concentration	NN	O
and	CC	O
area	NN	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration-time	JJ	O
curve	NN	O
increased	VBD	O
and	CC	O
oral	JJ	O
clearance	NN	O
decreased	VBD	O
disproportionately	RB	O
with	IN	O
dose	JJ	O
.	.	O

Mofegiline	NNP	Pharmacological
rapidly	RB	O
and	CC	O
markedly	RB	O
inhibited	JJ	O
platelet	NN	O
monoamine	NN	O
oxidase	NN	O
B	NNP	O
(	(	O
MAOB	NNP	O
)	)	O
activity	NN	O
,	,	O
which	WDT	O
returned	VBD	O
to	TO	O
baseline	VB	O
within	IN	O
14	CD	O
days	NNS	O
.	.	O

Urinary	JJ	O
excretion	NN	O
of	IN	O
phenylethylamine	NN	O
increased	VBN	O
proportionately	RB	O
with	IN	O
doses	NNS	O
up	RB	O
to	TO	O
24	CD	O
mg.	NN	O
No	NNP	O
changes	NNS	O
in	IN	O
urinary	JJ	O
elimination	NN	O
of	IN	O
catecholamines	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
,	,	O
or	CC	O
ECG	NNP	O
were	VBD	O
observed	VBN	O
.	.	O

A	DT	O
classic	JJ	O
maximum	NN	O
tolerated	VBD	O
dose	NN	O
was	VBD	O
not	RB	O
achieved	VBN	O
in	IN	O
these	DT	O
studies	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
48	CD	O
mg	NN	O
single	JJ	O
dose	NN	O
and	CC	O
the	DT	O
24	CD	O
mg	NN	O
multiple	JJ	O
daily	JJ	O
dose	NN	O
far	RB	O
exceeded	VBD	O
the	DT	O
dose	NN	O
(	(	O
1	CD	O
mg	NN	O
)	)	O
that	WDT	O
was	VBD	O
associated	VBN	O
with	IN	O
>	JJ	O
90	CD	O
%	NN	O
platelet	NN	O
MAOB	NNP	O
inhibition	NN	O
.	.	O

Peripheral	NNP	O
intravenous	JJ	O
line	NN	O
survival	NN	O
and	CC	O
phlebitis	NN	O
prevention	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
intravenous	JJ	O
antibiotics	NNS	Pharmacological
:	:	O
heparin/hydrocortisone	NN	O
versus	IN	O
in-line	JJ	O
filters	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
use	NN	O
of	IN	O
in-line	JJ	O
filtration	NN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
heparin/hydrocortisone	NN	Pharmacological
(	(	O
hep/hc	NN	O
)	)	O
to	TO	O
the	DT	O
infusate	NN	O
for	IN	O
both	DT	O
phlebitis	NN	O
prevention	NN	O
and	CC	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
line	NN	O
survival	NN	O
in	IN	O
peripheral	JJ	O
i.v	NN	O
.	.	O

catheters	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
specific	JJ	O
for	IN	O
a	DT	O
patient	NN	O
group	NN	O
receiving	VBG	O
prolonged	JJ	O
courses	NNS	O
of	IN	O
i.v	NN	O
.	.	O

antibiotics	NNS	O
.	.	O

Analysis	NN	O
of	IN	O
the	DT	O
two	CD	O
endpoints	NNS	O
for	IN	O
conventional	JJ	O
short	JJ	O
i.v	NN	Pharmacological
.	.	O

catheters	NNS	Pharmacological
(	(	O
short	JJ	O
lines	NNS	O
)	)	O
versus	NN	O
long	RB	O
(	(	O
30	CD	O
cm	NN	O
)	)	O
i.v	NN	O
.	.	O

catheters	NNS	O
(	(	O
long	JJ	O
lines	NNS	O
)	)	O
was	VBD	O
also	RB	O
performed	VBN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
cystic	JJ	O
fibrosis	NN	O
receiving	VBG	O
intermittent	JJ	O
i.v	NN	O
.	.	O

antibiotics	NNS	Pharmacological
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
receive	VB	O
their	PRP$	O
drugs	NNS	O
either	CC	O
through	IN	O
an	DT	O
in-line	JJ	O
filter	NN	O
using	VBG	O
a	DT	O
drug-free	JJ	O
infusate	NN	O
or	CC	O
with	IN	O
no	DT	O
filter	NN	O
and	CC	O
an	DT	O
infusate	NN	O
containing	VBG	O
heparin	JJ	Pharmacological
500	CD	O
units	NNS	O
and	CC	O
hydrocortisone	NN	Pharmacological
10	CD	O
mg/L	NN	O
.	.	O

Infusion	NN	O
sites	NNS	O
were	VBD	O
assessed	VBN	O
daily	RB	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
the	DT	O
hep/hc	NN	O
and	CC	O
filter	NN	O
groups	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
phlebitis	NN	O
incidence	NN	O
and	CC	O
i.v	NN	O
.	.	O

line	NN	O
survival	NN	O
when	WRB	O
analyzed	VBN	O
separately	RB	O
for	IN	O
both	DT	O
short	JJ	O
and	CC	O
long	JJ	O
lines	NNS	O
.	.	O

Long	NNP	O
lines	NNS	O
displayed	VBD	O
markedly	RB	O
prolonged	JJ	O
survival	NN	O
times	NNS	O
and	CC	O
reduced	JJ	O
phlebitis	NN	O
compared	VBN	O
with	IN	O
short	JJ	O
lines	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
effectiveness	NN	O
of	IN	O
i.v	NN	O
.	.	O

filters	NNS	O
in	IN	O
excluding	VBG	O
the	DT	O
large	JJ	O
particle	NN	O
load	NN	O
introduced	VBN	O
by	IN	O
i.v	NN	O
.	.	O

antibiotics	NNS	O
and	CC	O
hence	NN	O
in	IN	O
reducing	VBG	O
the	DT	O
subsequent	JJ	O
phlebitis	NN	O
makes	VBZ	O
them	PRP	O
a	DT	O
useful	JJ	O
alternative	NN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
hep/hc	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
filters	NNS	O
in	IN	O
this	DT	O
patient	JJ	O
group	NN	O
may	MD	O
offer	VB	O
advantages	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
ease	NN	O
of	IN	O
use	NN	O
and	CC	O
a	DT	O
possible	JJ	O
decrease	NN	O
in	IN	O
hep/hc-related	JJ	O
problems	NNS	O
.	.	O

Long	JJ	O
lines	NNS	O
offer	VBP	O
practical	JJ	O
advantages	NNS	O
over	IN	O
short	JJ	O
lines	NNS	O
for	IN	O
patients	NNS	O
requiring	VBG	O
longer	JJR	O
term	NN	O
i.v	NN	O
.	.	O

access	NN	O
.	.	O

The	DT	O
prognostic	JJ	O
value	NN	O
of	IN	O
testicular	JJ	Physical
biopsy	NN	Physical
in	IN	O
childhood	NN	O
acute	NN	O
lymphoblastic	JJ	O
leukemia	NN	O
:	:	O
a	DT	O
report	NN	O
from	IN	O
the	DT	O
Childrens	NNP	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
objectives	NNS	O
of	IN	O
Childrens	NNP	O
Cancer	NNP	O
Study	NNP	O
Group	NNP	O
(	(	O
CCSG	NNP	O
)	)	O
study	NN	O
141	CD	O
(	(	O
CCG-141	NNP	O
)	)	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
frequency	NN	O
of	IN	O
occult	NN	O
testicular	JJ	O
leukemia	NN	O
(	(	O
TL	NNP	O
)	)	O
after	IN	O
3	CD	O
years	NNS	O
of	IN	O
disease-free	JJ	O
survival	NN	O
(	(	O
DFS	NNP	O
)	)	O
and	CC	O
to	TO	O
retreat	VB	O
boys	NNS	O
with	IN	O
occult	NN	O
TL	NNP	O
to	TO	O
prolong	VB	O
their	PRP$	O
subsequent	JJ	O
DFS	NNP	O
.	.	O

Of	IN	O
the	DT	O
494	CD	O
boys	NNS	O
entered	VBD	O
on	IN	O
study	NN	O
,	,	O
255	CD	O
(	(	O
51.6	CD	O
%	NN	O
)	)	O
were	VBD	O
in	IN	O
complete	JJ	O
continuous	JJ	O
remission	NN	O
(	(	O
CCR	NNP	O
)	)	O
3	CD	O
years	NNS	O
after	IN	O
entering	VBG	O
remission	NN	O
and	CC	O
an	DT	O
additional	JJ	O
eight	CD	O
were	VBD	O
in	IN	O
CCR	NNP	O
3	CD	O
years	NNS	O
after	IN	O
localized	JJ	O
extramedullary	JJ	O
relapse	NN	O
and	CC	O
retreatment	NN	O
;	:	O
263	CD	O
boys	NNS	O
were	VBD	O
eligible	JJ	O
for	IN	O
testicular	JJ	Surgical
biopsy	NN	Surgical
.	.	O

Elective	JJ	O
testicular	JJ	Surgical
biopsy	NN	Surgical
was	VBD	O
performed	VBN	O
on	IN	O
235	CD	O
(	(	O
89.4	CD	O
%	NN	O
)	)	O
boys	VBZ	O
.	.	O

Of	IN	O
the	DT	O
204	CD	O
(	(	O
86.8	CD	O
%	NN	O
)	)	O
boys	VBZ	O
with	IN	O
negative	JJ	O
biopsies	NNS	O
,	,	O
175	CD	O
(	(	O
85.8	CD	O
%	NN	O
)	)	O
remained	VBD	O
in	IN	O
CCR	NNP	O
10	CD	O
to	TO	O
12	CD	O
years	NNS	O
after	IN	O
diagnosis	NN	O
and	CC	O
25	CD	O
(	(	O
12.3	CD	O
%	NN	O
)	)	O
relapsed	VBD	O
,	,	O
11	CD	O
(	(	O
44	CD	O
%	NN	O
)	)	O
of	IN	O
whom	WP	O
died	VBD	O
.	.	O

Isolated	NNP	O
overt	JJ	O
TL	NNP	O
occurred	VBD	O
in	IN	O
four	CD	O
(	(	O
2.0	CD	O
%	NN	O
)	)	O
and	CC	O
all	DT	O
remained	VBN	O
in	IN	O
CCR	NNP	O
22+	CD	O
to	TO	O
60+	CD	O
months	NNS	O
after	IN	O
re-treatment	JJ	O
.	.	O

Of	IN	O
the	DT	O
26	CD	O
boys	NNS	O
with	IN	O
occult	NN	O
TL	NNP	O
,	,	O
16	CD	O
(	(	O
62	CD	O
%	NN	O
)	)	O
remained	VBD	O
in	IN	O
CCR	NNP	O
.	.	O

Ten	NNP	O
(	(	O
38	CD	O
%	NN	O
)	)	O
relapsed	VBD	O
despite	IN	O
local	JJ	Physical
testicular	JJ	Physical
irradiation	NN	Physical
and	CC	O
systemic	JJ	Pharmacological
re-treatment	NN	Pharmacological
;	:	O
six	CD	O
of	IN	O
the	DT	O
10	CD	O
died	VBD	O
.	.	O

Of	IN	O
the	DT	O
26	CD	O
boys	NNS	O
who	WP	O
did	VBD	O
not	RB	O
undergo	JJ	O
biopsy	NN	Surgical
,	,	O
21	CD	O
(	(	O
80.8	CD	O
%	NN	O
)	)	O
remained	VBD	O
in	IN	O
CCR	NNP	O
;	:	O
two	CD	O
(	(	O
7.7	CD	O
%	NN	O
)	)	O
developed	VBD	O
isolated	JJ	O
overt	JJ	O
TL	NNP	O
.	.	O

DFS	NNP	O
after	IN	O
testicular	JJ	Surgical
biopsy	NN	Surgical
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
boys	NNS	O
without	IN	O
occult	NN	O
TL	NNP	O
(	(	O
P	NNP	O
=	NNP	O
.001	NNP	O
)	)	O
.	.	O

Occult	NNP	O
TL	NNP	O
after	IN	O
3	CD	O
years	NNS	O
of	IN	O
CCR	NNP	O
represents	VBZ	O
aggressive	JJ	O
minimal-residual	JJ	O
disease	NN	O
and	CC	O
carries	VBZ	O
a	DT	O
worse	JJR	O
prognosis	NN	O
than	IN	O
absence	NN	O
of	IN	O
TL	NNP	O
.	.	O

Initial	NNP	O
treatment	NN	O
should	MD	O
be	VB	O
directed	VBN	O
at	IN	O
obviating	VBG	O
occult	NN	O
and	CC	O
overt	JJ	O
testicular	JJ	O
relapse	NN	O
.	.	O

Conventional	JJ	O
therapy	NN	O
as	IN	O
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
was	VBD	O
suboptimal	JJ	O
in	IN	O
preventing	VBG	O
subsequent	JJ	O
bone	NN	O
marrow	NN	O
(	(	O
BM	NNP	O
)	)	O
relapse	NN	O
and	CC	O
death	NN	O
.	.	O

If	IN	O
occult	JJ	O
TR	NNP	O
is	VBZ	O
identified	VBN	O
during	IN	O
or	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
planned	JJ	O
therapy	NN	O
,	,	O
a	DT	O
higher	JJR	O
salvage	NN	O
rate	NN	O
may	MD	O
require	VB	O
intensified	JJ	O
alternate	JJ	O
therapy	NN	O
.	.	O

As	IN	O
such	JJ	O
,	,	O
testicular	JJ	Surgical
biopsies	NNS	Surgical
may	MD	O
be	VB	O
clinically	RB	O
useful	JJ	O
.	.	O

Further	JJ	O
investigation	NN	O
is	VBZ	O
limited	VBN	O
by	IN	O
the	DT	O
relative	JJ	O
rarity	NN	O
of	IN	O
,	,	O
and	CC	O
the	DT	O
lack	NN	O
of	IN	O
identifying	VBG	O
features	NNS	O
in	IN	O
boys	NNS	O
with	IN	O
occult	NN	O
TL	NNP	O
.	.	O

[	JJ	O
Intravesical	NNP	O
instillation	NN	O
of	IN	O
doxorubicin	NN	Pharmacological
or	CC	O
epirubicin	NN	Pharmacological
for	IN	O
chemoprophylaxis	NN	O
of	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
--	:	O
the	DT	O
fifth	JJ	O
study	NN	O
of	IN	O
the	DT	O
Japanese	JJ	O
Urological	JJ	O
Cancer	NNP	O
Research	NNP	O
Group	NNP	O
for	IN	O
Adriamycin/Farumorubicin	NNP	O
]	NNP	O
.	.	O

A	NNP	O
total	NN	O
of	IN	O
465	CD	O
patients	NNS	O
with	IN	O
primary	JJ	O
and	CC	O
multiple	JJ	O
or	CC	O
recurrent	NN	O
,	,	O
stages	VBZ	O
Ta	NNP	O
and	CC	O
T1	NNP	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
randomized	JJ	O
multicenter	NN	O
trial	NN	O
to	TO	O
compare	VB	O
the	DT	O
prophylactic	JJ	O
effect	NN	O
by	IN	O
17	CD	O
times	NNS	O
instillation	NN	O
of	IN	O
40	CD	Pharmacological
mg	NNS	Pharmacological
doxorubicin	VBD	Pharmacological
or	CC	O
40	CD	Physical
mg	NNS	Physical
epirubicin	VBP	Physical
with	IN	O
no	DT	O
instillation	NN	O
after	IN	O
transurethral	JJ	O
resection	NN	O
of	IN	O
tumor	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
first	JJ	O
recurrence	NN	O
after	IN	O
transurethral	JJ	O
resection	NN	O
.	.	O

Endoscopic	NNP	O
examination	NN	O
as	RB	O
well	RB	O
as	IN	O
urinary	JJ	O
cytology	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
each	DT	O
case	NN	O
every	DT	O
three	CD	O
months	NNS	O
.	.	O

It	PRP	O
became	VBD	O
evident	JJ	O
that	IN	O
the	DT	O
recurrence	NN	O
rate	NN	O
in	IN	O
the	DT	O
doxorubicin	NN	Pharmacological
or	CC	O
epirubicin	JJ	Pharmacological
instillation	NN	O
arm	NN	O
was	VBD	O
lower	JJR	O
that	IN	O
in	IN	O
the	DT	O
no	DT	O
instillation	NN	O
arm	NN	O
.	.	O

Toxicity	NN	O
was	VBD	O
mainly	RB	O
restricted	VBN	O
to	TO	O
bladder	VB	O
irritation	NN	O
in	IN	O
about	RB	O
10	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
each	DT	O
instillation	NN	O
arm	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
patient	JJ	Physical
position	NN	Physical
on	IN	O
the	DT	O
reproducibility	NN	O
of	IN	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
patient	JJ	Physical
position	NN	Physical
on	IN	O
the	DT	O
reproducibility	NN	O
of	IN	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
two-group	JJ	O
quasi-experimental	JJ	O
design	NN	O
.	.	O

Convenience	NN	O
sample	NN	O
.	.	O

SETTING	CC	O
The	DT	O
study	NN	O
involved	VBD	O
two	CD	O
intensive	JJ	O
care	NN	O
units	NNS	O
in	IN	O
two	CD	O
adult	NN	O
acute	NN	O
care	NN	O
hospitals	NNS	O
.	.	O

PATIENTS	NNP	O
Thirty	NNP	O
patients	NNS	O
admitted	VBD	O
to	TO	O
the	DT	O
intensive	JJ	O
care	NN	O
unit	NN	O
who	WP	O
had	VBD	O
a	DT	O
thermodilution	NN	O
pulmonary	JJ	O
artery	NN	O
catheter	NN	O
in	IN	O
place	NN	O
.	.	O

Ages	NNS	O
ranged	VBD	O
from	IN	O
39	CD	O
to	TO	O
80	CD	O
years	NNS	O
(	(	O
mean	NN	O
of	IN	O
66.4	CD	O
+/-	JJ	O
11.3	CD	O
years	NNS	O
)	)	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Thermodilution	NNP	O
cardiac	NN	O
output	NN	O
measurements	NNS	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
subjects	NNS	O
were	VBD	O
placed	VBN	O
in	IN	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
,	,	O
initially	RB	O
by	IN	O
flipping	VBG	O
a	DT	O
coin	NN	O
then	RB	O
into	IN	O
alternate	NN	O
groups	NNS	O
.	.	O

Group	NNP	O
A	NNP	O
subjects	NNS	O
were	VBD	O
placed	VBN	O
supine	NN	Physical
,	,	O
and	CC	O
after	IN	O
5	CD	O
minutes	NNS	O
had	VBD	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
performed	VBN	O
.	.	O

They	PRP	O
were	VBD	O
then	RB	O
placed	VBN	O
in	IN	O
the	DT	O
45-degree	JJ	Physical
upright	JJ	Physical
position	NN	Physical
,	,	O
and	CC	O
after	IN	O
an	DT	O
additional	JJ	O
5	CD	O
minutes	NNS	O
had	VBD	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
performed	VBN	O
.	.	O

Group	NNP	O
B	NNP	O
subjects	NNS	O
were	VBD	O
first	RB	O
placed	VBN	O
in	IN	O
the	DT	O
45-degree	JJ	Physical
upright	JJ	Physical
position	NN	Physical
,	,	O
and	CC	O
after	IN	O
5	CD	O
minutes	NNS	O
had	VBD	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
performed	VBN	O
.	.	O

They	PRP	O
were	VBD	O
then	RB	O
placed	VBN	O
in	IN	O
the	DT	O
supine	NN	Physical
flat	JJ	Physical
position	NN	Physical
,	,	O
and	CC	O
after	IN	O
an	DT	O
additional	JJ	O
5	CD	O
minutes	NNS	O
had	VBD	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Seventy	NNP	O
percent	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
of	IN	O
the	DT	O
sample	JJ	O
population	NN	O
displayed	VBD	O
a	DT	O
lower	JJR	O
cardiac	NN	O
output	NN	O
in	IN	O
the	DT	O
45-degree	JJ	O
upright	JJ	O
position	NN	O
than	IN	O
that	DT	O
obtained	VBN	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
,	,	O
with	IN	O
the	DT	O
decrease	NN	O
ranging	VBG	O
from	IN	O
1	CD	O
%	NN	O
to	TO	O
32	CD	O
%	NN	O
(	(	O
mean	JJ	O
decrease	NN	O
11	CD	O
%	NN	O
)	)	O
.	.	O

Forty	CD	O
percent	NN	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
of	IN	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
obtained	VBN	O
in	IN	O
the	DT	O
45-degree	JJ	O
upright	NN	O
were	VBD	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
10	CD	O
%	NN	O
less	JJR	O
than	IN	O
those	DT	O
obtained	VBN	O
in	IN	O
the	DT	O
supine	NN	O
flat	JJ	O
position	NN	O
.	.	O

The	DT	O
differences	NNS	O
in	IN	O
cardiac	JJ	O
output	NN	O
were	VBD	O
analyzed	VBN	O
with	IN	O
the	DT	O
paired	JJ	O
t	JJ	O
test	NN	O
.	.	O

which	WDT	O
produced	VBD	O
a	DT	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
from	IN	O
-0.539	NN	O
to	TO	O
-0.083	VB	O
.	.	O

The	DT	O
two-group	JJ	O
Wilcoxon	NNP	O
test	NN	O
was	VBD	O
used	VBN	O
to	TO	O
analyze	VB	O
the	DT	O
mean	JJ	O
cardiac	JJ	O
output	NN	O
with	IN	O
the	DT	O
patient	NN	O
in	IN	O
the	DT	O
supine	NN	O
,	,	O
flat	JJ	O
position	NN	O
and	CC	O
in	IN	O
the	DT	O
45-degree	JJ	O
upright	JJ	O
position	NN	O
.	.	O

The	DT	O
mean	JJ	O
cardiac	JJ	O
output	NN	O
at	IN	O
0	CD	O
degrees	NNS	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
statistically	RB	O
significant	JJ	O
higher	JJR	O
(	(	O
p	JJ	O
=	NNP	O
0.0083	CD	O
)	)	O
than	IN	O
the	DT	O
mean	JJ	O
cardiac	JJ	O
output	NN	O
at	IN	O
45	CD	O
degrees	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
coexisting	VBG	O
variables	NNS	O
was	VBD	O
analyzed	VBN	O
with	IN	O
the	DT	O
Kruskal-Wallis	NNP	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
vasoconstrictors	NNS	O
was	VBD	O
the	DT	O
only	JJ	O
variable	NN	O
that	WDT	O
had	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
change	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
associated	VBN	O
with	IN	O
a	DT	O
change	NN	O
in	IN	O
position	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
are	VBP	O
affected	VBN	O
by	IN	O
alterations	NNS	O
in	IN	O
patient	JJ	O
position	NN	O
.	.	O

To	TO	O
ensure	VB	O
accurate	JJ	O
comparisons	NNS	O
between	IN	O
consecutive	JJ	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
,	,	O
the	DT	O
researchers	NNS	O
recommend	VBP	O
that	IN	O
the	DT	O
position	NN	O
in	IN	O
which	WDT	O
the	DT	O
cardiac	NN	O
output	NN	O
measurements	NNS	O
are	VBP	O
performed	VBN	O
be	VB	O
documented	VBN	O
and	CC	O
the	DT	O
cardiac	JJ	O
output	NN	O
measurements	NNS	O
be	VB	O
conducted	VBN	O
in	IN	O
a	DT	O
uniform	JJ	O
position	NN	O
.	.	O

Trunk	NNP	Physical
exercise	NN	Physical
combined	VBN	Physical
with	IN	Physical
spinal	JJ	Physical
manipulative	NN	Physical
or	CC	O
NSAID	NNP	Pharmacological
therapy	NN	Pharmacological
for	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
observer-blinded	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
study	VB	O
the	DT	O
relative	JJ	O
efficacy	NN	O
of	IN	O
three	CD	O
different	JJ	O
treatment	NN	O
for	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
CLBP	NNP	O
)	)	O
.	.	O

Two	CD	O
preplanned	JJ	O
comparisons	NNS	O
were	VBD	O
made	VBN	O
:	:	O
(	(	O
a	DT	O
)	)	O
Spinal	NNP	Physical
manipulative	JJ	Physical
therapy	NN	Physical
(	(	Physical
SMT	NNP	Physical
)	)	Physical
combined	VBD	Physical
with	IN	Physical
trunk	NN	Physical
strengthening	VBG	Physical
exercises	NNS	Physical
(	(	Physical
TSE	NNP	Physical
)	)	Physical
vs.	FW	Physical
SMT	NNP	Physical
combined	VBD	Physical
with	IN	Physical
trunk	NN	Physical
stretching	VBG	Physical
exercises	NNS	Physical
,	,	Physical
and	CC	Physical
(	(	O
b	NN	O
)	)	O
SMT	NNP	Physical
combined	VBN	Physical
with	IN	Physical
TSE	NNP	Physical
vs.	FW	Physical
nonsteroidal	JJ	Pharmacological
anti-inflammatory	JJ	Pharmacological
drug	NN	Pharmacological
(	(	Pharmacological
NSAID	NNP	Pharmacological
)	)	Pharmacological
therapy	NN	Pharmacological
combined	VBN	Pharmacological
with	IN	Pharmacological
TSE	NNP	Pharmacological
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Interdisciplinary	NNP	O
,	,	O
prospective	JJ	O
,	,	O
observer-blinded	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
with	IN	O
a	DT	O
1-yr	JJ	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
trial	NN	O
evaluated	VBD	O
therapies	NNS	O
in	IN	O
combination	NN	O
only	RB	O
and	CC	O
was	VBD	O
not	RB	O
designed	VBN	O
to	TO	O
test	VB	O
the	DT	O
individual	JJ	O
treatment	NN	O
components	NNS	O
.	.	O

SETTING	NNP	O
Primary	NNP	O
contact	NN	O
,	,	O
college	NN	O
out-patient	JJ	O
clinic	NN	O
.	.	O

PATIENTS	NNP	O
In	IN	O
total	JJ	O
,	,	O
174	CD	O
patients	NNS	O
aged	VBN	O
20-60	JJ	O
yr	NNS	O
were	VBD	O
admitted	VBN	O
to	TO	O
the	DT	O
study	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Patient-rated	NNP	O
low	JJ	O
back	RB	O
pain	NN	O
,	,	O
disability	NN	O
,	,	O
and	CC	O
functional	JJ	O
health	NN	O
status	NN	O
at	IN	O
5	CD	O
and	CC	O
11	CD	O
wk	NN	O
.	.	O

INTERVENTIONS	NNP	O
Five	NNP	O
weeks	NNS	O
of	IN	O
SMT	NNP	Physical
or	CC	O
NSAID	NNP	Pharmacological
therapy	NN	Physical
in	IN	Physical
combination	NN	Physical
with	IN	Physical
supervised	JJ	Physical
trunk	NN	Physical
exercise	NN	Physical
,	,	O
followed	VBN	O
by	IN	O
and	CC	O
additional	JJ	O
6	CD	O
wk	NN	O
of	IN	O
supervised	JJ	Physical
exercise	NN	Physical
alone	RB	Physical
.	.	Physical

RESULTS	NNP	O
Individual	NNP	O
group	NN	O
comparisons	NNS	O
after	IN	O
5	CD	O
and	CC	O
11	CD	O
wk	NN	O
of	IN	O
intervention	NN	O
on	IN	O
all	DT	O
three	CD	O
main	JJ	O
outcome	NN	O
measures	NNS	O
did	VBD	O
not	RB	O
reveal	VB	O
any	DT	O
clear	JJ	O
clinically	RB	O
important	JJ	O
or	CC	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
.	.	O

There	EX	O
seemed	VBD	O
to	TO	O
be	VB	O
a	DT	O
sustained	JJ	O
reduction	NN	O
in	IN	O
medication	NN	O
use	NN	O
at	IN	O
the	DT	O
1-yr	JJ	O
follow-up	NN	O
.	.	O

in	IN	O
the	DT	O
SMT/TSE	NNP	O
group	NN	O
.	.	O

Continuance	NN	O
of	IN	O
exercise	NN	O
during	IN	O
the	DT	O
follow-up	JJ	O
year	NN	O
,	,	O
regardless	RB	O
of	IN	O
type	NN	O
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
better	JJR	O
outcome	NN	O
.	.	O

CONCLUSION	NNP	O
Each	DT	O
of	IN	O
the	DT	O
three	CD	O
therapeutic	JJ	O
regimens	NNS	O
was	VBD	O
associated	VBN	O
with	IN	O
similar	JJ	O
and	CC	O
clinically	RB	O
important	JJ	O
improvement	NN	O
over	IN	O
time	NN	O
that	WDT	O
was	VBD	O
considered	VBN	O
superior	JJ	O
to	TO	O
the	DT	O
expected	JJ	O
natural	JJ	O
history	NN	O
of	IN	O
long-standing	JJ	O
CLBP	NNP	O
.	.	O

For	IN	O
the	DT	O
management	NN	O
of	IN	O
CLBP	NNP	O
,	,	O
trunk	NN	O
exercise	NN	O
in	IN	O
combination	NN	O
with	IN	O
SMT	NNP	Physical
or	CC	O
NSAID	NNP	Pharmacological
therapy	NN	Pharmacological
seemed	VBD	O
to	TO	O
be	VB	O
beneficial	JJ	O
and	CC	O
worthwhile	JJ	O
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
nonspecific	JJ	O
therapeutic	JJ	O
(	(	Control
placebo	NN	Control
)	)	Control
effects	NNS	O
,	,	O
cost-effectiveness	NN	O
and	CC	O
relative	JJ	O
risks	NNS	O
of	IN	O
side	NN	O
effects	NNS	O
associated	VBN	O
with	IN	O
these	DT	O
types	NNS	O
of	IN	O
therapy	NN	O
need	NN	O
to	TO	O
be	VB	O
addressed	VBN	O
in	IN	O
future	JJ	O
studies	NNS	O
.	.	O

Middle	NNP	O
cerebral	JJ	O
arterial	JJ	O
blood	NN	O
flow	NN	O
velocity	NN	O
and	CC	O
hemodynamics	NNS	O
in	IN	O
heart	NN	O
surgery	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
propofol	NN	Pharmacological
,	,	O
isoflurane	NN	Pharmacological
,	,	O
and	CC	O
sevoflurane	NN	Pharmacological
on	IN	O
middle	JJ	O
cerebral	JJ	O
arterial	JJ	O
blood	NN	O
flow	NN	O
velocity	NN	O
during	IN	O
open	JJ	O
heart	NN	O
surgery	NN	O
,	,	O
and	CC	O
the	DT	O
relationship	NN	O
between	IN	O
these	DT	O
effects	NNS	O
and	CC	O
hemodynamic	JJ	O
parameters	NNS	O
.	.	O

Fifty-two	JJ	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
on	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
were	VBD	O
divided	VBN	O
randomly	RB	O
into	IN	O
3	CD	O
groups	NNS	O
:	:	O
the	DT	O
first	JJ	O
group	NN	O
received	VBD	O
100	CD	O
microg	NNS	O
x	JJ	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
x	VBP	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
propofol	NN	Pharmacological
,	,	O
the	DT	O
other	JJ	O
groups	NNS	O
received	VBD	O
one	CD	O
minimum	NN	O
alveolar	JJ	O
concentration	NN	O
of	IN	O
sevoflurane	NN	Pharmacological
or	CC	O
isoflurane	NN	Pharmacological
for	IN	O
anesthesia	JJ	Pharmacological
maintenance	NN	Pharmacological
.	.	O

Middle	NNP	O
cerebral	JJ	O
arterial	JJ	O
blood	NN	O
flow	NN	O
velocities	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
transcranial	JJ	O
Doppler	NNP	O
,	,	O
and	CC	O
hemodynamics	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
thermodilution	NN	O
technique	NN	O
.	.	O

Middle	NNP	O
cerebral	JJ	O
arterial	JJ	O
blood	NN	O
flow	NN	O
velocities	NNS	O
decreased	VBN	O
significantly	RB	O
after	IN	O
administration	NN	O
of	IN	O
isoflurane	NN	O
and	CC	O
propofol	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

After	IN	O
weaning	VBG	O
from	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
,	,	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
increased	VBD	O
and	CC	O
came	VBD	O
close	RB	O
to	TO	O
the	DT	O
value	NN	O
after	IN	O
induction	NN	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

The	DT	O
pulsatility	NN	O
index	NN	O
and	CC	O
resistivity	NN	O
index	NN	O
increased	VBD	O
significantly	RB	O
only	RB	O
after	IN	O
the	DT	O
propofol	NN	O
infusion	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Efficacy	NN	O
of	IN	O
patient	JJ	Educational
education	NN	Educational
and	CC	O
supervised	VBD	Physical
exercise	NN	Physical
vs	NN	O
patient	JJ	Educational
education	NN	Educational
alone	RB	Educational
in	IN	O
patients	NNS	O
with	IN	O
hip	JJ	O
osteoarthritis	NN	O
:	:	O
a	DT	O
single	JJ	O
blind	NN	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
patient	JJ	Educational
education	NN	Educational
and	CC	O
supervised	VBD	Other
exercise	NN	Other
with	IN	O
that	DT	O
of	IN	O
patient	JJ	Educational
education	NN	Educational
alone	RB	Educational
for	IN	O
the	DT	O
management	NN	O
of	IN	O
pain	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hip	NN	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Single	NNP	O
blind	IN	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NNP	O
Recruitment	NNP	O
of	IN	O
patients	NNS	O
from	IN	O
hospitals	NNS	O
,	,	O
primary	JJ	O
health	NN	O
care	NN	O
and	CC	O
advertisement	NN	O
,	,	O
Oslo	NNP	O
,	,	O
Norway	NNP	O
.	.	O

PARTICIPANTS	NNP	O
109	CD	O
patients	NNS	O
with	IN	O
radiographic	JJ	O
and	CC	O
symptomatic	JJ	O
hip	NN	O
OA	NNP	O
with	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
symptoms	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Patient	NNP	Educational
education	NN	Educational
(	(	Educational
PE	NNP	Educational
)	)	Educational
.	.	O

Patient	JJ	Educational
education	NN	Educational
and	CC	O
supervised	VBN	Physical
exercise	NN	Physical
(	(	O
PE+SE	NNP	O
)	)	O
.	.	O

PRIMARY	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
The	DT	O
pain	NN	O
subscale	NN	O
of	IN	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
pain	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
between	IN	O
group	NN	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	O
pain	NN	O
over	IN	O
the	DT	O
16-month	JJ	O
follow-up	NN	O
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
the	DT	O
secondary	JJ	O
outcome	NN	O
WOMAC	NNP	O
physical	JJ	O
function	NN	O
(	(	O
P=0.011	NNP	O
)	)	O
in	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
PE+SE	NNP	Physical
compared	VBN	O
to	TO	O
the	DT	O
group	NN	O
receiving	VBG	O
PE	NNP	Educational
only	RB	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
for	IN	O
WOMAC	NNP	O
stiffness	NN	O
,	,	O
the	DT	O
SF-36	JJ	O
subscales	NNS	O
or	CC	O
the	DT	O
activity	NN	O
scale	NN	O
.	.	O

The	DT	O
effect	NN	O
sizes	VBZ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
for	IN	O
WOMAC	NNP	O
pain	NN	O
were	VBD	O
-0.26	NNP	O
(	(	O
0.11	CD	O
,	,	O
-0.64	NN	O
)	)	O
,	,	O
-0.35	NNP	O
(	(	O
0.07	CD	O
,	,	O
-0.77	NN	O
)	)	O
,	,	O
and	CC	O
-0.30	NNP	O
(	(	O
0.15	CD	O
,	,	O
-0.75	NN	O
)	)	O
,	,	O
and	CC	O
for	IN	O
WOMAC	NNP	O
physical	JJ	O
function	NN	O
-0.29	NNP	O
(	(	O
0.09	CD	O
,	,	O
-0.67	NN	O
)	)	O
,	,	O
-0.48	NNP	O
(	(	O
-0.06	NNP	O
,	,	O
-0.91	NNP	O
)	)	O
,	,	O
and	CC	O
-0.47	NNP	O
(	(	O
-0.02	NNP	O
,	,	O
-0.93	NNP	O
)	)	O
at	IN	O
4	CD	O
,	,	O
10	CD	O
and	CC	O
16	CD	O
months	NNS	O
,	,	O
respectively	RB	O
,	,	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
group	NN	O
receiving	VBG	O
both	DT	O
PE	NNP	Educational
and	CC	O
SE	NNP	Physical
.	.	O

All	DT	O
patients	NNS	O
attended	VBD	O
the	DT	O
three-session	JJ	O
PE	NNP	Educational
program	NN	Educational
,	,	O
and	CC	O
75	CD	O
%	NN	O
performed	VBN	O
?16	JJ	O
sessions	NNS	O
of	IN	O
the	DT	O
12-week	JJ	O
SE	NNP	O
program	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
study	NN	O
could	MD	O
not	RB	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
pain	NN	O
reduction	NN	O
over	IN	O
time	NN	O
between	IN	O
PE+SE	NNP	O
vs	NNP	O
PE	NNP	O
alone	RB	O
.	.	O

Adding	VBG	O
SE	NNP	O
to	TO	O
PE	NNP	O
may	MD	O
improve	VB	O
physical	JJ	O
function	NN	O
,	,	O
but	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
possible	JJ	O
benefit	NN	O
is	VBZ	O
unknown	JJ	O
as	IN	O
the	DT	O
95	CD	O
%	NN	O
confidence	NN	O
intervals	NNS	O
around	IN	O
the	DT	O
mean	JJ	O
difference	NN	O
were	VBD	O
wide	JJ	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Clinical	NNP	O
Trials	NNP	O
NCT00319423	NNP	O
.	.	O

Pharmacokinetics	NNS	O
and	CC	O
follicular	JJ	O
dynamics	NNS	O
of	IN	O
corifollitropin	NN	Pharmacological
alfa	NN	Pharmacological
versus	NN	O
recombinant	JJ	Pharmacological
FSH	NNP	Pharmacological
during	IN	O
ovarian	JJ	O
stimulation	NN	O
for	IN	O
IVF	NNP	O
.	.	O

A	NNP	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	Pharmacological
alfa	NN	Pharmacological
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	Pharmacological
FSH	NNP	Pharmacological
(	(	Pharmacological
rFSH	NN	Pharmacological
)	)	Pharmacological
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

This	DT	O
double-blind	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
assessed	VBD	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
versus	IN	O
daily	JJ	O
200IU	CD	O
rFSH	NN	O
in	IN	O
1509	CD	O
patients	NNS	O
.	.	O

Comparative	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
(	(	O
pharmacokinetics	NNS	O
)	)	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
,	,	O
and	CC	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamics	NNS	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
follicular	JJ	O
development	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

By	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
,	,	O
33	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
corifollitropin	NN	O
alfa	NN	O
reached	VBD	O
the	DT	O
criterion	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
(	(	O
HCG	NNP	O
)	)	O
injection	NN	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
follicles	NNS	O
?11mm	NNP	O
was	VBD	O
slightly	RB	O
higher	JJR	O
after	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
at	IN	O
stimulation	NN	O
day	NN	O
8	CD	O
(	(	O
difference	NN	O
,	,	O
1.2	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.5-1.8	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
HCG	NNP	O
injection	NN	O
(	(	O
difference	NN	O
,	,	O
2.1	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
1.4-2.8	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

The	DT	O
rise	NN	O
of	IN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Although	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
and	CC	O
rFSH	NN	O
are	VBP	O
quite	RB	O
different	JJ	O
their	PRP$	O
pharmacodynamic	JJ	O
profiles	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

A	DT	O
single	JJ	O
injection	NN	O
of	IN	O
corifollitropin	NN	O
alfa	NN	O
can	MD	O
replace	VB	O
seven	CD	O
daily	JJ	O
injections	NNS	O
of	IN	O
recombinant	JJ	O
FSH	NNP	O
(	(	O
rFSH	NN	O
)	)	O
using	VBG	O
a	DT	O
gonadotrophin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
protocol	NN	O
in	IN	O
ovarian	JJ	O
stimulation	NN	O
prior	RB	O
to	TO	O
IVF	NNP	O
or	CC	O
intracytoplasmic	JJ	O
sperm	JJ	O
injection	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
corifollitropin	NN	O
alfa	JJ	O
versus	JJ	O
daily	JJ	O
rFSH	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
1509	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
to	TO	O
either	VB	O
a	DT	O
single	JJ	O
injection	NN	O
of	IN	O
150?g	CD	O
corifollitropin	NN	O
alfa	NN	O
or	CC	O
to	TO	O
daily	JJ	O
injections	NNS	O
of	IN	O
200IU	CD	O
rFSH	NN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
of	IN	O
ovarian	JJ	O
stimulation	NN	O
.	.	O

Serum	NNP	O
levels	NNS	O
of	IN	O
FSH	NNP	O
immunoreactivity	NN	O
were	VBD	O
analysed	VBN	O
(	(	O
pharmacokinetic	JJ	O
analysis	NN	O
)	)	O
,	,	O
together	RB	O
with	IN	O
the	DT	O
number	NN	O
and	CC	O
size	NN	O
of	IN	O
growing	VBG	O
follicles	NNS	O
and	CC	O
serum	NN	O
inhibin	NN	O
B	NNP	O
and	CC	O
oestradiol	JJ	O
concentrations	NNS	O
as	IN	O
biomarkers	NNS	O
of	IN	O
the	DT	O
ovarian	JJ	O
response	NN	O
(	(	O
pharmacodynamic	JJ	O
analysis	NN	O
)	)	O
.	.	O

Serum	NNP	O
FSH	NNP	O
immunoreactivity	NN	O
levels	NNS	O
were	VBD	O
higher	JJR	O
up	RB	O
to	TO	O
stimulation	VB	O
day	NN	O
5	CD	O
for	IN	O
corifollitropin	NN	O
alfa	NN	O
compared	VBN	O
with	IN	O
the	DT	O
daily	JJ	O
rFSH	NN	O
regimen	NNS	O
but	CC	O
were	VBD	O
similar	JJ	O
from	IN	O
day	NN	O
8	CD	O
onwards	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
started	VBD	O
rFSH	RB	O
if	IN	O
the	DT	O
criteria	NN	O
for	IN	O
human	JJ	O
chorionic	NN	O
gonadotrophin	NN	O
were	VBD	O
not	RB	O
yet	RB	O
reached	VBN	O
.	.	O

Corifollitropin	NNP	O
alfa	JJ	O
treatment	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
similar	JJ	O
growth	NN	O
rate	NN	O
of	IN	O
follicles	NNS	O
though	IN	O
a	DT	O
slightly	RB	O
higher	JJR	O
number	NN	O
of	IN	O
follicles	NNS	O
were	VBD	O
recruited	VBN	O
compared	VBN	O
with	IN	O
daily	JJ	O
rFSH	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
corifollitropin	NN	Pharmacological
alfa	NN	Pharmacological
and	CC	O
rFSH	NN	Pharmacological
are	VBP	O
quite	RB	O
different	JJ	O
but	CC	O
their	PRP$	O
induced	JJ	O
pharmacodynamic	JJ	O
effects	NNS	O
at	IN	O
the	DT	O
dosages	NNS	O
used	VBN	O
are	VBP	O
similar	JJ	O
.	.	O

Combination	NN	Pharmacological
peel	NN	Pharmacological
with	IN	Pharmacological
incorporated	JJ	Pharmacological
fractional	JJ	Pharmacological
prickle	NN	Pharmacological
coral	JJ	Pharmacological
calcium	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
keratosis	NN	O
pilaris	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Keratosis	NNP	O
pilaris	NN	O
(	(	O
KP	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
condition	NN	O
of	IN	O
follicular	JJ	O
plugging	VBG	O
with	IN	O
variable	JJ	O
erythema	NN	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
lack	NN	O
of	IN	O
reliable	JJ	O
response	NN	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
KP	NNP	O
.	.	O

OBJECTIVE	NNP	O
We	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
and	CC	O
safety	NN	O
of	IN	O
combination	NN	O
peel	NN	O
with	IN	O
fractional	JJ	O
prickle	JJ	O
coral	JJ	O
calcium	NN	O
(	(	O
FCR?	NNP	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
KP	NNP	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Sixteen	NNP	O
Korean	JJ	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
FCR?	NNP	O
on	IN	O
both	DT	O
upper	JJ	O
arms	NNS	O
for	IN	O
five	CD	O
sessions	NNS	O
at	IN	O
2-week	JJ	O
intervals	NNS	O
.	.	O

Clinical	JJ	O
evaluations	NNS	O
,	,	O
mexameter	NN	O
measurements	NNS	O
,	,	O
and	CC	O
assessment	NN	O
of	IN	O
patients	NNS	O
'	POS	O
satisfaction	NN	O
and	CC	O
adverse	JJ	O
events	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
every	DT	O
visit	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
treatments	NNS	O
,	,	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
the	DT	O
baseline	NN	O
KP	NNP	O
were	VBD	O
observed	VBN	O
in	IN	O
erythema	NN	O
and	CC	O
melanin	NN	O
index	NN	O
of	IN	O
mexameter	NN	O
on	IN	O
treated	JJ	O
upper	JJ	O
arms	NNS	O
.	.	O

Both	CC	O
the	DT	O
physicians	NNS	O
'	POS	O
and	CC	O
patients	NNS	O
'	POS	O
assessments	NNS	O
correlate	VBP	O
with	IN	O
the	DT	O
results	NNS	O
of	IN	O
mexameter	NN	O
scores	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
FCR?	NNP	O
should	MD	O
be	VB	O
considered	VBN	O
as	IN	O
an	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
treatment	NN	O
option	NN	O
for	IN	O
the	DT	O
patients	NNS	O
with	IN	O
KP	NNP	O
.	.	O

Correlation	NN	O
between	IN	O
in	IN	O
vivo	JJ	O
humoral	JJ	O
and	CC	O
in	IN	O
vitro	JJ	O
cellular	JJ	O
immune	NN	O
responses	NNS	O
following	VBG	O
immunization	NN	O
with	IN	O
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
surface	NN	Pharmacological
antigen	NN	Pharmacological
(	(	Pharmacological
HBsAg	NNP	Pharmacological
)	)	Pharmacological
vaccines	NNS	Pharmacological
.	.	Pharmacological

To	TO	O
study	VB	O
the	DT	O
regulation	NN	O
of	IN	O
the	DT	O
human	JJ	O
immune	NN	O
response	NN	O
to	TO	O
hepatitis	VB	Pharmacological
B	NNP	Pharmacological
surface	NN	Pharmacological
antigen	NN	Pharmacological
(	(	Pharmacological
HBsAg	NNP	Pharmacological
)	)	Pharmacological
we	PRP	O
have	VBP	O
carefully	RB	O
monitored	VBN	O
the	DT	O
in	IN	O
vivo	JJ	O
humoral	JJ	O
and	CC	O
in	IN	O
vitro	JJ	O
cellular	JJ	O
immune	NN	O
responses	NNS	O
to	TO	O
HBsAg	NNP	O
in	IN	O
50	CD	O
subjects	NNS	O
receiving	VBG	O
four	CD	O
doses	NNS	O
of	IN	O
hepatitis	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
according	VBG	O
to	TO	O
a	DT	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
12	CD	O
month	NN	O
vaccination	NN	O
scheme	NN	O
.	.	O

Twenty-three	JJ	O
subjects	NNS	O
were	VBD	O
given	VBN	O
a	DT	O
plasma-derived	JJ	Pharmacological
vaccine	NN	Pharmacological
(	(	Pharmacological
Hevac	NNP	Pharmacological
B	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
27	CD	O
received	VBD	O
a	DT	O
recombinant	JJ	Pharmacological
HBsAg	NNP	Pharmacological
vaccine	NN	Pharmacological
(	(	Pharmacological
yeast-derived	JJ	Pharmacological
;	:	Pharmacological
Engerix-B	NNP	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

The	DT	O
humoral	JJ	O
and	CC	O
cellular	JJ	O
immune	NN	O
responses	NNS	O
were	VBD	O
measured	VBN	O
before	IN	O
vaccination	NN	O
(	(	O
day	NN	O
0	CD	O
)	)	O
;	:	O
6	CD	O
days	NNS	O
after	IN	O
the	DT	O
second	JJ	O
dose	NN	O
(	(	O
day	NN	O
36	CD	O
)	)	O
;	:	O
6	CD	O
days	NNS	O
(	(	O
day	NN	O
66	CD	O
)	)	O
,	,	O
2	CD	O
months	NNS	O
(	(	O
day	NN	O
120	CD	O
)	)	O
and	CC	O
10	CD	O
months	NNS	O
(	(	O
day	NN	O
365	CD	O
)	)	O
after	IN	O
the	DT	O
third	JJ	O
dose	NN	O
and	CC	O
1	CD	O
month	NN	O
after	IN	O
the	DT	O
fourth	JJ	O
dose	NN	O
(	(	O
day	NN	O
395	CD	O
)	)	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
kinetics	NNS	O
of	IN	O
the	DT	O
humoral	JJ	O
immune	NN	O
responses	NNS	O
,	,	O
the	DT	O
vaccinees	NNS	O
could	MD	O
be	VB	O
classified	VBN	O
into	IN	O
fast	NN	O
,	,	O
intermediate	JJ	O
and	CC	O
slow/non-responders	NNS	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
(	(	O
anti-HBs	JJ	O
titre	NN	O
)	)	O
on	IN	O
day	NN	O
395	CD	O
,	,	O
the	DT	O
vaccinees	NNS	O
could	MD	O
be	VB	O
divided	VBN	O
into	IN	O
high	JJ	O
(	(	O
>	FW	O
or	CC	O
=	VB	O
2000	CD	O
U	NNP	O
l-1	NN	O
)	)	O
and	CC	O
low	JJ	O
(	(	O
<	CD	O
or	CC	O
=	VB	O
2000	CD	O
U	NNP	O
l-1	NN	O
)	)	O
responders	NNS	O
.	.	O

A	DT	O
close	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
kinetics	NNS	O
and	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
humoral	JJ	O
immune	NN	O
response	NN	O
was	VBD	O
observed	VBN	O
.	.	O

The	DT	O
in	IN	O
vivo	JJ	O
anti-HBs	JJ	O
response	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
commercially	RB	O
available	JJ	O
immunoradiometric	JJ	O
assays	NNS	O
.	.	O

The	DT	O
in	IN	O
vitro	NN	O
cellular	JJ	O
immune	JJ	O
response	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
HBsAg-specific	JJ	O
lymphoproliferation	NN	O
assay	NN	O
.	.	O

Because	IN	O
of	IN	O
interassay	JJ	O
variability	NN	O
the	DT	O
results	NNS	O
were	VBD	O
considered	VBN	O
as	IN	O
dichotomous	JJ	O
variables	NNS	O
(	(	O
proliferation	NN	O
versus	IN	O
non-proliferation	NN	O
)	)	O
for	IN	O
further	JJ	O
data	NNS	O
analysis	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
correlation	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
kinetics	NNS	O
and	CC	O
magnitude	NN	O
of	IN	O
the	DT	O
humoral	JJ	O
immune	JJ	O
response	NN	O
on	IN	O
the	DT	O
one	CD	O
hand	NN	O
and	CC	O
the	DT	O
in	IN	O
vitro	JJ	O
anti-HBs	JJ	O
response	NN	O
on	IN	O
the	DT	O
other	JJ	O
hand	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Dexamethasone	NNP	Pharmacological
versus	NN	O
prednisone	NN	Pharmacological
and	CC	O
daily	JJ	O
oral	JJ	O
versus	NN	O
weekly	RB	O
intravenous	JJ	Pharmacological
mercaptopurine	NN	Pharmacological
for	IN	O
patients	NNS	O
with	IN	O
standard-risk	JJ	O
acute	JJ	O
lymphoblastic	JJ	O
leukemia	NN	O
:	:	O
a	DT	O
report	NN	O
from	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Cancer	NNP	O
Group	NNP	O
.	.	O

Conventional	NNP	Pharmacological
therapy	NN	Pharmacological
for	IN	O
childhood	NN	O
acute	NN	O
lymphoblastic	JJ	O
leukemia	NN	O
(	(	O
ALL	DT	O
)	)	O
includes	VBZ	O
prednisone	NN	Pharmacological
and	CC	O
oral	JJ	O
6-mercaptopurine	JJ	Pharmacological
.	.	O

Prior	JJ	O
observations	NNS	O
suggested	VBD	O
potential	JJ	O
advantages	NNS	O
for	IN	O
dexamethasone	NN	Pharmacological
over	IN	O
prednisone	NN	Pharmacological
and	CC	O
for	IN	O
intravenous	JJ	Pharmacological
(	(	Pharmacological
IV	NNP	Pharmacological
)	)	Pharmacological
over	IN	O
oral	JJ	Pharmacological
6-mercaptopurine	CD	Pharmacological
,	,	O
which	WDT	O
remain	VBP	O
to	TO	O
be	VB	O
validated	VBN	O
.	.	O

We	PRP	O
report	VBP	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
more	JJR	O
than	IN	O
1000	CD	O
subjects	NNS	O
that	WDT	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
dexamethasone	NN	Pharmacological
and	CC	O
IV	NNP	Pharmacological
6-mercaptopurine	JJ	Pharmacological
.	.	O

Children	NNP	O
with	IN	O
National	NNP	O
Cancer	NNP	O
Institute	NNP	O
standard-risk	NN	O
ALL	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
in	IN	O
a	DT	O
2	CD	O
x	NN	O
2	CD	O
factorial	JJ	O
design	NN	O
to	TO	O
receive	VB	O
dexamethasone	NN	O
(	(	O
6	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
for	IN	O
28	CD	O
days	NNS	O
in	IN	O
induction	NN	O
,	,	O
plus	CC	Other
taper	NN	Other
,	,	O
compared	VBN	O
with	IN	O
prednisone	NN	Pharmacological
(	(	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
)	)	O
.	.	O

The	DT	O
second	JJ	O
randomized	JJ	O
assignment	NN	O
was	VBD	O
for	IN	O
daily	JJ	O
oral	JJ	O
or	CC	O
weekly	JJ	O
IV	NNP	Pharmacological
6-mercaptopurine	NN	Pharmacological
during	IN	O
consolidation	NN	O
.	.	O

During	IN	O
maintenance	NN	O
,	,	O
5	CD	O
days	NNS	O
of	IN	O
the	DT	O
randomized	JJ	O
steroid	NN	O
was	VBD	O
given	VBN	O
monthly	RB	O
,	,	O
at	IN	O
the	DT	O
same	JJ	O
dose	NN	O
,	,	O
and	CC	O
all	DT	O
patients	NNS	O
received	VBD	O
daily	JJ	O
oral	JJ	Pharmacological
6-mercaptopurine	JJ	Pharmacological
.	.	O

During	IN	O
delayed	JJ	O
intensification	NN	O
,	,	O
all	DT	O
patients	NNS	O
received	VBD	O
a	DT	O
dexamethasone	JJ	Pharmacological
dosage	NN	O
of	IN	O
10	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
/d	NN	O
for	IN	O
21	CD	O
days	NNS	O
,	,	O
with	IN	Other
taper	NN	Other
.	.	O

Intrathecal	NNP	Pharmacological
(	(	Pharmacological
IT	NNP	Pharmacological
)	)	Pharmacological
methotrexate	NN	Pharmacological
was	VBD	O
the	DT	O
sole	JJ	O
central	JJ	O
nervous	JJ	O
system-directed	JJ	O
therapy	NN	O
.	.	O

Patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
dexamethasone	NN	Pharmacological
had	VBD	O
a	DT	O
6-year	JJ	O
isolated	JJ	O
central	JJ	O
nervous	JJ	O
system-relapse	JJ	O
rate	NN	O
of	IN	O
3.7	CD	O
%	NN	O
+/-	JJ	O
0.8	CD	O
%	NN	O
,	,	O
compared	VBN	O
with	IN	O
7.1	CD	O
%	NN	O
+/-	JJ	O
1.1	CD	O
%	NN	O
for	IN	O
prednisone	NN	Pharmacological
(	(	O
P	NNP	O
=.01	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
a	DT	O
trend	NN	O
toward	IN	O
fewer	JJR	O
isolated	JJ	O
bone	NN	O
marrow	NN	O
relapses	VBZ	O
with	IN	O
dexamethasone	NN	Pharmacological
.	.	O

The	DT	O
6-year	JJ	O
event-free	JJ	O
survival	NN	O
(	(	O
EFS	NNP	O
)	)	O
was	VBD	O
85	CD	O
%	NN	O
+/-	JJ	O
2	CD	O
%	NN	O
for	IN	O
dexamethasone	NN	Pharmacological
and	CC	O
77	CD	O
%	NN	O
+/-	JJ	O
2	CD	O
%	NN	O
for	IN	O
prednisone	NN	Pharmacological
(	(	O
P	NNP	O
=.002	NNP	O
)	)	O
.	.	O

EFS	NNP	O
was	VBD	O
similar	JJ	O
with	IN	O
oral	JJ	Pharmacological
or	CC	Pharmacological
IV	JJ	Pharmacological
6-mercaptopurine	JJ	Pharmacological
;	:	O
however	RB	O
,	,	O
patients	NNS	O
assigned	VBD	O
to	TO	O
IV	NNP	Pharmacological
6-mercaptopurine	JJ	Pharmacological
had	VBD	O
decreased	VBN	O
survival	NN	O
after	IN	O
relapse	NN	O
.	.	O

Virtual	JJ	Psychological
reality	NN	Psychological
hypnosis	NN	Psychological
for	IN	O
pain	NN	O
associated	VBN	O
with	IN	O
recovery	NN	O
from	IN	O
physical	JJ	O
trauma	NN	O
.	.	O

Pain	VB	O
following	VBG	O
traumatic	JJ	O
injuries	NNS	O
is	VBZ	O
common	JJ	O
,	,	O
can	MD	O
impair	VB	O
injury	JJ	O
recovery	NN	O
and	CC	O
is	VBZ	O
often	RB	O
inadequately	RB	O
treated	VBN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
role	NN	O
of	IN	O
adjunctive	JJ	O
nonpharmacologic	JJ	Educational
analgesic	JJ	Educational
techniques	NNS	Educational
is	VBZ	O
unclear	JJ	O
.	.	O

The	DT	O
authors	NNS	O
report	VBP	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBD	O
study	NN	O
of	IN	O
21	CD	O
hospitalized	JJ	O
trauma	NN	O
patients	NNS	O
to	TO	O
assess	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
virtual	JJ	Psychological
reality	NN	Psychological
hypnosis	NN	Psychological
(	(	Psychological
VRH	NNP	Psychological
)	)	Psychological
-hypnotic	JJ	Psychological
induction	NN	Psychological
and	CC	O
analgesic	JJ	O
suggestion	NN	O
delivered	VBN	O
by	IN	O
customized	JJ	O
virtual	JJ	O
reality	NN	O
(	(	O
VR	NNP	O
)	)	O
hardware/software	NN	O
.	.	O

Subjective	JJ	O
pain	NN	O
ratings	NNS	O
were	VBD	O
obtained	VBN	O
immediately	RB	O
and	CC	O
8	CD	O
hours	NNS	O
after	IN	O
VRH	NNP	O
(	(	O
used	VBN	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
standard	VB	O
analgesic	JJ	O
care	NN	O
)	)	O
and	CC	O
compared	VBN	O
to	TO	O
both	DT	O
adjunctive	JJ	O
VR	NNP	O
without	IN	O
hypnosis	NN	O
and	CC	O
standard	JJ	O
care	NN	O
alone	RB	O
.	.	O

VRH	JJ	O
patients	NNS	O
reported	VBD	O
less	RBR	O
pain	JJ	O
intensity	NN	O
and	CC	O
less	JJR	O
pain	NN	O
unpleasantness	JJ	O
compared	VBN	O
to	TO	O
control	VB	O
groups	NNS	O
.	.	O

These	DT	O
preliminary	JJ	O
findings	NNS	O
suggest	VBP	O
that	IN	O
VRH	NNP	Psychological
analgesia	NN	O
is	VBZ	O
a	DT	O
novel	JJ	O
technology	NN	O
worthy	NN	O
of	IN	O
further	JJ	O
study	NN	O
,	,	O
both	DT	O
to	TO	O
improve	VB	O
pain	NN	O
management	NN	O
and	CC	O
to	TO	O
increase	VB	O
availability	NN	O
of	IN	O
hypnotic	JJ	O
analgesia	NN	O
to	TO	O
populations	NNS	O
without	IN	O
access	NN	O
to	TO	O
therapist-provided	JJ	O
hypnosis	NN	O
and	CC	O
suggestion	NN	O
.	.	O

Double-blind	NNP	O
,	,	O
placebo-controlled	JJ	Control
study	NN	O
of	IN	O
L-carnosine	NNP	Pharmacological
supplementation	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

L-Carnosine	NNP	Pharmacological
,	,	O
a	DT	O
dipeptide	NN	Pharmacological
,	,	O
can	MD	O
enhance	VB	O
frontal	JJ	O
lobe	NN	O
function	NN	O
or	CC	O
be	VB	O
neuroprotective	JJ	O
.	.	O

It	PRP	O
can	MD	O
also	RB	O
correlate	VB	O
with	IN	O
gamma-aminobutyric	JJ	O
acid	NN	O
(	(	O
GABA	NNP	O
)	)	O
-homocarnosine	NN	O
interaction	NN	O
,	,	O
with	IN	O
possible	JJ	O
anticonvulsive	JJ	O
effects	NNS	O
.	.	O

We	PRP	O
investigated	VBD	O
31	CD	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
in	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blinded	JJ	O
study	NN	O
to	TO	O
determine	VB	O
if	IN	O
800	CD	O
mg	JJ	O
L-carnosine	JJ	Pharmacological
daily	NN	O
would	MD	O
result	VB	O
in	IN	O
observable	JJ	O
changes	NNS	O
versus	VBP	O
placebo	NN	Control
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
Expressive	NNP	O
and	CC	O
Receptive	NNP	O
One-Word	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
tests	NNS	O
,	,	O
and	CC	O
Clinical	NNP	O
Global	NNP	O
Impressions	NNP	O
of	IN	O
Change	NNP	O
.	.	O

Children	NNP	O
on	IN	O
placebo	NN	Control
did	VBD	O
not	RB	O
show	VB	O
statistically	RB	O
significant	JJ	O
changes	NNS	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
on	IN	O
L-carnosine	NNP	Pharmacological
,	,	O
children	NNS	O
showed	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
on	IN	O
the	DT	O
Gilliam	NNP	O
Autism	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
total	JJ	O
score	NN	O
and	CC	O
the	DT	O
Behavior	NNP	O
,	,	O
Socialization	NNP	O
,	,	O
and	CC	O
Communication	NNP	O
subscales	NNS	O
)	)	O
and	CC	O
the	DT	O
Receptive	JJ	O
One-Word	NNP	O
Picture	NNP	O
Vocabulary	NNP	O
test	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Improved	VBN	O
trends	NNS	O
were	VBD	O
noted	VBN	O
on	IN	O
other	JJ	O
outcome	JJ	O
measures	NNS	O
.	.	O

Although	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
L-carnosine	NNP	Pharmacological
is	VBZ	O
not	RB	O
well	RB	O
understood	RB	O
,	,	O
it	PRP	O
may	MD	O
enhance	VB	O
neurologic	JJ	O
function	NN	O
,	,	O
perhaps	RB	O
in	IN	O
the	DT	O
enterorhinal	JJ	O
or	CC	O
temporal	JJ	O
cortex	NN	O
.	.	O

Aerobic	NNP	Physical
exercise	NN	Physical
improves	VBZ	O
self-reported	JJ	O
sleep	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
insomnia	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
moderate	JJ	Physical
aerobic	JJ	Physical
physical	JJ	Physical
activity	NN	Physical
with	IN	O
sleep	JJ	O
hygiene	NN	O
education	NN	O
to	TO	O
improve	VB	O
sleep	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
chronic	JJ	O
insomnia	NN	O
.	.	O

METHODS	NNP	O
Seventeen	NNP	O
sedentary	JJ	O
adults	NNS	O
aged	VBN	O
>	JJ	O
or=55	CD	O
years	NNS	O
with	IN	O
insomnia	NN	O
(	(	O
mean	JJ	O
age	NN	O
61.6	CD	O
[	NN	O
SD?4.3	NNP	O
]	NNP	O
years	NNS	O
;	:	O
16	CD	O
female	NN	O
)	)	O
participated	VBD	O
in	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
comparing	VBG	O
16	CD	O
weeks	NNS	O
of	IN	O
aerobic	JJ	O
physical	JJ	O
activity	NN	O
plus	CC	O
sleep	JJ	O
hygiene	NN	O
to	TO	O
non-physical	JJ	O
activity	NN	O
plus	CC	O
sleep	JJ	O
hygiene	NN	O
.	.	O

Eligibility	NNP	O
included	VBD	O
primary	JJ	O
insomnia	NN	O
for	IN	O
at	IN	O
least	JJS	O
3	CD	O
months	NNS	O
,	,	O
habitual	JJ	O
sleep	NN	O
duration	NN	O
<	POS	O
6.5h	CD	O
and	CC	O
a	DT	O
Pittsburgh	NNP	O
Sleep	NNP	O
Quality	NNP	O
Index	NNP	O
(	(	O
PSQI	NNP	O
)	)	O
score	VBD	O
>	JJ	O
5	CD	O
.	.	O

Outcomes	NNS	O
included	VBD	O
sleep	JJ	O
quality	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
(	(	O
PSQI	NNP	O
,	,	O
Epworth	NNP	O
Sleepiness	NNP	O
Scale	NNP	O
[	NNP	O
ESS	NNP	O
]	NNP	O
,	,	O
Short-form	NNP	O
36	CD	O
[	NNP	O
SF-36	NNP	O
]	NNP	O
,	,	O
Center	NNP	O
for	IN	O
Epidemiological	NNP	O
Studies	NNPS	O
Depression	NNP	O
Scale	NNP	O
[	NNP	O
CES-D	NNP	O
]	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
physical	JJ	O
activity	NN	O
group	NN	O
improved	VBD	O
in	IN	O
sleep	JJ	O
quality	NN	O
on	IN	O
the	DT	O
global	JJ	O
PSQI	NNP	O
(	(	O
p	JJ	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
sleep	JJ	O
latency	NN	O
(	(	O
p=.049	NN	O
)	)	O
,	,	O
sleep	JJ	O
duration	NN	O
(	(	O
p=.04	NN	O
)	)	O
,	,	O
daytime	JJ	O
dysfunction	NN	O
(	(	O
p=.027	NN	O
)	)	O
,	,	O
and	CC	O
sleep	JJ	O
efficiency	NN	O
(	(	O
p=.036	NN	O
)	)	O
PSQI	NNP	O
sub-scores	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

The	DT	O
physical	JJ	O
activity	NN	O
group	NN	O
also	RB	O
had	VBD	O
reductions	NNS	O
in	IN	O
depressive	JJ	O
symptoms	NNS	O
(	(	O
p=.044	NN	O
)	)	O
,	,	O
daytime	JJ	O
sleepiness	NN	O
(	(	O
p=.02	NN	O
)	)	O
and	CC	O
improvements	NNS	O
in	IN	O
vitality	NN	O
(	(	O
p=.017	NN	O
)	)	O
compared	VBN	O
to	TO	O
baseline	VB	O
scores	NNS	O
.	.	O

CONCLUSION	NNP	O
Aerobic	NNP	O
physical	JJ	O
activity	NN	O
with	IN	O
sleep	JJ	O
hygiene	NN	O
education	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
approach	NN	O
to	TO	O
improve	VB	O
sleep	JJ	O
quality	NN	O
,	,	O
mood	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
older	JJR	O
adults	NNS	O
with	IN	O
chronic	JJ	O
insomnia	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
sublingual	JJ	Pharmacological
immunotherapy	NN	Pharmacological
for	IN	O
respiratory	NN	O
allergy	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
different	JJ	O
dosage	NN	O
regimens	NNS	O
in	IN	O
the	DT	O
induction	NN	O
phase	NN	O
.	.	O

BACKGROUND	NNP	O
Sublingual	NNP	Pharmacological
administration	NN	Pharmacological
of	IN	Pharmacological
allergens	NNS	Pharmacological
is	VBZ	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
alternative	NN	O
to	TO	O
subcutaneous	JJ	O
immunotherapy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
respiratory	JJ	O
allergies	NNS	O
.	.	O

A	DT	O
drawback	NN	O
to	TO	O
this	DT	O
therapeutic	JJ	O
approach	NN	O
is	VBZ	O
the	DT	O
relatively	RB	O
long	JJ	O
and	CC	O
complex	JJ	O
management	NN	O
of	IN	O
the	DT	O
induction	NN	O
phase	NN	O
.	.	O

AIM	NNP	O
OF	IN	O
THE	NNP	O
STUDY	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
different	JJ	O
induction	NN	O
regimens	NNS	O
affect	VBP	O
the	DT	O
outcome	NN	O
of	IN	O
sublingual	JJ	Pharmacological
immunotherapy	NN	Pharmacological
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Adult	NNP	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
with	IN	O
allergic	JJ	O
rhinoconjunctivitis	NN	O
and/or	NN	O
asthma	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Ten	CD	O
subjects	VBZ	O
served	VBN	O
as	IN	O
controls	NNS	O
and	CC	O
received	VBN	O
symptomatic	JJ	Control
treatments	NNS	Control
.	.	O

Forty-three	JJ	O
subjects	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
sublingual	JJ	Pharmacological
immunotherapy	NN	Pharmacological
,	,	O
with	IN	O
three	CD	O
different	JJ	O
induction	NN	O
protocols	NNS	O
(	(	O
8-	CD	O
,	,	O
15-	CD	O
and	CC	O
20-day	JJ	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Symptom	NNP	O
and	CC	O
medication	NN	O
scores	NNS	O
,	,	O
skin	JJ	O
test	NN	O
results	NNS	O
and	CC	O
(	(	O
in	IN	O
asthmatic	JJ	O
patients	NNS	O
)	)	O
FEV1	NNP	O
values	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
two	CD	O
years	NNS	O
.	.	O

Adverse	JJ	O
effects	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

All	DT	O
induction	NN	O
regimens	NNS	O
produced	VBD	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
symptom	NN	O
and	CC	O
medication	NN	O
usage	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
;	:	O
skin	JJ	O
test	NN	O
scores	NNS	O
decreased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
FEV1	NNP	O
improved	VBD	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
symptom	NN	O
and	CC	O
skin	JJ	O
test	NN	O
scores	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
change	VBP	O
in	IN	O
controls	NNS	O
.	.	O

No	DT	O
relevant	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
induction	NN	O
regimens	VBZ	O
.	.	O

CONCLUSIONS	NNP	O
For	IN	O
patients	NNS	O
with	IN	O
respiratory	JJ	O
allergies	NNS	O
,	,	O
sublingual	JJ	Pharmacological
immunotherapy	NN	Pharmacological
with	IN	O
an	DT	O
8-day	JJ	O
induction	NN	O
protocol	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
effective	JJ	O
.	.	O

Our	PRP$	O
results	NNS	O
encourage	VB	O
the	DT	O
usage	NN	O
of	IN	O
shorter	JJR	O
induction	NN	O
regimens	NNS	O
,	,	O
which	WDT	O
produce	VBP	O
better	JJR	O
compliance	NN	O
with	IN	O
this	DT	O
therapy	NN	O
.	.	O

Anti-angiogenic	JJ	O
effects	NNS	O
of	IN	O
epigallocatechin-3-gallate	NN	Pharmacological
in	IN	O
human	JJ	O
skin	NN	O
.	.	O

Epigallocatechin-3-gallate	NNP	Pharmacological
(	(	Pharmacological
EGCG	NNP	Pharmacological
)	)	Pharmacological
is	VBZ	O
the	DT	O
main	JJ	O
polyphenol	JJ	O
component	NN	O
of	IN	O
green	JJ	O
tea	NN	O
.	.	O

This	DT	O
compound	NN	O
exhibits	VBZ	O
antioxidant	JJ	O
,	,	O
immunomodulatory	JJ	O
,	,	O
photoprotective	JJ	O
,	,	O
anti-angiogenic	JJ	O
,	,	O
and	CC	O
anti-inflammatory	JJ	O
properties	NNS	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
small	JJ	O
randomized	NN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
split	VBD	O
face	NN	O
trial	NN	O
using	VBG	O
a	DT	O
cream	NN	Pharmacological
containing	VBG	Pharmacological
2.5	CD	Pharmacological
%	NN	Pharmacological
w/w	NN	Pharmacological
of	IN	Pharmacological
EGCG	NNP	Pharmacological
.	.	Pharmacological

Four	CD	O
healthy	JJ	O
volunteers	NNS	O
with	IN	O
significant	JJ	O
erythema	NN	O
and	CC	O
telangiectasia	NN	O
on	IN	O
the	DT	O
face	NN	O
applied	VBD	O
EGCG	NNP	Pharmacological
cream	NN	Pharmacological
to	TO	O
one	CD	O
side	NN	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
and	CC	O
vehicle	NN	Pharmacological
control	NN	Pharmacological
cream	NN	Pharmacological
to	TO	O
the	DT	O
other	JJ	O
,	,	O
twice	JJ	O
daily	RB	O
for	IN	O
six	CD	O
weeks	NNS	O
.	.	O

After	IN	O
six	CD	O
weeks	NNS	O
,	,	O
biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
EGCG	NNP	Pharmacological
and	CC	O
vehicle	NN	Other
treated	VBN	Other
sites	NNS	O
.	.	O

Immunohistochemistry	NN	O
was	VBD	O
used	VBN	O
to	TO	O
measure	VB	O
VEGF	NNP	O
and	CC	O
HIF-1	NNP	O
?.	NNP	O
HIF-1	NNP	O
?	.	O
expression	NN	O
was	VBD	O
decreased	VBN	O
in	IN	O
EGCG	NNP	O
treated	VBD	O
sites	NNS	O
,	,	O
such	JJ	O
that	IN	O
28.4	CD	O
%	NN	O
of	IN	O
the	DT	O
epidermis	NN	O
showed	VBD	O
positive	JJ	O
staining	NN	O
in	IN	O
vehicle	NN	O
treated	VBD	O
vs.	FW	O
13.8	CD	O
%	NN	O
in	IN	O
EGCG	NNP	O
treated	VBD	O
sites	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

A	DT	O
similar	JJ	O
decrease	NN	O
in	IN	O
VEGF	NNP	O
expression	NN	O
was	VBD	O
found	VBN	O
(	(	O
6.7	CD	O
%	NN	O
in	IN	O
EGCG	NNP	O
vs.	FW	O
11.0	CD	O
%	NN	O
in	IN	O
in	IN	O
vehicle-treated	JJ	O
skin	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

EGCG	NNP	O
topical	JJ	O
treatments	NNS	O
influence	VB	O
HIF-1	NNP	O
?	.	O
induction	NN	O
and	CC	O
VEGF	NNP	O
expression	NN	O
and	CC	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
potential	JJ	O
agent	NN	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
telangiectasias	NN	O
.	.	O

The	DT	O
treatment	NN	O
of	IN	O
senile	JJ	O
dementia	NN	O
associated	VBN	O
with	IN	O
cerebrovascular	JJ	O
insufficiency	NN	O
:	:	O
a	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
buflomedil	NN	Pharmacological
and	CC	O
dihydrogenated	VBD	Pharmacological
ergot	JJ	Pharmacological
alkaloids	NNS	Pharmacological
.	.	O

Seventy-six	JJ	O
patients	NNS	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
comparative	JJ	O
study	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
buflomedil	NN	Pharmacological
hydrochloride	NN	Pharmacological
and	CC	O
dihydrogenated	VBD	Pharmacological
ergot	JJ	Pharmacological
alkaloids	NNS	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
senile	JJ	O
dementia	NN	O
associated	VBN	O
with	IN	O
cerebrovascular	JJ	O
insufficiency	NN	O
.	.	O

Efficacy	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
'	POS	O
performance	NN	O
in	IN	O
four	CD	O
psychometric	JJ	O
tests	NNS	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
a	DT	O
trend	NN	O
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
buflomedil	NN	O
group	NN	O
in	IN	O
three	CD	O
of	IN	O
the	DT	O
tests	NNS	O
became	VBD	O
statistically	RB	O
significant	JJ	O
in	IN	O
the	DT	O
fourth	JJ	O
.	.	O

Both	DT	O
drugs	NNS	O
appeared	VBD	O
to	TO	O
be	VB	O
safe	JJ	O
,	,	O
causing	VBG	O
no	DT	O
marked	JJ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
buflomedil	NN	O
is	VBZ	O
as	IN	O
effective	JJ	O
or	CC	O
more	RBR	O
effective	JJ	O
than	IN	O
dihydrogenated	VBN	O
ergot	JJ	O
alkaloids	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
senile	JJ	O
dementia	NN	O
associated	VBN	O
with	IN	O
cerebrovascular	JJ	O
insufficiency	NN	O
and	CC	O
could	MD	O
prove	VB	O
a	DT	O
valuable	JJ	O
addition	NN	O
to	TO	O
long-term	JJ	O
therapy	NN	O
if	IN	O
further	JJ	O
studies	NNS	O
support	VBP	O
the	DT	O
trend	NN	O
shown	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
two	CD	Physical
different	JJ	Physical
testosterone	NN	Physical
undecanoate	JJ	Physical
formulations	NNS	Physical
in	IN	O
hypogonadal	JJ	O
men	NNS	O
with	IN	O
metabolic	JJ	O
syndrome	NN	O
.	.	O

AIM	NNP	O
To	TO	O
investigate	VB	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
two	CD	Physical
different	JJ	Physical
preparations	NNS	Physical
of	IN	Physical
testosterone	NN	Physical
undecanoate	NN	Physical
(	(	Physical
TU	NNP	Physical
)	)	Physical
in	IN	O
52	CD	O
hypogonadal	JJ	O
men	NNS	O
[	VBP	O
mean	JJ	O
age	NN	O
57	CD	O
yr	NN	O
and	CC	O
mean	VB	O
testosterone	NN	O
(	(	O
T	NNP	O
)	)	O
<	VBD	O
320	CD	O
ng/dl	JJ	O
]	NN	O
with	IN	O
metabolic	JJ	O
syndrome	NN	O
(	(	O
MS	NNP	O
)	)	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
double-dummy	JJ	O
study	NN	O
with	IN	O
three	CD	O
parallel	JJ	O
treatment	NN	O
arms	NNS	O
[	VBP	O
oral	JJ	O
TU	NNP	O
;	:	O
transdermal	JJ	Control
placebo	NN	Control
gel	NN	Control
(	(	O
P	NNP	O
)	)	O
;	:	O
im	JJ	O
TU	NNP	Pharmacological
]	NNP	O
administration	NN	O
for	IN	O
12	CD	O
months	NNS	O
(	(	O
mo	NN	O
)	)	O
.	.	O

Each	DT	O
subject	NN	O
was	VBD	O
randomized	VBN	O
(	(	O
1:1:3	CD	O
)	)	O
to	TO	O
receive	VB	O
either	DT	O
oral	JJ	Pharmacological
TU	NNP	Pharmacological
(	(	O
2	CD	O
capsules	NNS	O
of	IN	O
40	CD	O
mg/twice	NNS	O
per	IN	O
day	NN	O
at	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
,	,	O
equalling	VBG	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
160	CD	O
mg/day	NN	O
;	:	O
no.=10	CC	O
)	)	O
for	IN	O
6	CD	O
mo	NN	O
and	CC	O
continued	VBN	O
with	IN	O
im	JJ	O
TU	NNP	O
for	IN	O
further	JJ	O
6	CD	O
mo	NN	O
,	,	O
or	CC	O
P	NNP	Control
(	(	O
3-4	JJ	O
g/day	NN	O
;	:	O
no.=10	CC	O
)	)	O
and	CC	O
im	JJ	Pharmacological
TU	NNP	Pharmacological
(	(	O
1000	CD	O
mg/12	NN	O
weeks	NNS	O
from	IN	O
week	NN	O
6	CD	O
;	:	O
no.=32	NNS	O
)	)	O
for	IN	O
12	CD	O
mo	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
6	CD	O
mo	NN	O
,	,	O
im	JJ	O
TU	NNP	Pharmacological
increased	VBD	O
T	NNP	O
and	CC	O
free-	JJ	O
T	NNP	O
levels	NNS	O
(	(	O
p	VB	O
<	RB	O
0.0001	CD	O
)	)	O
,	,	O
and	CC	O
improved	VBN	O
metabolic	JJ	O
parameters	NNS	O
[	VBP	O
reduction	NN	O
in	IN	O
Homeostasis	NNP	O
Model	NNP	O
Assessment	NNP	O
(	(	O
HOMA	NNP	O
)	)	O
index	NN	O
,	,	O
p	NN	O
<	VBD	O
0.0001	CD	O
;	:	O
waist	JJ	O
circumference	NN	O
and	CC	O
fat	JJ	O
mass	NN	O
,	,	O
p	NN	O
<	VBD	O
0.001	CD	O
,	,	O
respectively	RB	O
]	JJ	O
,	,	O
in	IN	O
International	NNP	O
Index	NNP	O
of	IN	O
Erectile	NNP	O
Function-5	NNP	O
and	CC	O
Aging	NNP	O
Males	NNP	O
'	POS	O
Symptoms	NNP	O
scores	NNS	O
(	(	O
p	VB	O
<	RB	O
0.01	CD	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

After	IN	O
12	CD	O
months	NNS	O
,	,	O
im	JJ	Pharmacological
TU	NNP	Pharmacological
produced	VBD	O
further	JJ	O
increases	NNS	O
in	IN	O
T	NNP	O
and	CC	O
free-	JJ	O
T	NNP	O
levels	NNS	O
(	(	O
p	VB	O
<	RB	O
0.0001	CD	O
)	)	O
and	CC	O
metabolic	JJ	O
parameters	NNS	O
(	(	O
reduction	NN	O
in	IN	O
HOMA-index	NNP	O
,	,	O
p	NN	O
<	VBD	O
0.0001	CD	O
;	:	O
waist	JJ	O
circumference	NN	O
p	NN	O
<	VBZ	O
0.0001	CD	O
;	:	O
fat	JJ	O
mass	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
major	JJ	O
adverse	JJ	O
event	NN	O
due	JJ	O
to	TO	O
T	NNP	O
treatment	NN	O
occurred	VBD	O
.	.	O

CONCLUSIONS	NNP	O
Clinical	NNP	O
efficacy	NN	O
of	IN	O
T	NNP	O
replacement	NN	O
therapy	NN	O
in	IN	O
hypogonadal	JJ	O
men	NNS	O
with	IN	O
MS	NNP	O
is	VBZ	O
reached	VBN	O
when	WRB	O
its	PRP$	O
plasmatic	JJ	O
levels	NNS	O
approach	VBP	O
into	IN	O
the	DT	O
medium-high	JJ	O
range	NN	O
of	IN	O
normality	NN	O
(	(	O
>	JJ	O
5	CD	O
ng/ml	NN	O
)	)	O
,	,	O
although	IN	O
subjective	JJ	O
threshold	JJ	O
values	NNS	O
may	MD	O
be	VB	O
different	JJ	O
.	.	O

Administration	NN	O
of	IN	O
im	JJ	O
TU	NNP	Pharmacological
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
oral	JJ	O
TU	NNP	O
to	TO	O
reach	VB	O
the	DT	O
target	NN	O
for	IN	O
T	NNP	O
levels	NNS	O
and	CC	O
to	TO	O
improve	VB	O
MS	NNP	O
parameters	NNS	O
.	.	O

TU	NNP	O
was	VBD	O
safe	JJ	O
over	IN	O
12	CD	O
months	NNS	O
and	CC	O
discontinuation	NN	O
rates	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
placebo	VB	Control
.	.	O

Long-term	JJ	O
treatment	NN	O
with	IN	O
atomoxetine	NN	Pharmacological
for	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
symptoms	NNS	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
an	DT	O
open-label	JJ	O
extension	NN	O
study	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
long-term	JJ	O
treatment	NN	O
with	IN	O
atomoxetine	NN	Pharmacological
for	IN	O
symptoms	NNS	O
of	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
88	CD	O
patients	NNS	O
6-17	JJ	O
years	NNS	O
of	IN	O
age	NN	O
,	,	O
with	IN	O
ADHD	NNP	O
and	CC	O
ASD	NNP	O
,	,	O
were	VBD	O
treated	VBN	O
with	IN	O
1.2	CD	O
mg/kg/day	JJ	O
atomoxetine	NN	Pharmacological
for	IN	O
20	CD	O
weeks	NNS	O
as	IN	O
follow-up	NN	O
of	IN	O
an	DT	O
8	CD	O
week	NN	O
double-blind	JJ	O
placebo-controlled	JJ	Control
period	NN	O
.	.	O

Primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
ADHD	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
ADHD-RS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
After	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
initial	JJ	O
treatment	NN	O
,	,	O
the	DT	O
mean	JJ	O
total	NN	O
,	,	O
inattention	NN	O
,	,	O
and	CC	O
hyperactivity-impulsivity	NN	O
ADHD-RS	NNP	O
further	RB	O
decreased	VBD	O
significantly	RB	O
from	IN	O
34.9	CD	O
to	TO	O
27.0	CD	O
for	IN	O
the	DT	O
total	JJ	O
ADHD-RS	NNP	O
,	,	O
from	IN	O
18.3	CD	O
to	TO	O
14.5	CD	O
for	IN	O
the	DT	O
ADHD-RS	NNP	O
inattention	NN	O
subscale	NN	O
,	,	O
and	CC	O
from	IN	O
16.5	CD	O
to	TO	O
12.6	CD	O
for	IN	O
the	DT	O
hyperactivity-impulsivity	JJ	O
subscale	NN	O
.	.	O

Adverse	JJ	O
events	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
tended	VBD	O
to	TO	O
diminish	VB	O
over	IN	O
time	NN	O
during	IN	O
continued	JJ	O
treatment	NN	O
,	,	O
especially	RB	O
regarding	VBG	O
nausea	NN	O
and	CC	O
fatigue	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
present	JJ	O
analysis	NN	O
suggest	NN	O
that	WDT	O
continued	VBD	O
treatment	NN	O
with	IN	O
atomoxetine	NN	Pharmacological
up	RB	O
to	TO	O
28	CD	O
weeks	NNS	O
further	RBR	O
improve	VB	O
ADHD	NNP	O
symptoms	NNS	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
while	IN	O
adverse	JJ	O
events	NNS	O
tend	VBP	O
to	TO	O
subside	VB	O
.	.	O

Future	JJ	O
studies	NNS	O
investigating	VBG	O
the	DT	O
long-term	JJ	O
efficacy	NN	O
of	IN	O
atomoxetine	NN	Pharmacological
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
should	MD	O
be	VB	O
randomized	VBN	O
and	CC	O
placebo	VB	O
controlled	VBN	O
.	.	O

This	DT	O
study	NN	O
has	VBZ	O
been	VBN	O
registered	VBN	O
in	IN	O
ClinicalTrials.gov	NNP	O
(	(	O
www.clinicaltrials.gov	NN	O
)	)	O
under	IN	O
registration	NN	O
number	NN	O
NCT00380692	NNP	O
.	.	O

Tomato	NNP	Pharmacological
paste	NN	Pharmacological
rich	JJ	Pharmacological
in	IN	Pharmacological
lycopene	JJ	Pharmacological
protects	NNS	O
against	IN	O
cutaneous	JJ	O
photodamage	NN	O
in	IN	O
humans	NNS	O
in	IN	O
vivo	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Previous	NNP	O
epidemiological	JJ	O
,	,	O
animal	JJ	O
and	CC	O
human	JJ	O
data	NNS	O
report	NN	O
that	IN	O
lycopene	NN	O
has	VBZ	O
a	DT	O
protective	JJ	O
effect	NN	O
against	IN	O
ultraviolet	NN	O
radiation	NN	O
(	(	O
UVR	NNP	O
)	)	O
-induced	VBD	O
erythema	NN	O
.	.	O

OBJECTIVES	IN	O
We	PRP	O
examined	VBD	O
whether	IN	O
tomato	NN	Pharmacological
paste	NN	Pharmacological
--	:	Pharmacological
rich	JJ	Pharmacological
in	IN	Pharmacological
lycopene	NN	Pharmacological
,	,	O
a	DT	O
powerful	JJ	O
antioxidant	NN	O
--	:	O
can	MD	O
protect	VB	O
human	JJ	O
skin	NN	O
against	IN	O
UVR-induced	JJ	O
effects	NNS	O
partially	RB	O
mediated	VBN	O
by	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
i.e	NN	O
.	.	O

erythema	NN	O
,	,	O
matrix	NN	O
changes	NNS	O
and	CC	O
mitochondrial	JJ	O
DNA	NNP	O
(	(	O
mtDNA	NN	O
)	)	O
damage	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
study	NN	O
,	,	O
20	CD	O
healthy	JJ	O
women	NNS	O
(	(	O
median	JJ	O
age	NN	O
33	CD	O
years	NNS	O
,	,	O
range	VBP	O
21-47	JJ	O
;	:	O
phototype	JJ	O
I/II	NNP	O
)	)	O
ingested	VBD	O
55	CD	Physical
g	NN	Physical
tomato	NN	Physical
paste	NN	Physical
(	(	Physical
16	CD	Physical
mg	RB	Physical
lycopene	NN	Physical
)	)	Physical
in	IN	Physical
olive	JJ	Physical
oil	NN	Physical
,	,	Physical
or	CC	Physical
olive	JJ	Physical
oil	NN	Physical
alone	RB	Physical
,	,	Physical
daily	JJ	Physical
for	IN	Physical
12	CD	Physical
weeks	NNS	Physical
.	.	Physical

Pre-	NNP	O
and	CC	O
postsupplementation	NN	O
,	,	O
UVR	NNP	O
erythemal	JJ	O
sensitivity	NN	O
was	VBD	O
assessed	VBN	O
visually	RB	O
as	IN	O
the	DT	O
minimal	JJ	O
erythema	NN	O
dose	NN	O
(	(	O
MED	NNP	O
)	)	O
and	CC	O
quantified	VBN	O
with	IN	O
a	DT	O
reflectance	NN	O
instrument	NN	O
.	.	O

Biopsies	NNS	O
were	VBD	O
taken	VBN	O
from	IN	O
unexposed	JJ	O
and	CC	O
UVR-exposed	JJ	O
(	(	O
3	CD	O
?	.	O
MED	NNP	O
24	CD	O
h	NN	O
earlier	RBR	O
)	)	O
buttock	NN	O
skin	JJ	O
pre-	NN	O
and	CC	O
postsupplementation	NN	O
,	,	O
and	CC	O
analysed	VBD	O
immunohistochemically	RB	O
for	IN	O
procollagen	NN	O
(	(	O
pC	NN	O
)	)	O
I	PRP	O
,	,	O
fibrillin-1	JJ	O
and	CC	O
matrix	JJ	O
metalloproteinase	NN	O
(	(	O
MMP	NNP	O
)	)	O
-1	NN	O
,	,	O
and	CC	O
by	IN	O
quantitative	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
for	IN	O
mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
.	.	O

RESULTS	VB	O
Mean	NNP	O
?	.	O
SD	NNP	O
erythemal	JJ	O
D	NNP	O
(	(	O
30	CD	O
)	)	O
was	VBD	O
significantly	RB	O
higher	JJR	O
following	VBG	O
tomato	JJ	O
paste	NN	O
vs.	FW	O
control	NN	O
(	(	O
baseline	NN	O
,	,	O
26?5	CD	O
?	.	O
7?5	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
23	CD	O
?	.	O
6?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
36?6	CD	O
?	.	O
14?7	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
MED	NNP	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
between	IN	O
groups	NNS	O
(	(	O
baseline	NN	O
,	,	O
35?1	CD	O
?	.	O
9?9	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
control	NN	O
,	,	O
32?6	CD	O
?	.	O
9?6	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
;	:	O
tomato	CC	O
paste	NN	O
,	,	O
42?2	CD	O
?	.	O
11?3	CD	O
mJ	NN	O
cm	NN	O
(	(	O
-2	NNP	O
)	)	O
)	)	O
.	.	O

Presupplementation	NN	O
,	,	O
UVR	NNP	O
induced	VBD	O
an	DT	O
increase	NN	O
in	IN	O
MMP-1	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?03	CD	O
)	)	O
.	.	O

Postsupplementation	NN	O
,	,	O
UVR-induced	JJ	O
MMP-1	NNP	O
was	VBD	O
reduced	VBN	O
in	IN	O
the	DT	O
tomato	NN	O
paste	NN	O
vs.	FW	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?04	CD	O
)	)	O
,	,	O
while	IN	O
the	DT	O
UVR-induced	JJ	O
reduction	NN	O
in	IN	O
fibrillin-1	NN	O
was	VBD	O
similarly	RB	O
abrogated	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
pCI	JJ	O
deposition	NN	O
was	VBD	O
seen	VBN	O
following	VBG	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?05	CD	O
)	)	O
.	.	O

mtDNA	JJ	O
3895-bp	JJ	O
deletion	NN	O
following	VBG	O
3	CD	O
?	.	O
MED	NNP	O
UVR	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
postsupplementation	NN	O
with	IN	O
tomato	JJ	O
paste	NN	O
(	(	O
P	NNP	O
=	NNP	O
0?01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Tomato	NNP	O
paste	NN	O
containing	VBG	O
lycopene	NNP	O
provides	VBZ	O
protection	NN	O
against	IN	O
acute	NN	O
and	CC	O
potentially	RB	O
longer-term	JJ	O
aspects	NNS	O
of	IN	O
photodamage	NN	O
.	.	O

Ultrasonography-guided	JJ	Physical
bilateral	JJ	Physical
rectus	NN	Physical
sheath	NN	Physical
block	NN	Physical
vs	NN	O
local	JJ	Physical
anesthetic	JJ	Physical
infiltration	NN	Physical
after	IN	O
pediatric	JJ	O
umbilical	JJ	O
hernia	NN	O
repair	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

IMPORTANCE	NNP	O
Regional	NNP	Pharmacological
anesthetic	JJ	Pharmacological
techniques	NNS	Pharmacological
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
alleviate	VB	O
postoperative	JJ	O
pain	NN	O
in	IN	O
children	NNS	O
undergoing	VBG	O
pediatric	JJ	O
surgical	JJ	O
procedures	NNS	O
.	.	O

Use	NNP	O
of	IN	O
ultrasonographic	JJ	O
guidance	NN	O
for	IN	O
bilateral	JJ	O
rectus	NN	O
sheath	NN	O
block	NN	O
(	(	O
BRSB	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
improve	VB	O
immediate	JJ	O
pain	NN	O
scores	NNS	O
and	CC	O
reduce	VB	O
use	NN	O
of	IN	O
postoperative	JJ	O
analgesia	NN	O
in	IN	O
the	DT	O
postanesthesia	NN	O
care	NN	O
unit	NN	O
(	(	O
PACU	NNP	O
)	)	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
efficacy	NN	O
of	IN	O
ultrasonography-guided	JJ	O
BRSB	NNP	O
and	CC	O
local	JJ	O
anesthetic	JJ	O
infiltration	NN	O
(	(	O
LAI	NNP	O
)	)	O
in	IN	O
providing	VBG	O
postoperative	JJ	O
analgesia	NN	O
after	IN	O
pediatric	JJ	O
umbilical	JJ	O
hernia	NN	O
repair	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
observer-blinded	JJ	O
,	,	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	CC	O
Tertiary-referral	JJ	O
urban	JJ	O
children	NNS	O
's	POS	O
hospital	NN	O
.	.	O

PARTICIPANTS	NNP	O
Eligible	JJ	O
children	NNS	O
3	CD	O
to	TO	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
undergoing	JJ	O
elective	JJ	O
umbilical	JJ	O
hernia	NN	O
repair	NN	O
from	IN	O
November	NNP	O
16	CD	O
,	,	O
2009	CD	O
,	,	O
through	IN	O
May	NNP	O
31	CD	O
,	,	O
2011	CD	O
.	.	O

INTERVENTIONS	NNP	O
Ropivacaine	NNP	Pharmacological
hydrochloride	NN	Pharmacological
administered	VBD	O
at	IN	O
the	DT	O
conclusion	NN	O
of	IN	O
surgery	NN	Surgical
as	IN	O
LAI	NNP	O
by	IN	O
the	DT	O
surgeon	NN	O
(	(	O
n	JJ	O
=	NNP	O
25	CD	O
)	)	O
or	CC	O
as	IN	O
ultrasonography-guided	JJ	O
BRSB	NNP	O
by	IN	O
the	DT	O
anesthesiologist	NN	O
(	(	O
n	JJ	O
=	NNP	O
27	CD	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOMES	NNP	O
AND	NNP	O
MEASURES	NNP	O
Scores	NNP	O
on	IN	O
the	DT	O
FACES	NNP	O
Pain	NNP	O
Rating	NNP	O
Scale	NNP	O
measured	VBD	O
at	IN	O
10-minute	JJ	O
intervals	NNS	O
and	CC	O
all	DT	O
use	NN	O
of	IN	O
analgesic	JJ	O
medications	NNS	O
in	IN	O
the	DT	O
PACU	NNP	O
.	.	O

RESULTS	NNP	O
Median	JJ	O
FACES	NNP	O
scores	NNS	O
in	IN	O
the	DT	O
PACU	NNP	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
BRSB	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
LAI	NNP	O
group	NN	O
at	IN	O
10	CD	O
minutes	NNS	O
(	(	O
0	CD	O
vs	RB	O
1	CD	O
;	:	O
P	NNP	O
=	NNP	O
.04	NNP	O
)	)	O
,	,	O
30	CD	O
minutes	NNS	O
(	(	O
0	CD	O
vs	RB	O
1	CD	O
;	:	O
P	NNP	O
=	NNP	O
.01	NNP	O
)	)	O
,	,	O
and	CC	O
40	CD	O
minutes	NNS	O
or	CC	O
later	RB	O
(	(	O
0	CD	O
vs	RB	O
1	CD	O
;	:	O
P	NNP	O
=	NNP	O
.03	NNP	O
)	)	O
.	.	O

Fewer	JJR	O
doses	NNS	O
of	IN	O
opioid	NN	O
and	CC	O
nonopioid	JJ	O
medications	NNS	O
were	VBD	O
given	VBN	O
to	TO	O
the	DT	O
BRSB	NNP	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
LAI	NNP	O
group	NN	O
(	(	O
5	CD	O
vs	RB	O
11	CD	O
doses	NNS	O
for	IN	O
opioids	NNS	O
;	:	O
5	CD	O
vs	NN	O
10	CD	O
for	IN	O
nonopioids	NNS	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
AND	CC	O
RELEVANCE	NNP	O
In	IN	O
the	DT	O
PACU	NNP	O
,	,	O
ultrasonography-guided	JJ	O
BRSB	NNP	O
after	IN	O
umbilical	JJ	O
hernia	NN	O
repair	NN	O
in	IN	O
children	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
lower	JJR	O
median	JJ	O
FACES	NNP	O
scores	NNS	O
and	CC	O
decreased	VBN	O
use	NN	O
of	IN	O
opioid	NN	O
and	CC	O
nonopioid	JJ	O
medications	NNS	O
compared	VBN	O
with	IN	O
LAI	NNP	O
.	.	O

Future	NNP	O
studies	NNS	O
could	MD	O
examine	VB	O
the	DT	O
use	NN	O
of	IN	O
longer-acting	JJ	O
anesthetic	JJ	O
agents	NNS	O
with	IN	O
ultrasonography-guided	JJ	O
BRSB	NNP	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
clinicaltrials.gov	NN	O
Identifier	NNP	O
:	:	O
NCT01015053	NN	O
.	.	O

Lung	NNP	O
function	NN	O
measurement	NN	O
in	IN	O
general	JJ	O
practice	NN	O
:	:	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
Escort	NNP	Pharmacological
spirometer	NN	Pharmacological
with	IN	O
the	DT	O
Micromed	NNP	Pharmacological
turbine	NN	Pharmacological
spirometer	NN	Pharmacological
and	CC	O
the	DT	O
mini-Wright	JJ	Pharmacological
peak	NN	Pharmacological
flow	NN	Pharmacological
meter	NN	Pharmacological
.	.	Pharmacological

It	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
new	JJ	O
types	NNS	O
of	IN	O
spirometer	NN	Pharmacological
for	IN	O
widespread	JJ	O
clinical	JJ	O
use	NN	O
are	VBP	O
pragmatically	RB	O
evaluated	VBN	O
in	IN	O
primary	JJ	O
care	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
measurements	NNS	O
taken	VBN	O
by	IN	O
a	DT	O
new	JJ	Physical
portable	JJ	Physical
Fleisch	NNP	Physical
pneumotachograph	NN	Pharmacological
spirometer	NN	Pharmacological
(	(	O
known	VBN	O
as	IN	O
the	DT	O
Escort	NNP	O
)	)	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
commonly	NN	O
used	VBN	O
mini-Wright	JJ	Pharmacological
peak	NN	Pharmacological
flow	NN	Pharmacological
meter	NN	Pharmacological
and	CC	O
the	DT	O
Micromed	NNP	Pharmacological
Pocket	NNP	Pharmacological
turbine	NN	Pharmacological
spirometer	NN	Pharmacological
.	.	Pharmacological

A	NNP	O
pragmatic	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
two	CD	O
phases	NNS	O
during	IN	O
routine	JJ	O
surgeries	NNS	O
at	IN	O
Aldermoor	NNP	O
Health	NNP	O
Centre	NNP	O
,	,	O
Southampton	NNP	O
.	.	O

Phase	NNP	O
I	PRP	O
compared	VBN	O
the	DT	O
new	JJ	Pharmacological
spirometer	NN	Pharmacological
with	IN	O
the	DT	O
mini-Wright	JJ	Physical
peak	NN	Physical
flow	NN	Physical
meter	NN	Physical
and	CC	O
Phase	NNP	O
2	CD	O
compared	VBN	O
the	DT	O
new	JJ	Pharmacological
spirometer	NN	Pharmacological
and	CC	O
the	DT	O
turbine	NN	Pharmacological
spirometer	NN	Pharmacological
.	.	Pharmacological

One	CD	O
hundred	VBD	O
patients	NNS	O
aged	VBN	O
5-88	CD	O
years	NNS	O
(	(	O
56	CD	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
chronic	JJ	O
respiratory	NN	O
complaints	NNS	O
and	CC	O
44	CD	O
patients	NNS	O
without	IN	O
)	)	O
entered	VBD	O
Phase	NNP	O
1	CD	O
,	,	O
and	CC	O
100	CD	O
patients	NNS	O
aged	VBN	O
6-82	JJ	O
years	NNS	O
(	(	O
62	CD	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
chronic	JJ	O
respiratory	NN	O
complaints	NNS	O
and	CC	O
38	CD	O
patients	NNS	O
without	IN	O
)	)	O
entered	VBD	O
Phase	NNP	O
2	CD	O
.	.	O

Each	DT	O
patient	NN	O
contributed	VBD	O
only	RB	O
once	RB	O
to	TO	O
each	DT	O
phase	NN	O
,	,	O
but	CC	O
some	DT	O
entered	VBD	O
both	DT	O
phases	NNS	O
on	IN	O
separate	JJ	O
occasions	NNS	O
.	.	O

Ninety-five	JJ	O
percent	NN	O
limits	NNS	O
of	IN	O
agreement	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
were	VBD	O
wide	JJ	O
for	IN	O
all	DT	O
comparisons	NNS	O
.	.	O

Graphical	JJ	O
plots	NNS	O
revealed	VBD	O
trends	NNS	O
towards	IN	O
higher	JJR	O
Escort	NN	O
values	NNS	O
as	IN	O
mean	NN	O
values	NNS	O
rose	VBD	O
compared	VBN	O
with	IN	O
both	DT	O
mini-Wright	JJ	O
and	CC	O
turbine	JJ	O
readings	NNS	O
for	IN	O
peak	JJ	O
expiratory	JJ	O
flow	NN	O
rate	NN	O
and	CC	O
forced	VBD	O
expiratory	JJ	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
.	.	O

Possible	JJ	O
over-reading	NN	O
of	IN	O
peak	JJ	O
expiratory	JJ	O
flow	NN	O
rate	NN	O
with	IN	O
the	DT	O
mini-Wright	JJ	Physical
meter	NN	Physical
at	IN	O
low	JJ	O
mean	NN	O
values	NNS	O
was	VBD	O
also	RB	O
seen	VBN	O
.	.	O

Readings	NNS	O
taken	VBN	O
with	IN	O
these	DT	O
different	JJ	O
types	NNS	O
of	IN	O
meter	NN	O
can	MD	O
not	RB	O
be	VB	O
interchanged	VBN	O
with	IN	O
confidence	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

The	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
the	DT	O
theoretically	RB	O
more	RBR	O
accurate	JJ	O
measures	NNS	O
of	IN	O
lung	NN	O
function	NN	O
produced	VBN	O
with	IN	O
the	DT	O
new	JJ	O
meter	NN	O
,	,	O
and	CC	O
indeed	RB	O
of	IN	O
spirometry	NN	O
itself	PRP	O
,	,	O
needs	VBZ	O
further	JJ	O
investigation	NN	O
.	.	O

Safety	NN	O
,	,	O
pharmacokinetics	NNS	O
and	CC	O
pharmocodynamics	NNS	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
in	IN	O
healthy	JJ	O
subjects	NNS	O
and	CC	O
asymptomatic	JJ	O
carriers	NNS	O
of	IN	O
the	DT	O
acute	JJ	O
intermittent	NN	O
porphyria	NNS	O
gene	NN	O
who	WP	O
have	VBP	O
increased	VBN	O
porphyrin	NN	O
precursor	NN	O
excretion	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
OBJECTIVE	NNP	O
Acute	NNP	O
intermittent	NN	O
porphyria	NN	O
is	VBZ	O
an	DT	O
autosomal	JJ	O
dominant	JJ	O
disorder	NN	O
caused	VBN	O
by	IN	O
deficient	JJ	O
activity	NN	O
of	IN	O
the	DT	O
third	JJ	O
enzyme	NN	O
in	IN	O
the	DT	O
haem	NN	O
biosynthetic	JJ	O
pathway	NN	O
,	,	O
porphobilinogen	NN	O
deaminase	NN	O
.	.	O

It	PRP	O
is	VBZ	O
characterised	VBN	O
by	IN	O
acute	NN	O
,	,	O
potentially	RB	O
life-threatening	JJ	O
neurological	JJ	O
attacks	NNS	O
that	WDT	O
are	VBP	O
precipitated	VBN	O
by	IN	O
various	JJ	O
drugs	NNS	O
,	,	O
reproductive	JJ	O
hormones	NNS	O
and	CC	O
other	JJ	O
factors	NNS	O
.	.	O

During	IN	O
acute	JJ	O
attacks	NNS	O
,	,	O
the	DT	O
porphyrin	JJ	O
precursors	NNS	O
5-aminolevulinic	JJ	O
acid	NN	O
and	CC	O
porphobilinogen	NN	O
accumulate	NN	O
and	CC	O
are	VBP	O
excreted	VBN	O
at	IN	O
high	JJ	O
concentrations	NNS	O
in	IN	O
the	DT	O
urine	NN	O
.	.	O

Current	JJ	O
treatment	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
glucose	JJ	O
loading	NN	O
and	CC	O
parenteral	JJ	O
haem	NN	O
replenishment	NN	O
,	,	O
which	WDT	O
reduce	VB	O
the	DT	O
accumulation	NN	O
of	IN	O
5-aminolevulinic	JJ	O
acid	NN	O
and	CC	O
porphobilinogen	NN	O
.	.	O

Recently	RB	O
,	,	O
a	DT	O
new	JJ	O
form	NN	O
of	IN	O
treatment	NN	O
based	VBN	O
on	IN	O
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
enzyme	JJ	Pharmacological
replacement	NN	Pharmacological
therapy	NN	Pharmacological
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
an	DT	O
acute	JJ	O
intermittent	NN	O
porphyria	NN	O
mouse	NN	O
model	NN	O
which	WDT	O
,	,	O
during	IN	O
phenobarbital	JJ	O
(	(	O
phenobarbitone	NN	O
)	)	O
induction	NN	O
of	IN	O
haem	JJ	O
biosynthesis	NN	O
,	,	O
mimics	VBZ	O
the	DT	O
biochemical	JJ	O
pattern	NN	O
of	IN	O
acute	JJ	O
porphyric	JJ	O
attacks	NNS	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
,	,	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
(	(	O
P	NNP	O
9808	CD	O
)	)	O
,	,	O
administered	VBN	O
to	TO	O
healthy	JJ	O
subjects	NNS	O
and	CC	O
asymptomatic	JJ	O
porphobilinogen	NN	O
deaminase-deficient	JJ	O
subjects	NNS	O
with	IN	O
high	JJ	O
concentrations	NNS	O
of	IN	O
porphobilinogen	NN	O
,	,	O
the	DT	O
substrate	NN	O
of	IN	O
porphobilinogen	NN	O
deaminase	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Forty	NNP	O
individuals	NNS	O
participated	VBD	O
in	IN	O
this	DT	O
two-part	JJ	O
study	NN	O
:	:	O
20	CD	O
asymptomatic	JJ	O
porphobilinogen	NN	O
deaminase-deficient	JJ	O
subjects	NNS	O
(	(	O
both	DT	O
male	NN	O
and	CC	O
female	NN	O
)	)	O
with	IN	O
>	NN	O
or	CC	O
=4	JJ	O
times	NNS	O
the	DT	O
upper	JJ	O
reference	NN	O
urinary	JJ	O
porphobilinogen	NN	O
level	NN	O
,	,	O
and	CC	O
20	CD	O
healthy	JJ	O
male	JJ	O
subjects	NNS	O
.	.	O

Four	CD	O
different	JJ	O
doses	NNS	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
were	VBD	O
studied	VBN	O
(	(	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
4	CD	O
mg/kg	NNS	O
bodyweight	VBN	O
)	)	O
.	.	O

Part	VB	O
A	NNP	O
included	VBD	O
12	CD	O
asymptomatic	JJ	O
porphobilinogen	NN	O
deaminase-deficient	JJ	O
subjects	NNS	O
,	,	O
and	CC	O
the	DT	O
enzyme	NN	O
was	VBD	O
administered	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
,	,	O
single-dose	JJ	O
design	NN	O
.	.	O

Part	NN	O
B	NNP	O
included	VBD	O
20	CD	O
asymptomatic	JJ	O
porphobilinogen	NN	O
deaminase-deficient	JJ	O
subjects	NNS	O
and	CC	O
20	CD	O
healthy	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
same	JJ	O
enzyme	NN	O
dosages	NNS	O
were	VBD	O
administered	VBN	O
as	IN	O
divided	JJ	O
doses	NNS	O
every	DT	O
12	CD	O
hours	NNS	O
for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
.	.	O

The	DT	O
washout	NN	O
period	NN	O
between	IN	O
Parts	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
was	VBD	O
2	CD	O
weeks	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
concentrations	NNS	O
of	IN	O
recombinant	JJ	O
human	JJ	O
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
and	CC	O
titres	NNS	O
of	IN	O
antibodies	NNS	O
against	IN	O
recombinant	JJ	O
human	JJ	O
porphobilinogen	NN	O
deaminase	NN	O
were	VBD	O
analysed	VBN	O
by	IN	O
ELISA	NNP	O
.	.	O

Plasma	NNP	O
porphobilinogen	NN	O
and	CC	O
5-aminolevulinic	JJ	O
acid	NN	O
concentrations	NNS	O
were	VBD	O
analysed	VBN	O
using	VBG	O
a	DT	O
novel	JJ	O
liquid	JJ	O
chromatography-tandem	JJ	O
mass	NN	O
spectrometry	NN	O
method	NN	O
.	.	O

Urinary	JJ	O
porphobilinogen	NN	O
,	,	O
5-aminolevulinic	JJ	O
acid	NN	O
and	CC	O
porphyrin	NN	O
concentrations	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
plasma	NN	O
porphyrin	NN	O
concentrations	NNS	O
,	,	O
were	VBD	O
analysed	VBN	O
using	VBG	O
standard	JJ	O
methods	NNS	O
.	.	O

The	DT	O
pharmacodynamic	JJ	O
effect	NN	O
of	IN	O
the	DT	O
enzyme	NN	O
was	VBD	O
studied	VBN	O
through	IN	O
changes	NNS	O
in	IN	O
plasma	NN	O
porphobilinogen	NN	O
concentrations	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Seven	JJ	O
subjects	NNS	O
(	(	O
four	CD	O
healthy	JJ	O
men	NNS	O
and	CC	O
three	CD	O
asymptomatic	JJ	O
porphobilinogen	NN	O
deaminase-deficient	JJ	O
subjects	NNS	O
)	)	O
developed	VBD	O
antibodies	NNS	O
against	IN	O
recombinant	JJ	O
human	JJ	Pharmacological
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
but	CC	O
did	VBD	O
not	RB	O
experience	VB	O
allergic	JJ	O
manifestations	NNS	O
.	.	O

The	DT	O
mean	JJ	O
elimination	NN	O
half-lives	NNS	O
of	IN	O
the	DT	O
highest	JJS	O
doses	NNS	O
of	IN	O
recombinant	JJ	O
human	JJ	Pharmacological
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
ranged	VBD	O
between	IN	O
1.7	CD	O
and	CC	O
2.5	CD	O
hours	NNS	O
for	IN	O
both	DT	O
healthy	JJ	O
men	NNS	O
and	CC	O
asymptomatic	JJ	O
porphobilinogen	NN	O
deaminase-deficient	JJ	O
subjects	NNS	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration-time	JJ	O
curve	NN	O
was	VBD	O
proportional	JJ	O
to	TO	O
the	DT	O
respective	JJ	O
dose	NN	O
.	.	O

In	IN	O
asymptomatic	JJ	O
porphobilinogen	NN	O
deaminase-deficient	JJ	O
subjects	NNS	O
,	,	O
plasma	NN	O
porphobilinogen	NN	O
concentrations	NNS	O
decreased	VBD	O
below	IN	O
measurable	JJ	O
levels	NNS	O
almost	RB	O
instantaneously	RB	O
after	IN	O
administration	NN	O
of	IN	O
any	DT	O
dose	NN	O
of	IN	O
the	DT	O
enzyme	NN	O
.	.	O

The	DT	O
effect	NN	O
lasted	VBD	O
for	IN	O
approximately	RB	O
2	CD	O
hours	NNS	O
,	,	O
after	IN	O
which	WDT	O
the	DT	O
plasma	NN	O
porphobilinogen	NN	O
concentration	NN	O
slowly	RB	O
increased	VBD	O
,	,	O
reaching	VBG	O
about	IN	O
70	CD	O
%	NN	O
of	IN	O
the	DT	O
initial	JJ	O
values	NNS	O
12	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
effect	NN	O
on	IN	O
plasma	NN	O
5-aminolevulinic	JJ	O
acid	NN	O
concentrations	NNS	O
,	,	O
and	CC	O
there	RB	O
was	VBD	O
a	DT	O
transitory	JJ	O
increment	NN	O
in	IN	O
porphyrin	JJ	O
concentrations	NNS	O
.	.	O

The	DT	O
corresponding	JJ	O
concentrations	NNS	O
of	IN	O
metabolites	NNS	O
in	IN	O
the	DT	O
urine	NN	O
reflected	VBD	O
the	DT	O
pattern	NN	O
observed	VBN	O
in	IN	O
the	DT	O
plasma	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
enzyme	JJ	Pharmacological
preparation	NN	Pharmacological
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
to	TO	O
administer	VB	O
and	CC	O
effective	JJ	O
for	IN	O
removal	NN	O
of	IN	O
the	DT	O
accumulated	JJ	O
metabolite	NN	O
porphobilinogen	NN	O
from	IN	O
plasma	NN	O
and	CC	O
urine	NN	O
.	.	O

The	DT	O
pharmacokinetic	JJ	O
profile	NN	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
porphobilinogen	NN	Pharmacological
deaminase	NN	Pharmacological
showed	VBD	O
dose	JJ	O
proportionality	NN	O
,	,	O
and	CC	O
the	DT	O
elimination	NN	O
half-life	NN	O
was	VBD	O
about	IN	O
2.0	CD	O
hours	NNS	O
for	IN	O
the	DT	O
two	CD	O
highest	JJS	O
doses	NNS	O
.	.	O

Thus	RB	O
,	,	O
clinical	JJ	O
grounds	NNS	O
were	VBD	O
established	VBN	O
for	IN	O
investigation	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
enzyme	NN	O
during	IN	O
periods	NNS	O
of	IN	O
overt	JJ	O
disease	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
intermittent	NN	O
porphyria	NN	O
.	.	O

Visual	JJ	Educational
and	CC	Educational
kinesthetic	JJ	Educational
locomotor	NN	Educational
imagery	NN	Educational
training	NN	Educational
integrated	VBN	O
with	IN	O
auditory	JJ	Educational
step	NN	Educational
rhythm	NN	Educational
for	IN	O
walking	VBG	O
performance	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
stroke	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effect	NN	O
of	IN	O
visual	JJ	Educational
and	CC	Educational
kinesthetic	JJ	Educational
locomotor	NN	Educational
imagery	NN	Educational
training	NN	Educational
on	IN	O
walking	VBG	O
performance	NN	O
and	CC	O
to	TO	O
determine	VB	O
the	DT	O
clinical	JJ	O
feasibility	NN	O
of	IN	O
incorporating	VBG	O
auditory	JJ	Educational
step	NN	Educational
rhythm	NN	Educational
into	IN	O
the	DT	O
training	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
crossover	NN	O
trial	NN	O
.	.	O

SETTING	NNP	O
Laboratory	NNP	O
of	IN	O
a	DT	O
Department	NNP	O
of	IN	O
Physical	NNP	O
Therapy	NNP	O
.	.	O

SUBJECTS	NNP	O
Fifteen	NNP	O
subjects	VBZ	O
with	IN	O
post-stroke	JJ	O
hemiparesis	NN	O
.	.	O

INTERVENTION	NNP	O
Four	NNP	O
locomotor	NN	Educational
imagery	NN	Educational
trainings	NNS	Educational
on	IN	O
walking	VBG	O
performance	NN	O
:	:	O
visual	JJ	Educational
locomotor	NN	Educational
imagery	NN	Educational
training	NN	Educational
,	,	Educational
kinesthetic	JJ	Educational
locomotor	NN	Educational
imagery	NN	Educational
training	NN	Educational
,	,	Educational
visual	JJ	Educational
locomotor	NN	Educational
imagery	NN	Educational
training	NN	Educational
with	IN	Educational
auditory	JJ	Educational
step	NN	Educational
rhythm	NN	Educational
and	CC	Educational
kinesthetic	JJ	Educational
locomotor	NN	Educational
imagery	NN	Educational
training	NN	Educational
with	IN	Educational
auditory	JJ	Educational
step	NN	Educational
rhythm	NN	Educational
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
timed	JJ	O
up-and-go	JJ	O
test	NN	O
and	CC	O
electromyographic	JJ	O
and	CC	O
kinematic	JJ	O
analyses	NNS	O
of	IN	O
the	DT	O
affected	JJ	O
lower	JJR	O
limb	NN	O
during	IN	O
one	CD	O
gait	NN	O
cycle	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
the	DT	O
interventions	NNS	O
,	,	O
significant	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
the	DT	O
timed	JJ	O
up-and-go	JJ	O
test	NN	O
results	NNS	O
between	IN	O
the	DT	O
visual	JJ	Educational
locomotor	NN	Educational
imagery	NN	Educational
training	NN	Educational
(	(	O
25.69	CD	O
?	.	O
16.16	CD	O
to	TO	O
23.97	CD	O
?	.	O
14.30	CD	O
)	)	O
and	CC	O
the	DT	O
kinesthetic	JJ	O
locomotor	NN	O
imagery	NN	O
training	NN	O
with	IN	O
auditory	JJ	O
step	NN	O
rhythm	NN	O
(	(	O
22.68	CD	O
?	.	O
12.35	CD	O
to	TO	O
15.77	CD	O
?	.	O
8.58	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

During	IN	O
the	DT	O
swing	NN	O
and	CC	O
stance	NN	O
phases	NNS	O
,	,	O
the	DT	O
kinesthetic	JJ	O
locomotor	NN	O
imagery	NN	O
training	NN	O
exhibited	VBN	O
significantly	RB	O
increased	VBN	O
activation	NN	O
in	IN	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
muscles	NNS	O
and	CC	O
increased	VBD	O
angular	JJ	O
displacement	NN	O
of	IN	O
the	DT	O
knee	NN	O
and	CC	O
ankle	NN	O
joints	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
visual	JJ	O
locomotor	NN	O
imagery	NN	O
training	NN	O
,	,	O
and	CC	O
these	DT	O
effects	NNS	O
were	VBD	O
more	RBR	O
prominent	JJ	O
when	WRB	O
auditory	JJ	O
step	NN	O
rhythm	NN	O
was	VBD	O
integrated	VBN	O
into	IN	O
each	DT	O
form	NN	O
of	IN	O
locomotor	NN	O
imagery	NN	O
training	NN	O
.	.	O

The	DT	O
activation	NN	O
of	IN	O
the	DT	O
hamstring	NN	O
during	IN	O
the	DT	O
swing	JJ	O
phase	NN	O
and	CC	O
the	DT	O
gastrocnemius	NN	O
during	IN	O
the	DT	O
stance	NN	O
phase	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
kinematic	JJ	O
data	NNS	O
of	IN	O
the	DT	O
knee	NN	O
joint	NN	O
,	,	O
were	VBD	O
significantly	RB	O
different	JJ	O
for	IN	O
posttest	JJS	O
values	NNS	O
between	IN	O
the	DT	O
visual	JJ	O
locomotor	NN	O
imagery	NN	O
training	NN	O
and	CC	O
the	DT	O
kinesthetic	JJ	O
locomotor	NN	O
imagery	NN	O
training	NN	O
with	IN	O
auditory	JJ	O
step	NN	O
rhythm	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
therapeutic	JJ	O
effect	NN	O
may	MD	O
be	VB	O
further	RB	O
enhanced	VBN	O
in	IN	O
the	DT	O
kinesthetic	JJ	O
locomotor	NN	O
imagery	NN	O
training	NN	O
than	IN	O
in	IN	O
the	DT	O
visual	JJ	O
locomotor	NN	O
imagery	NN	O
training	NN	O
.	.	O

The	DT	O
auditory	JJ	O
step	NN	O
rhythm	VBZ	O
together	RB	O
with	IN	O
the	DT	O
locomotor	NN	O
imagery	NN	O
training	NN	O
produces	VBZ	O
a	DT	O
greater	JJR	O
positive	JJ	O
effect	NN	O
in	IN	O
improving	VBG	O
the	DT	O
walking	VBG	O
performance	NN	O
of	IN	O
patients	NNS	O
with	IN	O
post-stroke	JJ	O
hemiparesis	NN	O
.	.	O

The	DT	O
competition	NN	O
between	IN	O
enamel	NN	O
and	CC	O
dentin	NN	O
adhesion	NN	O
within	IN	O
a	DT	O
cavity	NN	O
:	:	O
an	DT	O
in	IN	O
vitro	JJ	O
evaluation	NN	O
of	IN	O
class	NN	O
V	NNP	O
restorations	NNS	O
.	.	O

To	TO	O
gain	VB	O
more	JJR	O
insight	NN	O
into	IN	O
the	DT	O
consequences	NNS	O
of	IN	O
curing	VBG	O
contraction	NN	O
within	IN	O
the	DT	O
tooth	JJ	O
cavity	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
margin	NN	O
behavior	NN	O
of	IN	O
12	CD	O
contemporary	JJ	O
restorative	JJ	O
systems	NNS	O
in	IN	O
class	NN	O
V	NNP	O
restorations	NNS	O
with	IN	O
margins	NNS	O
located	VBN	O
on	IN	O
enamel	NN	O
and	CC	O
dentin	NN	O
after	IN	O
mechanical	JJ	O
loading	NN	O
and	CC	O
water	NN	O
storage	NN	O
.	.	O

Mixed	JJ	O
class	NN	O
V	NNP	O
cavities	NNS	O
were	VBD	O
prepared	VBN	O
on	IN	O
extracted	JJ	O
human	JJ	O
molars	NNS	O
and	CC	O
restored	VBD	O
using	VBG	O
five	CD	Physical
etch	NN	Physical
and	CC	Physical
rinse	NN	Physical
and	CC	O
seven	CD	Physical
self-etch	JJ	Physical
adhesive	JJ	Physical
systems	NNS	Physical
with	IN	O
their	PRP$	O
corresponding	NN	O
composites	NNS	O
.	.	O

Marginal	JJ	O
adaptation	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
using	VBG	O
a	DT	O
computer-assisted	JJ	O
quantitative	JJ	O
marginal	JJ	O
analysis	NN	O
in	IN	O
a	DT	O
scanning	NN	Physical
electron	NN	Physical
microscope	NN	Physical
(	(	O
SEM	NNP	O
)	)	O
on	IN	O
epoxy	JJ	O
replicas	NN	O
before	IN	O
,	,	O
after	IN	O
thermal	JJ	O
and	CC	O
mechanical	JJ	O
stressing	NN	O
and	CC	O
after	IN	O
1	CD	O
year	NN	O
of	IN	O
water	NN	O
storage	NN	O
.	.	O

The	DT	O
interactions	NNS	O
of	IN	O
testing	VBG	O
conditions	NNS	O
,	,	O
adhesive-composite	JJ	O
combination	NN	O
and	CC	O
tooth	JJ	O
substrate	NN	O
with	IN	O
marginal	JJ	O
adaptation	NN	O
were	VBD	O
evaluated	VBN	O
by	IN	O
two-way	JJ	O
ANOVA	NNP	O
.	.	O

Fatigue	NNP	O
,	,	O
stress	NN	O
and	CC	O
storage	NN	O
conditions	NNS	O
had	VBD	O
significant	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
marginal	JJ	O
adaptation	NN	O
.	.	O

Only	RB	O
two	CD	O
groups	NNS	O
(	(	O
Optibond	NNP	O
FL	NNP	O
and	CC	O
G	NNP	O
Bond	NNP	O
)	)	O
presented	VBD	O
equal	JJ	O
percentages	NNS	O
of	IN	O
marginal	JJ	O
adaptation	NN	O
on	IN	O
enamel	NN	O
and	CC	O
dentin	NN	O
;	:	O
in	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
degradation	NN	O
was	VBD	O
product	NN	O
dependent	NN	O
.	.	O

All	DT	O
materials	NNS	O
tested	VBN	O
showed	VBD	O
a	DT	O
distinct	JJ	O
behavior	NN	O
on	IN	O
enamel	NN	O
and	CC	O
dentin	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
mechanical	JJ	O
resistance	NN	O
and	CC	O
long-term	JJ	O
stability	NN	O
,	,	O
differences	NNS	O
within	IN	O
materials	NNS	O
also	RB	O
exist	VBP	O
in	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
simultaneously	RB	O
bond	NN	O
to	TO	O
enamel	VB	O
and	CC	O
dentin	VB	O
.	.	O

Implementing	VBG	O
a	DT	O
simplified	JJ	Educational
neonatal	JJ	Educational
resuscitation	NN	Educational
protocol-helping	JJ	Educational
babies	NNS	O
breathe	VBP	O
at	IN	O
birth	NN	O
(	(	O
HBB	NNP	O
)	)	O
-	:	O
at	IN	O
a	DT	O
tertiary	JJ	O
level	NN	O
hospital	NN	O
in	IN	O
Nepal	NNP	O
for	IN	O
an	DT	O
increased	JJ	O
perinatal	NN	O
survival	NN	O
.	.	O

BACKGROUND	NNP	O
Reducing	NNP	O
neonatal	JJ	O
death	NN	O
has	VBZ	O
been	VBN	O
an	DT	O
emerging	VBG	O
challenge	NN	O
in	IN	O
low	JJ	O
and	CC	O
middle	JJ	O
income	NN	O
countries	NNS	O
in	IN	O
the	DT	O
past	JJ	O
decade	NN	O
.	.	O

The	DT	O
development	NN	O
of	IN	O
the	DT	O
low	JJ	O
cost	NN	O
interventions	NNS	O
and	CC	O
their	PRP$	O
effective	JJ	O
delivery	NN	O
are	VBP	O
needed	VBN	O
to	TO	O
reduce	VB	O
deaths	NNS	O
from	IN	O
birth	NN	O
asphyxia	NN	O
.	.	O

This	DT	O
study	NN	O
will	MD	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
simplified	JJ	Educational
neonatal	JJ	Educational
resuscitation	NN	Educational
protocol	NN	Educational
provided	VBN	O
by	IN	O
Helping	VBG	O
Babies	NNS	O
Breathe	NNP	O
(	(	O
HBB	NNP	O
)	)	O
at	IN	O
a	DT	O
tertiary	JJ	O
hospital	NN	O
in	IN	O
Nepal	NNP	O
.	.	O

Perinatal	NNP	O
outcomes	NNS	O
and	CC	O
performance	NN	O
of	IN	O
skilled	JJ	O
birth	NN	O
attendants	NNS	O
on	IN	O
management	NN	O
of	IN	O
intrapartum-related	JJ	O
neonatal	JJ	O
hypoxia	NN	O
will	MD	O
be	VB	O
the	DT	O
main	JJ	O
measurements	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
The	DT	O
study	NN	O
will	MD	O
be	VB	O
carried	VBN	O
out	RP	O
at	IN	O
a	DT	O
tertiary	JJ	O
level	NN	O
maternity	NN	O
hospital	NN	O
in	IN	O
Nepal	NNP	O
.	.	O

A	DT	O
prospective	JJ	O
cohort-study	NN	O
will	MD	O
include	VB	O
a	DT	O
six-month	JJ	O
baseline	NN	O
a	DT	O
six	CD	O
month	NN	O
intervention	NN	O
period	NN	O
and	CC	O
a	DT	O
three-month	JJ	O
post	NN	O
intervention	NN	O
period	NN	O
.	.	O

A	DT	O
quality	NN	O
improvement	NN	O
process	NN	O
cycle	NN	O
will	MD	O
introduce	VB	O
the	DT	O
neonatal	JJ	O
resuscitation	NN	O
protocol	NN	O
.	.	O

A	DT	O
surveillance	NN	O
system	NN	O
,	,	O
including	VBG	O
CCD	NNP	Physical
cameras	NNS	Physical
and	CC	Educational
pulse	JJ	Physical
oximeters	NNS	Physical
,	,	O
will	MD	O
be	VB	O
set	VBN	O
up	RP	O
to	TO	O
evaluate	VB	O
the	DT	O
intervention	NN	O
.	.	O

DISCUSSION	NNP	O
Along	IN	O
with	IN	O
a	DT	O
technique	NN	O
to	TO	O
improve	VB	O
health	NN	O
workers	NNS	O
performance	NN	O
on	IN	O
the	DT	O
protocol	NN	O
,	,	O
the	DT	O
study	NN	O
will	MD	O
generate	VB	O
evidence	NN	O
on	IN	O
the	DT	O
research	NN	O
gap	NN	O
on	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
simplified	JJ	O
neonatal	JJ	O
resuscitation	NN	O
protocol	NN	O
on	IN	O
intrapartum	NN	O
outcome	NN	O
and	CC	O
early	JJ	O
neonatal	JJ	O
survival	NN	O
.	.	O

This	DT	O
will	MD	O
generate	VB	O
a	DT	O
global	JJ	O
interest	NN	O
and	CC	O
inform	NN	O
policymaking	NN	O
in	IN	O
relation	NN	O
to	TO	O
delivery	NN	O
care	NN	O
in	IN	O
all	DT	O
income	NN	O
settings	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ISRCTN97846009	NNP	O
.	.	O

Trachoma	NNP	O
prevalence	NN	O
and	CC	O
associated	VBN	O
risk	NN	O
factors	NNS	O
in	IN	O
the	DT	O
gambia	NN	O
and	CC	O
Tanzania	NNP	O
:	:	O
baseline	NN	O
results	NNS	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Blinding	NNP	O
trachoma	NN	O
,	,	O
caused	VBN	O
by	IN	O
ocular	JJ	O
infection	NN	O
with	IN	O
Chlamydia	NNP	O
trachomatis	NN	O
,	,	O
is	VBZ	O
targeted	VBN	O
for	IN	O
global	JJ	O
elimination	NN	O
by	IN	O
2020	CD	O
.	.	O

Knowledge	NNP	O
of	IN	O
risk	NN	O
factors	NNS	O
can	MD	O
help	VB	O
target	VB	O
control	JJ	O
interventions	NNS	O
.	.	O

METHODOLOGY/PRINCIPAL	NNP	O
FINDINGS	NNP	O
As	IN	O
part	NN	O
of	IN	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
the	DT	O
baseline	NN	O
prevalence	NN	O
of	IN	O
,	,	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
,	,	O
active	JJ	O
trachoma	NN	O
and	CC	O
ocular	JJ	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
randomly	RB	O
selected	VBN	O
children	NNS	O
aged	VBN	O
0-5	CD	O
years	NNS	O
from	IN	O
48	CD	O
Gambian	JJ	O
and	CC	O
36	CD	O
Tanzanian	JJ	O
communities	NNS	O
.	.	O

Both	DT	O
children	NNS	O
's	POS	O
eyes	NNS	O
were	VBD	O
examined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
(	(	O
WHO	NNP	O
)	)	O
simplified	VBD	O
grading	VBG	O
system	NN	O
,	,	O
and	CC	O
an	DT	Physical
ocular	JJ	Physical
swab	NN	Physical
was	VBD	Physical
taken	VBN	Physical
from	IN	Physical
each	DT	Physical
child	NN	Physical
's	POS	Physical
right	JJ	Physical
eye	NN	Physical
and	CC	Physical
processed	VBN	Physical
by	IN	Physical
Amplicor	NNP	Physical
polymerase	NN	Physical
chain	NN	Physical
reaction	NN	Physical
to	TO	Physical
test	VB	Physical
for	IN	Physical
the	DT	Physical
presence	NN	Physical
of	IN	Physical
C.	NNP	Physical
trachomatis	NN	O
DNA	NNP	O
.	.	O

Prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
was	VBD	O
6.7	CD	O
%	NN	O
(	(	O
335/5033	CD	O
)	)	O
in	IN	O
The	DT	O
Gambia	NNP	O
and	CC	O
32.3	CD	O
%	NN	O
(	(	O
1008/3122	CD	O
)	)	O
in	IN	O
Tanzania	NNP	O
.	.	O

The	DT	O
countries	NNS	O
'	POS	O
corresponding	VBG	O
Amplicor	NNP	O
positive	JJ	O
prevalences	NNS	O
were	VBD	O
0.8	CD	O
%	NN	O
and	CC	O
21.9	CD	O
%	NN	O
.	.	O

After	IN	O
adjustment	NN	O
,	,	O
risk	NN	O
factors	NNS	O
for	IN	O
follicular	JJ	O
trachoma	NN	O
(	(	O
TF	NNP	O
)	)	O
in	IN	O
both	DT	O
countries	NNS	O
were	VBD	O
ocular	JJ	O
or	CC	O
nasal	JJ	O
discharge	NN	O
,	,	O
a	DT	O
low	JJ	O
level	NN	O
of	IN	O
household	NN	O
head	NN	O
education	NN	O
,	,	O
and	CC	O
being	VBG	O
aged	VBN	O
?	.	O
1	CD	O
year	NN	O
.	.	O

Additional	NNP	O
risk	NN	O
factors	NNS	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
flies	NNS	O
on	IN	O
the	DT	O
child	NN	O
's	POS	O
face	NN	O
,	,	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
,	,	O
and	CC	O
crowding	NN	O
(	(	O
the	DT	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
household	NN	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
in	IN	O
Tanzania	NNP	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
for	IN	O
TF	NNP	O
,	,	O
with	IN	O
the	DT	O
exclusion	NN	O
of	IN	O
flies	NNS	O
and	CC	O
crowding	VBG	O
.	.	O

In	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
.	.	O

CONCLUSIONS/SIGNIFICANCE	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
although	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
active	JJ	O
trachoma	NN	O
and	CC	O
Amplicor	NNP	O
positives	NNS	O
were	VBD	O
very	RB	O
different	JJ	O
between	IN	O
the	DT	O
two	CD	O
countries	NNS	O
,	,	O
the	DT	O
risk	NN	O
factors	NNS	O
for	IN	O
active	JJ	O
trachoma	NN	O
were	VBD	O
similar	JJ	O
but	CC	O
those	DT	O
for	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
were	VBD	O
different	JJ	O
.	.	O

The	DT	O
lack	NN	O
of	IN	O
an	DT	O
association	NN	O
between	IN	O
being	VBG	O
Amplicor	NNP	O
positive	JJ	O
and	CC	O
TF	NNP	O
in	IN	O
The	DT	O
Gambia	NNP	O
highlights	VBZ	O
the	DT	O
poor	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
presence	NN	O
of	IN	O
trachoma	JJ	O
clinical	JJ	O
signs	NNS	O
and	CC	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
infection	NN	O
in	IN	O
this	DT	O
setting	NN	O
.	.	O

Only	RB	O
ocular	JJ	O
discharge	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
evidence	NN	O
of	IN	O
C.	NNP	O
trachomatis	NN	O
DNA	NN	O
in	IN	O
The	DT	O
Gambia	NNP	O
,	,	O
suggesting	VBG	O
that	IN	O
at	IN	O
this	DT	O
low	JJ	O
endemicity	NN	O
,	,	O
this	DT	O
may	MD	O
be	VB	O
the	DT	O
most	RBS	O
important	JJ	O
risk	NN	O
factor	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
NCT00792922	NNP	O
.	.	O

Effect	NN	O
of	IN	O
L-arginine	NNP	Pharmacological
or	CC	O
L-citrulline	JJ	Pharmacological
oral	JJ	Pharmacological
supplementation	NN	Pharmacological
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
right	JJ	O
ventricular	NN	O
function	NN	O
in	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
with	IN	O
preserved	JJ	O
ejection	NN	O
fraction	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
effect	NN	O
of	IN	O
L-arginine	NNP	Pharmacological
and	CC	O
L-citrulline	NNP	Pharmacological
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
right	JJ	O
ventricular	NN	O
function	NN	O
in	IN	O
heart	NN	O
failure	NN	O
patients	NNS	O
with	IN	O
preserved	JJ	O
ejection	NN	O
fraction	NN	O
(	(	O
HFpEF	NNP	O
)	)	O
is	VBZ	O
unknown	JJ	O
.	.	O

We	PRP	O
have	VBP	O
therefore	RB	O
evaluated	VBN	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
these	DT	O
aminoacids	NNS	O
in	IN	O
chronic	JJ	O
outstanding	JJ	O
and	CC	O
stable	JJ	O
patients	NNS	O
with	IN	O
HFpEF	NNP	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
All	NNP	O
patients	NNS	O
underwent	VBD	O
an	DT	O
echocardiogram	NN	Physical
and	CC	Physical
radioisotopic	NN	Physical
ventriculography	NN	Physical
rest/exercise	NN	Physical
,	,	O
and	CC	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
consecutive	JJ	O
manner	NN	O
to	TO	O
the	DT	O
L-arginine	NNP	Pharmacological
group	NN	Pharmacological
(	(	O
n	JJ	O
=	VBZ	O
15	CD	O
;	:	O
8	CD	O
g/day	NN	O
)	)	O
;	:	O
and	CC	O
the	DT	O
citrulline	NN	Pharmacological
malate	NN	Pharmacological
group	NN	Pharmacological
(	(	O
n	JJ	O
=	VBZ	O
15	CD	O
;	:	O
3	CD	O
g/day	NN	O
)	)	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
follow-up	NN	O
was	VBD	O
two	CD	O
months	NNS	O
.	.	O

The	DT	O
principal	JJ	O
echocardiographic	JJ	O
finding	NN	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	O
in	IN	O
pulmonary	JJ	O
artery	NN	O
pressure	NN	O
in	IN	O
the	DT	O
L-arginine	NNP	Pharmacological
(	(	O
56.3	CD	O
?	.	O
10	CD	O
vs	NN	O
44	CD	O
?	.	O
16.5	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
the	DT	O
citrulline	NN	O
(	(	O
56.67	CD	O
?	.	O
7.96	CD	O
vs	NN	O
47.67	CD	O
?	.	O
8.59	CD	O
mm	NN	O
Hg	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.05	CD	O
)	)	O
groups	NNS	O
.	.	O

Duration	NN	O
on	IN	O
treadmill	NN	O
and	CC	O
right	JJ	O
ventricular	NN	O
ejection	NN	O
fraction	NN	O
post	NN	O
exercise	NN	O
increased	VBD	O
,	,	O
while	IN	O
diastolic	JJ	O
and	CC	O
systolic	JJ	O
artery	NN	O
pressure	NN	O
decreased	VBN	O
significantly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
other	JJ	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Administration	NNP	O
of	IN	O
L-arginine	NNP	O
and	CC	O
citrulline	NN	O
to	TO	O
patients	NNS	O
with	IN	O
HFpEF	NNP	O
improved	VBD	O
right	JJ	O
ventricular	NN	O
function	NN	O
by	IN	O
increasing	VBG	O
right	JJ	O
ventricular	NN	O
ejection	NN	O
fraction	NN	O
,	,	O
and	CC	O
probably	RB	O
decreasing	VBG	O
systolic	JJ	O
pulmonary	JJ	O
artery	NN	O
pressure	NN	O
.	.	O

Assessing	VBG	O
drug	NN	O
use	NN	O
prevalence	NN	O
in	IN	O
the	DT	O
workplace	NN	O
:	:	O
a	DT	O
comparison	NN	O
of	IN	O
self-report	JJ	O
methods	NNS	O
and	CC	O
urinalysis	NN	O
.	.	O

A	DT	O
random	JJ	O
sample	NN	O
of	IN	O
800	CD	O
employees	NNS	O
of	IN	O
a	DT	O
steel	NN	O
manufacturing	VBG	O
company	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
self-report	JJ	Educational
methods	NNS	Educational
of	IN	O
assessing	VBG	O
illicit	JJ	O
drug	NN	O
use	NN	O
:	:	O
1	CD	O
)	)	O
Individual	NNP	Educational
interview	NN	Educational
in	IN	Educational
the	DT	Educational
workplace	NN	Educational
,	,	O
2	CD	O
)	)	O
group-administered	JJ	Educational
questionnaire	NN	Educational
in	IN	Educational
the	DT	Educational
workplace	NN	Educational
,	,	O
3	CD	O
)	)	O
telephone	NN	Educational
interview	NN	Educational
,	,	O
and	CC	O
4	CD	O
)	)	O
individual	JJ	Educational
interview	NN	Educational
off	IN	Educational
the	DT	Educational
worksite	NN	Educational
.	.	O

All	DT	O
621	CD	O
subjects	NNS	O
participating	VBG	O
in	IN	O
the	DT	O
research	NN	O
were	VBD	O
also	RB	O
tested	VBN	O
by	IN	O
urinalysis	NN	O
.	.	O

Rates	NNS	O
of	IN	O
drug	NN	O
use	IN	O
self-report	NN	O
were	VBD	O
highest	JJS	O
in	IN	O
the	DT	O
workplace	NN	O
interview	NN	O
condition	NN	O
and	CC	O
lowest	JJS	O
in	IN	O
the	DT	O
overall	JJ	O
group	NN	O
questionnaire	NN	O
condition	NN	O
.	.	O

Although	IN	O
the	DT	O
overall	JJ	O
prevalence	NN	O
rates	NNS	O
produced	VBN	O
by	IN	O
self-reports	NNS	O
and	CC	O
urinalysis	NN	O
were	VBD	O
similar	JJ	O
,	,	O
there	EX	O
was	VBD	O
little	JJ	O
concordance	NN	O
between	IN	O
urinalysis	NN	O
positives	NNS	O
and	CC	O
self-report	JJ	O
positives	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicated	VBD	O
that	IN	O
self-reports	NNS	O
and	CC	O
urinalysis	NN	O
are	VBP	O
complementary	JJ	O
methods	NNS	O
of	IN	O
drug	NN	O
use	NN	O
assessment	NN	O
,	,	O
and	CC	O
are	VBP	O
best	JJS	O
used	VBN	O
in	IN	O
combination	NN	O
.	.	O

Role	NNP	O
of	IN	O
angiotensin-converting	JJ	Physical
enzyme	NN	Physical
inhibitors	NNS	Physical
in	IN	O
early	JJ	O
antihypertensive	JJ	O
treatment	NN	O
in	IN	O
non-insulin	JJ	O
dependent	NN	O
diabetes	VBZ	O
mellitus	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
captopril	NN	Pharmacological
monotherapy	NN	Pharmacological
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
metabolism	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
placebo-controlled	JJ	Control
study	NN	O
in	IN	O
30	CD	O
non-insulin	JJ	O
dependent	NN	O
(	(	O
Type	NNP	O
II	NNP	O
)	)	O
diabetic	JJ	O
subjects	NNS	O
during	IN	O
a	DT	O
3-week	JJ	O
observation	NN	O
period	NN	O
(	(	O
run-in/drug	JJ	O
;	:	O
placebo/wash-out	NN	O
)	)	O
on	IN	O
a	DT	O
metabolic	JJ	O
ward	NN	O
.	.	O

Captopril	NNP	Pharmacological
significantly	RB	O
reduced	VBD	O
both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
154/90	CD	O
+/-	JJ	O
5/2	CD	O
vs.	FW	O
144/86	CD	O
+/-	JJ	O
4/3	CD	O
mmHg	NN	O
)	)	O
without	IN	O
major	JJ	O
side	NN	O
effects	NNS	O
.	.	O

Mean	JJ	O
run-in	JJ	O
postprandial	JJ	O
blood	NN	O
glucose	JJ	O
concentrations	NNS	O
were	VBD	O
also	RB	O
reduced	VBN	O
upon	IN	O
ACE-inhibition	NNP	O
(	(	O
9	CD	O
a.m.	RB	O
:	:	O
12.7	CD	O
+/-	JJ	O
0.4	CD	O
vs.	FW	O
11.1	CD	O
+/-	JJ	O
0.4	CD	O
mmol/l	NN	O
;	:	O
1	CD	O
p.m.	NN	O
:	:	O
11.0	CD	O
+/-	JJ	O
0.3	CD	O
vs.	FW	O
8.9	CD	O
+/-	JJ	O
0.3	CD	O
mmol/l	NN	O
;	:	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
,	,	O
while	IN	O
blood	NN	O
kinin	NN	O
concentrations	NNS	O
(	(	O
40.0	CD	O
+/-	JJ	O
2.5	CD	O
pmol/l	NN	O
)	)	O
were	VBD	O
approximately	RB	O
doubled	VBN	O
(	(	O
108.8	CD	O
+/-	JJ	O
23.5	CD	O
pmol/l	NN	O
;	:	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Body	NNP	O
mass	NN	O
index	NN	O
,	,	O
fasting	VBG	O
plasma	JJ	O
insulin	NN	O
,	,	O
serum	JJ	O
electrolyte	NN	O
pattern	NN	O
,	,	O
uric	JJ	O
acid	NN	O
,	,	O
white	JJ	O
blood	NN	O
count	NN	O
,	,	O
lipid	JJ	O
profile	NN	O
as	RB	O
well	RB	O
as	IN	O
hepatic	JJ	O
and	CC	O
renal	JJ	O
function	NN	O
parameters	NNS	O
remained	VBD	O
unaltered	JJ	O
throughout	IN	O
the	DT	O
observation	NN	O
period	NN	O
.	.	O

The	DT	O
data	NNS	O
are	VBP	O
in	IN	O
line	NN	O
with	IN	O
recent	JJ	O
experimental	JJ	O
studies	NNS	O
showing	VBG	O
a	DT	O
beneficial	JJ	O
metabolic	JJ	O
effect	NN	O
of	IN	O
captopril	NN	Pharmacological
in	IN	O
Type	NNP	O
II	NNP	O
diabetes	VBZ	O
.	.	O

ACE	NNP	Physical
inhibitors	NNS	Physical
might	MD	O
therefore	VB	O
become	JJ	O
first-line	JJ	O
drugs	NNS	O
in	IN	O
early	JJ	O
antihypertensive	JJ	O
intervention	NN	O
in	IN	O
Type	NNP	O
II	NNP	O
diabetic	JJ	O
patients	NNS	O
.	.	O

Dexamethasone	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depression	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
authors	NNS	O
'	POS	O
goal	NN	O
was	VBD	O
to	TO	O
assess	VB	O
dexamethasone	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depression	NN	O
.	.	O

METHOD	NNP	O
Thirty-seven	JJ	O
outpatients	NNS	O
(	(	O
11	CD	O
men	NNS	O
and	CC	O
26	CD	O
women	NNS	O
)	)	O
meeting	VBG	O
DSM-III-R	JJ	O
criteria	NNS	O
for	IN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
placebo	NN	Control
or	CC	O
4	CD	O
mg/day	NN	O
of	IN	O
oral	JJ	Pharmacological
dexamethasone	NN	Pharmacological
for	IN	O
4	CD	O
days	NNS	O
.	.	O

Baseline	NNP	O
Hamilton	NNP	O
depression	NN	O
scale	NN	O
scores	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
scores	NNS	O
obtained	VBN	O
14	CD	O
days	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
study	NN	O
medication	NN	O
.	.	O

Data	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
two-sample	JJ	O
t	NN	O
tests	NNS	O
,	,	O
chi-square	JJ	O
methods	NNS	O
,	,	O
and	CC	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
.	.	O

RESULTS	VB	O
Seven	NNP	O
(	(	O
37	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
19	CD	O
patients	NNS	O
given	VBN	O
dexamethasone	NN	O
but	CC	O
only	RB	O
one	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
18	CD	O
patients	NNS	O
given	VBN	O
placebo	NNS	O
responded	VBD	O
positively	RB	O
.	.	O

No	UH	O
adverse	JJ	O
events	NNS	O
or	CC	O
side	NN	O
effects	NNS	O
were	VBD	O
reported	VBN	O
,	,	O
and	CC	O
all	DT	O
patients	NNS	O
who	WP	O
entered	VBD	O
the	DT	O
study	NN	O
completed	VBD	O
it	PRP	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
brief	JJ	O
course	NN	O
of	IN	O
oral	JJ	O
dexamethasone	NN	Pharmacological
(	(	O
4	CD	O
days	NNS	O
)	)	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
placebo	NN	Control
within	IN	O
14	CD	O
days	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
depression	NN	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
of	IN	O
depressed	JJ	O
outpatients	NNS	O
.	.	O

Low	JJ	Physical
power	NN	Physical
laser	NN	Physical
therapy	NN	Physical
of	IN	O
shoulder	NN	O
tendonitis	NN	O
.	.	O

30	CD	O
patients	NNS	O
with	IN	O
supraspinatus	NN	O
or	CC	O
bicipital	JJ	O
tendonitis	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
active	JJ	Physical
infrared	VBN	Physical
laser	NN	Physical
therapy	NN	Physical
at	IN	O
904	CD	O
nm	JJ	O
three	CD	O
times	NNS	O
weekly	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
,	,	O
dummy	JJ	Control
laser	NN	Control
or	CC	Physical
drug	NN	Physical
treatment	NN	Physical
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Objectively	RB	O
maximum	JJ	O
active	JJ	O
extension	NN	O
,	,	O
flexion	NN	O
and	CC	O
abduction	NN	O
of	IN	O
the	DT	O
shoulder	NN	O
,	,	O
and	CC	O
subjectively	RB	O
pain	VB	O
stiffness	JJ	O
movement	NN	O
and	CC	O
function	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
0	CD	O
and	CC	O
2	CD	O
weeks	NNS	O
.	.	O

Significant	JJ	O
improvement	NN	O
of	IN	O
active	JJ	O
over	IN	O
dummy	JJ	O
laser	NN	O
was	VBD	O
noted	VBN	O
for	IN	O
all	DT	O
seven	CD	O
assessments	NNS	O
.	.	O

Active	NNP	O
laser	NN	O
therapy	NN	O
produced	VBD	O
significant	JJ	O
improvement	NN	O
over	IN	O
drug	NN	O
therapy	NN	O
for	IN	O
all	DT	O
three	CD	O
objective	JJ	O
measures	NNS	O
and	CC	O
pain	NN	O
.	.	O

Naproxen	NNP	Pharmacological
sodium	NN	Pharmacological
significantly	RB	O
improved	VBN	O
only	RB	O
movement	NN	O
and	CC	O
function	NN	O
compared	VBN	O
to	TO	O
dummy	VB	O
laser	NN	O
.	.	O

These	DT	O
results	NNS	O
demonstrate	VBP	O
the	DT	O
effectiveness	NN	O
of	IN	O
laser	NN	O
therapy	NN	O
in	IN	O
tendonitis	NN	O
of	IN	O
the	DT	O
shoulder	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
of	IN	O
single-incision	NN	Surgical
laparoscopic	NN	Surgical
vs	JJ	O
conventional	JJ	Surgical
3-port	JJ	Surgical
laparoscopic	NN	Surgical
appendectomy	NN	Surgical
for	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
appendicitis	NN	O
.	.	O

BACKGROUND	NNP	O
Proponents	NNPS	O
of	IN	O
single-incision	NN	Surgical
laparoscopic	NN	Surgical
surgery	NN	Surgical
(	(	Surgical
SILS	NNP	Surgical
)	)	Surgical
claim	NN	O
patients	NNS	O
have	VBP	O
less	JJR	O
pain	NN	O
,	,	O
faster	JJR	O
recovery	NN	O
,	,	O
and	CC	O
better	JJR	O
long-term	JJ	O
cosmetic	JJ	O
results	NNS	O
than	IN	O
patients	NNS	O
who	WP	O
undergo	VBP	O
multiport	NN	Surgical
laparoscopy	NN	Surgical
.	.	O

However	RB	O
,	,	O
randomized	JJ	O
comparisons	NNS	O
are	VBP	O
lacking	VBG	O
.	.	O

This	DT	O
study	NN	O
presents	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
SILS	NNP	Surgical
or	CC	O
3-port	JJ	Surgical
laparoscopic	NN	Surgical
appendectomy	NN	Surgical
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Adults	NNP	O
with	IN	O
uncomplicated	JJ	O
acute	NN	O
appendicitis	NN	O
were	VBD	O
randomized	VBN	O
1:1	CD	O
to	TO	O
either	DT	O
SILS	NNP	Surgical
or	CC	O
3-port	JJ	Surgical
laparoscopic	NN	Surgical
appendectomy	NN	Surgical
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
early	JJ	O
postoperative	JJ	O
pain	NN	O
(	(	O
measured	VBN	O
by	IN	O
opiate	JJ	O
usage	NN	O
and	CC	O
pain	NN	O
score	NN	O
in	IN	O
the	DT	O
first	JJ	O
12	CD	O
hours	NNS	O
)	)	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
operative	JJ	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
(	(	O
including	VBG	O
conversions	NNS	O
)	)	O
,	,	O
and	CC	O
recovery	NN	O
time	NN	O
(	(	O
days	NNS	O
of	IN	O
oral	JJ	O
opiate	JJ	O
usage	NN	O
and	CC	O
return	NN	O
to	TO	O
work	VB	O
)	)	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
body	NN	O
image	NN	O
and	CC	O
cosmetic	JJ	O
appearance	NN	O
were	VBD	O
assessed	VBN	O
using	VBG	O
a	DT	O
validated	JJ	O
survey	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
trial	NN	O
was	VBD	O
planned	VBN	O
for	IN	O
150	CD	O
patients	NNS	O
,	,	O
but	CC	O
was	VBD	O
halted	VBN	O
after	IN	O
75	CD	O
patients	NNS	O
when	WRB	O
planned	VBN	O
interim	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
SILS	NNP	Surgical
patients	NNS	O
had	VBD	O
more	RBR	O
postoperative	JJ	O
pain	NN	O
(	(	O
pain	NN	O
score	NN	O
:	:	O
4.4	CD	O
?	.	O
1.6	CD	O
vs	NN	O
3.5	CD	O
?	.	O
1.5	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.01	CD	O
)	)	O
and	CC	O
higher	JJR	O
inpatient	NN	O
opiate	NN	O
usage	NN	O
(	(	O
hydromorphone	NN	O
use	NN	O
:	:	O
3.9	CD	O
?	.	O
1.9	CD	O
mg	NN	O
vs	NN	O
2.8	CD	O
?	.	O
1.7	CD	O
mg	NN	O
;	:	O
p	CC	O
=	VB	O
0.01	CD	O
)	)	O
than	IN	O
3-port	JJ	O
laparoscopy	NN	O
.	.	O

Operative	JJ	O
time	NN	O
for	IN	O
SILS	NNP	O
averaged	VBD	O
40	CD	O
%	NN	O
longer	JJR	O
(	(	O
54	CD	O
?	.	O
17	CD	O
minutes	NNS	O
vs	RB	O
38	CD	O
?	.	O
11	CD	O
minutes	NNS	O
;	:	O
p	VB	O
<	$	O
0.01	CD	O
)	)	O
.	.	O

Only	RB	O
1	CD	O
SILS	NNP	O
case	NN	O
was	VBD	O
converted	VBN	O
to	TO	O
3-port	JJ	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
length	NN	O
of	IN	O
stay	NN	O
,	,	O
complications	NNS	O
,	,	O
oral	JJ	O
pain	NN	O
medication	NN	O
usage	NN	O
after	IN	O
discharge	NN	O
,	,	O
or	CC	O
return	VB	O
to	TO	O
work	VB	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
,	,	O
body	NN	O
image	NN	O
and	CC	O
cosmetic	JJ	O
appearance	NN	O
were	VBD	O
excellent	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
and	CC	O
indistinguishable	JJ	O
by	IN	O
most	JJS	O
measures	NNS	O
.	.	O

However	RB	O
,	,	O
3-port	JJ	O
patients	NNS	O
reported	VBD	O
better	RBR	O
physical	JJ	O
attractiveness	NN	O
(	(	O
4.0	CD	O
?	.	O
0.4	CD	O
vs	NN	O
3.8	CD	O
?	.	O
0.4	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.04	CD	O
)	)	O
and	CC	O
SILS	NNP	O
patients	NNS	O
reported	VBD	O
better	JJR	O
scars	NNS	O
(	(	O
score	VB	O
18.4	CD	O
?	.	O
2.7	CD	O
vs	NN	O
16.4	CD	O
?	.	O
3.0	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.01	CD	O
)	)	O
.	.	O

Results	NNS	O
are	VBP	O
reported	VBN	O
as	IN	O
mean	NN	O
?	.	O
SD	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Single-incision	NNP	O
laparoscopic	NN	O
surgery	NN	O
appendectomy	NN	O
resulted	VBD	O
in	IN	O
more	RBR	O
pain	NN	O
and	CC	O
longer	RB	O
operative	JJ	O
times	NNS	O
without	IN	O
improving	VBG	O
short-term	JJ	O
recovery	NN	O
or	CC	O
complications	NNS	O
.	.	O

Long-term	JJ	O
body	NN	O
image	NN	O
and	CC	O
cosmetic	JJ	O
appearance	NN	O
were	VBD	O
excellent	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
captopril	NN	Pharmacological
and	CC	O
enalapril	NN	Pharmacological
on	IN	O
electroencephalogram	NN	O
and	CC	O
cognitive	JJ	O
performance	NN	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

OBJECTIVE	NNP	O
Captopril	NNP	Pharmacological
and	CC	O
enalapril	NNS	Pharmacological
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
influence	VB	O
cognitive	JJ	O
functions	NNS	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
effects	NNS	O
of	IN	O
captopril	NN	Pharmacological
(	(	O
12.5	CD	O
mg	NN	O
and	CC	O
25	CD	O
mg	NN	O
)	)	O
and	CC	O
enalapril	$	Pharmacological
(	(	O
5	CD	O
mg	NN	O
and	CC	O
10	CD	O
mg	NN	O
)	)	O
administered	VBD	O
during	IN	O
7-day	JJ	O
periods	NNS	O
on	IN	O
electroencephalogram	NN	Physical
(	(	O
EEG	NNP	O
)	)	O
,	,	O
cognitive	JJ	O
functions	NNS	O
,	,	O
and	CC	O
subjective	JJ	O
assessments	NNS	O
were	VBD	O
investigated	VBN	O
in	IN	O
healthy	JJ	O
males	NNS	O
.	.	O

RESULTS	NNP	O
Neither	NNP	O
captopril	NN	O
nor	CC	O
enalapril	NN	O
influenced	VBN	O
EEG	NNP	O
and	CC	O
cognitive	JJ	O
functions	NNS	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Captopril	NNP	Pharmacological
12.5	CD	O
mg	NN	O
decreased	VBD	O
subjective	JJ	O
activity	NN	O
compared	VBN	O
with	IN	O
placebo	NN	Control
.	.	O

Enalapril	NNP	Pharmacological
did	VBD	O
not	RB	O
alter	VB	O
subjective	JJ	O
ratings	NNS	O
.	.	O

Both	DT	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
after	IN	O
administration	NN	O
of	IN	O
captopril	JJ	Pharmacological
25	CD	O
mg	NN	O
,	,	O
whereas	WP	O
blood	NN	O
pressure	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
enalapril	NNS	Pharmacological
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
central	JJ	O
effects	NNS	O
of	IN	O
captopril	NN	Pharmacological
and	CC	O
enalapril	NN	Pharmacological
were	VBD	O
minor	JJ	O
and	CC	O
not	RB	O
constant	JJ	O
in	IN	O
young	JJ	O
healthy	JJ	O
men	NNS	O
.	.	O

Effect	NN	O
of	IN	O
protein	NN	Pharmacological
ingestion	NN	Pharmacological
on	IN	O
the	DT	O
glucose	JJ	O
appearance	NN	O
rate	NN	O
in	IN	O
people	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

Amino	NNP	O
acids	NNS	O
derived	VBD	O
from	IN	O
ingested	VBN	O
protein	NN	O
are	VBP	O
potential	JJ	O
substrates	NNS	O
for	IN	O
gluconeogenesis	NN	O
.	.	O

However	RB	O
,	,	O
several	JJ	O
laboratories	NNS	O
have	VBP	O
reported	VBN	O
that	IN	O
protein	JJ	O
ingestion	NN	O
does	VBZ	O
not	RB	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
circulating	NN	O
glucose	JJ	O
concentration	NN	O
in	IN	O
people	NNS	O
with	IN	O
or	CC	O
without	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

The	DT	O
reason	NN	O
for	IN	O
this	DT	O
has	VBZ	O
remained	VBN	O
unclear	JJ	O
.	.	O

In	IN	O
people	NNS	O
without	IN	O
diabetes	NNS	O
it	PRP	O
seems	VBZ	O
to	TO	O
be	VB	O
due	JJ	O
to	TO	O
less	RBR	O
glucose	JJ	O
being	VBG	O
produced	VBN	O
and	CC	O
entering	VBG	O
the	DT	O
circulation	NN	O
than	IN	O
the	DT	O
calculated	JJ	O
theoretical	JJ	O
amount	NN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
were	VBD	O
interested	JJ	O
in	IN	O
determining	VBG	O
whether	IN	O
this	DT	O
also	RB	O
was	VBD	O
the	DT	O
case	NN	O
in	IN	O
people	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
.	.	O

Ten	CD	O
male	JJ	O
subjects	NNS	O
with	IN	O
untreated	JJ	O
type	NN	O
2	CD	O
diabetes	NNS	O
were	VBD	O
given	VBN	O
,	,	O
in	IN	O
random	JJ	O
sequence	NN	O
,	,	O
50	CD	Pharmacological
g	NN	Pharmacological
protein	NN	Pharmacological
in	IN	Pharmacological
the	DT	Pharmacological
form	NN	Pharmacological
of	IN	Pharmacological
very	RB	Pharmacological
lean	JJ	Pharmacological
beef	NN	Pharmacological
or	CC	O
only	RB	Control
water	NN	Control
at	IN	O
0800	CD	O
h	NN	O
and	CC	O
studied	VBN	O
over	IN	O
the	DT	O
subsequent	JJ	O
8	CD	O
h.	NN	O
Protein	NNP	Pharmacological
ingestion	NN	O
resulted	VBD	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
circulating	VBG	O
insulin	NN	O
,	,	O
C-peptide	NNP	O
,	,	O
glucagon	NN	O
,	,	O
alpha	NN	O
amino	NN	O
and	CC	O
urea	JJ	O
nitrogen	NN	O
,	,	O
and	CC	O
triglycerides	NNS	O
;	:	O
a	DT	O
decrease	NN	O
in	IN	O
nonesterified	JJ	O
fatty	JJ	O
acids	NNS	O
;	:	O
and	CC	O
a	DT	O
modest	JJ	O
increase	NN	O
in	IN	O
respiratory	JJ	O
quotient	NN	O
.	.	O

The	DT	O
total	JJ	O
amount	NN	O
of	IN	O
protein	NN	O
deaminated	VBN	O
and	CC	O
the	DT	O
amino	NN	O
groups	NNS	O
incorporated	VBD	O
into	IN	O
urea	NN	O
was	VBD	O
calculated	VBN	O
to	TO	O
be	VB	O
approximately	RB	O
20-23	JJ	O
g.	VBP	O
The	DT	O
net	JJ	O
amount	NN	O
of	IN	O
glucose	NN	O
estimated	VBN	O
to	TO	O
be	VB	O
produced	VBN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
quantity	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
deaminated	VBD	O
,	,	O
was	VBD	O
approximately	RB	O
11-13	JJ	O
g.	NN	O
However	RB	O
,	,	O
the	DT	O
amount	NN	O
of	IN	O
glucose	JJ	O
appearing	VBG	O
in	IN	O
the	DT	O
circulation	NN	O
was	VBD	O
only	RB	O
approximately	RB	O
2	CD	O
g.	VBD	O
The	DT	O
peripheral	JJ	O
plasma	NN	O
glucose	JJ	O
concentration	NN	O
decreased	VBN	O
by	IN	O
approximately	RB	O
1	CD	O
mM	NNS	O
after	IN	O
ingestion	NN	O
of	IN	O
either	DT	O
protein	NN	O
or	CC	O
water	NN	O
,	,	O
confirming	VBG	O
that	IN	O
ingested	JJ	O
protein	NN	O
does	VBZ	O
not	RB	O
result	VB	O
in	IN	O
a	DT	O
net	JJ	O
increase	NN	O
in	IN	O
glucose	JJ	O
concentration	NN	O
,	,	O
and	CC	O
results	NNS	O
in	IN	O
only	RB	O
a	DT	O
modest	JJ	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
glucose	JJ	O
disappearance	NN	O
.	.	O

How	WRB	O
well	RB	O
do	VB	O
blood	NN	Physical
folate	VB	Physical
concentrations	NNS	O
predict	VBP	O
dietary	JJ	Other
folate	NN	Other
intakes	NNS	Other
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
Canadian	JJ	O
lactating	VBG	O
women	NNS	O
exposed	VBN	O
to	TO	O
high	JJ	O
levels	NNS	O
of	IN	O
folate	NN	O
?	.	O
An	DT	O
observational	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
1998	CD	O
,	,	O
mandatory	JJ	O
folic	JJ	O
acid	JJ	O
fortification	NN	O
of	IN	O
white	JJ	O
flour	NN	O
and	CC	O
select	JJ	O
cereal	NN	O
grain	NN	O
products	NNS	O
was	VBD	O
implemented	VBN	O
in	IN	O
Canada	NNP	O
with	IN	O
the	DT	O
intention	NN	O
to	TO	O
increase	VB	O
dietary	JJ	O
folate	JJ	O
intakes	NNS	O
of	IN	O
reproducing	VBG	O
women	NNS	O
.	.	O

Folic	NNP	O
acid	JJ	O
fortification	NN	O
has	VBZ	O
produced	VBN	O
a	DT	O
dramatic	JJ	O
increase	NN	O
in	IN	O
blood	NN	O
folate	JJ	O
concentrations	NNS	O
among	IN	O
reproductive	JJ	O
age	NN	O
women	NNS	O
,	,	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
neural	JJ	O
tube	NN	O
defect	NN	O
(	(	O
NTD	NNP	O
)	)	O
-affected	VBD	O
pregnancies	NNS	O
.	.	O

In	IN	O
response	NN	O
to	TO	O
improved	VBN	O
blood	NN	O
folate	NN	O
concentrations	NNS	O
,	,	O
many	JJ	O
health	NN	O
care	NN	O
professionals	NNS	O
are	VBP	O
asking	VBG	O
whether	IN	O
a	DT	O
folic	JJ	Pharmacological
acid	NN	Pharmacological
supplement	NN	Pharmacological
is	VBZ	O
necessary	JJ	O
for	IN	O
NTD	NNP	O
prevention	NN	O
among	IN	O
women	NNS	O
with	IN	O
high	JJ	O
blood	NN	O
folate	NN	O
values	NNS	O
,	,	O
and	CC	O
how	WRB	O
reliably	RB	O
high	JJ	O
RBC	NNP	O
folate	NN	O
concentrations	NNS	O
predict	VBP	O
folate	JJ	O
intakes	NNS	O
shown	VBN	O
in	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
to	TO	O
be	VB	O
protective	JJ	O
against	IN	O
NTDs	NNP	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
how	WRB	O
predictive	JJ	O
blood	NN	Physical
folate	NN	Physical
concentrations	NNS	O
and	CC	O
folate	NN	O
intakes	NNS	O
are	VBP	O
of	IN	O
each	DT	O
other	JJ	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
well-educated	JJ	O
lactating	VBG	O
Canadian	JJ	O
women	NNS	O
exposed	VBN	O
to	TO	O
high	JJ	O
levels	NNS	O
of	IN	O
synthetic	JJ	O
folate	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
relationship	NN	O
between	IN	O
blood	NN	Physical
folate	NN	Physical
concentrations	NNS	O
and	CC	O
dietary	JJ	O
folate	NN	O
intakes	NNS	O
,	,	O
determined	VBN	O
by	IN	O
weighed	VBN	O
food	NN	O
records	NNS	O
,	,	O
were	VBD	O
assessed	VBN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
predominantly	RB	O
university-educated	JJ	O
lactating	VBG	O
women	NNS	O
(	(	O
32	CD	O
+/-	JJ	O
4	CD	O
yr	NN	O
)	)	O
at	IN	O
4-	JJ	O
(	(	O
n	JJ	O
=	NNP	O
53	CD	O
)	)	O
and	CC	O
16-wk	JJ	O
postpartum	NN	O
(	(	O
n	JJ	O
=	NNP	O
55	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
Median	JJ	O
blood	NN	Physical
folate	NN	Physical
concentrations	NNS	O
of	IN	O
all	DT	O
participants	NNS	O
were	VBD	O
well	RB	O
above	IN	O
plasma	NN	O
and	CC	O
RBC	NNP	O
folate	VBP	O
cut-off	NN	O
levels	NNS	O
indicative	CD	O
of	IN	O
deficiency	NN	O
(	(	O
6.7	CD	O
and	CC	O
317	CD	O
nmol/L	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
all	DT	O
,	,	O
except	IN	O
for	IN	O
2	CD	O
subjects	NNS	O
,	,	O
were	VBD	O
above	IN	O
the	DT	O
cut-off	NN	O
for	IN	O
NTD-risk	NNP	O
reduction	NN	O
(	(	O
>	$	O
906	CD	O
nmol/L	NN	O
)	)	O
.	.	O

Only	RB	O
modest	JJ	O
associations	NNS	O
existed	VBD	O
between	IN	O
total	JJ	Physical
folate	NN	Physical
intakes	NNS	Physical
and	CC	O
plasma	NN	O
(	(	O
r	JJ	O
=	NN	O
0.46	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
RBC	NNP	O
(	(	O
r	VB	O
=	RB	O
0.36	CD	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
folate	NN	O
concentrations	NNS	O
at	IN	O
16-wk	JJ	O
postpartum	NN	O
.	.	O

Plasma	NNP	O
and	CC	O
RBC	NNP	O
folate	VBP	O
values	NNS	O
at	IN	O
16-wk	JJ	O
postpartum	NN	O
correctly	RB	O
identified	VBD	O
the	DT	O
quartile	NN	O
of	IN	O
folate	JJ	O
intake	NN	O
of	IN	O
only	RB	O
26	CD	O
of	IN	O
55	CD	O
(	(	O
47	CD	O
%	NN	O
)	)	O
and	CC	O
18	CD	O
of	IN	O
55	CD	O
(	(	O
33	CD	O
%	NN	O
)	)	O
of	IN	O
subjects	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	O
RBC	NNP	O
folate	NN	O
concentration	NN	O
of	IN	O
women	NNS	O
consuming	VBG	O
151-410	JJ	O
microg/d	NN	O
of	IN	O
synthetic	JJ	O
folate	NN	O
(	(	O
2nd	CD	O
quartile	NN	O
of	IN	O
intake	NN	O
)	)	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
of	IN	O
women	NNS	O
consuming	VBG	O
>	JJ	O
410	CD	O
microg/d	NN	O
(	(	O
3rd	CD	O
and	CC	O
4th	CD	O
quartile	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Folate	NNP	Pharmacological
intakes	NNS	Pharmacological
,	,	O
estimated	VBN	O
by	IN	O
food	NN	O
composition	NN	O
tables	NNS	O
,	,	O
and	CC	O
blood	NN	O
folate	NN	O
concentrations	NNS	O
are	VBP	O
not	RB	O
predictive	JJ	O
of	IN	O
each	DT	O
other	JJ	O
in	IN	O
Canadian	JJ	O
lactating	VBG	O
women	NNS	O
exposed	VBN	O
to	TO	O
high	JJ	O
levels	NNS	O
of	IN	O
folate	NN	O
.	.	O

Synthetic	JJ	O
intakes	NNS	O
>	VBP	O
151-410	JJ	O
microg/d	NN	O
in	IN	O
these	DT	O
women	NNS	O
produced	VBD	O
little	JJ	O
additional	JJ	O
benefit	NN	O
in	IN	O
terms	NNS	O
of	IN	O
maximizing	VBG	O
RBC	NNP	O
content	NN	O
.	.	O

More	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
examine	VB	O
the	DT	O
relationship	NN	O
between	IN	O
blood	NN	Physical
folate	NN	Physical
concentration	NN	O
and	CC	O
NTD	NNP	O
risk	NN	O
.	.	O

Until	IN	O
data	NNS	O
from	IN	O
such	JJ	O
studies	NNS	O
are	VBP	O
available	JJ	O
,	,	O
women	NNS	O
planning	VBG	O
a	DT	O
pregnancy	NN	O
should	MD	O
continue	VB	O
to	TO	O
consume	VB	O
a	DT	O
daily	JJ	O
folic	JJ	Pharmacological
acid	JJ	Pharmacological
supplement	NN	Pharmacological
of	IN	O
400	CD	O
microg	NN	O
.	.	O

Does	NNS	O
waiting	VBG	O
matter	NN	O
?	.	O
A	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
of	IN	O
new	JJ	O
non-urgent	JJ	O
rheumatology	NN	O
out-patient	JJ	O
referrals	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
waiting	VBG	O
times	NNS	O
on	IN	O
the	DT	O
health	NN	O
status	NN	O
of	IN	O
patients	NNS	O
referred	VBN	O
for	IN	O
a	DT	O
non-urgent	JJ	O
rheumatology	NN	O
opinion	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
evaluating	VBG	O
a	DT	O
'fast	JJ	Other
track	NN	Other
'	POS	Other
appointment	NN	Other
with	IN	Other
a	DT	Other
6-week	JJ	Other
target	NN	Other
waiting	VBG	Other
time	NN	Other
against	IN	O
an	DT	O
'ordinary	JJ	Control
'	POS	Control
appointment	NN	Control
in	IN	O
the	DT	O
main	JJ	O
city	NN	O
out-patient	JJ	O
clinic	NN	O
of	IN	O
the	DT	O
rheumatology	NN	O
service	NN	O
for	IN	O
the	DT	O
Lothian	JJ	O
and	CC	O
Borders	NNPS	O
region	NN	O
(	(	O
population	NN	O
approximately	RB	O
1	CD	O
million	CD	O
)	)	O
.	.	O

Health	NNP	O
status	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
the	DT	O
SF12	NNP	O
physical	JJ	O
and	CC	O
mental	JJ	O
summary	JJ	O
component	NN	O
T-scores	NNS	O
and	CC	O
pain	NN	O
was	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
100	CD	O
mm	NN	O
visual	JJ	O
analogue	NN	O
pain	NN	O
scale	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
health	NN	O
utility	NN	O
and	CC	O
perceived	VBD	O
health	NN	O
both	DT	O
measured	VBN	O
with	IN	O
the	DT	O
EuroQol	NNP	O
instrument	NN	O
,	,	O
mental	JJ	O
health	NN	O
measured	VBN	O
with	IN	O
the	DT	O
Hospital	NNP	O
Anxiety	NNP	O
and	CC	O
Depression	NNP	O
scale	NN	O
,	,	O
disability	NN	O
with	IN	O
the	DT	O
modified	JJ	O
Health	NNP	O
Assessment	NNP	O
Questionnaire	NNP	O
and	CC	O
economic	JJ	O
costs	NNS	O
measured	VBN	O
from	IN	O
a	DT	O
societal	JJ	O
perspective	NN	O
.	.	O

RESULTS	JJ	O
Mean	NNP	O
waiting	VBG	O
times	NNS	O
were	VBD	O
43	CD	O
days	NNS	O
(	(	O
sigma	JJ	O
=	NNP	O
+/-16	NN	O
)	)	O
and	CC	O
105	CD	O
days	NNS	O
(	(	O
sigma	JJ	O
=	NNP	O
+/-51	NN	O
)	)	O
for	IN	O
'fast	$	O
track	NN	O
'	''	O
and	CC	O
'ordinary	NNP	O
'	POS	O
appointments	NNS	O
,	,	O
respectively	RB	O
.	.	O

Both	DT	O
groups	NNS	O
showed	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
mean	JJ	O
[	JJ	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
]	NN	O
scores	NNS	O
for	IN	O
pain	NN	O
:	:	O
11	CD	O
(	(	O
7	CD	O
,	,	O
16	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
physical	JJ	O
health	NN	O
status	NN	O
:	:	O
4	CD	O
(	(	O
2	CD	O
,	,	O
5	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
mental	JJ	O
health	NN	O
status	NN	O
:	:	O
2	CD	O
(	(	O
0.1	CD	O
,	,	O
4	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.02	CD	O
)	)	O
;	:	O
and	CC	O
health	NN	O
utility	NN	O
:	:	O
0.11	CD	O
(	(	O
0.07	CD	O
,	,	O
0.16	CD	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
15-month	JJ	O
period	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
either	DT	O
arm	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

CONCLUSIONS	NNP	O
Rationing	NNP	O
by	IN	O
delay	NN	O
was	VBD	O
not	RB	O
detrimental	JJ	O
to	TO	O
either	DT	O
mental	JJ	O
or	CC	O
physical	JJ	O
health	NN	O
and	CC	O
patients	NNS	O
in	IN	O
both	DT	O
arms	NNS	O
of	IN	O
the	DT	O
study	NN	O
showed	VBD	O
significant	JJ	O
and	CC	O
similar	JJ	O
improvement	NN	O
in	IN	O
health	NN	O
by	IN	O
15	CD	O
months	NNS	O
.	.	O

Expenditure	NN	O
of	IN	O
resources	NNS	O
on	IN	O
waiting	VBG	O
times	NNS	O
without	IN	O
regard	NN	O
to	TO	O
clinical	JJ	O
outcomes	NNS	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
wasteful	JJ	O
and	CC	O
additional	JJ	O
resources	NNS	O
should	MD	O
be	VB	O
directed	VBN	O
at	IN	O
achieving	VBG	O
the	DT	O
greatest	JJS	O
clinical	JJ	O
benefit	NN	O
.	.	O

More	JJR	O
research	NN	O
into	IN	O
effective	JJ	O
methods	NNS	O
of	IN	O
controlling	VBG	O
demand	NN	O
and	CC	O
better	JJR	O
identification	NN	O
of	IN	O
those	DT	O
who	WP	O
would	MD	O
benefit	VB	O
from	IN	O
access	NN	O
to	TO	O
specialist	VB	O
care	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

Divalproex	NNP	Pharmacological
sodium	NN	Pharmacological
vs.	FW	O
placebo	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
behaviours	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

Autism	NNP	O
is	VBZ	O
a	DT	O
neurodevelopmental	JJ	O
disorder	NN	O
characterized	VBN	O
by	IN	O
impairment	NN	O
in	IN	O
three	CD	O
core	NN	O
symptom	NN	O
domains	NNS	O
:	:	O
socialization	NN	O
,	,	O
communication	NN	O
,	,	O
and	CC	O
repetitive/stereotyped	VBD	O
behaviours	NNS	O
.	.	O

Other	JJ	O
associated	JJ	O
symptom	NN	O
domains	NNS	O
are	VBP	O
also	RB	O
affected	JJ	O
including	VBG	O
impulsivity/aggression	NN	O
,	,	O
self-injury	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
mood	NN	O
lability	NN	O
.	.	O

Divalproex	NNP	Pharmacological
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
efficacy	NN	O
in	IN	O
treating	VBG	O
epilepsy	NN	O
,	,	O
bipolar	JJ	O
disorder	NN	O
,	,	O
mood	NN	O
lability	NN	O
,	,	O
and	CC	O
impulsive	JJ	O
aggression	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
evaluated	VBD	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
repetitive	JJ	O
,	,	O
compulsive-like	JJ	O
symptoms	NNS	O
of	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Thirteen	JJ	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
participated	VBD	O
in	IN	O
an	DT	O
8-wk	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
divalproex	NN	Pharmacological
sodium	NN	Pharmacological
vs.	FW	O
placebo	NN	Control
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
group	NN	O
difference	NN	O
on	IN	O
improvement	NN	O
in	IN	O
repetitive	JJ	O
behaviours	NNS	O
as	IN	O
measured	VBN	O
by	IN	O
the	DT	O
Children	NNP	O
's	POS	O
Yale-Brown	JJ	O
Obsessive	NNP	O
Compulsive	NNP	O
Scale	NNP	O
(	(	O
C-YBOCS	NNP	O
)	)	O
(	(	O
p=0.037	NN	O
)	)	O
and	CC	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
(	(	O
d=1.616	NN	O
)	)	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
preliminary	JJ	O
support	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
divalproex	NN	Pharmacological
in	IN	O
treating	VBG	O
repetitive	JJ	O
behaviours	NNS	O
in	IN	O
ASD	NNP	O
.	.	O

Further	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
specificity	NN	O
and	CC	O
mechanism	NN	O
of	IN	O
action	NN	O
of	IN	O
these	DT	O
findings	NNS	O
.	.	O

Alternating	VBG	Physical
chemotherapy	NN	Physical
in	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
hypothesis	NN	O
of	IN	O
Goldie	NNP	O
and	CC	O
Coldman	NNP	O
,	,	O
rapid	JJ	Pharmacological
cyclic	JJ	Pharmacological
alternating	VBG	Pharmacological
chemotherapy	NN	Pharmacological
has	VBZ	O
been	VBN	O
supposed	VBN	O
to	TO	O
be	VB	O
a	DT	O
favorable	JJ	O
treatment	NN	O
modality	NN	O
in	IN	O
small	JJ	O
cell	NN	O
lung	NN	O
cancer	NN	O
.	.	O

This	DT	O
approach	NN	O
has	VBZ	O
been	VBN	O
tested	VBN	O
in	IN	O
a	DT	O
large	JJ	O
series	NN	O
of	IN	O
trials	NNS	O
since	IN	O
the	DT	O
late	JJ	O
70	CD	O
's	POS	O
.	.	O

A	NNP	O
few	JJ	O
trials	NNS	O
performed	VBD	O
randomization	NN	O
between	IN	O
alternating	VBG	O
and	CC	O
continuous	JJ	O
treatment	NN	O
after	IN	O
a	DT	O
period	NN	O
of	IN	O
initial	JJ	Pharmacological
common	JJ	Pharmacological
continuous	JJ	Pharmacological
therapy	NN	Pharmacological
.	.	O

The	DT	O
results	NNS	O
of	IN	O
these	DT	O
studies	NNS	O
are	VBP	O
controversial	JJ	O
and	CC	O
their	PRP$	O
interpretation	NN	O
is	VBZ	O
complicated	VBN	O
by	IN	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
continuous	JJ	O
pretreatment	NN	O
.	.	O

Recently	RB	O
,	,	O
most	JJS	O
trials	NNS	O
were	VBD	O
designed	VBN	O
as	IN	O
2-arm	JJ	O
approaches	NNS	O
with	IN	O
a	DT	O
comparison	NN	O
of	IN	O
continuous	JJ	Physical
standard	NN	Physical
therapy	NN	Physical
based	VBN	Physical
on	IN	Physical
the	DT	Physical
CAV-	NNP	Pharmacological
or	CC	Pharmacological
CMC-protocol	NNP	Pharmacological
with	IN	Pharmacological
an	DT	Pharmacological
alternating	VBG	Pharmacological
schedule	NN	Pharmacological
often	RB	Pharmacological
consisting	VBG	Pharmacological
of	IN	Pharmacological
the	DT	Pharmacological
CAV-	NNP	Pharmacological
or	CC	Pharmacological
CMC-derived	JJ	Pharmacological
combinations	NNS	Pharmacological
and	CC	O
a	DT	O
second	JJ	Pharmacological
regimen	NN	Pharmacological
including	VBG	Pharmacological
cisplatinum	NN	Pharmacological
and/or	NN	Pharmacological
etoposide	NN	Pharmacological
.	.	O

In	IN	O
these	DT	O
trials	NNS	O
the	DT	O
addition	NN	O
of	IN	O
the	DT	O
second	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
alternating	NN	O
treatment	NN	O
arms	NNS	O
has	VBZ	O
improved	VBN	O
the	DT	O
treatment	NN	O
results	NNS	O
.	.	O

However	RB	O
,	,	O
these	DT	O
trials	NNS	O
could	MD	O
not	RB	O
clarify	VB	O
whether	IN	O
this	DT	O
advantage	NN	O
was	VBD	O
due	JJ	O
to	TO	O
the	DT	O
concept	NN	O
of	IN	O
alternating	VBG	O
treatment	NN	O
or	CC	O
to	TO	O
the	DT	O
high	JJ	O
activity	NN	O
of	IN	O
new	JJ	O
drugs	NNS	O
given	VBN	O
early	RB	O
in	IN	O
the	DT	O
course	NN	O
of	IN	O
therapy	NN	O
in	IN	O
the	DT	O
alternating	NN	O
treatment	NN	O
arms	NNS	O
.	.	O

To	TO	O
ameliorate	VB	O
this	DT	O
weakness	NN	O
,	,	O
3	CD	O
studies	NNS	O
were	VBD	O
designed	VBN	O
as	IN	O
3-arms	JJ	O
approaches	NNS	O
using	VBG	O
both	DT	O
alternating	VBG	O
protocols	NNS	O
as	IN	O
continuous	JJ	O
control	NN	O
arms	NNS	O
.	.	O

Whereas	IN	O
one	CD	O
investigation	NN	O
noticed	VBD	O
an	DT	O
advantage	NN	O
of	IN	O
the	DT	O
alternating	NN	O
schedule	NN	O
,	,	O
the	DT	O
two	CD	O
others	NNS	O
observed	VBD	O
no	DT	O
difference	NN	O
.	.	O

These	DT	O
studies	NNS	O
did	VBD	O
not	RB	O
report	VB	O
their	PRP$	O
criteria	NNS	O
for	IN	O
shifting	VBG	O
non-responding	JJ	O
patients	NNS	O
from	IN	O
continuous	JJ	O
treatment	NN	O
to	TO	O
second	JJ	O
line	NN	O
therapy	NN	O
.	.	O

The	DT	O
longer	JJR	O
these	DT	O
patients	NNS	O
stayed	VBD	O
on	IN	O
the	DT	O
continuous	JJ	O
protocol	NN	O
the	DT	O
more	JJR	O
the	DT	O
study	NN	O
design	NN	O
favoured	VBD	O
the	DT	O
alternating	VBG	O
therapy	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Effects	NNS	O
of	IN	O
electro-acupuncture	NN	Physical
on	IN	O
T	NNP	O
cell	NN	O
subpopulations	NNS	O
,	,	O
NK	NNP	O
activity	NN	O
,	,	O
humoral	JJ	O
immunity	NN	O
and	CC	O
leukocyte	NN	O
count	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
chemotherapy	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
observe	VB	O
the	DT	O
effects	NNS	O
of	IN	O
electro-acupuncture	NN	Physical
on	IN	O
T	NNP	O
cell	NN	O
subpopulations	NNS	O
,	,	O
natural	JJ	O
killer	NN	O
cell	NN	O
(	(	O
NK	NNP	O
)	)	O
activity	NN	O
,	,	O
humoral	JJ	O
immunity	NN	O
and	CC	O
leukocyte	NN	O
count	NN	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
chemotherapy	NN	Pharmacological
.	.	O

METHODS	NNP	O
Electro-acupuncture	NN	Physical
was	VBD	O
added	VBN	O
for	IN	O
patients	NNS	O
undergoing	JJ	O
chemotherapy	NN	Pharmacological
.	.	O

Tests	NNS	O
were	VBD	O
done	VBN	O
on	IN	O
T	NNP	O
cell	NN	O
subpopulations	NNS	O
,	,	O
NK	NNP	O
activity	NN	O
,	,	O
humoral	JJ	O
immunity	NN	O
and	CC	O
leukocyte	JJ	O
count	NN	O
before	IN	O
treatment	NN	O
and	CC	O
after	IN	O
4	CD	O
courses	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
4	CD	O
courses	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
chemotherapy	NN	Pharmacological
and	CC	O
electro-acupuncture	NN	Physical
,	,	O
no	DT	O
obvious	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
T	NNP	O
cell	NN	O
subpopulations	NNS	O
,	,	O
NK	NNP	O
activity	NN	O
,	,	O
humoral	JJ	O
immunity	NN	O
and	CC	O
leukocyte	NN	O
count	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
as	IN	O
compared	VBN	O
with	IN	O
those	DT	O
before	IN	O
treatment	NN	O
.	.	O

Patients	NNS	O
undergoing	VBG	O
chemotherapy	NN	Pharmacological
combined	VBN	O
with	IN	O
electro-acupuncture	NN	Physical
showed	VBD	O
obviously	RB	O
higher	JJR	O
leukocyte	NN	O
count	NN	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
given	VBN	O
no	DT	O
leukogenic	JJ	O
drugs	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Electro-acupuncture	NN	Physical
may	MD	O
reduce	VB	O
immunologic	JJ	O
damage	NN	O
caused	VBN	O
by	IN	O
chemotherapy	NN	Pharmacological
,	,	O
thus	RB	O
it	PRP	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
the	DT	O
auxiliary	JJ	O
therapy	NN	O
for	IN	O
patients	NNS	O
undergoing	JJ	O
chemotherapy	NN	Pharmacological
.	.	O

Beta	NNP	Physical
radiation	NN	Physical
as	IN	O
an	DT	O
adjunct	JJ	O
to	TO	O
low-risk	JJ	O
trabeculectomy	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
assess	VB	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intraoperative	JJ	Physical
beta	NN	Physical
radiation	NN	Physical
used	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
success	NN	O
rate	NN	O
of	IN	O
trabeculectomy	NN	O
in	IN	O
a	DT	O
population	NN	O
of	IN	O
low-risk	JJ	O
glaucoma	NN	O
patients	NNS	O
in	IN	O
whom	WP	O
antimetabolites	NNS	O
might	MD	O
not	RB	O
be	VB	O
indicated	VBN	O
.	.	O

METHODS	VB	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
of	IN	O
65	CD	O
eyes	NNS	O
was	VBD	O
designed	VBN	O
,	,	O
with	IN	O
31	CD	O
eyes	NNS	O
receiving	VBG	O
750	CD	Physical
rads	NNS	Physical
of	IN	Physical
intraoperative	JJ	Physical
beta	NN	Physical
radiation	NN	Physical
(	(	O
group	NN	O
1	CD	O
)	)	O
,	,	O
and	CC	O
34	CD	O
eyes	NNS	O
receiving	VBG	Control
no	DT	Control
supplementation	NN	Control
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

RESULTS	JJ	O
Mean	JJ	O
follow-up	JJ	O
time	NN	O
was	VBD	O
24	CD	O
months	NNS	O
.	.	O

Mean	NNP	O
postoperative	JJ	O
intraocular	JJ	O
pressure	NN	O
was	VBD	O
12.2	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
13.7	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.16	CD	O
)	)	O
.	.	O

Mean	JJ	O
decrease	NN	O
in	IN	O
intraocular	JJ	O
pressure	NN	O
was	VBD	O
10.3	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
9.3	CD	O
mmHg	NN	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.49	CD	O
)	)	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
surgical	JJ	O
complications	NNS	O
.	.	O

CONCLUSION	NN	O
For	IN	O
this	DT	O
population	NN	O
of	IN	O
low-risk	JJ	O
patients	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
outcome	NN	O
after	IN	O
applications	NNS	O
of	IN	O
a	DT	O
single	JJ	O
intraoperative	JJ	O
dose	NN	O
of	IN	O
beta	NN	Physical
radiation	NN	Physical
.	.	O

Phase	NNP	O
III	NNP	O
study	NN	O
of	IN	O
two	CD	O
different	JJ	O
dosing	VBG	O
schedules	NNS	O
of	IN	O
erythropoietin	NN	Pharmacological
in	IN	O
anemic	JJ	O
patients	NNS	O
with	IN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
maintenance	NN	O
epoetin	NN	Pharmacological
alfa	NN	Pharmacological
administered	VBD	O
once	RB	O
every	DT	O
3	CD	O
weeks	NNS	O
with	IN	O
continued	JJ	O
weekly	JJ	O
epoetin	NN	Pharmacological
alfa	NN	Pharmacological
for	IN	O
patients	NNS	O
with	IN	O
cancer-associated	JJ	O
anemia	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Eligible	JJ	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
at	IN	O
enrollment	NN	O
to	TO	O
receive	VB	O
three	CD	Pharmacological
weekly	JJ	Pharmacological
doses	NNS	Pharmacological
of	IN	Pharmacological
epoetin	NN	Pharmacological
alfa	NN	Pharmacological
40,000	CD	Pharmacological
U	NNP	Pharmacological
subcutaneously	RB	Pharmacological
(	(	O
SC	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
either	DT	O
standard	JJ	O
weekly	JJ	O
epoetin	NN	Pharmacological
alfa	NN	Pharmacological
(	(	O
40K	CD	O
arm	NN	O
)	)	O
or	CC	O
120,000	CD	O
U	NNP	O
of	IN	O
epoetin	NN	Pharmacological
alfa	NN	Pharmacological
(	(	O
120K	CD	O
arm	NN	O
)	)	O
SC	NNP	O
every	DT	O
3	CD	O
weeks	NNS	O
for	IN	O
18	CD	O
additional	JJ	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
Three	CD	O
hundred	VBD	O
sixty-five	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

One	CD	O
hundred	VBD	O
eighty-three	JJ	O
patients	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
40K	CD	O
arm	NN	O
,	,	O
and	CC	O
182	CD	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
120K	CD	O
arm	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
requiring	VBG	O
transfusions	NNS	O
during	IN	O
the	DT	O
study	NN	O
(	(	O
23	CD	O
%	NN	O
in	IN	O
40K	CD	O
arm	NN	O
and	CC	O
18	CD	O
%	NN	O
in	IN	O
120K	CD	O
arm	NN	O
,	,	O
P	NNP	O
=	NNP	O
.22	NNP	O
)	)	O
or	CC	O
specifically	RB	O
during	IN	O
the	DT	O
maintenance	NN	O
phase	NN	O
(	(	O
13	CD	O
%	NN	O
in	IN	O
40K	CD	O
arm	NN	O
v	NN	O
15	CD	O
%	NN	O
in	IN	O
120K	CD	O
arm	NN	O
,	,	O
P	NNP	O
=	NNP	O
.58	NNP	O
)	)	O
.	.	O

Patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
the	DT	O
40K	CD	O
arm	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
>	NN	O
or	CC	O
=	VB	O
2	CD	O
or	CC	O
>	CD	O
or	CC	O
=	VB	O
3	CD	O
g/dL	NN	O
hemoglobin	NN	O
(	(	O
Hb	NNP	O
)	)	O
increment	NN	O
,	,	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
a	DT	O
drug	NN	O
dose	RB	O
held	VBD	O
because	IN	O
of	IN	O
high	JJ	O
Hb	NNP	O
,	,	O
and	CC	O
had	VBD	O
higher	JJR	O
mean	JJ	O
end-of-study	JJ	O
Hb	NNP	O
levels	NNS	O
.	.	O

Toxicities	NNS	O
,	,	O
including	VBG	O
thromboembolism	NN	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
were	VBD	O
similar	JJ	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
40K	CD	O
arm	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
global	JJ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
at	IN	O
baseline	NN	O
for	IN	O
unclear	JJ	O
reasons	NNS	O
,	,	O
whereas	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
120K	CD	O
arm	NN	O
had	VBD	O
a	DT	O
greater	JJR	O
global	JJ	O
QOL	NNP	O
improvement	NN	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
so	IN	O
end-of-study	JJ	O
QOL	NNP	O
was	VBD	O
equivalent	JJ	O
.	.	O

CONCLUSION	NN	O
After	IN	O
three	CD	O
weekly	JJ	O
doses	NNS	O
of	IN	O
epoetin	NN	Pharmacological
alfa	NN	Pharmacological
40,000	CD	O
U	NNP	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
120,000	CD	O
U	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
safely	RB	O
once	RB	O
every	DT	O
3	CD	O
weeks	NNS	O
without	IN	O
increasing	VBG	O
transfusion	NN	O
needs	NNS	O
or	CC	O
sacrificing	VBG	O
QOL	NNP	O
.	.	O

The	DT	O
Hb	NNP	O
increment	NN	O
is	VBZ	O
somewhat	RB	O
greater	JJR	O
with	IN	O
continued	JJ	O
weekly	JJ	O
epoetin	NN	Pharmacological
alfa	NN	Pharmacological
.	.	O

Lack	NNP	O
of	IN	O
blinding	VBG	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
different	JJ	O
treatment	NN	O
schedules	NNS	O
may	MD	O
have	VB	O
confounded	VBN	O
results	NNS	O
.	.	O

Effect	NN	O
of	IN	O
beta-blocking	NN	O
drugs	NNS	O
on	IN	O
beta-cell	NN	O
function	NN	O
and	CC	O
insulin	NN	O
sensitivity	NN	O
in	IN	O
hypertensive	JJ	O
non-diabetic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
two	CD	O
beta-blocking	JJ	O
drugs	NNS	O
on	IN	O
endogenous	JJ	O
insulin	NN	O
secretion	NN	O
and	CC	O
insulin	NN	O
sensitivity	NN	O
were	VBD	O
investigated	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
cross-over	NN	O
study	NN	O
in	IN	O
13	CD	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
each	DT	O
of	IN	O
three	CD	O
2-week	JJ	O
treatment	NN	O
periods	NNS	O
with	IN	O
propranolol	JJ	Pharmacological
80	CD	Pharmacological
mg	NN	Pharmacological
b.i.d.	NN	Pharmacological
,	,	O
atenolol	RB	Pharmacological
50	CD	Pharmacological
mg	NN	Pharmacological
b.i.d	NN	Pharmacological
.	.	Pharmacological

and	CC	Control
placebo	JJ	Control
b.i.d	NN	Control
.	.	Control

Endogenous	JJ	O
insulin	NN	O
secretion	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
measuring	VBG	O
serum	JJ	O
insulin	NN	O
and	CC	O
C-peptide	NNP	O
before	IN	O
and	CC	O
6	CD	O
min	NN	O
after	IN	O
iv	JJ	O
administration	NN	O
of	IN	O
glucagon	NN	O
;	:	O
insulin	JJ	O
sensitivity	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
measuring	VBG	O
insulin	NN	O
binding	VBG	O
to	TO	O
erythrocytes	NNS	O
,	,	O
and	CC	O
as	IN	O
the	DT	O
glucose	JJ	O
disappearance	NN	O
rate	NN	O
(	(	O
KITT	NNP	O
)	)	O
after	IN	O
i.v	NN	O
.	.	O

insulin	NN	O
.	.	O

Fasting	VBG	O
concentrations	NNS	O
of	IN	O
serum	JJ	O
free	JJ	O
fatty	NN	O
acids	NNS	O
(	(	O
S-FFA	NNP	O
)	)	O
and	CC	O
plasma	JJ	O
gastric	JJ	O
inhibitory	NN	O
polypeptide	NN	O
(	(	O
P-GIP	NNP	O
)	)	O
were	VBD	O
also	RB	O
recorded	VBN	O
during	IN	O
the	DT	O
three	CD	O
study	NN	O
periods	NNS	O
.	.	O

Both	DT	O
propranolol	NN	Pharmacological
and	CC	O
atenolol	NN	Pharmacological
reduced	VBD	O
blood	NN	O
pressure	NN	O
,	,	O
heart	NN	O
rate	NN	O
and	CC	O
S-FFA	NNP	O
concentrations	NNS	O
compared	VBN	O
to	TO	O
placebo	VB	Control
,	,	O
and	CC	O
all	DT	O
patients	NNS	O
showed	VBD	O
measurable	JJ	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
propranolol	NN	O
and	CC	O
atenolol	NN	O
.	.	O

The	DT	O
results	NNS	O
can	MD	O
be	VB	O
considered	VBN	O
representative	JJ	O
,	,	O
therefore	RB	O
,	,	O
of	IN	O
clinical	JJ	O
beta-blockade	NN	O
.	.	O

The	DT	O
two	CD	O
drugs	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
influence	VB	O
the	DT	O
fasting	NN	O
blood	NN	O
glucose	JJ	O
level	NN	O
.	.	O

There	EX	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
fasting	VBG	O
and	CC	O
glucagon-stimulated	JJ	O
serum	NN	O
C-peptide	NNP	O
concentration	NN	O
during	IN	O
propranolol	JJ	O
therapy	NN	O
compared	VBN	O
with	IN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NN	O
0.037	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.030	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
although	IN	O
this	DT	O
was	VBD	O
not	RB	O
reflected	VBN	O
by	IN	O
a	DT	O
significant	JJ	O
change	NN	O
in	IN	O
serum	JJ	O
insulin	NN	O
.	.	O

Propranolol	NNP	Pharmacological
and	CC	O
atenolol	RB	O
did	VBD	O
not	RB	O
significantly	RB	O
influence	JJ	O
insulin	NN	O
binding	NN	O
to	TO	O
erythrocytes	NNS	O
,	,	O
but	CC	O
they	PRP	O
clearly	RB	O
reduced	VBD	O
the	DT	O
glucose	JJ	O
disappearance	NN	O
rate	NN	O
KITT	NNP	O
was	VBD	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
p	JJ	O
=	NN	O
0.0036	CD	O
and	CC	O
p	VB	O
=	NNP	O
0.0003	CD	O
)	)	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

The	DT	O
findings	NNS	O
support	VBP	O
the	DT	O
view	NN	O
that	IN	O
beta-blocking	JJ	O
drugs	NNS	O
can	MD	O
influence	VB	O
glucose	JJ	O
metabolism	NN	O
by	IN	O
mechanisms	NNS	O
other	JJ	O
than	IN	O
inhibition	NN	O
of	IN	O
endogenous	JJ	O
insulin	NN	O
secretion	NN	O
.	.	O

Clinical	JJ	O
and	CC	O
prognostic	JJ	O
significance	NN	O
of	IN	O
serum	NN	O
magnesium	NN	O
concentration	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
chronic	JJ	O
congestive	JJ	O
heart	NN	O
failure	NN	O
:	:	O
the	DT	O
PROMISE	NNP	O
Study	NNP	O
.	.	O

OBJECTIVES	NNP	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
prognostic	JJ	O
significance	NN	O
of	IN	O
alterations	NNS	O
in	IN	O
serum	JJ	O
magnesium	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
congestive	JJ	O
heart	NN	O
failure	NN	O
.	.	O

BACKGROUND	NNP	O
Reductions	NNPS	O
in	IN	O
serum	NN	O
magnesium	NN	O
have	VBP	O
been	VBN	O
postulated	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
promoting	VBG	O
arrhythmias	NN	O
and	CC	O
to	TO	O
have	VB	O
an	DT	O
adverse	JJ	O
impact	NN	O
on	IN	O
survival	NN	O
in	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
although	IN	O
support	NN	O
for	IN	O
this	DT	O
postulate	NN	O
is	VBZ	O
lacking	VBG	O
.	.	O

METHODS	NNP	O
Serum	NNP	O
magnesium	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
1,068	CD	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
a	DT	O
survival	NN	O
study	NN	O
of	IN	O
class	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
heart	NN	O
failure	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
double-blind	JJ	O
randomization	NN	O
to	TO	O
milrinone	VB	Pharmacological
,	,	O
a	DT	O
phosphodiesterase	NN	Pharmacological
inhibitor	NN	Pharmacological
,	,	O
or	CC	O
placebo	NN	Control
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
conventional	JJ	Pharmacological
therapy	NN	Pharmacological
with	IN	Pharmacological
digoxin	NN	Pharmacological
,	,	Pharmacological
diuretic	JJ	Pharmacological
drugs	NNS	Pharmacological
and	CC	Pharmacological
a	DT	Pharmacological
converting	VBG	Pharmacological
enzyme	NN	Pharmacological
inhibitor	NN	Pharmacological
throughout	IN	O
the	DT	O
trial	NN	O
.	.	O

The	DT	O
median	JJ	O
follow-up	JJ	O
period	NN	O
was	VBD	O
6.1	CD	O
months	NNS	O
(	(	O
range	VB	O
1	CD	O
day	NN	O
to	TO	O
20	CD	O
months	NNS	O
)	)	O
.	.	O

RESULTS	JJ	O
Patients	NNS	O
with	IN	O
high	JJ	O
serum	NN	O
magnesium	NN	O
(	(	O
defined	VBN	O
as	IN	O
>	NN	O
or	CC	O
=	$	O
1.9	CD	O
mEq/liter	NN	O
,	,	O
n	JJ	O
=	NNP	O
242	CD	O
)	)	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
survive	VB	O
than	IN	O
were	VBD	O
patients	NNS	O
with	IN	O
a	DT	O
normal	JJ	O
magnesium	NN	O
level	NN	O
(	(	O
n	JJ	O
=	NNP	O
627	CD	O
)	)	O
(	(	O
p	JJ	O
<	NN	O
0.05	CD	O
,	,	O
risk	NN	O
ratio	NN	O
=	NNP	O
1.41	CD	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
low	JJ	O
magnesium	NN	O
level	NN	O
(	(	O
defined	VBN	O
as	IN	O
<	NN	O
or	CC	O
=	$	O
1.5	CD	O
mEq/liter	NN	O
,	,	O
n	JJ	O
=	NNP	O
199	CD	O
)	)	O
had	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	O
compared	VBN	O
with	IN	O
the	DT	O
group	NN	O
with	IN	O
a	DT	O
normal	JJ	O
magnesium	NN	O
level	NN	O
(	(	O
p	JJ	O
=	NNP	O
NS	NNP	O
,	,	O
risk	NN	O
ratio	NN	O
=	NNP	O
0.89	CD	O
)	)	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
high	JJ	O
magnesium	NN	O
group	NN	O
were	VBD	O
older	JJR	O
and	CC	O
had	VBD	O
more	RBR	O
severe	JJ	O
functional	JJ	O
and	CC	O
renal	JJ	O
impairment	NN	O
.	.	O

An	DT	O
analysis	NN	O
after	IN	O
adjustment	NN	O
for	IN	O
these	DT	O
variables	NNS	O
demonstrated	VBD	O
no	DT	O
difference	NN	O
in	IN	O
survival	NN	O
comparing	VBG	O
the	DT	O
low	JJ	O
,	,	O
normal	JJ	O
and	CC	O
high	JJ	O
magnesium	NN	O
groups	NNS	O
.	.	O

Although	IN	O
the	DT	O
three	CD	O
groups	NNS	O
had	VBD	O
no	DT	O
difference	NN	O
in	IN	O
frequency	NN	O
of	IN	O
ventricular	JJ	O
tachycardia	NN	O
,	,	O
length	NN	O
of	IN	O
longest	JJS	O
run	NN	O
or	CC	O
frequency	NN	O
of	IN	O
ventricular	JJ	O
premature	NN	O
beats	NNS	O
on	IN	O
baseline	NN	O
Holter	NNP	O
monitoring	NN	O
,	,	O
the	DT	O
group	NN	O
with	IN	O
hypomagnesemia	NN	O
had	VBD	O
more	RBR	O
frequent	JJ	O
ventricular	JJ	O
couplets	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Serum	NNP	O
magnesium	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
an	DT	O
independent	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
either	DT	O
sudden	JJ	O
death	NN	O
or	CC	O
death	NN	O
due	JJ	O
to	TO	O
all	DT	O
causes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
heart	NN	O
failure	NN	O
.	.	O

Hypomagnesemia	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
frequency	NN	O
of	IN	O
certain	JJ	O
forms	NNS	O
of	IN	O
ventricular	JJ	O
ectopic	NN	O
activity	NN	O
,	,	O
but	CC	O
this	DT	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
clinical	JJ	O
events	NNS	O
.	.	O

The	DT	O
higher	JJR	O
mortality	NN	O
rate	NN	O
among	IN	O
the	DT	O
patients	NNS	O
with	IN	O
hypermagnesemia	NN	O
is	VBZ	O
attributable	JJ	O
to	TO	O
older	JJR	O
age	NN	O
,	,	O
more	RBR	O
advanced	JJ	O
heart	NN	O
failure	NN	O
and	CC	O
renal	JJ	O
insufficiency	NN	O
.	.	O

Comparative	JJ	O
clinical	JJ	O
and	CC	O
microbiological	JJ	O
effects	NNS	O
of	IN	O
subgingival	JJ	O
metronidazole	JJ	Pharmacological
application	NN	O
in	IN	O
adult	NN	O
periodontitis	NN	O
;	:	O
12-months	JJ	O
results	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
clinical	JJ	O
and	CC	O
microbiological	JJ	O
effects	NNS	O
of	IN	O
subgingival	JJ	O
application	NN	O
of	IN	O
25	CD	O
%	NN	O
metronidazole	JJ	Pharmacological
dental	JJ	Pharmacological
gel	NN	Pharmacological
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
scaling	NN	Physical
and	CC	Physical
root	NN	Physical
planing	NN	Physical
(	(	Physical
SRP	NNP	Physical
)	)	Physical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adult	NN	O
periodontitis	NN	O
.	.	O

Eighty	NNP	O
teeth	VBZ	O
in	IN	O
18	CD	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
split	NN	O
mouth	NN	O
design	NN	O
.	.	O

The	DT	O
test	NN	O
teeth	NN	O
received	VBD	O
SRP	NNP	Physical
and	CC	O
a	DT	O
25	CD	O
%	NN	O
metronidazole	JJ	Pharmacological
gel	NN	Pharmacological
applied	VBN	O
subgingivally	RB	O
on	IN	O
days	NNS	O
0	CD	O
and	CC	O
7	CD	O
.	.	O

The	DT	O
control	NN	O
teeth	VBZ	O
received	VBN	O
SRP	NNP	Control
only	RB	Control
.	.	O

Clinical	JJ	O
and	CC	O
microbiological	JJ	O
examinations	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
before	IN	O
treatment	NN	O
and	CC	O
on	IN	O
weeks	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
13	CD	O
,	,	O
26	CD	O
,	,	O
38	CD	O
and	CC	O
52	CD	O
of	IN	O
the	DT	O
experimental	JJ	O
period	NN	O
.	.	O

Colony	NNP	O
forming	VBG	O
units	NNS	O
of	IN	O
Porphyromonas	NNP	O
gingivalis	NN	O
and	CC	O
Prevotella	NNP	O
intermedia	VBP	O
/	NNP	O
Prevotella	NNP	O
nigrescens	NNS	O
were	VBD	O
determined	VBN	O
.	.	O

Both	DT	O
treatments	NNS	O
provided	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
all	PDT	O
the	DT	O
clinical	JJ	O
and	CC	O
microbiological	JJ	O
parameters	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
differences	NNS	O
between	IN	O
the	DT	O
study	NN	O
groups	NNS	O
were	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

As	IN	O
a	DT	O
conclusion	NN	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
does	VBZ	O
not	RB	O
provide	VB	O
evidence	NN	O
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
routine	JJ	O
use	NN	O
of	IN	O
adjunctive	JJ	O
metronidazole	JJ	O
dental	NN	O
gel	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adult	NN	O
periodontitis	NN	O
.	.	O

Effects	NNS	O
of	IN	O
Saccharomyces	NNP	Pharmacological
boulardii	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
.	.	O

AIM	NNP	O
Certain	NNP	O
probiotic	JJ	O
agents	NNS	O
,	,	O
e.g	NN	O
.	.	O

Lactobacillus	CC	O
GG	NNP	O
,	,	O
have	VBP	O
shown	VBN	O
efficacy	NN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
childhood	NN	O
diarrhoea	NN	O
,	,	O
but	CC	O
few	JJ	O
studies	NNS	O
have	VBP	O
examined	VBN	O
the	DT	O
effect	NN	O
of	IN	O
Saccharomyces	NNP	Pharmacological
boulardii	NN	Pharmacological
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
S.	NNP	O
boulardii	NN	O
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
.	.	O

METHODS	NNP	O
Two	CD	O
hundred	VBD	O
children	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
S.	NNP	O
boulardii	NN	O
in	IN	O
a	DT	O
granulated	JJ	O
form	NN	O
in	IN	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
250	CD	O
mg	NN	O
(	(	Pharmacological
S.	NNP	Pharmacological
boulardii	NNP	Pharmacological
group	NN	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	Control
placebo	JJ	Control
group	NN	O
)	)	O
for	IN	O
5	CD	O
d.	JJ	O
Clinical	NNP	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
on	IN	O
admission	NN	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
study	NN	O
groups	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
medians	NNS	O
of	IN	O
the	DT	O
average	JJ	O
stool	NN	O
frequency	NN	O
after	IN	O
the	DT	O
second	JJ	O
day	NN	O
of	IN	O
the	DT	O
treatment	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
diarrhoea	NN	O
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
4.7	CD	O
vs	RB	O
5.5	CD	O
d	NN	O
,	,	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
S.	NNP	O
boulardii	NN	O
on	IN	O
watery	NN	O
diarrhoea	NN	O
became	VBD	O
apparent	JJ	O
after	IN	O
the	DT	O
second	JJ	O
day	NN	O
of	IN	O
the	DT	O
treatment	NN	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
was	VBD	O
shorter	JJR	O
in	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
2.9	CD	O
vs	RB	O
3.9	CD	O
d	NN	O
,	,	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Four	CD	O
children	NNS	O
from	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
versus	VBD	O
only	RB	O
one	CD	O
child	NN	O
from	IN	O
the	DT	O
S.	NNP	O
boulardii	NN	O
group	NN	O
had	VBD	O
persisting	VBG	O
diarrhoea	NN	O
.	.	O

CONCLUSION	VB	O
The	DT	O
placebo-controlled	JJ	Control
study	NN	O
suggested	VBD	O
that	IN	O
S.	NNP	O
boulardii	VBP	O
significantly	RB	O
reduced	VBN	O
the	DT	O
duration	NN	O
of	IN	O
acute	JJ	O
diarrhoea	NN	O
and	CC	O
the	DT	O
duration	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
.	.	O

S.	NNP	O
boulardii	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
a	DT	O
promising	JJ	O
agent	NN	O
for	IN	O
the	DT	O
amelioration	NN	O
of	IN	O
the	DT	O
course	NN	O
of	IN	O
acute	JJ	O
diarrhoea	NN	O
in	IN	O
children	NNS	O
when	WRB	O
used	VBN	O
therapeutically	RB	O
.	.	O

Moist	NN	Pharmacological
Exposed	VBD	Pharmacological
Burn	NNP	Pharmacological
Ointment	NNP	Pharmacological
(	(	Pharmacological
MEBO	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
partial	JJ	O
thickness	NN	O
burns	NNS	O
-	:	O
a	DT	O
randomized	JJ	O
,	,	O
comparative	JJ	O
open	JJ	O
mono-center	NN	O
study	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
dermaheal	NN	Pharmacological
(	(	Pharmacological
MEBO	NNP	Pharmacological
)	)	Pharmacological
ointment	NN	O
on	IN	O
thermal	JJ	O
2nd	CD	O
degree	NN	O
burns	NNS	O
compared	VBN	O
to	TO	O
conventional	JJ	O
therapy	NN	O
.	.	O

OBJECTIVE	NNP	O
Wound	NNP	O
healing	NN	O
in	IN	O
burn	NN	O
wounds	NNS	O
presents	VBZ	O
a	DT	O
challenge	NN	O
in	IN	O
healthcare	NN	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
still	RB	O
a	DT	O
lack	NN	O
of	IN	O
alternatives	NNS	O
in	IN	O
topical	JJ	O
burn	NN	O
wound	NN	O
treatments	NNS	O
.	.	O

-	:	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
therapeutic	JJ	O
ointment	NN	O
(	(	O
MEBO	NNP	Pharmacological
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
partial	JJ	O
thickness	NN	O
burns	NNS	O
.	.	O

METHODS	NNP	O
40	CD	O
patients	NNS	O
received	VBD	O
either	RB	O
topical	JJ	O
treatment	NN	O
with	IN	O
Moist	NNP	Pharmacological
Exposed	VBD	Pharmacological
Burn	NNP	Pharmacological
Ointment	NNP	Pharmacological
(	(	Pharmacological
MEBO	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
standard	JJ	O
Flammazine	NNP	Pharmacological
treatment	NN	Pharmacological
.	.	O

All	DT	O
patients	NNS	O
suffered	VBD	O
from	IN	O
partial-thickness	JJ	O
burn	NN	O
injuries	NNS	O
(	(	O
<	VB	O
20	CD	O
%	NN	O
TBSA	NNP	O
)	)	O
.	.	O

Wounds	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
60	CD	O
up	RB	O
to	TO	O
days	NNS	O
regarding	VBG	O
wound	NN	O
healing	NN	O
,	,	O
water	NN	O
loss	NN	O
,	,	O
inflammation	NN	O
,	,	O
and	CC	O
pain	NN	O
alleviation	NN	O
.	.	O

RESULTS	NNP	O
For	IN	O
transepidermal	JJ	O
water	NN	O
loss	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
difference	NN	O
of	IN	O
2.3	CD	O
gr/m2/h	NN	O
between	IN	O
MEBO	NNP	Pharmacological
,	,	O
and	CC	O
Flammazine	NNP	Pharmacological
,	,	O
favoring	VBG	O
MEBO	NNP	Pharmacological
.	.	O

However	RB	O
,	,	O
this	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p=0.78	NN	O
)	)	O
.	.	O

For	IN	O
all	DT	O
secondary	JJ	O
efficacy	NN	O
parameter	NN	O
results	NNS	O
were	VBD	O
similar	JJ	O
.	.	O

-	:	O
CONCLUSIONS	NN	O
This	DT	O
study	NN	O
showed	VBD	O
that	IN	O
MEBO	NNP	Pharmacological
ointment	NN	Pharmacological
for	IN	O
topical	JJ	O
treatment	NN	O
of	IN	O
burn	NN	O
injuries	NNS	O
presents	VBZ	O
an	DT	O
attractive	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
topical	JJ	O
treatment	NN	O
of	IN	O
limited	JJ	O
partial	JJ	O
thickness	NN	O
thermal	JJ	O
burns	NNS	O
.	.	O

Modulation	NN	Physical
of	IN	Physical
oxidant	JJ	Physical
stress	NN	Physical
in	IN	Physical
vivo	NN	Physical
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

BACKGROUND	NNP	O
Free	JJ	O
radical-induced	JJ	O
oxidative	JJ	O
damage	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
diseases	NNS	O
associated	VBN	O
with	IN	O
cigarette	NN	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
production	NN	O
of	IN	O
8-epi-prostaglandin	JJ	Pharmacological
(	(	Pharmacological
PG	NNP	Pharmacological
)	)	Pharmacological
F2	NNP	Pharmacological
alpha	NN	Pharmacological
,	,	Pharmacological
a	DT	Pharmacological
stable	JJ	Pharmacological
product	NN	Pharmacological
of	IN	Pharmacological
lipid	JJ	Pharmacological
peroxidation	NN	Pharmacological
in	IN	Pharmacological
vivo	NN	Pharmacological
,	,	O
and	CC	O
its	PRP$	O
modulation	NN	O
by	IN	O
aspirin	NN	Pharmacological
and	CC	O
antioxidant	JJ	Pharmacological
vitamins	NNS	Pharmacological
in	IN	O
chronic	JJ	O
cigarette	NN	O
smokers	NNS	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
the	DT	O
following	JJ	O
studies	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
cross-sectional	JJ	O
comparison	NN	O
of	IN	O
smokers	NNS	O
and	CC	O
control	NN	O
subjects	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
an	DT	O
examination	NN	O
of	IN	O
the	DT	O
dose-response	JJ	O
relationship	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
an	DT	O
exploration	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
smoking	VBG	Educational
cessation	NN	Educational
(	(	O
3	CD	O
weeks	NNS	O
)	)	O
and	CC	O
nicotine	JJ	Pharmacological
patch	NN	Pharmacological
supplementation	NN	Pharmacological
,	,	O
(	(	O
4	CD	O
)	)	O
the	DT	O
effect	NN	O
of	IN	O
aspirin	NN	Pharmacological
consumption	NN	Pharmacological
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
the	DT	O
effects	NNS	O
of	IN	O
5	CD	O
days	NNS	O
'	POS	O
dosing	VBG	O
with	IN	O
vitamin	NN	Pharmacological
E	NNP	Pharmacological
(	(	O
100	CD	O
and	CC	O
800	CD	O
U	NNP	O
)	)	O
,	,	O
vitamin	FW	Pharmacological
C	NNP	Pharmacological
(	(	O
2	CD	O
g	NN	O
)	)	O
,	,	O
and	CC	O
their	PRP$	O
combination	NN	O
.	.	O

8-epi-PGF2	JJ	O
alpha	JJ	O
excretion	NN	O
(	(	O
in	IN	O
pmol/mmol	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
SEM	NNP	O
)	)	O
was	VBD	O
176.5+/-30.6	JJ	O
in	IN	O
heavy	JJ	O
smokers	NNS	O
,	,	O
92.7+/-4.8	CD	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
in	IN	O
moderate	JJ	O
smokers	NNS	O
,	,	O
and	CC	O
54.1+/-2.7	JJ	O
(	(	O
P	NNP	O
<	NNP	O
.005	NNP	O
)	)	O
in	IN	O
nonsmokers	NNS	O
.	.	O

Urinary	JJ	O
levels	NNS	O
fell	VBD	O
from	IN	O
145.5+/-24.9	CD	O
to	TO	O
114.6+/-27.1	CD	O
(	(	O
week	NN	O
2	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
112.6+/-24.9	JJ	O
(	(	O
week	NN	O
3	CD	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
on	IN	O
cessation	NN	O
of	IN	O
smoking	NN	O
.	.	O

Aspirin	NNP	Pharmacological
treatment	NN	Pharmacological
failed	VBD	O
to	TO	O
suppress	VB	O
urinary	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
despite	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
urinary	JJ	O
11-dehydro-TxB2	JJ	O
production	NN	O
and	CC	O
suppression	NN	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
and	CC	O
TxB2	NNP	O
in	IN	O
serum	NN	O
.	.	O

Vitamin	NNP	Pharmacological
C	NNP	Pharmacological
(	(	O
pre	NN	O
,	,	O
194.6+/-40.9	JJ	O
;	:	O
post	NN	O
,	,	O
137.2+/-34.1	JJ	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
a	DT	O
combination	NN	Pharmacological
of	IN	Pharmacological
vitamin	JJ	Pharmacological
C	NNP	Pharmacological
and	CC	Pharmacological
E	NNP	Pharmacological
(	(	O
pre	NN	O
,	,	O
171.0+/-39.8	JJ	O
;	:	O
post	NN	O
,	,	O
133.5+/-29.6	JJ	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
suppressed	VBD	O
urinary	JJ	O
8-epi-PGF2	JJ	O
alpha	NN	O
,	,	O
whereas	IN	O
vitamin	JJ	Pharmacological
E	NNP	Pharmacological
alone	RB	O
had	VBD	O
no	DT	O
effect	NN	O
.	.	O

CONCLUSIONS	NNP	O
Urinary	NNP	O
8-epi-PGF2	JJ	O
alpha	NN	O
may	MD	O
represent	VB	O
a	DT	O
noninvasive	JJ	O
,	,	O
quantitative	JJ	O
index	NN	O
of	IN	O
oxidant	JJ	O
stress	NN	O
in	IN	O
vivo	NN	O
.	.	O

Elevated	JJ	O
levels	NNS	O
of	IN	O
8-epi-PGF2	JJ	O
alpha	NN	O
in	IN	O
smokers	NNS	O
may	MD	O
be	VB	O
modulated	VBN	O
by	IN	O
quitting	VBG	Educational
cigarettes	NNS	Educational
and	CC	O
switching	VBG	Pharmacological
to	TO	Pharmacological
nicotine	VB	Pharmacological
patches	NNS	Pharmacological
or	CC	O
by	IN	O
antioxidant	JJ	Pharmacological
vitamin	NN	Pharmacological
therapy	NN	Pharmacological
.	.	O

Abdominoperineal	NNP	Physical
resection	NN	Physical
and	CC	O
anterior	JJ	Physical
resection	NN	Physical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
rectal	JJ	O
cancer	NN	O
:	:	O
results	NNS	O
in	IN	O
relation	NN	O
to	TO	O
adjuvant	VB	Physical
preoperative	JJ	Physical
radiotherapy	NN	Physical
.	.	O

The	DT	O
outcome	NN	O
of	IN	O
patients	NNS	O
with	IN	O
rectal	JJ	O
cancer	NN	O
treated	VBN	O
by	IN	O
abdominoperineal	NN	Surgical
or	CC	Surgical
anterior	JJ	Surgical
resection	NN	Surgical
,	,	Physical
with	IN	Physical
or	CC	Physical
without	IN	Physical
preoperative	JJ	Physical
radiotherapy	NN	Physical
,	,	O
was	VBD	O
assessed	VBN	O
to	TO	O
detect	VB	O
any	DT	O
differences	NNS	O
attributable	JJ	O
to	TO	O
the	DT	O
operative	JJ	O
method	NN	O
and	CC	O
interactions	NNS	O
between	IN	O
radiotherapy	NN	O
and	CC	O
type	NN	O
of	IN	O
surgery	NN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
based	VBN	O
on	IN	O
1292	CD	O
patients	NNS	O
included	VBN	O
in	IN	O
two	CD	O
consecutive	JJ	O
controlled	VBN	O
randomized	JJ	O
trials	NNS	O
of	IN	O
preoperative	JJ	Physical
radiotherapy	NN	Physical
in	IN	O
operable	JJ	O
rectal	JJ	O
carcinoma	NN	O
.	.	O

The	DT	O
outcome	NN	O
was	VBD	O
not	RB	O
related	VBN	O
to	TO	O
surgical	JJ	O
method	NN	O
.	.	O

Radiotherapy	NNP	O
increased	VBD	O
postoperative	JJ	O
mortality	NN	O
and	CC	O
complications	NNS	O
and	CC	O
reduced	JJ	O
local	JJ	O
and	CC	O
distant	JJ	O
recurrence	NN	O
,	,	O
but	CC	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
overall	JJ	O
survival	NN	O
.	.	O

Effects	NNS	O
of	IN	O
radiotherapy	NN	Physical
were	VBD	O
similar	JJ	O
irrespective	NN	O
of	IN	O
the	DT	O
type	NN	O
of	IN	O
surgery	NN	O
,	,	O
except	IN	O
that	IN	O
the	DT	O
increase	NN	O
in	IN	O
postoperative	JJ	O
mortality	NN	O
in	IN	O
irradiated	JJ	O
patients	NNS	O
was	VBD	O
greater	JJR	O
in	IN	O
those	DT	O
treated	VBN	O
with	IN	O
abdominoperineal	JJ	O
resection	NN	O
.	.	O

Sphincter-saving	JJ	Educational
procedures	NNS	Educational
appear	VBP	O
to	TO	O
have	VB	O
no	DT	O
adverse	JJ	O
effects	NNS	O
on	IN	O
outcome	NN	O
of	IN	O
rectal	JJ	O
cancer	NN	O
,	,	O
but	CC	O
the	DT	O
optimum	JJ	O
use	NN	O
of	IN	O
radiotherapy	NN	O
is	VBZ	O
still	RB	O
to	TO	O
be	VB	O
defined	VBN	O
.	.	O

Amonafide	NN	Pharmacological
:	:	O
An	DT	O
active	JJ	O
agent	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
previously	RB	O
untreated	VBN	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
--	:	O
a	DT	O
cancer	NN	O
and	CC	O
leukemia	NN	O
group	NN	O
B	NNP	O
study	NN	O
(	(	O
CALGB	NNP	O
8642	CD	O
)	)	O
.	.	O

Amonafide	NNP	Pharmacological
is	VBZ	O
a	DT	O
new	JJ	O
imide	JJ	O
derivative	NN	O
of	IN	O
naphthalic	JJ	O
acid	NN	O
.	.	O

The	DT	O
drug	NN	O
had	VBD	O
demonstrated	VBN	O
significant	JJ	O
activity	NN	O
in	IN	O
preclinical	JJ	O
studies	NNS	O
and	CC	O
some	DT	O
activity	NN	O
in	IN	O
Phase	NNP	O
I	PRP	O
trials	NNS	O
.	.	O

The	DT	O
drug	NN	O
is	VBZ	O
extensively	RB	O
metabolized	VBN	O
and	CC	O
detected	VBN	O
in	IN	O
plasma	NN	O
and	CC	O
urine	NN	O
.	.	O

Its	PRP$	O
toxicity	NN	O
has	VBZ	O
previously	RB	O
been	VBN	O
correlated	VBN	O
to	TO	O
the	DT	O
formation	NN	O
of	IN	O
an	DT	O
active	JJ	O
metabolite	NN	O
,	,	O
N-acetyl-amonafide	NNP	O
.	.	O

Amonafide	NNP	Pharmacological
was	VBD	O
chosen	VBN	O
for	IN	O
inclusion	NN	O
in	IN	O
the	DT	O
Cancer	NNP	O
and	CC	O
Leukemia	NNP	O
Group	NNP	O
B	NNP	O
(	(	O
CALGB	NNP	O
)	)	O
master	NN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
protocol	NN	O
.	.	O

CALGB	NNP	O
8642	CD	O
randomizes	VBZ	O
previously	RB	O
untreated	VBN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
either	CC	O
to	TO	O
one	CD	O
of	IN	O
several	JJ	O
Phase	NNP	O
II	NNP	O
agents	NNS	O
given	VBN	O
for	IN	O
up	IN	O
to	TO	O
four	CD	O
cycles	NNS	O
and	CC	O
then	RB	O
followed	VBN	O
by	IN	O
standard	JJ	Pharmacological
cyclophosphamide-doxorubicin-5-fluorouracil	NN	Pharmacological
,	,	O
or	CC	O
to	TO	O
immediate	VB	Physical
treatment	NN	Physical
with	IN	Physical
standard	JJ	Physical
cyclophosphamide-doxorubicin-5-fluorouracil	NN	Physical
.	.	O

The	DT	O
end	NN	O
point	NN	O
of	IN	O
CALGB	NNP	O
8642	CD	O
is	VBZ	O
to	TO	O
assess	VB	O
the	DT	O
difference	NN	O
in	IN	O
survival	NN	O
,	,	O
toxicity	NN	O
,	,	O
and	CC	O
overall	JJ	O
response	NN	O
when	WRB	O
limited	JJ	O
exposure	NN	O
to	TO	O
Phase	NNP	O
II	NNP	O
agents	NNS	O
precedes	VBZ	O
standard	JJ	O
chemotherapy	NN	O
.	.	O

This	DT	O
report	NN	O
deals	VBZ	O
only	RB	O
with	IN	O
amonafide	RB	Pharmacological
as	IN	O
a	DT	O
Phase	NNP	O
II	NNP	O
agent	NN	O
.	.	O

Comparisons	NNS	O
with	IN	O
the	DT	O
cyclophosphamide-doxorubicin-5-fluorouracil	JJ	Pharmacological
arm	NN	O
will	MD	O
not	RB	O
be	VB	O
addressed	VBN	O
.	.	O

Patients	NNS	O
had	VBD	O
to	TO	O
have	VB	O
histologically	RB	O
documented	VBN	O
measurable	JJ	O
breast	NN	O
cancer	NN	O
and	CC	O
a	DT	O
performance	NN	O
status	NN	O
of	IN	O
0-1	NNP	O
.	.	O

Patients	NNS	O
could	MD	O
not	RB	O
have	VB	O
had	VBN	O
prior	JJ	O
chemotherapy	NN	O
for	IN	O
metastatic	JJ	O
disease	NN	O
.	.	O

Prior	NNP	O
adjuvant	JJ	O
chemotherapy	NN	O
was	VBD	O
permitted	VBN	O
.	.	O

Patients	NNS	O
could	MD	O
not	RB	O
have	VB	O
visceral	JJ	O
crisis	NN	O
.	.	O

Amonafide	NNP	Pharmacological
was	VBD	O
given	VBN	O
at	IN	O
300	CD	O
mg/m2/day	JJ	O
i.v	NN	O
.	.	O

for	IN	O
5	CD	O
days	NNS	O
,	,	O
and	CC	O
repeated	VBD	O
at	IN	O
21-day	JJ	O
intervals	NNS	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
four	CD	O
cycles	NNS	O
.	.	O

Escalation	NN	O
and	CC	O
reduction	NN	O
in	IN	O
dose	NN	O
was	VBD	O
mandated	VBN	O
dependent	NN	O
on	IN	O
hematotoxicity	NN	O
or	CC	O
lack	NN	O
thereof	NN	O
.	.	O

Toxicity	NN	O
was	VBD	O
primarily	RB	O
hematological	JJ	O
and	CC	O
bimodal	NN	O
:	:	O
32	CD	O
%	NN	O
had	VBD	O
grade	VBN	O
3	CD	O
or	CC	O
4	CD	O
leukopenia	NN	O
and	CC	O
24	CD	O
%	NN	O
had	VBD	O
grade	VBN	O
3	CD	O
or	CC	O
4	CD	O
thrombocytopenia	NN	O
;	:	O
22	CD	O
%	NN	O
had	VBD	O
no	DT	O
leukopenia	NN	O
and	CC	O
44	CD	O
%	NN	O
had	VBD	O
no	DT	O
thrombocytopenia	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
was	VBD	O
18	CD	O
%	NN	O
,	,	O
including	VBG	O
one	CD	O
complete	JJ	O
response	NN	O
.	.	O

When	WRB	O
response	NN	O
was	VBD	O
analyzed	VBN	O
by	IN	O
hematological	JJ	O
toxicity	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
35.7	CD	O
%	NN	O
response	NN	O
if	IN	O
patients	NNS	O
had	VBD	O
leukopenia	VBN	O
grade	NN	O
3/4	CD	O
(	(	O
versus	IN	O
8.3	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.08	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
50	CD	O
%	NN	O
response	NN	O
if	IN	O
patients	NNS	O
had	VBD	O
thrombocytopenia	VBN	O
grade	NN	O
3/4	CD	O
(	(	O
versus	IN	O
7.1	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
amonafide	NN	Pharmacological
is	VBZ	O
somewhat	RB	O
active	JJ	O
in	IN	O
previously	RB	O
untreated	VBN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
.	.	O

There	EX	O
may	MD	O
be	VB	O
a	DT	O
steep	JJ	O
dose-response	NN	O
curve	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
significant	JJ	O
correlation	NN	O
between	IN	O
myelosuppression	NN	O
and	CC	O
response	NN	O
.	.	O

Rates	NNS	O
of	IN	O
responses	NNS	O
in	IN	O
patients	NNS	O
adequately	RB	O
dosed	VBN	O
(	(	O
i.e.	FW	O
,	,	O
with	IN	O
significant	JJ	O
hematotoxicity	NN	O
)	)	O
with	IN	O
amonafide	NN	O
ranged	VBD	O
from	IN	O
35	CD	O
to	TO	O
50	CD	O
%	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
will	MD	O
incorporate	VB	O
individualized	JJ	O
dosing	NN	O
based	VBN	O
on	IN	O
pretreatment	NN	O
acetylator	NN	O
phenotyping	NN	O
.	.	O

Butorphanol	NNP	Pharmacological
and	CC	O
meperidine	NN	Pharmacological
compared	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
ureteral	JJ	O
colic	NN	O
.	.	O

Pain	NNP	O
relief	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
81	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
ureteral	JJ	O
colic	NN	O
and	CC	O
the	DT	O
confirmed	JJ	O
presence	NN	O
of	IN	O
a	DT	O
calculus	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	JJ	O
comparison	NN	O
of	IN	O
intramuscular	JJ	O
2	CD	O
and	CC	O
4	CD	O
mg.	NN	O
butorphanol	NN	Pharmacological
and	CC	O
80	CD	O
mg.	NNS	O
meperidine	NN	Pharmacological
was	VBD	O
used	VBN	O
.	.	O

Pain	NNP	O
intensity	NN	O
and	CC	O
pain	NN	O
relief	NN	O
were	VBD	O
evaluated	VBN	O
at	IN	O
half	JJ	O
hour	NN	O
and	CC	O
hourly	JJ	O
intervals	NNS	O
for	IN	O
4	CD	O
hours	NNS	O
.	.	O

A	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	Pharmacological
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
analgesically	RB	O
equivalent	JJ	O
to	TO	O
80	CD	O
mg.	NNS	O
meperidine	NN	Pharmacological
,	,	O
while	IN	O
a	DT	O
4	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	Pharmacological
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
80	CD	O
mg.	JJ	O
meperidine	NN	Pharmacological
and	CC	O
2	CD	O
mg.	NN	O
butorphanol	NN	Pharmacological
.	.	O

Each	DT	O
patient	NN	O
received	VBD	O
up	RB	O
to	TO	O
2	CD	O
doses	NNS	O
of	IN	O
analgesic	JJ	O
medication	NN	O
when	WRB	O
necessary	JJ	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
among	IN	O
treatments	NNS	O
.	.	O

One	CD	O
patient	NN	O
had	VBD	O
visual	JJ	O
hallucinations	NNS	O
after	IN	O
a	DT	O
2	CD	O
mg.	NN	O
dose	NN	O
of	IN	O
butorphanol	NN	Pharmacological
,	,	O
possibly	RB	O
owing	VBG	O
to	TO	O
its	PRP$	O
antagonistic	JJ	O
activity	NN	O
to	TO	O
significant	JJ	O
narcotic	JJ	O
experience	NN	O
given	VBN	O
previously	RB	O
at	IN	O
another	DT	O
hospital	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
other	JJ	O
evidence	NN	O
of	IN	O
toxicity	NN	O
with	IN	O
butorphanol	NN	Pharmacological
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
,	,	O
effective	JJ	O
and	CC	O
wall	RB	O
tolerated	JJ	O
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ureteral	JJ	O
colic	NN	O
and	CC	O
is	VBZ	O
recommended	VBN	O
in	IN	O
place	NN	O
of	IN	O
narcotics	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
sitaxsentan	JJ	Pharmacological
50	CD	O
and	CC	O
100	CD	O
mg	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
arterial	JJ	O
hypertension	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
assess	VB	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
sitaxsentan	JJ	O
50	CD	O
and	CC	O
100	CD	O
mg	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
pulmonary	JJ	O
arterial	JJ	O
hypertension	NN	O
(	(	O
PAH	NNP	O
)	)	O
.	.	O

BACKGROUND	NNP	O
Sitaxsentan	NNP	O
is	VBZ	O
a	DT	O
highly	RB	O
selective	JJ	O
endothelin-A	JJ	O
receptor	NN	O
antagonist	NN	O
that	WDT	O
was	VBD	O
recently	RB	O
withdrawn	VBN	O
by	IN	O
the	DT	O
manufacturer	NN	O
because	IN	O
of	IN	O
a	DT	O
pattern	NN	O
of	IN	O
idiosyncratic	JJ	O
liver	JJ	O
injury	NN	O
.	.	O

METHODS	NNP	O
Before	IN	O
sitaxsentan	NN	O
withdrawal	NN	O
,	,	O
this	DT	O
18-week	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
randomized	VBD	O
patients	NNS	O
with	IN	O
PAH	NNP	O
to	TO	O
receive	VB	O
placebo	NN	O
or	CC	O
sitaxsentan	VB	O
50	CD	O
or	CC	O
100	CD	O
mg	NNS	O
once	RB	O
daily	RB	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
6-min	JJ	O
walk	NN	O
distance	NN	O
(	(	O
6MWD	CD	O
)	)	O
at	IN	O
week	NN	O
18	CD	O
.	.	O

Changes	NNS	O
in	IN	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
(	(	O
WHO	NNP	O
)	)	O
functional	JJ	O
class	NN	O
and	CC	O
time	NN	O
to	TO	O
clinical	JJ	O
worsening	NN	O
(	(	O
TTCW	NNP	O
)	)	O
were	VBD	O
secondary	JJ	O
endpoints	NNS	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
analysis	NN	O
was	VBD	O
powered	VBN	O
for	IN	O
sitaxsentan	JJ	O
100	CD	O
mg	NN	O
versus	NN	O
placebo	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
98	CD	O
randomized	JJ	O
patients	NNS	O
,	,	O
61	CD	O
%	NN	O
were	VBD	O
WHO	NNP	O
functional	JJ	O
class	NN	O
II	NNP	O
at	IN	O
baseline	NN	O
.	.	O

Improvement	NN	O
from	IN	O
baseline	NN	O
to	TO	O
week	NN	O
18	CD	O
in	IN	O
6MWD	CD	O
occurred	VBD	O
with	IN	O
sitaxsentan	JJ	O
100	CD	O
but	CC	O
not	RB	O
50	CD	O
mg	NNS	O
;	:	O
a	DT	O
strong	JJ	O
placebo	NN	O
effect	NN	O
was	VBD	O
observed	VBN	O
.	.	O

At	IN	O
week	NN	O
18	CD	O
,	,	O
WHO	NNP	O
functional	VBP	O
class	NN	O
was	VBD	O
improved	VBN	O
or	CC	O
maintained	VBN	O
in	IN	O
more	RBR	O
patients	NNS	O
receiving	VBG	O
sitaxsentan	JJ	O
100	CD	O
mg	NN	O
than	IN	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
;	:	O
0	CD	O
%	NN	O
versus	IN	O
12	CD	O
%	NN	O
of	IN	O
patients	NNS	O
deteriorated	VBN	O
,	,	O
respectively	RB	O
.	.	O

TTCW	NNP	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
for	IN	O
100-mg	JJ	O
sitaxsentan	NN	O
patients	NNS	O
than	IN	O
placebo	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.090	CD	O
)	)	O
.	.	O

Adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
occurring	VBG	O
more	RBR	O
frequently	RB	O
with	IN	O
sitaxsentan	NN	O
(	(	O
50	CD	O
or	CC	O
100	CD	O
mg	NN	O
)	)	O
included	VBD	O
headache	NN	O
,	,	O
peripheral	JJ	O
edema	NN	O
,	,	O
dizziness	NN	O
,	,	O
nausea	NN	O
,	,	O
extremity	NN	O
pain	NN	O
,	,	O
and	CC	O
fatigue	NN	O
;	:	O
most	JJS	O
AEs	NNP	O
were	VBD	O
of	IN	O
mild	NN	O
or	CC	O
moderate	JJ	O
severity	NN	O
.	.	O

CONCLUSION	NNP	O
Sitaxsentan	NNP	O
100	CD	O
mg	NN	O
improved	VBD	O
functional	JJ	O
class	NN	O
but	CC	O
not	RB	O
6MWD	CD	O
in	IN	O
PAH	NNP	O
patients	NNS	O
who	WP	O
were	VBD	O
mostly	RB	O
WHO	NNP	O
functional	JJ	O
class	NN	O
II	NNP	O
at	IN	O
baseline	NN	O
.	.	O

No	DT	O
patient	NN	O
receiving	VBG	O
sitaxsentan	JJ	O
100	CD	O
mg	NN	O
experienced	VBD	O
clinical	JJ	O
worsening	NN	O
;	:	O
sitaxsentan	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

A	DT	O
trial	NN	O
with	IN	O
3'-azido-2',3'-dideoxythymidine	JJ	Pharmacological
and	CC	O
human	JJ	O
interferon-?	NN	O
in	IN	O
cats	NNS	O
naturally	RB	O
infected	VBN	O
with	IN	O
feline	JJ	O
leukaemia	NN	O
virus	NN	O
.	.	O

Feline	NNP	O
leukaemia	NN	O
virus	NN	O
(	(	O
FeLV	NNP	O
)	)	O
infection	NN	O
is	VBZ	O
still	RB	O
one	CD	O
of	IN	O
the	DT	O
leading	JJ	O
causes	NNS	O
of	IN	O
infection-related	JJ	O
deaths	NNS	O
in	IN	O
domestic	JJ	O
cats	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
various	JJ	O
drugs	NNS	O
has	VBZ	O
been	VBN	O
attempted	VBN	O
,	,	O
but	CC	O
none	NN	O
has	VBZ	O
resulted	VBN	O
in	IN	O
cure	NN	O
or	CC	O
complete	JJ	O
virus	NN	O
elimination	NN	O
.	.	O

Human	JJ	O
interferon-?2a	JJ	O
(	(	O
huIFN-?2a	JJ	O
)	)	O
and	CC	O
3'-azido-2',3'-dideoxythymidine	JJ	O
(	(	O
AZT	NNP	O
)	)	O
have	VBP	O
been	VBN	O
proven	VBN	O
to	TO	O
decrease	VB	O
antigenaemia	NN	O
in	IN	O
cats	NNS	O
infected	VBN	O
experimentally	RB	O
with	IN	O
FeLV	NNP	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
huIFN-?2a	NN	O
,	,	O
AZT	NNP	O
and	CC	O
a	DT	O
combination	NN	O
of	IN	O
both	DT	O
drugs	NNS	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
in	IN	O
a	DT	O
placebo-controlled	JJ	O
double-blinded	JJ	O
trial	NN	O
.	.	O

Fourty-four	CD	O
FeLV-infected	JJ	O
cats	NNS	O
in	IN	O
which	WDT	O
free	JJ	O
FeLV	NNP	O
p27	NN	O
antigen	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
serum	NN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	JJ	O
assay	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Cats	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
treatment	NN	O
groups	NNS	O
that	WDT	O
received	VBD	O
either	RB	O
high	JJ	O
dose	JJ	O
huIFN-?2a	NN	O
(	(	O
10	CD	O
(	(	O
5	CD	O
)	)	O
IU/kg	NNP	O
q24h	NN	O
;	:	O
12	CD	O
cats	NNS	O
)	)	O
,	,	O
AZT	NNP	O
(	(	O
5	CD	O
mg/kg	NN	O
q12h	NN	O
;	:	O
10	CD	O
cats	NNS	O
,	,	O
both	DT	O
of	IN	O
these	DT	O
treatments	NNS	O
(	(	O
12	CD	O
cats	NNS	O
)	)	O
or	CC	O
placebo	NN	O
(	(	O
10	CD	O
cats	NNS	O
)	)	O
.	.	O

All	DT	O
cats	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
,	,	O
including	VBG	O
stomatitis	NN	O
,	,	O
and	CC	O
laboratory	NN	O
parameters	NNS	O
,	,	O
such	JJ	O
as	IN	O
CD4	NNP	O
(	(	O
+	NNP	O
)	)	O
and	CC	O
CD8	NNP	O
(	(	O
+	NNP	O
)	)	O
counts	NNS	O
and	CC	O
serum	NN	O
FeLV	NNP	O
p	VBZ	O
27	CD	O
antigen	NN	O
concentration	NN	O
,	,	O
were	VBD	O
recorded	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
among	IN	O
the	DT	O
groups	NNS	O
was	VBD	O
observed	VBN	O
during	IN	O
the	DT	O
treatment	NN	O
period	NN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
parameters	NNS	O
.	.	O

Aside	RB	O
from	IN	O
anaemia	NN	O
in	IN	O
one	CD	O
cat	NN	O
treated	VBN	O
with	IN	O
AZT	NNP	O
,	,	O
no	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

It	PRP	O
was	VBD	O
not	RB	O
possible	JJ	O
to	TO	O
demonstrate	VB	O
efficacy	NN	O
of	IN	O
huIFN-?2a	NN	O
or	CC	O
AZT	NNP	O
alone	RB	O
or	CC	O
together	RB	O
in	IN	O
cats	NNS	O
infected	VBN	O
naturally	RB	O
with	IN	O
FeLV	NNP	O
when	WRB	O
given	VBN	O
according	VBG	O
to	TO	O
this	DT	O
regimen	NNS	O
for	IN	O
6	CD	O
weeks	NNS	O
;	:	O
however	RB	O
,	,	O
no	DT	O
notable	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

Naltrexone	NN	Pharmacological
in	IN	O
autistic	JJ	O
children	NNS	O
:	:	O
a	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
critically	RB	O
the	DT	O
effects	NNS	O
of	IN	O
naltrexone	NN	Pharmacological
on	IN	O
behavioral	JJ	O
symptoms	NNS	O
and	CC	O
learning	VBG	O
in	IN	O
autistic	JJ	O
children	NNS	O
,	,	O
and	CC	O
its	PRP$	O
safety	NN	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
preliminary	JJ	O
report	NN	O
on	IN	O
18	CD	O
children	NNS	O
,	,	O
ages	VBZ	O
3.08	CD	O
to	TO	O
7.99	CD	O
years	NNS	O
,	,	O
who	WP	O
completed	VBD	O
this	DT	O
ongoing	JJ	O
study	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
naltrexone	CD	Pharmacological
or	CC	O
placebo	NN	Control
and	CC	O
received	VBD	O
daily	JJ	O
doses	NNS	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
21	CD	O
days	NNS	O
.	.	O

Naltrexone	NN	Pharmacological
was	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	Control
according	VBG	O
to	TO	O
blind	VB	O
Clinical	JJ	O
Global	NNP	O
Consensus	NNP	O
Ratings	NNP	O
(	(	O
unpublished	JJ	O
scale	NN	O
)	)	O
.	.	O

However	RB	O
,	,	O
other	JJ	O
behavioral	JJ	O
rating	NN	O
measures	NNS	O
did	VBD	O
not	RB	O
confirm	VB	O
this	DT	O
result	NN	O
.	.	O

There	EX	O
was	VBD	O
only	RB	O
a	DT	O
suggestion	NN	O
that	IN	O
naltrexone	NN	Pharmacological
reduced	VBD	O
fidgety	NN	O
and	CC	O
hyperactive	JJ	O
behavior	NN	O
and	CC	O
tended	VBD	O
to	TO	O
alleviate	VB	O
overall	JJ	O
symptomatology	NN	O
in	IN	O
older	JJR	O
children	NNS	O
.	.	O

Naltrexone	NN	Pharmacological
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
affect	VB	O
discrimination	NN	O
learning	VBG	O
.	.	O

Results	NNS	O
are	VBP	O
preliminary	JJ	O
and	CC	O
,	,	O
owing	VBG	O
to	TO	O
the	DT	O
small	JJ	O
sample	NN	O
size	NN	O
,	,	O
can	MD	O
be	VB	O
considered	VBN	O
only	RB	O
suggestive	JJ	O
until	IN	O
this	DT	O
study	NN	O
is	VBZ	O
completed	VBN	O
or	CC	O
replication	NN	O
is	VBZ	O
obtained	VBN	O
from	IN	O
independent	JJ	O
research	NN	O
.	.	O

Treatment	NN	O
of	IN	O
multiple	JJ	O
myeloma	NN	O
according	VBG	O
to	TO	O
the	DT	O
extension	NN	O
of	IN	O
the	DT	O
disease	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
study	NN	O
comparing	VBG	O
a	DT	O
less	RBR	O
with	IN	O
a	DT	O
more	RBR	O
aggressive	JJ	Pharmacological
cystostatic	JJ	Pharmacological
policy	NN	O
.	.	O

Cooperative	NNP	O
Group	NNP	O
of	IN	O
Study	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Multiple	NNP	O
Myeloma	NNP	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
ascertain	VB	O
whether	IN	O
the	DT	O
prognostic	JJ	O
significance	NN	O
of	IN	O
staging	VBG	O
in	IN	O
multiple	JJ	O
myeloma	NN	O
(	(	O
MM	NNP	O
)	)	O
is	VBZ	O
influenced	VBN	O
by	IN	O
the	DT	O
aggressiveness	NN	Pharmacological
of	IN	Pharmacological
effective	JJ	Pharmacological
induction	NN	Pharmacological
treatment	NN	Pharmacological
and/or	NN	O
by	IN	O
continuing	VBG	O
or	CC	O
discontinuing	VBG	O
maintenance	NN	O
chemotherapy	NN	O
.	.	O

Patients	NNS	O
with	IN	O
untreated	JJ	O
stage	NN	O
I	PRP	O
MM	NNP	O
(	(	O
defined	VBN	O
according	VBG	O
to	TO	O
Durie	NNP	O
and	CC	O
Salmon	NNP	O
)	)	O
were	VBD	O
randomised	VBN	O
between	IN	O
being	VBG	O
followed	VBN	Physical
without	IN	Physical
cytostatics	NNS	Physical
until	IN	O
the	DT	O
disease	NN	O
progressed	VBD	O
and	CC	O
receiving	VBG	O
six	CD	O
courses	NNS	O
of	IN	O
melphalan	NN	O
and	CC	O
prednisone	NN	O
(	(	O
MP-P	NNP	O
)	)	O
just	RB	O
after	IN	O
diagnosis	NN	O
;	:	O
stage	NN	O
II	NNP	O
patients	NNS	O
were	VBD	O
uniformly	RB	O
treated	VBN	O
with	IN	O
MPH-P	NNP	O
and	CC	O
stage	NN	O
III	NNP	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
between	IN	O
MPH-P	NNP	O
and	CC	O
four	CD	O
courses	NNS	O
of	IN	O
combination	NN	O
chemotherapy	NN	O
with	IN	O
Peptichemio	NNP	O
,	,	O
vincristine	NN	O
and	CC	O
prednisone	NN	O
(	(	O
PTC-VCR-P	NNP	O
)	)	O
.	.	O

Within	IN	O
each	DT	O
stage	NN	O
,	,	O
responsive	JJ	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
between	IN	O
receiving	VBG	O
additional	JJ	O
therapy	NN	O
only	RB	O
until	IN	O
maximal	JJ	O
tumour	NNS	O
reduction	NN	O
was	VBD	O
reached	VBN	O
(	(	O
plateau	JJ	O
phase	NN	O
)	)	O
and	CC	O
continuing	VBG	O
induction	NN	O
therapy	NN	O
indefinitely	RB	O
until	IN	O
relapse	NN	O
.	.	O

With	IN	O
resistant	JJ	O
,	,	O
progressive	JJ	O
or	CC	O
relapsing	VBG	O
disease	NN	O
,	,	O
patients	NNS	O
originally	RB	O
treated	VBN	O
with	IN	O
MPH-P	NNP	O
for	IN	O
induction	NN	O
received	VBN	O
combination	NN	O
chemotherapy	NN	O
and	CC	O
vice	NN	O
versa	NN	O
.	.	O

The	DT	O
overall	JJ	O
first	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
43.8	CD	O
%	NN	O
(	(	O
42.2	CD	O
%	NN	O
in	IN	O
206	CD	O
stage	NN	O
I	PRP	O
,	,	O
II	NNP	O
and	CC	O
III	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
MPH-P	NNP	O
and	CC	O
48.0	CD	O
%	NN	O
in	IN	O
75	CD	O
stage	NN	O
III	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
combination	NN	O
chemotherapy	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Combination	NNP	O
chemotherapy	NN	O
was	VBD	O
more	RBR	O
myelotoxic	JJ	O
than	IN	O
MPH-P	NNP	O
and	CC	O
,	,	O
in	IN	O
particular	JJ	O
,	,	O
caused	VBD	O
more	RBR	O
non-haematological	JJ	O
side-effects	NNS	O
.	.	O

Both	CC	O
the	DT	O
less	JJR	O
and	CC	O
the	DT	O
more	RBR	O
aggressive	JJ	O
induction	NN	O
policies	NNS	O
gave	VBD	O
the	DT	O
same	JJ	O
disease	NN	O
control	NN	O
.	.	O

Progression	NN	O
of	IN	O
disease	NN	O
was	VBD	O
statistically	RB	O
similar	JJ	O
in	IN	O
stage	NN	O
I	PRP	O
patients	NNS	O
who	WP	O
were	VBD	O
initially	RB	O
left	VBN	O
untreated	JJ	O
and	CC	O
in	IN	O
t	JJ	O
hose	NN	O
who	WP	O
received	VBD	O
MPH-P	NNP	O
just	RB	O
after	IN	O
diagnosis	NN	O
;	:	O
median	JJ	O
duration	NN	O
of	IN	O
first	JJ	O
response	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
stage	NN	O
III	NNP	O
patients	NNS	O
receiving	VBG	O
MPH-P	NNP	O
and	CC	O
in	IN	O
those	DT	O
on	IN	O
combination	NN	O
chemotherapy	NN	O
.	.	O

In	IN	O
all	DT	O
stages	NNS	O
,	,	O
discontinuing	VBG	O
or	CC	O
continuing	VBG	O
maintenance	NN	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
median	JJ	O
duration	NN	O
of	IN	O
first	JJ	O
response	NN	O
.	.	O

The	DT	O
overall	JJ	O
second	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
28.5	CD	O
%	NN	O
(	(	O
34.0	CD	O
%	NN	O
to	TO	O
MPH-P	NNP	O
and	CC	O
25.3	CD	O
%	NN	O
to	TO	O
combination	NN	O
chemotherapy	NN	O
,	,	O
P	NNP	O
=	NNP	O
NS	NNP	O
)	)	O
.	.	O

Median	JJ	O
survival	NN	O
was	VBD	O
greater	JJR	O
than	IN	O
78	CD	O
months	NNS	O
in	IN	O
stage	NN	O
I	PRP	O
,	,	O
was	VBD	O
46.3	CD	O
months	NNS	O
in	IN	O
stage	NN	O
II	NNP	O
and	CC	O
was	VBD	O
24.3	CD	O
months	NNS	O
in	IN	O
stage	NN	O
III	NNP	O
patients	NNS	O
,	,	O
still	RB	O
independent	JJ	O
of	IN	O
both	DT	O
induction	NN	O
and	CC	O
post-induction	NN	O
policies	NNS	O
.	.	O

In	IN	O
MM	NNP	O
,	,	O
the	DT	O
significance	NN	O
of	IN	O
staging	VBG	O
for	IN	O
survival	NN	O
is	VBZ	O
independent	JJ	O
of	IN	O
both	DT	O
the	DT	O
aggressiveness	NN	O
of	IN	O
induction	NN	O
and	CC	O
of	IN	O
continuing	VBG	O
or	CC	O
discontinuing	VBG	O
maintenance	NN	O
chemotherapy	NN	O
after	IN	O
the	DT	O
maximal	JJ	O
tumor	NN	O
reduction	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
.	.	O

Both	DT	O
MPH-P	NNP	O
and	CC	O
and	CC	O
the	DT	O
association	NN	O
of	IN	O
PTC	NNP	O
,	,	O
VCR	NNP	O
and	CC	O
P	NNP	O
are	VBP	O
effective	JJ	O
in	IN	O
inducing	VBG	O
first	JJ	O
response	NN	O
and	CC	O
also	RB	O
second	JJ	O
response	NN	O
in	IN	O
patients	NNS	O
failing	VBG	O
on	IN	O
the	DT	O
alternative	JJ	O
regimen	NNS	O
,	,	O
but	CC	O
PTC-VCR-P	NNP	O
causes	VBZ	O
more	JJR	O
side	JJ	O
effects	NNS	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
overwhelming	JJ	O
majority	NN	O
of	IN	O
patients	NNS	O
with	IN	O
MM	NNP	O
can	MD	O
safely	RB	O
be	VB	O
given	VBN	O
MPH-P	NNP	O
as	IN	O
first	JJ	O
therapy	NN	O
,	,	O
and	CC	O
this	DT	O
treatment	NN	O
may	MD	O
be	VB	O
delayed	VBN	O
in	IN	O
early	JJ	O
diseases	NNS	O
.	.	O

Cross-over	JJ	O
trial	NN	O
of	IN	O
intensive	JJ	O
monotherapy	NN	O
with	IN	O
atorvastatin	NN	Pharmacological
and	CC	O
combined	VBN	O
therapy	NN	O
with	IN	O
atorvastatin	NN	Pharmacological
and	CC	O
colestimide	NN	Pharmacological
for	IN	O
Japanese	JJ	O
familial	JJ	O
hypercholesterolemia	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
familial	JJ	O
hypercholesterolemia	NN	O
(	(	O
FH	NNP	O
)	)	O
,	,	O
low-density	JJ	O
lipoprotein-cholesterol	NN	O
(	(	O
LDL-C	NNP	O
)	)	O
-lowering	VBG	O
therapy	NN	O
is	VBZ	O
important	JJ	O
to	TO	O
avoid	VB	O
predisposition	NN	O
to	TO	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

This	DT	O
study	NN	O
investigated	VBD	O
the	DT	O
advantages	NNS	O
of	IN	O
combined	JJ	O
therapy	NN	O
with	IN	O
atorvastatin	NN	Pharmacological
and	CC	O
colestimide	NN	Pharmacological
vs	NN	O
intensive	JJ	O
monotherapy	NN	O
with	IN	O
atorvastatin	NN	Pharmacological
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
The	DT	O
trial	NN	O
used	VBD	O
a	DT	O
randomized	JJ	O
cross-over	NN	O
design	NN	O
consisting	VBG	O
of	IN	O
2	CD	O
16-week	JJ	O
periods	NNS	O
of	IN	O
open-label	JJ	O
drug	NN	O
therapy	NN	O
.	.	O

Among	IN	O
the	DT	O
24	CD	O
initial	JJ	O
patients	NNS	O
,	,	O
17	CD	O
heterozygous	JJ	O
FH	NNP	O
patients	NNS	O
(	(	O
age	NN	O
:	:	O
54.1	CD	O
years	NNS	O
;	:	O
5	CD	O
males	NNS	O
)	)	O
were	VBD	O
enrolled	VBN	O
after	IN	O
20	CD	Pharmacological
mg/day	JJ	Pharmacological
atorvastatin	RB	Pharmacological
failed	VBD	O
to	TO	O
achieve	VB	O
their	PRP$	O
target	NN	O
level	NN	O
.	.	O

The	DT	O
patients	NNS	O
received	VBD	O
20	CD	O
mg/day	JJ	O
atorvastatin	NN	Pharmacological
and	CC	O
3	CD	O
g/day	JJ	O
colestimide	NN	Pharmacological
or	CC	O
40	CD	O
mg/day	JJ	O
atorvastatin	NN	Pharmacological
.	.	O

Fifteen	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
trial	NN	O
and	CC	O
their	PRP$	O
LDL-C	JJ	O
reduced	VBN	O
from	IN	O
5.07	CD	O
+/-	JJ	O
1.10	CD	O
mmol/L	NN	O
to	TO	O
3.76	CD	O
+/-	JJ	O
0.90	CD	O
mmol/L	NN	O
with	IN	O
the	DT	O
combined	JJ	O
therapy	NN	O
and	CC	O
to	TO	O
3.81	CD	O
+/-	JJ	O
0.50	CD	O
mmol/L	NN	O
with	IN	O
the	DT	O
intensive	JJ	O
monotherapy	NN	O
.	.	O

Although	IN	O
the	DT	O
2	CD	O
therapies	NNS	O
showed	VBD	O
comparable	JJ	O
mean	JJ	O
effects	NNS	O
for	IN	O
decreasing	VBG	O
LDL-C	NNP	O
,	,	O
similar	JJ	O
adverse	JJ	O
reaction	NN	O
and	CC	O
cost	NN	O
,	,	O
each	DT	O
therapy	NN	O
was	VBD	O
predominantly	RB	O
more	RBR	O
effective	JJ	O
in	IN	O
some	DT	O
patients	NNS	O
than	IN	O
in	IN	O
others	NNS	O
.	.	O

The	DT	O
triglyceride	NN	O
and	CC	O
high-density	NN	O
lipoprotein	NNS	O
cholesterol	NN	O
levels	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
therapies	NNS	O
.	.	O

CONCLUSIONS	NNP	O
To	TO	O
achieve	VB	O
the	DT	O
therapeutic	JJ	O
target	NN	O
of	IN	O
LDL-C	NNP	O
level	NN	O
for	IN	O
refractory	NN	O
FH	NNP	O
,	,	O
the	DT	O
LDL-C-lowering	JJ	O
therapy	NN	O
selected	VBN	O
can	MD	O
be	VB	O
either	RB	O
intensive	JJ	O
monotherapy	NN	O
or	CC	O
combined	VBN	O
therapy	NN	O
as	IN	O
the	DT	O
next	JJ	O
to	TO	O
standard	VB	O
statin	NN	O
therapy	NN	O
.	.	O

Clinical	JJ	O
efficacy	NN	O
of	IN	O
fluvoxamine	NN	Pharmacological
and	CC	O
functional	JJ	O
polymorphism	NN	O
in	IN	O
a	DT	O
serotonin	NN	O
transporter	NN	O
gene	NN	O
on	IN	O
childhood	NN	O
autism	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
correlation	NN	O
between	IN	O
response	NN	O
to	TO	O
fluvoxamine	VB	Pharmacological
and	CC	O
serotonin	VB	O
transporter	NN	O
gene	NN	O
promoter	NN	O
region	NN	O
polymorphism	NN	O
(	(	O
5-HTTLPR	JJ	O
)	)	O
.	.	O

Eighteen	JJ	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
completed	VBD	O
a	DT	O
12-week	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
randomized	VBN	O
crossover	NN	O
study	NN	O
of	IN	O
fluvoxamine	NN	Pharmacological
.	.	O

Behavioral	JJ	O
assessments	NNS	O
were	VBD	O
obtained	VBN	O
before	IN	O
and	CC	O
at	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

5-HTTLPR	JJ	O
(	(	O
long	JJ	O
(	(	O
l	NN	O
)	)	O
or	CC	O
short	JJ	O
(	(	O
s	PRP	O
)	)	O
)	)	O
,	,	O
was	VBD	O
analyzed	VBN	O
by	IN	O
the	DT	O
PCR	NNP	O
method	NN	O
.	.	O

Ten	CD	O
out	IN	O
of	IN	O
18	CD	O
patients	NNS	O
responded	VBD	O
to	TO	O
fluvoxamine	VB	Pharmacological
treatment	NN	O
;	:	O
allele	CC	O
type	JJ	O
analysis	NN	O
revealed	VBD	O
that	IN	O
clinical	JJ	O
global	JJ	O
effectiveness	NN	O
was	VBD	O
noted	VBN	O
significantly	RB	O
more	RBR	O
in	IN	O
the	DT	O
l	NN	O
allele	NN	O
than	IN	O
in	IN	O
the	DT	O
s	NN	O
allele	NN	O
.	.	O

However	RB	O
,	,	O
with	IN	O
respect	NN	O
to	TO	O
language	NN	O
use	NN	O
,	,	O
a	DT	O
significant	JJ	O
effectiveness	NN	O
was	VBD	O
noted	VBN	O
in	IN	O
the	DT	O
s	NN	O
allele	NN	O
.	.	O

5-HTTLPR	JJ	O
may	MD	O
influence	VB	O
the	DT	O
individual	NN	O
responses	VBZ	O
to	TO	O
fluvoxamine	VB	Pharmacological
administration	NN	O
.	.	O

[	JJ	Pharmacological
Local	NNP	Pharmacological
therapy	NN	Pharmacological
of	IN	Pharmacological
grade	NN	Pharmacological
1	CD	Pharmacological
and	CC	Pharmacological
2	CD	Pharmacological
hemorrhoids	NNS	Pharmacological
.	.	Pharmacological

Effectiveness	NN	O
of	IN	O
a	DT	O
combination	NN	Pharmacological
preparation	NN	Pharmacological
with	IN	Pharmacological
standardized	JJ	Pharmacological
blood	NN	Pharmacological
leech	NN	Pharmacological
extract	NN	Pharmacological
]	NNP	Pharmacological
.	.	O

AIMS	NNP	O
Testing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
topical	JJ	Pharmacological
combination	NN	Pharmacological
preparation	NN	Pharmacological
containing	VBG	Pharmacological
standardized	VBN	Pharmacological
leech	JJ	Pharmacological
extract	NN	Pharmacological
,	,	Pharmacological
polidocanol	NN	Pharmacological
and	CC	Pharmacological
allantoin	NN	Pharmacological
.	.	Pharmacological

STUDY	NNP	O
DESIGN	NNP	O
Placebo-controlled	NNP	Control
,	,	O
double-blind	NN	O
study	NN	O
in	IN	O
80	CD	O
patients	NNS	O
with	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
;	:	O
duration	NN	O
of	IN	O
treatment	NN	O
one	CD	O
week	NN	O
;	:	O
examinations	NNS	O
performed	VBD	O
on	IN	O
admission	NN	O
and	CC	O
on	IN	O
days	NNS	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
and	CC	O
8	CD	O
.	.	O

RESULTS	VB	O
Both	DT	O
the	DT	O
subjective	NN	O
and	CC	O
objective	JJ	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
improved	VBN	O
during	IN	O
the	DT	O
one	CD	O
week	NN	O
of	IN	O
treatment	NN	O
statistically	RB	O
significantly	RB	O
more	RBR	O
rapidly	RB	O
under	IN	O
the	DT	O
test	NN	Educational
preparation	NN	Educational
as	IN	O
compared	VBN	O
with	IN	O
placebo	NN	O
.	.	O

Histologically	NNP	O
demonstrable	JJ	O
signs	NNS	O
of	IN	O
inflammation	NN	O
were	VBD	O
more	JJR	O
clearly	RB	O
improved	VBN	O
in	IN	O
the	DT	O
preparation	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

No	DT	O
side	NN	O
effects	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
good	JJ	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
a	DT	O
topical	JJ	Pharmacological
therapeutic	JJ	Pharmacological
preparation	NN	Pharmacological
in	IN	O
first	JJ	O
and	CC	O
second	JJ	O
degree	NN	O
hemorrhoids	NNS	O
have	VBP	O
been	VBN	O
convincingly	RB	O
demonstrated	VBN	O
.	.	O

Combination	NN	O
of	IN	O
arteriovenous	JJ	Physical
extracorporeal	NN	Physical
lung	NN	Physical
assist	NN	Physical
and	CC	O
high-frequency	NN	Physical
oscillatory	NN	Physical
ventilation	NN	Physical
in	IN	O
a	DT	O
porcine	JJ	O
model	NN	O
of	IN	O
lavage-induced	JJ	O
acute	NN	O
lung	NN	O
injury	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
compare	VB	O
the	DT	O
combined	JJ	O
effects	NNS	O
of	IN	O
arteriovenous	JJ	Physical
extracorporeal	NN	Physical
lung	NN	Physical
assist	NN	Physical
(	(	Physical
AV-ECLA	NNP	Physical
)	)	Physical
and	CC	O
high-frequency	JJ	Physical
oscillatory	NN	Physical
ventilation	NN	Physical
(	(	Physical
HFOV	NNP	Physical
)	)	Physical
on	IN	O
pulmonary	NN	O
gas	NN	O
exchange	NN	O
,	,	O
hemodynamics	NNS	O
,	,	O
and	CC	O
respiratory	NN	O
parameters	NNS	O
in	IN	O
a	DT	O
lavage-induced	JJ	O
porcine	NN	O
lung	NN	O
injury	NN	O
model	NN	O
.	.	O

METHODS	CC	O
A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
animal	NN	O
study	NN	O
.	.	O

Saline	NNP	Physical
lung	NN	Physical
lavage	NN	Physical
was	VBD	O
performed	VBN	O
in	IN	O
33	CD	O
healthy	JJ	O
female	NN	O
pigs	NNS	O
,	,	O
weighing	VBG	O
52	CD	O
+/-	JJ	O
4.1	CD	O
kg	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
,	,	O
until	IN	O
the	DT	O
Pao2	NNP	O
decreased	VBD	O
to	TO	O
53	CD	O
+/-	JJ	O
8	CD	O
mm	NN	O
Hg	NNP	O
.	.	O

After	IN	O
a	DT	O
stabilization	NN	O
period	NN	O
of	IN	O
60	CD	O
minutes	NNS	O
,	,	O
the	DT	O
animals	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
four	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
,	,	O
pressure-controlled	JJ	Physical
ventilation	NN	Physical
(	(	Physical
PCV	NNP	Physical
)	)	Physical
with	IN	O
a	DT	O
tidal	JJ	O
volume	NN	O
of	IN	O
6	CD	O
mL/kg	NNS	O
;	:	O
group	NN	O
2	CD	O
,	,	O
PCV	NNP	Physical
with	IN	O
a	DT	O
tidal	JJ	O
volume	NN	O
of	IN	O
6	CD	O
mL/kg	NNS	O
and	CC	O
AV-ECLA	NNP	Physical
;	:	Surgical
group	NN	O
3	CD	O
,	,	O
HFOV	NNP	Physical
;	:	O
group	NN	O
4	CD	O
,	,	O
HFOV	NNP	Physical
and	CC	Physical
AV-ECLA	NNP	Physical
.	.	O

In	IN	O
groups	NNS	O
2	CD	O
and	CC	O
4	CD	O
,	,	O
the	DT	O
femoral	JJ	O
artery	NN	O
and	CC	O
vein	NN	O
were	VBD	O
cannulated	VBN	O
and	CC	O
a	DT	O
low-resistance	NN	O
membrane	NN	O
lung	NN	O
was	VBD	O
interposed	VBN	O
.	.	O

After	IN	O
isolated	JJ	O
evaluation	NN	O
of	IN	O
AV-ECLA	NNP	Physical
,	,	O
the	DT	O
mean	JJ	O
airway	NN	O
pressure	NN	O
was	VBD	O
increased	VBN	O
by	IN	O
3	CD	O
cm	NNS	O
H2O	NNP	O
from	IN	O
16	CD	O
to	TO	O
34	CD	O
cm	NNS	O
H2O	NNP	O
every	DT	O
20	CD	O
minutes	NNS	O
,	,	O
accompanied	VBN	O
by	IN	O
blood	NN	O
gas	NN	O
analyses	NNS	O
and	CC	O
measurements	NNS	O
of	IN	O
respiratory	NN	O
and	CC	O
hemodynamic	JJ	O
variables	NNS	O
.	.	O

RESULTS	NNP	O
Only	RB	O
in	IN	O
AV-ECLA-treated	JJ	Physical
animals	NNS	O
was	VBD	O
normocapnia	RB	O
achieved	VBN	O
.	.	O

No	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
Pao2	NNP	O
attributable	JJ	O
to	TO	O
AV-ECLA	NNP	Physical
alone	RB	O
was	VBD	O
detected	VBN	O
.	.	O

Mean	NNP	O
airway	JJ	O
pressure	NN	O
augmentation	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
Pao2	NNP	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

Peak	NNP	O
inspiratory	JJ	O
pressure	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
HFOV-treated	JJ	O
animals	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
combination	NN	O
of	IN	O
AV-ECLA	NNP	Physical
and	CC	O
HFOV	NNP	Physical
resulted	VBD	O
in	IN	O
normocapnia	NN	O
and	CC	O
comparable	JJ	O
Pao2	NNP	O
,	,	O
although	IN	O
a	DT	O
smaller	JJR	O
ventilator	NN	O
pressure	NN	O
amplitude	NN	O
was	VBD	O
applied	VBN	O
.	.	O

Long-term	JJ	O
animal	JJ	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
assess	VB	O
whether	IN	O
this	DT	O
approach	NN	O
results	NNS	O
in	IN	O
further	JJ	O
lung	NN	O
protection	NN	O
.	.	O

Clozapine	NNP	Pharmacological
versus	NN	O
placebo	NN	Control
in	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
:	:	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
comparative	JJ	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
establish	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
atypical	JJ	O
neuroleptic	JJ	O
clozapine	NN	Pharmacological
on	IN	O
chorea	NN	O
,	,	O
voluntary	JJ	O
motor	NN	O
performance	NN	O
,	,	O
and	CC	O
functional	JJ	O
disability	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
three	CD	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
participated	VBD	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
randomised	VBD	O
trial	NN	O
.	.	O

A	DT	O
maximum	NN	O
of	IN	O
150	CD	O
mg/day	JJ	O
clozapine	NN	Pharmacological
or	CC	O
placebo	NN	Control
equivalent	NN	O
was	VBD	O
given	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
31	CD	O
days	NNS	O
.	.	O

Assessments	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
week	NN	O
before	IN	O
and	CC	O
at	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

Chorea	NNP	O
was	VBD	O
scored	VBN	O
using	VBG	O
the	DT	O
abnormal	JJ	O
involuntary	JJ	O
movement	NN	O
scale	NN	O
(	(	O
AIMS	NNP	O
)	)	O
,	,	O
the	DT	O
chorea	NN	O
score	NN	O
of	IN	O
the	DT	O
unified	JJ	O
Huntington	NNP	O
's	POS	O
disease	NN	O
rating	NN	O
scale	NN	O
(	(	O
UHDRS	NNP	O
)	)	O
,	,	O
and	CC	O
judgement	NN	O
of	IN	O
video	JJ	O
recordings	NNS	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
UHDRS	NNP	O
motor	NN	O
scale	NN	O
.	.	O

Patients	NNS	O
and	CC	O
their	PRP$	O
partners	NNS	O
completed	VBD	O
a	DT	O
questionnaire	NN	O
regarding	VBG	O
functional	JJ	O
disability	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
already	RB	O
used	VBD	O
other	JJ	O
neuroleptic	JJ	O
medication	NN	O
,	,	O
which	WDT	O
was	VBD	O
kept	FW	O
unchanged	JJ	O
during	IN	O
the	DT	O
trial	NN	O
period	NN	O
.	.	O

Results	NNS	O
of	IN	O
neuroleptic	JJ	O
naive	JJ	O
and	CC	O
neuroleptic	JJ	O
treated	JJ	O
patients	NNS	O
were	VBD	O
analysed	VBN	O
separately	RB	O
.	.	O

RESULTS	NNP	O
Clozapine	NNP	Pharmacological
tended	VBD	O
to	TO	O
reduce	VB	O
chorea	NN	O
in	IN	O
neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
only	RB	O
(	(	O
AIMS	NNP	O
)	)	O
;	:	O
improvement	NN	O
seemed	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
higher	JJR	O
doses	NNS	O
of	IN	O
clozapine	NN	O
.	.	O

Other	JJ	O
measures	NNS	O
of	IN	O
chorea	NN	O
(	(	O
UHDRS	NNP	O
chorea	NN	O
score	NN	O
,	,	O
video	JJ	O
ratings	NNS	O
)	)	O
showed	VBD	O
no	DT	O
improvement	NN	O
.	.	O

Clozapine	NNP	Pharmacological
had	VBD	O
no	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
chorea	NN	O
in	IN	O
patients	NNS	O
already	RB	O
receiving	VBG	O
neuroleptic	JJ	O
medication	NN	O
.	.	O

Voluntary	JJ	O
motor	NN	O
performance	NN	O
did	VBD	O
not	RB	O
improve	VB	O
with	IN	O
clozapine	NN	O
.	.	O

Neuroleptic	JJ	O
naive	JJ	O
patients	NNS	O
reported	VBN	O
aggravation	NN	O
of	IN	O
functional	JJ	O
disability	NN	O
,	,	O
possibly	RB	O
reflecting	VBG	O
the	DT	O
frequent	JJ	O
occurrence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Adverse	JJ	O
reactions	NNS	O
forced	VBD	O
trial	NN	O
termination	NN	O
in	IN	O
six	CD	O
patients	NNS	O
and	CC	O
dose	JJ	O
reduction	NN	O
in	IN	O
another	DT	O
eight	CD	O
,	,	O
and	CC	O
consisted	VBD	O
mainly	RB	O
of	IN	O
drowsiness	NN	O
,	,	O
fatigue	NN	O
,	,	O
anticholinergic	NN	O
symptoms	NNS	O
,	,	O
and	CC	O
walking	VBG	O
difficulties	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Clozapine	NNP	Pharmacological
has	VBZ	O
little	JJ	O
beneficial	JJ	O
effect	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
,	,	O
although	IN	O
individual	JJ	O
patients	NNS	O
may	MD	O
tolerate	VB	O
doses	NNS	O
high	JJ	O
enough	RB	O
to	TO	O
reduce	VB	O
chorea	NN	O
.	.	O

Because	IN	O
adverse	JJ	O
reactions	NNS	O
are	VBP	O
often	RB	O
encountered	VBN	O
,	,	O
clozapine	NN	Pharmacological
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
restraint	NN	O
in	IN	O
this	DT	O
patient	NN	O
group	NN	O
.	.	O

Nateglinide	NNP	Pharmacological
reduces	VBZ	O
carotid	JJ	O
intima-media	JJ	O
thickening	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
under	IN	O
good	JJ	O
glycemic	JJ	O
control	NN	O
.	.	O

OBJECTIVE	NNP	O
Postprandial	NNP	O
hyperglycemia	NN	O
observed	VBD	O
in	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
mellitus	NN	O
is	VBZ	O
a	DT	O
risk	NN	O
factor	NN	O
for	IN	O
atherosclerosis	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
strict	JJ	Pharmacological
glycemic	NNS	Pharmacological
control	NN	Pharmacological
by	IN	O
nateglinide	NN	O
on	IN	O
common	JJ	O
carotid	NN	O
far	RB	O
wall	JJ	O
intima-media	JJ	O
thickness	NN	O
in	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
who	WP	O
were	VBD	O
already	RB	O
under	IN	O
good	JJ	O
glycemic	JJ	O
control	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
an	DT	O
open	JJ	O
labeled	VBN	O
randomized	JJ	O
prospective	JJ	O
trial	NN	O
on	IN	O
78	CD	O
drug-naive	JJ	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
whose	WP$	O
HbA1c	NNP	O
was	VBD	O
less	JJR	O
than	IN	O
6.5	CD	O
%	NN	O
.	.	O

Thirty-eight	JJ	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
nateglinide	NN	Pharmacological
(	(	O
270	CD	O
mg/dL	NN	O
)	)	O
and	CC	O
40	CD	O
to	TO	O
control	VB	Control
group	NN	Control
(	(	Control
no	DT	Control
treatment	NN	Control
)	)	Control
.	.	O

After	IN	O
12	CD	O
months	NNS	O
,	,	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
HbA1c	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
nateglinide	JJ	O
group	NN	O
,	,	O
whereas	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
HbA1c	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
untreated	JJ	O
group	NN	O
.	.	O

The	DT	O
carotid	JJ	O
intima-media	JJ	O
thickness	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
1-year	JJ	O
follow-up	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
the	DT	O
nateglinide	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
the	DT	O
untreated	JJ	Educational
group	NN	O
(	(	O
-0.017+/-0.054	JJ	O
mm/year	VBP	O
versus	IN	O
0.024+/-0.066	JJ	O
mm/year	NN	O
,	,	O
P=0.0064	NNP	O
)	)	O
.	.	O

Whereas	NNP	O
nateglinide	JJ	O
treatment	NN	O
also	RB	O
reduced	VBD	O
triglyceride	JJ	O
,	,	O
highly-sensitive	JJ	O
C-reactive	JJ	O
protein	NN	O
,	,	O
and	CC	O
E-selectin	NNP	O
,	,	O
multiple	JJ	O
regression	NN	O
analysis	NN	O
identified	VBN	O
HbA1c	NNP	O
as	IN	O
the	DT	O
only	JJ	O
significant	JJ	O
independent	JJ	O
determinant	NN	O
of	IN	O
the	DT	O
change	NN	O
in	IN	O
carotid	JJ	O
intima-media	JJ	O
thickness	NN	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
type	NN	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
good	JJ	O
glycemic	NNS	O
control	NN	O
,	,	O
further	JJ	O
strict	JJ	Pharmacological
glycemic	NNS	Pharmacological
control	NN	Pharmacological
by	IN	Pharmacological
nateglinide	JJ	Pharmacological
results	NNS	O
in	IN	O
regression	NN	O
of	IN	O
carotid	JJ	O
intima-media	JJ	O
thickness	NN	O
.	.	O

Variability	NN	O
of	IN	O
thrombolytic	JJ	Physical
coronary	JJ	Physical
reperfusion	NN	Physical
:	:	Physical
an	DT	O
angiographic	JJ	O
study	NN	O
of	IN	O
streptokinase	NN	Physical
and	CC	O
anistreplase	NN	Physical
.	.	Physical

A	DT	O
total	NN	O
of	IN	O
1,615	CD	O
angiographic	JJ	O
readings	NNS	O
in	IN	O
240	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
were	VBD	O
analyzed	VBN	O
from	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
intravenous	JJ	Physical
anistreplase	NN	Physical
(	(	Physical
Eminase	NNP	Physical
)	)	Physical
,	,	Physical
also	RB	Physical
known	VBN	Physical
as	IN	Physical
anisoylated	JJ	Physical
plasminogen	NN	Physical
streptokinase	JJ	Physical
activator	NN	Physical
complex	NN	Physical
(	(	Physical
APSAC	NNP	Physical
)	)	Physical
,	,	O
versus	FW	O
intracoronary	JJ	O
streptokinase	NN	Physical
.	.	O

Coronary	JJ	O
arteriography	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
15	CD	O
,	,	O
30	CD	O
,	,	O
45	CD	O
,	,	O
60	CD	O
,	,	O
75	CD	O
,	,	O
and	CC	O
90	CD	O
minutes	NNS	O
after	IN	O
drug	NN	O
infusion	NN	O
.	.	O

Coronary	NNP	O
flow	NN	O
in	IN	O
the	DT	O
infarct-related	JJ	O
artery	NN	O
was	VBD	O
defined	VBN	O
using	VBG	O
the	DT	O
TIMI	NNP	O
criteria	NNS	O
.	.	O

Some	DT	O
serial	JJ	O
change	NN	O
in	IN	O
perfusion	NN	O
was	VBD	O
noted	VBN	O
in	IN	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
patient	JJ	O
population	NN	O
and	CC	O
in	IN	O
49	CD	O
%	NN	O
of	IN	O
all	DT	O
reperfusion	NN	O
patients	NNS	O
.	.	O

Complete	JJ	O
loss	NN	O
of	IN	O
perfusion	NN	O
(	(	O
grade	JJ	O
2	CD	O
or	CC	O
3	CD	O
to	TO	O
grade	VB	O
0	CD	O
or	CC	O
1	CD	O
)	)	O
occurred	VBD	O
in	IN	O
35	CD	O
%	NN	O
of	IN	O
all	DT	O
reperfused	JJ	O
patients	NNS	O
.	.	O

Half	NNP	O
of	IN	O
these	DT	O
patients	NNS	O
ultimately	RB	O
developed	VBD	O
complete	JJ	O
loss	NN	O
of	IN	O
perfusion	NN	O
at	IN	O
the	DT	O
study	NN	O
endpoint	NN	O
.	.	O

All	DT	O
of	IN	O
these	DT	O
changes	NNS	O
in	IN	O
flow	NN	O
were	VBD	O
statistically	RB	O
more	JJR	O
common	JJ	O
for	IN	O
the	DT	O
circumflex	JJ	O
coronary	JJ	O
artery	NN	O
and	CC	O
early	JJ	O
treatment	NN	O
(	(	O
less	JJR	O
than	IN	O
4	CD	O
h	NN	O
)	)	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
differ	VB	O
for	IN	O
anistreplase	NN	Physical
or	CC	O
streptokinase	NN	Physical
.	.	O

We	PRP	O
conclude	VBP	O
that	DT	O
frequent	JJ	O
alterations	NNS	O
in	IN	O
coronary	JJ	O
blood	NN	O
flow	NN	O
occur	VBD	O
early	JJ	O
during	IN	O
reperfusion	NN	Psychological
therapy	NN	Psychological
and	CC	O
that	IN	O
these	DT	O
findings	NNS	O
may	MD	O
explain	VB	O
reports	NNS	O
with	IN	O
varying	VBG	O
results	NNS	O
of	IN	O
thrombolytic	JJ	Psychological
therapy	NN	Psychological
.	.	O

Any	DT	O
angiographic	JJ	O
assessment	NN	O
of	IN	O
thrombolytic	JJ	Pharmacological
drug	NN	Pharmacological
efficacy	NN	O
should	MD	O
take	VB	O
these	DT	O
variations	NNS	O
as	RB	O
well	RB	O
as	IN	O
interobserver	NN	O
variability	NN	O
into	IN	O
account	NN	O
.	.	O

Randomized	NNP	O
clinical	JJ	O
study	NN	O
comparing	VBG	O
Compeed	NNP	Pharmacological
cold	VBD	Pharmacological
sore	RB	Pharmacological
patch	NN	Pharmacological
to	TO	O
acyclovir	VB	Pharmacological
cream	RB	Pharmacological
5	CD	Pharmacological
%	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
herpes	NNS	O
simplex	JJ	O
labialis	NN	O
.	.	O

BACKGROUND	NNP	O
Hydrocolloid	NNP	O
technology	NN	O
has	VBZ	O
been	VBN	O
proven	RB	O
effective	JJ	O
in	IN	O
treating	VBG	O
dermal	JJ	O
wounds	NNS	O
.	.	O

A	DT	O
previous	JJ	O
study	NN	O
showed	VBD	O
that	IN	O
a	DT	O
newly	RB	O
developed	VBN	O
thin	JJ	Pharmacological
hydrocolloid	NN	Pharmacological
patch	NN	Pharmacological
[	NNP	Pharmacological
Compeed	NNP	Pharmacological
cold	VBD	Pharmacological
sore	RB	Pharmacological
patch	NN	Pharmacological
(	(	Pharmacological
CSP	NNP	Pharmacological
)	)	Pharmacological
]	NN	Pharmacological
provided	VBD	O
multiple	JJ	O
wound-healing	JJ	O
benefits	NNS	O
across	IN	O
all	DT	O
stages	NNS	O
of	IN	O
a	DT	O
herpes	NNS	O
simplex	JJ	O
labialis	NN	O
(	(	O
HSL	NNP	O
)	)	O
outbreak	NN	O
.	.	O

METHODS	NNP	O
An	DT	O
assessment	NN	O
of	IN	O
CSP	NNP	O
efficacy	NN	O
and	CC	O
safety	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
an	DT	O
international	JJ	O
,	,	O
multicentre	JJ	O
,	,	O
assessor-blinded	JJ	O
study	NN	O
,	,	O
which	WDT	O
enrolled	VBD	O
728	CD	O
subjects	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
recurrent	NN	O
HSL	NNP	O
.	.	O

Of	IN	O
these	DT	O
,	,	O
351	CD	O
experienced	VBD	O
an	DT	O
HSL	NNP	O
outbreak	NN	O
and	CC	O
were	VBD	O
randomized	VBN	O
to	TO	O
use	VB	O
CSP	NNP	O
(	(	O
n	JJ	O
=	NNP	O
179	CD	O
)	)	O
or	CC	O
acyclovir	JJ	Pharmacological
cream	NN	Pharmacological
5	CD	Pharmacological
%	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
172	CD	O
)	)	O
at	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
until	IN	O
the	DT	O
lesion	NN	O
healed	VBD	O
,	,	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
10	CD	O
days	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
subject	NN	O
's	POS	O
global	JJ	O
assessment	NN	O
of	IN	O
therapy	NN	O
(	(	O
SGAT	NNP	O
;	:	O
0-10	JJ	O
scale	NN	O
;	:	O
0	CD	O
=	IN	O
no	DT	O
response	NN	O
,	,	O
10	CD	O
=	JJ	O
excellent	JJ	O
response	NN	O
)	)	O
.	.	O

Multiple	NNP	O
secondary	JJ	O
end	NN	O
points	NNS	O
included	VBD	O
clinician-assessed	JJ	O
healing	NN	O
time	NN	O
and	CC	O
subject	JJ	O
assessment	NN	O
of	IN	O
lesion	NN	O
protection	NN	O
,	,	O
noticeability	NN	O
and	CC	O
social	JJ	O
embarrassment	NN	O
.	.	O

RESULTS	NNP	O
CSP	NNP	Pharmacological
and	CC	O
acyclovir	NNS	Pharmacological
were	VBD	O
highly	RB	O
effective	JJ	O
(	(	O
mean	JJ	O
SGAT	NNP	O
=	NNP	O
7.89	CD	O
and	CC	O
8.00	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
observed	VBD	O
(	(	O
P	NNP	O
=	NNP	O
0.65	CD	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
in	IN	O
healing	VBG	O
times	NNS	O
between	IN	O
products	NNS	O
was	VBD	O
not	RB	O
significant	JJ	O
(	(	O
median	JJ	O
,	,	O
7.57	CD	O
days	NNS	O
with	IN	O
CSP	NNP	O
vs.	FW	O
7.03	CD	O
days	NNS	O
with	IN	O
acyclovir	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.37	CD	O
)	)	O
.	.	O

Both	DT	O
treatments	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

CONCLUSION	NNP	O
CSP	NNP	Pharmacological
using	VBG	Pharmacological
hydrocolloid	JJ	Pharmacological
technology	NN	Pharmacological
provides	VBZ	O
an	DT	O
efficacious	JJ	O
and	CC	O
safe	JJ	O
alternative	NN	O
to	TO	O
topical	JJ	O
antivirals	NNS	O
in	IN	O
treating	VBG	O
HSL	NNP	O
as	IN	O
a	DT	O
wound	NN	O
while	IN	O
affording	VBG	O
additional	JJ	O
immediate	JJ	O
benefits	NNS	O
of	IN	O
wound	NN	O
protection	NN	O
,	,	O
discretion	NN	O
and	CC	O
relief	NN	O
of	IN	O
social	JJ	O
embarrassment	NN	O
.	.	O

Untoward	NNP	O
effects	NNS	O
of	IN	O
fenfluramine	NN	Pharmacological
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

Several	JJ	O
recent	JJ	O
studies	NNS	O
have	VBP	O
described	VBN	O
the	DT	O
benefits	NNS	O
of	IN	O
fenfluramine	NN	Pharmacological
for	IN	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
infantile	JJ	O
autism	NN	O
.	.	O

No	DT	O
large	JJ	O
surveys	NNS	O
of	IN	O
side	JJ	O
effects	NNS	O
of	IN	O
this	DT	O
drug	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
untoward	JJ	O
effects	NNS	O
of	IN	O
fenfluramine	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
12	CD	O
subjects	NNS	O
were	VBD	O
systematically	RB	O
studied	VBN	O
.	.	O

Medication	NNP	O
was	VBD	O
administered	VBN	O
in	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
cross-over	NN	O
study	NN	O
.	.	O

Parents	NNS	O
were	VBD	O
trained	VBN	O
in	IN	O
monitoring	VBG	O
untoward	JJ	O
effects	NNS	O
.	.	O

These	DT	O
observations	NNS	O
were	VBD	O
compiled	VBN	O
in	IN	O
detailed	JJ	O
daily	JJ	O
notes	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
four	CD	O
cases	NNS	O
describing	VBG	O
unusual	JJ	O
effects	NNS	O
found	VBN	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
170	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
fenfluramine	NN	Pharmacological
are	VBP	O
also	RB	O
reported	VBN	O
.	.	O

In	IN	O
the	DT	O
initial	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
active	JJ	O
drug	NN	O
listlessness	NN	O
,	,	O
food	NN	O
refusal	NN	O
,	,	O
and	CC	O
stomach	NN	O
upset	NN	O
were	VBD	O
frequently	RB	O
seen	VBN	O
.	.	O

A	DT	O
different	JJ	O
pattern	NN	O
of	IN	O
untoward	JJ	O
effects	NNS	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
final	JJ	O
14	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Irritability	NNP	O
,	,	O
agitation	NN	O
,	,	O
and	CC	O
crying	VBG	O
along	RB	O
with	IN	O
continued	VBN	O
food	NN	O
refusal	NN	O
were	VBD	O
noted	VBN	O
.	.	O

The	DT	O
subjects	NNS	O
lost	VBD	O
2.1	CD	O
%	NN	O
of	IN	O
body	NN	O
weight	NN	O
during	IN	O
active	JJ	O
drug	NN	O
phase	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
rebound	NN	O
weight	NN	O
gain	NN	O
during	IN	O
the	DT	O
subsequent	JJ	O
placebo	NN	Control
phase	NN	O
.	.	O

A	DT	O
thorough	JJ	O
understanding	NN	O
of	IN	O
fenfluramine	NN	Pharmacological
's	POS	Pharmacological
side	NN	O
effects	NNS	O
and	CC	O
adverse	JJ	O
reactions	NNS	O
is	VBZ	O
necessary	JJ	O
so	RB	O
as	IN	O
to	TO	O
differentiate	VB	O
them	PRP	O
from	IN	O
the	DT	O
multiple	NN	O
symptoms	NNS	O
inherent	NN	O
in	IN	O
the	DT	O
syndrome	NN	O
of	IN	O
autism	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
of	IN	O
phenytoin	NN	Pharmacological
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
.	.	O

STUDY	NNP	O
OBJECTIVE	NNP	O
We	PRP	O
determine	VBP	O
the	DT	O
efficacy	NN	O
of	IN	O
prophylactic	JJ	O
phenytoin	NN	Pharmacological
in	IN	O
preventing	VBG	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
.	.	O

METHODS	NNP	O
Children	NNP	O
younger	JJR	O
than	IN	O
16	CD	O
years	NNS	O
and	CC	O
experiencing	VBG	O
moderate	JJ	O
to	TO	O
severe	VB	O
blunt	NN	O
head	JJ	O
injury	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
phenytoin	NN	Pharmacological
or	CC	O
placebo	NN	Control
within	IN	O
60	CD	O
minutes	NNS	O
of	IN	O
presentation	NN	O
at	IN	O
3	CD	O
pediatric	JJ	O
trauma	NN	O
centers	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
posttraumatic	JJ	O
seizures	NNS	O
within	IN	O
48	CD	O
hours	NNS	O
;	:	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
survival	JJ	O
and	CC	O
neurologic	JJ	O
outcome	NN	O
30	CD	O
days	NNS	O
after	IN	O
injury	NN	O
.	.	O

A	DT	O
Bayesian	JJ	O
decision-theoretic	JJ	O
clinical	JJ	O
trial	NN	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
probability	NN	O
of	IN	O
remaining	VBG	O
posttraumatic	JJ	O
seizure	NN	O
free	JJ	O
for	IN	O
each	DT	O
treatment	NN	O
group	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
age	NN	O
of	IN	O
6.1	CD	O
years	NNS	O
.	.	O

Sixty-eight	JJ	O
percent	NN	O
were	VBD	O
boys	NNS	O
.	.	O

The	DT	O
2	CD	O
treatment	NN	O
groups	NNS	O
were	VBD	O
well	RB	O
matched	VBN	O
.	.	O

During	IN	O
the	DT	O
48-hour	JJ	O
observation	NN	O
period	NN	O
,	,	O
3	CD	O
(	(	O
7	CD	O
%	NN	O
)	)	O
of	IN	O
46	CD	O
patients	NNS	O
given	VBN	O
phenytoin	NNS	Pharmacological
and	CC	O
3	CD	O
(	(	O
5	CD	O
%	NN	O
)	)	O
of	IN	O
56	CD	O
patients	NNS	O
given	VBN	O
placebo	NNS	Control
experienced	VBD	O
a	DT	O
posttraumatic	JJ	O
seizure	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
in	IN	O
survival	NN	O
or	CC	O
neurologic	JJ	O
outcome	NN	O
after	IN	O
30	CD	O
days	NNS	O
.	.	O

According	VBG	O
to	TO	O
these	DT	O
results	NNS	O
,	,	O
the	DT	O
probability	NN	O
that	WDT	O
phenytoin	NN	Pharmacological
has	VBZ	O
the	DT	O
originally	RB	O
hypothesized	VBN	O
effect	NN	O
of	IN	O
reducing	VBG	O
the	DT	O
rate	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
by	IN	O
12.5	CD	O
%	NN	O
is	VBZ	O
0.0053	CD	O
.	.	O

The	DT	O
probability	NN	O
that	WDT	O
phenytoin	NN	Pharmacological
has	VBZ	O
any	DT	O
prophylactic	JJ	O
efficacy	NN	O
is	VBZ	O
0.383	CD	O
.	.	O

The	DT	O
median	JJ	O
effect	NN	O
size	NN	O
in	IN	O
this	DT	O
trial	NN	O
was	VBD	O
-0.015	NNP	O
(	(	O
seizure	JJ	O
rate	NN	O
increased	VBN	O
by	IN	O
1.5	CD	O
%	NN	O
in	IN	O
the	DT	O
phenytoin	NN	Pharmacological
group	NN	O
)	)	O
,	,	O
95	CD	O
%	NN	O
probability	NN	O
interval	NN	O
-0.127	NN	O
to	TO	O
0.091	CD	O
(	(	O
12.7	CD	O
%	NN	O
higher	JJR	O
rate	NN	O
of	IN	O
posttraumatic	JJ	O
seizures	NNS	O
to	TO	O
a	DT	O
9.1	CD	O
%	NN	O
lower	JJR	O
rate	NN	O
of	IN	O
posttraumatic	JJ	O
seizures	NNS	O
with	IN	O
phenytoin	NN	Pharmacological
)	)	O
.	.	O

CONCLUSION	VB	O
The	DT	O
rate	NN	O
of	IN	O
early	JJ	O
posttraumatic	JJ	O
seizures	NNS	O
in	IN	O
children	NNS	O
may	MD	O
be	VB	O
much	RB	O
lower	JJR	O
than	IN	O
previously	RB	O
reported	VBN	O
.	.	O

Phenytoin	VB	Pharmacological
did	VBD	O
not	RB	O
substantially	RB	O
reduce	VB	O
that	DT	O
rate	NN	O
.	.	O

Divalproex	NNP	Pharmacological
sodium	NN	Pharmacological
vs	NN	O
placebo	NN	Control
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

Autism	NNP	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASDs	NNP	O
)	)	O
are	VBP	O
neurodevelopmental	JJ	O
disorders	NNS	O
characterized	VBN	O
by	IN	O
social	JJ	O
and	CC	O
language	NN	O
deficits	NNS	O
and	CC	O
by	IN	O
repetitive	JJ	O
behaviors	NNS	O
and	CC	O
interests	NNS	O
.	.	O

Irritability/aggression	NN	O
is	VBZ	O
a	DT	O
significant	JJ	O
comorbid	NN	O
symptom	NN	O
in	IN	O
this	DT	O
population	NN	O
,	,	O
which	WDT	O
greatly	RB	O
impacts	VBZ	O
burden	NN	O
of	IN	O
care	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
divalproex	NN	Pharmacological
sodium	NN	Pharmacological
for	IN	O
irritability/aggression	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

This	DT	O
was	VBD	O
a	DT	O
12-week	JJ	O
randomized	NN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
.	.	O

All	DT	O
efficacy	NN	O
measures	NNS	O
were	VBD	O
obtained	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
evaluator	NN	O
blinded	VBD	O
to	TO	O
randomization	VB	O
condition	NN	O
and	CC	O
side	NN	O
effects	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
55	CD	O
subjects	NNS	O
gavetheir	JJ	O
consent	NN	O
and	CC	O
27	CD	O
were	VBD	O
randomized	VBN	O
in	IN	O
a	DT	O
1	CD	O
:	:	O
1	CD	O
manner	NN	O
(	(	O
mean	JJ	O
age	NN	O
9.46+/-2.46	CD	O
,	,	O
mean	FW	O
nonverbal	JJ	O
IQ	NNP	O
63.3+/-23.9	NN	O
)	)	O
.	.	O

Two	CD	O
subjects	NNS	O
from	IN	O
the	DT	O
active	JJ	O
group	NN	O
and	CC	O
one	CD	O
subject	NN	O
from	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
discontinued	VBD	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
either	CC	O
a	DT	O
lack	NN	O
of	IN	O
efficacy	NN	O
or	CC	O
side	NN	O
effects	NNS	O
(	(	O
increased	JJ	O
irritability	NN	O
)	)	O
.	.	O

Primary	JJ	O
outcome	JJ	O
measures	NNS	O
were	VBD	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Irritability	NNP	O
subscale	NN	O
and	CC	O
Clinical	JJ	O
Global	NNP	O
Impression-Improvement	NNP	O
,	,	O
which	WDT	O
focused	VBD	O
on	IN	O
irritability	NN	O
.	.	O

Overall	NNP	O
,	,	O
62.5	CD	O
%	NN	O
of	IN	O
divalproex	JJ	Pharmacological
subjects	NNS	O
vs	VBP	O
9	CD	O
%	NN	O
of	IN	O
placebo	JJ	Control
subjects	NNS	O
were	VBD	O
responders	NNS	O
(	(	O
CGI-irritability	NN	O
OR	NNP	O
:	:	O
16.7	CD	O
,	,	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
p=0.008	NN	O
)	)	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
was	VBD	O
also	RB	O
noted	VBN	O
on	IN	O
the	DT	O
ABC-Irritability	NNP	O
subscale	NN	O
(	(	O
p=0.048	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
responders	NNS	O
to	TO	O
have	VB	O
higher	JJR	O
valproate	NN	O
blood	NN	O
levels	NNS	O
compared	VBN	O
with	IN	O
nonresponders	NNS	O
.	.	O

This	DT	O
study	NN	O
suggests	VBZ	O
the	DT	O
efficacy	NN	O
of	IN	O
divalproex	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
irritability	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Larger	NNP	O
sample	JJ	O
follow-up	JJ	O
studies	NNS	O
are	VBP	O
warranted	VBN	O
.	.	O

Recovery	NN	O
profile	NN	O
after	IN	O
desflurane	NN	Pharmacological
with	IN	Pharmacological
or	CC	Pharmacological
without	IN	Pharmacological
ondansetron	NNS	Pharmacological
compared	VBN	O
with	IN	O
propofol	NN	Pharmacological
in	IN	O
patients	NNS	O
undergoing	JJ	O
outpatient	JJ	O
gynecological	JJ	O
laparoscopy	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
combining	VBG	O
prophylactic	JJ	Pharmacological
ondansetron	NN	Pharmacological
(	(	O
4	CD	O
mg	NN	O
intravenously	RB	O
[	NNP	O
IV	NNP	O
]	NNP	O
)	)	O
to	TO	O
desflurane-based	JJ	Pharmacological
anesthesia	NN	Pharmacological
in	IN	O
90	CD	O
ASA	NNP	O
grade	NN	O
I	PRP	O
or	CC	O
11	CD	O
women	NNS	O
undergoing	VBG	O
outpatient	JJ	O
gynecological	JJ	Surgical
laparoscopy	NN	Surgical
.	.	O

Recovery	NN	O
after	IN	O
anesthesia	NN	O
,	,	O
with	IN	O
special	JJ	O
focus	NN	O
on	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
(	(	O
PONV	NNP	O
)	)	O
,	,	O
was	VBD	O
assessed	VBN	O
.	.	O

Control	NNP	O
groups	NNS	O
received	VBD	O
a	DT	O
similar	JJ	O
desflurane	NN	Control
anesthetic	NN	Control
(	(	Control
placebo	NN	Control
)	)	Control
or	CC	O
a	DT	O
propofol-infusion-based	JJ	Pharmacological
(	(	Pharmacological
active	JJ	Pharmacological
control	NN	Pharmacological
)	)	Pharmacological
anesthetic	NN	Pharmacological
.	.	O

The	DT	O
study	NN	O
design	NN	O
was	VBD	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
and	CC	O
double-blind	NN	O
(	(	O
regarding	VBG	O
ondansetron	NN	Pharmacological
)	)	O
and	CC	O
single-blind	JJ	O
(	(	O
regarding	VBG	O
the	DT	O
anesthetic	JJ	O
technique	NN	O
)	)	O
.	.	O

Early	JJ	O
recovery	NN	O
(	(	O
eye	NN	O
opening	NN	O
,	,	O
orientation	NN	O
,	,	O
following	VBG	O
commands	NNS	O
,	,	O
sitting	VBG	O
)	)	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

However	RB	O
,	,	O
overall	JJ	O
home	NN	O
readiness	NN	O
(	(	O
toleration	NN	O
of	IN	O
oral	JJ	O
fluids	NNS	O
,	,	O
walking	VBG	O
,	,	O
pain	NN	O
tolerable	JJ	O
by	IN	O
oral	JJ	O
analgesics	NNS	O
,	,	O
no	DT	O
or	CC	O
only	RB	O
mild	JJ	O
nausea	NN	O
)	)	O
was	VBD	O
achieved	VBN	O
faster	RBR	O
in	IN	O
the	DT	O
desflurane	NN	O
group	NN	O
receiving	VBG	O
ondansetron	NN	Pharmacological
(	(	O
109	CD	O
[	RB	O
21-937	JJ	O
]	NNP	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
in	IN	O
the	DT	O
propofol	NN	O
group	NN	O
(	(	O
110	CD	O
[	RB	O
33-642	JJ	O
]	NNP	O
min	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
when	WRB	O
compared	VBN	O
to	TO	O
the	DT	O
desflurane	NN	Pharmacological
only	RB	O
group	NN	O
(	(	O
372	CD	O
[	RB	O
45-723	JJ	O
]	NNP	O
min	NN	O
)	)	O
(	(	O
median	JJ	O
[	NNP	O
range	NN	O
]	NN	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
incidence	NN	O
of	IN	O
PONV	NNP	O
in	IN	O
the	DT	O
desflurane-only	JJ	Pharmacological
group	NN	O
was	VBD	O
80	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
compared	VBN	O
to	TO	O
40	CD	O
%	NN	O
and	CC	O
20	CD	O
%	NN	O
in	IN	O
the	DT	O
desflurane	NN	Pharmacological
group	NN	O
receiving	VBG	O
ondansetron	NN	O
and	CC	O
the	DT	O
propofol	NN	Pharmacological
group	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
postoperative	JJ	O
antiemetic	JJ	O
requirements	NNS	O
were	VBD	O
consistently	RB	O
and	CC	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
higher	JJR	O
in	IN	O
the	DT	O
desflurane-only	JJ	Pharmacological
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
other	JJ	O
two	CD	O
groups	NNS	O
.	.	O

Postoperative	JJ	O
sedation	NN	O
,	,	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
and	CC	O
psychomotor	NN	O
recovery	NN	O
(	(	O
assessed	VBN	O
by	IN	O
the	DT	O
Maddox	NNP	O
Wing	NNP	O
and	CC	O
the	DT	O
Digit	NNP	O
Symbol	NNP	O
Substitution	NNP	O
Tests	NNP	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
three	CD	O
groups	NNS	O
.	.	O

Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
in	IN	O
order	NN	O
to	TO	O
achieve	VB	O
a	DT	O
propofol-like	JJ	Pharmacological
recovery	NN	O
profile	NN	O
in	IN	O
patients	NNS	O
with	IN	O
a	DT	O
high	JJ	O
likelihood	NN	O
of	IN	O
PONV	NNP	O
,	,	O
desflurane	NN	Pharmacological
should	MD	O
be	VB	O
combined	VBN	O
with	IN	O
a	DT	O
potent	JJ	O
antiemetic	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
ondansetron	NN	O
)	)	O
.	.	O

A	DT	O
randomized	VBN	O
study	NN	O
comparing	VBG	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Ligaclip	NNP	Surgical
with	IN	O
bipolar	JJ	O
energy	NN	O
to	TO	O
prevent	VB	O
lymphocele	NN	O
during	IN	O
laparoscopic	JJ	O
pelvic	JJ	O
lymphadenectomy	NN	O
for	IN	O
gynecologic	JJ	O
cancer	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
prospective	JJ	O
randomized	NN	O
pilot	NN	O
study	NN	O
compared	VBN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Ligaclip	NNP	O
(	(	O
Ethicon	NNP	O
Endo-Surgery	NNP	O
,	,	O
Cincinnati	NNP	O
,	,	O
OH	NNP	O
)	)	O
with	IN	O
bipolar	JJ	O
coagulation	NN	O
in	IN	O
preventing	VBG	O
lymphoceles	NNS	O
after	IN	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
for	IN	O
gynecologic	JJ	O
cancer	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Thirty	NNP	O
patients	NNS	O
with	IN	O
gynecologic	JJ	O
malignancy	NN	O
,	,	O
who	WP	O
had	VBD	O
laparoscopic	VBN	O
pelvic	JJ	O
lymphadenectomy	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
for	IN	O
lymphadenectomy	NN	Surgical
in	IN	O
1	CD	O
side	NN	O
of	IN	O
the	DT	O
pelvis	NN	O
using	VBG	O
the	DT	O
Ligaclip	NNP	Surgical
,	,	O
whereas	RB	O
,	,	O
in	IN	O
the	DT	O
other	JJ	O
side	NN	O
,	,	O
the	DT	O
bipolar	JJ	Surgical
coagulation	NN	Surgical
to	TO	Surgical
seal	VB	Surgical
lymphatic	JJ	Surgical
vessels	NNS	Surgical
was	VBD	O
used	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
ultrasound	JJ	O
examination	NN	O
,	,	O
we	PRP	O
detected	VBD	O
lymphocele	NNS	O
in	IN	O
10	CD	O
patients	NNS	O
(	(	O
33	CD	O
%	NN	O
)	)	O
.	.	O

Lymphocele	NNP	O
developed	VBD	O
in	IN	O
9	CD	O
(	(	O
30	CD	O
%	NN	O
)	)	O
patients	NNS	O
on	IN	O
the	DT	O
side	NN	O
where	WRB	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
was	VBD	O
perfomed	VBN	O
using	VBG	O
bipolar	JJ	O
coagulation	NN	O
,	,	O
and	CC	O
in	IN	O
1	CD	O
(	(	O
3.3	CD	O
%	NN	O
)	)	O
patient	NN	O
on	IN	O
the	DT	O
side	NN	O
where	WRB	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
Ligaclip	NNP	O
.	.	O

Univariate	NNP	O
analysis	NN	O
revealed	VBD	O
that	IN	O
the	DT	O
Ligaclip	NNP	O
's	POS	O
use	NN	O
compared	VBN	O
with	IN	O
electrocoagulation	NN	O
in	IN	O
the	DT	O
laparoscopic	NN	O
pelvic	JJ	O
lymphadenectomy	NN	O
is	VBZ	O
an	DT	O
independent	JJ	O
predictive	JJ	O
factor	NN	O
for	IN	O
development	NN	O
of	IN	O
lymphocele	NN	O
(	(	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
.	.	O

CONCLUSION	VB	O
This	DT	O
study	NN	O
demonstrates	VBZ	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
Ligaclip	NNP	O
to	TO	O
close	VB	O
lymphatic	JJ	O
vessels	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
lymphoceles	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
laparoscopic	JJ	O
pelvic	JJ	O
lymphadenectomy	NN	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
a	DT	O
new	JJ	O
food	NN	O
supplement	NN	O
,	,	O
ViviScal	NNP	Pharmacological
,	,	Pharmacological
with	IN	Pharmacological
fish	JJ	Pharmacological
extract	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hereditary	JJ	O
androgenic	JJ	O
alopecia	NN	O
in	IN	O
young	JJ	O
males	NNS	O
.	.	O

A	DT	O
controlled	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
parallel-group	JJ	O
study	NN	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
ViviScal	NNP	Pharmacological
(	(	Pharmacological
a	DT	Pharmacological
new	JJ	Pharmacological
food	NN	Pharmacological
supplement	NN	Pharmacological
incorporating	VBG	Pharmacological
special	JJ	Pharmacological
marine	JJ	Pharmacological
extracts	NNS	Pharmacological
and	CC	Pharmacological
a	DT	Pharmacological
silica	JJ	Pharmacological
compound	NN	Pharmacological
)	)	Pharmacological
with	IN	O
those	DT	O
of	IN	O
a	DT	O
fish	JJ	Surgical
extract	NN	Surgical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
young	JJ	O
males	NNS	O
with	IN	O
hereditary	JJ	O
androgenic	JJ	O
alopecia	NN	O
.	.	O

The	DT	O
pretreatment	JJ	O
histological	JJ	O
diagnosis	NN	O
was	VBD	O
alopecia	VBN	O
with	IN	O
a	DT	O
mild	NN	O
to	TO	O
moderate	VB	O
perifollicular	JJ	O
inflammation	NN	O
zone	NN	O
.	.	O

The	DT	O
study	NN	O
consisted	VBD	O
of	IN	O
20	CD	O
subjects	NNS	O
who	WP	O
received	VBD	O
two	CD	Pharmacological
tablets	NNS	Pharmacological
of	IN	Pharmacological
ViviScal	NNP	Pharmacological
once	RB	Pharmacological
daily	RB	Pharmacological
and	CC	O
20	CD	O
who	WP	O
received	VBD	O
two	CD	Control
tablets	NNS	Control
of	IN	Control
fish	JJ	Control
extract	NN	Control
once	RB	Control
daily	JJ	Control
for	IN	O
6	CD	O
months	NNS	O
.	.	O

The	DT	O
mean	JJ	O
patient	NN	O
age	NN	O
and	CC	O
mean	JJ	O
duration	NN	O
and	CC	O
severity	NN	O
of	IN	O
baldness	NN	O
compared	VBN	O
well	RB	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Most	JJS	O
patients	NNS	O
had	VBD	O
been	VBN	O
treated	VBN	O
with	IN	O
long-term	JJ	O
topical	JJ	O
2	CD	O
%	NN	O
minoxidil	NN	Pharmacological
for	IN	O
1	CD	O
year	NN	O
or	CC	O
more	JJR	O
prior	JJ	O
to	TO	O
the	DT	O
study	NN	O
.	.	O

At	IN	O
baseline	NN	O
and	CC	O
after	IN	O
6	CD	O
months	NNS	O
'	POS	O
treatment	NN	O
,	,	O
a	DT	O
biopsy	NN	O
was	VBD	O
taken	VBN	O
for	IN	O
histological	JJ	O
examination	NN	O
.	.	O

A	DT	O
non-vellus	JJ	O
hair	NN	O
count	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
6	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
fish	JJ	Pharmacological
extract	NN	Pharmacological
treatment	NN	O
group	NN	O
three	CD	O
patients	NNS	O
withdrew	VBD	O
from	IN	O
the	DT	O
study	NN	O
before	IN	O
the	DT	O
fourth	JJ	O
month	NN	O
due	JJ	O
to	TO	O
lack	VB	O
of	IN	O
therapeutic	JJ	O
effect	NN	O
.	.	O

After	IN	O
6	CD	O
months	NNS	O
'	POS	O
treatment	NN	O
,	,	O
patients	NNS	O
receiving	VBG	O
ViviScal	NNP	Pharmacological
showed	VBD	O
a	DT	O
mean	JJ	O
increase	NN	O
in	IN	O
non-vellus	JJ	O
hair	NN	O
of	IN	O
38	CD	O
%	NN	O
compared	VBN	O
with	IN	O
a	DT	O
2	CD	O
%	NN	O
increase	NN	O
in	IN	O
the	DT	O
fish	JJ	Pharmacological
extract	NN	Pharmacological
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
ViviScal	NNP	Pharmacological
group	NN	O
,	,	O
19	CD	O
(	(	O
95	CD	O
%	NN	O
)	)	O
subjects	VBZ	O
showed	VBN	O
both	DT	O
clinical	JJ	O
and	CC	O
histological	JJ	O
cure	NN	O
,	,	O
whereas	IN	O
none	NN	O
treated	VBN	O
with	IN	O
fish	JJ	O
extract	NN	O
showed	VBD	O
any	DT	O
clinical	JJ	O
or	CC	O
histological	JJ	O
difference	NN	O
after	IN	O
6	CD	O
months	NNS	O
'	POS	O
treatment	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
a	DT	O
minimal	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
erythemal	JJ	O
index	NN	O
was	VBD	O
observed	VBN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
ViviScal	JJ	Pharmacological
appears	VBZ	O
to	TO	O
be	VB	O
the	DT	O
first	JJ	O
highly	RB	O
active	JJ	O
treatment	NN	O
for	IN	O
androgenic	JJ	O
alopecia	NN	O
in	IN	O
young	JJ	O
males	NNS	O
.	.	O

Cost-effectiveness	NN	O
of	IN	O
a	DT	O
telephone-delivered	JJ	Educational
intervention	NN	Educational
for	IN	Educational
physical	JJ	Educational
activity	NN	Educational
and	CC	Educational
diet	NN	Educational
.	.	O

BACKGROUND	NNP	O
Given	NNP	O
escalating	VBG	O
rates	NNS	O
of	IN	O
chronic	JJ	O
disease	NN	O
,	,	O
broad-reach	NN	O
and	CC	O
cost-effective	JJ	O
interventions	NNS	O
to	TO	O
increase	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
improve	VB	O
dietary	JJ	O
intake	NN	O
are	VBP	O
needed	VBN	O
.	.	O

The	DT	O
cost-effectiveness	NN	O
of	IN	O
a	DT	O
Telephone	NNP	Educational
Counselling	NNP	Educational
intervention	NN	Educational
to	TO	O
improve	VB	O
physical	JJ	O
activity	NN	O
and	CC	O
diet	NN	O
,	,	O
targeting	VBG	O
adults	NNS	O
with	IN	O
established	VBN	O
chronic	JJ	O
diseases	NNS	O
in	IN	O
a	DT	O
low	JJ	O
socio-economic	JJ	O
area	NN	O
of	IN	O
a	DT	O
major	JJ	O
Australian	JJ	O
city	NN	O
was	VBD	O
examined	VBN	O
.	.	O

METHODOLOGY/PRINCIPAL	NNP	O
FINDINGS	NNP	O
A	NNP	O
cost-effectiveness	NN	O
modelling	NN	O
study	NN	O
using	VBG	O
data	NNS	O
collected	VBN	O
between	IN	O
February	NNP	O
2005	CD	O
and	CC	O
November	NNP	O
2007	CD	O
from	IN	O
a	DT	O
cluster-randomised	JJ	O
trial	NN	O
that	WDT	O
compared	VBN	O
Telephone	NNP	O
Counselling	NNP	O
with	IN	O
a	DT	O
Usual	NNP	O
Care	NNP	O
(	(	O
brief	JJ	O
intervention	NN	O
)	)	O
alternative	NN	O
.	.	O

Economic	JJ	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
a	DT	O
state-transition	NN	O
Markov	NNP	O
model	NN	O
,	,	O
which	WDT	O
predicted	VBD	O
the	DT	O
progress	NN	O
of	IN	O
participants	NNS	O
through	IN	O
five	CD	O
health	NN	O
states	NNS	O
relating	VBG	O
to	TO	O
physical	JJ	O
activity	NN	O
and	CC	O
dietary	JJ	O
improvement	NN	O
,	,	O
for	IN	O
ten	CD	O
years	NNS	O
after	IN	O
recruitment	NN	O
.	.	O

The	DT	O
costs	NNS	O
and	CC	O
health	NN	O
benefits	NNS	O
of	IN	O
Telephone	NNP	Educational
Counselling	NNP	Educational
,	,	Physical
Usual	NNP	Physical
Care	NNP	Physical
and	CC	Physical
an	DT	Physical
existing	VBG	Control
practice	NN	Control
(	(	Control
Real	NNP	Control
Control	NNP	Control
)	)	Control
group	NN	O
were	VBD	O
compared	VBN	O
.	.	O

Telephone	CD	Educational
Counselling	VBG	Educational
compared	VBN	O
to	TO	O
Usual	NNP	Physical
Care	NNP	Physical
was	VBD	O
not	RB	O
cost-effective	JJ	O
(	(	O
$	$	O
78,489	CD	O
per	IN	O
quality	NN	O
adjusted	VBN	O
life	NN	O
year	NN	O
gained	VBN	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
Usual	NNP	Physical
Care	NNP	Physical
group	NN	O
did	VBD	O
not	RB	O
represent	VB	O
existing	VBG	O
practice	NN	O
and	CC	O
is	VBZ	O
not	RB	O
a	DT	O
useful	JJ	O
comparator	NN	O
for	IN	O
decision	NN	O
making	NN	O
.	.	O

Comparing	VBG	O
Telephone	CD	Educational
Counselling	VBG	Educational
outcomes	NNS	O
to	TO	O
existing	VBG	O
practice	NN	O
(	(	O
Real	NNP	O
Control	NNP	O
)	)	O
,	,	O
the	DT	O
intervention	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
cost-effective	JJ	O
(	(	O
$	$	O
29,375	CD	O
per	IN	O
quality	NN	O
adjusted	VBN	O
life	NN	O
year	NN	O
gained	VBN	O
)	)	O
.	.	O

Usual	JJ	Other
Care	NNP	Other
(	(	Other
brief	JJ	Other
intervention	NN	Other
)	)	Other
compared	VBN	O
to	TO	O
existing	VBG	Control
practice	NN	Control
(	(	Control
Real	NNP	Control
Control	NNP	Control
)	)	Control
was	VBD	O
also	RB	O
cost-effective	JJ	O
(	(	O
$	$	O
12,153	CD	O
per	IN	O
quality	NN	O
adjusted	VBN	O
life	NN	O
year	NN	O
gained	VBN	O
)	)	O
.	.	O

CONCLUSIONS/SIGNIFICANCE	VB	O
This	DT	O
modelling	NN	O
study	NN	O
shows	VBZ	O
that	IN	O
a	DT	O
decision	NN	O
to	TO	O
adopt	VB	O
a	DT	O
Telephone	CD	O
Counselling	VBG	O
program	NN	O
over	IN	O
existing	VBG	O
practice	NN	O
(	(	O
Real	NNP	O
Control	NNP	O
)	)	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
cost-effective	JJ	O
.	.	O

Choosing	VBG	O
the	DT	O
'Usual	JJ	Physical
Care	NNP	Physical
'	POS	Physical
brief	NN	Physical
intervention	NN	Physical
over	IN	O
existing	VBG	O
practice	NN	O
(	(	O
Real	NNP	O
Control	NNP	O
)	)	O
shows	VBZ	O
a	DT	O
lower	JJR	O
cost	NN	O
per	IN	O
quality	NN	O
adjusted	VBN	O
life	NN	O
year	NN	O
,	,	O
but	CC	O
the	DT	O
lack	NN	O
of	IN	O
supporting	VBG	O
evidence	NN	O
for	IN	O
efficacy	NN	O
or	CC	O
sustainability	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
consideration	NN	O
for	IN	O
decision	NN	O
makers	NNS	O
.	.	O

The	DT	O
economics	NNS	O
of	IN	O
behavioural	JJ	O
approaches	NNS	O
to	TO	O
improving	VBG	O
health	NN	O
must	MD	O
be	VB	O
made	VBN	O
explicit	JJ	O
if	IN	O
decision	NN	O
makers	NNS	O
are	VBP	O
to	TO	O
be	VB	O
convinced	VBN	O
that	IN	O
allocating	VBG	O
resources	NNS	O
toward	IN	O
such	JJ	O
programs	NNS	O
is	VBZ	O
worthwhile	JJ	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
This	DT	O
paper	NN	O
uses	VBZ	O
data	NNS	O
collected	VBN	O
in	IN	O
a	DT	O
previous	JJ	O
clinical	JJ	O
trial	NN	O
registered	VBD	O
at	IN	O
the	DT	O
Australian	JJ	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
,	,	O
Australian	JJ	O
New	NNP	O
Zealand	NNP	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
:	:	O
Anzcrt.org.au	NNP	O
ACTRN012607000195459	NNP	O
.	.	O

A	DT	O
comparative	JJ	O
study	NN	O
of	IN	O
ofloxacin	NN	Pharmacological
and	CC	O
cefixime	NN	Pharmacological
for	IN	O
treatment	NN	O
of	IN	O
typhoid	JJ	O
fever	NN	O
in	IN	O
children	NNS	O
.	.	O

The	DT	O
Dong	NNP	O
Nai	NNP	O
Pediatric	NNP	O
Center	NNP	O
Typhoid	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
Despite	IN	O
concerns	NNS	O
about	IN	O
safety	NN	O
in	IN	O
children	NNS	O
,	,	O
fluoroquinolone	NN	Pharmacological
antibiotics	NNS	Pharmacological
have	VBP	O
become	VBN	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
in	IN	O
patients	NNS	O
with	IN	O
multidrug-resistant	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
Vietnam	NNP	O
.	.	O

However	RB	O
,	,	O
quinolone-resistant	JJ	O
strains	NNS	O
of	IN	O
Salmonella	NNP	O
typhi	NN	O
have	VBP	O
recently	RB	O
been	VBN	O
reported	VBN	O
from	IN	O
Vietnam	NNP	O
;	:	O
and	CC	O
if	IN	O
quinolone	JJ	O
resistance	NN	O
becomes	NNS	O
established	VBN	O
,	,	O
alternative	JJ	O
oral	JJ	O
treatment	NN	O
options	NNS	O
will	MD	O
be	VB	O
needed	VBN	O
.	.	O

OBJECTIVE	NNP	O
Cefixime	NNP	Pharmacological
,	,	O
an	DT	O
orally	RB	O
administered	VBN	O
third	JJ	O
generation	NN	O
cephalosporin	NN	Pharmacological
,	,	O
was	VBD	O
compared	VBN	O
with	IN	O
ofloxacin	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
uncomplicated	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
children	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
an	DT	O
open	JJ	O
trial	NN	O
children	NNS	O
with	IN	O
suspected	JJ	O
typhoid	NN	O
fever	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
ofloxacin	NN	Pharmacological
(	(	O
10	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
or	CC	O
cefixime	NN	Pharmacological
(	(	O
20	CD	O
mg/kg/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
)	)	O
for	IN	O
7	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
S.	NNP	O
typhi	NN	O
was	VBD	O
isolated	VBN	O
from	IN	O
82	CD	O
patients	NNS	O
(	(	O
44	CD	O
in	IN	O
the	DT	O
cefixime	NN	Pharmacological
group	NN	O
,	,	O
38	CD	O
in	IN	O
the	DT	O
ofloxacin	JJ	Pharmacological
group	NN	O
)	)	O
and	CC	O
70	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
isolates	NNS	O
were	VBD	O
multidrug-resistant	JJ	O
.	.	O

Median	JJ	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
range	NN	O
)	)	O
fever	NN	O
clearance	NN	O
times	NNS	O
were	VBD	O
4.4	CD	O
(	(	O
4	CD	O
to	TO	O
5.2	CD	O
,	,	O
0.2	CD	O
to	TO	O
9.9	CD	O
)	)	O
days	NNS	O
for	IN	O
ofloxacin	JJ	Pharmacological
recipients	NNS	O
and	CC	O
8.5	CD	O
(	(	O
4.2	CD	O
to	TO	O
9	CD	O
,	,	O
1.8	CD	O
to	TO	O
15.2	CD	O
)	)	O
days	NNS	O
for	IN	O
cefixime-treated	JJ	Pharmacological
patients	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
11	CD	O
treatment	NN	O
failures	NNS	O
(	(	O
10	CD	O
acute	NN	O
and	CC	O
one	CD	O
relapse	NN	O
)	)	O
in	IN	O
the	DT	O
cefixime	NN	Pharmacological
group	NN	O
and	CC	O
1	CD	O
acute	NN	O
treatment	NN	O
failure	NN	O
in	IN	O
the	DT	O
ofloxacin	NN	Pharmacological
group	NN	O
(	(	O
mean	JJ	O
difference	NN	O
,	,	O
22	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
9	CD	O
to	TO	O
36	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Short	NNP	O
course	NN	O
treatment	NN	O
with	IN	O
cefixime	NN	Pharmacological
may	MD	O
provide	VB	O
a	DT	O
useful	JJ	O
alternative	JJ	O
treatment	NN	O
in	IN	O
cases	NNS	O
of	IN	O
uncomplicated	JJ	O
typhoid	NN	O
fever	NN	O
in	IN	O
children	NNS	O
,	,	O
but	CC	O
it	PRP	O
is	VBZ	O
less	RBR	O
effective	JJ	O
than	IN	O
short	JJ	O
course	NN	O
treatment	NN	O
with	IN	O
ofloxacin	NN	Pharmacological
.	.	O

A	DT	O
randomised	JJ	O
comparison	NN	O
of	IN	O
UK	NNP	Educational
genetic	JJ	Educational
risk	NN	Educational
counselling	NN	Educational
services	NNS	Educational
for	IN	O
familial	JJ	O
cancer	NN	O
:	:	O
psychosocial	JJ	O
outcomes	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
psychosocial	JJ	O
outcomes	NNS	O
for	IN	O
50	CD	O
new	JJ	O
clinic	JJ	O
attendees	NNS	O
,	,	O
referred	VBD	O
for	IN	O
cancer	NN	Educational
genetic	JJ	Educational
counselling	NN	Educational
to	TO	O
five	CD	O
UK	NNP	O
centres	NNS	O
.	.	O

The	DT	O
centres	NNS	O
represented	VBD	O
England	NNP	O
,	,	O
Scotland	NNP	O
and	CC	O
Wales	NNP	O
,	,	O
and	CC	O
were	VBD	O
randomly	RB	O
selected	VBN	O
from	IN	O
groups	NNS	O
ranked	VBN	O
by	IN	O
different	JJ	O
levels	NNS	O
of	IN	O
clinical	JJ	O
activity	NN	O
in	IN	O
cancer	NN	O
genetics	NNS	O
practice	NN	O
.	.	O

Questionnaires	NNS	O
assessed	VBD	O
demographic	JJ	O
data	NNS	O
,	,	O
risk	NN	O
perception	NN	O
,	,	O
mental	JJ	O
health	NN	O
and	CC	O
use	NN	O
of	IN	O
health	NN	O
services	NNS	O
pre-consultation	NN	O
and	CC	O
at	IN	O
1	CD	O
and	CC	O
12	CD	O
months	NNS	O
follow-up	RB	O
.	.	O

Satisfaction	NN	O
was	VBD	O
measured	VBN	O
for	IN	O
attendees	NNS	O
and	CC	O
referring	VBG	O
doctors	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
256	CD	O
unaffected	JJ	O
adults	NNS	O
fulfilled	VBD	O
the	DT	O
study	NN	O
criteria	NNS	O
.	.	O

The	DT	O
five	CD	O
centres	NNS	O
varied	VBD	O
widely	RB	O
with	IN	O
respect	NN	O
to	TO	O
service	NN	O
organisation	NN	O
and	CC	O
activity	NN	O
,	,	O
but	CC	O
all	DT	O
had	VBD	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
unaffected	JJ	O
attendees	NNS	O
with	IN	O
a	DT	O
breast	NN	O
cancer	NN	O
risk	NN	O
(	(	O
61-91	CD	O
%	NN	O
)	)	O
than	IN	O
either	CC	O
a	DT	O
bowel	NN	O
cancer	NN	O
risk	NN	O
(	(	O
0-33	CD	O
%	NN	O
)	)	O
or	CC	O
ovarian	JJ	O
cancer	NN	O
risk	NN	O
(	(	O
3-25	CD	O
%	NN	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
psychosocial	JJ	O
data	NN	O
between	IN	O
centres	NNS	O
pre-counselling	VBG	Educational
.	.	Educational

No	DT	O
significant	JJ	O
change	NN	O
over	IN	O
time	NN	O
occurred	VBN	O
for	IN	O
any	DT	O
of	IN	O
the	DT	O
centres	NNS	O
for	IN	O
risk	NN	O
perception	NN	O
or	CC	O
general	JJ	O
psychological	JJ	O
distress	NN	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
differences	NNS	O
between	IN	O
centres	NNS	O
in	IN	O
reduction	NN	O
of	IN	O
cancer	NN	O
worry	NN	O
from	IN	O
baseline	NN	O
to	TO	O
12	CD	O
months	NNS	O
and	CC	O
with	IN	O
the	DT	O
number	NN	O
of	IN	O
women	NNS	O
who	WP	O
were	VBD	O
recommended	VBN	O
to	TO	O
have	VB	O
mammographic	JJ	O
surveillance	NN	O
who	WP	O
had	VBD	O
not	RB	O
received	VBN	O
this	DT	O
.	.	O

Overall	JJ	O
,	,	O
one-third	JJ	O
of	IN	O
women	NNS	O
for	IN	O
whom	WP	O
mammography	NN	O
had	VBD	O
been	VBN	O
recommended	VBN	O
had	VBD	O
not	RB	O
been	VBN	O
screened	VBN	O
within	IN	O
1	CD	O
year	NN	O
of	IN	O
follow-up	NN	O
.	.	O

Subsequent	JJ	O
attendance	NN	O
at	IN	O
the	DT	O
GP	NNP	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
a	DT	O
hospital	NN	O
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
risk	NN	O
level	NN	O
,	,	O
but	CC	O
differences	NNS	O
between	IN	O
centres	NNS	O
could	MD	O
not	RB	O
be	VB	O
analysed	VBN	O
.	.	O

Satisfaction	NN	O
differed	VBD	O
significantly	RB	O
between	IN	O
centres	NNS	O
for	IN	O
4	CD	O
:	:	O
14	CD	O
aspects	NNS	O
of	IN	O
service	NN	O
provision	NN	O
and	CC	O
with	IN	O
3	CD	O
:	:	O
17	CD	O
items	NNS	O
concerning	VBG	O
communication	NN	O
;	:	O
satisfaction	NN	O
was	VBD	O
high	JJ	O
overall	JJ	O
.	.	O

Over	IN	O
90	CD	O
%	NN	O
of	IN	O
referring	VBG	O
doctors	NNS	O
were	VBD	O
moderately/very	RB	O
satisfied	VBN	O
with	IN	O
the	DT	O
service	NN	O
,	,	O
but	CC	O
23	CD	O
%	NN	O
were	VBD	O
dissatisfied	VBN	O
with	IN	O
waiting	VBG	O
times	NNS	O
and	CC	O
19	CD	O
%	NN	O
with	IN	O
access	NN	O
to	TO	O
preventive	VB	O
treatment	NN	O
.	.	O

Results	NNS	O
differed	VBD	O
significantly	RB	O
between	IN	O
centres	NNS	O
for	IN	O
doctor	NN	O
's	POS	O
satisfaction	NN	O
with	IN	O
the	DT	O
provision	NN	O
of	IN	O
referral	JJ	O
criteria	NNS	O
and	CC	O
prescribing	VBG	O
information	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
there	EX	O
were	VBD	O
relatively	RB	O
few	JJ	O
significant	JJ	O
differences	NNS	O
in	IN	O
psychosocial	JJ	O
outcomes	NNS	O
between	IN	O
centres	NNS	O
,	,	O
considering	VBG	O
the	DT	O
wide	JJ	O
variation	NN	O
in	IN	O
service	NN	O
organisation	NN	O
and	CC	O
activity	NN	O
.	.	O

These	DT	O
significant	JJ	O
differences	NNS	O
were	VBD	O
not	RB	O
consistent	JJ	O
across	IN	O
the	DT	O
centres	NNS	O
,	,	O
therefore	RB	O
,	,	O
differences	NNS	O
could	MD	O
not	RB	O
be	VB	O
linked	VBN	O
to	TO	O
specific	JJ	O
aspects	NNS	O
of	IN	O
service	NN	O
provision	NN	O
.	.	O

Coping	VBG	O
with	IN	O
distress	NN	O
and	CC	O
self	JJ	O
harm	NN	O
:	:	O
the	DT	O
impact	NN	O
of	IN	O
a	DT	O
primary	JJ	Psychological
prevention	NN	Psychological
program	NN	Psychological
among	IN	O
adolescents	NNS	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
school-based	JJ	Psychological
primary	JJ	Psychological
prevention	NN	Psychological
psychological	JJ	Psychological
program	NN	Psychological
is	VBZ	O
assessed	VBN	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
.	.	O

The	DT	O
program	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
improve	NN	O
students	NNS	O
'	POS	O
distress-coping	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
prepare	VB	O
them	PRP	O
as	IN	O
gatekeepers	NNS	O
with	IN	O
regard	NN	O
to	TO	O
self-destructive	JJ	O
behavior	NN	O
of	IN	O
peers	NNS	O
and	CC	O
(	(	O
c	NN	O
)	)	O
assess	IN	O
the	DT	O
program	NN	O
's	POS	O
face	NN	O
validity	NN	O
and	CC	O
social	JJ	O
validity	NN	O
.	.	O

The	DT	O
program	NN	O
was	VBD	O
primarily	RB	O
based	VBN	O
on	IN	O
cognitive-behavioral	JJ	O
modification	NN	O
principles	NNS	O
,	,	O
procedures	NNS	O
and	CC	O
techniques	NNS	O
.	.	O

Two	CD	O
hundred	CD	O
and	CC	O
thirty-seven	JJ	O
students	NNS	O
,	,	O
drawn	NN	O
from	IN	O
six	CD	O
homeroom	NN	O
grade	NN	O
eight	CD	O
classes	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
experimental	VB	O
and	CC	O
control	VB	O
(	(	O
no	DT	O
intervention	NN	O
)	)	O
conditions	NNS	O
.	.	O

The	DT	O
program	NN	O
consisted	VBN	O
of	IN	O
seven	CD	O
units	NNS	O
passed	VBN	O
during	IN	O
twelve	JJ	O
weekly	JJ	O
one-hour	JJ	O
sessions	NNS	O
.	.	O

Overall	NNP	O
,	,	O
the	DT	O
program	NN	O
had	VBD	O
a	DT	O
positive	JJ	O
effect	NN	O
on	IN	O
attitudes	NNS	O
,	,	O
emotions	NNS	O
,	,	O
knowledge	NN	O
and	CC	O
awareness	NN	O
of	IN	O
distress	NN	O
coping	VBG	O
skills	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
it	PRP	O
had	VBD	O
some	DT	O
degree	NN	O
of	IN	O
face	NN	O
validity	NN	O
and	CC	O
social	JJ	O
validity	NN	O
from	IN	O
the	DT	O
students	NNS	O
'	POS	O
vantage	NN	O
point	NN	O
.	.	O

These	DT	O
results	NNS	O
lend	VBP	O
support	NN	O
to	TO	O
the	DT	O
feasibility	NN	O
of	IN	O
a	DT	O
cognitive-behavioral	JJ	Psychological
,	,	Psychological
school-based	JJ	Psychological
prevention	NN	Psychological
program	NN	Psychological
for	IN	O
students	NNS	O
'	POS	O
distress-coping	JJ	O
enhancement	NN	O
.	.	O

Fine	NNP	Surgical
needle	JJ	Surgical
aspiration	NN	Surgical
coupled	VBN	Surgical
with	IN	Surgical
real-time	JJ	Physical
PCR	NNP	Physical
:	:	O
a	DT	O
painless	JJ	O
methodology	NN	O
to	TO	O
study	VB	O
adaptive	JJ	O
functional	JJ	O
changes	NNS	O
in	IN	O
skeletal	JJ	O
muscle	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
AIM	NNP	O
In	IN	O
this	DT	O
study	NN	O
we	PRP	O
developed	VBD	O
a	DT	O
new	JJ	O
methodology	NN	Physical
for	IN	O
obtaining	VBG	O
human	JJ	O
skeletal	JJ	O
muscle	NN	O
samples	NNS	O
to	TO	O
evaluate	VB	O
gene	NN	O
expression	NN	O
.	.	O

This	DT	O
approach	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
a	DT	O
fine	JJ	Physical
needle	JJ	Physical
aspiration	NN	Physical
technique	NN	Physical
,	,	O
which	WDT	O
allows	VBZ	O
us	PRP	O
to	TO	O
extract	VB	O
a	DT	O
small	JJ	O
tissue	NN	O
sample	NN	O
in	IN	O
a	DT	O
significantly	RB	O
less	RBR	O
invasive	JJ	O
manner	NN	O
than	IN	O
with	IN	O
classic	JJ	O
biopsy	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
Multiplex	NNP	Physical
tandem	VBD	Physical
RT-PCR	NNP	Physical
was	VBD	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
mRNA	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
ATP	NNP	O
production	NN	O
and	CC	O
mitochondrial	JJ	O
biogenesis	NN	O
in	IN	O
muscle	NN	O
tissue	NN	O
.	.	O

Samples	NNS	O
of	IN	O
vastus	NN	O
lateralis	NNS	O
muscle	NN	O
were	VBD	O
obtained	VBN	O
from	IN	O
21	CD	O
healthy	JJ	O
subjects	NNS	O
with	IN	O
different	JJ	O
fitness	NN	O
levels	NNS	O
.	.	O

The	DT	O
principal	JJ	O
findings	NNS	O
in	IN	O
our	PRP$	O
study	NN	O
show	VB	O
a	DT	O
strong	JJ	O
correlation	NN	O
between	IN	O
PGC-1alpha	NNP	O
and	CC	O
COX5B	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
between	IN	O
PGC-1alpha	NNP	O
and	CC	O
MT-CO2	NNP	O
(	(	O
p=0.017	NN	O
)	)	O
expression	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
a	DT	O
significant	JJ	O
positive	JJ	O
correlation	NN	O
between	IN	O
mtDNA	NN	O
content	NN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
MHCI	NNP	O
present	NN	O
in	IN	O
the	DT	O
aspired	JJ	O
samples	NNS	O
were	VBD	O
found	VBN	O
(	(	O
p=0.028	NN	O
)	)	O
.	.	O

These	DT	O
data	NNS	O
are	VBP	O
in	IN	O
agreement	NN	O
with	IN	O
current	JJ	O
knowledge	NN	O
on	IN	O
skeletal	JJ	O
muscle	NN	O
physiology	NN	O
and	CC	O
show	VB	O
the	DT	O
reliability	NN	O
of	IN	O
the	DT	O
proposed	VBN	O
method	NN	O
.	.	O

CONCLUSION	VB	O
This	DT	O
painless	JJ	Physical
methodology	NN	Physical
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
investigate	VB	O
,	,	O
in	IN	O
vivo	NN	O
,	,	O
human	JJ	O
muscle	NN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
adaptations	NNS	O
in	IN	O
response	NN	O
to	TO	O
either	DT	O
physiological	JJ	O
and/or	NN	O
pharmacological	JJ	O
stimuli	NN	O
.	.	O

This	DT	O
method	NN	O
has	VBZ	O
major	JJ	O
clinical	JJ	O
relevance	NN	O
,	,	O
such	JJ	O
as	IN	O
its	PRP$	O
application	NN	O
in	IN	O
clarifying	VBG	O
the	DT	O
mechanisms	NN	O
underling	VBG	O
metabolic	JJ	O
and	CC	O
systemic	JJ	O
disorders	NNS	O
.	.	O

Enhancing	VBG	O
implementation	NN	O
of	IN	O
tobacco	NN	Educational
use	NN	Educational
prevention	NN	Educational
and	CC	Educational
cessation	NN	Educational
counselling	VBG	Educational
guideline	NN	Educational
among	IN	O
dental	JJ	O
providers	NNS	O
:	:	O
a	DT	O
cluster	NN	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Tobacco	NNP	O
use	NN	O
adversely	RB	O
affects	VBZ	O
oral	JJ	O
health	NN	O
.	.	O

Tobacco	NNP	Educational
use	NN	Educational
prevention	NN	Educational
and	CC	Educational
cessation	NN	Educational
(	(	Educational
TUPAC	NNP	Educational
)	)	Educational
counselling	VBG	Educational
guidelines	NNS	Educational
recommend	VBP	O
that	IN	O
healthcare	NN	O
providers	NNS	O
ask	VBP	O
about	IN	O
each	DT	O
patient	NN	O
's	POS	O
tobacco	NN	O
use	NN	O
,	,	O
assess	IN	O
the	DT	O
patient	NN	O
's	POS	O
readiness	NN	O
and	CC	O
willingness	NN	O
to	TO	O
stop	VB	O
,	,	O
document	NN	O
tobacco	NN	O
use	NN	O
habits	NNS	O
,	,	O
advise	VBP	O
the	DT	O
patient	NN	O
to	TO	O
stop	VB	O
,	,	O
assist	NN	O
and	CC	O
help	NN	O
in	IN	O
quitting	NN	O
,	,	O
and	CC	O
arrange	JJ	O
monitoring	NN	O
of	IN	O
progress	NN	O
at	IN	O
follow-up	JJ	O
appointments	NNS	O
.	.	O

Adherence	NN	O
to	TO	O
such	JJ	O
guidelines	NNS	O
,	,	O
especially	RB	O
among	IN	O
dental	JJ	O
providers	NNS	O
,	,	O
is	VBZ	O
poor	JJ	O
.	.	O

To	TO	O
improve	VB	O
guideline	NN	O
implementation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
to	TO	O
understand	VB	O
factors	NNS	O
influencing	VBG	O
it	PRP	O
and	CC	O
find	VB	O
effective	JJ	O
ways	NNS	O
to	TO	O
influence	VB	O
those	DT	O
factors	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
protocol	NN	O
is	VBZ	O
to	TO	O
introduce	VB	O
a	DT	O
theory-based	JJ	Educational
approach	NN	Educational
to	TO	Educational
diagnose	VB	Educational
implementation	NN	Educational
difficulties	NNS	Educational
of	IN	Educational
TUPAC	NNP	Educational
counselling	VBG	Educational
guidelines	NNS	Educational
among	IN	Educational
dental	JJ	Educational
providers	NNS	Educational
.	.	Educational

METHODS	NNP	O
Theories	NNPS	O
of	IN	O
behaviour	NN	O
change	NN	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
identify	VB	O
key	JJ	O
theoretical	JJ	O
domains	NNS	O
relevant	VBP	O
to	TO	O
the	DT	O
behaviours	NN	O
of	IN	O
healthcare	JJ	O
providers	NNS	O
involved	VBN	O
in	IN	O
implementing	VBG	O
clinical	JJ	O
guidelines	NNS	O
.	.	O

These	DT	O
theoretical	JJ	O
domains	NNS	O
will	MD	O
inform	VB	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
questionnaire	NN	O
aimed	VBN	O
at	IN	O
assessing	VBG	O
the	DT	O
implementation	NN	O
of	IN	O
the	DT	O
TUPAC	NNP	Educational
counselling	VBG	Educational
guidelines	NNS	Educational
among	IN	O
Finnish	JJ	O
municipal	JJ	O
dental	JJ	O
providers	NNS	O
.	.	O

Specific	JJ	O
items	NNS	O
will	MD	O
be	VB	O
drawn	VBN	O
from	IN	O
the	DT	O
guidelines	NNS	O
and	CC	O
the	DT	O
literature	NN	O
on	IN	O
TUPAC	NNP	Educational
studies	NNS	O
.	.	O

After	IN	O
identifying	VBG	O
potential	JJ	O
implementation	NN	O
difficulties	NNS	O
,	,	O
we	PRP	O
will	MD	O
design	VB	O
two	CD	O
interventions	NNS	O
using	VBG	O
theories	NNS	Educational
of	IN	Educational
behaviour	JJ	Educational
change	NN	Educational
to	TO	O
link	VB	O
them	PRP	O
with	IN	O
relevant	JJ	O
behaviour	NN	O
change	NN	O
techniques	NNS	O
aiming	VBG	O
to	TO	O
improve	VB	O
guideline	NN	Educational
adherence	NN	Educational
.	.	Educational

For	IN	O
assessing	VBG	O
the	DT	O
implementation	NN	O
of	IN	O
TUPAC	NNP	Educational
guidelines	NNS	Educational
,	,	O
the	DT	O
electronic	JJ	O
dental	NN	O
record	NN	O
audit	NN	O
and	CC	O
self-reported	JJ	O
questionnaires	NNS	O
will	MD	O
be	VB	O
used	VBN	O
.	.	O

DISCUSSION	NNP	O
To	TO	O
improve	VB	O
guideline	NN	O
adherence	NN	O
,	,	O
the	DT	O
theoretical-domains	NNS	O
approach	NN	O
could	MD	O
provide	VB	O
a	DT	O
comprehensive	JJ	O
basis	NN	O
for	IN	O
assessing	VBG	O
implementation	NN	O
difficulties	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
designing	VBG	O
and	CC	O
evaluating	VBG	O
interventions	NNS	O
.	.	O

After	IN	O
having	VBG	O
identified	VBN	O
implementation	NN	O
difficulties	NNS	O
,	,	O
we	PRP	O
will	MD	O
design	VB	O
and	CC	O
test	VB	O
two	CD	O
interventions	NNS	O
to	TO	O
enhance	VB	O
TUPAC	NNP	Educational
guideline	JJ	Educational
adherence	NN	O
.	.	O

Using	VBG	O
the	DT	O
cluster	NN	O
randomised	VBD	O
controlled	JJ	O
design	NN	O
,	,	O
we	PRP	O
aim	VBP	O
to	TO	O
provide	VB	O
further	JJ	O
evidence	NN	O
on	IN	O
intervention	NN	O
effects	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
on	IN	O
the	DT	O
validity	NN	O
and	CC	O
feasibility	NN	O
of	IN	O
the	DT	O
theoretical-domain	JJ	O
approach	NN	O
.	.	O

The	DT	O
empirical	JJ	O
data	NNS	O
collected	VBN	O
within	IN	O
this	DT	O
trial	NN	O
will	MD	O
be	VB	O
useful	JJ	O
in	IN	O
testing	VBG	O
whether	IN	O
this	DT	O
theoretical-domain	JJ	Educational
approach	NN	Educational
can	MD	O
improve	VB	O
our	PRP$	O
understanding	NN	O
of	IN	O
the	DT	O
implementation	NN	O
of	IN	O
TUPAC	NNP	Educational
guidelines	NNS	Educational
among	IN	O
dental	JJ	O
providers	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN15427433	NNP	O
.	.	O

Seven-star	NNP	Physical
needle	JJ	Physical
stimulation	NN	Physical
improves	VBZ	O
language	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
of	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
randomized	JJ	O
controlled	VBN	O
trial	NN	O
that	WDT	O
aimed	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
Seven-star	NNP	Physical
Needle	NNP	Physical
Stimulation	NNP	Physical
treatment	NN	O
on	IN	O
children	NNS	O
with	IN	O
Autistic	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Thirty-two	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
into	IN	O
the	DT	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
underwent	VBD	O
30	CD	O
sessions	NNS	O
of	IN	O
stimulation	NN	O
over	IN	O
6	CD	O
weeks	NNS	O
,	,	O
while	IN	O
children	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
on	IN	O
a	DT	O
waiting	VBG	O
list	NN	O
and	CC	O
did	VBD	O
not	RB	O
receive	VB	O
treatment	NN	O
during	IN	O
this	DT	O
period	NN	O
of	IN	O
time	NN	O
.	.	O

Intervention	NNP	O
consisted	VBD	O
of	IN	O
a	DT	O
treatment	NN	O
regime	NN	O
comprising	NN	O
of	IN	O
30	CD	Physical
sessions	NNS	Physical
of	IN	Physical
Seven-star	NNP	Physical
Needle	NNP	Physical
Stimulation	NNP	Physical
,	,	O
delivered	VBD	O
over	IN	O
6	CD	O
weeks	NNS	O
.	.	O

Each	DT	O
session	NN	O
lasted	VBD	O
5	CD	O
to	TO	O
10	CD	O
min	NN	O
,	,	O
children	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
were	VBD	O
stimulated	VBN	O
at	IN	O
the	DT	O
front	NN	O
and	CC	O
back	RB	O
sides	NNS	O
of	IN	O
their	PRP$	O
body	NN	O
and	CC	O
the	DT	O
head	NN	O
by	IN	O
using	VBG	O
Seven-star	JJ	Physical
Needles	NNP	Physical
.	.	O

The	DT	O
change	NN	O
in	IN	O
the	DT	O
children	NNS	O
's	POS	O
behavior	NN	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
parents	NNS	O
'	POS	O
report	NN	O
and	CC	O
neurophysiological	JJ	O
changes	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
quantitative	JJ	O
EEG	NNP	O
(	(	O
qEEG	NN	O
)	)	O
.	.	O

Results	CC	O
showed	VBD	O
that	IN	O
the	DT	O
treatment	NN	O
group	NN	O
demonstrated	VBD	O
significant	JJ	O
improvement	NN	O
in	IN	O
language	NN	O
and	CC	O
social	JJ	O
interaction	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
stereotyped	JJ	O
behavior	NN	O
or	CC	O
motor	NN	O
function	NN	O
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

qEEG	JJ	O
spectral	JJ	O
amplitudes	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
were	VBD	O
also	RB	O
reduced	VBN	O
significantly	RB	O
.	.	O

The	DT	O
results	NNS	O
suggested	VBD	O
that	IN	O
Seven-star	NNP	Physical
Needle	NNP	Physical
Stimulation	NNP	Physical
might	MD	O
be	VB	O
an	DT	O
effective	JJ	O
intervention	NN	O
to	TO	O
improve	VB	O
language	NN	O
and	CC	O
social	JJ	O
functioning	NN	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
fish-oil	JJ	Pharmacological
and	CC	Pharmacological
vegetable-oil	JJ	Pharmacological
formula	NN	Pharmacological
on	IN	O
aggregation	NN	O
and	CC	O
ethanolamine-containing	JJ	O
lysophospholipid	JJ	O
generation	NN	O
in	IN	O
activated	JJ	O
human	JJ	O
platelets	NNS	O
and	CC	O
on	IN	O
leukotriene	JJ	O
production	NN	O
in	IN	O
stimulated	JJ	O
neutrophils	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
consuming	VBG	O
a	DT	O
liquid	JJ	Pharmacological
formula	NN	Pharmacological
containing	VBG	Pharmacological
either	CC	Pharmacological
fish	JJ	Pharmacological
oil	NN	Pharmacological
enriched	VBN	Pharmacological
in	IN	Pharmacological
omega-3	JJ	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
or	CC	O
vegetable	JJ	Pharmacological
oil	NN	Pharmacological
enriched	VBN	Pharmacological
in	IN	Pharmacological
oleic	JJ	Pharmacological
acid	NN	Pharmacological
was	VBD	O
evaluated	VBN	O
in	IN	O
20	CD	O
male	JJ	O
subjects	NNS	O
randomly	RB	O
allocated	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
over	IN	O
a	DT	O
42-d	JJ	O
period	NN	O
.	.	O

A	DT	O
decrease	NN	O
in	IN	O
collagen-induced	JJ	O
aggregation	NN	O
by	IN	O
using	VBG	O
washed	JJ	O
platelet	NN	O
suspensions	NNS	O
was	VBD	O
found	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
after	IN	O
nutritional	JJ	O
supplementation	NN	O
.	.	O

A	DT	O
considerable	JJ	O
rise	NN	O
in	IN	O
omega-3	JJ	O
and	CC	O
a	DT	O
decrease	NN	O
in	IN	O
omega-6	JJ	O
fatty	JJ	O
acids	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
platelet	NN	O
phospholipid	JJ	O
with	IN	O
fish-oil	JJ	Pharmacological
consumption	NN	Pharmacological
.	.	O

The	DT	O
degree	NN	O
of	IN	O
eicosapentaenoic	NN	O
acid	NN	O
(	(	O
EPA	NNP	O
,	,	O
20:5n-3	JJ	O
)	)	O
enrichment	NN	O
(	(	O
fish-oil	JJ	O
group	NN	O
)	)	O
was	VBD	O
dramatically	RB	O
greater	JJR	O
in	IN	O
the	DT	O
ether-containing	JJ	O
plasmenylethanolamine	NN	O
(	(	O
13.5	CD	O
mol	CD	O
%	NN	O
of	IN	O
fatty	JJ	O
acids	NNS	O
;	:	O
mol	CD	O
%	NN	O
of	IN	O
fatty	JJ	O
acids	NNS	O
=	VBP	O
moles	NNS	O
per	IN	O
100	CD	O
moles	NNS	O
of	IN	O
total	JJ	O
fatty	JJ	O
acids	NNS	O
)	)	O
than	IN	O
in	IN	O
phosphatidylethanolamine	NN	O
(	(	O
2.8	CD	O
mol	CD	O
%	NN	O
)	)	O
or	CC	O
phosphatidylcholine	NN	O
(	(	O
2.9	CD	O
mol	CD	O
%	NN	O
)	)	O
.	.	O

Neither	CC	O
treatment	NN	O
significantly	RB	O
influenced	VBD	O
the	DT	O
agonist-induced	JJ	O
accumulation	NN	O
of	IN	O
lysoplasmenylethanolamine	NN	O
as	IN	O
derived	JJ	O
via	IN	O
phospholipase	NN	O
A2	NNP	O
hydrolysis	NN	O
of	IN	O
plasmenylethanolamine	NN	O
.	.	O

HPLC	NNP	O
measurements	NNS	O
of	IN	O
eicosanoid	JJ	O
production	NN	O
in	IN	O
A23187-stimulated	NNP	O
neutrophils	NNS	O
revealed	VBD	O
a	DT	O
considerable	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
arachidonic	JJ	O
acid-derived	JJ	O
leukotriene	NN	O
B4	NNP	O
(	(	O
LTB4	NNP	O
)	)	O
,	,	O
by	IN	O
41	CD	O
%	NN	O
,	,	O
and	CC	O
5-HETE	JJ	O
(	(	O
5-hydroxyeicosatetraenoic	JJ	O
acid	NN	O
)	)	O
,	,	O
by	IN	O
30	CD	O
%	NN	O
,	,	O
in	IN	O
the	DT	O
fish-oil	JJ	O
group	NN	O
along	IN	O
with	IN	O
the	DT	O
appearance	NN	O
of	IN	O
the	DT	O
corresponding	JJ	O
EPA-derived	JJ	O
products	NNS	O
[	JJ	O
LTB5	NNP	O
and	CC	O
5-HEPE	JJ	O
(	(	O
5-hydroxyeicosapentaenoic	JJ	O
acid	NN	O
)	)	O
]	NN	O
.	.	O

No	DT	O
such	JJ	O
alterations	NNS	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
lipoxygenase	NN	O
products	NNS	O
were	VBD	O
found	VBN	O
with	IN	O
the	DT	O
vegetable	JJ	Pharmacological
oil	NN	Pharmacological
treatment	NN	Pharmacological
.	.	O

The	DT	O
Relaxation	NNP	O
Inventory	NN	O
:	:	O
self-report	JJ	O
scales	NNS	O
of	IN	O
relaxation	NN	Physical
training	NN	Physical
effects	NNS	Physical
.	.	O

The	DT	O
development	NN	O
of	IN	O
a	DT	O
self-report	JJ	O
measure	NN	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
relaxation	NN	O
training	NN	O
was	VBD	O
examined	VBN	O
.	.	O

A	DT	O
rigorous	JJ	O
statistical	JJ	O
method	NN	O
of	IN	O
scale	JJ	O
construction	NN	O
consisting	NN	O
of	IN	O
a	DT	O
modification	NN	O
of	IN	O
the	DT	O
scale	JJ	O
discrimination	NN	O
technique	NN	O
was	VBD	O
employed	VBN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
45-item	JJ	Educational
questionnaire	NN	Educational
representing	VBG	O
three	CD	O
orthogonally	RB	O
derived	VBN	O
scales	NNS	O
.	.	O

The	DT	O
three	CD	O
scales	NNS	O
,	,	O
Physiological	NNP	O
Tension	NNP	O
,	,	O
Physical	NNP	O
Assessment	NNP	O
,	,	O
and	CC	O
Cognitive	NNP	O
Tension	NNP	O
,	,	O
demonstrated	VBD	O
adequate	JJ	O
internal	JJ	O
consistency	NN	O
with	IN	O
KR20	NNP	O
reliability	NN	O
coefficients	NNS	O
of	IN	O
.89	NNP	O
,	,	O
.95	NNP	O
,	,	O
and	CC	O
.81	NNP	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
study	NN	O
of	IN	O
predictive	JJ	O
validity	NN	O
,	,	O
40	CD	O
individuals	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
conditions	NNS	O
:	:	O
relaxation	NN	Psychological
training	NN	Psychological
,	,	O
tension	NN	Psychological
inducement	NN	Psychological
,	,	O
pre-postcontrol	NN	Psychological
,	,	Psychological
or	CC	Psychological
postcontrol	NN	Psychological
.	.	O

Univariate	NNP	O
analysis	NN	O
of	IN	O
variance	NN	O
indicated	VBN	O
significant	JJ	O
findings	NNS	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
three	CD	O
dimensions	NNS	O
of	IN	O
the	DT	O
inventory	NN	O
.	.	O

The	DT	O
Physiological	JJ	O
Tension	NNP	O
Scale	NNP	O
detected	VBD	O
significant	JJ	O
increases	NNS	O
in	IN	O
tension	NN	O
following	VBG	O
tension	NN	O
inducement	NN	O
,	,	O
whereas	IN	O
the	DT	O
Physical	NNP	O
Assessment	NNP	O
Scale	NNP	O
and	CC	O
Cognitive	NNP	O
Tension	NNP	O
Scale	NNP	O
detected	VBD	O
increases	NNS	O
in	IN	O
relaxation	NN	O
following	VBG	O
relaxation	NN	Psychological
training	NN	Psychological
.	.	O

Recommendations	NNS	O
were	VBD	O
made	VBN	O
for	IN	O
future	JJ	O
research	NN	O
on	IN	O
the	DT	O
inventory	NN	O
.	.	O

Stapled	VBN	Surgical
hemorrhoidopexy	JJ	Surgical
versus	NN	O
milligan-morgan	JJ	Surgical
hemorrhoidectomy	NN	Surgical
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
multicenter	RBR	O
trial	NN	O
with	IN	O
2-year	JJ	O
postoperative	NN	O
follow	VB	O
up	RP	O
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
outcome	NN	O
of	IN	O
stapled	JJ	Surgical
hemorrhoidopexy	NN	Surgical
(	(	Surgical
SH	NNP	Surgical
group	NN	Surgical
)	)	Surgical
performed	VBD	O
using	VBG	O
a	DT	O
circular	JJ	O
stapler	NN	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
Milligan-Morgan	NNP	Surgical
technique	NN	Surgical
(	(	Surgical
MM	NNP	Surgical
group	NN	Surgical
)	)	Surgical
.	.	O

The	DT	O
goals	NNS	O
of	IN	O
the	DT	O
study	NN	O
were	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
reproducibility	NN	O
of	IN	O
stapled	JJ	Surgical
hemorrhoidopexy	NN	Surgical
and	CC	O
define	VB	O
its	PRP$	O
place	NN	O
among	IN	O
conventional	JJ	O
techniques	NNS	O
.	.	O

METHODS	VB	O
A	NNP	O
series	NN	O
of	IN	O
134	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
at	IN	O
7	CD	O
hospital	NN	O
centers	NNS	O
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
according	VBG	O
to	TO	O
a	DT	O
single-masked	JJ	O
design	NN	O
and	CC	O
stratified	VBN	O
by	IN	O
center	NN	O
(	(	O
with	IN	O
balancing	VBG	O
every	DT	O
4	CD	O
patients	NNS	O
)	)	O
.	.	O

Patients	NNS	O
were	VBD	O
clinically	RB	O
evaluated	VBN	O
preoperatively	RB	O
and	CC	O
at	IN	O
6	CD	O
weeks	NNS	O
,	,	O
1	CD	O
year	NN	O
,	,	O
and	CC	O
a	DT	O
minimum	NN	O
of	IN	O
2	CD	O
years	NNS	O
after	IN	O
treatment	NN	O
.	.	O

Patients	NNS	O
completed	VBD	O
a	DT	O
questionnaire	NN	Educational
before	IN	O
and	CC	O
1	CD	O
year	NN	O
after	IN	O
surgery	NN	O
to	TO	O
evaluate	VB	O
symptoms	NNS	O
,	,	O
function	NN	O
,	,	O
and	CC	O
overall	JJ	O
satisfaction	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
mean	JJ	O
follow-up	JJ	O
period	NN	O
was	VBD	O
2.21	CD	O
years	NNS	O
+/-	JJ	O
0.26	CD	O
(	(	O
1.89-3.07	JJ	O
)	)	O
.	.	O

Nine	JJ	O
patients	NNS	O
(	(	O
7	CD	O
%	NN	O
)	)	O
could	MD	O
not	RB	O
be	VB	O
monitored	VBN	O
at	IN	O
1	CD	O
or	CC	O
2	CD	O
years	NNS	O
,	,	O
but	CC	O
4	CD	O
of	IN	O
these	DT	O
9	CD	O
nevertheless	RB	O
filled	VBN	O
in	IN	O
the	DT	O
1-year	JJ	O
questionnaire	NN	O
.	.	O

The	DT	O
patients	NNS	O
in	IN	O
the	DT	O
SH	NNP	Surgical
group	NN	O
experienced	VBD	O
less	RBR	O
postoperative	JJ	O
pain/discomfort	NN	O
as	IN	O
scored	VBN	O
by	IN	O
pain	NN	O
during	IN	O
bowel	NN	O
movement	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
total	JJ	O
analgesic	JJ	O
requirement	NN	O
over	IN	O
the	DT	O
first	JJ	O
3	CD	O
days	NNS	O
(	(	O
according	VBG	O
to	TO	O
the	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
[	NNP	O
WHO	NNP	O
]	NNP	O
class	NN	O
II	NNP	O
analgesics	NNS	O
[	VBP	O
P	NNP	O
=	NNP	O
0.002	CD	O
]	NNP	O
;	:	O
class	NN	O
III	NNP	O
[	NNP	O
P	NNP	O
=	VBD	O
0.066	CD	O
]	NN	O
)	)	O
,	,	O
and	CC	O
per-patient	JJ	O
consumption	NN	O
frequency	NN	O
of	IN	O
class	NN	O
III	NNP	O
analgesics	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.089	CD	O
)	)	O
.	.	O

A	DT	O
clear	JJ	O
difference	NN	O
in	IN	O
morphine	JJ	O
requirement	NN	O
became	VBD	O
evident	JJ	O
after	IN	O
24	CD	O
hours	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
.	.	O

Hospital	NNP	O
stay	NN	O
was	VBD	O
significantly	RB	O
shorter	JJR	O
in	IN	O
the	DT	O
SH	NNP	Surgical
group	NN	O
(	(	O
SH	NNP	O
2.2	CD	O
+/-	JJ	O
1.2	CD	O
[	JJ	O
0	CD	O
;	:	O
5.0	CD	O
]	NNP	O
versus	NN	O
MM	NNP	Surgical
3.1	CD	O
+/-	JJ	O
1.7	CD	O
[	JJ	O
1	CD	O
;	:	O
8.0	CD	O
]	NN	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

At	IN	O
1	CD	O
year	NN	O
,	,	O
no	DT	O
differences	NNS	O
in	IN	O
the	DT	O
resolution	NN	O
of	IN	O
symptoms	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
,	,	O
and	CC	O
over	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
overall	JJ	O
incidence	NN	O
of	IN	O
complications	NNS	O
was	VBD	O
the	DT	O
same	JJ	O
,	,	O
specifically	RB	O
fecaloma	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
in	IN	O
the	DT	O
MM	NNP	Surgical
group	NN	O
and	CC	O
external	JJ	O
hemorrhoidal	NN	O
thrombosis	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
in	IN	O
the	DT	O
SH	NNP	Surgical
group	NN	O
.	.	O

Impaired	NNP	O
sphincter	NN	O
function	NN	O
was	VBD	O
observed	VBN	O
at	IN	O
1	CD	O
year	NN	O
with	IN	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
for	IN	O
urgency	NN	O
(	(	O
12	CD	O
%	NN	O
)	)	O
,	,	O
continence	NN	O
problems	NNS	O
(	(	O
10	CD	O
%	NN	O
)	)	O
,	,	O
or	CC	O
tenesmus	NN	O
(	(	O
3	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
patient	NN	O
needed	VBD	O
a	DT	O
second	JJ	O
procedure	NN	O
for	IN	O
recurrence	NN	O
within	IN	O
2	CD	O
years	NNS	O
,	,	O
although	IN	O
partial	JJ	O
residual	JJ	O
prolapse	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
4	CD	O
SH	JJ	Surgical
patients	NNS	O
(	(	O
7.5	CD	O
%	NN	O
)	)	O
versus	NN	O
1	CD	O
MM	NNP	Surgical
patient	NN	O
(	(	O
1.8	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.194	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Stapled	VBD	Surgical
hemorrhoidopexy	JJ	Surgical
causes	NNS	O
significantly	RB	O
less	RBR	O
postoperative	JJ	O
pain	NN	O
.	.	O

The	DT	O
technique	NN	O
is	VBZ	O
reproducible	JJ	O
and	CC	O
can	MD	O
achieve	VB	O
comparable	JJ	O
outcomes	NNS	O
as	IN	O
those	DT	O
of	IN	O
the	DT	O
MM	NNP	Surgical
technique	NN	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
well-described	JJ	O
steps	NNS	O
of	IN	O
the	DT	O
technique	NN	O
are	VBP	O
followed	VBN	O
.	.	O

Like	IN	O
with	IN	O
conventional	JJ	O
surgery	NN	Surgical
,	,	O
anorectal	JJ	O
dysfunction	NN	O
can	MD	O
occur	VB	O
after	IN	O
stapled	JJ	Surgical
hemorrhoidopexy	NN	Surgical
in	IN	O
some	DT	O
patients	NNS	O
.	.	O

Its	PRP$	O
effectiveness	NN	O
in	IN	O
relieving	VBG	O
symptoms	NNS	O
is	VBZ	O
equivalent	JJ	O
to	TO	O
conventional	JJ	O
surgery	NN	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
hemorrhoidal	JJ	O
prolapse	NN	O
recurrences	NNS	O
at	IN	O
2	CD	O
years	NNS	O
is	VBZ	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

Hemorroidopexy	NNP	Surgical
is	VBZ	O
applicable	JJ	O
for	IN	O
treating	VBG	O
reducible	JJ	O
hemorrhoidal	JJ	O
prolapse	NN	O
.	.	O

Use	NNP	O
of	IN	O
hormonal	JJ	Pharmacological
contraceptives	NNS	Pharmacological
and	CC	O
risk	NN	O
of	IN	O
HIV-1	NNP	O
transmission	NN	O
:	:	O
a	DT	O
prospective	JJ	O
cohort	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Hormonal	NNP	Pharmacological
contraceptives	NNS	Pharmacological
are	VBP	O
used	VBN	O
widely	RB	O
but	CC	O
their	PRP$	O
effects	NNS	O
on	IN	O
HIV-1	NNP	O
risk	NN	O
are	VBP	O
unclear	JJ	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
assess	VB	O
the	DT	O
association	NN	O
between	IN	O
hormonal	JJ	Pharmacological
contraceptive	NN	Pharmacological
use	NN	O
and	CC	O
risk	NN	O
of	IN	O
HIV-1	NNP	O
acquisition	NN	O
by	IN	O
women	NNS	O
and	CC	O
HIV-1	JJ	O
transmission	NN	O
from	IN	O
HIV-1-infected	JJ	O
women	NNS	O
to	TO	O
their	PRP$	O
male	JJ	O
partners	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
study	NN	O
,	,	O
we	PRP	O
followed	VBD	O
up	RP	O
3790	CD	O
heterosexual	JJ	O
HIV-1-serodiscordant	JJ	O
couples	NNS	O
participating	VBG	O
in	IN	O
two	CD	O
longitudinal	JJ	O
studies	NNS	O
of	IN	O
HIV-1	NNP	O
incidence	NN	O
in	IN	O
seven	CD	O
African	JJ	O
countries	NNS	O
.	.	O

Among	IN	O
injectable	JJ	O
and	CC	O
oral	JJ	O
hormonal	JJ	Pharmacological
contraceptive	NN	Pharmacological
users	NNS	O
and	CC	O
non-users	NNS	O
,	,	O
we	PRP	O
compared	VBN	O
rates	NNS	O
of	IN	O
HIV-1	NNP	O
acquisition	NN	O
by	IN	O
women	NNS	O
and	CC	O
HIV-1	JJ	O
transmission	NN	O
from	IN	O
women	NNS	O
to	TO	O
men	NNS	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
HIV-1	JJ	O
seroconversion	NN	O
.	.	O

We	PRP	O
used	VBD	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
and	CC	O
marginal	JJ	O
structural	JJ	O
modelling	NN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
contraceptive	NN	O
use	NN	O
on	IN	O
HIV-1	NNP	O
risk	NN	O
.	.	O

FINDINGS	NNP	O
Among	IN	O
1314	CD	O
couples	NNS	O
in	IN	O
which	WDT	O
the	DT	O
HIV-1-seronegative	JJ	O
partner	NN	O
was	VBD	O
female	JJ	O
(	(	O
median	JJ	O
follow-up	NN	O
18?0	CD	O
[	JJ	O
IQR	NNP	O
12?6-24?2	JJ	O
]	NNP	O
months	NNS	O
)	)	O
,	,	O
rates	NNS	O
of	IN	O
HIV-1	NNP	O
acquisition	NN	O
were	VBD	O
6?61	CD	O
per	IN	O
100	CD	O
person-years	NNS	O
in	IN	O
women	NNS	O
who	WP	O
used	VBD	O
hormonal	JJ	O
contraception	NN	O
and	CC	O
3?78	CD	O
per	IN	O
100	CD	O
person-years	NNS	O
in	IN	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
(	(	O
adjusted	VBN	O
hazard	RB	O
ratio	JJ	O
1?98	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1?06-3?68	CD	O
,	,	O
p=0?03	NN	O
)	)	O
.	.	O

Among	IN	O
2476	CD	O
couples	NNS	O
in	IN	O
which	WDT	O
the	DT	O
HIV-1-seronegative	JJ	O
partner	NN	O
was	VBD	O
male	JJ	O
(	(	O
median	JJ	O
follow-up	NN	O
18?7	CD	O
[	JJ	O
IQR	NNP	O
12?8-24?2	JJ	O
]	NNP	O
months	NNS	O
)	)	O
,	,	O
rates	NNS	O
of	IN	O
HIV-1	NNP	O
transmission	NN	O
from	IN	O
women	NNS	O
to	TO	O
men	NNS	O
were	VBD	O
2?61	CD	O
per	IN	O
100	CD	O
person-years	NNS	O
in	IN	O
couples	NNS	O
in	IN	O
which	WDT	O
women	NNS	O
used	VBD	O
hormonal	JJ	O
contraception	NN	O
and	CC	O
1?51	CD	O
per	IN	O
100	CD	O
person-years	NNS	O
in	IN	O
couples	NNS	O
in	IN	O
which	WDT	O
women	NNS	O
did	VBD	O
not	RB	O
use	VB	O
hormonal	JJ	O
contraception	NN	O
(	(	O
adjusted	VBN	O
hazard	RB	O
ratio	JJ	O
1?97	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1?12-3?45	CD	O
,	,	O
p=0?02	NN	O
)	)	O
.	.	O

Marginal	JJ	O
structural	JJ	O
model	NN	O
analyses	NNS	O
generated	VBD	O
much	RB	O
the	DT	O
same	JJ	O
results	NNS	O
to	TO	O
the	DT	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
regression	NN	O
.	.	O

INTERPRETATION	NNP	O
Women	NNP	O
should	MD	O
be	VB	O
counselled	VBN	O
about	IN	O
potentially	RB	O
increased	VBN	O
risk	NN	O
of	IN	O
HIV-1	NNP	O
acquisition	NN	O
and	CC	O
transmission	NN	O
with	IN	O
hormonal	JJ	O
contraception	NN	O
,	,	O
especially	RB	O
injectable	JJ	O
methods	NNS	O
,	,	O
and	CC	O
about	IN	O
the	DT	O
importance	NN	O
of	IN	O
dual	JJ	O
protection	NN	O
with	IN	O
condoms	NNS	O
to	TO	O
decrease	VB	O
HIV-1	NNP	O
risk	NN	O
.	.	O

Non-hormonal	JJ	O
or	CC	O
low-dose	JJ	O
hormonal	JJ	O
contraceptive	NN	O
methods	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
for	IN	O
women	NNS	O
with	IN	O
or	CC	O
at-risk	JJ	O
for	IN	O
HIV-1	NNP	O
.	.	O

FUNDING	NNP	O
US	NNP	O
National	NNP	O
Institutes	NNP	O
of	IN	O
Health	NNP	O
and	CC	O
the	DT	O
Bill	NNP	O
&	CC	O
Melinda	NNP	O
Gates	NNP	O
Foundation	NNP	O
.	.	O

The	DT	O
peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	JJ	O
agonist	NN	O
pioglitazone	NN	Pharmacological
increases	VBZ	O
number	NN	O
and	CC	O
function	NN	O
of	IN	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

OBJECTIVE	CC	O
Peroxisome	JJ	O
proliferator-activated	JJ	O
receptor-gamma	NN	O
(	(	O
PPAR	NNP	O
gamma	NN	O
)	)	O
agonists	VBZ	O
(	(	O
thiazolidinediones	NNS	Pharmacological
[	NNP	Pharmacological
TZDs	NNP	Pharmacological
]	NNP	O
)	)	O
are	VBP	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diabetes	NNS	O
.	.	O

Bone	CD	O
marrow-derived	JJ	O
endothelial	JJ	O
progenitor	NN	O
cells	NNS	O
(	(	O
EPCs	NNP	O
)	)	O
improve	VB	O
vascular	JJ	O
function	NN	O
and	CC	O
predict	NN	O
cardiovascular	NN	O
risk	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
pioglitazone	NN	Pharmacological
therapy	NN	O
on	IN	O
EPCs	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
AND	NNP	O
RESULTS	NNP	O
We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
on	IN	O
patients	NNS	O
with	IN	O
documented	JJ	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
and	CC	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
.	.	O

Of	IN	O
54	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
fasting	VBG	O
glucose	JJ	O
levels	NNS	O
,	,	O
18	CD	O
showed	VBD	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
and	CC	O
36	CD	O
patients	NNS	O
with	IN	O
normal	JJ	O
glucose	JJ	O
tolerance	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
30-day	JJ	O
treatment	NN	O
with	IN	O
pioglitazone	NN	Pharmacological
(	(	O
45	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
in	IN	O
addition	NN	O
to	TO	O
optimal	VB	O
medical	JJ	O
therapy	NN	O
.	.	O

All	DT	O
patients	NNS	O
in	IN	O
the	DT	O
TZD	NNP	Pharmacological
group	NN	O
showed	VBD	O
an	DT	O
increase	NN	O
of	IN	O
adiponectin	JJ	O
levels	NNS	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
compliance	NN	O
(	(	O
11.4	CD	O
+/-	JJ	O
1.1	CD	O
to	TO	O
36.8	CD	O
+/-	JJ	O
2.1	CD	O
microg/ml	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

TZD	NNP	Pharmacological
,	,	O
but	CC	O
not	RB	O
placebo	VB	O
,	,	O
decreased	VBN	O
mean	JJ	O
high-sensitivity	NN	O
C-reactive	JJ	O
protein	NN	O
to	TO	O
43	CD	O
+/-	JJ	O
19	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Pioglitazone	NN	O
increased	VBD	O
CD34	NNP	O
(	(	O
+	NNP	O
)	)	O
/kinase	NN	O
insert	JJ	O
domain	NN	O
receptor	NN	O
(	(	O
+	NNP	O
)	)	O
EPCs	NNP	O
to	TO	O
142	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
and	CC	O
cultured	VBD	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	JJ	O
acetylated	JJ	O
LDL	NNP	O
(	(	O
+	NNP	O
)	)	O
/lectin	NN	O
(	(	O
+	NNP	O
)	)	O
EPCs	NNP	O
to	TO	O
180	CD	O
+/-	JJ	O
3	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

EPC	JJ	O
numbers	NNS	O
were	VBD	O
not	RB	O
changed	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
.	.	O

TZD	NNP	O
increased	VBD	O
the	DT	O
SDF-1-induced	NNP	O
migratory	NN	O
capacity	NN	O
to	TO	O
146	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
per	IN	O
EPC	NNP	O
number	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
upregulated	VBD	O
the	DT	O
clonogenic	JJ	O
potential	NN	O
of	IN	O
EPCs	NNP	O
,	,	O
increasing	VBG	O
the	DT	O
colony-forming	JJ	O
units	NNS	O
to	TO	O
172	CD	O
+/-	JJ	O
12	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
cultured	JJ	O
human	JJ	O
EPCs	NNP	O
,	,	O
TZD	NNP	Pharmacological
increased	VBD	O
EPC	NNP	O
numbers	NNS	O
and	CC	O
migration	NN	O
and	CC	O
reduced	JJ	O
NADPH-oxidase	NNP	O
activity	NN	O
.	.	O

The	DT	O
TZD	NNP	Pharmacological
effect	NN	O
was	VBD	O
reversed	VBN	O
by	IN	O
the	DT	O
PPAR	NNP	O
gamma	NN	O
antagonist	NN	O
GW9662	NNP	O
and	CC	O
mimicked	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
adiponectin	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
PPAR	NNP	O
gamma	NN	O
agonist	NN	O
pioglitazone	NN	Pharmacological
increases	VBZ	O
the	DT	O
number	NN	O
and	CC	O
function	NN	O
of	IN	O
EPCs	NNP	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

The	DT	O
effect	NN	O
represents	VBZ	O
a	DT	O
potential	JJ	O
regenerative	NN	O
mechanism	NN	O
in	IN	O
atherosclerosis	NN	O
and	CC	O
is	VBZ	O
observed	VBN	O
in	IN	O
normoglycemic	JJ	O
individuals	NNS	O
with	IN	O
stable	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

Direct	JJ	Surgical
aortic	JJ	Surgical
cannulation	NN	Surgical
in	IN	O
minimally	RB	O
invasive	JJ	O
mitral-valve	JJ	O
operations	NNS	O
.	.	O

The	DT	O
minimally	RB	Surgical
invasive	JJ	Surgical
Port-Access	NNP	Surgical
(	(	O
Heartport	NNP	O
,	,	O
Redwood	NNP	O
City	NNP	O
,	,	O
CA	NNP	O
)	)	O
approach	NN	O
in	IN	O
mitral-valve	JJ	O
operations	NNS	O
originally	RB	O
required	VBN	O
femoral	JJ	Surgical
arterial	JJ	Surgical
cannulation	NN	Surgical
,	,	O
which	WDT	O
is	VBZ	O
considered	VBN	O
a	DT	O
disadvantage	NN	O
,	,	O
especially	RB	O
in	IN	O
patients	NNS	O
with	IN	O
peripheral	JJ	O
vessel	NN	O
disease	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
20	CD	O
patients	NNS	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
,	,	O
to	TO	O
undergo	VB	O
either	RB	O
standard	JJ	Physical
femoral	NN	Physical
(	(	O
group	NN	O
A	NNP	O
)	)	O
or	CC	O
direct	JJ	Surgical
aortic	JJ	Surgical
cannulation	NN	Surgical
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Pre-	JJ	O
and	CC	O
postoperative	JJ	O
data	NNS	O
as	RB	O
well	RB	O
as	IN	O
markers	NNS	O
for	IN	O
myocardial	JJ	O
damage	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

Postoperatively	RB	O
,	,	O
patients	NNS	O
of	IN	O
group	NN	O
B	NNP	O
showed	VBD	O
lower	JJR	O
levels	NNS	O
of	IN	O
damage	NN	O
,	,	O
indicating	VBG	O
that	IN	O
direct	JJ	Surgical
aortic	JJ	Surgical
cannulation	NN	Surgical
might	MD	O
provide	VB	O
better	JJR	O
myocardial	JJ	O
protection	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
the	DT	O
direct	JJ	Surgical
aortic	JJ	Surgical
cannulation	NN	Surgical
technique	NN	O
may	MD	O
eliminate	VB	O
complications	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
standard	JJ	Surgical
femoral	JJ	Surgical
artery	NN	Surgical
cannulation	NN	Surgical
.	.	O

Intravenous	JJ	O
pretreatment	NN	O
of	IN	O
hypertonic	JJ	Pharmacological
saline	NN	Pharmacological
can	MD	O
prevent	VB	O
systemic	JJ	O
hypotension	NN	O
induced	VBN	O
by	IN	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

BACKGROUND	NNP	O
Hypertonic	NNP	O
saline	NN	O
improves	VBZ	O
organ	JJ	O
perfusion	NN	O
and	CC	O
patient	JJ	O
survival	NN	O
during	IN	O
hemorrhagic	NN	O
shock	NN	O
because	IN	O
it	PRP	O
expands	VBZ	O
plasma	JJ	O
volume	NN	O
and	CC	O
increases	VBZ	O
tissue	NN	O
oxygenation	NN	O
.	.	O

Its	PRP$	O
beneficial	JJ	O
results	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
hypotension	NN	O
during	IN	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
influence	NN	O
between	IN	O
prehydration	NN	O
with	IN	O
3	CD	O
%	NN	O
hypertonic	JJ	Pharmacological
saline	NN	Pharmacological
and	CC	Pharmacological
with	IN	Pharmacological
isotonic	JJ	Pharmacological
lactated	VBN	Pharmacological
Ringer	NNP	Pharmacological
's	POS	Pharmacological
solution	NN	Pharmacological
on	IN	O
the	DT	O
hemodynamic	JJ	O
changes	NNS	O
and	CC	O
serum	NN	O
electrolyte	NN	O
concentrations	NNS	O
in	IN	O
patients	NNS	O
undergoing	JJ	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
ASA	NNP	O
class	NN	O
I	PRP	O
patients	NNS	O
scheduled	VBN	O
for	IN	O
herniorrhapy	NN	Surgical
under	IN	O
spinal	JJ	O
anesthesia	NN	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

Group	NNP	O
1	CD	O
=	NN	O
patients	NNS	O
were	VBD	O
prehydrated	VBN	Pharmacological
with	IN	Pharmacological
isotonic	JJ	Pharmacological
lactated	VBN	Pharmacological
Ringer	NNP	Pharmacological
's	POS	Pharmacological
solution	NN	Pharmacological
at	IN	Pharmacological
7	CD	Pharmacological
mg/kg	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
;	:	O
Group	NNP	O
2	CD	O
=	NN	O
patients	NNS	O
were	VBD	O
given	VBN	O
prehydration	NN	Pharmacological
with	IN	Pharmacological
3	CD	Pharmacological
%	NN	Pharmacological
hypertonic	JJ	Pharmacological
saline	NN	Pharmacological
at	IN	Pharmacological
7	CD	Pharmacological
ml/kg	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
.	.	O

Following	VBG	O
prehydration	NN	O
,	,	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
were	VBD	O
recorded	VBN	O
and	CC	O
serum	JJ	O
electrolyte	NN	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
incidence	NN	O
of	IN	O
hypotension	NN	O
was	VBD	O
17/30	CD	O
(	(	O
57	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
isotonic	JJ	O
lactated	VBD	O
Ringer	NNP	O
's	POS	O
solution	NN	O
group	NN	O
as	IN	O
against	IN	O
7/30	CD	O
(	(	O
23	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
hypertonic	JJ	O
saline	NN	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
two	CD	O
groups	NNS	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
level	NN	O
of	IN	O
anesthesia	NN	O
or	CC	O
maximal	JJ	O
heart	NN	O
rate	NN	O
,	,	O
and	CC	O
electrolyte	JJ	O
imbalance	NN	O
did	VBD	O
not	RB	O
occur	VB	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Prior	NNP	O
to	TO	O
spinal	VB	O
anesthesia	NN	O
,	,	O
hydration	NN	O
with	IN	O
small	JJ	O
amount	NN	O
of	IN	O
hypertonic	JJ	Pharmacological
saline	NN	Pharmacological
is	VBZ	O
effective	JJ	O
to	TO	O
minimize	VB	O
hypotension	NN	O
associated	VBN	O
with	IN	O
spinal	JJ	O
anesthesia	NN	O
.	.	O

If	IN	O
so	RB	O
administered	VBN	O
it	PRP	O
would	MD	O
not	RB	O
increase	VB	O
bodily	RB	O
sodium	JJ	O
load	NN	O
and	CC	O
unlike	IN	O
isotonic	JJ	O
crystalloid	NN	O
solution	NN	O
it	PRP	O
dose	VBD	O
not	RB	O
cause	JJ	O
accumulation	NN	O
of	IN	O
water	NN	O
in	IN	O
the	DT	O
body	NN	O
on	IN	O
equipollent	JJ	O
basis	NN	O
.	.	O

Ultrasound	NNP	Physical
therapy	NN	Physical
for	IN	O
recalcitrant	JJ	O
diabetic	JJ	O
foot	NN	O
ulcers	NNS	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
controlled	VBN	O
,	,	O
multicenter	NN	O
study	NN	O
.	.	O

An	DT	O
estimated	JJ	O
15	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
will	MD	O
develop	VB	O
a	DT	O
foot	NN	O
ulcer	NN	O
sometime	RB	O
in	IN	O
their	PRP$	O
life	NN	O
,	,	O
making	VBG	O
them	PRP	O
30	CD	O
to	TO	O
40	CD	O
times	NNS	O
more	RBR	O
likely	JJ	O
to	TO	O
undergo	VB	O
amputation	NN	O
due	JJ	O
to	TO	O
a	DT	O
non-healing	JJ	O
foot	NN	O
ulcer	NN	O
than	IN	O
the	DT	O
non-diabetic	JJ	O
population	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
,	,	O
non-contact	JJ	Physical
,	,	Physical
kilohertz	VB	Physical
ultrasound	JJ	Physical
therapy	NN	Physical
for	IN	O
the	DT	O
healing	NN	O
of	IN	O
recalcitrant	JJ	O
diabetic	JJ	O
foot	NN	O
ulcers	NNS	O
-	:	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
on	IN	O
total	JJ	O
closure	NN	O
and	CC	O
quantitative	JJ	O
bacterial	JJ	O
cultures	NNS	O
and	CC	O
the	DT	O
effect	NN	O
on	IN	O
healing	NN	O
of	IN	O
various	JJ	O
levels	NNS	O
of	IN	O
sharp/surgical	JJ	O
debridement	NN	O
-	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
sham-controlled	JJ	O
,	,	O
multicenter	NN	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
hospital-based	JJ	O
and	CC	O
private	JJ	O
wound	NN	O
care	NN	O
clinics	NNS	O
.	.	O

Patients	NNS	O
(	(	O
55	CD	O
met	VBD	O
criteria	NNS	O
for	IN	O
efficacy	NN	O
analysis	NN	O
)	)	O
received	VBD	O
standard	NN	O
of	IN	O
care	NN	O
,	,	O
which	WDT	O
included	VBD	O
products	NNS	O
that	WDT	O
provide	VBP	O
a	DT	O
moist	NN	O
environment	NN	O
,	,	O
offloading	VBG	O
diabetic	JJ	O
shoes	NNS	O
and	CC	O
socks	NNS	O
,	,	O
debridement	NN	O
,	,	O
wound	JJ	O
evaluation	NN	O
,	,	O
and	CC	O
measurement	NN	O
.	.	O

The	DT	O
therapy	NN	O
was	VBD	O
either	RB	O
active	JJ	Physical
40	CD	Physical
KHz	NNP	Physical
ultrasound	NN	Physical
delivered	VBN	Physical
by	IN	Physical
a	DT	Physical
saline	JJ	Physical
mist	NN	Physical
or	CC	Physical
a	DT	Physical
sham	NN	Control
device	NN	Control
which	WDT	Control
delivered	VBD	Control
a	DT	Control
saline	JJ	Control
mist	NN	Control
without	IN	Control
the	DT	Control
use	NN	Control
of	IN	Control
ultrasound	NN	Control
.	.	O

After	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
care	NN	O
,	,	O
the	DT	O
proportion	NN	O
of	IN	O
wounds	NNS	O
healed	VBN	O
(	(	O
defined	VBN	O
as	IN	O
complete	JJ	O
epithelialization	NN	O
without	IN	O
drainage	NN	O
)	)	O
in	IN	O
the	DT	O
active	JJ	O
ultrasound	NN	O
therapy	NN	O
device	NN	O
group	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
sham	NN	O
control	NN	O
group	NN	O
(	(	O
40.7	CD	O
%	NN	O
versus	IN	O
14.3	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.0366	CD	O
,	,	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
)	)	O
.	.	O

The	DT	O
ultrasound	JJ	Physical
treatment	NN	Physical
was	VBD	O
easy	JJ	O
to	TO	O
use	VB	O
and	CC	O
no	DT	O
difference	NN	O
in	IN	O
the	DT	O
number	NN	O
and	CC	O
type	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
was	VBD	O
noted	VBN	O
.	.	O

Of	IN	O
interest	NN	O
,	,	O
wounds	NNS	O
were	VBD	O
debrided	VBN	O
at	IN	O
baseline	NN	O
followed	VBN	O
by	IN	O
a	DT	O
quantitative	JJ	O
culture	NN	O
biopsy	NN	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
these	DT	O
cultures	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
bioburden	NN	O
(	(	O
greater	JJR	O
than	IN	O
10	CD	O
(	(	O
5	CD	O
)	)	O
)	)	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
cases	NNS	O
,	,	O
despite	IN	O
a	DT	O
lack	NN	O
of	IN	O
clinical	JJ	O
signs	NNS	O
of	IN	O
infection	NN	O
.	.	O

Compared	VBN	O
to	TO	O
control	VB	O
,	,	O
this	DT	O
therapeutic	JJ	O
modality	NN	O
was	VBD	O
found	VBN	O
to	TO	O
increase	VB	O
the	DT	O
healing	VBG	O
rate	NN	O
of	IN	O
recalcitrant	NN	O
,	,	O
diabetic	JJ	O
foot	NN	O
ulcers	NNS	O
.	.	O

Beliefs	NNP	Educational
underlying	VBG	O
the	DT	O
intention	NN	O
to	TO	O
donate	VB	O
again	RB	O
among	IN	O
first-time	JJ	O
blood	NN	O
donors	NNS	O
who	WP	O
experience	VBP	O
a	DT	O
mild	JJ	O
adverse	JJ	O
event	NN	O
.	.	O

Using	VBG	O
the	DT	O
belief	JJ	Educational
basis	NN	Educational
of	IN	Educational
the	DT	Educational
theory	NN	Educational
of	IN	Educational
planned	VBN	Educational
behavior	NN	Educational
(	(	Educational
TPB	NNP	Educational
)	)	Educational
,	,	O
the	DT	O
current	JJ	O
study	NN	O
explored	VBD	O
the	DT	O
rate	NN	O
of	IN	O
mild	JJ	O
reactions	NNS	O
reported	VBN	O
by	IN	O
donors	NNS	O
in	IN	O
relation	NN	O
to	TO	O
their	PRP$	O
first	JJ	O
donation	NN	O
and	CC	O
the	DT	O
intention	NN	O
and	CC	O
beliefs	NN	O
of	IN	O
those	DT	O
donors	NNS	O
with	IN	O
regard	NN	O
to	TO	O
returning	VBG	O
to	TO	O
donate	VB	O
again	RB	O
.	.	O

A	DT	O
high	JJ	O
proportion	NN	O
of	IN	O
first-time	JJ	O
donors	NNS	O
indicated	VBD	O
that	IN	O
they	PRP	O
had	VBD	O
experienced	VBN	O
a	DT	O
reaction	NN	O
to	TO	O
blood	VB	O
donation	NN	O
.	.	O

Further	NNP	O
,	,	O
donors	NNS	O
who	WP	O
reacted	VBD	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
intend	VB	O
to	TO	O
return	VB	O
to	TO	O
donate	VB	O
.	.	O

Regression	NNP	O
analyses	VBZ	O
suggested	VBD	O
that	IN	O
targeting	VBG	Educational
different	JJ	Educational
beliefs	NNS	Educational
for	IN	O
those	DT	O
donors	NNS	O
who	WP	O
had	VBD	O
and	CC	O
had	VBD	O
not	RB	O
reacted	VBN	O
would	MD	O
yield	VB	O
most	JJS	O
benefit	NN	O
in	IN	O
bolstering	VBG	O
donors	NNS	O
'	POS	O
intentions	NNS	O
to	TO	O
remain	VB	O
donating	JJ	O
.	.	O

The	DT	O
findings	NNS	O
provide	VBP	O
insight	NN	O
into	IN	O
those	DT	O
messages	NNS	Educational
that	WDT	O
could	MD	O
be	VB	O
communicated	VBN	O
via	IN	O
the	DT	O
mass	NN	O
media	NNS	O
or	CC	O
in	IN	O
targeted	JJ	O
communications	NNS	O
to	TO	O
retain	VB	O
first-time	JJ	O
donors	NNS	O
who	WP	O
have	VBP	O
experienced	VBN	O
a	DT	O
mild	JJ	O
vasovagal	JJ	O
reaction	NN	O
.	.	O

A	DT	O
1.5-year	JJ	O
follow-up	NN	O
of	IN	O
an	DT	O
Internet-based	JJ	Educational
intervention	NN	Educational
for	IN	O
complicated	JJ	O
grief	NN	O
.	.	O

Only	RB	O
recently	RB	O
have	VBP	O
psychotherapeutic	JJ	Educational
interventions	NNS	Educational
for	IN	O
complicated	JJ	O
grief	NN	O
been	VBN	O
developed	VBN	O
and	CC	O
evaluated	VBN	O
in	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
.	.	O

These	DT	O
trials	NNS	O
have	VBP	O
reported	VBN	O
significant	JJ	O
reductions	NNS	O
in	IN	O
complicated	JJ	O
grief	NN	O
and	CC	O
related	JJ	O
symptoms	NNS	O
in	IN	O
response	NN	O
to	TO	O
treatment	NN	O
relative	JJ	O
to	TO	O
control	VB	Control
groups	NNS	Control
.	.	O

However	RB	O
,	,	O
little	JJ	O
is	VBZ	O
known	VBN	O
about	IN	O
the	DT	O
long-term	JJ	O
outcomes	NNS	O
of	IN	O
these	DT	O
treatments	NNS	O
.	.	O

The	DT	O
authors	NNS	O
present	VBP	O
an	DT	O
evaluation	NN	O
of	IN	O
a	DT	O
1.5-year	JJ	O
follow-up	NN	O
of	IN	O
an	DT	O
Internet-based	JJ	Educational
cognitive-behavioral	JJ	Educational
intervention	NN	Educational
for	IN	O
complicated	JJ	O
grief	NN	O
.	.	O

Treatment	NNP	O
group	NN	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
were	VBD	O
administered	VBN	O
various	JJ	O
assessments	NNS	O
of	IN	O
complicated	JJ	O
grief	NN	O
indicators	NNS	O
,	,	O
including	VBG	O
the	DT	O
Impact	NN	O
of	IN	O
Event	NNP	O
Scale	NNP	O
,	,	O
the	DT	O
anxiety	NN	O
and	CC	O
depression	NN	O
subscales	NNS	O
of	IN	O
the	DT	O
Brief	NNP	O
Symptom	NNP	O
Inventory	NNP	O
,	,	O
and	CC	O
the	DT	O
SF-12	NNP	O
.	.	O

Results	NNP	O
indicate	VBP	O
that	IN	O
the	DT	O
reduction	NN	O
in	IN	O
symptoms	NNS	O
of	IN	O
complicated	JJ	O
grief	NN	O
observed	VBN	O
at	IN	O
posttreatment	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
1.5-year	JJ	O
follow-up	NN	O
.	.	O

Tensile	IN	O
bond	NN	O
strength	NN	O
of	IN	O
a	DT	O
lithium-disilicate	JJ	Physical
pressed	JJ	Physical
glass	NN	Physical
ceramic	NN	Physical
to	TO	O
dentin	VB	O
of	IN	O
different	JJ	O
surface	NN	O
treatments	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
desensitizer	NN	O
,	,	O
disinfectant	NN	O
,	,	O
saliva	NN	O
,	,	O
blood	NN	O
,	,	O
and	CC	O
hydrogen	NN	O
peroxide	NN	O
on	IN	O
the	DT	O
tensile	JJ	O
bond	NN	O
strength	NN	O
between	IN	O
adhesive	JJ	O
and	CC	O
ceramic	JJ	O
as	RB	O
well	RB	O
as	IN	O
between	IN	O
adhesive	JJ	O
and	CC	O
dentin	NN	O
were	VBD	O
examined	VBN	O
.	.	O

Sixty	NNP	O
7x3	CD	O
mm	NN	O
pressed	VBN	O
ceramic	JJ	O
discs	NN	O
of	IN	O
IPS	NNP	O
e.max	NN	O
were	VBD	O
fabricated	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
six	CD	O
groups	NNS	O
of	IN	O
different	JJ	O
dentin	NN	Physical
surface	NN	Physical
treatments	NNS	Physical
(	(	O
control	NN	Physical
,	,	O
desensitizer	NN	Physical
,	,	O
disinfectant	NN	Physical
,	,	O
saliva	NN	Physical
,	,	O
blood	NN	Physical
,	,	O
and	CC	O
hydrogen	VB	Pharmacological
peroxide	NN	Pharmacological
)	)	O
.	.	O

Representative	JJ	O
samples	NNS	O
of	IN	O
fractured	JJ	O
specimens	NNS	O
were	VBD	O
observed	VBN	O
by	IN	O
SEM	NNP	O
(	(	O
scanning	VBG	Physical
electron	RB	Physical
microscopy	NN	Physical
)	)	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
saliva	NN	O
,	,	O
blood	NN	O
,	,	O
and	CC	O
hydrogen	NN	O
peroxide	NN	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
any	DT	O
other	JJ	O
dentin	JJ	O
surface	NN	O
treatment	NN	O
groups	NNS	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Results	NNS	O
of	IN	O
this	DT	O
study	NN	O
suggested	VBD	O
that	IN	O
only	RB	O
saliva	NN	O
,	,	O
blood	NN	O
,	,	O
and	CC	O
hydrogen	NN	O
peroxide	NN	O
influenced	VBD	O
the	DT	O
tensile	NN	O
bond	NN	O
strength	NN	O
between	IN	O
dentin	NN	O
and	CC	O
ceramic	NN	O
.	.	O

Recombinant	JJ	Pharmacological
human	JJ	Pharmacological
granulocyte	NN	Pharmacological
and	CC	Pharmacological
granulocyte-macrophage	JJ	Pharmacological
colony-stimulating	JJ	Pharmacological
factor	NN	Pharmacological
(	(	Pharmacological
G-CSF	NNP	Pharmacological
and	CC	Pharmacological
GM-CSF	NNP	Pharmacological
)	)	Pharmacological
administered	VBD	O
following	VBG	O
cytotoxic	NN	Pharmacological
chemotherapy	NNS	Pharmacological
have	VBP	O
a	DT	O
similar	JJ	O
ability	NN	O
to	TO	O
mobilize	VB	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cells	NNS	O
.	.	O

The	DT	O
availability	NN	O
of	IN	O
hematopoietic	JJ	O
growth	NN	O
factors	NNS	O
has	VBZ	O
greatly	RB	O
facilitated	VBN	O
the	DT	O
mobilization	NN	O
and	CC	O
collection	NN	O
of	IN	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cells	NNS	O
(	(	O
PBSC	NNP	O
)	)	O
.	.	O

It	PRP	O
was	VBD	O
the	DT	O
aim	NN	O
of	IN	O
this	DT	O
double-blind	NN	O
study	NN	O
to	TO	O
compare	VB	O
the	DT	O
PBSC-mobilizing	NNP	O
efficacy	NN	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
G-CSF	NNP	Pharmacological
and	CC	O
GM-CSF	NNP	Pharmacological
when	WRB	O
administered	VBN	O
post-chemotherapy	NN	Pharmacological
.	.	O

Twenty-six	JJ	O
patients	NNS	O
with	IN	O
relapsed	JJ	O
Hodgkin	NNP	O
's	POS	O
disease	NN	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Their	PRP$	O
median	JJ	O
age	NN	O
was	VBD	O
31	CD	O
years	NNS	O
(	(	O
range	NN	O
,	,	O
22-59	JJ	O
)	)	O
and	CC	O
14	CD	O
patients	NNS	O
were	VBD	O
males	NNS	O
and	CC	O
12	CD	O
were	VBD	O
females	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
pretreated	VBN	O
with	IN	O
a	DT	O
median	NN	O
of	IN	O
eight	CD	O
cycles	NNS	O
of	IN	O
cytotoxic	NN	Pharmacological
chemotherapy	NN	Pharmacological
,	,	O
while	IN	O
18	CD	O
patients	NNS	O
had	VBD	O
undergone	JJ	O
extended	JJ	O
field	NN	O
irradiation	NN	O
.	.	O

The	DT	O
patients	NNS	O
received	VBD	O
dexamethasone	RB	Pharmacological
24	CD	Pharmacological
mg	JJ	Pharmacological
days	NNS	Pharmacological
1-7	CD	Pharmacological
,	,	Pharmacological
melphalan	FW	Pharmacological
30	CD	Pharmacological
mg/m2	NNS	Pharmacological
day	NN	Pharmacological
3	CD	Pharmacological
,	,	Pharmacological
BCNU	NNP	Pharmacological
60	CD	Pharmacological
mg/m2	NN	Pharmacological
day	NN	Pharmacological
3	CD	Pharmacological
,	,	Pharmacological
etoposide	RB	Pharmacological
75	CD	Pharmacological
mg/m2	JJ	Pharmacological
days	NNS	Pharmacological
4-7	CD	Pharmacological
,	,	Pharmacological
Ara-C	NNP	Pharmacological
100	CD	Pharmacological
mg/m2	NN	Pharmacological
twice	RB	Pharmacological
daily	JJ	Pharmacological
days	NNS	Pharmacological
4-7	JJ	Pharmacological
(	(	Pharmacological
Dexa-BEAM	NNP	Pharmacological
)	)	Pharmacological
.	.	O

Twelve	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	Pharmacological
5/microg/kg/day	CD	Pharmacological
G-CSF	NNP	Pharmacological
and	CC	O
14	CD	O
patients	NNS	O
to	TO	O
receive	VB	O
5	CD	Pharmacological
microg/kg/day	JJ	Pharmacological
GM-CSF	NNP	Pharmacological
,	,	O
both	DT	O
administered	VBN	O
subcutaneously	RB	O
starting	VBG	O
on	IN	O
day	NN	O
1	CD	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
Dexa-BEAM	NNP	Pharmacological
.	.	O

Primary	JJ	O
endpoints	NNS	O
of	IN	O
the	DT	O
study	NN	O
were	VBD	O
the	DT	O
number	NN	O
of	IN	O
CD34+	NNP	O
cells	NNS	O
harvested	VBD	O
per	IN	O
kg	NN	O
body	NN	O
weight	VBD	O
on	IN	O
the	DT	O
occasion	NN	O
of	IN	O
six	CD	O
consecutive	JJ	O
leukaphereses	NNS	O
and	CC	O
the	DT	O
time	NN	O
needed	VBN	O
for	IN	O
hematological	JJ	O
reconstitution	NN	O
following	VBG	O
autografting	VBG	O
.	.	O

Twenty-one	CD	O
patients	NNS	O
completed	VBN	O
PBSC	NNP	O
collection	NN	O
,	,	O
and	CC	O
six	CD	O
patients	NNS	O
of	IN	O
the	DT	O
G-CSF	NNP	O
group	NN	O
and	CC	O
nine	CD	O
of	IN	O
the	DT	O
GM-CSF	NNP	O
group	NN	O
were	VBD	O
autografted	VBN	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
observed	VBN	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
median	JJ	O
yield	NN	O
of	IN	O
CFU-GM	NNP	O
and	CC	O
CD34+	NNP	O
cells	NNS	O
:	:	O
32.5	CD	O
x	$	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/kg	NN	O
vs	$	O
31.3	CD	O
x	$	O
10	CD	O
(	(	O
4	CD	O
)	)	O
/kg	CD	O
CFU-GM	NNP	O
,	,	O
and	CC	O
7.6	CD	O
x	NNS	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/kg	NN	O
vs	$	O
5.6	CD	O
x	$	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/kg	NN	O
CD34+	NNP	O
cells	NNS	O
,	,	O
for	IN	O
G-CSF	NNP	Pharmacological
and	CC	O
GM-CSF	NNP	Pharmacological
,	,	O
respectively	RB	O
(	(	O
U	NNP	O
test	NN	O
,	,	O
P=	NNP	O
0.837	CD	O
and	CC	O
0.696	CD	O
)	)	O
.	.	O

High-dose	JJ	O
chemotherapy	NN	O
consisted	VBN	O
of	IN	O
cyclophosphamide	NN	Pharmacological
1.7	CD	O
g/m2	JJ	O
days	NNS	O
1-4	CD	O
,	,	O
BCNU	NNP	Pharmacological
150	CD	O
mg/m2	NN	O
days	NNS	O
1-4	CD	O
,	,	O
etoposide	RB	Pharmacological
400	CD	O
mg/m2	JJ	O
days	NNS	O
1-4	JJ	O
.	.	O

All	DT	O
patients	NNS	O
transplanted	VBN	O
with	IN	O
more	JJR	O
than	IN	O
5	CD	O
x	JJ	O
10	CD	O
(	(	O
6	CD	O
)	)	O
CD34+	NNP	O
cells/kg	NN	O
had	VBD	O
a	DT	O
rapid	JJ	O
platelet	NN	O
recovery	NN	O
(	(	O
20	CD	O
x	RB	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/l	NN	O
)	)	O
between	IN	O
6	CD	O
and	CC	O
11	CD	O
days	NNS	O
and	CC	O
neutrophil	JJ	O
recovery	NN	O
(	(	O
0.5	CD	O
x	RB	O
10	CD	O
(	(	O
9	CD	O
)	)	O
/1	NN	O
)	)	O
between	IN	O
9	CD	O
and	CC	O
16	CD	O
days	NNS	O
,	,	O
while	IN	O
patients	NNS	O
transplanted	VBN	O
with	IN	O
less	JJR	O
than	IN	O
5	CD	O
x	JJ	O
10	CD	O
(	(	O
6	CD	O
)	)	O
/kg	NN	O
had	VBD	O
a	DT	O
delayed	VBN	O
reconstitution	NN	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
kind	NN	O
of	IN	O
growth	NN	O
factor	NN	O
used	VBN	O
for	IN	O
PBSC	NNP	O
mobilization	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
our	PRP$	O
data	NNS	O
indicate	VBP	O
that	IN	O
in	IN	O
patients	NNS	O
with	IN	O
Hodgkin	NNP	O
's	POS	O
disease	NN	O
G-CSF	NNP	O
and	CC	O
GM-CSF	NNP	O
given	VBN	O
after	IN	O
salvage	NN	O
chemotherapy	NN	O
appear	VBP	O
to	TO	O
be	VB	O
not	RB	O
different	JJ	O
in	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
mobilize	VB	O
PBSC	NNP	O
resulting	VBG	O
in	IN	O
a	DT	O
similar	JJ	O
time	NN	O
needed	VBN	O
for	IN	O
hematological	JJ	O
reconstitution	NN	O
when	WRB	O
autografted	VBD	O
following	VBG	O
high-dose	JJ	O
therapy	NN	O
.	.	O

Dipyridamole	NNP	Pharmacological
in	IN	O
chronic	JJ	O
stable	JJ	O
angina	NN	O
pectoris	NN	O
;	:	O
a	DT	O
randomized	VBN	O
,	,	O
double	JJ	O
blind	NN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Oral	NNP	O
dipyridamole	NN	Pharmacological
induces	NNS	O
accumulation	NN	O
of	IN	O
endogenous	JJ	O
adenosine	NN	O
,	,	O
which	WDT	O
in	IN	O
a	DT	O
hypoxic	NN	O
milieu	NN	O
exerts	VBZ	O
experimentally	RB	O
an	DT	O
angiogenic	JJ	O
effect	NN	O
on	IN	O
coronary	JJ	O
collateral	NN	O
circulation	NN	O
.	.	O

A	DT	O
meta-analysis	NN	O
of	IN	O
13	CD	O
randomized	JJ	O
placebo-controlled	JJ	O
trials	NNS	O
published	VBN	O
between	IN	O
1960	CD	O
and	CC	O
1992	CD	O
showed	VBD	O
evidence	NN	O
of	IN	O
benefit	NN	O
for	IN	O
dipyridamole	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
angina	JJ	O
pectoris	NN	O
,	,	O
especially	RB	O
with	IN	O
longer	JJR	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

Aim	NNP	O
To	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
dipyridamole	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
stable	JJ	O
angina	NN	O
in	IN	O
a	DT	O
large	JJ	O
scale	NN	O
,	,	O
international	JJ	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
.	.	O

METHODS	NNP	O
Four	CD	O
hundred	VBD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
stable	JJ	O
angina	NN	O
pectoris	NN	O
and	CC	O
a	DT	O
positive	JJ	O
treadmill	NN	O
exercise	NN	O
test	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	RB	O
modified	JJ	Pharmacological
release	NN	Pharmacological
dipyridamole	NN	Pharmacological
(	(	O
200	CD	O
mg	NN	O
b.i.d	NN	O
.	.	O

p.o.	NN	O
,	,	O
n=198	NN	O
)	)	O
or	CC	O
corresponding	VBG	O
placebo	NN	Control
(	(	O
n=202	JJ	O
)	)	O
,	,	O
for	IN	O
24	CD	O
weeks	NNS	O
as	IN	O
an	DT	O
add-on	JJ	O
to	TO	O
conventional	JJ	Pharmacological
antianginal	JJ	Pharmacological
therapy	NN	Pharmacological
and	CC	O
for	IN	O
4	CD	O
additional	JJ	O
weeks	NNS	O
as	IN	O
monotherapy	NN	O
--	:	O
the	DT	O
latter	NN	O
after	IN	O
withdrawal	NN	Pharmacological
of	IN	Pharmacological
standard	JJ	Pharmacological
treatment	NN	Pharmacological
with	IN	Pharmacological
calcium	NN	Pharmacological
antagonists	NNS	Pharmacological
and/or	VBP	Pharmacological
beta-blockers	NNS	Pharmacological
and/or	JJ	Pharmacological
long-acting	JJ	Pharmacological
(	(	Pharmacological
prophylactic	JJ	Pharmacological
)	)	Pharmacological
nitrates	NNS	Pharmacological
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
198	CD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
dipyridamole	VB	Pharmacological
,	,	O
134	CD	O
completed	VBD	O
the	DT	O
add-on	NN	O
and	CC	O
only	RB	O
12	CD	O
the	DT	O
monotherapy	NN	O
phase	NN	O
.	.	O

Of	IN	O
the	DT	O
202	CD	O
patients	NNS	O
randomized	VBN	O
to	TO	O
placebo	VB	Control
,	,	O
162	CD	O
reached	VBD	O
the	DT	O
add-on	JJ	O
and	CC	O
only	RB	O
12	CD	O
the	DT	O
monotherapy	NN	O
phase	NN	O
.	.	O

Serious	JJ	O
adverse	JJ	O
events	NNS	O
occurred	VBD	O
in	IN	O
15	CD	O
patients	NNS	O
with	IN	O
dipyridamole	JJ	O
and	CC	O
in	IN	O
12	CD	O
with	IN	O
placebo	NN	O
(	(	O
7.6	CD	O
%	NN	O
vs	NN	O
6.0	CD	O
,	,	O
P=0.52	NNP	O
)	)	O
.	.	O

Increase	NN	O
over	IN	O
the	DT	O
baseline	NN	O
treadmill	NN	O
exercise	NN	O
test	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
at	IN	O
each	DT	O
stage	NN	O
of	IN	O
the	DT	O
trial	NN	O
for	IN	O
all	PDT	O
the	DT	O
main	JJ	O
efficacy	NN	O
parameters	NNS	O
:	:	O
total	JJ	O
treadmill	NN	O
exercise	NN	O
test	NN	O
duration	NN	O
;	:	O
time	NN	O
to	TO	O
first	JJ	O
anginal	JJ	O
pain	NN	O
(	(	O
except	IN	O
for	IN	O
a	DT	O
-13	NN	O
s	NN	O
difference	NN	O
in	IN	O
favour	NN	O
of	IN	O
placebo	NN	O
at	IN	O
week	NN	O
24	CD	O
;	:	O
P=0.040	NNP	O
)	)	O
;	:	O
time	NN	O
to	TO	O
ST	NNP	O
segment	NN	O
depression	NN	O
>	VBD	O
0.1	CD	O
mVolt	NN	O
(	(	O
except	IN	O
for	IN	O
a	DT	O
+21	JJ	O
s	NN	O
difference	NN	O
in	IN	O
favour	NN	O
of	IN	O
dipyridamole	NN	O
at	IN	O
week	NN	O
8	CD	O
;	:	O
P=0.024	NNP	O
;	:	O
this	DT	O
latter	JJ	O
difference	NN	O
was	VBD	O
totally	RB	O
attributable	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
lower	JJR	O
exercise	NN	O
tolerance	NN	O
--	:	O
Bruce	NNP	O
stage	NN	O
II	NNP	O
at	IN	O
study	NNP	O
entry	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
stable	JJ	O
angina	NN	O
treated	VBN	O
with	IN	O
regular	JJ	O
antianginal	JJ	O
background	NN	O
medication	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
oral	JJ	O
dipyridamole	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
.	.	O

Antianginal	NNP	O
and	CC	O
antiischaemic	JJ	O
efficacy	NN	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
exercise	NN	O
testing	NN	O
,	,	O
is	VBZ	O
comparable	JJ	O
to	TO	O
placebo	VB	O
,	,	O
except	IN	O
for	IN	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
time	NN	O
to	TO	O
ischaemia	VB	O
after	IN	O
2	CD	O
months	NNS	O
,	,	O
totally	RB	O
attributable	JJ	O
to	TO	O
patients	NNS	O
with	IN	O
lower	JJR	O
exercise	NN	O
tolerance	NN	O
at	IN	O
study	NN	O
entry	NN	O
.	.	O

Evaluating	VBG	O
a	DT	O
test	NN	O
protocol	NN	O
for	IN	O
predicting	VBG	O
maximum	JJ	O
lactate	NN	O
steady	JJ	O
state	NN	O
.	.	O

BACKGROUND	NNP	O
Maximum	NNP	O
lactate	NN	O
steady	JJ	O
state	NN	O
(	(	O
MLSS	NNP	O
)	)	O
is	VBZ	O
defined	VBN	O
as	IN	O
the	DT	O
highest	JJS	O
steady	JJ	O
state	NN	O
exercise	NN	O
level	NN	O
one	CD	O
can	MD	O
maintain	VB	O
while	IN	O
also	RB	O
maintaining	VBG	O
an	DT	O
equilibrium	NN	O
between	IN	O
the	DT	O
elimination	NN	O
of	IN	O
blood	NN	O
lactate	NN	O
and	CC	O
the	DT	O
diffusion	NN	O
of	IN	O
lactate	NN	O
into	IN	O
the	DT	O
blood	NN	O
.	.	O

MLSS	NNP	O
is	VBZ	O
an	DT	O
excellent	JJ	O
tool	NN	O
for	IN	O
assessing	VBG	O
fitness	JJ	O
level	NN	O
,	,	O
predicting	VBG	O
endurance	NN	O
performance	NN	O
,	,	O
and	CC	O
designing	VBG	O
training	NN	O
programs	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
investigation	NN	O
assesses	VBZ	O
the	DT	O
validity	NN	O
of	IN	O
the	DT	O
Lactate	NNP	Physical
Minimum	NNP	Physical
Test	NNP	Physical
(	(	Physical
LMT	NNP	Physical
)	)	Physical
,	,	O
which	WDT	O
consists	VBZ	O
of	IN	O
inducing	VBG	O
lactic	JJ	O
acidosis	NN	O
through	IN	O
a	DT	O
VO2peak	NNP	O
test	NN	O
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
eight-minute	JJ	O
walking	NN	O
recovery	NN	O
and	CC	O
an	DT	O
incremental	JJ	O
exercise	NN	O
test	NN	O
,	,	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
running	VBG	O
velocity	NN	O
associated	VBN	O
with	IN	O
the	DT	O
minimum	JJ	O
lactate	NN	O
value	NN	O
predicts	VBZ	O
the	DT	O
MLSS	NNP	O
velocity	NN	O
.	.	O

Following	VBG	O
this	DT	O
LMT	NNP	O
,	,	O
two	CD	O
constant	JJ	O
velocity	NN	O
28-minute	JJ	O
runs	NNS	O
were	VBD	O
performed	VBN	O
,	,	O
one	CD	O
at	IN	O
the	DT	O
predicted	JJ	O
MLSS	NNP	O
velocity	NN	O
(	(	O
trial	NN	O
1	CD	O
)	)	O
and	CC	O
the	DT	O
other	JJ	O
0.13	CD	O
m	JJ	O
sec-1	JJ	O
(	(	O
4-8	CD	O
%	NN	O
)	)	O
above	IN	O
the	DT	O
predicted	JJ	O
MLSS	NNP	O
velocity	NN	O
(	(	O
trial	NN	O
2	CD	O
)	)	O
.	.	O

Ten	CD	O
active	JJ	O
female	JJ	O
subjects	NNS	O
participated	VBD	O
(	(	O
32	CD	O
+/-	JJ	O
7	CD	O
yrs	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SD	NNP	O
)	)	O
;	:	O
65.7	CD	O
+/-	JJ	O
16.4	CD	O
kg	NN	O
;	:	O
VO2peak	NNP	O
40.0	CD	O
+/-	JJ	O
7.5	CD	O
ml.kg-1.min-1	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
During	IN	O
trial	NN	O
1	CD	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
-0.6	JJ	O
+/-	JJ	O
0.3	CD	O
mmol	JJ	O
l-1	NN	O
(	(	O
mean	JJ	O
+/-	NNP	O
SE	NNP	O
)	)	O
change	NN	O
in	IN	O
lactate	NN	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
definition	NN	O
of	IN	O
lactate	NN	O
steady	JJ	O
state	NN	O
(	(	O
LSS	NNP	O
)	)	O
as	IN	O
less	JJR	O
than	IN	O
a	DT	O
0.5	CD	O
mmol.l-1	JJ	O
increase	NN	O
,	,	O
this	DT	O
value	NN	O
signified	VBD	O
LSS	NNP	O
.	.	O

A	DT	O
similar	JJ	O
comparison	NN	O
during	IN	O
trial	NN	O
2	CD	O
revealed	VBD	O
a	DT	O
1.8	CD	O
+/-	JJ	O
0.3	CD	O
mmol.l-1	JJ	O
increase	NN	O
in	IN	O
lactate	NN	O
,	,	O
signifying	VBG	O
a	DT	O
workload	NN	O
above	IN	O
LSS	NNP	O
and	CC	O
therefore	RB	O
confirming	VBG	O
trial	NN	O
1	CD	O
as	IN	O
the	DT	O
maximum	JJ	O
LSS	NNP	O
(	(	O
MLSS	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
test	NN	O
protocol	NN	O
accurately	RB	O
predicted	VBD	O
the	DT	O
MLSS	NNP	O
velocity	NN	O
.	.	O

Plasma	NNP	O
dilution	NN	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
of	IN	O
Ringer	NNP	Pharmacological
's	POS	Pharmacological
solution	NN	Pharmacological
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
volume	NN	O
of	IN	O
the	DT	O
fluid	JJ	O
space	NN	O
expanded	VBN	O
by	IN	O
i.v	NN	O
.	.	O

infusion	NN	O
of	IN	O
Ringer	NNP	Pharmacological
's	POS	Pharmacological
acetate	JJ	Pharmacological
solution	NN	Pharmacological
have	VBP	O
been	VBN	O
analysed	VBN	O
recently	RB	O
using	VBG	O
mathematical	JJ	O
models	NNS	O
.	.	O

Data	NNS	O
obtained	VBN	O
by	IN	O
such	JJ	O
analyses	NNS	O
allow	VBP	O
simulation	NN	O
of	IN	O
the	DT	O
dilution	NN	O
of	IN	O
the	DT	O
plasma	NN	O
volume	NN	O
during	IN	O
infusion	NN	O
of	IN	O
the	DT	O
solution	NN	O
at	IN	O
different	JJ	O
rates	NNS	O
.	.	O

To	TO	O
obtain	VB	O
basic	JJ	O
kinetic	JJ	O
data	NNS	O
for	IN	O
such	JJ	O
simulations	NNS	O
,	,	O
the	DT	O
plasma	JJ	O
dilution-time	JJ	O
curves	NNS	O
were	VBD	O
measured	VBN	O
during	IN	O
and	CC	O
after	IN	O
i.v	NN	Pharmacological
.	.	Pharmacological

infusion	NN	Pharmacological
of	IN	Pharmacological
Ringer	NNP	Pharmacological
's	POS	Pharmacological
solution	NN	Pharmacological
25	CD	O
ml	NN	O
kg-1	NN	O
over	IN	O
30	CD	O
min	NNS	O
in	IN	O
15	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
(	(	O
mean	JJ	O
age	NN	O
31	CD	O
yr	NN	O
)	)	O
and	CC	O
over	IN	O
30	CD	O
,	,	O
45	CD	O
and	CC	O
80	CD	O
min	NN	O
in	IN	O
six	CD	O
females	NNS	O
(	(	O
mean	JJ	O
age	NN	O
32	CD	O
yr	NN	O
)	)	O
.	.	O

Based	VBN	O
on	IN	O
these	DT	O
experiments	NNS	O
,	,	O
nomograms	NNS	O
were	VBD	O
constructed	VBN	O
from	IN	O
which	WDT	O
the	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
of	IN	O
Ringer	NNP	Pharmacological
's	POS	Pharmacological
solution	NN	Pharmacological
and	CC	O
the	DT	O
infusion	NN	O
time	NN	O
required	VBN	O
to	TO	O
obtain	VB	O
a	DT	O
defined	JJ	O
plasma	NN	O
dilution	NN	O
in	IN	O
both	DT	O
males	NNS	O
and	CC	O
females	NNS	O
can	MD	O
be	VB	O
estimated	VBN	O
together	RB	O
with	IN	O
the	DT	O
infusion	NN	O
rate	NN	O
needed	VBN	O
to	TO	O
maintain	VB	O
the	DT	O
dilution	NN	O
at	IN	O
the	DT	O
level	NN	O
reached	VBD	O
.	.	O

Longitudinal	JJ	O
follow-up	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
receiving	VBG	O
targeted	VBN	O
interventions	NNS	O
on	IN	O
joint	JJ	Educational
attention	NN	Educational
and	CC	O
play	NN	Educational
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
examines	VBZ	O
the	DT	O
cognitive	NN	O
and	CC	O
language	NN	O
outcomes	NNS	O
of	IN	O
children	NNS	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
over	IN	O
a	DT	O
5-year	JJ	O
period	NN	O
after	IN	O
receiving	VBG	O
targeted	VBD	Educational
early	JJ	Educational
interventions	NNS	Educational
that	WDT	Educational
focused	VBD	Educational
on	IN	Educational
joint	JJ	Educational
attention	NN	Educational
and	CC	Educational
play	NN	Educational
skills	NNS	Educational
.	.	Educational

METHOD	NNP	O
Forty	NNP	O
children	NNS	O
from	IN	O
the	DT	O
original	JJ	O
study	NN	O
(	(	O
n	JJ	O
=	NNP	O
58	CD	O
)	)	O
had	VBD	O
complete	JJ	O
data	NNS	O
at	IN	O
the	DT	O
5-year	JJ	O
follow-up	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
all	DT	O
,	,	O
80	CD	O
%	NN	O
of	IN	O
children	NNS	O
had	VBD	O
achieved	VBN	O
functional	JJ	O
use	NN	O
of	IN	O
spoken	JJ	O
language	NN	O
with	IN	O
baseline	JJ	O
play	NN	O
level	NN	O
predicting	VBG	O
spoken	JJ	O
language	NN	O
at	IN	O
the	DT	O
5-year	JJ	O
follow-up	NN	O
.	.	O

Of	IN	O
children	NNS	O
who	WP	O
were	VBD	O
using	VBG	O
spoken	JJ	O
language	NN	O
at	IN	O
age	NN	O
8	CD	O
years	NNS	O
,	,	O
several	JJ	O
baseline	NN	O
behaviors	NNS	O
predicted	VBD	O
their	PRP$	O
later	JJ	O
ability	NN	O
,	,	O
including	VBG	O
earlier	JJR	O
age	NN	O
of	IN	O
entry	NN	O
into	IN	O
the	DT	O
study	NN	O
,	,	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
skill	NN	O
,	,	O
play	VB	O
level	NN	O
,	,	O
and	CC	O
assignment	NN	O
to	TO	O
either	VB	O
the	DT	O
joint	JJ	Educational
attention	NN	Educational
or	CC	Educational
symbolic	JJ	Educational
play	NN	Educational
intervention	NN	O
group	NN	O
.	.	O

Only	RB	O
baseline	JJ	O
play	NN	O
diversity	NN	O
predicted	VBD	O
cognitive	JJ	O
scores	NNS	O
at	IN	O
age	NN	O
8	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
only	JJ	O
long-term	JJ	O
follow-up	JJ	O
studies	NNS	O
of	IN	O
children	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
preschool	NN	O
early	JJ	O
interventions	NNS	O
aimed	VBN	O
at	IN	O
targeting	VBG	O
core	NN	O
developmental	NN	O
difficulties	NNS	O
.	.	O

The	DT	O
study	NN	O
findings	NNS	O
suggest	VBP	O
that	IN	O
focusing	VBG	O
on	IN	O
joint	JJ	O
attention	NN	O
and	CC	O
play	NN	O
skills	NNS	O
in	IN	O
comprehensive	JJ	O
treatment	NN	O
models	NNS	O
is	VBZ	O
important	JJ	O
for	IN	O
long-term	JJ	O
spoken	JJ	O
language	NN	O
outcomes	NNS	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
preoperative	JJ	O
antibiotics	NNS	Pharmacological
on	IN	O
success	NN	O
of	IN	O
endosseous	JJ	Physical
implants	NNS	Physical
up	IN	O
to	TO	O
and	CC	O
including	VBG	O
stage	NN	O
II	NNP	O
surgery	NN	O
:	:	O
a	DT	O
study	NN	O
of	IN	O
2,641	CD	O
implants	NNS	O
.	.	O

According	VBG	O
to	TO	O
the	DT	O
American	NNP	O
College	NNP	O
of	IN	O
Surgeons	NNP	O
,	,	O
complex	JJ	O
oral	JJ	O
surgical	JJ	O
procedures	NNS	O
,	,	O
including	VBG	O
the	DT	O
transoral	JJ	O
placement	NN	O
of	IN	O
endosseous	JJ	O
implants	NNS	O
,	,	O
are	VBP	O
of	IN	O
the	DT	O
type	NN	O
that	WDT	O
may	MD	O
require	VB	O
prophylactic	JJ	Pharmacological
antibiotics	NNS	Pharmacological
.	.	O

However	RB	O
,	,	O
the	DT	O
routine	JJ	O
use	NN	O
of	IN	O
prophylactic	JJ	Pharmacological
antibiotics	NNS	Pharmacological
in	IN	O
the	DT	O
field	NN	O
of	IN	O
dental	JJ	O
implantology	NN	O
continues	VBZ	O
to	TO	O
be	VB	O
controversial	JJ	O
,	,	O
and	CC	O
their	PRP$	O
utilization	NN	O
varies	NNS	O
widely	RB	O
.	.	O

No	UH	O
data	NN	O
from	IN	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
clinical	JJ	O
study	NN	O
of	IN	O
the	DT	O
prophylactic	JJ	O
use	NN	O
of	IN	O
antibiotics	NNS	Pharmacological
in	IN	O
implant	JJ	O
surgery	NN	O
have	VBP	O
been	VBN	O
previously	RB	O
published	VBN	O
.	.	O

As	IN	O
part	NN	O
of	IN	O
the	DT	O
comprehensive	JJ	O
Dental	NNP	O
Implant	NNP	O
Clinical	NNP	O
Research	NNP	O
Group	NNP	O
clinical	JJ	O
implant	NN	O
study	NN	O
,	,	O
the	DT	O
preoperative	NN	O
or	CC	O
postoperative	JJ	O
use	NN	O
of	IN	O
antibiotics	NNS	Pharmacological
,	,	O
the	DT	O
type	NN	O
used	VBN	O
,	,	O
and	CC	O
the	DT	O
duration	NN	O
of	IN	O
coverage	NN	O
was	VBD	O
left	VBN	O
to	TO	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
surgeon	NN	O
.	.	O

These	DT	O
data	NNS	O
were	VBD	O
recorded	VBN	O
and	CC	O
correlated	VBN	O
with	IN	O
failure	NN	O
of	IN	O
osseointegration	NN	O
during	IN	O
healing	VBG	O
(	(	O
stage	NN	O
I	PRP	O
)	)	O
and	CC	O
at	IN	O
stage	NN	O
II	NNP	O
surgery	NN	O
(	(	O
uncovering	VBG	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
significantly	RB	O
fewer	JJR	O
failures	NNS	O
occurred	VBD	O
when	WRB	O
preoperative	JJ	O
antibiotics	NNS	Pharmacological
were	VBD	O
used	VBN	O
.	.	O

Skeletal	JJ	O
muscle	NN	O
total	JJ	O
creatine	NN	O
content	NN	O
and	CC	O
creatine	NN	O
transporter	NN	O
gene	NN	O
expression	NN	O
in	IN	O
vegetarians	NNS	O
prior	JJ	O
to	TO	O
and	CC	O
following	VBG	O
creatine	JJ	Pharmacological
supplementation	NN	Pharmacological
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
vegetarianism	NN	O
on	IN	O
skeletal	JJ	O
muscle	NN	O
total	JJ	O
creatine	NN	O
(	(	O
TCr	NNP	O
)	)	O
content	NN	O
and	CC	O
creatine	NN	O
transporter	NN	O
(	(	O
CreaT	NNP	O
)	)	O
gene	NN	O
expression	NN	O
,	,	O
prior	RB	O
to	TO	O
and	CC	O
during	IN	O
5	CD	O
d	NN	O
of	IN	O
Cr	NNP	Pharmacological
supplementation	NN	Pharmacological
(	(	Pharmacological
CrS	NNP	Pharmacological
)	)	Pharmacological
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
crossover	NN	O
design	NN	O
,	,	O
7	CD	O
vegetarians	NNS	O
(	(	O
VEG	NNP	O
)	)	O
and	CC	O
nonvegetarians	NNS	O
(	(	O
NVEG	NNP	O
)	)	O
were	VBD	O
assigned	VBN	O
Cr	NNP	Pharmacological
or	CC	O
placebo	NN	Control
supplements	NNS	Control
for	IN	O
5	CD	O
d	NN	O
and	CC	O
after	IN	O
5	CD	O
wk	NN	O
,	,	O
received	VBD	O
the	DT	O
alternative	JJ	O
treatment	NN	O
.	.	O

Muscle	NNP	Physical
sampling	VBG	Physical
occurred	VBD	O
before	IN	O
,	,	O
and	CC	O
after	IN	O
1	CD	O
and	CC	O
5	CD	O
d	NN	O
of	IN	O
treatment	NN	O
ingestion	NN	O
.	.	O

Basal	NNP	O
muscle	NN	O
TCr	NNP	O
content	NN	O
was	VBD	O
lower	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
VEG	NNP	O
compared	VBN	O
with	IN	O
NVEG	NNP	O
.	.	O

Muscle	NNP	O
TCr	NNP	O
increased	VBD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
throughout	IN	O
the	DT	O
Cr	NNP	Pharmacological
trial	NN	O
in	IN	O
both	DT	O
groups	NNS	O
but	CC	O
was	VBD	O
greater	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
VEG	NNP	O
compared	VBN	O
with	IN	O
NVEG	NNP	O
,	,	O
at	IN	O
days	NNS	O
1	CD	O
and	CC	O
5	CD	O
.	.	O

CreaT	NNP	O
gene	NN	O
expression	NN	O
was	VBD	O
not	RB	O
different	JJ	O
between	IN	O
VEG	NNP	O
and	CC	O
NVEG	NNP	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
VEG	NNP	O
have	VBP	O
a	DT	O
lower	JJR	O
muscle	NN	O
TCr	NNP	O
content	NN	O
and	CC	O
an	DT	O
increased	VBN	O
capacity	NN	O
to	TO	O
load	VB	O
Cr	NNP	Pharmacological
into	IN	O
muscle	NN	O
following	VBG	O
CrS	NNP	Pharmacological
.	.	O

Muscle	NNP	O
CreaT	NNP	O
gene	NN	O
expression	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
affected	VBN	O
by	IN	O
vegetarianism	NN	O
.	.	O

Lengthening	VBG	O
the	DT	O
moment	NN	O
arm	NN	O
of	IN	O
the	DT	O
patella	NN	O
confers	NNS	O
enhanced	VBD	O
extensor	NN	O
mechanism	NN	O
power	NN	O
following	VBG	O
total	JJ	O
knee	JJ	O
arthroplasty	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
a	DT	O
postulated	JJ	O
biomechanical	JJ	O
advantage	NN	O
conferred	VBD	O
to	TO	O
the	DT	O
extensor	NN	O
mechanism	NN	O
by	IN	O
a	DT	O
change	NN	O
in	IN	O
knee	NN	O
implant	JJ	O
design	NN	O
was	VBD	O
detectable	JJ	O
in	IN	O
patients	NNS	O
by	IN	O
direct	JJ	O
physical	JJ	O
testing	NN	O
.	.	O

212	CD	O
TKA	JJ	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
to	TO	O
receive	VB	O
either	CC	O
a	DT	O
traditional	JJ	Physical
implant	NN	Physical
or	CC	Physical
one	CD	Physical
which	WDT	Physical
incorporated	VBD	Physical
new	JJ	Physical
design	NN	Physical
features	NNS	Physical
.	.	O

Extensor	NNP	O
mechanism	NN	O
power	NN	O
output	NN	O
and	CC	O
physical	JJ	O
performance	NN	O
on	IN	O
a	DT	O
battery	NN	O
of	IN	O
timed	JJ	O
functional	JJ	O
activities	NNS	O
was	VBD	O
assessed	VBN	O
pre-operatively	RB	O
and	CC	O
then	RB	O
at	IN	O
6	CD	O
,	,	O
26	CD	O
,	,	O
and	CC	O
52	CD	O
weeks	NNS	O
post-operatively	RB	O
.	.	O

Significantly	RB	O
enhanced	JJ	O
power	NN	O
output	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
post-arthroplasty	VBP	O
;	:	O
however	RB	O
,	,	O
the	DT	O
new	JJ	Physical
design	NN	Physical
implant	JJ	Physical
group	NN	O
demonstrated	VBD	O
a	DT	O
greater	JJR	O
change	NN	O
in	IN	O
power	NN	O
output	NN	O
than	IN	O
the	DT	O
traditional	JJ	Physical
implant	NN	Physical
group	NN	O
.	.	O

Posthoc	NNP	O
testing	VBG	O
of	IN	O
between	IN	O
group	NN	O
differences	NNS	O
highlighted	VBD	O
greater	JJR	O
improvement	NN	O
at	IN	O
all	DT	O
post-operative	JJ	O
assessments	NNS	O
.	.	O

At	IN	O
52	CD	O
weeks	NNS	O
,	,	O
patients	NNS	O
receiving	VBG	O
the	DT	O
implant	NN	O
with	IN	O
the	DT	O
postulated	JJ	O
biomechanical	JJ	O
advantage	NN	O
achieved	VBD	O
116	CD	O
%	NN	O
of	IN	O
the	DT	O
power	NN	O
output	NN	O
of	IN	O
their	PRP$	O
contralateral	JJ	O
limb	NN	O
,	,	O
whereas	JJ	O
patients	NNS	O
with	IN	O
the	DT	O
traditional	JJ	O
design	NN	O
achieved	VBD	O
90	CD	O
%	NN	O
.	.	O

No	DT	O
between	IN	O
group	NN	O
difference	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
patient	NN	O
's	POS	O
time	NN	O
to	TO	O
complete	VB	O
functional	JJ	O
tasks	NNS	O
.	.	O

Thus	RB	O
,	,	O
patients	NNS	O
receiving	VBG	O
a	DT	O
knee	NN	Physical
implant	NN	Physical
of	IN	Physical
a	DT	Physical
modern	JJ	Physical
design	NN	Physical
(	(	O
theoretically	RB	O
able	JJ	O
to	TO	O
confer	VB	O
a	DT	O
mechanical	JJ	O
advantage	NN	O
to	TO	O
the	DT	O
extensor	NN	O
mechanism	NN	O
)	)	O
were	VBD	O
found	VBN	O
to	TO	O
generate	VB	O
significantly	RB	O
greater	JJR	O
extensor	NN	O
power	NN	O
than	IN	O
those	DT	O
receiving	VBG	O
a	DT	O
traditional	JJ	Physical
implant	NN	Physical
without	IN	O
the	DT	O
postulated	JJ	O
mechanical	JJ	O
advantage	NN	O
.	.	O

[	JJ	O
Stent	NNP	Surgical
and	CC	Surgical
surgery	NN	Surgical
for	IN	O
symptomatic	JJ	O
carotid	NN	O
stenosis	NN	O
.	.	O

SPACE	NNP	O
study	NN	O
results	NNS	O
]	NNP	O
.	.	O

The	DT	O
SPACE	NNP	O
trial	NN	O
compared	VBN	O
risk	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
stent-supported	JJ	Surgical
angioplasty	NN	Surgical
(	(	Surgical
CAS	NNP	Surgical
)	)	Surgical
vs	NN	O
carotid	NN	Surgical
endarterectomy	NN	Surgical
(	(	Surgical
CEA	NNP	Surgical
)	)	Surgical
using	VBG	O
a	DT	O
noninferiority	NN	O
design	NN	O
in	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
stenoses	NNS	O
.	.	O

Intention-to-treat	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
entire	JJ	O
study	NN	O
population	NN	O
of	IN	O
1,214	CD	O
patients	NNS	O
showed	VBD	O
that	IN	O
primary	JJ	O
endpoint	NN	O
events	NNS	O
(	(	O
ipsilateral	JJ	O
stroke	NN	O
or	CC	O
death	NN	O
between	IN	O
randomisation	NN	O
and	CC	O
day	NN	O
30	CD	O
)	)	O
occurred	VBD	O
in	IN	O
6.92	CD	O
%	NN	O
of	IN	O
the	DT	O
CAS	NNP	Surgical
group	NN	O
and	CC	O
6.45	CD	O
%	NN	O
of	IN	O
the	DT	O
CEA	NNP	Surgical
group	NN	O
.	.	O

The	DT	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
of	IN	O
the	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
ranged	VBD	O
from	IN	O
-1.94	CD	O
%	NN	O
to	TO	O
+2.87	CD	O
%	NN	O
,	,	O
therefore	RB	O
the	DT	O
noninferiority	NN	O
was	VBD	O
not	RB	O
proven	RB	O
.	.	O

The	DT	O
same	JJ	O
was	VBD	O
true	JJ	O
for	IN	O
the	DT	O
analysis	NN	O
of	IN	O
protocols	NNS	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
methods	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
primary	JJ	O
or	CC	O
any	DT	O
of	IN	O
the	DT	O
secondary	JJ	O
endpoints	NNS	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
differences	NNS	O
in	IN	O
short-term	JJ	O
prevention	NN	O
.	.	O

The	DT	O
endpoint	JJ	O
'ipsilateral	JJ	O
ischemic	JJ	O
stroke	NN	O
or	CC	O
vascular	JJ	O
death	NN	O
between	IN	O
randomisation	NN	O
and	CC	O
6	CD	O
months	NNS	O
'	POS	O
occurred	VBD	O
in	IN	O
7.4	CD	O
%	NN	O
of	IN	O
the	DT	O
CAS	NNP	Surgical
and	CC	O
6.5	CD	O
%	NN	O
of	IN	O
the	DT	O
CEA	NNP	Surgical
patients	NNS	O
(	(	O
odds	NNS	O
ratio	VBP	O
1.16	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
0.74-1.82	NN	O
)	)	O
.	.	O

Instent	JJ	O
restenoses	NNS	O
were	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
CAS	NNP	Surgical
group	NN	O
(	(	O
4.6	CD	O
%	NN	O
vs	JJ	O
2.2	CD	O
%	NN	O
,	,	O
odds	NNS	O
ratio	VBP	O
2.14	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.10-4.18	CD	O
)	)	O
.	.	O

Surgery	NN	O
remains	VBZ	O
the	DT	O
gold	JJ	O
standard	NN	O
in	IN	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
carotid	NN	O
artery	NN	O
stenosis	NN	O
.	.	O

Stent-supported	JJ	Surgical
angioplasty	NN	Surgical
can	MD	O
be	VB	O
an	DT	O
alternative	JJ	O
only	RB	O
in	IN	O
the	DT	O
hands	NNS	O
of	IN	O
an	DT	O
experienced	JJ	O
interventionalist	NN	O
with	IN	O
proven	JJ	O
low	JJ	O
periprocedural	JJ	O
complication	NN	O
rate	NN	O
.	.	O

[	JJ	Pharmacological
Bupivacaine-CO2	NNP	Pharmacological
and	CC	Pharmacological
bupivacaine-HCl	NN	Pharmacological
at	IN	O
various	JJ	O
injection	NN	O
temperatures	NNS	O
in	IN	O
peridural	JJ	Pharmacological
anesthesia	NN	Pharmacological
for	IN	O
extracorporeal	NN	O
shock	NN	O
wave	VBP	O
lithotripsy	VBN	O
]	NNP	O
.	.	O

INTRODUCTION	NNP	O
The	DT	O
effect	NN	O
of	IN	O
different	JJ	O
injection	NN	O
temperatures	NNS	O
on	IN	O
carbonated	JJ	Pharmacological
anesthetics	NNS	Pharmacological
has	VBZ	O
been	VBN	O
controversial	JJ	O
since	IN	O
1965	CD	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
determine	VB	O
onset	JJ	O
times	NNS	O
of	IN	O
sensory	NN	O
and	CC	O
motor	NN	O
blockade	NN	O
after	IN	O
epidural	JJ	Pharmacological
anesthesia	NN	Pharmacological
with	IN	O
0.5	CD	O
%	NN	O
bupivacaine-CO2	JJ	Pharmacological
and	CC	O
0.5	CD	O
%	NN	O
bupivacaine-HCl	NN	Pharmacological
at	IN	O
various	JJ	O
injection	NN	O
temperatures	NNS	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
90	CD	O
ASA	NNP	O
class	NN	O
I-II	NNP	O
urologic	JJ	O
patients	NNS	O
during	IN	O
extracorporeal	JJ	Physical
shock	NN	Physical
wave	NN	Physical
lithotripsy	NN	Physical
.	.	Physical

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
six	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
either	RB	O
0.5	CD	O
%	NN	O
bupivacaine-CO2	NN	Pharmacological
or	CC	O
0.5	CD	O
%	NN	O
bupivacaine-HCl	NN	Pharmacological
at	IN	O
temperatures	NNS	O
of	IN	O
4	CD	O
degrees	NNS	O
,	,	O
20	CD	O
degrees	NNS	O
,	,	O
or	CC	O
36	CD	O
degrees	NNS	O
C.	NNP	O
The	DT	O
six	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
in	IN	O
age	NN	O
,	,	O
height	NN	O
,	,	O
and	CC	O
weight	NN	O
.	.	O

Epidural	JJ	Pharmacological
anesthesia	NN	Pharmacological
was	VBD	O
performed	VBN	O
at	IN	O
the	DT	O
L2-3	NNP	O
interspace	NN	O
with	IN	O
an	DT	O
18-gauge	JJ	Physical
Tuohy	NNP	Physical
needle	MD	O
using	VBG	O
loss	NN	O
of	IN	O
resistance	NN	O
.	.	O

A	DT	O
catheter	NN	O
was	VBD	O
advanced	JJ	O
4	CD	O
cm	NN	O
in	IN	O
the	DT	O
epidural	JJ	O
space	NN	O
and	CC	O
4	CD	O
ml	NNS	O
0.5	CD	O
%	NN	O
bupivacaine	NN	Pharmacological
with	IN	Pharmacological
adrenaline	JJ	Pharmacological
1:200,000	CD	O
was	VBD	O
given	VBN	O
as	IN	O
a	DT	O
test	NN	O
dose	NN	O
.	.	O

After	IN	O
4	CD	O
min	VBD	O
the	DT	O
full	JJ	O
anesthetic	JJ	O
dose	NN	O
,	,	O
based	VBN	O
on	IN	O
body	NN	O
size	NN	O
,	,	O
was	VBD	O
injected	VBN	O
with	IN	O
the	DT	O
patient	JJ	O
supine	NN	O
.	.	O

Sensory	NNP	O
blockade	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
pinprick	NN	O
method	NN	O
and	CC	O
motor	NN	O
blockade	NN	O
by	IN	O
the	DT	O
Bromage	NNP	O
method	NN	O
at	IN	O
2-min	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
20	CD	O
min	NN	O
,	,	O
at	IN	O
5-min	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
next	JJ	O
10	CD	O
min	NN	O
,	,	O
and	CC	O
then	RB	O
every	DT	O
15	CD	O
min	NN	O
to	TO	O
a	DT	O
total	NN	O
of	IN	O
240	CD	O
min	NN	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
done	VBN	O
by	IN	O
the	DT	O
Mann-Whitney	NNP	O
test	NN	O
,	,	O
with	IN	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
considered	VBN	O
significant	JJ	O
.	.	O

RESULTS	NNP	O
Spread	NNP	O
of	IN	O
sensory	NN	O
blockade	NN	O
was	VBD	O
significantly	RB	O
faster	RBR	O
with	IN	O
bupivacaine-CO2	JJ	Pharmacological
and	CC	O
-HCl	NN	Pharmacological
at	IN	O
a	DT	O
temperature	NN	O
of	IN	O
36	CD	O
degrees	NNS	O
C	NNP	O
as	IN	O
compared	VBN	O
to	TO	O
4	CD	O
degrees	NNS	O
or	CC	O
20	CD	O
degrees	NNS	O
C	NNP	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
(	(	O
Figs	NNP	O
.	.	O

1	CD	O
,	,	O
2	CD	O
and	CC	O
Table	NNP	O
2	CD	O
)	)	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Tracheal	NNP	O
soiling	VBG	O
with	IN	O
blood	NN	O
during	IN	O
intranasal	NN	Surgical
surgery	NN	Surgical
--	:	O
comparison	NN	O
of	IN	O
two	CD	O
endotracheal	JJ	O
tubes	NNS	O
.	.	O

Sixty	NNP	O
adult	NN	O
patients	NNS	O
,	,	O
ASA	NNP	O
Classes	NNP	O
I	PRP	O
&	CC	O
II	NNP	O
,	,	O
were	VBD	O
involved	VBN	O
in	IN	O
a	DT	O
study	NN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
Mallinckrodt	NNP	Surgical
Hi-Lo-Evac	NNP	Surgical
tube	NN	Surgical
and	CC	O
Portex	NNP	Surgical
blue	JJ	Surgical
line	NN	Surgical
tube	NN	Surgical
in	IN	O
preventing	VBG	O
soiling	NN	O
of	IN	O
the	DT	O
lower	JJR	O
airways	NNS	O
during	IN	O
intranasal	NN	O
surgery	NN	O
.	.	O

The	DT	O
Hi-Lo-Evac	JJ	O
tube	NN	O
with	IN	O
and	CC	O
without	IN	O
pack	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
Portex	NNP	O
tube	NN	O
with	IN	O
pharyngeal	JJ	O
pack	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.002	CD	O
)	)	O
and	CC	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
respectively	RB	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
when	WRB	O
the	DT	O
Hi-Lo-Evac	NNP	O
tube	NN	O
was	VBD	O
used	VBN	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
pack	NN	O
(	(	O
P	NNP	O
greater	JJR	O
than	IN	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
more	RBR	O
effective	JJ	O
protection	NN	O
of	IN	O
the	DT	O
lower	JJR	O
airways	NNS	O
by	IN	O
the	DT	O
Hi-Lo-Evac	NNP	O
tube	NN	O
is	VBZ	O
attributed	VBN	O
to	TO	O
the	DT	O
facility	NN	O
of	IN	O
subglottic	JJ	O
aspiration	NN	O
during	IN	O
surgery	NN	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
Hi-Lo-Evac	NNP	O
tube	NN	O
could	MD	O
be	VB	O
used	VBN	O
with	IN	O
safety	NN	O
during	IN	O
intranasal	JJ	O
surgery	NN	O
in	IN	O
order	NN	O
to	TO	O
reduce	VB	O
postoperative	JJ	O
morbidity	NN	O
associated	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
pharyngeal	JJ	O
pack	NN	O
.	.	O

Event-related	JJ	O
potential	JJ	O
indices	NNS	O
of	IN	O
auditory	JJ	O
selective	JJ	O
attention	NN	O
in	IN	O
dependent	JJ	O
amphetamine	NN	O
users	NNS	O
.	.	O

BACKGROUND	VB	O
The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
further	JJ	O
investigate	VB	O
a	DT	O
previously	RB	O
reported	VBN	O
attention-related	JJ	O
impairment	NN	O
in	IN	O
dependent	JJ	O
amphetamine	NN	O
users	NNS	O
using	VBG	O
event-related	JJ	O
potential	NN	O
(	(	O
ERP	NNP	O
)	)	O
indices	NNS	O
of	IN	O
selective	JJ	O
attention	NN	O
.	.	O

METHODS	NNP	O
ERPs	NNP	O
were	VBD	O
recorded	VBN	O
during	IN	O
an	DT	O
auditory	JJ	Educational
selective	JJ	Educational
attention	NN	Educational
task	NN	Educational
(	(	Educational
SAT	NNP	Educational
)	)	Educational
that	WDT	O
involved	VBD	O
detecting	VBG	O
infrequent	JJ	O
long-duration	NN	O
target	NN	O
tones	NNS	O
presented	VBN	O
among	IN	O
short-duration	JJ	O
tones	NNS	O
that	WDT	O
varied	VBD	O
in	IN	O
location	NN	O
(	(	O
left	VBN	O
vs.	RB	O
right	JJ	O
ear	NN	O
)	)	O
and	CC	O
pitch	NN	O
(	(	O
low	JJ	O
vs.	FW	O
high	JJ	O
)	)	O
.	.	O

Amphetamine	JJ	O
users	NNS	O
(	(	O
n	JJ	O
=	NNP	O
19	CD	O
)	)	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
high	JJ	O
dependence	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
and	CC	O
low	JJ	O
dependence	NN	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
,	,	O
based	VBN	O
on	IN	O
amphetamine	JJ	O
Severity	NNP	O
of	IN	O
Dependence	NNP	O
Scale	NNP	O
scores	NNS	O
,	,	O
and	CC	O
compared	VBN	O
to	TO	O
an	DT	O
age-matched	JJ	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
high-dependence	NN	O
group	NN	O
showed	VBD	O
slowed	VBN	O
reaction	NN	O
time	NN	O
and	CC	O
reduced	VBD	O
early	JJ	O
processing	NN	O
negativity	NN	O
and	CC	O
peak	NN	O
N1	NNP	O
amplitude	NN	O
to	TO	O
location-relevant	JJ	O
nontarget	NN	O
stimuli	NN	O
.	.	O

Poor	NNP	O
performance	NN	O
on	IN	O
the	DT	O
SAT	NNP	O
was	VBD	O
highly	RB	O
correlated	VBN	O
with	IN	O
deficits	NNS	O
in	IN	O
early	JJ	O
processing	NN	O
,	,	O
which	WDT	O
were	VBD	O
also	RB	O
related	VBN	O
to	TO	O
poor	JJ	O
performance	NN	O
on	IN	O
the	DT	O
Wechsler	NNP	O
Memory	NNP	O
Scale	NNP	O
Attention/Concentration	NNP	O
index	NN	O
.	.	O

CONCLUSIONS	VB	O
It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
severely	RB	O
dependent	JJ	O
users	NNS	O
suffer	VBP	O
an	DT	O
inability	NN	O
to	TO	O
selectively	RB	O
enhance	VB	O
the	DT	O
sensory	JJ	O
processing	NN	O
of	IN	O
relevant	JJ	O
auditory	JJ	O
information	NN	O
.	.	O

This	DT	O
may	MD	O
produce	VB	O
poor	JJ	O
automatic	JJ	O
preferential	NN	O
processing	NN	O
of	IN	O
relevant	JJ	O
information	NN	O
and	CC	O
increase	VB	O
load	NN	O
on	IN	O
limited	JJ	O
attentional	JJ	O
resources	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
weight	NN	Physical
training	NN	Physical
on	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
and	CC	O
bone	NN	O
turnover	NN	O
in	IN	O
postmenopausal	JJ	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
with	IN	O
bone	JJ	O
loss	NN	O
:	:	O
a	DT	O
24-month	JJ	O
randomized	NN	O
controlled	VBD	O
trial	NN	O
.	.	O

SUMMARY	VB	O
This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
24	CD	O
months	NNS	O
of	IN	O
weight	JJ	Physical
training	NN	Physical
exercises	NNS	Physical
enhanced	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
risedronate	NN	Pharmacological
,	,	Pharmacological
calcium	NN	Pharmacological
,	,	O
and	CC	O
vitamin	NN	Pharmacological
D	NNP	Pharmacological
in	IN	O
maintaining	VBG	O
or	CC	O
improving	VBG	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
in	IN	O
223	CD	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
>	NNP	O
or	CC	O
=50	CD	O
%	NN	O
adherent	NN	O
to	TO	O
exercise	VB	Physical
had	VBN	O
no	DT	O
improvement	NN	O
in	IN	O
BMD	NNP	O
but	CC	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
lose	VB	O
BMD	NNP	O
.	.	O

INTRODUCTION	NNP	O
This	DT	O
study	NN	O
examined	VBD	O
whether	IN	O
(	(	O
1	CD	O
)	)	O
postmenopausal	NN	O
breast	NN	O
cancer	NN	O
survivors	NNS	O
(	(	O
BCS	NNP	O
)	)	O
with	IN	O
bone	NN	O
loss	NN	O
taking	VBG	O
24	CD	O
months	NNS	O
of	IN	O
risedronate	NN	Pharmacological
,	,	Pharmacological
calcium	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
vitamin	NN	Pharmacological
D	NNP	Pharmacological
had	VBD	O
increased	VBN	O
bone	RB	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
at	IN	O
the	DT	O
total	JJ	O
hip	NN	O
,	,	O
femoral	JJ	O
neck	NN	O
,	,	O
L1-L4	NNP	O
spine	NN	O
,	,	O
total	JJ	O
radius	NN	O
and	CC	O
33	CD	O
%	NN	O
radius	NN	O
,	,	O
and	CC	O
decreased	VBD	O
bone	NN	O
turnover	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
subjects	NNS	O
who	WP	O
also	RB	O
participated	VBD	O
in	IN	O
strength/weight	JJ	Physical
training	NN	Physical
(	(	Physical
ST	NNP	Physical
)	)	Physical
exercises	NNS	Physical
had	VBD	O
greater	JJR	O
increases	NNS	O
in	IN	O
BMD	NNP	O
and	CC	O
greater	JJR	O
decreases	NNS	O
in	IN	O
bone	NN	O
turnover	NN	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
subjects	NNS	O
who	WP	O
also	RB	O
exercised	VBD	Physical
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
preserve	VB	O
(	(	O
at	IN	O
least	JJS	O
maintain	NN	O
)	)	O
BMD	NNP	O
.	.	O

METHODS	NNP	O
Postmenopausal	NNP	O
BCS	NNP	O
(	(	O
223	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
exercise	VB	Physical
plus	JJ	Educational
medication	NN	Pharmacological
or	CC	O
medication	NN	Pharmacological
only	RB	Pharmacological
groups	NNS	O
.	.	O

Both	DT	O
groups	NNS	O
received	VBD	O
24	CD	O
months	NNS	O
of	IN	O
1,200	CD	O
mg	NN	O
of	IN	O
calcium	NN	Pharmacological
and	CC	O
400	CD	O
IU	NNP	O
of	IN	O
vitamin	NNP	Pharmacological
D	NNP	Pharmacological
daily	RB	O
and	CC	O
35	CD	O
mg	NN	O
of	IN	O
risedronate	JJ	Pharmacological
weekly	JJ	O
,	,	O
and	CC	O
the	DT	O
exercise	NN	Physical
group	NN	O
additionally	RB	O
had	VBD	O
ST	NNP	Physical
exercises	NNS	Physical
twice	RB	O
weekly	RB	O
.	.	O

RESULTS	NNP	O
After	IN	O
24	CD	O
months	NNS	O
,	,	O
women	NNS	O
who	WP	O
took	VBD	O
medications	NNS	Physical
without	IN	Physical
exercising	VBG	Physical
had	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
BMD	NNP	O
at	IN	O
the	DT	O
total	JJ	O
hip	NN	O
(	(	O
+1.81	CD	O
%	NN	O
)	)	O
and	CC	O
spine	NN	O
(	(	O
+2.85	CD	O
%	NN	O
)	)	O
and	CC	O
significant	JJ	O
decreases	NNS	O
in	IN	O
Alkphase	NNP	O
B	NNP	O
(	(	O
-8.7	NNP	O
%	NN	O
)	)	O
and	CC	O
serum	JJ	O
NTx	NNP	O
(	(	O
-16.7	NNP	O
%	NN	O
)	)	O
.	.	O

Women	NNS	O
who	WP	O
also	RB	O
exercised	VBD	O
had	VBD	O
additional	JJ	O
increases	NNS	O
in	IN	O
BMD	NNP	O
at	IN	O
the	DT	O
femoral	JJ	O
neck	NN	O
(	(	O
+0.29	CD	O
%	NN	O
)	)	O
,	,	O
total	JJ	O
hip	NN	O
(	(	O
+0.34	CD	O
%	NN	O
)	)	O
,	,	O
spine	NN	O
(	(	O
+0.23	CD	O
%	NN	O
)	)	O
,	,	O
total	JJ	O
radius	NN	O
(	(	O
+0.30	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
additional	JJ	O
decreases	NNS	O
in	IN	O
Alkphase	NNP	O
B	NNP	O
(	(	O
-2.4	NNP	O
%	NN	O
)	)	O
and	CC	O
Serum	NNP	O
NTx	NNP	O
(	(	O
-6.5	NNP	O
%	NN	O
)	)	O
.	.	O

Additional	JJ	O
changes	NNS	O
in	IN	O
BMD	NNP	O
and	CC	O
bone	NN	O
turnover	NN	O
with	IN	O
exercise	NN	O
were	VBD	O
not	RB	O
significant	JJ	O
.	.	O

Subjects	NNS	O
who	WP	O
were	VBD	O
>	NNP	O
or	CC	O
=50	CD	O
%	NN	O
adherent	NN	O
to	TO	O
exercise	VB	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
lose	VB	O
BMD	NNP	O
at	IN	O
the	DT	O
total	JJ	O
hip	NN	O
(	(	O
chi-square	JJ	O
[	NN	O
1	CD	O
]	NNP	O
=	NNP	O
4.66	CD	O
,	,	O
p	NN	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
femoral	JJ	O
neck	NN	O
(	(	O
chi-square	JJ	O
[	NN	O
1	CD	O
]	NNP	O
=	NNP	O
4.63	CD	O
,	,	O
p	NN	O
=	NNP	O
0.03	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Strength/weight	NNP	O
training	NN	O
exercises	NNS	O
may	MD	O
prevent	VB	O
loss	NN	O
of	IN	O
BMD	NNP	O
in	IN	O
postmenopausal	NN	O
BCS	NNP	O
at	IN	O
risk	NN	O
for	IN	O
bone	NN	O
loss	NN	O
.	.	O

Helping	VBG	O
women	NNS	O
make	VBP	O
choices	NNS	O
about	IN	O
mammography	NN	O
screening	NN	O
:	:	O
an	DT	O
online	NN	O
randomized	VBN	O
trial	NN	O
of	IN	O
a	DT	O
decision	NN	O
aid	NN	O
for	IN	O
40-year-old	JJ	O
women	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
decision	NN	Educational
aid	NN	Educational
(	(	Educational
DA	NNP	Educational
)	)	Educational
on	IN	O
women	NNS	O
's	POS	O
knowledge	NN	O
of	IN	O
the	DT	O
benefits	NNS	O
and	CC	O
harms	NNS	O
of	IN	O
screening	VBG	O
and	CC	O
on	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
make	VB	O
an	DT	O
informed	JJ	O
decision	NN	O
.	.	O

METHODS	NNP	O
An	DT	O
online	NN	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
among	IN	O
321	CD	O
women	NNS	O
aged	VBN	O
38-45	CD	O
years	NNS	O
was	VBD	O
conducted	VBN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
immediate	JJ	Educational
or	CC	Educational
delayed	JJ	Educational
access	NN	Educational
to	TO	Educational
the	DT	Educational
online	NN	Educational
DA	NNP	Educational
which	WDT	O
(	(	O
i	NN	O
)	)	O
explained	VBD	O
the	DT	O
benefits	NNS	O
and	CC	O
harms	NNS	O
,	,	O
(	(	O
ii	NN	O
)	)	O
included	VBD	O
a	DT	O
values	NNS	O
clarification	NN	O
exercise	NN	O
and	CC	O
a	DT	O
worksheet	NN	O
to	TO	O
support	VB	O
decision	NN	O
making	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
,	,	O
knowledge	NN	O
of	IN	O
benefits	NNS	O
and	CC	O
harms	NNS	O
of	IN	O
screening	NN	O
,	,	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
,	,	O
informed	VBN	O
choice	NN	O
(	(	O
composite	JJ	O
of	IN	O
knowledge	NN	O
,	,	O
values	NNS	O
and	CC	O
intention	NN	O
)	)	O
,	,	O
anxiety	NN	O
and	CC	O
acceptability	NN	O
of	IN	O
the	DT	O
DA	NNP	O
were	VBD	O
measured	VBN	O
using	VBG	O
online	JJ	O
questionnaires	NNS	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
were	VBD	O
more	RBR	O
knowledgeable	JJ	O
(	(	O
mean	VB	O
score	NN	O
out	IN	O
of	IN	O
10	CD	O
,	,	O
7.35	CD	O
vs	NN	O
6.27	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
made	VBN	O
a	DT	O
decision	NN	O
(	(	O
82	CD	O
%	NN	O
vs	JJ	O
61	CD	O
%	NN	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Of	IN	O
those	DT	O
who	WP	O
made	VBD	O
a	DT	O
decision	NN	O
,	,	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
start	VB	O
screening	VBG	O
now	RB	O
(	(	O
52	CD	O
%	NN	O
vs	JJ	O
65	CD	O
%	NN	O
p=0.05	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
women	NNS	O
who	WP	O
made	VBD	O
an	DT	O
informed	JJ	O
choice	NN	O
(	(	O
71	CD	O
%	NN	O
intervention	NN	O
group	NN	O
vs	VBD	O
64	CD	O
%	NN	O
control	NN	Control
group	NN	O
,	,	O
p=0.24	NN	O
)	)	O
.	.	O

The	DT	O
DA	NNP	O
was	VBD	O
helpful	JJ	O
,	,	O
balanced	JJ	O
and	CC	O
clear	JJ	O
,	,	O
and	CC	O
did	VBD	O
not	RB	O
make	VB	O
women	NNS	O
anxious	JJ	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
DA	NNP	O
increased	VBD	O
knowledge	NN	O
and	CC	O
reduced	JJ	O
indecision	NN	O
,	,	O
without	IN	O
increasing	VBG	O
feelings	NNS	O
of	IN	O
anxiety	NN	O
.	.	O

PRACTICE	NNP	O
IMPLICATIONS	NNP	O
This	DT	O
decision	NN	O
aid	NN	O
is	VBZ	O
easy	JJ	O
to	TO	O
access	NN	O
online	NN	O
and	CC	O
could	MD	O
be	VB	O
an	DT	O
inexpensive	JJ	O
way	NN	O
of	IN	O
supporting	VBG	O
women	NNS	O
aged	VBN	O
40	CD	O
who	WP	O
are	VBP	O
considering	VBG	O
whether	IN	O
to	TO	O
start	VB	O
screening	VBG	O
now	RB	O
,	,	O
or	CC	O
wait	VBP	O
until	IN	O
they	PRP	O
are	VBP	O
50	CD	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
demonstrate	VB	O
the	DT	O
potential	NN	O
of	IN	O
DAs	NNP	O
to	TO	O
help	VB	O
inform	VB	O
women	NNS	O
about	IN	O
both	DT	O
the	DT	O
benefits	NNS	O
and	CC	O
risks	NNS	O
of	IN	O
screening	VBG	O
at	IN	O
this	DT	O
age	NN	O
and	CC	O
to	TO	O
support	VB	O
women	NNS	O
and	CC	O
clinicians	NNS	O
in	IN	O
this	DT	O
decision	NN	O
making	VBG	O
process	NN	O
.	.	O

Effects	NNS	O
of	IN	O
omeprazole	NN	Pharmacological
and	CC	O
amoxycillin	NN	Pharmacological
on	IN	O
the	DT	O
human	JJ	O
oral	JJ	O
and	CC	O
gastrointestinal	JJ	O
microflora	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
Helicobacter	NNP	O
pylori	JJ	O
infection	NN	O
.	.	O

Fourteen	JJ	O
patients	NNS	O
with	IN	O
Helicobacter	NNP	O
pylori	FW	O
infection	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
omeprazole	JJ	Pharmacological
capsules	NNS	O
20	CD	O
mg	NNS	O
and	CC	O
amoxycillin	NN	Pharmacological
capsules	NNS	O
1000	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
and	CC	O
14	CD	O
patients	NNS	O
with	IN	O
omeprazole	JJ	Pharmacological
capsules	NNS	O
20	CD	O
mg	NNS	O
and	CC	O
placebo	VB	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
.	.	O

Samples	NNS	O
from	IN	O
saliva	NN	O
,	,	O
dental	JJ	O
plaque	NN	O
and	CC	O
faeces	NNS	O
and	CC	O
biopsies	NNS	O
from	IN	O
antrum	NN	O
and	CC	O
corpus	NN	O
were	VBD	O
analysed	VBN	O
in	IN	O
order	NN	O
to	TO	O
determine	VB	O
the	DT	O
ecological	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
normal	JJ	O
microflora	NN	O
.	.	O

Several	JJ	O
microorganisms	NNS	O
were	VBD	O
affected	VBN	O
by	IN	O
both	DT	O
treatment	NN	O
regimens	NNS	O
.	.	O

Two	CD	O
patients	NNS	O
were	VBD	O
colonised	VBN	O
with	IN	O
enterobacteria	NNS	O
in	IN	O
the	DT	O
oral	JJ	O
cavity	NN	O
and	CC	O
stomach	NN	O
during	IN	O
the	DT	O
omeprazole	JJ	Pharmacological
plus	CC	Pharmacological
amoxycillin	JJ	Pharmacological
treatment	NN	O
.	.	O

A	DT	O
general	JJ	O
increase	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
microorganisms	NNS	O
from	IN	O
gastric	JJ	O
mucosa	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

A	DT	O
selection	NN	O
of	IN	O
resistant	JJ	O
enterobacteria	NN	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
beta-lactamase	JJ	O
production	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
faecal	JJ	O
samples	NNS	O
during	IN	O
the	DT	O
omeprazole	JJ	Pharmacological
plus	CC	Pharmacological
amoxycillin	JJ	Pharmacological
treatment	NN	O
.	.	O

Eradication	NN	O
of	IN	O
H.	NNP	O
pylori	NN	O
in	IN	O
the	DT	O
omeprazole-amoxycillin	JJ	Pharmacological
group	NN	O
was	VBD	O
50	CD	O
%	NN	O
and	CC	O
in	IN	O
the	DT	O
omeprazole	JJ	O
placebo	NN	O
group	NN	O
0	CD	O
%	NN	O
four	CD	O
weeks	NNS	O
after	IN	O
treatment	NN	O
.	.	O

No	DT	O
viable	JJ	O
H.	NNP	O
pylori	NN	O
were	VBD	O
cultivated	VBN	O
in	IN	O
the	DT	O
saliva	NN	O
,	,	O
dental	JJ	O
plaque	NN	O
or	CC	O
faecal	JJ	O
samples	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
omeprazole	JJ	O
20	CD	O
mg	NN	O
and	CC	O
amoxycillin	NN	O
1000	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
altered	VBD	O
the	DT	O
normal	JJ	O
microflora	NN	O
in	IN	O
the	DT	O
oral	JJ	O
,	,	O
gastric	JJ	O
and	CC	O
intestinal	JJ	O
tract	NN	O
and	CC	O
antibiotic	JJ	O
resistant	JJ	O
microorganisms	NNS	O
increased	VBD	O
in	IN	O
numbers	NNS	O
in	IN	O
the	DT	O
intestinal	JJ	O
microflora	NN	O
.	.	O

[	JJ	O
Comparison	NNP	O
of	IN	O
two	CD	O
methods	NNS	O
of	IN	O
local	JJ	Pharmacological
anaesthesia	NN	Pharmacological
prior	RB	O
to	TO	O
transrectal	VB	O
ultrasound-guided	JJ	O
prostate	NN	O
biopsies	NNS	O
]	VBP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
rectal	JJ	O
administration	NN	O
of	IN	O
Lidoca?ne	NNP	O
gel	NN	O
with	IN	O
Lidoca?ne	NNP	O
periprostatic	JJ	O
infiltration	NN	O
prior	RB	O
to	TO	O
transrectal	VB	O
ultrasound-guided	JJ	O
prostate	NN	O
biopsies	NNS	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
July	NNP	O
2002	CD	O
and	CC	O
July	NNP	O
2003	CD	O
,	,	O
candidates	NNS	O
to	TO	O
prostate	VB	O
biopsies	NNS	O
were	VBD	O
randomised	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
group	NN	O
1	CD	O
,	,	O
15	CD	O
ml	VBD	O
2	CD	O
%	NN	O
Lidoca?ne	NNP	O
gel	NN	O
was	VBD	O
administered	VBN	O
intra-rectally	RB	O
10	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
biopsies	NNS	O
and	CC	O
patients	NNS	O
included	VBD	O
in	IN	O
group	NN	O
2	CD	O
received	VBD	O
10	CD	O
ml	NN	O
of	IN	O
1	CD	O
%	NN	O
Lidoca?ne	NNP	O
in	IN	O
two	CD	O
p?riprostatique	JJ	O
equivalent	JJ	O
injections	NNS	O
,	,	O
4	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
prostate	VB	O
biopsies	NNS	O
.	.	O

Pain	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
Visual	JJ	O
Analog	NNP	O
Scale	NNP	O
,	,	O
during	IN	O
anaesthesia	NN	O
(	(	O
VAS	NNP	O
1	CD	O
)	)	O
,	,	O
during	IN	O
the	DT	O
biopsies	NNS	O
procedure	NN	O
(	(	O
VAS	NNP	O
2	CD	O
)	)	O
and	CC	O
30	CD	O
minutes	NNS	O
after	IN	O
them	PRP	O
(	(	O
VAS	NNP	O
3	CD	O
)	)	O
.	.	O

RESULTS	$	O
308	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
trial	NN	O
with	IN	O
156	CD	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
152	CD	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

Group	NNP	O
1	CD	O
experienced	VBD	O
statistically	RB	O
less	JJR	O
pain	NN	O
for	IN	O
VAS	NNP	O
1	CD	O
(	(	O
0.1	CD	O
versus	NN	O
1.4	CD	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
VAS	$	O
3	CD	O
(	(	O
0.8	CD	O
versus	NN	O
1.4	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
but	CC	O
no	DT	O
significative	JJ	O
difference	NN	O
could	MD	O
be	VB	O
demonstrated	VBN	O
for	IN	O
VAS	NNP	O
2	CD	O
(	(	O
1.8	CD	O
versus	IN	O
2.0	CD	O
)	)	O
.	.	O

No	DT	O
major	JJ	O
complication	NN	O
was	VBD	O
noted	VBN	O
.	.	O

CONCLUSION	NNP	O
Rectal	NNP	O
administration	NN	O
of	IN	O
Lidoca?ne	NNP	O
gel	NN	O
and	CC	O
infiltration	NN	O
of	IN	O
Lidoca?ne	NNP	O
lead	NN	O
to	TO	O
a	DT	O
comparable	JJ	O
level	NN	O
of	IN	O
anaesthesia	NN	O
during	IN	O
prostatic	JJ	O
biopsies	NNS	O
procedure	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
Lidoca?ne	NNP	O
gel	NN	O
,	,	O
being	VBG	O
both	DT	O
safe	JJ	O
and	CC	O
simple	JJ	O
,	,	O
tends	VBZ	O
to	TO	O
maintain	VB	O
a	DT	O
better	JJR	O
comfort	NN	O
of	IN	O
the	DT	O
patient	NN	O
30	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
biopsies	NNS	O
.	.	O

Primary	JJ	Surgical
deep	JJ	Surgical
sclerectomy	NN	Surgical
versus	IN	O
primary	JJ	Surgical
deep	JJ	Surgical
sclerectomy	NN	Surgical
with	IN	Surgical
the	DT	Surgical
use	NN	Surgical
of	IN	Surgical
mitomycin	NN	Surgical
C	NNP	Surgical
in	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
prospectively	RB	O
study	VB	O
and	CC	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
the	DT	O
safety	NN	O
of	IN	O
primary	JJ	O
deep	JJ	O
sclerectomy	NN	O
with	IN	O
and	CC	O
without	IN	O
the	DT	O
use	NN	O
of	IN	O
mitomycin	NN	O
C	NNP	O
in	IN	O
eyes	NNS	O
with	IN	O
open-angle	JJ	O
glaucoma	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
90	CD	O
eyes	NNS	O
of	IN	O
90	CD	O
patients	NNS	O
with	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
or	CC	O
pseudoexfoliative	JJ	O
glaucoma	NN	O
underwent	JJ	O
deep	JJ	O
sclerectomy	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
enrolled	VBN	O
consecutively	RB	O
and	CC	O
assigned	VBD	O
randomly	RB	O
to	TO	O
undergo	VB	O
deep	JJ	Surgical
sclerectomy	NN	Surgical
without	IN	Surgical
the	DT	Surgical
use	NN	Surgical
of	IN	Surgical
mitomycin	NN	Surgical
C	NNP	Surgical
(	(	Surgical
DS	NNP	Surgical
group	NN	Surgical
)	)	Surgical
and	CC	O
deep	JJ	Surgical
sclerectomy	NN	Surgical
with	IN	Surgical
the	DT	Surgical
application	NN	Surgical
of	IN	Surgical
mitomycin	NN	Surgical
C	NNP	Surgical
(	(	Surgical
DSMMC	NNP	Surgical
group	NN	Surgical
)	)	Surgical
in	IN	O
a	DT	O
concentration	NN	O
of	IN	O
0.2	CD	O
mg/mL	NN	O
for	IN	O
2.5	CD	O
minutes	NNS	O
,	,	O
before	IN	O
the	DT	O
superficial	JJ	O
scleral	JJ	O
flap	NN	O
formation	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intraocular	JJ	O
pressure	NN	O
was	VBD	O
significantly	RB	O
decreased	VBN	O
by	IN	O
7.13	CD	O
mm	NNS	O
Hg	NNP	O
or	CC	O
27.59	CD	O
%	NN	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
and	CC	O
by	IN	O
11.68	CD	O
mm	NNS	O
Hg	NNP	O
or	CC	O
42.25	CD	O
%	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
intraocular	JJ	O
pressure	NN	O
reduction	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
complete	JJ	O
(	(	O
IOP	NNP	O
<	VBZ	O
22	CD	O
mm	NN	O
Hg	NNP	O
without	IN	O
medication	NN	O
)	)	O
and	CC	O
qualified	VBN	O
(	(	O
IOP	NNP	O
<	VBZ	O
22	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
or	CC	O
without	IN	O
medication	NN	O
)	)	O
success	NN	O
rates	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
were	VBD	O
42.5	CD	O
%	NN	O
and	CC	O
72.5	CD	O
%	NN	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
and	CC	O
50	CD	O
%	NN	O
and	CC	O
95	CD	O
%	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
.	.	O

The	DT	O
qualified	JJ	O
success	NN	O
rate	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
was	VBD	O
statistically	RB	O
significant	JJ	O
when	WRB	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
the	DT	O
DS	NNP	O
group	NN	O
.	.	O

Differences	NNS	O
in	IN	O
complications	NNS	O
(	(	O
choroidal	JJ	O
detachment	NN	O
,	,	O
hyphema	NN	O
,	,	O
leakage	NN	O
)	)	O
seen	VBN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
statistically	RB	O
nonsignificant	JJ	O
.	.	O

A	DT	O
hemorrhagic	JJ	O
detachment	NN	O
of	IN	O
the	DT	O
Descemet	NNP	O
membrane	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
one	CD	O
eye	NN	O
in	IN	O
the	DT	O
DSMMC	NNP	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
The	DT	O
use	NN	O
of	IN	O
intraoperative	JJ	O
mitomycin	NN	O
C	NNP	O
during	IN	O
deep	JJ	O
sclerectomy	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
postoperative	JJ	O
IOP	NNP	O
and	CC	O
increased	VBD	O
the	DT	O
success	NN	O
rate	NN	O
of	IN	O
the	DT	O
procedure	NN	O
.	.	O

General	NNP	Pharmacological
anaesthesia	NN	Pharmacological
for	IN	O
caesarean	JJ	O
section	NN	O
in	IN	O
severe	JJ	O
pre-eclampsia	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
renal	JJ	O
and	CC	O
hepatic	JJ	O
effects	NNS	O
of	IN	O
enflurane	NN	Pharmacological
and	CC	O
halothane	NN	Pharmacological
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
patients	NNS	O
undergoing	VBG	O
Caesarean	JJ	O
section	NN	O
,	,	O
either	CC	O
enflurane	NN	Pharmacological
(	(	O
mean	JJ	O
0.24	CD	O
MAC-h	NN	O
)	)	O
or	CC	O
halothane	NN	Pharmacological
(	(	O
mean	JJ	O
0.23	CD	O
MAC-h	NN	O
)	)	O
and	CC	O
50	CD	O
%	NN	O
nitrous	JJ	Pharmacological
oxide	NN	Pharmacological
in	IN	Pharmacological
oxygen	NN	Pharmacological
were	VBD	O
administered	VBN	O
to	TO	O
women	NNS	O
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
with	IN	O
severe	JJ	O
pre-eclampsia-eclampsia	NN	O
and	CC	O
to	TO	O
16	CD	O
healthy	JJ	O
pregnant	JJ	O
patients	NNS	O
with	IN	O
normal	JJ	O
renal	JJ	O
and	CC	O
hepatic	JJ	O
function	NN	O
.	.	O

No	DT	O
evidence	NN	O
of	IN	O
nephrotoxicity	NN	O
was	VBD	O
found	VBN	O
in	IN	O
any	DT	O
pre-eclamptic	JJ	O
or	CC	O
normal	JJ	O
patient	NN	O
.	.	O

Metabolism	NN	O
of	IN	O
enflurane	NN	Pharmacological
resulted	VBD	O
in	IN	O
plasma	NN	O
inorganic	JJ	O
fluoride	NN	O
concentrations	NNS	O
(	(	O
max	$	O
15	CD	O
mumol	NN	O
litre	NN	O
-1	NNP	O
)	)	O
which	WDT	O
were	VBD	O
well	RB	O
below	IN	O
the	DT	O
toxic	NN	O
value	NN	O
.	.	O

Postoperative	JJ	O
liver	NN	O
function	NN	O
tests	NNS	O
showed	VBD	O
no	DT	O
important	JJ	O
changes	NNS	O
from	IN	O
preoperative	JJ	O
values	NNS	O
,	,	O
although	IN	O
reductive	JJ	O
metabolites	NNS	O
of	IN	O
halothane	NN	Pharmacological
were	VBD	O
not	RB	O
measured	VBN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
pre-eclampsia	NN	O
there	EX	O
appears	VBZ	O
no	DT	O
contraindication	NN	O
to	TO	O
enflurane	VB	Pharmacological
or	CC	O
,	,	O
probably	RB	O
,	,	O
halothane	NN	Pharmacological
as	IN	O
volatile	JJ	O
supplements	NNS	O
during	IN	O
general	JJ	Pharmacological
anaesthesia	NN	Pharmacological
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
face	NN	Educational
expertise	NN	Educational
training	NN	Educational
on	IN	O
the	DT	O
behavioral	JJ	O
performance	NN	O
and	CC	O
brain	NN	O
activity	NN	O
of	IN	O
adults	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
expertise	NN	Educational
training	NN	Educational
with	IN	Educational
faces	VBZ	Educational
was	VBD	O
studied	VBN	O
in	IN	O
adults	NNS	O
with	IN	O
ASD	NNP	O
who	WP	O
showed	VBD	O
initial	JJ	O
impairment	NN	O
in	IN	O
face	NN	O
recognition	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
computerized	JJ	Educational
training	NN	Educational
program	NN	Educational
involving	VBG	Educational
either	CC	Educational
faces	VBZ	Educational
or	CC	Educational
houses	NNS	Educational
.	.	O

Pre-	JJ	O
and	CC	O
post-testing	NN	O
included	VBD	O
standardized	JJ	O
and	CC	O
experimental	JJ	O
measures	NNS	O
of	IN	O
behavior	NN	O
and	CC	O
event-related	JJ	O
brain	NN	O
potentials	NNS	O
(	(	O
ERPs	NNP	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
interviews	NNS	O
after	IN	O
training	NN	O
.	.	O

After	IN	O
training	NN	O
,	,	O
all	DT	O
participants	NNS	O
met	VBD	O
behavioral	JJ	O
criteria	NNS	O
for	IN	O
expertise	NN	O
with	IN	O
the	DT	O
specific	JJ	O
stimuli	NN	O
on	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
training	NN	O
.	.	O

Scores	NNS	O
on	IN	O
standardized	JJ	O
measures	NNS	O
improved	VBN	O
after	IN	O
training	VBG	O
for	IN	O
both	DT	O
groups	NNS	O
,	,	O
but	CC	O
only	RB	O
the	DT	O
face	NN	O
training	NN	O
group	NN	O
showed	VBD	O
an	DT	O
increased	JJ	O
face	NN	O
inversion	NN	O
effect	NN	O
behaviorally	RB	O
and	CC	O
electrophysiological	JJ	O
changes	NNS	O
to	TO	O
faces	VBZ	O
in	IN	O
the	DT	O
P100	NNP	O
component	NN	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
individuals	NNS	O
with	IN	O
ASD	NNP	O
can	MD	O
gain	VB	O
expertise	NN	O
in	IN	O
face	NN	O
processing	NN	O
through	IN	O
training	NN	Educational
.	.	O

Enteral	JJ	O
nutrition	NN	O
with	IN	O
eicosapentaenoic	JJ	Pharmacological
acid	NN	Pharmacological
,	,	Pharmacological
gamma-linolenic	JJ	Pharmacological
acid	NN	Pharmacological
,	,	O
and	CC	O
antioxidants	NNS	Pharmacological
reduces	NNS	O
alveolar	JJ	O
inflammatory	JJ	O
mediators	NNS	O
and	CC	O
protein	NN	O
influx	NN	O
in	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
.	.	O

OBJECTIVE	NNP	O
Previously	RB	O
,	,	O
we	PRP	O
showed	VBD	O
that	IN	O
acute	JJ	O
respiratory	NN	O
distress	JJ	O
syndrome	JJ	O
patients	NNS	O
fed	VBD	O
an	DT	O
enteral	JJ	O
diet	NN	O
containing	VBG	O
eicosapentaenoic	JJ	Pharmacological
acid	NN	Pharmacological
and	CC	O
gamma-linolenic	JJ	Pharmacological
acid	NN	Pharmacological
and	CC	O
elevated	JJ	O
antioxidants	NNS	Pharmacological
(	(	O
EPA+GLA	NNP	O
;	:	O
Oxepa	NNP	O
)	)	O
had	VBD	O
significantly	RB	O
reduced	VBN	O
pulmonary	JJ	O
inflammation	NN	O
,	,	O
increased	JJ	O
oxygenation	NN	O
,	,	O
and	CC	O
improved	JJ	O
clinical	JJ	O
outcomes	NNS	O
.	.	O

In	IN	O
a	DT	O
subset	NN	O
of	IN	O
acute	JJ	O
respiratory	NN	O
distress	JJ	O
syndrome	JJ	O
patients	NNS	O
from	IN	O
this	DT	O
trial	NN	O
,	,	O
we	PRP	O
performed	VBD	O
a	DT	O
preliminary	JJ	O
examination	NN	O
of	IN	O
the	DT	O
potential	JJ	O
mechanisms	NN	O
underlying	VBG	O
these	DT	O
clinical	JJ	O
improvements	NNS	O
by	IN	O
retrospectively	RB	O
testing	VBG	O
the	DT	O
hypothesis	NN	O
that	IN	O
enteral	JJ	O
feeding	VBG	O
with	IN	O
EPA+GLA	NNP	O
could	MD	O
reduce	VB	O
alveolar-capillary	JJ	O
membrane	NN	O
protein	NN	O
permeability	NN	O
and	CC	O
the	DT	O
production	NN	O
of	IN	O
interleukin	NN	O
(	(	O
IL	NNP	O
)	)	O
-8	NN	O
,	,	O
IL-6	NNP	O
,	,	O
tumor	NN	O
necrosis	NN	O
factor-alpha	NN	O
,	,	O
and	CC	O
leukotriene	JJ	O
B4	NNP	O
that	WDT	O
are	VBP	O
responsible	JJ	O
,	,	O
in	IN	O
part	NN	O
,	,	O
for	IN	O
pulmonary	JJ	O
inflammation	NN	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
double-blind	NN	O
,	,	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
Intensive	JJ	O
Care	NNP	O
Unit	NNP	O
of	IN	O
the	DT	O
Ohio	NNP	O
State	NNP	O
University	NNP	O
Medical	NNP	O
Center	NNP	O
.	.	O

PATIENTS	VB	O
A	DT	O
total	NN	O
of	IN	O
67	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
who	WP	O
met	VBD	O
defined	VBN	O
criteria	NNS	O
for	IN	O
acute	NN	O
lung	NN	O
injury/acute	NN	O
respiratory	NN	O
distress	JJ	O
syndrome	NN	O
.	.	O

INTERVENTIONS	VBZ	O
A	DT	O
total	NN	O
of	IN	O
43	CD	O
of	IN	O
67	CD	O
evaluable	JJ	O
patients	NNS	O
randomly	RB	O
received	VBD	O
either	CC	O
EPA+GLA	NNP	O
or	CC	O
an	DT	O
isonitrogenous	JJ	Pharmacological
,	,	O
isocaloric	JJ	O
standard	NN	O
diet	NN	O
that	WDT	O
was	VBD	O
tube	JJ	O
fed	VBN	O
at	IN	O
a	DT	O
minimum	JJ	O
caloric	JJ	O
delivery	NN	O
of	IN	O
75	CD	O
%	NN	O
of	IN	O
basal	NN	O
energy	NN	O
expenditure	NN	O
times	VBZ	O
1.33	CD	O
for	IN	O
at	IN	O
least	JJS	O
4	CD	O
to	TO	O
7	CD	O
days	NNS	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Bronchoalveolar	NNP	O
lavage	NN	O
(	(	O
BAL	NNP	O
)	)	O
was	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
study	NN	O
days	NNS	O
4	CD	O
and	CC	O
7	CD	O
to	TO	O
obtain	VB	O
BAL	NNP	O
fluid	NN	O
(	(	O
BALF	NNP	O
)	)	O
for	IN	O
measurement	NN	O
of	IN	O
total	JJ	O
protein	NN	O
,	,	O
ceruloplasmin	NN	O
,	,	O
and	CC	O
transferrin	NN	O
,	,	O
total	JJ	O
neutrophil	NN	O
count	NN	O
,	,	O
IL-8	NNP	O
,	,	O
IL-6	NNP	O
,	,	O
tumor	NN	O
necrosis	NN	O
factor-alpha	NN	O
,	,	O
and	CC	O
leukotriene	JJ	O
B4	NNP	O
.	.	O

Oxygenation	NNP	O
,	,	O
measured	VBD	O
as	IN	O
Pao2/Fio2	NNP	O
,	,	O
was	VBD	O
assessed	VBN	O
before	IN	O
BAL	NNP	O
.	.	O

Patients	NNS	O
fed	JJ	O
EPA+GLA	NNP	Pharmacological
had	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
BALF	NNP	O
ceruloplasmin	NN	O
and	CC	O
IL-8	NNP	O
during	IN	O
the	DT	O
study	NN	O
as	IN	O
compared	VBN	O
with	IN	O
patients	NNS	O
fed	VBP	O
the	DT	O
control	NN	O
diet	NN	O
.	.	O

BALF	NNP	O
levels	NNS	O
of	IN	O
total	JJ	O
protein	NN	O
,	,	O
neutrophils	NNS	O
,	,	O
and	CC	O
leukotriene	JJ	O
B4	NNP	O
tended	VBD	O
to	TO	O
decrease	VB	O
in	IN	O
EPA+GLA	NNP	O
patients	NNS	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
study	NN	O
as	IN	O
compared	VBN	O
with	IN	O
control	NN	O
patients	NNS	O
.	.	O

BALF	NNP	O
levels	NNS	O
of	IN	O
IL-6	NNP	O
declined	VBD	O
similarly	RB	O
during	IN	O
the	DT	O
study	NN	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

A	DT	O
trend	NN	O
toward	IN	O
a	DT	O
reduction	NN	O
in	IN	O
BALF	NNP	O
tumor	NN	O
necrosis	NN	O
factor-alpha	NN	O
was	VBD	O
observed	VBN	O
on	IN	O
study	NN	O
day	NN	O
7	CD	O
in	IN	O
the	DT	O
EPA+GLA	NNP	O
group	NN	O
as	IN	O
compared	VBN	O
with	IN	O
control	NN	O
patients	NNS	O
.	.	O

Significant	JJ	O
improvements	NNS	O
in	IN	O
oxygenation	NN	O
(	(	O
Pao2/Fio2	NNP	O
)	)	O
occurred	VBD	O
in	IN	O
EPA+GLA	NNP	O
patients	NNS	O
on	IN	O
study	NN	O
day	NN	O
4	CD	O
as	IN	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Correlation	NN	O
analysis	NN	O
revealed	VBD	O
significant	JJ	O
relationships	NNS	O
between	IN	O
BALF	NNP	O
neutrophil	JJ	O
counts	NNS	O
and	CC	O
indices	NNS	O
of	IN	O
alveolar-capillary	JJ	O
membrane	NN	O
protein	NN	O
permeability	NN	O
,	,	O
IL-8	NNP	O
,	,	O
and	CC	O
leukotriene	JJ	O
B4	NNP	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
preliminary	JJ	O
investigation	NN	O
showing	VBG	O
a	DT	O
decrease	NN	O
in	IN	O
BALF	NNP	O
levels	NNS	O
of	IN	O
IL-8	NNP	O
and	CC	O
leukotriene	JJ	O
B4	NNP	O
and	CC	O
the	DT	O
associated	JJ	O
reduction	NN	O
of	IN	O
BALF	NNP	O
neutrophils	NNS	O
and	CC	O
alveolar	JJ	O
membrane	NN	O
protein	NN	O
permeability	NN	O
in	IN	O
acute	JJ	O
respiratory	NN	O
distress	JJ	O
syndrome	JJ	O
patients	NNS	O
fed	VBP	O
EPA+GLA	NNP	O
support	NN	O
,	,	O
in	IN	O
part	NN	O
,	,	O
the	DT	O
potential	JJ	O
mechanisms	NN	O
underlying	VBG	O
the	DT	O
previously	RB	O
described	VBN	O
clinical	JJ	O
improvements	NNS	O
with	IN	O
this	DT	O
diet	NN	O
.	.	O

Additional	NNP	O
controlled	VBD	O
studies	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
confirm	VB	O
these	DT	O
findings	NNS	O
.	.	O

Naltrexone	NN	Pharmacological
in	IN	O
young	JJ	O
autistic	JJ	O
children	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
crossover	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
naltrexone	NN	Pharmacological
,	,	O
an	DT	O
opiate	NN	O
blocker	NN	O
,	,	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
autism	NN	O
.	.	O

METHOD	NNP	O
Thirteen	NNP	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
,	,	O
aged	VBD	O
3.4	CD	O
to	TO	O
8.3	CD	O
years	NNS	O
(	(	O
mean	VB	O
5.4	CD	O
)	)	O
,	,	O
were	VBD	O
studied	VBN	O
in	IN	O
home	NN	O
,	,	O
school	NN	O
,	,	O
and	CC	O
outpatient	JJ	O
laboratory	NN	O
.	.	O

Naltrexone	NNP	Pharmacological
,	,	Pharmacological
1.0	CD	Pharmacological
mg/kg	NN	Pharmacological
,	,	O
was	VBD	O
given	VBN	O
daily	RB	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Physical
crossover	NN	Physical
design	NN	Physical
.	.	O

Dependent	JJ	O
measures	NNS	O
included	VBD	O
parent	NN	O
and	CC	O
teacher	RB	O
Clinical	JJ	O
Global	NNP	O
Impressions	NNP	O
(	(	O
CGI	NNP	O
)	)	O
,	,	O
Conners	NNPS	O
Rating	NNP	O
Scales	NNP	O
,	,	O
and	CC	O
Naltrexone	NNP	O
Side-Effects	NNP	O
(	(	O
SE	NNP	O
)	)	O
Rating	NNP	O
Scale	NNP	O
;	:	O
laboratory	NN	O
CGI	NNP	O
,	,	O
movement	NN	O
actometer	NN	O
readings	NNS	O
,	,	O
and	CC	O
a	DT	O
10-second	JJ	O
interval	NN	O
recording	VBG	O
system	NN	O
analysis	NN	O
of	IN	O
on-task	NN	O
,	,	O
communication	NN	Educational
initiations	NNS	Educational
,	,	Educational
disruptive	JJ	Educational
behavior	NN	Educational
,	,	Educational
and	CC	Educational
self-stimulation	NN	Educational
.	.	O

RESULTS	NNP	O
Eight	NNP	O
of	IN	O
13	CD	O
subjects	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
or	CC	O
more	JJR	O
settings	NNS	O
.	.	O

Changes	NNS	O
in	IN	O
parent	NN	O
measures	NNS	O
(	(	O
CGI	NNP	O
,	,	O
Conners	NNP	O
Impulsivity-Hyperactivity	NNP	O
Factor	NNP	O
,	,	O
and	CC	O
SE-Restlessness	NNP	O
)	)	O
and	CC	O
Teacher	NNP	O
CGI	NNP	O
achieved	VBD	O
statistical	JJ	O
significance	NN	O
.	.	O

Teacher	CC	O
SE-Restlessness	JJ	O
and	CC	O
initiation	NN	O
of	IN	O
communication	NN	O
in	IN	O
the	DT	O
clinic	NN	O
showed	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
improvement	NN	O
.	.	O

Actometer	NNP	O
readings	NNS	O
improved	VBN	O
in	IN	O
two	CD	O
children	NNS	O
who	WP	O
were	VBD	O
very	RB	O
active	JJ	O
at	IN	O
baseline	NN	O
.	.	O

Adverse	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
behavioral	JJ	O
,	,	O
mild	JJ	O
,	,	O
and	CC	O
transient	NN	O
.	.	O

Administering	VBG	O
the	DT	O
bitter	JJ	O
tablet	NN	O
was	VBD	O
a	DT	O
challenge	NN	O
.	.	O

CONCLUSIONS	NNP	O
Naltrexone	NNP	Pharmacological
offers	VBZ	O
promise	RB	O
as	IN	O
an	DT	O
agent	NN	O
for	IN	O
modest	JJ	O
improvement	NN	O
of	IN	O
behavior	NN	O
and	CC	O
social	JJ	O
communication	NN	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Parent	NN	O
and	CC	O
teacher	NN	O
measures	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
in	IN	O
outpatient	JJ	O
trials	NNS	O
to	TO	O
evaluate	VB	O
change	NN	O
.	.	O

Short-term	NNP	Pharmacological
intravenous	JJ	Pharmacological
antibiotic	JJ	Pharmacological
treatment	NN	Pharmacological
of	IN	O
acute	JJ	O
hematogenous	JJ	O
bone	NN	O
and	CC	O
joint	JJ	O
infection	NN	O
in	IN	O
children	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

Thirty-three	JJ	O
cases	NNS	O
of	IN	O
acute	JJ	O
hematogenous	JJ	O
bone	NN	O
or	CC	O
joint	JJ	O
infection	NN	O
in	IN	O
children	NNS	O
were	VBD	O
randomly	RB	O
treated	VBN	O
with	IN	O
short-term	JJ	Physical
(	(	O
7	CD	O
days	NNS	O
for	IN	O
joint	JJ	O
infection	NN	O
,	,	O
10	CD	O
days	NNS	O
for	IN	O
bone	JJ	O
infection	NN	O
)	)	O
or	CC	O
long-term	JJ	Physical
(	(	O
14	CD	O
days	NNS	O
and	CC	O
21	CD	O
days	NNS	O
,	,	O
respectively	RB	O
)	)	O
intravenous	JJ	Pharmacological
antibiotics	NNS	Pharmacological
after	IN	O
surgical	JJ	Surgical
drainage	NN	Surgical
.	.	O

The	DT	O
treatment	NN	O
outcome	NN	O
was	VBD	O
measured	VBN	O
through	IN	O
a	DT	O
detailed	JJ	O
scoring	NN	O
system	NN	O
that	WDT	O
included	VBD	O
the	DT	O
ability	NN	O
to	TO	O
eradicate	VB	O
infection	NN	O
,	,	O
the	DT	O
functional	JJ	O
status	NN	O
of	IN	O
the	DT	O
limb	NN	O
,	,	O
and	CC	O
the	DT	O
radiographic	JJ	O
appearance	NN	O
of	IN	O
the	DT	O
bone	NN	O
and	CC	O
joint	NN	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
showing	VBG	O
the	DT	O
added	JJ	O
benefit	NN	O
of	IN	O
a	DT	O
shorter	JJR	O
hospital	NN	O
stay	NN	O
for	IN	O
children	NNS	O
with	IN	O
blood-borne	JJ	O
musculoskeletal	JJ	O
infection	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
this	DT	O
scoring	VBG	O
system	NN	O
in	IN	O
choosing	VBG	O
the	DT	O
route	NN	O
of	IN	O
antibiotic	JJ	Pharmacological
administration	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Midlife	NNP	O
women	NNS	O
online	NN	O
:	:	O
evaluation	NN	O
of	IN	O
an	DT	O
internet-based	JJ	O
program	NN	O
to	TO	O
prevent	VB	O
unintended	JJ	O
pregnancy	NN	O
&	CC	O
STIs	NNP	O
.	.	O

BACKGROUND	NNP	O
Midlife	NNP	O
women	NNS	O
are	VBP	O
an	DT	O
underserved	JJ	O
population	NN	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
unintended	JJ	O
pregnancy	NN	O
and	CC	O
STI	NNP	O
prevention	NN	O
yet	RB	O
remain	VBP	O
at	IN	O
risk	NN	O
for	IN	O
both	DT	O
health	NN	O
conditions	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	VBD	O
controlled	JJ	O
trial	NN	O
of	IN	O
an	DT	O
Internet-based	JJ	Educational
multimedia	NN	Educational
program	NN	Educational
to	TO	O
reduce	VB	O
risk	NN	O
of	IN	O
unintended	JJ	O
pregnancy	NN	O
and	CC	O
STIs	NNP	O
among	IN	O
midlife	JJ	O
women	NNS	O
was	VBD	O
conducted	VBN	O
with	IN	O
164	CD	O
women	NNS	O
ages	VBZ	O
40-55	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

RESULTS	NNP	O
Women	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
condition	NN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
condition	NN	O
reported	VBD	O
significant	JJ	O
gains	NNS	O
in	IN	O
attitudes	NNS	O
,	,	O
self-efficacy	NN	O
,	,	O
and	CC	O
behavioral	JJ	O
intentions	NNS	O
at	IN	O
posttest	JJS	O
.	.	O

CONCLUSION	NNP	O
Interventions	NNP	O
specifically	RB	O
targeted	VBD	O
to	TO	O
midlife	VB	O
women	NNS	O
can	MD	O
impact	VB	O
constructs	NNS	O
known	VBN	O
to	TO	O
reduce	VB	O
risk	NN	O
.	.	O

Implications	NNS	O
for	IN	O
future	JJ	O
research	NN	O
and	CC	O
intervention	NN	O
development	NN	O
are	VBP	O
presented	VBN	O
.	.	O

Effectiveness	NN	O
of	IN	O
education	NN	O
for	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
controlled	JJ	O
prospective	JJ	O
trial	NN	O
comparing	VBG	O
interactive	JJ	Educational
vs.	FW	Educational
lecture-based	JJ	Educational
programs	NNS	Educational
.	.	O

OBJECTIVE	CC	O
Although	IN	O
patient	JJ	Educational
education	NN	Educational
may	MD	O
enhance	VB	O
knowledge	NN	O
,	,	O
coping	VBG	O
with	IN	O
illness	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
among	IN	O
cancer	NN	O
patients	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
uncertain	JJ	O
which	WDT	O
didactic	JJ	O
method	NN	O
is	VBZ	O
most	RBS	O
effective	JJ	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
impact	NN	O
of	IN	O
an	DT	O
interactive	JJ	Educational
,	,	Educational
patient-oriented	JJ	Educational
group	NN	Educational
program	NN	Educational
to	TO	O
a	DT	O
lecture-based	JJ	Educational
,	,	Educational
information-only	JJ	Educational
program	NN	Educational
in	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
prospective	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
,	,	O
121	CD	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
attending	VBG	O
inpatient	JJ	O
rehabilitation	NN	O
after	IN	O
surgical	JJ	O
treatment	NN	O
received	VBD	O
either	CC	O
the	DT	O
interactive	JJ	Educational
intervention	NN	Educational
or	CC	Educational
lectures	VBZ	Educational
providing	VBG	Educational
information	NN	Educational
.	.	Educational

The	DT	O
outcomes	NNS	O
were	VBD	O
patients	NNS	O
'	POS	O
disease-related	JJ	O
knowledge	NN	O
,	,	O
active	JJ	O
coping	VBG	O
with	IN	O
illness	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
their	PRP$	O
stay	NN	O
and	CC	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
thereafter	RB	O
.	.	O

RESULTS	NNP	O
Both	NNP	O
groups	NNS	O
improved	VBD	O
their	PRP$	O
knowledge	NN	O
and	CC	O
QoL	NNP	O
during	IN	O
rehabilitation	NN	O
;	:	O
however	RB	O
,	,	O
knowledge	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
interactive	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
the	DT	O
lecture	NN	O
group	NN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
maintained	VBN	O
at	IN	O
the	DT	O
6-	JJ	O
and	CC	O
12-months	JJ	O
follow-ups	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
interactive	JJ	O
group	NN	O
proved	VBD	O
superior	JJ	O
to	TO	O
the	DT	O
lecture	NN	O
group	NN	O
regarding	VBG	O
active	JJ	O
coping	NN	O
with	IN	O
illness	NN	O
and	CC	O
QoL	NNP	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
rehabilitation	NN	O
,	,	O
but	CC	O
not	RB	O
during	IN	O
follow-up	JJ	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
structured	JJ	O
,	,	O
interactive	JJ	O
patient	JJ	O
education	NN	O
program	NN	O
proved	VBD	O
superior	JJ	O
to	TO	O
lecture-based	JJ	O
provision	NN	O
of	IN	O
information	NN	O
in	IN	O
regards	NNS	O
to	TO	O
short-term	JJ	O
and	CC	O
long-term	JJ	O
knowledge	NN	O
as	RB	O
well	RB	O
as	IN	O
short-term	JJ	O
coping	NN	O
and	CC	O
QoL	NNP	O
.	.	O

PRACTICE	NNP	O
IMPLICATIONS	NNP	O
In	IN	O
gastric	JJ	O
cancer	NN	O
patients	NNS	O
,	,	O
interactive	JJ	Educational
patient	NN	Educational
education	NN	Educational
seems	VBZ	O
preferable	JJ	O
over	IN	O
lectures	NNS	O
.	.	O

Association	NNP	O
of	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
disease	NN	O
with	IN	O
increased	JJ	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
knee	JJ	O
osteoarthritis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
association	NN	O
between	IN	O
severity	NN	O
of	IN	O
coexisting	VBG	O
patellofemoral	JJ	O
(	(	O
PF	NNP	O
)	)	O
disease	NN	O
with	IN	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
tibiofemoral	JJ	O
(	(	O
TF	NNP	O
)	)	O
osteoarthritis	NN	O
(	(	O
OA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Radiographic	NNP	Physical
views	NNS	Physical
of	IN	O
the	DT	O
TF	NNP	O
and	CC	O
PF	NNP	O
compartments	NNS	O
,	,	O
knee	VB	Physical
extension	NN	Physical
strength	NN	Physical
,	,	O
and	CC	O
knee	VB	Physical
range	NN	Physical
of	IN	Physical
motion	NN	Physical
were	VBD	O
obtained	VBN	O
for	IN	O
167	CD	O
patients	NNS	O
with	IN	O
knee	JJ	O
OA	NNP	O
.	.	O

Additionally	RB	O
,	,	O
knee-specific	JJ	O
symptoms	NNS	O
and	CC	O
functional	JJ	O
limitations	NNS	O
were	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
Western	NNP	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
Osteoarthritis	NNP	O
Index	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
and	CC	O
the	DT	O
Activities	NNS	O
of	IN	O
Daily	NNP	O
Living	NNP	O
Scale	NNP	O
(	(	O
ADLS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Moderate/severe	NNP	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
lower	JJR	O
knee	NN	O
extension	NN	O
strength	NN	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.4	CD	O
?	.	O
0.5	CD	O
Nm/body	NN	O
weight	VBD	O
[	NNP	O
BW	NNP	O
]	NNP	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
1.8	CD	O
?	.	O
0.5	CD	O
Nm/BW	NNP	O
)	)	O
.	.	O

Additionally	RB	O
,	,	O
total	JJ	O
knee	NN	O
range	NN	O
of	IN	O
motion	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
for	IN	O
patients	NNS	O
with	IN	O
moderate/severe	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
120.8?	CD	O
?	.	O
14.4?	CD	O
)	)	O
compared	VBN	O
to	TO	O
no	DT	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
133.5?	CD	O
?	.	O
10.7?	CD	O
)	)	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
(	(	O
mean	VB	O
?	.	O
SD	NNP	O
125.8?	CD	O
?	.	O
13.0?	CD	O
)	)	O
.	.	O

Moderate/severe	NNP	O
PFOA	NNP	O
and	CC	O
mild	JJ	O
PFOA	NNP	O
were	VBD	O
also	RB	O
associated	VBN	O
with	IN	O
less	JJR	O
pain	NN	O
while	IN	O
standing	VBG	O
(	(	O
odds	NNS	O
ratio	VBP	O
[	CD	O
OR	NNP	O
]	$	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
]	NNP	O
0.1-0.7	JJ	O
and	CC	O
OR	NNP	O
0.2	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.1-0.6	CD	O
,	,	O
respectively	RB	O
)	)	O
on	IN	O
the	DT	O
WOMAC	NNP	O
,	,	O
and	CC	O
moderate/severe	RB	O
PFOA	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
greater	JJR	O
difficulty	NN	O
with	IN	O
going	VBG	O
downstairs	NNS	O
(	(	O
OR	NNP	O
2.9	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
1.0-8.1	CD	O
)	)	O
on	IN	O
the	DT	O
ADLS	NNP	O
.	.	O

CONCLUSION	VB	O
It	PRP	O
appears	VBZ	O
that	IN	O
knees	NNS	O
with	IN	O
more	RBR	O
severe	JJ	O
coexisting	VBG	O
PF	NNP	O
disease	NN	O
demonstrate	NN	O
features	NNS	O
distinct	VBP	O
from	IN	O
those	DT	O
observed	VBN	O
in	IN	O
TFOA	NNP	O
in	IN	O
isolation	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
mild	JJ	O
PF	NNP	O
disease	NN	O
.	.	O

Treatment	NNP	O
strategies	VBZ	O
targeting	VBG	O
the	DT	O
PF	NNP	O
joint	NN	O
may	MD	O
be	VB	O
warranted	VBN	O
to	TO	O
mitigate	VB	O
the	DT	O
specific	JJ	O
lower	JJR	O
extremity	NN	O
impairments	NNS	O
and	CC	O
functional	JJ	O
problems	NNS	O
present	JJ	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

Providing	VBG	O
live	JJ	Other
supervision	NN	Other
via	IN	Other
teleconferencing	VBG	Other
improves	JJ	O
acquisition	NN	O
of	IN	O
motivational	JJ	O
interviewing	NN	O
skills	NNS	O
after	IN	O
workshop	NN	O
attendance	NN	O
.	.	O

Teleconferencing	VBG	Other
Supervision	NNP	Other
is	VBZ	O
a	DT	O
method	NN	O
for	IN	O
training	VBG	O
community-based	JJ	O
substance	NN	O
abuse	NN	O
clinicians	NNS	O
in	IN	O
Motivational	NNP	Educational
Interviewing	NNP	Educational
(	(	Educational
MI	NNP	Educational
)	)	Educational
.	.	O

Following	VBG	O
a	DT	O
2-day	JJ	O
workshop	NN	O
,	,	O
13	CD	O
clinicians	NNS	O
received	VBD	O
live	JJ	Other
supervision	NN	Other
via	IN	Other
telephone	NN	Other
during	IN	O
5	CD	O
counseling	VBG	O
sessions	NNS	O
conducted	VBN	O
at	IN	O
their	PRP$	O
community	NN	O
treatment	NN	O
facilities	NNS	O
.	.	O

Clinicians	NNPS	O
were	VBD	O
assessed	VBN	O
for	IN	O
skill	JJ	O
level	NN	O
at	IN	O
post-workshop	NN	O
,	,	O
at	IN	O
post-training	NN	O
,	,	O
and	CC	O
3	CD	O
months	NNS	O
later	RB	O
;	:	O
learning	VBG	O
was	VBD	O
assessed	VBN	O
using	VBG	O
the	DT	O
MI	NNP	O
Treatment	NNP	O
Integrity	NNP	O
instrument	NN	O
.	.	O

All	DT	O
summary	JJ	O
scores	NNS	O
and	CC	O
therapist	JJ	O
behavior	NN	O
frequency	NN	O
counts	NNS	O
improved	VBN	O
by	IN	O
post-training	NN	O
or	CC	O
by	IN	O
the	DT	O
3	CD	O
month	NN	O
follow-up	RB	O
,	,	O
although	IN	O
some	DT	O
gains	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Teleconferencing	VBG	Other
Supervision	NN	Other
may	MD	O
help	VB	O
facilitate	VB	O
the	DT	O
proficient	NN	O
use	NN	O
of	IN	O
MI	NNP	O
community	NN	O
clinicians	NNS	O
following	VBG	O
workshop	NN	O
instruction	NN	O
.	.	O

Non-verbal	JJ	Educational
communication	NN	Educational
of	IN	Educational
compassion	NN	Educational
:	:	O
measuring	NN	O
psychophysiologic	JJ	O
effects	NNS	O
.	.	O

BACKGROUND	NNP	O
Calm	NNP	O
,	,	O
compassionate	NN	O
clinicians	NNS	O
comfort	VBP	O
others	NNS	O
.	.	O

To	TO	O
evaluate	VB	O
the	DT	O
direct	JJ	O
psychophysiologic	JJ	O
benefits	NNS	O
of	IN	O
non-verbal	JJ	Educational
communication	NN	Educational
of	IN	Educational
compassion	NN	Educational
(	(	Educational
NVCC	NNP	Educational
)	)	Educational
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
minimize	VB	O
the	DT	O
effect	NN	O
of	IN	O
subjects	NNS	O
'	POS	O
expectation	NN	O
.	.	O

This	DT	O
preliminary	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
a	DT	O
)	)	O
test	NN	O
the	DT	O
feasibility	NN	O
of	IN	O
two	CD	O
strategies	NNS	O
for	IN	O
maintaining	VBG	O
subject	JJ	O
blinding	VBG	O
to	TO	O
non-verbal	JJ	Educational
communication	NN	Educational
of	IN	Educational
compassion	NN	Educational
(	(	Educational
NVCC	NNP	Educational
)	)	Educational
,	,	O
and	CC	O
b	NN	O
)	)	O
determine	NN	O
whether	IN	O
blinded	JJ	O
subjects	NNS	O
would	MD	O
experience	VB	O
psychophysiologic	JJ	O
effects	NNS	O
from	IN	O
NVCC	NNP	O
.	.	O

METHODS	NNP	O
Subjects	NNPS	O
were	VBD	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
were	VBD	O
told	VBN	O
the	DT	O
study	NN	O
was	VBD	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
time	NN	O
and	CC	O
touch	NN	O
on	IN	O
the	DT	O
autonomic	JJ	O
nervous	JJ	O
system	NN	O
.	.	O

The	DT	O
practitioner	NN	O
had	VBD	O
more	JJR	O
than	IN	O
10	CD	O
years	NNS	O
'	POS	O
experience	NN	O
with	IN	O
loving-kindness	JJ	Educational
meditation	NN	Educational
(	(	O
LKM	NNP	O
)	)	O
,	,	O
a	DT	O
form	NN	O
of	IN	O
NVCC	NNP	Educational
.	.	O

Subjects	NNS	O
completed	VBD	O
10-point	JJ	O
visual	JJ	O
analog	NN	O
scales	NNS	O
(	(	O
VAS	NNP	O
)	)	O
for	IN	O
stress	NN	O
,	,	O
relaxation	NN	O
,	,	O
and	CC	O
peacefulness	NN	O
before	IN	O
and	CC	O
after	IN	O
LKM	NNP	O
.	.	O

To	TO	O
assess	VB	O
physiologic	JJ	O
effects	NNS	O
,	,	O
practitioners	NNS	O
and	CC	O
subjects	NNS	O
wore	VBP	O
cardiorespiratory	JJ	O
monitors	NNS	O
to	TO	O
assess	VB	O
respiratory	JJ	O
rate	NN	O
(	(	O
RR	NNP	O
)	)	O
,	,	O
heart	NN	O
rate	NN	O
(	(	O
HR	NNP	O
)	)	O
and	CC	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
throughout	IN	O
the	DT	O
4	CD	O
10-minute	JJ	O
study	NN	O
periods	NNS	O
:	:	O
Baseline	NNP	O
(	(	O
both	DT	O
practitioner	NN	Educational
and	CC	Educational
subjects	NNS	Educational
read	VBP	Educational
neutral	JJ	Educational
material	NN	Educational
)	)	Educational
;	:	O
non-tactile-LKM	JJ	O
(	(	O
subjects	NNS	Educational
read	VBP	Educational
while	IN	Educational
the	DT	Educational
practitioner	NN	Educational
practiced	VBD	Educational
LKM	NNP	Educational
while	IN	Educational
pretending	VBG	Educational
to	TO	Educational
read	VB	Educational
)	)	O
;	:	O
tactile-LKM	JJ	O
(	(	O
subjects	NNS	Educational
rested	VBN	Educational
while	IN	Educational
the	DT	Educational
practitioner	NN	Educational
practiced	VBD	Educational
LKM	NNP	Educational
while	IN	Educational
lightly	RB	Educational
touching	VBG	Educational
the	DT	Educational
subject	NN	Educational
on	IN	Educational
arms	NNS	Educational
,	,	Educational
shoulders	NNS	Educational
,	,	Educational
hands	NNS	Educational
,	,	Educational
feet	NNS	Educational
,	,	Educational
and	CC	Educational
legs	NNS	Educational
)	)	O
;	:	O
Post-Intervention	JJ	O
Rest	NNP	O
(	(	O
subjects	NNS	Educational
rested	VBN	Educational
;	:	Educational
the	DT	Educational
practitioner	NN	Educational
read	NN	Educational
)	)	O
.	.	O

To	TO	O
assess	VB	O
blinding	NN	O
,	,	O
subjects	NNS	O
were	VBD	O
asked	VBN	O
after	IN	O
the	DT	O
interventions	NNS	O
what	WP	O
the	DT	O
practitioner	NN	O
was	VBD	O
doing	VBG	O
during	IN	O
each	DT	O
period	NN	O
(	(	O
reading	NN	O
,	,	O
touch	NN	O
,	,	O
or	CC	O
something	NN	O
else	RB	O
)	)	O
.	.	O

RESULTS	JJ	O
Subjects	NNPS	O
'	POS	O
mean	JJ	O
age	NN	O
was	VBD	O
43.6	CD	O
years	NNS	O
;	:	O
all	DT	O
were	VBD	O
women	NNS	O
.	.	O

Blinding	NNP	O
was	VBD	O
maintained	VBN	O
and	CC	O
the	DT	O
practitioner	NN	O
was	VBD	O
able	JJ	O
to	TO	O
maintain	VB	O
meditation	NN	O
for	IN	O
both	DT	O
tactile	JJ	O
and	CC	O
non-tactile	JJ	O
LKM	NNP	O
interventions	NNS	O
as	IN	O
reflected	VBN	O
in	IN	O
significantly	RB	O
reduced	VBN	O
RR	NNP	O
.	.	O

Despite	IN	O
blinding	NN	O
,	,	O
subjects	NNS	O
'	POS	O
VAS	NNP	O
scores	NNS	O
improved	VBN	O
from	IN	O
baseline	NN	O
to	TO	O
post-intervention	NN	O
for	IN	O
stress	NN	O
(	(	O
5.5	CD	O
vs.	FW	O
2.2	CD	O
)	)	O
,	,	O
relaxation	NN	O
(	(	O
3.8	CD	O
vs.	FW	O
8.8	CD	O
)	)	O
and	CC	O
peacefulness	NN	O
(	(	O
3.8	CD	O
vs.	FW	O
9.0	CD	O
,	,	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
all	DT	O
comparisons	NNS	O
)	)	O
.	.	O

Subjects	NNS	O
also	RB	O
had	VBD	O
significant	JJ	O
reductions	NNS	O
in	IN	O
RR	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
improved	VBN	O
HRV	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
both	DT	O
tactile	JJ	O
and	CC	O
non-tactile	JJ	O
LKM	NNP	O
.	.	O

CONCLUSION	NNP	O
It	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
test	VB	O
the	DT	O
effects	NNS	O
of	IN	O
LKM	NNP	O
with	IN	O
tactile	JJ	O
and	CC	O
non-tactile	JJ	O
blinding	NN	O
strategies	NNS	O
;	:	O
even	RB	O
with	IN	O
blinding	VBG	O
in	IN	O
this	DT	O
small	JJ	O
preliminary	JJ	O
study	NN	O
,	,	O
subjects	NNS	O
reported	VBD	O
significant	JJ	O
improvements	NNS	O
in	IN	O
well-being	NN	O
which	WDT	O
were	VBD	O
reflected	VBN	O
in	IN	O
objective	JJ	O
physiologic	JJ	O
measures	NNS	O
of	IN	O
autonomic	JJ	O
activity	NN	O
.	.	O

Extending	VBG	O
compassion	NN	O
is	VBZ	O
not	RB	O
only	RB	O
good	JJ	O
care	NN	O
;	:	O
it	PRP	O
may	MD	O
also	RB	O
be	VB	O
good	JJ	O
medicine	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NUMBER	NNP	O
US	NNP	O
National	NNP	O
ClinicalTrials.gov	NNP	O
registration	NN	O
number	NN	O
,	,	O
NCT01428674	NNP	O
.	.	O

Endurance	NN	O
training	NN	O
has	VBZ	O
little	JJ	O
effect	NN	O
on	IN	O
active	JJ	O
muscle	NN	O
free	JJ	O
fatty	NN	O
acid	NN	O
,	,	O
lipoprotein	FW	O
cholesterol	NN	O
,	,	O
or	CC	O
triglyceride	JJ	O
net	JJ	O
balances	NNS	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
net	JJ	O
leg	NN	O
total	JJ	O
FFA	NNP	O
,	,	O
LDL-C	NNP	O
,	,	O
and	CC	O
TG	NNP	O
uptake	JJ	O
and	CC	O
HDL-C	JJ	O
release	NN	O
during	IN	O
moderate-intensity	NN	O
cycling	NN	O
exercise	NN	O
would	MD	O
be	VB	O
increased	VBN	O
following	VBG	O
endurance	NN	O
training	NN	O
.	.	O

Eight	NNP	O
sedentary	JJ	O
men	NNS	O
(	(	O
26	CD	O
+/-	JJ	O
1	CD	O
yr	NN	O
,	,	O
77.4	CD	O
+/-	JJ	O
3.7	CD	O
kg	NN	O
)	)	O
were	VBD	O
studied	VBN	O
in	IN	O
the	DT	O
postprandial	JJ	O
state	NN	O
during	IN	O
90	CD	O
min	NNS	O
of	IN	O
rest	NN	O
and	CC	O
60	CD	O
min	NN	O
of	IN	O
exercise	NN	O
twice	NN	O
before	IN	O
(	(	O
45	CD	O
%	NN	O
and	CC	O
65	CD	O
%	NN	O
V	NNP	O
(	(	O
O2	NNP	O
peak	NN	O
)	)	O
)	)	O
and	CC	O
twice	RB	O
after	IN	O
9	CD	O
wk	NN	O
of	IN	O
endurance	NN	Physical
training	NN	Physical
(	(	O
55	CD	O
%	NN	O
and	CC	O
65	CD	O
%	NN	O
posttraining	VBG	O
V	NNP	O
(	(	O
O2	NNP	O
peak	NN	O
)	)	O
)	)	O
.	.	O

Measurements	NNS	O
across	IN	O
an	DT	O
exercising	VBG	O
leg	NN	O
were	VBD	O
taken	VBN	O
to	TO	O
be	VB	O
a	DT	O
surrogate	NN	O
for	IN	O
active	JJ	O
skeletal	JJ	O
muscle	NN	O
.	.	O

To	TO	O
determine	VB	O
limb	NN	O
lipid	JJ	O
exchange	NN	O
,	,	O
femoral	JJ	O
arterial	NN	O
and	CC	O
venous	JJ	O
blood	NN	O
samples	NNS	O
drawn	VBP	O
simultaneously	RB	O
at	IN	O
rest	NN	O
and	CC	O
during	IN	O
exercise	NN	O
were	VBD	O
analyzed	VBN	O
for	IN	O
total	JJ	O
and	CC	O
individual	JJ	O
FFA	NNP	O
(	(	O
e.g.	NN	O
,	,	O
palmitate	NN	O
,	,	O
oleate	NN	O
)	)	O
,	,	O
LDL-C	NNP	O
,	,	O
HDL-C	NNP	O
,	,	O
and	CC	O
TG	NNP	O
concentrations	NNS	O
,	,	O
and	CC	O
limb	NN	O
blood	NN	O
flow	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
thermodilution	NN	O
.	.	O

The	DT	O
transition	NN	O
from	IN	O
rest	NN	O
to	TO	O
exercise	VB	O
resulted	VBN	O
in	IN	O
a	DT	O
shift	NN	O
from	IN	O
net	JJ	O
leg	NN	O
total	JJ	O
FFA	NNP	O
release	NN	O
(	(	O
-44	JJ	O
+/-	JJ	O
16	CD	O
micromol/min	NN	O
)	)	O
to	TO	O
uptake	VB	O
(	(	O
193	CD	O
+/-	JJ	O
49	CD	O
micromol/min	NN	O
)	)	O
that	WDT	O
was	VBD	O
unaffected	VBN	O
by	IN	O
either	DT	O
exercise	NN	O
intensity	NN	O
or	CC	O
endurance	NN	O
training	NN	O
.	.	O

The	DT	O
relative	JJ	O
net	NN	O
leg	NN	O
release	NN	O
and	CC	O
uptake	NN	O
of	IN	O
individual	JJ	O
FFA	NNP	O
closely	RB	O
resembled	VBD	O
their	PRP$	O
relative	JJ	O
abundances	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
with	IN	O
approximately	RB	O
21	CD	O
and	CC	O
41	CD	O
%	NN	O
of	IN	O
net	JJ	O
leg	NN	O
total	JJ	O
FFA	NNP	O
uptake	NN	O
during	IN	O
exercise	NN	O
accounted	VBN	O
for	IN	O
by	IN	O
palmitate	NN	O
and	CC	O
oleate	NN	O
,	,	O
respectively	RB	O
.	.	O

Endurance	NNP	Physical
training	NN	Physical
resulted	VBD	O
in	IN	O
significant	JJ	O
changes	NNS	O
in	IN	O
arterial	JJ	O
concentrations	NNS	O
of	IN	O
HDL-C	NNP	O
(	(	O
49	CD	O
+/-	JJ	O
5	CD	O
vs.	FW	O
52	CD	O
+/-	JJ	O
5	CD	O
mg/dl	NN	O
,	,	O
pre	NN	O
vs.	FW	O
post	NN	O
)	)	O
and	CC	O
LDL-C	NNP	O
(	(	O
82	CD	O
+/-	JJ	O
9	CD	O
vs.	FW	O
76	CD	O
+/-	JJ	O
9	CD	O
mg/dl	NN	O
,	,	O
pre	NN	O
vs.	FW	O
post	NN	O
)	)	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
net	JJ	O
TG	NN	O
or	CC	O
LDL-C	JJ	O
uptake	NN	O
or	CC	O
HDL-C	JJ	O
release	NN	O
across	IN	O
the	DT	O
resting	NN	O
or	CC	O
active	JJ	O
leg	NN	O
before	IN	O
or	CC	O
after	IN	O
endurance	JJ	O
training	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
endurance	NN	O
training	NN	O
favorably	RB	O
affects	VBZ	O
blood	NN	O
lipoprotein	NN	O
profiles	NNS	O
,	,	O
even	RB	O
in	IN	O
young	JJ	O
,	,	O
healthy	JJ	O
normolipidemic	JJ	O
men	NNS	O
,	,	O
but	CC	O
muscle	NN	O
contractions	NNS	O
per	IN	O
se	NN	O
have	VBP	O
little	JJ	O
effect	NN	O
on	IN	O
net	JJ	O
leg	NN	O
LDL-C	NNP	O
,	,	O
or	CC	O
TG	NNP	O
uptake	VBP	O
or	CC	O
HDL-C	JJ	O
release	NN	O
during	IN	O
moderate-intensity	NN	O
cycling	NN	O
exercise	NN	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
favorable	JJ	O
effects	NNS	O
of	IN	O
physical	JJ	O
activity	NN	O
on	IN	O
the	DT	O
lipid	JJ	O
profiles	NNS	O
of	IN	O
young	JJ	O
,	,	O
healthy	JJ	O
normolipidemic	JJ	O
men	NNS	O
in	IN	O
the	DT	O
postprandial	JJ	O
state	NN	O
are	VBP	O
not	RB	O
attributable	JJ	O
to	TO	O
changes	NNS	O
in	IN	O
HDL-C	NNP	O
or	CC	O
LDL-C	NNP	O
exchange	NN	O
across	IN	O
active	JJ	O
skeletal	JJ	O
muscle	NN	O
.	.	O

Social	JJ	O
robots	NNS	O
as	IN	O
embedded	JJ	O
reinforcers	NNS	O
of	IN	O
social	JJ	O
behavior	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
we	PRP	O
examined	VBD	O
the	DT	O
social	JJ	O
behaviors	NNS	O
of	IN	O
4-	JJ	O
to	TO	O
12-year-old	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
;	:	O
N	NNP	O
=	NNP	O
24	CD	O
)	)	O
during	IN	O
three	CD	O
tradic	JJ	O
interactions	NNS	O
with	IN	O
an	DT	O
adult	NN	O
confederate	NN	O
and	CC	O
an	DT	O
interaction	NN	O
partner	NN	O
,	,	O
where	WRB	O
the	DT	O
interaction	NN	O
partner	NN	O
varied	VBD	O
randomly	RB	O
among	IN	O
(	(	O
1	CD	O
)	)	O
another	DT	O
adult	NN	O
human	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
a	DT	O
touchscreen	JJ	O
computer	NN	O
game	NN	O
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
a	DT	O
social	JJ	O
dinosaur	NN	O
robot	NN	O
.	.	O

Children	NNP	O
spoke	VBD	O
more	RBR	O
in	IN	O
general	JJ	O
,	,	O
and	CC	O
directed	VBD	O
more	JJR	O
speech	NN	O
to	TO	O
the	DT	O
adult	NN	O
confederate	NN	O
,	,	O
when	WRB	O
the	DT	O
interaction	NN	O
partner	NN	O
was	VBD	O
a	DT	O
robot	NN	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
human	NN	O
or	CC	O
computer	NN	O
game	NN	O
interaction	NN	O
partner	NN	O
.	.	O

Children	NNP	O
spoke	VBD	O
as	RB	O
much	JJ	O
to	TO	O
the	DT	O
robot	NN	O
as	IN	O
to	TO	O
the	DT	O
adult	NN	O
interaction	NN	O
partner	NN	O
.	.	O

This	DT	O
study	NN	O
provides	VBZ	O
the	DT	O
largest	JJS	O
demonstration	NN	O
of	IN	O
social	JJ	O
human-robot	JJ	O
interaction	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
to	TO	O
date	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
social	JJ	O
robots	NNS	O
may	MD	O
be	VB	O
developed	VBN	O
into	IN	O
useful	JJ	O
tools	NNS	O
for	IN	O
social	JJ	O
skills	NNS	O
and	CC	O
communication	NN	O
therapies	NNS	O
,	,	O
specifically	RB	O
by	IN	O
embedding	VBG	O
social	JJ	O
interaction	NN	O
into	IN	O
intrinsic	JJ	O
reinforcers	NNS	O
and	CC	O
motivators	NNS	O
.	.	O

Gamma-hydroxybutyric	JJ	Pharmacological
acid	NN	Pharmacological
versus	NN	O
clomethiazole	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcohol	NN	O
withdrawal	NN	O
syndrome	NN	O
in	IN	O
a	DT	O
medical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
:	:	O
an	DT	O
open	JJ	O
,	,	O
single-center	JJ	O
randomized	VBN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Clomethiazole	NNP	Pharmacological
(	(	Pharmacological
CLO	NNP	Pharmacological
)	)	Pharmacological
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
treating	VBG	O
alcohol	NN	O
withdrawal	NN	O
syndrome	NN	O
(	(	O
AWS	NNP	O
)	)	O
.	.	O

Gamma-Hydroxybutyric	JJ	Pharmacological
acid	NN	Pharmacological
(	(	Pharmacological
GHB	NNP	Pharmacological
)	)	Pharmacological
has	VBZ	O
also	RB	O
been	VBN	O
introduced	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
alcoholic	JJ	O
patients	NNS	O
and	CC	O
is	VBZ	O
effective	JJ	O
in	IN	O
surgical	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
ICU	NNP	O
)	)	O
patients	NNS	O
in	IN	O
preventing	VBG	O
and	CC	O
treating	VBG	O
AWS	NNP	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
comparative	JJ	O
studies	NNS	O
between	IN	O
CLO	NNP	Pharmacological
and	CC	O
GHB	NNP	Pharmacological
in	IN	O
a	DT	O
medical	JJ	O
ICU	NNP	O
setting	NN	O
.	.	O

METHODS	NNP	O
Twenty-six	NNP	O
alcoholic	JJ	O
patients	NNS	O
with	IN	O
severe	JJ	O
AWS	NNP	O
and	CC	O
concomitant	JJ	O
medical	JJ	O
diseases	NNS	O
were	VBD	O
randomally	RB	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

CLO	NNP	Pharmacological
was	VBD	O
given	VBN	O
orally	RB	O
to	TO	O
12	CD	O
patients	NNS	O
in	IN	O
a	DT	O
dosage	NN	O
of	IN	O
250	CD	O
mg	NN	O
every	DT	O
4	CD	O
hours	NNS	O
as	IN	O
a	DT	O
liquid	NN	O
;	:	O
GHB	NNP	Pharmacological
(	(	O
initially	RB	O
30	CD	O
mg/kg	NNS	O
body	NN	O
weight	NN	O
(	(	O
BW	NNP	O
)	)	O
followed	VBN	O
by	IN	O
15	CD	O
mg/kg	NNS	O
BW	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
intravenously	RB	O
to	TO	O
14	CD	O
patients	NNS	O
.	.	O

Four	CD	O
major	JJ	O
AWS	NNP	O
symptoms	NNS	O
(	(	O
tremor	NN	O
,	,	O
sweating	VBG	O
,	,	O
nausea	NN	O
,	,	O
restlessness	NN	O
)	)	O
were	VBD	O
scored	VBN	O
,	,	O
and	CC	O
the	DT	O
administration	NN	O
of	IN	O
additional	JJ	O
medication	NN	O
was	VBD	O
registered	VBN	O
.	.	O

RESULTS	NNP	O
GHB	NNP	Pharmacological
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
treating	VBG	O
AWS	NNP	O
symptoms	NNS	O
.	.	O

In	IN	O
the	DT	O
GHB	NNP	Pharmacological
group	NN	O
,	,	O
AWS	NNP	O
score	NN	O
dropped	VBD	O
from	IN	O
6.6	CD	O
+/-	JJ	O
2.6	CD	O
to	TO	O
1.8	CD	O
+/-	JJ	O
2.1	CD	O
(	(	O
p	JJ	O
<	NNP	O
.01	NNP	O
)	)	O
,	,	O
while	IN	O
in	IN	O
the	DT	O
CLO	NNP	Pharmacological
group	NN	O
,	,	O
the	DT	O
score	NN	O
dropped	VBD	O
from	IN	O
6	CD	O
+/-	JJ	O
2.5	CD	O
to	TO	O
4.1	CD	O
+/-	JJ	O
2.4	CD	O
(	(	O
n.	JJ	O
s.	NN	O
)	)	O
.	.	O

Differences	NNS	O
between	IN	O
groups	NNS	O
were	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
=.021	NN	O
,	,	O
two-way	JJ	O
ANOVA	NNP	O
)	)	O
.	.	O

The	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
alter	VB	O
outcome	NN	O
or	CC	O
the	DT	O
duration	NN	O
of	IN	O
ICU	NNP	O
stay	NN	O
.	.	O

No	DT	O
serious	JJ	O
side	NN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
.	.	O

CONCLUSION	NNP	O
GHB	NNP	Pharmacological
effectively	RB	O
controls	VBZ	O
AWS	NNP	O
symptoms	NNS	O
in	IN	O
medical	JJ	O
ICU	NNP	O
patients	NNS	O
.	.	O

The	DT	O
rapid	JJ	O
initial	JJ	O
treatment	NN	O
response	NN	O
of	IN	O
GHB	NNP	O
in	IN	O
contrast	NN	O
to	TO	O
CLO	NNP	Pharmacological
has	VBZ	O
no	DT	O
influence	NN	O
on	IN	O
duration	NN	O
of	IN	O
patient	NN	O
withdrawal	NN	O
.	.	O

Zolmitriptan	NNP	Pharmacological
(	(	Pharmacological
311C90	CD	Pharmacological
)	)	Pharmacological
does	VBZ	O
not	RB	O
interact	VB	O
with	IN	O
fluoxetine	NN	Pharmacological
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

Zolmitriptan	NNP	Pharmacological
(	(	Pharmacological
Zomig	NNP	Pharmacological
,	,	Pharmacological
formerly	RB	Pharmacological
311C90	CD	Pharmacological
)	)	Pharmacological
is	VBZ	O
a	DT	O
selective	JJ	Pharmacological
5-hydroxytryptamine	JJ	Pharmacological
(	(	Pharmacological
5-HT	JJ	Pharmacological
)	)	Pharmacological
1B/1D-receptor	JJ	Pharmacological
agonist	NN	Pharmacological
with	IN	O
central	JJ	O
and	CC	O
peripheral	JJ	O
activity	NN	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
crossover	NN	O
study	NN	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
fluoxetine	JJ	Pharmacological
administration	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
zolmitriptan	NN	Pharmacological
.	.	O

Twenty	CD	O
volunteers	NNS	O
were	VBD	O
given	VBN	O
single	JJ	O
doses	NNS	O
of	IN	O
fluoxetine	JJ	Pharmacological
20	CD	Pharmacological
mg	NN	Pharmacological
or	CC	O
an	DT	O
identical	JJ	O
placebo	NN	Control
daily	RB	O
for	IN	O
28	CD	O
days	NNS	O
prior	RB	O
to	TO	O
receiving	VBG	O
a	DT	O
single	JJ	O
10	CD	O
mg	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
zolmitriptan	NN	Pharmacological
.	.	O

Sixteen	JJ	O
volunteers	NNS	O
completed	VBD	O
the	DT	O
two	CD	O
treatment	NN	O
phases	NNS	O
.	.	O

The	DT	O
pharmacokinetic	JJ	O
parameters	NNS	O
of	IN	O
zolmitriptan	NN	Pharmacological
and	CC	O
its	PRP$	O
metabolites	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
affected	VBN	O
by	IN	O
fluoxetine	JJ	Pharmacological
pretreatment	NN	O
.	.	O

The	DT	O
pharmacodynamic	JJ	O
effects	NNS	O
of	IN	O
zolmitriptan	NN	Pharmacological
were	VBD	O
also	RB	O
unaffected	VBN	O
by	IN	O
fluoxetine	JJ	Pharmacological
pretreatment	NN	O
.	.	O

There	EX	O
were	VBD	O
small	JJ	O
,	,	O
clinically	RB	O
insignificant	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
following	VBG	O
zolmitriptan	NN	Pharmacological
which	WDT	O
were	VBD	O
unaltered	VBN	O
by	IN	O
fluoxetine	NN	Pharmacological
.	.	O

Zolmitriptan	NNP	Pharmacological
was	VBD	O
well	RB	O
tolerated	VBN	O
when	WRB	O
given	VBN	O
alone	RB	O
or	CC	O
concomitantly	RB	O
with	IN	O
fluoxetine	NN	Pharmacological
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
there	EX	O
is	VBZ	O
no	DT	O
contraindication	NN	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
zolmitriptan	NN	Pharmacological
in	IN	O
patients	NNS	O
treated	VBN	O
concurrently	RB	O
with	IN	O
selective	JJ	Pharmacological
serotonin	NNS	Pharmacological
reuptake	VBP	Pharmacological
inhibitors	NNS	Pharmacological
and	CC	O
that	IN	O
no	DT	O
adjustment	NN	O
of	IN	O
the	DT	O
zolmitriptan	NN	Pharmacological
dose	NN	O
is	VBZ	O
required	VBN	O
in	IN	O
these	DT	O
circumstances	NNS	O
.	.	O

Triple	JJ	Pharmacological
antiretroviral	JJ	Pharmacological
compared	VBN	O
with	IN	O
zidovudine	NN	Pharmacological
and	CC	O
single-dose	JJ	O
nevirapine	JJ	Pharmacological
prophylaxis	NN	Pharmacological
during	IN	O
pregnancy	NN	O
and	CC	O
breastfeeding	NN	O
for	IN	O
prevention	NN	O
of	IN	O
mother-to-child	JJ	O
transmission	NN	O
of	IN	O
HIV-1	NNP	O
(	(	O
Kesho	NNP	O
Bora	NNP	O
study	NN	O
)	)	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Breastfeeding	NNP	O
is	VBZ	O
essential	JJ	O
for	IN	O
child	JJ	O
health	NN	O
and	CC	O
development	NN	O
in	IN	O
low-resource	JJ	O
settings	NNS	O
but	CC	O
carries	VBZ	O
a	DT	O
significant	JJ	O
risk	NN	O
of	IN	O
transmission	NN	O
of	IN	O
HIV-1	NNP	O
,	,	O
especially	RB	O
in	IN	O
late	JJ	O
stages	NNS	O
of	IN	O
maternal	JJ	O
disease	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
triple	JJ	O
antiretroviral	JJ	O
compared	VBN	O
with	IN	O
zidovudine	NN	O
and	CC	O
single-dose	JJ	O
nevirapine	NN	O
prophylaxis	NN	O
in	IN	O
pregnant	JJ	O
women	NNS	O
infected	VBN	O
with	IN	O
HIV	NNP	O
.	.	O

METHODS	NNP	O
Pregnant	NNP	O
women	NNS	O
with	IN	O
WHO	NNP	O
stage	VBP	O
1	CD	O
,	,	O
2	CD	O
,	,	O
or	CC	O
3	CD	O
HIV-1	JJ	O
infection	NN	O
who	WP	O
had	VBD	O
CD4	NNP	O
cell	NN	O
counts	NNS	O
of	IN	O
200-500	JJ	O
cells	NNS	O
per	IN	O
?L	NN	O
were	VBD	O
enrolled	VBN	O
at	IN	O
five	CD	O
study	NN	O
sites	NNS	O
in	IN	O
Burkina	NNP	O
Faso	NNP	O
,	,	O
Kenya	NNP	O
,	,	O
and	CC	O
South	NNP	O
Africa	NNP	O
to	TO	O
start	VB	O
study	VB	O
treatment	NN	O
at	IN	O
28-36	JJ	O
weeks	NNS	O
'	POS	O
gestation	NN	O
.	.	O

Women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
(	(	O
1:1	CD	O
)	)	O
by	IN	O
a	DT	O
computer	NN	O
generated	VBD	O
random	JJ	O
sequence	NN	O
to	TO	O
either	DT	O
triple	JJ	O
antiretroviral	JJ	O
prophylaxis	NN	O
(	(	O
a	DT	O
combination	NN	O
of	IN	O
300	CD	O
mg	NNS	O
zidovudine	NN	O
,	,	O
150	CD	O
mg	NN	O
lamivudine	NN	O
,	,	O
and	CC	O
400	CD	O
mg	NN	O
lopinavir	NN	O
plus	CC	O
100	CD	O
mg	NN	O
ritonavir	NN	O
twice	RB	O
daily	RB	O
until	IN	O
cessation	NN	O
of	IN	O
breastfeeding	VBG	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
6?5	CD	O
months	NNS	O
post	RB	O
partum	VBP	O
)	)	O
or	CC	O
zidovudine	NN	O
and	CC	O
single-dose	JJ	O
nevirapine	NN	O
(	(	O
300	CD	O
mg	NN	O
zidovudine	NN	O
twice	RB	O
daily	RB	O
until	IN	O
delivery	NN	O
and	CC	O
a	DT	O
dose	NN	O
of	IN	O
600	CD	O
mg	NNS	O
zidovudine	JJ	O
plus	CC	O
200	CD	O
mg	JJ	O
nevirapine	NN	O
at	IN	O
the	DT	O
onset	NN	O
of	IN	O
labour	NN	O
and	CC	O
,	,	O
after	IN	O
a	DT	O
protocol	NN	O
amendment	NN	O
in	IN	O
December	NNP	O
,	,	O
2006	CD	O
,	,	O
1	CD	O
week	NN	O
post-partum	JJ	O
zidovudine	NN	O
300	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
and	CC	O
lamivudine	VB	O
150	CD	O
mg	JJ	O
twice	RB	O
daily	RB	O
)	)	O
.	.	O

All	DT	O
infants	NNS	O
received	VBD	O
a	DT	O
0?6	CD	O
mL	NN	O
dose	NN	O
of	IN	O
nevirapine	NN	O
at	IN	O
birth	NN	O
and	CC	O
,	,	O
from	IN	O
December	NNP	O
,	,	O
2006	CD	O
,	,	O
4	CD	O
mg/kg	NN	O
twice	RB	O
daily	RB	O
of	IN	O
zidovudine	NN	O
for	IN	O
1	CD	O
week	NN	O
after	IN	O
birth	NN	O
.	.	O

Patients	NNS	O
and	CC	O
investigators	NNS	O
were	VBD	O
not	RB	O
masked	VBN	O
to	TO	O
treatment	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoints	NNS	O
were	VBD	O
HIV-free	JJ	O
infant	JJ	O
survival	NN	O
at	IN	O
6	CD	O
weeks	NNS	O
and	CC	O
12	CD	O
months	NNS	O
;	:	O
HIV-free	NNP	O
survival	NN	O
at	IN	O
12	CD	O
months	NNS	O
in	IN	O
infants	NNS	O
who	WP	O
were	VBD	O
ever	RB	O
breastfed	VBN	O
;	:	O
AIDS-free	JJ	O
survival	NN	O
in	IN	O
mothers	NNS	O
at	IN	O
18	CD	O
months	NNS	O
;	:	O
and	CC	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
mothers	NNS	O
and	CC	O
babies	NNS	O
.	.	O

Analysis	NN	O
was	VBD	O
by	IN	O
intention	NN	O
to	TO	O
treat	VB	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
,	,	O
ISRCTN71468401	NNP	O
.	.	O

FINDINGS	NNP	O
From	IN	O
June	NNP	O
,	,	O
2005	CD	O
,	,	O
to	TO	O
August	NNP	O
,	,	O
2008	CD	O
,	,	O
882	CD	O
women	NNS	O
were	VBD	O
enrolled	VBN	O
,	,	O
824	CD	O
of	IN	O
whom	WP	O
were	VBD	O
randomised	VBN	O
and	CC	O
gave	VBD	O
birth	NN	O
to	TO	O
805	CD	O
singleton	NN	O
or	CC	O
first	JJ	O
,	,	O
liveborn	JJ	O
infants	NNS	O
.	.	O

The	DT	O
cumulative	JJ	O
rate	NN	O
of	IN	O
HIV	NNP	O
transmission	NN	O
at	IN	O
6	CD	O
weeks	NNS	O
was	VBD	O
3?3	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
1?9-5?6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
triple	JJ	O
antiretroviral	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
5?0	CD	O
%	NN	O
(	(	O
3?3-7?7	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
zidovudine	NN	O
and	CC	O
single-dose	JJ	O
nevirapine	NN	O
group	NN	O
,	,	O
and	CC	O
at	IN	O
12	CD	O
months	NNS	O
was	VBD	O
5?4	CD	O
%	NN	O
(	(	O
3?6-8?1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
triple	JJ	O
antiretroviral	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
9?5	CD	O
%	NN	O
(	(	O
7?0-12?9	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
zidovudine	NN	O
and	CC	O
single-dose	JJ	O
nevirapine	NN	O
group	NN	O
(	(	O
p=0?029	NN	O
)	)	O
.	.	O

The	DT	O
cumulative	JJ	O
rate	NN	O
of	IN	O
HIV	NNP	O
transmission	NN	O
or	CC	O
death	NN	O
at	IN	O
12	CD	O
months	NNS	O
was	VBD	O
10?2	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
7?6-13?6	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
triple	JJ	O
antiretroviral	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
16?0	CD	O
%	NN	O
(	(	O
12?7-20?0	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
zidovudine	NN	O
and	CC	O
single-dose	JJ	O
nevirapine	NN	O
group	NN	O
(	(	O
p=0?017	NN	O
)	)	O
.	.	O

In	IN	O
infants	NNS	O
whose	WP$	O
mothers	NNS	O
declared	VBD	O
they	PRP	O
intended	VBD	O
to	TO	O
breastfeed	VB	O
,	,	O
the	DT	O
cumulative	JJ	O
rate	NN	O
of	IN	O
HIV	NNP	O
transmission	NN	O
at	IN	O
12	CD	O
months	NNS	O
was	VBD	O
5?6	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
3?4-8?9	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
triple	JJ	O
antiretroviral	JJ	O
group	NN	O
compared	VBN	O
with	IN	O
10?7	CD	O
%	NN	O
(	(	O
7?6-14?8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
zidovudine	NN	O
and	CC	O
single-dose	JJ	O
nevirapine	NN	O
group	NN	O
(	(	O
p=0?02	NN	O
)	)	O
.	.	O

AIDS-free	JJ	O
survival	NN	O
in	IN	O
mothers	NNS	O
at	IN	O
18	CD	O
months	NNS	O
will	MD	O
be	VB	O
reported	VBN	O
in	IN	O
a	DT	O
different	JJ	O
publication	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
laboratory	NN	O
and	CC	O
clinical	JJ	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
in	IN	O
both	DT	O
mothers	NNS	O
and	CC	O
their	PRP$	O
babies	NNS	O
was	VBD	O
similar	JJ	O
between	IN	O
groups	NNS	O
.	.	O

INTERPRETATION	NNP	O
Triple	NNP	O
antiretroviral	JJ	O
prophylaxis	NN	O
during	IN	O
pregnancy	NN	O
and	CC	O
breastfeeding	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
reduces	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
HIV	NNP	O
transmission	NN	O
to	TO	O
infants	NNS	O
.	.	O

Revised	VBN	O
WHO	WP	O
guidelines	NNS	O
now	RB	O
recommend	VBP	O
antiretroviral	JJ	O
prophylaxis	NN	O
(	(	O
either	DT	O
to	TO	O
the	DT	O
mother	NN	O
or	CC	O
to	TO	O
the	DT	O
baby	NN	O
)	)	O
during	IN	O
breastfeeding	VBG	O
if	IN	O
the	DT	O
mother	NN	O
is	VBZ	O
not	RB	O
already	RB	O
receiving	VBG	O
antiretroviral	JJ	O
treatment	NN	O
for	IN	O
her	PRP$	O
own	JJ	O
health	NN	O
.	.	O

FUNDING	NN	O
Agence	NNP	O
nationale	NN	O
de	IN	O
recherches	NNS	O
sur	VBP	O
le	JJ	O
sida	NN	O
et	NN	O
les	VBZ	O
h?patites	NNS	O
virales	NNS	O
,	,	O
Department	NNP	O
for	IN	O
International	NNP	O
Development	NNP	O
,	,	O
European	NNP	O
and	CC	O
Developing	NNP	O
Countries	NNP	O
Clinical	NNP	O
Trials	NNP	O
Partnership	NNP	O
,	,	O
Thrasher	NNP	O
Research	NNP	O
Fund	NNP	O
,	,	O
Belgian	JJ	O
Directorate	NNP	O
General	NNP	O
for	IN	O
International	NNP	O
Cooperation	NNP	O
,	,	O
Centers	NNPS	O
for	IN	O
Disease	NNP	O
Control	NNP	O
and	CC	O
Prevention	NNP	O
,	,	O
Eunice	NNP	O
Kennedy	NNP	O
Shriver	NNP	O
National	NNP	O
Institute	NNP	O
of	IN	O
Child	NNP	O
Health	NNP	O
and	CC	O
Human	NNP	O
Development	NNP	O
,	,	O
and	CC	O
UNDP/UNFPA/World	NNP	O
Bank/WHO	NNP	O
Special	NNP	O
Programme	NNP	O
of	IN	O
Research	NNP	O
,	,	O
Development	NNP	O
and	CC	O
Research	NNP	O
Training	NNP	O
in	IN	O
Human	NNP	O
Reproduction	NNP	O
.	.	O

Chemotherapy	NNP	O
of	IN	O
advanced	JJ	O
gastric	JJ	O
carcinoma	NN	O
(	(	O
stage	JJ	O
IV	NNP	O
)	)	O
:	:	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
FAM	NNP	Pharmacological
versus	IN	O
5-FU	JJ	Pharmacological
plus	JJ	Pharmacological
BCNU	NNP	Pharmacological
.	.	O

Forty-six	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
gastric	JJ	O
carcinoma	NN	O
(	(	O
Stage	NNP	O
IV	NNP	O
)	)	O
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
comparison	NN	O
of	IN	O
two	CD	O
chemotherapy	NN	Pharmacological
regimens	NNS	O
(	(	O
FAM	NNP	Pharmacological
versus	IN	O
5-FU	JJ	Pharmacological
plus	CC	Pharmacological
BCNU	NNP	Pharmacological
)	)	Pharmacological
to	TO	O
identify	VB	O
therapeutic	JJ	O
activity	NN	O
.	.	O

Treatment	NN	O
groups	NNS	O
were	VBD	O
well	RB	O
balanced	VBN	O
with	IN	O
respect	NN	O
to	TO	O
known	VBN	O
prognostic	JJ	O
factors	NNS	O
.	.	O

Thirty-three	JJ	O
patients	NNS	O
had	VBD	O
measurable	JJ	O
disease	NN	O
and	CC	O
thirteen	NN	O
had	VBD	O
only	RB	O
microscopic	JJ	O
residual	JJ	O
disease	NN	O
in	IN	O
the	DT	O
resection	NN	O
margins	NNS	O
.	.	O

The	DT	O
overall	JJ	O
median	JJ	O
survival	NN	O
of	IN	O
the	DT	O
entire	JJ	O
group	NN	O
was	VBD	O
13.2	CD	O
months	NNS	O
.	.	O

Two	CD	O
(	(	O
6	CD	O
%	NN	O
)	)	O
patients	NNS	O
with	IN	O
measurable	JJ	O
disease	NN	O
reached	VBD	O
complete	JJ	O
response	NN	O
(	(	O
CR	NNP	O
)	)	O
,	,	O
1	CD	O
(	(	O
3	CD	O
%	NN	O
)	)	O
partial	JJ	O
response	NN	O
(	(	O
PR	NNP	O
)	)	O
,	,	O
12	CD	O
(	(	O
36	CD	O
%	NN	O
)	)	O
had	VBD	O
stable	JJ	O
disease	NN	O
(	(	O
SD	NNP	O
)	)	O
and	CC	O
18	CD	O
(	(	O
56	CD	O
%	NN	O
)	)	O
had	VBD	O
progressive	JJ	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
.	.	O

The	DT	O
responders	NNS	O
had	VBD	O
not	RB	O
reached	VBN	O
the	DT	O
median	JJ	O
survival	NN	O
yet	RB	O
,	,	O
the	DT	O
patients	NNS	O
with	IN	O
SD	NNP	O
had	VBD	O
a	DT	O
median	JJ	O
survival	NN	O
of	IN	O
14.7	CD	O
months	NNS	O
and	CC	O
the	DT	O
PD	NNP	O
9.5	CD	O
months	NNS	O
.	.	O

In	IN	O
the	DT	O
FAM	NNP	Pharmacological
arm	NN	O
there	EX	O
were	VBD	O
3	CD	O
(	(	O
18	CD	O
%	NN	O
)	)	O
responders	NNS	O
(	(	O
2	CD	O
CR	NNP	O
and	CC	O
1	CD	O
PR	NNP	O
)	)	O
,	,	O
7	CD	O
(	(	O
41	CD	O
%	NN	O
)	)	O
SD	NNP	O
and	CC	O
7	CD	O
(	(	O
41	CD	O
%	NN	O
)	)	O
PD	NNP	O
,	,	O
versus	NN	O
O	NNP	O
responders	NNS	O
,	,	O
5	CD	O
(	(	O
31	CD	O
%	NN	O
)	)	O
SD	NNP	O
and	CC	O
11	CD	O
(	(	O
69	CD	O
%	NN	O
)	)	O
PD	NNP	O
in	IN	O
the	DT	O
5-FU	JJ	O
plus	CC	O
BCNU	NNP	O
arm	NN	O
.	.	O

In	IN	O
the	DT	O
FAM	NNP	Pharmacological
arm	NN	O
the	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
15.7	CD	O
months	NNS	O
versus	IN	O
9.9	CD	O
months	NNS	O
in	IN	O
the	DT	O
other	JJ	O
therapeutic	JJ	O
arm	NN	O
.	.	O

The	DT	O
statistical	JJ	O
analysis	NN	O
indicated	VBD	O
that	IN	O
survival	NN	O
associated	VBN	O
with	IN	O
FAM	NNP	Pharmacological
regimen	NNS	O
was	VBD	O
superior	JJ	O
to	TO	O
that	DT	O
reached	VBN	O
with	IN	O
the	DT	O
5-FU	JJ	Pharmacological
plus	CC	Pharmacological
BCNU	JJ	Pharmacological
regimen	NNS	O
.	.	O

Thirteen	JJ	O
patients	NNS	O
with	IN	O
unmeasurable	JJ	O
disease	NN	O
had	VBD	O
a	DT	O
median	JJ	O
survival	NN	O
of	IN	O
15.9	CD	O
months	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
asthma	NN	O
knowledge	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
Hungarian	JJ	O
asthmatics	NNS	O
.	.	O

BACKGROUND	IN	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
develop	VB	O
an	DT	O
educational	JJ	Educational
instrument	NN	Educational
,	,	O
to	TO	O
assess	VB	O
its	PRP$	O
impact	NN	O
as	IN	O
an	DT	O
intervention	NN	O
instrument	NN	O
and	CC	O
to	TO	O
examine	VB	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
.	.	O

METHODS	$	O
119	CD	O
asthmatics	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
64	CD	O
in	IN	O
the	DT	O
intervention	NN	O
and	CC	O
55	CD	O
in	IN	O
the	DT	O
reference	NN	Educational
group	NN	O
)	)	O
.	.	O

The	DT	O
education	NN	Educational
instrument	NN	Educational
was	VBD	O
developed	VBN	O
based	VBN	O
on	IN	O
the	DT	O
EuroPharm-Forum	NNP	O
Guidelines	NNP	O
and	CC	O
its	PRP$	O
impact	NN	O
assessed	VBN	O
by	IN	O
a	DT	O
self-developed	JJ	O
questionnaire	NN	O
.	.	O

Patients	NNS	O
'	POS	O
QoL	NNP	O
,	,	O
asthma	NN	O
knowledge	NN	O
was	VBD	O
assessed	VBN	O
twice	RB	O
,	,	O
once	RB	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
education	NN	Educational
seminar	NN	Educational
,	,	O
education	NN	O
was	VBD	O
only	RB	O
provided	VBN	O
for	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

QoL	NNP	O
was	VBD	O
measured	VBN	O
with	IN	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
and	CC	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
We	PRP	O
found	VBD	O
significant	JJ	O
differences	NNS	O
in	IN	O
answers	NNS	O
to	TO	O
the	DT	O
asthma	JJ	O
questions	NNS	O
,	,	O
by	IN	O
40	CD	O
%	NN	O
improvement	NN	O
,	,	O
but	CC	O
no	DT	O
changes	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

In	IN	O
inhaler-use	NN	O
technique	NN	O
,	,	O
we	PRP	O
could	MD	O
not	RB	O
find	VB	O
significant	JJ	O
changes	NNS	O
neither	CC	O
in	IN	O
the	DT	O
intervention	NN	O
nor	CC	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
two	CD	O
visits	NNS	O
neither	CC	O
with	IN	O
the	DT	O
VAS	NNP	O
nor	CC	O
with	IN	O
the	DT	O
SGRQ	NNP	O
on	IN	O
the	DT	O
QoL	NNP	O
data	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
asthmatics	NNS	O
experience	VB	O
lower	JJR	O
QoL	NNP	O
.	.	O

As	IN	O
the	DT	O
subjects	NNS	O
were	VBD	O
regularly	RB	O
controlled	VBN	O
asthmatics	NNS	O
they	PRP	O
had	VBD	O
better	RBR	O
general	JJ	O
knowledge	NN	O
and	CC	O
inhaler-use	NN	O
technique	NN	O
was	VBD	O
expected	VBN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
regularly	VB	O
refresh	JJ	O
asthma	NN	O
knowledge	NN	O
,	,	O
to	TO	O
assess	VB	O
patients	NNS	O
'	POS	O
self-management	JJ	O
plans	NNS	O
to	TO	O
achieve	VB	O
long-term	JJ	O
effectiveness	NN	O
of	IN	O
asthma	JJ	O
management	NN	O
.	.	O

Safety	NN	O
of	IN	O
the	DT	O
combination	NN	Pharmacological
of	IN	Pharmacological
valsartan	NN	Pharmacological
and	CC	O
benazepril	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
renal	JJ	O
disease	NN	O
.	.	O

European	JJ	O
Group	NNP	O
for	IN	O
the	DT	O
Investigation	NNP	O
of	IN	O
Valsartan	NNP	Pharmacological
in	IN	O
Chronic	NNP	O
Renal	NNP	O
Disease	NNP	O
.	.	O

OBJECTIVE	NNP	O
Several	JJ	O
experimental	JJ	O
and	CC	O
clinical	JJ	O
studies	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
renin	NN	O
system	NN	O
may	MD	O
play	VB	O
a	DT	O
pivotal	JJ	O
role	NN	O
in	IN	O
progressing	VBG	O
renal	JJ	O
disease	NN	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
and	CC	O
an	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
could	MD	O
provide	VB	O
a	DT	O
higher	JJR	O
degree	NN	O
of	IN	O
blockade	NN	O
of	IN	O
the	DT	O
renin-angiotensin	NN	O
system	NN	O
than	IN	O
either	DT	O
agent	JJ	O
alone	RB	O
.	.	O

Such	JJ	O
enhanced	JJ	O
suppression	NN	O
might	MD	O
be	VB	O
of	IN	O
benefit	NN	O
for	IN	O
patients	NNS	O
exhibiting	VBG	O
a	DT	O
progressive	JJ	O
decline	NN	O
in	IN	O
renal	JJ	O
function	NN	O
because	IN	O
of	IN	O
chronic	JJ	O
renal	JJ	O
disease	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
pilot	NN	O
multinational	NN	O
,	,	O
multicentre	NN	O
,	,	O
randomized	VBN	O
,	,	O
active-controlled	JJ	O
,	,	O
parallel	JJ	O
group	NN	O
open-label	JJ	O
study	NN	O
has	VBZ	O
been	VBN	O
conducted	VBN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
patients	NNS	O
with	IN	O
progressive	JJ	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
(	(	O
creatinine	JJ	O
clearance	NN	O
20-45	JJ	O
ml/min	NN	O
)	)	O
either	CC	O
with	IN	O
or	CC	O
without	IN	O
proteinuria	NNS	O
and	CC	O
hypertension	NN	O
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
the	DT	O
combination	NN	Pharmacological
of	IN	Pharmacological
valsartan	NN	Pharmacological
and	CC	O
benazepril	NN	Pharmacological
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
group	NN	O
1	CD	O
received	VBD	O
valsartan	JJ	Pharmacological
160	CD	Pharmacological
mg	NN	Pharmacological
once	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
22	CD	O
)	)	O
;	:	O
group	NN	O
2	CD	O
received	VBD	O
valsartan	JJ	Pharmacological
80	CD	Pharmacological
mg	NN	Pharmacological
once	RB	Pharmacological
daily	JJ	Pharmacological
plus	CC	O
benazepril	JJ	Pharmacological
5	CD	Pharmacological
or	CC	Pharmacological
10	CD	Pharmacological
mg	NNS	Pharmacological
once	RB	Pharmacological
daily	JJ	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
;	:	O
group	NN	O
3	CD	O
received	VBD	O
valsartan	JJ	Pharmacological
160	CD	Pharmacological
mg	NN	Pharmacological
once	RB	O
daily	JJ	O
plus	CC	O
benazepril	JJ	Pharmacological
5	CD	Pharmacological
or	CC	Pharmacological
10	CD	Pharmacological
mg	NNS	Pharmacological
once	RB	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
44	CD	O
)	)	O
.	.	O

The	DT	O
study	NN	O
lasted	VBD	O
for	IN	O
5	CD	O
weeks	NNS	O
,	,	O
and	CC	O
in	IN	O
groups	NNS	O
2	CD	O
and	CC	O
3	CD	O
benazepril	NN	O
was	VBD	O
added	VBN	O
on	IN	O
top	NN	O
of	IN	O
valsartan	NN	O
after	IN	O
the	DT	O
first	JJ	O
week	NN	O
of	IN	O
therapy	NN	O
with	IN	O
the	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
.	.	O

RESULTS	NNP	O
Serum	NNP	O
creatinine	NN	O
increased	VBN	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
(	(	O
mean	JJ	O
change	NN	O
within	IN	O
a	DT	O
group	NN	O
:	:	O
11	CD	O
micromol/l	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
P=	NNP	O
0.045	CD	O
;	:	O
9	CD	O
micromol/l	NN	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
P=	NNP	O
0.030	CD	O
;	:	O
15	CD	O
micromol/l	NN	O
in	IN	O
group	NN	O
3	CD	O
,	,	O
P=	NNP	O
0.0006	CD	O
)	)	O
.	.	O

Serum	NNP	O
potassium	NN	O
also	RB	O
increased	VBN	O
in	IN	O
all	DT	O
three	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
(	(	O
mean	JJ	O
change	NN	O
within	IN	O
a	DT	O
group	NN	O
:	:	O
0.28	CD	O
mmol/l	NN	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
P=	NNP	O
0.28	CD	O
;	:	O
0.48	CD	O
mmol/l	NN	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
P=	NNP	O
0.0008	CD	O
;	:	O
0.36	CD	O
mmol/l	NN	O
in	IN	O
group	NN	O
3	CD	O
,	,	O
P=	NNP	O
0.02	CD	O
)	)	O
.	.	O

After	IN	O
5	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
largest	JJS	O
decrease	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
group	NN	O
3	CD	O
(	(	O
the	DT	O
mean	NN	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
seated	VBN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
SDBP	NNP	O
)	)	O
and	CC	O
seated	VBN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
SSBP	NNP	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
were	VBD	O
:	:	O
-2.0	NN	O
and	CC	O
-11.5	NNP	O
mmHg	NN	O
in	IN	O
group	NN	O
1	CD	O
;	:	O
-7.6	NNS	O
and	CC	O
-15.4	NNP	O
mmHg	NN	O
in	IN	O
group	NN	O
2	CD	O
;	:	O
-12.6	NNS	O
and	CC	O
-21.6	NNP	O
mmHg	NN	O
in	IN	O
group	NN	O
3	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
both	DT	O
combination	NN	O
treatments	NNS	O
resulted	VBD	O
in	IN	O
the	DT	O
reduction	NN	O
of	IN	O
proteinuria	NN	O
.	.	O

The	DT	O
total	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
adverse	JJ	O
experiences	NNS	O
were	VBD	O
10	CD	O
(	(	O
45.5	CD	O
%	NN	O
)	)	O
,	,	O
14	CD	O
(	(	O
33.3	CD	O
%	NN	O
)	)	O
and	CC	O
11	CD	O
(	(	O
25	CD	O
%	NN	O
)	)	O
in	IN	O
groups	NNS	O
1,2	CD	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
six	CD	O
patients	NNS	O
(	(	O
5.6	CD	O
%	NN	O
)	)	O
therapy	NN	O
was	VBD	O
discontinued	VBN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
adverse	JJ	O
experiences	NNS	O
.	.	O

Only	RB	O
one	CD	O
patient	NN	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
combined	JJ	O
therapy	NN	O
groups	NNS	O
withdrew	VBD	O
from	IN	O
the	DT	O
study	NN	O
because	IN	O
of	IN	O
hyperkalaemia	NN	O
and	CC	O
no	DT	O
patients	NNS	O
were	VBD	O
forced	VBN	O
to	TO	O
withdraw	VB	O
because	IN	O
of	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
creatinine	NN	O
,	,	O
acute	JJ	O
renal	JJ	O
failure	NN	O
or	CC	O
hospitalization	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
short-term	JJ	O
combination	NN	O
of	IN	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
and	CC	O
an	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
is	VBZ	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
chronic	JJ	O
renal	JJ	O
failure	NN	O
.	.	O

Effect	NN	O
of	IN	O
intravenous	JJ	O
dezocine	NN	Pharmacological
on	IN	O
fentanyl-induced	JJ	O
cough	NN	O
during	IN	O
general	JJ	O
anesthesia	JJ	O
induction	NN	O
:	:	O
a	DT	O
double-blinded	JJ	O
,	,	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
suppressive	JJ	O
effect	NN	O
of	IN	O
intravenous	JJ	O
dezocine	NN	Pharmacological
on	IN	O
fentanyl-induced	JJ	O
cough	NN	O
during	IN	O
the	DT	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
120	CD	O
patients	NNS	O
,	,	O
American	NNP	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
(	(	O
ASA	NNP	O
)	)	O
physical	JJ	O
status	NN	O
I-II	NNP	O
,	,	O
were	VBD	O
randomized	VBN	O
into	IN	O
two	CD	O
equally	RB	O
sized	JJ	O
groups	NNS	O
(	(	O
n	JJ	O
=	NNP	O
60	CD	O
)	)	O
.	.	O

These	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
given	VBN	O
either	RB	O
intravenous	JJ	Pharmacological
dezocine	NN	Pharmacological
0.1	CD	O
mg/kg	NN	O
or	CC	O
a	DT	O
matching	JJ	Control
placebo	NN	Control
(	(	O
equal	JJ	O
volume	NN	O
of	IN	O
0.9	CD	O
%	NN	O
saline	NN	O
)	)	O
10	CD	O
min	NN	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
induced	VBN	O
with	IN	O
midazolam	JJ	O
0.1	CD	O
mg/kg	NN	O
,	,	O
fentanyl	VBP	O
5	CD	O
?g/kg	NN	O
,	,	O
propofol	JJ	O
1-1.5	JJ	O
mg/kg	NN	O
,	,	O
and	CC	O
suxamethonium	NN	O
1.5	CD	O
mg/kg	NN	O
.	.	O

The	DT	O
injection	NN	O
time	NN	O
of	IN	O
fentanyl	NN	O
was	VBD	O
less	JJR	O
than	IN	O
2	CD	O
s	NNS	O
in	IN	O
all	DT	O
patients	NNS	O
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
cough	NN	O
was	VBD	O
recorded	VBN	O
2	CD	O
min	NN	O
after	IN	O
fentanyl	JJ	O
bolus	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
patient	NN	O
in	IN	O
the	DT	O
dezocine	NN	O
group	NN	O
had	VBD	O
cough	VBN	O
,	,	O
and	CC	O
42	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
had	VBD	O
cough	NN	O
.	.	O

This	DT	O
difference	NN	O
was	VBD	O
statistically	RB	O
different	JJ	O
between	IN	O
these	DT	O
two	CD	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.000	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
intravenous	JJ	O
dezocine	NN	O
0.1	CD	O
mg/kg	NN	O
10	CD	O
min	NN	O
prior	RB	O
to	TO	O
induction	NN	O
was	VBD	O
effective	JJ	O
in	IN	O
suppressing	VBG	O
fentanyl-induced	JJ	O
cough	NN	O
in	IN	O
our	PRP$	O
patients	NNS	O
.	.	O

Effectiveness	NN	O
of	IN	O
Dader	NNP	Educational
Method	NNP	Educational
for	IN	O
pharmaceutical	JJ	O
care	NN	O
on	IN	O
control	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
total	JJ	O
cholesterol	NN	O
in	IN	O
outpatients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
or	CC	O
cardiovascular	JJ	O
risk	NN	O
:	:	O
EMDADER-CV	JJ	O
randomized	NNS	O
controlled	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
some	DT	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
pharmacist	JJ	Educational
intervention	NN	Educational
can	MD	O
improve	VB	O
drug	NN	O
therapy	NN	O
among	IN	O
patients	NNS	O
with	IN	O
cardiovascular	JJ	O
disease	NN	O
(	(	O
CVD	NNP	O
)	)	O
,	,	O
more	JJR	O
evidence	NN	O
derived	VBN	O
from	IN	O
randomized	VBN	O
controlled	VBN	O
trials	NNS	O
(	(	O
RCTs	NNP	O
)	)	O
is	VBZ	O
needed	VBN	O
,	,	O
including	VBG	O
assessment	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
community	NN	Educational
pharmacist	NN	Educational
interventions	NNS	Educational
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
Dader	NNP	Educational
Method	NNP	Educational
for	IN	Educational
pharmaceutical	JJ	Educational
care	NN	Educational
on	IN	O
achieving	VBG	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
total	JJ	O
cholesterol	NN	O
(	(	O
TC	NNP	O
)	)	O
,	,	O
and	CC	O
both	DT	O
BP	NNP	O
and	CC	O
TC	NNP	O
(	(	O
BP/TC	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	O
or	CC	O
intermediate	JJ	O
cardiovascular	NN	O
(	(	O
CV	NNP	O
)	)	O
risk	NN	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
aged	VBD	O
25	CD	O
to	TO	O
74	CD	O
years	NNS	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
with	IN	O
a	DT	O
prescription	NN	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
drug	NN	O
indicated	VBN	O
for	IN	O
CVD	NNP	O
or	CC	O
CV	NNP	O
risk	NN	O
factors	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
:	:	O
an	DT	O
intervention	NN	Educational
group	NN	Educational
that	WDT	Educational
received	VBD	Educational
pharmaceutical	JJ	Educational
care	NN	Educational
,	,	Educational
which	WDT	Educational
was	VBD	Educational
provided	VBN	Educational
by	IN	Educational
specially	RB	Educational
trained	JJ	Educational
pharmacists	NNS	Educational
working	VBG	Educational
in	IN	Educational
collaboration	NN	Educational
with	IN	Educational
physicians	NNS	Educational
,	,	O
and	CC	O
a	DT	O
control	NN	Educational
group	NN	Educational
that	WDT	Educational
received	VBD	Educational
usual	JJ	Educational
care	NN	Educational
(	(	Educational
routine	JJ	Educational
dispensing	VBG	Educational
counseling	NN	Educational
)	)	Educational
and	CC	Educational
verbal	JJ	Educational
and	CC	Educational
written	VBN	Educational
counseling	VBG	Educational
regarding	VBG	Educational
CVD	NNP	Educational
prevention	NN	Educational
.	.	O

Patients	NNS	O
were	VBD	O
recruited	VBN	O
from	IN	O
December	NNP	O
2005	CD	O
to	TO	O
September	NNP	O
2006	CD	O
,	,	O
and	CC	O
both	DT	O
groups	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
8	CD	O
months	NNS	O
.	.	O

Study	NNP	O
outcomes	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
16	CD	O
and	CC	O
32	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
achieving	VBG	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
therapeutic	JJ	O
goals	NNS	O
(	(	O
BP	NNP	O
lower	JJR	O
than	IN	O
140/90	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
uncomplicated	JJ	O
hypertension	NN	O
and	CC	O
lower	JJR	O
than	IN	O
130/80	CD	O
mm	NNS	O
Hg	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
,	,	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
,	,	O
or	CC	O
history	NN	O
of	IN	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
stroke	NN	O
;	:	O
TC	NNP	O
lower	JJR	O
than	IN	O
200	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
without	IN	O
CVD	NNP	O
and	CC	O
lower	JJR	O
than	IN	O
175	CD	O
mg	NNS	O
per	IN	O
dL	NN	O
for	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
mean	JJ	O
BP	NNP	O
and	CC	O
TC	NNP	O
values	NNS	O
.	.	O

BP	NNP	O
was	VBD	O
assessed	VBN	O
manually	RB	O
by	IN	O
the	DT	O
pharmacist	NN	O
after	IN	O
a	DT	O
10-minute	JJ	O
rest	NN	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
.	.	O

This	DT	O
measurement	NN	O
was	VBD	O
performed	VBN	O
twice	RB	O
for	IN	O
every	DT	O
participant	NN	O
,	,	O
and	CC	O
the	DT	O
average	NN	O
of	IN	O
the	DT	O
2	CD	O
measurements	NNS	O
was	VBD	O
calculated	VBN	O
.	.	O

TC	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
the	DT	O
pharmacist	NN	O
during	IN	O
the	DT	O
study	NN	O
visit	NN	O
using	VBG	O
the	DT	O
enzymatic	JJ	O
dry	JJ	O
method	NN	O
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
2-tailed	JJ	O
McNemar	NNP	O
tests	NNS	O
,	,	O
Pearson	NNP	O
chi-square	NN	O
tests	NNS	O
,	,	O
and	CC	O
Student	NNP	O
's	POS	O
t-tests	NNS	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
.	.	O

RESULTS	VB	O
714	CD	O
patients	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
(	(	O
356	CD	O
intervention	NN	O
,	,	O
358	CD	O
control	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
mean	JJ	O
[	NNP	O
SD	NNP	O
]	NNP	O
age	NN	O
was	VBD	O
62.8	CD	O
[	JJ	O
8.1	CD	O
]	JJ	O
years	NNS	O
.	.	O

The	DT	O
2	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
at	IN	O
baseline	NN	O
in	IN	O
clinical	JJ	O
and	CC	O
demographic	JJ	O
characteristics	NNS	O
,	,	O
including	VBG	O
the	DT	O
proportion	NN	O
of	IN	O
patients	NNS	O
at	IN	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
.	.	O

After	IN	O
8	CD	O
months	NNS	O
of	IN	O
follow-up	NN	O
,	,	O
there	EX	O
were	VBD	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
favor	NN	O
of	IN	O
pharmaceutical	JJ	O
care	NN	O
in	IN	O
the	DT	O
proportions	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
therapeutic	JJ	O
goals	NNS	O
for	IN	O
BP	NNP	O
(	(	O
52.5	CD	O
%	NN	O
vs.	FW	O
43.0	CD	O
%	NN	O
,	,	O
P=0.017	NNP	O
)	)	O
,	,	O
TC	NNP	O
(	(	O
56.5	CD	O
%	NN	O
vs.	FW	O
44.1	CD	O
%	NN	O
,	,	O
P=0.001	NNP	O
)	)	O
,	,	O
and	CC	O
BP/TC	NNP	O
(	(	O
37.1	CD	O
%	NN	O
vs.	FW	O
21.8	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Compared	NNP	O
with	IN	O
usual	JJ	O
care	NN	O
plus	CC	O
written	VBN	O
education	NN	O
,	,	O
pharmaceutical	JJ	O
care	NN	O
focused	VBN	O
on	IN	O
patient	JJ	O
evaluation	NN	O
and	CC	O
follow-up	NN	O
in	IN	O
collaboration	NN	O
with	IN	O
physicians	NNS	O
improved	VBN	O
the	DT	O
achievement	NN	O
of	IN	O
BP	NNP	O
,	,	O
TC	NNP	O
,	,	O
and	CC	O
BP/TC	NNP	O
treatment	NN	O
goals	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
CVD	NNP	O
and/or	VBP	O
high	JJ	O
or	CC	O
intermediate	JJ	O
CV	NNP	O
risk	NN	O
attending	VBG	O
community	NN	O
pharmacies	NNS	O
in	IN	O
Spain	NNP	O
.	.	O

Secretin	NNP	O
and	CC	O
autism	NN	O
:	:	O
a	DT	O
two-part	JJ	O
clinical	JJ	O
investigation	NN	O
.	.	O

Recent	JJ	O
anecdotal	JJ	O
reports	NNS	O
have	VBP	O
touted	VBN	O
the	DT	O
gastrointestinal	NN	O
(	(	O
GI	NNP	O
)	)	O
hormone	NN	O
secretin	NN	Physical
as	IN	O
a	DT	O
treatment	NN	O
modality	NN	O
for	IN	O
autism	NN	O
,	,	O
though	IN	O
there	EX	O
is	VBZ	O
little	JJ	O
clinical	JJ	O
evidence	NN	O
or	CC	O
literature	NN	O
to	TO	O
support	VB	O
its	PRP$	O
viability	NN	O
.	.	O

We	PRP	O
undertook	VBD	O
a	DT	O
two-part	JJ	O
clinical	JJ	O
trial	NN	O
to	TO	O
investigate	VB	O
these	DT	O
claims	NNS	O
.	.	O

Fifty-six	JJ	O
patients	NNS	O
(	(	O
49	CD	O
boys	NNS	O
,	,	O
7	CD	O
girls	NNS	O
,	,	O
mean	JJ	O
age	NN	O
=	VBD	O
6.4	CD	O
years	NNS	O
,	,	O
SD	NNP	O
=	NNP	O
2.7	CD	O
)	)	O
enrolled	VBN	O
in	IN	O
an	DT	O
open-label	JJ	O
trial	NN	O
of	IN	O
secretin	NN	Physical
,	,	O
during	IN	O
which	WDT	O
they	PRP	O
received	VBD	O
one	CD	O
injection	NN	O
of	IN	O
the	DT	O
hormone	NN	O
(	(	O
2	CD	O
IU/kg	NNP	O
)	)	O
.	.	O

All	DT	O
subjects	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
their	PRP$	O
parents	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
follow-up	JJ	O
visits	NNS	O
(	(	O
3-6	JJ	O
weeks	NNS	O
later	RB	O
,	,	O
M	NNP	O
=	NNP	O
3.7	CD	O
,	,	O
SD	NNP	O
=	VBZ	O
1.4	CD	O
weeks	NNS	O
)	)	O
with	IN	O
Childhood	NNP	O
Autism	NNP	O
Rating	NNP	O
Scales	NNP	O
(	(	O
CARS	NNP	O
)	)	O
.	.	O

Thirty-four	JJ	O
patients	NNS	O
were	VBD	O
labeled	VBN	O
with	IN	O
Pervasive	NNP	O
Developmental	NNP	O
Disorder	NNP	O
Not	RB	O
Otherwise	NNP	O
Specified	NNP	O
,	,	O
and	CC	O
22	CD	O
met	VBD	O
diagnostic	JJ	O
criteria	NNS	O
for	IN	O
Autistic	JJ	O
Disorder	NNP	O
.	.	O

Forty-five	JJ	O
patients	NNS	O
were	VBD	O
concurrently	RB	O
on	IN	O
other	JJ	O
drug	NN	O
treatments	NNS	O
.	.	O

At	IN	O
follow-up	NN	O
,	,	O
some	DT	O
reported	VBD	O
minimal	JJ	O
but	CC	O
potentially	RB	O
significant	JJ	O
improvements	NNS	O
including	VBG	O
changes	NNS	O
in	IN	O
GI	NNP	O
symptoms	NNS	O
,	,	O
expressive	JJ	O
and/or	NN	O
receptive	JJ	O
language	NN	O
function	NN	O
,	,	O
and	CC	O
improved	JJ	O
awareness	NN	O
and	CC	O
social	JJ	O
interactions	NNS	O
.	.	O

No	DT	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
reported	VBN	O
or	CC	O
observed	VBN	O
.	.	O

Subsequently	NNP	O
,	,	O
17	CD	O
of	IN	O
the	DT	O
most	RBS	O
responsive	JJ	O
patients	NNS	O
from	IN	O
Study	NNP	O
1	CD	O
began	VBD	O
a	DT	O
double-blind	JJ	O
trial	NN	O
that	WDT	O
also	RB	O
included	VBD	O
8	CD	O
newly	RB	O
enrolled	VBN	O
patients	NNS	O
.	.	O

Patients	NNS	O
in	IN	O
this	DT	O
second	JJ	O
study	NN	O
were	VBD	O
alternatively	RB	O
entered	VBN	O
into	IN	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
and	CC	O
received	VBD	O
injections	NNS	O
of	IN	O
secretin	NN	O
or	CC	O
placebo	NN	Control
with	IN	O
crossover	NN	O
at	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
from	IN	O
Study	NNP	O
1	CD	O
entered	VBD	O
into	IN	O
Study	NNP	O
2	CD	O
at	IN	O
an	DT	O
average	NN	O
of	IN	O
6.5	CD	O
(	(	O
SD	NNP	O
=	NNP	O
0.8	CD	O
)	)	O
weeks	NNS	O
after	IN	O
beginning	VBG	O
Study	NNP	O
1	CD	O
.	.	O

Results	NNS	O
of	IN	O
both	DT	O
inquiries	NNS	O
indicate	VBP	O
that	IN	O
although	IN	O
treatment	NN	O
with	IN	O
secretin	NN	Physical
was	VBD	O
reported	VBN	O
to	TO	O
cause	VB	O
transient	JJ	O
changes	NNS	O
in	IN	O
speech	NN	O
and	CC	O
behavior	NN	O
in	IN	O
some	DT	O
children	NNS	O
,	,	O
overall	JJ	O
it	PRP	O
produced	VBD	O
few	JJ	O
clinically	RB	O
meaningful	JJ	O
changes	NNS	O
when	WRB	O
compared	VBN	O
to	TO	O
children	NNS	O
given	VBN	O
placebo	JJ	Control
injections	NNS	O
.	.	O

Control	NN	O
of	IN	O
the	DT	O
lumbar	NN	O
neutral	JJ	O
zone	NN	O
decreases	VBZ	O
low	JJ	O
back	RB	O
pain	NN	O
and	CC	O
improves	VBZ	O
self-evaluated	JJ	O
work	NN	O
ability	NN	O
:	:	O
a	DT	O
12-month	JJ	O
randomized	NN	O
controlled	VBD	O
study	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
randomized	NN	O
controlled	VBD	O
study	NN	O
with	IN	O
12	CD	O
months	NNS	O
intervention	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
study	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
training	NN	Educational
intervention	NN	Educational
with	IN	Educational
emphases	NNS	Educational
on	IN	Educational
the	DT	Educational
control	NN	Educational
of	IN	Educational
lumbar	JJ	Educational
neutral	JJ	Educational
zone	NN	Educational
(	(	O
NZ	NNP	O
)	)	O
and	CC	O
behavior	JJ	Educational
modeling	NN	Educational
as	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
low	JJ	O
back	RB	O
pain	NN	O
(	(	O
LBP	NNP	O
)	)	O
and	CC	O
disability	NN	O
.	.	O

SUMMARY	NNP	O
OF	IN	O
BACKGROUND	NNP	O
DATA	NNP	O
Improving	NNP	O
the	DT	O
control	NN	O
of	IN	O
lumbar	NN	O
NZ	NNP	O
and	CC	O
enhancing	VBG	O
muscle	NN	O
activation	NN	O
patterns	NNS	O
ensuring	VBG	O
spinal	JJ	O
stability	NN	O
have	VBP	O
been	VBN	O
proposed	VBN	O
as	IN	O
means	NNS	O
for	IN	O
secondary	JJ	O
prevention	NN	O
of	IN	O
LBP	NNP	O
and	CC	O
disability	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
cognitive	JJ	Educational
behavior	NN	Educational
interventions	NNS	Educational
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
recurrence	NN	O
of	IN	O
LBP	NNP	O
and	CC	O
long-term	JJ	O
disability	NN	O
.	.	O

METHODS	NNP	O
Middle-aged	JJ	O
working	VBG	O
men	NNS	O
with	IN	O
recent	JJ	O
LBP	NNP	O
but	CC	O
without	IN	O
severe	JJ	O
disability	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
a	DT	O
training	NN	Educational
(	(	O
TG	NNP	O
,	,	O
n	JJ	O
=	NNP	O
52	CD	O
)	)	O
or	CC	O
control	VB	Control
group	NN	Control
(	(	O
CG	NNP	O
,	,	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
.	.	O

The	DT	O
aim	NN	O
was	VBD	O
to	TO	O
exercise	VB	O
twice	RB	O
a	DT	O
week	NN	O
for	IN	O
12	CD	O
months	NNS	O
,	,	O
once	RB	O
guided	VBN	O
and	CC	O
once	RB	O
independently	RB	O
.	.	O

The	DT	O
outcome	NN	O
measures	NNS	O
were	VBD	O
the	DT	O
changes	NNS	O
in	IN	O
intensity	NN	O
of	IN	O
LBP	NNP	O
,	,	O
disability	NN	O
,	,	O
self-evaluated	JJ	O
future	NN	O
work	NN	O
ability	NN	O
,	,	O
and	CC	O
neuromuscular	JJ	O
fitness	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
intensity	NN	O
of	IN	O
LBP	NNP	O
decreased	VBD	O
significantly	RB	O
more	JJR	O
(	(	O
39	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
TG	NNP	O
than	IN	O
in	IN	O
CG	NNP	O
at	IN	O
12	CD	O
months	NNS	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
negative	JJ	O
expectations	NNS	O
about	IN	O
their	PRP$	O
future	NN	O
work	NN	O
ability	NN	O
decreased	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
;	:	O
however	RB	O
,	,	O
the	DT	O
proportion	NN	O
was	VBD	O
significantly	RB	O
bigger	JJR	O
in	IN	O
TG	NNP	O
compared	VBN	O
with	IN	O
CG	NNP	O
(	(	O
P	NNP	O
=	NNP	O
0.028	CD	O
)	)	O
.	.	O

There	EX	O
effects	NNS	O
on	IN	O
disability	NN	O
indexes	NNS	O
and	CC	O
fitness	NN	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Controlling	NNP	O
lumbar	NN	O
NZ	NNP	O
is	VBZ	O
a	DT	O
specific	JJ	O
form	NN	O
of	IN	O
exercise	NN	Other
and	CC	Other
daily	JJ	Other
self-care	NN	Other
with	IN	O
potential	JJ	O
for	IN	O
prevention	NN	O
of	IN	O
recurrent	NN	O
nonspecific	JJ	O
LBP	NNP	O
and	CC	O
disability	NN	O
among	IN	O
middle	JJ	O
aged	VBN	O
working	VBG	O
men	NNS	O
.	.	O

Community-based	JJ	Educational
treatment	NN	Educational
for	IN	O
opioid	JJ	O
dependent	JJ	O
offenders	NNS	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Primary	NNP	Educational
care	NN	Educational
opioid	JJ	Educational
substitution	NN	Educational
treatment	NN	Educational
(	(	Educational
OST	NNP	Educational
)	)	Educational
has	VBZ	O
not	RB	O
been	VBN	O
compared	VBN	O
to	TO	O
program-based	JJ	O
OST	NNP	Pharmacological
for	IN	O
community-supervised	JJ	O
offenders	NNS	O
.	.	O

OBJECTIVE	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
project	NN	O
was	VBD	O
to	TO	O
compare	VB	O
primary	JJ	O
care	NN	O
to	TO	O
specialist	VB	O
supervised	JJ	O
OST	NNP	O
for	IN	O
opioid	JJ	O
dependent	JJ	O
offenders	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
substance	NN	O
use	NN	O
and	CC	O
HIV	NNP	O
risk	NN	O
outcomes	NNS	O
.	.	O

METHODS	NNP	O
This	DT	O
project	NN	O
randomly	RB	O
assigned	VBD	O
15	CD	O
jail	NN	O
diversion	NN	O
participants	NNS	O
to	TO	O
either	DT	O
:	:	O
(	(	O
i	NN	O
)	)	O
primary	NN	Educational
care	NN	Educational
buprenorphine	NN	Other
OST	NNP	Educational
,	,	O
(	(	O
ii	NN	O
)	)	O
specialist	NN	Educational
facility	NN	Educational
buprenorphine	NN	Other
OST	NNP	Educational
,	,	O
or	CC	O
(	(	O
iii	JJ	O
)	)	O
specialist	NN	Educational
facility	NN	Educational
methadone	NN	Other
OST	NNP	Educational
.	.	O

Participation	NNP	O
lasted	VBD	O
13.5	CD	O
months	NNS	O
(	(	O
12-month	JJ	O
active	JJ	O
treatment	NN	O
plus	CC	O
a	DT	O
post-participation	JJ	O
visit	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
All	NNP	O
subjects	VBZ	O
endorsed	VBN	O
0	CD	O
days	NNS	O
of	IN	O
opioid	JJ	O
use	NN	O
in	IN	O
the	DT	O
previous	JJ	O
14	CD	O
at	IN	O
follow-up	NN	O
.	.	O

Specialty	NNP	O
care	NN	O
reduced	VBD	O
HIV	NNP	O
risk	NN	O
(	(	O
Risk	NNP	O
Assessment	NNP	O
Battery	NNP	O
composite	JJ	O
score	NN	O
)	)	O
over	IN	O
6	CD	O
months	NNS	O
(	(	O
-.24	VB	O
?	.	O
.17	NN	O
)	)	O
compared	VBN	O
to	TO	O
primary	VB	O
care	NN	O
(	(	O
.02	VB	O
?	.	O
.14	NN	O
;	:	O
p	CC	O
=	NNP	O
.032	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Findings	NNP	O
support	NN	O
primary	NN	O
care	NN	O
OST	NNP	O
feasibility	NN	O
for	IN	O
a	DT	O
community-supervised	JJ	O
offender	NN	O
sample	NN	O
.	.	O

Specialist	NNP	O
care	NN	O
may	MD	O
facilitate	VB	O
improvements	NNS	O
in	IN	O
secondary	JJ	O
outcomes	NNS	O
,	,	O
such	JJ	O
as	IN	O
HIV	NNP	O
risk	NN	O
behaviors	NNS	O
.	.	O

SCIENTIFIC	NNP	O
SIGNIFICANCE	NNP	O
Further	NNP	O
research	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
clarify	VB	O
(	(	O
i	NN	O
)	)	O
the	DT	O
role	NN	O
of	IN	O
primary	JJ	O
care	NN	O
in	IN	O
addicted	VBN	O
offender	NN	O
management	NN	O
,	,	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
the	DT	O
matching	NN	O
of	IN	O
offenders	NNS	O
,	,	O
based	VBN	O
upon	IN	O
history	NN	O
and	CC	O
co-morbidity	NN	O
,	,	O
to	TO	O
care	VB	O
coordination	NN	O
conditions	NNS	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
investigating	VBG	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
aripiprazole	NN	Pharmacological
in	IN	O
the	DT	O
long-term	JJ	O
maintenance	NN	O
treatment	NN	O
of	IN	O
pediatric	JJ	O
patients	NNS	O
with	IN	O
irritability	NN	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
aripiprazole	JJ	Pharmacological
versus	NN	O
placebo	NN	Control
in	IN	O
preventing	VBG	O
relapse	NN	O
of	IN	O
irritability	NN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
in	IN	O
pediatric	JJ	O
patients	NNS	O
.	.	O

METHOD	NNP	O
This	DT	O
multicenter	NN	O
,	,	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
relapse-prevention	JJ	O
trial	NN	O
enrolled	VBD	O
patients	NNS	O
(	(	O
6-17	CD	O
years	NNS	O
)	)	O
who	WP	O
met	VBD	O
the	DT	O
current	JJ	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
,	,	O
Text	NNP	O
Revision	NNP	O
(	(	O
DMS-IV-TR	NNP	O
)	)	O
criteria	NN	O
for	IN	O
autistic	JJ	O
disorder	NN	O
and	CC	O
who	WP	O
also	RB	O
had	VBD	O
serious	JJ	O
behavioral	JJ	O
problems	NNS	O
(	(	O
ie	VB	O
,	,	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
self-injurious	JJ	O
behavior	NN	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
these	DT	O
behavioral	JJ	O
problems	NNS	O
)	)	O
between	IN	O
March	NNP	O
2011	CD	O
and	CC	O
June	NNP	O
2012	CD	O
.	.	O

In	IN	O
phase	NN	O
1	CD	O
,	,	O
single-blind	JJ	O
aripiprazole	NN	Pharmacological
was	VBD	O
flexibly	RB	O
dosed	VBN	O
(	(	O
2-15	JJ	O
mg/d	NN	O
)	)	O
for	IN	O
13-26	JJ	O
weeks	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
a	DT	O
stable	JJ	O
response	NN	O
(	(	O
?	.	O
25	CD	O
%	NN	O
decrease	NN	O
in	IN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-irritability	NNP	O
subscale	NN	O
score	NN	O
and	CC	O
a	DT	O
rating	NN	O
of	IN	O
much	JJ	O
improved	VBN	O
or	CC	O
very	RB	O
much	JJ	O
improved	VBN	O
on	IN	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impressions-Improvement	NNP	O
scale	NN	O
)	)	O
for	IN	O
12	CD	O
consecutive	JJ	O
weeks	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
phase	NN	O
2	CD	O
to	TO	O
continue	VB	O
aripiprazole	NN	O
or	CC	O
switch	VB	O
to	TO	O
placebo	VB	O
.	.	O

Treatment	NN	O
was	VBD	O
continued	VBN	O
until	IN	O
relapse	NN	O
or	CC	O
up	RB	O
to	TO	O
16	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
time	NN	O
from	IN	O
randomization	NN	O
to	TO	O
relapse	VB	O
.	.	O

RESULTS	NNP	O
Eighty-five	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
phase	NN	O
2	CD	O
.	.	O

The	DT	O
difference	NN	O
in	IN	O
time	NN	O
to	TO	O
relapse	VB	O
between	IN	O
aripiprazole	NN	O
and	CC	O
placebo	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
=	NNP	O
.097	NNP	O
)	)	O
.	.	O

Kaplan-Meier	NNP	O
relapse	NN	O
rates	NNS	O
at	IN	O
week	NN	O
16	CD	O
were	VBD	O
35	CD	O
%	NN	O
for	IN	O
aripiprazole	NN	O
and	CC	O
52	CD	O
%	NN	O
for	IN	O
placebo	NN	O
(	(	O
hazard	JJ	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
=	NNP	O
0.57	CD	O
;	:	O
number	NN	O
needed	VBN	O
to	TO	O
treat	VB	O
[	JJ	O
NNT	NNP	O
]	NNP	O
=	NNP	O
6	CD	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
adverse	JJ	O
events	NNS	O
during	IN	O
phase	NN	O
1	CD	O
were	VBD	O
weight	JJ	O
increase	NN	O
(	(	O
25.2	CD	O
%	NN	O
)	)	O
,	,	O
somnolence	NN	O
(	(	O
14.8	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
vomiting	VBG	O
(	(	O
14.2	CD	O
%	NN	O
)	)	O
;	:	O
and	CC	O
,	,	O
during	IN	O
phase	NN	O
2	CD	O
(	(	O
aripiprazole	JJ	O
vs	NN	O
placebo	NN	O
)	)	O
,	,	O
they	PRP	O
were	VBD	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
infection	NN	O
(	(	O
10.3	CD	O
%	NN	O
vs	JJ	O
2.3	CD	O
%	NN	O
)	)	O
,	,	O
constipation	NN	O
(	(	O
5.1	CD	O
%	NN	O
vs	JJ	O
0	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
movement	NN	O
disorder	NN	O
(	(	O
5.1	CD	O
%	NN	O
vs	JJ	O
0	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
aripiprazole	NN	O
and	CC	O
placebo	NN	O
in	IN	O
time	NN	O
to	TO	O
relapse	VB	O
during	IN	O
maintenance	NN	O
therapy	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
HR	NNP	O
and	CC	O
NNT	NNP	O
suggest	VBP	O
some	DT	O
patients	NNS	O
will	MD	O
benefit	VB	O
from	IN	O
maintenance	NN	O
treatment	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
aripiprazole	NN	O
should	MD	O
be	VB	O
periodically	RB	O
reassessed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
continued	JJ	O
need	NN	O
for	IN	O
treatment	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials.gov	NNP	O
identifier	NN	O
:	:	O
NCT01227668	NNP	O
.	.	O

Women	NNP	O
's	POS	O
responses	NNS	O
to	TO	O
information	NN	O
on	IN	O
mammographic	JJ	O
breast	NN	O
density	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
the	DT	O
negative	JJ	O
and	CC	O
positive	JJ	O
outcomes	NNS	O
of	IN	O
providing	VBG	O
mammographic	JJ	O
breast	NN	O
density	NN	O
(	(	O
MBD	NNP	O
)	)	O
information	NN	O
to	TO	O
participants	NNS	O
of	IN	O
a	DT	O
screening	JJ	Physical
program	NN	Physical
.	.	O

A	DT	O
randomized	JJ	O
experiment	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
a	DT	O
sample	NN	O
of	IN	O
618	CD	O
women	NNS	O
50	CD	O
years	NNS	O
or	CC	O
older	JJR	O
with	IN	O
MBD	NNP	O
greater	JJR	O
than	IN	O
50	CD	O
%	NN	O
of	IN	O
breast	NN	O
volume	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
reporting	VBG	Physical
the	DT	Physical
presence	NN	Physical
of	IN	Physical
MBD	NNP	Physical
in	IN	Physical
the	DT	Physical
screening	NN	Physical
mammography	NN	Physical
results	NNS	Physical
letter	NN	Physical
that	WDT	Physical
was	VBD	Physical
sent	VBN	Physical
along	IN	Physical
with	IN	Physical
an	DT	Physical
information	NN	Physical
pamphlet	NN	Physical
.	.	O

Compared	VBN	O
to	TO	O
the	DT	O
controls	NNS	Control
,	,	O
more	JJR	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
described	VBD	O
the	DT	O
term	NN	O
breast	NN	O
density	NN	O
correctly	RB	O
and	CC	O
recognized	VBD	O
it	PRP	O
as	IN	O
a	DT	O
risk	NN	O
factor	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Although	IN	O
at	IN	O
the	DT	O
4-week	JJ	O
follow-up	NN	O
the	DT	O
intervention	NN	O
group	NN	O
indicated	VBD	O
that	IN	O
they	PRP	O
were	VBD	O
very	RB	O
likely	JJ	O
to	TO	O
have	VB	O
an	DT	O
annual	JJ	Physical
clinical	JJ	Physical
breast	NN	Physical
examination	NN	Physical
more	RBR	O
frequently	RB	O
than	IN	O
controls	NNS	O
,	,	O
no	DT	O
differences	NNS	O
were	VBD	O
detected	VBN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
on	IN	O
other	JJ	O
behavioural	JJ	O
or	CC	O
psychological	JJ	O
measures	NNS	O
,	,	O
although	IN	O
at	IN	O
the	DT	O
4-week	JJ	O
follow-up	JJ	O
the	DT	O
control	NN	O
group	NN	O
perceived	VBD	O
their	PRP$	O
risk	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
,	,	O
relative	VBP	O
to	TO	O
other	JJ	O
women	NNS	O
their	PRP$	O
age	NN	O
,	,	O
as	IN	O
a	DT	O
lot	NN	O
lower	JJR	O
than	IN	O
did	VBD	O
women	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

The	DT	O
results	NNS	O
demonstrate	VBP	O
a	DT	O
feasible	JJ	O
and	CC	O
non-threatening	JJ	O
way	NN	O
to	TO	O
provide	VB	O
women	NNS	O
with	IN	O
important	JJ	O
personalized	VBN	O
information	NN	O
about	IN	O
breast	NN	O
cancer	NN	O
risk	NN	O
.	.	O

Esmolol	NNP	Pharmacological
versus	NN	O
verapamil	NN	Pharmacological
in	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
atrial	JJ	O
flutter	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
esmolol	NN	Pharmacological
,	,	O
an	DT	O
ultrashort-acting	JJ	O
beta	NN	O
blocker	NN	O
,	,	O
and	CC	O
verapamil	NN	Pharmacological
were	VBD	O
compared	VBN	O
in	IN	O
controlling	VBG	O
ventricular	JJ	O
response	NN	O
in	IN	O
45	CD	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
atrial	JJ	O
flutter	NN	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
parallel	JJ	O
,	,	O
open-label	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
with	IN	O
either	DT	O
new	JJ	O
onset	NN	O
(	(	O
less	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
,	,	O
n	JJ	O
=	NNP	O
31	CD	O
)	)	O
or	CC	O
old	JJ	O
onset	NN	O
(	(	O
greater	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
,	,	O
n	JJ	O
=	NNP	O
14	CD	O
)	)	O
of	IN	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
flutter	NN	O
with	IN	O
rapid	JJ	O
ventricular	JJ	O
rate	NN	O
were	VBD	O
stratified	VBN	O
to	TO	O
receive	VB	O
esmolol	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
or	CC	O
verapamil	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
.	.	O

Drug	NNP	O
efficacy	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
ventricular	JJ	O
rate	NN	O
reduction	NN	O
and	CC	O
conversion	NN	O
to	TO	O
sinus	VB	O
rhythm	NN	O
.	.	O

The	DT	O
heart	NN	O
rate	NN	O
declined	VBD	O
with	IN	O
esmolol	NN	Pharmacological
from	IN	O
139	CD	O
to	TO	O
100	CD	O
beats/min	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
with	IN	O
verapamil	NN	Pharmacological
from	IN	O
142	CD	O
to	TO	O
97	CD	O
beats/min	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

Fifty	NNP	O
percent	NN	O
of	IN	O
esmolol-treated	JJ	Pharmacological
patients	NNS	O
with	IN	O
new	JJ	O
onset	NN	O
of	IN	O
arrhythmias	NNS	O
converted	VBN	O
to	TO	O
sinus	VB	O
rhythm	NN	O
,	,	O
whereas	IN	O
only	RB	O
12	CD	O
%	NN	O
of	IN	O
those	DT	O
who	WP	O
received	VBD	O
verapamil	RB	Pharmacological
converted	VBN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.03	CD	O
)	)	O
.	.	O

Mild	NNP	O
hypotension	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

Esmolol	NNP	Pharmacological
compares	VBZ	O
favorably	RB	O
with	IN	O
verapamil	NN	Pharmacological
with	IN	O
respect	NN	O
to	TO	O
both	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
in	IN	O
acutely	RB	O
decreasing	VBG	O
ventricular	JJ	O
response	NN	O
during	IN	O
atrial	JJ	O
fibrillation	NN	O
or	CC	O
flutter	NN	O
.	.	O

Moreover	RB	O
,	,	O
conversion	NN	O
to	TO	O
sinus	VB	O
rhythm	NN	O
is	VBZ	O
significantly	RB	O
more	RBR	O
likely	JJ	O
with	IN	O
esmolol	NN	Pharmacological
.	.	O

Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	Physical
impedance	NN	Physical
threshold	JJ	Physical
device	NN	Physical
on	IN	Physical
a	DT	Physical
facemask	NN	Physical
and	CC	Physical
endotracheal	VB	Physical
tube	NN	Physical
to	TO	O
reduce	VB	O
intrathoracic	JJ	O
pressures	NNS	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
.	.	O

INTRODUCTION	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
inspiratory	JJ	Physical
impedance	NN	Physical
threshold	NN	Physical
device	NN	Physical
(	(	Physical
ITD	NNP	Physical
)	)	Physical
significantly	RB	O
increases	VBZ	O
coronary	JJ	O
perfusion	NN	O
pressures	NNS	O
and	CC	O
survival	NN	O
in	IN	O
patients	NNS	O
ventilated	VBN	O
with	IN	O
an	DT	O
endotracheal	JJ	Physical
tube	NN	Physical
(	(	Physical
ETT	NNP	Physical
)	)	Physical
during	IN	O
active	JJ	Physical
compression-decompression	NN	Physical
cardiopulmonary	JJ	Physical
resuscitation	NN	Physical
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
ITD	NNP	Physical
could	MD	O
lower	VB	O
intratracheal	NN	O
pressures	NNS	O
when	WRB	O
attached	VBN	O
to	TO	O
either	VB	O
a	DT	O
facemask	NN	Physical
or	CC	Physical
ETT	NNP	Physical
.	.	O

METHODS	NNP	O
An	DT	O
active	JJ	Physical
and	CC	Physical
sham	JJ	Physical
ITD	NNP	Physical
were	VBD	O
randomly	RB	O
applied	VBN	O
first	RB	O
to	TO	O
a	DT	O
facemask	NN	Physical
and	CC	O
then	RB	O
to	TO	O
an	DT	O
ETT	NNP	Physical
during	IN	O
active	JJ	Physical
compression-decompression	NN	Physical
cardiopulmonary	JJ	Physical
resuscitation	NN	Physical
in	IN	O
13	CD	O
out-of-hospital	JJ	O
cardiac	JJ	O
arrest	NN	O
patients	NNS	O
in	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blinded	JJ	O
,	,	O
prospective	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
compression-to-bag-valve	JJ	O
ventilation	NN	O
ratio	NN	O
was	VBD	O
15:2	CD	O
.	.	O

Airway	NN	O
pressures	NNS	O
(	(	O
surrogate	NN	O
for	IN	O
intrathoracic	JJ	O
pressure	NN	O
)	)	O
were	VBD	O
measured	VBN	O
with	IN	O
a	DT	O
pressure	NN	O
transducer	NN	O
.	.	O

A	DT	O
sham	NN	Physical
and	CC	Physical
an	DT	Physical
active	JJ	Physical
ITD	NNP	Physical
were	VBD	O
used	VBN	O
for	IN	O
1	CD	O
min	NNS	O
each	DT	O
in	IN	O
a	DT	O
randomized	JJ	O
order	NN	O
,	,	O
first	RB	O
on	IN	O
a	DT	O
facemask	NN	Physical
and	CC	O
then	RB	O
on	IN	O
an	DT	O
ETT	NNP	Physical
.	.	O

Statistical	JJ	O
analyses	NNS	O
were	VBD	O
made	VBN	O
using	VBG	O
Friedman	NNP	O
's	POS	O
and	CC	O
Wilcoxon	NNP	O
's	POS	O
rank-sum	JJ	O
tests	NNS	O
.	.	O

RESULTS	NNP	O
For	IN	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
,	,	O
mean	JJ	O
+/-	JJ	O
sd	NN	O
maximum	JJ	O
negative	JJ	O
intrathoracic	NN	O
pressures	NNS	O
(	(	O
mm	VB	O
Hg	NNP	O
)	)	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
were	VBD	O
-1.0	JJ	O
+/-	JJ	O
0.73	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	Physical
vs.	FW	O
-4.6	NNP	O
+/-	JJ	O
3.7	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	Physical
ITD	NN	Physical
on	IN	O
the	DT	O
facemask	NN	O
(	(	O
p	JJ	O
=	NNP	O
.003	NNP	O
)	)	O
and	CC	O
-1.3	JJ	O
+/-	JJ	O
1.3	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
a	DT	O
sham	NN	O
ITD	NNP	O
vs.	IN	O
-7.3	NNP	O
+/-	JJ	O
4.5	CD	O
mm	NN	O
Hg	NNP	O
with	IN	O
an	DT	O
active	JJ	O
ITD	NNP	O
on	IN	O
an	DT	O
ETT	NNP	O
(	(	O
p	JJ	O
=	NNP	O
.0009	NNP	O
)	)	O
.	.	O

Decompression	NNP	O
phase	NN	O
airway	NN	O
pressures	NNS	O
with	IN	O
the	DT	O
facemask	NN	Physical
and	CC	Physical
ETT	NNP	Physical
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Use	NNP	O
of	IN	O
an	DT	O
active	JJ	Physical
ITD	NNP	Physical
attached	VBD	Physical
to	TO	Physical
a	DT	Physical
facemask	NN	Physical
or	CC	Physical
an	DT	Physical
ETT	NNP	Physical
resulted	VBD	O
in	IN	O
a	DT	O
significantly	RB	O
lower	JJR	O
negative	JJ	O
intratracheal	JJ	O
pressure	NN	O
during	IN	O
the	DT	O
decompression	NN	O
phase	NN	O
of	IN	O
active	JJ	O
compression-decompression	NN	O
cardiopulmonary	JJ	O
resuscitation	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
controls	NNS	O
.	.	O

Airway	NNP	O
pressures	VBZ	O
with	IN	O
an	DT	O
ITD	NNP	Physical
on	IN	O
either	CC	O
a	DT	O
facemask	NN	Physical
or	CC	O
ETT	NNP	Physical
were	VBD	O
similar	JJ	O
.	.	O

The	DT	O
ITD-facemask	JJ	Physical
combination	NN	Physical
was	VBD	O
practical	JJ	O
and	CC	O
enables	VBZ	O
rapid	JJ	O
deployment	NN	O
of	IN	O
this	DT	O
life-saving	JJ	O
technology	NN	O
.	.	O

Rosiglitazone	NN	Pharmacological
and	CC	O
cognitive	JJ	O
function	NN	O
in	IN	O
clozapine-treated	JJ	Pharmacological
patients	NNS	O
with	IN	O
schizophrenia	NN	O
:	:	O
a	DT	O
pilot	NN	O
study	NN	O
.	.	O

Studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
insulin	NN	O
resistance	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
cognitive	JJ	O
impairment	NN	O
.	.	O

Peroxisome	VB	O
proliferator-activated	JJ	O
receptor-?	NN	O
(	(	O
PPAR-?	NNP	O
)	)	O
agonists	VBZ	O
improve	JJ	O
insulin	NN	O
sensitivity	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
rosiglitazone	NN	O
,	,	O
a	DT	O
PPAR-?	JJ	O
agonist	NN	O
,	,	O
on	IN	O
cognition	NN	O
in	IN	O
clozapine-treated	JJ	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

In	IN	O
an	DT	O
eight-week	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	O
pilot	NN	O
trial	NN	O
,	,	O
clozapine-treated	JJ	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
rosiglitazone	NN	O
(	(	O
4mg/day	CD	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

A	DT	O
neuropsychological	JJ	O
battery	NN	O
including	VBG	O
the	DT	O
Digit	NNP	O
Span	NNP	O
subtest	JJS	O
from	IN	O
the	DT	O
Wechsler	NNP	O
Adult	NNP	O
Intelligence	NNP	O
Scale-III	NNP	O
(	(	O
WAIS-III	NNP	O
)	)	O
,	,	O
the	DT	O
verbal	JJ	O
fluency	NN	O
test	NN	O
,	,	O
the	DT	O
Hopkins	NNP	O
Verbal	NNP	O
Learning	NNP	O
Test	NNP	O
(	(	O
HVLT	NNP	O
)	)	O
,	,	O
the	DT	O
Trail-Making	JJ	O
Test	NNP	O
(	(	O
TMT	NNP	O
)	)	O
and	CC	O
the	DT	O
Wisconsin	NNP	O
Card	NNP	O
Sorting	NNP	O
Test	NNP	O
(	(	O
WCST	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
week	NN	O
eight	CD	O
.	.	O

Nineteen	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
on	IN	O
any	DT	O
demographic	JJ	O
or	CC	O
general	JJ	O
clinical	JJ	O
variables	NNS	O
between	IN	O
the	DT	O
rosiglitazone	NN	O
group	NN	O
(	(	O
n=9	CC	O
)	)	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
n=10	RB	O
)	)	O
.	.	O

When	WRB	O
baseline	NN	O
scores	NNS	O
were	VBD	O
controlled	VBN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
change	NN	O
scores	NNS	O
of	IN	O
cognitive	JJ	O
performance	NN	O
over	IN	O
eight	CD	O
weeks	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
this	DT	O
pilot	NN	O
study	NN	O
,	,	O
rosiglitazone	NN	O
had	VBD	O
no	DT	O
cognitive	JJ	O
benefit	NN	O
in	IN	O
clozapine-treated	JJ	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

Future	JJ	O
studies	NNS	O
with	IN	O
longer	JJR	O
treatment	NN	O
duration	NN	O
and	CC	O
larger	JJR	O
sample	NN	O
size	NN	O
are	VBP	O
needed	VBN	O
to	TO	O
further	RBR	O
explore	VB	O
the	DT	O
potential	JJ	O
role	NN	O
of	IN	O
rosiglitazone	NN	O
in	IN	O
improving	VBG	O
cognitive	JJ	O
function	NN	O
in	IN	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
patient	NN	Educational
and	CC	Educational
physician	JJ	Educational
computer	NN	Educational
mediated	VBD	Educational
communication	NN	Educational
skill	NN	Educational
training	VBG	Educational
on	IN	O
reported	VBN	O
communication	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
parallel	JJ	O
patient	NN	O
and	CC	O
physician	JJ	O
computer-mediated	JJ	O
communication	NN	O
skill	NN	O
training	VBG	O
on	IN	O
participants	NNS	O
'	POS	O
report	NN	O
of	IN	O
skill	NN	O
use	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
.	.	O

METHODS	NNP	O
Separate	NNP	O
patient	NN	Other
and	CC	Other
clinician	JJ	Other
web-tools	NNS	Other
comprised	VBN	O
of	IN	O
over	IN	O
500	CD	Educational
,	,	Educational
10-s	JJ	Educational
video	NN	Educational
clips	NNS	Educational
demonstrating	VBG	Educational
patient-centered	JJ	Educational
skills	NNS	Educational
in	IN	O
various	JJ	O
ways	NNS	O
.	.	O

Four	CD	O
clinician	JJ	O
members	NNS	O
of	IN	O
the	DT	O
American	NNP	O
Academy	NNP	O
of	IN	O
Family	NNP	O
Physicians	NNP	O
National	NNP	O
Research	NNP	O
Network	NNP	O
participated	VBN	O
by	IN	O
enrolling	VBG	O
194	CD	O
patients	NNS	O
into	IN	O
a	DT	O
randomized	JJ	O
patient	NN	O
trial	NN	O
and	CC	O
29	CD	O
physicians	NNS	O
into	IN	O
a	DT	O
non-randomized	JJ	O
clinician	JJ	O
trial	NN	O
of	IN	O
respective	JJ	O
interventions	NNS	O
.	.	O

All	DT	O
participants	NNS	O
completed	VBN	O
baseline	NN	O
and	CC	O
follow-up	JJ	O
self-report	JJ	O
measures	NNS	O
of	IN	O
visit	NN	O
communication	NN	O
and	CC	O
satisfaction	NN	O
.	.	O

RESULTS	NNP	O
Intervention	NNP	O
patients	NNS	O
reported	VBD	O
using	VBG	O
more	JJR	O
skills	NNS	O
than	IN	O
controls	NNS	O
in	IN	O
five	CD	O
of	IN	O
six	CD	O
skill	JJ	O
areas	NNS	O
,	,	O
including	VBG	O
identification	NN	O
of	IN	O
problems/concerns	NNS	O
,	,	O
information	NN	O
exchange	NN	O
,	,	O
treatment	NN	O
adherence	NN	O
,	,	O
shared	VBN	O
decision-making	NN	O
and	CC	O
interpersonal	JJ	O
rapport	NN	O
(	(	O
all	DT	O
p	NN	O
<	NNP	O
.05	NNP	O
)	)	O
;	:	O
post	VBN	O
intervention	NN	O
,	,	O
physicians	NNS	O
reported	VBD	O
using	VBG	O
more	JJR	O
skills	NNS	O
in	IN	O
the	DT	O
same	JJ	O
5	CD	O
areas	NNS	O
(	(	O
all	DT	O
p	NN	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

Intervention	NNP	O
group	NN	O
patients	NNS	O
reported	VBD	O
higher	JJR	O
levels	NNS	O
of	IN	O
satisfaction	NN	O
than	IN	O
controls	NNS	O
in	IN	O
five	CD	O
of	IN	O
six	CD	O
domains	NNS	O
(	(	O
all	DT	O
p	NN	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Communication	NNP	Educational
skill	VBZ	Educational
training	VBG	Educational
delivered	VBN	O
in	IN	O
a	DT	O
computer	NN	O
mediated	VBN	O
format	NN	O
had	VBD	O
a	DT	O
positive	JJ	O
and	CC	O
parallel	JJ	O
impact	NN	O
on	IN	O
both	DT	O
patient	NN	O
and	CC	O
clinician	NN	O
reported	VBN	O
use	NN	O
of	IN	O
patient-centered	JJ	O
communication	NN	O
and	CC	O
in	IN	O
patient	JJ	O
satisfaction	NN	O
.	.	O

PRACTICE	NNP	O
IMPLICATIONS	NNP	O
Computer-mediated	JJ	O
interventions	NNS	O
are	VBP	O
cost	VBN	O
and	CC	O
time	NN	O
effective	JJ	O
thereby	RB	O
increasing	VBG	O
patient	NN	O
and	CC	O
clinician	JJ	O
willingness	NN	O
to	TO	O
undertake	VB	O
training	NN	O
.	.	O

Human	NNP	O
papillomavirus	NN	O
genotypes	NNS	O
in	IN	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
grade	VBD	O
3	CD	O
.	.	O

BACKGROUND	VB	O
There	EX	O
are	VBP	O
few	JJ	O
large	JJ	O
case	NN	O
series	NN	O
describing	VBG	O
the	DT	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
genotypes	VBZ	O
found	VBN	O
in	IN	O
women	NNS	O
diagnosed	VBN	O
with	IN	O
rigorously	RB	O
reviewed	VBN	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
grade	VBD	O
3	CD	O
(	(	O
CIN3	NNP	O
)	)	O
,	,	O
cervical	JJ	O
precancer	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
Atypical	NNP	O
Squamous	NNP	O
Cells	NNP	O
of	IN	O
Undetermined	VBN	O
Significance	NNP	O
(	(	O
ASCUS	NNP	O
)	)	O
and	CC	O
Low-Grade	NNP	O
Squamous	NNP	O
Intraepithelial	NNP	O
Lesion	NNP	O
(	(	O
LSIL	NNP	O
)	)	O
Triage	NN	O
Study	NNP	O
(	(	O
ALTS	NNP	O
)	)	O
was	VBD	O
a	DT	O
clinical	JJ	O
trial	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
best	JJS	O
management	NN	O
strategies	NNS	O
for	IN	O
women	NNS	O
with	IN	O
equivocal	JJ	O
(	(	O
ASCUS	NNP	O
)	)	O
or	CC	O
mildly	RB	O
abnormal	JJ	O
(	(	O
LSIL	NNP	O
)	)	O
Pap	NNP	O
tests	NNS	O
.	.	O

During	IN	O
enrollment	NN	O
and	CC	O
the	DT	O
2-year	JJ	O
follow-up	NN	O
,	,	O
608	CD	O
women	NNS	O
had	VBD	O
a	DT	O
histopathologic	JJ	O
diagnosis	NN	O
of	IN	O
CIN3	NNP	O
and	CC	O
PCR-based	JJ	Physical
HPV	NNP	Physical
genotyping	VBG	Physical
results	NNS	Physical
on	IN	O
cervical	JJ	O
specimens	NNS	O
.	.	O

The	DT	O
genotyping	VBG	O
results	NNS	O
were	VBD	O
ranked	VBN	O
hierarchically	RB	O
according	VBG	O
to	TO	O
cancer	NN	O
risk	NN	O
:	:	O
HPV16	NNP	O
>	VBZ	O
other	JJ	O
carcinogenic	JJ	O
HPV	NNP	O
>	NNP	O
noncarcinogenic	JJ	O
HPV	NNP	O
>	NNP	O
PCR	NNP	O
negative	JJ	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
608	CD	O
women	NNS	O
diagnosed	VBN	O
with	IN	O
CIN3	NNP	O
,	,	O
601	CD	O
(	(	O
98.8	CD	O
%	NN	O
)	)	O
cases	NNS	O
were	VBD	O
positive	JJ	O
for	IN	O
any	DT	O
HPV	NNP	O
genotype	NN	O
and	CC	O
95.4	CD	O
%	NN	O
for	IN	O
any	DT	O
carcinogenic	JJ	O
HPV	NNP	O
.	.	O

HPV16	NNP	O
(	(	O
59.9	CD	O
%	NN	O
)	)	O
,	,	O
HPV31	NNP	O
(	(	O
18.1	CD	O
%	NN	O
)	)	O
,	,	O
HPV52	NNP	O
(	(	O
14.8	CD	O
%	NN	O
)	)	O
,	,	O
HPV51	NNP	O
(	(	O
14.0	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
HPV18	NNP	O
(	(	O
13.2	CD	O
%	NN	O
)	)	O
were	VBD	O
the	DT	O
five	CD	O
most	JJS	O
common	JJ	O
HPV	NNP	O
genotypes	NNS	O
detected	VBD	O
.	.	O

Younger	JJR	O
age	NN	O
,	,	O
consensus	NN	O
histologic	JJ	O
confirmation	NN	O
,	,	O
smoking	NN	O
,	,	O
and	CC	O
multiparity	NN	O
increased	VBD	O
the	DT	O
likelihood	NN	O
of	IN	O
testing	VBG	O
HPV	NNP	O
16	CD	O
positive	JJ	O
.	.	O

Specifically	RB	O
,	,	O
HPV16-positive	JJ	O
CIN3	NNP	O
occurred	VBD	O
at	IN	O
a	DT	O
younger	JJR	O
age	NN	O
than	IN	O
CIN3	NNP	O
positive	JJ	O
for	IN	O
other	JJ	O
carcinogenic	JJ	O
HPV	NNP	O
genotypes	NNS	O
(	(	O
median	NN	O
of	IN	O
23.5	CD	O
years	NNS	O
versus	IN	O
25	CD	O
years	NNS	O
,	,	O
respectively	RB	O
;	:	O
P	NNP	O
=	VBZ	O
0.0003	CD	O
,	,	O
Kruskal-Wallis	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
HPV16-positive	JJ	O
CIN3	NNP	O
was	VBD	O
more	RBR	O
commonly	RB	O
diagnosed	VBN	O
in	IN	O
younger	JJR	O
women	NNS	O
(	(	O
versus	IN	O
older	JJR	O
women	NNS	O
)	)	O
,	,	O
with	IN	O
consensus	NN	O
diagnosis	NN	O
(	(	O
versus	IN	O
some	DT	O
disagreement	NN	O
between	IN	O
reviewers	NNS	O
)	)	O
,	,	O
and	CC	O
in	IN	O
smokers	NNS	O
(	(	O
versus	IN	O
nonsmokers	NNS	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
less	JJR	O
commonly	RB	O
diagnosed	VBN	O
in	IN	O
multiparous	JJ	O
women	NNS	O
compared	VBN	O
CIN3	NNP	O
positive	JJ	O
for	IN	O
other	JJ	O
carcinogenic	JJ	O
HPV	NNP	O
genotypes	NNS	O
.	.	O

IMPACT	NNP	O
In	IN	O
populations	NNS	O
vaccinated	VBN	O
against	IN	O
HPV16	NNP	Physical
(	(	Physical
and	CC	Physical
HPV18	NNP	Physical
)	)	Physical
,	,	O
the	DT	O
median	JJ	O
age	NN	O
of	IN	O
CIN3	NNP	O
in	IN	O
women	NNS	O
with	IN	O
ASCUS	NNP	O
and	CC	O
LSIL	NNP	O
cytology	NN	O
should	MD	O
shift	VB	O
to	TO	O
older	JJR	O
ages	NNS	O
,	,	O
possibly	RB	O
permitting	VBG	O
later	RB	O
age	NN	O
at	IN	O
first	JJ	O
screening	NN	O
.	.	O

Lung	NNP	O
function	NN	O
and	CC	O
respiratory	NN	O
symptoms	NNS	O
in	IN	O
a	DT	O
1-year	JJ	O
randomized	JJ	O
smoking	NN	O
cessation	NN	O
trial	NN	O
of	IN	O
varenicline	NN	Pharmacological
in	IN	O
COPD	NNP	O
patients	NNS	O
.	.	O

UNLABELLED	IN	O
There	EX	O
are	VBP	O
few	JJ	O
data	NNS	O
concerning	VBG	O
changes	NNS	O
in	IN	O
lung	NN	O
function	NN	O
and	CC	O
respiratory	NN	O
symptoms	NNS	O
in	IN	O
smokers	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
weeks	NNS	O
to	TO	O
months	NNS	O
after	IN	O
quitting	VBG	O
smoking	NN	O
.	.	O

We	PRP	O
examined	VBD	O
serial	JJ	O
changes	NNS	O
in	IN	O
spirometry	NN	O
and	CC	O
Clinical	NNP	O
COPD	NNP	O
Questionnaire	NNP	O
(	(	O
CCQ	NNP	O
)	)	O
scores	VBZ	O
(	(	O
measuring	VBG	O
respiratory	NN	O
symptoms	NNS	O
and	CC	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
)	)	O
in	IN	O
COPD	NNP	O
participants	NNS	O
by	IN	O
smoking	VBG	O
status	NN	O
during	IN	O
a	DT	O
smoking	NN	O
cessation	NN	O
trial	NN	O
.	.	O

In	IN	O
this	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
,	,	O
smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
varenicline	JJ	Pharmacological
1	CD	Pharmacological
mg	NN	Pharmacological
b.i.d	NN	Pharmacological
.	.	Pharmacological

or	CC	O
placebo	NN	Control
for	IN	O
12	CD	O
weeks	NNS	O
and	CC	O
followed	VBD	O
to	TO	O
Week	VB	O
52	CD	O
.	.	O

Primary	JJ	O
endpoints	NNS	O
of	IN	O
abstinence	NN	O
were	VBD	O
previously	RB	O
reported	VBN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
were	VBD	O
mean	JJ	O
changes	NNS	O
from	IN	O
baseline	NN	O
in	IN	O
post-bronchodilator	NN	O
forced	VBN	O
expired	JJ	O
volume	NN	O
in	IN	O
1	CD	O
s	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
and	CC	O
CCQ	NNP	O
scores	NNS	O
.	.	O

Change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
post-bronchodilator	NN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
was	VBD	O
significantly	RB	O
improved	VBN	O
in	IN	O
continuous	JJ	O
abstainers	NNS	O
(	(	O
121.8	CD	O
mL	NN	O
)	)	O
vs.	FW	O
continuous	JJ	O
smokers	NNS	O
(	(	O
37.9	CD	O
mL	NN	O
)	)	O
at	IN	O
Week	$	O
12	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.0069	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
Weeks	NNP	O
24	CD	O
or	CC	O
52	CD	O
.	.	O

Mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
at	IN	O
Week	NNP	O
12	CD	O
in	IN	O
CCQ	NNP	O
Total	NNP	O
Score	NNP	O
was	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
continuous	JJ	O
abstainers	NNS	O
(	(	O
-1.04	NN	O
)	)	O
vs.	FW	O
continuous	JJ	O
smokers	NNS	O
(	(	O
-0.53	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
:	:	O
this	DT	O
improvement	NN	O
was	VBD	O
sustained	VBN	O
at	IN	O
Weeks	NNP	O
24	CD	O
and	CC	O
52	CD	O
.	.	O

In	IN	O
a	DT	O
1-year	JJ	O
cessation	NN	O
trial	NN	O
of	IN	O
smokers	NNS	O
with	IN	O
COPD	NNP	O
,	,	O
continuous	JJ	O
abstinence	NN	O
compared	VBN	O
with	IN	O
continuous	JJ	O
smoking	VBG	O
significantly	RB	O
improved	VBN	O
post-bronchodilator	NN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
at	IN	O
Week	$	O
12	CD	O
(	(	O
although	IN	O
the	DT	O
difference	NN	O
narrowed	VBD	O
subsequently	RB	O
)	)	O
and	CC	O
CCQ	NNP	O
Total	NNP	O
Scores	NNP	O
at	IN	O
Week	NNP	O
12	CD	O
,	,	O
with	IN	O
sustained	JJ	O
improvement	NN	O
thereafter	RB	O
.	.	O

(	(	O
TRIAL	NNP	O
REGISTRY	NNP	O
http	NN	O
:	:	O
//www.clinicaltrials.gov	NN	O
;	:	O
trial	NN	O
identifier	NN	O
:	:	O
NCT00285012	NNP	O
)	)	O
.	.	O

What	WP	O
is	VBZ	O
the	DT	O
optimum	JJ	O
maximal	JJ	O
gonadotropin	NN	Pharmacological
dosage	NN	O
used	VBN	O
in	IN	O
microdose	JJ	O
flare-up	JJ	O
cycles	NNS	O
in	IN	O
poor	JJ	O
responders	NNS	O
?	.	O
OBJECTIVE	NNP	O
To	TO	O
find	VB	O
out	RP	O
the	DT	O
optimum	JJ	O
maximal	JJ	O
dosage	NN	O
of	IN	O
recombinant	JJ	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
(	(	O
rFSH	NN	O
)	)	O
in	IN	O
microdose	JJ	O
gonadotropin-releasing	JJ	Pharmacological
hormone	NN	Pharmacological
analog	NN	Pharmacological
(	(	Pharmacological
GnRH-a	NNP	Pharmacological
)	)	Pharmacological
flare	NN	O
cycles	NNS	O
in	IN	O
poor	JJ	O
responders	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
randomized	VBD	O
study	NN	O
.	.	O

SETTING	NNP	O
Private	NNP	O
infertility	NN	O
clinic	NN	O
.	.	O

PATIENT	NNP	O
(	(	O
S	NNP	O
)	)	O
A	NNP	O
total	NN	O
of	IN	O
119	CD	O
women	NNS	O
were	VBD	O
taken	VBN	O
into	IN	O
the	DT	O
study	NN	O
.	.	O

INTERVENTION	NNP	O
(	(	O
S	NNP	O
)	)	O
The	DT	O
study	NN	O
group	NN	O
underwent	VBD	O
a	DT	O
microdose	JJ	O
protocol	NN	O
with	IN	O
a	DT	O
GnRH-agonist	JJ	Physical
followed	VBN	O
by	IN	O
rFSH	JJ	Physical
administration	NN	Physical
.	.	O

On	IN	O
the	DT	O
third	JJ	O
day	NN	O
of	IN	O
GnRH-a	NNP	Pharmacological
administration	NN	O
,	,	O
119	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
in	IN	O
three	CD	O
groups	NNS	O
to	TO	O
receive	VB	O
daily	JJ	O
fixed	VBN	O
doses	NNS	O
of	IN	O
300	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	Physical
(	(	O
group	NN	O
A	NNP	O
,	,	O
n	JJ	O
=	NNP	O
38	CD	O
)	)	O
,	,	O
or	CC	O
450	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	O
(	(	O
group	NN	O
B	NNP	O
,	,	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
,	,	O
or	CC	O
600	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	O
(	(	O
group	NN	O
C	NNP	O
,	,	O
n	JJ	O
=	NNP	O
42	CD	O
)	)	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
(	(	O
S	NNP	O
)	)	O
Peak	NNP	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
levels	NNS	O
,	,	O
days	NNS	O
of	IN	O
stimulation	NN	O
with	IN	O
rFSH	NN	O
,	,	O
total	JJ	O
rFSH	NN	O
dosage	NN	O
,	,	O
total	JJ	O
number	NN	O
of	IN	O
oocytes	NNS	O
retrieved	VBN	O
,	,	O
M2	NNP	O
oocytes	VBZ	O
retrieved	VBN	O
,	,	O
total	JJ	O
number	NN	O
of	IN	O
embryos	NN	O
,	,	O
number	NN	O
of	IN	O
embryos	NN	O
transferred	VBN	O
,	,	O
number	NN	O
of	IN	O
Grade-1	NNP	O
embryos	NN	O
transferred	VBD	O
,	,	O
clinical	JJ	O
pregnancy	NN	O
rate	NN	O
(	(	O
positive	JJ	O
fetal	JJ	O
cardiac	JJ	O
activity	NN	O
)	)	O
,	,	O
and	CC	O
cancellation	NN	O
rates	NNS	O
of	IN	O
stimulation	NN	O
and	CC	O
embryo	NN	O
transfer	NN	O
.	.	O

RESULT	NNP	O
(	(	O
S	NNP	O
)	)	O
Clinical	NNP	O
pregnancy	NN	O
rates	NNS	O
were	VBD	O
13.1	CD	O
%	NN	O
,	,	O
15.3	CD	O
%	NN	O
,	,	O
and	CC	O
16.1	CD	O
%	NN	O
for	IN	O
group	NN	O
A	NNP	O
,	,	O
group	NN	O
B	NNP	O
,	,	O
and	CC	O
group	NN	O
C	NNP	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
age	NN	O
,	,	O
peak	JJ	O
serum	NN	O
E	NNP	O
(	(	O
2	CD	O
)	)	O
concentration	NN	O
,	,	O
days	NNS	O
of	IN	O
stimulation	NN	O
with	IN	O
rFSH	NN	O
,	,	O
total	JJ	O
number	NN	O
of	IN	O
M2	NNP	O
oocytes	VBZ	O
retrieved	VBN	O
,	,	O
number	NN	O
of	IN	O
embryos	NN	O
transferred	VBN	O
,	,	O
clinical	JJ	O
pregnancy	NN	O
rates	NNS	O
,	,	O
and	CC	O
cancellation	NN	O
rates	NNS	O
of	IN	O
stimulation	NN	O
and	CC	O
embryo	NN	O
transfer	NN	O
between	IN	O
the	DT	O
three	CD	O
groups	NNS	O
except	IN	O
for	IN	O
total	JJ	O
rFSH	JJ	O
dosage	NN	O
.	.	O

CONCLUSION	NNP	O
(	(	O
S	NNP	O
)	)	O
There	EX	O
is	VBZ	O
no	DT	O
need	NN	O
to	TO	O
use	VB	O
doses	NNS	O
above	IN	O
300	CD	O
IU	NNP	O
of	IN	O
rFSH	NN	O
to	TO	O
increase	VB	O
the	DT	O
pregnancy	NN	O
rate	NN	O
in	IN	O
microdose	JJ	O
cycles	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
because	IN	O
the	DT	O
duration	NN	O
of	IN	O
stimulation	NN	O
does	VBZ	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
groups	NNS	O
,	,	O
the	DT	O
usage	NN	O
of	IN	O
300	CD	O
IU	NNP	O
rFSH	NN	O
in	IN	O
microdose	JJ	O
cycles	NNS	O
results	NNS	O
in	IN	O
less	JJR	O
total	JJ	O
amount	NN	O
of	IN	O
rFSH	NN	O
consumed	VBN	O
in	IN	O
a	DT	O
cycle	NN	O
compared	VBN	O
with	IN	O
higher	JJR	O
dosages	NNS	O
,	,	O
and	CC	O
this	DT	O
would	MD	O
obviously	RB	O
cost	VB	O
less	JJR	O
money	NN	O
to	TO	O
the	DT	O
patients	NNS	O
.	.	O

Long-term	JJ	O
(	(	O
96-week	JJ	O
)	)	O
follow-up	NN	O
of	IN	O
antiretroviral-na?ve	JJ	O
HIV-infected	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
first-line	JJ	O
lopinavir/ritonavir	NN	O
monotherapy	NN	Physical
in	IN	O
the	DT	O
MONARK	NNP	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
toxicities	NNS	O
,	,	O
cost	NN	O
and	CC	O
complexity	NN	O
of	IN	O
triple	JJ	O
combinations	NNS	O
warrant	VBP	O
the	DT	O
search	NN	O
for	IN	O
other	JJ	O
treatment	NN	O
options	NNS	O
,	,	O
such	JJ	O
as	IN	O
boosted	JJ	O
protease	NN	O
inhibitor	NN	O
(	(	O
PI	NNP	O
)	)	O
monotherapy	NN	O
.	.	O

MONotherapy	NNP	O
AntiRetroviral	NNP	O
Kaletra	NNP	O
(	(	O
MONARK	NNP	O
)	)	O
is	VBZ	O
the	DT	O
first	JJ	O
randomized	JJ	O
trial	NN	O
comparing	VBG	O
lopinavir/ritonavir	JJ	O
monotherapy	NN	O
to	TO	O
triple	VB	O
combination	NN	O
therapy	NN	O
with	IN	O
zidovudine/lamivudine	NN	O
and	CC	O
lopinavir/ritonavir	NN	O
in	IN	O
antiretroviral-na?ve	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
136	CD	O
antiretroviral-na?ve	JJ	O
patients	NNS	O
,	,	O
with	IN	O
a	DT	O
CD4	NNP	O
cell	NN	O
count	NN	O
above	IN	O
100	CD	O
cells/microL	NN	O
and	CC	O
a	DT	O
plasma	NN	O
HIV	NNP	O
RNA	NNP	O
below	IN	O
100,000	CD	O
HIV-1	JJ	O
RNA	NNP	O
copies/mL	NN	O
,	,	O
were	VBD	O
randomized	VBN	O
and	CC	O
dosed	VBN	O
with	IN	O
either	DT	O
lopinavir/ritonavir	JJ	O
monotherapy	NN	O
(	(	O
n	JJ	O
=	NNP	O
83	CD	O
)	)	O
or	CC	O
lopinavir/ritonavir	JJ	Pharmacological
+	JJ	O
zidovudine/lamivudine	NN	O
(	(	O
n	JJ	O
=	NNP	O
53	CD	O
)	)	O
.	.	O

We	PRP	O
focus	VBP	O
here	RB	O
on	IN	O
patients	NNS	O
in	IN	O
the	DT	O
lopinavir/ritonavir	NN	O
monotherapy	NN	O
arm	NN	O
followed	VBD	O
to	TO	O
week	NN	O
96	CD	O
.	.	O

The	DT	O
intent-to-treat	NN	O
(	(	O
ITT	NNP	O
)	)	O
analysis	NN	O
initially	RB	O
involved	VBD	O
all	DT	O
patients	NNS	O
randomized	VBN	O
to	TO	O
lopinavir/ritonavir	VB	O
monotherapy	NN	O
(	(	O
n	JJ	O
=	NNP	O
83	CD	O
)	)	O
,	,	O
and	CC	O
then	RB	O
focused	VBD	O
on	IN	O
patients	NNS	O
who	WP	O
had	VBD	O
an	DT	O
HIV	NNP	O
RNA	NNP	O
<	VBD	O
50	CD	O
copies/mL	NN	O
at	IN	O
week	NN	O
48	CD	O
(	(	O
n	JJ	O
=	NNP	O
56	CD	O
)	)	O
.	.	O

RESULTS	VBN	O
At	IN	O
week	NN	O
96	CD	O
,	,	O
39	CD	O
of	IN	O
83	CD	O
patients	NNS	O
(	(	O
47	CD	O
%	NN	O
)	)	O
had	VBD	O
HIV	NNP	O
RNA	NNP	O
<	VBD	O
50	CD	O
copies/mL	NN	O
,	,	O
five	CD	O
of	IN	O
83	CD	O
had	VBD	O
HIV	NNP	O
RNA	NNP	O
between	IN	O
50	CD	O
and	CC	O
400	CD	O
copies/mL	NN	O
,	,	O
and	CC	O
three	CD	O
of	IN	O
83	CD	O
had	VBD	O
HIV	NNP	O
RNA	NNP	O
>	VBD	O
400	CD	O
copies/mL	NN	O
.	.	O

Focusing	VBG	O
on	IN	O
the	DT	O
56	CD	O
patients	NNS	O
with	IN	O
an	DT	O
HIV	NNP	O
RNA	NNP	O
<	VBD	O
50	CD	O
copies/mL	NN	O
at	IN	O
week	NN	O
48	CD	O
,	,	O
38	CD	O
of	IN	O
56	CD	O
patients	NNS	O
(	(	O
68	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
sustained	VBN	O
HIV	NNP	O
RNA	NNP	O
<	VBD	O
50	CD	O
copies/mL	NN	O
to	TO	O
week	NN	O
96	CD	O
.	.	O

To	TO	O
week	NN	O
96	CD	O
,	,	O
a	DT	O
total	NN	O
of	IN	O
28	CD	O
patients	NNS	O
(	(	O
34	CD	O
%	NN	O
)	)	O
had	VBD	O
discontinued	VBN	O
the	DT	O
study	NN	O
treatment	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
the	DT	O
allocated	JJ	O
treatment	NN	O
was	VBD	O
changed	VBN	O
for	IN	O
seven	CD	O
patients	NNS	O
.	.	O

PI-associated	JJ	O
resistance	NN	O
mutations	NNS	O
were	VBD	O
evident	JJ	O
in	IN	O
five	CD	O
of	IN	O
83	CD	O
patients	NNS	O
in	IN	O
the	DT	O
monotherapy	NN	O
arm	NN	O
from	IN	O
baseline	NN	O
to	TO	O
week	NN	O
96	CD	O
.	.	O

CONCLUSION	NN	O
By	IN	O
ITT	NNP	O
analysis	NN	O
,	,	O
39	CD	O
of	IN	O
the	DT	O
83	CD	O
patients	NNS	O
initially	RB	O
randomized	VBN	O
to	TO	O
lopinavir/ritonavir	VB	O
monotherapy	NN	O
had	VBD	O
HIV	NNP	O
RNA	NNP	O
<	VBD	O
50	CD	O
copies/mL	NN	O
at	IN	O
week	NN	O
96	CD	O
.	.	O

The	DT	O
occurrence	NN	O
in	IN	O
some	DT	O
patients	NNS	O
of	IN	O
low-level	JJ	O
viraemia	NN	O
(	(	O
50-500	JJ	O
copies/mL	NN	O
)	)	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
drug	NN	O
resistance	NN	O
.	.	O

First-line	JJ	O
lopinavir/ritonavir	JJ	O
monotherapy	NN	O
can	MD	O
not	RB	O
be	VB	O
systematically	RB	O
recommended	VBN	O
.	.	O

Prevention	NN	O
of	IN	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
comparing	VBG	O
enoxaparin	NN	Pharmacological
with	IN	O
warfarin	NN	Pharmacological
.	.	Pharmacological

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
safety	NN	O
of	IN	O
fixed-dose	JJ	Pharmacological
enoxaparin	NN	Pharmacological
and	CC	O
adjusted	VBD	Pharmacological
dose	JJ	Pharmacological
warfarin	NN	Pharmacological
in	IN	O
preventing	VBG	O
venous	JJ	O
thromboembolism	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

DESIGN	VB	O
A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

SETTING	NN	O
8	CD	O
university	NN	O
hospitals	NNS	O
.	.	O

PATIENTS	VB	O
670	CD	O
consecutive	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
knee	VBN	O
arthroplasty	RB	O
.	.	O

INTERVENTION	NN	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
enoxaparin	NN	Pharmacological
(	(	Pharmacological
30	CD	Pharmacological
mg	NN	Pharmacological
subcutaneously	RB	Pharmacological
every	DT	Pharmacological
12	CD	Pharmacological
hours	NNS	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
adjusted-dose	JJ	Pharmacological
warfarin	NN	Pharmacological
(	(	Pharmacological
international	JJ	Pharmacological
normalized	VBN	Pharmacological
ratio	NN	Pharmacological
,	,	Pharmacological
2.0	CD	Pharmacological
to	TO	Pharmacological
3.0	CD	Pharmacological
)	)	Pharmacological
.	.	O

Both	DT	O
regimens	NNS	O
were	VBD	O
started	VBN	O
after	IN	O
surgery	NN	O
.	.	O

MEASUREMENTS	PDT	O
The	DT	O
primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
adequate	JJ	O
bilateral	JJ	O
venograms	NNS	O
;	:	O
the	DT	O
secondary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
hemorrhage	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
417	CD	O
patients	NNS	O
with	IN	O
adequate	JJ	O
venograms	NNS	O
,	,	O
109	CD	O
of	IN	O
211	CD	O
warfarin	NN	Pharmacological
recipients	NNS	O
(	(	O
51.7	CD	O
%	NN	O
)	)	O
had	VBD	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
compared	VBN	O
with	IN	O
76	CD	O
of	IN	O
206	CD	O
enoxaparin	NN	Pharmacological
recipients	NNS	O
(	(	O
36.9	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
14.8	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
enoxaparin	NN	Pharmacological
(	(	O
95	CD	O
%	NN	O
Cl	NNP	O
,	,	O
5.3	CD	O
%	NN	O
to	TO	O
24.1	CD	O
%	NN	O
)	)	O
Twenty-two	NNP	O
warfarin	NN	Pharmacological
recipients	NNS	O
(	(	O
10.4	CD	O
%	NN	O
)	)	O
and	CC	O
24	CD	O
enoxaparin	NN	Pharmacological
recipients	NNS	O
(	(	O
11.7	CD	O
%	NN	O
)	)	O
had	VBD	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
1.2	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	Pharmacological
(	(	O
Cl	NNP	O
,	,	O
-7.2	NNP	O
%	NN	O
to	TO	O
4.8	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
major	JJ	O
bleeding	NN	O
was	VBD	O
1.8	CD	O
%	NN	O
(	(	O
6	CD	O
of	IN	O
334	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
warfarin	NN	O
group	NN	O
and	CC	O
2.1	CD	O
%	NN	O
(	(	O
7	CD	O
of	IN	O
336	CD	O
patients	NNS	O
)	)	O
in	IN	O
the	DT	O
enoxaparin	NN	O
group	NN	O
(	(	O
P	NNP	O
>	NNP	O
0.2	CD	O
)	)	O
.	.	O

The	DT	O
absolute	NN	O
risk	NN	O
difference	NN	O
was	VBD	O
0.3	CD	O
%	NN	O
in	IN	O
favor	NN	O
of	IN	O
warfarin	NN	O
(	(	O
Cl	NNP	O
,	,	O
-2.4	NNP	O
%	NN	O
to	TO	O
1.8	CD	O
%	NN	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
postoperative	JJ	O
,	,	O
fixed-dose	JJ	O
enoxaparin	NN	Pharmacological
regimen	NNS	O
is	VBZ	O
more	RBR	O
effective	JJ	O
than	IN	O
adjusted-dose	JJ	O
warfarin	NN	Pharmacological
in	IN	O
preventing	VBG	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
after	IN	O
knee	NN	O
arthroplasty	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
venous	JJ	O
thrombosis	NN	O
or	CC	O
clinically	RB	O
overt	JJ	O
hemorrhage	NN	O
.	.	O

[	JJ	O
Pleural	NNP	Surgical
tent	NN	Surgical
after	IN	O
upper	JJ	O
lobectomy	NN	O
--	:	O
randomized	VBD	O
study	NN	O
of	IN	O
it	PRP	O
's	VBZ	O
efficacy	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
effect	NN	O
]	NNP	O
.	.	O

UNLABELLED	IN	O
The	DT	O
aim	NN	O
of	IN	O
our	PRP$	O
study	NN	O
is	VBZ	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
,	,	O
efficacy	NN	O
and	CC	O
also	RB	O
the	DT	O
maximum	JJ	O
duration	NN	O
of	IN	O
effect	NN	O
of	IN	O
the	DT	O
pleural	JJ	Surgical
tent	NN	Surgical
in	IN	O
reducing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
air	NN	O
leak	NN	O
after	IN	O
upper	JJ	O
lobectomy	NN	O
.	.	O

METHODS	NNP	O
Sixty	NNP	O
patients	NNS	O
who	WP	O
underwent	VBP	O
upper	JJ	O
lobectomy	NN	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
30	CD	O
patients	NNS	O
had	VBD	O
creation	NN	Other
of	IN	Other
pleural	JJ	Surgical
tent	NN	Surgical
(	(	O
group	NN	O
1	CD	O
)	)	O
and	CC	O
30	CD	O
did	VBD	Control
not	RB	Control
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

The	DT	O
preoperative	JJ	O
,	,	O
operative	JJ	O
,	,	O
and	CC	O
postoperative	JJ	O
characteristics	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

Then	RB	O
multivariate	JJ	O
analyses	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
identify	VB	O
factors	NNS	O
predictive	CD	O
of	IN	O
prolonged	JJ	O
air	NN	O
leaks	NNS	O
and	CC	O
their	PRP$	O
duration	NN	O
.	.	O

The	DT	O
reduction	NN	O
of	IN	O
incidences	NNS	O
of	IN	O
air	NN	O
leak	NN	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
was	VBD	O
subsequently	RB	O
compared	VBN	O
during	IN	O
successive	JJ	O
postoperative	JJ	O
periods	NNS	O
.	.	O

RESULTS	NNP	O
Demographic	NNP	O
and	CC	O
clinical	JJ	O
profiles	NNS	O
of	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
.	.	O

The	DT	O
tented	JJ	O
patients	NNS	O
had	VBD	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
mean	JJ	O
duration	NN	O
of	IN	O
air	NN	O
leak	NN	O
in	IN	O
days	NNS	O
(	(	O
4.9	CD	O
+/-	JJ	O
1.79	CD	O
vs	JJ	O
8.2	CD	O
+/-	JJ	O
4.2	CD	O
)	)	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
days	NNS	O
of	IN	O
a	DT	O
chest	NN	O
tube	NN	O
duration	NN	O
(	(	O
7.3	CD	O
+/-	JJ	O
1.14	CD	O
vs	JJ	O
12.46	CD	O
+/-	JJ	O
3.6	CD	O
)	)	O
,	,	O
the	DT	O
length	NN	O
of	IN	O
postoperative	JJ	O
in-hospital	JJ	O
stay	NN	O
in	IN	O
days	NNS	O
(	(	O
9.4	CD	O
+/-	JJ	O
1.86	CD	O
vs	JJ	O
13.6	CD	O
+/-	JJ	O
2.49	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
hospital	NN	O
stay	NN	O
cost	NN	O
per	IN	O
patient	NN	O
(	(	O
leva	NN	O
,	,	O
3840	CD	O
+/-	JJ	O
298	CD	O
vs	JJ	O
5160	CD	O
+/-	JJ	O
3890	CD	O
)	)	O
.	.	O

Logistic	JJ	O
regression	NN	O
analyses	NNS	O
showed	VBD	O
that	IN	O
no	DT	O
having	VBG	O
creation	NN	O
a	DT	O
pleural	JJ	Surgical
tent	NN	Surgical
procedure	NN	O
was	VBD	O
the	DT	O
most	RBS	O
significant	JJ	O
predictive	JJ	O
factor	NN	O
of	IN	O
the	DT	O
occurrence	NN	O
and	CC	O
duration	NN	O
of	IN	O
prolonged	JJ	O
air	NN	O
leaks	NNS	O
.	.	O

A	DT	O
greater	JJR	O
reduction	NN	O
in	IN	O
the	DT	O
duration	NN	O
of	IN	O
air	NN	O
leaks	NNS	O
was	VBD	O
observed	VBN	O
before	IN	O
postoperative	JJ	O
day	NN	O
4	CD	O
in	IN	O
group	NN	O
1	CD	O
,	,	O
and	CC	O
logistic	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
having	VBG	O
a	DT	O
pleural	JJ	O
tent	NN	O
procedure	NN	O
was	VBD	O
the	DT	O
most	RBS	O
significant	JJ	O
predictive	JJ	O
factor	NN	O
of	IN	O
air	NN	O
leaks	NNS	O
that	WDT	O
persisted	VBD	O
for	IN	O
less	JJR	O
than	IN	O
4	CD	O
days	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Pleural	NNP	O
tent	NN	O
creation	NN	O
after	IN	O
upper	JJ	O
lobectomy	NN	O
is	VBZ	O
a	DT	O
simple	JJ	O
and	CC	O
safe	JJ	O
procedure	NN	O
that	WDT	O
reduces	VBZ	O
the	DT	O
duration	NN	O
of	IN	O
air	NN	O
leaks	NNS	O
and	CC	O
the	DT	O
hospital	NN	O
stay	NN	O
costs	NNS	O
.	.	O

The	DT	O
benefit	NN	O
from	IN	O
that	DT	O
procedure	NN	O
is	VBZ	O
achieved	VBN	O
before	IN	O
postoperative	JJ	O
day	NN	O
4	CD	O
.	.	O

Effects	NNS	O
of	IN	O
halothane	NN	Pharmacological
and	CC	O
isoflurane	NN	Pharmacological
on	IN	O
transient	JJ	O
renal	JJ	O
dysfunction	NN	O
associated	VBN	O
with	IN	O
infrarenal	JJ	O
aortic	JJ	O
cross-clamping	NN	O
.	.	O

Aortic	JJ	O
cross-clamping	NN	O
for	IN	O
reconstructive	JJ	O
aortic	JJ	O
surgery	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
impairment	NN	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

Halothane	NNP	Pharmacological
or	CC	O
isoflurane	NN	Pharmacological
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
influence	NN	O
of	IN	O
volatile	JJ	O
anesthesia	NN	O
on	IN	O
renal	JJ	O
hemodynamics	NNS	O
during	IN	O
aortic	JJ	O
surgery	NN	O
.	.	O

Nineteen	JJ	O
patients	NNS	O
with	IN	O
normal	JJ	O
preoperative	JJ	O
creatinine	NN	O
clearances	NNS	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
reconstructive	JJ	O
aortic	JJ	O
surgery	NN	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
halothane	NN	Pharmacological
group	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
and	CC	O
isoflurane	JJ	Physical
group	NN	Physical
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
.	.	O

Induction	NN	O
of	IN	O
anesthesia	NN	O
consisted	VBN	O
of	IN	O
midazolam	NN	Pharmacological
,	,	O
fentanyl	NN	Pharmacological
,	,	O
and	CC	O
pancuronium	NN	Pharmacological
.	.	O

Anesthesia	NNP	O
was	VBD	O
maintained	VBN	O
with	IN	O
fentanyl	NN	Pharmacological
and	CC	O
halothane	NN	Pharmacological
or	CC	O
isoflurane	NN	Pharmacological
in	IN	Pharmacological
nitrous	JJ	Pharmacological
oxide	NN	Pharmacological
and	CC	Pharmacological
oxygen	NN	Pharmacological
(	(	O
50/50	CD	O
)	)	O
.	.	O

Systemic	JJ	O
hemodynamics	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
throughout	IN	O
surgery	NN	O
.	.	O

Before	IN	O
aortic	JJ	O
cross-clamping	NN	O
,	,	O
effective	JJ	O
renal	JJ	O
plasma	NN	O
flow	NN	O
(	(	O
ERPF	NNP	O
)	)	O
(	(	O
131I-hippuran	JJ	O
clearance	NN	O
)	)	O
and	CC	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
GFR	NNP	O
)	)	O
(	(	O
99Tc-DTPA	JJ	O
clearance	NN	O
)	)	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
halothane	NN	O
group	NN	O
(	(	O
118.4	CD	O
+/-	JJ	O
25.6	CD	O
and	CC	O
19.7	CD	O
+/-	JJ	O
5.2	CD	O
mL/min	NN	O
,	,	O
respectively	RB	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
isoflurane	NN	Pharmacological
group	NN	O
(	(	O
253.4	CD	O
+/-	JJ	O
51.5	CD	O
and	CC	O
44.9	CD	O
+/-	JJ	O
8.4	CD	O
mL/min	NN	O
)	)	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
.	.	O

During	IN	O
cross-clamping	NN	O
,	,	O
the	DT	O
renal	JJ	O
variables	NNS	O
were	VBD	O
not	RB	O
markedly	RB	O
affected	VBN	O
in	IN	O
either	DT	O
group	NN	O
and	CC	O
remained	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
isoflurane-anesthetized	JJ	O
patients	NNS	O
(	(	O
232.9	CD	O
+/-	JJ	O
47.1	CD	O
and	CC	O
49.5	CD	O
+/-	JJ	O
1.2	CD	O
mL/min	NN	O
for	IN	O
ERPF	NNP	O
and	CC	O
GFR	NNP	O
,	,	O
respectively	RB	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
halothane-anesthetized	JJ	Pharmacological
patients	NNS	O
(	(	O
132.4	CD	O
+/-	JJ	O
31.6	CD	O
and	CC	O
14.8	CD	O
+/-	JJ	O
3.7	CD	O
mL/min	NN	O
,	,	O
respectively	RB	O
)	)	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

After	IN	O
aortic	JJ	O
unclamping	NN	O
,	,	O
ERPF	NNP	O
increased	VBD	O
markedly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
467.8	CD	O
+/-	JJ	O
122	CD	O
and	CC	O
362.5	CD	O
+/-	JJ	O
57.7	CD	O
mL/min	NN	O
in	IN	O
the	DT	O
halothane	NN	O
and	CC	O
isoflurane	NN	O
groups	NNS	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
as	IN	O
did	VBD	O
GFR	NNP	O
(	(	O
74.8	CD	O
+/-	JJ	O
22	CD	O
and	CC	O
71.8	CD	O
+/-	JJ	O
13.1	CD	O
mL/min	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
anesthesia	NN	Pharmacological
with	IN	O
halothane	NN	Pharmacological
is	VBZ	O
associated	VBN	O
with	IN	O
transient	JJ	O
renal	JJ	O
vasoconstriction	NN	O
during	IN	O
abdominal	JJ	O
surgery	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
aortic	JJ	O
cross-clamping	NN	O
during	IN	O
isoflurane	NN	O
anesthesia	NN	O
was	VBD	O
not	RB	O
associated	VBN	O
with	IN	O
renal	JJ	O
hemodynamic	JJ	O
impairment	NN	O
.	.	O

Multi-institutional	JJ	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
the	DT	O
epothilone	NN	O
B	NNP	O
analog	NN	O
ixabepilone	NN	O
(	(	O
BMS-247550	NNP	O
)	)	O
with	IN	O
or	CC	O
without	IN	O
estramustine	JJ	O
phosphate	NN	O
in	IN	O
patients	NNS	O
with	IN	O
progressive	JJ	O
castrate	NN	O
metastatic	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
antitumor	NN	O
activity	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
epothilone	NN	Pharmacological
B	NNP	Pharmacological
analog	NN	Pharmacological
,	,	Pharmacological
ixabepilone	NN	Pharmacological
,	,	Pharmacological
with	IN	Pharmacological
or	CC	Pharmacological
without	IN	Pharmacological
estramustine	JJ	Pharmacological
phosphate	NN	Pharmacological
(	(	Pharmacological
EMP	NNP	Pharmacological
)	)	Pharmacological
,	,	O
in	IN	O
chemotherapy-naive	JJ	O
patients	NNS	O
with	IN	O
progressive	JJ	O
castrate	NN	O
metastatic	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
ixabepilone	NN	Pharmacological
(	(	O
35	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
every	DT	O
3	CD	O
weeks	NNS	O
with	IN	O
or	CC	O
without	IN	O
EMP	NNP	Pharmacological
280	CD	O
mg	NN	O
orally	RB	O
three	CD	O
times	NNS	O
daily	RB	O
on	IN	O
days	NNS	O
1	CD	O
to	TO	O
5	CD	O
.	.	O

RESULTS	NN	O
Between	NNP	O
December	NNP	O
2001	CD	O
and	CC	O
October	NNP	O
2003	CD	O
,	,	O
92	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
ixabepilone	NN	Pharmacological
alone	RB	Pharmacological
(	(	O
45	CD	O
patients	NNS	O
)	)	O
or	CC	O
in	IN	O
combination	NN	Pharmacological
with	IN	Pharmacological
EMP	NNP	Pharmacological
(	(	O
47	CD	O
patients	NNS	O
)	)	O
.	.	O

Grades	$	O
3	CD	O
and	CC	O
4	CD	O
toxicities	NNS	O
experienced	VBN	O
by	IN	O
more	JJR	O
than	IN	O
5	CD	O
%	NN	O
of	IN	O
patients	NNS	O
included	VBN	O
neutropenia	RB	O
(	(	O
22	CD	O
%	NN	O
)	)	O
,	,	O
fatigue	NN	O
(	(	O
9	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
neuropathy	JJ	O
(	(	O
13	CD	O
%	NN	O
)	)	O
on	IN	O
the	DT	O
ixabepilone	NN	O
arm	NN	O
,	,	O
and	CC	O
neutropenia	NN	O
(	(	O
29	CD	O
%	NN	O
)	)	O
,	,	O
febrile	JJ	O
neutropenia	NN	O
(	(	O
9	CD	O
%	NN	O
)	)	O
,	,	O
fatigue	NN	O
(	(	O
9	CD	O
%	NN	O
)	)	O
,	,	O
neuropathy	JJ	O
(	(	O
7	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
thrombosis	NN	O
(	(	O
6	CD	O
%	NN	O
)	)	O
on	IN	O
the	DT	O
ixabepilone	NN	O
+	NNP	O
EMP	NNP	O
arm	NN	O
.	.	O

Post-treatment	JJ	O
declines	NNS	O
in	IN	O
prostate-specific	JJ	O
antigen	NN	O
of	IN	O
>	NN	O
or	CC	O
=	VB	O
50	CD	O
%	NN	O
were	VBD	O
achieved	VBN	O
in	IN	O
21	CD	O
of	IN	O
44	CD	O
patients	NNS	O
(	(	O
48	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
33	CD	O
%	NN	O
to	TO	O
64	CD	O
%	NN	O
)	)	O
on	IN	O
the	DT	O
ixabepilone	NN	O
arm	NN	O
,	,	O
and	CC	O
31	CD	O
of	IN	O
45	CD	O
patients	NNS	O
(	(	O
69	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
55	CD	O
%	NN	O
to	TO	O
82	CD	O
%	NN	O
)	)	O
on	IN	O
the	DT	O
ixabepilone	NN	O
+	NNP	O
EMP	NNP	O
arm	NN	O
.	.	O

In	IN	O
patients	NNS	O
with	IN	O
measurable	JJ	O
disease	NN	O
,	,	O
partial	JJ	O
responses	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
eight	CD	O
of	IN	O
25	CD	O
patients	NNS	O
(	(	O
32	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
14	CD	O
%	NN	O
to	TO	O
50	CD	O
%	NN	O
)	)	O
on	IN	O
the	DT	O
ixabepilone	NN	O
arm	NN	O
,	,	O
and	CC	O
11	CD	O
of	IN	O
23	CD	O
(	(	O
48	CD	O
%	NN	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
27	CD	O
%	NN	O
to	TO	O
68	CD	O
%	NN	O
)	)	O
on	IN	O
the	DT	O
ixabepilone	NN	O
+	NNP	O
EMP	NNP	O
arm	NN	O
.	.	O

Time	NN	O
to	TO	O
prostate-specific	JJ	O
antigen	NN	O
progression	NN	O
was	VBD	O
4.4	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
3.1	CD	O
to	TO	O
6.9	CD	O
months	NNS	O
)	)	O
on	IN	O
the	DT	O
ixabepilone-alone	JJ	O
arm	NN	O
and	CC	O
5.2	CD	O
months	NNS	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
4.5	CD	O
to	TO	O
6.8	CD	O
months	NNS	O
)	)	O
on	IN	O
the	DT	O
combination	NN	O
arm	NN	O
.	.	O

CONCLUSION	NNP	O
Ixabepilone	NNP	Pharmacological
,	,	O
with	IN	O
or	CC	O
without	IN	O
estramustine	JJ	Pharmacological
phosphate	NN	Pharmacological
,	,	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
has	VBZ	O
antitumor	VBN	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
castrate	JJ	O
metastatic	JJ	O
prostate	NN	O
cancer	NN	O
.	.	O

Review	NN	O
of	IN	O
the	DT	O
Multicenter	NNP	O
Trial	NNP	O
Committee	NNP	O
report	NN	O
:	:	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
on	IN	O
the	DT	O
prophylaxis	NN	O
of	IN	O
postoperative	JJ	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
.	.	O

The	DT	O
etiology	NN	O
of	IN	O
postoperative	JJ	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
DVT	NNP	O
)	)	O
is	VBZ	O
thought	VBN	O
to	TO	O
be	VB	O
due	JJ	O
to	TO	O
a	DT	O
combination	NN	O
of	IN	O
factors	NNS	O
including	VBG	O
stasis	NN	O
,	,	O
a	DT	O
hypercoagulable	JJ	O
state	NN	O
and	CC	O
venous	JJ	O
endothelial	JJ	O
damage	NN	O
.	.	O

Methods	NNS	O
of	IN	O
prophylaxis	NN	O
are	VBP	O
directed	VBN	O
toward	IN	O
correcting	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
these	DT	O
pathologic	JJ	O
events	NNS	O
.	.	O

Methods	NNS	O
counteracting	VBG	O
more	JJR	O
than	IN	O
one	CD	O
of	IN	O
these	DT	O
factors	NNS	O
can	MD	O
be	VB	O
expected	VBN	O
to	TO	O
be	VB	O
even	RB	O
more	RBR	O
effective	JJ	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
dihydroergotamine	NN	Pharmacological
(	(	Pharmacological
DHE	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
heparin	NN	Pharmacological
was	VBD	O
anticipated	VBN	O
to	TO	O
minimize	VB	O
stasis	NN	O
and	CC	O
the	DT	O
hypercoagulable	JJ	O
state	NN	O
respectively	RB	O
.	.	O

Based	VBN	O
upon	IN	O
current	JJ	O
experimental	JJ	O
evidence	NN	O
and	CC	O
current	JJ	O
theory	NN	O
,	,	O
an	DT	O
additional	JJ	O
benefit	NN	O
might	MD	O
include	VB	O
minimizing	VBG	O
venous	JJ	O
endothelial	JJ	O
injury	NN	O
by	IN	O
controlling	VBG	O
venomotor	NN	O
tone	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
multicenter	JJ	O
trial	NN	O
was	VBD	O
designed	VBN	O
and	CC	O
performed	VBN	O
in	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
evaluating	VBG	O
the	DT	O
prophylactic	JJ	O
efficacy	NN	O
of	IN	O
DHE	NNP	Pharmacological
0.5	CD	Pharmacological
mg	NN	Pharmacological
plus	CC	Pharmacological
heparin	JJ	Pharmacological
5000	CD	Pharmacological
U	NNP	Pharmacological
,	,	Pharmacological
DHE	NNP	Pharmacological
0.5	CD	Pharmacological
mg	NN	Pharmacological
plus	CC	Pharmacological
heparin	JJ	Pharmacological
2500	CD	Pharmacological
U	NNP	Pharmacological
,	,	Pharmacological
heparin	NN	Pharmacological
5000	CD	Pharmacological
U	NNP	Pharmacological
,	,	O
and	CC	O
DHE	NNP	Pharmacological
0.5	CD	Pharmacological
mg	NN	Pharmacological
versus	NN	O
placebo	NN	Control
.	.	O

General	NNP	O
surgical	JJ	O
patients	NNS	O
including	VBG	O
those	DT	O
undergoing	JJ	O
noncardiac	JJ	O
thoracic	NN	O
and	CC	O
pelvic	JJ	O
operations	NNS	O
who	WP	O
were	VBD	O
identified	VBN	O
at	IN	O
moderate	JJ	O
to	TO	O
high	JJ	O
risk	NN	O
for	IN	O
postop	JJ	O
DVT	NNP	O
were	VBD	O
included	VBN	O
.	.	O

Study	NNP	O
medications	NNS	O
were	VBD	O
injected	VBN	O
subcutaneously	RB	O
two	CD	O
hours	NNS	O
preoperatively	RB	O
and	CC	O
every	DT	O
12	CD	O
hours	NNS	O
postoperatively	RB	O
for	IN	O
5-7	JJ	O
days	NNS	O
or	CC	O
until	IN	O
the	DT	O
125I-fibrinogen-uptake	JJ	O
test	NN	O
(	(	O
RFUT	NNP	O
)	)	O
became	VBD	O
positive	JJ	O
.	.	O

Eight	NNP	O
hundred	VBD	O
and	CC	O
eighty	JJ	O
eight	CD	O
patients	NNS	O
were	VBD	O
entered	VBN	O
into	IN	O
this	DT	O
trial	NN	O
and	CC	O
744	CD	O
(	(	O
85	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

Results	NNP	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
benefit	NN	O
from	IN	O
DHE/Hep	NNP	Pharmacological
5000	CD	O
compared	VBN	O
to	TO	O
placebo	VB	Control
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
and	CC	O
compared	VBN	O
to	TO	O
other	JJ	O
active	JJ	O
agents	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
other	JJ	O
active	JJ	O
agents	NNS	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
prophylactic	JJ	O
benefit	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
of	IN	O
melphalan	NN	Pharmacological
and	CC	Pharmacological
cis-platinum	JJ	Pharmacological
versus	NN	O
hexamethylmelamine	NN	Pharmacological
,	,	Pharmacological
adriamycin	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
cyclophosphamide	NN	Pharmacological
in	IN	O
advanced	JJ	O
ovarian	JJ	O
cancer	NN	O
.	.	O

From	CD	O
May	NNP	O
1978	CD	O
until	IN	O
November	NNP	O
1980	CD	O
,	,	O
169	CD	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
with	IN	O
advanced	JJ	O
epithelial	JJ	O
ovarian	JJ	O
cancer	NN	O
were	VBD	O
entered	VBN	O
into	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
comparing	VBG	O
the	DT	O
combination	NN	O
of	IN	O
hexamethylmelamine	NN	Pharmacological
,	,	Pharmacological
Adriamycin	NNP	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
cyclophosphamide	NN	Pharmacological
(	(	Pharmacological
HAC	NNP	Pharmacological
)	)	Pharmacological
to	TO	O
a	DT	O
combination	NN	Pharmacological
of	IN	Pharmacological
melphalan	NN	Pharmacological
and	CC	Pharmacological
cis-platinum	NN	Pharmacological
.	.	O

Eleven	JJ	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
analysis	NN	O
and	CC	O
another	DT	O
5	CD	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
from	IN	O
response	NN	O
analysis	NN	O
.	.	O

Of	IN	O
153	CD	O
patients	NNS	O
evaluable	JJ	O
for	IN	O
response	NN	O
,	,	O
there	EX	O
were	VBD	O
47	CD	O
,	,	O
or	CC	O
30.7	CD	O
%	NN	O
,	,	O
complete	JJ	O
responders	NNS	O
(	(	O
all	DT	O
determined	VBN	O
surgically	RB	O
)	)	O
,	,	O
6	CD	O
partial	JJ	O
responders	NNS	O
,	,	O
and	CC	O
100	CD	O
nonresponders	NNS	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
for	IN	O
the	DT	O
HAC	NNP	Pharmacological
group	NN	O
was	VBD	O
31	CD	O
%	NN	O
and	CC	O
for	IN	O
the	DT	O
melphalan-platinum	JJ	Pharmacological
group	NN	O
was	VBD	O
37.8	CD	O
%	NN	O
.	.	O

The	DT	O
overall	JJ	O
response	NN	O
rate	NN	O
was	VBD	O
34.6	CD	O
%	NN	O
.	.	O

Residual	JJ	O
tumor	NN	O
diameter	NN	O
(	(	O
less	JJR	O
than	IN	O
or	CC	O
greater	JJR	O
than	IN	O
2	CD	O
cm	NN	O
)	)	O
exerted	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
effect	NN	O
on	IN	O
response	NN	O
--	:	O
47.8	CD	O
vs	JJ	O
24.4	CD	O
%	NN	O
.	.	O

Of	IN	O
the	DT	O
47	CD	O
complete	JJ	O
responders	NNS	O
,	,	O
7	CD	O
,	,	O
or	CC	O
14.9	CD	O
%	NN	O
,	,	O
have	VBP	O
relapsed	VBN	O
,	,	O
with	IN	O
the	DT	O
median	JJ	O
duration	NN	O
of	IN	O
remission	NN	O
of	IN	O
44+	CD	O
months	NNS	O
.	.	O

Of	IN	O
the	DT	O
158	CD	O
patients	NNS	O
evaluable	JJ	O
for	IN	O
survival	NN	O
,	,	O
90	CD	O
patients	NNS	O
have	VBP	O
died	VBN	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
survival	NN	O
time	NN	O
of	IN	O
27.9	CD	O
months	NNS	O
(	(	O
HAC	NNP	Pharmacological
=	VBZ	O
26.4	CD	O
months	NNS	O
,	,	O
melphalan-platinum	JJ	Pharmacological
=	NN	O
29.6	CD	O
months	NNS	O
)	)	O
.	.	O

Age	NNP	O
,	,	O
FIGO	NNP	O
stage	NN	O
,	,	O
histologic	JJ	O
grade	NN	O
,	,	O
and	CC	O
residual	JJ	O
disease	NN	O
all	DT	O
exerted	VBD	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
survival	JJ	O
time	NN	O
.	.	O

Second-line	JJ	O
therapy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
failures	NNS	O
was	VBD	O
of	IN	O
no	DT	O
benefit	NN	O
.	.	O

Hematologic	NNP	O
toxicity	NN	O
was	VBD	O
greater	JJR	O
in	IN	O
the	DT	O
melphalan-platinum	JJ	Pharmacological
group	NN	O
.	.	O

Gastrointestinal	NNP	O
toxicity	NN	O
was	VBD	O
severe	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Other	JJ	O
toxicities	NNS	O
were	VBD	O
minor	JJ	O
and	CC	O
infrequent	NN	O
.	.	O

Safety	NN	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
immunogenicity	NN	O
after	IN	O
1	CD	O
and	CC	O
2	CD	O
doses	NNS	O
of	IN	O
zoster	NN	Pharmacological
vaccine	NN	Pharmacological
in	IN	O
healthy	JJ	O
adults	NNS	O
?60	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

BACKGROUND	NNP	O
Incidence	NNP	O
and	CC	O
severity	NN	O
of	IN	O
herpes	NNS	O
zoster	NNP	O
(	(	O
HZ	NNP	O
)	)	O
and	CC	O
postherpetic	JJ	O
neuralgia	JJ	O
increase	NN	O
with	IN	O
age	NN	O
,	,	O
associated	VBN	O
with	IN	O
age-related	JJ	O
decrease	NN	O
in	IN	O
immunity	NN	O
to	TO	O
varicella-zoster	JJ	O
virus	NN	O
(	(	O
VZV	NNP	O
)	)	O
.	.	O

One	CD	O
dose	NN	O
of	IN	O
zoster	NN	O
vaccine	NN	O
(	(	O
ZV	NNP	O
)	)	O
has	VBZ	O
demonstrated	VBN	O
substantial	JJ	O
protection	NN	O
against	IN	O
HZ	NNP	O
;	:	O
this	DT	O
study	NN	O
examined	VBD	O
impact	NN	O
of	IN	O
a	DT	O
second	JJ	O
dose	NN	O
of	IN	O
ZV	NNP	O
.	.	O

METHODS	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
multicenter	NN	O
study	NN	O
with	IN	O
210	CD	O
subjects	NNS	O
?60	CD	O
years	NNS	O
old	JJ	O
compared	VBN	O
immunity	NN	O
and	CC	O
safety	NN	O
profiles	NNS	O
after	IN	O
one	CD	O
and	CC	O
two	CD	O
doses	NNS	O
of	IN	O
ZV	NNP	O
,	,	O
separated	VBN	O
by	IN	O
6	CD	O
weeks	NNS	O
,	,	O
vs.	FW	O
placebo	NN	O
.	.	O

Immunogenicity	NNP	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
VZV	NNP	O
interferon-gamma	JJ	O
(	(	O
IFN-?	NNP	O
)	)	O
enzyme-linked	JJ	O
immunospot	NN	O
(	(	O
ELISPOT	NNP	O
)	)	O
assay	NN	O
and	CC	O
VZV	NNP	O
glycoprotein	VBD	O
enzyme-linked	JJ	O
immunosorbent	NN	O
antibody	NN	O
(	(	O
gpELISA	NN	O
)	)	O
assay	NN	O
.	.	O

Adverse	JJ	O
experiences	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
recorded	VBN	O
on	IN	O
a	DT	O
standardized	JJ	O
Vaccination	NNP	O
Report	NNP	O
Card	NNP	O
.	.	O

RESULTS	NNP	O
No	NNP	O
serious	JJ	O
vaccine-related	JJ	O
AEs	NNP	O
occurred	VBD	O
.	.	O

VZV	NNP	O
IFN-?	NNP	O
ELISPOT	NNP	O
geometric	JJ	O
mean	NN	O
count	NN	O
(	(	O
GMC	NNP	O
)	)	O
of	IN	O
spot-forming	JJ	O
cells	NNS	O
per	IN	O
10	CD	O
(	(	O
6	CD	O
)	)	O
peripheral	JJ	O
blood	NN	O
mononuclear	JJ	O
cells	NNS	O
increased	VBN	O
in	IN	O
the	DT	O
ZV	NNP	O
group	NN	O
from	IN	O
16.9	CD	O
prevaccination	NN	O
to	TO	O
49.5	CD	O
and	CC	O
32.8	CD	O
at	IN	O
2	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
postdose	RB	O
1	CD	O
,	,	O
respectively	RB	O
.	.	O

Two	CD	O
weeks	NNS	O
,	,	O
6	CD	O
weeks	NNS	O
and	CC	O
6	CD	O
months	NNS	O
postdose	RB	O
2	CD	O
,	,	O
GMC	NNP	O
was	VBD	O
44.3	CD	O
,	,	O
42.9	CD	O
,	,	O
and	CC	O
36.5	CD	O
,	,	O
respectively	RB	O
.	.	O

GMC	NNP	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
did	VBD	O
not	RB	O
change	NN	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
peak	JJ	O
ELISPOT	NNP	O
response	NN	O
occurred	VBD	O
?2	NNP	O
weeks	NNS	O
after	IN	O
each	DT	O
ZV	NNP	O
dose	NN	O
.	.	O

The	DT	O
gpELISA	NN	O
geometric	JJ	O
mean	NN	O
titers	NNS	O
(	(	O
GMTs	NNP	O
)	)	O
in	IN	O
the	DT	O
ZV	NNP	O
group	NN	O
were	VBD	O
higher	JJR	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
at	IN	O
6	CD	O
weeks	NNS	O
after	IN	O
each	DT	O
dose	NN	O
.	.	O

Correlation	NN	O
between	IN	O
the	DT	O
IFN-?	NNP	O
ELISPOT	NNP	O
and	CC	O
gpELISA	NN	O
assays	NNS	O
was	VBD	O
poor	JJ	O
.	.	O

CONCLUSIONS	NNP	O
ZV	NNP	O
was	VBD	O
generally	RB	O
well-tolerated	JJ	O
and	CC	O
immunogenic	JJ	O
in	IN	O
adults	NNS	O
?60	CD	O
years	NNS	O
old	JJ	O
.	.	O

A	DT	O
second	JJ	O
dose	NN	O
of	IN	O
ZV	NNP	O
was	VBD	O
generally	RB	O
safe	JJ	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
boost	VB	O
VZV-specific	NNP	O
immunity	NN	O
beyond	IN	O
levels	NNS	O
achieved	VBN	O
postdose	RB	O
1	CD	O
.	.	O

Interventions	NNS	O
in	IN	O
the	DT	O
initial	JJ	O
prodromal	JJ	O
states	NNS	O
of	IN	O
psychosis	NN	O
in	IN	O
Germany	NNP	O
:	:	O
concept	NN	O
and	CC	O
recruitment	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
Early	JJ	O
Detection	NN	O
and	CC	O
Intervention	NNP	O
Programme	NNP	O
of	IN	O
the	DT	O
German	JJ	O
Research	NNP	O
Network	NNP	O
on	IN	O
Schizophrenia	NNP	O
(	(	O
GRNS	NNP	O
)	)	O
investigates	VBZ	O
the	DT	O
initial	JJ	O
prodromal	JJ	O
phase	NN	O
of	IN	O
psychosis	NN	O
in	IN	O
a	DT	O
multidimensional	JJ	O
approach	NN	O
.	.	O

Two	CD	O
intervention	NN	O
strategies	NNS	O
are	VBP	O
being	VBG	O
studied	VBN	O
by	IN	O
two	CD	O
large-scale	JJ	O
multicentre	JJ	O
projects	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
present	VB	O
the	DT	O
concept	NN	O
of	IN	O
the	DT	O
intervention	NN	O
studies	NNS	O
,	,	O
and	CC	O
to	TO	O
provide	VB	O
an	DT	O
interim	JJ	O
report	NN	O
of	IN	O
the	DT	O
recruitment	JJ	O
procedure	NN	O
.	.	O

METHOD	NNP	O
Comprehensive	NNP	Psychological
cognitive-behavioural	JJ	Psychological
therapy	NN	Psychological
has	VBZ	O
been	VBN	O
developed	VBN	O
for	IN	O
patients	NNS	O
in	IN	O
the	DT	O
early	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
.	.	O

For	IN	O
patients	NNS	O
in	IN	O
the	DT	O
late	JJ	O
initial	JJ	O
prodromal	JJ	O
state	NN	O
the	DT	O
atypical	JJ	Pharmacological
neuroleptic	JJ	Pharmacological
amisulpride	NN	Pharmacological
is	VBZ	O
explored	VBN	O
.	.	O

Both	DT	O
interventions	NNS	O
are	VBP	O
evaluated	VBN	O
in	IN	O
randomised	JJ	O
controlled	VBN	O
trials	NNS	O
using	VBG	O
clinical	JJ	O
management	NN	O
as	IN	O
the	DT	O
control	NN	O
condition	NN	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
January	NNP	O
2001	CD	O
and	CC	O
March	NNP	O
2003	CD	O
,	,	O
1212	CD	O
individuals	NNS	O
seeking	VBG	O
help	NN	O
for	IN	O
mental	JJ	O
health	NN	O
problems	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
putative	JJ	O
prodromal	NN	O
symptoms	NNS	O
at	IN	O
four	CD	O
university	NN	O
centres	NNS	O
.	.	O

More	JJR	O
than	IN	O
388	CD	O
individuals	NNS	O
fulfilled	VBD	O
criteria	NNS	O
for	IN	O
both	DT	O
interventions	NNS	O
and	CC	O
188	CD	O
(	(	O
48.5	CD	O
%	NN	O
)	)	O
gave	VBD	O
informed	VBN	O
consent	NN	O
to	TO	O
participate	VB	O
in	IN	O
the	DT	O
trials	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
screening	NN	O
procedure	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
feasible	JJ	O
and	CC	O
trial	NN	O
participation	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
acceptable	JJ	O
to	TO	O
a	DT	O
relevant	JJ	O
proportion	NN	O
of	IN	O
people	NNS	O
at	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
developing	VBG	O
psychosis	NN	O
.	.	O

The	DT	O
benefits	NNS	O
of	IN	O
including	VBG	O
clinical	JJ	O
factors	NNS	O
in	IN	O
rectal	JJ	O
normal	JJ	O
tissue	NN	O
complication	NN	Other
probability	NN	Other
modeling	NN	Other
after	IN	O
radiotherapy	NN	O
for	IN	O
prostate	NN	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
study	VB	O
the	DT	O
impact	NN	O
of	IN	O
clinical	JJ	O
predisposing	VBG	O
factors	NNS	O
on	IN	O
rectal	JJ	O
normal	JJ	O
tissue	NN	O
complication	NN	O
probability	NN	O
modeling	VBG	O
using	VBG	O
the	DT	O
updated	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Dutch	JJ	O
prostate	NN	O
dose-escalation	NN	O
trial	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Toxicity	NNP	O
data	NN	O
of	IN	O
512	CD	O
patients	NNS	O
(	(	O
conformally	RB	O
treated	VBN	O
to	TO	O
68	CD	O
Gy	NNP	O
[	NNP	O
n	VBD	O
=	$	O
284	CD	O
]	NNP	O
and	CC	O
78	CD	O
Gy	NNP	O
[	NNP	O
n	VBD	O
=	$	O
228	CD	O
]	NN	O
)	)	O
with	IN	O
complete	JJ	O
follow-up	NN	O
at	IN	O
3	CD	O
years	NNS	O
after	IN	O
radiotherapy	NN	Physical
were	VBD	O
studied	VBN	O
.	.	O

Scored	JJ	O
end	NN	O
points	NNS	O
were	VBD	O
rectal	JJ	O
bleeding	NN	O
,	,	O
high	JJ	O
stool	NN	O
frequency	NN	O
,	,	O
and	CC	O
fecal	JJ	O
incontinence	NN	O
.	.	O

Two	CD	Other
traditional	JJ	Other
dose-based	JJ	Other
models	NNS	Other
(	(	Other
Lyman-Kutcher-Burman	NNP	Other
(	(	Other
LKB	NNP	Other
)	)	Other
and	CC	Other
Relative	JJ	Other
Seriality	NNP	Other
(	(	Other
RS	NNP	Other
)	)	Other
and	CC	Other
a	DT	Other
logistic	JJ	Other
model	NN	Other
were	VBD	O
fitted	VBN	O
using	VBG	O
a	DT	O
maximum	JJ	O
likelihood	NN	O
approach	NN	O
.	.	O

Furthermore	RB	O
,	,	O
these	DT	O
model	FW	O
fits	NNS	O
were	VBD	O
improved	VBN	O
by	IN	O
including	VBG	O
the	DT	O
most	RBS	O
significant	JJ	O
clinical	JJ	O
factors	NNS	O
.	.	O

The	DT	O
area	NN	O
under	IN	O
the	DT	O
receiver	NN	O
operating	VBG	O
characteristic	JJ	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
was	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
the	DT	O
discriminating	VBG	O
ability	NN	O
of	IN	O
all	DT	O
fits	NNS	O
.	.	O

RESULTS	NNP	O
Including	NNP	O
clinical	JJ	O
factors	NNS	O
significantly	RB	O
increased	VBD	O
the	DT	O
predictive	JJ	O
power	NN	O
of	IN	O
the	DT	O
models	NNS	O
for	IN	O
all	DT	O
end	NN	O
points	NNS	O
.	.	O

In	IN	O
the	DT	O
optimal	JJ	O
LKB	NNP	O
,	,	O
RS	NNP	O
,	,	O
and	CC	O
logistic	JJ	O
models	NNS	O
for	IN	O
rectal	JJ	O
bleeding	NN	O
and	CC	O
fecal	JJ	O
incontinence	NN	O
,	,	O
the	DT	O
first	JJ	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.011-0.013	NN	O
)	)	O
clinical	JJ	O
factor	NN	O
was	VBD	O
previous	JJ	O
abdominal	JJ	O
surgery	NN	O
.	.	O

As	IN	O
second	JJ	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.012-0.016	NN	O
)	)	O
factor	NN	O
,	,	O
cardiac	JJ	O
history	NN	O
was	VBD	O
included	VBN	O
in	IN	O
all	DT	O
three	CD	O
rectal	JJ	O
bleeding	VBG	O
fits	NNS	O
,	,	O
whereas	IN	O
including	VBG	O
diabetes	NNS	O
was	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.039-0.048	NN	O
)	)	O
in	IN	O
fecal	JJ	O
incontinence	NN	O
modeling	NN	O
but	CC	O
only	RB	O
in	IN	O
the	DT	O
LKB	NNP	O
and	CC	O
logistic	JJ	O
models	NNS	O
.	.	O

High	JJ	O
stool	NN	O
frequency	NN	O
fits	VBZ	O
only	RB	O
benefitted	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
0.003-0.006	NN	O
)	)	O
from	IN	O
the	DT	O
inclusion	NN	O
of	IN	O
the	DT	O
baseline	NN	O
toxicity	NN	O
score	NN	O
.	.	O

For	IN	O
all	DT	O
models	NNS	O
rectal	VBP	O
bleeding	VBG	O
fits	NNS	O
had	VBD	O
the	DT	O
highest	JJS	O
AUC	NNP	O
(	(	O
0.77	CD	O
)	)	O
where	WRB	O
it	PRP	O
was	VBD	O
0.63	CD	O
and	CC	O
0.68	CD	O
for	IN	O
high	JJ	O
stool	NN	O
frequency	NN	O
and	CC	O
fecal	JJ	O
incontinence	NN	O
,	,	O
respectively	RB	O
.	.	O

LKB	NNP	O
and	CC	O
logistic	JJ	O
model	NN	O
fits	NNS	O
resulted	VBN	O
in	IN	O
similar	JJ	O
values	NNS	O
for	IN	O
the	DT	O
volume	NN	O
parameter	NN	O
.	.	O

The	DT	O
steepness	NN	O
parameter	NN	O
was	VBD	O
somewhat	RB	O
higher	JJR	O
in	IN	O
the	DT	O
logistic	JJ	O
model	NN	O
,	,	O
also	RB	O
resulting	VBG	O
in	IN	O
a	DT	O
slightly	RB	O
lower	JJR	O
D	NNP	O
(	(	O
50	CD	O
)	)	O
.	.	O

Anal	NNP	O
wall	NN	O
DVHs	NNP	O
were	VBD	O
used	VBN	O
for	IN	O
fecal	JJ	O
incontinence	NN	O
,	,	O
whereas	IN	O
anorectal	JJ	O
wall	NN	O
dose	NN	O
best	RBS	O
described	VBD	O
the	DT	O
other	JJ	O
two	CD	O
endpoints	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Comparable	JJ	O
prediction	NN	O
models	NNS	O
were	VBD	O
obtained	VBN	O
with	IN	O
LKB	NNP	O
,	,	O
RS	NNP	O
,	,	O
and	CC	O
logistic	JJ	O
NTCP	NNP	O
models	NNS	O
.	.	O

Including	VBG	O
clinical	JJ	O
factors	NNS	O
improved	VBD	O
the	DT	O
predictive	JJ	O
power	NN	O
of	IN	O
all	DT	O
models	NNS	O
significantly	RB	O
.	.	O

Using	VBG	O
a	DT	O
laryngeal	JJ	Physical
tube	NN	Physical
suction-device	NN	Physical
(	(	Physical
LTS-D	NNP	Physical
)	)	Physical
reduces	VBZ	O
the	DT	O
no	DT	O
flow	JJ	O
time	NN	O
in	IN	O
a	DT	O
single	JJ	O
rescuer	NN	O
manikin	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
2005	CD	O
,	,	O
the	DT	O
European	JJ	O
Resuscitation	NNP	O
Council	NNP	O
and	CC	O
the	DT	O
American	NNP	O
Heart	NNP	O
Association	NNP	O
published	VBD	O
new	JJ	O
guidelines	NNS	O
for	IN	O
Advanced	NNP	O
Life	NNP	O
Support	NNP	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
points	NNS	O
was	VBD	O
to	TO	O
reduce	VB	O
the	DT	O
time	NN	O
without	IN	O
chest	JJS	O
compressions	NNS	O
in	IN	O
the	DT	O
first	JJ	O
phase	NN	O
of	IN	O
cardiac	JJ	O
arrest	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
evaluated	VBD	O
in	IN	O
a	DT	O
manikin	JJ	O
model	NN	O
whether	IN	O
using	VBG	O
the	DT	O
single-use	JJ	Physical
laryngeal	NN	Physical
tube	NN	Physical
with	IN	Physical
suction	NN	Physical
option	NN	Physical
(	(	Physical
LTS-D	NNP	Physical
)	)	Physical
instead	RB	Surgical
of	IN	O
endotracheal	JJ	Surgical
intubation	NN	Surgical
(	(	Surgical
ET	NNP	Surgical
)	)	Surgical
and	CC	Surgical
bag-mask-valve	JJ	Surgical
ventilation	NN	Surgical
(	(	Surgical
BMV	NNP	Surgical
)	)	Surgical
for	IN	Surgical
emergency	NN	Surgical
airway	NN	Surgical
management	NN	Surgical
could	MD	Surgical
reduce	VB	O
the	DT	O
no-flow	JJ	O
time	NN	O
(	(	O
NFT	NNP	O
)	)	O
.	.	O

The	DT	O
NFT	NNP	O
is	VBZ	O
defined	VBN	O
as	IN	O
the	DT	O
time	NN	O
during	IN	O
resuscitation	NN	O
when	WRB	O
no	DT	O
chest	NN	O
compressions	NNS	O
take	VBP	O
place	NN	O
.	.	O

METHODS	CC	O
A	DT	O
randomized	JJ	O
,	,	O
prospective	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
with	IN	O
150	CD	O
volunteers	NNS	O
who	WP	O
performed	VBD	O
management	NN	O
of	IN	O
a	DT	O
standardized	JJ	O
simulated	JJ	O
cardiac	NN	O
arrest	NN	O
in	IN	O
a	DT	O
manikin	NN	O
.	.	O

Every	DT	O
participant	NN	O
was	VBD	O
randomized	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
different	JJ	O
airway	RB	O
management	NN	O
groups	NNS	O
(	(	O
LTS-D	JJ	O
vs	NN	O
.	.	O

ET	NNP	O
vs.	IN	O
BMV	NNP	O
)	)	O
.	.	O

RESULTS	VB	O
The	DT	O
LTS-D	NNP	Physical
was	VBD	O
inserted	VBN	O
significantly	RB	O
faster	RBR	O
than	IN	O
the	DT	O
ET	NNP	O
tube	NN	O
(	(	O
15	CD	O
s	NN	O
vs.	FW	O
44	CD	O
s	NN	O
,	,	O
respectively	RB	O
,	,	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

During	IN	O
the	DT	O
cardiac	JJ	O
arrest	NN	O
simulation	NN	O
,	,	O
establishing	VBG	O
and	CC	O
performing	VBG	O
ventilation	NN	O
took	VBD	O
an	DT	O
average	NN	O
of	IN	O
57	CD	O
s	NN	O
with	IN	O
the	DT	O
LTS-D	NNP	Physical
compared	VBN	O
to	TO	O
116	CD	O
s	NN	O
with	IN	O
ET	NNP	Surgical
and	CC	O
111	CD	O
s	NN	O
with	IN	O
the	DT	O
BMV	NNP	Surgical
.	.	O

Using	VBG	O
the	DT	O
LTS-D	NNP	Physical
significantly	RB	O
reduced	VBD	O
NFT	NNP	O
compared	VBN	O
to	TO	O
ET	NNP	Surgical
and	CC	O
the	DT	O
BMV	NNP	Surgical
(	(	O
125	CD	O
s	NN	O
vs.	FW	O
207	CD	O
s	NN	O
vs.	FW	O
160	CD	O
s	NN	O
;	:	O
p	CC	O
<	VB	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NN	O
In	IN	O
our	PRP$	O
manikin	NN	O
study	NN	O
,	,	O
NFT	NNP	O
was	VBD	O
reduced	VBN	O
significantly	RB	O
when	WRB	O
the	DT	O
LTS-D	NNP	Physical
was	VBD	O
used	VBN	O
when	WRB	O
compared	VBN	O
to	TO	O
ET	NNP	Surgical
and	CC	O
BMV	NNP	Surgical
.	.	O

The	DT	O
results	NNS	O
of	IN	O
our	PRP$	O
manikin	NN	O
study	NN	O
suggest	VBP	O
that	IN	O
for	IN	O
personnel	NNS	O
not	RB	O
experienced	VBN	O
in	IN	O
tracheal	JJ	O
intubation	NN	O
,	,	O
the	DT	O
LTS-D	NNP	Physical
offers	VBZ	O
a	DT	O
good	JJ	O
alternative	NN	O
to	TO	O
ET	NNP	Surgical
and	CC	O
BMV	NNP	Surgical
to	TO	O
manage	VB	O
the	DT	O
airway	NN	O
during	IN	O
resuscitation	NN	O
,	,	O
and	CC	O
to	TO	O
avoid	VB	O
the	DT	O
failure	NN	O
to	TO	O
achieve	VB	O
tracheal	JJ	O
intubation	NN	O
with	IN	O
the	DT	O
ET	NNP	Surgical
,	,	O
and	CC	O
the	DT	O
failure	NN	O
to	TO	O
achieve	VB	O
adequate	JJ	O
ventilation	NN	O
with	IN	O
the	DT	O
BMV	NNP	Surgical
.	.	O

Post	NNP	O
hoc	NN	O
analysis	NN	O
of	IN	O
a	DT	O
single	JJ	O
IV	NNP	O
infusion	NN	O
of	IN	O
zoledronic	JJ	Pharmacological
acid	NNS	Pharmacological
versus	VBP	O
daily	JJ	O
oral	JJ	O
risedronate	NN	Pharmacological
on	IN	O
lumbar	NN	O
spine	NN	O
bone	NN	O
mineral	JJ	O
density	NN	O
in	IN	O
different	JJ	O
subgroups	NNS	O
with	IN	O
glucocorticoid-induced	JJ	O
osteoporosis	NN	O
.	.	O

This	DT	O
study	NN	O
summarizes	VBZ	O
the	DT	O
treatment	NN	O
effect	NN	O
of	IN	O
zoledronic	JJ	Pharmacological
acid	JJ	Pharmacological
infusion	NN	O
on	IN	O
lumbar	NN	O
spine	NN	O
bone	NN	O
mineral	JJ	O
density	NN	O
in	IN	O
different	JJ	O
subgroups	NNS	O
with	IN	O
glucocorticoid-induced	JJ	O
osteoporosis	NN	O
.	.	O

Zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
is	VBZ	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
risedronate	NN	Pharmacological
in	IN	O
increasing	VBG	O
lumbar	NN	O
spine	NN	O
(	(	O
LS	NNP	O
)	)	O
bone	NN	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
in	IN	O
both	DT	O
prevention	NN	O
and	CC	O
treatment	NN	O
of	IN	O
glucocorticoid-induced	JJ	O
osteoporosis	NN	O
.	.	O

Introduction	NN	O
In	IN	O
patients	NNS	O
on	IN	O
glucocorticoids	NNS	Pharmacological
,	,	O
a	DT	O
single	JJ	O
zoledronic	NN	Pharmacological
acid	NN	Pharmacological
infusion	NN	O
significantly	RB	O
increased	VBD	O
BMD	NNP	O
versus	IN	O
daily	JJ	O
oral	JJ	O
risedronate	NN	Pharmacological
.	.	O

We	PRP	O
assessed	VBD	O
treatment	NN	O
effect	NN	O
on	IN	O
LS	NNP	O
BMD	NNP	O
in	IN	O
different	JJ	O
patient	NN	O
subgroups	NNS	O
at	IN	O
month	NN	O
12	CD	O
that	WDT	O
contributed	VBD	O
to	TO	O
the	DT	O
risk	NN	O
of	IN	O
osteoporosis	NN	O
in	IN	O
addition	NN	O
to	TO	O
glucocorticoids	NNS	O
.	.	O

Methods	NNS	O
Patients	NNPS	O
randomized	VBN	O
to	TO	O
a	DT	O
single	JJ	O
IV	NNP	O
infusion	NN	O
of	IN	O
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
5	CD	O
mg	NN	O
or	CC	O
risedronate	NN	Pharmacological
(	(	O
5	CD	O
mg/day	NN	O
)	)	O
and	CC	O
stratified	VBN	O
based	VBN	O
on	IN	O
glucocorticoids	NNS	Pharmacological
duration	NN	O
[	FW	O
treatment	NN	O
(	(	O
>	JJ	O
3	CD	O
months	NNS	O
)	)	O
and	CC	O
prevention	NN	O
(	(	O
?	.	O
3	CD	O
months	NNS	O
)	)	O
subpopulations	NNS	O
]	VBP	O
were	VBD	O
subgrouped	VBN	O
by	IN	O
age	NN	O
;	:	O
gender	NN	O
;	:	O
menopausal	NN	O
status	NN	O
in	IN	O
women	NNS	O
;	:	O
dose	VB	O
and	CC	O
duration	NN	O
of	IN	O
prednisone	NN	O
during	IN	O
the	DT	O
trial	NN	O
;	:	O
and	CC	O
baseline	VB	O
serum	JJ	O
25-OH	JJ	O
vitamin	NN	O
D	NNP	O
,	,	O
LS	NNP	O
BMD	NNP	O
T-score	NNP	O
,	,	O
creatinine	JJ	O
clearance	NN	O
,	,	O
and	CC	O
concomitant	JJ	O
medication	NN	O
use	NN	O
.	.	O

Results	NNS	O
At	IN	O
month	NN	O
12	CD	O
,	,	O
zoledronic	JJ	O
acid	NN	O
significantly	RB	O
increased	VBD	O
LS	NNP	O
BMD	NNP	O
versus	NN	O
risedronate	NN	O
in	IN	O
patients	NNS	O
?	.	O
74	CD	O
years	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
in	IN	O
the	DT	O
treatment	NN	O
and	CC	O
65-74	JJ	O
years	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.0008	CD	O
)	)	O
in	IN	O
the	DT	O
prevention	NN	O
subpopulation	NN	O
.	.	O

At	IN	O
month	NN	O
12	CD	O
,	,	O
zoledronic	JJ	O
acid	NN	O
significantly	RB	O
increased	VBD	O
LS	NNP	O
BMD	NNP	O
versus	NN	O
risedronate	NN	O
in	IN	O
both	DT	O
subpopulations	NNS	O
irrespective	VBP	O
of	IN	O
gender	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
cumulative	JJ	O
prednisone	NN	O
dose	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
postmenopausal	NN	O
status	NN	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

In	IN	O
premenopausal	JJ	O
women	NNS	O
,	,	O
in	IN	O
both	DT	O
subpopulations	NNS	O
,	,	O
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
significantly	RB	O
increased	VBD	O
total	JJ	O
hip	NN	O
BMD	NNP	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
versus	NN	O
risedronate	NN	Pharmacological
at	IN	O
month	NN	O
12	CD	O
but	CC	O
not	RB	O
LS	NNP	O
BMD	NNP	O
.	.	O

Osteoporotic	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
prevention	NN	O
(	(	O
P=0.0189	NNP	O
)	)	O
and	CC	O
osteopenic	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
subpopulation	NN	O
(	(	O
P=0.0305	NNP	O
)	)	O
showed	VBD	O
significant	JJ	O
LS	NNP	O
BMD	NNP	O
increases	VBZ	O
with	IN	O
zoledronic	JJ	O
acid	NNS	O
versus	NN	O
risedronate	NN	O
at	IN	O
month	NN	O
12	CD	O
.	.	O

Conclusions	NNS	O
This	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
suggests	VBZ	O
that	IN	O
zoledronic	JJ	O
acid	NN	O
is	VBZ	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
risedronate	NN	O
in	IN	O
increasing	VBG	O
LS	NNP	O
BMD	NNP	O
in	IN	O
prevention	NN	O
and	CC	O
treatment	NN	O
of	IN	O
glucocorticoid-induced	JJ	O
osteoporosis	NN	O
across	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
patients	NNS	O
.	.	O

Evaluating	VBG	O
the	DT	O
impact	NN	O
of	IN	O
peer	NN	Educational
,	,	Educational
nurse	JJ	Educational
case-managed	JJ	Educational
,	,	Educational
and	CC	Educational
standard	JJ	Other
HIV	NNP	Other
risk-reduction	NN	Other
programs	NNS	Other
on	IN	O
psychosocial	JJ	O
and	CC	O
health-promoting	JJ	O
behavioral	JJ	O
outcomes	NNS	O
among	IN	O
homeless	JJ	O
women	NNS	O
.	.	O

Investigators	NNS	O
examined	VBD	O
the	DT	O
6-month	JJ	O
impact	NN	O
of	IN	O
three	CD	O
cognitive-behavioral	JJ	Educational
HIV	NNP	Educational
risk-reduction	NN	Educational
programs	NNS	Educational
on	IN	O
behavioral	JJ	O
factors	NNS	O
(	(	O
substance	NN	O
use	NN	O
and	CC	O
sexual	JJ	O
risk	NN	O
behaviors	NNS	O
)	)	O
and	CC	O
cognitive	JJ	O
and	CC	O
psychological	JJ	O
resources	NNS	O
of	IN	O
325	CD	O
women	NNS	O
who	WP	O
resided	VBD	O
in	IN	O
emergency	NN	O
or	CC	O
sober-living	NN	O
shelters	NNS	O
and	CC	O
their	PRP$	O
308	CD	O
intimate	JJ	O
sexual	JJ	O
partners	NNS	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
by	IN	O
shelter	NN	O
to	TO	O
a	DT	O
peer-mentored	JJ	Educational
,	,	Educational
a	DT	Educational
nurse	JJ	Educational
case-managed	JJ	Educational
,	,	O
or	CC	O
a	DT	O
standard	JJ	Control
care	NN	Control
HIV	NNP	Control
risk-reduction	NN	Control
program	NN	Control
.	.	O

Significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
all	DT	O
groups	NNS	O
in	IN	O
all	DT	O
behavioral	JJ	O
factors	NNS	O
and	CC	O
cognitive	JJ	O
and	CC	O
psychological	JJ	O
resources	NNS	O
except	IN	O
for	IN	O
self-esteem	NN	O
.	.	O

Participants	NNS	O
in	IN	O
the	DT	O
peer-mentored	JJ	Educational
and	CC	Educational
nurse	JJ	Educational
case-managed	JJ	Educational
groups	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
from	IN	O
the	DT	O
standard	JJ	Control
group	NN	Control
in	IN	O
self-esteem	NN	O
,	,	O
life	NN	O
satisfaction	NN	O
,	,	O
psychological	JJ	O
well-being	NN	O
,	,	O
use	NN	O
of	IN	O
noninjection	NN	O
drugs	NNS	O
,	,	O
sex	NN	O
with	IN	O
multiple	JJ	O
partners	NNS	O
,	,	O
and	CC	O
unprotected	JJ	O
sex	NN	O
at	IN	O
6	CD	O
months	NNS	O
(	(	O
n	JJ	O
=	NNP	O
633	CD	O
)	)	O
.	.	O

It	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
a	DT	O
standard	JJ	O
approach	NN	O
by	IN	O
health	NN	O
care	NN	O
professionals	NNS	O
appears	VBZ	O
to	TO	O
effectively	RB	O
modify	VB	O
HIV	NNP	O
risk	NN	O
behaviors	NNS	O
for	IN	O
a	DT	O
majority	NN	O
of	IN	O
homeless	JJ	O
participants	NNS	O
and	CC	O
may	MD	O
have	VB	O
important	JJ	O
economic	JJ	O
and	CC	O
policy	NN	O
implications	NNS	O
.	.	O

Further	NNP	O
,	,	O
the	DT	O
impact	NN	O
of	IN	O
short-term	JJ	O
programs	NNS	O
that	WDT	O
address	VBP	O
psychological	JJ	O
vulnerabilities	NNS	O
of	IN	O
impoverished	JJ	O
populations	NNS	O
needs	NNS	O
to	TO	O
be	VB	O
studied	VBN	O
further	JJ	O
.	.	O

Argon	NNP	Physical
laser	NN	Physical
trabeculoplasty	NN	Physical
in	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
--	:	O
results	NNS	O
in	IN	O
black	JJ	O
Jamaican	JJ	O
population	NN	O
.	.	O

A	DT	O
controlled	JJ	O
,	,	O
randomised	VBD	O
,	,	O
prospective	JJ	O
trial	NN	O
of	IN	O
Argon	NNP	Surgical
laser	NN	Surgical
trabeculoplasty	NN	Surgical
(	(	Surgical
ALT	NNP	Surgical
)	)	Surgical
was	VBD	O
carried	VBN	O
out	RP	O
on	IN	O
48	CD	O
eyes	NNS	O
of	IN	O
30	CD	O
black	JJ	O
Jamaican	JJ	O
patients	NNS	O
with	IN	O
primary	JJ	O
open-angle	JJ	O
glaucoma	NN	O
.	.	O

All	DT	O
eyes	NNS	O
had	VBD	O
uncontrolled	VBN	O
intra-ocular	JJ	O
pressures	NNS	O
(	(	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
22	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
despite	IN	O
medical	JJ	O
therapy	NN	O
.	.	O

Treatment	NN	O
was	VBD	O
successful	JJ	O
in	IN	O
controlling	VBG	O
intraocular	JJ	O
pressure	NN	O
in	IN	O
68	CD	O
%	NN	O
of	IN	O
eyes	NNS	O
after	IN	O
12	CD	O
months	NNS	O
follow-up	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.004	CD	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
drop	NN	O
in	IN	O
intraocular	JJ	O
pressure	NN	O
attributable	JJ	O
to	TO	O
ALT	NNP	Physical
was	VBD	O
6.6	CD	O
mmHg	NN	O
.	.	O

Argon	NNP	Physical
laser	NN	Physical
trabeculoplasty	NN	Physical
is	VBZ	O
an	DT	O
effective	JJ	O
adjunct	NN	O
in	IN	O
managing	VBG	O
to	TO	O
control	VB	O
intraocular	JJ	O
pressure	NN	O
in	IN	O
black	JJ	O
Jamaican	NNP	O
glaucoma	NN	O
patients	NNS	O
.	.	O

Bovine	NNP	Surgical
carotid	NN	Surgical
artery	NN	Surgical
heterografts	NNS	Surgical
versus	VBP	Surgical
polytetrafluoroethylene	JJ	Surgical
grafts	NNS	Surgical
.	.	Surgical

A	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
comparison	NN	O
of	IN	O
BCAH	NNP	Surgical
and	CC	Surgical
PTFE	NNP	Surgical
vascular	JJ	Surgical
access	NN	Surgical
grafts	NNS	Surgical
resulted	VBD	O
in	IN	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
when	WRB	O
analyzed	VBN	O
for	IN	O
survival	JJ	O
rates	NNS	O
of	IN	O
complications	NNS	O
,	,	O
types	NNS	O
of	IN	O
complications	NNS	O
,	,	O
reasons	NNS	O
for	IN	O
failure	NN	O
,	,	O
and	CC	O
clot	NN	O
salvageability	NN	O
.	.	O

The	DT	O
results	NNS	O
in	IN	O
diabetic	JJ	O
patients	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
in	IN	O
nondiabetic	JJ	O
patients	NNS	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
retrospective	JJ	O
studies	NNS	O
and	CC	O
subjective	JJ	O
experiences	NNS	O
favor	VBP	O
PTFE	NNP	Surgical
grafts	NNS	Surgical
over	IN	O
BCAHs	NNP	Surgical
.	.	O

The	DT	O
explanation	NN	O
may	MD	O
be	VB	O
part	NN	O
that	IN	O
BCAH	NNP	Surgical
preceded	VBD	O
PTFE	NNP	Surgical
grafts	NNS	Surgical
into	IN	O
clinical	JJ	O
use	NN	O
,	,	O
and	CC	O
inexperience	NN	O
in	IN	O
the	DT	O
operating	NN	O
room	NN	O
and	CC	O
in	IN	O
the	DT	O
dialysis	NN	O
unit	NN	O
had	VBD	O
an	DT	O
effect	NN	O
on	IN	O
BCAH	NNP	O
results	NNS	O
.	.	O

A	DT	O
review	NN	O
of	IN	O
impressions	NNS	O
of	IN	O
the	DT	O
graft	NN	O
materials	NNS	O
indicated	VBD	O
a	DT	O
decided	JJ	O
preference	NN	O
for	IN	O
PTFE	NNP	Surgical
grafts	NNS	Surgical
.	.	Surgical

Early	JJ	O
combination	NN	O
disease-modifying	JJ	O
antirheumatic	JJ	Pharmacological
drug	NN	Pharmacological
therapy	NN	Pharmacological
and	CC	O
tight	JJ	O
disease	NN	O
control	NN	O
improve	VB	O
long-term	JJ	O
radiologic	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
rheumatoid	NN	O
arthritis	NN	O
:	:	O
the	DT	O
11-year	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Finnish	NNP	O
Rheumatoid	NNP	O
Arthritis	NNP	O
Combination	NNP	O
Therapy	NNP	O
trial	NN	O
.	.	O

INTRODUCTION	NNP	O
Early	NNP	O
treatment	NN	O
of	IN	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
retard	VB	O
the	DT	O
development	NN	O
of	IN	O
joint	JJ	O
damage	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
up	IN	O
to	TO	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
radiologic	JJ	O
progression	NN	O
beyond	IN	O
that	DT	O
time	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
RA	NNP	O
initially	RB	O
treated	VBD	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
three	CD	Pharmacological
disease-modifying	JJ	Pharmacological
antirheumatic	JJ	Pharmacological
drugs	NNS	Pharmacological
(	(	Pharmacological
DMARDs	NNP	Pharmacological
)	)	Pharmacological
or	CC	O
a	DT	O
single	JJ	Pharmacological
DMARD	NNP	Pharmacological
.	.	O

METHODS	NNP	O
A	NNP	O
cohort	NN	O
of	IN	O
199	CD	O
patients	NNS	O
with	IN	O
early	JJ	O
active	JJ	O
RA	NNP	O
were	VBD	O
initially	RB	O
randomized	VBN	O
to	TO	O
receive	VB	O
treatment	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
methotrexate	NN	Pharmacological
,	,	O
sulfasalazine	NN	Pharmacological
,	,	O
and	CC	O
hydroxychloroquine	NN	Pharmacological
with	IN	Pharmacological
prednisolone	NN	Pharmacological
(	(	Pharmacological
FIN-RACo	NNP	Pharmacological
)	)	Pharmacological
,	,	O
or	CC	O
treatment	NN	O
with	IN	O
a	DT	O
single	JJ	Pharmacological
DMARD	NNP	Pharmacological
(	(	Pharmacological
initially	RB	Pharmacological
,	,	Pharmacological
sulfasalazine	NN	Pharmacological
)	)	Pharmacological
with	IN	O
or	CC	O
without	IN	O
prednisolone	NN	Pharmacological
(	(	Pharmacological
SINGLE	NNP	Pharmacological
)	)	Pharmacological
.	.	O

After	IN	O
2	CD	O
years	NNS	O
,	,	O
the	DT	O
drug-treatment	JJ	O
strategy	NN	O
became	VBD	O
unrestricted	JJ	O
,	,	O
but	CC	O
still	RB	O
targeted	VBN	O
remission	NN	O
.	.	O

The	DT	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
using	VBG	O
the	DT	O
Larsen	NNP	O
score	NN	O
at	IN	O
baseline	NN	O
,	,	O
2	CD	O
,	,	O
5	CD	O
,	,	O
and	CC	O
11	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
radiographs	NN	O
of	IN	O
large	JJ	O
joints	NNS	O
,	,	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
Sixty-five	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	Pharmacological
and	CC	O
65	CD	O
in	IN	O
the	DT	O
SINGLE	NNP	Pharmacological
group	NN	O
had	VBD	O
radiographs	NN	O
of	IN	O
hands	NNS	O
and	CC	O
feet	NNS	O
available	JJ	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

The	DT	O
mean	JJ	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
11	CD	O
years	NNS	O
in	IN	O
Larsen	NNP	O
score	NN	O
was	VBD	O
17	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
12	CD	O
to	TO	O
26	CD	O
)	)	O
in	IN	O
the	DT	O
FIN-RACo	NNP	Pharmacological
group	NN	O
and	CC	O
27	CD	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
22	CD	O
to	TO	O
33	CD	O
)	)	O
in	IN	O
the	DT	O
SINGLE	NNP	Pharmacological
group	NN	O
(	(	O
P=0.037	NNP	O
)	)	O
.	.	O

In	IN	O
total	JJ	O
,	,	O
87	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
74	CD	O
to	TO	O
94	CD	O
)	)	O
and	CC	O
72	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
58	CD	O
to	TO	O
84	CD	O
)	)	O
of	IN	O
the	DT	O
patients	NNS	O
in	IN	O
the	DT	O
FIN-RACo	NNP	O
and	CC	O
the	DT	O
SINGLE	NNP	O
treatment	NN	O
arms	NNS	O
,	,	O
respectively	RB	O
,	,	O
had	VBD	O
no	DT	O
erosive	JJ	O
changes	NNS	O
in	IN	O
large	JJ	O
joints	NNS	O
at	IN	O
11	CD	O
years	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Targeting	VBG	O
to	TO	O
remission	NN	O
with	IN	O
tight	JJ	O
clinical	JJ	O
controls	NNS	O
results	NNS	O
in	IN	O
low	JJ	O
radiologic	JJ	O
progression	NN	O
in	IN	O
most	JJS	O
RA	JJ	O
patients	NNS	O
.	.	O

Patients	NNS	O
treated	VBD	O
initially	RB	O
with	IN	O
a	DT	O
combination	NN	Pharmacological
of	IN	Pharmacological
DMARDs	NNP	Pharmacological
have	VBP	O
less	RBR	O
long-term	JJ	O
radiologic	NN	O
damage	NN	O
than	IN	O
do	VBP	O
those	DT	O
treated	VBN	O
initially	RB	O
with	IN	O
DMARD	NNP	Pharmacological
monotherapy	NN	Pharmacological
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Current	NNP	O
Controlled	NNP	O
Trials	NNP	O
ISRCTN18445519	NNP	O
.	.	O

Parenteral	NNP	O
troxerutin	NN	Pharmacological
and	CC	Pharmacological
carbazochrome	JJ	Pharmacological
combination	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
post-hemorrhoidectomy	JJ	O
status	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
,	,	O
phase	NN	O
IV	NNP	O
study	NN	O
.	.	O

Flavonoids	NNP	O
,	,	O
such	JJ	O
as	IN	O
troxerutin	NN	Pharmacological
,	,	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
effective	JJ	O
agents	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
venous	JJ	O
insufficiency	NN	O
.	.	O

The	DT	O
fixed	JJ	O
combination	NN	O
between	IN	O
troxerutin	$	Pharmacological
150	CD	O
mg	NN	O
and	CC	O
carbazochrome	VB	Pharmacological
1.5	CD	O
mg	NN	O
(	(	O
Fleboside	NNP	O
ampoules	NNS	O
)	)	O
was	VBD	O
previously	RB	O
shown	VBN	O
to	TO	O
have	VB	O
a	DT	O
good	JJ	O
efficacy	NN	O
and	CC	O
safety	NN	O
profile	NN	O
in	IN	O
non-surgical	JJ	O
patients	NNS	O
with	IN	O
acute	JJ	O
uncomplicated	JJ	O
hemorrhoids	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
the	DT	O
active	JJ	O
combination	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
post-hemorrhoidectomy	JJ	O
patients	NNS	O
.	.	O

30	CD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
two	CD	O
treatments	NNS	O
:	:	O
troxerutin	NN	Pharmacological
150	CD	Pharmacological
mg	NN	Pharmacological
and	CC	Pharmacological
carbazochrome	VB	Pharmacological
1.5	CD	Pharmacological
mg	NN	Pharmacological
,	,	O
or	CC	O
placebo	NN	Control
,	,	O
i.m	NN	O
.	.	O

3	CD	O
ml	JJ	O
ampoules	NNS	O
twice	RB	O
a	DT	O
day	NN	O
for	IN	O
five	CD	O
consecutive	JJ	O
days	NNS	O
after	IN	O
the	DT	O
surgical	JJ	O
procedure	NN	O
,	,	O
starting	VBG	O
from	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
.	.	O

Efficacy	NN	O
parameters	NNS	O
were	VBD	O
assessed	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
at	IN	O
baseline	NN	O
(	(	O
T1	NNP	O
)	)	O
,	,	O
after	IN	O
the	DT	O
first	JJ	O
administration	NN	O
(	(	O
T2	NNP	O
;	:	O
day	NN	O
of	IN	O
surgery	NN	O
)	)	O
,	,	O
the	DT	O
second	JJ	O
day	NN	O
after	IN	O
the	DT	O
surgical	JJ	O
procedure	NN	O
(	(	O
T3	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
fifth	JJ	O
day	NN	O
after	IN	O
the	DT	O
surgical	JJ	O
procedure	NN	O
(	(	O
T4	NNP	O
)	)	O
;	:	O
hemorrhoidal	PRP$	O
symptoms	NNS	O
based	VBN	O
on	IN	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
(	(	O
VAS	NNP	O
)	)	O
:	:	O
pain	NN	O
,	,	O
discharge	NN	O
,	,	O
bleeding	NN	O
,	,	O
inflammation	NN	O
,	,	O
and	CC	O
pruritus	NN	O
;	:	O
analgesic	JJ	O
intake	NN	O
,	,	O
if	IN	O
any	DT	O
;	:	O
time	NN	O
to	TO	O
restore	VB	O
a	DT	O
physiological	JJ	O
defecation	NN	O
;	:	O
edema	CC	O
evaluation	NN	O
(	(	O
based	VBN	O
on	IN	O
a	DT	O
four-point	JJ	O
scale	NN	O
:	:	O
0	CD	O
=	JJ	O
absent	NN	O
;	:	O
1	CD	O
=	NNP	O
mild	NN	O
;	:	O
2	CD	O
=	NN	O
moderate	NN	O
;	:	O
3	CD	O
=	NNP	O
severe	RB	O
)	)	O
;	:	O
camera	NN	O
pictures	VBZ	O
taken	VBN	O
at	IN	O
T1	NNP	O
and	CC	O
T4	NNP	O
(	(	O
in	IN	O
selected	VBN	O
patients	NNS	O
)	)	O
;	:	O
and	CC	O
blood	NN	O
coagulation	NN	O
tests	NNS	O
.	.	O

Analysis	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
revealed	VBD	O
a	DT	O
highly	RB	O
significant	JJ	O
difference	NN	O
at	IN	O
T3	NNP	O
and	CC	O
T4	NNP	O
for	IN	O
the	DT	O
total	JJ	O
VAS	NNP	O
score	NN	O
(	(	O
p	JJ	O
=	NN	O
0.007	CD	O
and	CC	O
p	VB	O
=	JJ	O
0.001	CD	O
,	,	O
respectively	RB	O
)	)	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
active	JJ	O
combination	NN	O
treatment	NN	O
.	.	O

A	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
for	IN	O
bleeding	NN	O
and	CC	O
pruritus	NN	O
at	IN	O
T3	NNP	O
and	CC	O
for	IN	O
these	DT	O
two	CD	O
parameters	NNS	O
and	CC	O
both	DT	O
inflammation	NN	O
and	CC	O
edema	NN	O
at	IN	O
T4	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
in	IN	O
favor	NN	O
of	IN	O
the	DT	O
active	JJ	O
combination	NN	O
group	NN	O
.	.	O

No	DT	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
.	.	O

Neither	CC	O
the	DT	O
active	JJ	O
combination	NN	O
nor	CC	O
placebo	NN	O
affected	VBD	O
blood	NN	O
coagulation	NN	O
tests	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
intramuscular	JJ	O
administration	NN	O
of	IN	O
the	DT	O
fixed	JJ	O
combination	NN	Pharmacological
of	IN	Pharmacological
troxerutin	$	Pharmacological
150	CD	O
mg	NN	O
and	CC	O
carbazochrome	VB	Pharmacological
1.5	CD	O
mg	NN	O
is	VBZ	O
effective	JJ	O
,	,	O
well	RB	O
tolerated	VBN	O
and	CC	O
superior	JJ	O
to	TO	O
placebo	VB	Control
in	IN	O
improving	VBG	O
hemorrhoidal	NN	O
and	CC	O
post-surgical	JJ	O
symptoms	NNS	O
during	IN	O
the	DT	O
five	CD	O
days	NNS	O
following	VBG	O
surgery	NN	O
.	.	O

Promoting	VBG	O
question-asking	NN	Educational
in	IN	O
school-aged	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
effectiveness	NN	O
of	IN	O
a	DT	O
robot	NN	Educational
intervention	NN	Educational
compared	VBN	O
to	TO	O
a	DT	O
human-trainer	JJ	Educational
intervention	NN	Educational
.	.	O

OBJECTIVE	CC	O
The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
applied	JJ	Educational
behaviour	NN	Educational
analysis	NN	Educational
(	(	Educational
ABA	NNP	Educational
)	)	Educational
-based	VBD	Educational
intervention	NN	Educational
conducted	VBN	Educational
by	IN	Educational
a	DT	Educational
robot	NN	Educational
compared	VBN	Educational
to	TO	Educational
an	DT	Educational
ABA-based	JJ	Educational
intervention	NN	Educational
conducted	VBN	Educational
by	IN	Educational
a	DT	Educational
human	JJ	Educational
trainer	NN	Educational
in	IN	O
promoting	VBG	O
self-initiated	JJ	O
questions	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
Data	NNP	O
were	VBD	O
collected	VBN	O
in	IN	O
a	DT	O
combined	JJ	O
crossover	NN	O
multiple	JJ	O
baseline	NN	O
design	NN	O
across	IN	O
participants	NNS	O
.	.	O

Six	CD	O
children	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
two	CD	O
experimental	JJ	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
Results	NNP	O
revealed	VBD	O
that	IN	O
the	DT	O
number	NN	O
of	IN	O
self-initiated	JJ	O
questions	NNS	O
for	IN	O
both	DT	O
experimental	JJ	O
groups	NNS	O
increased	VBD	O
between	IN	O
baseline	NN	O
and	CC	O
the	DT	O
first	JJ	O
intervention	NN	O
and	CC	O
was	VBD	O
maintained	VBN	O
during	IN	O
follow-up	NN	O
.	.	O

The	DT	O
high	JJ	O
number	NN	O
of	IN	O
self-initiated	JJ	O
questions	NNS	O
during	IN	O
follow-up	JJ	O
indicates	NNS	O
that	IN	O
both	DT	O
groups	NNS	O
maintained	VBD	O
this	DT	O
skill	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
interventions	NNS	Educational
conducted	VBN	Educational
by	IN	Educational
a	DT	Educational
robot	NN	Educational
and	CC	Educational
a	DT	Educational
human	JJ	Educational
trainer	NN	Educational
were	VBD	O
both	DT	O
effective	JJ	O
in	IN	O
promoting	VBG	O
self-initiated	JJ	O
questions	NNS	O
in	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

No	DT	O
conclusion	NN	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
differential	JJ	O
effectiveness	NN	O
of	IN	O
both	DT	O
interventions	NNS	O
could	MD	O
be	VB	O
drawn	VBN	O
.	.	O

Implications	NNS	O
of	IN	O
the	DT	O
results	NNS	O
and	CC	O
directions	NNS	O
for	IN	O
future	JJ	O
research	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
a	DT	O
5	CD	O
day	NN	O
regimen	NNS	O
of	IN	O
cefdinir	NN	Pharmacological
with	IN	O
a	DT	O
10	CD	O
day	NN	O
regimen	NNS	O
of	IN	O
cefprozil	NN	Pharmacological
for	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
.	.	O

Patients	NNS	O
with	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
cefdinir	NN	Pharmacological
300	CD	O
mg	NN	O
bd	NN	O
for	IN	O
5	CD	O
days	NNS	O
or	CC	O
cefprozil	JJ	Pharmacological
500	CD	O
mg	NN	O
bd	NN	O
for	IN	O
10	CD	O
days	NNS	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
multicentre	JJ	O
study	NN	O
.	.	O

Of	IN	O
the	DT	O
548	CD	O
patients	NNS	O
enrolled	VBD	O
,	,	O
281	CD	O
(	(	O
51	CD	O
%	NN	O
)	)	O
were	VBD	O
evaluable	JJ	O
.	.	O

The	DT	O
clinical	JJ	O
cure	NN	O
rates	NNS	O
at	IN	O
the	DT	O
test-of-cure	JJ	O
visit	NN	O
were	VBD	O
80	CD	O
%	NN	O
(	(	O
114/142	CD	O
)	)	O
and	CC	O
72	CD	O
%	NN	O
(	(	O
100/139	CD	O
)	)	O
for	IN	O
the	DT	O
evaluable	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
cefdinir	NN	Pharmacological
and	CC	O
cefprozil	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

Respiratory	NNP	O
tract	JJ	O
pathogens	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
409	CD	O
(	(	O
75	CD	O
%	NN	O
)	)	O
of	IN	O
548	CD	O
admission	NN	O
sputum	NN	O
specimens	NNS	O
,	,	O
with	IN	O
the	DT	O
predominant	NN	O
pathogens	VBZ	O
being	VBG	O
Haemophilus	NNP	O
parainfluenzae	NN	O
,	,	O
Haemophilus	NNP	O
influenzae	NN	O
,	,	O
Staphylococcus	NNP	O
aureus	NN	O
and	CC	O
Moraxella	NNP	O
catarrhalis	NN	O
.	.	O

The	DT	O
microbiological	JJ	O
eradication	NN	O
rates	NNS	O
at	IN	O
the	DT	O
test-of-cure	JJ	O
visit	NN	O
were	VBD	O
81	CD	O
%	NN	O
(	(	O
157	CD	O
of	IN	O
193	CD	O
pathogens	NNS	O
)	)	O
and	CC	O
84	CD	O
%	NN	O
(	(	O
166	CD	O
of	IN	O
198	CD	O
pathogens	NNS	O
)	)	O
for	IN	O
the	DT	O
evaluable	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
cefdinir	NN	Pharmacological
and	CC	O
cefprozil	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

Adverse	JJ	O
event	NN	O
rates	NNS	O
while	IN	O
on	IN	O
treatment	NN	O
were	VBD	O
equivalent	JJ	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
groups	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
diarrhoea	NN	O
during	IN	O
therapy	NN	O
was	VBD	O
higher	JJR	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
cefdinir	NN	Pharmacological
(	(	O
17	CD	O
%	NN	O
)	)	O
than	IN	O
for	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
cefprozil	NN	Pharmacological
(	(	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
but	CC	O
most	JJS	O
cases	NNS	O
were	VBD	O
mild	JJ	O
and	CC	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
discontinuation	NN	O
of	IN	O
treatment	NN	O
.	.	O

These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
a	DT	O
5	CD	O
day	NN	O
regimen	NNS	O
of	IN	O
cefdinir	NN	Pharmacological
is	VBZ	O
as	IN	O
effective	JJ	O
and	CC	O
safe	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
acute	JJ	O
exacerbations	NNS	O
of	IN	O
chronic	JJ	O
bronchitis	NN	O
as	IN	O
a	DT	O
10	CD	O
day	NN	O
regimen	NNS	O
of	IN	O
cefprozil	NN	Pharmacological
.	.	O

Moderate-intensity	NNP	Physical
exercise	NN	Physical
training	NN	Physical
with	IN	O
elements	NNS	O
of	IN	O
step	NN	O
aerobics	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
chronic	JJ	O
heart	NN	O
failure	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
evaluate	VB	O
whether	IN	O
a	DT	O
specific	JJ	O
program	NN	O
of	IN	O
moderate-intensity	JJ	Physical
step	NN	Physical
aerobics	NNS	Physical
training	NN	Physical
may	MD	O
be	VB	O
sufficient	JJ	O
to	TO	O
improve	VB	O
the	DT	O
exercise	NN	O
tolerance	NN	O
of	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
chronic	JJ	O
heart	NN	O
failure	NN	O
.	.	O

PATIENTS	VB	O
Twenty-six	JJ	O
patients	NNS	O
(	(	O
22	CD	O
men	NNS	O
,	,	O
4	CD	O
women	NNS	O
;	:	O
mean	VB	O
+/-	JJ	O
SD	NNP	O
age	NN	O
,	,	O
54	CD	O
+/-	JJ	O
9yrs	CD	O
)	)	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
severe	JJ	O
chronic	JJ	O
heart	NN	O
failure	NN	O
(	(	O
left	JJ	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
of	IN	O
18	CD	O
%	NN	O
+/-	JJ	O
8	CD	O
%	NN	O
)	)	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
controlled	VBD	O
trial	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
exercise	NN	O
and	CC	O
control	NN	O
groups	NNS	O
.	.	O

All	DT	O
patients	NNS	O
underwent	VBD	O
a	DT	O
clinical	JJ	O
examination	NN	O
and	CC	O
a	DT	O
ramp	NN	O
pattern	JJ	O
cycle	NN	O
exercise	NN	O
test	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
observation	NN	O
period	NN	O
.	.	O

The	DT	O
exercise	NN	O
group	NN	O
underwent	VBD	O
a	DT	O
moderate-intensity	NN	Physical
(	(	Physical
50	CD	Physical
%	NN	Physical
of	IN	Physical
peak	NN	Physical
oxygen	NN	Physical
uptake	NN	Physical
)	)	Physical
12-week	JJ	Physical
training	NN	Physical
program	NN	Physical
,	,	O
progressing	VBG	Physical
to	TO	Physical
100	CD	Physical
minutes	NNS	Physical
per	IN	Physical
week	NN	Physical
of	IN	Physical
step	NN	Physical
aerobics	NNS	Physical
and	CC	Physical
50	CD	Physical
minutes	NNS	Physical
per	IN	Physical
week	NN	Physical
of	IN	Physical
cycling	NN	Physical
.	.	O

The	DT	O
control	NN	O
group	NN	O
did	VBD	O
not	RB	O
perform	VB	Physical
a	DT	Physical
training	NN	Physical
program	NN	Physical
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Peak	NNP	O
oxygen	NN	O
uptake	NN	O
,	,	O
peak	JJ	O
workload	NN	O
,	,	O
percent	NN	O
of	IN	O
predicted	JJ	O
power	NN	O
ability	NN	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
increases	NNS	O
in	IN	O
peak	NN	O
oxygen	NN	O
uptake	NN	O
(	(	O
15	CD	O
+/-	JJ	O
3.4	CD	O
to	TO	O
18.5	CD	O
+/-	JJ	O
2.9mL/kg/min	CD	O
;	:	O
p	NN	O
=	NNP	O
.001	NNP	O
)	)	O
,	,	O
peak	JJ	O
workload	NN	O
(	(	O
77	CD	O
+/-	JJ	O
26	CD	O
to	TO	O
99	CD	O
+/-	JJ	O
31	CD	O
watts	NN	O
;	:	O
p	CC	O
=	NNP	O
.000	NNP	O
)	)	O
,	,	O
and	CC	O
percent	NN	O
of	IN	O
predicted	JJ	O
power	NN	O
ability	NN	O
(	(	O
43	CD	O
%	NN	O
+/-	JJ	O
10	CD	O
%	NN	O
to	TO	O
56	CD	O
%	NN	O
+/-	JJ	O
13	CD	O
%	NN	O
;	:	O
p	CC	O
=	NNP	O
.000	NNP	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
baseline	NN	O
parameters	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
critical	JJ	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
or	CC	O
blood	NN	O
pressure	NN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Moderate-intensity	NNP	O
step	NN	O
aerobics	NNS	O
training	VBG	O
significantly	RB	O
increases	VBZ	O
peak	JJ	O
oxygen	NN	O
uptake	NN	O
and	CC	O
peak	JJ	O
workloads	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
chronic	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Effects	NNS	O
of	IN	O
guided	JJ	Psychological
imagery	NN	Psychological
with	IN	Psychological
relaxation	NN	Psychological
training	NN	Psychological
on	IN	O
anxiety	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
among	IN	O
patients	NNS	O
with	IN	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
.	.	O

BACKGROUND	NNP	O
Inflammatory	NNP	O
Bowel	NNP	O
Disease	NNP	O
(	(	O
IBD	NNP	O
)	)	O
impacts	VBZ	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
.	.	O

Psychological	JJ	O
factors	NNS	O
influence	VBP	O
the	DT	O
course	NN	O
of	IN	O
the	DT	O
disease	NN	O
and	CC	O
should	MD	O
be	VB	O
targeted	VBN	O
for	IN	O
intervention	NN	O
.	.	O

METHODS	NNP	O
Our	PRP$	O
study	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
,	,	O
randomised	VBD	O
control	NN	O
trial	NN	O
.	.	O

Fifty-six	JJ	O
outpatients	NNS	O
were	VBD	O
randomly	RB	O
chosen	VBN	O
and	CC	O
allocated	VBN	O
to	TO	O
a	DT	O
treatment	NN	Physical
group	NN	O
or	CC	O
a	DT	O
waiting-list	JJ	O
control	NN	Control
group	NN	O
.	.	O

Treatment	NNP	O
group	NN	O
patients	NNS	O
attended	VBD	O
three	CD	Educational
relaxation-training	JJ	Educational
sessions	NNS	Educational
and	CC	Educational
received	VBD	Educational
an	DT	Educational
audio	JJ	Educational
disc	NN	Educational
for	IN	Educational
home	NN	Educational
practice	NN	Educational
.	.	Educational

Evaluations	NNS	O
performed	VBD	O
pre	JJ	O
and	CC	O
post-treatment	JJ	O
:	:	O
state	NN	O
anxiety	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
the	DT	O
State-Trait	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
,	,	O
QoL	NNP	O
with	IN	O
the	DT	O
IBD	NNP	O
Questionnaire	NNP	O
.	.	O

The	DT	O
Visual	NNP	O
Analogue	NNP	O
Scale	NNP	O
assessed	VBD	O
pain	NN	O
,	,	O
depression	NN	O
,	,	O
stress	NN	O
and	CC	O
mood	NN	O
.	.	O

Patients	NNS	O
completed	VBD	O
a	DT	O
symptom	JJ	O
monitoring	NN	O
diary	NN	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
's	POS	O
symptoms	NNS	O
were	VBD	O
monitored	VBN	O
without	IN	O
study-related	JJ	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Thirty-nine	JJ	O
subjects	NNS	O
completed	VBD	O
the	DT	O
study	NN	O
and	CC	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
data	NN	O
analysis	NN	O
.	.	O

Following	VBG	O
the	DT	O
relaxation-training	JJ	O
intervention	NN	O
,	,	O
the	DT	O
treatment	NN	O
group	NN	O
's	POS	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
measured	VBN	O
results	NNS	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
improvement	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
(	(	O
time	NN	O
by	IN	O
treatment	NN	O
interaction	NN	O
)	)	O
:	:	O
anxiety	NN	O
levels	NNS	O
decreased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
QoL	NNP	O
and	CC	O
mood	NN	O
improved	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
while	IN	O
levels	NNS	O
of	IN	O
pain	NN	O
and	CC	O
stress	NN	O
decreased	VBN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Findings	NNP	O
indicate	VBP	O
IBD	NNP	O
patients	NNS	O
may	MD	O
benefit	VB	O
from	IN	O
relaxation	NN	O
training	NN	O
in	IN	O
their	PRP$	O
holistic	JJ	O
care	NN	O
.	.	O

New	NNP	O
studies	NNS	O
as	RB	O
well	RB	O
as	IN	O
further	JJ	O
investigation	NN	O
of	IN	O
the	DT	O
subject	NN	O
are	VBP	O
warranted	VBN	O
.	.	O

Comparison	NNP	O
of	IN	O
antihypertensive	JJ	O
effects	NNS	O
of	IN	O
captopril	NN	Pharmacological
and	CC	O
propranolol	NN	Pharmacological
in	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

The	DT	O
antihypertensive	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
oral	JJ	O
converting	NN	O
enzyme	NN	O
inhibitor	NN	O
captopril	NN	Pharmacological
and	CC	O
of	IN	O
propranolol	NNS	Pharmacological
were	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
single-blind	JJ	O
trial	NN	O
of	IN	O
12	CD	O
weeks	NNS	O
in	IN	O
19	CD	O
ambulatory	JJ	O
men	NNS	O
with	IN	O
moderated	VBN	O
essential	JJ	O
hypertension	NN	O
(	(	O
supine	JJ	O
diastolic	NN	O
blood	NN	O
pressure	NN	O
[	NNP	O
DPB	NNP	O
]	NNP	O
,	,	O
100	CD	O
to	TO	O
120	CD	O
mm	NNS	O
Hg	NNP	O
after	IN	O
receiving	VBG	O
placebo	NN	Control
for	IN	O
two	CD	O
weeks	NNS	O
)	)	O
whose	WP$	O
sodium	JJ	O
intake	NN	O
was	VBD	O
unrestricted	VBN	O
.	.	O

The	DT	O
captopril	NN	Pharmacological
group	NN	O
included	VBD	O
12	CD	O
patients	NNS	O
and	CC	O
the	DT	O
propranolol	NN	Pharmacological
group	NN	O
seven	CD	O
.	.	O

After	IN	O
the	DT	O
initial	JJ	O
dose-finding	JJ	O
period	NN	O
of	IN	O
four	CD	O
weeks	NNS	O
,	,	O
supine	JJ	O
DBP	NNP	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
in	IN	O
eight	CD	O
patients	NNS	O
receiving	VBG	O
captopril	NN	Pharmacological
and	CC	O
in	IN	O
four	CD	O
of	IN	O
the	DT	O
patients	NNS	O
receiving	VBG	O
propranolol	NN	Pharmacological
.	.	O

In	IN	O
these	DT	O
patients	NNS	O
DBP	VBP	O
decreased	VBN	O
throughout	IN	O
the	DT	O
following	JJ	O
eight	CD	O
weeks	NNS	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
from	IN	O
each	DT	O
group	NN	O
,	,	O
DBP	NNP	O
was	VBD	O
not	RB	O
reduced	VBN	O
by	IN	O
either	DT	O
drug	NN	O
given	VBN	O
alone	RB	O
at	IN	O
maximum	JJ	O
allowable	JJ	O
dosages	NNS	O
during	IN	O
dose-finding	JJ	O
periods	NNS	O
,	,	O
nor	CC	O
by	IN	O
combined	JJ	O
administration	NN	O
in	IN	O
following	VBG	O
weeks	NNS	O
.	.	O

No	DT	O
adverse	JJ	O
side	NN	O
effects	NNS	O
attributable	JJ	O
to	TO	O
captopril	VB	Pharmacological
were	VBD	O
noted	VBN	O
,	,	O
except	IN	O
in	IN	O
one	CD	O
patient	NN	O
in	IN	O
whom	WP	O
proteinuria	NN	O
developed	VBD	O
after	IN	O
seven	CD	O
weeks	NNS	O
.	.	O

Captopril	NNP	Pharmacological
has	VBZ	O
potential	JJ	O
value	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
essential	JJ	O
hypertension	NN	O
.	.	O

Global	JJ	O
contour	NN	O
saliency	NN	O
and	CC	O
local	JJ	O
colinear	NN	O
interactions	NNS	O
.	.	O

Our	PRP$	O
visual	JJ	O
system	NN	O
can	MD	O
link	VB	O
components	NNS	O
of	IN	O
contours	NNS	O
and	CC	O
segregate	JJ	O
contours	NNS	O
from	IN	O
complex	JJ	O
backgrounds	NNS	O
based	VBN	O
on	IN	O
geometric	JJ	O
grouping	NN	O
rules	NNS	O
.	.	O

This	DT	O
is	VBZ	O
an	DT	O
important	JJ	O
intermediate	JJ	O
step	NN	O
in	IN	O
object	JJ	O
recognition	NN	O
.	.	O

The	DT	O
substrate	NN	O
for	IN	O
contour	JJ	O
integration	NN	O
may	MD	O
be	VB	O
based	VBN	O
on	IN	O
contextual	JJ	O
interactions	NNS	O
and	CC	O
intrinsic	JJ	O
horizontal	NN	O
connections	NNS	O
seen	VBN	O
in	IN	O
primary	JJ	O
visual	JJ	O
cortex	NN	O
(	(	O
V1	NNP	O
)	)	O
.	.	O

We	PRP	O
examined	VBD	O
the	DT	O
perceptual	JJ	O
rules	NNS	O
governing	VBG	O
contour	NN	O
saliency	NN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
spatial	JJ	O
extents	NNS	O
of	IN	O
contextual	JJ	O
interactions	NNS	O
and	CC	O
horizontal	JJ	O
connections	NNS	O
match	VBP	O
those	DT	O
mediating	JJ	O
saliency	NN	O
.	.	O

To	TO	O
quantify	VB	O
these	DT	O
rules	NNS	O
,	,	O
we	PRP	O
used	VBD	O
stimuli	NNS	Physical
composed	VBN	Physical
of	IN	Physical
randomly	RB	Physical
oriented	VBN	Physical
nonoverlapping	JJ	Physical
line	NN	Physical
segments	NNS	Physical
.	.	O

Salient	NN	O
contours	NN	O
within	IN	O
this	DT	O
complex	JJ	O
background	NN	O
were	VBD	O
formed	VBN	O
by	IN	O
colinear	JJ	O
alignment	NN	O
of	IN	O
nearby	JJ	O
segments	NNS	O
.	.	O

Contour	NNP	O
detectability	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
2-interval-forced-choice	JJ	Physical
design	NN	Physical
.	.	O

Contour	NNP	O
detectability	NN	O
deteriorated	VBN	O
with	IN	O
increasing	VBG	O
spacing	VBG	O
between	IN	O
contour	JJ	O
elements	NNS	O
and	CC	O
improved	VBN	O
as	IN	O
the	DT	O
number	NN	O
of	IN	O
colinear	JJ	O
line	NN	O
elements	NNS	O
was	VBD	O
increased	VBN	O
.	.	O

At	IN	O
short	JJ	O
contour	NN	O
spacing	NN	O
,	,	O
the	DT	O
detectability	NN	O
reached	VBD	O
a	DT	O
plateau	NN	O
with	IN	O
alignment	NN	O
of	IN	O
a	DT	O
few	JJ	O
line	NN	O
segments	NNS	O
that	IN	O
together	RB	O
formed	VBD	O
a	DT	O
contour	NN	O
subtending	VBG	O
several	JJ	O
visual	JJ	O
degrees	NNS	O
.	.	O

At	IN	O
intermediate	JJ	O
spacing	NN	O
,	,	O
saliency	NN	O
built	VBD	O
up	RP	O
progressively	RB	O
with	IN	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
colinear	JJ	O
lines	NNS	O
,	,	O
extending	VBG	O
up	RP	O
to	TO	O
30	CD	O
degrees	NNS	O
.	.	O

When	WRB	O
contour	NN	O
spacing	NN	O
was	VBD	O
beyond	IN	O
a	DT	O
critical	JJ	O
range	NN	O
(	(	O
about	IN	O
2	CD	O
degrees	NNS	O
)	)	O
,	,	O
however	RB	O
,	,	O
the	DT	O
detectability	NN	O
dropped	VBD	O
to	TO	O
chance	NN	O
levels	NNS	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
number	NN	O
of	IN	O
colinear	JJ	O
lines	NNS	O
.	.	O

Contour	NNP	O
detectability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
a	DT	O
function	NN	O
not	RB	O
only	RB	O
of	IN	O
the	DT	O
relative	JJ	O
spacing	NN	O
of	IN	O
contour	JJ	O
elements	NNS	O
with	IN	O
respect	NN	O
to	TO	O
the	DT	O
noise	NN	O
elements	NNS	O
but	CC	O
also	RB	O
of	IN	O
the	DT	O
average	JJ	O
density	NN	O
of	IN	O
the	DT	O
overall	JJ	O
pattern	NN	O
.	.	O

Furthermore	NNP	O
,	,	O
training	VBG	O
significantly	RB	O
improved	VBN	O
contour	JJ	O
detection	NN	O
,	,	O
increasing	VBG	O
the	DT	O
critical	JJ	O
spacing	NN	O
of	IN	O
line	NN	O
elements	NNS	O
beyond	IN	O
which	WDT	O
contours	NNS	O
were	VBD	O
no	RB	O
longer	RBR	O
detectable	JJ	O
.	.	O

Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
global	JJ	O
contour	NN	O
integration	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
mechanisms	NNS	O
of	IN	O
limited	JJ	O
spatial	JJ	O
extent	NN	O
,	,	O
comparable	JJ	O
to	TO	O
the	DT	O
interactions	NNS	O
observed	VBD	O
in	IN	O
V1	NNP	O
.	.	O

These	DT	O
interactions	NNS	O
can	MD	O
cascade	VB	O
over	IN	O
larger	JJR	O
distances	NNS	O
provided	VBD	O
the	DT	O
spacing	NN	O
of	IN	O
stimulus	JJ	O
elements	NNS	O
is	VBZ	O
kept	VBN	O
within	IN	O
a	DT	O
limited	JJ	O
range	NN	O
.	.	O

Effect	NN	O
of	IN	O
gravity	NN	O
on	IN	O
robot-assisted	JJ	Physical
motor	NN	Physical
training	NN	Physical
after	IN	O
chronic	JJ	O
stroke	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

OBJECTIVES	UH	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
2	CD	O
distinct	JJ	O
6-week	JJ	O
robot-assisted	JJ	Physical
reaching	NN	Physical
programs	NNS	Physical
compared	VBN	O
with	IN	O
an	DT	O
intensive	JJ	O
conventional	JJ	Physical
arm	NN	Physical
exercise	NN	Physical
program	NN	Physical
(	(	O
ICAE	NNP	O
)	)	O
for	IN	O
chronic	NN	O
,	,	O
stroke-related	JJ	O
upper-extremity	NN	O
(	(	O
UE	NNP	O
)	)	O
impairment	NN	O
.	.	O

To	TO	O
examine	VB	O
whether	IN	O
the	DT	O
addition	NN	O
of	IN	O
robot-assisted	JJ	Physical
training	VBG	Physical
out	IN	O
of	IN	O
the	DT	O
horizontal	JJ	O
plane	NN	O
leads	VBZ	O
to	TO	O
improved	VBN	O
outcomes	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
controlled	VBD	O
trial	NN	O
,	,	O
single-blinded	JJ	O
,	,	O
with	IN	O
12-week	JJ	O
follow-up	NN	O
.	.	O

SETTING	NNP	O
Research	NNP	O
setting	VBG	O
in	IN	O
a	DT	O
large	JJ	O
medical	JJ	O
center	NN	O
.	.	O

PARTICIPANTS	NNP	O
Adults	NNP	O
(	(	O
N=62	NNP	O
)	)	O
with	IN	O
chronic	JJ	O
,	,	O
stroke-related	JJ	O
arm	NN	O
weakness	NN	O
stratified	VBN	O
by	IN	O
impairment	JJ	O
severity	NN	O
using	VBG	O
baseline	JJ	O
UE	NNP	O
motor	NN	O
assessments	NNS	O
.	.	O

INTERVENTIONS	NNP	O
Sixty	NNP	O
minutes	NNS	O
,	,	O
3	CD	O
times	NNS	O
a	DT	O
week	NN	O
for	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
robot-assisted	JJ	Physical
planar	NN	Physical
reaching	NN	Physical
(	(	Physical
gravity	NN	Physical
compensated	VBN	Physical
)	)	Physical
,	,	O
combined	VBN	Physical
planar	NN	Physical
with	IN	Physical
vertical	JJ	Physical
robot-assisted	JJ	Physical
reaching	NN	Physical
,	,	O
or	CC	O
intensive	JJ	Physical
conventional	JJ	Physical
arm	NN	Physical
exercise	NN	Physical
program	NN	Physical
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURE	NNP	O
UE	NNP	O
Fugl-Meyer	NNP	O
Assessment	NNP	O
(	(	O
FMA	NNP	O
)	)	O
mean	VBP	O
change	NN	O
from	IN	O
baseline	NN	O
to	TO	O
final	JJ	O
training	NN	O
.	.	O

RESULTS	NNP	O
All	DT	O
groups	NNS	O
showed	VBD	O
modest	JJ	O
gains	NNS	O
in	IN	O
the	DT	O
FMA	NNP	O
from	IN	O
baseline	NN	O
to	TO	O
final	JJ	O
with	IN	O
no	DT	O
significant	JJ	O
between	IN	O
group	NN	O
differences	NNS	O
.	.	O

Most	JJS	O
change	NN	O
occurred	VBD	O
in	IN	O
the	DT	O
planar	NN	O
robot	NN	O
group	NN	O
(	(	O
mean	JJ	O
change	NN	O
?	.	O
SD	NNP	O
,	,	O
2.94	CD	O
?	.	O
0.77	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.40-4.47	JJ	O
)	)	O
.	.	O

Participants	NNS	O
with	IN	O
greater	JJR	O
motor	NN	O
impairment	NN	O
(	(	O
n=41	JJ	O
)	)	O
demonstrated	VBD	O
a	DT	O
larger	JJR	O
difference	NN	O
in	IN	O
response	NN	O
(	(	O
mean	JJ	O
change	NN	O
?	.	O
SD	NNP	O
,	,	O
2.29	CD	O
?	.	O
0.72	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.85-3.72	NNP	O
)	)	O
for	IN	O
planar	JJ	O
robot-assisted	JJ	O
exercise	NN	O
compared	VBN	O
with	IN	O
the	DT	O
intensive	JJ	O
conventional	JJ	O
arm	NN	O
exercise	NN	O
program	NN	O
(	(	O
mean	JJ	O
change	NN	O
?	.	O
SD	NNP	O
,	,	O
0.43	CD	O
?	.	O
0.72	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
-1.00	NNP	O
to	TO	O
1.86	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Chronic	NNP	O
UE	NNP	O
deficits	NNS	O
because	IN	O
of	IN	O
stroke	NN	O
are	VBP	O
responsive	JJ	O
to	TO	O
intensive	JJ	O
motor	NN	O
task	NN	O
training	NN	O
.	.	O

However	RB	O
,	,	O
training	VBG	O
outside	IN	O
the	DT	O
horizontal	JJ	O
plane	NN	O
in	IN	O
a	DT	O
gravity	NN	O
present	JJ	O
environment	NN	O
using	VBG	O
a	DT	O
combination	NN	O
of	IN	O
vertical	JJ	O
with	IN	O
planar	JJ	O
robots	NNS	O
was	VBD	O
not	RB	O
superior	JJ	O
to	TO	O
training	VBG	O
with	IN	O
the	DT	O
planar	NN	O
robot	NN	O
alone	RB	O
.	.	O

Once-daily	RB	O
topical	JJ	Pharmacological
brimonidine	NN	Pharmacological
tartrate	NN	Pharmacological
gel	VBD	Pharmacological
0?5	CD	O
%	NN	O
is	VBZ	O
a	DT	O
novel	JJ	O
treatment	NN	O
for	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
facial	JJ	O
erythema	NN	O
of	IN	O
rosacea	NN	O
:	:	O
results	NNS	O
of	IN	O
two	CD	O
multicentre	NNS	O
,	,	O
randomized	VBN	O
and	CC	O
vehicle-controlled	JJ	O
studies	NNS	O
.	.	O

BACKGROUND	NNP	O
Erythema	NNP	O
of	IN	O
rosacea	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
result	VB	O
from	IN	O
abnormal	JJ	O
cutaneous	JJ	O
vasomotor	NN	O
activity	NN	O
.	.	O

Brimonidine	NNP	O
tartrate	NN	O
(	(	O
BT	NNP	O
)	)	O
is	VBZ	O
a	DT	O
highly	RB	O
selective	JJ	O
?	.	O
(	(	O
2	CD	O
)	)	O
-adrenergic	NN	O
receptor	NN	O
agonist	NN	O
with	IN	O
vasoconstrictive	JJ	O
activity	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
concentration	NN	O
and	CC	O
dose	JJ	O
regimen	NNS	O
of	IN	O
topical	JJ	O
BT	NNP	O
gel	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
erythema	NN	O
of	IN	O
rosacea	NN	O
and	CC	O
to	TO	O
evaluate	VB	O
its	PRP$	O
efficacy	NN	O
and	CC	O
safety	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
study	NN	O
A	NNP	O
,	,	O
122	CD	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
single	JJ	O
application	NN	O
of	IN	O
BT	NNP	O
0?07	CD	O
%	NN	O
,	,	O
0?18	CD	O
%	NN	O
,	,	O
0?5	CD	O
%	NN	O
or	CC	O
vehicle	NN	O
.	.	O

In	IN	O
study	NN	O
B	NNP	O
(	(	O
4-week	JJ	O
treatment	NN	O
and	CC	O
4-week	JJ	O
follow-up	NN	O
)	)	O
,	,	O
269	CD	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
BT	NNP	O
0?5	CD	O
%	NN	O
once	RB	O
daily	JJ	O
,	,	O
BT	NNP	O
0?18	CD	O
%	NN	O
once	RB	O
daily	JJ	O
,	,	O
vehicle	NN	O
once	RB	O
daily	RB	O
,	,	O
BT	NNP	O
0?18	CD	O
%	NN	O
twice	JJ	O
daily	RB	O
or	CC	O
vehicle	NN	O
twice	RB	O
daily	RB	O
.	.	O

Evaluations	NNS	O
included	VBD	O
Clinician	NNP	O
's	POS	O
Erythema	NNP	O
Assessment	NNP	O
(	(	O
CEA	NNP	O
)	)	O
,	,	O
Patient	NNP	O
's	POS	O
Self-Assessment	JJ	O
(	(	O
PSA	NNP	O
)	)	O
,	,	O
Chroma	NNP	O
Meter	NNP	O
measurements	NNS	O
and	CC	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
In	IN	O
study	NN	O
A	NNP	O
,	,	O
a	DT	O
single	JJ	O
application	NN	O
of	IN	O
topical	JJ	O
BT	NNP	O
gel	NN	O
reduced	VBD	O
facial	JJ	O
erythema	NN	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
fashion	NN	O
.	.	O

A	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
BT	NNP	O
0?5	CD	O
%	NN	O
and	CC	O
vehicle	NN	O
in	IN	O
Chroma	NNP	O
Meter	NNP	O
redness	NN	O
value	NN	O
was	VBD	O
observed	VBN	O
from	IN	O
30min	CD	O
to	TO	O
12h	CD	O
after	IN	O
application	NN	O
.	.	O

In	IN	O
study	NN	O
B	NNP	O
,	,	O
BT	NNP	O
0?5	CD	O
%	NN	O
once	RB	O
daily	JJ	O
had	VBD	O
a	DT	O
statistically	RB	O
superior	JJ	O
success	NN	O
profile	NN	O
(	(	O
defined	VBN	O
as	IN	O
a	DT	O
two-grade	JJ	O
improvement	NN	O
on	IN	O
both	DT	O
CEA	NNP	O
and	CC	O
PSA	NNP	O
over	IN	O
12h	CD	O
)	)	O
compared	VBN	O
with	IN	O
vehicle	NN	O
once	RB	O
daily	RB	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
15	CD	O
and	CC	O
29	CD	O
(	(	O
all	DT	O
P	NNP	O
<	NNP	O
0?001	CD	O
)	)	O
.	.	O

No	DT	O
tachyphylaxis	NN	O
,	,	O
rebound	NN	O
of	IN	O
erythema	NN	O
or	CC	O
aggravation	NN	O
of	IN	O
other	JJ	O
disease	NN	O
signs	NNS	O
(	(	O
telangiectasia	NN	O
,	,	O
inflammatory	JJ	O
lesions	NNS	O
)	)	O
was	VBD	O
observed	VBN	O
.	.	O

All	DT	O
regimens	NNS	O
were	VBD	O
safe	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
with	IN	O
similarly	RB	O
low	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Once-daily	JJ	O
BT	NNP	O
gel	VBD	O
0?5	CD	O
%	NN	O
is	VBZ	O
well	RB	O
tolerated	JJ	O
and	CC	O
provides	VBZ	O
significantly	RB	O
greater	JJR	O
efficacy	NN	O
than	IN	O
vehicle	NN	O
gel	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
erythema	NN	O
of	IN	O
rosacea	NN	O
.	.	O

Acute	NNP	O
and	CC	O
long-term	JJ	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
risperidone	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Treatment-emergent	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
were	VBD	O
monitored	VBN	O
during	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
risperidone	NN	Pharmacological
(	(	O
0.5-3.5	JJ	O
mg/day	NN	O
)	)	O
in	IN	O
101	CD	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
a	DT	O
lifetime	JJ	O
diagnosis	NN	O
of	IN	O
autistic	JJ	O
disorder	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
37	CD	O
placebo	NN	O
nonresponders	NNS	O
received	VBD	O
open-label	JJ	O
risperidone	NN	Pharmacological
for	IN	O
another	DT	O
8	CD	O
weeks	NNS	O
.	.	O

Of	IN	O
all	PDT	O
the	DT	O
risperidone	NN	Pharmacological
responders	NNS	O
(	(	O
n=65	NN	O
)	)	O
,	,	O
63	CD	O
entered	VBD	O
an	DT	O
open	JJ	O
extension	NN	O
of	IN	O
another	DT	O
16	CD	O
weeks	NNS	O
(	(	O
6	CD	O
months	NNS	O
total	JJ	O
risperidone	NN	Pharmacological
exposure	NN	O
)	)	O
,	,	O
and	CC	O
32	CD	O
of	IN	O
them	PRP	O
were	VBD	O
rerandomized	VBN	O
to	TO	O
either	DT	O
continued	VBN	O
risperidone	NN	Pharmacological
therapy	NN	O
(	(	O
n=16	JJ	O
)	)	O
or	CC	O
gradual	JJ	O
replacement	NN	O
with	IN	O
placebo	NN	Pharmacological
(	(	O
n=16	JJ	O
)	)	O
over	IN	O
8	CD	O
weeks	NNS	O
.	.	O

We	PRP	O
collected	VBD	O
the	DT	O
following	JJ	O
measures	NNS	O
of	IN	O
safety	NN	O
and	CC	O
tolerability	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
laboratory	NN	O
blood	NN	O
assessments	NNS	O
(	(	O
CBC	NNP	O
with	IN	O
differential	JJ	O
,	,	O
electrolytes	NNS	O
,	,	O
and	CC	O
liver	JJ	O
function	NN	O
tests	NNS	O
)	)	O
and	CC	O
urinalyses	NNS	O
,	,	O
(	(	O
2	CD	O
)	)	O
vital	NN	O
signs	NNS	O
,	,	O
(	(	O
3	CD	O
)	)	O
Side	NNP	O
Effects	NNP	O
Review	NNP	O
of	IN	O
AEs	NNP	O
thought	VBD	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
risperidone	NN	O
,	,	O
(	(	O
4	CD	O
)	)	O
sleep	NN	O
records	NNS	O
,	,	O
(	(	O
5	CD	O
)	)	O
Simpson	NNP	O
Angus	NNP	O
Neurological	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
SARS	NNP	O
)	)	O
,	,	O
(	(	O
6	CD	O
)	)	O
Abnormal	NNP	O
Involuntary	NNP	O
Movement	NNP	O
Scale	NNP	O
(	(	O
AIMS	NNP	O
)	)	O
,	,	O
and	CC	O
(	(	O
7	CD	O
)	)	O
height	NN	O
and	CC	O
weight	NN	O
.	.	O

No	DT	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
were	VBD	O
found	VBN	O
on	IN	O
the	DT	O
lab	NN	O
tests	NNS	O
.	.	O

During	IN	O
the	DT	O
8-week	JJ	O
acute	JJ	O
trial	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
AEs	NNP	O
on	IN	O
the	DT	O
Side	NNP	O
Effects	NNP	O
Review	NNP	O
,	,	O
scored	VBD	O
as	IN	O
moderate	JJ	O
or	CC	O
higher	JJR	O
,	,	O
were	VBD	O
as	IN	O
follows	VBZ	O
(	(	O
placebo	NN	O
and	CC	O
risperidone	NN	O
,	,	O
respectively	RB	O
)	)	O
:	:	O
Somnolence	NN	O
(	(	O
12	CD	O
%	NN	O
and	CC	O
37	CD	O
%	NN	O
)	)	O
,	,	O
enuresis	NN	O
(	(	O
29	CD	O
%	NN	O
and	CC	O
33	CD	O
%	NN	O
)	)	O
,	,	O
excessive	JJ	O
appetite	NN	O
(	(	O
10	CD	O
%	NN	O
and	CC	O
33	CD	O
%	NN	O
)	)	O
,	,	O
rhinitis	NN	O
(	(	O
8	CD	O
%	NN	O
and	CC	O
16	CD	O
%	NN	O
)	)	O
,	,	O
difficulty	NN	O
waking	NN	O
(	(	O
8	CD	O
%	NN	O
and	CC	O
12	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
constipation	NN	O
(	(	O
12	CD	O
%	NN	O
and	CC	O
10	CD	O
%	NN	O
)	)	O
.	.	O

Difficulty	NN	O
falling	VBG	O
asleep	JJ	O
and	CC	O
anxiety	NN	O
actually	RB	O
favored	VBD	O
the	DT	O
risperidone	NN	O
condition	NN	O
at	IN	O
statistically	RB	O
significant	JJ	O
levels	NNS	O
.	.	O

The	DT	O
same	JJ	O
AEs	NNP	O
tended	VBD	O
to	TO	O
recur	VB	O
through	IN	O
6	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
,	,	O
although	IN	O
often	RB	O
at	IN	O
reduced	VBN	O
levels	NNS	O
.	.	O

Using	VBG	O
Centers	NNPS	O
for	IN	O
Disease	NNP	O
Control	NNP	O
(	(	O
CDC	NNP	O
)	)	O
standardized	VBD	O
scores	NNS	O
,	,	O
both	DT	O
weight	NN	O
and	CC	O
body	NN	O
mass	NN	O
index	NN	O
(	(	O
BMI	NNP	O
)	)	O
increased	VBD	O
with	IN	O
risperidone	NN	Pharmacological
during	IN	O
the	DT	O
acute	JJ	O
trial	NN	O
(	(	O
0.5	CD	O
and	CC	O
0.6	CD	O
SDs	NNP	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
risperidone	NN	Pharmacological
;	:	Pharmacological
0.0	CD	O
and	CC	O
0.1	CD	O
SDs	NNP	O
,	,	O
respectively	RB	O
,	,	O
for	IN	O
placebo	NN	O
)	)	O
and	CC	O
into	IN	O
open-label	JJ	O
extension	NN	O
(	(	O
0.19	CD	O
and	CC	O
0.16	CD	O
SDs	NNP	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
although	IN	O
the	DT	O
amount	NN	O
of	IN	O
gain	NN	O
decelerated	VBN	O
with	IN	O
time	NN	O
.	.	O

Extrapyramidal	NNP	O
symptoms	NNS	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
the	DT	O
SARS	NNP	O
,	,	O
were	VBD	O
no	DT	O
more	RBR	O
common	JJ	O
for	IN	O
drug	NN	O
than	IN	O
placebo	NN	O
,	,	O
although	IN	O
drooling	NN	O
was	VBD	O
reported	VBN	O
more	RBR	O
often	RB	O
in	IN	O
the	DT	O
risperidone	NN	Pharmacological
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
between	IN	O
groups	NNS	O
on	IN	O
the	DT	O
AIMS	NNP	O
.	.	O

Two	CD	O
subjects	NNS	O
had	VBD	O
seizures	NNS	O
(	(	O
one	CD	O
taking	VBG	O
placebo	NN	O
)	)	O
,	,	O
but	CC	O
these	DT	O
were	VBD	O
considered	VBN	O
unrelated	JJ	O
to	TO	O
active	JJ	O
drug	NN	O
.	.	O

Most	JJS	O
AEs	NNPS	O
were	VBD	O
mild	JJ	O
to	TO	O
moderate	VB	O
and	CC	O
failed	VBD	O
to	TO	O
interfere	VB	O
with	IN	O
therapeutic	JJ	O
changes	NNS	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
unanticipated	JJ	O
AEs	NNP	O
.	.	O

The	DT	O
side	NN	O
effects	NNS	O
of	IN	O
most	JJS	O
concern	NN	O
were	VBD	O
somnolence	NN	O
and	CC	O
weight	JJ	O
gain	NN	O
.	.	O

Relaxing	VBG	Physical
retinotomy	NN	Physical
with	IN	Physical
silicone	JJ	Physical
oil	NN	Physical
or	CC	Physical
long-acting	NN	Physical
gas	NN	Physical
in	IN	O
eyes	NNS	O
with	IN	O
severe	JJ	O
proliferative	JJ	O
vitreoretinopathy	NN	O
.	.	O

Silicone	NNP	O
Study	NNP	O
Report	NNP	O
5	CD	O
.	.	O

The	DT	O
Silicone	NNP	O
Study	NNP	O
Group	NNP	O
.	.	O

In	IN	O
the	DT	O
Silicone	NNP	O
Study	NNP	O
,	,	O
117	CD	O
of	IN	O
404	CD	O
eyes	NNS	O
(	(	O
29	CD	O
%	NN	O
)	)	O
with	IN	O
severe	JJ	O
proliferative	JJ	O
vitreoretinopathy	NN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
C-3	NNP	O
,	,	O
full-thickness	JJ	O
retinal	JJ	O
folds	NNS	O
in	IN	O
three	CD	O
or	CC	O
more	JJR	O
quadrants	NNS	O
)	)	O
enrolled	VBD	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
vitrectomy	NN	Pharmacological
,	,	O
underwent	VBD	O
a	DT	O
relaxing	VBG	Physical
retinotomy	NN	Physical
,	,	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	Pharmacological
with	IN	Pharmacological
long-acting	JJ	Pharmacological
gas	NN	Pharmacological
or	CC	Pharmacological
silicone	NN	Pharmacological
oil	NN	Pharmacological
.	.	O

Forty-six	JJ	O
eyes	NNS	O
(	(	O
20	CD	O
%	NN	O
)	)	O
had	VBD	O
undergone	JJ	O
no	DT	O
previous	JJ	O
vitrectomy	NN	O
(	(	O
group	NN	O
1	CD	O
)	)	O
;	:	O
71	CD	O
eyes	NNS	O
(	(	O
42	CD	O
%	NN	O
)	)	O
had	VBD	O
undergone	JJ	O
previous	JJ	O
vitrectomy	NN	O
(	(	O
group	NN	O
2	CD	O
)	)	O
with	IN	O
intraocular	JJ	O
gas	NN	O
tamponade	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Group	NNP	O
1	CD	O
eyes	NNS	O
not	RB	O
undergoing	VBG	O
retinotomy	NN	O
had	VBD	O
better	JJR	O
anatomic	JJ	O
(	(	O
six	CD	O
months	NNS	O
)	)	O
and	CC	O
visual	JJ	O
(	(	O
six	CD	O
and	CC	O
24	CD	O
months	NNS	O
)	)	O
outcomes	NNS	O
and	CC	O
less	JJR	O
hypotony	NN	O
(	(	O
six	CD	O
months	NNS	O
)	)	O
than	IN	O
eyes	NNS	O
that	WDT	O
did	VBD	O
regardless	RB	O
of	IN	O
tamponade	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

For	IN	O
eyes	NNS	O
undergoing	VBG	O
retinotomy	NN	O
,	,	O
silicone	NN	O
oil	NN	O
decreased	VBD	O
the	DT	O
likelihood	NN	O
of	IN	O
hypotony	NN	O
(	(	O
six	CD	O
months	NNS	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

These	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
found	VBN	O
in	IN	O
group	NN	O
2	CD	O
eyes	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
eyes	NNS	O
undergoing	VBG	O
a	DT	O
vitreous	JJ	O
operation	NN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
proliferative	JJ	O
vitreoretinopathy	NN	O
can	MD	O
in	IN	O
most	JJS	O
instances	NNS	O
be	VB	O
successfully	RB	O
treated	VBN	O
by	IN	O
conventional	JJ	O
techniques	NNS	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
relaxing	VBG	O
retinotomy	NN	O
.	.	O

Retinotomy	NNP	O
may	MD	O
be	VB	O
required	VBN	O
more	RBR	O
often	RB	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
repeat	NN	O
vitreous	JJ	O
surgery	NN	O
for	IN	O
proliferative	JJ	O
vitreoretinopathy	NN	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
both	DT	O
silicone	NN	O
oil	NN	O
and	CC	O
long-acting	NN	O
perflouropropane	NN	Pharmacological
gas	NN	O
appear	VBP	O
to	TO	O
be	VB	O
equally	RB	O
effective	JJ	O
.	.	O

Primary	JJ	O
prophylaxis	NN	O
with	IN	O
pyrimethamine	NN	Pharmacological
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
advanced	JJ	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
disease	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

Terry	NNP	O
Beirn	NNP	O
Community	NNP	O
Programs	NNP	O
for	IN	O
Clinical	NNP	O
Research	NNP	O
on	IN	O
AIDS	NNP	O
.	.	O

Pyrimethamine	NNP	Pharmacological
,	,	O
25	CD	O
mg	NN	O
thrice	NN	O
weekly	RB	O
,	,	O
was	VBD	O
evaluated	VBN	O
as	IN	O
primary	JJ	O
prophylaxis	NN	O
for	IN	O
toxoplasmic	JJ	O
encephalitis	NN	O
(	(	O
TE	NNP	O
)	)	O
in	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBD	O
clinical	JJ	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
disease	NN	O
,	,	O
absolute	JJ	O
CD4	NNP	O
lymphocyte	NN	O
count	NN	O
of	IN	O
<	$	O
200/microL	CD	O
(	(	O
or	CC	O
prior	RB	O
AIDS-defining	NNP	O
opportunistic	JJ	O
infection	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
serum	NN	O
IgG	NNP	O
to	TO	O
Toxoplasma	NNP	O
gondii	NN	O
.	.	O

Leucovorin	NNP	Pharmacological
was	VBD	O
coadministered	VBN	O
only	RB	O
for	IN	O
hematologic	JJ	O
toxicity	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
death	NN	O
rate	NN	O
among	IN	O
patients	NNS	O
receiving	VBG	O
pyrimethamine	NN	Pharmacological
(	(	O
relative	JJ	O
risk	NN	O
[	NNP	O
RR	NNP	O
]	NNP	O
,	,	O
2.5	CD	O
;	:	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
[	NNP	O
CI	NNP	O
]	NNP	O
,	,	O
1.3-4.8	JJ	O
;	:	O
P	NNP	O
=	NNP	O
.006	NNP	O
)	)	O
,	,	O
even	RB	O
after	IN	O
adjusting	VBG	O
for	IN	O
factors	NNS	O
predictive	CD	O
of	IN	O
survival	NN	O
.	.	O

The	DT	O
TE	NNP	O
event	NN	O
rate	NN	O
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

Only	RB	O
1	CD	O
of	IN	O
218	CD	O
patients	NNS	O
taking	VBG	O
trimethoprim-sulfamethoxazole	JJ	Pharmacological
but	CC	O
7	CD	O
of	IN	O
117	CD	O
taking	VBG	O
aerosolized	JJ	Pharmacological
pentamidine	NN	Pharmacological
for	IN	O
prophylaxis	NN	O
against	IN	O
Pneumocystis	NNP	O
carinii	NN	O
pneumonia	NN	O
developed	VBD	O
TE	NNP	O
(	(	O
adjusted	VBN	O
RR	NNP	O
for	IN	O
the	DT	O
trimethoprim-sulfamethoxazole	JJ	Pharmacological
group	NN	O
,	,	O
0.16	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
0.01-1.79	NNP	O
;	:	O
P	NNP	O
=	NNP	O
.14	NNP	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
for	IN	O
HIV-infected	JJ	O
patients	NNS	O
receiving	VBG	O
trimethoprim-sulfamethoxazole	JJ	Pharmacological
,	,	O
additional	JJ	O
prophylaxis	NN	O
for	IN	O
TE	NNP	O
appears	VBZ	O
unnecessary	JJ	O
.	.	O

An	DT	O
exploratory	NN	O
,	,	O
pragmatic	JJ	O
,	,	O
cluster	NN	O
randomised	VBD	O
trial	NN	O
of	IN	O
practice	NN	Educational
nurse	JJ	Educational
training	NN	Educational
in	IN	O
the	DT	O
use	NN	O
of	IN	O
asthma	JJ	O
action	NN	O
plans	NNS	O
.	.	O

INTRODUCTION	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
improving	VBG	O
asthma	JJ	O
management	NN	O
-	:	O
in	IN	O
particular	JJ	O
,	,	O
the	DT	O
implementation	NN	O
of	IN	O
individualised	JJ	Physical
asthma	JJ	Physical
action	NN	Physical
plans	NNS	Physical
(	(	Physical
AAPs	NNP	Physical
)	)	Physical
for	IN	O
poorly-controlled	JJ	O
adult	NN	O
asthma	NN	O
patients	NNS	O
-	:	O
by	IN	O
providing	VBG	O
training	NN	O
in	IN	O
asthma-focused	JJ	O
clinical	JJ	O
and	CC	O
communication	NN	O
skills	NNS	O
for	IN	O
practice	NN	O
nurses	NNS	O
who	WP	O
deliver	VBP	O
asthma	JJ	O
clinics	NNS	O
.	.	O

METHODS	NNP	O
A	NNP	O
pragmatic	JJ	O
,	,	O
cluster	NN	O
randomised	VBD	O
trial	NN	O
with	IN	O
an	DT	O
intervention	NN	O
(	(	O
an	DT	O
interactive	JJ	O
seminar	NN	O
)	)	O
delivered	VBD	O
at	IN	O
practice	NN	O
level	NN	O
(	(	O
n=13	JJ	O
practices	NNS	O
;	:	O
6=intervention	CD	O
,	,	O
7=control	CD	O
)	)	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
assessed	VBN	O
against	IN	O
patient	JJ	O
outcomes	NNS	O
:	:	O
routinely	RB	O
available	JJ	O
asthma	JJ	O
outcome	NN	O
measures	NNS	O
(	(	O
beta2-agonist	JJ	O
prescription	NN	O
rate	NN	O
and	CC	O
number	NN	O
of	IN	O
oral	JJ	O
steroid	NN	O
courses	NNS	O
)	)	O
for	IN	O
asthma	NN	O
patients	NNS	O
identified	VBN	O
as	IN	O
being	VBG	O
poorly-controlled	JJ	O
from	IN	O
practice	NN	O
records	NNS	O
;	:	O
and	CC	O
questionnaire	VB	O
data	NNS	O
-	:	O
Mini	NNP	O
Asthma	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
Questionnaire	NNP	O
(	(	O
AQLQ	NNP	O
)	)	O
and	CC	O
the	DT	O
Asthma	NNP	O
Control	NNP	O
Questionnaire	NNP	O
(	(	O
ACQ	NNP	O
)	)	O
-	:	O
from	IN	O
a	DT	O
subset	NN	O
of	IN	O
consenting	VBG	O
patients	NNS	O
.	.	O

Data	NNP	O
was	VBD	O
collected	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

ANALYSISs	NN	O
:	:	O
Routine	NNP	O
data	NN	O
was	VBD	O
analysed	VBN	O
for	IN	O
629	CD	O
patients	NNS	O
.	.	O

236	CD	O
(	(	O
37	CD	O
%	NN	O
)	)	O
of	IN	O
these	DT	O
patients	NNS	O
consented	VBD	O
to	TO	O
provide	VB	O
questionnaire	NN	O
data	NNS	O
at	IN	O
baseline	NN	O
,	,	O
with	IN	O
75	CD	O
%	NN	O
returning	VBG	O
questionnaires	NNS	O
at	IN	O
follow-up	NN	O
.	.	O

After	IN	O
adjustment	NN	O
for	IN	O
baseline	NN	O
and	CC	O
practice	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
at	IN	O
followup	NN	O
between	IN	O
intervention	NN	O
and	CC	O
control	NN	O
practices	NNS	O
on	IN	O
the	DT	O
Mini	NNP	O
AQLQ	NNP	O
only	RB	O
(	(	O
p=0.03	NN	O
)	)	O
.	.	O

Estimates	NNS	O
for	IN	O
subsequent	JJ	O
sample	NN	O
sizes	NNS	O
to	TO	O
inform	VB	O
future	JJ	O
trials	NNS	O
of	IN	O
asthma	JJ	O
training	NN	O
were	VBD	O
identified	VBN	O
.	.	O

CONCLUSION	NNP	O
Training	NNP	O
designed	VBD	O
to	TO	O
support	VB	O
practice	NN	O
nurses	NNS	O
in	IN	O
implementing	VBG	O
individualised	JJ	O
AAPs	NNP	O
impacted	VBD	O
on	IN	O
one	CD	O
patient	NN	O
outcome	NN	O
only	RB	O
.	.	O

This	DT	O
disappointing	JJ	O
outcome	NN	O
may	MD	O
have	VB	O
been	VBN	O
due	JJ	O
to	TO	O
many	JJ	O
different	JJ	O
factors	NNS	O
such	JJ	O
as	IN	O
outcome	JJ	O
measure	NN	O
limitations	NNS	O
,	,	O
data	NNS	O
collection	NN	O
problems	NNS	O
,	,	O
and	CC	O
underestimating	VBG	O
the	DT	O
complexity	NN	O
of	IN	O
supporting	VBG	O
practice	NN	O
nurses	NNS	O
in	IN	O
behaviour	JJ	O
change	NN	O
.	.	O

Analgesic	JJ	O
efficacy	NN	O
of	IN	O
low-dose	JJ	O
diclofenac	NN	Pharmacological
versus	NN	O
paracetamol	NN	Pharmacological
and	CC	O
placebo	NN	Control
in	IN	O
postoperative	JJ	O
dental	NN	O
pain	NN	O
.	.	O

AIMS	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
diclofenac-K	NN	Pharmacological
(	(	O
12.5	CD	O
mg	NN	O
)	)	O
vs	NN	O
paracetamol	NN	Pharmacological
(	(	O
500	CD	O
mg	NN	O
)	)	O
and	CC	O
placebo	VB	Control
given	VBN	O
in	IN	O
a	DT	O
flexible	JJ	O
dosage	NN	O
regimen	NNS	O
to	TO	O
treat	VB	O
pain	NN	O
resulting	VBG	O
from	IN	O
extraction	NN	O
of	IN	O
impacted	JJ	O
third	JJ	O
molar	JJ	O
teeth	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
2-day	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
,	,	O
randomized	VBN	O
,	,	O
parallel-group	JJ	O
,	,	O
placebo-controlled	JJ	Control
study	NN	O
of	IN	O
diclofenac-K	NN	Pharmacological
(	(	Pharmacological
12.5	CD	Pharmacological
mg	NN	Pharmacological
)	)	Pharmacological
tablets	VBZ	Pharmacological
vs	JJ	Pharmacological
paracetamol	NN	Pharmacological
(	(	O
500	CD	O
mg	NN	O
)	)	O
tablets	NNS	O
and	CC	O
placebo	NN	Control
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
pain	NN	O
within	IN	O
8	CD	O
hours	NNS	O
of	IN	O
extraction	NN	O
of	IN	O
impacted	JJ	O
third	JJ	O
molars	NNS	O
.	.	O

RESULTS	NNP	O
After	IN	O
the	DT	O
first	JJ	O
2-tablet	JJ	O
dose	NN	O
,	,	O
patients	NNS	O
took	VBD	O
on	IN	O
average	JJ	O
2.5	CD	O
additional	JJ	O
tablets	NNS	O
of	IN	O
diclofenac-K	NN	Pharmacological
or	CC	O
2.4	CD	O
tablets	NNS	O
of	IN	O
paracetamol	NN	Pharmacological
,	,	O
almost	RB	O
all	DT	O
as	IN	O
1-tablet	JJ	O
doses	NNS	O
.	.	O

Most	JJS	O
placebo	JJ	Control
patients	NNS	O
discontinued	VBN	O
by	IN	O
taking	VBG	O
rescue	JJ	O
medication	NN	O
(	(	O
ibuprofen	JJ	O
200	CD	O
mg	NN	O
)	)	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
.	.	O

Pain	NNP	O
relief	NN	O
after	IN	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
diclofenac-K	NN	Pharmacological
(	(	O
2	CD	O
x	RB	O
12.5	CD	O
mg	NN	O
)	)	O
was	VBD	O
superior	JJ	O
to	TO	O
placebo	VB	Control
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
for	IN	O
all	DT	O
efficacy	NN	O
outcomes	NNS	O
)	)	O
and	CC	O
comparable	JJ	O
to	TO	O
paracetamol	VB	Pharmacological
(	(	O
2	CD	O
x	RB	O
500	CD	O
mg	NN	O
)	)	O
.	.	O

About	IN	O
30	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
each	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
took	VBD	O
rescue	NN	O
medication	NN	O
during	IN	O
the	DT	O
study	NN	O
,	,	O
compared	VBN	O
to	TO	O
78	CD	O
%	NN	O
on	IN	O
placebo	NN	Control
.	.	O

About	IN	O
70	CD	O
%	NN	O
in	IN	O
each	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
considered	VBD	O
the	DT	O
overall	JJ	O
pain	NN	O
relief	NN	O
to	TO	O
be	VB	O
some	DT	O
,	,	O
a	DT	O
lot	NN	O
,	,	O
or	CC	O
complete	JJ	O
compared	VBN	O
to	TO	O
only	RB	O
15	CD	O
%	NN	O
on	IN	O
placebo	NN	Control
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
in	IN	O
each	DT	O
active	JJ	O
treatment	NN	O
group	NN	O
was	VBD	O
low	JJ	O
and	CC	O
comparable	JJ	O
between	IN	O
the	DT	O
treatments	NNS	O
.	.	O

CONCLUSION	NNP	O
An	DT	O
initial	JJ	O
double-dose	NN	O
of	IN	O
diclofenac-K	NN	Pharmacological
(	(	O
2	CD	O
x	RB	O
12.5	CD	O
mg	NN	O
)	)	O
or	CC	O
paracetamol	NN	Pharmacological
(	(	O
2	CD	O
x	RB	O
500	CD	O
mg	NNS	O
)	)	O
adequately	RB	O
relieved	VBD	O
the	DT	O
most	RBS	O
intense	JJ	O
postoperative	NN	O
pain	NN	O
,	,	O
and	CC	O
the	DT	O
flexible	JJ	O
multiple	NN	O
dose	JJ	O
regimen	NNS	O
(	(	O
1	CD	O
or	CC	O
2	CD	O
tablets	NNS	O
)	)	O
maintained	VBD	O
adequate	JJ	O
pain	NN	O
relief	NN	O
thereafter	RB	O
.	.	O

Most	JJS	O
patients	NNS	O
needed	VBN	O
only	RB	O
1-tablet	JJ	O
doses	NNS	O
following	VBG	O
the	DT	O
initial	JJ	O
2-tablet	JJ	O
dose	NN	O
.	.	O

Ranitidine	NNP	O
improves	VBZ	O
lymphocyte	JJ	O
function	NN	O
after	IN	O
severe	JJ	O
head	NN	O
injury	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
study	VB	O
the	DT	O
immunomodulatory	JJ	O
effect	NN	O
of	IN	O
the	DT	O
histamine	NN	O
receptor	NN	O
antagonist	NN	O
,	,	O
ranitidine	NN	O
,	,	O
in	IN	O
patients	NNS	O
admitted	VBN	O
to	TO	O
the	DT	O
intensive	JJ	O
care	NN	O
unit	NN	O
after	IN	O
severe	JJ	O
head	NN	O
injury	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

SETTING	NNP	O
Surgical	NNP	O
intensive	JJ	O
care	NN	O
unit	NN	O
of	IN	O
a	DT	O
university	NN	O
Level	NNP	O
I	PRP	O
trauma	VBP	O
center	NN	O
.	.	O

PATIENTS	NNP	O
Twenty	NNP	O
patients	NNS	O
admitted	VBD	O
with	IN	O
a	DT	O
Glasgow	NNP	O
Coma	NNP	O
Scale	NNP	O
score	NN	O
of	IN	O
<	$	O
10	CD	O
who	WP	O
were	VBD	O
enrolled	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
prospective	JJ	O
,	,	O
multicenter	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
multiple	JJ	O
risk	NN	O
factors	NNS	O
and	CC	O
ranitidine	VB	O
prophylaxis	NN	O
on	IN	O
the	DT	O
development	NN	O
of	IN	O
stress-related	JJ	O
upper	JJ	O
gastrointestinal	NN	O
bleeding	NN	O
.	.	O

INTERVENTIONS	NNP	O
Continuous	NNP	Pharmacological
infusion	NN	Pharmacological
of	IN	Pharmacological
ranitidine	NN	Pharmacological
at	IN	Pharmacological
6.25	CD	Pharmacological
mg/hr	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
9	CD	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
for	IN	O
a	DT	O
maximum	NN	O
of	IN	O
5	CD	O
days	NNS	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
MAIN	NNP	O
RESULTS	NNP	O
Before	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
and	CC	O
on	IN	O
completion	NN	O
of	IN	O
treatment	NN	O
,	,	O
lymphocyte	JJ	O
cell-surface	NN	O
antigen	NN	O
expression	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
flow	JJ	O
cytometry	NN	O
(	(	O
n	JJ	O
=	$	O
14	CD	O
patients	NNS	O
)	)	O
;	:	O
mitogen-stimulated	JJ	O
interferon-gamma	JJ	O
and	CC	O
interleukin-2	JJ	O
production	NN	O
were	VBD	O
measured	VBN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
n	JJ	O
=	$	O
19	CD	O
patients	NNS	O
)	)	O
.	.	O

Treatment	NN	O
with	IN	O
ranitidine	NN	Pharmacological
,	,	O
but	CC	O
not	RB	O
placebo	VB	Control
,	,	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
CD4+	NNP	O
lymphocytes	NNS	O
(	(	O
33	CD	O
%	NN	O
to	TO	O
49	CD	O
%	NN	O
;	:	O
p	CC	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
CD8+	NNP	O
lymphocytes	NNS	O
(	(	O
41	CD	O
%	NN	O
to	TO	O
27	CD	O
%	NN	O
;	:	O
p	CC	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
mitogen-stimulated	JJ	O
interferon-gamma	JJ	O
production	NN	O
increased	VBD	O
from	IN	O
121	CD	O
to	TO	O
269	CD	O
pg/mL	NN	O
(	(	O
p	JJ	O
<	NNP	O
.05	NNP	O
)	)	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
ranitidine	NN	Pharmacological
,	,	O
but	CC	O
not	RB	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
placebo	NN	Control
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
interleukin-2	JJ	O
production	NN	O
or	CC	O
circulating	VBG	O
B-cell	NNP	O
concentrations	NNS	O
between	IN	O
both	DT	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
This	DT	O
study	NN	O
demonstrates	VBZ	O
an	DT	O
immunostimulatory	JJ	O
effect	NN	O
of	IN	O
the	DT	O
histamine-2-receptor	JJ	O
antagonist	NN	O
,	,	O
ranitidine	NN	O
,	,	O
both	DT	O
at	IN	O
the	DT	O
cellular	JJ	O
and	CC	O
mediator	NN	O
levels	NNS	O
in	IN	O
patients	NNS	O
after	IN	O
head	JJ	O
injury	NN	O
.	.	O

Paracetamol	NNP	Pharmacological
and	CC	O
opioid	JJ	O
pathways	NNS	O
:	:	O
a	DT	O
pilot	NN	O
randomized	VBN	O
clinical	JJ	O
trial	NN	O
.	.	O

Previous	JJ	O
studies	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
antinociceptive	JJ	O
action	NN	O
of	IN	O
paracetamol	NN	Pharmacological
(	(	Pharmacological
acetaminophen	NN	Pharmacological
,	,	Pharmacological
APAP	NNP	Pharmacological
)	)	Pharmacological
might	MD	O
involve	VB	O
descending	VBG	O
inhibitory	JJ	O
pain	NN	O
pathways	NNS	O
and	CC	O
the	DT	O
opioidergic	JJ	O
system	NN	O
:	:	O
this	DT	O
study	NN	O
explores	VBZ	O
this	DT	O
issue	NN	O
in	IN	O
humans	NNS	O
with	IN	O
naloxone	NN	Pharmacological
,	,	O
the	DT	O
opioid	JJ	Pharmacological
antagonist	NN	Pharmacological
.	.	O

After	IN	O
ethical	JJ	O
approval	NN	O
,	,	O
12	CD	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
this	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
double-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
four-arm	JJ	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
administered	VBN	O
intravenous	JJ	Pharmacological
paracetamol	NN	Pharmacological
(	(	O
APAP	NNP	O
1	CD	O
g	NN	O
)	)	O
or	CC	O
saline	NN	Control
(	(	O
placebo	NN	Control
,	,	O
pl	NN	O
)	)	O
followed	VBD	O
at	IN	O
100	CD	O
min	NN	O
with	IN	O
IV	NNP	Pharmacological
naloxone	NN	Pharmacological
(	(	O
Nal	NNP	O
8	CD	O
mg	NN	O
)	)	O
or	CC	O
saline	NN	Control
,	,	O
every	DT	O
week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

The	DT	O
amplitude	NN	O
of	IN	O
cerebral	JJ	O
potentials	NNS	O
evoked	VBN	O
by	IN	O
thermal/painful	JJ	O
stimuli	NNS	O
applied	VBN	O
on	IN	O
the	DT	O
arm	NN	O
was	VBD	O
recorded	VBN	O
nine	CD	O
times	NNS	O
over	IN	O
150	CD	O
min	NNS	O
,	,	O
witnessing	VBG	O
of	IN	O
pain	NN	O
integration	NN	O
at	IN	O
central	JJ	O
level	NN	O
.	.	O

Amplitude	NNP	O
changes	NNS	O
as	RB	O
well	RB	O
as	IN	O
areas	NNS	O
under	IN	O
the	DT	O
curve	NN	O
(	(	O
AUCs	NNP	O
)	)	O
over	IN	O
150	CD	O
min	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
the	DT	O
four	CD	O
treatments	NNS	O
by	IN	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
(	(	O
significance	NN	O
0.05	CD	O
)	)	O
.	.	O

Amplitude	NNP	O
changes	NNS	O
were	VBD	O
significant	JJ	O
for	IN	O
APAP/pl	NNP	Pharmacological
vs.	FW	O
pl/pl	NN	O
at	IN	O
t150	NN	O
:	:	O
-44	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-58	NNP	O
to	TO	O
-30	VB	O
)	)	O
vs.	FW	O
-27	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-37	NNP	O
to	TO	O
-17	VB	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
but	CC	O
not	RB	O
vs.	IN	O
APAP/Nal	NNP	Pharmacological
.	.	O

AUC	NNP	O
(	(	O
0-150	JJ	O
)	)	O
of	IN	O
APAP/pl	NNP	O
is	VBZ	O
significantly	RB	O
different	JJ	O
from	IN	O
pl/pl	NN	O
(	(	O
-3452	CD	O
%	NN	O
.min	NNP	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-4705	NNP	O
to	TO	O
-2199	VB	O
)	)	O
vs.	FW	O
-933	CD	O
%	NN	O
min	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-2273	NNP	O
to	TO	O
407	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.015	CD	O
)	)	O
but	CC	O
not	RB	O
from	IN	O
APAP/Nal	NNP	Pharmacological
(	(	O
-1731	CD	O
%	NN	O
min	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-3676	NNP	O
to	TO	O
214	CD	O
;	:	O
P	NNP	O
=	NNP	O
0.08	CD	O
)	)	O
and	CC	O
other	JJ	O
treatments	NNS	O
.	.	O

AUC	NNP	O
(	(	O
90-150	CD	O
)	)	O
is	VBZ	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

This	DT	O
pilot	NN	O
study	NN	O
shows	VBZ	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
in	IN	O
human	JJ	O
volunteers	NNS	O
that	WDT	O
naloxone	RB	Pharmacological
does	VBZ	O
not	RB	O
inhibit	VB	O
paracetamol	JJ	Pharmacological
antinociception	NN	O
,	,	O
suggesting	VBG	O
no	DT	O
significant	JJ	O
implication	NN	O
of	IN	O
the	DT	O
opioid	NN	O
system	NN	O
in	IN	O
paracetamol	JJ	Pharmacological
mechanism	NN	O
of	IN	O
action	NN	O
:	:	O
this	DT	O
needs	VBZ	O
be	VB	O
confirmed	VBN	O
on	IN	O
a	DT	O
larger	JJR	O
number	NN	O
of	IN	O
subjects	NNS	O
.	.	O

Microtensile	NNP	O
bond	NN	O
strength	NN	O
of	IN	O
a	DT	O
repair	NN	O
composite	JJ	O
to	TO	O
leucite-reinforced	JJ	O
feldspathic	JJ	O
ceramic	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
microtensile	NN	O
bond	NN	O
strength	NN	O
of	IN	O
a	DT	O
repair	NN	O
composite	JJ	O
resin	NN	O
to	TO	O
a	DT	O
leucite-reinforced	JJ	O
feldspathic	JJ	O
ceramic	NN	O
(	(	O
Omega	NNP	O
900	CD	O
,	,	O
VITA	NNP	O
)	)	O
submitted	VBD	O
to	TO	O
two	CD	O
surface	NN	O
conditionings	NNS	O
methods	NNS	O
:	:	O
1	CD	O
)	)	O
etching	VBG	Pharmacological
with	IN	Pharmacological
hydrofluoric	JJ	Pharmacological
acid	NN	Pharmacological
+	NNP	Pharmacological
silane	NN	Pharmacological
application	NN	Pharmacological
or	CC	O
2	CD	O
)	)	O
tribochemical	NN	Pharmacological
silica	NN	Pharmacological
coating	NN	Pharmacological
.	.	O

The	DT	O
null	JJ	O
hypothesis	NN	O
is	VBZ	O
that	IN	O
both	DT	O
surface	NN	O
treatments	NNS	O
can	MD	O
generate	VB	O
similar	JJ	O
bond	NN	O
strengths	NNS	O
.	.	O

Ten	CD	O
ceramic	JJ	O
blocks	NNS	O
(	(	O
6x6x6	CD	O
mm	NN	O
)	)	O
were	VBD	O
fabricated	VBN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
to	TO	O
2	CD	O
groups	NNS	O
(	(	O
n=5	NN	O
)	)	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
conditioning	NN	O
method	NN	O
:	:	O
G1-	JJ	O
10	CD	O
%	NN	O
hydrofluoric	JJ	Pharmacological
acid	NN	Pharmacological
application	NN	O
for	IN	O
2	CD	O
min	NN	O
plus	CC	O
rinsing	NN	O
and	CC	O
drying	NN	O
,	,	O
followed	VBN	O
by	IN	O
silane	NN	Pharmacological
application	NN	O
for	IN	O
30	CD	O
s	NNS	O
;	:	O
G2-	NNP	O
airborne	JJ	O
particle	NN	O
abrasion	NN	O
with	IN	O
30	CD	O
microm	NNS	O
silica	JJ	O
oxide	IN	O
particles	NNS	O
(	(	O
CoJet-Sand	NNP	O
)	)	O
for	IN	O
20	CD	O
s	NNS	O
using	VBG	O
a	DT	O
chairside	JJ	O
air-abrasion	NN	O
device	NN	O
(	(	O
CoJet	NNP	O
System	NNP	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
silane	NN	O
application	NN	O
for	IN	O
5	CD	O
min	NN	O
.	.	O

Single	NNP	O
Bond	NNP	O
adhesive	JJ	O
system	NN	O
was	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
surfaces	NNS	O
and	CC	O
light	NN	O
cured	VBN	O
(	(	O
40	CD	O
s	NN	O
)	)	O
.	.	O

Z-250	JJ	O
composite	JJ	O
resin	NN	O
was	VBD	O
placed	VBN	O
incrementally	RB	O
on	IN	O
the	DT	O
treated	JJ	O
ceramic	JJ	O
surface	NN	O
to	TO	O
build	VB	O
a	DT	O
6x6x6	CD	O
mm	NN	O
block	NN	O
.	.	O

Bar	NNP	O
specimens	VBZ	O
with	IN	O
an	DT	O
adhesive	JJ	O
area	NN	O
of	IN	O
approximately	RB	O
1	CD	O
+/-	JJ	O
0.1	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
composite-ceramic	JJ	O
blocks	NNS	O
(	(	O
6	CD	O
per	IN	O
block	NN	O
and	CC	O
30	CD	O
per	IN	O
group	NN	O
)	)	O
for	IN	O
microtensile	NN	O
testing	VBG	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
between	IN	O
G1	NNP	O
(	(	O
10.19	CD	O
+/-	JJ	O
3.1	CD	O
MPa	NNP	O
)	)	O
and	CC	O
G2	NNP	O
(	(	O
10.17	CD	O
+/-	JJ	O
3.1	CD	O
MPa	NNP	O
)	)	O
(	(	O
p=0.982	NN	O
)	)	O
(	(	O
Student	NNP	O
's	POS	O
t	JJ	O
test	NN	O
;	:	O
?	.	O
=	$	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
null	JJ	O
hypothesis	NN	O
was	VBD	O
,	,	O
therefore	RB	O
,	,	O
accepted	VBD	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
both	DT	O
surface	VBP	O
conditioning	VBG	O
methods	NNS	O
provided	VBD	O
similar	JJ	O
microtensile	NN	O
bond	NN	O
strengths	NNS	O
between	IN	O
the	DT	O
repair	NN	O
composite	JJ	O
resin	NN	O
and	CC	O
the	DT	O
ceramic	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
using	VBG	O
long-term	JJ	O
aging	NN	O
procedures	NNS	O
should	MD	O
be	VB	O
conducted	VBN	O
.	.	O

Dose-response	JJ	O
and	CC	O
concentration-response	JJ	O
relation	NN	O
of	IN	O
rocuronium	NN	Pharmacological
infusion	NN	Pharmacological
during	IN	O
propofol-nitrous	JJ	Pharmacological
oxide	NN	Pharmacological
and	CC	O
isoflurane-nitrous	JJ	Pharmacological
oxide	NN	Pharmacological
anaesthesia	NN	Pharmacological
.	.	O

The	DT	O
dose-response	JJ	O
and	CC	O
concentration-response	JJ	O
relation	NN	O
of	IN	O
rocuronium	NN	Pharmacological
infusion	NN	Pharmacological
was	VBD	O
studied	VBN	O
in	IN	O
20	CD	O
adult	NN	O
surgical	JJ	O
patients	NNS	O
during	IN	O
propofol-nitrous	JJ	Pharmacological
oxide	NN	Pharmacological
and	CC	O
isoflurane	NN	Pharmacological
(	(	Pharmacological
1	CD	Pharmacological
MAC	NNP	Pharmacological
)	)	Pharmacological
-nitrous	JJ	Pharmacological
oxide	JJ	Pharmacological
anaesthesia	NN	Pharmacological
.	.	O

Neuromuscular	JJ	O
block	NN	O
was	VBD	O
kept	VBN	O
constant	JJ	O
,	,	O
initially	RB	O
at	IN	O
90	CD	O
%	NN	O
and	CC	O
then	RB	O
at	IN	O
50	CD	O
%	NN	O
with	IN	O
a	DT	O
closed-loop	JJ	Physical
feedback	NN	Physical
controller	NN	Physical
.	.	O

At	IN	O
90	CD	O
%	NN	O
block	NN	O
the	DT	O
steady-state	JJ	Pharmacological
infusion	NN	Pharmacological
of	IN	Pharmacological
rocuronium	NN	Pharmacological
was	VBD	O
0.55	CD	O
+/-	JJ	O
0.16	CD	O
mg	JJ	O
kg-1	JJ	O
h-1	NN	O
and	CC	O
the	DT	O
corresponding	JJ	O
concentration	NN	O
1714	CD	O
+/-	JJ	O
281	CD	O
ng	JJ	O
mL-1	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
propofol	NN	Pharmacological
.	.	O

At	IN	O
50	CD	O
%	NN	O
block	NN	O
the	DT	O
corresponding	JJ	O
infusion	NN	O
rate	NN	O
was	VBD	O
0.27	CD	O
+/-	JJ	O
0.11	CD	O
mg	JJ	O
kg-1	JJ	O
h-1	NN	O
and	CC	O
the	DT	O
concentration	NN	O
1077	CD	O
+/-	JJ	O
244	CD	O
ng	JJ	O
mL-1	NN	O
,	,	O
respectively	RB	O
.	.	O

At	IN	O
50	CD	O
%	NN	O
block	NN	O
isoflurane	NN	Pharmacological
reduced	VBD	O
the	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
by	IN	O
52	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
and	CC	O
the	DT	O
concentration	NN	O
by	IN	O
59	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
;	:	O
at	IN	O
90	CD	O
%	NN	O
block	NN	O
both	CC	O
the	DT	O
mean	JJ	O
infusion	NN	O
rate	NN	O
and	CC	O
the	DT	O
concentration	NN	O
of	IN	O
rocuronium	NN	Pharmacological
were	VBD	O
reduced	VBN	O
by	IN	O
35	CD	O
%	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
rocuronium	NN	Pharmacological
clearance	NN	O
at	IN	O
50	CD	O
%	NN	O
block	NN	O
was	VBD	O
unaffected	VBN	O
by	IN	O
the	DT	O
type	NN	O
of	IN	O
anaesthesia	NN	Pharmacological
;	:	O
it	PRP	O
was	VBD	O
4.1	CD	O
+/-	JJ	O
1.6	CD	O
and	CC	O
4.9	CD	O
+/-	JJ	O
2.7	CD	O
mL	JJ	O
kg-1	JJ	O
min-1	NN	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
propofol	NN	Pharmacological
and	CC	O
isoflurane	NN	Pharmacological
anaesthesia	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
isoflurane	NN	O
reduces	VBZ	O
the	DT	O
infusion	NN	O
requirements	NNS	O
of	IN	O
rocuronium	NN	Pharmacological
by	IN	O
changing	VBG	O
the	DT	O
pharmacodynamic	JJ	O
behaviour	NN	O
.	.	O

Treatment	NN	O
of	IN	O
adults	NNS	O
with	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukemia	NN	O
:	:	O
do	VB	O
the	DT	O
specifics	NNS	O
of	IN	O
the	DT	O
regimen	NNS	O
matter	NN	O
?	.	O
:	:	O
Results	NNS	O
from	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Induction	NNP	O
therapy	NN	O
for	IN	O
adults	NNS	O
with	IN	O
acute	JJ	O
lymphoblastic	JJ	O
leukemia	NN	O
(	(	O
ALL	DT	O
)	)	O
is	VBZ	O
similar	JJ	O
across	IN	O
essentially	RB	O
all	DT	O
regimens	NNS	O
,	,	O
comprised	VBN	O
of	IN	O
vincristine	NN	Pharmacological
,	,	Pharmacological
corticosteroids	NNS	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
anthracyclines	NNS	Pharmacological
intensified	VBN	Pharmacological
with	IN	Pharmacological
cyclophosphamide	NN	Pharmacological
,	,	Pharmacological
asparaginase	NN	Pharmacological
,	,	Pharmacological
or	CC	Pharmacological
both	DT	Pharmacological
.	.	O

Given	VBN	O
the	DT	O
lack	NN	O
of	IN	O
randomized	VBN	O
data	NNS	O
,	,	O
to	TO	O
date	NN	O
,	,	O
no	DT	O
regimen	NN	O
has	VBZ	O
emerged	VBN	O
as	IN	O
standard	NN	O
.	.	O

The	DT	O
authors	NNS	O
previously	RB	O
evaluated	VBD	O
cytarabine	JJ	Pharmacological
3	CD	O
g/m	NN	O
(	(	O
2	CD	O
)	)	O
daily	RB	O
for	IN	O
5	CD	O
days	NNS	O
with	IN	O
mitoxantrone	NN	Pharmacological
80	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
(	(	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
)	)	O
as	IN	O
a	DT	O
novel	JJ	O
induction	NN	O
regimen	NNS	O
.	.	O

Compared	VBN	O
with	IN	O
historic	JJ	O
controls	NNS	O
,	,	O
the	DT	O
ALL-2	NNP	O
regimen	NN	O
was	VBD	O
superior	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
incidence	NN	O
of	IN	O
complete	JJ	O
remission	NN	O
,	,	O
failure	NN	O
with	IN	O
resistant	JJ	O
disease	NN	O
,	,	O
and	CC	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Philadelphia	NNP	O
chromosome	NN	O
(	(	O
Ph	NNP	O
)	)	O
-positive	VBP	O
ALL	NNP	O
.	.	O

METHODS	NNP	O
The	DT	O
authors	NNS	O
conducted	VBD	O
a	DT	O
multicenter	NN	O
,	,	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
compared	VBN	O
with	IN	O
a	DT	O
standard	JJ	O
4-drug	JJ	Pharmacological
induction	NN	Pharmacological
(	(	Pharmacological
the	DT	Pharmacological
L-20	NNP	Pharmacological
regimen	NNS	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

Patients	NNS	O
also	RB	O
received	VBD	O
consolidation	NN	Pharmacological
,	,	Pharmacological
maintenance	NN	Pharmacological
therapy	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
central	JJ	Pharmacological
nervous	JJ	Pharmacological
system	NN	Pharmacological
prophylaxis	NN	Pharmacological
.	.	O

The	DT	O
trial	NN	O
accrued	VBD	O
patients	NNS	O
from	IN	O
August	NNP	O
1996	CD	O
to	TO	O
October	NNP	O
2004	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
follow-up	NN	O
for	IN	O
survivors	NNS	O
was	VBD	O
7	CD	O
years	NNS	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
patient	NN	O
age	NN	O
was	VBD	O
43	CD	O
years	NNS	O
.	.	O

Responses	NNS	O
were	VBD	O
evaluated	VBN	O
in	IN	O
164	CD	O
patients	NNS	O
.	.	O

The	DT	O
treatment	NN	O
arms	NNS	O
were	VBD	O
balanced	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
pretreatment	NN	O
characteristics	NNS	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
complete	JJ	O
remission	NN	O
for	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
versus	IN	O
the	DT	O
L-20	JJ	O
regimen	NN	O
was	VBD	O
83	CD	O
%	NN	O
versus	IN	O
71	CD	O
%	NN	O
(	(	O
P	NNP	O
=	NNP	O
.06	NNP	O
)	)	O
.	.	O

More	JJR	O
patients	NNS	O
on	IN	O
the	DT	O
L-20	NNP	O
arm	NN	O
failed	VBD	O
with	IN	O
resistant	JJ	O
disease	NN	O
(	(	O
21	CD	O
%	NN	O
vs	JJ	O
8	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.02	NNP	O
)	)	O
.	.	O

Induction	NNP	O
deaths	NNS	O
were	VBD	O
comparable	JJ	O
at	IN	O
9	CD	O
%	NN	O
(	(	O
ALL-2	NNP	O
)	)	O
versus	VBD	O
7	CD	O
%	NN	O
(	(	O
L-20	NNP	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
survival	NN	O
was	VBD	O
similar	JJ	O
;	:	O
and	CC	O
,	,	O
at	IN	O
5	CD	O
years	NNS	O
,	,	O
the	DT	O
survival	NN	O
rate	NN	O
was	VBD	O
33	CD	O
%	NN	O
alive	JJ	O
on	IN	O
the	DT	O
ALL-2	NNP	O
arm	NN	O
versus	NN	O
27	CD	O
%	NN	O
on	IN	O
the	DT	O
L-20	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
superior	JJ	O
results	NNS	O
of	IN	O
induction	NN	O
therapy	NN	O
with	IN	O
the	DT	O
ALL-2	NNP	O
regimen	NNS	O
,	,	O
this	DT	O
treatment	NN	O
did	VBD	O
not	RB	O
improve	VB	O
long-term	JJ	O
outcomes	NNS	O
.	.	O

When	WRB	O
coupled	VBN	O
to	TO	O
the	DT	O
reported	VBN	O
experience	NN	O
of	IN	O
other	JJ	O
studies	NNS	O
in	IN	O
adults	NNS	O
with	IN	O
ALL	NNP	O
,	,	O
the	DT	O
results	NNS	O
of	IN	O
this	DT	O
randomized	VBN	O
trial	NN	O
raise	NN	O
the	DT	O
possibility	NN	O
that	WDT	O
ultimate	JJ	O
outcomes	NNS	O
in	IN	O
adult	NN	O
ALL	NNP	O
may	MD	O
be	VB	O
independent	JJ	O
of	IN	O
the	DT	O
specific	JJ	O
regimen	NNS	O
chosen	VBN	O
.	.	O

Cancer	NN	O
2013	CD	O
.	.	O

?	.	O
2012	CD	O
American	JJ	O
Cancer	NNP	O
Society	NNP	O
.	.	O

Transcutaneous	JJ	Physical
electrical	JJ	Physical
nerve	NN	Physical
stimulation	NN	Physical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
myofascial	JJ	O
pain	NN	O
dysfunction	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
transcutaneous	JJ	Physical
electrical	JJ	Physical
nerve	NN	Physical
stimulation	NN	Physical
(	(	Physical
TENS	NNP	Physical
)	)	Physical
plus	CC	Pharmacological
conservative	JJ	Pharmacological
therapy	NN	Pharmacological
(	(	Pharmacological
ibuprofen	JJ	Pharmacological
,	,	O
bite	JJ	Pharmacological
plate	NN	Pharmacological
,	,	O
self-physiotherapy	NN	Physical
)	)	O
on	IN	O
myofascial	JJ	O
pain	NN	O
dysfunction	NN	O
(	(	O
MPD	NNP	O
)	)	O
was	VBD	O
determined	VBN	O
.	.	O

A	DT	O
single-blind	JJ	O
trial	NN	O
as	IN	O
done	VBN	O
in	IN	O
10	CD	O
patients	NNS	O
with	IN	O
MPD	NNP	O
with	IN	O
subthreshold	JJ	Physical
TENS	NNP	Physical
(	(	O
frequency	NN	O
35	CD	O
Hz	NNP	O
,	,	O
pulse	RB	O
width	VBZ	O
100	CD	O
milliseconds	NNS	O
,	,	O
modulation	NN	O
50	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
sham	NN	Physical
TENS	NNP	Physical
at	IN	O
8	CD	O
visits	NNS	O
over	IN	O
14	CD	O
weeks	NNS	O
.	.	O

Pain	NNP	O
was	VBD	O
assessed	VBN	O
on	IN	O
a	DT	O
visual	JJ	O
analogue	NN	O
scale	NN	O
before	IN	O
and	CC	O
after	IN	O
TENS	NNP	Physical
at	IN	O
each	DT	O
visit	NN	O
and	CC	O
the	DT	O
data	NNS	O
were	VBD	O
analysed	VBN	O
with	IN	O
the	DT	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
for	IN	O
repeated	VBN	O
measures	NNS	O
.	.	O

A	DT	O
highly	RB	O
significant	JJ	O
effect	NN	O
was	VBD	O
seen	VBN	O
for	IN	O
time	NN	O
(	(	O
F	NNP	O
=	NNP	O
4.80	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.0003	CD	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
TENS	NNP	Physical
.	.	O

Subthreshold	NNP	Physical
TENS	NNP	Physical
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
symptom	JJ	O
relief	NN	O
produced	VBN	O
by	IN	O
conservative	JJ	O
treatment	NN	O
with	IN	O
the	DT	O
protocol	NN	O
used	VBN	O
.	.	O

Impact	NN	O
of	IN	O
angiotensin-converting	JJ	O
enzyme	JJ	O
gene	NN	O
polymorphism	NN	O
on	IN	O
neurohormonal	JJ	O
responses	NNS	O
to	TO	O
high-	JJ	O
versus	NN	O
low-dose	JJ	O
enalapril	NN	O
in	IN	O
advanced	JJ	O
heart	NN	O
failure	NN	O
.	.	O

BACKGROUND	CC	O
The	DT	O
impact	NN	O
of	IN	O
angiotensin-converting	JJ	O
enzyme	NN	O
(	(	O
ACE	NNP	O
)	)	O
gene	NN	O
polymorphism	NN	O
on	IN	O
neurohormonal	JJ	O
dose	JJ	O
response	NN	O
to	TO	O
ACE	NNP	Pharmacological
inhibitor	NN	O
therapy	NN	O
is	VBZ	O
unclear	JJ	O
.	.	O

METHODS	NNP	O
ACE	NNP	O
Insertion	NNP	O
(	(	O
I	PRP	O
)	)	O
or	CC	O
Deletion	NNP	O
(	(	O
D	NNP	O
)	)	O
genotype	NN	O
was	VBD	O
determined	VBN	O
in	IN	O
74	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
heart	NN	O
failure	NN	O
who	WP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	Pharmacological
high-dose	JJ	Pharmacological
or	CC	Pharmacological
low-dose	JJ	Pharmacological
enalapril	NN	Pharmacological
over	IN	Pharmacological
a	DT	Pharmacological
period	NN	Pharmacological
of	IN	Pharmacological
6	CD	Pharmacological
months	NNS	Pharmacological
.	.	O

Monthly	JJ	O
pre-enalapril	JJ	O
and	CC	O
post-enalapril	JJ	O
neurohormone	NN	O
levels	NNS	O
(	(	O
serum	JJ	O
ACE	NNP	O
activity	NN	O
(	(	O
sACE	NN	O
)	)	O
,	,	O
plasma	JJ	O
angiotensin	NN	O
II	NNP	O
(	(	O
A-II	NNP	O
)	)	O
,	,	O
plasma	JJ	O
renin	NN	O
activity	NN	O
(	(	O
PRA	NNP	O
)	)	O
,	,	O
and	CC	O
serum	VB	O
aldosterone	NN	O
(	(	O
ALDO	NNP	O
)	)	O
were	VBD	O
compared	VBN	O
between	IN	O
genotype	NN	O
subgroups	NNS	O
and	CC	O
between	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
high-	JJ	O
or	CC	O
low-dose	JJ	O
enalapril	NN	Pharmacological
within	IN	O
each	DT	O
genotype	NN	O
subgroup	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
predose/postdose	JJ	O
sACE	NN	O
and	CC	O
postdose	JJ	O
PRA	NNP	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
DD	NNP	O
genotype	NN	O
.	.	O

At	IN	O
6-month	JJ	O
follow-up	NN	O
,	,	O
postdose	JJ	O
sACE	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
fashion	NN	O
in	IN	O
all	DT	O
three	CD	O
genotypes	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

However	RB	O
,	,	O
predose	JJ	O
and	CC	O
postdose	JJ	O
ALDO	NNP	O
and	CC	O
A-II	NNP	O
levels	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
each	DT	O
genotype	NN	O
subgroup	NN	O
at	IN	O
baseline	NN	O
or	CC	O
by	IN	O
enalapril	JJ	O
dose	NN	O
within	IN	O
each	DT	O
genotype	NN	O
subgroup	NN	O
.	.	O

ALDO	NNP	O
escape	NN	O
and	CC	O
A-II	JJ	O
reactivation	NN	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
ACE	NNP	O
genotype	NN	O
or	CC	O
enalapril	JJ	O
dosage	NN	O
.	.	O

CONCLUSIONS	NNP	O
Predose	NNP	O
sACE	NN	O
were	VBD	O
consistently	RB	O
higher	JJR	O
in	IN	O
the	DT	O
DD	NNP	O
genotype	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
ID	NNP	O
or	CC	O
II	NNP	O
subgroups	NNS	O
.	.	O

Despite	IN	O
a	DT	O
dose-dependent	JJ	O
suppression	NN	O
of	IN	O
sACE	NN	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
observed	VBN	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
ALDO	NNP	O
and	CC	O
A-II	NNP	O
suppression	NN	O
or	CC	O
escape	NN	O
with	IN	O
escalating	VBG	O
doses	NNS	O
of	IN	O
enalapril	NN	O
within	IN	O
each	DT	O
subgroup	NN	O
.	.	O

Effects	NNS	O
of	IN	O
prelinguistic	JJ	Educational
milieu	NN	Educational
teaching	NN	Educational
and	CC	Educational
parent	NN	Educational
responsivity	NN	Educational
education	NN	Educational
on	IN	O
dyads	NNS	O
involving	VBG	O
children	NNS	O
with	IN	O
intellectual	JJ	O
disabilities	NNS	O
.	.	O

This	DT	O
study	NN	O
tested	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
method	NN	O
of	IN	O
facilitating	VBG	Educational
prelinguistic	JJ	Educational
communication	NN	Educational
on	IN	O
parents	NNS	O
'	POS	O
responsivity	NN	O
and	CC	O
children	NNS	O
's	POS	O
communication	NN	O
and	CC	O
productive	JJ	O
language	NN	O
development	NN	O
.	.	O

The	DT	O
method	NN	O
involved	VBN	O
Responsivity	NNP	Educational
education	NN	Educational
for	IN	Educational
the	DT	Educational
parents	NNS	Educational
and	CC	O
Prelinguistic	NNP	Educational
Milieu	NNP	Educational
Teaching	NNP	Educational
for	IN	Educational
the	DT	Educational
children	NNS	Educational
(	(	Educational
RPMT	NNP	Educational
)	)	Educational
.	.	Educational

Thirty-nine	JJ	O
prelinguistic	JJ	O
toddlers	NNS	O
with	IN	O
intellectual	JJ	O
disabilities	NNS	O
and	CC	O
their	PRP$	O
primary	JJ	O
caregivers	NNS	O
participated	VBD	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Parent-child	JJ	O
pairs	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
either	CC	O
the	DT	O
RPMT	NNP	Educational
group	NN	O
or	CC	O
a	DT	O
control	NN	Control
group	NN	Control
.	.	Control

Communication	NNP	O
and	CC	O
language	NN	O
were	VBD	O
assessed	VBN	O
at	IN	O
study	NN	O
entry	NN	O
and	CC	O
6	CD	O
,	,	O
9	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
later	RB	O
.	.	O

RPMT	NNP	Educational
facilitated	VBD	O
parental	JJ	O
responsivity	NN	O
in	IN	O
the	DT	O
posttreatment	JJ	O
period	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
RPMT	NNP	Educational
on	IN	O
growth	NN	O
rate	NN	O
of	IN	O
child-initiated	JJ	O
comments	NNS	O
(	(	O
i.e.	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
type	NN	O
of	IN	O
initiating	VBG	O
joint	JJ	O
attention	NN	O
)	)	O
varied	VBN	O
by	IN	O
pretreatment	JJ	O
measures	NNS	O
of	IN	O
that	DT	O
variable	JJ	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
RPMT	NNP	Educational
on	IN	O
growth	NN	O
rate	NN	O
of	IN	O
child-initiated	JJ	O
requests	NNS	O
(	(	O
i.e.	NN	O
,	,	O
the	DT	O
most	RBS	O
common	JJ	O
type	NN	O
of	IN	O
initiating	VBG	O
behavior	JJ	O
regulation	NN	O
)	)	O
varied	VBN	O
by	IN	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
Down	NNP	O
syndrome	NN	O
.	.	O

Finally	RB	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
RPMT	NNP	Educational
on	IN	O
growth	NN	O
of	IN	O
productive	JJ	O
language	NN	O
varied	VBN	O
by	IN	O
pretreatment	JJ	O
frequency	NN	O
of	IN	O
canonical	JJ	O
vocal	JJ	O
communication	NN	O
.	.	O

Recommended	VBN	O
alterations	NNS	O
in	IN	O
PMT	NNP	Educational
and	CC	O
implications	NNS	O
for	IN	O
defining	VBG	O
which	WDT	O
nonspeaking	VBG	O
children	NNS	O
are	VBP	O
appropriate	JJ	O
for	IN	O
prelinguistic	JJ	O
goals	NNS	O
and	CC	O
treatment	NN	O
were	VBD	O
discussed	VBN	O
.	.	O

Brief	JJ	O
report	NN	O
:	:	O
mediation	NN	O
of	IN	O
treatment	NN	O
effect	NN	O
in	IN	O
a	DT	O
communication	NN	O
intervention	NN	O
for	IN	O
pre-school	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Tests	NNS	O
of	IN	O
mediation	NN	O
in	IN	O
treatment	NN	O
trials	NNS	O
can	MD	O
illuminate	VB	O
processes	NNS	O
of	IN	O
change	NN	O
and	CC	O
suggest	NN	O
causal	NN	O
influences	NNS	O
in	IN	O
development	NN	O
.	.	O

We	PRP	O
conducted	VBD	O
a	DT	O
mediation	NN	O
analysis	NN	O
of	IN	O
a	DT	O
previously	RB	O
published	VBN	O
randomised	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
parent-mediated	JJ	Psychological
communication-focused	JJ	Psychological
treatment	NN	Psychological
for	IN	O
autism	NN	O
against	IN	O
ordinary	JJ	O
care	NN	O
,	,	O
with	IN	O
28	CD	O
children	NNS	O
aged	VBN	O
2-5	CD	O
years	NNS	O
(	(	O
Aldred	NNP	O
et	RB	O
al	RB	O
.	.	O

in	IN	O
J	NNP	O
Child	NNP	O
Psychol	NNP	O
Psychiatr	NNP	O
45:1-11	CD	O
,	,	O
2004	CD	O
)	)	O
.	.	O

The	DT	O
hypothesised	JJ	O
mediating	NN	O
process	NN	O
,	,	O
targeted	VBN	O
by	IN	O
the	DT	O
intervention	NN	O
,	,	O
was	VBD	O
an	DT	O
increase	NN	O
in	IN	O
parental	JJ	O
synchronous	JJ	O
response	NN	O
within	IN	O
parent-child	JJ	O
interaction	NN	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
partial	JJ	O
mediation	NN	O
,	,	O
with	IN	O
change	NN	O
in	IN	O
synchrony	NN	O
accounting	NN	O
for	IN	O
34	CD	O
%	NN	O
of	IN	O
the	DT	O
positive	JJ	O
intervention	NN	O
effect	NN	O
on	IN	O
autism	NN	O
symptomatology	NN	O
(	(	O
Autism	NNP	O
Diagnostic	NNP	O
Observation	NNP	O
Schedule	NNP	O
communication	NN	O
and	CC	O
social	JJ	O
domain	NN	O
algorithm	NN	O
)	)	O
;	:	O
the	DT	O
result	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
bootstrap	NN	O
estimation	NN	O
.	.	O

Improved	VBN	O
parental	JJ	O
synchronous	JJ	O
response	NN	O
to	TO	O
child	VB	O
communication	NN	O
can	MD	O
alter	VB	O
short-term	JJ	O
autism	NN	O
symptom	VBZ	O
outcome	RP	O
with	IN	O
targeted	JJ	O
therapy	NN	O
.	.	O

Is	VBZ	O
successful	JJ	O
rehabilitation	NN	O
of	IN	O
complex	JJ	O
regional	JJ	O
pain	NN	O
syndrome	NN	O
due	JJ	O
to	TO	O
sustained	JJ	O
attention	NN	O
to	TO	O
the	DT	O
affected	JJ	O
limb	NN	O
?	.	O
A	DT	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

In	IN	O
complex	JJ	O
regional	JJ	O
pain	NN	O
syndrome	NN	O
(	(	O
CRPS1	NNP	O
)	)	O
initiated	VBN	O
by	IN	O
wrist	JJ	O
fracture	NN	O
,	,	O
a	DT	O
motor	NN	Other
imagery	NN	Other
program	NN	Other
(	(	O
MIP	NNP	O
)	)	O
,	,	O
consisting	VBG	O
of	IN	O
hand	NN	O
laterality	NN	O
recognition	NN	O
followed	VBN	O
by	IN	O
imagined	JJ	Physical
movements	NNS	Physical
and	CC	O
then	RB	O
mirror	NN	Physical
movements	NNS	Physical
,	,	O
reduces	NNS	O
pain	VBP	O
and	CC	O
disability	NN	O
,	,	O
but	CC	O
the	DT	O
mechanism	NN	O
of	IN	O
effect	NN	O
is	VBZ	O
unclear	JJ	O
.	.	O

Possibilities	NNS	O
include	VBP	O
sustained	JJ	O
attention	NN	O
to	TO	O
the	DT	O
affected	JJ	O
limb	NN	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
the	DT	O
order	NN	O
of	IN	O
MIP	NNP	O
components	NNS	O
would	MD	O
not	RB	O
alter	VB	O
the	DT	O
effect	NN	O
,	,	O
and	CC	O
sequential	JJ	O
activation	NN	O
of	IN	O
cortical	JJ	O
motor	NN	O
networks	NNS	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
it	PRP	O
would	MD	O
.	.	O

Twenty	VB	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
CRPS1	NNP	O
initiated	VBN	O
by	IN	O
wrist	JJ	O
fracture	NN	O
and	CC	O
who	WP	O
satisfied	VBD	O
stringent	JJ	O
inclusion	NN	O
criteria	NNS	O
,	,	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
groups	NNS	O
:	:	O
hand	NN	Physical
laterality	NN	Physical
recognition	NN	Physical
,	,	Physical
imagined	VBD	Physical
movements	NNS	Physical
,	,	Physical
mirror	NN	Physical
movements	NNS	Physical
(	(	Physical
RecImMir	NNP	Physical
,	,	Physical
MIP	NNP	Physical
)	)	Physical
;	:	Physical
imagined	VBN	Physical
movements	NNS	Physical
,	,	Physical
recognition	NN	Physical
,	,	Physical
imagined	VBD	Physical
movements	NNS	Physical
(	(	Physical
ImRecIm	NNP	Physical
)	)	Physical
;	:	Physical
recognition	NN	Physical
,	,	Physical
mirror	NN	Physical
movements	NNS	Physical
,	,	Physical
recognition	NN	Physical
(	(	Physical
RecMirRec	NNP	Physical
)	)	Physical
.	.	Physical

At	IN	O
6	CD	O
and	CC	O
18	CD	O
weeks	NNS	O
,	,	O
reduced	VBD	O
pain	NN	O
and	CC	O
disability	NN	O
were	VBD	O
greater	JJR	O
for	IN	O
the	DT	O
RecImMir	NNP	O
group	NN	O
than	IN	O
for	IN	O
the	DT	O
other	JJ	O
groups	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Hand	NNP	O
laterality	NN	O
recognition	NN	O
imparted	VBD	O
a	DT	O
consistent	JJ	O
reduction	NN	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
across	IN	O
groups	NNS	O
,	,	O
however	RB	O
,	,	O
this	DT	O
effect	NN	O
was	VBD	O
limited	VBN	O
in	IN	O
magnitude	NN	O
.	.	O

Imagined	VBD	O
movements	NNS	O
imparted	VBD	O
a	DT	O
further	JJ	O
reduction	NN	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
,	,	O
but	CC	O
only	RB	O
if	IN	O
they	PRP	O
followed	VBD	O
hand	NN	O
laterality	NN	O
recognition	NN	O
.	.	O

Mirror	NN	O
movements	NNS	O
also	RB	O
imparted	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
pain	NN	O
and	CC	O
disability	NN	O
,	,	O
but	CC	O
only	RB	O
when	WRB	O
they	PRP	O
followed	VBD	O
imagined	JJ	O
movements	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
MIP	NNP	O
seems	VBZ	O
to	TO	O
be	VB	O
dependent	JJ	O
on	IN	O
the	DT	O
order	NN	O
of	IN	O
components	NNS	O
,	,	O
which	WDT	O
suggests	VBZ	O
that	IN	O
it	PRP	O
is	VBZ	O
not	RB	O
due	JJ	O
to	TO	O
sustained	JJ	O
attention	NN	O
to	TO	O
the	DT	O
affected	JJ	O
limb	NN	O
,	,	O
but	CC	O
is	VBZ	O
consistent	JJ	O
with	IN	O
sequential	JJ	O
activation	NN	O
of	IN	O
cortical	JJ	O
motor	NN	O
networks	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
phenytoin	NN	Pharmacological
on	IN	O
the	DT	O
absorption	NN	O
of	IN	O
synthetic	JJ	O
folic	JJ	O
acid	NN	O
polyglutamate	NN	O
.	.	O

The	DT	O
absorption	NN	O
of	IN	O
synthetic	JJ	O
pteroyltriglutamate	NN	O
has	VBZ	O
been	VBN	O
measured	VBN	O
in	IN	O
nine	CD	O
normal	JJ	O
students	NNS	O
with	IN	O
and	CC	O
without	IN	O
the	DT	O
anticonvulsant	JJ	O
drug	NN	O
phenytoin	NN	Pharmacological
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
phenytoin	NN	Pharmacological
has	VBZ	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
absorption	NN	O
of	IN	O
this	DT	O
folate	JJ	O
polyglutamate	NN	O
.	.	O

The	DT	O
reasons	NNS	O
are	VBP	O
discussed	VBN	O
for	IN	O
the	DT	O
disparity	NN	O
between	IN	O
this	DT	O
result	NN	O
and	CC	O
those	DT	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
when	WRB	O
folate	NN	O
polyglutamates	NNS	O
derived	VBN	O
from	IN	O
yeast	NN	O
were	VBD	O
used	VBN	O
.	.	O

The	DT	O
A-V	NNP	Physical
Impulse	NNP	Physical
System	NNP	Physical
reduces	VBZ	O
deep-vein	JJ	O
thrombosis	NN	O
and	CC	O
swelling	NN	O
after	IN	O
hemiarthroplasty	NN	O
for	IN	O
hip	NN	O
fracture	NN	O
.	.	O

We	PRP	O
performed	VBD	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
the	DT	O
A-V	NNP	Physical
Impulse	NNP	Physical
System	NNP	Physical
in	IN	O
82	CD	O
patients	NNS	O
treated	VBN	O
by	IN	O
hemiarthroplasty	NN	O
for	IN	O
subcapital	JJ	O
fracture	NN	O
of	IN	O
the	DT	O
femoral	JJ	O
neck	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
deep-vein	JJ	O
thrombosis	NN	O
as	IN	O
assessed	VBN	O
by	IN	O
Doppler	NNP	Physical
ultrasonography	NN	Physical
was	VBD	O
23	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
0	CD	O
%	NN	O
in	IN	O
those	DT	O
using	VBG	O
the	DT	O
device	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Calf	NNP	O
and	CC	O
thigh	JJ	O
circumferences	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
both	DT	O
groups	NNS	O
at	IN	O
seven	CD	O
to	TO	O
ten	VB	O
days	NNS	O
after	IN	O
operation	NN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
group	NN	O
there	EX	O
was	VBD	O
a	DT	O
mean	JJ	O
relative	JJ	O
reduction	NN	O
of	IN	O
postoperative	JJ	O
swelling	NN	O
of	IN	O
the	DT	O
thigh	NN	O
by	IN	O
3.27	CD	O
cm	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
and	CC	O
of	IN	O
the	DT	O
calf	NN	O
by	IN	O
1.55	CD	O
cm	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
A-V	NNP	O
Impulse	NNP	O
System	NNP	O
appears	VBZ	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
method	NN	O
of	IN	O
reducing	VBG	O
the	DT	O
incidence	NN	O
of	IN	O
proximal	JJ	O
deep-vein	JJ	O
thrombosis	NN	O
,	,	O
and	CC	O
of	IN	O
postoperative	JJ	O
swelling	NN	O
.	.	O

Pharmacokinetic	JJ	O
and	CC	O
safety	NN	O
evaluation	NN	O
of	IN	O
high-dose	JJ	O
combinations	NNS	O
of	IN	O
fosamprenavir	NN	O
and	CC	O
ritonavir	NN	O
.	.	O

High-dose	JJ	O
combinations	NNS	O
of	IN	O
fosamprenavir	NN	Pharmacological
(	(	Pharmacological
FPV	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
ritonavir	NN	Pharmacological
(	(	Pharmacological
RTV	NNP	Pharmacological
)	)	Pharmacological
were	VBD	O
evaluated	VBN	O
in	IN	O
healthy	JJ	O
adult	NN	O
subjects	NNS	O
in	IN	O
order	NN	O
to	TO	O
select	VB	O
doses	NNS	O
for	IN	O
further	JJ	O
study	NN	O
in	IN	O
multiple	JJ	O
protease	NN	O
inhibitor	NN	O
(	(	O
PI	NNP	O
)	)	O
-experienced	VBD	O
patients	NNS	O
infected	VBN	O
with	IN	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
type	NN	O
1	CD	O
.	.	O

Two	CD	O
high-dose	JJ	O
regimens	NNS	O
,	,	O
FPV	NNP	Pharmacological
1,400	CD	O
mg	NN	O
twice	RB	O
a	DT	O
day	NN	O
(	(	O
BID	NNP	O
)	)	O
plus	CC	O
RTV	$	Pharmacological
100	CD	O
mg	NN	O
BID	NNP	O
and	CC	O
FPV	NNP	Pharmacological
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	Pharmacological
200	CD	O
mg	NN	O
BID	NNP	O
,	,	O
were	VBD	O
planned	VBN	O
to	TO	O
be	VB	O
compared	VBN	O
to	TO	O
the	DT	O
approved	JJ	O
regimen	NNS	O
,	,	O
FPV	NNP	Pharmacological
700	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	Pharmacological
100	CD	O
mg	NN	O
BID	NNP	O
,	,	O
in	IN	O
a	DT	O
randomized	JJ	O
three-period	NN	O
crossover	NN	O
study	NN	O
.	.	O

Forty-two	NNP	O
healthy	JJ	O
adult	NN	O
subjects	NNS	O
were	VBD	O
enrolled	VBN	O
,	,	O
and	CC	O
39	CD	O
subjects	NNS	O
completed	VBN	O
period	NN	O
1	CD	O
.	.	O

Due	JJ	O
to	TO	O
marked	VB	O
hepatic	JJ	O
transaminase	NN	O
elevations	NNS	O
,	,	O
predominantly	RB	O
with	IN	O
FPV	NNP	Pharmacological
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	Pharmacological
200	CD	O
mg	NN	O
BID	NNP	O
,	,	O
the	DT	O
study	NN	O
was	VBD	O
terminated	VBN	O
prematurely	RB	O
.	.	O

For	IN	O
FPV	NNP	Pharmacological
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	Pharmacological
100	CD	O
mg	NN	O
BID	NNP	O
,	,	O
the	DT	O
values	NNS	O
for	IN	O
plasma	NN	O
amprenavir	NN	O
(	(	O
APV	NNP	O
)	)	O
area	NN	O
under	IN	O
the	DT	O
concentration-time	JJ	O
profile	NN	O
over	IN	O
the	DT	O
dosing	VBG	O
interval	NN	O
(	(	O
tau	NN	O
)	)	O
at	IN	O
steady	JJ	O
state	NN	O
[	NNS	O
AUC	NNP	O
(	(	O
0-tau	JJ	O
)	)	O
]	NN	O
,	,	O
maximum	JJ	O
concentration	NN	O
of	IN	O
drug	NN	O
in	IN	O
plasma	NN	O
(	(	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
,	,	O
and	CC	O
plasma	JJ	O
concentration	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
tau	NN	O
at	IN	O
steady	JJ	O
state	NN	O
(	(	O
C	NNP	O
(	(	O
tau	NN	O
)	)	O
)	)	O
were	VBD	O
54	CD	O
,	,	O
81	CD	O
,	,	O
and	CC	O
26	CD	O
%	NN	O
higher	JJR	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
values	NNS	O
for	IN	O
plasma	NN	O
RTV	NNP	O
AUC	NNP	O
(	(	O
0-tau	JJ	O
)	)	O
,	,	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
,	,	O
and	CC	O
C	NNP	O
(	(	O
tau	NN	O
)	)	O
were	VBD	O
49	CD	O
%	NN	O
higher	JJR	O
,	,	O
71	CD	O
%	NN	O
higher	JJR	O
,	,	O
and	CC	O
11	CD	O
%	NN	O
lower	JJR	O
,	,	O
respectively	RB	O
,	,	O
than	IN	O
those	DT	O
for	IN	O
FPV	NNP	Pharmacological
700	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
100	CD	O
mg	NN	O
BID	NNP	O
.	.	O

For	IN	O
FPV	NNP	Pharmacological
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	O
200	CD	O
mg	NN	O
BID	NNP	O
,	,	O
the	DT	O
values	NNS	O
for	IN	O
plasma	NN	O
APV	NNP	O
AUC	NNP	O
(	(	O
0-tau	JJ	O
)	)	O
,	,	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
,	,	O
and	CC	O
C	NNP	O
(	(	O
tau	NN	O
)	)	O
were	VBD	O
26	CD	O
,	,	O
48	CD	O
,	,	O
and	CC	O
32	CD	O
%	NN	O
higher	JJR	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
values	NNS	O
for	IN	O
plasma	NN	O
RTV	NNP	O
AUC	NNP	O
(	(	O
0-tau	JJ	O
)	)	O
,	,	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
,	,	O
and	CC	O
C	NNP	O
(	(	O
tau	NN	O
)	)	O
increased	VBD	O
4.15-fold	JJ	O
,	,	O
4.17-fold	JJ	O
,	,	O
and	CC	O
3.99-fold	JJ	O
,	,	O
respectively	RB	O
,	,	O
compared	VBN	O
to	TO	O
those	DT	O
for	IN	O
FPV	NNP	Pharmacological
700	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	Pharmacological
100	CD	O
mg	NN	O
BID	NNP	O
.	.	O

FPV	NNP	Pharmacological
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	Pharmacological
200	CD	O
mg	NN	O
BID	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
due	JJ	O
to	TO	O
an	DT	O
increased	VBN	O
rate	NN	O
of	IN	O
marked	VBN	O
hepatic	JJ	O
transaminase	NN	O
elevations	NNS	O
and	CC	O
lack	NN	O
of	IN	O
pharmacokinetic	JJ	O
advantage	NN	O
.	.	O

FPV	NNP	Pharmacological
1,400	CD	O
mg	NN	O
BID	NNP	O
plus	CC	O
RTV	NNP	Pharmacological
100	CD	O
mg	NN	O
BID	NNP	O
is	VBZ	O
currently	RB	O
under	IN	O
clinical	JJ	O
evaluation	NN	O
in	IN	O
multiple	JJ	O
PI-experienced	JJ	O
patients	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
enflurane	NN	Pharmacological
and	CC	O
halothane	NN	Pharmacological
in	IN	O
hypotensive	JJ	O
eye	NN	O
surgery	NN	O
.	.	O

Thirty	NN	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
eye	NN	O
surgery	NN	O
had	VBD	O
anaesthesia	NNS	O
induced	VBN	O
with	IN	O
sodium	NN	Pharmacological
thiopentone	NN	Pharmacological
,	,	O
suxamethonium	NN	Pharmacological
and	CC	O
d-tubocurarine	JJ	Pharmacological
chloride	NN	Pharmacological
.	.	O

Patients	NNS	O
were	VBD	O
ventilated	VBN	O
with	IN	O
nitrous	JJ	Pharmacological
oxide	NN	Pharmacological
,	,	O
oxygen	NN	Pharmacological
and	CC	O
either	DT	O
halothane	NN	Pharmacological
or	CC	O
enflurane	NN	Pharmacological
.	.	O

The	DT	O
volatile	JJ	O
agents	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
decrease	VB	O
the	DT	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
to	TO	O
80	CD	O
mmHg	NN	O
.	.	O

The	DT	O
volatile	JJ	O
agent	NN	O
concentration	NN	O
in	IN	O
the	DT	O
blood	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
30	CD	O
min	NN	O
intervals	NNS	O
.	.	O

Both	DT	O
agents	NNS	O
were	VBD	O
effective	JJ	O
in	IN	O
producing	VBG	O
hypotension	NN	O
,	,	O
but	CC	O
enflurane	NN	O
was	VBD	O
the	DT	O
more	RBR	O
potent	JJ	O
hypotensive	JJ	O
agent	NN	O
in	IN	O
terms	NNS	O
of	IN	O
MAC	NNP	O
equivalents	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
agents	NNS	O
with	IN	O
respect	NN	O
to	TO	O
speed	NN	O
of	IN	O
recovery	NN	O
.	.	O

Pilot	NNP	O
study	NN	O
of	IN	O
a	DT	O
moderate	JJ	Pharmacological
dose	JJ	Pharmacological
multivitamin/mineral	JJ	Pharmacological
supplement	NN	Pharmacological
for	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorder	NN	O
.	.	O

OBJECTIVE	NNP	O
Determine	NNP	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
moderate	JJ	O
dose	JJ	O
multivitamin/mineral	JJ	Pharmacological
supplement	NN	Pharmacological
on	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorder	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
3-month	JJ	O
study	NN	O
.	.	O

SUBJECTS	NNP	O
Twenty	NNP	O
(	(	O
20	CD	O
)	)	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorder	NN	O
,	,	O
ages	VBZ	O
3-8	CD	O
years	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
Global	JJ	O
Impressions	NNP	O
parental	NN	O
questionnaire	NN	O
found	VBD	O
that	IN	O
the	DT	O
supplement	NN	O
group	NN	O
reported	VBD	O
statistically	RB	O
significant	JJ	O
improvements	NNS	O
in	IN	O
sleep	NN	O
and	CC	O
gastrointestinal	JJ	O
problems	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	Control
group	NN	O
.	.	O

An	DT	O
evaluation	NN	O
of	IN	O
vitamin	NN	O
B	NNP	O
(	(	O
6	CD	O
)	)	O
levels	NNS	O
prior	RB	O
to	TO	O
the	DT	O
study	NN	O
found	VBD	O
that	IN	O
the	DT	O
autistic	JJ	O
children	NNS	O
had	VBD	O
substantially	RB	O
elevated	VBN	O
levels	NNS	O
of	IN	O
B6	NNP	O
compared	VBN	O
to	TO	O
a	DT	O
control	NN	O
group	NN	O
of	IN	O
typical	JJ	O
children	NNS	O
(	(	O
75	CD	O
%	NN	O
higher	JJR	O
,	,	O
p	JJ	O
<	NNP	O
0.0000001	CD	O
)	)	O
.	.	O

Vitamin	NNP	O
C	NNP	O
levels	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
placebo	NN	O
group	NN	O
had	VBD	O
levels	NNS	O
that	WDT	O
were	VBD	O
significantly	RB	O
below	JJ	O
average	NN	O
for	IN	O
typical	JJ	O
children	NNS	O
,	,	O
whereas	IN	O
the	DT	O
supplement	NN	O
group	NN	O
had	VBD	O
near-average	JJ	O
levels	NNS	O
.	.	O

DISCUSSION	VB	O
The	DT	O
finding	NN	O
of	IN	O
high	JJ	O
vitamin	NN	O
B	NNP	O
(	(	O
6	CD	O
)	)	O
levels	NNS	O
is	VBZ	O
consistent	JJ	O
with	IN	O
recent	JJ	O
reports	NNS	O
of	IN	O
low	JJ	O
levels	NNS	O
of	IN	O
pyridoxal-5-phosphate	NN	O
and	CC	O
low	JJ	O
activity	NN	O
of	IN	O
pyridoxal	NN	O
kinase	NN	O
(	(	O
i.e.	FW	O
,	,	O
pyridoxal	NN	O
is	VBZ	O
only	RB	O
poorly	RB	O
converted	VBN	O
to	TO	O
pyridoxal-5-phosphate	NN	O
,	,	O
the	DT	O
enzymatically	RB	O
active	JJ	O
form	NN	O
)	)	O
.	.	O

This	DT	O
may	MD	O
explain	VB	O
the	DT	O
functional	JJ	O
need	NN	O
for	IN	O
high-dose	JJ	O
vitamin	NN	Pharmacological
B	NNP	Pharmacological
(	(	Pharmacological
6	CD	Pharmacological
)	)	Pharmacological
supplementation	NN	Pharmacological
in	IN	O
many	JJ	O
children	NNS	O
and	CC	O
adults	NNS	O
with	IN	O
autism	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
prepackaged	VBN	Pharmacological
,	,	Pharmacological
low	JJ	Pharmacological
residual	JJ	Pharmacological
test	NN	Pharmacological
meals	NNS	Pharmacological
with	IN	Pharmacological
4L	CD	Pharmacological
polyethylene	NN	Pharmacological
glycol	NN	Pharmacological
versus	IN	O
a	DT	O
clear	JJ	Pharmacological
liquid	NN	Pharmacological
diet	NN	Pharmacological
with	IN	Pharmacological
4L	CD	Pharmacological
polyethylene	NN	Pharmacological
glycol	NN	Pharmacological
bowel	NN	Pharmacological
preparation	NN	Pharmacological
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
AND	NNP	O
STUDY	NNP	O
AIMS	NNP	O
A	NNP	O
prepackaged	VBD	O
low	JJ	O
residue	JJ	O
one-day	JJ	O
diet	NN	O
(	(	O
breakfast	NN	O
,	,	O
lunch	NN	O
and	CC	O
dinner	NN	O
)	)	O
has	VBZ	O
been	VBN	O
recently	RB	O
developed	VBN	O
to	TO	O
improve	VB	O
patient	NN	O
tolerance	NN	O
for	IN	O
bowel	NN	O
preparation	NN	O
prior	RB	O
to	TO	O
colonoscopy	VB	O
.	.	O

The	DT	O
aims	NNS	O
of	IN	O
this	DT	O
study	NN	O
were	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
bowel	NN	O
preparation	NN	O
protocols	NNS	O
based	VBN	O
on	IN	O
a	DT	O
low	JJ	Pharmacological
residue	JJ	Pharmacological
diet	NN	Pharmacological
and	CC	O
4L	CD	Pharmacological
polyethylene	NN	Pharmacological
glycol	NN	Pharmacological
(	(	Pharmacological
PEG	NNP	Pharmacological
)	)	Pharmacological
solution	NN	Pharmacological
,	,	O
and	CC	O
to	TO	O
compare	VB	O
these	DT	O
new	JJ	O
options	NNS	O
with	IN	O
the	DT	O
traditional	JJ	Pharmacological
liquid	NN	Pharmacological
diet	NN	Pharmacological
and	CC	Pharmacological
the	DT	Pharmacological
PEG	NNP	Pharmacological
4L	CD	Pharmacological
lavage	NN	Pharmacological
.	.	O

METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
214	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
54.1	CD	O
years	NNS	O
;	:	O
120	CD	O
male	NN	O
,	,	O
94	CD	O
female	NN	O
)	)	O
from	IN	O
four	CD	O
university	NN	O
hospitals	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
analysis	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
clear	JJ	Pharmacological
liquid	NN	Pharmacological
diet	NN	Pharmacological
and	CC	Pharmacological
the	DT	Pharmacological
PEG	NNP	Pharmacological
4L	CD	Pharmacological
regimen	NNS	Pharmacological
(	(	O
106	CD	O
patients	NNS	O
)	)	O
or	CC	O
the	DT	O
low	JJ	Pharmacological
residue	JJ	Pharmacological
test	NN	Pharmacological
meals	NNS	Pharmacological
and	CC	Pharmacological
the	DT	Pharmacological
PEG	NNP	Pharmacological
4L	CD	Pharmacological
regimen	NNS	Pharmacological
(	(	Pharmacological
TM-PEG	JJ	Pharmacological
4L	CD	O
,	,	O
108	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
colon	NN	O
cleansing	VBG	O
efficacy	NN	O
of	IN	O
the	DT	O
different	JJ	O
preparations	NNS	O
was	VBD	O
rated	VBN	O
using	VBG	O
the	DT	O
Ottawa	NNP	O
bowel	NN	O
preparation	NN	O
scale	NN	O
.	.	O

RESULTS	NNP	O
No	NNP	O
significant	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
according	VBG	O
to	TO	O
the	DT	O
Ottawa	NNP	O
cleansing	VBG	O
scale	JJ	O
findings	NNS	O
(	(	O
PEG	NNP	O
4L	CD	O
:	:	O
2.97	CD	O
vs	IN	O
TM-PEG	JJ	O
4L	CD	O
:	:	O
2.46	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.063	CD	O
)	)	O
.	.	O

The	DT	O
overall	JJ	O
tolerability	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
TM-PEG	NNP	O
4L	CD	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
PEG	NNP	O
4L	CD	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.036	CD	O
)	)	O
.	.	O

No	DT	O
difference	NN	O
was	VBD	O
found	VBN	O
when	WRB	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
compared	VBN	O
with	IN	O
regard	NN	O
to	TO	O
adverse	JJ	O
events	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.599	CD	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
prepackaged	JJ	O
low	JJ	O
residue	JJ	O
one-day	JJ	O
diet	NN	O
provided	VBD	O
cleansing	VBG	O
efficacy	NN	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
clear	JJ	O
liquid	NN	O
diet	NN	O
and	CC	O
offered	VBD	O
the	DT	O
benefit	NN	O
of	IN	O
improved	JJ	O
tolerability	NN	O
compared	VBN	O
to	TO	O
the	DT	O
conventional	JJ	O
PEG	NNP	O
4L	CD	O
regimen	NNS	O
.	.	O

Safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
IMVAMUNE	NNP	Pharmacological
,	,	O
a	DT	O
promising	JJ	O
candidate	NN	O
as	IN	O
a	DT	O
third	JJ	O
generation	NN	O
smallpox	NN	O
vaccine	NN	O
.	.	O

A	DT	O
Phase	NN	O
I	PRP	O
trial	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
safety	NN	O
and	CC	O
immunogenicity	NN	O
of	IN	O
the	DT	O
third	JJ	Pharmacological
generation	NN	Pharmacological
smallpox	VBD	Pharmacological
vaccine	JJ	Pharmacological
MVA-BN	NNP	Pharmacological
(	(	Pharmacological
IMVAMUNE	NNP	Pharmacological
)	)	Pharmacological
,	,	O
a	DT	O
highly	RB	O
attenuated	VBN	O
clone	NN	O
derived	VBN	O
from	IN	O
the	DT	O
Modified	NNP	O
Vaccinia	NNP	O
Virus	NNP	O
Ankara	NNP	O
strain	NN	O
571	CD	O
,	,	O
in	IN	O
naive	JJ	O
and	CC	O
pre-immunized	JJ	O
subjects	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
86	CD	O
healthy	JJ	O
subjects	NNS	O
received	VBD	O
the	DT	O
vaccine	NN	Pharmacological
in	IN	O
five	CD	O
groups	NNS	O
using	VBG	O
different	JJ	O
doses	NNS	O
and	CC	O
routes	NNS	O
of	IN	O
administration	NN	O
.	.	O

All	DT	O
38	CD	O
subjects	NNS	O
seroconverted	VBN	O
in	IN	O
the	DT	O
groups	NNS	O
receiving	VBG	O
the	DT	O
highest	JJS	O
dose	NN	O
(	(	O
10	CD	O
(	(	O
8	CD	O
)	)	O
TCID50	NN	O
)	)	O
.	.	O

All	DT	O
vaccinations	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
with	IN	O
mainly	RB	O
mild	NN	O
or	CC	O
moderate	JJ	O
pain	NN	O
at	IN	O
the	DT	O
injection	NN	O
site	NN	O
being	VBG	O
the	DT	O
most	RBS	O
frequent	JJ	O
symptom	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
MVA-BN	NNP	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
be	VB	O
developed	VBN	O
as	IN	O
an	DT	O
efficient	NN	O
and	CC	O
safe	JJ	O
alternative	NN	O
to	TO	O
the	DT	O
conventional	JJ	O
smallpox	JJ	O
vaccines	NNS	O
such	JJ	O
as	IN	O
Lister-Elstree	NNP	Pharmacological
or	CC	O
Dryvax	NNP	Pharmacological
.	.	O

Unique	NNP	O
attributes	VBZ	O
render	VBP	O
it	PRP	O
a	DT	O
promising	JJ	O
candidate	NN	O
for	IN	O
prophylactic	JJ	O
mass	NN	O
immunization	NN	O
,	,	O
even	RB	O
in	IN	O
subjects	NNS	O
for	IN	O
whom	WP	O
conventional	JJ	O
smallpox	NN	O
vaccines	NNS	O
are	VBP	O
contraindicated	VBN	O
.	.	O

Phase	NNP	O
III	NNP	O
trial	NN	O
of	IN	O
gemcitabine	NN	Pharmacological
plus	CC	Pharmacological
docetaxel	JJ	Pharmacological
versus	NN	O
capecitabine	NN	Pharmacological
plus	CC	Pharmacological
docetaxel	NN	Pharmacological
with	IN	O
planned	VBN	O
crossover	NN	O
to	TO	O
the	DT	O
alternate	NN	O
single	JJ	O
agent	NN	O
in	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

BACKGROUND	NNP	O
Safety	NNP	O
and	CC	O
efficacy	NN	O
of	IN	O
gemcitabine	JJ	Pharmacological
plus	CC	Pharmacological
docetaxel	JJ	Pharmacological
(	(	Pharmacological
GD	NNP	Pharmacological
)	)	Pharmacological
and	CC	O
capecitabine	JJ	Pharmacological
plus	CC	Pharmacological
docetaxel	JJ	Pharmacological
(	(	Pharmacological
CD	NN	Pharmacological
)	)	Pharmacological
were	VBD	O
compared	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
breast	NN	O
cancer	NN	O
,	,	O
where	WRB	O
the	DT	O
alternate	NN	O
crossover	NN	O
monotherapy	NN	O
(	(	O
GD?C	NNP	O
or	CC	O
CD?G	NNP	O
)	)	O
was	VBD	O
predetermined	VBN	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
3-week	JJ	O
cycles	NNS	O
of	IN	O
either	DT	O
gemcitabine	NN	O
1000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
days	NNS	O
1	CD	O
and	CC	O
8	CD	O
plus	CC	O
docetaxel	JJ	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
on	IN	O
day	NN	O
1	CD	O
or	CC	O
capecitabine	VB	O
1000	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
twice	RB	O
daily	RB	O
on	IN	O
days	NNS	O
1-14	JJ	O
plus	JJ	O
docetaxel	NN	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
day	NN	O
1	CD	O
.	.	O

Upon	IN	O
progression	NN	O
,	,	O
patients	NNS	O
received	VBD	O
crossover	JJ	O
monotherapy	NN	O
.	.	O

Primary	JJ	O
end	NN	O
point	NN	O
was	VBD	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
TtP	NNP	O
)	)	O
.	.	O

Secondary	JJ	O
end	NN	O
points	NNS	O
evaluated	VBD	O
overall	JJ	O
response	NN	O
rate	NN	O
(	(	O
ORR	NNP	O
)	)	O
,	,	O
overall	JJ	O
survival	NN	O
(	(	O
OS	NNP	O
)	)	O
,	,	O
and	CC	O
adverse	JJ	O
events	NNS	O
(	(	O
AEs	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
Despite	IN	O
over-accrual	JJ	O
of	IN	O
475	CD	O
patients	NNS	O
,	,	O
the	DT	O
trial	NN	O
matured	VBD	O
with	IN	O
only	RB	O
324	CD	O
of	IN	O
385	CD	O
planned	JJ	O
TtP	NNP	O
events	NNS	O
due	JJ	O
to	TO	O
patient	JJ	O
discontinuations	NNS	O
.	.	O

Human	NNP	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
2	CD	O
status	NN	O
was	VBD	O
not	RB	O
captured	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

More	JJR	O
CD	NN	O
patients	NNS	O
(	(	O
28	CD	O
%	NN	O
)	)	O
discontinued	VBD	O
due	JJ	O
to	TO	O
AEs	NNP	O
than	IN	O
GD	NNP	O
patients	NNS	O
(	(	O
18.0	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.009	CD	O
)	)	O
.	.	O

TtP	NNP	O
[	NNP	O
hazard	NN	O
ratio	NN	O
(	(	O
HR	NNP	O
)	)	O
=	VBD	O
1.101	CD	O
,	,	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
0.885-1.370	NN	O
,	,	O
P	NNP	O
=	VBZ	O
0.387	CD	O
]	NN	O
and	CC	O
OS	NNP	O
(	(	O
HR	NNP	O
=	NNP	O
1.031	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.830-1.280	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.785	CD	O
)	)	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
comparing	VBG	O
GD	NNP	O
and	CC	O
CD	NNP	O
.	.	O

ORR	NNP	O
was	VBD	O
not	RB	O
statistically	RB	O
different	JJ	O
(	(	O
P	NNP	O
=	NNP	O
0.239	CD	O
)	)	O
comparing	VBG	O
GD	NNP	O
(	(	O
72	CD	O
of	IN	O
207	CD	O
,	,	O
34.8	CD	O
%	NN	O
)	)	O
and	CC	O
CD	NNP	O
(	(	O
78	CD	O
of	IN	O
191	CD	O
,	,	O
40.8	CD	O
%	NN	O
)	)	O
.	.	O

TtP	NNP	O
,	,	O
OS	NNP	O
,	,	O
and	CC	O
ORR	NNP	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
comparing	VBG	O
crossover	NN	O
groups	NNS	O
.	.	O

GD	NNP	O
caused	VBD	O
greater	JJR	O
fatigue	NN	O
,	,	O
hepatotoxicity	NN	O
,	,	O
neutropenia	NN	O
,	,	O
and	CC	O
thrombocytopenia	NNS	O
but	CC	O
not	RB	O
febrile	JJ	O
neutropenia	NN	O
;	:	O
CD	NN	O
caused	VBD	O
more	JJR	O
hand-foot	JJ	O
syndrome	NN	O
,	,	O
gastrointestinal	JJ	O
toxicity	NN	O
,	,	O
and	CC	O
mucositis	NN	O
.	.	O

CONCLUSIONS	NNP	O
GD	NNP	O
and	CC	O
CD	NNP	O
produced	VBD	O
similar	JJ	O
efficacy	NN	O
and	CC	O
toxicity	NN	O
profiles	NNS	O
consistent	JJ	O
with	IN	O
prior	JJ	O
clinical	JJ	O
experience	NN	O
.	.	O

Effect	NN	O
of	IN	O
systemic	JJ	O
nitric	JJ	Pharmacological
oxide	IN	Pharmacological
synthase	JJ	Pharmacological
inhibition	NN	O
on	IN	O
postexercise	NN	O
hypotension	NN	O
in	IN	O
humans	NNS	O
.	.	O

An	DT	O
acute	JJ	O
bout	NN	O
of	IN	O
aerobic	JJ	O
exercise	NN	O
results	NNS	O
in	IN	O
a	DT	O
reduced	JJ	O
blood	NN	O
pressure	NN	O
that	WDT	O
lasts	VBZ	O
several	JJ	O
hours	NNS	O
.	.	O

Animal	NNP	O
studies	NNS	O
suggest	VBP	O
this	DT	O
response	NN	O
is	VBZ	O
mediated	VBN	O
by	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
.	.	O

We	PRP	O
tested	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
[	NNP	O
N	NNP	O
(	(	O
G	NNP	O
)	)	O
-monomethyl-L-arginine	NN	O
(	(	O
L-NMMA	NNP	O
)	)	O
]	NN	O
can	MD	O
reverse	VB	O
the	DT	O
drop	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
that	WDT	O
occurs	VBZ	O
after	IN	O
exercise	NN	O
in	IN	O
humans	NNS	O
.	.	O

Eight	NNP	O
healthy	JJ	O
subjects	NNS	O
underwent	JJ	O
parallel	JJ	O
experiments	NNS	O
on	IN	O
2	CD	O
separate	JJ	O
days	NNS	O
.	.	O

The	DT	O
order	NN	O
of	IN	O
the	DT	O
experiments	NNS	O
was	VBD	O
randomized	VBN	O
between	IN	O
sham	NN	O
(	(	O
60	CD	O
min	NN	O
of	IN	O
seated	JJ	Physical
upright	JJ	Physical
rest	NN	Physical
)	)	O
and	CC	O
exercise	NN	O
(	(	O
60	CD	Physical
min	NN	Physical
of	IN	Physical
upright	JJ	Physical
cycling	NN	Physical
at	IN	O
60	CD	O
%	NN	O
peak	NN	O
aerobic	JJ	O
capacity	NN	O
)	)	O
.	.	O

After	IN	O
both	DT	O
sham	NN	O
and	CC	O
exercise	NN	O
,	,	O
subjects	VBZ	O
received	VBN	O
,	,	O
in	IN	O
sequence	NN	O
,	,	O
systemic	JJ	O
alpha-adrenergic	JJ	O
blockade	NN	O
(	(	O
phentolamine	NN	O
)	)	O
and	CC	O
L-NMMA	NNP	O
.	.	O

Phentolamine	NNP	O
was	VBD	O
given	VBN	O
first	RB	O
to	TO	O
isolate	VB	O
the	DT	O
contribution	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
to	TO	O
postexercise	VB	O
hypotension	NN	O
by	IN	O
preventing	VBG	O
reflex	JJ	O
changes	NNS	O
in	IN	O
sympathetic	JJ	O
tone	NN	O
that	WDT	O
result	NN	O
from	IN	O
systemic	JJ	O
nitric	JJ	O
oxide	IN	O
synthase	JJ	O
inhibition	NN	O
and	CC	O
to	TO	O
control	VB	O
for	IN	O
alterations	NNS	O
in	IN	O
resting	VBG	O
sympathetic	JJ	O
activity	NN	O
after	IN	O
exercise	NN	O
.	.	O

During	IN	O
each	DT	O
condition	NN	O
,	,	O
systemic	JJ	O
and	CC	O
regional	JJ	O
hemodynamics	NNS	O
were	VBD	O
measured	VBN	O
.	.	O

Throughout	IN	O
the	DT	O
study	NN	O
,	,	O
arterial	JJ	O
pressure	NN	O
and	CC	O
vascular	JJ	O
resistances	NNS	O
remained	VBD	O
lower	JJR	O
postexercise	NN	O
vs.	FW	O
postsham	NN	O
despite	IN	O
nitric	JJ	O
oxide	JJ	O
synthase	NN	O
inhibition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
after	IN	O
L-NMMA	NNP	O
was	VBD	O
108.0+/-2.4	JJ	O
mmHg	NN	O
postsham	NN	O
vs.	FW	O
102.1+/-3.3	JJ	O
mmHg	NN	O
postexercise	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Thus	VB	O
it	PRP	O
does	VBZ	O
not	RB	O
appear	VB	O
that	IN	O
postexercise	NN	O
hypotension	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
increased	JJ	O
production	NN	O
of	IN	O
nitric	JJ	O
oxide	NN	O
in	IN	O
humans	NNS	O
.	.	O

Influence	NN	O
of	IN	O
ibopamine	NN	Pharmacological
on	IN	O
heart	NN	O
rate	NN	O
and	CC	O
arrhythmic	JJ	O
pattern	NN	O
in	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
multicentre	NN	O
study	NN	O
.	.	O

Ibopamine	NNP	Pharmacological
is	VBZ	O
a	DT	O
dopaminergic	NN	O
and	CC	O
adrenergic	JJ	O
receptor	NN	O
agonist	NN	O
,	,	O
which	WDT	O
is	VBZ	O
active	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
.	.	O

Since	IN	O
the	DT	O
long-term	JJ	O
prognosis	NN	O
for	IN	O
patients	NNS	O
with	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
remains	VBZ	O
very	RB	O
poor	JJ	O
and	CC	O
the	DT	O
incidence	NN	O
of	IN	O
arrhythmic	JJ	O
death	NN	O
is	VBZ	O
high	JJ	O
,	,	O
every	DT	O
new	JJ	O
drug	NN	O
to	TO	O
be	VB	O
employed	VBN	O
against	IN	O
this	DT	O
disease	NN	O
should	MD	O
be	VB	O
thoroughly	RB	O
tested	VBN	O
in	IN	O
order	NN	O
to	TO	O
rule	VB	O
out	RP	O
any	DT	O
possible	JJ	O
arrhythmogenic	JJ	O
action	NN	O
.	.	O

This	DT	O
multicentre	NN	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
ibopamine	NN	Pharmacological
versus	NN	O
placebo	NN	Control
in	IN	O
double-blind	JJ	O
conditions	NNS	O
on	IN	O
heart	NN	O
rate	NN	O
,	,	O
rhythm	NN	O
and	CC	O
electrical	JJ	O
safety	NN	O
.	.	O

Ibopamine	NNP	Pharmacological
was	VBD	Pharmacological
employed	VBN	Pharmacological
at	IN	Pharmacological
a	DT	Pharmacological
dose	NN	Pharmacological
of	IN	Pharmacological
100	CD	Pharmacological
mg	NN	Pharmacological
t.i.d	NN	Pharmacological
.	.	Pharmacological

in	IN	Physical
97	CD	Physical
patients	NNS	Physical
(	(	Physical
aged	VBN	Physical
31-83	CD	Physical
years	NNS	Physical
)	)	Physical
belonging	VBG	Physical
to	TO	Physical
NYHA	NNP	Physical
class	NN	Physical
II	NNP	Physical
and	CC	Physical
III	NNP	Physical
with	IN	Physical
congestive	JJ	Physical
heart	NN	Physical
failure	NN	Physical
of	IN	Physical
different	JJ	Physical
aetiology	NN	Physical
,	,	O
but	CC	Physical
without	IN	Physical
any	DT	Physical
complex	JJ	Physical
ventricular	NN	Physical
arrhythmias	NN	Physical
in	IN	Physical
basal	NN	Physical
conditions	NNS	Physical
(	(	Physical
couplets	NNS	Physical
with	IN	Physical
R'-R	NNP	Physical
less	JJR	Physical
than	IN	Physical
or	CC	Physical
equal	JJ	Physical
to	TO	Physical
400	CD	Physical
msec	NNS	Physical
,	,	Physical
ventricular	JJ	Physical
tachycardia	NN	Physical
,	,	O
R	NNP	Other
on	IN	Other
T	NNP	Other
phenomena	NN	Other
)	)	O
.	.	O

Using	VBG	O
a	DT	O
random	JJ	O
cross-over	NN	O
design	NN	O
the	DT	O
patients	NNS	O
were	VBD	O
submitted	VBN	O
to	TO	O
48	CD	O
hr	NN	O
.	.	O

Holter	NNP	Pharmacological
recordings	NNS	Pharmacological
in	IN	Pharmacological
basal	NN	Pharmacological
conditions	NNS	Pharmacological
and	CC	Pharmacological
following	VBG	Pharmacological
7	CD	Pharmacological
days	NNS	Pharmacological
of	IN	Pharmacological
ibopamine	NN	Pharmacological
and	CC	O
placebo	NN	O
treatment	NN	O
.	.	O

No	DT	O
influence	NN	O
on	IN	O
heart	NN	O
rhythm	NN	O
was	VBD	O
noted	VBN	O
.	.	O

No	DT	O
significant	JJ	O
variations	NNS	O
in	IN	O
maximum	JJ	O
heart	NN	O
rate	NN	O
(	(	O
ibopamine	JJ	O
117.7	CD	O
+/-	JJ	O
20.9	CD	O
;	:	O
placebo	NN	O
118.1	CD	O
+/-	JJ	O
20.7	CD	O
)	)	O
,	,	O
medium	JJ	O
heart	NN	O
rate	NN	O
(	(	O
ibopamine	JJ	O
71.8	CD	O
+/-	JJ	O
10.2	CD	O
;	:	O
placebo	NN	O
72.6	CD	O
+/-	JJ	O
10.1	CD	O
)	)	O
or	CC	O
minimum	JJ	O
heart	NN	O
rate	NN	O
(	(	O
ibopamine	JJ	O
55.3	CD	O
+/-	JJ	O
11.7	CD	O
;	:	O
placebo	NN	O
54.6	CD	O
+/-	JJ	O
10.6	CD	O
)	)	O
were	VBD	O
observed	VBN	O
.	.	O

The	DT	O
mean	JJ	O
number/hr	NN	O
.	.	O

of	IN	O
ectopic	JJ	O
supraventricular	JJ	O
beats	NNS	O
was	VBD	O
26.1	CD	O
+/-	JJ	O
61.9	CD	O
after	IN	O
ibopamine	NN	O
and	CC	O
21.7	CD	O
+/-	JJ	O
35.8	CD	O
after	IN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
ns	NN	O
)	)	O
.	.	O

The	DT	O
complexity	NN	O
of	IN	O
ectopic	NN	O
supraventricular	JJ	O
beats	NNS	O
did	VBD	O
not	RB	O
change	NN	O
.	.	O

The	DT	O
mean	JJ	O
number/hr	NN	O
.	.	O

of	IN	O
ectopic	JJ	O
ventricular	JJ	O
beats	NNS	O
was	VBD	O
31.1	CD	O
+/-	JJ	O
52.5	CD	O
after	IN	O
ibopamine	NN	O
and	CC	O
30.4	CD	O
+/-	JJ	O
57.8	CD	O
after	IN	O
placebo	NN	O
(	(	O
p	JJ	O
=	NNP	O
ns	NN	O
)	)	O
.	.	O

Neither	CC	O
the	DT	O
distribution	NN	O
of	IN	O
the	DT	O
patients	NNS	O
among	IN	O
Lown	JJ	O
classification	NN	O
nor	CC	O
the	DT	O
Final	NNP	O
Score	NN	O
of	IN	O
the	DT	O
Italian	JJ	O
Lown	NNP	O
Classification	NNP	O
(	(	O
26.1	CD	O
+/-	JJ	O
18.0	CD	O
and	CC	O
26.6	CD	O
+/-	JJ	O
17.9	CD	O
in	IN	O
the	DT	O
1st	CD	O
and	CC	O
2nd	CD	O
day	NN	O
of	IN	O
monitoring	NN	O
after	IN	O
ibopamine	NN	O
and	CC	O
25.7	CD	O
+/-	JJ	O
18.6	CD	O
and	CC	O
25.7	CD	O
+/-	JJ	O
18.8	CD	O
after	IN	O
placebo	NN	O
;	:	O
p	CC	O
=	NNP	O
ns	NN	O
)	)	O
showed	VBD	O
any	DT	O
difference	NN	O
between	IN	O
active	JJ	O
treatment	NN	O
and	CC	O
placebo	NN	O
.	.	O

Similar	JJ	O
results	NNS	O
were	VBD	O
achieved	VBN	O
when	WRB	O
the	DT	O
patients	NNS	O
were	VBD	O
sub-divided	JJ	O
into	IN	O
subgroups	NNS	O
according	VBG	O
to	TO	O
sequences	NNS	O
of	IN	O
treatment	NN	O
(	(	O
basal	NN	O
--	:	O
--	:	O
ibopamine	NN	O
--	:	O
--	:	O
placebo	NN	O
and	CC	O
basal	NN	O
--	:	O
--	:	O
placebo	NN	O
--	:	O
--	:	O
ibopamine	NN	O
)	)	O
,	,	O
NYHA	NNP	O
class	NN	O
II	NNP	O
or	CC	O
III	NNP	O
,	,	O
aetiology	NN	O
of	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
(	(	O
dilatative	JJ	O
cardiomyopathy	NN	O
,	,	O
ischemic	JJ	O
cardiomyopathy	NN	O
and	CC	O
other	JJ	O
aetiologies	NNS	O
)	)	O
,	,	O
associated	VBN	O
treatment	NN	O
with	IN	O
digitalis	NN	O
or	CC	O
diuretics	NNS	O
and	CC	O
the	DT	O
number	NN	O
and	CC	O
complexity	NN	O
of	IN	O
base	NN	O
ectopic	NN	O
ventricular	JJ	O
beats	NNS	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
patients	NNS	O
experienced	VBD	O
sustained	JJ	O
ventricular	JJ	O
tachycardia	NN	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
400	CD	O
WORDS	NNP	O
)	)	O
Antiinflammatory	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
phosphodiesterase-4	JJ	Pharmacological
inhibitor	NN	Pharmacological
cilomilast	NN	Pharmacological
(	(	Pharmacological
Ariflo	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

Cilomilast	NNP	Pharmacological
(	(	Pharmacological
Ariflo	NNP	Pharmacological
)	)	Pharmacological
,	,	O
a	DT	O
new	JJ	O
oral	JJ	Pharmacological
phosphodiesterase-4	JJ	Pharmacological
selective	JJ	Pharmacological
inhibitor	NN	Pharmacological
,	,	O
improves	VBZ	O
lung	JJ	O
function	NN	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

We	PRP	O
have	VBP	O
evaluated	VBN	O
its	PRP$	O
antiinflammatory	JJ	O
effects	NNS	O
in	IN	O
59	CD	O
patients	NNS	O
with	IN	O
COPD	NNP	O
randomized	VBD	O
to	TO	O
receive	VB	O
cilomilast	NN	Pharmacological
,	,	O
15	CD	O
mg	NN	O
two	CD	O
times	NNS	O
a	DT	O
day	NN	O
,	,	O
or	CC	O
placebo	NN	Control
for	IN	O
12	CD	O
weeks	NNS	O
.	.	O

Induced	NNP	O
sputum	JJ	O
differential	NN	O
cell	NN	O
counts	NNS	O
were	VBD	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
five	CD	O
further	JJ	O
visits	NNS	O
.	.	O

Interleukin-8	NNP	O
and	CC	O
neutrophil	JJ	O
elastase	NN	O
were	VBD	O
measured	VBN	O
in	IN	O
sputum	NN	O
supernatant	NN	O
.	.	O

Bronchial	JJ	O
biopsies	NNS	O
obtained	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
Week	NNP	O
10	CD	O
were	VBD	O
immunostained	VBN	O
and	CC	O
counted	VBN	O
for	IN	O
neutrophils	NNS	O
,	,	O
CD8+	NNP	O
and	CC	O
CD4+	NNP	O
T-lymphocyte	NNP	O
subsets	NNS	O
,	,	O
and	CC	O
CD68+	NNP	O
macrophages	NNS	O
.	.	O

Cells	NNP	O
expressing	VBG	O
the	DT	O
genes	NNS	O
for	IN	O
interleukin-8	NN	O
and	CC	O
tumor	NN	O
necrosis	NN	O
factor-alpha	NN	O
were	VBD	O
identified	VBN	O
by	IN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
and	CC	O
quantified	VBD	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
of	IN	O
the	DT	O
change	NN	O
from	IN	O
baseline	NN	O
showed	VBD	O
that	IN	O
cilomilast	NN	Pharmacological
did	VBD	O
not	RB	O
alter	VB	O
any	DT	O
sputum	JJ	O
endpoint	NN	O
or	CC	O
FEV1	NNP	O
.	.	O

However	RB	O
,	,	O
bronchial	JJ	O
biopsies	NNS	O
demonstrated	VBD	O
that	IN	O
cilomilast	NN	Pharmacological
treatment	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
reductions	NNS	O
in	IN	O
CD8+	NNP	O
(	(	O
p	JJ	O
=	VBZ	O
0.001	CD	O
;	:	O
ANOVA	NNP	O
)	)	O
and	CC	O
CD68+	NNP	O
cells	NNS	O
(	(	O
p	JJ	O
<	VBZ	O
0.05	CD	O
;	:	O
ANOVA	NNP	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
by	IN	O
Poisson	NNP	O
analysis	NN	O
,	,	O
comparison	NN	O
of	IN	O
cell	NN	O
counts	NNS	O
analyzed	VBN	O
as	IN	O
a	DT	O
ratio	NN	O
of	IN	O
active	JJ	O
to	TO	O
placebo	VB	O
demonstrated	JJ	O
reductions	NNS	O
of	IN	O
CD8+	NNP	O
(	(	O
48	CD	O
%	NN	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
CD68+	NNP	O
(	(	O
47	CD	O
%	NN	O
p	NN	O
=	NNP	O
0.001	CD	O
)	)	O
cells	NNS	O
.	.	O

This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
demonstration	NN	O
of	IN	O
reduction	NN	O
by	IN	O
any	DT	O
agent	NN	O
of	IN	O
airway	JJ	O
tissue	NN	O
inflammatory	NN	O
cells	NNS	O
characteristic	JJ	O
of	IN	O
COPD	NNP	O
.	.	O

Phosphodiesterase-4	JJ	Pharmacological
inhibitors	NNS	Pharmacological
represent	VBP	O
a	DT	O
promising	JJ	O
new	JJ	O
class	NN	O
of	IN	O
substances	NNS	O
for	IN	O
use	NN	O
in	IN	O
antiinflammatory	JJ	O
treatment	NN	O
of	IN	O
this	DT	O
disease	NN	O
.	.	O

Differential	JJ	O
effects	NNS	O
of	IN	O
two	CD	O
dihydropyridine	JJ	Pharmacological
calcium	NN	Pharmacological
antagonists	NNS	Pharmacological
in	IN	O
humans	NNS	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
after	IN	O
single	JJ	O
doses	NNS	O
of	IN	O
niguldipine	NN	Pharmacological
(	(	O
0.3	CD	O
,	,	O
0.6	CD	O
,	,	O
and	CC	O
0.9	CD	O
mg	NN	O
intravenously	RB	O
;	:	O
8	CD	O
and	CC	O
16	CD	O
mg	NNS	O
orally	RB	O
)	)	O
and	CC	O
nifedipine	JJ	Pharmacological
(	(	O
2	CD	O
mg	NN	O
intravenously	RB	O
;	:	O
20	CD	O
mg	NNS	O
orally	RB	O
)	)	O
in	IN	O
healthy	JJ	O
male	NN	O
volunteers	NNS	O
in	IN	O
randomized	JJ	O
placebo-controlled	JJ	Control
experiments	NNS	O
.	.	O

Total	JJ	O
peripheral	JJ	O
resistance	NN	O
(	(	O
TPR	NNP	O
)	)	O
,	,	O
heart	NN	O
rate-corrected	JJ	O
electromechanical	JJ	O
systole	NN	O
(	(	O
QS2c	NNP	O
)	)	O
,	,	O
and	CC	O
preejection	NN	O
period	NN	O
(	(	O
PEPc	NNP	O
)	)	O
were	VBD	O
assessed	VBN	O
noninvasively	RB	O
.	.	O

Both	DT	O
drugs	NNS	O
induced	VBD	O
a	DT	O
similar	JJ	O
pronounced	NN	O
decreased	VBD	O
in	IN	O
TRP	NNP	O
,	,	O
indicating	VBG	O
peripheral	JJ	O
vasodilation	NN	O
,	,	O
followed	VBN	O
by	IN	O
increasing	VBG	O
heart	NN	O
rate	NN	O
and	CC	O
cardiac	JJ	O
output	NN	O
,	,	O
a	DT	O
decrease	NN	O
in	IN	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
a	DT	O
shortening	NN	O
of	IN	O
the	DT	O
PEPc	NNP	O
.	.	O

QS2c	NNP	O
was	VBD	O
unchanged	JJ	O
after	IN	O
niguldipine	NN	O
.	.	O

The	DT	O
prolongation	NN	O
of	IN	O
QS2c	NNP	O
after	IN	O
oral	JJ	O
nifedipine	NN	Pharmacological
is	VBZ	O
suggestive	JJ	O
of	IN	O
a	DT	O
negative	JJ	O
inotropic	NN	O
effect	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
vasodilatory	JJ	O
effects	NNS	O
of	IN	O
dihydropyridines	NNS	Pharmacological
may	MD	O
(	(	O
as	IN	O
for	IN	O
nifedipine	NN	Pharmacological
)	)	O
or	CC	O
may	MD	O
not	RB	O
(	(	O
as	IN	O
for	IN	O
niguldipine	NN	Pharmacological
)	)	O
be	VB	O
associated	VBN	O
with	IN	O
changes	NNS	O
that	WDT	O
are	VBP	O
suggestive	JJ	O
of	IN	O
negative	JJ	O
inotropic	NN	O
effects	NNS	O
,	,	O
and	CC	O
that	IN	O
this	DT	O
difference	NN	O
is	VBZ	O
detectable	JJ	O
by	IN	O
noninvasive	JJ	O
methods	NNS	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
a	DT	O
brief	JJ	Psychological
Early	JJ	Psychological
Start	NNP	Psychological
Denver	NNP	Psychological
model	NN	Psychological
(	(	Psychological
ESDM	NNP	Psychological
)	)	Psychological
-based	VBD	Psychological
parent	NN	Psychological
intervention	NN	Psychological
on	IN	Psychological
toddlers	NNS	Psychological
at	IN	O
risk	NN	O
for	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	VB	O
This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
12-week	JJ	O
,	,	O
low-intensity	JJ	Psychological
(	(	Psychological
1-hour/wk	CD	Psychological
of	IN	Psychological
therapist	JJ	Psychological
contact	NN	Psychological
)	)	Psychological
,	,	Psychological
parent-delivered	JJ	Psychological
intervention	NN	Psychological
for	IN	Psychological
toddlers	NNS	Psychological
at	IN	O
risk	NN	O
for	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
aged	VBD	O
14	CD	O
to	TO	O
24	CD	O
months	NNS	O
and	CC	O
their	PRP$	O
families	NNS	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomized	VBD	O
controlled	VBN	O
trial	NN	O
involving	VBG	O
98	CD	O
children	NNS	O
and	CC	O
families	NNS	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
three	CD	O
different	JJ	O
sites	NNS	O
investigating	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
parent	NN	O
delivery	NN	O
of	IN	O
the	DT	O
Early	JJ	Educational
Start	NNP	Educational
Denver	NNP	Educational
model	NN	Educational
(	(	Educational
P-ESDM	NNP	Educational
)	)	Educational
,	,	O
which	WDT	O
fosters	VBZ	O
parental	JJ	O
use	NN	O
of	IN	O
a	DT	O
child-centered	JJ	O
responsive	JJ	O
interaction	NN	O
style	NN	O
that	WDT	O
embeds	VBZ	O
many	JJ	O
teaching	VBG	O
opportunities	NNS	O
into	IN	O
play	NN	O
,	,	O
compared	VBN	Control
to	TO	Control
community	NN	Control
treatment	NN	Control
as	IN	Control
usual	JJ	Control
.	.	Control

Assessments	NNS	O
were	VBD	O
completed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
12	CD	O
weeks	NNS	O
later	RB	O
,	,	O
immediately	RB	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
parent	NN	O
coaching	NN	O
sessions	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
effect	NN	O
of	IN	O
group	NN	O
assignment	NN	O
on	IN	O
parent-child	JJ	O
interaction	NN	O
characteristics	NNS	O
or	CC	O
on	IN	O
any	DT	O
child	JJ	O
outcomes	NNS	O
.	.	O

Both	DT	O
groups	NNS	O
of	IN	O
parents	NNS	O
improved	VBN	O
interaction	NN	O
skills	NNS	O
,	,	O
and	CC	O
both	DT	O
groups	NNS	O
of	IN	O
children	NNS	O
demonstrated	JJ	O
progress	NN	O
.	.	O

Parents	NNS	O
receiving	VBG	O
P-ESDM	NNP	O
demonstrated	VBD	O
significantly	RB	O
stronger	JJR	O
working	VBG	O
alliances	NNS	O
with	IN	O
their	PRP$	O
therapists	NNS	O
than	IN	O
did	VBD	O
the	DT	O
community	NN	O
group	NN	O
.	.	O

Children	NNP	O
in	IN	O
the	DT	O
community	NN	O
group	NN	O
received	VBD	O
significantly	RB	O
more	JJR	O
intervention	NN	O
hours	NNS	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
P-ESDM	NNP	O
group	NN	O
.	.	O

For	IN	O
the	DT	O
group	NN	O
as	IN	O
a	DT	O
whole	NN	O
,	,	O
both	DT	O
younger	JJR	O
child	NN	O
age	NN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
intervention	NN	O
and	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
intervention	NN	O
hours	NNS	O
were	VBD	O
positively	RB	O
related	VBN	O
to	TO	O
the	DT	O
degree	NN	O
of	IN	O
improvement	NN	O
in	IN	O
children	NNS	O
's	POS	O
behavior	NN	O
for	IN	O
most	JJS	O
variables	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Parent-implemented	JJ	O
intervention	NN	O
studies	NNS	O
for	IN	O
early	JJ	O
ASD	NNP	O
thus	RB	O
far	RB	O
have	VBP	O
not	RB	O
demonstrated	VBN	O
the	DT	O
large	JJ	O
effects	NNS	O
seen	VBN	O
in	IN	O
intensive-treatment	JJ	O
studies	NNS	O
.	.	O

Evidence	NN	O
that	IN	O
both	DT	O
younger	JJR	O
age	NN	O
and	CC	O
more	JJR	O
intervention	NN	O
hours	NNS	O
positively	RB	O
affect	VBP	O
developmental	JJ	O
rates	NNS	O
has	VBZ	O
implications	NNS	O
for	IN	O
clinical	JJ	O
practice	NN	O
,	,	O
service	NN	O
delivery	NN	O
,	,	O
and	CC	O
public	JJ	O
policy	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
,	,	O
onset	NN	O
of	IN	O
action	NN	O
,	,	O
and	CC	O
tolerability	NN	O
of	IN	O
ibuprofen	JJ	Pharmacological
arginate	NN	Pharmacological
and	CC	O
ibuprofen	NN	Pharmacological
in	IN	O
postoperative	JJ	O
dental	NN	O
pain	NN	O
.	.	O

BACKGROUND	NNP	O
Because	IN	O
of	IN	O
its	PRP$	O
enhanced	JJ	O
pharmacokinetic	JJ	O
characteristics	NNS	O
,	,	O
ibuprofen	JJ	Pharmacological
arginate	NN	Pharmacological
might	MD	O
be	VB	O
expected	VBN	O
to	TO	O
provide	VB	O
faster	JJR	O
pain	NN	O
relief	NN	O
than	IN	O
standard	JJ	Pharmacological
ibuprofen	JJ	Pharmacological
formulations	NNS	O
in	IN	O
patients	NNS	O
experiencing	VBG	O
acute	JJ	O
pain	NN	O
.	.	O

OBJECTIVE	CC	O
This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
analgesic	JJ	O
efficacy	NN	O
,	,	O
speed	NN	O
of	IN	O
onset	NN	O
,	,	O
and	CC	O
tolerability	NN	O
of	IN	O
ibuprofen	JJ	O
arginate	NN	O
compared	VBN	O
with	IN	O
a	DT	O
commercially	RB	O
available	JJ	O
form	NN	O
of	IN	O
ibuprofen	NN	O
in	IN	O
patients	NNS	O
with	IN	O
postoperative	JJ	O
dental	NN	O
pain	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
ibuprofen	JJ	Pharmacological
arginate	NN	Pharmacological
200	CD	Pharmacological
or	CC	Pharmacological
400	CD	Pharmacological
mg	NN	Pharmacological
,	,	Pharmacological
ibuprofen	JJ	Pharmacological
200	CD	Pharmacological
or	CC	Pharmacological
400	CD	Pharmacological
mg	NN	Pharmacological
,	,	Pharmacological
or	CC	O
placebo	NN	Control
in	IN	O
this	DT	O
multicenter	NN	O
,	,	O
double-blind	JJ	O
,	,	O
double-dummy	JJ	O
,	,	O
parallel-group	JJ	O
trial	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
6	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
study	NN	O
medication	NN	O
.	.	O

A	DT	O
repeated-dose	JJ	O
,	,	O
open-label	JJ	O
phase	NN	O
followed	VBD	O
.	.	O

Pain	NNP	O
intensity	NN	O
and	CC	O
pain	NN	O
relief	NN	O
were	VBD	O
measured	VBN	O
using	VBG	O
traditional	JJ	O
verbal	JJ	O
descriptor	NN	O
scales	NNS	O
;	:	O
onset	VBN	O
of	IN	O
analgesia	NN	O
was	VBD	O
assessed	VBN	O
using	VBG	O
2	CD	O
stopwatches	NNS	O
to	TO	O
measure	VB	O
the	DT	O
time	NN	O
to	TO	O
achievement	NN	O
of	IN	O
specific	JJ	O
pain	NN	O
relief	NN	O
criteria	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
498	CD	O
patients	NNS	O
(	(	O
219	CD	O
men	NNS	O
,	,	O
279	CD	O
women	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
21.5	CD	O
years	NNS	O
)	)	O
participated	VBD	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

Baseline	NNP	O
pain	NN	O
was	VBD	O
moderate	JJ	O
in	IN	O
388	CD	O
patients	NNS	O
(	(	O
78	CD	O
%	NN	O
)	)	O
and	CC	O
severe	JJ	O
in	IN	O
110	CD	O
patients	NNS	O
(	(	O
22	CD	O
%	NN	O
)	)	O
.	.	O

Meaningful	JJ	O
pain	NN	O
relief	NN	O
was	VBD	O
reached	VBN	O
after	IN	O
a	DT	O
median	NN	O
of	IN	O
29	CD	O
and	CC	O
28	CD	O
minutes	NNS	O
with	IN	O
ibuprofen	JJ	Pharmacological
arginate	NN	Pharmacological
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
after	IN	O
52	CD	O
and	CC	O
44	CD	O
minutes	NNS	O
with	IN	O
ibuprofen	JJ	Pharmacological
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
,	,	O
respectively	RB	O
(	(	O
all	DT	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
percentages	NNS	O
of	IN	O
patients	NNS	O
who	WP	O
achieved	VBD	O
meaningful	JJ	O
pain	NN	O
relief	NN	O
within	IN	O
the	DT	O
first	JJ	O
hour	NN	O
after	IN	O
treatment	NN	O
were	VBD	O
77.6	CD	O
%	NN	O
and	CC	O
83.7	CD	O
%	NN	O
for	IN	O
ibuprofen	JJ	Pharmacological
arginate	NN	Pharmacological
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
,	,	O
respectively	RB	O
,	,	O
61.0	CD	O
%	NN	O
and	CC	O
63.0	CD	O
%	NN	O
for	IN	O
ibuprofen	JJ	Pharmacological
200	CD	O
and	CC	O
400	CD	O
mg	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
39.8	CD	O
%	NN	O
for	IN	O
placebo	NN	O
.	.	O

The	DT	O
differences	NNS	O
between	IN	O
ibuprofen	JJ	O
arginate	NN	O
and	CC	O
ibuprofen	NN	O
were	VBD	O
statistically	RB	O
significant	JJ	O
(	(	O
both	DT	O
doses	NNS	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Significantly	RB	O
greater	JJR	O
numbers	NNS	O
of	IN	O
patients	NNS	O
achieved	VBN	O
meaningful	JJ	O
pain	NN	O
relief	NN	O
with	IN	O
ibuprofen	JJ	Pharmacological
arginate	NN	Pharmacological
400	CD	O
mg	NN	O
compared	VBN	O
with	IN	O
placebo	NN	Control
from	IN	O
20	CD	O
minutes	NNS	O
through	IN	O
6	CD	O
hours	NNS	O
and	CC	O
with	IN	O
ibuprofen	JJ	O
arginate	NN	O
200	CD	O
mg	NN	O
from	IN	O
30	CD	O
minutes	NNS	O
through	IN	O
6	CD	O
hours	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Compared	VBN	O
with	IN	O
placebo	NN	O
,	,	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
achieved	VBN	O
meaningful	JJ	O
pain	NN	O
relief	NN	O
with	IN	O
ibuprofen	JJ	Pharmacological
400	CD	O
mg	NN	O
from	IN	O
45	CD	O
minutes	NNS	O
through	IN	O
6	CD	O
hours	NNS	O
;	:	O
with	IN	O
ibuprofen	NN	O
200	CD	O
mg.	NN	O
the	DT	O
corresponding	JJ	O
interval	NN	O
was	VBD	O
from	IN	O
I	PRP	O
through	IN	O
6	CD	O
hours	NNS	O
.	.	O

After	IN	O
the	DT	O
first	JJ	O
hour	NN	O
,	,	O
pain	NN	O
reduction	NN	O
was	VBD	O
similar	JJ	O
for	IN	O
the	DT	O
similar	JJ	O
doses	NNS	O
of	IN	O
the	DT	O
2	CD	O
ibuprofen	JJ	Pharmacological
preparations	NNS	O
.	.	O

Median	JJ	O
remedication	NN	O
times	NNS	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
ibuprofen	JJ	Pharmacological
arginate	NN	Pharmacological
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
ibuprofen	NN	O
,	,	O
ranging	VBG	O
from	IN	O
4.0	CD	O
to	TO	O
5.2	CD	O
hours	NNS	O
.	.	O

Adverse-event	JJ	O
profiles	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
2	CD	O
active	JJ	O
medications	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Ibuprofen	NNP	Pharmacological
arginate	NN	Pharmacological
was	VBD	O
effective	JJ	O
in	IN	O
this	DT	O
population	NN	O
of	IN	O
patients	NNS	O
experiencing	VBG	O
moderate	JJ	O
to	TO	O
severe	VB	O
pain	NN	O
after	IN	O
surgical	JJ	O
extraction	NN	O
of	IN	O
>	NN	O
or	CC	O
=	$	O
1	CD	O
impacted	JJ	O
third	JJ	O
molar	NN	O
,	,	O
with	IN	O
16	CD	O
to	TO	O
24	CD	O
minutes	NNS	O
'	POS	O
faster	NN	O
time	NN	O
to	TO	O
meaningful	VB	O
pain	NN	O
relief	NN	O
than	IN	O
with	IN	O
ibuprofen	NN	O
.	.	O

The	DT	O
2	CD	O
formulations	NNS	O
had	VBD	O
similar	JJ	O
tolerability	NN	O
profiles	NNS	O
.	.	O

Why	WRB	O
does	VBZ	O
lag	NN	Psychological
affect	VB	O
the	DT	O
durability	NN	O
of	IN	O
memory-based	JJ	O
automaticity	NN	O
:	:	O
loss	NN	O
of	IN	O
memory	NN	O
strength	NN	O
or	CC	O
interference	NN	O
?	.	O
In	IN	O
Rickard	NNP	O
,	,	O
Lau	NNP	O
,	,	O
and	CC	O
Pashler	NNP	O
's	POS	O
(	(	O
2008	CD	O
)	)	O
investigation	NN	O
of	IN	O
the	DT	O
lag	NN	O
effect	NN	O
on	IN	O
memory-based	JJ	O
automaticity	NN	O
,	,	O
response	NN	O
times	NNS	O
were	VBD	O
faster	RBR	O
and	CC	O
proportion	NN	O
of	IN	O
trials	NNS	Educational
retrieved	VBN	O
was	VBD	O
higher	JJR	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
practice	NN	Educational
for	IN	O
short	JJ	O
lag	NN	O
items	NNS	O
than	IN	O
for	IN	O
long	JJ	O
lag	NN	O
items	NNS	O
.	.	O

However	RB	O
,	,	O
during	IN	O
testing	VBG	Educational
after	IN	Educational
a	DT	Educational
delay	NN	Educational
,	,	O
response	NN	O
times	NNS	O
were	VBD	O
slower	JJR	O
and	CC	O
proportion	NN	O
of	IN	O
trials	NNS	O
retrieved	VBN	O
was	VBD	O
lower	JJR	O
for	IN	O
short	JJ	O
lag	NN	O
items	NNS	O
than	IN	O
for	IN	O
long	JJ	O
lag	NN	O
items	NNS	O
.	.	O

The	DT	O
current	JJ	O
study	NN	O
investigated	VBD	O
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
the	DT	O
lag	NN	O
effect	NN	O
on	IN	O
the	DT	O
durability	NN	O
of	IN	O
memory-based	JJ	O
automaticity	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
interference	VB	O
or	CC	O
to	TO	O
the	DT	O
loss	NN	O
of	IN	O
memory	NN	O
strength	NN	O
with	IN	O
time	NN	O
.	.	O

Participants	NNS	O
repeatedly	RB	O
practiced	VBD	O
alphabet	JJ	Educational
subtraction	NN	Educational
items	NNS	Educational
in	IN	Educational
short	JJ	Educational
lag	NN	Educational
and	CC	Educational
long	JJ	Educational
lag	NN	Educational
conditions	NNS	Educational
.	.	Educational

After	IN	O
practice	NN	O
,	,	O
half	NN	O
of	IN	O
the	DT	O
participants	NNS	O
were	VBD	O
immediately	RB	Educational
tested	VBN	Educational
and	CC	O
the	DT	O
other	JJ	O
half	NN	O
were	VBD	O
tested	VBN	Educational
after	IN	Educational
a	DT	Educational
7-day	JJ	Educational
delay	NN	Educational
.	.	Educational

Results	VB	O
indicate	JJ	O
that	IN	O
the	DT	O
lag	NN	O
effect	NN	O
on	IN	O
the	DT	O
durability	NN	O
of	IN	O
memory-based	JJ	O
automaticity	NN	O
is	VBZ	O
primarily	RB	O
due	JJ	O
to	TO	O
interference	VB	O
.	.	O

We	PRP	O
discuss	VBP	O
potential	JJ	O
modification	NN	O
of	IN	O
current	JJ	O
memory-based	JJ	O
processing	NN	O
theories	NNS	O
to	TO	O
account	VB	O
for	IN	O
these	DT	O
effects	NNS	O
.	.	O

Reduced	VBN	O
mortality	NN	O
among	IN	O
children	NNS	O
in	IN	O
southern	JJ	O
India	NNP	O
receiving	VBG	O
a	DT	O
small	JJ	O
weekly	JJ	O
dose	NN	O
of	IN	O
vitamin	NN	Pharmacological
A	NNP	Pharmacological
.	.	O

BACKGROUND	NNP	O
Clinical	NNP	O
vitamin	VBD	O
A	DT	O
deficiency	NN	O
affects	VBZ	O
millions	NNS	O
of	IN	O
children	NNS	O
worldwide	IN	O
,	,	O
and	CC	O
subclinical	JJ	O
deficiency	NN	O
is	VBZ	O
even	RB	O
more	RBR	O
common	JJ	O
.	.	O

Supplemental	JJ	O
vitamin	NN	O
A	NNP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
reduce	VB	O
mortality	NN	O
among	IN	O
these	DT	O
children	NNS	O
,	,	O
but	CC	O
the	DT	O
results	NNS	O
have	VBP	O
been	VBN	O
questioned	VBN	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
controlled	VBN	O
,	,	O
masked	VBD	O
clinical	JJ	O
trial	NN	O
for	IN	O
one	CD	O
year	NN	O
in	IN	O
southern	JJ	O
India	NNP	O
involving	VBG	O
15,419	CD	O
preschool-age	JJ	O
children	NNS	O
who	WP	O
received	VBD	O
either	CC	O
8.7	CD	Pharmacological
mumol	NN	Pharmacological
(	(	O
8333	CD	O
IU	NNP	O
)	)	O
of	IN	O
vitamin	NN	Pharmacological
A	NNP	Pharmacological
and	CC	O
46	CD	Pharmacological
mumol	NN	Pharmacological
(	(	Pharmacological
20	CD	Pharmacological
mg	NN	Pharmacological
)	)	Pharmacological
of	IN	Pharmacological
vitamin	NN	Pharmacological
E	NNP	Pharmacological
(	(	O
the	DT	O
treated	VBN	O
group	NN	O
)	)	O
or	CC	O
vitamin	JJ	Pharmacological
E	NNP	Pharmacological
alone	RB	O
(	(	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
.	.	O

Vitamin	JJ	Pharmacological
supplements	NNS	Pharmacological
were	VBD	O
delivered	VBN	O
weekly	JJ	O
by	IN	O
community	NN	O
health	NN	O
volunteers	NNS	O
who	WP	O
also	RB	O
recorded	VBD	O
mortality	NN	O
and	CC	O
morbidity	NN	O
.	.	O

Weekly	JJ	O
contact	NN	O
was	VBD	O
made	VBN	O
with	IN	O
at	IN	O
least	JJS	O
88	CD	O
percent	NN	O
of	IN	O
the	DT	O
children	NNS	O
in	IN	O
both	DT	O
study	NN	O
groups	NNS	O
.	.	O

The	DT	O
base-line	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
children	NNS	O
were	VBD	O
similar	JJ	O
and	CC	O
documented	VBD	O
a	DT	O
high	JJ	O
prevalence	NN	O
of	IN	O
vitamin	NN	O
A	NNP	O
deficiency	NN	O
and	CC	O
undernutrition	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
twenty-five	JJ	O
deaths	NNS	O
occurred	VBD	O
,	,	O
of	IN	O
which	WDT	O
117	CD	O
were	VBD	O
not	RB	O
accidental	JJ	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
death	NN	O
in	IN	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
vitamin	NN	O
A	NNP	O
was	VBD	O
less	JJR	O
than	IN	O
half	NN	O
that	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
relative	JJ	O
risk	NN	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.30	CD	O
to	TO	O
0.71	CD	O
)	)	O
.	.	O

The	DT	O
risk	NN	O
was	VBD	O
most	RBS	O
reduced	JJ	O
among	IN	O
children	NNS	O
under	IN	O
3	CD	O
years	NNS	O
of	IN	O
age	NN	O
(	(	O
6	CD	O
to	TO	O
11	CD	O
months	NNS	O
--	:	O
relative	JJ	O
risk	NN	O
,	,	O
0.28	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.09	CD	O
to	TO	O
0.85	CD	O
;	:	O
12	CD	O
to	TO	O
35	CD	O
months	NNS	O
--	:	O
relative	JJ	O
risk	NN	O
,	,	O
0.46	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.26	CD	O
to	TO	O
0.81	CD	O
)	)	O
and	CC	O
among	IN	O
those	DT	O
who	WP	O
were	VBD	O
chronically	RB	O
undernourished	JJ	O
,	,	O
as	IN	O
manifested	VBN	O
by	IN	O
stunting	VBG	O
(	(	O
relative	JJ	O
risk	NN	O
,	,	O
0.11	CD	O
;	:	O
95	CD	O
percent	NN	O
confidence	NN	O
interval	NN	O
,	,	O
0.03	CD	O
to	TO	O
0.36	CD	O
)	)	O
.	.	O

The	DT	O
symptom-specific	JJ	O
risk	NN	O
of	IN	O
mortality	NN	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
diarrhea	NN	O
,	,	O
convulsions	NNS	O
,	,	O
and	CC	O
other	JJ	O
infection-related	JJ	O
symptoms	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
regular	JJ	O
provision	NN	O
of	IN	O
a	DT	O
supplement	NN	O
of	IN	O
vitamin	NN	Pharmacological
A	NNP	Pharmacological
to	TO	O
children	NNS	O
,	,	O
at	IN	O
a	DT	O
level	NN	O
potentially	RB	O
obtainable	JJ	O
from	IN	O
foods	NNS	O
,	,	O
in	IN	O
an	DT	O
area	NN	O
where	WRB	O
vitamin	NN	O
A	DT	O
deficiency	NN	O
and	CC	O
under-nutrition	NN	O
are	VBP	O
documented	VBN	O
public	JJ	O
health	NN	O
problems	NNS	O
contributed	VBD	O
substantially	RB	O
to	TO	O
children	NNS	O
's	POS	O
survival	NN	O
;	:	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
on	IN	O
average	NN	O
by	IN	O
54	CD	O
percent	NN	O
.	.	O

Evaluation	NN	O
of	IN	O
the	DT	O
safety	NN	O
,	,	O
immunogenicity	NN	O
,	,	O
and	CC	O
pharmacokinetic	JJ	O
profile	NN	O
of	IN	O
a	DT	O
new	JJ	O
,	,	O
highly	RB	Pharmacological
purified	VBN	Pharmacological
,	,	Pharmacological
heat-treated	JJ	Pharmacological
equine	NN	Pharmacological
rabies	NNS	Pharmacological
immunoglobulin	VBP	Pharmacological
,	,	O
administered	VBD	O
either	CC	O
alone	RB	O
or	CC	O
in	IN	O
association	NN	O
with	IN	O
a	DT	O
purified	JJ	O
,	,	O
Vero-cell	NNP	Pharmacological
rabies	VBZ	Pharmacological
vaccine	NN	Pharmacological
.	.	Pharmacological

A	DT	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	O
,	,	O
purified	JJ	Pharmacological
,	,	Pharmacological
heat-treated	JJ	Pharmacological
equine	NN	Pharmacological
rabies	NNS	Pharmacological
immunoglobulin	VBP	Pharmacological
(	(	Pharmacological
PHT-Erig	NNP	Pharmacological
)	)	Pharmacological
,	,	O
F	NNP	Pharmacological
(	(	Pharmacological
ab	IN	Pharmacological
'	POS	Pharmacological
)	)	Pharmacological
2	CD	Pharmacological
preparation	NN	Pharmacological
,	,	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
Thailand	NNP	O
and	CC	O
in	IN	O
the	DT	O
Philippines-two	JJ	O
countries	NNS	O
where	WRB	O
rabies	NNS	O
is	VBZ	O
endemic	JJ	O
.	.	O

An	DT	O
initial	JJ	O
prospective	NN	O
,	,	O
randomised	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
(	(	O
Study	NNP	O
1	CD	O
)	)	O
,	,	O
compared	VBN	O
the	DT	O
safety	NN	O
and	CC	O
pharmacokinetics	NNS	O
(	(	O
serum	JJ	O
concentrations	NNS	O
of	IN	O
rabies	NNS	O
antibodies	NNS	O
)	)	O
after	IN	O
administration	NN	O
either	DT	O
of	IN	O
PHT-Erig	NNP	Pharmacological
or	CC	O
of	IN	O
a	DT	O
commercially-available	JJ	O
,	,	O
equine	JJ	Pharmacological
rabies	NNS	Pharmacological
immune	VBP	Pharmacological
globulin	NN	Pharmacological
(	(	Pharmacological
Erig	NNP	Pharmacological
PMC	NNP	Pharmacological
)	)	Pharmacological
.	.	O

A	DT	O
second	JJ	O
trial	NN	O
(	(	O
Study	NNP	O
2	CD	O
)	)	O
simulated	VBD	O
post-exposure	JJ	O
rabies	NNS	O
prophylaxis	VBN	O
by	IN	O
using	VBG	O
a	DT	O
reference	NN	O
cell	NN	O
culture	NN	O
vaccine	NN	O
,	,	O
the	DT	O
purified	JJ	Pharmacological
Vero-cell	NNP	Pharmacological
rabies	NNS	Pharmacological
vaccine	NN	Pharmacological
(	(	Pharmacological
PVRV	NNP	Pharmacological
)	)	Pharmacological
,	,	O
administered	VBN	O
in	IN	O
association	NN	O
with	IN	O
either	DT	O
Erig	NNP	Pharmacological
PMC	NNP	Pharmacological
or	CC	O
PHT-Erig	NNP	Pharmacological
.	.	O

In	IN	O
Study	NNP	O
1	CD	O
,	,	O
27	CD	O
healthy	JJ	O
,	,	O
Thai	NNP	O
adults	NNS	O
received	VBD	O
a	DT	O
40	CD	O
IU	NNP	O
kg	NN	O
(	(	O
-1	NNP	O
)	)	O
dose	NN	O
of	IN	O
either	DT	O
Erig	NNP	Pharmacological
PMC	NNP	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
12	CD	O
)	)	O
or	CC	O
PHT-Erig	NNP	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
via	IN	O
the	DT	O
intramuscular	NN	O
(	(	O
i.m	JJ	O
.	.	O

)	)	O
route	NN	O
;	:	O
half	NN	O
of	IN	O
the	DT	O
dose	NN	O
was	VBD	O
injected	VBN	O
into	IN	O
the	DT	O
deltoid	JJ	O
area	NN	O
and	CC	O
the	DT	O
other	JJ	O
half	NN	O
into	IN	O
the	DT	O
buttocks	NNS	O
.	.	O

Serum	NNP	O
for	IN	O
rabies	NNS	O
antibody	JJ	O
determination	NN	O
and	CC	O
F	NNP	O
(	(	O
ab	IN	O
'	POS	O
)	)	O
2	CD	O
concentration	NN	O
was	VBD	O
collected	VBN	O
at	IN	O
hours	NNS	O
(	(	O
H	NNP	O
)	)	O
0	CD	O
,	,	O
6	CD	O
and	CC	O
12	CD	O
,	,	O
and	CC	O
on	IN	O
day	NN	O
(	(	O
D	NNP	O
)	)	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
and	CC	O
15	CD	O
.	.	O

Both	DT	O
products	NNS	O
were	VBD	O
safe	JJ	O
,	,	O
with	IN	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
,	,	O
and	CC	O
in	IN	O
particular	JJ	O
,	,	O
no	DT	O
anaphylactic	JJ	O
reactions	NNS	O
or	CC	O
serum	NN	O
sickness	NN	O
was	VBD	O
reported	VBN	O
.	.	O

A	DT	O
statistical	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
pharmacokinetic	JJ	O
parameters	NNS	O
did	VBD	O
not	RB	O
demonstrate	VB	O
bioequivalence	NN	O
of	IN	O
the	DT	O
two	CD	O
products	NNS	O
.	.	O

Nonetheless	RB	O
,	,	O
the	DT	O
relative	JJ	O
bioavailability	NN	O
of	IN	O
93	CD	O
%	NN	O
and	CC	O
the	DT	O
similar	JJ	O
absorption	NN	O
rates	NNS	O
suggest	VBP	O
the	DT	O
pharmacokinetic	JJ	O
profiles	NNS	O
of	IN	O
Erig	NNP	O
and	CC	O
PHT-Erig	NNP	O
are	VBP	O
similar	JJ	O
.	.	O

The	DT	O
antibody	NN	O
level	NN	O
in	IN	O
either	DT	O
group	NN	O
were	VBD	O
low	JJ	O
throughout	IN	O
the	DT	O
15-day	JJ	O
study	NN	O
period	NN	O
.	.	O

The	DT	O
geometric	JJ	O
mean	NN	O
titer	NN	O
(	(	O
GMT	NNP	O
)	)	O
values	NNS	O
ranged	VBD	O
from	IN	O
group	NN	O
0.027-0.117	CD	O
IU	NNP	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
in	IN	O
the	DT	O
Erig	NNP	O
group	NN	O
and	CC	O
from	IN	O
0.029	CD	O
to	TO	O
0.072	CD	O
IU	NNP	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
in	IN	O
the	DT	O
PHT-Erig	NNP	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
evolution	NN	O
of	IN	O
GMT	NNP	O
values	NNS	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

In	IN	O
Study	NNP	O
2	CD	O
,	,	O
71	CD	O
healthy	JJ	O
volunteers	NNS	O
received	VBD	O
40	CD	O
IU	NNP	O
kg	NN	O
(	(	O
-1	JJ	O
)	)	O
via	IN	O
the	DT	O
intramuscular	JJ	O
route	NN	O
of	IN	O
either	DT	O
Erig	NNP	O
PMC	NNP	O
(	(	O
n	JJ	O
=	NNP	O
36	CD	O
)	)	O
or	CC	O
PHT-Erig	NNP	O
(	(	O
n	JJ	O
=	NNP	O
35	CD	O
)	)	O
on	IN	O
D0	NNP	O
,	,	O
in	IN	O
association	NN	O
with	IN	O
five	CD	O
doses	NNS	O
of	IN	O
PVRV	NNP	O
on	IN	O
D0	NNP	O
,	,	O
D3	NNP	O
,	,	O
D7	NNP	O
,	,	O
D14	NNP	O
and	CC	O
D28	NNP	O
.	.	O

The	DT	O
safety	NN	O
evaluation	NN	O
was	VBD	O
performed	VBN	O
during	IN	O
the	DT	O
28-day	JJ	O
follow-up	NN	O
and	CC	O
serum	NN	O
samples	NNS	O
for	IN	O
anti-rabies	NNS	O
antibody	JJ	O
titration	NN	O
were	VBD	O
collected	VBN	O
on	IN	O
D0	NNP	O
(	(	O
before	IN	O
injection	NN	O
)	)	O
D3	NNP	O
,	,	O
D7	NNP	O
,	,	O
D14	NNP	O
and	CC	O
D28	NNP	O
.	.	O

No	NNP	O
serious	JJ	O
reactions	NNS	O
were	VBD	O
reported	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
no	DT	O
immediate	JJ	O
(	(	O
anaphylactic	JJ	O
type	NN	O
)	)	O
or	CC	O
delayed	VBN	O
(	(	O
serum	JJ	O
sickness	NN	O
)	)	O
allergic	NN	O
reactions	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Over	IN	O
the	DT	O
28-day	JJ	O
follow-up	JJ	O
period	NN	O
,	,	O
GMT	NNP	O
profiles	NNS	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
statistically	RB	O
equivalent	JJ	O
.	.	O

On	IN	O
D14	NNP	O
,	,	O
100	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
had	VBD	O
protective	JJ	O
antibody	NN	O
titers	NNS	O
(	(	O
anti-rabies	JJ	O
antibodies	NNS	O
>	VBP	O
or	CC	O
=	VBP	O
0.5	CD	O
IU	NNP	O
ml	NN	O
(	(	O
-1	NNP	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
the	DT	O
WHO-recommended	JJ	O
level	NN	O
of	IN	O
seroconversion	NN	O
)	)	O
,	,	O
and	CC	O
Erig	NNP	O
PMC	NNP	O
and	CC	O
PHT-Erig	NNP	O
were	VBD	O
indistinguishable	JJ	O
according	VBG	O
to	TO	O
the	DT	O
clinical	JJ	O
definition	NN	O
chosen	VBN	O
.	.	O

On	IN	O
D28	NNP	O
,	,	O
the	DT	O
GMT	NNP	O
values	NNS	O
were	VBD	O
33.2	CD	O
IU	NNP	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
23.8-46.1	JJ	O
IU	NNP	O
ml	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
in	IN	O
the	DT	O
Erig	NNP	O
PMC/PVRV	NNP	O
group	NN	O
and	CC	O
31.4	CD	O
IU	NNP	O
ml	NN	O
(	(	O
-1	NN	O
)	)	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
,	,	O
CI	NNP	O
,	,	O
23.4-42.2	JJ	O
IU	NNP	O
ml	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
in	IN	O
the	DT	O
PHT-Erig/PVRV	NNP	O
group	NN	O
,	,	O
showing	VBG	O
evidence	NN	O
of	IN	O
adequate	JJ	O
vaccine-induced	JJ	O
antibody	NN	O
responses	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
increased	JJ	O
purity	NN	O
,	,	O
the	DT	O
heat-treatment	JJ	O
step	NN	O
introduced	VBN	O
in	IN	O
the	DT	O
manufacturing	NN	O
process	NN	O
of	IN	O
PHT-Erig	NNP	O
,	,	O
and	CC	O
the	DT	O
good	JJ	O
clinical	JJ	O
results	NNS	O
substantiate	VBP	O
the	DT	O
use	NN	O
of	IN	O
this	DT	O
new	JJ	O
generation	NN	O
,	,	O
purified	JJ	O
equine	NN	O
F	NNP	O
(	(	O
ab	IN	O
'	POS	O
)	)	O
2	CD	O
preparation	NN	O
in	IN	O
the	DT	O
post-exposure	JJ	O
prophylaxis	NN	O
of	IN	O
rabies	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
neighborhood-based	JJ	Educational
community	NN	Educational
organizing	VBG	Educational
:	:	O
results	NNS	O
from	IN	O
the	DT	O
Seattle	NNP	O
Minority	NNP	O
Youth	NNP	O
Health	NNP	O
Project	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
community	NN	Educational
mobilization	NN	Educational
and	CC	Educational
youth	NN	Educational
development	NN	Educational
strategy	NN	Educational
to	TO	O
prevent	VB	O
drug	NN	O
abuse	NN	O
,	,	O
violence	NN	O
,	,	O
and	CC	O
risky	JJ	O
sexual	JJ	O
activity	NN	O
.	.	O

DATA	NNP	O
SOURCES/STUDY	NNP	O
SETTING	NNP	O
Primary	NNP	O
surveys	NNS	O
of	IN	O
youth	NN	O
,	,	O
parents	NNS	O
,	,	O
and	CC	O
key	JJ	O
neighborhood	NN	O
leaders	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
baseline	NN	O
(	(	O
1994	CD	O
)	)	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
intervention	NN	O
period	NN	O
(	(	O
1997	CD	O
)	)	O
.	.	O

The	DT	O
study	NN	O
took	VBD	O
place	NN	O
in	IN	O
four	CD	O
intervention	NN	O
and	CC	O
six	CD	O
control	NN	O
neighborhoods	NNS	O
in	IN	O
Seattle	NNP	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
The	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
as	IN	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
with	IN	O
neighborhood	NN	O
as	IN	O
the	DT	O
unit	NN	O
of	IN	O
randomization	NN	O
.	.	O

The	DT	O
intervention	NN	O
consisted	VBD	O
of	IN	O
a	DT	O
paid	VBN	Educational
community	NN	Educational
organizer	NN	Educational
in	IN	Educational
each	DT	Educational
neighborhood	NN	Educational
who	WP	Educational
recruited	VBD	Educational
a	DT	Educational
group	NN	Educational
of	IN	Educational
residents	NNS	Educational
to	TO	Educational
serve	VB	Educational
as	IN	Educational
a	DT	Educational
community	NN	Educational
action	NN	Educational
board	NN	Educational
.	.	Educational

Key	NNP	O
variables	NNS	O
included	VBD	O
perceptions	NNS	O
of	IN	O
neighborhood	NN	O
mobilization	NN	O
by	IN	O
youth	NN	O
,	,	O
parents	NNS	O
,	,	O
and	CC	O
key	JJ	O
neighborhood	NN	O
leaders	NNS	O
.	.	O

DATA	NNP	O
COLLECTION/EXTRACTION	NNP	O
METHODS	NNP	O
Youth	NNP	O
surveys	NNS	O
were	VBD	O
self-administered	JJ	O
during	IN	O
school	NN	O
hours	NNS	O
.	.	O

Parent	NN	O
and	CC	O
neighborhood	NN	O
leader	NN	O
surveys	NNS	O
were	VBD	O
conducted	VBN	O
over	IN	O
the	DT	O
phone	NN	O
by	IN	O
trained	JJ	O
interviewers	NNS	O
.	.	O

PRINCIPAL	NNP	O
FINDINGS	NNP	O
Survey	NNP	O
results	NNS	O
showed	VBD	O
that	IN	O
mobilization	NN	O
increased	VBD	O
to	TO	O
the	DT	O
same	JJ	O
degree	NN	O
in	IN	O
both	DT	O
intervention	NN	O
and	CC	O
control	NN	O
neighborhoods	NNS	O
with	IN	O
no	DT	O
evidence	NN	O
of	IN	O
an	DT	O
overall	JJ	O
intervention	NN	O
effect	NN	O
.	.	O

There	EX	O
did	VBD	O
appear	VB	O
to	TO	O
be	VB	O
a	DT	O
relative	JJ	O
increase	NN	O
in	IN	O
mobilization	NN	O
in	IN	O
the	DT	O
neighborhood	NN	O
with	IN	O
the	DT	O
highest	JJS	O
level	NN	O
of	IN	O
intervention	NN	O
activity	NN	O
.	.	O

CONCLUSION	NN	O
This	DT	O
randomized	VBN	O
study	NN	O
failed	VBD	O
to	TO	O
demonstrate	VB	O
a	DT	O
measurable	JJ	O
effect	NN	O
for	IN	O
a	DT	O
community	NN	Educational
mobilization	NN	Educational
intervention	NN	Educational
.	.	O

It	PRP	O
is	VBZ	O
uncertain	JJ	O
whether	IN	O
the	DT	O
negative	JJ	O
finding	NN	O
was	VBD	O
because	IN	O
of	IN	O
a	DT	O
lack	NN	O
of	IN	O
strength	NN	O
of	IN	O
the	DT	O
interventions	NNS	O
or	CC	O
problems	NNS	O
detecting	VBG	O
intervention	NN	O
effects	NNS	O
using	VBG	O
individual-level	JJ	O
closed-end	JJ	O
surveys	NNS	O
.	.	O

Evaluation	NN	O
of	IN	O
umbilical	JJ	Pharmacological
cord	NN	Pharmacological
serum	NN	Pharmacological
therapy	NN	Pharmacological
for	IN	O
persistent	JJ	O
corneal	JJ	O
epithelial	JJ	O
defects	NNS	O
.	.	O

AIMS	NNP	O
To	TO	O
evaluate	VB	O
umbilical	JJ	Pharmacological
cord	NN	Pharmacological
serum	NN	Pharmacological
therapy	NN	Pharmacological
as	IN	O
a	DT	O
means	NN	O
of	IN	O
promoting	VBG	O
the	DT	O
healing	NN	O
of	IN	O
persistent	JJ	O
corneal	JJ	O
epithelial	JJ	O
defects	NNS	O
.	.	O

METHODS	NNP	O
Umbilical	NNP	Pharmacological
cord	NN	Pharmacological
serum	NN	Pharmacological
or	CC	Pharmacological
autologous	JJ	Pharmacological
serum	NN	Pharmacological
drops	NNS	Pharmacological
were	VBD	O
used	VBN	O
to	TO	O
promote	VB	O
the	DT	O
healing	NN	O
of	IN	O
persistent	JJ	O
epithelial	JJ	O
defects	NNS	O
.	.	O

The	DT	O
study	NN	O
design	NN	O
was	VBD	O
a	DT	O
prospective	JJ	O
randomised	VBN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
.	.	O

60	CD	O
eyes	NNS	O
of	IN	O
59	CD	O
patients	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
,	,	O
31	CD	O
in	IN	O
the	DT	O
cord	NN	Pharmacological
serum	NN	Pharmacological
group	NN	O
and	CC	O
29	CD	O
in	IN	O
the	DT	O
autologous	JJ	Control
serum	NN	Control
control	NN	Control
group	NN	Educational
.	.	Educational

Epithelial	JJ	O
defects	NNS	O
measuring	VBG	O
at	IN	O
least	JJS	O
2	CD	O
mm	NN	O
in	IN	O
linear	JJ	O
dimension	NN	O
resistant	NN	O
to	TO	O
conventional	JJ	O
medical	JJ	O
management	NN	O
were	VBD	O
included	VBN	O
.	.	O

Serial	JJ	O
measurements	NNS	O
of	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
epithelial	JJ	O
defects-namely	RB	O
,	,	O
two	CD	O
maximum	JJ	O
linear	JJ	O
dimensions	NNS	O
perpendicular	VBP	O
to	TO	O
each	DT	O
other	JJ	O
,	,	O
and	CC	O
the	DT	O
area	NN	O
and	CC	O
perimeter	NN	O
was	VBD	O
done	VBN	O
at	IN	O
start	NN	O
of	IN	O
therapy	NN	O
and	CC	O
follow	VB	O
up	RP	O
days	NNS	O
3	CD	O
,	,	O
7	CD	O
,	,	O
14	CD	O
,	,	O
21	CD	O
.	.	O

Rate	NN	O
of	IN	O
healing	NN	O
of	IN	O
the	DT	O
epithelial	JJ	O
defects	NNS	O
were	VBD	O
measured	VBN	O
as	IN	O
percentage	NN	O
decrease	NN	O
from	IN	O
the	DT	O
baseline	NN	O
parameter	NN	O
at	IN	O
each	DT	O
subsequent	NN	O
follow	VBP	O
up	RB	O
.	.	O

The	DT	O
data	NNS	O
were	VBD	O
analysed	VBN	O
by	IN	O
the	DT	O
non-parametric	JJ	O
Wilcoxon	NNP	O
rank	NN	O
sum	NN	O
test	NN	O
using	VBG	O
STATA	NNP	O
7.0	CD	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
percentage	NN	O
decrease	NN	O
in	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
epithelial	JJ	O
defect	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
cord	NN	Pharmacological
serum	NN	Pharmacological
group	NN	O
at	IN	O
days	NNS	O
7	CD	O
,	,	O
14	CD	O
and	CC	O
21	CD	O
(	(	O
p	NN	O
<	RB	O
0.05	CD	O
)	)	O
when	WRB	O
measured	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
area	NN	O
and	CC	O
perimeter	NN	O
.	.	O

A	DT	O
greater	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
showed	VBD	O
complete	JJ	O
re-epithelialisation	NN	O
with	IN	O
umbilical	JJ	O
cord	NN	Pharmacological
serum	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
than	IN	O
with	IN	O
autologous	JJ	O
serum	NN	O
(	(	O
n	JJ	O
=	NNP	O
11	CD	O
)	)	O
(	(	O
Pearson	NNP	O
chi	VBZ	O
=	NNP	O
0.19	CD	O
)	)	O
.	.	O

None	NN	O
of	IN	O
the	DT	O
patients	NNS	O
reported	VBD	O
any	DT	O
side	NN	O
effects	NNS	O
or	CC	O
discomfort	NN	O
with	IN	O
either	DT	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Umbilical	NNP	Pharmacological
cord	NN	Pharmacological
serum	NN	Pharmacological
leads	VBZ	O
to	TO	O
faster	RBR	O
healing	NN	O
of	IN	O
the	DT	O
persistent	JJ	O
corneal	NN	O
epithelial	JJ	O
defects	NNS	O
refractory	NN	O
to	TO	O
all	DT	O
medical	JJ	O
management	NN	O
compared	VBN	O
to	TO	O
autologous	JJ	Pharmacological
serum	NN	Pharmacological
.	.	O

Verapamil	NNP	Pharmacological
augmentation	NN	O
of	IN	O
lithium	NN	Pharmacological
treatment	NN	O
improves	VBZ	O
outcome	VBN	O
in	IN	O
mania	NN	O
unresponsive	JJ	O
to	TO	O
lithium	VB	Pharmacological
alone	RB	O
:	:	O
preliminary	JJ	O
findings	NNS	O
and	CC	O
a	DT	O
discussion	NN	O
of	IN	O
therapeutic	JJ	O
mechanisms	NNS	O
.	.	O

OBJECTIVES	NNP	O
Attenuation	NNP	O
of	IN	O
protein	NN	O
kinase	NN	O
C	NNP	O
(	(	O
PKC	NNP	O
)	)	O
is	VBZ	O
a	DT	O
mechanism	NN	O
common	JJ	O
to	TO	O
both	DT	O
established	VBN	O
(	(	Pharmacological
lithium	NN	Pharmacological
,	,	Pharmacological
valproate	NN	Pharmacological
)	)	Pharmacological
and	CC	O
some	DT	Pharmacological
novel	NN	Pharmacological
(	(	Pharmacological
tamoxifen	NN	Pharmacological
)	)	Pharmacological
antimanic	JJ	Pharmacological
agents	NNS	Pharmacological
.	.	O

Verapamil	NNP	Pharmacological
,	,	O
although	IN	O
primarily	RB	O
known	VBN	O
as	IN	O
a	DT	O
calcium	NN	O
channel	NN	O
blocker	NN	O
,	,	O
also	RB	O
has	VBZ	O
PKC	NNP	O
inhibitory	NN	O
activity	NN	O
.	.	O

Verapamil	NNP	Pharmacological
has	VBZ	O
shown	VBN	O
antimanic	JJ	O
activity	NN	O
in	IN	O
some	DT	O
but	CC	O
not	RB	O
all	DT	O
studies	NNS	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
verapamil	NN	Pharmacological
,	,	Pharmacological
used	VBD	Pharmacological
alone	RB	Pharmacological
or	CC	Pharmacological
as	IN	Pharmacological
an	DT	Pharmacological
adjunctive	JJ	Pharmacological
treatment	NN	Pharmacological
,	,	O
in	IN	O
manic	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
respond	VB	O
to	TO	O
an	DT	O
initial	JJ	O
adequate	JJ	O
trial	NN	O
of	IN	O
lithium	NN	Pharmacological
.	.	O

METHODS	NNP	O
Each	DT	O
study	NN	O
phase	NN	O
lasted	VBD	O
three	CD	O
weeks	NNS	O
.	.	O

Subjects	NNS	O
were	VBD	O
treated	VBN	O
openly	RB	O
with	IN	O
lithium	NN	Pharmacological
in	IN	O
Phase	NNP	O
1	CD	O
(	(	O
n	JJ	O
=	NNP	O
45	CD	O
)	)	O
.	.	O

Those	DT	O
who	WP	O
failed	VBD	O
to	TO	O
respond	VB	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
in	IN	O
Phase	NNP	O
2	CD	O
with	IN	O
either	DT	O
verapamil	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
or	CC	O
continued-lithium	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
.	.	O

Phase	$	O
2	CD	O
nonresponders	NNS	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
were	VBD	O
assigned	VBN	O
to	TO	O
combined	VB	Pharmacological
verapamil/lithium	NN	Pharmacological
in	IN	O
Phase	NNP	O
3	CD	O
.	.	O

RESULTS	NNP	O
Response	NNP	O
in	IN	O
Phase	NNP	O
2	CD	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
verapamil	NNS	Pharmacological
and	CC	O
continued-lithium	NN	Pharmacological
.	.	O

During	IN	O
Phase	NNP	O
3	CD	O
,	,	O
response	NN	O
to	TO	O
combined	VBN	O
treatment	NN	O
was	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
overall	JJ	O
response	NN	O
to	TO	O
monotherapy	VB	O
in	IN	O
Phase	NNP	O
2	CD	O
(	(	O
Fisher	NNP	O
's	POS	O
Exact	NNP	O
test	NN	O
,	,	O
p	NN	O
=	NNP	O
0.043	CD	O
)	)	O
.	.	O

Mania	NNP	O
ratings	NNS	O
improved	VBN	O
during	IN	O
combined	JJ	O
treatment	NN	O
in	IN	O
Phase	NNP	O
3	CD	O
by	IN	O
88.2	CD	O
%	NN	O
(	(	O
linear	JJ	O
mixed	JJ	O
model	NN	O
analysis	NN	O
,	,	O
F	NNP	O
=	NNP	O
4.34	CD	O
,	,	O
p	NN	O
=	NNP	O
0.013	CD	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
10.5	CD	O
%	NN	O
improvement	NN	O
during	IN	O
Phase	NNP	O
2	CD	O
.	.	O

CONCLUSIONS	NN	O
In	IN	O
this	DT	O
preliminary	JJ	O
investigation	NN	O
,	,	O
verapamil	JJ	Pharmacological
monotherapy	NN	O
did	VBD	O
not	RB	O
demonstrate	VB	O
antimanic	JJ	O
efficacy	NN	O
.	.	O

By	IN	O
contrast	NN	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
verapamil	JJ	Pharmacological
plus	CC	Pharmacological
lithium	NN	Pharmacological
was	VBD	O
highly	RB	O
efficacious	JJ	O
.	.	O

Our	PRP$	O
findings	NNS	O
thus	RB	O
suggest	VBP	O
that	IN	O
verapamil	NN	Pharmacological
may	MD	O
have	VB	O
potential	JJ	O
utility	NN	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
lithium	NN	Pharmacological
.	.	O

This	DT	O
effect	NN	O
may	MD	O
be	VB	O
mediated	VBN	O
by	IN	O
additive	JJ	O
actions	NNS	O
on	IN	O
PKC	NNP	O
inhibition	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
an	DT	O
important	JJ	O
mechanism	NN	O
for	IN	O
antimanic	JJ	O
agents	NNS	O
in	IN	O
general	JJ	O
.	.	O

Bronchodilatory	JJ	O
responses	NNS	O
to	TO	O
formoterol	VB	Pharmacological
,	,	O
ipratropium	NN	Pharmacological
,	,	O
and	CC	O
their	PRP$	O
combination	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
stable	JJ	O
COPD	NNP	O
.	.	O

We	PRP	O
studied	VBD	O
27	CD	O
patients	NNS	O
with	IN	O
stable	JJ	O
chronic	JJ	O
obstuctive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
within-patient	JJ	O
,	,	O
placebo-controlled	JJ	Control
clinical	JJ	O
study	NN	O
.	.	O

Each	DT	O
patient	NN	O
was	VBD	O
assigned	VBN	O
on	IN	O
six	CD	O
separate	JJ	O
days	NNS	O
to	TO	O
receive	VB	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
drug	NN	O
regimens	NNS	O
in	IN	O
random	JJ	O
order	NN	O
:	:	O
A	DT	O
.	.	O

40	CD	O
micrograms	JJ	O
ipratropium	NN	Pharmacological
bromide	NN	Pharmacological
(	(	Pharmacological
Atrovent	NNP	Pharmacological
MDI	NNP	Pharmacological
,	,	Pharmacological
20	CD	Pharmacological
micrograms/puff	NN	Pharmacological
)	)	Pharmacological
plus	CC	O
2	CD	Control
puffs	NNS	Control
placebo	NN	Control
;	:	O
B	NNP	O
.	.	O

12	CD	O
micrograms	NNS	O
formoterol	JJ	Pharmacological
fumarate	NN	Pharmacological
(	(	Pharmacological
Foradil	NNP	Pharmacological
MDI	NNP	Pharmacological
,	,	Pharmacological
12	CD	Pharmacological
micrograms/puff	NN	Pharmacological
)	)	Pharmacological
plus	CC	O
3	CD	Control
puffs	NNS	Control
placebo	VBP	Control
;	:	O
C.	NNP	O
80	CD	Pharmacological
micrograms	NNS	Pharmacological
ipratropium	NN	Pharmacological
;	:	O
D.	NNP	O
24	CD	Pharmacological
micrograms	NNS	Pharmacological
formoterol	JJ	Pharmacological
plus	CC	Pharmacological
2	CD	Pharmacological
puffs	NNS	Pharmacological
placebo	VBP	Pharmacological
;	:	O
E.	NNP	O
12	CD	Pharmacological
micrograms	NNS	Pharmacological
formoterol	JJ	Pharmacological
plus	CC	O
40	CD	Pharmacological
micrograms	NNS	Pharmacological
ipratropium	JJ	Pharmacological
plus	CC	O
1	CD	Control
puff	NN	Control
placebo	NN	Control
;	:	O
F.	NNP	O
4	CD	Control
puffs	NNS	Control
placebo	NN	Control
.	.	O

On	IN	O
each	DT	O
study	NN	O
day	NN	O
,	,	O
spirometric	JJ	O
indices	NNS	O
and	CC	O
vital	JJ	O
signs	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
5	CD	O
,	,	O
10	CD	O
,	,	O
15	CD	O
and	CC	O
60	CD	O
minutes	NNS	O
,	,	O
and	CC	O
hourly	RB	O
thereafter	RB	O
up	IN	O
to	TO	O
and	CC	O
including	VBG	O
12	CD	O
hours	NNS	O
after	IN	O
study	JJ	O
drug	NN	O
administration	NN	O
.	.	O

Mean	NNP	O
peak	JJ	O
FEV1	NNP	O
change	NN	O
(	(	O
primary	JJ	O
endpoint	NN	O
)	)	O
was	VBD	O
maximum	JJ	O
with	IN	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
combination	NN	O
of	IN	O
ipratropium	NN	Pharmacological
and	CC	O
formoterol	NN	Pharmacological
(	(	O
335.2	CD	O
ml	NN	O
,	,	O
SE	NNP	O
24.6	CD	O
)	)	O
,	,	O
and	CC	O
it	PRP	O
differed	VBD	O
significantly	RB	O
from	IN	O
the	DT	O
observed	JJ	O
peak	NN	O
changes	NNS	O
following	VBG	O
single	JJ	O
administration	NN	O
of	IN	O
the	DT	O
two	CD	O
tested	VBD	O
doses	NNS	O
of	IN	O
ipratropium	NN	Pharmacological
(	(	O
p	JJ	O
<	NN	O
0.05	CD	O
and	CC	O
p	VB	O
<	JJ	O
0.05	CD	O
respectively	RB	O
)	)	O
.	.	O

Safety	NN	O
and	CC	O
tolerability	NN	O
were	VBD	O
satisfactory	JJ	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
prostaglandin	NN	O
inhibition	NN	O
by	IN	O
indomethacin	NN	Pharmacological
on	IN	O
blood	NN	O
pressure	NN	O
and	CC	O
renal	JJ	O
function	NN	O
in	IN	O
hypertensive	JJ	O
patients	NNS	O
treated	VBN	O
with	IN	O
cilazapril	NN	Pharmacological
.	.	O

1	CD	O
.	.	O

In	IN	O
a	DT	O
placebo-controlled	JJ	Control
double-blind	JJ	O
cross-over	NN	O
study	NN	O
lasting	VBG	O
6	CD	O
weeks	NNS	O
,	,	O
twenty	JJ	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
placebo	NN	Control
for	IN	O
2	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
oral	JJ	Pharmacological
cilazapril	NN	Pharmacological
2.5	CD	O
mg	NN	O
once	RB	O
a	DT	O
day	NN	O
or	CC	O
oral	JJ	Pharmacological
indomethacin	NN	Pharmacological
50	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
2	CD	O
weeks	NNS	O
.	.	O

Afterwards	NNS	O
they	PRP	O
received	VBD	O
the	DT	O
combination	NN	O
of	IN	O
both	DT	O
drugs	NNS	O
for	IN	O
a	DT	O
further	JJ	O
2	CD	O
weeks	NNS	O
.	.	O

2	CD	O
.	.	O

Cilazapril	NNP	Pharmacological
significantly	RB	O
lowered	VBD	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
24	CD	O
h	NNS	O
post	JJ	O
administration	NN	O
.	.	O

3	CD	O
.	.	O

Indomethacin	NNP	Pharmacological
significantly	RB	O
attenuated	VBD	O
the	DT	O
antihypertensive	JJ	O
activity	NN	O
of	IN	O
cilazapril	NN	Pharmacological
.	.	O

This	DT	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
those	DT	O
patients	NNS	O
who	WP	O
were	VBD	O
treated	VBN	O
for	IN	O
the	DT	O
initial	JJ	O
2	CD	O
weeks	NNS	O
with	IN	O
indomethacin	JJ	Control
plus	CC	Control
placebo	NN	Control
(	(	O
and	CC	O
subsequently	RB	O
with	IN	O
cilazapril	NN	Pharmacological
in	IN	O
addition	NN	O
)	)	O
than	IN	O
in	IN	O
the	DT	O
subjects	NNS	O
who	WP	O
first	RB	O
received	VBD	O
cilazapril	JJ	Control
plus	CC	Control
placebo	NN	Control
and	CC	O
then	RB	O
the	DT	O
combination	NN	O
.	.	O

4	CD	O
.	.	O

Correspondingly	VB	O
the	DT	O
decrease	NN	O
of	IN	O
plasma	JJ	O
renin	NN	O
activity	NN	O
(	(	O
PRA	NNP	O
)	)	O
and	CC	O
urinary	JJ	O
prostaglandin	NN	O
excretion	NN	O
(	(	O
PGE2	NNP	O
)	)	O
was	VBD	O
more	RBR	O
pronounced	JJ	O
in	IN	O
those	DT	O
patients	NNS	O
treated	VBD	O
initially	RB	O
with	IN	O
indomethacin	NN	Pharmacological
.	.	O

5	CD	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
indomethacin	NN	Pharmacological
on	IN	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
cilazapril	NN	Pharmacological
appears	VBZ	O
to	TO	O
depend	VB	O
upon	IN	O
the	DT	O
sequence	NN	O
of	IN	O
drug	NN	O
administration	NN	O
.	.	O

A	DT	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
D-cycloserine	NNP	Pharmacological
added	VBD	O
to	TO	O
conventional	JJ	O
neuroleptics	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
schizophrenia	NN	O
.	.	O

BACKGROUND	NNP	O
In	IN	O
a	DT	O
preliminary	JJ	O
dose-finding	NN	O
study	NN	O
,	,	O
D-cycloserine	NNP	Pharmacological
,	,	O
a	DT	O
partial	JJ	O
agonist	NN	O
at	IN	O
the	DT	O
glycine	NN	O
modulatory	NN	O
site	NN	O
of	IN	O
the	DT	O
glutamatergic	JJ	O
N-methyl-D-aspartate	NNP	O
(	(	O
NMDA	NNP	O
)	)	O
receptor	NN	O
,	,	O
improved	VBN	O
negative	JJ	O
symptoms	NNS	O
and	CC	O
cognitive	JJ	O
function	NN	O
when	WRB	O
added	VBD	O
to	TO	O
conventional	JJ	O
neuroleptics	NNS	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
50	CD	O
mg/d	NN	O
.	.	O

METHODS	NNP	O
Forty-seven	JJ	O
patients	NNS	O
with	IN	O
schizophrenia	JJ	O
meeting	NN	O
criteria	NNS	O
for	IN	O
deficit	NN	O
syndrome	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
D-cycloserine	NNP	Pharmacological
,	,	O
50	CD	O
mg/d	NN	O
(	(	O
n=23	JJ	O
)	)	O
or	CC	O
placebo	NN	Control
(	(	O
n=24	JJ	O
)	)	O
added	VBD	O
to	TO	O
their	PRP$	O
conventional	JJ	O
neuroleptic	JJ	O
for	IN	O
an	DT	O
8-week	JJ	O
,	,	O
double-blind	JJ	O
trial	NN	O
.	.	O

Clinical	JJ	O
assessments	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
weeks	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
8	CD	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
D-cycloserine	NNP	Pharmacological
,	,	O
relevant	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
and	CC	O
homovanillic	JJ	O
acid	NN	O
were	VBD	O
assayed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
weeks	NNS	O
4	CD	O
and	CC	O
8	CD	O
.	.	O

A	DT	O
cognitive	JJ	O
battery	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
week	NN	O
8	CD	O
.	.	O

RESULTS	VB	O
Thirty-nine	JJ	O
patients	NNS	O
completed	VBD	O
the	DT	O
8-week	JJ	O
trial	NN	O
.	.	O

Seven	NNP	O
dropouts	NNS	O
occurred	VBD	O
in	IN	O
the	DT	O
D-cycloserine	NNP	Pharmacological
group	NN	O
and	CC	O
1	CD	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
.	.	O

The	DT	O
mean	JJ	O
reduction	NN	O
in	IN	O
negative	JJ	O
symptoms	NNS	O
with	IN	O
D-cycloserine	NNP	Pharmacological
(	(	O
23	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
with	IN	O
placebo	NN	Control
(	(	O
7	CD	O
%	NN	O
)	)	O
as	IN	O
calculated	VBN	O
by	IN	O
slopes	NNS	O
representing	VBG	O
Scale	NNP	O
for	IN	O
the	DT	O
Assessment	NNP	O
of	IN	O
Negative	NNP	O
Symptoms	NNP	O
(	(	O
SANS	NNP	O
)	)	O
total	JJ	O
scores	NNS	O
.	.	O

Improvement	NNP	O
of	IN	O
negative	JJ	O
symptoms	NNS	O
was	VBD	O
predicted	VBN	O
by	IN	O
low	JJ	O
neuroleptic	JJ	O
dose	NN	O
and	CC	O
low	JJ	O
baseline	NN	O
SANS	NNP	O
total	JJ	O
score	NN	O
.	.	O

No	DT	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
performance	NN	O
on	IN	O
any	DT	O
cognitive	JJ	O
test	NN	O
between	IN	O
groups	NNS	O
or	CC	O
in	IN	O
changes	NNS	O
in	IN	O
any	DT	O
other	JJ	O
clinical	JJ	O
measure	NN	O
.	.	O

Clinical	JJ	O
response	NN	O
did	VBD	O
not	RB	O
correlate	VB	O
significantly	RB	O
with	IN	O
serum	NN	O
amino	NN	O
acid	JJ	O
concentrations	NNS	O
at	IN	O
baseline	NN	O
or	CC	O
with	IN	O
concentrations	NNS	O
of	IN	O
D-cycloserine	NNP	Pharmacological
at	IN	O
weeks	NNS	O
4	CD	O
and	CC	O
8	CD	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
results	NNS	O
support	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
agents	VBZ	O
acting	VBG	O
at	IN	O
the	DT	O
glycine	NN	O
modulatory	NN	O
site	NN	O
of	IN	O
the	DT	O
NMDA	NNP	O
receptor	NN	O
improve	VBP	O
primary	JJ	O
negative	JJ	O
symptoms	NNS	O
.	.	O

Assisted	VBN	Physical
exercise	NN	Physical
and	CC	O
bone	NN	O
strength	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
.	.	O

Studies	NNS	O
have	VBP	O
previously	RB	O
demonstrated	VBN	O
that	IN	O
brief	NN	O
(	(	O
4	CD	O
weeks	NNS	O
)	)	O
passive	VBP	O
range-of-motion	NN	O
exercise	NN	Physical
is	VBZ	O
beneficial	JJ	O
for	IN	O
bone	NN	O
development	NN	O
in	IN	O
very	RB	O
low	JJ	O
birth	NN	O
weight	NN	O
(	(	O
VLBW	NNP	O
)	)	O
preterm	NN	O
infants	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
optimal	JJ	O
duration	NN	O
of	IN	O
exercise	NN	O
for	IN	O
bone	NN	O
development	NN	O
in	IN	O
preterm	JJ	O
infants	NNS	O
is	VBZ	O
yet	RB	O
unknown	JJ	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
present	JJ	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
effect	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
assisted	JJ	Physical
exercise	NN	Physical
on	IN	O
bone	NN	O
strength	NN	O
and	CC	O
metabolism	NN	O
in	IN	O
VLBW	NNP	O
premature	NN	O
infants	NNS	O
.	.	O

Sixteen	JJ	O
infants	NNS	O
(	(	O
mean	JJ	O
+/-	JJ	O
standard	NN	O
error	NN	O
of	IN	O
the	DT	O
mean	JJ	O
birth	NN	O
weight	VBD	O
1,009	CD	O
+/-	JJ	O
55	CD	O
g	NN	O
and	CC	O
gestational	JJ	O
age	NN	O
27.3	CD	O
+/-	JJ	O
0.3	CD	O
weeks	NNS	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
into	IN	O
exercise	NN	O
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
and	CC	O
control	NN	Control
(	(	O
n	JJ	O
=	NNP	O
8	CD	O
)	)	O
groups	NNS	O
.	.	O

The	DT	O
intervention	NN	O
started	VBD	O
at	IN	O
the	DT	O
first	JJ	O
week	NN	O
of	IN	O
life	NN	O
and	CC	O
involved	VBD	O
8	CD	O
weeks	NNS	O
of	IN	O
daily	JJ	Physical
passive	JJ	Physical
extension	NN	Physical
and	CC	Physical
flexion	NN	Physical
range-of-motion	NN	Physical
exercise	NN	Physical
of	IN	O
the	DT	O
upper	JJ	O
and	CC	O
lower	JJR	O
extremities	NNS	O
.	.	O

Biochemical	JJ	O
markers	NNS	O
of	IN	O
bone	NN	O
turnover	NN	O
were	VBD	O
measured	VBN	O
at	IN	O
enrollment	NN	O
and	CC	O
after	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Bone	NNP	O
strength	NN	O
was	VBD	O
measured	VBN	O
weekly	JJ	O
by	IN	O
quantitative	JJ	O
ultrasound	JJ	O
measurement	NN	O
of	IN	O
tibial	JJ	O
bone	NN	O
speed	NN	O
of	IN	O
sound	NN	O
(	(	O
SOS	NNP	O
)	)	O
.	.	O

Bone	NNP	O
SOS	NNP	O
decreased	VBD	O
significantly	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
-108.1	JJ	O
+/-	JJ	O
33.7	CD	O
m/second	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
while	IN	O
remaining	VBG	O
stable	JJ	O
in	IN	O
the	DT	O
exercise	NN	O
group	NN	O
(	(	O
11.3	CD	O
+/-	JJ	O
22.8	CD	O
m/second	NN	O
)	)	O
.	.	O

The	DT	O
main	JJ	O
beneficial	JJ	O
effect	NN	O
of	IN	O
exercise	NN	O
occurred	VBN	O
in	IN	O
the	DT	O
first	JJ	O
4	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
intervention	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
bone	NN	O
turnover	NN	O
marker	NN	O
changes	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

There	EX	O
is	VBZ	O
a	DT	O
significant	JJ	O
postnatal	JJ	O
decrease	NN	O
in	IN	O
bone	NN	O
SOS	NNP	O
in	IN	O
VLBW	NNP	O
preterm	NN	O
infants	NNS	O
.	.	O

Eight	NNP	O
weeks	NNS	O
of	IN	O
assisted	JJ	O
range-of-motion	NN	O
exercise	NN	Physical
attenuates	VBZ	O
the	DT	O
decrease	NN	O
in	IN	O
bone	NN	O
strength	NN	O
and	CC	O
may	MD	O
decrease	VB	O
the	DT	O
risk	NN	O
of	IN	O
osteopenia	NN	O
in	IN	O
premature	JJ	O
infants	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
of	IN	O
5-fluorouracil	JJ	Pharmacological
,	,	O
with	IN	O
or	CC	O
without	IN	O
human	JJ	Pharmacological
interferon-beta	NN	Pharmacological
,	,	O
for	IN	O
advanced	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

This	DT	O
study	NN	O
compared	VBN	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
5-fluorouracil	JJ	Pharmacological
(	(	Pharmacological
5-FU	JJ	Pharmacological
)	)	Pharmacological
monotherapy	NN	Pharmacological
to	TO	O
that	DT	O
of	IN	O
5-FU	JJ	Pharmacological
combined	VBN	Pharmacological
with	IN	Pharmacological
natural	JJ	Pharmacological
human	JJ	Pharmacological
interferon-beta	NN	Pharmacological
(	(	Pharmacological
IFN-beta	NNP	Pharmacological
)	)	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
unresectable	JJ	O
,	,	O
advanced	JJ	O
colorectal	JJ	O
carcinoma	NN	O
.	.	O

Forty-nine	JJ	O
chemotherapy-naive	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
or	CC	O
to	TO	O
the	DT	O
combination	NN	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	JJ	O
)	)	O
day	NN	O
(	(	O
-1	JJ	O
)	)	O
5-FU	NN	O
for	IN	O
5	CD	O
days	NNS	O
by	IN	O
continuous	JJ	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O

)	)	O
infusion	NN	O
,	,	O
followed	VBD	O
after	IN	O
day	NN	O
15	CD	O
by	IN	O
a	DT	O
weekly	JJ	O
i.v	NN	O
.	.	O

bolus	NN	O
of	IN	O
750	CD	O
mg	NNS	O
m	NN	O
(	(	O
-2	NNP	O
)	)	O
.	.	O

IFN-beta	NNP	Pharmacological
was	VBD	O
injected	VBN	O
intramuscularly	RB	O
three	CD	O
times	NNS	O
weekly	RB	O
at	IN	O
9	CD	O
M	NNP	O
IU	NNP	O
.	.	O

Treatment	NNP	O
continued	VBD	O
for	IN	O
52	CD	O
weeks	NNS	O
,	,	O
or	CC	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
intolerable	JJ	O
toxicity	NN	O
.	.	O

Clinical	JJ	O
endpoints	NNS	O
were	VBD	O
tumor	JJ	O
response	NN	O
,	,	O
time	NN	O
to	TO	O
progression	NN	O
,	,	O
survival	NN	O
and	CC	O
toxicity	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
IFN-3	NNP	Pharmacological
to	TO	Pharmacological
5-FU	CD	Pharmacological
significantly	RB	O
improved	VBN	O
response	NN	O
rate	NN	O
(	(	O
33.3	CD	O
%	NN	O
vs	JJ	O
4.5	CD	O
%	NN	O
for	IN	O
evaluable	JJ	O
patients	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.021	CD	O
)	)	O
,	,	O
time	NN	O
to	TO	O
progression	NN	O
(	(	O
median	JJ	O
7.2	CD	O
vs	JJ	O
4.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.0435	CD	O
)	)	O
,	,	O
and	CC	O
survival	JJ	O
time	NN	O
(	(	O
median	JJ	O
15.9	CD	O
vs	JJ	O
7.2	CD	O
months	NNS	O
;	:	O
P	NNP	O
=	NNP	O
0.038	CD	O
)	)	O
without	IN	O
significantly	RB	O
increasing	VBG	O
toxicity	NN	O
compared	VBN	O
to	TO	O
5-FU	JJ	O
alone	RB	O
.	.	O

Cumulative	JJ	O
5-FU	JJ	Pharmacological
dose	NN	O
was	VBD	O
higher	JJR	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
:	:	O
more	JJR	O
patients	NNS	O
receiving	VBG	O
monotherapy	JJ	O
discontinued	VBN	O
treatment	NN	O
because	IN	O
of	IN	O
disease	NN	O
progression	NN	O
.	.	O

Fever	NNP	O
was	VBD	O
more	RBR	O
frequent	JJ	O
with	IN	O
combined	JJ	O
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
;	:	O
there	EX	O
were	VBD	O
no	DT	O
other	JJ	O
differences	NNS	O
in	IN	O
toxicity	NN	O
.	.	O

The	DT	O
only	JJ	O
grade	NN	O
IV	NNP	O
toxicity	NN	O
observed	VBD	O
was	VBD	O
neutropenia	JJ	O
(	(	O
two	CD	O
patients	NNS	O
per	IN	O
group	NN	O
)	)	O
.	.	O

A	DT	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
has	VBZ	O
been	VBN	O
initiated	VBN	O
to	TO	O
confirm	VB	O
the	DT	O
synergy	NN	O
between	IN	O
5-FU	JJ	Pharmacological
and	CC	O
IFN-beta	NNP	Pharmacological
.	.	O

Speech	NN	Educational
following	VBG	Educational
sign	JJ	Educational
language	NN	Educational
training	NN	Educational
in	IN	O
autistic	JJ	O
children	NNS	O
with	IN	O
minimal	JJ	O
verbal	JJ	O
language	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
test	VB	O
the	DT	O
main	JJ	O
and	CC	O
interaction	JJ	O
effects	NNS	O
of	IN	O
training	VBG	O
condition	NN	O
and	CC	O
pretreatment-elicited	JJ	O
verbal	JJ	O
imitation	NN	O
ability	NN	O
when	WRB	O
predicting	VBG	O
spoken	JJ	O
language	NN	O
use	NN	O
during	IN	O
language	NN	Educational
training	NN	Educational
of	IN	O
60	CD	O
minimally	RB	O
verbal	JJ	O
autistic	JJ	O
children	NNS	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
Speech	NNP	Educational
Alone	NNP	Educational
,	,	Educational
Sign	NNP	Educational
Alone	NNP	Educational
,	,	Educational
Simultaneous	NNP	Educational
Presentation	NNP	Educational
of	IN	Educational
Sign	NNP	Educational
and	CC	Educational
Speech	NNP	Educational
,	,	Educational
and	CC	Educational
Alternating	NNP	Educational
Presentation	NNP	Educational
of	IN	Educational
Sign	NNP	Educational
and	CC	Educational
Speech	NNP	Educational
training	NN	Educational
conditions	NNS	Educational
.	.	Educational

Speech	NNP	Educational
Alone	RB	Educational
,	,	Educational
Simultaneous	JJ	Educational
Presentation	NNP	Educational
,	,	O
and	CC	O
Alternating	NNP	Educational
Presentation	NNP	Educational
condition	NN	O
facilitated	VBD	O
more	RBR	O
child-initiated	JJ	O
speech	NN	O
during	IN	O
treatment	NN	O
than	IN	O
did	VBD	O
the	DT	O
Sign	NNP	Educational
Alone	NNP	Educational
condition	NN	O
.	.	O

Regardless	NNP	O
of	IN	O
training	VBG	O
condition	NN	O
,	,	O
pretreatment	NN	O
verbal	JJ	O
imitation	NN	O
ability	NN	O
positively	RB	O
predicted	VBD	O
the	DT	O
size	NN	O
of	IN	O
child-initiated	JJ	O
spoken	JJ	O
vocabulary	JJ	O
observed	VBD	O
during	IN	O
training	NN	O
.	.	O

Exploratory	JJ	O
analyses	NNS	O
indicated	VBD	O
that	IN	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
verbal	JJ	O
imitation	NN	O
,	,	O
pretreatment	JJ	O
age	NN	O
and	CC	O
IQ	NNP	O
may	MD	O
also	RB	O
predict	VB	O
spoken	JJ	O
language	NN	O
developed	VBD	O
during	IN	O
training	NN	O
.	.	O

An	DT	O
empirical	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Disease	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
setting	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
Chronic	NNP	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
CRQ	NNP	O
)	)	O
and	CC	O
the	DT	O
St	NNP	O
George	NNP	O
's	POS	O
Respiratory	NNP	O
Questionnaire	NNP	O
(	(	O
SGRQ	NNP	O
)	)	O
are	VBP	O
the	DT	O
two	CD	O
most	JJS	O
widely	RB	O
used	VBN	O
quality	NN	O
of	IN	O
life	NN	O
questionnaires	NNS	O
in	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
.	.	O

A	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
compare	VB	O
directly	RB	O
the	DT	O
self-administered	JJ	O
version	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
with	IN	O
respect	NN	O
to	TO	O
feasibility	NN	O
,	,	O
internal	JJ	O
consistency	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
sensitivity	NN	O
to	TO	O
changes	NNS	O
resulting	VBG	O
from	IN	O
bronchodilator	NN	O
therapy	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	CD	O
and	CC	O
forty	VB	O
four	CD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
or	CC	O
severe	JJ	O
COPD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
three	CD	O
months	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
either	DT	O
salmeterol	NN	Pharmacological
,	,	O
salmeterol	NN	Pharmacological
+	NNP	O
ipratropium	NN	Pharmacological
bromide	NN	Pharmacological
,	,	O
or	CC	O
placebo	NN	Control
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
12	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
proportions	NNS	O
of	IN	O
missing	VBG	O
values	NNS	O
per	IN	O
patient	NN	O
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
0.54	CD	O
%	NN	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
2	CD	O
%	NN	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

The	DT	O
internal	JJ	O
consistency	NN	O
was	VBD	O
good	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
(	(	O
Cronbach	NNP	O
's	POS	O
alpha	NN	O
coefficients	NNS	O
>	VBP	O
/=	$	O
0.84	CD	O
for	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
>	NNP	O
/=	NNP	O
0.76	CD	O
for	IN	O
the	DT	O
SGRQ	NNP	O
)	)	O
.	.	O

Factor	NNP	O
analysis	NN	O
confirmed	VBD	O
the	DT	O
original	JJ	O
domain	NN	O
structure	NN	O
of	IN	O
the	DT	O
CRQ	NNP	O
but	CC	O
not	RB	O
of	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

Correlations	NNS	O
with	IN	O
forced	JJ	O
expiratory	NN	O
volume	NN	O
in	IN	O
one	CD	O
second	NN	O
(	(	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
)	)	O
%	NN	O
predicted	VBN	O
and	CC	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
rate	NN	O
(	(	O
PEFR	NNP	O
)	)	O
were	VBD	O
low	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
but	CC	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
than	IN	O
for	IN	O
the	DT	O
CRQ	NNP	O
.	.	O

The	DT	O
ability	NN	O
to	TO	O
discriminate	VB	O
between	IN	O
subjects	NNS	O
with	IN	O
different	JJ	O
levels	NNS	O
of	IN	O
FEV	NNP	O
(	(	O
1	CD	O
)	)	O
was	VBD	O
somewhat	RB	O
better	JJR	O
for	IN	O
the	DT	O
SGRQ	NNP	O
.	.	O

The	DT	O
correlations	NNS	O
with	IN	O
symptom	JJ	O
scores	NNS	O
were	VBD	O
comparable	JJ	O
for	IN	O
both	DT	O
questionnaires	NNS	O
.	.	O

Cross	NNP	O
sectionally	RB	O
,	,	O
the	DT	O
scores	NNS	O
of	IN	O
the	DT	O
two	CD	O
questionnaires	NNS	O
were	VBD	O
moderately	RB	O
to	TO	O
highly	RB	O
correlated	VBN	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.35	CD	O
to	TO	O
0.72	CD	O
)	)	O
.	.	O

Longitudinally	RB	O
,	,	O
these	DT	O
correlations	NNS	O
were	VBD	O
lower	JJR	O
(	(	O
coefficients	NNS	O
ranged	VBD	O
from	IN	O
0.17	CD	O
to	TO	O
0.54	CD	O
)	)	O
but	CC	O
were	VBD	O
still	RB	O
significant	JJ	O
.	.	O

The	DT	O
CRQ	NNP	O
total	NN	O
and	CC	O
emotions	NNS	O
score	NN	O
and	CC	O
the	DT	O
SGRQ	NNP	O
symptoms	NNS	O
score	NN	O
were	VBD	O
the	DT	O
most	RBS	O
responsive	JJ	O
to	TO	O
change	VB	O
.	.	O

The	DT	O
SGRQ	NNP	O
symptoms	NNS	O
domain	NN	O
was	VBD	O
the	DT	O
only	JJ	O
domain	NN	O
where	WRB	O
the	DT	O
improvement	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
combination	NN	O
treatment	NN	O
crossed	VBD	O
the	DT	O
threshold	NN	O
for	IN	O
clinical	JJ	O
relevance	NN	O
.	.	O

CONCLUSIONS	NNP	O
Since	IN	O
this	DT	O
analysis	NN	O
of	IN	O
reliability	NN	O
,	,	O
validity	NN	O
,	,	O
and	CC	O
responsiveness	NN	O
to	TO	O
change	VB	O
did	VBD	O
not	RB	O
clearly	RB	O
favour	VBP	O
one	CD	O
instrument	NN	O
above	IN	O
the	DT	O
other	JJ	O
,	,	O
the	DT	O
choice	NN	O
between	IN	O
the	DT	O
CRQ	NNP	O
and	CC	O
the	DT	O
SGRQ	NNP	O
can	MD	O
be	VB	O
based	VBN	O
on	IN	O
other	JJ	O
considerations	NNS	O
such	JJ	O
as	IN	O
the	DT	O
required	JJ	O
sample	NN	O
size	NN	O
or	CC	O
the	DT	O
availability	NN	O
of	IN	O
reference	NN	O
values	NNS	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
a	DT	O
24-h	JJ	O
psychological	JJ	Educational
training	NN	Educational
program	NN	Educational
on	IN	O
attitudes	NNS	O
,	,	O
communication	NN	O
skills	NNS	O
and	CC	O
occupational	JJ	O
stress	NN	O
in	IN	O
oncology	NN	O
:	:	O
a	DT	O
randomised	JJ	O
study	NN	O
.	.	O

The	DT	O
usefulness	NN	O
of	IN	O
psychological	JJ	Educational
training	NN	Educational
programs	NNS	Educational
(	(	Educational
P.T.P	NNP	Educational
.	.	Educational

)	)	Educational
in	IN	O
health	NN	O
care	NN	O
settings	NNS	O
devoted	VBN	O
to	TO	O
cancer	NN	O
care	NN	O
is	VBZ	O
beginning	VBG	O
to	TO	O
be	VB	O
recognised	VBN	O
but	CC	O
their	PRP$	O
content	NN	O
,	,	O
form	NN	O
and	CC	O
effectiveness	VB	O
need	NN	O
further	JJ	O
investigation	NN	O
.	.	O

Seventy-two	JJ	O
oncology	NN	O
nurses	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
24-h	JJ	Educational
P.T.P	NNP	Educational
.	.	Educational

or	CC	Control
to	TO	Control
a	DT	Control
waiting	VBG	Control
list	NN	Control
period	NN	Control
.	.	O

Attitudes	NNS	O
were	VBD	O
assessed	VBN	Educational
by	IN	Educational
a	DT	Educational
semantic	JJ	Educational
differential	NN	Educational
questionnaire	NN	Educational
,	,	O
occupational	JJ	Educational
stress	NN	Educational
was	VBD	Educational
assessed	VBN	Educational
by	IN	Educational
the	DT	Educational
Nursing	NNP	Educational
Stress	NNP	Educational
Scale	NNP	Educational
and	CC	Educational
communication	NN	Educational
skills	NNS	Educational
were	VBD	Educational
assessed	VBN	Educational
by	IN	Educational
standardised	JJ	Educational
videotaped	VBD	Educational
role-playing	NN	Educational
exercises	NNS	Educational
.	.	O

These	DT	O
were	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
trained	JJ	O
(	(	O
T.S	NNP	O
.	.	O

)	)	O
and	CC	O
control	NN	O
subjects	NNS	O
(	(	O
C.S.	NNP	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
show	VBP	O
a	DT	O
significant	JJ	O
training	NN	O
effect	NN	O
on	IN	O
attitudes	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
,	,	O
especially	RB	O
on	IN	O
those	DT	O
related	VBN	O
to	TO	O
self	VB	O
concept	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
level	NN	O
of	IN	O
occupational	JJ	O
stress	NN	O
related	VBN	O
to	TO	O
inadequate	VB	O
preparation	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Limited	VBN	O
changes	NNS	O
were	VBD	O
found	VBN	O
regarding	VBG	O
post-training	JJ	O
communication	NN	O
skills	NNS	O
.	.	O

T.S	NNP	O
.	.	O

were	VBD	O
significantly	RB	O
more	RBR	O
in	IN	O
control	NN	O
of	IN	O
the	DT	O
interview	NN	O
than	IN	O
C.S	NNP	O
.	.	O

(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
24-h	JJ	O
P.T.P	NNP	Educational
.	.	O

assessed	VBN	O
here	RB	O
are	VBP	O
effective	JJ	O
.	.	O

The	DT	O
data	NN	O
also	RB	O
demonstrate	VBP	O
the	DT	O
need	NN	O
to	TO	O
consolidate	VB	O
the	DT	O
skills	NNS	O
acquired	VBN	O
by	IN	O
regular	JJ	O
post-training	JJ	O
sessions	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
Thai	NNP	O
traditional	JJ	O
massage	NN	O
on	IN	O
autistic	JJ	O
children	NNS	O
's	POS	O
behavior	NN	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
access	NN	O
whether	IN	O
there	EX	O
were	VBD	O
any	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
Thai	NNP	Educational
Traditional	NNP	Educational
Massage	NNP	Educational
(	(	Educational
TTM	NNP	Educational
)	)	Educational
on	IN	O
major	JJ	O
behavioral	JJ	O
and	CC	O
emotional	JJ	O
disturbances	NNS	O
in	IN	O
Thai	NNP	O
autistic	JJ	O
children	NNS	O
.	.	O

DESIGN	NN	O
This	DT	O
was	VBD	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
study	NN	O
.	.	O

SETTINGS/LOCATION	NNP	O
The	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
at	IN	O
the	DT	O
Rehabilitation	NNP	O
Centre	NNP	O
of	IN	O
the	DT	O
Thai	NNP	O
Red	NNP	O
Cross	NNP	O
Society	NNP	O
.	.	O

SUBJECTS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
60	CD	O
autistic	JJ	O
children	NNS	O
between	IN	O
the	DT	O
ages	NNS	O
of	IN	O
3	CD	O
and	CC	O
10	CD	O
completed	VBD	O
this	DT	O
study	NN	O
.	.	O

INTERVENTIONS	NNP	O
Standard	NNP	Educational
sensory	JJ	Educational
integration	NN	Educational
therapy	NN	Educational
(	(	Educational
SI	NNP	Educational
)	)	Educational
was	VBD	O
compared	VBN	O
to	TO	O
the	DT	O
SI	NNP	O
with	IN	O
TTM	NNP	Educational
treatments	NNS	O
.	.	O

OUTCOME	NNP	O
MEASURES	NNP	O
Parents	NNP	O
and	CC	O
teachers	NNS	O
assessed	VBD	O
major	JJ	O
behavior	NN	O
disturbances	NNS	O
using	VBG	O
the	DT	O
Conners	NNPS	O
'	POS	O
Rating	VBG	O
Scales	NNS	O
at	IN	O
0	CD	O
and	CC	O
8	CD	O
weeks	NNS	O
.	.	O

Sleep	JJ	O
Diary	NNP	O
(	(	O
SD	NNP	O
)	)	O
,	,	O
recorded	VBN	O
by	IN	O
the	DT	O
parents	NNS	O
,	,	O
assessed	VBD	O
the	DT	O
patient	NN	O
's	POS	O
sleeping	NN	O
patterns	NNS	O
every	DT	O
week	NN	O
.	.	O

RESULTS	NNP	O
Sixty	NNP	O
(	(	O
60	CD	O
)	)	O
autistic	JJ	O
children	NNS	O
,	,	O
mean	JJ	O
age	NN	O
4.67	CD	O
+/-	JJ	O
1.82	CD	O
,	,	O
were	VBD	O
recruited	VBN	O
.	.	O

No	DT	O
statistical	JJ	O
differences	NNS	O
were	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
demographic	JJ	O
and	CC	O
baseline	JJ	O
data	NN	O
among	IN	O
both	DT	O
groups	NNS	O
.	.	O

From	IN	O
both	CC	O
the	DT	O
Conners	NNPS	O
'	POS	O
Teacher	NNP	O
Questionnaire	NNP	O
and	CC	O
SD	NNP	O
,	,	O
statistical	JJ	O
improvement	NN	O
was	VBD	O
detected	VBN	O
for	IN	O
conduct	NN	O
problem	NN	O
,	,	O
hyperactivity	NN	O
,	,	O
inattention-passivity	NN	O
,	,	O
hyperactivity	NN	O
index	NN	O
,	,	O
and	CC	O
sleeping	VBG	O
behavior	NN	O
.	.	O

However	RB	O
,	,	O
results	NNS	O
from	IN	O
the	DT	O
Conners	NNP	O
'	POS	O
Parent	NNP	O
Questionnaire	NNP	O
revealed	VBD	O
an	DT	O
improvement	NN	O
only	RB	O
for	IN	O
anxiety	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
the	DT	O
massage	NN	O
group	NN	O
,	,	O
whereas	IN	O
when	WRB	O
both	DT	O
groups	NNS	O
were	VBD	O
compared	VBN	O
,	,	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
conduct	NN	O
problem	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.03	CD	O
)	)	O
and	CC	O
anxiety	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
was	VBD	O
found	VBN	O
.	.	O

Results	NNS	O
indicated	VBD	O
that	IN	O
TTM	NNP	O
may	MD	O
have	VB	O
a	DT	O
positive	JJ	O
effect	NN	O
in	IN	O
improving	VBG	O
stereotypical	JJ	O
behaviors	NNS	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Over	IN	O
a	DT	O
period	NN	O
of	IN	O
8	CD	O
weeks	NNS	O
,	,	O
our	PRP$	O
findings	NNS	O
suggested	VBD	O
that	IN	O
TTM	NNP	O
could	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
complementary	JJ	O
therapy	NN	O
for	IN	O
autistic	JJ	O
children	NNS	O
in	IN	O
Thailand	NNP	O
.	.	O

Prophylactic	JJ	Pharmacological
lidocaine	NN	Pharmacological
in	IN	O
the	DT	O
early	JJ	O
phase	NN	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Four	CD	O
hundred	VBD	O
two	CD	O
patients	NNS	O
with	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
seen	VBN	O
within	IN	O
6	CD	O
hours	NNS	O
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
entered	VBD	O
a	DT	O
double-blind	JJ	O
randomized	JJ	O
trial	NN	O
of	IN	O
lidocaine	NN	Pharmacological
vs	NN	O
placebo	NN	Control
.	.	O

During	IN	O
the	DT	O
1	CD	O
hour	NN	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
the	DT	O
incidence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
or	CC	O
sustained	VBN	O
ventricular	JJ	O
tachycardia	NN	O
among	IN	O
the	DT	O
204	CD	O
patients	NNS	O
with	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
low	JJ	O
,	,	O
1.5	CD	O
%	NN	O
.	.	O

Lidocaine	NNP	Pharmacological
,	,	O
given	VBN	O
in	IN	O
a	DT	O
300	CD	O
mg	NN	O
dose	VBD	O
intramuscularly	RB	O
followed	VBN	O
by	IN	O
100	CD	O
mg	NN	O
intravenously	RB	O
,	,	O
did	VBD	O
not	RB	O
prevent	VB	O
sustained	JJ	O
ventricular	JJ	O
tachycardia	NN	O
,	,	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
warning	VBG	O
arrhythmias	NNS	O
between	IN	O
15	CD	O
and	CC	O
45	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	NN	Pharmacological
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
average	JJ	O
plasma	JJ	O
lidocaine	JJ	Pharmacological
level	NN	O
10	CD	O
minutes	NNS	O
after	IN	O
administration	NN	O
for	IN	O
patients	NNS	O
without	IN	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
for	IN	O
patients	NNS	O
with	IN	O
an	DT	O
acute	JJ	O
infarction	NN	O
.	.	O

The	DT	O
mean	JJ	O
plasma	NN	O
lidocaine	JJ	Pharmacological
level	NN	O
of	IN	O
patients	NNS	O
on	IN	O
beta-blocking	JJ	O
agents	NNS	O
was	VBD	O
no	DT	O
different	JJ	O
from	IN	O
that	DT	O
in	IN	O
patients	NNS	O
not	RB	O
on	IN	O
beta	NN	O
blocking	VBG	O
agents	NNS	O
.	.	O

During	IN	O
the	DT	O
1-hour	JJ	O
study	NN	O
period	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
side	NN	O
effects	NNS	O
was	VBD	O
significantly	RB	O
greater	JJR	O
in	IN	O
the	DT	O
lidocaine	NN	O
group	NN	O
,	,	O
hypotension	NN	O
occurred	VBD	O
in	IN	O
11	CD	O
patients	NNS	O
,	,	O
nine	CD	O
of	IN	O
whom	WP	O
had	VBD	O
received	VBN	O
lidocaine	NN	O
,	,	O
and	CC	O
four	CD	O
patients	NNS	O
died	VBD	O
from	IN	O
asystole	NN	O
,	,	O
three	CD	O
of	IN	O
whom	WP	O
had	VBD	O
had	VBN	O
lidocaine	NN	Pharmacological
.	.	O

We	PRP	O
can	MD	O
not	RB	O
advocate	VB	O
the	DT	O
administration	NN	O
of	IN	O
lidocaine	JJ	Pharmacological
prophylactically	RB	O
in	IN	O
the	DT	O
early	JJ	O
hours	NNS	O
of	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
.	.	O

Venlafaxine	NNP	Pharmacological
versus	NN	O
clonidine	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hot	JJ	O
flashes	NNS	O
in	IN	O
breast	NN	O
cancer	NN	O
patients	NNS	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
cross-over	NN	O
study	NN	O
.	.	O

PURPOSE	NNP	O
Breast	NNP	O
cancer	NN	O
patients	NNS	O
with	IN	O
treatment-induced	JJ	O
menopause	NN	O
experience	NN	O
frequent	NN	O
and	CC	O
severe	JJ	O
hot	JJ	O
flashes	NNS	O
(	(	O
HF	NNP	O
)	)	O
.	.	O

We	PRP	O
compared	VBN	O
venlafaxine	NN	Pharmacological
and	CC	O
clonidine	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HF	NNP	O
with	IN	O
regard	NN	O
to	TO	O
side	VB	O
effects	NNS	O
,	,	O
efficacy	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
sexual	JJ	O
functioning	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
a	DT	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
study	NN	O
,	,	O
60	CD	O
breast	NN	O
cancer	NN	O
patients	NNS	O
experiencing	VBG	O
HF	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
8	CD	O
weeks	NNS	O
venlafaxine	NN	Pharmacological
followed	VBN	O
by	IN	O
2	CD	O
weeks	NNS	O
wash-out	RB	O
,	,	O
and	CC	O
8	CD	O
weeks	NNS	O
clonidine	NN	Pharmacological
or	CC	O
vice	NN	O
versa	NN	O
.	.	O

HF	NNP	O
frequency	NN	O
and	CC	O
severity	NN	O
,	,	O
side	NN	O
effects	NNS	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
sexuality	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Thirty	NNP	O
patients	NNS	O
started	VBD	O
with	IN	O
venlafaxine	NN	Pharmacological
and	CC	O
30	CD	O
with	IN	O
clonidine	NN	Pharmacological
.	.	O

Premature	JJ	O
discontinuation	NN	O
for	IN	O
toxicity	NN	O
occurred	VBD	O
in	IN	O
14/59	CD	O
during	IN	O
venlafaxine	NN	Pharmacological
and	CC	O
5/53	CD	O
during	IN	O
clonidine	NN	Pharmacological
(	(	O
P	NNP	O
=	NNP	O
.038	NNP	O
)	)	O
.	.	O

Venlafaxine	NNP	Pharmacological
induced	VBD	O
more	JJR	O
side	JJ	O
effects	NNS	O
.	.	O

Median	JJ	O
reduction	NN	O
in	IN	O
HF	NNP	O
score	NN	O
was	VBD	O
49	CD	O
%	NN	O
for	IN	O
venlafaxine	NN	Pharmacological
and	CC	O
55	CD	O
%	NN	O
for	IN	O
clonidine	NN	Pharmacological
(	(	O
ns	JJ	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Venlafaxine	NNP	Pharmacological
and	CC	O
clonidine	NN	Pharmacological
are	VBP	O
equally	RB	O
,	,	O
but	CC	O
moderately	RB	O
effective	JJ	O
in	IN	O
HF	NNP	O
reduction	NN	O
.	.	O

Side	NN	O
effects	NNS	O
are	VBP	O
the	DT	O
main	JJ	O
reason	NN	O
for	IN	O
drug	NN	O
discontinuation	NN	O
,	,	O
occurring	VBG	O
more	RBR	O
often	RB	O
with	IN	O
venlafaxine	NN	Pharmacological
.	.	O

The	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
duration	NN	O
on	IN	O
defibrillation	NN	O
efficacy	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
prospectively	RB	O
investigate	VB	O
the	DT	O
influence	NN	O
of	IN	O
ventricular	JJ	O
fibrillation	NN	O
(	(	O
VF	NNP	O
)	)	O
durations	NNS	O
of	IN	O
5	CD	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
on	IN	O
the	DT	O
defibrillation	NN	O
threshold	NN	O
(	(	O
DFT	NNP	O
)	)	O
during	IN	O
implantable	JJ	O
cardioverter-defibrillator	NN	O
(	(	O
ICD	NNP	O
)	)	O
implantation	NN	O
.	.	O

BACKGROUND	NNP	O
Although	IN	O
the	DT	O
DFT	NNP	O
using	VBG	O
monophasic	JJ	O
waveforms	NNS	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
with	IN	O
VF	NNP	O
duration	NN	O
in	IN	O
humans	NNS	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
VF	NNP	O
duration	NN	O
on	IN	O
defibrillation	NN	O
efficacy	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

METHODS	NNP	O
Thirty	NNP	O
patients	NNS	O
undergoing	VBG	O
primary	JJ	O
ICD	NNP	O
implantation	NN	O
or	CC	O
pulse	JJ	O
generator	NN	O
replacement	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
have	VB	O
the	DT	O
DFT	NNP	Physical
determined	VBD	Physical
using	VBG	Physical
biphasic	JJ	Physical
shocks	NNS	Physical
at	IN	O
two	CD	O
durations	NNS	O
of	IN	O
VF	NNP	Physical
each	DT	O
(	(	O
5	CD	O
and	CC	O
10	CD	O
s	NN	O
,	,	O
10	CD	O
and	CC	O
20	CD	O
s	NN	O
or	CC	O
5	CD	O
and	CC	O
20	CD	O
s	NN	O
)	)	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
mean	JJ	O
DFT	NNP	O
comparing	VBG	O
VF	NNP	O
durations	NNS	O
of	IN	O
5	CD	O
s	NNS	O
(	(	O
9.5+/-6.0	CD	O
J	NNP	O
)	)	O
and	CC	O
10	CD	O
s	NN	O
(	(	O
10.8+/-7.0	JJ	O
J	NNP	O
)	)	O
(	(	O
p=0.4	NN	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
DFT	NNP	O
significantly	RB	O
increased	VBD	O
from	IN	O
10.9+/-6.1	JJ	O
J	NNP	O
at	IN	O
10	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
12.6+/-5.6	JJ	O
J	NNP	O
(	(	O
p=0.03	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
,	,	O
and	CC	O
from	IN	O
7.0+/-3.5	JJ	O
J	NNP	O
at	IN	O
5	CD	O
s	NN	O
of	IN	O
VF	NNP	O
to	TO	O
10.5+/-6.3	JJ	O
J	NNP	O
(	(	O
p=0.04	NN	O
)	)	O
at	IN	O
20	CD	O
s	NN	O
of	IN	O
VF	NNP	O
.	.	O

An	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	O
was	VBD	O
observed	VBN	O
in	IN	O
14	CD	O
patients	NNS	O
as	IN	O
VF	NNP	O
duration	NN	O
increased	VBD	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
clinical	JJ	O
characteristics	NNS	O
that	WDT	O
differentiated	VBD	O
patients	NNS	O
with	IN	O
and	CC	O
without	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
DFT	NNP	O
.	.	O

CONCLUSIONS	NNP	O
Defibrillation	NNP	O
efficacy	NN	O
decreases	VBZ	O
with	IN	O
increasing	VBG	O
VF	NNP	O
duration	NN	O
using	VBG	O
biphasic	JJ	O
waveforms	NNS	O
in	IN	O
humans	NNS	O
.	.	O

Ventricular	JJ	O
fibrillation	NN	O
durations	NNS	O
greater	JJR	O
than	IN	O
10	CD	O
s	NN	O
may	MD	O
negatively	RB	O
affect	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
ICD	NNP	O
therapy	NN	O
.	.	O

Left	NNP	Surgical
internal	JJ	Surgical
thoracic	NN	Surgical
artery-radial	JJ	Surgical
artery	NN	Surgical
composite	JJ	Surgical
grafts	NNS	Surgical
as	IN	O
the	DT	O
technique	NN	O
of	IN	O
choice	NN	O
for	IN	O
myocardial	JJ	O
revascularization	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
evaluation	NN	O
.	.	O

OBJECTIVES	IN	O
The	DT	O
technique	NN	O
of	IN	O
choice	NN	O
for	IN	O
myocardial	JJ	O
revascularization	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
remains	VBZ	O
a	DT	O
debated	JJ	O
issue	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
potential	JJ	O
advantages	NNS	O
of	IN	O
the	DT	O
use	NN	O
of	IN	O
left	JJ	Surgical
internal	JJ	Surgical
thoracic	NN	Surgical
artery-radial	JJ	Surgical
artery	NN	Surgical
composite	JJ	Surgical
grafts	NNS	Surgical
compared	VBN	O
with	IN	O
conventional	JJ	Surgical
coronary	JJ	Surgical
artery	NN	Surgical
bypass	NN	Surgical
grafts	NNS	Surgical
in	IN	O
elderly	JJ	O
patients	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
prospectively	RB	O
enrolled	VBD	O
160	CD	O
patients	NNS	O
aged	VBD	O
more	JJR	O
than	IN	O
70	CD	O
years	NNS	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
isolated	JJ	Surgical
myocardial	JJ	Surgical
revascularization	NN	Surgical
.	.	O

Patients	NNS	O
were	VBD	O
assigned	VBN	O
at	IN	O
random	NN	O
to	TO	O
group	NN	O
1	CD	O
,	,	O
80	CD	O
patients	NNS	O
undergoing	JJ	O
total	JJ	Surgical
arterial	JJ	Surgical
revascularization	NN	Surgical
(	(	Surgical
left	VBN	Surgical
internal	JJ	Surgical
thoracic	NN	Surgical
artery	NN	Surgical
on	IN	Surgical
left	JJ	Surgical
anterior	JJ	Surgical
descending	VBG	Surgical
coronary	JJ	Surgical
artery	NN	Surgical
plus	CC	Surgical
radial	JJ	Surgical
artery	NN	Surgical
)	)	Surgical
,	,	O
or	CC	O
group	NN	O
2	CD	O
,	,	O
80	CD	O
patients	NNS	O
undergoing	JJ	O
standard	JJ	Surgical
coronary	JJ	Surgical
artery	NN	Surgical
bypass	NN	Surgical
graft	NN	Surgical
surgery	NN	Surgical
(	(	Surgical
left	VBN	Surgical
internal	JJ	Surgical
thoracic	NN	Surgical
artery	NN	Surgical
on	IN	Surgical
left	JJ	Surgical
anterior	JJ	Surgical
descending	VBG	Surgical
coronary	JJ	Surgical
artery	NN	Surgical
plus	CC	Surgical
saphenous	JJ	Surgical
veins	NNS	Surgical
)	)	Surgical
.	.	Surgical

The	DT	O
radial	JJ	O
artery	NN	O
was	VBD	O
used	VBN	O
in	IN	O
all	DT	O
cases	NNS	O
as	IN	O
a	DT	O
composite	JJ	Surgical
Y-graft	NN	Surgical
.	.	O

RESULTS	NNP	O
Preoperative	JJ	O
characteristics	NNS	O
and	CC	O
risk	NN	O
factors	NNS	O
(	(	O
EuroSCORE	NNP	O
:	:	O
group	NN	O
1	CD	O
=	$	O
7.9	CD	O
vs	NN	O
group	NN	O
2	CD	O
=	$	O
8.1	CD	O
)	)	O
,	,	O
number	NN	O
of	IN	O
grafted	JJ	O
coronary	JJ	O
vessels	NNS	O
(	(	O
group	NN	O
1	CD	O
=	$	O
2.4	CD	O
vs	NN	O
group	NN	O
2	CD	O
=	$	O
2.5	CD	O
)	)	O
,	,	O
aortic	JJ	O
crossclamping	NN	O
time	NN	O
(	(	O
group	NN	O
1	CD	O
=	$	O
37	CD	O
+/-	JJ	O
7	CD	O
minutes	NNS	O
vs	JJ	O
group	NN	O
2	CD	O
=	$	O
38	CD	O
+/-	JJ	O
7	CD	O
minutes	NNS	O
)	)	O
,	,	O
ventilation	NN	O
time	NN	O
(	(	O
group	NN	O
1	CD	O
=	$	O
22	CD	O
+/-	JJ	O
12	CD	O
hours	NNS	O
vs	JJ	O
group	NN	O
2	CD	O
=	$	O
23	CD	O
+/-	JJ	O
11	CD	O
hours	NNS	O
)	)	O
,	,	O
intensive	JJ	O
care	NN	O
unit	NN	O
stay	NN	O
(	(	O
group	NN	O
1	CD	O
=	$	O
39	CD	O
+/-	JJ	O
10	CD	O
hours	NNS	O
vs	JJ	O
group	NN	O
2	CD	O
=	$	O
40	CD	O
+/-	JJ	O
9	CD	O
hours	NNS	O
)	)	O
,	,	O
and	CC	O
hospital	JJ	O
mortality	NN	O
(	(	O
group	NN	O
1	CD	O
=	RB	O
3.8	CD	O
%	NN	O
vs	NN	O
group	NN	O
2	CD	O
=	RB	O
5	CD	O
%	NN	O
)	)	O
were	VBD	O
comparable	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Comparison	NNP	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
early	JJ	O
postoperative	JJ	O
complications	NNS	O
showed	VBD	O
a	DT	O
higher	JJR	O
incidence	NN	O
of	IN	O
cerebrovascular	JJ	O
accidents	NNS	O
in	IN	O
group	NN	O
2	CD	O
(	(	O
group	NN	O
1	CD	O
=	$	O
0	CD	O
patients	NNS	O
vs	JJ	O
group	NN	O
2	CD	O
=	$	O
4	CD	O
patients	NNS	O
,	,	O
5	CD	O
%	NN	O
)	)	O
.	.	O

At	IN	O
a	DT	O
mean	JJ	O
follow-up	NN	O
of	IN	O
16	CD	O
+/-	JJ	O
3	CD	O
months	NNS	O
,	,	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
showed	VBD	O
superior	JJ	O
clinical	JJ	O
results	NNS	O
with	IN	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
graft	NN	O
occlusion	NN	O
(	(	O
group	NN	O
1	CD	O
=	$	O
2	CD	O
vs	NN	O
group	NN	O
2	CD	O
=	$	O
11	CD	O
;	:	O
P	NNP	O
=.06	NNP	O
)	)	O
and	CC	O
angina	JJ	O
recurrence	NN	O
(	(	O
group	NN	O
1	CD	O
=	$	O
2	CD	O
patients	NNS	O
vs	JJ	O
group	NN	O
2	CD	O
=	$	O
12	CD	O
patients	NNS	O
;	:	O
P	NNP	O
=.03	NNP	O
)	)	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
identified	VBD	O
saphenous	JJ	O
vein	NNS	O
grafts	NNS	O
as	IN	O
independent	JJ	O
predictors	NNS	O
for	IN	O
graft	NN	O
occlusion	NN	O
and	CC	O
angina	JJ	O
recurrence	NN	O
.	.	O

CONCLUSIONS	NNP	O
Left	NNP	O
internal	JJ	O
thoracic	NN	O
artery-radial	JJ	O
artery	NN	O
composite	JJ	O
grafts	NNS	O
proved	VBD	O
to	TO	O
be	VB	O
a	DT	O
safe	JJ	O
procedure	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
.	.	O

It	PRP	O
improved	VBD	O
the	DT	O
clinical	JJ	O
outcome	NN	O
,	,	O
providing	VBG	O
a	DT	O
significantly	RB	O
higher	JJR	O
graft	NN	O
patency	NN	O
rate	NN	O
and	CC	O
a	DT	O
lower	JJR	O
incidence	NN	O
of	IN	O
late	JJ	O
cardiac	JJ	O
events	NNS	O
.	.	O

Osteocalcin	NNP	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
.	.	O

A	DT	O
one-year	JJ	O
followup	NN	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
analyze	VB	O
clinical	JJ	O
,	,	O
radiological	JJ	O
,	,	O
and	CC	O
drug	NN	O
(	(	O
disease	NN	O
modifying	VBG	O
antirheumatic	JJ	O
drug	NN	O
,	,	O
DMARD	NNP	O
)	)	O
dependent	NN	O
factors	NNS	O
influencing	VBG	O
bone	NN	O
turnover	NN	O
in	IN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
in	IN	O
a	DT	O
one-year	JJ	O
double	JJ	O
blind	NN	O
randomized	VBD	O
study	NN	O
comparing	VBG	O
intramuscular	JJ	Pharmacological
(	(	Pharmacological
im	NN	Pharmacological
)	)	Pharmacological
gold	NN	Pharmacological
with	IN	Pharmacological
im	JJ	Pharmacological
methotrexate	NN	Pharmacological
(	(	Pharmacological
MTX	NNP	Pharmacological
)	)	Pharmacological
,	,	O
whether	IN	O
the	DT	O
variation	NN	O
of	IN	O
inflammatory	JJ	O
activity	NN	O
or	CC	O
functional	JJ	O
capacity	NN	O
,	,	O
the	DT	O
ascending	VBG	O
anatomic	JJ	O
stage	NN	O
,	,	O
or	CC	O
DMARD	NNP	O
treatments	NNS	O
have	VBP	O
an	DT	O
influence	NN	O
on	IN	O
bone	NN	O
formation	NN	O
(	(	O
osteocalcin	NN	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
.	.	O

RESULTS	NNP	O
Patients	NNPS	O
(	(	O
n	JJ	O
=	NNP	O
48	CD	O
)	)	O
enrolled	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
of	IN	O
our	PRP$	O
study	NN	O
had	VBD	O
significantly	RB	O
increased	VBN	O
osteocalcin	NN	O
levels	NNS	O
(	(	O
3.45	CD	O
+/-	JJ	O
0.93	CD	O
--	:	O
>	JJ	O
4.42	CD	O
+/-	JJ	O
1.39	CD	O
ng/ml	JJ	O
p	NN	O
<	NNP	O
0.02	CD	O
)	)	O
after	IN	O
one	CD	O
year	NN	O
if	IN	O
inflammatory	JJ	O
activity	NN	O
decreased	VBN	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
1	CD	O
SD	NNP	O
:	:	O
erythrocyte	JJ	O
sedimentation	NN	O
rate	NN	O
(	(	O
ESR	NNP	O
)	)	O
26.4	CD	O
mm/h	NN	O
,	,	O
C-reactive	JJ	O
protein	NN	O
(	(	O
CRP	NNP	O
)	)	O
3.8	CD	O
mg/dl	NN	O
)	)	O
.	.	O

We	PRP	O
found	VBD	O
a	DT	O
significant	JJ	O
negative	JJ	O
correlation	NN	O
of	IN	O
the	DT	O
one-year	JJ	O
CRP-	NNP	O
(	(	O
r	NN	O
=	NNP	O
-0.44	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
or	CC	O
ESR	NNP	O
differences	NNS	O
(	(	O
r	NN	O
=	NNP	O
-0.45	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
the	DT	O
corresponding	JJ	O
osteocalcin	NN	O
differences	NNS	O
.	.	O

This	DT	O
was	VBD	O
also	RB	O
evident	JJ	O
if	IN	O
these	DT	O
patients	NNS	O
were	VBD	O
pooled	VBN	O
with	IN	O
15	CD	O
patients	NNS	O
excluded	VBN	O
from	IN	O
the	DT	O
double	JJ	O
blind	NN	O
study	NN	O
as	IN	O
already	RB	O
receiving	VBG	O
DMARD	NNP	Pharmacological
treatment	NN	Pharmacological
(	(	O
n	JJ	O
=	VBZ	O
63	CD	O
;	:	O
p	NN	O
<	VBZ	O
0.01	CD	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
impaired	JJ	O
functional	JJ	O
capacity	NN	O
also	RB	O
had	VBD	O
significantly	RB	O
reduced	VBN	O
osteocalcin	NN	O
levels	NNS	O
(	(	O
p	VB	O
<	RB	O
0.01	CD	O
)	)	O
.	.	O

In	IN	O
both	DT	O
cases	NNS	O
,	,	O
alkaline	JJ	O
phosphatase	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
.	.	O

CONCLUSIONS	VB	O
Our	PRP$	O
data	NNS	O
suggest	VBP	O
that	IN	O
osteocalcin	NN	O
,	,	O
a	DT	O
useful	JJ	O
followup	NN	O
variable	NN	O
of	IN	O
bone	NN	O
turnover	NN	O
,	,	O
is	VBZ	O
changed	VBN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.02	CD	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
regarding	VBG	O
inflammatory	JJ	O
activity	NN	O
and	CC	O
functional	JJ	O
capacity	NN	O
.	.	O

In	IN	O
contrast	NN	O
to	TO	O
alkaline	VB	O
phosphatase	NN	O
,	,	O
a	DT	O
fall	NN	O
in	IN	O
inflammatory	JJ	O
activity	NN	O
stimulated	VBN	O
and	CC	O
impairment	NN	O
of	IN	O
functional	JJ	O
capacity	NN	O
significantly	RB	O
decreased	VBD	O
osteocalcin	JJ	O
levels	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
RA	NNP	O
.	.	O

Cardiovascular	JJ	O
safety	NN	O
of	IN	O
degarelix	NN	Pharmacological
:	:	O
results	NNS	O
from	IN	O
a	DT	O
12-month	JJ	O
,	,	O
comparative	JJ	O
,	,	O
randomized	VBN	O
,	,	O
open	JJ	O
label	NN	O
,	,	O
parallel	JJ	O
group	NN	O
phase	NN	O
III	NNP	O
trial	NN	O
in	IN	O
patients	NNS	O
with	IN	O
prostate	JJ	O
cancer	NN	O
.	.	O

PURPOSE	NNP	O
We	PRP	O
assessed	VBD	O
the	DT	O
cardiovascular	JJ	O
safety	NN	O
profile	NN	O
of	IN	O
degarelix	NN	Pharmacological
,	,	O
a	DT	O
new	JJ	O
gonadotropin-releasing	JJ	O
hormone	NN	O
antagonist	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
is	VBZ	O
the	DT	O
first	JJ	O
report	NN	O
to	TO	O
our	PRP$	O
knowledge	NN	O
on	IN	O
cardiovascular	JJ	O
safety	NN	O
data	NNS	O
from	IN	O
a	DT	O
completed	VBN	O
1-year	JJ	O
randomized	NNS	O
controlled	VBD	O
trial	NN	O
of	IN	O
leuprolide	JJ	Pharmacological
acetate	NN	Pharmacological
vs	NN	O
degarelix	NN	Pharmacological
.	.	O

Outcomes	CC	O
considered	VBN	O
in	IN	O
these	DT	O
analyses	NNS	O
included	VBD	O
the	DT	O
QT	NNP	O
interval	NN	O
by	IN	O
central	JJ	O
reading	NN	O
and	CC	O
analysis	NN	O
,	,	O
and	CC	O
cardiovascular	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

On	IN	O
multivariate	NN	O
analyses	NNS	O
relationships	VBP	O
between	IN	O
selected	VBN	O
baseline	NN	O
factors	NNS	O
and	CC	O
cardiovascular	JJ	O
events	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	VB	O
There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
groups	NNS	O
for	IN	O
mean	JJ	O
change	NN	O
in	IN	O
Fridericia	NNP	O
's	POS	O
correction	NN	O
of	IN	O
QT	NNP	O
during	IN	O
the	DT	O
trial	NN	O
.	.	O

Markedly	RB	O
abnormal	JJ	O
Fridericia	NNP	O
's	POS	O
correction	NN	O
of	IN	O
QT	NNP	O
values	NNS	O
(	(	O
500	CD	O
milliseconds	NNS	O
or	CC	O
greater	JJR	O
)	)	O
were	VBD	O
observed	VBN	O
in	IN	O
only	RB	O
a	DT	O
small	JJ	O
number	NN	O
of	IN	O
subjects	NNS	O
by	IN	O
treatment	NN	O
group	NN	O
,	,	O
that	WDT	O
is	VBZ	O
2	CD	O
(	(	O
less	JJR	O
than	IN	O
1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
pooled	JJ	O
degarelix	NN	Pharmacological
group	NN	O
and	CC	O
2	CD	O
(	(	O
1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
leuprolide	NN	Pharmacological
group	NN	O
.	.	O

Supraventricular	JJ	O
arrhythmias	NN	O
were	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
type	NN	O
of	IN	O
arrhythmias	NN	O
,	,	O
affecting	VBG	O
2	CD	O
%	NN	O
of	IN	O
subjects	NNS	O
in	IN	O
the	DT	O
pooled	JJ	O
degarelix	NN	Pharmacological
group	NN	O
and	CC	O
4	CD	O
%	NN	O
in	IN	O
the	DT	O
leuprolide	NN	Pharmacological
group	NN	O
.	.	O

Other	JJ	O
arrhythmias	JJ	O
occurred	VBN	O
in	IN	O
1	CD	O
%	NN	O
or	CC	O
less	JJR	O
of	IN	O
subjects	NNS	O
by	IN	O
treatment	NN	O
group	NN	O
.	.	O

The	DT	O
most	RBS	O
frequently	RB	O
reported	VBD	O
cardiac	JJ	O
disorder	NN	O
was	VBD	O
ischemic	JJ	O
heart	NN	O
disease	NN	O
,	,	O
which	WDT	O
occurred	VBD	O
in	IN	O
4	CD	O
%	NN	O
of	IN	O
subjects	NNS	O
treated	VBN	O
with	IN	O
degarelix	NN	Pharmacological
and	CC	O
10	CD	O
%	NN	O
of	IN	O
those	DT	O
on	IN	O
leuprolide	NN	Pharmacological
.	.	O

Cox	NNP	O
proportional	JJ	O
hazard	NN	O
ratio	NN	O
estimates	NNS	O
for	IN	O
selected	VBN	O
baseline	NN	O
covariates	NNS	O
showed	VBD	O
a	DT	O
significantly	RB	O
increased	VBN	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
by	IN	O
age	NN	O
(	(	O
p=0.0459	NN	O
)	)	O
and	CC	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
(	(	O
p=0.0061	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
men	NNS	O
with	IN	O
prostate	NN	O
cancer	NN	O
degarelix	NN	Pharmacological
and	CC	O
leuprolide	NN	Pharmacological
have	VBP	O
similar	JJ	O
cardiovascular	JJ	O
safety	NN	O
profiles	NNS	O
.	.	O

These	DT	O
observations	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
cardiovascular	JJ	O
events	NNS	O
associated	VBN	O
with	IN	O
both	DT	O
agents	NNS	O
result	VBP	O
from	IN	O
hypogonadism	NN	O
rather	RB	O
than	IN	O
a	DT	O
direct	JJ	O
drug	NN	O
effect	NN	O
.	.	O

Evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
is	VBZ	O
related	VBN	O
to	TO	O
baseline	VB	O
severity	NN	O
--	:	O
a	DT	O
prospective	JJ	O
quantitative	JJ	O
angiographic	JJ	O
analysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
coronary	JJ	O
disease	NN	O
.	.	O

INTACT	JJ	O
Investigators	NNPS	O
.	.	O

International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
.	.	O

A	DT	O
correlation	NN	O
of	IN	O
the	DT	O
angiographic	JJ	O
evolution	NN	O
of	IN	O
coronary	JJ	O
stenoses	NNS	O
(	(	O
stenosis	NN	O
diameter	NN	O
>	NN	O
or	CC	O
=	VB	O
20	CD	O
%	NN	O
)	)	O
with	IN	O
morphological	JJ	O
stenosis	NN	O
parameters	NNS	O
at	IN	O
baseline	NN	O
could	MD	O
help	VB	O
to	TO	O
identify	VB	O
the	DT	O
risk	NN	O
of	IN	O
progressive	JJ	O
stenoses	NNS	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
data	NN	O
of	IN	O
the	DT	O
prospective	JJ	O
INTACT	NNP	O
study	NN	O
(	(	O
International	NNP	O
Nifedipine	NNP	O
Trial	NNP	O
on	IN	O
Antiatherosclerotic	NNP	O
Therapy	NNP	O
)	)	O
were	VBD	O
reviewed	VBN	O
.	.	O

In	IN	O
348	CD	O
patients	NNS	O
with	IN	O
moderate	JJ	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
standardized	VBD	Physical
coronary	JJ	Physical
angiograms	NNS	Physical
were	VBD	O
taken	VBN	O
3	CD	O
years	NNS	O
apart	RB	O
and	CC	O
were	VBD	O
quantitatively	RB	O
analysed	VBN	O
.	.	O

Changes	NNS	O
in	IN	O
the	DT	O
minimal	JJ	O
diameter	NN	O
of	IN	O
the	DT	O
1063	CD	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
compared	VBN	O
between	IN	O
both	DT	O
angiograms	NNS	O
were	VBD	O
set	VBN	O
in	IN	O
relation	NN	O
to	TO	O
a	DT	O
number	NN	O
of	IN	O
conventional	JJ	O
stenosis	NN	O
parameters	NNS	O
at	IN	O
baseline	NN	O
.	.	O

Regression	NNP	O
analysis	NN	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
correlation	NN	O
of	IN	O
the	DT	O
changes	NNS	O
in	IN	O
minimal	JJ	O
diameter	NN	O
with	IN	O
baseline	NN	O
%	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
r	JJ	O
=	VBZ	O
0.30	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
minimal	JJ	O
diameter	NN	O
(	(	O
r	JJ	O
=	NNP	O
-0.28	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
reference	NN	O
diameter	NN	O
of	IN	O
stenoses	NNS	O
(	(	O
r	NN	O
=	NNP	O
-0.14	NNP	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
changes	NNS	O
were	VBD	O
not	RB	O
correlated	VBN	O
with	IN	O
stenosis	NN	O
length	NN	O
and	CC	O
plaque	JJ	O
area	NN	O
.	.	O

The	DT	O
baseline	NN	O
parameters	NNS	O
of	IN	O
22	CD	O
preexisting	VBG	O
stenoses	NNS	O
progressing	VBG	O
to	TO	O
occlusions	NNS	O
differed	VBN	O
from	IN	O
those	DT	O
remaining	VBG	O
patent	NN	O
only	RB	O
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
%	NN	O
diameter	NN	O
stenosis	NN	O
(	(	O
43	CD	O
+/-	JJ	O
9	CD	O
%	NN	O
vs	JJ	O
39	CD	O
+/-	JJ	O
11	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Additional	JJ	O
progression	NN	O
of	IN	O
coronary	JJ	O
disease	NN	O
became	VBD	O
manifest	JJS	O
through	IN	O
development	NN	O
of	IN	O
228	CD	O
stenoses	NNS	O
and	CC	O
19	CD	O
occlusions	NNS	O
at	IN	O
arterial	JJ	O
sites	NNS	O
free	VBP	O
from	IN	O
definitive	JJ	O
stenoses	NNS	O
in	IN	O
the	DT	O
baseline	NN	O
angiograms	NN	O
.	.	O

Thus	RB	O
,	,	O
progression	NN	O
of	IN	O
atherosclerosis	NN	O
predominantly	RB	O
occurred	VBD	O
in	IN	O
mild	NN	O
preexisting	VBG	O
coronary	JJ	O
stenoses	NNS	O
and	CC	O
developed	VBN	O
at	IN	O
previously	RB	O
angiographically	RB	O
normal	JJ	O
sites	NNS	O
.	.	O

Since	IN	O
the	DT	O
conventional	JJ	O
angiographic	JJ	O
parameters	NNS	O
analysed	VBN	O
in	IN	O
this	DT	O
study	NN	O
failed	VBD	O
to	TO	O
identify	VB	O
individual	JJ	O
arterial	JJ	O
sites	NNS	O
with	IN	O
an	DT	O
increased	VBN	O
risk	NN	O
for	IN	O
progression	NN	O
,	,	O
definition	NN	O
of	IN	O
new	JJ	O
angiographic	JJ	O
parameters	NNS	O
or	CC	O
application	NN	O
of	IN	O
new	JJ	O
techniques	NNS	O
seem	VBP	O
mandatory	JJ	O
to	TO	O
this	DT	O
end	NN	O
.	.	O

Changes	NNS	O
in	IN	O
motor	NN	O
cortex	NN	O
excitability	NN	O
associated	VBN	O
with	IN	O
temporal	JJ	Physical
repetitive	JJ	Physical
transcranial	JJ	Physical
magnetic	JJ	Physical
stimulation	NN	Physical
in	IN	O
tinnitus	NN	O
:	:	O
hints	NNS	O
for	IN	O
cross-modal	JJ	O
plasticity	NN	O
?	.	O
BACKGROUND	NNP	O
Motor	NNP	O
cortex	VBP	O
excitability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
changed	VBN	O
after	IN	O
repetitive	JJ	Physical
transcranial	JJ	Physical
magnetic	JJ	Physical
stimulation	NN	Physical
(	(	Physical
rTMS	NN	Physical
)	)	Physical
of	IN	O
the	DT	O
temporal	JJ	O
cortex	NN	O
highlighting	VBG	O
the	DT	O
occurrence	NN	O
of	IN	O
cross-modal	JJ	O
plasticity	NN	O
in	IN	O
non-invasive	JJ	O
brain	NN	O
stimulation	NN	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
temporal	JJ	Physical
low-frequency	NN	Physical
rTMS	NN	Physical
on	IN	O
motor	NN	O
cortex	NN	O
plasticity	NN	O
in	IN	O
a	DT	O
large	JJ	O
sample	NN	O
of	IN	O
tinnitus	NN	O
patients	NNS	O
.	.	O

In	IN	O
116	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
tinnitus	NN	O
different	JJ	O
parameters	NNS	O
of	IN	O
cortical	JJ	O
excitability	NN	O
were	VBD	O
assessed	VBN	O
before	IN	O
and	CC	O
after	IN	O
ten	JJ	O
rTMS	JJ	Physical
treatment	NN	O
sessions	NNS	O
.	.	O

Patients	NNS	O
received	VBD	O
one	CD	O
of	IN	O
three	CD	O
different	JJ	O
protocols	NNS	O
all	DT	O
including	VBG	O
1	CD	O
Hz	NNP	O
rTMS	NN	O
over	IN	O
the	DT	O
left	JJ	O
temporal	JJ	O
cortex	NN	O
.	.	O

Treatment	NNP	O
response	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
improvement	NN	O
by	IN	O
at	IN	O
least	JJS	O
five	CD	O
points	NNS	O
in	IN	O
the	DT	O
tinnitus	NN	O
questionnaire	NN	O
(	(	O
TQ	NNP	O
)	)	O
.	.	O

Variables	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
resting	VBG	O
motor	NN	O
threshold	NN	O
(	(	O
RMT	NNP	O
)	)	O
,	,	O
short-interval	JJ	O
intra-cortical	JJ	O
inhibition	NN	O
(	(	O
SICI	NNP	O
)	)	O
,	,	O
intracortical	JJ	O
facilitation	NN	O
(	(	O
ICF	NNP	O
)	)	O
,	,	O
and	CC	O
cortical	JJ	O
silent	JJ	O
period	NN	O
(	(	O
CSP	NNP	O
)	)	O
.	.	O

RESULTS	NNP	O
After	IN	O
rTMS	JJ	Physical
treatment	NN	O
RMT	NNP	O
was	VBD	O
decreased	VBN	O
by	IN	O
about	IN	O
1	CD	O
%	NN	O
of	IN	O
stimulator	NN	O
output	NN	O
near-significantly	RB	O
in	IN	O
the	DT	O
whole	JJ	O
group	NN	O
of	IN	O
patients	NNS	O
.	.	O

SICI	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
significant	JJ	O
changes	NNS	O
with	IN	O
respect	NN	O
to	TO	O
treatment	NN	O
response	NN	O
.	.	O

The	DT	O
group	NN	O
of	IN	O
treatment	NN	O
responders	NNS	O
showed	VBD	O
a	DT	O
decrease	NN	O
of	IN	O
SICI	NNP	O
over	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
group	NN	O
of	IN	O
non-responders	NNS	O
the	DT	O
reverse	NN	O
pattern	NN	O
.	.	O

CONCLUSIONS	NNP	O
Minor	NNP	O
RMT	NNP	O
changes	NNS	O
during	IN	O
rTMS	NN	Physical
treatment	NN	O
do	VBP	O
not	RB	O
necessarily	RB	O
suggest	VB	O
the	DT	O
need	NN	O
for	IN	O
systematic	JJ	O
re-examination	NN	O
of	IN	O
the	DT	O
RMT	NNP	O
for	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
issues	NNS	O
.	.	O

Treatment	NNP	O
response	NN	O
to	TO	O
rTMS	VB	Physical
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
related	VBN	O
to	TO	O
changes	NNS	O
in	IN	O
SICI	NNP	O
that	WDT	O
might	MD	O
reflect	VB	O
modulation	NN	O
of	IN	O
GABAergic	NNP	O
mechanisms	FW	O
directly	RB	O
or	CC	O
indirectly	RB	O
related	VBN	O
to	TO	O
rTMS	VB	O
treatment	NN	O
effects	NNS	O
.	.	O

Is	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
mobile	JJ	Physical
phone	NN	Physical
radiofrequency	NN	Physical
waves	NNS	Physical
on	IN	O
human	JJ	O
skin	JJ	O
perfusion	NN	O
non-thermal	JJ	O
?	.	O
OBJECTIVE	UH	O
To	TO	O
establish	VB	O
whether	IN	O
SkBF	NNP	O
can	MD	O
be	VB	O
modified	VBN	O
by	IN	O
exposure	NN	O
to	TO	O
the	DT	O
radiofrequency	NN	Physical
waves	NNS	Physical
emitted	VBN	Physical
by	IN	Physical
a	DT	Physical
mobile	JJ	Physical
phone	NN	Physical
when	WRB	O
the	DT	O
latter	NN	O
is	VBZ	O
held	VBN	O
against	IN	O
the	DT	O
jaw	NN	O
and	CC	O
ear	NN	O
.	.	O

METHODS	NNP	O
Variations	NNP	O
in	IN	O
SkBF	NNP	O
and	CC	O
Tsk	NNP	O
in	IN	O
adult	NN	O
volunteers	NNS	O
were	VBD	O
simultaneously	RB	O
recorded	VBN	Physical
with	IN	Physical
a	DT	Physical
thermostatic	JJ	Physical
laser	NN	Physical
Doppler	NNP	Physical
system	NN	Physical
during	IN	Physical
a	DT	Physical
20-minute	JJ	Physical
radiofrequency	NN	Physical
exposure	NN	Physical
session	NN	Physical
and	CC	Physical
a	DT	Physical
20-minute	JJ	Physical
sham	NN	Physical
session	NN	Physical
.	.	O

The	DT	O
skin	JJ	O
microvessels	NNS	O
'	POS	O
vasodilatory	NN	O
reserve	NN	O
was	VBD	O
assessed	VBN	O
with	IN	O
a	DT	O
heat	NN	O
challenge	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
protocol	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
the	DT	O
radiofrequency	NN	Physical
exposure	NN	Physical
session	NN	Physical
,	,	O
SkBF	NNP	O
increased	VBD	O
(	(	O
vs.	FW	O
baseline	NN	O
)	)	O
more	JJR	O
than	IN	O
during	IN	O
the	DT	O
sham	JJ	Physical
exposure	NN	Physical
session	NN	Physical
.	.	O

The	DT	O
sessions	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significant	JJ	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
Tsk	NNP	O
time-course	JJ	O
response	NN	O
.	.	O

The	DT	O
skin	JJ	O
microvessels	NNS	O
'	POS	O
vasodilatory	NN	O
ability	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
greater	JJR	O
during	IN	O
radiofrequency	NN	O
exposure	NN	O
than	IN	O
during	IN	O
sham	JJ	O
exposure	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
reveal	VBP	O
the	DT	O
existence	NN	O
of	IN	O
a	DT	O
specific	JJ	O
vasodilatory	JJ	O
effect	NN	O
of	IN	O
mobile	JJ	Physical
phone	NN	Physical
radiofrequency	NN	Physical
emission	NN	Physical
on	IN	O
skin	JJ	O
perfusion	NN	O
.	.	O

Treatment	NN	O
of	IN	O
adult	NN	O
asthma	NN	O
:	:	O
controlled	VBN	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
oxitropium	NN	Pharmacological
bromide	NN	Pharmacological
.	.	O

Sixteen	NNP	O
young	JJ	O
adult	NN	O
sufferers	NNS	O
from	IN	O
extrinsic	JJ	O
paroxysmal	JJ	O
asthma	NN	O
with	IN	O
pollen	JJ	O
hypersensitivity	NN	O
took	VBD	O
part	NN	O
in	IN	O
a	DT	O
therapeutic	JJ	O
trial	NN	O
of	IN	O
the	DT	O
synthetic	JJ	Pharmacological
anticholinergic	NN	Pharmacological
agent	NN	Pharmacological
oxitropium	NN	Pharmacological
bromide	NN	Pharmacological
administered	VBN	O
by	IN	O
a	DT	O
metered	VBN	O
dose	NN	O
inhaler	NN	O
.	.	O

The	DT	O
study	NN	O
comprised	VBD	O
three	CD	O
3-week	JJ	O
periods	NNS	O
.	.	O

The	DT	O
first	JJ	O
,	,	O
run-in	JJ	O
period	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
confirm	VB	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
patients	NNS	O
to	TO	O
maintain	VB	O
a	DT	O
daily	JJ	O
record	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

During	IN	O
the	DT	O
second	JJ	O
and	CC	O
third	JJ	O
periods	NNS	O
,	,	O
the	DT	O
patient	NN	O
received	VBD	O
3	CD	O
X	NNP	O
2	CD	O
inhalations	NNS	O
of	IN	O
drug	NN	O
or	CC	O
placebo	NN	Control
in	IN	O
a	DT	O
cross-over	JJ	O
design	NN	O
.	.	O

The	DT	O
medical	JJ	O
staff	NN	O
was	VBD	O
blind	NN	O
to	TO	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
aerosol	NN	O
(	(	O
drug	NN	Pharmacological
or	CC	O
placebo	NN	Control
)	)	Control
,	,	O
which	WDT	O
was	VBD	O
given	VBN	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

The	DT	O
run-in	JJ	O
clinical	JJ	O
score	NN	O
was	VBD	O
high	JJ	O
.	.	O

Asymptomatic	JJ	O
days	NNS	O
were	VBD	O
relatively	RB	O
infrequent	JJ	O
and	CC	O
daily	JJ	O
drug	NN	O
consumption	NN	O
was	VBD	O
high	JJ	O
.	.	O

Functional	JJ	O
studies	NNS	O
between	IN	O
the	DT	O
cross-over	NN	O
periods	NNS	O
showed	VBD	O
flow-rate	JJ	O
values	NNS	O
close	RB	O
to	TO	O
normal	JJ	O
,	,	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
residual	JJ	O
volume	NN	O
and	CC	O
functional	JJ	O
residual	JJ	O
capacity	NN	O
.	.	O

During	IN	O
treatment	NN	O
either	CC	O
with	IN	O
placebo	NN	Control
or	CC	O
oxitropium	NN	Pharmacological
,	,	O
there	EX	O
was	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
decrease	NN	O
in	IN	O
clinical	JJ	O
scores	NNS	O
.	.	O

Results	NNS	O
for	IN	O
oxitropium	JJ	Pharmacological
bromide	NN	Pharmacological
treatment	NN	O
were	VBD	O
significantly	RB	O
better	JJR	O
than	IN	O
the	DT	O
run-in	JJ	O
values	NNS	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.005	CD	O
)	)	O
and	CC	O
the	DT	O
placebo	NN	Control
period	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.02	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
change	NN	O
in	IN	O
non-trial	JJ	O
drug	NN	O
consumption	NN	O
.	.	O

Functional	NNP	O
values	NNS	O
showed	VBD	O
no	DT	O
difference	NN	O
in	IN	O
terms	NNS	O
of	IN	O
flow	NN	O
rate	NN	O
,	,	O
although	IN	O
oxitropium	NN	O
did	VBD	O
cause	VB	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
RV/TLC	NNP	O
ratio	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

No	DT	O
adverse	JJ	O
reactions	NNS	O
were	VBD	O
reported	VBN	O
.	.	O

Effect	NN	O
of	IN	O
entacapone	NN	Pharmacological
,	,	O
a	DT	O
peripherally	RB	O
acting	VBG	O
catechol-O-methyltransferase	NN	O
inhibitor	NN	O
,	,	O
on	IN	O
the	DT	O
motor	NN	O
response	NN	O
to	TO	O
acute	VB	O
treatment	NN	O
with	IN	O
levodopa	NN	O
in	IN	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O

Catechol-O-methyltransferase	NNP	O
(	(	O
COMT	NNP	O
)	)	O
inhibitors	NNS	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
by	IN	O
improving	VBG	O
the	DT	O
bioavailability	NN	O
of	IN	O
levodopa	NN	O
and	CC	O
by	IN	O
prolonging	VBG	O
its	PRP$	O
effects	NNS	O
.	.	O

Entacapone	NNP	Pharmacological
(	(	Pharmacological
OR-611	NNP	Pharmacological
)	)	Pharmacological
,	,	O
a	DT	O
novel	JJ	Pharmacological
COMT	NNP	Pharmacological
inhibitor	NN	Pharmacological
,	,	O
which	WDT	O
does	VBZ	O
not	RB	O
cross	VB	O
the	DT	O
blood	NN	O
brain	NN	O
barrier	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
in	IN	O
12	CD	O
patients	NNS	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
and	CC	O
motor	NN	O
fluctuations	NNS	O
in	IN	O
a	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
cross-over	JJ	O
,	,	O
single	JJ	O
dose	NN	O
study	NN	O
.	.	O

The	DT	O
magnitude	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
response	NN	O
to	TO	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
200	CD	O
mg	NNS	O
levodopa/50	JJ	Pharmacological
mg	FW	O
carbidopa	NN	Pharmacological
was	VBD	O
evaluated	VBN	O
after	IN	O
concomitant	JJ	O
placebo	NN	Control
,	,	O
or	CC	O
200	CD	O
or	CC	O
800	CD	O
mg	NN	O
entacapone	NN	Pharmacological
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
motor	NN	O
response	NN	O
to	TO	O
levodopa	NN	O
was	VBD	O
seen	VBN	O
when	WRB	O
200	CD	O
mg	NN	O
entacapone	NN	O
was	VBD	O
given	VBN	O
with	IN	O
levodopa/carbidopa	NN	O
.	.	O

Plasma	NNP	O
levodopa	JJ	O
concentrations	NNS	O
were	VBD	O
increased	VBN	O
with	IN	O
both	DT	O
doses	NNS	O
of	IN	O
the	DT	O
COMT	NNP	O
inhibitor	NN	O
.	.	O

The	DT	O
latency	NN	O
to	TO	O
onset	VB	O
of	IN	O
motor	NN	O
response	NN	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
between	IN	O
active	JJ	O
drug	NN	O
and	CC	O
placebo	NN	O
.	.	O

Entacapone	NN	O
may	MD	O
prove	VB	O
useful	JJ	O
in	IN	O
prolonging	VBG	O
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
benefit	NN	O
obtained	VBN	O
from	IN	O
individual	JJ	O
doses	NNS	O
of	IN	O
levodopa	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	Pharmacological
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
autism	NN	O
:	:	O
neuropsychological	JJ	O
measures	NNS	O
.	.	O

OBJECTIVE	NNP	O
There	EX	O
has	VBZ	O
been	VBN	O
recent	JJ	O
interest	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
cognitive	JJ	Pharmacological
enhancing	VBG	Pharmacological
drugs	NNS	Pharmacological
,	,	O
such	JJ	O
as	IN	O
cholinesterase	NN	Physical
inhibitors	NNS	Physical
,	,	O
as	IN	O
a	DT	O
possible	JJ	O
treatment	NN	O
for	IN	O
executive	NN	O
functioning	NN	O
(	(	O
EF	NNP	O
)	)	O
deficits	NNS	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
tolerability	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
efficacy	NN	O
of	IN	O
donepezil	NN	O
on	IN	O
EF	NNP	O
in	IN	O
a	DT	O
sample	NN	O
of	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

METHOD	NNP	O
Thirty-four	JJ	O
children	NNS	O
and	CC	O
adolescents	NNS	O
with	IN	O
ASD	NNP	O
(	(	O
age	NN	O
range	NN	O
8-17	CD	O
years	NNS	O
;	:	O
IQ	NNP	O
>	NNP	O
75	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
10-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
of	IN	O
donepezil	NN	Pharmacological
(	(	O
doses	NNS	O
of	IN	O
5	CD	O
and	CC	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10-week	JJ	O
open	JJ	O
label	NN	O
trial	NN	O
for	IN	O
placebo	NN	O
nonresponders	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
effect	NN	O
of	IN	O
donepezil	NN	O
treatment	NN	O
on	IN	O
EF	NNP	O
was	VBD	O
examined	VBN	O
.	.	O

Despite	IN	O
improvement	NN	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
EF	NNP	O
measures	NNS	O
,	,	O
no	DT	O
statistically	RB	O
significant	JJ	O
between-group	JJ	O
differences	NNS	O
were	VBD	O
found	VBN	O
(	(	O
with	IN	O
gains	NNS	O
observed	VBN	O
for	IN	O
both	DT	O
the	DT	O
placebo	NN	O
and	CC	O
donepezil	NN	O
groups	NNS	O
)	)	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
short-term	JJ	O
treatment	NN	O
with	IN	O
donepezil	NN	O
may	MD	O
have	VB	O
limited	VBN	O
impact	NN	O
on	IN	O
cognitive	JJ	O
functioning	NN	O
in	IN	O
ASD	NNP	O
.	.	O

Future	NNP	O
controlled	VBD	O
trials	NNS	O
may	MD	O
need	VB	O
to	TO	O
consider	VB	O
a	DT	O
longer	RBR	O
treatment	NN	O
period	NN	O
to	TO	O
detect	VB	O
significant	JJ	O
gains	NNS	O
on	IN	O
EF	NNP	O
measures	NNS	O
.	.	O

Using	VBG	O
the	DT	O
transporters	NNS	Other
DVD	NNP	Other
as	IN	O
a	DT	O
learning	NN	Educational
tool	NN	Educational
for	IN	O
children	NNS	O
with	IN	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Data	NNS	O
from	IN	O
two	CD	O
groups	NNS	O
of	IN	O
children	NNS	O
who	WP	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
those	DT	O
groups	NNS	O
showed	VBD	O
that	IN	O
the	DT	O
ability	NN	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
to	TO	O
identify	VB	O
and	CC	O
label	VB	O
basic	JJ	O
and	CC	O
complex	JJ	O
facial	JJ	O
expressions	NNS	O
following	VBG	O
a	DT	O
3-week	JJ	O
home	NN	Educational
based	VBN	Educational
DVD	NNP	Educational
intervention	NN	Educational
significantly	RB	O
improved	VBN	O
when	WRB	O
viewing	VBG	O
The	DT	Other
Transporters	NNPS	Other
DVD	NNP	Other
.	.	O

Improvements	NNS	O
in	IN	O
emotion	NN	O
recognition	NN	O
appear	RB	O
related	VBN	O
to	TO	O
the	DT	O
content	NN	O
of	IN	O
the	DT	O
DVD	NNP	Other
as	IN	O
participants	NNS	O
in	IN	O
a	DT	O
control	NN	O
group	NN	O
who	WP	O
observed	VBD	O
an	DT	O
alternate	NN	Other
DVD	NNP	Other
showed	VBD	O
no	DT	O
such	JJ	O
improvement	NN	O
.	.	O

Although	IN	O
social	JJ	O
behaviour	NN	O
improved	VBD	O
significantly	RB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
watching	VBG	O
The	DT	O
Transporters	NNPS	O
,	,	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
social	JJ	O
behaviour	NN	O
was	VBD	O
however	RB	O
,	,	O
also	RB	O
observed	VBN	O
in	IN	O
the	DT	O
Thomas	NNP	O
the	DT	O
Tank	NNP	O
Engine	NNP	O
condition	NN	O
suggesting	VBG	O
the	DT	O
unique	JJ	O
content	NN	O
of	IN	O
The	DT	O
Transporters	NNP	Other
DVD	NNP	Other
was	VBD	O
not	RB	O
pivotal	JJ	O
to	TO	O
the	DT	O
improvement	NN	O
of	IN	O
social	JJ	O
behaviour	NN	O
in	IN	O
general	JJ	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
daily	JJ	O
sodium	NN	Pharmacological
intake	NN	O
on	IN	O
posttransplant	JJ	O
hypertension	NN	O
in	IN	O
kidney	NN	O
allograft	NN	O
recipients	NNS	O
.	.	O

INTRODUCTION	NNP	O
Posttransplant	NNP	O
hypertension	NN	O
is	VBZ	O
a	DT	O
well-known	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
long-term	JJ	O
allograft	NN	O
failure	NN	O
and	CC	O
mortality	NN	O
in	IN	O
kidney	NN	O
recipients	NNS	O
.	.	O

Although	IN	O
dietary	JJ	O
sodium	NN	O
restriction	NN	O
is	VBZ	O
a	DT	O
widely	RB	O
recommended	JJ	O
nonpharmacological	JJ	O
measure	NN	O
for	IN	O
control	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
,	,	O
no	DT	O
detailed	JJ	O
investigation	NN	O
has	VBZ	O
been	VBN	O
conducted	VBN	O
regarding	VBG	O
the	DT	O
impact	NN	O
of	IN	O
dietary	JJ	O
sodium	NN	O
restriction	NN	O
on	IN	O
this	DT	O
condition	NN	O
.	.	O

METHODS	NNP	O
Thirty-two	JJ	O
patients	NNS	O
on	IN	O
antihypertensive	JJ	O
treatment	NN	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
:	:	O
controls	NNS	Control
(	(	O
group	NN	O
1	CD	O
)	)	O
versus	NN	Pharmacological
strict	JJ	Pharmacological
sodium	NN	Pharmacological
diet	NN	Pharmacological
(	(	O
group	NN	O
2	CD	O
;	:	O
80	CD	O
to	TO	O
100	CD	O
mmol	NNS	O
sodium	JJ	Pharmacological
daily	RB	O
)	)	O
.	.	O

After	IN	O
randomization	NN	O
,	,	O
24-hour	JJ	O
urine	NN	O
for	IN	O
sodium	NN	O
measurement	NN	O
,	,	O
BP	NNP	O
,	,	O
and	CC	O
allograft	NN	O
functions	NNS	O
were	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
3	CD	O
months	NNS	O
.	.	O

BP	NNP	O
treatment	NN	O
was	VBD	O
reevaluated	VBN	O
at	IN	O
each	DT	O
visit	NN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
At	IN	O
baseline	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
serum	JJ	O
creatinine	NN	O
,	,	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
BP	NNP	O
,	,	O
antihypertensive	JJ	O
drugs	NNS	O
,	,	O
or	CC	O
24-hour	JJ	O
urinary	JJ	O
sodium	NN	O
levels	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

After	IN	O
3	CD	O
months	NNS	O
,	,	O
daily	JJ	O
urinary	JJ	O
sodium	NN	O
excretion	NN	O
(	(	O
from	IN	O
190+/-75	CD	O
to	TO	O
106+/-48	JJ	O
mEq/d	NN	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
,	,	O
systolic	JJ	O
BP	NNP	O
(	(	O
from	IN	O
146+/-21	CD	O
to	TO	O
116+/-11	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
,	,	O
and	CC	O
diastolic	JJ	O
BP	NNP	O
(	(	O
from	IN	O
89+/-8	CD	O
to	TO	O
72+/-10	CD	O
mm	NNS	O
Hg	NNP	O
)	)	O
had	VBD	O
significantly	RB	O
decreased	VBN	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
while	IN	O
no	DT	O
significant	JJ	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
group	NN	O
1	CD	O
.	.	O

CONCLUSION	NNP	O
Low	NNP	O
sodium	NN	O
intake	NN	O
in	IN	O
combination	NN	O
with	IN	O
antihypertensive	JJ	O
treatment	NN	O
appears	VBZ	O
to	TO	O
efficiently	VB	O
control	NN	O
BP	NNP	O
in	IN	O
kidney	NN	O
allograft	NN	O
recipients	NNS	O
with	IN	O
hypertension	NN	O
.	.	O

Twenty-four-hour	JJ	O
urinary	JJ	O
sodium	NN	O
excretion	NN	O
should	MD	O
be	VB	O
checked	VBN	O
regularly	RB	O
in	IN	O
these	DT	O
patients	NNS	O
as	IN	O
a	DT	O
useful	JJ	O
marker	NN	O
to	TO	O
indicate	VB	O
whether	IN	O
the	DT	O
patient	NN	O
complies	NNS	O
with	IN	O
low	JJ	O
sodium	NN	O
intake	NN	O
.	.	O

Consumer-directed	JJ	O
care	NN	O
for	IN	O
beneficiaries	NNS	O
with	IN	O
mental	JJ	O
illness	NN	O
:	:	O
lessons	NNS	O
from	IN	O
New	NNP	O
Jersey	NNP	O
's	POS	O
Cash	NNP	O
and	CC	O
Counseling	NNP	O
program	NN	O
.	.	O

OBJECTIVE	NNP	O
Previous	NNP	O
research	NN	O
from	IN	O
the	DT	O
Cash	NNP	O
and	CC	O
Counseling	NNP	O
Demonstration	NNP	O
and	CC	O
Evaluation	NNP	O
(	(	O
CCDE	NNP	O
)	)	O
programs	NNS	O
in	IN	O
New	NNP	O
Jersey	NNP	O
,	,	O
Arkansas	NNP	O
,	,	O
and	CC	O
Florida	NNP	O
suggests	VBZ	O
that	IN	O
consumers	NNS	O
'	POS	O
control	NN	O
over	IN	O
personal	JJ	O
care	NN	O
greatly	RB	O
improves	VBZ	O
their	PRP$	O
satisfaction	NN	O
with	IN	O
care	NN	O
arrangements	NNS	O
and	CC	O
their	PRP$	O
outlook	NN	O
on	IN	O
life	NN	O
.	.	O

Still	RB	O
,	,	O
some	DT	O
argue	VBP	O
that	IN	O
consumer-directed	JJ	O
care	NN	O
may	MD	O
not	RB	O
be	VB	O
appropriate	JJ	O
for	IN	O
consumers	NNS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
mental	JJ	O
illness	NN	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
CCDE	NNP	O
program	NN	O
for	IN	O
those	DT	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
mental	JJ	O
illness	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
examined	VBD	O
nonelderly	RB	O
Medicaid	NNP	O
beneficiaries	NNS	O
in	IN	O
New	NNP	O
Jersey	NNP	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
mental	JJ	O
illness	NN	O
and	CC	O
compared	VBN	Educational
and	CC	Educational
contrasted	VBN	Educational
the	DT	Educational
experiences	NNS	Educational
of	IN	Educational
those	DT	Educational
in	IN	Educational
New	NNP	Educational
Jersey	NNP	Educational
's	POS	Educational
CCDE	NNP	Educational
program	NN	Educational
(	(	Educational
N=109	NNP	Educational
)	)	Educational
and	CC	Educational
those	DT	Educational
who	WP	Educational
received	VBD	Educational
services	NNS	Educational
provided	VBN	Educational
by	IN	Educational
an	DT	Educational
agency	NN	Educational
(	(	Educational
N=119	NNP	Educational
)	)	Educational
.	.	O

Logistic	JJ	Educational
regression	NN	Educational
analyses	NNS	Educational
were	VBD	Educational
performed	VBN	Educational
on	IN	Educational
baseline	NN	Educational
and	CC	Educational
nine-month	JJ	Educational
follow-up	JJ	Educational
data	NNS	Educational
.	.	O

RESULTS	VBN	O
By	IN	O
examining	VBG	O
outcome	JJ	O
measures	NNS	O
--	:	O
including	VBG	O
satisfaction	NN	O
with	IN	O
care	NN	O
arrangements	NNS	O
,	,	O
consumers	NNS	O
'	POS	O
perceptions	NNS	O
of	IN	O
paid	JJ	O
caregivers	NNS	O
'	POS	O
attitudes	NNS	O
,	,	O
unmet	JJ	O
needs	NNS	O
,	,	O
adverse	JJ	O
events	NNS	O
,	,	O
and	CC	O
satisfaction	NN	O
with	IN	O
life	NN	O
--	:	O
this	DT	O
study	NN	O
offers	VBZ	O
evidence	NN	O
that	IN	O
,	,	O
from	IN	O
the	DT	O
perspective	NN	O
of	IN	O
consumers	NNS	O
,	,	O
the	DT	O
CCDE	NNP	O
program	NN	O
is	VBZ	O
appropriate	JJ	O
for	IN	O
participants	NNS	O
with	IN	O
a	DT	O
mental	JJ	O
illness	NN	O
diagnosis	NN	O
.	.	O

For	IN	O
most	JJS	O
outcome	JJ	O
measures	NNS	O
the	DT	O
CCDE	NNP	O
program	NN	O
demonstrated	VBD	O
a	DT	O
positive	JJ	O
effect	NN	O
after	IN	O
baseline	NN	O
characteristics	NNS	O
were	VBD	O
controlled	VBN	O
for	IN	O
.	.	O

The	DT	O
analysis	NN	O
of	IN	O
measures	NNS	O
of	IN	O
adverse	JJ	O
events	NNS	O
,	,	O
health	NN	O
problems	NNS	O
,	,	O
and	CC	O
general	JJ	O
health	NN	O
status	NN	O
did	VBD	O
not	RB	O
yield	VB	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
the	DT	O
treatment	NN	O
group	NN	O
,	,	O
indicating	VBG	O
that	IN	O
CCDE	NNP	O
care	NN	O
was	VBD	O
at	IN	O
least	JJS	O
as	RB	O
safe	JJ	O
as	IN	O
agency-directed	JJ	O
care	NN	O
.	.	O

CONCLUSIONS	NNP	O
Considering	VBG	O
the	DT	O
growing	VBG	O
need	NN	O
for	IN	O
long-term	JJ	O
care	NN	O
services	NNS	O
and	CC	O
the	DT	O
limited	JJ	O
resources	NNS	O
available	JJ	O
,	,	O
a	DT	O
consumer-directed	JJ	O
option	NN	O
can	MD	O
be	VB	O
a	DT	O
valuable	JJ	O
alternative	NN	O
for	IN	O
persons	NNS	O
with	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
mental	JJ	O
illness	NN	O
.	.	O

To	TO	O
share	NN	O
or	CC	O
not	RB	O
to	TO	O
share	NN	O
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
consent	NN	Educational
for	IN	Educational
data	NNS	Educational
sharing	VBG	Educational
in	IN	O
genome	JJ	O
research	NN	O
.	.	O

PURPOSE	NNP	O
Despite	IN	O
growing	VBG	O
concerns	NNS	O
toward	IN	O
maintaining	VBG	O
participants	NNS	O
'	POS	O
privacy	NN	O
,	,	O
individual	JJ	O
investigators	NNS	O
collecting	VBG	O
tissue	NN	O
and	CC	O
other	JJ	O
biological	JJ	O
specimens	NNS	O
for	IN	O
genomic	JJ	O
analysis	NN	O
are	VBP	O
encouraged	VBN	O
to	TO	O
obtain	VB	O
informed	JJ	Educational
consent	NN	Educational
for	IN	O
broad	JJ	O
data	NNS	O
sharing	VBG	O
.	.	O

Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
on	IN	O
research	NN	O
enrollment	NN	O
and	CC	O
data	NNS	O
sharing	VBG	O
decisions	NNS	O
of	IN	O
three	CD	O
different	JJ	O
consent	NN	O
types	NNS	O
(	(	O
traditional	JJ	O
,	,	O
binary	JJ	O
,	,	O
or	CC	O
tiered	VBN	O
)	)	O
with	IN	O
varying	VBG	O
levels	NNS	O
of	IN	O
control	NN	O
and	CC	O
choices	NNS	O
regarding	VBG	O
data	NNS	O
sharing	VBG	O
.	.	O

METHODS	VB	O
A	DT	O
single-blinded	JJ	O
,	,	O
randomized	VBN	O
controlled	VBD	Control
trial	NN	O
was	VBD	O
conducted	VBN	O
with	IN	O
323	CD	O
eligible	JJ	O
adult	NN	O
participants	NNS	O
being	VBG	O
recruited	VBN	O
into	IN	O
one	CD	O
of	IN	O
six	CD	O
genome	JJ	O
studies	NNS	O
at	IN	O
Baylor	NNP	O
College	NNP	O
of	IN	O
Medicine	NNP	O
in	IN	O
Houston	NNP	O
,	,	O
Texas	NNP	O
,	,	O
between	IN	O
January	NNP	O
2008	CD	O
and	CC	O
August	NNP	O
2009	CD	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
experimental	JJ	Educational
consent	NN	Educational
documents	NNS	Educational
(	(	O
traditional	JJ	O
,	,	O
n	JJ	O
=	VBP	O
110	CD	O
;	:	O
binary	JJ	O
,	,	O
n	JJ	O
=	VBP	O
103	CD	O
;	:	O
and	CC	O
tiered	VBD	O
,	,	O
n	JJ	O
=	NNP	O
110	CD	O
)	)	O
.	.	O

Debriefing	VBG	O
in	IN	O
follow-up	JJ	O
visits	NNS	O
provided	VBD	O
participants	NNS	O
a	DT	O
detailed	JJ	O
review	NN	O
of	IN	O
all	DT	O
consent	NN	O
types	NNS	O
and	CC	O
the	DT	O
chance	NN	O
to	TO	O
change	VB	O
data	NNS	O
sharing	VBG	O
choices	NNS	O
or	CC	O
decline	VB	O
genome	NN	O
study	NN	O
participation	NN	O
.	.	O

RESULTS	NNP	O
Before	IN	O
debriefing	VBG	O
,	,	O
83.9	CD	O
%	NN	O
of	IN	O
participants	NNS	O
chose	JJ	O
public	JJ	O
data	NNS	O
release	NN	O
.	.	O

After	IN	O
debriefing	VBG	O
,	,	O
53.1	CD	O
%	NN	O
chose	JJ	O
public	JJ	O
data	NNS	O
release	NN	O
,	,	O
33.1	CD	O
%	NN	O
chose	NN	O
restricted	VBN	O
(	(	O
controlled	JJ	O
access	NN	O
database	NN	O
)	)	O
release	NN	O
,	,	O
and	CC	O
13.7	CD	O
%	NN	O
opted	VBN	O
out	IN	O
of	IN	O
data	NNS	Educational
sharing	VBG	Educational
.	.	Educational

Only	RB	O
one	CD	O
participant	NN	O
declined	VBD	O
genome	JJ	O
study	NN	O
participation	NN	O
due	JJ	O
to	TO	O
data	VB	O
sharing	NN	O
concerns	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
findings	NNS	O
indicate	VBP	O
that	IN	O
most	JJS	O
participants	NNS	O
are	VBP	O
willing	JJ	O
to	TO	O
publicly	RB	O
release	VB	O
their	PRP$	O
genomic	JJ	O
data	NNS	O
;	:	O
however	RB	O
,	,	O
a	DT	O
significant	JJ	O
portion	NN	O
prefers	NNS	O
restricted	VBD	O
release	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
discordance	NN	O
between	IN	O
existing	VBG	O
data	NNS	O
sharing	VBG	O
policies	NNS	O
and	CC	O
participants	NNS	O
'	POS	O
judgments	NNS	O
and	CC	O
desires	NNS	O
.	.	O

Effect	NN	O
of	IN	O
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
on	IN	O
disseminated	JJ	O
tumour	NN	O
cells	NNS	O
in	IN	O
women	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
:	:	O
an	DT	O
open	JJ	O
label	NN	O
,	,	O
randomised	VBN	O
,	,	O
phase	VB	O
2	CD	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Treatment	NNP	O
with	IN	O
bisphosphonates	NNS	Pharmacological
decreases	NNS	O
bone	VBP	O
loss	NN	O
and	CC	O
can	MD	O
increase	VB	O
disease-free	JJ	O
survival	NN	O
in	IN	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
our	PRP$	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
on	IN	O
clearance	NN	O
of	IN	O
disseminated	JJ	O
tumour	NN	O
cells	NNS	O
(	(	O
DTCs	NNP	O
)	)	O
from	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
in	IN	O
women	NNS	O
undergoing	VBG	O
neoadjuvant	JJ	O
chemotherapy	NN	O
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
were	VBD	O
recruited	VBN	O
for	IN	O
this	DT	O
open-label	JJ	O
,	,	O
phase	VB	O
2	CD	O
randomised	JJ	O
trial	NN	O
between	IN	O
March	NNP	O
17	CD	O
,	,	O
2003	CD	O
,	,	O
and	CC	O
May	NNP	O
19	CD	O
,	,	O
2006	CD	O
,	,	O
at	IN	O
a	DT	O
single	JJ	O
centre	NN	O
.	.	O

Eligible	JJ	O
patients	NNS	O
had	VBD	O
clinical	JJ	O
stage	NN	O
II-III	NNP	O
(	(	O
>	CD	O
or	CC	O
=	VB	O
T2	NNP	O
and/or	JJ	O
>	NN	O
or	CC	O
=	VB	O
N1	NNP	O
)	)	O
newly	RB	O
diagnosed	VBN	O
breast	NN	O
cancer	NN	O
,	,	O
Eastern	NNP	O
Cooperative	NNP	O
Oncology	NNP	O
Group	NNP	O
performance	NN	O
status	NN	O
of	IN	O
0	CD	O
or	CC	O
1	CD	O
,	,	O
and	CC	O
normal	JJ	O
cardiac	NN	O
,	,	O
renal	JJ	O
,	,	O
and	CC	O
liver	JJ	O
function	NN	O
.	.	O

120	CD	O
women	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
,	,	O
using	VBG	O
allocation	NN	O
concealment	NN	O
,	,	O
to	TO	O
receive	VB	O
4	CD	Pharmacological
mg	NN	Pharmacological
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
intravenously	RB	Pharmacological
every	DT	Pharmacological
3	CD	O
weeks	NNS	O
(	(	O
n=60	NN	O
)	)	O
,	,	O
or	CC	O
no	DT	Pharmacological
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
(	(	O
n=60	JJ	O
)	)	O
,	,	O
for	IN	O
1	CD	O
year	NN	O
concomitant	NN	O
with	IN	O
four	CD	Pharmacological
cycles	NNS	Pharmacological
of	IN	Pharmacological
neoadjuvant	JJ	Pharmacological
epirubicin	NN	Pharmacological
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
plus	CC	O
docetaxel	JJ	Pharmacological
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
and	CC	Pharmacological
two	CD	Pharmacological
cycles	NNS	Pharmacological
of	IN	Pharmacological
adjuvant	JJ	Pharmacological
epirubicin	JJ	Pharmacological
plus	CC	Pharmacological
docetaxel	JJ	Pharmacological
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
detectable	JJ	O
DTCs	NNP	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

Final	NNP	O
analysis	NN	O
was	VBD	O
done	VBN	O
1	CD	O
year	NN	O
after	IN	O
the	DT	O
last	JJ	O
patient	NN	O
was	VBD	O
enrolled	VBN	O
.	.	O

Analyses	NNS	O
were	VBD	O
done	VBN	O
for	IN	O
all	DT	O
patients	NNS	O
with	IN	O
available	JJ	O
data	NNS	O
at	IN	O
3	CD	O
months	NNS	O
.	.	O

This	DT	O
study	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
ClinicalTrials.gov	NNP	O
,	,	O
number	NN	O
NCT00242203	NNP	O
.	.	O

FINDINGS	NNP	O
Of	IN	O
the	DT	O
120	CD	O
patients	NNS	O
initially	RB	O
enrolled	VBD	O
,	,	O
one	CD	O
withdrew	NN	O
after	IN	O
signing	VBG	O
consent	NN	O
and	CC	O
one	CD	O
patient	NN	O
's	POS	O
baseline	NN	O
bone	NN	O
marrow	NN	O
was	VBD	O
not	RB	O
available	JJ	O
.	.	O

Both	DT	O
of	IN	O
these	DT	O
patients	NNS	O
were	VBD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

At	IN	O
3	CD	O
months	NNS	O
,	,	O
109	CD	O
bone-marrow	NN	O
samples	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
analysis	NN	O
.	.	O

In	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
group	NN	O
,	,	O
bone	NN	O
marrow	NN	O
was	VBD	O
not	RB	O
collected	VBN	O
from	IN	O
one	CD	O
patient	NN	O
because	IN	O
of	IN	O
disease	NN	O
progression	NN	O
,	,	O
one	CD	O
patient	NN	O
was	VBD	O
taken	VBN	O
off	RP	O
study	NN	O
because	IN	O
of	IN	O
severe	JJ	O
diarrhoea	NN	O
,	,	O
and	CC	O
two	CD	O
patients	NNS	O
had	VBD	O
not	RB	O
consented	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
surgery	NN	O
.	.	O

In	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
bone	NN	O
marrow	NN	O
was	VBD	O
not	RB	O
collected	VBN	O
from	IN	O
two	CD	O
patients	NNS	O
because	IN	O
of	IN	O
disease	NN	O
progression	NN	O
,	,	O
one	CD	O
patient	NN	O
withdrew	VBD	O
consent	NN	O
,	,	O
and	CC	O
three	CD	O
patients	NNS	O
were	VBD	O
not	RB	O
consented	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
surgery	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
DTCs	NNP	O
were	VBD	O
detected	VBN	O
in	IN	O
26	CD	O
of	IN	O
60	CD	O
patients	NNS	O
in	IN	O
the	DT	O
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
group	NN	O
and	CC	O
28	CD	O
of	IN	O
58	CD	O
patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

At	IN	O
3	CD	O
months	NNS	O
,	,	O
17	CD	O
of	IN	O
56	CD	O
patients	NNS	O
receiving	VBG	O
zoledronic	JJ	O
acid	NN	O
versus	IN	O
25	CD	O
of	IN	O
53	CD	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
receive	VB	O
zoledronic	JJ	O
acid	NN	O
had	VBD	O
detectable	JJ	O
DTCs	NNP	O
(	(	O
p=0.054	NN	O
)	)	O
.	.	O

The	DT	O
most	RBS	O
common	JJ	O
grade	NN	O
3-4	JJ	O
toxicities	NNS	O
were	VBD	O
infection	NN	O
(	(	O
five	CD	O
of	IN	O
60	CD	O
patients	NNS	O
in	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
group	NN	O
and	CC	O
six	CD	O
of	IN	O
59	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
and	CC	O
thrombosis	NN	O
(	(	O
five	CD	O
of	IN	O
60	CD	O
in	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
and	CC	O
two	CD	O
of	IN	O
59	CD	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
one	CD	O
documented	JJ	O
case	NN	O
of	IN	O
osteonecrosis	NN	O
in	IN	O
the	DT	O
zoledronic	JJ	O
acid	NN	O
group	NN	O
.	.	O

INTERPRETATION	NNP	O
Zoledronic	NNP	Pharmacological
acid	NN	Pharmacological
administered	VBD	O
with	IN	O
chemotherapy	NN	O
resulted	VBN	O
in	IN	O
a	DT	O
decreased	JJ	O
proportion	NN	O
of	IN	O
patients	NNS	O
with	IN	O
DTCs	NNP	O
detected	VBD	O
in	IN	O
the	DT	O
bone	NN	O
marrow	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
surgery	NN	O
.	.	O

Our	PRP$	O
study	NN	O
supports	VBZ	O
the	DT	O
hypothesis	NN	O
that	IN	O
the	DT	O
antimetastatic	JJ	O
effects	NNS	O
of	IN	O
zoledronic	JJ	Pharmacological
acid	NN	Pharmacological
may	MD	O
be	VB	O
through	IN	O
effects	NNS	O
on	IN	O
DTCs	NNP	O
.	.	O

FUNDING	NN	O
Novartis	NN	O
Pharmaceuticals	NNP	O
and	CC	O
Pfizer	NNP	O
Inc	NNP	O
.	.	O

Design	NN	O
and	CC	O
subject	JJ	O
characteristics	NNS	O
in	IN	O
the	DT	O
federally-funded	JJ	O
citalopram	NN	Pharmacological
trial	NN	O
in	IN	O
children	NNS	O
with	IN	O
pervasive	JJ	O
developmental	NN	O
disorders	NNS	O
.	.	O

The	DT	O
Studies	NNPS	O
to	TO	O
Advance	NNP	O
Autism	NNP	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
Network	NNP	O
conducted	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
with	IN	O
citalopram	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
Pervasive	NNP	O
developmental	NN	O
disorders	NNS	O
(	(	O
PDDs	NNP	O
)	)	O
.	.	O

We	PRP	O
present	VBD	O
the	DT	O
rationale	NN	O
,	,	O
design	NN	O
and	CC	O
sample	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
citalopram	JJ	Pharmacological
trial	NN	O
.	.	O

Subjects	NNS	O
(	(	O
128	CD	O
boys	NNS	O
,	,	O
21	CD	O
girls	NNS	O
)	)	O
had	VBD	O
a	DT	O
mean	JJ	O
age	NN	O
of	IN	O
9.3	CD	O
(	(	O
?3.12	NN	O
)	)	O
years	NNS	O
;	:	O
132	CD	O
(	(	O
88.6	CD	O
%	NN	O
)	)	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
autistic	JJ	O
disorder	NN	O
(	(	O
4.7	CD	O
%	NN	O
with	IN	O
Asperger	NNP	O
's	POS	O
Disorder	NNP	O
;	:	O
6.7	CD	O
%	NN	O
with	IN	O
PDD-not	NNP	O
otherwise	RB	O
specified	VBD	O
)	)	O
.	.	O

Less	JJR	O
than	IN	O
half	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
were	VBD	O
intellectually	RB	O
disabled	VBN	O
;	:	O
117	CD	O
(	(	O
78.5	CD	O
%	NN	O
)	)	O
were	VBD	O
rated	VBN	O
Moderate	NNP	O
or	CC	O
Marked	VBN	O
on	IN	O
the	DT	O
Clinical	NNP	O
Global	NNP	O
Impression	NNP	O
for	IN	O
Severity	NNP	O
.	.	O

Study	NNP	O
measures	NNS	O
were	VBD	O
similar	JJ	O
to	TO	O
previous	JJ	O
Research	NNP	O
Units	NNP	O
on	IN	O
Pediatric	NNP	O
Psychopharmacology	NNP	O
trials	NNS	O
.	.	O

Subjects	NNS	O
in	IN	O
this	DT	O
trial	NN	O
were	VBD	O
slightly	RB	O
older	JJR	O
and	CC	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
complaints	NNS	O
of	IN	O
repetitive	JJ	O
behavior	NN	O
than	IN	O
participants	NNS	O
in	IN	O
RUPP	NNP	O
trials	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
two	CD	O
sedation	NN	Pharmacological
techniques	NNS	Pharmacological
in	IN	O
patients	NNS	O
undergoing	VBG	O
surgical	JJ	O
procedures	NNS	O
under	IN	O
regional	JJ	O
anaesthesia	NN	O
.	.	O

OBJECTIVE	NNP	O
Intraoperative	NNP	O
comfort	NN	O
and	CC	O
patient	JJ	O
satisfaction	NN	O
during	IN	O
surgical	JJ	O
procedures	NNS	O
under	IN	O
regional	JJ	O
anaesthesia	NN	O
can	MD	O
be	VB	O
improved	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
supplemental	JJ	O
intravenous	JJ	O
sedation	NN	O
.	.	O

The	DT	O
authors	NNS	O
conducted	VBD	O
a	DT	O
study	NN	O
to	TO	O
compare	VB	O
two	CD	O
sedation	NN	O
techniques	NNS	O
for	IN	O
surgical	JJ	O
procedures	NNS	O
performed	VBN	O
under	IN	O
regional	JJ	O
anaesthesia	NN	O
,	,	O
i.e.	FW	O
,	,	O
midazolam	NN	Pharmacological
and	CC	O
pethidine	NN	Pharmacological
combination	NN	Pharmacological
compared	VBN	O
with	IN	O
midazolam	NN	Pharmacological
and	CC	O
tramadol	JJ	Pharmacological
combination	NN	Pharmacological
.	.	O

METHODS	NNP	O
Forty	NNP	O
adult	JJ	O
American	JJ	O
Society	NNP	O
of	IN	O
Anaesthesiologists	NNP	O
(	(	O
ASA	NNP	O
)	)	O
grade	VBD	O
1-111	JJ	O
patients	NNS	O
,	,	O
aged	VBN	O
between	IN	O
40-65	JJ	O
years	NNS	O
undergoing	VBG	O
surgery	NN	O
under	IN	O
regional	JJ	O
anaesthesia	NN	O
(	(	O
sub-arachnoid	JJ	O
block	NN	O
)	)	O
were	VBD	O
included	VBN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
divided	VBN	O
into	IN	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
standardized	JJ	O
premedication	NN	O
,	,	O
intraoperative	JJ	O
monitoring	NN	O
and	CC	O
oxygen	NN	O
therapy	NN	O
.	.	O

Group	NNP	O
A	NNP	O
patients	NNS	O
received	VBD	O
midazolam	JJ	Pharmacological
0.03	CD	Pharmacological
mg/kg	NN	Pharmacological
followed	VBN	Pharmacological
by	IN	Pharmacological
pethidine	NN	Pharmacological
20	CD	Pharmacological
mg	NN	Pharmacological
intravenously	RB	Pharmacological
,	,	O
and	CC	O
group	NN	O
B	NNP	O
patients	NNS	O
received	VBD	O
midazolam	JJ	Pharmacological
0.03	CD	Pharmacological
mg/kg	NN	Pharmacological
followed	VBN	Pharmacological
by	IN	Pharmacological
tramadol	NN	Pharmacological
20	CD	Pharmacological
mg	NN	Pharmacological
intravenously	RB	O
after	IN	O
the	DT	O
institution	NN	O
of	IN	O
regional	JJ	O
anaesthesia	NN	O
.	.	O

Monitoring	NNP	O
included	VBD	O
ECG	NNP	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
respiratory	NN	O
rate	NN	O
,	,	O
oxygen	NN	O
saturation	NN	O
and	CC	O
sedation	NN	O
score	NN	O
.	.	O

Complications	NNS	O
,	,	O
if	IN	O
any	DT	O
,	,	O
were	VBD	O
recorded	VBN	O
.	.	O

Monitoring	NN	O
was	VBD	O
continued	VBN	O
during	IN	O
the	DT	O
recovery	NN	O
room	NN	O
stay	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
interviewed	VBN	O
in	IN	O
the	DT	O
evening	NN	O
and	CC	O
time	NN	O
of	IN	O
ambulation	NN	O
and	CC	O
rating	NN	O
of	IN	O
OR	NNP	O
experience	NN	O
was	VBD	O
noted	VBN	O
.	.	O

RESULTS	NNP	O
Data	NNP	O
analysis	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
pethidine	NN	Pharmacological
and	CC	O
tramadol	NN	Pharmacological
for	IN	O
all	PDT	O
the	DT	O
haemodynamic	JJ	O
variables	NNS	O
(	(	O
p	JJ	O
=	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
also	RB	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
patient	NN	O
's	POS	O
and	CC	O
surgeon	NN	O
's	POS	O
assessment	NN	O
of	IN	O
their	PRP$	O
experience	NN	O
.	.	O

Complications	NNS	O
and	CC	O
recovery	NN	O
characteristics	NNS	O
also	RB	O
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
significant	JJ	O
difference	NN	O
.	.	O

CONCLUSION	NNP	O
Midazolam-tramadol	NNP	Pharmacological
combination	NN	Pharmacological
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
alternative	JJ	O
to	TO	O
midazolam-pethidine	JJ	Pharmacological
combination	NN	Pharmacological
for	IN	O
sedation	NN	O
during	IN	O
surgical	JJ	O
procedures	NNS	O
performed	VBN	O
under	IN	O
regional	JJ	O
anaesthesia	NN	O
.	.	O

Strength	NN	O
of	IN	O
vital	JJ	O
force	NN	O
in	IN	O
classical	JJ	O
homeopathy	NN	O
:	:	O
bio-psycho-social-spiritual	JJ	O
correlates	NNS	O
within	IN	O
a	DT	O
complex	JJ	O
systems	NNS	O
context	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
explore	VB	O
associations	NNS	O
between	IN	O
a	DT	O
global	JJ	O
rating	NN	O
for	IN	O
the	DT	O
classical	JJ	O
homeopathic	JJ	O
construct	NN	O
of	IN	O
vital	JJ	O
force	NN	O
and	CC	O
clinician	JJ	O
and	CC	O
patient	JJ	O
ratings	NNS	O
on	IN	O
previously	RB	O
validated	VBN	O
bio-psycho-social-spiritual	JJ	O
questionnaires	NNS	O
.	.	O

METHODS	NNP	O
Sixty-two	NNP	O
(	(	O
62	CD	O
)	)	O
community-recruited	JJ	O
patients	NNS	O
with	IN	O
fibromyalgia	NN	O
(	(	O
FM	NNP	O
)	)	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
prior	RB	O
to	TO	O
a	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
individualized	JJ	O
homeopathy	NN	O
.	.	O

Two	CD	O
homeopaths	NNS	O
jointly	RB	O
performed	VBD	O
case-taking	JJ	Psychological
interviews	NNS	Psychological
.	.	O

A	DT	O
conventional	JJ	O
medical	JJ	O
provider	NN	O
independently	RB	O
evaluated	VBD	O
patients	NNS	O
with	IN	O
a	DT	O
standardized	JJ	O
history	NN	O
and	CC	O
physical	JJ	O
examination	NN	O
.	.	O

Homeopaths	NNP	O
rated	VBD	O
each	DT	O
patient	NN	O
's	POS	O
vital	JJ	O
force	NN	O
(	(	O
five-point	JJ	O
Likert	NNP	O
scale	NN	O
,	,	O
with	IN	O
1	CD	O
=	JJ	O
very	RB	O
weak	JJ	O
to	TO	O
5	CD	O
=	NNS	O
very	RB	O
strong	JJ	O
)	)	O
.	.	O

Homeopaths	NNP	O
and	CC	O
the	DT	O
conventional	JJ	O
medical	JJ	O
provider	NN	O
rated	VBN	O
their	PRP$	O
Clinical	JJ	O
Global	NNP	O
Impression	NNP	O
(	(	O
CGI	NNP	O
)	)	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
illness	NN	O
(	(	O
1	CD	O
=	NNP	O
normal	JJ	O
;	:	O
7	CD	O
=	NN	O
among	IN	O
the	DT	O
most	RBS	O
extremely	RB	O
ill	JJ	O
)	)	O
.	.	O

Patients	NNS	O
completed	VBD	O
self-rating	JJ	Educational
scales	NNS	Educational
on	IN	O
pain	NN	O
,	,	O
global	JJ	O
health	NN	O
,	,	O
mood	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
coping	VBG	O
style	NN	O
,	,	O
health	NN	O
locus	NN	O
of	IN	O
control	NN	O
,	,	O
multidimensional	JJ	O
well-being	NN	O
,	,	O
spirituality	NN	O
,	,	O
sense	NN	O
of	IN	O
coherence	NN	O
,	,	O
positive	JJ	O
states	NNS	O
of	IN	O
mind	NN	O
,	,	O
and	CC	O
social	JJ	O
desirability	NN	O
.	.	O

RESULTS	NNP	O
Greater	NNP	O
vital	JJ	O
force	NN	O
ratings	NNS	O
(	(	O
mean	VB	O
2.9	CD	O
standard	JJ	O
deviation	NN	O
[	NNP	O
SD	NNP	O
]	NNP	O
0.6	CD	O
)	)	O
correlated	VBN	O
moderately	RB	O
(	(	O
p	JJ	O
<	NN	O
or	CC	O
=	VB	O
0.005	CD	O
)	)	O
with	IN	O
less	JJR	O
severe	JJ	O
CGI	NNP	O
illness	NN	O
ratings	NNS	O
by	IN	O
the	DT	O
homeopaths	NNS	O
(	(	O
r	VB	O
=-0.59	NN	O
)	)	O
,	,	O
decreased	VBD	O
patient-rated	JJ	O
mental	JJ	O
confusion	NN	O
(	(	O
r	VB	O
=-0.43	NN	O
)	)	O
,	,	O
higher	JJR	O
vigor	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.38	CD	O
)	)	O
,	,	O
and	CC	O
greater	JJR	O
positive	JJ	O
states	NNS	O
of	IN	O
mind	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.36	CD	O
)	)	O
.	.	O

Vital	NNP	O
force	NN	O
also	RB	O
showed	VBD	O
correlations	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
lower	JJR	O
CGI	NNP	O
ratings	NNS	O
by	IN	O
the	DT	O
conventional	JJ	O
medical	JJ	O
provider	NN	O
(	(	O
r	VB	O
=-0.32	NN	O
)	)	O
,	,	O
better	RB	O
selfrated	VBN	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.33	CD	O
)	)	O
,	,	O
lesser	JJR	O
fatigue	NN	O
(	(	O
r	VB	O
=-0.31	NN	O
)	)	O
,	,	O
better	JJR	O
global	JJ	O
health	NN	O
(	(	O
r	VB	O
=	RB	O
0.29	CD	O
)	)	O
,	,	O
greater	JJR	O
sense	NN	O
of	IN	O
coherence	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.28	CD	O
)	)	O
,	,	O
powerful-others	JJ	O
health	NN	O
locus	NN	O
of	IN	O
control	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.27	CD	O
)	)	O
,	,	O
increased	VBD	O
emotional	JJ	O
well-being	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.27	CD	O
)	)	O
,	,	O
and	CC	O
higher	JJR	O
social	JJ	O
desirability	NN	O
(	(	O
r	JJ	O
=	NNP	O
0.27	CD	O
)	)	O
,	,	O
but	CC	O
not	RB	O
with	IN	O
age	NN	O
,	,	O
pain	NN	O
,	,	O
or	CC	O
illness	JJ	O
duration	NN	O
.	.	O

CONCLUSION	NNP	O
Homeopathic	NNP	O
vital	JJ	O
force	NN	O
ratings	NNS	O
reflect	VBP	O
better	JJR	O
perceived	VBN	O
mental	JJ	O
function	NN	O
,	,	O
energy	NN	O
,	,	O
and	CC	O
positive	JJ	O
dimensions	NNS	O
of	IN	O
the	DT	O
individual	NN	O
,	,	O
beyond	IN	O
absence	NN	O
of	IN	O
disease	NN	O
.	.	O

Local	JJ	O
warming	NN	O
and	CC	O
insertion	NN	O
of	IN	O
peripheral	JJ	O
venous	JJ	O
cannulas	NNS	O
:	:	O
single	JJ	O
blinded	VBD	O
prospective	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
and	CC	O
single	JJ	O
blinded	VBD	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
determine	VB	O
whether	IN	O
local	JJ	O
warming	NN	O
of	IN	O
the	DT	O
lower	JJR	O
arm	NN	O
and	CC	O
hand	NN	O
facilitates	NNS	O
peripheral	VBP	O
venous	JJ	O
cannulation	NN	O
.	.	O

DESIGN	NNP	O
Single	NNP	O
blinded	VBD	O
prospective	JJ	O
randomised	VBN	O
controlled	VBN	O
trial	NN	O
and	CC	O
single	JJ	O
blinded	VBD	O
randomised	VBN	O
crossover	RB	O
trial	NN	O
.	.	O

SETTING	NNP	O
Neurosurgical	JJ	O
unit	NN	O
and	CC	O
haematology	NN	O
ward	NN	O
of	IN	O
university	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	CC	O
100	CD	O
neurosurgical	JJ	O
patients	NNS	O
and	CC	O
40	CD	O
patients	NNS	O
with	IN	O
leukaemia	NNS	O
who	WP	O
required	VBD	O
chemotherapy	NN	O
.	.	O

INTERVENTIONS	NNP	O
Neurosurgical	JJ	O
patients	NNS	O
'	POS	O
hands	NNS	Physical
and	CC	Physical
forearms	NNS	Physical
were	VBD	Physical
covered	VBN	Physical
for	IN	Physical
15	CD	Physical
minutes	NNS	Physical
with	IN	Physical
a	DT	Physical
carbon	NN	Physical
fibre	NN	Physical
heating	VBG	Physical
mitt	NN	Physical
.	.	O

Patients	NNS	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
active	JJ	Physical
warming	NN	Physical
at	IN	Physical
52	CD	Physical
degrees	NNS	Physical
C	NNP	Physical
or	CC	O
passive	JJ	Control
insulation	NN	Control
(	(	O
heater	NN	O
not	RB	O
activated	VBN	O
)	)	O
.	.	O

The	DT	O
same	JJ	O
warming	NN	O
system	NN	O
was	VBD	O
used	VBN	O
for	IN	O
10	CD	O
minutes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
leukaemia	NN	O
.	.	O

They	PRP	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
active	JJ	O
warming	NN	O
or	CC	O
passive	JJ	O
insulation	NN	O
on	IN	O
day	NN	O
1	CD	O
and	CC	O
given	VBN	O
alternative	JJ	O
treatment	NN	O
during	IN	O
the	DT	O
subsequent	JJ	O
visit	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
PRIMARY	NNP	O
:	:	O
success	NN	O
rate	NN	O
for	IN	O
insertion	NN	O
of	IN	O
18	CD	O
gauge	NN	O
cannula	NN	O
into	IN	O
vein	NN	O
on	IN	O
back	NN	O
of	IN	O
hand	NN	O
.	.	O

SECONDARY	NN	O
:	:	O
time	NN	O
required	VBN	O
for	IN	O
successful	JJ	O
cannulation	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
neurosurgical	JJ	O
patients	NNS	O
,	,	O
it	PRP	O
took	VBD	O
36	CD	O
seconds	NNS	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
31	CD	O
to	TO	O
40	CD	O
seconds	NNS	O
)	)	O
to	TO	O
insert	VB	O
a	DT	O
cannula	NN	O
in	IN	O
the	DT	O
active	JJ	O
warming	NN	O
group	NN	O
and	CC	O
62	CD	O
(	(	O
50	CD	O
to	TO	O
74	CD	O
)	)	O
seconds	NNS	O
in	IN	O
the	DT	O
passive	JJ	O
insulation	NN	O
group	NN	O
(	(	O
P=0.002	NNP	O
)	)	O
.	.	O

Three	NNP	O
(	(	O
6	CD	O
%	NN	O
)	)	O
first	RB	O
attempts	VBZ	O
failed	VBN	O
in	IN	O
the	DT	O
active	JJ	O
warming	VBG	O
group	NN	O
compared	VBN	O
with	IN	O
14	CD	O
(	(	O
28	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
passive	JJ	O
insulation	NN	O
group	NN	O
(	(	O
P=0.008	NNP	O
)	)	O
.	.	O

The	DT	O
crossover	NN	O
study	NN	O
in	IN	O
patients	NNS	O
with	IN	O
leukaemia	NN	O
showed	VBD	O
that	IN	O
insertion	NN	O
time	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
20	CD	O
seconds	NNS	O
(	(	O
8	CD	O
to	TO	O
32	CD	O
,	,	O
P=0.013	NNP	O
)	)	O
with	IN	O
active	JJ	O
warming	NN	O
and	CC	O
that	IN	O
failure	NN	O
rates	NNS	O
at	IN	O
first	JJ	O
attempt	NN	O
were	VBD	O
6	CD	O
%	NN	O
with	IN	O
warming	VBG	O
and	CC	O
30	CD	O
%	NN	O
with	IN	O
passive	JJ	O
insulation	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Local	NNP	O
warming	VBG	O
facilitates	VBZ	O
the	DT	O
insertion	NN	O
of	IN	O
peripheral	JJ	O
venous	JJ	O
cannulas	NNS	O
,	,	O
reducing	VBG	O
both	DT	O
time	NN	O
and	CC	O
number	NN	O
of	IN	O
attempts	NNS	O
required	VBN	O
.	.	O

This	DT	O
may	MD	O
decrease	VB	O
the	DT	O
time	NN	O
staff	NN	O
spend	VBP	O
inserting	VBG	O
cannulas	NN	O
,	,	O
reduce	VB	O
supply	NN	O
costs	NNS	O
,	,	O
and	CC	O
improve	VB	O
patient	JJ	O
satisfaction	NN	O
.	.	O

?-Blockers	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
in	IN	O
arterial	JJ	O
occlusive	JJ	O
disease	NN	O
trial	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
?-receptor	NN	O
blockers	NNS	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
is	VBZ	O
controversial	JJ	O
for	IN	O
their	PRP$	O
impact	NN	O
on	IN	O
vasomotor	NN	O
tone	NN	O
.	.	O

The	DT	O
?-blocker	NN	O
nebivolol	NN	O
possesses	VBZ	O
vasodilating	VBG	O
,	,	O
endothelium-dependent	JJ	O
,	,	O
NO-releasing	JJ	O
properties	NNS	O
that	WDT	O
might	MD	O
be	VB	O
beneficial	JJ	O
in	IN	O
peripheral	JJ	O
arterial	JJ	O
disease	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
and	CC	O
tolerability	NN	O
of	IN	O
nebivolol	NN	O
in	IN	O
comparison	NN	O
with	IN	O
metoprolol	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
128	CD	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
essential	JJ	O
hypertension	NN	O
were	VBD	O
included	VBN	O
and	CC	O
double-blind	JJ	O
randomized	VBN	O
to	TO	O
receive	VB	O
5	CD	O
mg	NN	O
of	IN	O
nebivolol	NN	O
(	(	O
N=65	NNP	O
)	)	O
or	CC	O
95	CD	O
mg	NN	O
of	IN	O
metoprolol	NN	O
(	(	O
N=63	NNP	O
)	)	O
once	RB	O
daily	JJ	O
.	.	O

End	NN	O
points	NNS	O
were	VBD	O
changes	NNS	O
in	IN	O
ankle-brachial	JJ	O
index	NN	O
,	,	O
initial	JJ	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
,	,	O
endothelial	JJ	O
function	NN	O
assessed	VBN	O
by	IN	O
flow-mediated	JJ	O
dilatation	NN	O
of	IN	O
the	DT	O
brachial	JJ	O
artery	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
using	VBG	O
the	DT	O
claudication	NN	O
scale	NN	O
questionnaire	NN	O
.	.	O

End	NN	O
point	NN	O
analysis	NN	O
was	VBD	O
possible	JJ	O
in	IN	O
109	CD	O
patients	NNS	O
(	(	O
85.2	CD	O
%	NN	O
)	)	O
.	.	O

After	IN	O
the	DT	O
48-week	JJ	O
treatment	NN	O
period	NN	O
,	,	O
ankle-brachial	JJ	O
index	NN	O
and	CC	O
absolute	JJ	O
claudication	NN	O
distance	NN	O
improved	VBD	O
significantly	RB	O
in	IN	O
both	DT	O
patient	JJ	O
groups	NNS	O
(	(	O
P	NNP	O
<	VBZ	O
0.05	CD	O
for	IN	O
both	DT	O
)	)	O
,	,	O
with	IN	O
no	DT	O
difference	NN	O
across	IN	O
treatments	NNS	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
nebivolol	JJ	O
group	NN	O
.	.	O

Adjusted	VBN	O
mean	JJ	O
change	NN	O
of	IN	O
initial	JJ	O
claudication	NN	O
distance	NN	O
was	VBD	O
33.9	CD	O
%	NN	O
after	IN	O
nebivolol	NN	O
(	(	O
P=0.003	NNP	O
)	)	O
and	CC	O
16.6	CD	O
%	NN	O
after	IN	O
metoprolol	NN	O
(	(	O
P=0.12	NNP	O
)	)	O
treatment	NN	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
was	VBD	O
not	RB	O
influenced	VBN	O
by	IN	O
either	DT	O
treatment	NN	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
relevant	JJ	O
change	NN	O
in	IN	O
flow-mediated	JJ	O
dilatation	NN	O
in	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
nebivolol	NN	O
or	CC	O
metoprolol	NN	O
(	(	O
P=0.16	NNP	O
)	)	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
equally	RB	O
effective	JJ	O
in	IN	O
lowering	VBG	O
blood	NN	O
pressure	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
?-blocker	JJ	O
therapy	NN	O
was	VBD	O
well	RB	O
tolerated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
intermittent	JJ	O
claudication	NN	O
and	CC	O
arterial	JJ	O
hypertension	NN	O
during	IN	O
a	DT	O
treatment	NN	O
period	NN	O
of	IN	O
?1	JJ	O
year	NN	O
.	.	O

In	IN	O
the	DT	O
direct	JJ	O
comparison	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
nebivolol	NNS	O
and	CC	O
metoprolol	NN	O
.	.	O

Randomised	VBN	O
clinical	JJ	O
trial	NN	O
:	:	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
synbiotic	JJ	Pharmacological
formulation	NN	Pharmacological
containing	VBG	Pharmacological
Lactobacillus	NNP	Pharmacological
paracasei	NN	Pharmacological
B21060	NNP	Pharmacological
plus	CC	Pharmacological
arabinogalactan	JJ	Pharmacological
and	CC	Pharmacological
xilooligosaccharides	NNS	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
.	.	O

BACKGROUND	NNP	O
Acute	NNP	O
diarrhoea	NN	O
is	VBZ	O
a	DT	O
frequent	JJ	O
problem	NN	O
in	IN	O
children	NNS	O
with	IN	O
heavy	JJ	O
economic	JJ	O
burden	NN	O
for	IN	O
families	NNS	O
and	CC	O
society	NN	O
.	.	O

AIM	NNP	O
To	TO	O
test	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
new	JJ	O
synbiotic	JJ	Pharmacological
formulation	NN	Pharmacological
containing	VBG	Pharmacological
Lactobacillus	NNP	Pharmacological
paracasei	NN	Pharmacological
B21060	NNP	Pharmacological
,	,	Pharmacological
arabinogalactan	NN	Pharmacological
and	CC	Pharmacological
xilooligosaccharides	NNS	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
.	.	O

METHODS	NNP	O
Double-blind	NNP	O
,	,	O
randomised	VBD	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
,	,	O
including	VBG	O
children	NNS	O
(	(	O
age	NN	O
3-36	CD	O
m	NN	O
)	)	O
with	IN	O
acute	JJ	O
diarrhoea	NNS	O
who	WP	O
were	VBD	O
allocated	VBN	O
to	TO	O
placebo	VB	O
or	CC	O
synbiotic	JJ	O
group	NN	O
.	.	O

Major	NNP	O
outcome	NN	O
was	VBD	O
resolution	JJ	O
rate	NN	O
of	IN	O
diarrhoea	NN	O
at	IN	O
72	CD	O
h.	JJ	O
Total	NNP	O
duration	NN	O
of	IN	O
diarrhoea	NN	O
,	,	O
daily	JJ	O
stool	NN	O
outputs	NNS	O
,	,	O
stool	NN	O
consistency	NN	O
,	,	O
working	VBG	O
days	NNS	O
lost	VBN	O
by	IN	O
parents	NNS	O
,	,	O
adjunctive	JJ	O
medications	NNS	O
,	,	O
and	CC	O
hospitalisation	NN	O
were	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
We	PRP	O
enrolled	VBD	O
55	CD	O
children	NNS	O
in	IN	O
placebo	NN	Control
group	NN	O
and	CC	O
52	CD	O
in	IN	O
synbiotic	JJ	Pharmacological
group	NN	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
similar	JJ	O
for	IN	O
demographic	JJ	O
and	CC	O
clinical	JJ	O
characteristics	NNS	O
.	.	O

Resolution	NNP	O
rate	NN	O
of	IN	O
diarrhoea	NN	O
at	IN	O
72	CD	O
h	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
synbiotic	JJ	O
group	NN	O
(	(	O
67	CD	O
%	NN	O
)	)	O
compared	VBN	O
to	TO	O
placebo	VB	Control
group	NN	O
(	(	O
40	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
.	.	O

Children	NNP	O
in	IN	O
synbiotic	JJ	O
group	NN	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
duration	NN	O
of	IN	O
diarrhoea	NN	O
(	(	O
90.5	CD	O
h	NN	O
,	,	O
78.1-102.9	JJ	O
vs.	FW	O
109.8	CD	O
h	NN	O
,	,	O
96.0-123.5	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.040	CD	O
)	)	O
,	,	O
daily	JJ	O
stool	NN	O
outputs	NNS	O
(	(	O
3.3	CD	O
,	,	O
2.8-3.8	JJ	O
vs.	FW	O
2.4	CD	O
,	,	O
1.9-2.8	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
and	CC	O
stool	JJ	O
consistency	NN	O
(	(	O
1.3	CD	O
,	,	O
0.9-1.6	JJ	O
vs.	FW	O
0.6	CD	O
,	,	O
0.4-0.9	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.002	CD	O
)	)	O
compared	VBN	O
to	TO	O
placebo	VB	Control
group	NN	O
(	(	O
data	NNS	O
expressed	VBN	O
as	IN	O
mean	NN	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
.	.	O

Rate	NN	O
of	IN	O
parents	NNS	O
that	WDT	O
missed	VBD	O
at	IN	O
least	JJS	O
one	CD	O
working	VBG	O
day	NN	O
(	(	O
41.8	CD	O
%	NN	O
vs.	FW	O
15.4	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
,	,	O
rate	NN	O
of	IN	O
children	NNS	O
that	WDT	O
needed	VBD	O
adjunctive	JJ	O
medications	NNS	O
(	(	O
25.5	CD	O
%	NN	O
vs.	FW	O
5.8	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.005	CD	O
)	)	O
or	CC	O
hospitalisation	NN	O
(	(	O
10.9	CD	O
%	NN	O
vs.	FW	O
0	CD	O
%	NN	O
,	,	O
P	NNP	O
=	NNP	O
0.014	CD	O
)	)	O
after	IN	O
the	DT	O
first	JJ	O
72	CD	O
h	NN	O
of	IN	O
treatment	NN	O
,	,	O
were	VBD	O
reduced	VBN	O
in	IN	O
synbiotic	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
synbiotic	JJ	Pharmacological
formulation	NN	Pharmacological
studied	VBN	O
is	VBZ	O
effective	JJ	O
in	IN	O
children	NNS	O
with	IN	O
acute	JJ	O
diarrhoea	NN	O
.	.	O

Australian	JJ	O
New	NNP	O
Zealand	NNP	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
(	(	O
ACTRN12611000641998	NNP	O
)	)	O
.	.	O

A	DT	O
controlled	JJ	O
trial	NN	O
of	IN	O
extended	JJ	Surgical
radical	JJ	Surgical
versus	NN	O
radical	JJ	Surgical
mastectomy	NN	Surgical
.	.	O

Ten-year	JJ	O
results	NNS	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
increasing	VBG	O
debate	NN	O
over	IN	O
possible	JJ	O
benefit	NN	O
of	IN	O
more	JJR	O
complete	JJ	O
surgery	NN	O
compared	VBN	O
to	TO	O
conservative	JJ	O
procedures	NNS	O
,	,	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
contrasting	VBG	O
the	DT	O
then	RB	O
standard	NN	Surgical
Halsted	NNP	Surgical
radical	NN	Surgical
(	(	Surgical
RDL	NNP	Surgical
)	)	Surgical
operation	NN	Surgical
with	IN	O
the	DT	O
more	RBR	O
complete	JJ	Surgical
extended	JJ	Surgical
radical	NN	Surgical
(	(	Surgical
EXT	NNP	Surgical
)	)	Surgical
mastectomy	NN	Surgical
was	VBD	O
initiated	VBN	O
in	IN	O
1973	CD	O
.	.	O

Between	IN	O
November	NNP	O
1973	CD	O
and	CC	O
July	NNP	O
1982	CD	O
,	,	O
123	CD	O
women	NNS	O
younger	JJR	O
than	IN	O
70	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
at	IN	O
clinical	JJ	O
Stages	NNP	O
I	PRP	O
and	CC	O
II	NNP	O
were	VBD	O
enrolled	VBN	O
.	.	O

Of	IN	O
the	DT	O
total	JJ	O
series	NN	O
,	,	O
112	CD	O
were	VBD	O
treated	VBN	O
by	IN	O
the	DT	O
same	JJ	O
surgeon	NN	O
and	CC	O
confirmed	VBD	O
pathologically	RB	O
as	IN	O
having	VBG	O
invasive	JJ	O
mammary	JJ	O
carcinoma	NN	O
.	.	O

In	IN	O
this	DT	O
more	RBR	O
homogeneous	JJ	O
subgroup	NN	O
,	,	O
the	DT	O
10-year	JJ	O
survival	NN	O
rates	NNS	O
(	(	O
and	CC	O
standard	JJ	O
errors	NNS	O
)	)	O
were	VBD	O
for	IN	O
RDL	NNP	O
,	,	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
7	CD	O
%	NN	O
)	)	O
and	CC	O
for	IN	O
EXT	NNP	O
,	,	O
74	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
value	NN	O
for	IN	O
comparison	NN	O
of	IN	O
survival	JJ	O
curves	NNS	O
=	VBP	O
0.13	CD	O
)	)	O
.	.	O

In	IN	O
patients	NNS	O
from	IN	O
this	DT	O
subgroup	NN	O
with	IN	O
central-medial	JJ	O
tumors	NNS	O
,	,	O
comprising	VBG	O
62	CD	O
%	NN	O
of	IN	O
the	DT	O
total	NN	O
,	,	O
survival	NN	O
after	IN	O
RDL	NNP	O
at	IN	O
10	CD	O
years	NNS	O
was	VBD	O
60	CD	O
%	NN	O
(	(	O
+/-	JJ	O
8	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
after	IN	O
EXT	NNP	O
86	CD	O
%	NN	O
(	(	O
+/-	JJ	O
6	CD	O
%	NN	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
remaining	VBG	O
patients	NNS	O
with	IN	O
lateral	JJ	O
tumors	NNS	O
,	,	O
survival	JJ	O
rates	NNS	O
were	VBD	O
unaffected	VBN	O
by	IN	O
treatment	NN	O
:	:	O
58	CD	O
%	NN	O
(	(	O
+/-	JJ	O
13	CD	O
%	NN	O
)	)	O
and	CC	O
56	CD	O
%	NN	O
(	(	O
+/-	JJ	O
11	CD	O
%	NN	O
)	)	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.62	CD	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
a	DT	O
nonrandomized	JJ	O
series	NN	O
of	IN	O
266	CD	O
RDL	NNP	O
and	CC	O
124	CD	O
EXT	NNP	O
patients	NNS	O
treated	VBD	O
between	IN	O
1960	CD	O
and	CC	O
1978	CD	O
found	VBD	O
differences	NNS	O
consistent	JJ	O
with	IN	O
those	DT	O
of	IN	O
the	DT	O
randomized	VBN	O
study	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

The	DT	O
additive	JJ	O
analgesic	JJ	O
efficacy	NN	O
of	IN	O
acetaminophen	NN	Pharmacological
,	,	O
1000	CD	O
mg	NN	O
,	,	O
and	CC	O
codeine	NN	Pharmacological
,	,	O
60	CD	O
mg	NN	O
,	,	O
in	IN	O
dental	JJ	O
pain	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	NN	O
,	,	O
randomized	VBN	O
,	,	O
single-dose	JJ	O
trial	NN	O
the	DT	O
analgesic	JJ	O
contribution	NN	O
of	IN	O
acetaminophen	NN	Pharmacological
,	,	Pharmacological
1000	CD	Pharmacological
mg	NN	Pharmacological
,	,	O
and	CC	O
codeine	NN	Pharmacological
,	,	Pharmacological
60	CD	Pharmacological
mg	NN	Pharmacological
,	,	O
was	VBD	O
determined	VBN	O
.	.	O

The	DT	O
study	NN	O
was	VBD	O
a	DT	O
2	CD	O
X	NN	O
2	CD	O
factorial	JJ	O
experiment	NN	O
in	IN	O
which	WDT	O
120	CD	O
patients	NNS	O
suffering	VBG	O
from	IN	O
pain	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
oral	JJ	O
surgery	NN	O
rated	VBD	O
their	PRP$	O
pain	NN	O
intensity	NN	O
and	CC	O
pain	NN	O
relief	NN	O
for	IN	O
up	IN	O
to	TO	O
5	CD	O
hours	NNS	O
after	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
one	CD	O
of	IN	O
:	:	O
1000	CD	O
mg	NN	O
acetaminophen	NN	Pharmacological
,	,	O
60	CD	O
mg	NN	O
codeine	NN	O
,	,	O
1000	CD	O
mg	NN	O
acetaminophen	NN	Pharmacological
plus	CC	Pharmacological
60	CD	Pharmacological
mg	NN	Pharmacological
codeine	NN	Pharmacological
,	,	O
or	CC	O
placebo	NN	Control
.	.	Control

The	DT	O
factorial	JJ	O
analysis	NN	O
showed	VBD	O
that	IN	O
both	DT	O
1000	CD	O
mg	NN	O
acetaminophen	NN	Pharmacological
and	CC	O
60	CD	O
mg	NN	O
codeine	NN	Pharmacological
made	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
contribution	NN	O
to	TO	O
the	DT	O
analgesic	JJ	O
effectiveness	NN	O
of	IN	O
the	DT	O
combination	NN	O
on	IN	O
all	DT	O
measures	NNS	O
of	IN	O
efficacy	NN	O
(	(	O
sum	NN	O
of	IN	O
pain	NN	O
intensity	NN	O
differences	NNS	O
,	,	O
largest	JJS	O
pain	NN	O
intensity	NN	O
difference	NN	O
,	,	O
total	JJ	O
pain	NN	O
relief	NN	O
,	,	O
largest	JJS	O
pain	NN	O
relief	NN	O
,	,	O
and	CC	O
time	NN	O
to	TO	O
remedication	NN	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
differ	VB	O
among	IN	O
the	DT	O
treatments	NNS	O
,	,	O
including	VBG	O
placebo	NN	O
.	.	O

Postoperative	JJ	O
radiotherapy	NN	Surgical
in	IN	O
breast	NN	O
cancer	NN	O
--	:	O
long-term	JJ	O
results	NNS	O
from	IN	O
the	DT	O
Oslo	NNP	O
study	NN	O
.	.	O

The	DT	O
long-term	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
postoperative	JJ	Surgical
radiotherapy	NN	Surgical
as	IN	O
an	DT	O
adjuvant	NN	O
to	TO	O
radical	JJ	Surgical
mastectomy	NN	Surgical
are	VBP	O
presented	VBN	O
.	.	O

There	EX	O
were	VBD	O
1115	CD	O
patients	NNS	O
including	VBG	O
27	CD	O
protocol	JJ	O
deviants	NNS	O
.	.	O

The	DT	O
follow-up	JJ	O
time	NN	O
is	VBZ	O
11-20	JJ	O
years	NNS	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
part	NN	O
a	DT	O
conventional	JJ	Physical
roentgen	NN	Physical
unit	NN	Physical
was	VBD	O
used	VBN	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
second	JJ	O
part	NN	O
a	DT	O
60Co	CD	Physical
unit	NN	Physical
,	,	O
with	IN	O
considerably	RB	O
increased	VBN	O
dosage	NN	O
and	CC	O
altered	VBD	O
treatment	NN	O
plan	NN	O
.	.	O

Both	DT	O
types	NNS	O
of	IN	O
radiation	NN	O
techniques	NNS	O
lowered	VBD	O
the	DT	O
incidence	NN	O
of	IN	O
loco-regional	JJ	O
recurrences	NNS	O
significantly	RB	O
,	,	O
but	CC	O
had	VBD	O
no	DT	O
significant	JJ	O
influence	NN	O
on	IN	O
the	DT	O
overall	JJ	O
survival	NN	O
.	.	O

The	DT	O
relapse-free	JJ	O
survival	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
by	IN	O
60Co	CD	Physical
radiation	NN	Physical
in	IN	O
Stage	NNP	O
II	NNP	O
patients	NNS	O
,	,	O
but	CC	O
was	VBD	O
unaffected	VBN	O
by	IN	O
radiation	NN	O
in	IN	O
the	DT	O
other	JJ	O
subgroups	NNS	O
.	.	O

Regarding	VBG	O
survival	NN	O
,	,	O
Stage	NNP	O
II	NNP	O
patients	NNS	O
with	IN	O
medially	RB	O
located	VBN	O
tumors	NNS	O
seemed	VBD	O
to	TO	O
benefit	VB	O
more	JJR	O
from	IN	O
60Co	CD	Physical
radiation	NN	Physical
than	IN	O
those	DT	O
with	IN	O
lateral	JJ	O
tumors	NNS	O
.	.	O

A	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
deaths	NNS	O
caused	VBN	O
by	IN	O
myocardial	JJ	O
infarction	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
Stage	NNP	O
I	PRP	O
patients	NNS	O
having	VBG	O
60Co	CD	O
radiation	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
radiation	NN	O
dose	NN	O
to	TO	O
the	DT	O
heart	NN	O
is	VBZ	O
of	IN	O
significance	NN	O
.	.	O

Randomized	VBN	O
study	NN	O
of	IN	O
six	CD	O
umbilical	JJ	Pharmacological
cord	NN	Pharmacological
care	NN	Pharmacological
regimens	VBZ	Pharmacological
.	.	Pharmacological

Comparing	VBG	O
length	NN	O
of	IN	O
attachment	NN	O
,	,	O
microbial	JJ	O
control	NN	O
,	,	O
and	CC	O
satisfaction	NN	O
.	.	O

Two	CD	O
hundred	VBD	O
and	CC	O
seventy	VB	O
one	CD	O
infants	NNS	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
study	NN	O
to	TO	O
compare	VB	O
six	CD	O
different	JJ	O
methods	NNS	O
of	IN	O
treating	VBG	O
the	DT	O
umbilical	JJ	O
cord	NN	O
.	.	O

Antimicrobial	NNP	O
control	NN	O
was	VBD	O
equal	JJ	O
for	IN	O
all	DT	O
methods	NNS	O
.	.	O

Repeated	VBN	O
triple	JJ	Pharmacological
dye	NN	Pharmacological
application	NN	Pharmacological
was	VBD	O
considered	VBN	O
least	JJS	O
acceptable	JJ	O
by	IN	O
staff	NN	O
and	CC	O
parents	NNS	O
and	CC	O
had	VBD	O
the	DT	O
longest	JJS	O
attachment	JJ	O
time	NN	O
.	.	O

Povidone-iodine	NN	Pharmacological
was	VBD	O
associated	VBN	O
with	IN	O
the	DT	O
shortest	JJS	O
attachment	JJ	O
time	NN	O
and	CC	O
was	VBD	O
most	RBS	O
liked	JJ	O
.	.	O

If	IN	O
there	EX	O
is	VBZ	O
no	DT	O
special	JJ	O
need	NN	O
to	TO	O
treat	VB	O
a	DT	O
specific	JJ	O
nosocomial	JJ	O
outbreak	NN	O
,	,	O
duration	NN	O
of	IN	O
cord	NN	O
attachment	NN	O
and	CC	O
satisfaction	NN	O
of	IN	O
staff	NN	O
and	CC	O
parents	NNS	O
can	MD	O
help	VB	O
clinicians	NNS	O
decide	VB	O
on	IN	O
a	DT	O
cord	NN	O
care	NN	O
regimen	NNS	O
.	.	O

Paracetamol	NNP	Pharmacological
reduces	NNS	O
postoperative	VBP	O
pain	NN	O
and	CC	O
rescue	NN	Pharmacological
analgesic	JJ	Pharmacological
demand	NN	O
after	IN	O
robot-assisted	JJ	Surgical
endoscopic	NN	Surgical
thyroidectomy	NN	Surgical
by	IN	Surgical
the	DT	Surgical
transaxillary	JJ	Surgical
approach	NN	Surgical
.	.	O

BACKGROUND	NNP	O
Postoperative	NNP	O
pain	NN	O
following	VBG	O
endoscopic	NN	Surgical
thyroidectomy	NN	Surgical
,	,	O
although	IN	O
less	JJR	O
severe	JJ	O
than	IN	O
after	IN	O
open	JJ	O
methods	NNS	O
,	,	O
is	VBZ	O
still	RB	O
a	DT	O
source	NN	O
of	IN	O
marked	JJ	O
discomfort	NN	O
and	CC	O
surgical	JJ	O
stress	NN	O
.	.	O

This	DT	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
determine	VB	O
if	IN	O
repeated	VBN	O
intravenous	JJ	Pharmacological
paracetamol	NN	Pharmacological
could	MD	O
decrease	VB	O
postoperative	JJ	O
pain	NN	O
and	CC	O
rescue	NN	O
analgesic	NN	O
requirements	NNS	O
after	IN	O
robot-assisted	JJ	Surgical
endoscopic	JJ	Surgical
thyroidectomy	NN	Surgical
via	IN	O
the	DT	O
transaxillary	JJ	Surgical
approach	NN	Surgical
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
This	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blinded	JJ	O
,	,	O
and	CC	O
placebo-controlled	JJ	Control
study	NN	O
enrolled	VBD	O
124	CD	O
women	NNS	O
21-60	CD	O
years	NNS	O
of	IN	O
age	NN	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
elective	JJ	Surgical
gasless	NN	Surgical
robot-assisted	JJ	Surgical
endoscopic	NN	Surgical
thyroidectomy	NN	Surgical
via	IN	O
the	DT	O
transaxillary	JJ	Surgical
approach	NN	Surgical
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
given	VBN	O
placebo	NNS	Control
or	CC	O
1	CD	O
g	NN	O
of	IN	O
paracetamol	NN	Pharmacological
as	IN	O
a	DT	O
100	CD	O
ml	JJ	O
solution	NN	O
infused	VBD	O
over	IN	O
15	CD	O
min	NNS	O
1	CD	O
h	NN	O
before	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	Pharmacological
,	,	O
and	CC	O
then	RB	O
at	IN	O
6-h	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
following	JJ	O
24	CD	O
h.	JJ	O
RESULTS	NNP	O
Postoperative	NNP	O
pain	NN	O
scores	NNS	O
were	VBD	O
significantly	RB	O
lower	JJR	O
at	IN	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
surgery	NN	O
in	IN	O
the	DT	O
paracetamol	NN	Pharmacological
group	NN	O
than	IN	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
.	.	O

Significantly	RB	O
fewer	JJR	O
patients	NNS	O
in	IN	O
the	DT	O
paracetamol	NN	Pharmacological
group	NN	O
received	VBD	O
rescue	NN	Pharmacological
analgesics	NNS	Pharmacological
compared	VBN	O
to	TO	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
9.5	CD	O
%	NN	O
vs.	FW	O
65.6	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

First	NNP	O
analgesic	JJ	Pharmacological
time	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Postoperative	JJ	O
nausea	NN	O
(	(	O
44.3	CD	O
%	NN	O
vs.	FW	O
22.2	CD	O
%	NN	O
)	)	O
and	CC	O
vomiting	VBG	O
(	(	O
21.3	CD	O
%	NN	O
vs.	FW	O
6.3	CD	O
%	NN	O
)	)	O
were	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
than	IN	O
in	IN	O
the	DT	O
paracetamol	NN	Pharmacological
group	NN	O
.	.	O

Other	JJ	O
postoperative	JJ	O
side	NN	O
effects	NNS	O
,	,	O
including	VBG	O
sedation	NN	O
,	,	O
confusion	NN	O
,	,	O
and	CC	O
pruritus	NN	O
,	,	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
concluded	VBD	O
that	IN	O
repeated	JJ	O
administration	NN	O
of	IN	O
1	CD	O
g	NN	O
of	IN	O
intravenous	JJ	Pharmacological
paracetamol	NN	Pharmacological
over	IN	O
24	CD	O
h	NN	O
is	VBZ	O
easy	JJ	O
,	,	O
effective	JJ	O
,	,	O
safe	JJ	O
,	,	O
and	CC	O
well	RB	O
tolerated	VBN	O
for	IN	O
pain	NN	O
management	NN	O
in	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
postoperative	JJ	O
pain	NN	O
after	IN	O
gasless	JJ	Physical
robot-assisted	JJ	Physical
endoscopic	NN	Physical
thyroidectomy	NN	Physical
performed	VBD	O
via	IN	O
the	DT	O
transaxillary	JJ	Physical
approach	NN	Physical
.	.	O

The	DT	O
effect	NN	O
of	IN	O
two	CD	O
types	NNS	O
of	IN	O
teacher	NN	Educational
training	NN	Educational
on	IN	O
implementation	NN	O
of	IN	O
Smart	NNP	Educational
Choices	NNPS	Educational
:	:	O
a	DT	O
tobacco	NN	Educational
prevention	NN	Educational
curriculum	NN	Educational
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
the	DT	O
implementation	NN	O
phase	NN	O
of	IN	O
a	DT	O
four-year	JJ	O
research	NN	O
project	NN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
strategies	NNS	O
to	TO	O
increase	VB	O
diffusion	NN	O
of	IN	O
Smart	NNP	O
Choices	NNP	O
,	,	O
a	DT	O
school-based	JJ	Educational
tobacco	NN	Educational
prevention	NN	Educational
program	NN	Educational
.	.	O

The	DT	O
impact	NN	O
on	IN	O
curriculum	JJ	O
implementation	NN	O
of	IN	O
two	CD	O
approaches	NNS	O
to	TO	O
teacher	VB	O
training	NN	O
are	VBP	O
compared	VBN	O
.	.	O

School	JJ	O
districts	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
a	DT	O
live	JJ	Educational
workshop	NN	Educational
training	NN	Educational
or	CC	O
video	NN	Educational
training	NN	Educational
condition	NN	Educational
.	.	O

The	DT	O
outcome	NN	O
of	IN	O
the	DT	O
evaluation	NN	O
was	VBD	O
teachers	NNS	O
'	POS	O
implementation	NN	O
of	IN	O
Smart	NNP	O
Choices	NNP	O
.	.	O

Results	NNP	O
show	VBP	O
a	DT	O
lower	JJR	O
proportion	NN	O
of	IN	O
video-trained	JJ	Educational
teachers	NNS	O
implemented	VBD	O
the	DT	O
curriculum	NN	O
,	,	O
but	CC	O
overall	JJ	O
completeness	NN	O
and	CC	O
fidelity	NN	O
of	IN	O
implementation	NN	O
for	IN	O
those	DT	O
teachers	NNS	O
who	WP	O
did	VBD	O
teach	VB	O
the	DT	O
curriculum	NN	O
were	VBD	O
comparable	JJ	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Video-trained	JJ	Educational
teachers	NNS	O
,	,	O
however	RB	O
,	,	O
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
brainstorming	NN	O
and	CC	O
student	NN	O
presentations/role	NN	O
plays	NNS	O
,	,	O
two	CD	O
of	IN	O
the	DT	O
methods	NNS	O
prescribed	VBN	O
by	IN	O
the	DT	O
curriculum	NN	O
.	.	O

Implications	NNS	O
of	IN	O
the	DT	O
results	NNS	O
for	IN	O
teacher	JJ	O
training	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

A	DT	O
shortened	JJ	O
versus	NN	O
standard	NN	O
matched	VBD	O
postpartum	JJ	Pharmacological
magnesium	NN	Pharmacological
sulphate	NN	Pharmacological
regimen	NNS	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
eclampsia	NN	O
:	:	O
a	DT	O
randomised	JJ	O
controlled	VBN	O
trial	NN	O
.	.	O

Magnesium	NN	Pharmacological
sulphate	NN	Pharmacological
is	VBZ	O
currently	RB	O
the	DT	O
most	RBS	O
ideal	JJ	O
drug	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
eclampsia	NN	O
but	CC	O
its	PRP$	O
use	NN	O
in	IN	O
Nigeria	NNP	O
is	VBZ	O
still	RB	O
limited	JJ	O
due	JJ	O
its	PRP$	O
cost	NN	O
and	CC	O
clinicians	NNS	O
inexperience	NN	O
with	IN	O
the	DT	O
drug	NN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
a	DT	O
shortened	JJ	O
postpartum	NN	O
course	NN	O
of	IN	O
magnesium	NN	Pharmacological
sulphate	NN	Pharmacological
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
standard	JJ	O
Pritchard	NNP	O
regimen	NN	O
in	IN	O
controlling	VBG	O
fits	NNS	O
in	IN	O
eclampsia	NN	O
Between	NNP	O
January	NNP	O
and	CC	O
June	NNP	O
2011	CD	O
,	,	O
98	CD	O
eclamptic	JJ	O
mothers	NNS	O
presenting	VBG	O
at	IN	O
the	DT	O
labour	JJ	O
ward	NN	O
of	IN	O
the	DT	O
University	NNP	O
of	IN	O
Maiduguri	NNP	O
Teaching	NNP	O
Hospital	NNP	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	RB	O
the	DT	O
standard	JJ	Pharmacological
Pritchard	NNP	Pharmacological
regimen	NN	Pharmacological
of	IN	Pharmacological
magnesium	NN	Pharmacological
sulphate	NN	Pharmacological
or	CC	O
a	DT	O
shortened	JJ	O
postpartum	NN	O
course	NN	O
in	IN	O
which	WDT	O
only	RB	O
two	CD	O
doses	NNS	O
of	IN	O
intramuscular	JJ	Pharmacological
magnesium	NN	Pharmacological
sulphate	NN	Pharmacological
is	VBZ	O
given	VBN	O
four	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
maternal	JJ	O
and	CC	O
fetal	JJ	O
outcomes	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
recurrence	NN	O
of	IN	O
fits	NNS	O
.	.	O

The	DT	O
recurrence	NN	O
of	IN	O
fits	NNS	O
and	CC	O
other	JJ	O
maternal	JJ	O
complications	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

The	DT	O
total	JJ	O
dosage	NN	O
of	IN	O
magnesium	NN	Pharmacological
sulphate	NN	Pharmacological
in	IN	O
the	DT	O
shortened	JJ	O
group	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
40	CD	O
%	NN	O
in	IN	O
66	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

The	DT	O
shortened	JJ	O
postpartum	NN	O
course	NN	O
of	IN	O
magnesium	NN	Pharmacological
sulphate	NN	Pharmacological
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
standard	JJ	O
Pritchard	NNP	O
regimen	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
eclampsia	NN	O
.	.	O

[	VB	O
The	DT	O
effect	NN	O
of	IN	O
losartan	JJ	Pharmacological
versus	NN	O
atenolol	NN	Pharmacological
on	IN	O
cardiovascular	JJ	O
morbidity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetes	NNS	O
mellitus	NNS	O
in	IN	O
the	DT	O
LIFE-study	NNP	O
]	NNP	O
.	.	O

INTRODUCTION	NNP	O
The	DT	O
most	RBS	O
suitable	JJ	O
antihypertensive	JJ	O
drug	NN	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
and	CC	O
diabetes	VBZ	O
is	VBZ	O
unclear	JJ	O
.	.	O

In	IN	O
a	DT	O
prespecified	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
LIFE-study	NNP	O
we	PRP	O
compared	VBN	O
the	DT	O
effects	NNS	O
of	IN	O
losartan	NN	Pharmacological
and	CC	O
atenolol	NN	Pharmacological
on	IN	O
cardiovascular	JJ	O
morbidity	NN	O
and	CC	O
mortality	NN	O
in	IN	O
diabetic	JJ	O
patients	NNS	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
1195	CD	O
patients	NNS	O
in	IN	O
the	DT	O
LIFE-study	NNP	O
had	VBD	O
diabetes	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
randomisation	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
for	IN	O
double-blind	JJ	O
treatment	NN	O
with	IN	O
losartan	JJ	Pharmacological
versus	NN	O
atenolol	NN	Pharmacological
.	.	O

The	DT	O
patients	NNS	O
had	VBD	O
ECG-verified	JJ	O
left	JJ	O
ventricular	NN	O
hypertrophy	NN	O
,	,	O
mean	JJ	O
age	NN	O
67	CD	O
years	NNS	O
,	,	O
blood	NN	O
pressure	NN	O
177/96	CD	O
mmHg	NN	O
after	IN	O
two	CD	O
weeks	NNS	O
placebo	JJ	Control
run-in	JJ	O
period	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
at	IN	O
least	JJS	O
four	CD	O
years	NNS	O
(	(	O
mean	JJ	O
4.7	CD	O
years	NNS	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
composite	JJ	O
endpoint	NN	O
was	VBD	O
cardiovascular	JJ	O
death	NN	O
,	,	O
stroke	VBD	O
or	CC	O
myocardial	JJ	O
infarction	NN	O
.	.	O

RESULTS	NNP	O
Blood	NNP	O
pressure	NN	O
was	VBD	O
reduced	VBN	O
to	TO	O
146/79	CD	O
and	CC	O
148/79	CD	O
in	IN	O
losartan-treated	JJ	Pharmacological
patients	NNS	O
and	CC	O
atenolol-treated	JJ	Pharmacological
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
occurred	VBD	O
in	IN	O
103	CD	O
patients	NNS	O
assigned	VBN	O
losartan	JJ	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
586	CD	O
)	)	O
and	CC	O
139	CD	O
assigned	VBN	O
atenolol	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
609	CD	O
)	)	O
.	.	O

Relative	JJ	O
risk	NN	O
reduction	NN	O
24	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.031	CD	O
)	)	O
.	.	O

Cardiovascular	JJ	O
mortality	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
37	CD	O
%	NN	O
in	IN	O
favour	NN	O
of	IN	O
losartan	NN	Pharmacological
(	(	O
p	JJ	O
<	NNP	O
0.028	CD	O
)	)	O
,	,	O
and	CC	O
all	DT	O
cause	NN	O
mortality	NN	O
by	IN	O
39	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.002	CD	O
)	)	O
.	.	O

DISCUSSION	NNP	O
Losartan	NNP	Pharmacological
was	VBD	O
very	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
cardiovascular	JJ	O
morbidity	NN	O
and	CC	O
mortality	NN	O
as	RB	O
compared	VBN	O
to	TO	O
atenolol	VB	Pharmacological
.	.	O

These	DT	O
results	NNS	O
will	MD	O
have	VB	O
a	DT	O
major	JJ	O
impact	NN	O
on	IN	O
the	DT	O
choice	NN	O
of	IN	O
anti-hypertensive	JJ	O
treatment	NN	O
for	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
and	CC	O
diabetes	NNS	O
.	.	O

Association	NNP	O
of	IN	O
race	NN	Educational
with	IN	O
complications	NNS	O
and	CC	O
prognosis	NN	O
following	VBG	O
acute	JJ	O
coronary	JJ	O
syndromes	NNS	O
.	.	O

The	DT	O
baseline	NN	O
characteristics	NNS	O
,	,	O
complications	NNS	O
,	,	O
and	CC	O
survival	NN	O
of	IN	O
489	CD	O
black	JJ	O
and	CC	O
6,890	CD	O
non-black	JJ	O
patients	NNS	O
with	IN	O
acute	JJ	O
coronary	JJ	O
syndromes	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

Important	NNP	O
racial	JJ	O
differences	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
demographic	JJ	O
features	NNS	O
,	,	O
atherosclerosis	NN	O
risk	NN	O
factors	NNS	O
,	,	O
and	CC	O
treatment	NN	Educational
strategies	NNS	Educational
;	:	O
however	RB	O
,	,	O
despite	IN	O
these	DT	O
differences	NNS	O
,	,	O
no	DT	O
independent	JJ	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
clinical	JJ	O
outcomes	NNS	O
according	VBG	O
to	TO	O
race	NN	O
.	.	O

The	DT	O
1-year	JJ	O
mortality	NN	O
rate	NN	O
was	VBD	O
2.9	CD	O
%	NN	O
for	IN	O
black	JJ	O
patients	NNS	O
and	CC	O
2.5	CD	O
%	NN	O
for	IN	O
non-black	JJ	O
patients	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.93	CD	O
)	)	O
.	.	O

CDP571	NNP	Pharmacological
,	,	O
a	DT	O
humanized	JJ	O
monoclonal	JJ	O
antibody	NN	O
to	TO	O
tumour	VB	O
necrosis	NN	O
factor-alpha	NN	O
,	,	O
for	IN	O
steroid-dependent	JJ	O
Crohn	NNP	O
's	POS	O
disease	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
.	.	O

BACKGROUND	NNP	O
More	JJR	O
than	IN	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
Crohn	NNP	O
's	POS	O
disease	NN	O
become	NN	O
either	CC	O
steroid	JJ	O
resistant	NN	O
or	CC	O
dependent	NN	O
.	.	O

Accordingly	RB	O
,	,	O
development	NN	O
of	IN	O
new	JJ	O
treatments	NNS	O
for	IN	O
steroid-dependent	JJ	O
Crohn	NNP	O
's	POS	O
disease	NN	O
is	VBZ	O
a	DT	O
research	NN	O
priority	NN	O
.	.	O

AIM	NNP	O
To	TO	O
evaluate	VB	O
CDP571	NNP	Pharmacological
,	,	O
a	DT	O
humanized	VBN	O
antibody	NN	O
to	TO	O
tumour	VB	O
necrosis	NN	O
factor-alpha	NN	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
steroid-dependent	JJ	O
Crohn	NNP	O
's	POS	O
disease	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
steroid-dependent	JJ	O
Crohn	NNP	O
's	POS	O
disease	NN	O
(	(	O
n	JJ	O
=	NNP	O
271	CD	O
)	)	O
were	VBD	O
enrolled	VBN	O
in	IN	O
a	DT	O
36-week	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
.	.	O

Steroid	JJ	O
dependence	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
use	NN	O
of	IN	O
prednisolone	NN	O
or	CC	O
prednisone	NN	Pharmacological
(	(	O
15-40	JJ	O
mg/day	NN	O
)	)	O
or	CC	O
budesonide	NN	O
(	(	O
9	CD	O
mg/day	NN	O
)	)	O
for	IN	O
>	NN	O
or	CC	O
=8	JJ	O
weeks	NNS	O
,	,	O
a	DT	O
previous	JJ	O
failed	JJ	O
attempt	NN	O
to	TO	O
decrease	VB	O
or	CC	O
discontinue	VB	O
steroids	NNS	O
within	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
screening	NN	O
,	,	O
and	CC	O
a	DT	O
Crohn	NNP	O
's	POS	O
Disease	NNP	O
Activity	NNP	O
Index	NNP	O
score	NN	O
of	IN	O
<	NN	O
or	CC	O
=150	JJ	O
points	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
intravenous	JJ	O
CDP571	NNP	Control
10	CD	O
mg/kg	NN	O
or	CC	O
placebo	NN	O
8-weekly	RB	O
through	IN	O
to	TO	O
week	NN	O
32	CD	O
.	.	O

Steroids	NNS	O
were	VBD	O
then	RB	O
tapered	VBN	O
using	VBG	O
a	DT	O
defined	JJ	O
schedule	NN	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
endpoint	NN	O
was	VBD	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
with	IN	O
steroid	JJ	O
sparing	NN	O
,	,	O
defined	VBD	O
as	IN	O
discontinuation	NN	O
of	IN	O
steroid	JJ	O
therapy	NN	Pharmacological
without	IN	O
a	DT	O
disease	NN	O
flare	NN	O
(	(	O
Crohn	NNP	O
's	POS	O
Disease	NNP	O
Activity	NNP	O
Index	NNP	O
score	VBD	O
>	NNP	O
or	CC	O
=220	NNP	O
points	NNS	O
)	)	O
at	IN	O
week	NN	O
36	CD	O
.	.	O

RESULTS	NNP	O
Steroid	NNP	O
sparing	VBG	O
occurred	VBD	O
in	IN	O
53	CD	O
of	IN	O
181	CD	O
(	(	O
29.3	CD	O
%	NN	O
)	)	O
CDP571	NNP	Pharmacological
patients	NNS	O
and	CC	O
33	CD	O
of	IN	O
90	CD	O
(	(	O
36.7	CD	O
%	NN	O
)	)	O
placebo	NN	Control
patients	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.24	CD	O
)	)	O
.	.	O

Adverse	JJ	O
events	NNS	O
occurred	VBD	O
at	IN	O
similar	JJ	O
frequencies	NNS	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
CDP571	NNP	Pharmacological
was	VBD	O
ineffective	JJ	O
for	IN	O
sparing	VBG	O
steroids	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
steroid-dependent	JJ	O
Crohn	NNP	O
's	POS	O
disease	NN	O
.	.	O

CDP571	NNP	Pharmacological
was	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Do	VB	O
cervical	JJ	O
cancer	NN	O
screening	VBG	O
rates	NNS	O
increase	VBP	O
in	IN	O
association	NN	O
with	IN	O
an	DT	O
intervention	NN	O
designed	VBN	O
to	TO	O
increase	VB	O
mammography	NN	O
usage	NN	O
?	.	O
OBJECTIVES	UH	O
To	TO	O
assess	VB	O
cervical	JJ	O
cancer	NN	O
screening	VBG	O
behaviors	NNS	O
among	IN	O
underserved	JJ	O
women	NNS	O
participating	VBG	O
in	IN	O
an	DT	O
intervention	NN	O
designed	VBN	O
to	TO	O
increase	VB	O
mammography	NN	O
use	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
897	CD	O
women	NNS	O
from	IN	O
three	CD	O
racial	JJ	O
groups	NNS	O
(	(	O
white	JJ	O
,	,	O
African	JJ	O
American	NNP	O
,	,	O
Native	JJ	O
American	NNP	O
)	)	O
living	NN	O
in	IN	O
a	DT	O
rural	JJ	O
county	NN	O
in	IN	O
North	NNP	O
Carolina	NNP	O
.	.	O

Baseline	NNP	O
and	CC	O
followup	JJ	O
surveys	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
815	CD	O
women	NNS	O
;	:	O
775	CD	O
women	NNS	O
provided	VBD	O
data	NNS	O
to	TO	O
be	VB	O
included	VBN	O
in	IN	O
these	DT	O
analyses	NNS	O
.	.	O

The	DT	O
intervention	NN	O
group	NN	O
received	VBD	O
an	DT	O
educational	JJ	Educational
program	NN	Educational
focused	VBN	Educational
on	IN	Educational
mammography	NN	Educational
delivered	VBN	Educational
by	IN	Educational
a	DT	Educational
lay	NN	Educational
health	NN	Educational
advisor	NN	Educational
,	,	O
and	CC	O
the	DT	O
control	NN	O
group	NN	O
received	VBD	O
a	DT	O
physician	JJ	Educational
letter/brochure	NN	Educational
focusing	VBG	Educational
on	IN	Educational
Pap	NNP	Educational
tests	NNS	Educational
.	.	O

RESULTS	NNP	O
Women	NNP	O
in	IN	O
both	CC	O
the	DT	O
intervention	NN	O
(	(	O
OR	NNP	O
1.70	CD	O
;	:	O
1.31	CD	O
,	,	O
2.21	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
OR	NNP	O
1.38	CD	O
;	:	O
1.04	CD	O
,	,	O
1.82	CD	O
,	,	O
p	NN	O
=	NNP	O
0.025	CD	O
)	)	O
significantly	RB	O
increased	VBD	O
cervical	JJ	O
cancer	NN	O
screening	VBG	O
rates	NNS	O
within	IN	O
risk	NN	O
appropriate	JJ	O
guidelines	NNS	O
.	.	O

No	DT	O
differences	NNS	O
by	IN	O
racial	JJ	O
group	NN	O
were	VBD	O
documented	VBN	O
.	.	O

Women	NNP	O
categorized	VBD	O
in	IN	O
the	DT	O
high-risk	JJ	O
group	NN	O
for	IN	O
developing	VBG	O
cervical	JJ	O
cancer	NN	O
(	(	O
>	$	O
2	CD	O
sexual	JJ	O
partners	NNS	O
,	,	O
age	NN	O
<	VBD	O
18	CD	O
years	NNS	O
at	IN	O
first	JJ	O
sexual	JJ	O
intercourse	NN	O
,	,	O
smoker	NN	O
;	:	O
treated	VBN	O
for	IN	O
sexually	RB	O
transmitted	VBN	O
disease	NN	O
[	NNP	O
STD	NNP	O
]	NNP	O
or	CC	O
partner	NN	O
with	IN	O
treated	JJ	O
STD	NNP	O
)	)	O
significantly	RB	O
(	(	O
OR	NNP	O
1.88	CD	O
;	:	O
1.54	CD	O
,	,	O
2.28	CD	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
increased	VBD	O
Pap	NNP	O
test	NN	O
completion	NN	O
.	.	O

However	RB	O
,	,	O
a	DT	O
nonsignificant	JJ	O
increase	NN	O
(	(	O
OR	NNP	O
1.25	CD	O
;	:	O
0.87	CD	O
,	,	O
1.79	CD	O
,	,	O
p	NN	O
=	NNP	O
0.221	CD	O
)	)	O
in	IN	O
Pap	NNP	O
test	NN	O
completion	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
women	NNS	O
categorized	VBN	O
as	IN	O
low	JJ	O
risk	NN	O
for	IN	O
cervical	JJ	O
cancer	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
suggests	VBZ	O
that	IN	O
women	NNS	O
in	IN	O
an	DT	O
intensive	JJ	Educational
behavioral	JJ	Educational
intervention	NN	Educational
designed	VBN	Educational
to	TO	Educational
increase	VB	Educational
mammography	NN	Educational
use	NN	Educational
may	MD	O
also	RB	O
increase	VB	O
Pap	NNP	O
test	JJS	O
completion	NN	O
,	,	O
similar	JJ	O
to	TO	O
a	DT	O
minimal	JJ	O
intervention	NN	O
focused	VBD	O
only	RB	O
on	IN	O
increasing	VBG	O
Pap	NNP	O
test	NN	O
completion	NN	O
.	.	O

These	DT	O
results	NNS	O
have	VBP	O
implications	NNS	O
for	IN	O
the	DT	O
design	NN	O
and	CC	O
evaluation	NN	O
of	IN	O
behavioral	JJ	O
intervention	NN	O
studies	NNS	O
.	.	O

Outcomes	NNS	O
and	CC	O
biochemical	JJ	O
parameters	NNS	O
following	VBG	O
cardiac	JJ	Surgical
surgery	NN	Surgical
:	:	Surgical
effects	NNS	O
of	IN	O
transfusion	NN	Physical
of	IN	Physical
residual	JJ	Physical
blood	NN	Physical
using	VBG	O
centrifugation	NN	Physical
and	CC	Physical
multiple-pass	NN	Physical
hemoconcentration	NN	Physical
.	.	Physical

OBJECTIVES	UH	O
To	TO	O
determine	VB	O
whether	IN	O
or	CC	O
not	RB	O
there	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
methods	NNS	O
of	IN	O
centrifugation	NN	O
(	(	O
CF	NNP	O
)	)	O
and	CC	O
multiple-pass	JJ	O
hemoconcentration	NN	O
(	(	O
MPH	NNP	O
)	)	O
of	IN	O
the	DT	O
residual	JJ	O
cardiopulmonary-bypass	NN	O
volume	NN	O
in	IN	O
relation	NN	O
to	TO	O
biochemical	JJ	O
measurements	NNS	O
and	CC	O
patient	JJ	O
outcomes	NNS	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBN	O
,	,	O
and	CC	O
controlled	VBD	O
.	.	O

SETTING	NN	O
Conducted	VBN	O
at	IN	O
a	DT	O
western	JJ	O
Canadian	JJ	O
tertiary	NN	O
care	NN	O
hospital	NN	O
.	.	O

PARTICIPANTS	NNP	O
Consisted	NNP	O
of	IN	O
61	CD	O
consecutive	JJ	O
male	NN	O
and	CC	O
female	JJ	O
patients	NNS	O
from	IN	O
ages	NNS	O
40	CD	O
to	TO	O
80	CD	O
who	WP	O
were	VBD	O
scheduled	VBN	O
for	IN	O
cardiac	JJ	Surgical
surgery	NN	Surgical
with	IN	O
cardiopulmonary	JJ	Surgical
bypass	NN	Surgical
.	.	Surgical

INTERVENTIONS	NNP	O
Either	CC	O
the	DT	O
centrifugation	NN	Physical
or	CC	O
multiple-pass	NN	Physical
hemoconcentration	NN	Physical
method	NN	Physical
was	VBD	O
used	VBN	O
to	TO	O
process	VB	O
the	DT	O
residual	JJ	O
blood	NN	O
from	IN	O
the	DT	O
cardiopulmonary	JJ	O
bypass	NN	O
circuit	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
12-hour	JJ	O
postoperative	JJ	O
levels	NNS	O
of	IN	O
serum	NN	O
hemoglobin	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
the	DT	O
centrifugation	NN	Physical
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
multiple-pass	JJ	Physical
hemoconcentration	NN	Physical
group	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
serum	NN	O
levels	NNS	O
of	IN	O
total	JJ	O
protein	NN	O
and	CC	O
albumin	NN	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
multiple-pass	JJ	Physical
hemoconcentration	NN	Physical
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
centrifugation	NN	Physical
group	NN	O
.	.	O

Additionally	RB	O
,	,	O
after	IN	O
12-hours	JJ	O
postoperatively	RB	O
,	,	O
the	DT	O
serum	NN	O
fibrinogen	NN	O
and	CC	O
platelet	NN	O
counts	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
multiple-pass	JJ	Physical
hemoconcentration	NN	Physical
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
those	DT	O
of	IN	O
the	DT	O
centrifugation	NN	Physical
group	NN	O
.	.	O

The	DT	O
allogeneic	JJ	O
product	NN	O
transfusion	NN	O
index	NN	O
and	CC	O
the	DT	O
chest-tube	JJ	O
blood	NN	O
drainage	NN	O
indices	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
the	DT	O
multiple-pass	JJ	Physical
hemoconcentration	NN	Physical
group	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
centrifugation	NN	Physical
group	NN	O
.	.	O

CONCLUSION	NNP	O
Although	IN	O
the	DT	O
CF	NNP	Physical
method	NN	Physical
provided	VBD	O
a	DT	O
product	NN	O
in	IN	O
a	DT	O
shorter	JJR	O
turnaround	NN	O
time	NN	O
,	,	O
with	IN	O
consistent	JJ	O
clearance	NN	O
of	IN	O
heparin	NN	Pharmacological
,	,	O
the	DT	O
MPH	NNP	Physical
method	NN	Physical
trended	VBD	O
towards	NNS	O
enhanced	VBN	O
biochemical	JJ	O
and	CC	O
clinical	JJ	O
patient	NN	O
outcomes	VBZ	O
over	IN	O
the	DT	O
12-hour	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

Longterm	NNP	O
safety	NN	O
,	,	O
efficacy	NN	O
,	,	O
and	CC	O
radiographic	JJ	O
outcome	NN	O
with	IN	O
etanercept	JJ	Pharmacological
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
rheumatoid	NN	O
arthritis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
safety	NN	O
,	,	O
efficacy	NN	O
,	,	O
and	CC	O
radiographic	JJ	O
progression	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
rheumatoid	NN	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
undergoing	VBG	O
longterm	JJ	O
treatment	NN	O
with	IN	O
etanercept	NN	Pharmacological
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
early	JJ	O
RA	NNP	O
(	(	O
disease	JJ	O
duration	NN	O
of	IN	O
3	CD	O
years	NNS	O
or	CC	O
less	JJR	O
)	)	O
who	WP	O
had	VBD	O
completed	VBN	O
a	DT	O
2-year	JJ	O
efficacy	NN	O
study	NN	O
comparing	VBG	O
etanercept	NNS	Pharmacological
and	CC	O
methotrexate	NN	Pharmacological
(	(	O
MTX	NNP	O
)	)	O
were	VBD	O
followed	VBN	O
in	IN	O
an	DT	O
extension	NN	O
where	WRB	O
they	PRP	O
received	VBD	O
25	CD	O
mg	NNS	O
etanercept	JJ	Pharmacological
twice	RB	O
weekly	RB	O
.	.	O

Safety	NNP	O
was	VBD	O
summarized	VBN	O
descriptively	RB	O
and	CC	O
compared	VBN	O
with	IN	O
data	NNS	O
from	IN	O
the	DT	O
efficacy	NN	O
study	NN	O
.	.	O

Efficacy	NNP	O
and	CC	O
radiographic	JJ	O
progression	NN	O
were	VBD	O
assessed	VBN	O
using	VBG	O
American	JJ	O
College	NNP	O
of	IN	O
Rheumatology	NNP	O
response	NN	O
criteria	NNS	O
,	,	O
disease	NN	O
activity	NN	O
scores	VBZ	O
,	,	O
and	CC	O
Total	NNP	O
Sharp	NNP	O
Score	NNP	O
(	(	O
TSS	NNP	O
)	)	O
.	.	O

RESULTS	JJ	O
Rates	NNS	O
of	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
and	CC	O
serious	JJ	O
infections	NNS	O
did	VBD	O
not	RB	O
increase	VB	O
with	IN	O
longterm	JJ	O
exposure	NN	O
to	TO	O
etanercept	VB	O
,	,	O
and	CC	O
were	VBD	O
similar	JJ	O
to	TO	O
rates	NNS	O
reported	VBN	O
for	IN	O
the	DT	O
blinded	JJ	O
portion	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
study	NN	O
.	.	O

Efficacy	NNP	O
was	VBD	O
sustained	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
completed	VBD	O
5	CD	O
years	NNS	O
of	IN	O
etanercept	JJ	Pharmacological
treatment	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
this	DT	O
report	NN	O
(	(	O
N	NNP	O
=	NNP	O
201	CD	O
)	)	O
,	,	O
even	RB	O
in	IN	O
those	DT	O
who	WP	O
decreased	VBD	O
or	CC	O
discontinued	VBN	O
use	NN	O
of	IN	O
MTX	NNP	O
or	CC	O
corticosteroids	NNS	O
.	.	O

No	DT	O
radiographic	JJ	O
progression	NN	O
(	(	O
change	NN	O
in	IN	O
TSS	NNP	O
<	NNP	O
or	CC	O
=	VB	O
0	CD	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
55	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
5-year	JJ	O
radiographs	NN	O
;	:	O
negative	JJ	O
change	NN	O
(	(	O
TSS	NNP	O
<	NNP	O
0	CD	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
11	CD	O
%	NN	O
.	.	O

CONCLUSION	NNP	O
Etanercept	NNP	Pharmacological
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
RA	NNP	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
for	IN	O
up	RB	O
to	TO	O
5	CD	O
years	NNS	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
sustained	VBN	O
efficacy	NN	O
and	CC	O
decreased	JJ	O
rate	NN	O
of	IN	O
radiographic	JJ	O
progression	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
radiographic	JJ	O
progression	NN	O
was	VBD	O
low	JJ	O
compared	VBN	O
with	IN	O
other	JJ	O
studies	NNS	O
,	,	O
emphasizing	VBG	O
the	DT	O
benefit	NN	O
gained	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
early	JJ	O
aggressive	JJ	O
RA	NNP	O
who	WP	O
undergo	VBP	O
longterm	JJ	O
treatment	NN	O
with	IN	O
etanercept	NN	Pharmacological
.	.	O

Successful	JJ	O
new	JJ	O
method	NN	O
of	IN	O
extracorporeal	JJ	Surgical
percutaneous	JJ	Surgical
endoscopic	NN	Surgical
gastrostomy	NN	Surgical
(	(	Surgical
E-PEG	NNP	Surgical
)	)	Surgical
.	.	Surgical

BACKGROUND	NNP	O
Although	IN	O
percutaneous	JJ	Surgical
endoscopic	NNS	Surgical
gastrostomy	NN	Surgical
(	(	Surgical
PEG	NNP	Surgical
)	)	Surgical
has	VBZ	O
become	VBN	O
popular	JJ	O
for	IN	O
patients	NNS	O
with	IN	O
swallowing	VBG	O
disorders	NNS	O
as	IN	O
a	DT	O
nutrition	NN	O
support	NN	O
or	CC	O
a	DT	O
decompressant	NN	O
of	IN	O
gastrointestine	NN	O
,	,	O
perioperative	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
PEG	NNP	Surgical
have	VBP	O
not	RB	O
decreased	VBN	O
,	,	O
especially	RB	O
peristomal	JJ	O
infections	NNS	O
.	.	O

To	TO	O
reduce	VB	O
peristomal	JJ	O
infections	NNS	O
,	,	O
we	PRP	O
designed	VBD	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
gastrostomy	NN	O
by	IN	O
extracorporeal	JJ	O
approach	NN	O
under	IN	O
endoscopic	JJ	O
observation	NN	O
,	,	O
named	VBN	O
as	IN	O
extra-corporeal	JJ	Surgical
PEG	NNP	Surgical
(	(	Surgical
E-PEG	NNP	Surgical
)	)	Surgical
.	.	O

METHODS	NNP	O
Experimental	NNP	O
studies	NNS	O
for	IN	O
E-PEG	NNP	Surgical
were	VBD	O
performed	VBN	O
repeatedly	RB	O
using	VBG	O
pigs	NNS	O
under	IN	O
general	JJ	O
anesthesia	NN	Pharmacological
to	TO	O
confirm	VB	O
the	DT	O
safety	NN	O
of	IN	O
its	PRP$	O
procedure	NN	O
for	IN	O
human	JJ	O
use	NN	O
.	.	O

After	IN	O
approval	NN	O
of	IN	O
institutional	JJ	O
ethics	NNS	O
review	VBP	O
board	NN	O
in	IN	O
our	PRP$	O
university	NN	O
,	,	O
thirty	JJ	O
patients	NNS	O
with	IN	O
prior	JJ	O
consent	NN	O
participated	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

The	DT	O
operation	NN	O
time	NN	O
,	,	O
the	DT	O
incidence	NN	O
rate	NN	O
of	IN	O
complications	NNS	O
and	CC	O
the	DT	O
hospital	NN	O
stay	NN	O
were	VBD	O
compared	VBN	O
between	IN	O
E-PEG	NNP	Surgical
and	CC	Surgical
ordinary	JJ	Surgical
pull-method	JJ	Surgical
PEG	NNP	Surgical
groups	NNS	Surgical
.	.	O

RESULTS	NNP	O
Two	CD	O
patients	NNS	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
in	IN	O
E-PEG	NNP	Surgical
group	NN	O
had	VBD	O
postoperative	JJ	O
complications	NNS	O
,	,	O
i.e.	FW	O
,	,	O
aspiration	NN	O
pneumonia	NN	O
and	CC	O
surgical	JJ	O
site	NN	O
infection	NN	O
.	.	O

The	DT	O
operation	NN	O
time	NN	O
of	IN	O
E-PEG	NNP	Surgical
group	NN	O
was	VBD	O
5-16	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
10.3	CD	O
+/-	JJ	O
2.96	CD	O
)	)	O
min	NN	O
as	IN	O
compared	VBN	O
to	TO	O
14-37	JJ	O
(	(	O
mean	JJ	O
+/-	JJ	O
SD	NN	O
:	:	O
26.9	CD	O
+/-	JJ	O
8.39	CD	O
)	)	O
min	NN	O
with	IN	O
pull-method	JJ	O
PEG	NNP	Surgical
.	.	O

The	DT	O
postoperative	JJ	O
hospital	NN	O
day	NN	O
of	IN	O
E-PEG	NNP	Surgical
was	VBD	O
within	IN	O
two	CD	O
days	NNS	O
except	IN	O
for	IN	O
the	DT	O
two	CD	O
complicated	VBD	O
cases	NNS	O
.	.	O

Significance	NNP	O
differences	NNS	O
of	IN	O
operation	NN	O
time	NN	O
,	,	O
complication	NN	O
rate	NN	O
and	CC	O
postoperative	JJ	O
hospital	NN	O
stay	NN	O
between	IN	O
those	DT	O
groups	NNS	O
observed	VBD	O
statistically	RB	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
E-PEG	NNP	Surgical
was	VBD	O
safe	JJ	O
,	,	O
tolerable	JJ	O
and	CC	O
speedy	NN	O
when	WRB	O
compared	VBN	O
ordinary	JJ	O
pull-method	JJ	O
PEG	NNP	Surgical
.	.	O

Effects	NNS	O
of	IN	O
statins	NNS	Pharmacological
on	IN	O
progression	NN	O
of	IN	O
subclinical	JJ	O
brain	NN	O
infarct	NN	O
.	.	O

BACKGROUND	NNP	O
Subclinical	NNP	O
brain	NN	O
infarct	NN	O
(	(	O
SBI	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
subsequent	JJ	O
stroke	NN	O
and	CC	O
cognitive	JJ	O
decline	NN	O
.	.	O

A	DT	O
longitudinal	JJ	O
epidemiological	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
statins	NNS	Pharmacological
may	MD	O
prevent	VB	O
development	NN	O
of	IN	O
SBI	NNP	O
.	.	O

We	PRP	O
investigated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
statins	NNS	Pharmacological
upon	IN	O
development	NN	O
of	IN	O
brain	NN	O
infarct	NN	O
by	IN	O
performing	VBG	O
a	DT	O
post-hoc	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
Regression	NNP	O
of	IN	O
Cerebral	NNP	O
Artery	NNP	O
Stenosis	NNP	O
(	(	O
ROCAS	NNP	O
)	)	O
study	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
ROCAS	NNP	O
study	NN	O
is	VBZ	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
evaluating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
simvastatin	NN	Pharmacological
20	CD	O
mg	JJ	O
daily	JJ	O
upon	IN	O
progression	NN	O
of	IN	O
asymptomatic	JJ	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
stenosis	NN	O
among	IN	O
stroke-free	JJ	O
individuals	NNS	O
over	IN	O
2	CD	O
years	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
227	CD	O
subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
114	CD	O
)	)	O
or	CC	O
simvastatin	$	Pharmacological
20	CD	O
mg	JJ	O
daily	JJ	O
(	(	O
n	JJ	O
=	NNP	O
113	CD	O
)	)	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
brain	NN	O
infarcts	NNS	O
as	IN	O
detected	VBN	O
by	IN	O
MRI	NNP	O
was	VBD	O
recorded	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
number	NN	O
of	IN	O
new	JJ	O
brain	NN	O
infarcts	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
Among	IN	O
the	DT	O
227	CD	O
randomized	JJ	O
subjects	NNS	O
,	,	O
33	CD	O
(	(	O
14.5	CD	O
%	NN	O
)	)	O
had	VBD	O
SBI	VBN	O
at	IN	O
baseline	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
significantly	RB	O
fewer	JJR	O
subjects	NNS	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
1	CD	O
)	)	O
had	VBD	O
new	JJ	O
brain	NN	O
infarcts	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
n	JJ	O
=	VBZ	O
8	CD	O
;	:	O
p	NN	O
=	VBZ	O
0.018	CD	O
)	)	O
.	.	O

The	DT	O
new	JJ	O
brain	NN	O
infarcts	NNS	O
of	IN	O
subjects	NNS	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
were	VBD	O
subclinical	JJ	O
.	.	O

Among	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
,	,	O
the	DT	O
new	JJ	O
brain	NN	O
infarcts	NNS	O
of	IN	O
3	CD	O
subjects	NNS	O
were	VBD	O
symptomatic	JJ	O
while	IN	O
those	DT	O
of	IN	O
the	DT	O
remaining	VBG	O
5	CD	O
subjects	NNS	O
were	VBD	O
subclinical	JJ	O
.	.	O

Among	IN	O
putative	JJ	O
variables	NNS	O
,	,	O
multivariate	JJ	O
regression	NN	O
analysis	NN	O
showed	VBD	O
that	IN	O
only	RB	O
the	DT	O
baseline	NN	O
number	NN	O
of	IN	O
SBIs	NNP	O
(	(	O
OR	NNP	O
=	VBZ	O
6.27	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
2.4-16.5	CD	O
)	)	O
and	CC	O
simvastatin	JJ	Pharmacological
treatment	NN	O
(	(	O
OR	NNP	O
=	VBZ	O
0.09	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
0.01-0.82	NN	O
)	)	O
independently	RB	O
predicted	VBD	O
the	DT	O
development	NN	O
of	IN	O
new	JJ	O
brain	NN	O
infarcts	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Consistent	NNP	O
with	IN	O
findings	NNS	O
of	IN	O
the	DT	O
epidemiological	JJ	O
study	NN	O
,	,	O
our	PRP$	O
study	NN	O
suggests	VBZ	O
that	IN	O
statins	NNS	O
may	MD	O
prevent	VB	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
new	JJ	O
brain	NN	O
infarct	NN	O
.	.	O

A	DT	O
phase	NN	O
III	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
multicenter	NN	O
study	NN	O
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
antithrombin	NN	Pharmacological
in	IN	O
heparin-resistant	JJ	O
patients	NNS	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
cardiac	JJ	O
surgery	NN	O
necessitating	VBG	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
recombinant	JJ	Pharmacological
human	JJ	Pharmacological
antithrombin	NN	Pharmacological
(	(	Pharmacological
rhAT	NN	Pharmacological
)	)	Pharmacological
for	IN	O
restoring	VBG	O
heparin	NN	O
responsiveness	NN	O
in	IN	O
heparin	NN	O
resistant	JJ	O
patients	NNS	O
undergoing	VBG	O
cardiac	JJ	O
surgery	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
in	IN	O
heparin-resistant	JJ	O
patients	NNS	O
undergoing	VBG	O
cardiac	JJ	O
surgery	NN	O
with	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

Heparin	NNP	Pharmacological
resistance	NN	O
was	VBD	O
diagnosed	VBN	O
when	WRB	O
the	DT	O
activated	VBN	O
clotting	NN	O
time	NN	O
was	VBD	O
less	JJR	O
than	IN	O
480	CD	O
s	NNS	O
after	IN	O
400	CD	O
U/kg	NNP	O
heparin	NN	Pharmacological
.	.	O

Fifty-four	JJ	O
heparin-resistant	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
.	.	O

One	CD	O
cohort	NN	O
received	VBD	Pharmacological
75	CD	Pharmacological
U/kg	NNP	Pharmacological
rhAT	NN	Pharmacological
,	,	O
and	CC	O
the	DT	O
other	JJ	O
received	VBD	Pharmacological
normal	JJ	Pharmacological
saline	NN	Pharmacological
.	.	O

If	IN	O
the	DT	O
activated	JJ	O
clotting	NN	O
time	NN	O
remained	VBD	O
less	JJR	O
than	IN	O
480	CD	O
s	NN	O
,	,	O
this	DT	O
was	VBD	O
considered	VBN	O
treatment	NN	O
failure	NN	O
,	,	O
and	CC	O
2	CD	O
units	NNS	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
was	VBD	O
transfused	VBN	O
.	.	O

Patients	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
Only	RB	O
19	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
rhAT	NN	Pharmacological
group	NN	O
received	VBD	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
,	,	O
compared	VBN	O
with	IN	O
81	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

During	IN	O
their	PRP$	O
hospitalization	NN	O
,	,	O
48	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
rhAT	NN	Pharmacological
group	NN	O
received	VBD	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
,	,	O
compared	VBN	O
with	IN	O
85	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.009	CD	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
required	VBD	O
higher	JJR	O
heparin	NN	Pharmacological
doses	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.005	CD	O
)	)	O
for	IN	O
anticoagulation	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
associated	VBN	O
with	IN	O
rhAT	NN	Pharmacological
.	.	O

There	EX	O
was	VBD	O
increased	VBN	O
blood	NN	O
loss	NN	O
12	CD	O
h	NN	O
postoperatively	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.05	CD	O
)	)	O
with	IN	O
a	DT	O
trend	NN	O
toward	IN	O
increased	VBN	O
24-h	JJ	O
bleeding	NN	O
in	IN	O
the	DT	O
rhAT	NN	Pharmacological
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.06	CD	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
blood	NN	O
and	CC	O
platelet	NN	O
transfusions	NNS	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
75	CD	O
U/kg	NNP	O
rhAT	NN	Pharmacological
is	VBZ	O
effective	JJ	O
in	IN	O
restoring	VBG	O
heparin	NN	O
responsiveness	NN	O
and	CC	O
promoting	VBG	O
therapeutic	JJ	O
anticoagulation	NN	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
heparin-resistant	JJ	O
patients	NNS	O
.	.	O

Treating	VBG	O
heparin-resistant	JJ	O
patients	NNS	O
with	IN	O
rhAT	NN	Pharmacological
may	MD	O
decrease	VB	O
the	DT	O
requirement	NN	O
for	IN	O
heparin	NN	O
and	CC	O
fresh	JJ	O
frozen	JJ	O
plasma	NN	O
.	.	O

Early	RB	O
clinical	JJ	O
outcomes	NNS	O
and	CC	O
toxicity	NN	O
of	IN	O
intensity	NN	O
modulated	VBN	O
versus	IN	O
conventional	JJ	O
pelvic	JJ	O
radiation	NN	O
therapy	NN	O
for	IN	O
locally	RB	O
advanced	JJ	O
cervix	NN	O
carcinoma	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	NN	O
study	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
toxicity	NN	O
and	CC	O
clinical	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	JJ	O
cervical	JJ	O
cancer	NN	O
(	(	O
LACC	NNP	O
)	)	O
treated	VBD	O
with	IN	O
whole	JJ	Pharmacological
pelvic	JJ	Pharmacological
conventional	JJ	Pharmacological
radiation	NN	Pharmacological
therapy	NN	Pharmacological
(	(	O
WP-CRT	NNP	O
)	)	O
versus	NN	O
intensity	NN	Pharmacological
modulated	VBN	Pharmacological
radiation	NN	Pharmacological
therapy	NN	Pharmacological
(	(	O
WP-IMRT	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
MATERIALS	NNP	O
Between	NNP	O
January	NNP	O
2010	CD	O
and	CC	O
January	NNP	O
2012	CD	O
,	,	O
44	CD	O
patients	NNS	O
with	IN	O
International	NNP	O
Federation	NNP	O
of	IN	O
Gynecology	NNP	O
and	CC	O
Obstetrics	NNP	O
(	(	O
FIGO	NNP	O
2009	CD	O
)	)	O
stage	NN	O
IIB-IIIB	NNP	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
of	IN	O
the	DT	O
cervix	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
50.4	CD	O
Gy	NNP	O
in	IN	O
28	CD	O
fractions	NNS	O
delivered	VBN	O
via	IN	O
either	DT	O
WP-CRT	JJ	Physical
or	CC	O
WP-IMRT	JJ	Physical
with	IN	O
concurrent	JJ	O
weekly	JJ	O
cisplatin	NN	O
40	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
.	.	O

Acute	NNP	O
toxicity	NN	O
was	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Common	NNP	O
Terminology	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNP	O
,	,	O
version	NN	O
3.0	CD	O
,	,	O
and	CC	O
late	JJ	O
toxicity	NN	O
was	VBD	O
graded	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Radiation	NNP	O
Therapy	NNP	O
Oncology	NNP	O
Group	NNP	O
system	NN	O
.	.	O

The	DT	O
primary	JJ	O
and	CC	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
acute	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
and	CC	O
disease-free	JJ	O
survival	NN	O
,	,	O
respectively	RB	O
.	.	O

RESULTS	NNP	O
Of	IN	O
44	CD	O
patients	NNS	O
,	,	O
22	CD	O
patients	NNS	O
received	VBD	O
WP-CRT	NNP	Pharmacological
and	CC	O
22	CD	O
received	VBD	O
WP-IMRT	NNP	Pharmacological
.	.	O

In	IN	O
the	DT	O
WP-CRT	JJ	Pharmacological
arm	NN	O
,	,	O
13	CD	O
patients	NNS	O
had	VBD	O
stage	NN	O
IIB	NNP	O
disease	NN	O
and	CC	O
9	CD	O
had	VBD	O
stage	NN	O
IIIB	NNP	O
disease	NN	O
;	:	O
in	IN	O
the	DT	O
IMRT	NNP	Pharmacological
arm	NN	O
,	,	O
12	CD	O
patients	NNS	O
had	VBD	O
stage	NN	O
IIB	NNP	O
disease	NN	O
and	CC	O
10	CD	O
had	VBD	O
stage	NN	O
IIIB	NNP	O
disease	NN	O
.	.	O

The	DT	O
median	JJ	O
follow-up	JJ	O
time	NN	O
in	IN	O
the	DT	O
WP-CRT	JJ	O
arm	NN	O
was	VBD	O
21.7	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
10.7-37.4	JJ	O
months	NNS	O
)	)	O
,	,	O
and	CC	O
in	IN	O
the	DT	O
WP-IMRT	JJ	O
arm	NN	O
it	PRP	O
was	VBD	O
21.6	CD	O
months	NNS	O
(	(	O
range	NN	O
,	,	O
7.7-34.4	JJ	O
months	NNS	O
)	)	O
.	.	O

At	IN	O
27	CD	O
months	NNS	O
,	,	O
disease-free	JJ	O
survival	NN	O
was	VBD	O
79.4	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-CRT	NNP	Pharmacological
group	NN	O
versus	VBD	O
60	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-IMRT	NNP	Pharmacological
group	NN	O
(	(	O
P=.651	NNP	O
)	)	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
was	VBD	O
76	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-CRT	NNP	O
group	NN	O
versus	VBD	O
85.7	CD	O
%	NN	O
in	IN	O
the	DT	O
WP-IMRT	NNP	O
group	NN	O
(	(	O
P=.645	NNP	O
)	)	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
WP-IMRT	JJ	O
arm	NN	O
experienced	VBD	O
significantly	RB	O
fewer	JJR	O
grade	NN	O
?2	NNP	O
acute	VBZ	O
gastrointestinal	JJ	O
toxicities	NNS	O
(	(	O
31.8	CD	O
%	NN	O
vs	JJ	O
63.6	CD	O
%	NN	O
,	,	O
P=.034	NNP	O
)	)	O
and	CC	O
grade	JJ	O
?3	NNP	O
gastrointestinal	JJ	O
toxicities	NNS	O
(	(	O
4.5	CD	O
%	NN	O
vs	JJ	O
27.3	CD	O
%	NN	O
,	,	O
P=.047	NNP	O
)	)	O
than	IN	O
did	VBD	O
patients	NNS	O
receiving	VBG	O
WP-CRT	NNP	O
and	CC	O
had	VBD	O
less	JJR	O
chronic	JJ	O
gastrointestinal	JJ	O
toxicity	NN	O
(	(	O
13.6	CD	O
%	NN	O
vs	JJ	O
50	CD	O
%	NN	O
,	,	O
P=.011	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
WP-IMRT	NNP	O
is	VBZ	O
associated	VBN	O
with	IN	O
significantly	RB	O
less	JJR	O
toxicity	NN	O
compared	VBN	O
with	IN	O
WP-CRT	NNP	O
and	CC	O
has	VBZ	O
a	DT	O
comparable	JJ	O
clinical	JJ	O
outcome	NN	O
.	.	O

Further	JJ	O
studies	NNS	O
with	IN	O
larger	JJR	O
sample	NN	O
sizes	NNS	O
and	CC	O
longer	JJR	O
follow-up	JJ	O
times	NNS	O
are	VBP	O
warranted	VBN	O
to	TO	O
justify	VB	O
its	PRP$	O
use	NN	O
in	IN	O
routine	JJ	O
clinical	JJ	O
practice	NN	O
.	.	O

Minimal	NNP	O
clinically	RB	O
important	JJ	O
change	NN	O
for	IN	O
pain	NN	O
intensity	NN	O
,	,	O
functional	JJ	O
status	NN	O
,	,	O
and	CC	O
general	JJ	O
health	NN	O
status	NN	O
in	IN	O
patients	NNS	O
with	IN	O
nonspecific	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Cohort	NNP	O
study	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
estimate	VB	O
the	DT	O
Minimal	NNP	O
Clinically	NNP	O
Important	NNP	O
Change	NNP	O
(	(	O
MCIC	NNP	O
)	)	O
of	IN	O
the	DT	O
pain	NN	O
intensity	NN	O
numerical	JJ	O
rating	NN	O
scale	NN	O
(	(	O
PI-NRS	NNP	O
)	)	O
,	,	O
the	DT	O
Quebec	NNP	O
Back	NNP	O
Pain	NNP	O
Disability	NNP	O
Scale	NNP	O
(	(	O
QBPDS	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
Euroqol	NNP	O
(	(	O
EQ	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

SUMMARY	NNP	O
OF	IN	O
BACKGROUND	NNP	O
DATA	NNP	O
MCIC	NNP	O
can	MD	O
provide	VB	O
valuable	JJ	O
information	NN	O
for	IN	O
researchers	NNS	O
,	,	O
healthcare	NN	O
providers	NNS	O
,	,	O
and	CC	O
policymakers	NNS	O
.	.	O

METHODS	NNP	O
Data	NNP	O
from	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
with	IN	O
442	CD	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
were	VBD	O
used	VBN	O
.	.	O

The	DT	O
MCIC	NNP	O
was	VBD	O
estimated	VBN	O
over	IN	O
a	DT	O
12-week	JJ	O
period	NN	O
,	,	O
and	CC	O
three	CD	O
different	JJ	O
methods	NNS	O
were	VBD	O
used	VBN	O
:	:	O
1	CD	O
)	)	O
mean	NN	O
change	NN	O
scores	NNS	O
,	,	O
2	CD	O
)	)	O
minimal	NN	O
detectable	JJ	O
change	NN	O
,	,	O
and	CC	O
3	CD	O
)	)	O
optimal	VBD	O
cutoff	NN	O
point	NN	O
in	IN	O
receiver	NN	O
operant	JJ	O
curves	NNS	O
.	.	O

The	DT	O
global	JJ	O
perceived	JJ	O
effect	NN	O
scale	NN	O
(	(	O
GPE	NNP	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
an	DT	O
external	JJ	O
criterion	NN	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
initial	JJ	O
scores	NNS	O
on	IN	O
the	DT	O
MCIC	NNP	O
was	VBD	O
also	RB	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
MCIC	NNP	O
of	IN	O
the	DT	O
PI-NRS	NNP	O
ranged	VBD	O
from	IN	O
3.5	CD	O
to	TO	O
4.7	CD	O
points	NNS	O
in	IN	O
(	(	O
sub	NN	O
)	)	O
acute	NN	O
patients	NNS	O
and	CC	O
2.5	CD	O
to	TO	O
4.5	CD	O
points	NNS	O
in	IN	O
chronic	JJ	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

The	DT	O
MCIC	NNP	O
of	IN	O
the	DT	O
QBPDS	NNP	O
was	VBD	O
estimated	VBN	O
between	IN	O
17.5	CD	O
to	TO	O
32.9	CD	O
points	NNS	O
and	CC	O
8.5	CD	O
to	TO	O
24.6	CD	O
points	NNS	O
for	IN	O
(	(	O
sub	NN	O
)	)	O
acute	NN	O
and	CC	O
chronic	JJ	O
patients	NNS	O
with	IN	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

The	DT	O
MCIC	NNP	O
for	IN	O
the	DT	O
EQ	NNP	O
ranged	VBD	O
from	IN	O
0.07	CD	O
to	TO	O
0.58	CD	O
in	IN	O
(	(	O
sub	NN	O
)	)	O
acute	NN	O
patients	NNS	O
and	CC	O
0.09	CD	O
to	TO	O
0.28	CD	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
low	JJ	O
back	RB	O
pain	NN	O
.	.	O

CONCLUSION	NNP	O
Reporting	VBG	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
made	VBN	O
a	DT	O
MCIC	NNP	O
adds	VBZ	O
to	TO	O
the	DT	O
interpretability	NN	O
of	IN	O
study	NN	O
results	NNS	O
.	.	O

We	PRP	O
present	VBD	O
a	DT	O
range	NN	O
of	IN	O
MCIC	NNP	O
values	NNS	O
and	CC	O
advocate	VB	O
the	DT	O
choice	NN	O
of	IN	O
a	DT	O
single	JJ	O
MCIC	NNP	O
value	NN	O
according	VBG	O
to	TO	O
the	DT	O
specific	JJ	O
context	NN	O
.	.	O

Bacteremia	NNP	O
due	JJ	O
to	TO	O
Bacteroides	NNP	O
fragilis	NN	O
after	IN	O
elective	JJ	O
appendectomy	NN	O
in	IN	O
renal	JJ	O
transplant	NN	O
recipients	NNS	O
.	.	O

Bacteremia	NNP	O
caused	VBN	O
by	IN	O
Bacteroides	NNP	O
fragilis	NN	O
occurred	VBD	O
in	IN	O
four	CD	O
of	IN	O
75	CD	O
children	NNS	O
after	IN	O
renal	JJ	O
transplantation	NN	O
,	,	O
and	CC	O
B.	NNP	O
fragilis	NN	O
was	VBD	O
the	DT	O
most	RBS	O
common	JJ	O
cause	NN	O
of	IN	O
postoperative	JJ	O
bacteremia	NN	O
.	.	O

Bacteroides	NNP	O
bacteremia	NN	O
was	VBD	O
significantly	RB	O
associated	VBN	O
with	IN	O
performance	NN	O
of	IN	O
elective	JJ	Physical
appendectomy	NN	Physical
at	IN	O
the	DT	O
time	NN	O
of	IN	O
transplantation	NN	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
and	CC	O
with	IN	O
profound	JJ	O
lymphocytopenia	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
.	.	O

No	DT	O
patient	NN	O
received	VBD	O
antibiotics	NNS	Pharmacological
at	IN	O
the	DT	O
time	NN	O
of	IN	O
surgery	NN	O
or	CC	O
prior	RB	O
to	TO	O
the	DT	O
first	JJ	O
positive	JJ	O
blood	NN	O
culture	NN	O
,	,	O
yet	RB	O
B.	NNP	O
fragilis	NN	O
was	VBD	O
the	DT	O
single	JJ	O
organism	NN	O
isolated	VBN	O
from	IN	O
blood	NN	O
and	CC	O
abscesses	NNS	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	O

A	DT	O
role	NN	O
for	IN	O
lymphocytes	NNS	O
in	IN	O
containment	NN	O
of	IN	O
B.	NNP	O
fragilis	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
suggested	VBN	O
previously	RB	O
,	,	O
although	IN	O
unexplained	JJ	O
occurrence	NN	O
of	IN	O
bacteroides	NNS	O
bacteremia	VBP	O
in	IN	O
immunocompromised	JJ	O
patients	NNS	O
has	VBZ	O
occasionally	RB	O
been	VBN	O
reported	VBN	O
.	.	O

Lymphocytes	VBZ	O
themselves	PRP	O
may	MD	O
be	VB	O
important	JJ	O
in	IN	O
this	DT	O
host-bacterium	JJ	O
interaction	NN	O
,	,	O
or	CC	O
lymphocytopenia	NN	O
may	MD	O
be	VB	O
the	DT	O
marker	NN	O
for	IN	O
a	DT	O
more	RBR	O
generalized	JJ	O
deficiency	NN	O
in	IN	O
host	NN	O
defenses	NNS	O
.	.	O

Effects	NNS	O
of	IN	O
perioperative	JJ	O
indomethacin	NN	Pharmacological
on	IN	O
intracranial	JJ	O
pressure	NN	O
,	,	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
,	,	O
and	CC	O
cerebral	JJ	O
metabolism	NN	O
in	IN	O
patients	NNS	O
subjected	VBN	O
to	TO	O
craniotomy	VB	O
for	IN	O
cerebral	JJ	O
tumors	NNS	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
perioperative	JJ	O
indomethacin	NN	O
on	IN	O
intracranial	JJ	O
pressure	NN	O
(	(	O
ICP	NNP	O
)	)	O
,	,	O
cerebral	JJ	O
blood	NN	O
flow	NN	O
(	(	O
CBF	NNP	O
)	)	O
,	,	O
and	CC	O
cerebral	JJ	O
metabolism	NN	O
.	.	O

Twenty	CD	O
patients	NNS	O
subjected	VBN	O
to	TO	O
craniotomy	VB	O
for	IN	O
supratentorial	JJ	O
cerebral	JJ	O
tumors	NNS	O
were	VBD	O
anesthetized	VBN	Pharmacological
with	IN	Pharmacological
thiopental	JJ	Pharmacological
,	,	Pharmacological
fentanyl	JJ	Pharmacological
,	,	Pharmacological
nitrous	JJ	Pharmacological
oxide	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
isoflurane	NN	Pharmacological
.	.	Pharmacological

A	DT	O
PaCO2	NNP	O
level	NN	O
averaging	VBG	O
4.8	CD	O
kPa	NN	O
(	(	O
median	JJ	O
)	)	O
was	VBD	O
achieved	VBN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
intravenous	JJ	Pharmacological
indomethacin	JJ	Pharmacological
50	CD	Pharmacological
mg	NN	Pharmacological
or	CC	O
placebo	NN	Pharmacological
administrated	VBN	Pharmacological
after	IN	Pharmacological
exposure	NN	Pharmacological
of	IN	Pharmacological
the	DT	Pharmacological
dura	NN	Pharmacological
.	.	O

ICP	NNP	Physical
was	VBD	Physical
measured	VBN	Physical
continuously	RB	Physical
subdurally	RB	Physical
with	IN	Physical
a	DT	Physical
22-gauge	JJ	Physical
canula	NN	Physical
connected	VBN	Physical
to	TO	Physical
a	DT	Physical
transducer	NN	Physical
.	.	O

CBF	NNP	O
and	CC	O
the	DT	O
arteriovenous	JJ	O
difference	NN	O
of	IN	O
oxygen	NN	O
(	(	O
AVDO2	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
twice	RB	O
,	,	O
before	IN	O
and	CC	O
after	IN	O
indomethacin/placebo	JJ	O
administration	NN	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
ICP	NNP	O
from	IN	O
6.5	CD	O
to	TO	O
1.5	CD	O
mm	NNS	O
Hg	NNP	O
(	(	O
median	JJ	O
)	)	O
was	VBD	O
found	VBN	O
after	IN	O
indomethacin	JJ	O
administration	NN	O
.	.	O

This	DT	O
decrease	NN	O
was	VBD	O
caused	VBN	O
by	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
CBF	NNP	O
associated	VBD	O
with	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
AVDO2	NNP	O
.	.	O

Indomethacin	NNP	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
rate	NN	O
of	IN	O
oxygen	NN	O
,	,	O
the	DT	O
arteriovenous	JJ	O
difference	NN	O
of	IN	O
lactate	NN	O
,	,	O
or	CC	O
the	DT	O
lactate/oxygen	NN	O
index	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
indomethacin	NN	O
did	VBD	O
not	RB	O
provoke	VB	O
global	JJ	O
cerebral	JJ	O
ischemia	NN	O
.	.	O

In	IN	O
the	DT	O
indomethacin	NN	O
group	NN	O
,	,	O
dura	NN	O
was	VBD	O
sufficiently	RB	O
relaxed	VBN	O
in	IN	O
eight	CD	O
of	IN	O
nine	CD	O
patients	NNS	O
and	CC	O
dura	NN	O
was	VBD	O
opened	VBN	O
without	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
cerebral	JJ	O
swelling	VBG	O
.	.	O

In	IN	O
one	CD	O
patient	NN	O
,	,	O
mannitol	FW	O
treatment	NN	O
was	VBD	O
necessary	JJ	O
to	TO	O
prevent	VB	O
dural	JJ	O
tightness	NN	O
.	.	O

In	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
mannitol	RB	O
supplemented	VBN	O
with	IN	O
hypocapnia	NN	O
was	VBD	O
applied	VBN	O
in	IN	O
five	CD	O
patients	NNS	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
that	IN	O
perioperative	JJ	O
treatment	NN	O
with	IN	O
indomethacin	NN	Pharmacological
is	VBZ	O
an	DT	O
excellent	JJ	O
treatment	NN	O
of	IN	O
intracranial	JJ	O
hypertension	NN	O
during	IN	O
normocapnic	JJ	O
isoflurane	NN	O
anesthesia	NN	O
for	IN	O
craniotomy	NN	O
.	.	O

Impact	NN	O
of	IN	O
dronedarone	NN	Pharmacological
on	IN	O
hospitalization	NN	O
burden	NN	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
:	:	O
results	NNS	O
from	IN	O
the	DT	O
ATHENA	NNP	O
study	NN	O
.	.	O

AIMS	NNP	O
Cardiovascular	NNP	O
(	(	O
CV	NNP	O
)	)	O
hospitalization	NN	O
is	VBZ	O
a	DT	O
predictor	NN	O
of	IN	O
CV	NNP	O
mortality	NN	O
and	CC	O
has	VBZ	O
a	DT	O
negative	JJ	O
impact	NN	O
on	IN	O
patients	NNS	O
'	POS	O
quality	NN	O
of	IN	O
life	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
of	IN	O
A	NNP	O
placebo-controlled	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
parallel-arm	JJ	O
Trial	NNP	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
dronedarone	NN	Pharmacological
400	CD	O
mg	NN	O
bid	NN	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
cardiovascular	JJ	O
Hospitalization	NNP	O
or	CC	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
in	IN	O
patiENTs	NN	O
with	IN	O
Atrial	NNP	O
fibrillation/atrial	JJ	O
flutter	NN	O
(	(	O
ATHENA	NNP	O
)	)	O
,	,	O
a	DT	O
composite	NN	O
of	IN	O
first	JJ	O
CV	NNP	O
hospitalization	NN	O
or	CC	O
death	NN	O
from	IN	O
any	DT	O
cause	NN	O
,	,	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
dronedarone	NN	Pharmacological
.	.	O

This	DT	O
post	NN	O
hoc	NN	O
analysis	NN	O
evaluated	VBD	O
the	DT	O
secondary	JJ	O
endpoint	NN	O
of	IN	O
CV	NNP	O
hospitalization	NN	O
and	CC	O
the	DT	O
clinical	JJ	O
benefit	NN	O
of	IN	O
dronedarone	NN	Pharmacological
on	IN	O
the	DT	O
number	NN	O
and	CC	O
duration	NN	O
of	IN	O
CV	NNP	O
hospitalizations	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
atrial	JJ	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
ATHENA	NNP	O
was	VBD	O
a	DT	O
double-blind	NN	O
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
in	IN	O
4628	CD	O
patients	NNS	O
with	IN	O
a	DT	O
history	NN	O
of	IN	O
paroxysmal/persistent	NN	O
AF	NNP	O
and	CC	O
additional	JJ	O
risk	NN	O
factors	NNS	O
,	,	O
treated	VBN	O
with	IN	O
placebo	NN	Pharmacological
or	CC	O
dronedarone	NN	Pharmacological
.	.	O

Dronedarone	NNP	Pharmacological
treatment	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
risk	NN	O
of	IN	O
first	JJ	O
CV	NNP	O
hospitalization	NN	O
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	Control
)	)	O
,	,	O
while	IN	O
the	DT	O
risk	NN	O
of	IN	O
first	JJ	O
non-CV	JJ	O
hospitalization	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
P	NNP	O
=	NNP	O
0.77	CD	O
)	)	O
.	.	O

About	IN	O
half	NN	O
of	IN	O
the	DT	O
CV	NNP	O
hospitalizations	NNS	O
were	VBD	O
AF-related	JJ	O
,	,	O
with	IN	O
a	DT	O
median	JJ	O
duration	NN	O
of	IN	O
hospital	JJ	O
stay	NN	O
of	IN	O
four	CD	O
nights	NNS	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
any	DT	O
hospitalization	NN	O
for	IN	O
AF	NNP	O
[	NNP	O
hazard	NN	O
ratio	NN	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
)	)	O
0.626	CD	O
(	(	O
0.546-0.719	NN	O
)	)	O
]	NN	O
and	CC	O
duration	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
by	IN	O
dronedarone	NN	Pharmacological
(	(	O
P	NNP	O
<	VBZ	O
0.0001	CD	O
vs.	FW	O
placebo	NN	Control
)	)	O
.	.	O

Dronedarone	NNP	Pharmacological
treatment	NN	O
reduced	VBD	O
total	JJ	O
hospitalizations	NNS	O
for	IN	O
acute	JJ	O
coronary	JJ	O
syndrome	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0105	CD	O
)	)	O
and	CC	O
the	DT	O
time	NN	O
between	IN	O
the	DT	O
first	JJ	O
AF/atrial	NNP	O
flutter	NN	O
recurrence	NN	O
and	CC	O
CV	NNP	O
hospitalization/death	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.0048	CD	O
)	)	O
.	.	O

Hospitalization	NNP	O
burden	NN	O
was	VBD	O
significantly	RB	O
reduced	VBN	O
across	IN	O
all	DT	O
levels	NNS	O
of	IN	O
care	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Cumulative	JJ	O
incidence	NN	O
data	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
effects	NNS	O
of	IN	O
dronedarone	NN	Pharmacological
persisted	VBN	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
months	NNS	O
.	.	O

CONCLUSION	NNP	O
Dronedarone	NNP	Pharmacological
reduced	VBD	O
the	DT	O
risk	NN	O
for	IN	O
CV	NNP	O
hospitalization	NN	O
and	CC	O
the	DT	O
total	JJ	O
hospitalization	NN	O
burden	NN	O
in	IN	O
this	DT	O
patient	NN	O
group	NN	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
under	IN	O
ClinicalTrials.gov	NNP	O
#	#	O
NCT	NNP	O
00174785	CD	O
.	.	O

Comparison	NNP	O
between	IN	O
intermittent	JJ	Physical
mandatory	JJ	Physical
ventilation	NN	Physical
and	CC	O
synchronized	JJ	Physical
intermittent	NN	Physical
mandatory	JJ	Physical
ventilation	NN	Physical
with	IN	O
pressure	NN	Physical
support	NN	Physical
in	IN	O
children	NNS	O
.	.	O

OBJECTIVE	NN	O
To	TO	O
compare	VB	O
intermittent	JJ	Physical
mandatory	JJ	Physical
ventilation	NN	Physical
(	(	Physical
IMV	NNP	Physical
)	)	Physical
with	IN	O
synchronized	JJ	Physical
intermittent	JJ	Physical
mandatory	NN	Physical
ventilation	NN	Physical
plus	CC	Physical
pressure	NN	Physical
support	NN	Physical
(	(	Physical
SIMV+PS	NNP	Physical
)	)	Physical
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
mechanical	JJ	O
ventilation	NN	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
and	CC	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
a	DT	O
pediatric	JJ	O
intensive	JJ	O
care	NN	O
unit	NN	O
(	(	O
PICU	NNP	O
)	)	O
.	.	O

METHODS	NNP	O
This	DT	O
was	VBD	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
that	WDT	O
enrolled	VBD	O
children	NNS	O
aged	VBN	O
28	CD	O
days	NNS	O
to	TO	O
4	CD	O
years	NNS	O
who	WP	O
were	VBD	O
admitted	VBN	O
to	TO	O
a	DT	O
PICU	NNP	O
between	IN	O
October	NNP	O
of	IN	O
2005	CD	O
and	CC	O
June	NNP	O
of	IN	O
2007	CD	O
and	CC	O
put	VB	O
on	IN	O
mechanical	JJ	Physical
ventilation	NN	Physical
(	(	Physical
MV	NNP	Physical
)	)	Physical
for	IN	O
more	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
allocated	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
by	IN	O
drawing	VBG	O
lots	NNS	O
:	:	O
IMV	NNP	Physical
group	NN	O
(	(	Physical
IMVG	NNP	Physical
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
and	CC	O
SIMV+PS	NNP	Physical
group	NN	O
(	(	O
SIMVG	NNP	Physical
;	:	O
n	CC	O
=	VB	O
35	CD	O
)	)	O
.	.	O

Children	NNP	O
were	VBD	O
excluded	VBN	O
if	IN	O
they	PRP	O
had	VBD	O
undergone	JJ	O
tracheotomy	NN	O
or	CC	O
had	VBD	O
chronic	JJ	O
respiratory	NN	O
diseases	NNS	O
.	.	O

Data	NNS	O
on	IN	O
oxygenation	NN	O
and	CC	O
ventilation	NN	O
were	VBD	O
recorded	VBN	O
at	IN	O
admission	NN	O
and	CC	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
weaning	VBG	O
.	.	O

RESULTS	CC	O
There	EX	O
were	VBD	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
indication	NN	O
for	IN	O
MV	NNP	O
,	,	O
PRISM	NNP	O
score	NN	O
,	,	O
Comfort	NNP	O
scale	NN	O
,	,	O
use	NN	O
of	IN	O
sedatives	NNS	O
or	CC	O
ventilation	NN	O
and	CC	O
oxygenation	NN	O
parameters	NNS	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
on	IN	O
MV	NNP	O
was	VBD	O
5	CD	O
days	NNS	O
for	IN	O
both	DT	O
groups	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.120	CD	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
also	RB	O
no	DT	O
statistical	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
for	IN	O
duration	NN	O
of	IN	O
weaning	VBG	O
[	JJ	O
IMVG	NNP	Physical
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	Physical
:	:	O
1	CD	O
day	NN	O
(	(	O
1-6	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.262	CD	O
]	NN	O
or	CC	O
length	NN	O
of	IN	O
hospital	NN	O
stay	NN	O
[	JJ	O
IMVG	NNP	Physical
:	:	O
8	CD	O
days	NNS	O
(	(	O
2-22	JJ	O
)	)	O
vs.	FW	O
SIMVG	NNP	Physical
:	:	O
6	CD	O
days	NNS	O
(	(	O
3-20	JJ	O
)	)	O
;	:	O
p	CC	O
=	$	O
0.113	CD	O
]	NNP	O
.	.	O

CONCLUSION	NNP	O
Among	IN	O
the	DT	O
children	NNS	O
studied	VBN	O
here	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
IMV	NNP	Physical
and	CC	O
SIMV+PS	NNP	Physical
in	IN	O
terms	NNS	O
of	IN	O
time	NN	O
on	IN	O
MV	NNP	O
,	,	O
duration	NN	O
of	IN	O
weaning	VBG	O
or	CC	O
time	NN	O
spent	VBN	O
in	IN	O
the	DT	O
PICU	NNP	O
.	.	O

ClinicalTrials.govID	NN	O
:	:	O
NCT00549809	NNP	O
.	.	O

Efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
recombinant	JJ	Educational
human	JJ	Educational
nerve	NN	Educational
growth	NN	Educational
factor	NN	Educational
in	IN	O
patients	NNS	O
with	IN	O
diabetic	JJ	O
polyneuropathy	NN	O
:	:	O
A	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

rhNGF	VB	O
Clinical	NNP	O
Investigator	NNP	O
Group	NNP	O
.	.	O

CONTEXT	NNP	O
Nerve	NNP	O
growth	NN	O
factor	NN	O
is	VBZ	O
a	DT	O
neurotrophic	JJ	O
factor	NN	O
that	WDT	O
promotes	VBZ	O
the	DT	O
survival	NN	O
of	IN	O
small	JJ	O
fiber	NNP	O
sensory	JJ	O
neurons	NNS	O
and	CC	O
sympathetic	JJ	O
neurons	NNS	O
in	IN	O
the	DT	O
peripheral	JJ	O
nervous	JJ	O
system	NN	O
.	.	O

Recombinant	JJ	Educational
human	JJ	Educational
nerve	NN	Educational
growth	NN	Educational
factor	NN	Educational
(	(	Educational
rhNGF	NN	Educational
)	)	Educational
has	VBZ	O
demonstrated	VBN	O
efficacy	NN	O
as	IN	O
treatment	NN	O
for	IN	O
peripheral	JJ	O
neuropathy	NN	O
in	IN	O
experimental	JJ	O
models	NNS	O
and	CC	O
phase	VB	O
2	CD	O
clinical	JJ	O
trials	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
a	DT	O
12-month	JJ	O
regimen	NN	O
of	IN	O
rhNGF	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diabetic	JJ	O
polyneuropathy	NN	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
phase	NN	O
3	CD	O
trial	NN	O
conducted	VBN	O
from	IN	O
July	NNP	O
1997	CD	O
through	IN	O
May	NNP	O
1999	CD	O
.	.	O

SETTING	VB	O
Eighty-four	JJ	O
outpatient	NN	O
centers	NNS	O
throughout	IN	O
the	DT	O
United	NNP	O
States	NNPS	O
.	.	O

PATIENTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1019	CD	O
men	NNS	O
and	CC	O
women	NNS	O
aged	VBD	O
18	CD	O
to	TO	O
74	CD	O
years	NNS	O
with	IN	O
either	DT	O
type	NN	O
1	CD	O
or	CC	O
type	VB	O
2	CD	O
diabetes	NNS	O
and	CC	O
a	DT	O
sensory	JJ	O
polyneuropathy	NN	O
attributable	JJ	O
to	TO	O
diabetes	NNS	O
.	.	O

INTERVENTIONS	JJ	O
Patients	NNPS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
rhNGF	NN	Pharmacological
,	,	O
0.1	CD	O
microg/kg	NN	O
(	(	O
n	JJ	O
=	NNP	O
504	CD	O
)	)	O
,	,	O
or	CC	O
placebo	NN	Control
(	(	O
n	JJ	O
=	NNP	O
515	CD	O
)	)	O
by	IN	O
subcutaneous	JJ	O
injection	NN	O
3	CD	O
times	NNS	O
per	IN	O
week	NN	O
for	IN	O
48	CD	O
weeks	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
,	,	O
12	CD	O
weeks	NNS	O
,	,	O
24	CD	O
weeks	NNS	O
,	,	O
and	CC	O
48	CD	O
weeks	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
a	DT	O
change	NN	O
in	IN	O
neuropathy	JJ	O
between	IN	O
baseline	NN	O
and	CC	O
week	NN	O
48	CD	O
,	,	O
demonstrated	VBN	O
by	IN	O
the	DT	O
Neuropathy	NNP	O
Impairment	NNP	O
Score	NNP	O
for	IN	O
the	DT	O
Lower	NNP	O
Limbs	NNP	O
,	,	O
compared	VBN	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Secondary	JJ	O
outcome	NN	O
measures	NNS	O
included	VBD	O
quantitative	JJ	O
sensory	NN	O
tests	NNS	O
using	VBG	O
the	DT	O
CASE	NNP	O
IV	NNP	O
System	NNP	O
,	,	O
the	DT	O
Neuropathy	NNP	O
Symptom	NNP	O
and	CC	O
Change	NNP	O
questionnaire	NN	O
,	,	O
the	DT	O
Patient	NNP	O
Benefit	NNP	O
Questionnaire	NNP	O
(	(	O
PBQ	NNP	O
)	)	O
,	,	O
and	CC	O
a	DT	O
global	JJ	O
symptom	NN	O
assessment	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
nerve	NN	O
conduction	NN	O
studies	NNS	O
and	CC	O
occurrence	NN	O
of	IN	O
new	JJ	O
plantar	JJ	O
foot	NN	O
ulcers	NNS	O
.	.	O

Patients	NNS	O
also	RB	O
were	VBD	O
evaluated	VBN	O
for	IN	O
presence	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

RESULTS	NNP	O
Among	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
rhNGF	NN	Educational
,	,	O
418	CD	O
(	(	O
83	CD	O
%	NN	O
)	)	O
completed	VBD	O
the	DT	O
regimen	NNS	O
compared	VBN	O
with	IN	O
461	CD	O
(	(	O
90	CD	O
%	NN	O
)	)	O
who	WP	O
received	VBD	O
placebo	NN	Control
.	.	O

Administration	NNP	O
of	IN	O
rhNGF	NN	Pharmacological
was	VBD	O
safe	JJ	O
,	,	O
with	IN	O
few	JJ	O
adverse	JJ	O
events	NNS	O
attributed	VBD	O
to	TO	O
treatment	NN	O
apart	RB	O
from	IN	O
injection	NN	O
site	NN	O
pain/hyperalgesia	NN	O
and	CC	O
other	JJ	O
pain	NN	O
syndromes	NNS	O
.	.	O

However	RB	O
,	,	O
neither	CC	O
the	DT	O
primary	JJ	O
end	NN	O
point	NN	O
(	(	O
P	NNP	O
=.25	NNP	O
)	)	O
nor	CC	O
most	JJS	O
of	IN	O
the	DT	O
secondary	JJ	O
end	NN	O
points	NNS	O
demonstrated	VBD	O
a	DT	O
significant	JJ	O
benefit	NN	O
of	IN	O
rhNGF	NN	Pharmacological
.	.	O

Exceptions	NNS	O
were	VBD	O
the	DT	O
global	JJ	O
symptom	NN	O
assessment	NN	O
(	(	O
P	NNP	O
=.03	NNP	O
)	)	O
and	CC	O
2	CD	O
of	IN	O
32	CD	O
comparisons	NNS	O
within	IN	O
the	DT	O
PBQ	NNP	O
,	,	O
which	WDT	O
showed	VBD	O
a	DT	O
modest	JJ	O
but	CC	O
significant	JJ	O
benefit	NN	O
of	IN	O
rhNGF	NN	Pharmacological
(	(	O
P	NNP	O
=.05	NNP	O
for	IN	O
severity	NN	O
of	IN	O
pain	NN	O
in	IN	O
the	DT	O
legs	NN	O
and	CC	O
P	NNP	O
=.003	NNP	O
for	IN	O
6-month	JJ	O
symptoms	NNS	O
in	IN	O
the	DT	O
feet	NNS	O
and	CC	O
legs	NNS	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Unlike	IN	O
previous	JJ	O
phase	NN	O
2	CD	O
trials	NNS	O
,	,	O
this	DT	O
phase	NN	O
3	CD	O
clinical	JJ	O
trial	NN	O
failed	VBD	O
to	TO	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
beneficial	JJ	O
effect	NN	O
of	IN	O
rhNGF	NN	O
on	IN	O
diabetic	JJ	O
polyneuropathy	NN	O
.	.	O

JAMA	NNP	O
.	.	O

2000	CD	O
;	:	O
284:2215-2221	JJ	O
.	.	O

Hexetidine	NNP	Pharmacological
(	(	Pharmacological
'Oraldene	NNP	Pharmacological
'	POS	Pharmacological
)	)	Pharmacological
:	:	O
a	DT	O
report	NN	O
on	IN	O
its	PRP$	O
antibacterial	JJ	O
and	CC	O
antifungal	JJ	O
properties	NNS	O
on	IN	O
the	DT	O
oral	JJ	O
flora	NNS	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
crossover	NN	O
trial	NN	O
,	,	O
in	IN	O
10	CD	O
adult	NN	O
healthy	JJ	O
subjects	NNS	O
,	,	O
was	VBD	O
carried	VBN	O
out	IN	O
to	TO	O
compare	VB	O
the	DT	O
antibacterial	JJ	O
and	CC	O
antifungal	JJ	O
activity	NN	O
of	IN	O
a	DT	O
0.1	CD	Pharmacological
%	NN	Pharmacological
solution	NN	Pharmacological
of	IN	Pharmacological
hexetidine	NN	Pharmacological
with	IN	O
that	DT	O
of	IN	O
placebo	NN	Control
.	.	O

The	DT	O
pre-dosing	JJ	O
oral	JJ	O
flora	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
was	VBD	O
assessed	VBN	O
from	IN	O
saliva	NN	O
samples	NNS	O
cultured	VBD	O
for	IN	O
aerobic	JJ	O
and	CC	O
anaerobic	JJ	O
bacteria	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
Candida	NNP	O
albicans	NNS	O
.	.	O

Subjects	NNS	O
then	RB	O
rinsed	VBD	O
their	PRP$	O
mouths	NNS	O
for	IN	O
1	CD	O
minute	JJ	O
3-times	NNS	O
a	DT	O
day	NN	O
with	IN	O
15	CD	O
ml	NNS	O
0.1	CD	O
%	NN	O
hexetidine	NN	Pharmacological
or	CC	O
placebo	NN	Control
,	,	O
saliva	NN	O
samples	NNS	O
being	VBG	O
collected	VBN	O
at	IN	O
2	CD	O
minutes	NNS	O
,	,	O
30	CD	O
minutes	NNS	O
,	,	O
1	CD	O
hour	NN	O
,	,	O
3	CD	O
hours	NNS	O
and	CC	O
5	CD	O
hours	NNS	O
post-dosing	JJ	O
.	.	O

Dosing	NN	O
was	VBD	O
continued	VBN	O
for	IN	O
8	CD	O
consecutive	JJ	O
days	NNS	O
on	IN	O
each	DT	O
treatment	NN	O
with	IN	O
an	DT	O
intervening	VBG	O
wash-out	JJ	O
period	NN	O
of	IN	O
1	CD	O
week	NN	O
.	.	O

Hexetidine	NNP	Pharmacological
reduced	VBD	O
aerobic	JJ	O
bacterial	JJ	O
counts	NNS	O
on	IN	O
Day	NNP	O
1	CD	O
and	CC	O
Day	NNP	O
8	CD	O
by	IN	O
a	DT	O
maximum	NN	O
of	IN	O
83	CD	O
%	NN	O
and	CC	O
86	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
at	IN	O
2	CD	O
minutes	NNS	O
post-dosing	JJ	O
.	.	O

The	DT	O
reductions	NNS	O
were	VBD	O
statistically	RB	O
significantly	RB	O
lower	JJR	O
than	IN	O
placebo	VB	Control
up	IN	O
to	TO	O
1	CD	O
hour	NN	O
post-dose	JJ	O
on	IN	O
Day	NNP	O
1	CD	O
and	CC	O
up	RB	O
to	TO	O
3	CD	O
hours	NNS	O
post-dose	JJ	O
on	IN	O
Day	NNP	O
8	CD	O
.	.	O

Similarly	RB	O
for	IN	O
anaerobic	JJ	O
bacterial	JJ	O
counts	NNS	O
,	,	O
92	CD	O
%	NN	O
and	CC	O
88	CD	O
%	NN	O
maximum	JJ	O
reductions	NNS	O
were	VBD	O
recorded	VBN	O
on	IN	O
Day	NNP	O
1	CD	O
and	CC	O
Day	NNP	O
8	CD	O
,	,	O
which	WDT	O
again	RB	O
were	VBD	O
significantly	RB	O
lower	JJR	O
than	IN	O
placebo	NN	O
for	IN	O
up	IN	O
to	TO	O
3	CD	O
hours	NNS	O
post-dose	JJ	O
.	.	O

For	IN	O
Candida	NNP	O
albicans	NNS	O
,	,	O
however	RB	O
,	,	O
the	DT	O
maximum	JJ	O
reduction	NN	O
was	VBD	O
91	CD	O
%	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
and	CC	O
67	CD	O
%	NN	O
on	IN	O
Day	NNP	O
8	CD	O
,	,	O
maintained	VBD	O
for	IN	O
30	CD	O
minutes	NNS	O
post-dosing	JJ	O
.	.	O

Although	IN	O
not	RB	O
eradicating	VBG	O
completely	RB	O
aerobic	JJ	O
and	CC	O
anaerobic	JJ	O
bacteria	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
the	DT	O
substantial	JJ	O
reduction	NN	O
in	IN	O
their	PRP$	O
numbers	NNS	O
should	MD	O
prove	VB	O
clinically	RB	O
useful	JJ	O
.	.	O

Development	NNP	O
of	IN	O
an	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
for	IN	O
the	DT	O
identification	NN	O
of	IN	O
auditory	NN	O
processing	NN	O
disorders	NNS	O
.	.	O

OBJECTIVE	CC	O
One	CD	O
type	NN	O
of	IN	O
test	NN	O
commonly	RB	O
used	VBD	O
to	TO	O
examine	VB	O
auditory	JJ	O
processing	NN	O
disorders	NNS	O
(	(	O
APD	NNP	O
)	)	O
is	VBZ	O
the	DT	O
low-pass	NN	Physical
filtered	VBD	Physical
speech	JJ	Physical
test	NN	Physical
(	(	O
LPFST	NNP	O
)	)	O
,	,	O
of	IN	O
which	WDT	O
there	EX	O
are	VBP	O
various	JJ	O
versions	NNS	O
.	.	O

In	IN	O
LPFSTs	NNP	O
,	,	O
a	DT	O
monaural	JJ	O
,	,	O
low-redundancy	JJ	O
speech	NN	O
sample	NN	O
is	VBZ	O
distorted	VBN	O
by	IN	O
using	VBG	O
filtering	VBG	O
to	TO	O
modify	VB	O
its	PRP$	O
frequency	NN	O
content	NN	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
richness	NN	O
of	IN	O
the	DT	O
neural	JJ	O
pathways	NNS	O
in	IN	O
the	DT	O
auditory	NN	O
system	NN	O
and	CC	O
the	DT	O
redundancy	NN	O
of	IN	O
acoustic	JJ	O
information	NN	O
in	IN	O
spoken	JJ	O
language	NN	O
,	,	O
a	DT	O
normal	JJ	O
listener	NN	O
is	VBZ	O
able	JJ	O
to	TO	O
recognize	VB	O
speech	NN	O
even	RB	O
when	WRB	O
parts	NNS	O
of	IN	O
the	DT	O
signal	NN	O
are	VBP	O
missing	VBG	O
,	,	O
whereas	IN	O
this	DT	O
ability	NN	O
is	VBZ	O
often	RB	O
impaired	VBN	O
in	IN	O
listeners	NNS	O
with	IN	O
APD	NNP	O
.	.	O

One	CD	O
limitation	NN	O
of	IN	O
the	DT	O
various	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
LPFST	NNP	Physical
is	VBZ	O
that	IN	O
they	PRP	O
are	VBP	O
carried	VBN	O
out	IN	O
using	VBG	O
a	DT	O
constant	JJ	O
level	NN	O
of	IN	O
low-pass	JJ	O
filtering	NN	O
(	(	O
e.g	NN	O
.	.	O

a	DT	O
fixed	JJ	O
1kHz	CD	O
corner	NN	O
frequency	NN	O
)	)	O
which	WDT	O
makes	VBZ	O
them	PRP	O
prone	VB	O
to	TO	O
ceiling	NN	O
and	CC	O
floor	NN	O
effects	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
counter	VB	O
these	DT	O
effects	NNS	O
by	IN	O
modifying	VBG	O
the	DT	O
LPFST	NNP	O
using	VBG	O
a	DT	O
computer-based	JJ	O
adaptive	JJ	O
procedure	NN	O
,	,	O
and	CC	O
to	TO	O
evaluate	VB	O
the	DT	O
performance	NN	O
of	IN	O
normal-hearing	JJ	O
participants	NNS	O
of	IN	O
varying	VBG	O
ages	NNS	O
on	IN	O
the	DT	O
test	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
preliminary	JJ	O
study	NN	O
,	,	O
33	CD	O
adults	NNS	O
and	CC	O
30	CD	O
children	NNS	O
(	(	O
aged	VBN	O
8-11	CD	O
years	NNS	O
)	)	O
with	IN	O
no	DT	O
known	JJ	O
history	NN	O
of	IN	O
listening	VBG	O
difficulties	NNS	O
were	VBD	O
tested	VBN	O
.	.	O

The	DT	Educational
University	NNP	Educational
of	IN	Educational
Canterbury	NNP	Educational
Adaptive	NNP	Educational
Speech	NNP	Educational
Test	NNP	Educational
(	(	Educational
UCAST	NNP	Educational
)	)	Educational
platform	NN	Educational
was	VBD	Educational
used	VBN	Educational
to	TO	Educational
administer	VB	Educational
a	DT	Educational
four-alternative	JJ	Educational
forced-choice	JJ	Educational
adaptive	JJ	Educational
test	NN	Educational
that	WDT	Educational
altered	VBD	Educational
a	DT	Educational
low-pass	JJ	Educational
filter	NN	Educational
(	(	Educational
LPF	NNP	Educational
)	)	Educational
to	TO	Educational
track	VB	Educational
the	DT	Educational
corner	NN	Educational
frequency	NN	Educational
at	IN	Educational
which	WDT	Educational
participants	NNS	Educational
correctly	RB	Educational
identified	VBN	Educational
a	DT	Educational
certain	JJ	Educational
percentage	NN	Educational
of	IN	Educational
the	DT	Educational
word	NN	Educational
stimuli	NN	Educational
.	.	Educational

RESULTS	NNP	O
Findings	NNP	O
on	IN	O
the	DT	O
University	NNP	O
of	IN	O
Canterbury	NNP	O
Adaptive	NNP	O
Speech	NNP	O
Test-Filtered	NNP	O
Words	NNP	O
(	(	O
UCAST-FW	NNP	O
)	)	O
indicated	VBD	O
a	DT	O
significant	JJ	O
maturational	JJ	O
effect	NN	O
.	.	O

Adult	NN	O
participants	NNS	O
performed	VBD	O
significantly	RB	O
better	RBR	O
on	IN	O
the	DT	O
UCAST-FW	NNP	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
child	NN	O
participants	NNS	O
.	.	O

The	DT	O
UCAST-FW	JJ	O
test	NN	O
was	VBD	O
reliable	JJ	O
over	IN	O
repeated	JJ	O
administrations	NNS	O
.	.	O

CONCLUSIONS	NNP	O
An	DT	O
adaptive	JJ	O
low-pass	NN	O
filtered	VBD	O
speech	JJ	O
test	NN	O
such	JJ	O
as	IN	O
the	DT	O
UCAST-FW	NNP	O
is	VBZ	O
sensitive	JJ	O
to	TO	O
maturational	JJ	O
changes	NNS	O
in	IN	O
auditory	NN	O
processing	NN	O
ability	NN	O
.	.	O

Influence	NN	O
of	IN	O
ball	NN	Educational
weight	NN	Educational
on	IN	O
junior	JJ	O
high	JJ	O
school	NN	O
girls	NNS	O
'	POS	O
volleyball	NN	O
performance	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
influence	NN	Educational
of	IN	Educational
a	DT	Educational
lighter	JJR	Educational
ball	NN	Educational
(	(	Educational
Tachikara	NNP	Educational
Volley	NNP	Educational
Lite	NNP	Educational
)	)	Educational
on	IN	Educational
72	CD	Educational
seventh-grade	JJ	Educational
girls	NNS	Educational
'	POS	Educational
tournament	NN	Educational
game	NN	Educational
play	NN	Educational
and	CC	Educational
pretest-to-posttest	JJ	Educational
improvement	NN	Educational
for	IN	Educational
a	DT	Educational
16-day	JJ	Educational
volleyball	NN	Educational
practice	NN	Educational
period	NN	Educational
.	.	O

Two	CD	O
intact	JJ	O
classes	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
groups	NNS	O
,	,	O
one	CD	O
of	IN	O
whom	WP	O
used	VBD	O
lighter	JJR	Educational
balls	NNS	Educational
during	IN	O
skills	NNS	O
progressions	NNS	O
while	IN	O
a	DT	O
second	JJ	O
used	JJ	O
regulation	NN	Educational
balls	NNS	Educational
.	.	O

All	DT	O
students	NNS	O
used	VBN	O
regulation	NN	Educational
balls	NNS	Educational
during	IN	O
tournament	JJ	O
game	NN	O
play	NN	O
and	CC	O
skills	NNS	O
tests	NNS	O
.	.	O

Both	DT	O
groups	NNS	O
significantly	RB	O
improved	VBD	O
the	DT	O
forearm	JJ	O
pass	NN	O
from	IN	O
pretest	NN	O
to	TO	O
posttest	VB	O
.	.	O

Analysis	NN	O
of	IN	O
covariance	NN	O
indicated	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
groups	NNS	O
on	IN	O
posttest	NN	O
means	NNS	O
for	IN	O
any	DT	O
skill	NN	O
.	.	O

A	DT	O
2	CD	O
x	NN	O
6	CD	O
(	(	O
treatment	NN	O
x	NNS	O
game	NN	O
day	NN	O
)	)	O
analysis	NN	O
of	IN	O
variance	NN	O
indicated	VBD	O
that	IN	O
the	DT	O
group	NN	O
practicing	VBG	O
with	IN	O
lighter	JJR	Educational
balls	NNS	Educational
had	VBD	O
significantly	RB	O
more	RBR	O
correct	JJ	O
sets	NNS	O
and	CC	O
a	DT	O
higher	JJR	O
average	JJ	O
daily	JJ	O
success	NN	O
rate	NN	O
for	IN	O
the	DT	O
set	NN	O
and	CC	O
underhand	JJ	O
serve	NN	O
on	IN	O
game	NN	O
days	NNS	O
than	IN	O
the	DT	O
group	NN	O
using	VBG	O
a	DT	O
regulation	NN	Educational
ball	NN	Educational
.	.	O

Evaluation	NN	O
of	IN	O
nonpharmacologic	JJ	Educational
methods	NNS	Educational
of	IN	O
pain	NN	Physical
and	CC	Physical
anxiety	NN	Physical
management	NN	Physical
for	IN	O
laceration	NN	O
repair	NN	O
in	IN	O
the	DT	O
pediatric	JJ	O
emergency	NN	O
department	NN	O
.	.	O

BACKGROUND	NNP	O
Nonpharmacologic	NNP	Educational
interventions	NNS	Educational
,	,	Educational
such	JJ	Educational
as	IN	Educational
distraction	NN	Educational
,	,	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
powerful	JJ	O
adjuncts	NNS	O
in	IN	O
reducing	VBG	O
pain	NN	O
and	CC	O
anxiety	NN	O
in	IN	O
children	NNS	O
with	IN	O
both	DT	O
acute	NN	O
and	CC	O
chronic	JJ	O
painful	JJ	O
conditions	NNS	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
controlled	JJ	O
studies	NNS	O
evaluating	VBG	O
these	DT	O
interventions	NNS	O
as	IN	O
adjuncts	NNS	O
to	TO	O
facilitate	VB	O
completion	NN	O
of	IN	O
painful	JJ	O
procedures	NNS	O
in	IN	O
the	DT	O
pediatric	JJ	O
emergency	NN	O
department	NN	O
(	(	O
ED	NNP	O
)	)	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
assessed	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
distraction	NN	Psychological
techniques	NNS	Psychological
in	IN	O
reducing	VBG	O
the	DT	O
sensory	NN	O
and	CC	O
affective	JJ	O
components	NNS	O
of	IN	O
pain	NN	O
among	IN	O
pediatric	JJ	O
patients	NNS	O
undergoing	JJ	O
laceration	NN	O
repair	NN	O
in	IN	O
the	DT	O
ED	NNP	O
.	.	O

METHODS	NNP	O
Eligible	JJ	O
children	NNS	O
between	IN	O
6	CD	O
and	CC	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
(	(	O
N	NNP	O
=	NNP	O
240	CD	O
)	)	O
presenting	NN	O
to	TO	O
the	DT	O
ED	NNP	O
for	IN	O
laceration	NN	O
repair	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
an	DT	O
intervention	NN	O
or	CC	O
control	NN	O
arm	NN	O
.	.	O

Those	DT	O
assigned	VBN	O
to	TO	O
the	DT	O
intervention	NN	O
arm	NN	O
were	VBD	O
given	VBN	O
a	DT	O
choice	NN	O
of	IN	O
age-appropriate	JJ	Educational
distracters	NNS	Educational
during	IN	O
laceration	NN	O
repair	NN	O
.	.	O

Quantitative	JJ	O
measures	NNS	O
of	IN	O
pain	NN	O
intensity	NN	O
,	,	O
situational	JJ	O
anxiety	NN	O
,	,	O
and	CC	O
pain	NN	O
distress	NN	O
(	(	O
as	IN	O
perceived	VBN	O
by	IN	O
the	DT	O
parent	NN	O
)	)	O
were	VBD	O
assessed	VBN	O
by	IN	O
using	VBG	O
the	DT	O
7-point	JJ	O
Facial	NNP	O
Pain	NNP	O
Scale	NNP	O
,	,	O
State	NNP	O
Trait	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
for	IN	O
Children	NNP	O
,	,	O
and	CC	O
a	DT	O
visual	JJ	O
analog	NN	O
scale	NN	O
,	,	O
respectively	RB	O
,	,	O
before	IN	O
and	CC	O
after	IN	O
laceration	NN	O
repair	NN	O
.	.	O

The	DT	O
State	NNP	O
Trait	NNP	O
Anxiety	NNP	O
Inventory	NNP	O
for	IN	O
Children	NNP	O
was	VBD	O
performed	VBN	O
in	IN	O
children	NNS	O
>	VBP	O
or	CC	O
=	VBP	O
10	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
mean	JJ	O
change	NN	O
in	IN	O
Facial	NNP	O
Pain	NNP	O
Scale	NNP	O
scores	VBZ	O
between	IN	O
the	DT	O
control	NN	O
and	CC	O
the	DT	O
intervention	NN	O
groups	NNS	O
in	IN	O
children	NNS	O
<	VBP	O
10	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Multivariate	NNP	O
analysis	NN	O
in	IN	O
this	DT	O
same	JJ	O
age	NN	O
group	NN	O
showed	VBD	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
a	DT	O
reduction	NN	O
in	IN	O
pain	NN	O
distress	NN	O
as	IN	O
perceived	VBN	O
by	IN	O
parents	NNS	O
based	VBN	O
on	IN	O
the	DT	O
mean	JJ	O
change	NN	O
in	IN	O
visual	JJ	O
analog	NN	O
scale	NN	O
scores	NNS	O
.	.	O

In	IN	O
older	JJR	O
children	NNS	O
,	,	O
the	DT	O
intervention	NN	O
was	VBD	O
independently	RB	O
associated	VBN	O
with	IN	O
reduction	NN	O
in	IN	O
situational	JJ	O
anxiety	NN	O
but	CC	O
not	RB	O
in	IN	O
pain	NN	O
intensity	NN	O
or	CC	O
in	IN	O
parental	JJ	O
perception	NN	O
of	IN	O
pain	NN	O
distress	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
use	NN	O
of	IN	O
distraction	NN	Educational
techniques	NNS	Educational
is	VBZ	O
effective	JJ	O
in	IN	O
reducing	VBG	O
situational	JJ	O
anxiety	NN	O
in	IN	O
older	JJR	O
children	NNS	O
and	CC	O
lowering	VBG	O
parental	JJ	O
perception	NN	O
of	IN	O
pain	NN	O
distress	NN	O
in	IN	O
younger	JJR	O
children	NNS	O
.	.	O

This	DT	O
technique	NN	O
may	MD	O
have	VB	O
a	DT	O
role	NN	O
in	IN	O
improving	VBG	O
the	DT	O
quality	NN	O
of	IN	O
management	NN	O
of	IN	O
procedural	JJ	O
pain	NN	O
in	IN	O
a	DT	O
pediatric	JJ	O
ED	NNP	O
setting	NN	O
.	.	O

Clinical	JJ	O
outcome	NN	O
of	IN	O
postoperative	JJ	O
adjuvant	JJ	O
immunochemotherapy	NN	O
with	IN	O
sizofiran	NN	Pharmacological
for	IN	O
patients	NNS	O
with	IN	O
resectable	JJ	O
gastric	JJ	O
cancer	NN	O
:	:	O
a	DT	O
randomised	VBN	O
controlled	VBN	O
study	NN	O
.	.	O

Adjuvant	NNP	Pharmacological
immunochemotherapy	NN	Pharmacological
using	VBG	Pharmacological
the	DT	Pharmacological
antitumour	JJ	Pharmacological
polysaccharide	NN	Pharmacological
sizofiran	NN	Pharmacological
(	(	Pharmacological
SPG	NNP	Pharmacological
)	)	Pharmacological
,	,	O
an	DT	O
extract	NN	O
from	IN	O
the	DT	O
culture	NN	O
broth	NN	O
of	IN	O
Schizophyllum	NNP	O
commune	NN	O
Fries	NNS	O
,	,	O
was	VBD	O
prescribed	VBN	O
randomly	RB	O
for	IN	O
386	CD	O
Japanese	JJ	O
patients	NNS	O
with	IN	O
resectable	JJ	O
gastric	JJ	O
cancer	NN	O
.	.	O

Although	IN	O
the	DT	O
overall	JJ	O
survival	NN	O
probability	NN	O
for	IN	O
5	CD	O
years	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
the	DT	O
SPG	NNP	O
and	CC	O
control	NN	O
groups	NNS	O
,	,	O
in	IN	O
264	CD	O
patients	NNS	O
with	IN	O
curatively	RB	O
resected	VBN	O
cancer	NN	O
,	,	O
the	DT	O
probability	NN	O
to	TO	O
5	CD	O
year	NN	O
survival	NN	O
and	CC	O
to	TO	O
recurrence	VB	O
in	IN	O
the	DT	O
sizofiran-administered	JJ	O
patients	NNS	O
was	VBD	O
better	JJR	O
than	IN	O
in	IN	O
the	DT	O
controls	NNS	O
.	.	O

In	IN	O
the	DT	O
multivariate	NN	O
analysis	NN	O
,	,	O
four	CD	O
of	IN	O
six	CD	O
prognostic	JJ	O
factors	NNS	O
correlated	VBD	O
with	IN	O
the	DT	O
prognosis	NN	O
of	IN	O
the	DT	O
264	CD	O
patients	NNS	O
who	WP	O
underwent	VBP	O
curative	JJ	O
surgery	NN	O
,	,	O
that	WDT	O
is	VBZ	O
,	,	O
nodal	JJ	O
involvement	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
21.426	CD	O
,	,	O
P	NNP	O
=	NNP	O
less	JJR	O
than	IN	O
0.0001	CD	O
)	)	O
,	,	O
age	NN	O
distribution	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
9.262	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.010	CD	O
)	)	O
,	,	O
sizofiran	JJ	O
administration	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
6.507	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
,	,	O
and	CC	O
primary	JJ	O
tumour	NN	O
size	NN	O
(	(	O
chi	JJ	O
2	CD	O
=	JJ	O
9.345	CD	O
,	,	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

Thus	RB	O
,	,	O
patients	NNS	O
with	IN	O
a	DT	O
curatively	RB	O
resected	VBN	O
gastric	JJ	O
cancer	NN	O
had	VBD	O
a	DT	O
better	JJR	O
prognosis	NN	O
when	WRB	O
sizofiran	NN	Pharmacological
was	VBD	O
prescribed	VBN	O
in	IN	O
combination	NN	O
with	IN	O
antitumour	JJ	O
drugs	NNS	O
.	.	O

Combination	NNP	Pharmacological
chemotherapy	NN	Pharmacological
and	CC	O
ALVAC-CEA/B7.1	NNP	Pharmacological
vaccine	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

PURPOSE	VB	O
The	DT	O
combination	NN	O
of	IN	O
vaccines	NNS	Pharmacological
and	CC	O
chemotherapy	NN	Pharmacological
holds	VBZ	O
promise	NN	O
for	IN	O
cancer	NN	O
therapy	NN	O
,	,	O
but	CC	O
the	DT	O
effect	NN	O
of	IN	O
cytotoxic	NN	O
chemotherapy	NN	O
on	IN	O
vaccine-induced	JJ	O
antitumor	NN	O
immunity	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
systemic	JJ	O
chemotherapy	NN	O
on	IN	O
ALVAC-CEA/B7.1-induced	NNP	O
T-cell	NNP	O
immunity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

EXPERIMENTAL	NNP	O
DESIGN	NNP	O
Patients	NNPS	O
with	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
were	VBD	O
treated	VBN	O
with	IN	O
fluorouracil	NN	Pharmacological
,	,	O
leucovorin	NN	Pharmacological
,	,	O
and	CC	O
irinotecan	JJ	Pharmacological
and	CC	O
were	VBD	O
also	RB	O
given	VBN	O
ALVAC-CEA/B7.1	NNP	Pharmacological
vaccine	NN	Pharmacological
with	IN	O
or	CC	O
without	IN	O
tetanus	JJ	Pharmacological
toxoid	NN	Pharmacological
adjuvant	NN	Pharmacological
.	.	O

Eligible	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
ALVAC	NNP	Pharmacological
followed	VBN	O
by	IN	O
chemotherapy	NN	Pharmacological
and	CC	O
booster	NN	Pharmacological
vaccination	NN	Pharmacological
(	(	O
group	NN	O
1	CD	O
)	)	O
,	,	O
ALVAC	NNP	Pharmacological
and	CC	O
tetanus	NN	Pharmacological
toxoid	NN	Pharmacological
followed	VBN	O
by	IN	O
chemotherapy	NN	Pharmacological
(	(	O
group	NN	O
2	CD	O
)	)	O
,	,	O
or	CC	O
chemotherapy	VB	Pharmacological
alone	RB	O
followed	VBN	O
by	IN	O
ALVAC	NNP	Pharmacological
in	IN	O
patients	NNS	O
without	IN	O
disease	JJ	O
progression	NN	O
(	(	O
group	NN	O
3	CD	O
)	)	O
.	.	O

Humoral	NNP	O
immune	JJ	O
responses	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
standard	JJ	O
ELISA	NNP	Physical
assay	NN	Physical
,	,	O
and	CC	O
carcinoembryonic	JJ	O
antigen	NN	O
(	(	O
CEA	NNP	O
)	)	O
-specific	VBD	O
T-cell	NNP	O
responses	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
IFN-gamma	NNP	Physical
enzyme-linked	JJ	Physical
immunospot	NN	Physical
assay	NN	Physical
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
eighteen	JJ	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
ALVAC	NNP	Pharmacological
before	IN	O
and	CC	O
concomitantly	RB	O
with	IN	O
chemotherapy	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
,	,	O
ALVAC	NNP	Pharmacological
with	IN	O
tetanus	NN	Pharmacological
adjuvant	NN	Pharmacological
before	IN	O
and	CC	O
concomitantly	RB	O
with	IN	O
chemotherapy	NN	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
40	CD	O
)	)	O
,	,	O
or	CC	O
chemotherapy	NN	Pharmacological
followed	VBN	O
by	IN	O
ALVAC	NNP	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
39	CD	O
)	)	O
.	.	O

Serious	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
largely	RB	O
gastrointestinal	JJ	O
(	(	O
n	JJ	O
=	NNP	O
30	CD	O
)	)	O
and	CC	O
hematologic	$	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
42	CD	O
patients	NNS	O
(	(	O
40.4	CD	O
%	NN	O
)	)	O
showed	VBD	O
objective	JJ	O
clinical	JJ	O
responses	NNS	O
.	.	O

All	DT	O
patients	NNS	O
developed	VBD	O
antibody	JJ	O
responses	NNS	O
against	IN	O
ALVAC	NNP	O
,	,	O
but	CC	O
increased	VBD	O
anti-CEA	JJ	O
antibody	NN	O
titers	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
only	RB	O
three	CD	O
patients	NNS	O
.	.	O

Increases	NNS	O
in	IN	O
CEA-specific	NNP	O
T	NNP	O
cells	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
50	CD	O
%	NN	O
,	,	O
37	CD	O
%	NN	O
,	,	O
and	CC	O
30	CD	O
%	NN	O
of	IN	O
patients	NNS	O
in	IN	O
groups	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
clinical	JJ	O
or	CC	O
immune	JJ	O
responses	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
The	DT	O
combination	NN	O
of	IN	O
ALVAC-CEA/B7.1	NNP	Pharmacological
vaccine	NN	Pharmacological
and	CC	O
systemic	JJ	O
chemotherapy	NN	Pharmacological
has	VBZ	O
an	DT	O
acceptable	JJ	O
safety	NN	O
profile	NN	O
in	IN	O
patients	NNS	O
with	IN	O
metastatic	JJ	O
colorectal	JJ	O
cancer	NN	O
.	.	O

Systemic	NNP	O
chemotherapy	NN	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
generation	NN	O
of	IN	O
CEA-specific	NNP	O
T-cell	NNP	O
responses	NNS	O
following	VBG	O
vaccination	NN	O
.	.	O

Rapeseed	NNP	Other
and	CC	Other
soybean	NN	Other
products	NNS	Other
as	IN	O
protein	NN	O
sources	NNS	O
for	IN	O
growing	VBG	O
turkeys	NNS	O
of	IN	O
different	JJ	O
ages	NNS	O
.	.	O

(	(	O
1	CD	O
)	)	O
Apparent	NNP	O
ileal	NN	O
and	CC	O
total	JJ	O
tract	NN	O
protein	NN	O
digestibilities	NNS	O
of	IN	O
rapeseed	NN	Other
meal	NN	Other
and	CC	Other
cake	NN	Other
and	CC	Other
soybean	NN	Other
meal	NN	Other
and	CC	Other
cake	NN	Other
were	VBD	O
assayed	VBN	O
in	IN	O
growing	VBG	O
turkeys	NNS	O
at	IN	O
4	CD	O
,	,	O
8	CD	O
and	CC	O
12	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
.	.	O

(	(	O
2	CD	O
)	)	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
effect	NN	O
of	IN	O
killing	VBG	O
technique	NN	O
on	IN	O
apparent	JJ	O
ileal	NN	O
protein	NN	O
digestibility	NN	O
values	NNS	O
obtained	VBN	O
by	IN	O
a	DT	O
slaughter	NN	O
method	NN	O
and	CC	O
effect	NN	O
of	IN	O
rapeseed	NN	Other
feeding	VBG	Other
on	IN	O
size	NN	O
of	IN	O
specific	JJ	O
organs	NNS	O
were	VBD	O
studied	VBN	O
.	.	O

(	(	O
3	CD	O
)	)	O
Protein	NNP	O
digestibility	NN	O
coefficients	NNS	O
of	IN	O
rapeseed	NN	Other
products	NNS	Other
were	VBD	O
mostly	RB	O
0.10	CD	O
to	TO	O
0.15	CD	O
units	NNS	O
lower	JJR	O
than	IN	O
those	DT	O
of	IN	O
soybean	JJ	Other
products	NNS	Other
.	.	Pharmacological

Ileal	NNP	O
digestibility	NN	O
of	IN	O
protein	NN	O
increased	VBD	O
slightly	RB	O
or	CC	O
remained	VBD	O
unchanged	JJ	O
from	IN	O
4	CD	O
to	TO	O
8	CD	O
weeks	NNS	O
and	CC	O
decreased	JJ	O
thereafter	NN	O
.	.	O

No	DT	O
effect	NN	O
of	IN	O
feed	NN	O
processing	NN	O
method	NN	O
(	(	O
meal	JJ	O
vs	NNS	O
cake	VBP	O
)	)	O
on	IN	O
ileal	NN	O
digestibility	NN	O
was	VBD	O
observed	VBN	O
.	.	O

(	(	O
4	CD	O
)	)	O
Killing	VBG	O
the	DT	O
birds	NNS	O
by	IN	O
carbon	NN	O
dioxide	NN	O
inhalation	NN	O
and	CC	O
bleeding	NN	O
led	VBD	O
to	TO	O
slightly	RB	O
lower	JJR	O
ileal	JJ	O
digestibility	NN	O
values	NNS	O
than	IN	O
mechanical	JJ	O
stunning	NN	O
and	CC	O
neck	NN	O
dislocation	NN	O
.	.	O

(	(	O
5	CD	O
)	)	O
Total	NNP	O
tract	JJ	O
digestibility	NN	O
of	IN	O
protein	NN	O
decreased	VBN	O
from	IN	O
4	CD	O
to	TO	O
8	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
for	IN	O
soybean	JJ	Other
meal	NN	Other
and	CC	O
rapeseed	VB	Other
meal	NN	Other
but	CC	O
increased	VBD	O
for	IN	O
soybean	JJ	Other
cake	NN	Other
and	CC	O
rapeseed	VB	Other
cake	NN	Other
.	.	O

From	IN	O
8	CD	O
to	TO	O
12	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
total	JJ	O
tract	JJ	O
digestibility	NN	O
of	IN	O
protein	NN	O
decreased	VBN	O
for	IN	O
all	PDT	O
the	DT	O
products	NNS	O
tested	VBN	O
.	.	O

(	(	O
6	CD	O
)	)	O
Feed	NN	O
containing	VBG	O
rapeseed	NN	Other
led	VBD	O
to	TO	O
enlargement	VB	O
of	IN	O
thyroid	JJ	O
glands	NNS	O
and	CC	O
hearts	NNS	O
,	,	O
but	CC	O
did	VBD	O
not	RB	O
affect	VB	O
liver	NN	O
size	NN	O
or	CC	O
mortality	NN	O
.	.	O

Relationship	NN	O
of	IN	O
dietary	JJ	Educational
intake	NN	Educational
to	TO	O
gastrointestinal	VB	O
symptoms	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
spectrum	NN	O
disorders	NNS	O
.	.	O

BACKGROUND	NNP	O
Gastrointestinal	NNP	O
(	(	O
GI	NNP	O
)	)	O
symptoms	NNS	O
and	CC	O
abnormalities	NNS	O
in	IN	O
stool	NN	O
consistency	NN	O
are	VBP	O
frequently	RB	O
reported	VBN	O
by	IN	O
parents	NNS	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
1	CD	O
)	)	O
describe	NN	O
dietary	JJ	O
intake	NN	O
of	IN	O
a	DT	O
cohort	NN	O
of	IN	O
children	NNS	O
with	IN	O
ASD	NNP	O
compared	VBN	O
with	IN	O
normative	JJ	O
data	NNS	O
and	CC	O
2	CD	O
)	)	O
determine	NN	O
whether	IN	O
GI	NNP	O
symptoms	NNS	O
and	CC	O
stool	JJ	O
consistency	NN	O
are	VBP	O
related	VBN	O
to	TO	O
dietary	JJ	O
intake	NN	O
.	.	O

METHODS	NNP	O
Data	NNP	Educational
from	IN	Educational
diet	JJ	Educational
diaries	NNS	Educational
of	IN	O
children	NNS	O
(	(	O
3-8	CD	O
years	NNS	O
)	)	O
with	IN	O
ASD	NNP	O
(	(	O
n	JJ	O
=	NNP	O
62	CD	O
)	)	O
were	VBD	O
analyzed	VBN	O
by	IN	O
a	DT	O
registered	JJ	O
pediatric	JJ	O
dietician	NN	O
to	TO	O
compare	VB	O
to	TO	O
RDA	NNP	O
standards	NNS	O
for	IN	O
total	JJ	O
calories	NNS	O
,	,	O
protein	NN	O
,	,	O
carbohydrate	NN	O
,	,	O
and	CC	O
fat	NN	O
.	.	O

Dietary	NNP	O
intake	NN	O
was	VBD	O
correlated	VBN	O
with	IN	O
descriptors	NNS	O
of	IN	O
stool	NN	O
consistency	NN	O
using	VBG	O
cumulative	JJ	O
logistic	JJ	O
regression	NN	O
methods	NNS	O
.	.	O

RESULTS	NNP	O
Intake	NNP	O
of	IN	O
calories	NNS	O
,	,	O
carbohydrates	NNS	O
,	,	O
and	CC	O
fat	NN	O
were	VBD	O
in	IN	O
the	DT	O
average	JJ	O
range	NN	O
;	:	O
protein	CC	O
intake	VB	O
was	VBD	O
increased	VBN	O
(	(	O
211	CD	O
%	NN	O
of	IN	O
RDA	NNP	O
)	)	O
.	.	O

Reported	VBN	O
frequency	NN	O
of	IN	O
GI	NNP	O
abnormalities	NNS	O
,	,	O
including	VBG	O
abnormal	JJ	O
stool	NN	O
consistency	NN	O
(	(	O
e.g.	JJ	O
,	,	O
bulky	NN	O
or	CC	O
loose	JJ	O
)	)	O
,	,	O
was	VBD	O
increased	VBN	O
(	(	O
54	CD	O
%	NN	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
relationships	NNS	O
between	IN	O
stool	NN	O
consistency	NN	O
and	CC	O
dietary	JJ	O
intake	NN	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
sample	NN	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
high	JJ	O
rate	NN	O
of	IN	O
reported	VBN	O
gastrointestinal	JJ	O
symptoms	NNS	O
,	,	O
despite	IN	O
lack	NN	O
of	IN	O
medical	JJ	O
causes	NNS	O
.	.	O

Intake	NNP	O
was	VBD	O
adequate	JJ	O
for	IN	O
calories	NNS	O
and	CC	O
carbohydrates	NNS	O
and	CC	O
increased	VBD	O
for	IN	O
protein	NN	O
.	.	O

The	DT	O
children	NNS	O
did	VBD	O
not	RB	O
exhibit	VB	O
excessive	JJ	O
carbohydrate	NN	O
intake	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
association	NN	O
of	IN	O
nutrient	JJ	O
intake	NN	O
to	TO	O
changes	NNS	O
in	IN	O
stool	NN	O
consistency	NN	O
.	.	O

Prophylactic	JJ	O
cranial	JJ	O
irradiation	NN	O
for	IN	O
patients	NNS	O
with	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
in	IN	O
complete	JJ	O
remission	NN	O
.	.	O

BACKGROUND	NNP	O
Prophylactic	NNP	Physical
cranial	JJ	Physical
irradiation	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
decreases	VBZ	O
the	DT	O
overall	JJ	O
rate	NN	O
of	IN	O
brain	NN	O
metastases	NNS	O
without	IN	O
an	DT	O
effect	NN	O
on	IN	O
overall	JJ	O
survival	NN	O
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
this	DT	O
treatment	NN	O
may	MD	O
increase	VB	O
neuropsychological	JJ	O
syndromes	NNS	O
and	CC	O
brain	NN	O
abnormalities	NNS	O
indicated	VBN	O
by	IN	O
computed	JJ	O
tomography	NN	O
scans	NNS	O
.	.	O

However	RB	O
,	,	O
other	JJ	O
retrospective	JJ	O
data	NNS	O
suggested	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
overall	JJ	O
survival	NN	O
for	IN	O
patients	NNS	O
in	IN	O
complete	JJ	O
remission	NN	O
.	.	O

PURPOSE	VB	O
Our	PRP$	O
purpose	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
prophylactic	JJ	Physical
cranial	JJ	Physical
irradiation	NN	Physical
on	IN	O
brain	NN	O
metastasis	NN	O
,	,	O
overall	JJ	O
survival	NN	O
,	,	O
and	CC	O
late-occurring	JJ	O
toxic	NN	O
effects	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
in	IN	O
complete	JJ	O
remission	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
prospective	JJ	O
study	NN	O
of	IN	O
300	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
small-cell	NN	O
lung	NN	O
cancer	NN	O
that	WDT	O
was	VBD	O
in	IN	O
complete	JJ	O
remission	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	RB	O
prophylactic	JJ	Physical
cranial	JJ	Physical
irradiation	NN	Physical
delivering	VBG	O
24	CD	O
Gy	NNP	O
in	IN	O
eight	CD	O
fractions	NNS	O
during	IN	O
12	CD	O
days	NNS	O
(	(	O
treatment	NN	O
group	NN	O
)	)	O
or	CC	O
no	DT	Physical
prophylactic	JJ	Physical
cranial	JJ	Physical
irradiation	NN	Physical
(	(	Physical
control	VB	Physical
group	NN	Physical
)	)	Physical
.	.	O

A	DT	O
neuropsychological	JJ	O
examination	NN	O
and	CC	O
a	DT	O
computed	JJ	O
tomography	NN	O
scan	NN	O
of	IN	O
the	DT	O
brain	NN	O
were	VBD	O
performed	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
random	JJ	O
assignment	NN	O
and	CC	O
repeatedly	RB	O
assessed	VBD	O
at	IN	O
6	CD	O
,	,	O
18	CD	O
,	,	O
30	CD	O
,	,	O
and	CC	O
48	CD	O
months	NNS	O
.	.	O

Patterns	NNP	O
of	IN	O
failure	NN	O
were	VBD	O
analyzed	VBN	O
according	VBG	O
to	TO	O
total	JJ	O
event	NN	O
rates	NNS	O
and	CC	O
also	RB	O
according	VBG	O
to	TO	O
an	DT	O
isolated	VBN	O
first	JJ	O
site	NN	O
of	IN	O
relapse	NN	O
,	,	O
using	VBG	O
a	DT	O
competing-risk	JJ	O
approach	NN	O
.	.	O

RESULTS	NNP	O
Two	CD	O
hundred	VBD	O
ninety-four	JJ	O
patients	NNS	O
who	WP	O
did	VBD	O
not	RB	O
have	VB	O
brain	NN	O
metastases	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
random	JJ	O
assignment	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

The	DT	O
2-year	JJ	O
cumulative	JJ	O
rate	NN	O
of	IN	O
brain	NN	O
metastasis	NN	O
as	IN	O
an	DT	O
isolated	JJ	O
first	JJ	O
site	NN	O
of	IN	O
relapse	NN	O
was	VBD	O
45	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
19	CD	O
%	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	VBZ	O
10	CD	O
(	(	O
-6	NNP	O
)	)	O
)	)	O
.	.	O

The	DT	O
total	JJ	O
2-year	JJ	O
rate	NN	O
of	IN	O
brain	NN	O
metastasis	NN	O
was	VBD	O
67	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
relative	JJ	O
risk	NN	O
=	VBD	O
0.35	CD	O
;	:	O
P	NNP	O
<	VBZ	O
10	CD	O
(	(	O
-13	NNP	O
)	)	O
)	)	O
.	.	O

The	DT	O
2-year	JJ	O
overall	JJ	O
survival	NN	O
rate	NN	O
was	VBD	O
21.5	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
and	CC	O
29	CD	O
%	NN	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
relative	JJ	O
risk	NN	O
=	VBD	O
0.83	CD	O
;	:	O
P	NNP	O
=	NNP	O
.14	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
terms	NNS	O
of	IN	O
neuropsychological	JJ	O
function	NN	O
or	CC	O
abnormalities	NNS	O
indicated	VBN	O
by	IN	O
computed	JJ	O
tomography	NN	O
brain	NN	O
scans	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Prophylactic	NNP	Physical
cranial	JJ	Physical
irradiation	NN	Physical
given	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
small-cell	JJ	O
lung	NN	O
cancer	NN	O
in	IN	O
complete	JJ	O
remission	NN	O
decreases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
brain	NN	O
metastasis	NN	O
threefold	VBD	O
without	IN	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
complications	NNS	O
.	.	O

A	DT	O
possible	JJ	O
beneficial	JJ	O
effect	NN	O
on	IN	O
overall	JJ	O
survival	NN	O
should	MD	O
be	VB	O
tested	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
statistical	JJ	O
power	NN	O
.	.	O

IMPLICATIONS	VBZ	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
trial	NN	O
favor	NN	O
,	,	O
at	IN	O
present	JJ	O
,	,	O
the	DT	O
indication	NN	O
of	IN	O
prophylactic	JJ	O
cranial	JJ	O
irradiation	NN	O
for	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
in	IN	O
complete	JJ	O
remission	NN	O
.	.	O

A	NNP	O
longer	JJR	O
follow-up	NN	O
and	CC	O
confirmatory	NN	O
trials	NNS	O
are	VBP	O
needed	VBN	O
to	TO	O
fully	RB	O
assess	VB	O
late-occurring	JJ	O
toxic	JJ	O
effects	NNS	O
.	.	O

The	DT	O
possible	JJ	O
effect	NN	O
on	IN	O
overall	JJ	O
survival	NN	O
needs	NNS	O
to	TO	O
be	VB	O
evaluated	VBN	O
with	IN	O
a	DT	O
larger	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
in	IN	O
complete	JJ	O
remission	NN	O
,	,	O
and	CC	O
a	DT	O
meta-analysis	NN	O
of	IN	O
similar	JJ	O
trials	NNS	O
is	VBZ	O
recommended	VBN	O
.	.	O

Immune	NNP	O
reconstitution	NN	O
after	IN	O
allogeneic	JJ	Surgical
marrow	NN	Surgical
transplantation	NN	Surgical
compared	VBN	O
with	IN	O
blood	NN	Surgical
stem	NN	Surgical
cell	NN	Surgical
transplantation	NN	Surgical
.	.	Surgical

Allogeneic	NNP	O
peripheral	JJ	O
blood	NN	O
stem	NN	O
cell	NN	O
grafts	NNS	O
contain	VBP	O
about	IN	O
10	CD	O
times	NNS	O
more	RBR	O
T	NNP	O
and	CC	O
B	NNP	O
cells	NNS	O
than	IN	O
marrow	JJ	O
grafts	NNS	O
.	.	O

Because	IN	O
these	DT	O
cells	NNS	O
may	MD	O
survive	VB	O
in	IN	O
transplant	JJ	O
recipients	NNS	O
for	IN	O
a	DT	O
long	JJ	O
time	NN	O
,	,	O
recipients	NNS	O
of	IN	O
blood	NN	O
stem	NN	O
cells	NNS	O
may	MD	O
be	VB	O
less	JJR	O
immunocompromised	JJ	O
than	IN	O
recipients	NNS	O
of	IN	O
marrow	NN	O
.	.	O

Immune	NNP	O
reconstitution	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
115	CD	O
patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
allogeneic	JJ	Surgical
marrow	NN	Surgical
or	CC	Surgical
filgrastim-mobilized	JJ	Surgical
blood	NN	Surgical
stem	NN	Surgical
cell	NN	Surgical
transplantation	NN	Surgical
.	.	Surgical

Between	NNP	O
day	NN	O
30	CD	O
and	CC	O
365	CD	O
after	IN	O
transplantation	NN	Physical
,	,	O
counts	NNS	O
of	IN	O
most	JJS	O
lymphocyte	JJ	O
subsets	NNS	O
were	VBD	O
higher	JJR	O
in	IN	O
the	DT	O
blood	NN	O
stem	NN	O
cell	NN	O
recipients	NNS	O
.	.	O

The	DT	O
difference	NN	O
was	VBD	O
most	RBS	O
striking	JJ	O
for	IN	O
CD4	NNP	O
T	NNP	O
cells	NNS	O
(	(	O
about	IN	O
4-fold	CD	O
higher	JJR	O
counts	NNS	O
for	IN	O
CD45RA	NNP	O
(	(	O
high	JJ	O
)	)	O
CD4	NNP	O
T	NNP	O
cells	NNS	O
and	CC	O
about	IN	O
2-fold	JJ	O
higher	JJR	O
counts	NNS	O
for	IN	O
CD45RA	NNP	O
(	(	O
low/-	JJ	O
)	)	O
CD4	NNP	O
T	NNP	O
cells	NNS	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

On	IN	O
assessment	NN	O
using	VBG	O
phytohemagglutinin	NN	O
and	CC	O
herpesvirus	VB	O
antigen-stimulated	JJ	O
proliferation	NN	O
,	,	O
T	NNP	O
cells	NNS	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
of	IN	O
patients	NNS	O
appeared	VBD	O
equally	RB	O
functional	JJ	O
.	.	O

Median	JJ	O
serum	NN	O
IgG	NNP	O
levels	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
definite	NN	O
infections	NNS	O
after	IN	O
engraftment	NN	O
was	VBD	O
1.7-fold	JJ	O
higher	JJR	O
in	IN	O
marrow	NN	O
recipients	NNS	O
(	(	O
P	NNP	O
=.001	NNP	O
)	)	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
severe	JJ	O
(	(	O
inpatient	JJ	O
treatment	NN	O
required	VBN	O
)	)	O
definite	NN	O
infections	NNS	O
after	IN	O
engraftment	NN	O
was	VBD	O
2.4-fold	JJ	O
higher	JJR	O
in	IN	O
marrow	NN	O
recipients	NNS	O
(	(	O
P	NNP	O
=.002	NNP	O
)	)	O
.	.	O

The	DT	O
difference	NN	O
in	IN	O
the	DT	O
rates	NNS	O
of	IN	O
definite	JJ	O
infections	NNS	O
was	VBD	O
greatest	JJS	O
for	IN	O
fungal	JJ	O
infections	NNS	O
,	,	O
intermediate	NN	O
for	IN	O
bacterial	JJ	O
infections	NNS	O
,	,	O
and	CC	O
lowest	JJS	O
for	IN	O
viral	JJ	O
infections	NNS	O
.	.	O

Death	NNP	O
associated	VBD	O
with	IN	O
a	DT	O
fungal	NN	O
or	CC	O
bacterial	JJ	O
infection	NN	O
occurred	VBD	O
between	IN	O
day	NN	O
30	CD	O
and	CC	O
day	NN	O
365	CD	O
after	IN	O
transplantation	NN	Physical
in	IN	O
9	CD	O
marrow	NN	Physical
recipients	NNS	O
and	CC	O
no	DT	O
blood	NN	Physical
stem	NN	Physical
cell	NN	Physical
recipients	NNS	O
(	(	O
P	NNP	O
=.008	NNP	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
blood	NN	O
stem	NN	O
cell	NN	O
recipients	NNS	O
have	VBP	O
higher	JJR	O
lymphocyte-subset	JJ	O
counts	NNS	O
and	CC	O
this	DT	O
appears	VBZ	O
to	TO	O
result	VB	O
in	IN	O
fewer	JJR	O
infections	NNS	O
.	.	O

(	(	O
Blood	NNP	O
.	.	O

2001	CD	O
;	:	O
97:3380-3389	CD	O
)	)	O
A	DT	O
potent	JJ	O
oral	JJ	O
P-selectin	NNP	Pharmacological
blocking	NN	Pharmacological
agent	NN	Pharmacological
improves	VBZ	O
microcirculatory	JJ	O
blood	NN	O
flow	NN	O
and	CC	O
a	DT	O
marker	NN	O
of	IN	O
endothelial	JJ	O
cell	NN	O
injury	NN	O
in	IN	O
patients	NNS	O
with	IN	O
sickle	JJ	O
cell	NN	O
disease	NN	O
.	.	O

Abnormal	JJ	O
blood	NN	O
flow	NN	O
accounts	NNS	O
for	IN	O
most	JJS	O
of	IN	O
the	DT	O
clinical	JJ	O
morbidity	NN	O
of	IN	O
sickle	NN	O
cell	NN	O
disease	NN	O
(	(	O
SCD	NNP	O
)	)	O
[	VBD	O
1,2	CD	O
]	NNP	O
.	.	O

Most	JJS	O
notably	RB	O
,	,	O
occlusion	NN	O
of	IN	O
flow	NN	O
in	IN	O
the	DT	O
microvasculature	NN	O
causes	VBZ	O
the	DT	O
acute	NN	O
pain	NN	O
crises	NNS	O
[	VBP	O
3	CD	O
]	NN	O
that	WDT	O
are	VBP	O
the	DT	O
commonest	NN	O
cause	NN	O
for	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
to	TO	O
seek	VB	O
medical	JJ	O
attention	NN	O
[	VBD	O
4	CD	O
]	NN	O
and	CC	O
major	JJ	O
determinants	NNS	O
of	IN	O
their	PRP$	O
quality	NN	O
of	IN	O
life	NN	O
[	$	O
5	CD	O
]	NNP	O
.	.	O

Based	VBN	O
on	IN	O
evidence	NN	O
that	IN	O
endothelial	JJ	O
P-selectin	NNP	O
is	VBZ	O
central	JJ	O
to	TO	O
the	DT	O
abnormal	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
SCD	NNP	O
we	PRP	O
provide	VBP	O
results	NNS	O
from	IN	O
four	CD	O
of	IN	O
our	PRP$	O
studies	NNS	O
that	WDT	O
are	VBP	O
germane	VBN	O
to	TO	O
microvascular	VB	O
blood	NN	O
flow	NN	O
in	IN	O
SCD	NNP	O
.	.	O

A	DT	O
proof-of-principle	JJ	O
study	NN	O
established	VBD	O
that	IN	O
doses	NNS	O
of	IN	O
heparin	NN	Pharmacological
lower	JJR	O
than	IN	O
what	WP	O
are	VBP	O
used	VBN	O
for	IN	O
anticoagulation	NN	O
but	CC	O
sufficient	JJ	O
to	TO	O
block	VB	O
P-selectin	NNP	O
improved	JJ	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
inpatients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

An	DT	O
in	IN	O
vitro	NN	O
study	NN	O
showed	VBD	O
that	IN	O
Pentosan	NNP	Pharmacological
Polysulfate	NNP	Pharmacological
Sodium	NNP	Pharmacological
(	(	Pharmacological
PPS	NNP	Pharmacological
)	)	Pharmacological
had	VBD	O
greater	JJR	O
P-selectin	JJ	O
blocking	NN	O
activity	NN	O
than	IN	O
heparin	NN	O
.	.	O

A	DT	O
Phase	NN	O
I	PRP	O
clinical	VBP	O
study	NN	O
demonstrated	VBD	O
that	IN	O
a	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
PPS	NNP	Pharmacological
increased	VBD	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

A	NNP	O
Phase	NNP	O
II	NNP	O
clinical	JJ	O
study	NN	O
that	WDT	O
was	VBD	O
not	RB	O
completed	VBN	O
documented	VBD	O
that	IN	O
daily	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
PPS	NNP	Pharmacological
administered	VBD	O
for	IN	O
8	CD	O
weeks	NNS	O
lowered	VBD	O
plasma	JJ	O
levels	NNS	O
of	IN	O
sVCAM-1	NN	O
and	CC	O
tended	VBD	O
to	TO	O
improve	VB	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
patients	NNS	O
with	IN	O
SCD	NNP	O
.	.	O

These	DT	O
data	NNS	O
support	NN	O
the	DT	O
concept	NN	O
that	IN	O
P-selectin	NNP	O
on	IN	O
the	DT	O
microvascular	JJ	O
endothelium	NN	O
is	VBZ	O
critical	JJ	O
to	TO	O
both	DT	O
acute	JJ	O
vascular	NN	O
occlusion	NN	O
and	CC	O
chronically	RB	O
impaired	JJ	O
microvascular	JJ	O
blood	NN	O
flow	NN	O
in	IN	O
SCD	NNP	O
.	.	O

They	PRP	O
also	RB	O
demonstrate	VBP	O
that	IN	O
oral	JJ	O
PPS	NNP	O
is	VBZ	O
beneficial	JJ	O
to	TO	O
microvascular	VB	O
sickle	NN	O
cell	NN	O
blood	NN	O
flow	NN	O
and	CC	O
has	VBZ	O
potential	JJ	O
as	IN	O
an	DT	O
efficacious	JJ	O
agent	NN	O
for	IN	O
long-term	JJ	O
prophylactic	JJ	O
therapy	NN	O
of	IN	O
SCD	NNP	O
.	.	O

Prospective	JJ	O
,	,	O
randomized	JJ	O
comparison	NN	O
of	IN	O
transperitoneal	JJ	Surgical
versus	NN	O
retroperitoneal	NN	Surgical
laparoscopic	JJ	Surgical
adrenalectomy	NN	Surgical
.	.	O

PURPOSE	NNP	O
We	PRP	O
report	VBP	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
comparison	NN	O
of	IN	O
transperitoneal	JJ	Surgical
laparoscopic	JJ	Surgical
adrenalectomy	NN	Surgical
(	(	Surgical
TLA	NNP	Surgical
)	)	Surgical
vs	FW	O
retroperitoneal	JJ	Surgical
laparoscopic	NN	Surgical
adrenalectomy	NN	Surgical
(	(	Surgical
RLA	NNP	Surgical
)	)	Surgical
for	IN	O
adrenal	JJ	O
lesions	NNS	O
with	IN	O
long-term	JJ	O
followup	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Between	NNP	O
December	NNP	O
1997	CD	O
and	CC	O
November	NNP	O
1999	CD	O
,	,	O
57	CD	O
consecutive	JJ	O
eligible	JJ	O
patients	NNS	O
with	IN	O
surgical	JJ	O
adrenal	JJ	O
disease	NN	O
were	VBD	O
prospectively	RB	O
randomized	VBN	O
to	TO	O
undergo	VB	O
TLA	NNP	Surgical
(	(	O
25	CD	O
)	)	O
or	CC	O
RLA	NNP	Surgical
(	(	O
32	CD	O
)	)	O
.	.	O

Study	NNP	O
exclusion	NN	O
criteria	NNS	O
were	VBD	O
patient	JJ	O
age	NN	O
greater	JJR	O
than	IN	O
80	CD	O
years	NNS	O
,	,	O
body	NN	O
mass	NN	O
index	NN	O
greater	JJR	O
than	IN	O
40	CD	O
,	,	O
bilateral	JJ	O
adrenalectomy	NN	O
and	CC	O
significant	JJ	O
prior	JJ	O
abdominal	JJ	O
surgery	NN	O
in	IN	O
the	DT	O
quadrant	NN	O
of	IN	O
interest	NN	O
.	.	O

Mean	NNP	O
followup	NN	O
was	VBD	O
5.96	CD	O
years	NNS	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
groups	NNS	O
were	VBD	O
matched	VBN	O
in	IN	O
regard	NN	O
to	TO	O
patient	JJ	O
age	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.84	CD	O
)	)	O
,	,	O
body	JJ	O
mass	NN	O
index	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.43	CD	O
)	)	O
,	,	O
American	NNP	O
Society	NNP	O
of	IN	O
Anesthesiologists	NNP	O
class	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.81	CD	O
)	)	O
and	CC	O
laterality	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.12	CD	O
)	)	O
.	.	O

Median	JJ	O
adrenal	JJ	O
mass	NN	O
size	NN	O
was	VBD	O
2.7	CD	O
cm	NN	O
(	(	O
range	VB	O
1	CD	O
to	TO	O
9	CD	O
)	)	O
in	IN	O
the	DT	O
TLA	NNP	O
group	NN	O
and	CC	O
2.6	CD	O
cm	NN	O
(	(	O
range	VB	O
0.5	CD	O
to	TO	O
6	CD	O
)	)	O
in	IN	O
the	DT	O
RLA	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.83	CD	O
)	)	O
.	.	O

TLA	NNP	O
was	VBD	O
comparable	JJ	O
to	TO	O
RLA	NNP	O
in	IN	O
terms	NNS	O
of	IN	O
operative	JJ	O
time	NN	O
(	(	O
130	CD	O
vs	NN	O
126.5	CD	O
minutes	NNS	O
,	,	O
p	VBP	O
=	RB	O
0.64	CD	O
)	)	O
,	,	O
estimated	VBN	O
blood	NN	O
loss	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.92	CD	O
)	)	O
,	,	O
specimen	NNS	O
weight	VBD	O
(	(	O
p	JJ	O
=	NNP	O
0.81	CD	O
)	)	O
,	,	O
analgesic	JJ	O
requirements	NNS	O
(	(	O
p	JJ	O
=	NNP	O
0.25	CD	O
)	)	O
,	,	O
hospital	JJ	O
stay	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.56	CD	O
)	)	O
and	CC	O
the	DT	O
complication	NN	O
rate	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.58	CD	O
)	)	O
.	.	O

One	CD	O
case	NN	O
per	IN	O
group	NN	O
was	VBD	O
electively	RB	O
converted	VBN	O
to	TO	O
open	VB	O
surgery	NN	O
.	.	O

Pathology	NNP	O
data	NNS	O
on	IN	O
the	DT	O
intact	JJ	O
extracted	JJ	O
specimens	NNS	O
were	VBD	O
similar	JJ	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Averaged	VBD	O
convalescence	NN	O
was	VBD	O
4.7	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
TLA	NNP	O
group	NN	O
and	CC	O
2.3	CD	O
weeks	NNS	O
in	IN	O
the	DT	O
RLA	NNP	O
group	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

During	IN	O
a	DT	O
mean	JJ	O
followup	NN	O
of	IN	O
6	CD	O
years	NNS	O
2	CD	O
patients	NNS	O
in	IN	O
the	DT	O
TLA	NNP	O
group	NN	O
had	VBD	O
a	DT	O
late	JJ	O
complication	NN	O
(	(	O
port	JJ	O
site	NN	O
hernia	NN	O
)	)	O
.	.	O

Mortality	NN	O
occurred	VBD	O
in	IN	O
5	CD	O
patients	NNS	O
,	,	O
including	VBG	O
1	CD	O
with	IN	O
TLA	NNP	O
and	CC	O
4	CD	O
with	IN	O
RLA	NNP	O
,	,	O
during	IN	O
the	DT	O
6-year	JJ	O
followup	NN	O
.	.	O

CONCLUSIONS	NNP	O
For	IN	O
most	JJS	O
benign	JJ	O
adrenal	JJ	O
lesions	NNS	O
requiring	VBG	O
surgery	NN	O
laparoscopic	NN	Surgical
adrenalectomy	NN	Surgical
can	MD	O
be	VB	O
performed	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
by	IN	O
the	DT	O
transperitoneal	NN	O
or	CC	O
the	DT	O
retroperitoneal	JJ	O
approach	NN	O
.	.	O

Lanthanum	NNP	Pharmacological
carbonate	NN	Pharmacological
(	(	Pharmacological
Fosrenol	NNP	Pharmacological
)	)	Pharmacological
efficacy	NN	O
and	CC	O
tolerability	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hyperphosphatemic	JJ	O
patients	NNS	O
with	IN	O
end-stage	JJ	O
renal	JJ	O
disease	NN	O
.	.	O

AIMS	NNP	O
High	NNP	O
serum	NN	O
phosphorus	NN	O
levels	NNS	O
are	VBP	O
a	DT	O
common	JJ	O
problem	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
long-term	JJ	O
dialysis	NN	O
treatment	NN	O
.	.	O

Lanthanum	NNP	Pharmacological
carbonate	NN	Pharmacological
(	(	Pharmacological
Fosrenol	NNP	Pharmacological
)	)	Pharmacological
is	VBZ	O
a	DT	O
new	JJ	O
non-aluminum	JJ	O
,	,	O
non-calcium	JJ	O
phosphate	NN	O
binder	NN	O
developed	VBD	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hyperphosphatemia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
end-stage	JJ	O
renal	JJ	O
disease	NN	O
(	(	O
ESRD	NNP	O
)	)	O
.	.	O

We	PRP	O
report	VBP	O
data	NNS	O
from	IN	O
a	DT	O
recent	JJ	O
trial	NN	O
,	,	O
which	WDT	O
,	,	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
,	,	O
assessed	VBD	O
the	DT	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
lanthanum	JJ	Pharmacological
carbonate	NN	Pharmacological
treatment	NN	Pharmacological
,	,	O
compared	VBN	O
with	IN	O
placebo	NN	Control
,	,	O
in	IN	O
Chinese	JJ	O
patients	NNS	O
with	IN	O
ESRD	NNP	O
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
Following	VBG	O
a	DT	O
one-	JJ	O
to	TO	O
three-week	JJ	O
washout	NN	O
phase	NN	O
and	CC	O
a	DT	O
four-week	JJ	O
,	,	O
open-label	JJ	O
lanthanum	NN	Pharmacological
carbonate	NN	Pharmacological
dose-titration	NN	O
phase	NN	O
,	,	O
male	NN	O
and	CC	O
female	JJ	O
hemodialysis	NN	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
(	(	O
1:1	CD	O
)	)	O
to	TO	O
receive	VB	O
either	DT	O
lanthanum	NN	Pharmacological
carbonate	NN	Pharmacological
or	CC	O
placebo	NN	Control
for	IN	O
four	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
efficacy	NN	O
parameter	NN	O
of	IN	O
the	DT	O
study	NN	O
was	VBD	O
the	DT	O
control	NN	O
of	IN	O
serum	JJ	O
phosphorus	NN	O
levels	NNS	O
(	(	O
<	CD	O
or	CC	O
=1.8	VB	O
mmol/l	JJ	O
[	NNP	O
<	NN	O
or	CC	O
=	$	O
5.6	CD	O
mg/dl	NN	O
]	NN	O
)	)	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
included	VBD	O
the	DT	O
profile	NN	O
of	IN	O
serum	JJ	O
phosphorus	NN	O
during	IN	O
titration	NN	O
and	CC	O
parathyroid	NN	O
hormone	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
calcium	NN	O
x	NN	O
phosphorus	NN	O
(	(	O
Ca	NNP	O
x	NNP	O
P	NNP	O
)	)	O
product	NN	O
levels	NNS	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
lanthanum	NN	Pharmacological
carbonate	NN	Pharmacological
were	VBD	O
assessed	VBN	O
by	IN	O
monitoring	VBG	O
adverse	JJ	O
events	NNS	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	NNP	O
Mean	NNP	O
serum	VBZ	O
phosphorus	JJ	O
level	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
washout	NN	O
was	VBD	O
2.5	CD	O
+/-	JJ	O
0.5	CD	O
mmol/l	NN	O
(	(	O
7.7	CD	O
+/-	JJ	O
1.5	CD	O
mg/dl	NN	O
;	:	O
n=73	CC	O
)	)	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
a	DT	O
difference	NN	O
in	IN	O
levels	NNS	O
between	IN	O
the	DT	O
treatment	NN	O
groups	NNS	O
pre-randomization	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
lanthanum	JJ	Pharmacological
carbonate-treated	JJ	Pharmacological
patients	NNS	O
had	VBD	O
significantly	RB	O
lower	JJR	O
phosphorus	NN	O
levels	NNS	O
(	(	O
1.6	CD	O
+/-	JJ	O
0.5	CD	O
mmol/l	NN	O
[	VBD	O
5.1	CD	O
+/-	JJ	O
1.5	CD	O
mg/dl	NN	O
]	NN	O
;	:	O
n=30	CC	O
)	)	O
than	IN	O
those	DT	O
receiving	VBG	O
placebo	NN	O
(	(	O
2.3	CD	O
+/-	JJ	O
0.4	CD	O
mmol/l	NN	O
[	VBD	O
7.2	CD	O
+/-	JJ	O
1.3	CD	O
mg/dl	NN	O
]	NN	O
;	:	O
n=31	CC	O
;	:	O
p	CC	O
<	VB	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
lanthanum	JJ	Pharmacological
carbonate	NN	Pharmacological
had	VBD	O
controlled	VBN	O
serum	JJ	O
phosphorus	NN	O
levels	NNS	O
(	(	O
60	CD	O
%	NN	O
)	)	O
compared	VBN	O
with	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
10	CD	O
%	NN	O
;	:	O
p	CC	O
<	VB	O
0.001	CD	O
)	)	O
.	.	O

Ca	NNP	O
x	JJ	O
P	NNP	O
product	NN	O
levels	NNS	O
were	VBD	O
also	RB	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
lanthanum	NN	Pharmacological
carbonate	NN	Pharmacological
group	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
randomized	JJ	O
treatment	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Lanthanum	NNP	Pharmacological
carbonate	NN	Pharmacological
was	VBD	O
well	RB	O
tolerated	VBN	O
;	:	O
only	RB	O
one	CD	O
serious	JJ	O
adverse	JJ	O
event	NN	O
was	VBD	O
reported	VBN	O
,	,	O
which	WDT	O
was	VBD	O
unrelated	JJ	O
to	TO	O
treatment	NN	O
.	.	O

CONCLUSIONS	NNP	O
Lanthanum	NNP	Pharmacological
carbonate	NN	Pharmacological
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
phosphate	NN	O
binder	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hyperphosphatemia	NN	O
in	IN	O
Chinese	JJ	O
patients	NNS	O
with	IN	O
ESRD	NNP	O
.	.	O

This	DT	O
finding	NN	O
supports	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
previous	JJ	O
US	NNP	O
and	CC	O
European	JJ	O
studies	NNS	O
,	,	O
which	WDT	O
have	VBP	O
also	RB	O
shown	VBN	O
that	IN	O
lanthanum	NN	Pharmacological
carbonate	NN	Pharmacological
treatment	NN	O
effectively	RB	O
controls	VBZ	O
serum	JJ	O
phosphorus	NN	O
levels	NNS	O
.	.	O

Mindfulness-based	JJ	Psychological
therapy	NN	Psychological
in	IN	O
adults	NNS	O
with	IN	O
an	DT	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

Research	NN	O
shows	VBZ	O
that	IN	O
depression	NN	O
and	CC	O
anxiety	NN	O
disorders	NNS	O
are	VBP	O
the	DT	O
most	RBS	O
common	JJ	O
psychiatric	JJ	O
concern	NN	O
in	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
.	.	O

Mindfulness-based	JJ	Psychological
therapy	NN	Psychological
(	(	Psychological
MBT	NNP	Psychological
)	)	Psychological
has	VBZ	O
been	VBN	O
found	VBN	O
effective	JJ	O
in	IN	O
reducing	VBG	O
anxiety	NN	O
and	CC	O
depression	NN	O
symptoms	NNS	O
,	,	O
however	RB	O
research	NN	O
in	IN	O
autism	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

Therefore	RB	O
,	,	O
we	PRP	O
examined	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
a	DT	O
modified	JJ	Psychological
MBT	NNP	Psychological
protocol	NN	Psychological
(	(	Psychological
MBT-AS	NNP	Psychological
)	)	Psychological
in	IN	O
high-functioning	NN	O
adults	NNS	O
with	IN	O
ASD	NNP	O
.	.	O

42	CD	O
participants	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
a	DT	O
9-week	JJ	O
MBT-AS	JJ	Educational
training	NN	Educational
or	CC	O
a	DT	O
wait-list	JJ	Control
control	NN	Control
group	NN	Physical
.	.	O

Results	NNP	O
showed	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
depression	NN	O
,	,	O
anxiety	NN	O
and	CC	O
rumination	NN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
,	,	O
as	IN	O
opposed	VBN	O
to	TO	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Furthermore	RB	O
,	,	O
positive	JJ	O
affect	NN	O
increased	VBN	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Concluding	NNP	O
,	,	O
the	DT	O
present	JJ	O
study	NN	O
is	VBZ	O
the	DT	O
first	JJ	O
controlled	VBN	O
trial	NN	O
to	TO	O
demonstrate	VB	O
that	IN	O
adults	NNS	O
with	IN	O
ASD	NNP	O
can	MD	O
benefit	VB	O
from	IN	O
MBT-AS	NNP	Psychological
.	.	Psychological

[	IN	O
The	DT	O
comparison	NN	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
enalapril	NN	Pharmacological
and	CC	O
indapamide	NN	Pharmacological
on	IN	O
the	DT	O
peripheral	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
central	JJ	O
blood	NN	O
pressure	NN	O
through	IN	O
pulse	JJ	O
wave	NN	O
analysis	NN	O
]	NNP	O
.	.	O

OBJECTIVES	CC	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
angiotensin-converting	JJ	Pharmacological
enzyme	NN	Pharmacological
(	(	Pharmacological
ACE	NNP	Pharmacological
)	)	Pharmacological
inhibitor	NN	Pharmacological
enalapril	NN	Pharmacological
and	CC	O
diuretic	JJ	Pharmacological
indapamide	NN	Pharmacological
on	IN	O
the	DT	O
peripheral	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
the	DT	O
central	JJ	O
blood	NN	O
pressure	NN	O
in	IN	O
Chinese	JJ	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

METHODS	NNP	O
This	DT	O
study	NN	O
was	VBD	O
a	DT	O
double	JJ	O
blind	NN	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

Informed	VBN	O
consent	NN	O
were	VBD	O
given	VBN	O
by	IN	O
all	DT	O
patients	NNS	O
.	.	O

After	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
placebo	JJ	Control
run-in	JJ	O
period	NN	O
,	,	O
105	CD	O
patients	NNS	O
with	IN	O
mild	JJ	O
or	CC	O
moderate	JJ	O
essential	JJ	O
hypertension	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
enalapril	NN	Pharmacological
(	(	O
10	CD	O
mg	NNS	O
per	IN	O
day	NN	O
)	)	O
or	CC	O
indapamide	NN	Pharmacological
(	(	O
2.5	CD	O
mg	NNS	O
per	IN	O
day	NN	O
)	)	O
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

Radial	JJ	O
pulse	JJ	O
wave	NN	O
recordings	NNS	O
were	VBD	O
performed	VBN	O
in	IN	O
all	PDT	O
the	DT	O
patients	NNS	O
before	IN	O
the	DT	O
active	JJ	O
treatments	NNS	O
were	VBD	O
given	VBN	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Only	RB	O
those	DT	O
patients	NNS	O
who	WP	O
have	VBP	O
finished	VBN	O
8	CD	O
weeks	NNS	O
of	IN	O
active	JJ	O
treatment	NN	O
in	IN	O
both	DT	O
groups	NNS	O
were	VBD	O
included	VBN	O
into	IN	O
the	DT	O
final	JJ	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
One	CD	O
hundred	VBD	O
one	CD	O
patients	NNS	O
(	(	O
51	CD	O
in	IN	O
enalapril	NN	Pharmacological
group	NN	O
and	CC	O
50	CD	O
in	IN	O
indapamide	JJ	Pharmacological
group	NN	O
)	)	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
(	(	O
all	DT	O
P	NNP	O
values	NNS	O
>	VBP	O
0.05	CD	O
)	)	O
was	VBD	O
found	VBN	O
in	IN	O
baseline	NN	O
data	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

After	IN	O
8	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
all	PDT	O
the	DT	O
parameters	NNS	O
of	IN	O
pulse	JJ	O
wave	NN	O
(	(	O
except	IN	O
heart	NN	O
rates	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
and	CC	O
augmentation	NN	O
index	NN	O
in	IN	O
indapamide	JJ	Pharmacological
group	NN	O
)	)	O
decreased	VBD	O
significantly	RB	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
2	CD	O
groups	NNS	O
showed	VBD	O
that	IN	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
(	(	O
all	DT	O
P	NNP	O
values	NNS	O
>	VBP	O
0.05	CD	O
)	)	O
in	IN	O
all	PDT	O
the	DT	O
parameters	NNS	O
of	IN	O
pulse	JJ	O
wave	NN	O
except	IN	O
that	IN	O
the	DT	O
central	JJ	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
,	,	O
augmentation	NN	O
and	CC	O
augmentation	NN	O
index	NN	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
enalapril	NN	Pharmacological
group	NN	O
than	IN	O
in	IN	O
indapamide	JJ	Pharmacological
group	NN	O
.	.	O

In	IN	O
enalapril	JJ	Pharmacological
group	NN	O
,	,	O
the	DT	O
reduced	JJ	O
values	NNS	O
of	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
and	CC	O
pulse	JJ	O
pressure	NN	O
in	IN	O
central	JJ	O
aorta	NNS	O
were	VBD	O
significantly	RB	O
larger	JJR	O
than	IN	O
those	DT	O
in	IN	O
brachial	JJ	O
artery	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
difference	NN	O
was	VBD	O
not	RB	O
observed	VBN	O
in	IN	O
indapamide	JJ	Pharmacological
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Enalapril	NNP	Pharmacological
and	CC	O
indapamide	NN	Pharmacological
are	VBP	O
both	DT	O
similarly	RB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
peripheral	JJ	O
arterial	JJ	O
blood	NN	O
pressure	NN	O
.	.	O

Moreover	RB	O
,	,	O
enalapril	NN	Pharmacological
is	VBZ	O
more	RBR	O
effective	JJ	O
in	IN	O
reducing	VBG	O
central	JJ	O
systolic	JJ	O
pressure	NN	O
and	CC	O
augmentation	NN	O
index	NN	O
than	IN	O
indapamide	NN	Pharmacological
.	.	O

The	DT	O
difference	NN	O
is	VBZ	O
probably	RB	O
due	JJ	O
to	TO	O
the	DT	O
reduction	NN	O
of	IN	O
wave	NN	O
reflection	NN	O
caused	VBN	O
by	IN	O
enalapril	NN	Pharmacological
.	.	O

Skin	NNP	O
manifestations	NNS	O
of	IN	O
inhaled	JJ	O
corticosteroids	NNS	Pharmacological
in	IN	O
COPD	NNP	O
patients	NNS	O
:	:	O
results	NNS	O
from	IN	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
define	VB	O
the	DT	O
relationship	NN	O
between	IN	O
skin	NN	O
bruising	NN	O
(	(	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
cutaneous	JJ	O
manifestations	NNS	O
)	)	O
and	CC	O
inhaled	VBN	O
corticosteroid	NN	Pharmacological
(	(	Pharmacological
ICS	NNP	Pharmacological
)	)	Pharmacological
therapy	NN	O
vs	NN	O
placebo	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
COPD	NNP	O
who	WP	O
were	VBD	O
participating	VBG	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
.	.	O

To	TO	O
explore	VB	O
the	DT	O
relationship	NN	O
between	IN	O
easy	JJ	O
skin	NN	O
bruising	NN	O
and	CC	O
other	JJ	O
systemic	JJ	O
effects	NNS	O
of	IN	O
ICS	NNP	O
therapy	NN	O
,	,	O
including	VBG	O
adrenal	JJ	O
suppression	NN	O
and	CC	O
loss	NN	O
of	IN	O
bone	JJ	O
mineral	JJ	O
density	NN	O
(	(	O
BMD	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Double-blind	NNP	O
,	,	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
triamcinolone	NN	Pharmacological
acetonide	NN	Pharmacological
(	(	O
1200	CD	O
microg	FW	O
daily	RB	O
)	)	O
vs	NN	O
placebo	NN	Control
in	IN	O
participants	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
.	.	O

SETTING	NNP	O
Lung	NNP	O
Health	NNP	O
Study	NNP	O
II	NNP	O
,	,	O
a	DT	O
clinical	JJ	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
ICS	NNP	Pharmacological
compared	VBN	O
to	TO	O
placebo	VB	O
in	IN	O
1,116	CD	O
participants	NNS	O
in	IN	O
10	CD	O
centers	NNS	O
over	IN	O
>	$	O
3.5	CD	O
to	TO	O
4.5	CD	O
years	NNS	O
.	.	O

PARTICIPANTS	VB	O
A	DT	O
total	NN	O
of	IN	O
1,116	CD	O
smokers	NNS	O
or	CC	O
recent	JJ	O
ex-smokers	NNS	O
with	IN	O
mild-to-moderate	JJ	O
COPD	NNP	O
(	(	O
age	NN	O
range	NN	O
,	,	O
40	CD	O
to	TO	O
69	CD	O
years	NNS	O
;	:	O
mean	JJ	O
age	NN	O
,	,	O
56.3	CD	O
years	NNS	O
;	:	O
37.2	CD	O
%	NN	O
female	NN	O
)	)	O
.	.	O

MEASUREMENTS	NNP	O
AND	CC	O
RESULTS	NNP	O
Every	NNP	O
6	CD	O
months	NNS	O
,	,	O
a	DT	O
structured	JJ	O
questionnaire	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
elicit	VB	O
reports	NNS	O
of	IN	O
any	DT	O
bruising	NN	O
and/or	NN	O
skin	NN	O
rashes	NNS	O
,	,	O
slow	JJ	O
healing	NN	O
of	IN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
,	,	O
or	CC	O
other	JJ	O
skin	JJ	O
changes	NNS	O
.	.	O

Compliance	NN	O
with	IN	O
inhaler	NN	O
use	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
canister	NN	O
weighing	VBG	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
proportion	NN	O
of	IN	O
ICS	NNP	Pharmacological
than	IN	O
placebo	NN	O
participants	NNS	O
who	WP	O
complied	VBD	O
with	IN	O
using	VBG	O
their	PRP$	O
inhaler	NN	O
reported	VBD	O
easy	JJ	O
bruising	NN	O
(	(	O
11.2	CD	O
%	NN	O
vs	JJ	O
3.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
and	CC	O
the	DT	O
slow	JJ	O
healing	NN	O
of	IN	O
skin	NN	O
cuts	NNS	O
or	CC	O
sores	NNS	O
(	(	O
2.4	CD	O
%	NN	O
vs	JJ	O
0.5	CD	O
%	NN	O
,	,	O
respectively	RB	O
)	)	O
.	.	O

Older	JJR	O
men	NNS	O
in	IN	O
the	DT	O
ICS	NNP	Pharmacological
group	NN	O
with	IN	O
good	JJ	O
inhaler	NN	O
compliance	NN	O
appeared	VBD	O
to	TO	O
be	VB	O
at	IN	O
the	DT	O
greatest	JJS	O
risk	NN	O
of	IN	O
bruising	VBG	O
.	.	O

In	IN	O
those	DT	O
participants	NNS	O
undergoing	VBG	O
serial	JJ	O
measurements	NNS	O
of	IN	O
adrenal	JJ	O
function	NN	O
and	CC	O
BMD	NNP	O
,	,	O
no	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
either	CC	O
the	DT	O
suppression	NN	O
of	IN	O
adrenal	JJ	O
function	NN	O
or	CC	O
the	DT	O
loss	NN	O
of	IN	O
BMD	NNP	O
as	IN	O
systemic	JJ	O
complications	NNS	O
of	IN	O
ICS	NNP	O
use	NN	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
findings	NNS	O
indicate	VBP	O
that	IN	O
moderate-to-high	JJ	O
doses	NNS	O
of	IN	O
ICSs	NNP	O
result	NN	O
in	IN	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
easy	JJ	O
bruising	NN	O
and	CC	O
impairment	NN	O
in	IN	O
skin	NN	O
healing	NN	O
in	IN	O
middle-aged	JJ	O
to	TO	O
elderly	JJ	O
persons	NNS	O
with	IN	O
COPD	NNP	O
.	.	O

No	DT	O
association	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
skin	JJ	O
bruising	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
systemic	JJ	O
toxicity	NN	O
from	IN	O
the	DT	O
use	NN	O
of	IN	O
ICSs	NNP	O
.	.	O

Early-stage	JJ	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
of	IN	O
the	DT	O
oropharynx	NN	O
:	:	O
radiotherapy	NN	Physical
vs.	IN	Surgical
trans-oral	JJ	Surgical
robotic	JJ	Surgical
surgery	NN	Surgical
(	(	Surgical
ORATOR	NNP	Surgical
)	)	Surgical
--	:	Surgical
study	NN	Surgical
protocol	NN	O
for	IN	O
a	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
trial	NN	O
.	.	O

BACKGROUND	VB	O
The	DT	O
incidence	NN	O
of	IN	O
oropharyngeal	JJ	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
(	(	O
OPSCC	NNP	O
)	)	O
has	VBZ	O
markedly	RB	O
increased	VBN	O
over	IN	O
the	DT	O
last	JJ	O
three	CD	O
decades	NNS	O
due	JJ	O
to	TO	O
newly	RB	O
found	VBN	O
associations	NNS	O
with	IN	O
human	JJ	O
papillomavirus	NN	O
(	(	O
HPV	NNP	O
)	)	O
infection	NN	O
.	.	O

Primary	JJ	Physical
radiotherapy	NN	Physical
(	(	Physical
RT	NNP	Physical
)	)	Physical
is	VBZ	O
the	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
OPSCC	NNP	O
at	IN	O
most	JJS	O
centers	NNS	O
,	,	O
and	CC	O
over	IN	O
the	DT	O
last	JJ	O
decade	NN	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
concurrent	NN	Physical
chemotherapy	NN	Physical
has	VBZ	O
led	VBN	O
to	TO	O
a	DT	O
significant	JJ	O
improvement	NN	O
in	IN	O
survival	NN	O
,	,	O
but	CC	O
at	IN	O
the	DT	O
cost	NN	O
of	IN	O
increased	VBN	O
acute	NN	O
and	CC	O
late	JJ	O
toxicity	NN	O
.	.	O

Transoral	NNP	Surgical
robotic	JJ	Surgical
surgery	NN	Surgical
(	(	Surgical
TORS	NNP	Surgical
)	)	Surgical
has	VBZ	O
emerged	VBN	O
as	IN	O
a	DT	O
promising	JJ	O
alternative	JJ	O
treatment	NN	O
,	,	O
with	IN	O
preliminary	JJ	O
case	NN	O
series	NN	O
demonstrating	VBG	O
encouraging	JJ	O
oncologic	NN	O
,	,	O
functional	JJ	O
,	,	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
outcomes	VBZ	O
.	.	O

However	RB	O
,	,	O
comparisons	NNS	O
of	IN	O
TORS	NNP	Surgical
and	CC	O
RT	NNP	Physical
in	IN	O
a	DT	O
non-randomized	JJ	O
fashion	NN	O
are	VBP	O
susceptible	JJ	O
to	TO	O
bias	VB	O
.	.	O

The	DT	O
goal	NN	O
of	IN	O
this	DT	O
randomized	JJ	O
phase	NN	O
II	NNP	O
study	NN	O
is	VBZ	O
to	TO	O
compare	VB	O
QOL	NNP	O
,	,	O
functional	JJ	O
outcomes	NNS	O
,	,	O
toxicity	NN	O
profiles	NNS	O
,	,	O
and	CC	O
survival	NN	O
following	VBG	O
primary	JJ	O
RT	NNP	O
(	(	O
?	.	O
chemotherapy	NN	O
)	)	O
vs.	FW	O
TORS	NNP	O
(	(	O
?	.	O
adjuvant	NN	O
[	NN	O
chemo	NN	O
]	NNP	O
RT	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
OPSCC	NNP	O
.	.	O

METHODS/DESIGN	NNP	O
The	DT	O
target	NN	O
patient	JJ	O
population	NN	O
comprises	NNS	O
OPSCC	NNP	O
patients	NNS	O
who	WP	O
would	MD	O
be	VB	O
unlikely	JJ	O
to	TO	O
require	VB	O
chemotherapy	JJ	O
post-resection	NN	O
:	:	O
Tumor	NN	O
stage	NN	O
T1-T2	NN	O
with	IN	O
likely	JJ	O
negative	JJ	O
margins	NNS	O
at	IN	O
surgery	NN	O
;	:	O
Nodal	NNP	O
stage	NN	O
N0-2	NNP	O
,	,	O
?3	NNP	O
cm	NN	O
in	IN	O
size	NN	O
,	,	O
with	IN	O
no	DT	O
evidence	NN	O
of	IN	O
extranodal	JJ	O
extension	NN	O
on	IN	O
imaging	VBG	O
.	.	O

Participants	NNS	O
will	MD	O
be	VB	O
randomized	VBN	O
in	IN	O
a	DT	O
1:1	CD	O
ratio	NN	O
between	IN	O
Arm	NNP	O
1	CD	O
(	(	O
RT	NNP	O
?	.	O
chemotherapy	NN	O
)	)	O
and	CC	O
Arm	$	O
2	CD	O
(	(	O
TORS	NNP	O
?	.	O
adjuvant	JJ	O
[	NN	O
chemo	NN	O
]	NNP	O
RT	NNP	O
)	)	O
.	.	O

In	IN	O
Arm	NNP	O
1	CD	O
,	,	O
patients	NNS	O
with	IN	O
N0	NNP	O
disease	NN	O
will	MD	O
receive	VB	O
RT	NNP	O
alone	RB	O
,	,	O
whereas	JJ	O
N1-2	JJ	O
patients	NNS	O
will	MD	O
receive	VB	O
concurrent	JJ	O
chemoradiation	NN	O
.	.	O

In	IN	O
Arm	NNP	O
2	CD	O
,	,	O
patients	NNS	O
will	MD	O
undergo	VB	O
TORS	NNP	O
along	IN	O
with	IN	O
selective	JJ	O
neck	NN	O
dissections	NNS	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
staged	VBN	O
.	.	O

Pathologic	NNP	O
high-risk	JJ	O
features	NNS	O
will	MD	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
requirement	NN	O
for	IN	O
adjuvant	JJ	O
radiotherapy	NN	O
+/-	JJ	O
chemotherapy	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
QOL	NNP	O
score	NN	O
using	VBG	O
the	DT	O
M.D	NNP	O
.	.	O

Anderson	NNP	O
Dysphagia	NNP	O
Inventory	NNP	O
(	(	O
MDADI	NNP	O
)	)	O
,	,	O
with	IN	O
secondary	JJ	O
endpoints	NNS	O
including	VBG	O
survival	NN	O
,	,	O
toxicity	NN	O
,	,	O
other	JJ	O
QOL	NNP	O
outcomes	NNS	O
,	,	O
and	CC	O
swallowing	VBG	O
function	NN	O
.	.	O

A	DT	O
sample	NN	O
of	IN	O
68	CD	O
patients	NNS	O
is	VBZ	O
required	VBN	O
.	.	O

DISCUSSION	VB	O
This	DT	O
study	NN	O
,	,	O
if	IN	O
successful	JJ	O
,	,	O
will	MD	O
provide	VB	O
a	DT	O
much-needed	JJ	O
randomized	JJ	O
comparison	NN	O
of	IN	O
the	DT	O
conventional	JJ	O
strategy	NN	O
of	IN	O
primary	JJ	O
RT	NNP	O
vs.	IN	O
the	DT	O
novel	JJ	O
strategy	NN	O
of	IN	O
primary	JJ	O
TORS	NNP	O
.	.	O

The	DT	O
trial	NN	O
is	VBZ	O
designed	VBN	O
to	TO	O
provide	VB	O
a	DT	O
definitive	JJ	O
QOL	NNP	O
comparison	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
,	,	O
and	CC	O
to	TO	O
inform	VB	O
the	DT	O
design	NN	O
of	IN	O
an	DT	O
eventual	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
for	IN	O
survival	JJ	O
outcomes	NNS	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
NCT01590355	NNP	O
.	.	O

Impact	NN	O
of	IN	O
a	DT	O
leptin	JJ	O
single	JJ	O
nucleotide	NN	O
polymorphism	NN	O
and	CC	O
zilpaterol	NN	Pharmacological
hydrochloride	NN	Pharmacological
on	IN	O
growth	NN	O
and	CC	O
carcass	NN	O
characteristics	NNS	O
in	IN	O
finishing	VBG	O
steers	NNS	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
4,178	CD	O
steers	NNS	O
(	(	O
mean	JJ	O
initial	JJ	O
BW	NNP	O
=	NN	O
403.9	CD	O
?	.	O
16.04	CD	O
kg	NN	O
)	)	O
were	VBD	O
used	VBN	O
to	TO	O
test	VB	O
the	DT	O
interactive	JJ	O
effects	NNS	O
,	,	O
if	IN	O
any	DT	O
,	,	O
of	IN	O
leptin	JJ	O
R25C	NNP	O
genotypes	NNS	O
(	(	O
CC	NNP	O
,	,	O
CT	NNP	O
,	,	O
or	CC	O
TT	NNP	O
)	)	O
and	CC	O
zilpaterol	$	O
hydrochloride	NN	O
(	(	O
ZH	NNP	O
)	)	O
feeding	VBG	O
duration	NN	O
on	IN	O
growth	NN	O
performance	NN	O
and	CC	O
carcass	NN	O
traits	NNS	O
.	.	O

Steers	NNS	O
were	VBD	O
blocked	VBN	O
by	IN	O
arrival	NN	O
at	IN	O
the	DT	O
feed	NN	O
yard	NN	O
,	,	O
genotyped	VBD	O
for	IN	O
the	DT	O
leptin	NN	O
SNP	NNP	O
,	,	O
allotted	VBD	O
to	TO	O
genotype-specific	JJ	O
pens	NNS	O
(	(	O
90	CD	O
steers/pen	NN	O
)	)	O
,	,	O
and	CC	O
assigned	VBD	O
randomly	RB	O
within	IN	O
genotype	NN	O
and	CC	O
block	NN	O
to	TO	O
0	CD	O
or	CC	O
21	CD	O
d	NN	O
of	IN	O
dietary	JJ	O
ZH	NNP	O
.	.	O

All	DT	O
pens	NNS	O
within	IN	O
a	DT	O
block	NN	O
were	VBD	O
slaughtered	VBN	O
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
(	(	O
132.1	CD	O
?	.	O
10.9	CD	O
d	NN	O
on	IN	O
feed	NN	O
)	)	O
.	.	O

Final	NNP	O
BW	NNP	O
of	IN	O
steers	NNS	O
fed	VBP	O
ZH	NNP	O
was	VBD	O
6.0	CD	O
kg	NN	O
heavier	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.008	CD	O
)	)	O
,	,	O
and	CC	O
ZH-fed	NNP	O
steers	NNS	O
had	VBD	O
greater	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
ADG	NNP	O
than	IN	O
steers	NNS	O
not	RB	O
fed	VBN	O
ZH	NNP	O
.	.	O

Feeding	VBG	O
ZH	NNP	O
decreased	VBD	O
DMI	NNP	O
in	IN	O
steers	NNS	O
with	IN	O
increased	JJ	O
frequency	NN	O
of	IN	O
the	DT	O
T	NNP	O
allele	NN	O
(	(	O
9.67	CD	O
,	,	O
9.53	CD	O
,	,	O
and	CC	O
9.28	CD	O
kg/d	NN	O
for	IN	O
CC	NNP	O
,	,	O
CT	NNP	O
,	,	O
and	CC	O
TT	NNP	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
but	CC	O
DMI	NNP	O
increased	VBD	O
with	IN	O
the	DT	O
frequency	NN	O
of	IN	O
the	DT	O
T	NNP	O
allele	NN	O
(	(	O
9.68	CD	O
,	,	O
9.90	CD	O
,	,	O
and	CC	O
10.1	CD	O
kg	NN	O
for	IN	O
CC	NNP	O
,	,	O
CT	NNP	O
,	,	O
and	CC	O
TT	NNP	O
,	,	O
respectively	RB	O
)	)	O
when	WRB	O
ZH	NNP	O
was	VBD	O
not	RB	O
fed	VBN	O
(	(	O
leptin	JJ	O
genotype	NN	O
?	.	O
ZH	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.011	CD	O
)	)	O
.	.	O

At	IN	O
the	DT	O
conclusion	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
ultrasonic	JJ	O
fat	NN	O
was	VBD	O
greatest	JJS	O
for	IN	O
TT	NNP	O
steers	NNS	O
(	(	O
11.4	CD	O
?	.	O
0.28	CD	O
mm	NN	O
)	)	O
and	CC	O
least	JJS	O
(	(	O
P	NNP	O
=	NNP	O
0.003	CD	O
)	)	O
for	IN	O
CC	NNP	O
steers	NNS	O
(	(	O
11.0	CD	O
?	.	O
0.25	CD	O
mm	NN	O
)	)	O
.	.	O

Regardless	NNP	O
of	IN	O
ZH-feeding	NNP	O
duration	NN	O
,	,	O
TT	NNP	O
steers	NNS	O
produced	VBD	O
a	DT	O
greater	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
percentage	NN	O
of	IN	O
USDA	NNP	O
yield	NN	O
grade	NN	O
(	(	O
YG	NNP	O
)	)	O
4	CD	O
or	CC	O
higher	JJR	O
carcasses	NNS	O
(	(	O
5.4	CD	O
vs.	FW	O
2.7	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
lesser	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
percentage	NN	O
of	IN	O
YG	NNP	O
1	CD	O
carcasses	NNS	O
(	(	O
17.7	CD	O
vs.	FW	O
26.8	CD	O
%	NN	O
)	)	O
than	IN	O
CC	NNP	O
steers	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
ZH-fed	NNP	O
steers	NNS	O
produced	VBD	O
a	DT	O
greater	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
percentage	NN	O
of	IN	O
USDA	NNP	O
YG	NNP	O
1	CD	O
carcasses	NNS	O
(	(	O
25.9	CD	O
vs.	FW	O
16.2	CD	O
%	NN	O
)	)	O
and	CC	O
a	DT	O
lesser	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
percentage	NN	O
of	IN	O
YG	NNP	O
4	CD	O
or	CC	O
higher	JJR	O
carcasses	NNS	O
(	(	O
1.6	CD	O
vs.	FW	O
6.0	CD	O
%	NN	O
)	)	O
than	IN	O
steers	NNS	O
fed	VBP	O
the	DT	O
control	NN	O
diet	NN	O
.	.	O

Marbling	VBG	O
scores	NNS	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
carcasses	NNS	O
grading	VBG	O
USDA	NNP	O
Choice	NNP	O
and	CC	O
Prime	NNP	O
were	VBD	O
greater	JJR	O
in	IN	O
TT	NNP	O
than	IN	O
CC	NNP	O
steers	NNS	O
when	WRB	O
fed	VBN	O
diets	NNS	O
devoid	VBP	O
of	IN	O
ZH	NNP	O
,	,	O
but	CC	O
both	DT	O
marbling	NN	O
and	CC	O
quality	NN	O
grades	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
among	IN	O
leptin	JJ	O
genotypes	NNS	O
when	WRB	O
fed	VBN	O
ZH	NNP	O
for	IN	O
21	CD	O
d	NN	O
(	(	O
leptin	JJ	O
genotype	NN	O
?	.	O
ZH	NNP	O
,	,	O
P	NNP	O
?	.	O
0.03	CD	O
)	)	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
HCW	NNP	O
gain	NN	O
tended	VBD	O
to	TO	O
be	VB	O
less	JJR	O
(	(	O
P	NNP	O
=	NNP	O
0.095	CD	O
)	)	O
for	IN	O
steers	NNS	O
of	IN	O
the	DT	O
TT	NNP	O
genotype	NN	O
(	(	O
12.7	CD	O
kg	NN	O
)	)	O
than	IN	O
either	DT	O
CC	NNP	O
(	(	O
16.3	CD	O
kg	NN	O
)	)	O
or	CC	O
CT	NNP	O
(	(	O
17.0	CD	O
kg	NN	O
)	)	O
genotypes	NNS	O
.	.	O

Results	NNS	O
indicated	VBD	O
that	IN	O
leptin	NN	O
R25C	NNP	O
genotype	NN	O
impacted	VBD	O
most	RBS	O
traits	NNS	O
associated	VBN	O
with	IN	O
fatness	JJ	O
whereas	NNS	O
feeding	VBG	O
ZH	NNP	O
for	IN	O
21	CD	O
d	NN	O
affected	VBD	O
HCW	NNP	O
and	CC	O
ADG	NNP	O
positively	RB	O
but	CC	O
impacted	VBD	O
feed	NN	O
intake	NN	O
,	,	O
marbling	NN	O
,	,	O
and	CC	O
USDA	NNP	O
quality	NN	O
grades	NNS	O
negatively	RB	O
.	.	O

Five-year	JJ	O
follow-up	NN	O
of	IN	O
the	DT	O
Fluorouracil	NNP	Surgical
Filtering	NNP	Surgical
Surgery	NNP	Surgical
Study	NNP	O
.	.	O

The	DT	O
Fluorouracil	NNP	Surgical
Filtering	NNP	Surgical
Surgery	NNP	Surgical
Study	NNP	O
Group	NNP	O
.	.	O

PURPOSE	NNP	O
To	TO	O
determine	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
subconjunctival	JJ	Pharmacological
5-	JJ	Pharmacological
fluorouracil	NN	Pharmacological
injections	NNS	Pharmacological
after	IN	O
trabeculectomy	NN	O
in	IN	O
patients	NNS	O
with	IN	O
poor	JJ	O
prognoses	NNS	O
,	,	O
to	TO	O
determine	VB	O
risk	NN	O
factors	NNS	O
for	IN	O
surgical	JJ	O
failure	NN	O
and	CC	O
to	TO	O
examine	VB	O
the	DT	O
relationship	NN	O
of	IN	O
intraocular	JJ	O
pressure	NN	O
and	CC	O
visual	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
In	IN	O
this	DT	O
multicenter	NN	O
clinical	JJ	O
trial	NN	O
,	,	O
213	CD	O
patients	NNS	O
with	IN	O
previous	JJ	O
cataract	NN	O
surgery	NN	O
or	CC	O
previous	JJ	O
failed	VBD	O
filtering	VBG	O
surgery	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
trabeculectomy	NN	Physical
alone	RB	Pharmacological
or	CC	Pharmacological
trabeculectomy	VB	Physical
with	IN	Pharmacological
postoperative	JJ	Pharmacological
subconjunctival	JJ	Pharmacological
5-fluorouracil	JJ	Pharmacological
injections	NNS	Pharmacological
.	.	Pharmacological

Measurements	NNS	O
of	IN	O
intraocular	JJ	O
pressure	NN	O
,	,	O
visual	JJ	O
acuity	NN	O
,	,	O
and	CC	O
visual	JJ	O
fields	NNS	O
were	VBD	O
performed	VBN	O
throughout	IN	O
the	DT	O
five	CD	O
years	NNS	O
,	,	O
with	IN	O
the	DT	O
clinician	JJ	O
masked	NN	O
to	TO	O
the	DT	O
treatment	NN	O
group	NN	O
.	.	O

Failure	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
a	DT	O
reoperation	NN	O
to	TO	O
control	VB	O
intraocular	JJ	O
pressure	NN	O
or	CC	O
an	DT	O
intraocular	JJ	O
pressure	NN	O
greater	JJR	O
than	IN	O
21	CD	O
mm	JJ	O
Hg	NNP	O
at	IN	O
or	CC	O
after	IN	O
the	DT	O
first-year	JJ	O
examination	NN	O
.	.	O

RESULTS	JJ	O
Fifty-four	NNP	O
(	(	O
51	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
105	CD	O
eyes	NNS	O
in	IN	O
the	DT	O
5-fluorouracil	JJ	Pharmacological
group	NN	O
and	CC	O
80	CD	O
(	(	O
74	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
108	CD	O
eyes	NNS	O
in	IN	O
the	DT	O
standard	NN	O
filtering	VBG	O
surgery	NN	O
group	NN	O
were	VBD	O
classified	VBN	O
as	IN	O
failures	NNS	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
,	,	O
Mantel-Cox	NNP	O
survival	NN	O
analysis	NN	O
)	)	O
.	.	O

Risk	NN	O
factors	NNS	O
for	IN	O
failure	NN	O
include	VBP	O
high	JJ	O
intraocular	JJ	O
pressure	NN	O
,	,	O
a	DT	O
short	JJ	O
time	NN	O
interval	NN	O
after	IN	O
the	DT	O
last	JJ	O
procedure	NN	O
involving	VBG	O
a	DT	O
conjunctival	JJ	O
incision	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
procedures	NNS	O
with	IN	O
conjunctival	JJ	O
incisions	NNS	O
,	,	O
and	CC	O
Hispanic	NNP	O
ethnicity	NN	O
.	.	O

Patients	NNS	O
in	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
with	IN	O
controlled	JJ	O
intraocular	JJ	O
pressures	NNS	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
maintain	VB	O
visual	JJ	O
acuity	NN	O
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
5-fluorouracil	JJ	Pharmacological
group	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
late-onset	JJ	O
bleb	NN	O
leaks	NNS	O
(	(	O
9	CD	O
%	NN	O
nine	CD	O
of	IN	O
105	CD	O
)	)	O
than	IN	O
those	DT	O
in	IN	O
the	DT	O
standard	NN	O
filtering	VBG	O
surgery	NN	O
group	NN	O
(	(	O
2	CD	O
%	NN	O
two	CD	O
of	IN	O
108	CD	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
.032	NNP	O
,	,	O
Fisher	NNP	O
's	POS	O
exact	JJ	O
test	NN	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
recommend	VBP	O
the	DT	O
use	NN	O
of	IN	O
subconjunctival	JJ	Pharmacological
5-fluorouracil	JJ	Pharmacological
after	IN	O
trabeculectomy	NN	O
in	IN	O
eyes	NNS	O
after	IN	O
previous	JJ	O
cataract	NN	O
surgery	NN	O
or	CC	O
unsuccessful	JJ	O
filtering	NN	O
surgery	NN	O
,	,	O
but	CC	O
caution	NN	O
against	IN	O
its	PRP$	O
routine	JJ	O
use	NN	O
in	IN	O
patients	NNS	O
with	IN	O
good	JJ	O
prognoses	NNS	O
.	.	O

Ciprofloxacin	NNP	Pharmacological
,	,	O
lomefloxacin	NN	Pharmacological
,	,	O
or	CC	O
levofloxacin	CC	Pharmacological
as	IN	O
treatment	NN	O
for	IN	O
chronic	JJ	O
osteomyelitis	NN	O
.	.	O

The	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
three	CD	O
oral	JJ	Pharmacological
fluoroquinolones	NNS	Pharmacological
(	(	O
lomefloxacin	NN	Pharmacological
,	,	O
levofloxacin	NN	Pharmacological
,	,	O
and	CC	O
ciprofloxacin	NN	Pharmacological
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
osteomyelitis	NN	O
were	VBD	O
analyzed	VBN	O
.	.	O

Twenty-seven	JJ	O
patients	NNS	O
had	VBD	O
documented	VBN	O
infections	NNS	O
with	IN	O
quinolone-sensitive	JJ	O
organisms	NNS	O
and	CC	O
received	VBD	O
either	DT	O
lomefloxacin	NN	Pharmacological
,	,	O
levofloxacin	NN	Pharmacological
,	,	O
or	CC	O
ciprofloxacin	NN	Pharmacological
.	.	O

Levofloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
9	CD	O
of	IN	O
15	CD	O
(	(	O
60	CD	O
%	NN	O
)	)	O
patients	NNS	O
.	.	O

Lomefloxacin	NNP	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
five	CD	O
of	IN	O
seven	CD	O
(	(	O
71	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
and	CC	O
ciprofloxacin	NN	O
was	VBD	O
effective	JJ	O
therapy	NN	O
for	IN	O
two	CD	O
of	IN	O
five	CD	O
patients	NNS	O
(	(	O
40	CD	O
%	NN	O
)	)	O
.	.	O

Average	JJ	O
follow-up	NN	O
was	VBD	O
11.8	CD	O
months	NNS	O
for	IN	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
course	NN	O
of	IN	O
therapy	NN	O
,	,	O
and	CC	O
the	DT	O
average	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
was	VBD	O
60.6	CD	O
days	NNS	O
.	.	O

Gram-positive	JJ	O
bacteria	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
18	CD	O
patients	NNS	O
,	,	O
and	CC	O
11	CD	O
patients	NNS	O
were	VBD	O
cured	VBN	O
.	.	O

Oral	JJ	O
fluoroquinolones	NNS	O
can	MD	O
be	VB	O
safe	JJ	O
,	,	O
effective	JJ	O
therapy	NN	O
if	IN	O
they	PRP	O
are	VBP	O
given	VBN	O
for	IN	O
a	DT	O
prolonged	JJ	O
course	NN	O
as	IN	O
treatment	NN	O
for	IN	O
infections	NNS	O
caused	VBN	O
by	IN	O
susceptible	JJ	O
gram-positive	JJ	O
as	RB	O
well	RB	O
as	IN	O
gram-negative	JJ	O
organisms	NNS	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
adequate	JJ	O
surgical	JJ	O
debridement	NN	O
.	.	O

Serum	NNP	O
biochemical	JJ	O
characteristics	NNS	O
of	IN	O
Beluga	NNP	O
,	,	O
Huso	NNP	O
huso	NN	O
(	(	O
L.	NNP	O
)	)	O
,	,	O
in	IN	O
response	NN	O
to	TO	O
blood	NN	O
sampling	NN	O
after	IN	O
clove	NN	Pharmacological
powder	NN	Pharmacological
solution	NN	Pharmacological
exposure	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
anesthesia	NN	O
on	IN	O
serum	NN	O
parameters	NNS	O
,	,	O
Beluga	NNP	O
,	,	O
Huso	NNP	O
huso	NN	O
(	(	O
L.	NNP	O
)	)	O
were	VBD	O
blood-sampled	JJ	O
immediately	RB	O
without	IN	Physical
anesthesia	NN	Physical
(	(	Physical
control	NN	Physical
)	)	Physical
or	CC	Physical
subjected	VBN	Physical
to	TO	Physical
following	VBG	Physical
anesthesia	JJ	Physical
procedure	NN	Physical
:	:	O
40	CD	O
,	,	O
120	CD	O
,	,	O
and	CC	O
240	CD	O
s	NN	O
exposure	NN	O
to	TO	O
3,000	CD	O
,	,	O
700	CD	O
,	,	O
and	CC	O
500	CD	O
mg	NN	O
l??	NN	O
clove	NN	O
solution	NN	O
,	,	O
respectively	RB	O
.	.	O

Blood	NN	O
samples	NNS	O
were	VBD	O
collected	VBN	O
after	IN	O
these	DT	O
periods	NNS	O
,	,	O
when	WRB	O
fish	NN	O
were	VBD	O
immobile	JJ	O
and	CC	O
reached	VBD	O
stage	NN	O
4	CD	O
anesthesia	NN	O
.	.	O

Results	NNS	O
showed	VBD	O
that	IN	O
cortisol	NN	O
and	CC	O
glucose	JJ	O
levels	NNS	O
were	VBD	O
significantly	RB	O
high	JJ	O
in	IN	O
700	CD	O
and	CC	O
500	CD	O
but	CC	O
not	RB	O
3,000	CD	O
mg	NNS	O
l??	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
control	VB	O
.	.	O

Serum	NNP	O
lactate	NN	O
levels	NNS	O
were	VBD	O
significantly	RB	O
high	JJ	O
in	IN	O
500	CD	O
mg	NNS	O
l??	JJ	O
group	NN	O
compared	VBN	O
to	TO	O
control	VB	O
group	NN	O
.	.	O

Lactate	NNP	O
levels	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
differed	VBN	O
between	IN	O
control	NN	O
,	,	O
3,000	CD	O
,	,	O
and	CC	O
700	CD	O
mg	NN	O
l??	NN	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
serum	NN	O
levels	NNS	O
of	IN	O
cholesterol	NN	O
,	,	O
total	JJ	O
protein	NN	O
,	,	O
lactate	JJ	O
dehydrogenase	NN	O
,	,	O
aspartate	JJ	O
aminotransferase	NN	O
,	,	O
alanine	JJ	O
aminotransferase	NN	O
,	,	O
Na?	NNP	O
,	,	O
Cl?	NNP	O
,	,	O
K?	NNP	O
,	,	O
and	CC	O
Ca??	NNP	O
.	.	O

Results	NNP	O
suggest	VBP	O
that	IN	O
rapid	JJ	O
anesthesia	NN	O
with	IN	O
higher	JJR	O
dose	NN	O
is	VBZ	O
better	JJR	O
than	IN	O
slow	JJ	O
anesthesia	NN	O
with	IN	O
lower	JJR	O
dose	NN	O
for	IN	O
blood	NN	O
sampling	NN	O
in	IN	O
Beluga	NNP	O
.	.	O

Is	VBZ	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	Physical
for	IN	O
transrectal	JJ	O
ultrasound	NN	O
guided	VBD	O
prostate	NN	O
biopsy	NN	O
associated	VBN	O
with	IN	O
increased	JJ	O
infectious	JJ	O
or	CC	O
hemorrhagic	JJ	O
complications	NNS	O
?	.	O
A	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
Periprostatic	NNP	O
local	JJ	O
anesthesia	NN	O
for	IN	O
prostate	NN	O
biopsy	NN	O
requires	VBZ	O
2	CD	O
or	CC	O
more	JJR	O
extra	JJ	O
needle	JJ	O
punctures	NNS	O
and	CC	O
injection	NN	O
of	IN	O
the	DT	O
local	JJ	O
anesthetic	NN	O
through	IN	O
the	DT	O
highly	RB	O
colonized	JJ	O
rectum	NN	O
.	.	O

To	TO	O
our	PRP$	O
knowledge	NN	O
we	PRP	O
report	VBP	O
the	DT	O
first	JJ	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
to	TO	O
assess	VB	O
the	DT	O
infectious	JJ	O
or	CC	O
hemorrhagic	JJ	O
complications	NNS	O
associated	VBN	O
with	IN	O
this	DT	O
method	NN	O
.	.	O

MATERIALS	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
total	NN	O
of	IN	O
100	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
sterile	JJ	O
urine	JJ	O
cultures	NNS	O
underwent	JJ	O
transrectal	JJ	Surgical
ultrasound	NN	Surgical
guided	VBD	Surgical
prostate	NN	Surgical
biopsy	NN	Surgical
.	.	O

They	PRP	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
periprostatic	JJ	Physical
nerve	NN	Physical
block	NN	Physical
or	CC	O
no	DT	Physical
anesthesia	NN	Physical
.	.	O

Patients	NNS	O
were	VBD	O
evaluated	VBN	O
for	IN	O
the	DT	O
amount	NN	O
of	IN	O
rectal	NN	Physical
and	CC	Physical
urethral	JJ	Physical
bleeding	NN	Physical
,	,	O
and	CC	O
symptoms	NNS	Physical
and	CC	Physical
signs	NNS	Physical
of	IN	Physical
infection	NN	Physical
after	IN	Physical
biopsy	NN	Surgical
.	.	O

RESULTS	VB	O
The	DT	O
amount	NN	O
of	IN	O
urethral	JJ	O
bleeding	NN	O
was	VBD	O
slight	JJ	O
and	CC	O
similar	JJ	O
in	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

Rectal	JJ	O
bleeding	NN	O
was	VBD	O
significantly	RB	O
less	RBR	O
in	IN	O
the	DT	O
patients	NNS	O
who	WP	O
received	VBD	O
anesthesia	NN	O
.	.	O

High	JJ	O
fever	NN	O
(	(	O
greater	JJR	O
than	IN	O
37.8C	CD	O
)	)	O
was	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
nerve	NN	O
block	NN	O
group	NN	O
and	CC	O
2	CD	O
patients	NNS	O
in	IN	O
this	DT	O
group	NN	O
required	VBD	O
rehospitalization	NN	O
.	.	O

Bacteriuria	NNP	O
in	IN	O
post-biopsy	JJ	O
urine	JJ	O
cultures	NNS	O
was	VBD	O
significantly	RB	O
more	JJR	O
common	JJ	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
periprostatic	JJ	O
local	JJ	O
anesthesia	NN	Physical
for	IN	O
prostate	JJ	O
biopsy	NN	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
urethral	JJ	O
bleeding	NN	O
.	.	O

It	PRP	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
decreased	JJ	O
incidence	NN	O
of	IN	O
rectal	JJ	O
bleeding	NN	O
,	,	O
presumably	RB	O
due	JJ	O
to	TO	O
decreased	JJ	O
patient	NN	O
discomfort	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
bacteriuria	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
anesthesia	NN	O
group	NN	O
.	.	O

High	NNP	O
fever	NN	O
and	CC	O
hospitalization	NN	O
due	JJ	O
to	TO	O
infectious	JJ	O
complications	NNS	O
were	VBD	O
also	RB	O
more	RBR	O
common	JJ	O
in	IN	O
the	DT	O
local	JJ	O
anesthesia	NN	O
group	NN	O
,	,	O
although	IN	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

Prospective	JJ	O
randomized	JJ	O
trials	NNS	O
seem	VBP	O
warranted	VBN	O
to	TO	O
determine	VB	O
the	DT	O
optimum	JJ	O
antibiotic	JJ	O
prophylaxis	NN	O
regimen	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
biopsy	NN	O
with	IN	O
a	DT	O
periprostatic	JJ	O
nerve	NN	O
block	NN	O
.	.	O

Plasma	NNP	O
pH	NN	O
does	VBZ	O
not	RB	O
influence	VB	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
maximal	JJ	O
whole	JJ	O
body	NN	O
exercise	NN	O
.	.	O

Exercise	NN	O
lowers	VBZ	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
of	IN	O
O2	NNP	O
to	TO	O
carbohydrate	VB	O
(	(	O
glucose+1/2	JJ	O
lactate	NN	O
)	)	O
and	CC	O
metabolic	JJ	O
acidosis	NN	O
appears	VBZ	O
to	TO	O
promote	VB	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
influence	NN	O
of	IN	O
pH	NN	O
on	IN	O
cerebral	JJ	O
lactate	JJ	O
uptake	NN	O
and	CC	O
,	,	O
in	IN	O
turn	NN	O
,	,	O
on	IN	O
the	DT	O
cerebral	JJ	O
metabolic	JJ	O
ratio	NN	O
during	IN	O
exercise	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Sodium	NN	Pharmacological
bicarbonate	NN	Pharmacological
(	(	O
Bicarb	NNP	O
,	,	O
1	CD	O
M	NNP	O
;	:	O
350-500	CD	O
ml	NN	O
)	)	O
or	CC	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
normal	JJ	Pharmacological
saline	NN	Pharmacological
(	(	O
Sal	NNP	O
)	)	O
was	VBD	O
infused	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
constant	JJ	O
rate	NN	O
during	IN	O
a	DT	O
'2000	CD	O
m	NN	O
'	''	O
maximal	JJ	O
ergometer	NN	Pharmacological
row	NN	Pharmacological
in	IN	O
six	CD	O
male	JJ	O
oarsmen	NNS	O
(	(	O
23?2	CD	O
years	NNS	O
;	:	O
mean?S.D.	NN	O
)	)	O
.	.	O

During	IN	O
the	DT	O
Sal	NNP	O
trial	NN	O
,	,	O
pH	NN	O
decreased	VBD	O
from	IN	O
7.41?0.01	CD	O
at	IN	O
rest	NN	O
to	TO	O
7.02?0.02	CD	O
but	CC	O
only	RB	O
to	TO	O
7.36?0.02	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
during	IN	O
the	DT	O
Bicarb	NNP	O
trial	NN	O
.	.	O

Arterial	JJ	O
lactate	NN	O
increased	VBD	O
to	TO	O
21.4?0.8	CD	O
and	CC	O
32.7?2.3	CD	O
mM	NN	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Also	RB	O
,	,	O
the	DT	O
arterial-jugular	JJ	O
venous	JJ	O
lactate	NN	O
difference	NN	O
increased	VBD	O
from-0.03?0.01	JJ	O
mM	NN	O
at	IN	O
rest	NN	O
to	TO	O
3.2?0.9	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
3.4?1.4	CD	O
mM	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
following	VBG	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
,	,	O
respectively	RB	O
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
decreased	VBD	O
equally	RB	O
during	IN	O
the	DT	O
Sal	NNP	O
and	CC	O
Bicarb	NNP	O
trials	NNS	O
:	:	O
from	IN	O
5.8?0.6	CD	O
at	IN	O
rest	NN	O
to	TO	O
1.7?0.1	CD	O
and	CC	O
1.8?0.2	CD	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
enlarged	JJ	O
blood-buffering	NN	O
capacity	NN	O
after	IN	O
infusion	NN	O
of	IN	O
Bicarb	NNP	O
eliminated	VBD	O
metabolic	JJ	O
acidosis	NN	O
during	IN	O
maximal	JJ	O
exercise	NN	O
but	CC	O
that	DT	O
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
cerebral	JJ	O
lactate	NN	O
uptake	NN	O
and	CC	O
,	,	O
therefore	RB	O
,	,	O
the	DT	O
decrease	NN	O
in	IN	O
the	DT	O
cerebral	JJ	O
metabolic	NN	O
ratio	NN	O
.	.	O

Effect	NN	O
of	IN	O
camel	NN	Pharmacological
milk	NN	Pharmacological
on	IN	O
thymus	NN	O
and	CC	O
activation-regulated	JJ	O
chemokine	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
:	:	O
double-blind	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
This	DT	O
study	NN	O
aimed	VBD	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
camel	NN	Pharmacological
milk	NN	Pharmacological
(	(	Pharmacological
CM	NNP	Pharmacological
)	)	Pharmacological
(	(	Pharmacological
raw	JJ	Pharmacological
and	CC	Pharmacological
boiled	VBN	Pharmacological
)	)	Pharmacological
on	IN	O
thymus	NN	O
and	CC	O
activation-regulated	JJ	O
chemokine	NN	O
(	(	O
TARC	NNP	O
)	)	O
serum	NN	O
levels	NNS	O
and	CC	O
childhood	NN	O
autism	NN	O
rating	NN	O
scale	NN	O
(	(	O
CARS	NNP	O
)	)	O
score	NN	O
in	IN	O
subjects	NNS	O
with	IN	O
autism	NN	O
and	CC	O
compared	VBN	O
to	TO	O
placebo	VB	Control
group	NN	Control
(	(	Control
cow	JJ	Control
milk	NN	Control
)	)	Control
.	.	O

METHODS	NNP	O
Forty-five	JJ	O
subjects	NNS	O
diagnosed	VBN	O
with	IN	O
autism	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
boiled	VBN	Pharmacological
CM	NNP	Pharmacological
for	IN	Pharmacological
group	NN	Pharmacological
I	PRP	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
,	,	O
raw	JJ	Pharmacological
CM	NNP	Pharmacological
for	IN	Pharmacological
group	NN	Pharmacological
II	NNP	Pharmacological
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
,	,	O
and	CC	O
placebo	NN	Control
for	IN	Control
group	NN	Control
III	NNP	Control
(	(	O
n	JJ	O
=	NNP	O
15	CD	O
)	)	O
for	IN	O
2	CD	O
wk	NN	O
.	.	O

Measures	NNS	O
included	VBD	O
changes	NNS	O
in	IN	O
professionally	RB	O
completed	VBN	O
CARS	NNP	O
score	NN	O
and	CC	O
blood	NN	O
samples	NNS	O
for	IN	O
TARC	NNP	O
serum	NN	O
level	NN	O
were	VBD	O
taken	VBN	O
before	RB	O
and	CC	O
after	IN	O
milk	NN	O
consumption	NN	O
of	IN	O
500	CD	O
ml	NNS	O
per	IN	O
day	NN	O
in	IN	O
children	NNS	O
's	POS	O
regular	JJ	O
daily	JJ	O
diet	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
serum	NN	O
levels	NNS	O
of	IN	O
TARC	NNP	O
decreased	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
in	IN	O
boiled	VBN	O
CM	NNP	O
and	CC	O
in	IN	O
raw	JJ	O
CM	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.01	CD	O
)	)	O
too	RB	O
,	,	O
but	CC	O
no	DT	O
effect	NN	O
was	VBD	O
observed	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.68	CD	O
)	)	O
in	IN	O
placebo	NN	O
group	NN	O
.	.	O

Furthermore	RB	O
,	,	O
significant	JJ	O
improvements	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
CARS	NNP	O
score	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
in	IN	O
raw	JJ	O
CM	NNP	O
group	NN	O
only	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
relationships	NNS	O
between	IN	O
the	DT	O
serum	NN	O
of	IN	O
TARC	NNP	O
level	NN	O
and	CC	O
the	DT	O
CARS	NNP	O
score	NN	O
,	,	O
age	NN	O
,	,	O
or	CC	O
gender	VB	O
for	IN	O
any	DT	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
CM	NNP	O
administered	VBD	O
for	IN	O
2	CD	O
wk	NNS	O
significantly	RB	O
improved	VBN	O
clinical	JJ	O
measurements	NNS	O
of	IN	O
autism	NN	O
severity	NN	O
and	CC	O
decreased	VBD	O
serum	JJR	O
level	NN	O
of	IN	O
TARC	NNP	O
in	IN	O
autistic	JJ	O
children	NNS	O
,	,	O
but	CC	O
subsequent	JJ	O
studies	NNS	O
are	VBP	O
recommended	VBN	O
.	.	O

Treatment	NN	O
of	IN	O
men	NNS	O
with	IN	O
flat	JJ	O
(	(	O
FC	NNP	O
)	)	O
or	CC	O
acuminata	NN	O
(	(	O
CA	NNP	O
)	)	O
condylomata	NN	O
with	IN	O
interferon	JJ	Pharmacological
alpha-2a	NN	Pharmacological
.	.	O

This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
CO2	NNP	Pharmacological
laser	NN	Pharmacological
vaporization	NN	Pharmacological
,	,	O
5-fluorouracil	JJ	Pharmacological
5	CD	Pharmacological
%	NN	Pharmacological
(	(	Pharmacological
5-FU	JJ	Pharmacological
)	)	Pharmacological
topical	JJ	Pharmacological
application	NN	Pharmacological
and	CC	O
Interferon	NNP	Pharmacological
alpha-2a	NN	Pharmacological
(	(	Pharmacological
IFA	NNP	Pharmacological
alpha-2a	NN	Pharmacological
)	)	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
C.A	NNP	O
.	.	O

or	CC	O
F.C	NNP	O
.	.	O

of	IN	O
the	DT	O
male	JJ	O
genital	JJ	O
tract	NN	O
.	.	O

From	IN	O
March	NNP	O
1986	CD	O
to	TO	O
September	NNP	O
1991	CD	O
,	,	O
1372	CD	O
men	NNS	O
,	,	O
sexual	JJ	O
partners	NNS	O
of	IN	O
women	NNS	O
with	IN	O
F.C	NNP	O
.	.	O

or	CC	O
C.A	NNP	O
.	.	O

or	CC	O
cervical	JJ	O
intraepithelial	JJ	O
neoplasia	NN	O
,	,	O
were	VBD	O
submitted	VBN	O
to	TO	O
peoscopy	VB	O
.	.	O

One	CD	O
thousand	NN	O
and	CC	O
nineteen	JJ	O
(	(	O
74.27	CD	O
%	NN	O
)	)	O
men	NNS	O
presented	VBN	O
with	IN	O
various	JJ	O
penile	JJ	O
lesions	NNS	O
caused	VBN	O
by	IN	O
HPV	NNP	O
(	(	O
histologically	RB	O
confirmed	VBN	O
)	)	O
;	:	O
of	IN	O
these	DT	O
505	CD	O
were	VBD	O
treated	VBN	O
for	IN	O
C.A	NNP	O
.	.	O

or	CC	O
F.C	NNP	O
.	.	O

or	CC	O
a	DT	O
combination	NN	O
of	IN	O
F.C	NNP	O
.	.	O

and	CC	O
C.A	NNP	O
.	.	O

The	DT	O
best	JJS	O
treatment	NN	O
modalities	NNS	O
,	,	O
irrespective	NN	O
of	IN	O
the	DT	O
kind	NN	O
of	IN	O
lesion	NN	O
,	,	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
the	DT	O
combination	NN	O
of	IN	O
5-FU	JJ	Pharmacological
plus	JJ	Pharmacological
IFN	NNP	Pharmacological
alpha-2a	NN	Pharmacological
(	(	O
high	JJ	O
dose	NN	O
)	)	O
(	(	O
98.27	CD	O
%	NN	O
)	)	O
,	,	O
the	DT	O
combination	NN	O
of	IN	O
CO2	NNP	Pharmacological
laser	NN	Pharmacological
vaporization	NN	Pharmacological
plus	CC	Pharmacological
5-FU	JJ	Pharmacological
plus	JJ	Pharmacological
IFN	NNP	Pharmacological
alpha-2a	NN	Pharmacological
(	(	Pharmacological
high	JJ	Pharmacological
dose	NN	Pharmacological
)	)	Pharmacological
(	(	Pharmacological
93.93	CD	Pharmacological
%	NN	Pharmacological
)	)	Pharmacological
and	CC	O
the	DT	O
combination	NN	Pharmacological
of	IN	Pharmacological
CO2	NNP	Pharmacological
laser	NN	Pharmacological
vaporization	NN	Pharmacological
plus	CC	Pharmacological
5-FU	JJ	Pharmacological
(	(	O
87.23	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
conclusion	NN	O
we	PRP	O
believe	VBP	O
that	IN	O
IFN	NNP	Pharmacological
alpha-2a	NN	Pharmacological
can	MD	O
be	VB	O
used	VBN	O
with	IN	O
excellent	JJ	O
results	NNS	O
as	IN	O
first	JJ	O
line	NN	O
treatment	NN	O
in	IN	O
combination	NN	O
with	IN	O
CO2	NNP	Pharmacological
laser	NN	Pharmacological
vaporization	NN	Pharmacological
or/plus	IN	Pharmacological
5-FU	JJ	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
C.A	NNP	O
.	.	O

or	CC	O
F.C	NNP	O
.	.	O

or	CC	O
combined	VBN	O
condylomata	NNS	O
.	.	O

Effect	NN	O
of	IN	O
ozone	NN	Physical
application	NN	Physical
on	IN	O
the	DT	O
resin-dentin	JJ	O
microtensile	NN	O
bond	NN	O
strength	NN	O
.	.	O

When	WRB	O
ozone	NN	O
is	VBZ	O
used	VBN	O
during	IN	O
caries	NNS	O
treatment	NN	O
,	,	O
bond	NN	O
strength	NN	O
can	MD	O
be	VB	O
compromised	VBN	O
by	IN	O
the	DT	O
release	NN	O
of	IN	O
oxygen	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
antioxidant	JJ	O
agents	NNS	O
neutralizes	VBZ	O
the	DT	O
free	JJ	O
oxygen	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
ozone	NN	Physical
and	CC	O
sodium	NN	Physical
ascorbate	NN	Physical
on	IN	O
resin-dentin	JJ	O
microtensile	NN	O
bond	NN	O
strength	NN	O
(	(	O
?TBS	NN	O
)	)	O
.	.	O

Forty	NNP	O
human	JJ	O
third	JJ	O
molars	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
four	CD	O
groups	NNS	O
:	:	O
Group	NNP	O
1	CD	O
,	,	O
not	RB	O
treated	VBN	O
with	IN	O
ozone	NN	O
;	:	O
Group	NNP	O
2	CD	O
,	,	O
ozone	NN	O
application	NN	O
followed	VBN	O
by	IN	O
acid	NN	O
etching	NN	O
;	:	O
Group	NNP	O
3	CD	O
,	,	O
acid	NN	O
etching	VBG	O
followed	VBN	O
by	IN	O
ozone	NN	O
application	NN	O
;	:	O
and	CC	O
Group	NNP	O
4	CD	O
,	,	O
ozone	NN	O
and	CC	O
application	NN	O
of	IN	O
sodium	NN	O
ascorbate	NN	O
.	.	O

Bonded	VBN	O
beams	NN	O
(	(	O
1.0	CD	O
mm	NN	O
(	(	O
2	CD	O
)	)	O
)	)	O
were	VBD	O
tested	VBN	O
under	IN	O
tension	NN	O
(	(	O
0.5	CD	O
mm	NN	O
min	NN	O
(	(	O
-1	NNP	O
)	)	O
)	)	O
.	.	O

The	DT	O
?TBS	JJ	O
values	NNS	O
were	VBD	O
analyzed	VBN	O
using	VBG	O
one-way	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
(	(	O
ANOVA	NNP	O
)	)	O
and	CC	O
the	DT	O
Tukey	NNP	O
test	NN	O
(	(	O
p=0.05	NN	O
)	)	O
.	.	O

All	DT	O
beams	NNS	O
that	WDT	O
fractured	VBD	O
were	VBD	O
analyzed	VBN	O
under	IN	O
stereomicroscopy	NN	O
(	(	O
40?	CD	O
)	)	O
.	.	O

Group	NNP	O
1	CD	O
had	VBD	O
significantly	RB	O
higher	JJR	O
?TBS	NN	O
values	NNS	O
than	IN	O
Group	NNP	O
2	CD	O
or	CC	O
3	CD	O
.	.	O

The	DT	O
?TBS	JJ	O
values	NNS	O
of	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
4	CD	O
were	VBD	O
similar	JJ	O
and	CC	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
Group	NNP	O
2	CD	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
ozone	NN	O
in	IN	O
Group	NNP	O
2	CD	O
resulted	VBD	O
in	IN	O
lower	JJR	O
values	NNS	O
of	IN	O
?TBS	NN	O
in	IN	O
all	DT	O
conditions	NNS	O
evaluated	VBN	O
.	.	O

The	DT	O
predominant	JJ	O
failure	NN	O
mode	NN	O
was	VBD	O
adhesive	JJ	O
.	.	O

The	DT	O
application	NN	O
of	IN	O
ozone	NN	O
decreased	VBD	O
the	DT	O
?TBS	NN	O
of	IN	O
the	DT	O
dentin-composite	JJ	O
resin	NN	O
interface	NN	O
.	.	O

These	DT	O
values	NNS	O
were	VBD	O
reversed	VBN	O
when	WRB	O
compared	VBN	O
with	IN	O
Groups	NNP	O
1	CD	O
and	CC	O
2	CD	O
when	WRB	O
sodium	NN	O
ascorbate	NN	O
was	VBD	O
used	VBN	O
.	.	O

Hemostatic	JJ	O
function	NN	O
of	IN	O
aspirin-treated	JJ	Pharmacological
platelets	NNS	O
vulnerable	JJ	O
to	TO	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

Altered	NNP	O
shear-induced	JJ	O
pathway	NN	O
.	.	O

The	DT	O
impaired	JJ	O
hemostasis	NN	O
of	IN	O
aspirin-treated	JJ	Pharmacological
patients	NNS	O
is	VBZ	O
an	DT	O
annoying	VBG	O
problem	NN	O
during	IN	O
and	CC	O
after	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
.	.	O

The	DT	O
hemostatic	JJ	O
function	NN	O
of	IN	O
platelets	NNS	O
comprises	NNS	O
two	CD	O
mechanisms	NNS	O
:	:	O
the	DT	O
shear-induced	JJ	O
and	CC	O
the	DT	O
cyclooxygenase	NN	O
pathways	NNS	O
.	.	O

Because	IN	O
the	DT	O
latter	NN	O
is	VBZ	O
inhibited	VBN	O
in	IN	O
aspirin-treated	JJ	Pharmacological
patients	NNS	O
,	,	O
the	DT	O
hemostatic	JJ	O
function	NN	O
depends	VBZ	O
mainly	RB	O
on	IN	O
the	DT	O
former	JJ	O
pathway	NN	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
on	IN	O
the	DT	O
shear-induced	JJ	O
pathway	NN	O
,	,	O
a	DT	O
double-blind	JJ	O
study	NN	O
of	IN	O
preoperative	JJ	O
aspirin	NN	Pharmacological
treatment	NN	O
(	(	O
325	CD	O
mg	NN	O
)	)	O
and	CC	O
placebo	NN	Pharmacological
was	VBD	O
conducted	VBN	O
in	IN	O
40	CD	O
patients	NNS	O
undergoing	JJ	O
coronary	JJ	Surgical
artery	NN	Surgical
bypass	NN	Surgical
grafting	NN	Surgical
.	.	O

Postoperative	JJ	O
blood	NN	O
loss	NN	O
was	VBD	O
higher	RBR	O
in	IN	O
the	DT	O
aspirin-treated	JJ	Pharmacological
patients	NNS	O
than	IN	O
in	IN	O
the	DT	O
placebo-treated	JJ	O
patients	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
shear-induced	JJ	O
hemostasis	NN	O
was	VBD	O
monitored	VBN	O
by	IN	O
the	DT	O
in	IN	O
vitro	NN	O
bleeding	VBG	O
test	NN	O
(	(	O
Thrombostat	NNP	O
)	)	O
,	,	O
which	WDT	O
mimics	VBD	O
bleeding	VBG	O
through	IN	O
an	DT	O
injured	JJ	O
arteriole	NN	O
.	.	O

The	DT	O
shear-induced	JJ	O
pathway	NN	O
of	IN	O
aspirin-treated	JJ	Pharmacological
platelets	NNS	O
was	VBD	O
not	RB	O
affected	VBN	O
before	IN	O
cardiopulmonary	JJ	O
bypass	NN	O
,	,	O
but	CC	O
it	PRP	O
was	VBD	O
impaired	VBN	O
more	RBR	O
during	IN	O
the	DT	O
operation	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
remained	VBD	O
worse	JJR	O
afterward	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
placebo-treated	JJ	Control
platelets	NNS	O
.	.	O

The	DT	O
inhibitory	JJ	O
effects	NNS	O
of	IN	O
aspirin	NN	Pharmacological
on	IN	O
thromboxane	NN	O
production	NN	O
and	CC	O
on	IN	O
collagen-induced	JJ	O
platelet	NN	O
aggregation	NN	O
remained	VBD	O
throughout	IN	O
the	DT	O
operation	NN	O
.	.	O

In	IN	O
aspirin-treated	JJ	Pharmacological
platelets	NNS	O
,	,	O
the	DT	O
aggregation	NN	O
capacity	NN	O
induced	VBN	O
by	IN	O
adenosine	JJ	O
diphosphate	NN	O
was	VBD	O
inhibited	VBN	O
before	IN	O
the	DT	O
operation	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
showed	VBD	O
substantial	JJ	O
recovery	NN	O
during	IN	O
the	DT	O
operation	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
shear-induced	JJ	O
pathway	NN	O
of	IN	O
aspirin-treated	JJ	Pharmacological
platelets	NNS	O
is	VBZ	O
more	RBR	O
vulnerable	JJ	O
to	TO	O
cardiopulmonary	JJ	O
bypass	NN	O
than	IN	O
the	DT	O
pathway	NN	O
in	IN	O
normal	JJ	O
platelets	NNS	O
and	CC	O
causes	NNS	O
severe	JJ	O
impairment	NN	O
of	IN	O
hemostasis	NN	O
afterward	NN	O
.	.	O

A	DT	O
randomized	JJ	O
double-blind	NN	O
study	NN	O
of	IN	O
atomoxetine	JJ	Pharmacological
versus	NN	O
placebo	NN	Control
for	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
symptoms	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
efficacy	NN	O
of	IN	O
atomoxetine	NN	Pharmacological
as	IN	O
treatment	NN	O
of	IN	O
symptoms	NNS	O
of	IN	O
attention-deficit/hyperactivity	NN	O
disorder	NN	O
(	(	O
ADHD	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
(	(	O
ASD	NNP	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

METHOD	NNP	O
In	IN	O
this	DT	O
study	NN	O
,	,	O
97	CD	O
patients	NNS	O
aged	VBD	O
6	CD	O
to	TO	O
17	CD	O
years	NNS	O
with	IN	O
ADHD	NNP	O
and	CC	O
ASD	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
with	IN	O
1.2	CD	O
mg/kg/day	JJ	O
atomoxetine	NN	Pharmacological
or	CC	O
placebo	NN	Control
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
ADHD	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
ADHD-RS	NNP	O
)	)	O
score	NN	O
;	:	O
secondary	JJ	O
endpoints	NNS	O
were	VBD	O
the	DT	O
Clinical	JJ	O
Global	NNP	O
Impression	NNP	O
of	IN	O
ADHD-Improvement	NNP	O
(	(	O
CGI-I	NNP	O
)	)	O
and	CC	O
the	DT	O
Conners	NNP	O
Teacher	NNP	O
Rating	VBG	O
Scale-Revised	JJ	O
:	:	O
Short	JJ	O
Form	NNP	O
(	(	O
CTRS-R	JJ	O
:	:	O
S	NN	O
)	)	O
score	NN	O
.	.	O

RESULTS	NNP	O
Baseline	NNP	O
mean	JJ	O
ADHD-RS	NNP	O
scores	NNS	O
for	IN	O
atomoxetine	JJ	Pharmacological
versus	NN	O
placebo	NN	Control
were	VBD	O
40.7	CD	O
and	CC	O
38.6	CD	O
;	:	O
after	IN	O
8	CD	O
weeks	NNS	O
,	,	O
mixed-effect	JJ	O
model	NN	O
repeated-measure	NN	O
means	NNS	O
were	VBD	O
31.6	CD	O
(	(	O
95	CD	O
%	NN	O
confidence	NN	O
interval	JJ	O
29.2-33.9	JJ	O
)	)	O
and	CC	O
38.3	CD	O
(	(	O
36.0-40.6	CD	O
)	)	O
,	,	O
respectively	RB	O
,	,	O
with	IN	O
a	DT	O
difference	NN	O
in	IN	O
least	JJS	O
square	JJ	O
means	NNS	O
of	IN	O
-6.7	NNP	O
(	(	O
-10.0	UH	O
to	TO	O
-3.4	VB	O
;	:	O
p	CC	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
CTRS-R	JJ	O
:	:	O
S	NNP	O
Hyperactivity	NNP	O
subscore	NN	O
also	RB	O
improved	VBN	O
significantly	RB	O
for	IN	O
atomoxetine	NN	Pharmacological
compared	VBN	O
with	IN	O
placebo	NN	Control
,	,	O
but	CC	O
not	RB	O
the	DT	O
other	JJ	O
CTRS-R	JJ	O
:	:	O
S	JJ	O
subscores	NNS	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
not	RB	O
significantly	RB	O
more	RBR	O
patients	NNS	O
on	IN	O
atomoxetine	NN	Pharmacological
(	(	O
20.9	CD	O
%	NN	O
)	)	O
who	WP	O
improved	VBD	O
much	RB	O
,	,	O
or	CC	O
very	RB	O
much	JJ	O
according	VBG	O
to	TO	O
the	DT	O
CGI-I	NNP	O
,	,	O
than	IN	O
on	IN	O
placebo	NN	Control
(	(	O
8.7	CD	O
%	NN	O
;	:	O
p	CC	O
=	VB	O
0.14	CD	O
)	)	O
.	.	O

Adverse	JJ	O
events	NNS	O
(	(	O
mostly	RB	O
nausea	RB	O
,	,	O
decrease	NN	O
in	IN	O
appetite	NN	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
early	JJ	O
morning	NN	O
awakening	VBG	O
)	)	O
were	VBD	O
reported	VBN	O
in	IN	O
81.3	CD	O
%	NN	O
of	IN	O
atomoxetine	JJ	Pharmacological
patients	NNS	O
and	CC	O
65.3	CD	O
%	NN	O
of	IN	O
placebo	NN	O
patients	NNS	O
(	(	O
p	JJ	O
>	NNP	O
.1	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Atomoxetine	NNP	Pharmacological
moderately	RB	O
improved	VBD	O
ADHD	NNP	O
symptoms	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

Adverse	JJ	O
events	NNS	O
in	IN	O
this	DT	O
study	NN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
in	IN	O
other	JJ	O
studies	NNS	O
with	IN	O
ADHD	NNP	O
patients	NNS	O
without	IN	O
ASD	NNP	O
.	.	O

Clinical	JJ	O
trial	NN	O
registration	NN	O
information-A	JJ	O
Randomized	NNP	O
Double-Blind	NNP	O
Study	NNP	O
of	IN	O
Atomoxetine	NNP	Pharmacological
Versus	NNP	O
Placebo	NNP	O
for	IN	O
ADHD	NNP	O
Symptoms	NNP	O
in	IN	O
Children	NNP	O
with	IN	O
ASD	NNP	O
;	:	O
www.clinicaltrials.gov	NN	O
;	:	O
NCT00380692	NNP	O
.	.	O

JobTIPS	NN	O
:	:	O
a	DT	O
transition	NN	O
to	TO	O
employment	NN	O
program	NN	O
for	IN	O
individuals	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
internet	NN	Educational
accessed	VBD	Educational
training	VBG	Educational
program	NN	Educational
that	WDT	O
included	VBD	O
Theory	NNP	O
of	IN	O
Mind-based	JJ	O
guidance	NN	O
,	,	O
video	NN	O
models	NNS	O
,	,	O
visual	JJ	O
supports	NNS	O
,	,	O
and	CC	O
virtual	JJ	O
reality	NN	O
practice	NN	O
sessions	NNS	O
in	IN	O
teaching	VBG	O
appropriate	JJ	O
job	NN	O
interview	NN	O
skills	NNS	O
to	TO	O
individuals	NNS	O
with	IN	O
high	JJ	O
functioning	VBG	O
Autism	NNP	O
Spectrum	NNP	O
Disorders	NNP	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
,	,	O
twenty-two	JJ	O
youth	NN	O
,	,	O
ages	VBZ	O
16-19	JJ	O
,	,	O
were	VBD	O
evaluated	VBN	O
during	IN	O
two	CD	O
employment	NN	O
interviews	NNS	O
.	.	O

Half	NNP	O
received	VBD	O
a	DT	O
training	NN	O
intervention	NN	O
following	VBG	O
the	DT	O
initial	JJ	O
interview	NN	O
and	CC	O
the	DT	O
half	NN	O
who	WP	O
served	VBD	O
as	IN	O
a	DT	O
contrast	NN	O
group	NN	O
did	VBD	O
not	RB	O
.	.	O

Their	PRP$	O
performance	NN	O
pre	NN	O
and	CC	O
post	NN	O
intervention	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
four	CD	O
independent	JJ	O
raters	NNS	O
using	VBG	O
a	DT	O
scale	NN	O
that	WDT	O
included	VBD	O
evaluation	NN	O
of	IN	O
both	DT	O
Content	NNP	O
and	CC	O
Delivery	NNP	O
.	.	O

Results	NNP	O
suggest	VBP	O
that	IN	O
youth	NN	O
who	WP	O
completed	VBD	O
the	DT	O
JobTIPS	NNP	O
employment	NN	O
program	NN	O
demonstrated	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
verbal	JJ	O
content	NN	O
skills	NNS	O
than	IN	O
those	DT	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

Intracapillary	JJ	Pharmacological
glomerular	NN	Pharmacological
metastases	NNS	Pharmacological
in	IN	O
a	DT	O
nephrectomy	JJ	O
specimen	NNS	O
removed	VBD	O
for	IN	O
ipsilateral	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
.	.	O

A	DT	O
case	NN	O
of	IN	O
intraglomerular	JJ	Pharmacological
metastases	NNS	Pharmacological
observed	VBN	O
in	IN	O
a	DT	O
nephrectomy	JJ	O
specimen	NNS	O
removed	VBD	O
for	IN	O
primary	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
is	VBZ	O
reported	VBN	O
.	.	O

The	DT	O
intraglomerular	JJ	Pharmacological
metastases	NNS	Pharmacological
arose	VBP	O
by	IN	O
dissemination	NN	O
of	IN	O
malignant	JJ	O
cells	NNS	O
into	IN	O
the	DT	O
systemic	JJ	O
circulation	NN	O
via	IN	O
invasion	NN	O
of	IN	O
the	DT	O
renal	JJ	O
veins	NNS	O
.	.	O

Intraglomerular	JJ	O
metastases	NNS	O
are	VBP	O
therefore	RB	O
an	DT	O
indicator	NN	O
of	IN	O
malignant	JJ	O
dissemination	NN	O
which	WDT	O
in	IN	O
turn	NN	O
should	MD	O
be	VB	O
associated	VBN	O
with	IN	O
a	DT	O
poor	JJ	O
prognosis	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
in	IN	O
nephrectomies	NNS	O
undertaken	VBP	O
for	IN	O
primary	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
at	IN	O
least	JJS	O
one	CD	O
random	NN	O
block	NN	O
of	IN	O
renal	JJ	O
cortex	NN	O
should	MD	O
be	VB	O
examined	VBN	Educational
to	TO	O
confirm	VB	O
or	CC	O
exclude	VB	O
intraglomerular	JJ	O
metastases	NNS	O
.	.	O

Oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	Pharmacological
after	IN	O
Roux-en-Y	NNP	Surgical
gastric	JJ	Surgical
bypass	NN	Surgical
surgery	NN	Surgical
.	.	O

OBJECTIVES	CC	O
Roux-en-Y	JJ	Surgical
gastric	JJ	Surgical
bypass	NN	Surgical
surgery	NN	Surgical
is	VBZ	O
the	DT	O
most	RBS	O
commonly	RB	O
performed	JJ	O
procedure	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
morbid	NN	O
obesity	NN	O
.	.	O

This	DT	O
anatomical	JJ	O
alteration	NN	O
may	MD	O
affect	VB	O
the	DT	O
absorption	NN	O
and	CC	O
consequently	RB	O
the	DT	O
bioavailability	NN	O
of	IN	O
oral	JJ	O
drugs	NNS	O
.	.	O

This	DT	O
study	NN	O
aims	VBZ	O
to	TO	O
investigate	VB	O
the	DT	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
moxifloxacin	NN	Pharmacological
in	IN	O
12	CD	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
underwent	VBP	O
gastric	JJ	Surgical
bypass	NN	Surgical
surgery	NN	Surgical
.	.	O

PATIENTS	NNP	O
AND	CC	O
METHODS	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
crossover	NN	O
study	NN	O
,	,	O
each	DT	O
subject	NN	O
received	VBD	O
two	CD	O
single	JJ	O
standard	NN	O
doses	NNS	O
of	IN	O
400	CD	Pharmacological
mg	NN	Pharmacological
of	IN	Pharmacological
moxifloxacin	NN	Pharmacological
orally	RB	Pharmacological
or	CC	Pharmacological
intravenously	RB	Pharmacological
administered	VBN	O
on	IN	O
two	CD	O
occasions	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
washout	JJ	O
period	NN	O
of	IN	O
1	CD	O
week	NN	O
.	.	O

Serial	JJ	O
venous	JJ	O
blood	NN	O
samples	NNS	O
were	VBD	O
drawn	VBN	O
up	RB	O
to	TO	O
72	CD	O
h	NN	O
after	IN	O
dosing	VBG	O
and	CC	O
moxifloxacin	JJ	Pharmacological
plasma	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
a	DT	O
validated	JJ	O
HPLC	NNP	O
method	NN	O
with	IN	O
fluorescence	NN	O
detection	NN	O
.	.	O

[	CC	O
clinicaltrials.gov	JJ	O
database	NN	O
(	(	O
identifier	NN	O
:	:	O
NCT01130922	NNP	O
)	)	O
.	.	O

]	JJ	O
RESULTS	NNP	O
After	IN	O
oral	JJ	O
dosing	NN	O
,	,	O
moxifloxacin	FW	Pharmacological
plasma	NN	O
concentrations	NNS	O
reached	VBD	O
a	DT	O
maximum	JJ	O
(	(	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
)	)	O
of	IN	O
3.38	CD	O
?	.	O
1.41	CD	O
mg/L	NN	O
after	IN	O
1.75	CD	O
h	NN	O
(	(	O
0.75-4.00	JJ	O
)	)	O
.	.	O

After	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
C	NNP	O
(	(	O
max	NN	O
)	)	O
and	CC	O
T	NNP	O
(	(	O
max	NN	O
)	)	O
were	VBD	O
4.53	CD	O
?	.	O
1.43	CD	O
mg/L	NN	O
and	CC	O
1.03	CD	O
h	NN	O
(	(	O
0.75-2.50	JJ	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
mean	JJ	O
areas	NNS	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration	NN	O
time	NN	O
curve	NN	O
extrapolated	VBD	O
to	TO	O
infinity	NN	O
(	(	O
AUC	NNP	O
(	(	O
?	.	O
)	)	O
)	)	O
were	VBD	O
46.2	CD	O
?	.	O
1.4	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
oral	JJ	O
dosing	NN	O
and	CC	O
52.3	CD	O
?	.	O
1.3	CD	O
mg	NN	O
?	.	O
h/L	NN	O
after	IN	O
intravenous	JJ	O
dosing	NN	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
mean	JJ	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
88.32	CD	O
%	NN	O
[	JJ	O
90	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
(	(	O
CI	NNP	O
)	)	O
85.64	CD	O
%	NN	O
-91.08	CD	O
%	NN	O
]	NN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
confirms	VBZ	O
that	IN	O
exposure	NN	O
to	TO	O
moxifloxacin	VB	O
is	VBZ	O
equivalent	JJ	O
for	IN	O
oral	JJ	O
and	CC	O
intravenous	JJ	O
administration	NN	O
of	IN	O
400	CD	O
mg	NN	O
dosages	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
who	WP	O
underwent	VBP	O
gastric	JJ	O
bypass	NN	O
surgery	NN	O
.	.	O

But	CC	O
these	DT	O
exposures	NNS	O
were	VBD	O
more	JJR	O
than	IN	O
50	CD	O
%	NN	O
higher	JJR	O
than	IN	O
those	DT	O
described	VBN	O
for	IN	O
subjects	NNS	O
without	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

This	DT	O
may	MD	O
suggest	VB	O
a	DT	O
higher	JJR	O
enterohepatic	JJ	O
recirculation	NN	O
of	IN	O
moxifloxacin	NN	O
after	IN	O
gastric	JJ	O
bypass	NN	O
.	.	O

[	JJ	O
Cardiac	NNP	O
protection	NN	O
is	VBZ	O
a	DT	O
clinical	JJ	O
evidence	NN	O
]	NN	O
.	.	O

AIM	NNP	O
Anaesthetics	NNPS	O
may	MD	O
have	VB	O
protective	JJ	O
effect	NN	O
against	IN	O
myocardial	JJ	O
ischemia	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
investigate	VB	O
if	IN	O
sevoflurane	JJ	O
administration	NN	O
could	MD	O
exert	VB	O
myocardial	JJ	O
protection	NN	O
during	IN	O
following	VBG	O
coronary	JJ	O
occlusion	NN	O
in	IN	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

METHODS	NNP	O
a	DT	O
)	)	O
.	.	O

EXPERIMENTAL	NNP	O
DESIGN	NNP	O
prospective	JJ	O
,	,	O
randomized	VBN	O
study	NN	O
.	.	O

b	NN	O
)	)	O
.	.	O

SETTING	NN	O
University	NNP	O
Hospital	NNP	O
,	,	O
cardiac	JJ	O
surgical	JJ	O
operative	NN	O
theatre	NN	O
.	.	O

c	NN	O
)	)	O
.	.	O

PATIENTS	$	O
42	CD	O
patients	NNS	O
with	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
coronary	JJ	O
surgery	NN	O
.	.	O

INCLUSION	NNP	O
CRITERIA	NNP	O
severe	JJ	O
coronary	JJ	O
stenosis	NN	O
of	IN	O
anterior	JJ	O
descending	VBG	O
coronary	JJ	O
artery	NN	O
;	:	O
no	DT	O
collateral	NN	O
flow	NN	O
on	IN	O
angiography	NN	O
;	:	O
at	IN	O
least	JJS	O
two	CD	O
normokinetic	JJ	O
segments	NNS	O
in	IN	O
the	DT	O
myocardial	JJ	O
region	NN	O
supplied	VBN	O
by	IN	O
the	DT	O
vessel	NN	O
being	VBG	O
bypassed	VBN	O
.	.	O

PATIENTS	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	Pharmacological
receive	VB	Pharmacological
(	(	Pharmacological
group	NN	Pharmacological
S	NNP	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
not	RB	Pharmacological
(	(	Pharmacological
group	NN	Pharmacological
C	NNP	Pharmacological
)	)	Pharmacological
sevoflurane	NN	Pharmacological
administration	NN	O
for	IN	O
15	CD	O
min	NN	O
just	RB	O
before	RB	O
coronary	JJ	O
occlusion	NN	O
.	.	O

d	NN	O
)	)	O
.	.	O

INTERVENTIONS	NNP	O
Transoesophageal	NNP	Physical
Tissue	NNP	Physical
Doppler	NNP	Physical
echocardiographic	JJ	Physical
examination	NN	Physical
of	IN	Physical
myocardial	JJ	Physical
systolic	NN	Physical
and	CC	O
early	JJ	Surgical
diastolic	NN	Surgical
velocities	NNS	Surgical
in	IN	Surgical
both	DT	Surgical
groups	NNS	Surgical
basally	RB	Surgical
and	CC	Surgical
60	CD	Surgical
s	NN	Surgical
after	IN	Surgical
coronary	JJ	Surgical
occlusion	NN	Surgical
by	IN	Surgical
the	DT	Surgical
surgeon	NN	Surgical
.	.	O

e	NN	O
)	)	O
.	.	O

MEASURES	NNP	O
systolic	JJ	O
and	CC	O
early	JJ	O
diastolic	JJ	O
velocities	NNS	O
were	VBD	O
registered	VBN	O
by	IN	O
Tissue	NNP	O
Doppler	NNP	O
from	IN	O
a	DT	O
long-axis	JJ	O
view	NN	O
of	IN	O
the	DT	O
interventricular	JJ	O
septum	NN	O
or	CC	O
the	DT	O
anterior	JJ	O
wall	NN	O
of	IN	O
the	DT	O
left	JJ	O
ventricle	NN	O
.	.	O

RESULTS	NNP	O
In	IN	O
group	NN	O
C	NNP	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
systolic	JJ	O
and	CC	O
diastolic	JJ	O
intramyocardial	JJ	O
velocities	NNS	O
was	VBD	O
found	VBN	O
during	IN	O
myocardial	JJ	O
ischemia	NN	O
due	JJ	O
to	TO	O
coronary	JJ	O
occlusion	NN	O
.	.	O

CONCLUSION	NNP	O
Treatment	NNP	O
with	IN	O
sevoflurane	NN	O
before	IN	O
coronary	JJ	O
occlusion	NN	O
seem	VBP	O
effective	JJ	O
in	IN	O
reducing	VBG	O
functional	JJ	O
myocardial	JJ	O
impairment	NN	O
due	JJ	O
to	TO	O
ischemia	VB	O
.	.	O

A	DT	O
single	JJ	O
dose	NN	O
of	IN	O
gabapentin	NN	Pharmacological
reduces	NNS	O
acute	VBP	O
pain	NN	O
and	CC	O
allodynia	NN	O
in	IN	O
patients	NNS	O
with	IN	O
herpes	NNS	O
zoster	NN	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
crossover	NN	O
study	NN	O
measured	VBD	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
oral	JJ	Pharmacological
gabapentin	NN	Pharmacological
(	(	O
900	CD	O
mg	NN	O
)	)	O
on	IN	O
pain	NN	O
and	CC	O
allodynia	NN	O
associated	VBN	O
with	IN	O
herpes	NNS	O
zoster	NN	O
.	.	O

Pain	NNP	O
severity	NN	O
decreased	VBN	O
by	IN	O
66	CD	O
%	NN	O
with	IN	O
gabapentin	NN	Pharmacological
compared	VBN	O
to	TO	O
33	CD	O
%	NN	O
with	IN	O
placebo	NN	Control
.	.	O

Reductions	NNS	O
in	IN	O
allodynia	JJ	O
area	NN	O
and	CC	O
severity	NN	O
,	,	O
and	CC	O
overall	JJ	O
pain	NN	O
relief	NN	O
,	,	O
were	VBD	O
also	RB	O
greater	JJR	O
with	IN	O
gabapentin	NN	Pharmacological
.	.	O

Conservative	JJ	Control
treatment	NN	Control
of	IN	O
plantar	NN	O
fasciitis	NN	O
.	.	O

A	DT	O
prospective	JJ	O
study	NN	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
prospective	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
individual	JJ	O
effectiveness	NN	O
of	IN	O
three	CD	O
types	NNS	O
of	IN	O
conservative	JJ	Physical
therapy	NN	Physical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
plantar	NN	O
fasciitis	NN	O
.	.	O

One	CD	O
hundred	VBD	O
three	CD	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
categories	NNS	O
:	:	O
anti-inflammatory	NN	Other
,	,	Other
accommodative	JJ	Other
,	,	Other
or	CC	Other
mechanical	JJ	Other
.	.	Other

Subjects	NNS	O
were	VBD	O
treated	VBN	O
for	IN	O
3	CD	O
months	NNS	O
,	,	O
with	IN	O
follow-up	JJ	O
visits	NNS	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
weeks	NNS	O
.	.	O

For	IN	O
the	DT	O
85	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
was	VBD	O
noted	VBN	O
between	IN	O
groups	NNS	O
,	,	O
with	IN	O
mechanical	JJ	Control
treatment	NN	Control
with	IN	Control
taping	VBG	Control
and	CC	Control
orthoses	NNS	Control
proving	VBG	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
than	IN	O
either	DT	O
anti-inflammatory	JJ	Other
or	CC	O
accommodative	JJ	Other
modalities	NNS	Other
.	.	Other

Improving	VBG	O
RBC	NNP	O
K	NNP	O
transport	NN	O
and	CC	O
hemoglobin-O2	JJ	O
binding	NN	O
by	IN	O
amiloride	NN	Pharmacological
:	:	O
A	DT	O
novel	JJ	O
therapeutic	JJ	O
approach	NN	O
for	IN	O
reversion	NN	O
of	IN	O
angina	NN	O
and	CC	O
myocardial	JJ	O
ischemia	NN	O
in	IN	O
coronary	JJ	O
heart	NN	O
diseases	NNS	O
.	.	O

UNLABELLED	NNP	O
Coronary	NNP	O
heart	NN	O
disease	NN	O
(	(	O
CHD	NNP	O
)	)	O
is	VBZ	O
the	DT	O
leading	VBG	O
cause	NN	O
of	IN	O
morbidity	NN	O
and	CC	O
mortality	NN	O
across	IN	O
the	DT	O
entire	JJ	O
world	NN	O
,	,	O
in	IN	O
which	WDT	O
reversion	NN	O
of	IN	O
angina	NN	O
or	CC	O
improvement	NN	O
of	IN	O
ECG	NNP	O
remains	VBZ	O
an	DT	O
unrealistic	JJ	O
therapeutic	JJ	O
option	NN	O
for	IN	O
most	JJS	O
patients	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
microvascular	JJ	O
dysfunction	NN	O
or	CC	O
impaired	JJ	O
oxygen	NN	O
delivery	NN	O
might	MD	O
be	VB	O
critical	JJ	O
factors	NNS	O
in	IN	O
CHD	NNP	O
.	.	O

This	DT	O
research	NN	O
article	NN	O
,	,	O
thus	RB	O
presents	VBZ	O
the	DT	O
rationale	JJ	O
basis	NN	O
,	,	O
clinical	JJ	O
and	CC	O
experimental	JJ	O
,	,	O
for	IN	O
the	DT	O
first	JJ	O
therapeutic	JJ	O
innovation	NN	O
addressing	VBG	O
the	DT	O
role	NN	O
of	IN	O
red	JJ	O
blood	NN	O
cell	NN	O
(	(	O
RBC	NNP	O
)	)	O
H/K	NNP	O
and	CC	O
O2/CO2	NNP	O
exchanges	NNS	O
in	IN	O
CHD	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
followed	VBN	O
by	IN	O
a	DT	O
randomized	JJ	O
single-blind	JJ	O
trial	NN	O
of	IN	O
Amiloride	NNP	Pharmacological
and	CC	Pharmacological
Optimal	NNP	Pharmacological
Medical	NNP	Pharmacological
Therapy	NNP	Pharmacological
(	(	O
OMT	NNP	O
,	,	O
n=35	JJ	O
cases	NNS	O
)	)	O
vs	VBP	O
OMT	NNP	Pharmacological
alone	RB	Pharmacological
(	(	O
n=35	JJ	O
cases	NNS	O
)	)	O
in	IN	O
patients	NNS	O
having	VBG	O
angina	RB	O
,	,	O
ST-T	JJ	O
alteration	NN	O
and	CC	O
a	DT	O
defective	JJ	O
RBC-K	JJ	O
transport	NN	O
.	.	O

All	DT	O
patients	NNS	O
had	VBD	O
serial	JJ	O
clinical	JJ	O
evaluation	NN	O
,	,	O
Ion	NNP	O
Transport	NNP	O
Studies	NNP	O
,	,	O
ECGs	NNP	O
and	CC	O
non-invasive	JJ	O
aortic	JJ	O
waveform	NN	O
and	CC	O
cardiovascular	JJ	O
hemodynamic	JJ	O
recordings	NNS	O
.	.	O

Statistical	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
SAS	NNP	O
.	.	O

RESULTS	NNP	O
Amiloride	NNP	O
rapidly	RB	O
improved	VBD	O
RBC-K	NNP	O
(	(	O
93.5	CD	O
?4	NNP	O
vs	NN	O
84.5	CD	O
?4	NN	O
mmol/lc	NN	O
,	,	O
p=	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
angina	RB	O
(	(	O
80	CD	O
%	NN	O
of	IN	O
cases	NNS	O
,	,	O
1.5	CD	O
?0.3	JJ	O
weeks	NNS	O
,	,	O
CI:1.72	NNP	O
to	TO	O
1.45	CD	O
)	)	O
,	,	O
CCS	NNP	O
Class	NNP	O
(	(	O
1.3	CD	O
?0.5	NNP	O
vs	NN	O
3.1	CD	O
?0.8	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
vs	NN	O
patients	NNS	O
with	IN	O
OMT	NNP	O
alone	RB	O
CCS	NNP	O
Class	NNP	O
(	(	O
3.2	CD	O
?	.	O
0.4	CD	O
vs	NN	O
3.3	CD	O
?	.	O
0.5	CD	O
,	,	O
p	FW	O
=0.21	NN	O
)	)	O
.	.	O

Reversion	NN	O
of	IN	O
angina	NN	O
was	VBD	O
sustained	VBN	O
through	IN	O
the	DT	O
next	JJ	O
6-months	JJ	O
(	(	O
87	CD	O
%	NN	O
vs	JJ	O
26	CD	O
%	NN	O
in	IN	O
OMT	NNP	O
,	,	O
RR	NNP	O
2.1	CD	O
,	,	O
odds	NNS	O
ratio	VBP	O
6.31	CD	O
,	,	O
Pearson	NNP	O
x2	NNP	O
34.6	CD	O
,	,	O
p	NN	O
<	VBD	O
0.0001	CD	O
at	IN	O
95	CD	O
%	NN	O
CI	NNP	O
)	)	O
and	CC	O
1-year	JJ	O
(	(	O
85	CD	O
%	NN	O
vs	JJ	O
37	CD	O
%	NN	O
OMT	NNP	O
)	)	O
.	.	O

At	IN	O
6-months	JJ	O
of	IN	O
amiloride	NN	O
,	,	O
ECG	NNP	O
became	VBD	O
normal	JJ	O
(	(	O
29	CD	O
%	NN	O
vs	JJ	O
0	CD	O
%	NN	O
,	,	O
RR	NNP	O
?	.	O
uncalculated-time	JJ	O
,	,	O
odds	NNS	O
ratio	NN	O
?	.	O
,	,	O
Pearson	NNP	O
x2	VBD	O
42.4	CD	O
at	IN	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
,	,	O
improved	VBN	O
(	(	O
55	CD	O
%	NN	O
vs	JJ	O
29	CD	O
%	NN	O
;	:	O
RR2.1	NNP	O
,	,	O
odds	VBZ	O
ratio	NN	O
3.16	CD	O
,	,	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
or	CC	O
unchanged	JJ	O
(	(	O
15	CD	O
%	NN	O
vs	JJ	O
67	CD	O
%	NN	O
OMT	NNP	O
)	)	O
.	.	O

At	IN	O
1-year	JJ	O
,	,	O
seven	CD	O
patients	NNS	O
on	IN	O
amiloride	NN	O
(	(	O
18	CD	O
%	NN	O
)	)	O
exhibited	VBD	O
evidence	NN	O
of	IN	O
electrical	JJ	O
regeneration	NN	O
of	IN	O
the	DT	O
heart	NN	O
,	,	O
not	RB	O
observed	VBN	O
with	IN	O
placebo	NN	Control
.	.	O

IN	NNP	O
CONCLUSION	NNP	O
This	DT	O
therapeutical	JJ	O
innovation	NN	O
of	IN	O
amiloride	JJ	O
improves	NNS	O
RBC	NNP	O
H/K	NNP	O
and	CC	O
O2/CO2	NNP	O
function	NN	O
,	,	O
and	CC	O
reverses	VBZ	O
angina	NNS	O
,	,	O
ST-T	JJ	O
alterations	NNS	O
while	IN	O
inducing	VBG	O
electrical	JJ	O
regeneration	NN	O
of	IN	O
the	DT	O
heart	NN	O
,	,	O
in	IN	O
patients	NNS	O
receiving	VBG	O
optimal	JJ	O
medical	JJ	O
treatment	NN	O
for	IN	O
angina	NN	O
.	.	O

The	DT	O
article	NN	O
has	VBZ	O
short	JJ	O
discussion	NN	O
on	IN	O
the	DT	O
relevant	JJ	O
patents	NNS	O
to	TO	O
the	DT	O
topic	NN	O
.	.	O

Effect	NN	O
of	IN	O
simvastatin	NN	Pharmacological
and	CC	O
fenofibrate	NN	Pharmacological
on	IN	O
endothelium	NN	O
in	IN	O
Type	NNP	O
2	CD	O
diabetes	NNS	O
.	.	O

Statins	NNS	O
and	CC	O
fibrates	NNS	O
influence	VBP	O
endothelial	JJ	O
activity	NN	O
and	CC	O
consequently	RB	O
atherogenesis	NN	O
but	CC	O
the	DT	O
mechanisms	NNS	O
are	VBP	O
not	RB	O
well	RB	O
understood	RB	O
.	.	O

Twenty	NNP	O
Type	NNP	O
2	CD	O
diabetic	JJ	O
patients	NNS	O
with	IN	O
dyslipidemia	NN	O
were	VBD	O
treated	VBN	O
3	CD	O
months	NNS	O
with	IN	O
simvastatin	NN	Pharmacological
(	(	O
20	CD	O
mg	NNS	O
daily	RB	O
)	)	O
and	CC	O
then	RB	O
3	CD	O
months	NNS	O
with	IN	O
fenofibrate	NN	Pharmacological
(	(	O
200	CD	O
mg	NNS	O
daily	RB	O
)	)	O
with	IN	O
2	CD	O
months	NNS	O
of	IN	O
wash-out	NN	O
between	IN	O
the	DT	O
two	CD	O
treatments	NNS	O
.	.	O

Laboratory	JJ	O
parameters	NNS	O
of	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
fibrinolysis	NN	O
and	CC	O
endothelial	JJ	O
function	NN	O
were	VBD	O
evaluated	VBN	O
before	RB	O
and	CC	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
treatment	NN	O
period	NN	O
.	.	O

The	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
serum	JJ	O
total	JJ	O
and	CC	O
LDL-cholesterol	JJ	O
concentrations	NNS	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
caused	VBN	O
by	IN	O
simvastatin	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	JJ	O
N-acetyl-beta-glucosaminidase	JJ	O
activity	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
ascorbic	JJ	O
acid	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
plasminogen	JJ	O
activator	NN	O
inhibitor	NN	O
(	(	O
PAI-1	NNP	O
)	)	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
vonWillebrand	FW	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
E-selectin	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
vascular	JJ	O
endothelial	JJ	O
growth	NN	O
factor	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
concentrations	NNS	O
and	CC	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
plasma	NN	O
glutathione	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
levels	NNS	O
.	.	O

Fenofibrate	NNP	O
caused	VBD	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
serum	JJ	O
triglyceride	JJ	O
concentration	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.0001	CD	O
)	)	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
plasma	NN	O
malondialdehyde	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
plasma	JJ	O
PAI-1	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
and	CC	O
P-selectin	NNP	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
concentrations	NNS	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
simvastatin	NN	O
and	CC	O
fenofibrate	NN	O
interact	NN	O
,	,	O
by	IN	O
different	JJ	O
mechanisms	NNS	O
,	,	O
with	IN	O
oxidative	JJ	O
stress	NN	O
,	,	O
a	DT	O
key	JJ	O
factor	NN	O
in	IN	O
the	DT	O
modification	NN	O
of	IN	O
fibrinolysis	NN	O
and	CC	O
endothelial	JJ	O
function	NN	O
in	IN	O
Type	NNP	O
2	CD	O
diabetes	NNS	O
.	.	O

Performance	NN	O
of	IN	O
a	DT	O
modified	VBN	O
starch	NN	O
hydrophilic	NN	O
matrix	NN	O
for	IN	O
the	DT	O
sustained	JJ	O
release	NN	O
of	IN	O
theophylline	NN	Pharmacological
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

Two	CD	O
experimental	JJ	O
formulations	NNS	O
of	IN	O
theophylline	NN	Pharmacological
with	IN	Pharmacological
a	DT	Pharmacological
hydrophilic	JJ	Pharmacological
starch	NN	Pharmacological
matrix	NN	Pharmacological
were	VBD	O
evaluated	VBN	O
for	IN	O
their	PRP$	O
sustained-release	JJ	O
characteristics	NNS	O
after	IN	O
single	JJ	O
administration	NN	O
in	IN	O
healthy	JJ	O
human	JJ	O
volunteers	NNS	O
.	.	O

Theo-dur	NN	Pharmacological
was	VBD	O
chosen	VBN	O
as	IN	O
a	DT	O
reference	NN	O
sustained-release	JJ	O
formulation	NN	O
.	.	O

In	IN	O
a	DT	O
first	JJ	O
study	NN	O
,	,	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
was	VBD	O
similar	JJ	O
for	IN	O
a	DT	O
syrup	NN	O
,	,	O
for	IN	O
Theo-dur	NNP	Pharmacological
,	,	O
and	CC	O
for	IN	O
the	DT	O
experimental	JJ	O
formulation	NN	O
of	IN	O
theophylline	NN	O
with	IN	O
70	CD	O
%	NN	O
drum-dried	JJ	O
corn	NN	O
starch	NN	O
as	IN	O
the	DT	O
sustained-release	JJ	O
agent	NN	O
(	(	O
DDCS-70	NNP	O
)	)	O
.	.	O

The	DT	O
maximal	JJ	O
plasma	NN	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
was	VBD	O
significantly	RB	O
lower	JJR	O
,	,	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
reach	VB	O
Cmax	NNP	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
time	NN	O
span	NN	O
during	IN	O
which	WDT	O
the	DT	O
plasma	NN	O
concentration	NN	O
was	VBD	O
at	IN	O
least	JJS	O
75	CD	O
%	NN	O
of	IN	O
the	DT	O
Cmax	NNP	O
were	VBD	O
significantly	RB	O
higher	JJR	O
for	IN	O
Theo-dur	NNP	O
than	IN	O
for	IN	O
the	DT	O
DDCS-70	NNP	O
formulation	NN	O
.	.	O

A	DT	O
sustained-release	JJ	O
profile	NN	O
,	,	O
as	IN	O
for	IN	O
Theo-dur	NNP	Pharmacological
,	,	O
was	VBD	O
not	RB	O
reached	VBN	O
for	IN	O
DDCS-70	NNP	O
.	.	O

In	IN	O
a	DT	O
second	JJ	O
study	NN	O
the	DT	O
influence	NN	O
of	IN	O
the	DT	O
starch	NN	O
:	:	O
drug	NN	O
ratio	NN	O
on	IN	O
the	DT	O
bioavailability	NN	O
was	VBD	O
investigated	VBN	O
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
starch	NN	O
content	NN	O
from	IN	O
70	CD	O
to	TO	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
formulation	NN	O
did	VBD	O
not	RB	O
improve	VB	O
the	DT	O
plasma	NN	O
concentration-time	JJ	O
profile	NN	O
towards	NNS	O
a	DT	O
sustained-release	JJ	O
profile	NN	O
.	.	O

A	DT	O
cost-benefit	JJ	O
comparison	NN	O
of	IN	O
intensive	JJ	Physical
diabetes	NNS	Physical
management	NN	Physical
with	IN	Physical
implantable	JJ	Physical
pumps	NNS	Physical
versus	IN	O
multiple	JJ	Pharmacological
subcutaneous	JJ	Pharmacological
injections	NNS	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
type	NN	O
I	PRP	O
diabetes	VBZ	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
investigate	VB	O
if	IN	O
intraperitoneal	JJ	Physical
(	(	Physical
IP	NNP	Physical
)	)	Physical
insulin	NN	Physical
infusion	NN	Physical
via	IN	Physical
programmable	JJ	Physical
implantable	JJ	Physical
pumps	NNS	Physical
is	VBZ	O
a	DT	O
potential	JJ	O
alternative	NN	O
to	TO	O
subcutaneous	JJ	Pharmacological
(	(	Pharmacological
SC	NNP	Pharmacological
)	)	Pharmacological
insulin	NN	Pharmacological
via	IN	Pharmacological
multiple	JJ	Pharmacological
injections	NNS	Pharmacological
.	.	O

RESEARCH	NNP	O
DESIGN	NNP	O
AND	NNP	O
METHODS	NNP	O
We	PRP	O
compared	VBN	O
the	DT	O
cost-benefits	NNS	O
of	IN	O
the	DT	O
two	CD	O
methods	NNS	O
using	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
prospective	JJ	O
,	,	O
6-month	JJ	O
,	,	O
crossover	JJ	O
design	NN	O
in	IN	O
10	CD	O
adult	NN	O
type	NN	O
I	PRP	O
diabetic	JJ	O
patients	NNS	O
.	.	O

RESULTS	NNP	O
When	WRB	O
judged	VBN	O
on	IN	O
the	DT	O
last	JJ	O
month	NN	O
of	IN	O
IP	NNP	O
versus	NN	O
SC	NNP	O
periods	NNS	O
in	IN	O
the	DT	O
nine	CD	O
patients	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
study	NN	O
,	,	O
metabolic	JJ	O
data	NN	O
showed	VBD	O
better	JJR	O
glycemic	JJ	O
control	NN	O
(	(	O
HbA1c	NNP	O
:	:	O
7.2	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
8.5	CD	O
+/-	JJ	O
0.7	CD	O
%	NN	O
SC	NNP	O
,	,	O
mean	JJ	O
+/-	JJ	O
SE	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
,	,	O
reduced	VBN	O
glycemic	JJ	O
fluctuations	NNS	O
(	(	O
SD	NNP	O
of	IN	O
capillary	JJ	O
glucose	JJ	O
values	NNS	O
:	:	O
3.4	CD	O
+/-	JJ	O
0.2	CD	O
IP	NNP	O
vs.	FW	O
4.6	CD	O
+/-	JJ	O
0.2	CD	O
mM	NN	O
SC	NNP	O
,	,	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
and	CC	O
fewer	JJR	O
mild	JJ	O
hypoglycemic	JJ	O
events	NNS	O
(	(	O
5.7	CD	O
+/-	JJ	O
2.0	CD	O
IP	NNP	O
vs.	FW	O
10.0	CD	O
+/-	JJ	O
3.1	CD	O
events/month	JJ	O
SC	NNP	O
,	,	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Quality	NN	O
of	IN	O
life	NN	O
,	,	O
judged	VBN	O
by	IN	O
Diabetes	NNP	O
Control	NNP	O
and	CC	O
Complications	NNP	O
Trial	NNP	O
questionnaires	NNS	O
,	,	O
was	VBD	O
unaffected	VBN	O
by	IN	O
pump	NN	Physical
therapy	NN	O
.	.	O

Direct	JJ	O
costs	NNS	O
,	,	O
including	VBG	O
pump	JJ	O
acquisition	NN	O
,	,	O
implantation	NN	O
,	,	O
and	CC	O
follow-up	NN	O
,	,	O
were	VBD	O
2.6-fold	JJ	O
higher	JJR	O
with	IN	O
IP	NNP	O
than	IN	O
with	IN	O
SC	NNP	O
delivery	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
implantable	JJ	Physical
pump	NN	Physical
is	VBZ	O
more	RBR	O
effective	JJ	O
in	IN	O
the	DT	O
short	JJ	O
term	NN	O
,	,	O
equally	RB	O
accepted	VBN	O
,	,	O
but	CC	O
more	RBR	O
costly	JJ	O
than	IN	O
multiple	JJ	Pharmacological
injections	NNS	Pharmacological
and	CC	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
patients	NNS	O
with	IN	O
unsatisfactory	JJ	O
glycemic	JJ	O
control	NN	O
despite	IN	O
intensive	JJ	O
diabetes	NNS	O
management	NN	O
with	IN	O
SC	NNP	O
insulin	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
longer-term	JJ	O
,	,	O
larger-scale	JJ	O
,	,	O
and	CC	O
comparative	JJ	O
evaluation	NN	O
is	VBZ	O
required	VBN	O
.	.	O

Plasma	NNP	O
Epstein-Barr	NNP	O
virus	NN	O
DNA	NNP	O
predicts	VBZ	O
outcome	VBN	O
in	IN	O
advanced	JJ	O
Hodgkin	NNP	O
lymphoma	NN	O
:	:	O
correlative	JJ	O
analysis	NN	O
from	IN	O
a	DT	O
large	JJ	O
North	JJ	O
American	JJ	O
cooperative	NN	O
group	NN	O
trial	NN	O
.	.	O

Epstein-Barr	JJ	O
virus	NN	O
(	(	O
EBV	NNP	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
Hodgkin	NNP	O
lymphoma	NN	O
(	(	O
HL	NNP	O
)	)	O
and	CC	O
can	MD	O
be	VB	O
detected	VBN	O
by	IN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
(	(	O
ISH	NNP	O
)	)	O
of	IN	O
viral	JJ	O
nucleic	JJ	O
acid	NN	O
(	(	O
EBER	NNP	O
)	)	O
in	IN	O
tumor	NN	O
cells	NNS	O
.	.	O

We	PRP	O
sought	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
plasma	JJ	O
EBV-DNA	NNP	O
could	MD	O
serve	VB	O
as	IN	O
a	DT	O
surrogate	NN	O
for	IN	O
EBER-ISH	NNP	O
and	CC	O
to	TO	O
explore	VB	O
its	PRP$	O
prognostic	JJ	O
utility	NN	O
in	IN	O
HL	NNP	O
.	.	O

Specimens	NNS	O
from	IN	O
the	DT	O
Cancer	NNP	O
Cooperative	NNP	O
Intergroup	NNP	O
Trial	NNP	O
E2496	NNP	O
were	VBD	O
used	VBN	O
to	TO	O
compare	VB	O
pretreatment	JJ	Physical
plasma	JJ	Physical
EBV-DNA	JJ	Physical
quantification	NN	Physical
with	IN	O
EBV	NNP	Physical
tumor	NN	Physical
status	NN	Physical
by	IN	Physical
EBER-ISH	NNP	Physical
.	.	O

A	NNP	O
cutoff	NN	O
of	IN	O
>	$	O
60	CD	O
viral	JJ	O
copies/100	NN	O
?L	NNP	O
plasma	NN	O
yielded	VBD	O
96	CD	O
%	NN	O
concordance	NN	O
with	IN	O
EBER-ISH	NNP	O
.	.	O

Pretreatment	NNP	O
and	CC	O
month	NN	O
6	CD	O
plasma	NN	O
specimens	NNS	O
were	VBD	O
designated	VBN	O
EBV	NNP	O
(	(	O
-	:	O
)	)	O
or	CC	O
EBV	NNP	O
(	(	O
+	NNP	O
)	)	O
by	IN	O
this	DT	O
cutoff	NN	O
.	.	O

Patients	NNS	O
with	IN	O
pretreatment	JJ	O
EBV	NNP	O
(	(	O
+	NNP	O
)	)	O
plasma	NN	O
(	(	O
n	JJ	O
=	NNP	O
54	CD	O
)	)	O
had	VBD	O
inferior	JJ	O
failure-free	JJ	O
survival	NN	O
(	(	O
FFS	NNP	O
)	)	O
compared	VBN	O
with	IN	O
those	DT	O
with	IN	O
pretreatment	JJ	O
EBV	NNP	O
(	(	O
-	:	O
)	)	O
plasma	NN	O
(	(	O
n	JJ	O
=	NNP	O
274	CD	O
)	)	O
,	,	O
log-rank	JJ	O
P	NNP	O
=	NNP	O
.009	NNP	O
.	.	O

By	IN	O
contrast	NN	O
,	,	O
no	DT	O
difference	NN	O
in	IN	O
FFS	NNP	O
was	VBD	O
observed	VBN	O
when	WRB	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
by	IN	O
EBER-ISH	NNP	O
.	.	O

Pretreatment	NNP	O
plasma	NN	O
EBV	NNP	O
positivity	NN	O
was	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
treatment	NN	O
failure	NN	O
on	IN	O
multivariate	NN	O
analyses	NNS	O
.	.	O

At	IN	O
month	NN	O
6	CD	O
,	,	O
plasma	NN	O
EBV	NNP	O
(	(	O
+	NNP	O
)	)	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
7	CD	O
)	)	O
had	VBD	O
inferior	JJ	O
FFS	NNP	O
compared	VBN	O
with	IN	O
plasma	NN	O
EBV	NNP	O
(	(	O
-	:	O
)	)	O
patients	NNS	O
(	(	O
n	JJ	O
=	NNP	O
125	CD	O
)	)	O
,	,	O
log-rank	JJ	O
P	NNP	O
=	NNP	O
.007	NNP	O
.	.	O

These	DT	O
results	NNS	O
confirm	VBP	O
that	IN	O
plasma	JJ	O
EBV-DNA	NNP	O
is	VBZ	O
highly	RB	O
concordant	JJ	O
with	IN	O
EBER-ISH	NNP	O
in	IN	O
HL	NNP	O
and	CC	O
suggest	VBP	O
that	IN	O
it	PRP	O
may	MD	O
have	VB	O
prognostic	JJ	O
utility	NN	O
both	DT	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
therapy	NN	O
.	.	O

This	DT	O
trial	NN	O
was	VBD	O
registered	VBN	O
at	IN	O
www.clinicaltrials.gov	NN	O
as	IN	O
#	#	O
NCT00003389	NNP	O
.	.	O

Scintigraphic	JJ	O
evaluation	NN	O
of	IN	O
a	DT	O
new	JJ	Pharmacological
capsule-type	JJ	Pharmacological
colon	NN	Pharmacological
specific	JJ	Pharmacological
drug	NN	Pharmacological
delivery	NN	Pharmacological
system	NN	Pharmacological
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

Colonic	JJ	Physical
drug	NN	Physical
delivery	NN	Physical
is	VBZ	O
intended	VBN	O
for	IN	O
local	JJ	O
or	CC	O
systemic	JJ	O
therapies	NNS	O
.	.	O

The	DT	O
lack	NN	O
of	IN	O
predictive	NN	O
in	IN	O
vitro	NN	O
or	CC	O
animal	JJ	O
model	NN	O
leads	VBZ	O
to	TO	O
considerable	JJ	O
time	NN	O
delays	NNS	O
in	IN	O
colonic	JJ	O
product	NN	O
development	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
scintigraphic	JJ	O
study	NN	O
was	VBD	O
to	TO	O
provide	VB	O
proof	NN	O
of	IN	O
concept	NN	O
for	IN	O
a	DT	O
novel	JJ	Physical
capsule-type	JJ	Physical
colonic	NN	Physical
delivery	NN	Physical
system	NN	Physical
(	(	Physical
Colon-Targeted	JJ	Physical
Delivery	NNP	Physical
Capsule	NNP	Physical
)	)	Physical
in	IN	O
healthy	JJ	O
volunteers	NNS	O
.	.	O

The	DT	O
human	JJ	O
data	NN	O
validates	VBZ	O
the	DT	O
design	NN	O
concept	NN	O
behind	IN	O
the	DT	O
release	NN	O
mechanism	NN	O
,	,	O
in	IN	O
that	DT	O
capsule	NN	O
disintegration	NN	O
,	,	O
and	CC	O
hence	RB	O
drug	NN	O
release	NN	O
,	,	O
did	VBD	O
not	RB	O
start	VB	O
until	IN	O
5	CD	O
h	NNS	O
after	IN	O
gastric	JJ	O
emptying	NN	O
,	,	O
irrespective	NN	O
of	IN	O
whether	IN	O
the	DT	O
product	NN	O
was	VBD	O
administered	VBN	O
to	TO	O
fasted	VBN	O
or	CC	O
fed	VBN	O
subjects	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
potential	NN	O
for	IN	O
prolonged	JJ	O
gastric	JJ	O
residence	NN	O
for	IN	O
large	JJ	O
enteric	JJ	O
coated	VBN	O
products	NNS	O
intended	VBN	O
for	IN	O
intestinal	JJ	O
targeting	NN	O
was	VBD	O
also	RB	O
observed	VBN	O
;	:	O
overall	JJ	O
,	,	O
the	DT	O
study	NN	O
provides	VBZ	O
a	DT	O
focus	NN	O
for	IN	O
subsequent	JJ	O
product	NN	O
development	NN	O
and	CC	O
highlights	NNS	O
the	DT	O
role	NN	O
of	IN	O
scintigraphy	NN	O
in	IN	O
dynamically	RB	O
visualizing	VBG	O
the	DT	O
drug	NN	O
delivery	NN	O
process	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
work	NN	O
productivity	NN	O
and	CC	O
medical	JJ	O
resource	NN	O
utilization	NN	O
of	IN	O
peginterferon	NN	Pharmacological
alpha	NN	Pharmacological
2a	CD	Pharmacological
vs	IN	O
the	DT	O
combination	NN	O
of	IN	O
interferon	NN	Pharmacological
alpha	NN	Pharmacological
2b	CD	Pharmacological
plus	CC	Pharmacological
ribavirin	VB	Pharmacological
as	IN	O
initial	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C.	NNP	O
The	DT	O
on-treatment	JJ	O
impact	NN	O
of	IN	O
interferon-based	JJ	O
therapies	NNS	O
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
,	,	O
work	NN	O
productivity	NN	O
,	,	O
and	CC	O
medical	JJ	O
resource	NN	O
utilization	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
systematically	RB	O
studied	VBN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
peginterferon	NN	Pharmacological
alpha	NN	Pharmacological
(	(	Pharmacological
pegIFNalpha	NN	Pharmacological
)	)	Pharmacological
2a	CD	O
monotherapy	NN	Physical
and	CC	O
the	DT	O
combination	NN	Pharmacological
of	IN	Pharmacological
interferon	NN	Pharmacological
alpha	NN	Pharmacological
(	(	Pharmacological
IFNalpha	NNP	Pharmacological
)	)	Pharmacological
2b	CD	Pharmacological
plus	CC	Pharmacological
ribavirin	NN	Pharmacological
(	(	Pharmacological
RBV	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
health-related	JJ	O
QOL	NNP	O
,	,	O
work	NN	O
productivity	NN	O
and	CC	O
resource	NN	O
utilization	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
412	CD	O
patients	NNS	O
with	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
open-label	JJ	Pharmacological
treatment	NN	Pharmacological
with	IN	Pharmacological
either	DT	Pharmacological
pegIFNalpha	NN	Pharmacological
2a	CD	Pharmacological
(	(	Pharmacological
n	JJ	Pharmacological
=	NNP	Pharmacological
206	CD	Pharmacological
)	)	Pharmacological
or	CC	O
IFNalpha	$	Pharmacological
2b/RBV	CD	Pharmacological
(	(	Pharmacological
n	JJ	Pharmacological
=	NNP	Pharmacological
206	CD	Pharmacological
)	)	Pharmacological
.	.	O

PegIFNalpha	$	Pharmacological
2a	CD	Pharmacological
was	VBD	O
administered	VBN	O
subcutaneously	RB	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
180	CD	O
microg	NN	O
once	RB	O
weekly	JJ	O
for	IN	O
48	CD	O
weeks	NNS	O
;	:	O
and	CC	O
IFNalpha	$	Pharmacological
2b/RBV	CD	Pharmacological
at	IN	O
doses	NNS	O
of	IN	O
3	CD	O
MU	NNP	O
thrice	JJ	O
weekly	RB	O
subcutaneously	RB	O
and	CC	O
1000-1200	JJ	O
mg/day	NN	O
orally	RB	O
.	.	O

Outcome	NNP	O
measures	NNS	O
included	VBD	O
the	DT	O
SF-36	NNP	O
Health	NNP	O
Survey	NNP	O
Questionnaire	NNP	O
and	CC	O
additional	JJ	O
generic	NN	O
and	CC	O
specific	JJ	O
scales	NNS	O
.	.	O

During	IN	O
treatment	NN	O
,	,	O
for	IN	O
all	DT	O
SF-36	NNP	O
summary	NN	O
and	CC	O
Hepatitis	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
Questionnaire	NNP	O
(	(	O
HQLQ	NNP	O
)	)	O
-specific	NN	O
scales	NNS	O
,	,	O
the	DT	O
pegIFNalpha	NN	Pharmacological
2a	CD	Pharmacological
group	NN	O
experienced	VBD	O
less	JJR	O
impairment	JJ	O
than	IN	O
did	VBD	O
the	DT	O
IFNalpha	NNP	Pharmacological
2b/RBV	CD	Pharmacological
patients	NNS	O
.	.	O

The	DT	O
between-treatment	JJ	O
differences	NNS	O
were	VBD	O
significant	JJ	O
for	IN	O
many	JJ	O
of	IN	O
the	DT	O
scores	NNS	O
particularly	RB	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

Across	IN	O
all	DT	O
measures	NNS	O
of	IN	O
work	NN	O
functioning	NN	O
and	CC	O
productivity	NN	O
at	IN	O
each	DT	O
visit	NN	O
,	,	O
patients	NNS	O
randomized	VBD	O
to	TO	O
pegIFNalpha	VB	Pharmacological
2a	CD	Pharmacological
treatment	NN	O
showed	VBD	O
less	RBR	O
impairment	JJ	O
relative	NN	O
to	TO	O
the	DT	O
group	NN	O
treated	VBD	O
with	IN	O
IFNalpha	NNP	Pharmacological
2b/RBV	CD	Pharmacological
.	.	O

Hence	NNP	O
treatment	NN	O
with	IN	O
pegIFNalpha	JJ	Pharmacological
2a	CD	Pharmacological
relative	JJ	O
to	TO	O
IFNalpha	NNP	Pharmacological
2b/RBV	CD	Pharmacological
minimizes	VBZ	O
the	DT	O
adverse	JJ	O
impact	NN	O
of	IN	O
therapy	NN	O
on	IN	O
health-related	JJ	O
QOL	NNP	O
.	.	O

Patients	NNS	O
randomized	VBD	O
to	TO	O
pegIFNalpha	VB	Pharmacological
2a	CD	Pharmacological
had	VBD	O
improved	VBN	O
work	NN	O
productivity	NN	O
,	,	O
less	JJR	O
activity	NN	O
impairment	NN	O
,	,	O
decreased	VBD	O
need	NN	O
for	IN	O
prescription	NN	O
drugs	NNS	O
to	TO	O
treat	VB	O
adverse	JJ	O
effects	NNS	O
,	,	O
and	CC	O
better	JJR	O
adherence	NN	O
to	TO	O
therapy	NN	O
.	.	O

Enhancing	VBG	O
the	DT	O
working	VBG	O
memory	NN	O
of	IN	O
stroke	NN	O
patients	NNS	O
using	VBG	O
tDCS	NN	Physical
.	.	O

OBJECTIVES	IN	O
We	PRP	O
investigated	VBD	O
whether	IN	O
anodal	JJ	O
transcranial	JJ	Physical
direct	JJ	Physical
current	JJ	Physical
stimulation	NN	Physical
over	IN	O
the	DT	O
left	JJ	O
dorsolateral	JJ	O
prefrontal	JJ	O
cortex	NN	O
affected	VBD	O
the	DT	O
working	JJ	O
memory	NN	O
performance	NN	O
of	IN	O
patients	NNS	O
after	IN	O
a	DT	O
stroke	NN	O
.	.	O

DESIGN	NNP	O
Ten	CD	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
47.7	CD	O
yrs	NN	O
)	)	O
with	IN	O
cognitive	JJ	O
deficits	NNS	O
after	IN	O
a	DT	O
first-ever	JJ	O
stroke	NN	O
participated	VBD	O
in	IN	O
this	DT	O
single-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
and	CC	O
sham-controlled	JJ	Control
experiment	NN	O
.	.	O

Each	DT	O
patient	NN	O
was	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
undergo	VB	O
two	CD	O
transcranial	JJ	Physical
direct	JJ	Physical
current	JJ	Physical
stimulation	NN	Physical
sessions	NNS	O
:	:	O
anodal	JJ	O
dorsolateral	JJ	O
prefrontal	NN	O
cortex	NN	O
and	CC	O
sham	JJ	O
stimulation	NN	O
within	IN	O
48	CD	O
hrs	NN	O
of	IN	O
a	DT	O
washout	NN	O
period	NN	O
.	.	O

All	DT	O
participants	NNS	O
performed	VBD	O
a	DT	O
two-back	JJ	O
working	JJ	O
memory	NN	O
task	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
transcranial	JJ	O
direct	JJ	O
current	JJ	O
stimulation	NN	O
.	.	O

Accuracy	NNP	O
(	(	O
correction	NN	O
rate	NN	O
)	)	O
,	,	O
recognition	NN	O
accuracy	NN	O
(	(	O
correction	NN	O
rate-commission	NN	O
error	NN	O
rate	NN	O
)	)	O
,	,	O
and	CC	O
response	NN	O
time	NN	O
were	VBD	O
measured	VBN	O
during	IN	O
each	DT	O
experiment	NN	O
.	.	O

RESULTS	NNP	O
Repeated-measures	JJ	O
analysis	NN	O
of	IN	O
variance	NN	O
indicated	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
effect	NN	O
of	IN	O
transcranial	JJ	O
direct	JJ	O
current	JJ	O
stimulation	NN	O
type	NN	O
and	CC	O
time	NN	O
on	IN	O
the	DT	O
recognition	NN	O
accuracy	NN	O
.	.	O

Post	NNP	O
hoc	NN	O
analyses	NNS	O
revealed	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
prestimulation	NN	O
and	CC	O
poststimulation	NN	O
in	IN	O
the	DT	O
anodal	JJ	O
stimulation	NN	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
sham	JJ	O
stimulation	NN	O
group	NN	O
.	.	O

Regarding	VBG	O
the	DT	O
accuracy	NN	O
,	,	O
the	DT	O
paired	JJ	O
t	JJ	O
test	NN	O
indicated	VBD	O
significant	JJ	O
improvement	NN	O
only	RB	O
after	IN	O
anodal	JJ	O
transcranial	JJ	Physical
direct	JJ	Physical
current	JJ	Physical
stimulation	NN	Physical
without	IN	O
a	DT	O
significant	JJ	O
interaction	NN	O
effect	NN	O
between	IN	O
the	DT	O
two	CD	O
transcranial	JJ	O
direct	JJ	O
current	JJ	O
stimulation	NN	O
types	NNS	O
.	.	O

The	DT	O
response	NN	O
time	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
the	DT	O
anodal	NN	O
and	CC	O
sham	JJ	O
stimulation	NN	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
demonstrated	VBD	O
that	IN	O
anodal	JJ	O
transcranial	JJ	Physical
direct	JJ	Physical
current	JJ	Physical
stimulation	NN	Physical
over	IN	O
the	DT	O
left	JJ	O
dorsolateral	JJ	O
prefrontal	NN	O
cortex	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
enhanced	JJ	O
working	VBG	O
memory	NN	O
performance	NN	O
as	IN	O
indexed	VBN	O
by	IN	O
the	DT	O
recognition	NN	O
accuracy	NN	O
in	IN	O
patients	NNS	O
after	IN	O
a	DT	O
stroke	NN	O
.	.	O

Effects	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
thin-ideal	JJ	O
media	NNS	O
images	NNS	O
on	IN	O
body	NN	O
dissatisfaction	NN	O
:	:	O
testing	VBG	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	Educational
versus	NN	O
warning	VBG	Educational
label	NN	Educational
.	.	O

The	DT	O
current	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
disclaimer	NN	O
(	(	O
i.e.	FW	O
,	,	O
Retouched	NNP	O
photograph	NN	O
aimed	VBN	O
at	IN	O
changing	VBG	O
a	DT	O
person	NN	O
's	POS	O
physical	JJ	O
appearance	NN	O
.	.	O

)	)	O
or	CC	O
warning	VBG	O
(	(	O
i.e.	FW	O
,	,	O
Warning	VBG	O
:	:	O
Trying	NN	O
to	TO	O
look	VB	O
as	RB	O
thin	JJ	O
as	IN	O
this	DT	O
model	NN	O
may	MD	O
be	VB	O
dangerous	JJ	O
to	TO	O
your	PRP$	O
health	NN	O
.	.	O

)	)	O
added	VBD	O
to	TO	O
images	NNS	O
of	IN	O
thin/attractive	JJ	O
models	NNS	O
would	MD	O
affect	VB	O
body	NN	O
dissatisfaction	NN	O
and	CC	O
intent	NN	O
to	TO	O
diet	VB	O
in	IN	O
female	JJ	O
undergraduate	JJ	O
students	NNS	O
(	(	O
n=342	NN	O
)	)	O
.	.	O

Participants	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
groups	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
disclaimer	NN	Educational
,	,	O
(	(	O
b	NN	O
)	)	O
warning	NN	Educational
,	,	O
(	(	O
c	NN	O
)	)	O
model	NN	Control
control	NN	Control
,	,	O
or	CC	O
(	(	O
d	NN	O
)	)	O
car	NN	Control
control	NN	Control
.	.	O

Results	NNP	O
revealed	VBD	O
a	DT	O
significant	JJ	O
interaction	NN	O
between	IN	O
group	NN	O
and	CC	O
time	NN	O
,	,	O
whereby	WRB	O
only	RB	O
the	DT	O
car	NN	O
control	NN	O
group	NN	O
reported	VBD	O
a	DT	O
significant	JJ	O
change	NN	O
(	(	O
i.e.	FW	O
,	,	O
decrease	NN	O
)	)	O
in	IN	O
body	NN	O
dissatisfaction	NN	O
over	IN	O
time	NN	O
.	.	O

Groups	NNP	O
did	VBD	O
not	RB	O
differ	VB	O
on	IN	O
intent	NN	O
to	TO	O
diet	VB	O
measured	VBN	O
at	IN	O
post-exposure	NN	O
.	.	O

The	DT	O
results	NNS	O
largely	RB	O
replicate	VBP	O
other	JJ	O
findings	NNS	O
in	IN	O
this	DT	O
area	NN	O
and	CC	O
call	VB	O
into	IN	O
question	NN	O
advocacy	NN	O
efforts	NNS	O
to	TO	O
label	VB	O
media	NNS	O
images	NNS	O
as	IN	O
a	DT	O
strategy	NN	O
to	TO	O
decrease	VB	O
women	NNS	O
's	POS	O
identification	NN	O
with	IN	O
the	DT	O
stimuli	NNS	O
.	.	O

Custom	NNP	O
tray	JJ	O
application	NN	O
of	IN	O
peroxide	JJ	Pharmacological
gel	NN	Pharmacological
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
scaling	NN	Surgical
and	CC	Physical
root	NN	Surgical
planing	NN	Surgical
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
periodontitis	NN	O
:	:	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
after	IN	O
six	CD	O
months	NNS	O
.	.	O

OBJECTIVE	NNP	O
Scaling	NNP	Surgical
and	CC	Surgical
root	NN	Surgical
planing	NN	Surgical
(	(	Surgical
SRP	NNP	Surgical
)	)	Surgical
is	VBZ	O
the	DT	O
primary	JJ	O
non-surgical	JJ	O
treatment	NN	O
for	IN	O
periodontitis	NN	O
,	,	O
but	CC	O
its	PRP$	O
effectiveness	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

Consequently	RB	O
,	,	O
various	JJ	O
adjunctive	JJ	O
therapies	NNS	O
have	VBP	O
been	VBN	O
investigated	VBN	O
to	TO	O
improve	VB	O
clinical	JJ	O
outcome	NN	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
clinical	JJ	O
effects	NNS	O
of	IN	O
one	CD	O
SRP	NNP	Surgical
procedure	NN	O
alone	RB	O
or	CC	O
combined	VBN	O
with	IN	O
local	JJ	O
administration	NN	O
of	IN	O
hydrogen	NN	Pharmacological
peroxide	NN	Pharmacological
gel	NN	Pharmacological
using	VBG	O
customized	JJ	O
trays	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
periodontitis	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
six	CD	O
months	NNS	O
.	.	O

METHODS	NNP	O
An	DT	O
examiner-blind	JJ	O
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
among	IN	O
30	CD	O
subjects	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
advanced	JJ	O
periodontitis	NN	O
who	WP	O
were	VBD	O
randomized	VBN	O
to	TO	O
SRP	VB	Surgical
alone	RB	O
or	CC	O
SRP	NNP	Surgical
combined	VBN	Physical
with	IN	O
prescription	NN	O
custom-tray	JJ	O
application	NN	O
(	(	O
Perio	NNP	O
Tray	NNP	O
)	)	O
of	IN	O
1.7	CD	Pharmacological
%	NN	Pharmacological
hydrogen	NN	Pharmacological
peroxide	NN	Pharmacological
gel	NN	Pharmacological
(	(	Pharmacological
Perio	NNP	Pharmacological
Gel	NNP	Pharmacological
)	)	Pharmacological
for	IN	O
a	DT	O
period	NN	O
of	IN	O
three	CD	O
months	NNS	O
,	,	O
then	RB	O
extended	VBD	O
to	TO	O
six	CD	O
months	NNS	O
.	.	O

Following	VBG	O
impressions	NNS	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
,	,	O
all	DT	O
subjects	NNS	O
brushed	VBN	Physical
twice	RB	Physical
daily	RB	Physical
with	IN	Physical
a	DT	Physical
regular	JJ	Physical
dentifrice	NN	Physical
and	CC	Physical
toothbrush	NN	Physical
for	IN	O
a	DT	O
four-week	JJ	O
acclimation	NN	O
phase	NN	O
to	TO	O
standardize	VB	O
oral	JJ	O
conditions	NNS	O
(	(	O
while	IN	O
trays	NNS	O
were	VBD	O
fabricated	VBN	O
)	)	O
prior	RB	O
to	TO	O
initiating	VBG	O
the	DT	O
treatment	NN	O
phase	NN	O
.	.	O

SRP	NNP	Surgical
was	VBD	O
performed	VBN	O
three	CD	O
weeks	NNS	O
after	IN	O
baseline	NN	O
,	,	O
and	CC	O
clinical	JJ	O
assessments	NNS	O
,	,	O
i.e.	FW	O
,	,	O
pocket	NN	O
probing	VBG	O
depth	NN	O
(	(	O
PPD	NNP	O
)	)	O
and	CC	O
bleeding	VBG	O
index	NN	O
(	(	O
BI	NNP	O
)	)	O
,	,	O
were	VBD	O
conducted	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
two	CD	O
,	,	O
five	CD	O
,	,	O
13	CD	O
,	,	O
and	CC	O
26	CD	O
weeks	NNS	O
of	IN	O
peroxide	JJ	Pharmacological
gel	NN	Pharmacological
applications	NNS	O
.	.	O

Clinical	JJ	O
variables	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
ANCOVA	NNP	O
and	CC	O
paired	VBD	O
t-tests	NNS	O
after	IN	O
each	DT	O
treatment	NN	O
interval	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
13	CD	O
test	NN	O
and	CC	O
15	CD	O
control	NN	O
subjects	NNS	O
completed	VBD	O
the	DT	O
original	JJ	O
three-month	JJ	O
trial	NN	O
,	,	O
of	IN	O
whom	WP	O
10	CD	O
test	NN	O
and	CC	O
13	CD	O
control	NN	O
subjects	NNS	O
finished	VBD	O
the	DT	O
three-month	JJ	O
extension	NN	O
.	.	O

After	IN	O
two	CD	O
weeks	NNS	O
of	IN	O
peroxide	NN	Pharmacological
gel	NN	Pharmacological
use	NN	O
prior	RB	O
to	TO	O
SRP	NNP	Surgical
,	,	O
mean	JJ	O
PPD	NNP	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
significantly	RB	O
decreased	VBN	O
from	IN	O
baseline	NN	O
by	IN	O
0.21	CD	O
mm	NNS	O
and	CC	O
mean	JJ	O
BI	NNP	O
significantly	RB	O
dropped	VBD	O
by	IN	O
0.14	CD	O
;	:	O
clinical	JJ	O
parameters	NNS	O
for	IN	O
the	DT	O
control	NN	O
group	NN	O
were	VBD	O
unchanged	JJ	O
.	.	O

Two	CD	O
weeks	NNS	O
following	VBG	O
SRP	NNP	Surgical
,	,	O
mean	JJ	O
PPD	NNP	O
significantly	RB	O
decreased	VBD	O
from	IN	O
baseline	NN	O
by	IN	O
0.65	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.17	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
;	:	O
mean	CC	O
BI	NNP	O
significantly	RB	O
dropped	VBD	O
by	IN	O
0.17	CD	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.05	CD	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

Ten	CD	O
weeks	NNS	O
following	VBG	O
SRP	NNP	Surgical
,	,	O
mean	JJ	O
PPD	NNP	O
decreases	NNS	O
were	VBD	O
0.77	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.13	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
,	,	O
and	CC	O
mean	JJ	O
BI	NNP	O
reductions	NNS	O
were	VBD	O
0.14	CD	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.00	CD	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

For	IN	O
subjects	NNS	O
who	WP	O
completed	VBD	O
the	DT	O
three-month	JJ	O
extension	NN	O
(	(	O
i.e.	JJ	O
,	,	O
23	CD	O
weeks	NNS	O
post-SRP	NN	O
)	)	O
,	,	O
mean	JJ	O
PPD	NNP	O
decreases	NNS	O
were	VBD	O
0.72	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.13	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
,	,	O
and	CC	O
mean	JJ	O
BI	NNP	O
reductions	NNS	O
were	VBD	O
0.05	CD	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.01	CD	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

Analysis	NN	O
of	IN	O
deeper	JJR	O
pockets	NNS	O
(	(	O
i.e.	NN	O
,	,	O
>	VBZ	O
5	CD	O
mm	NN	O
at	IN	O
baseline	NN	O
)	)	O
showed	VBD	O
the	DT	O
same	JJ	O
relationship	NN	O
for	IN	O
PPD	NNP	O
,	,	O
but	CC	O
with	IN	O
larger	JJR	O
differences	NNS	O
between	IN	O
groups	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
after	IN	O
two	CD	O
weeks	NNS	O
of	IN	O
peroxide	NN	Pharmacological
gel	NN	Pharmacological
use	NN	O
prior	RB	O
to	TO	O
SRP	NNP	Surgical
,	,	O
mean	JJ	O
PPD	NNP	O
decreased	VBN	O
by	IN	O
0.48	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
compared	VBN	O
to	TO	O
0.04	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

Two	CD	O
weeks	NNS	O
after	IN	O
SRP	NNP	Surgical
,	,	O
mean	JJ	O
PPD	NNP	O
decreased	VBD	O
from	IN	O
baseline	NN	O
by	IN	O
1.40	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.60	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
,	,	O
and	CC	O
10	CD	O
weeks	NNS	O
after	IN	O
SRP	NNP	O
by	IN	O
1.57	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.58	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

After	IN	O
the	DT	O
extension	NN	O
(	(	O
i.e.	JJ	O
,	,	O
23	CD	O
weeks	NNS	O
post-SRP	NN	O
)	)	O
,	,	O
mean	JJ	O
PPD	NNP	O
changed	VBD	O
from	IN	O
baseline	NN	O
by	IN	O
1.50	CD	O
mm	NN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
and	CC	O
0.55	CD	O
mm	NN	O
for	IN	O
the	DT	O
control	NN	O
.	.	O

With	IN	O
the	DT	O
exception	NN	O
of	IN	O
BI	NNP	O
at	IN	O
23	CD	O
weeks	NNS	O
post-SRP	JJ	O
,	,	O
all	DT	O
reductions	NNS	O
cited	VBN	O
above	IN	O
for	IN	O
the	DT	O
test	NN	O
group	NN	O
were	VBD	O
statistically	RB	O
significantly	RB	O
different	JJ	O
from	IN	O
the	DT	O
control	NN	O
group	NN	O
for	IN	O
both	DT	O
PPD	NNP	O
and	CC	O
BI	NNP	O
for	IN	O
all	DT	O
comparisons	NNS	O
.	.	O

CONCLUSION	NN	O
When	WRB	O
compared	VBN	O
with	IN	O
SRP	NNP	Surgical
alone	RB	O
,	,	O
clinical	JJ	O
improvements	NNS	O
in	IN	O
PPD	NNP	O
(	(	O
e.g.	NN	O
,	,	O
-1.0	NNP	O
mm	NN	O
for	IN	O
pockets	NNS	O
>	VBP	O
5	CD	O
mm	NN	O
at	IN	O
baseline	NN	O
)	)	O
were	VBD	O
maintained	VBN	O
for	IN	O
up	IN	O
to	TO	O
six	CD	O
months	NNS	O
after	IN	O
SRP	NNP	Surgical
with	IN	O
adjunctive	JJ	O
use	NN	O
of	IN	O
1.7	CD	O
%	NN	O
hydrogen	NN	Pharmacological
peroxide	NN	Pharmacological
gel	NN	Pharmacological
,	,	O
locally	RB	O
administered	VBN	O
using	VBG	O
prescription	NN	O
customized	VBD	O
trays	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
subjects	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
advanced	JJ	O
periodontitis	NN	O
.	.	O

Usefulness	NN	O
of	IN	O
temporal	JJ	O
changes	NNS	O
in	IN	O
neurohormones	NNS	O
as	IN	O
markers	NNS	O
of	IN	O
ventricular	JJ	O
remodeling	NN	O
and	CC	O
prognosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
left	JJ	O
ventricular	JJ	O
systolic	JJ	O
dysfunction	NN	O
and	CC	O
heart	NN	O
failure	NN	O
receiving	VBG	O
either	CC	O
candesartan	NN	Pharmacological
or	CC	O
enalapril	NN	Pharmacological
or	CC	O
both	DT	O
.	.	O

Although	IN	O
various	JJ	O
neurohormones	NNS	O
at	IN	O
initial	JJ	O
measurement	NN	O
confer	NN	O
prognostic	JJ	O
value	NN	O
in	IN	O
heart	NN	O
failure	NN	O
and	CC	O
correlate	NN	O
with	IN	O
the	DT	O
left	NN	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
(	(	O
EF	NNP	O
)	)	O
and	CC	O
cardiac	JJ	O
volumes	NNS	O
,	,	O
the	DT	O
significance	NN	O
of	IN	O
their	PRP$	O
temporal	JJ	O
changes	NNS	O
(	(	O
Delta	NNP	O
)	)	O
remains	VBZ	O
undetermined	JJ	O
.	.	O

This	DT	O
study	NN	O
examined	VBD	O
temporal	JJ	O
changes	NNS	O
in	IN	O
neurohormones	NNS	O
related	VBN	O
to	TO	O
cardiac	VB	O
remodeling	NN	O
and	CC	O
prognosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
systolic	JJ	O
dysfunction	NN	O
and	CC	O
heart	NN	O
failure	NN	O
receiving	VBG	O
therapeutic	JJ	O
inhibition	NN	O
of	IN	O
the	DT	O
renin-angiotensin-aldosterone	NN	O
system	NN	O
.	.	O

Temporal	JJ	O
changes	NNS	O
in	IN	O
plasma	NN	O
renin	NN	O
,	,	O
angiotensin-II	JJ	O
,	,	O
aldosterone	NN	O
,	,	O
epinephrine	NN	O
,	,	O
norepinephrine	JJ	O
,	,	O
B-type	JJ	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
BNP	NNP	O
)	)	O
,	,	O
and	CC	O
N-terminal	JJ	O
atrial	JJ	O
natriuretic	JJ	O
peptide	NN	O
(	(	O
NT-ANP	NNP	O
)	)	O
in	IN	O
768	CD	O
treated	JJ	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
measured	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
17	CD	O
and	CC	O
43	CD	O
weeks	NNS	O
after	IN	O
randomization	NN	O
were	VBD	O
examined	VBN	O
for	IN	O
their	PRP$	O
relations	NNS	O
with	IN	O
concurrent	NN	O
changes	NNS	O
in	IN	O
the	DT	O
EF	NNP	O
,	,	O
cardiac	JJ	O
volumes	NNS	O
,	,	O
and	CC	O
risk	NN	O
for	IN	O
subsequent	JJ	O
adverse	JJ	O
clinical	JJ	O
outcomes	NNS	O
.	.	O

Increasing	VBG	O
BNP	NNP	O
(	(	O
p	JJ	O
<	NNP	O
0.0001	CD	O
)	)	O
and	CC	O
NT-ANP	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.01	CD	O
)	)	O
over	IN	O
time	NN	O
were	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
concurrent	NN	O
decreasing	VBG	O
EF	NNP	O
,	,	O
increasing	VBG	O
end-diastolic	JJ	O
volume	NN	O
(	(	O
EDV	NNP	O
)	)	O
,	,	O
and	CC	O
increasing	VBG	O
end-systolic	JJ	O
volume	NN	O
(	(	O
ESV	NNP	O
;	:	O
all	DT	O
p	VBP	O
<	$	O
0.0001	CD	O
)	)	O
.	.	O

In	IN	O
multivariable	JJ	O
analysis	NN	O
,	,	O
DeltaBNP	NNP	O
and	CC	O
DeltaNT-ANP	NNP	O
were	VBD	O
independent	JJ	O
predictors	NNS	O
of	IN	O
DeltaESV	NNP	O
and	CC	O
DeltaEDV	NNP	O
,	,	O
whereas	JJ	O
DeltaBNP	NNP	O
also	RB	O
predicted	VBD	O
DeltaEF	NNP	O
(	(	O
all	DT	O
p	VBP	O
<	$	O
0.0001	CD	O
)	)	O
.	.	O

Patients	NNS	O
who	WP	O
died	VBD	O
or	CC	O
experienced	JJ	O
heart	NN	O
failure	NN	O
hospitalization	NN	O
had	VBD	O
larger	JJR	O
antecedent	NN	O
increases	NNS	O
in	IN	O
NT-ANP	NNP	O
(	(	O
+293.7	NNP	O
vs	RB	O
-21.5	NNP	O
pmol/ml	NN	O
,	,	O
p	NN	O
=	NNP	O
0.006	CD	O
)	)	O
and	CC	O
lesser	JJR	O
decreases	NNS	O
in	IN	O
norepinephrine	NN	O
(	(	O
-22.3	JJ	O
vs	NN	O
-48.5	NNP	O
pg/ml	NN	O
,	,	O
p	NN	O
=	NNP	O
0.04	CD	O
)	)	O
.	.	O

Increasing	VBG	O
NT-ANP	NNP	O
(	(	O
hazard	JJ	O
ratio	NN	O
[	NNP	O
HR	NNP	O
]	NNP	O
3.45	CD	O
,	,	O
p	NN	O
=	NNP	O
0.009	CD	O
)	)	O
and	CC	O
norepinephrine	JJ	O
(	(	O
HR	NNP	O
2.04	CD	O
,	,	O
p	NN	O
=	NNP	O
0.02	CD	O
)	)	O
over	IN	O
time	NN	O
independently	RB	O
predicted	VBD	O
increased	VBN	O
risk	NN	O
for	IN	O
subsequent	JJ	O
death	NN	O
or	CC	O
heart	NN	O
failure	NN	O
hospitalization	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
in	IN	O
treated	JJ	O
patients	NNS	O
with	IN	O
heart	NN	O
failure	NN	O
,	,	O
increasing	VBG	O
NT-ANP	NNP	O
and	CC	O
BNP	NNP	O
over	IN	O
time	NN	O
predict	VBP	O
a	DT	O
decreasing	NN	O
EF	NNP	O
and	CC	O
ventricular	JJ	O
dilatation	NN	O
,	,	O
while	IN	O
increasing	VBG	O
NT-ANP	NNP	O
and	CC	O
norepinephrine	VB	O
independently	RB	O
predict	VBP	O
greater	JJR	O
mortality	NN	O
and	CC	O
morbidity	NN	O
.	.	O

Serial	JJ	O
measurements	NNS	O
of	IN	O
these	DT	O
neurohormones	NNS	O
may	MD	O
serve	VB	O
as	IN	O
useful	JJ	O
surrogate	JJ	O
markers	NNS	O
of	IN	O
ventricular	JJ	O
remodeling	NN	O
and	CC	O
prognosticators	NNS	O
for	IN	O
clinical	JJ	O
risk	NN	O
stratification	NN	O
.	.	O

Randomized	VBN	O
controlled	VBD	O
study	NN	O
of	IN	O
customized	JJ	O
preventive	JJ	O
medicine	NN	O
reminder	NN	O
letters	NNS	O
in	IN	O
a	DT	O
community	NN	O
practice	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
customized	JJ	O
,	,	O
family-oriented	JJ	O
reminder	NN	O
letters	NNS	O
in	IN	O
activating	VBG	O
patients	NNS	O
to	TO	O
seek	VB	O
appropriate	JJ	O
preventive	JJ	O
services	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
clinical	JJ	O
trial	NN	O
.	.	O

One	CD	Educational
group	NN	Educational
received	VBD	Educational
computer-generated	JJ	Educational
,	,	Educational
customized	JJ	Educational
letters	NNS	Educational
explaining	VBG	Educational
recommended	VBD	Educational
preventive	JJ	Educational
procedures	NNS	Educational
for	IN	Educational
each	DT	Educational
family	NN	Educational
member	NN	Educational
.	.	Educational

A	DT	Other
second	JJ	Other
group	NN	Other
received	VBD	Other
a	DT	Other
form	JJ	Other
letter	NN	Other
listing	NN	Other
recommendations	NNS	Other
for	IN	Other
all	DT	Other
preventive	JJ	Other
procedures	NNS	Other
for	IN	Other
all	DT	Other
age	NN	Other
and	CC	Other
sex	NN	Other
groups	NNS	Other
.	.	Educational

A	DT	Control
third	JJ	Control
group	NN	Control
(	(	Control
control	VB	Control
group	NN	Control
)	)	Control
received	VBD	Control
no	DT	Control
letters	NNS	Control
.	.	Control

SETTING	VBG	O
A	DT	O
private	JJ	O
medical	JJ	O
centre	NN	O
,	,	O
without	IN	O
university	NN	O
affiliation	NN	O
,	,	O
in	IN	O
rural	JJ	O
Quebec	NNP	O
.	.	O

PARTICIPANTS	NN	O
From	IN	O
8770	CD	O
patients	NNS	O
who	WP	O
met	VBD	O
study	NN	O
criteria	NNS	O
,	,	O
719	CD	O
families	NNS	O
were	VBD	O
randomly	RB	O
selected	VBN	O
.	.	O

Data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
1971	CD	O
of	IN	O
1998	CD	O
patients	NNS	O
in	IN	O
these	DT	O
families	NNS	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
Family	NNP	O
Received	NNP	O
Index	NNP	O
is	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
all	DT	O
procedures	NNS	O
for	IN	O
which	WDT	O
a	DT	O
family	NN	O
was	VBD	O
overdue	JJ	O
that	IN	O
they	PRP	O
received	VBD	O
.	.	O

The	DT	O
Family	JJ	O
End-of-study	NNP	O
Up-to-date	NNP	O
Index	NNP	O
is	VBZ	O
the	DT	O
proportion	NN	O
of	IN	O
procedures	NNS	O
for	IN	O
which	WDT	O
the	DT	O
family	NN	O
was	VBD	O
eligible	JJ	O
and	CC	O
for	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
up-to-date	JJ	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
Family	NNP	O
Received	NNP	O
Index	NNP	O
for	IN	O
families	NNS	O
mailed	VBN	O
customized	JJ	Educational
letters	NNS	Educational
was	VBD	O
more	RBR	O
than	IN	O
double	RB	O
the	DT	O
index	NN	O
for	IN	O
patients	NNS	O
not	RB	O
mailed	VBN	O
letters	NNS	O
(	(	O
Kruskal-Wallis	NNP	O
P	NNP	O
=	NNP	O
.0139	NNP	O
)	)	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
Family	NNP	O
End-of-study	NNP	O
Up-to-date	NNP	O
indices	NNS	O
also	RB	O
demonstrated	VBD	O
that	IN	O
families	NNS	O
of	IN	O
patients	NNS	O
sent	JJ	O
customized	JJ	Educational
letters	NNS	Educational
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
up-to-date	JJ	O
than	IN	O
families	NNS	O
not	RB	O
sent	VBD	O
letters	NNS	O
(	(	O
Kruskal-Wallis	NNP	O
P	NNP	O
=	NNP	O
.0054	NNP	O
)	)	O
.	.	O

No	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
appeared	VBD	O
between	IN	O
the	DT	O
number	NN	O
of	IN	O
preventive	JJ	O
measures	NNS	O
received	VBN	O
by	IN	O
the	DT	O
control	NN	Control
group	NN	O
and	CC	O
the	DT	O
form-letter	JJ	Other
group	NN	O
.	.	O

CONCLUSIONS	NNP	O
This	DT	O
study	NN	O
demonstrates	VBZ	O
a	DT	O
clinically	RB	O
small	JJ	O
but	CC	O
statistically	RB	O
significant	JJ	O
value	NN	O
to	TO	O
customizing	VBG	Educational
reminder	NN	Educational
letters	NNS	Educational
.	.	Educational

[	JJ	O
Prophylactic	NNP	Physical
intraaortic	JJ	Physical
balloon	NN	Physical
pumping	VBG	Physical
in	IN	O
high-risk	JJ	O
cardiac	JJ	O
surgery	NN	O
patients	NNS	O
]	VBP	O
.	.	O

BACKGROUND	NNP	O
We	PRP	O
examined	VBD	O
the	DT	O
impact	NN	O
of	IN	O
prophylactic	JJ	Physical
IABP	NNP	Physical
insertion	NN	Physical
in	IN	O
EuroSCORE-stratified	JJ	O
high-risk	JJ	O
cardiac	NN	O
surgery	NN	O
patients	NNS	O
with	IN	O
a	DT	O
score	NN	O
?8	NN	O
.	.	O

MATERIAL	NNP	O
AND	NNP	O
METHODS	NNP	O
A	NNP	O
randomized	JJ	O
trial	NN	O
with	IN	O
104	CD	O
patients	NNS	O
either	CC	O
without	IN	O
prophylactic	JJ	O
IABP	NNP	O
insertion	NN	O
(	(	O
group	NN	O
A	NNP	O
,	,	O
n=52	NN	O
)	)	O
or	CC	O
with	IN	O
IABP	NNP	O
(	(	O
group	NN	O
B	NNP	O
,	,	O
n=52	NN	O
)	)	O
was	VBD	O
conducted	VBN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
30-day	JJ	O
mortality	NN	O
.	.	O

RESULTS	VB	O
The	DT	O
median	JJ	O
age	NN	O
of	IN	O
the	DT	O
patients	NNS	O
was	VBD	O
74	CD	O
years	NNS	O
and	CC	O
43	CD	O
%	NN	O
of	IN	O
participants	NNS	O
were	VBD	O
females	NNS	O
.	.	O

The	DT	O
30-day	JJ	O
mortality	NN	O
did	VBD	O
not	RB	O
differ	VB	O
between	IN	O
group	NN	O
A	NNP	O
(	(	O
17.3	CD	O
%	NN	O
)	)	O
and	CC	O
group	NN	O
B	NNP	O
(	(	O
13.4	CD	O
%	NN	O
;	:	O
p=0.78	NN	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
hospital	NN	O
stay	NN	O
was	VBD	O
14	CD	O
days	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Intra-	NNP	O
and	CC	O
postoperative	JJ	O
IABP	NNP	O
support	NN	O
was	VBD	O
required	VBN	O
by	IN	O
13	CD	O
patients	NNS	O
(	(	O
21	CD	O
%	NN	O
)	)	O
in	IN	O
group	NN	O
A	NNP	O
.	.	O

The	DT	O
median	JJ	O
ventilation	NN	O
time	NN	O
(	(	O
14	CD	O
hours	NNS	O
versus	VBD	O
13	CD	O
hours	NNS	O
)	)	O
,	,	O
median	JJ	O
catecholamine	NN	O
dose	NN	O
,	,	O
frequency	NN	O
of	IN	O
dialysis-dependent	JJ	O
acute	JJ	O
renal	JJ	O
failure	NN	O
(	(	O
28	CD	O
%	NN	O
versus	IN	O
18	CD	O
%	NN	O
)	)	O
,	,	O
cardiac	JJ	O
indices	NNS	O
,	,	O
and	CC	O
frequency	NN	O
of	IN	O
a	DT	O
low	JJ	O
cardiac	JJ	O
output	NN	O
syndrome	NN	O
(	(	O
26	CD	O
%	NN	O
versus	IN	O
25	CD	O
%	NN	O
)	)	O
did	VBD	O
not	RB	O
significantly	RB	O
differ	VBP	O
between	IN	O
groups	NNS	O
.	.	O

CONCLUSION	NNP	O
Prophylactic	NNP	O
preoperative	JJ	O
IABP	NNP	O
insertion	NN	O
in	IN	O
EuroSCORE-stratified	JJ	O
high-risk	JJ	O
patients	NNS	O
is	VBZ	O
not	RB	O
associated	VBN	O
with	IN	O
decreased	JJ	O
30-day	JJ	O
mortality	NN	O
.	.	O

A	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
of	IN	O
nerve	NN	O
monitoring	NN	O
of	IN	O
the	DT	O
external	JJ	O
branch	NN	O
of	IN	O
the	DT	O
superior	JJ	O
laryngeal	NN	O
nerve	NN	O
during	IN	O
thyroidectomy	NN	Physical
under	IN	O
local/regional	JJ	Pharmacological
anesthesia	NN	Pharmacological
and	CC	Pharmacological
IV	NNP	Pharmacological
sedation	NN	Pharmacological
.	.	O

BACKGROUND	IN	O
The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
the	DT	O
neuromonitoring	NN	O
of	IN	O
the	DT	O
external	JJ	O
branch	NN	O
of	IN	O
the	DT	O
superior	JJ	O
laryngeal	NN	O
nerve	NN	O
(	(	O
EBSLN	NNP	O
)	)	O
on	IN	O
the	DT	O
voice	NN	O
quality	NN	O
after	IN	O
mini-incision	NN	Physical
thyroidectomy	NN	Physical
under	IN	O
local/regional	JJ	Pharmacological
anesthesia	NN	Pharmacological
and	CC	Pharmacological
intravenous	JJ	Pharmacological
sedation	NN	Pharmacological
.	.	O

METHODS	NNP	O
Patients	NNPS	O
undergoing	VBG	O
mini-incision	JJ	Surgical
thyroidectomy	NN	Surgical
under	IN	Surgical
local	JJ	Surgical
anesthesia	NN	Surgical
were	VBD	O
prospectively	RB	O
randomized	VBN	O
for	IN	O
either	DT	O
nerve	JJ	Physical
monitoring	NN	Physical
of	IN	Physical
the	DT	Physical
EBSLN	NNP	Physical
(	(	O
group	NN	O
1	CD	O
)	)	O
or	CC	Physical
no	DT	Physical
nerve	NN	Physical
monitoring	NN	Physical
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

Voice	NNP	O
and	CC	O
swallowing	VBG	O
assessment	NN	O
were	VBD	O
obtained	VBN	O
by	IN	O
using	VBG	O
the	DT	O
Voice	NNP	O
Handicap	NNP	O
Index-10	NNP	O
(	(	O
VHI-10	NNP	O
)	)	O
and	CC	O
the	DT	O
Reflux	NNP	O
Symptom	NNP	O
Index	NNP	O
questionnaires	NNS	O
(	(	O
RSI	NNP	O
)	)	O
before	IN	O
surgery	NN	O
and	CC	O
at	IN	O
3	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

RESULTS	NNP	O
Recruitment	NNP	O
led	VBD	O
to	TO	O
22	CD	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
and	CC	O
25	CD	O
patients	NNS	O
in	IN	O
group	NN	O
2	CD	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
visualized	JJ	O
EBSLN	NNP	O
was	VBD	O
higher	RBR	O
in	IN	O
group	NN	O
1	CD	O
(	(	O
66	CD	O
%	NN	O
vs	JJ	O
21	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
.003	NNP	O
)	)	O
.	.	O

Contrary	JJ	O
to	TO	O
group	NN	O
1	CD	O
,	,	O
in	IN	O
group	NN	O
2	CD	O
,	,	O
the	DT	O
median	JJ	O
total	JJ	O
VHI-10	NNP	O
score	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
(	(	O
P	NNP	O
=	NNP	O
.034	NNP	O
)	)	O
compared	VBN	O
with	IN	O
preoperatively	RB	O
,	,	O
indicating	VBG	O
a	DT	O
subjective	JJ	O
voice	NN	O
handicap	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
median	JJ	O
total	NN	O
RSI	NNP	O
score	NN	O
before	IN	O
surgery	NN	O
or	CC	O
at	IN	O
3	CD	O
weeks	NNS	O
and	CC	O
3	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
.	.	O

CONCLUSION	NNP	O
Nerve	NNP	O
monitoring	NN	O
aids	NNS	O
in	IN	O
the	DT	O
visualization	NN	O
of	IN	O
the	DT	O
EBSLN	NNP	O
during	IN	O
mini-incision	JJ	Surgical
thyroidectomy	NN	Surgical
under	IN	O
local/regional	JJ	Pharmacological
anesthesia	NN	Pharmacological
and	CC	O
leads	VBZ	O
to	TO	O
an	DT	O
improvement	NN	O
in	IN	O
patient-assessed	JJ	O
voice	NN	O
quality	NN	O
after	IN	O
surgery	NN	O
but	CC	O
does	VBZ	O
not	RB	O
impact	VB	O
swallowing	VBG	O
.	.	O

Peritonsillar	JJ	O
infiltration	NN	O
with	IN	O
bupivacaine	NN	Pharmacological
for	IN	O
paediatric	JJ	O
tonsillectomy	NN	O
.	.	O

In	IN	O
a	DT	O
double-blind	JJ	O
study	NN	O
forty-two	JJ	O
children	NNS	O
scheduled	VBN	O
for	IN	O
elective	JJ	O
adenotonsillectomy	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
peritonsillar	JJ	O
infiltration	NN	Pharmacological
,	,	O
following	VBG	O
induction	NN	O
of	IN	O
anaesthesia	NN	O
,	,	O
with	IN	O
either	DT	O
0.25	CD	Pharmacological
%	NN	Pharmacological
plain	NN	Pharmacological
bupivacaine	NN	Pharmacological
or	CC	Pharmacological
0.9	CD	Pharmacological
%	NN	Pharmacological
saline	NN	Pharmacological
,	,	O
0.5	CD	O
ml/kg	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
10	CD	O
ml	NN	O
.	.	O

The	DT	O
children	NNS	O
were	VBD	O
assessed	VBN	O
on	IN	O
awakening	NN	O
,	,	O
and	CC	O
then	RB	O
10	CD	O
minutes	NNS	O
,	,	O
1	CD	O
hour	NN	O
,	,	O
4	CD	O
hours	NNS	O
and	CC	O
24	CD	O
hours	NNS	O
later	RB	O
.	.	O

On	IN	O
each	DT	O
occasion	NN	O
the	DT	O
observer	NN	O
gave	VBD	O
the	DT	O
child	NN	O
a	DT	O
pain	NN	O
score	NN	O
from	IN	O
1	CD	O
(	(	O
no	DT	O
pain	NN	O
)	)	O
to	TO	O
5	CD	O
(	(	O
severe	JJ	O
pain	NN	O
)	)	O
.	.	O

The	DT	O
scores	NNS	O
on	IN	O
awakening	VBG	O
and	CC	O
after	IN	O
10	CD	O
minutes	NNS	O
were	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
bupivacaine	NN	Pharmacological
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
,	,	O
Mann-Whitney	NNP	O
U	NNP	O
test	NN	O
)	)	O
.	.	O

Thereafter	RB	O
there	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

The	DT	O
authors	NNS	O
conclude	VBP	O
that	IN	O
peritonsillar	JJ	O
infiltration	NN	O
with	IN	O
bupivacaine	NN	Pharmacological
is	VBZ	O
only	RB	O
moderately	RB	O
useful	JJ	O
as	IN	O
analgesia	NN	O
for	IN	O
children	NNS	O
having	VBG	O
tonsillectomy	NN	O
.	.	O

A	DT	O
role	NN	O
for	IN	O
error	NN	Educational
training	NN	Educational
in	IN	O
surgical	JJ	Surgical
technical	JJ	Surgical
skill	NN	Surgical
instruction	NN	Surgical
and	CC	Surgical
evaluation	NN	Surgical
.	.	Surgical

BACKGROUND	NNP	O
During	IN	O
the	DT	O
evaluation	NN	O
of	IN	O
many	JJ	O
instances	NNS	O
of	IN	O
the	DT	O
same	JJ	O
basic	JJ	O
surgical	NN	O
skill	NN	O
,	,	O
we	PRP	O
observed	VBD	O
that	IN	O
there	EX	O
were	VBD	O
several	JJ	O
errors	NNS	O
that	WDT	O
occurred	VBD	O
frequently	RB	O
.	.	O

Two	CD	O
studies	NNS	O
were	VBD	O
undertaken	VBN	O
to	TO	O
examine	VB	O
the	DT	O
use	NN	O
of	IN	O
these	DT	O
errors	NNS	O
for	IN	O
improving	VBG	O
the	DT	O
instruction	NN	O
and	CC	O
evaluation	NN	O
of	IN	O
the	DT	O
skill	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
For	IN	O
both	DT	O
studies	NNS	O
,	,	O
two	CD	Educational
types	NNS	Educational
of	IN	Educational
rater	NN	Educational
training	NN	Educational
videotapes	NNS	Educational
were	VBD	O
developed	VBN	O
.	.	O

One	CD	O
involved	VBD	O
the	DT	O
use	NN	O
of	IN	O
examples	NNS	Educational
of	IN	Educational
common	JJ	Educational
errors	NNS	Educational
(	(	Educational
error	NN	Educational
)	)	Educational
and	CC	O
the	DT	O
other	JJ	O
demonstrated	VBD	O
the	DT	O
skill	NN	Educational
being	VBG	Educational
performed	VBN	Educational
correctly	RB	Educational
(	(	Educational
correct	NN	Educational
)	)	Educational
.	.	O

A	DT	O
testing	VBG	O
videotape	NN	O
was	VBD	O
created	VBN	O
consisting	NN	O
of	IN	O
24	CD	O
performances	NNS	O
of	IN	O
the	DT	O
skill	NN	O
that	WDT	O
ranged	VBD	O
in	IN	O
quality	NN	O
of	IN	O
the	DT	O
performance	NN	O
.	.	O

The	DT	O
first	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
error	NN	Educational
instruction	NN	Educational
on	IN	O
skill	JJ	O
acquisition	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
a	DT	O
group	NN	O
of	IN	O
30	CD	O
senior	JJ	O
medical	JJ	O
students	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
four	CD	O
different	JJ	O
training	VBG	O
groups	NNS	O
:	:	O
none	NN	Educational
,	,	Educational
error	NN	Educational
only	RB	Educational
,	,	Educational
correct	VBP	Educational
only	RB	Educational
,	,	Educational
and	CC	Educational
error+correct	NN	Educational
.	.	Educational

Subjects	NNS	O
were	VBD	O
videotaped	VBN	O
performing	VBG	O
the	DT	O
skill	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
training	NN	O
and	CC	O
three	CD	O
experts	NNS	O
evaluated	VBD	O
these	DT	O
performances	NNS	O
independently	RB	O
using	VBG	O
a	DT	O
7-point	JJ	O
rating	NN	O
scale	NN	O
.	.	O

The	DT	O
second	JJ	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
assess	VB	O
the	DT	O
impact	NN	O
of	IN	O
error	NN	Educational
training	NN	Educational
on	IN	O
skill	JJ	O
evaluation	NN	O
and	CC	O
was	VBD	O
done	VBN	O
using	VBG	O
both	DT	O
novice	NN	O
and	CC	O
expert	JJ	O
raters	NNS	O
.	.	O

The	DT	O
same	JJ	O
group	NN	O
of	IN	O
30	CD	O
senior	JJ	O
medical	JJ	O
students	NNS	O
used	VBN	O
in	IN	O
the	DT	O
first	JJ	O
study	NN	O
was	VBD	O
used	VBN	O
as	IN	O
novice	JJ	O
raters	NNS	O
.	.	O

Following	VBG	O
training	NN	O
in	IN	O
one	CD	O
of	IN	O
the	DT	O
four	CD	O
training	NN	O
groups	NNS	O
,	,	O
each	DT	O
subject	NN	O
rated	VBD	O
the	DT	O
24	CD	O
performances	NNS	O
on	IN	O
the	DT	O
testing	NN	Educational
videotape	NN	Educational
and	CC	Educational
interrater	NN	Educational
reliability	NN	Educational
was	VBD	O
assessed	VBN	O
for	IN	O
each	DT	O
group	NN	O
.	.	O

Surgical	NNP	O
faculty	NN	O
served	VBD	O
as	IN	O
expert	JJ	O
raters	NNS	O
in	IN	O
this	DT	O
study	NN	O
and	CC	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
error	NN	Educational
training	NN	Educational
or	CC	O
no	DT	Control
training	NN	Control
.	.	Control

Each	DT	O
subject	NN	O
viewed	VBD	O
the	DT	O
testing	NN	O
videotape	NN	O
,	,	O
rating	NN	O
the	DT	O
performances	NNS	O
and	CC	O
giving	VBG	O
feedback	JJ	O
commentary	NN	O
.	.	O

Interrater	NNP	O
reliability	NN	O
was	VBD	O
calculated	VBN	O
for	IN	O
the	DT	O
two	CD	O
groups	NNS	O
and	CC	O
the	DT	O
precision	NN	O
of	IN	O
the	DT	O
feedback	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Significant	JJ	O
improvement	NN	O
in	IN	O
posttest	JJ	O
performance	NN	O
scores	NNS	O
was	VBD	O
seen	VBN	O
only	RB	O
in	IN	O
the	DT	O
error+correct	JJ	Educational
training	NN	O
group	NN	O
.	.	O

Interrater	NNP	O
reliability	NN	O
was	VBD	O
somewhat	RB	O
lower	JJR	O
for	IN	O
the	DT	O
correct	NN	O
only	RB	O
and	CC	O
error	VBZ	O
only	RB	O
training	VBG	O
groups	NNS	O
in	IN	O
both	DT	O
the	DT	O
student	NN	O
and	CC	O
faculty	NN	O
studies	NNS	O
.	.	O

Faculty	NN	O
raters	NNS	O
receiving	VBG	O
error	NN	O
training	NN	O
had	VBD	O
a	DT	O
higher	JJR	O
proportion	NN	O
of	IN	O
specific	JJ	O
comments	NNS	O
than	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
no	DT	O
training	NN	O
although	IN	O
this	DT	O
difference	NN	O
was	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Instruction	NN	O
about	IN	O
common	JJ	O
errors	NNS	O
,	,	O
when	WRB	O
combined	VBN	O
with	IN	O
instruction	NN	O
about	IN	O
the	DT	O
correct	JJ	O
performance	NN	O
enhanced	VBD	O
the	DT	O
acquisition	NN	O
of	IN	O
this	DT	O
surgical	JJ	O
skill	NN	O
.	.	O

This	DT	O
suggests	VBZ	O
a	DT	O
role	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
errors	NNS	O
in	IN	O
surgical	JJ	Surgical
technical	JJ	Surgical
skill	NN	Surgical
instruction	NN	Surgical
.	.	Surgical

Our	PRP$	O
study	NN	O
provides	VBZ	O
no	DT	O
support	NN	O
for	IN	O
a	DT	O
role	NN	O
for	IN	O
error	NN	O
training	NN	O
in	IN	O
improving	VBG	O
skill	JJ	O
evaluation	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	Physical
heel	NN	Physical
lifts	NNS	Physical
on	IN	O
Achilles	NNP	O
tendon	NNP	O
force	NN	O
and	CC	O
strain	NN	O
during	IN	O
running	VBG	O
.	.	O

This	DT	O
study	NN	O
assessed	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
orthotic	JJ	Physical
heel	NN	Physical
lifts	NNS	Physical
on	IN	O
Achilles	NNP	O
tendon	NN	O
(	(	O
AT	NNP	O
)	)	O
force	NN	O
and	CC	O
strain	NN	O
during	IN	O
running	VBG	O
.	.	O

Ten	CD	O
females	NNS	O
ran	VBD	O
barefoot	NN	O
over	IN	O
a	DT	O
force	NN	O
plate	NN	O
in	IN	O
three	CD	O
conditions	NNS	O
:	:	O
no	DT	Control
heel	NN	Control
lifts	NNS	Control
(	(	O
NHL	NNP	O
)	)	O
,	,	O
with	IN	O
12	CD	Physical
mm	NNS	Physical
heel	JJ	Physical
lifts	NNS	Physical
(	(	O
12HL	CD	O
)	)	O
and	CC	O
with	IN	O
18	CD	Physical
mm	NNS	Physical
heel	JJ	Physical
lifts	NNS	Physical
(	(	O
18HL	CD	O
)	)	O
.	.	O

Kinematics	NNS	O
for	IN	O
the	DT	O
right	JJ	O
lower	JJR	O
limb	NN	O
were	VBD	O
collected	VBN	O
(	(	O
200	CD	O
Hz	NNP	O
)	)	O
.	.	O

AT	NNP	O
force	NN	O
was	VBD	O
calculated	VBN	O
from	IN	O
inverse	JJ	O
dynamics	NNS	O
.	.	O

AT	NNP	O
strain	NN	O
was	VBD	O
determined	VBN	O
from	IN	O
kinematics	NNS	O
and	CC	O
ultrasound	JJ	O
images	NNS	O
of	IN	O
medial	JJ	O
gastrocnemius	NN	O
(	(	O
50	CD	O
Hz	NNP	O
)	)	O
.	.	O

Peak	NNP	O
AT	NNP	O
strain	NN	O
was	VBD	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
5.5	CD	O
?	.	O
4.4	CD	O
%	NN	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
7.4	CD	O
?	.	O
4.2	CD	O
%	NN	O
)	)	O
(	(	O
p	JJ	O
=	NNP	O
.029	NNP	O
,	,	O
effect	NN	O
size	NN	O
[	NNP	O
ES	NNP	O
]	NNP	O
=	NNP	O
0.44	CD	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
5.8	CD	O
?	.	O
4.8	CD	O
%	NN	O
)	)	O
versus	NN	O
NHL	NNP	O
(	(	O
ES	NNP	O
=	NNP	O
0.35	CD	O
)	)	O
.	.	O

Peak	NNP	O
AT	NNP	O
force	NN	O
was	VBD	O
significantly	RB	O
(	(	O
p	JJ	O
=	NNP	O
.024	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.42	CD	O
)	)	O
less	JJR	O
for	IN	O
18HL	CD	O
(	(	O
2382	CD	O
?	.	O
717	CD	O
N	NNP	O
)	)	O
than	IN	O
for	IN	O
NHL	NNP	O
(	(	O
2710	CD	O
?	.	O
830	CD	O
N	NNP	O
)	)	O
but	CC	O
not	RB	O
for	IN	O
12HL	CD	O
(	(	O
2538	CD	O
?	.	O
823	CD	O
N	NNP	O
,	,	O
ES	NNP	O
=	NNP	O
0.21	CD	O
)	)	O
.	.	O

The	DT	O
18HL	CD	O
reduced	VBD	O
ankle	JJ	O
dorsiflexion	NN	O
but	CC	O
not	RB	O
flexion-extension	JJ	O
ankle	NN	O
moments	NNS	O
and	CC	O
increased	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
compared	VBN	O
with	IN	O
NHL	NNP	O
.	.	O

Thus	NNP	O
,	,	O
18HL	CD	O
reduced	VBN	O
force	NN	O
and	CC	O
strain	NN	O
on	IN	O
the	DT	O
AT	NNP	O
during	IN	O
running	VBG	O
via	IN	O
a	DT	O
reduction	NN	O
in	IN	O
dorsiflexion	NN	O
,	,	O
which	WDT	O
lengthened	VBD	O
the	DT	O
AT	NNP	O
moment	NN	O
arm	NN	O
.	.	O

Therefore	RB	O
,	,	O
heel	NN	O
lifts	NNS	O
could	MD	O
be	VB	O
used	VBN	O
to	TO	O
reduce	VB	O
AT	NNP	O
loading	NN	O
and	CC	O
strain	NN	O
during	IN	O
the	DT	O
rehabilitation	NN	O
of	IN	O
AT	NNP	O
injuries	NNS	O
.	.	O

Memantine	NNP	Pharmacological
as	IN	O
adjunctive	JJ	O
treatment	NN	O
to	TO	O
risperidone	VB	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
autistic	JJ	O
disorder	NN	O
:	:	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
.	.	O

Autism	NNP	O
is	VBZ	O
a	DT	O
neurodevelopmental	JJ	O
disorder	NN	O
that	WDT	O
causes	VBZ	O
significant	JJ	O
impairment	NN	O
in	IN	O
socialization	NN	O
and	CC	O
communication	NN	O
.	.	O

It	PRP	O
is	VBZ	O
also	RB	O
associated	VBN	O
with	IN	O
ritualistic	JJ	O
and	CC	O
stereotypical	JJ	O
behaviour	NN	O
.	.	O

Recent	JJ	O
studies	NNS	O
propose	VBP	O
both	DT	O
hyper-and	JJ	O
hypoglutamatergic	NN	O
ideologies	NNS	O
for	IN	O
autism	NN	O
.	.	O

The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
memantine	NN	Pharmacological
plus	CC	Pharmacological
risperidone	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Children	NNP	O
with	IN	O
autism	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
risperidone	VB	Pharmacological
plus	JJ	Pharmacological
memantine	NN	Pharmacological
or	CC	O
placebo	NN	Control
plus	CC	Control
risperidone	NN	Control
for	IN	O
a	DT	O
10-wk	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
risperidone	NN	Pharmacological
was	VBD	O
titrated	VBN	O
up	RB	O
to	TO	O
3	CD	O
mg/d	NNS	O
and	CC	O
memantine	NN	O
was	VBD	O
titrated	VBN	O
to	TO	O
20	CD	O
mg/d	NN	O
.	.	O

Children	NNP	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
and	CC	O
10	CD	O
wk	NN	O
of	IN	O
starting	VBG	O
medication	NN	O
protocol	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
irritability	NN	O
subscale	NN	O
of	IN	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist-Community	NNP	O
(	(	O
ABC-C	NNP	O
)	)	O
.	.	O

Difference	NN	O
between	IN	O
the	DT	O
two	CD	O
treatment	NN	O
arms	NNS	O
was	VBD	O
significant	JJ	O
as	IN	O
the	DT	O
group	NN	O
that	WDT	O
received	VBD	O
memantine	NN	O
had	VBD	O
greater	JJR	O
reduction	NN	O
in	IN	O
ABC-C	NNP	O
subscale	NN	O
scores	NNS	O
for	IN	O
irritability	NN	O
,	,	O
stereotypic	VB	O
behaviour	NN	O
and	CC	O
hyperactivity	NN	O
.	.	O

Eight	CD	O
side-effects	NNS	O
were	VBD	O
observed	VBN	O
over	IN	O
the	DT	O
trial	NN	O
,	,	O
out	IN	O
of	IN	O
the	DT	O
25	CD	O
side-effects	NNS	O
that	IN	O
the	DT	O
checklist	NN	O
included	VBD	O
.	.	O

The	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
the	DT	O
frequency	NN	O
of	IN	O
side-effects	NNS	O
was	VBD	O
not	RB	O
significant	JJ	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
suggests	VBZ	O
that	IN	O
memantine	NN	O
may	MD	O
be	VB	O
a	DT	O
potential	JJ	O
adjunctive	JJ	O
treatment	NN	O
strategy	NN	O
for	IN	O
autism	NN	O
and	CC	O
it	PRP	O
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

This	DT	O
trial	NN	O
is	VBZ	O
registered	VBN	O
with	IN	O
the	DT	O
Iranian	JJ	O
Clinical	NNP	O
Trials	NNP	O
Registry	NNP	O
(	(	O
IRCT1138901151556N10	NNP	O
;	:	O
www.irct.ir	NN	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
acupressure	NN	O
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
on	IN	O
subjective	JJ	O
and	CC	O
autonomic	JJ	O
responses	NNS	O
to	TO	O
needle	VB	O
insertion	NN	O
.	.	O

BACKGROUND	NNP	O
Premedication	NNP	O
with	IN	O
sedatives	NNS	O
can	MD	O
decrease	VB	O
the	DT	O
discomfort	NN	O
associated	VBN	O
with	IN	O
invasive	JJ	O
anesthetic	JJ	O
procedures	NNS	O
.	.	O

Some	DT	O
researchers	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
acupressure	NN	O
on	IN	O
the	DT	O
acupuncture	NN	O
extra	JJ	O
1	CD	O
point	NN	O
is	VBZ	O
effective	JJ	O
for	IN	O
sedation	NN	O
.	.	O

We	PRP	O
investigated	VBD	O
whether	IN	O
acupressure	NN	O
on	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
could	MD	O
alleviate	VB	O
the	DT	O
pain	NN	O
of	IN	O
needle	JJ	O
insertion	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
investigated	VBD	O
the	DT	O
effect	NN	O
of	IN	O
acupressure	NN	Physical
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
or	CC	O
a	DT	O
sham	JJ	O
point	NN	O
on	IN	O
needle	JJ	O
insertion	NN	O
using	VBG	O
verbal	JJ	O
rating	NN	O
scale	NN	O
(	(	O
VRS	NNP	O
)	)	O
pain	NN	O
scores	NNS	O
and	CC	O
heart	NN	O
rate	NN	O
variability	NN	O
(	(	O
HRV	NNP	O
)	)	O
.	.	O

Twenty-two	NNP	O
healthy	JJ	O
female	NN	O
volunteers	NNS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
two	CD	O
groups	NNS	O
:	:	O
the	DT	O
extra	JJ	O
1	CD	O
group	NN	O
received	VBD	O
acupressure	NN	Physical
at	IN	Physical
the	DT	Physical
extra	JJ	Physical
1	CD	Physical
point	NN	Physical
,	,	O
and	CC	O
the	DT	O
sham	NN	O
group	NN	O
received	VBD	O
acupressure	NN	Control
at	IN	Control
a	DT	Control
sham	JJ	Control
point	NN	Control
.	.	O

After	IN	O
starting	VBG	O
the	DT	O
electrocardiogram	NN	O
record	NN	O
,	,	O
a	DT	O
27-gauge	JJ	O
needle	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
the	DT	O
skin	NN	O
of	IN	O
a	DT	O
forearm	NN	O
.	.	O

Thereafter	NNP	O
,	,	O
another	DT	O
needle	NN	O
was	VBD	O
inserted	VBN	O
into	IN	O
the	DT	O
skin	NN	O
of	IN	O
the	DT	O
other	JJ	O
forearm	NN	O
during	IN	O
acupressure	NN	O
.	.	O

RESULTS	JJ	O
Acupressure	NN	Physical
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
VRS	NNP	O
,	,	O
but	CC	O
acupressure	NN	Physical
at	IN	O
the	DT	O
sham	NN	O
increased	VBD	O
the	DT	O
VRS	NNP	O
.	.	O

Acupressure	NN	Physical
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
significantly	RB	O
reduced	VBD	O
the	DT	O
low	JJ	O
frequency/high	JJ	O
frequency	NN	O
ratio	NN	O
of	IN	O
HRV	NNP	O
responding	VBG	O
to	TO	O
needle	DT	O
insertion	NN	O
.	.	O

CONCLUSIONS	JJ	O
Acupressure	NN	Physical
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
significantly	RB	O
reduced	VBD	O
needle	JJ	O
insertion	NN	O
pain	NN	O
compared	VBN	O
with	IN	O
acupressure	NN	Physical
at	IN	O
the	DT	O
sham	NN	O
point	NN	O
.	.	O

Also	RB	O
,	,	O
acupressure	NN	Physical
at	IN	O
the	DT	O
extra	JJ	O
1	CD	O
point	NN	O
significantly	RB	O
reduced	VBD	O
the	DT	O
low	JJ	O
frequency/high	JJ	O
frequency	NN	O
ratio	NN	O
of	IN	O
HRV	NNP	O
responding	VBG	O
to	TO	O
needle	VB	O
insertion	NN	O
,	,	O
which	WDT	O
implies	VBZ	O
a	DT	O
reduction	NN	O
in	IN	O
sympathetic	JJ	O
nervous	JJ	O
system	NN	O
activity	NN	O
.	.	O

Pulsatile	NNP	Physical
insulin	NN	Physical
delivery	NN	Physical
is	VBZ	O
more	RBR	O
efficient	JJ	O
than	IN	O
continuous	JJ	Physical
infusion	NN	Physical
in	IN	O
modulating	VBG	O
islet	NN	O
cell	NN	O
function	NN	O
in	IN	O
normal	JJ	O
subjects	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O

The	DT	O
respective	JJ	O
modulating	NN	O
effects	NNS	O
of	IN	O
continuous	JJ	Physical
and	CC	Physical
intermittent	JJ	Physical
insulin	NN	Physical
delivery	NN	Physical
on	IN	O
pancreatic	JJ	O
islet	NN	O
cell	NN	O
function	NN	O
were	VBD	O
studied	VBN	O
in	IN	O
seven	CD	O
normal	JJ	O
men	NNS	O
and	CC	O
nine	CD	O
insulin-dependent	NN	O
(	(	O
type	JJ	O
1	CD	O
)	)	O
diabetic	JJ	O
patients	NNS	O
.	.	O

In	IN	O
the	DT	O
normal	JJ	O
men	NNS	O
,	,	O
saline	NN	Pharmacological
or	CC	O
continuous	JJ	Pharmacological
(	(	O
0.8	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NN	O
)	)	O
or	CC	O
pulsatile	NN	Pharmacological
(	(	O
5.2	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NNS	O
,	,	O
with	IN	O
a	DT	O
switching	VBG	O
on/off	RP	O
length	NN	O
of	IN	O
2/11	CD	O
min	NN	O
)	)	O
human	JJ	O
insulin	NN	O
were	VBD	O
delivered	VBN	O
on	IN	O
different	JJ	O
days	NNS	O
and	CC	O
in	IN	O
random	JJ	O
order	NN	O
.	.	O

Despite	IN	O
hyperinsulinemia	NN	O
,	,	O
blood	NN	O
glucose	NN	O
was	VBD	O
kept	VBN	O
close	RB	O
to	TO	O
its	PRP$	O
basal	NN	O
value	NN	O
by	IN	O
the	DT	O
glucose	JJ	O
clamp	NN	O
technique	NN	O
.	.	O

The	DT	O
diabetic	JJ	O
patients	NNS	O
also	RB	O
were	VBD	O
infused	VBN	O
in	IN	O
random	JJ	O
order	NN	O
and	CC	O
on	IN	O
different	JJ	O
days	NNS	O
with	IN	O
either	DT	O
saline	NN	Pharmacological
or	CC	O
a	DT	O
smaller	JJR	Physical
amount	NN	Physical
of	IN	Physical
insulin	NN	Physical
delivered	VBN	Physical
continuously	RB	Physical
(	(	O
0.15	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NN	O
)	)	O
or	CC	O
in	IN	Pharmacological
a	DT	Pharmacological
pulsatile	JJ	Physical
manner	NN	Pharmacological
(	(	O
0.97	CD	O
mU	RB	O
kg-1	JJ	O
min-1	NN	O
for	IN	O
2	CD	O
min	NN	O
,	,	O
followed	VBN	O
by	IN	O
11	CD	O
min	NNS	O
during	IN	O
which	WDT	O
no	DT	O
insulin	NN	O
was	VBD	O
infused	VBN	O
)	)	O
.	.	O

In	IN	O
all	DT	O
experiments	NNS	O
,	,	O
5	CD	O
g	NN	O
arginine	NN	Pharmacological
were	VBD	O
given	VBN	O
iv	NNS	O
as	IN	O
a	DT	O
bolus	NN	O
dose	JJ	O
30	CD	O
min	NN	O
before	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
and	CC	O
plasma	VB	O
C-peptide	NNP	O
and	CC	O
glucagon	NN	O
levels	NNS	O
were	VBD	O
determined	VBN	O
to	TO	O
assess	VB	O
islet	NN	O
cell	NN	O
function	NN	O
.	.	O

In	IN	O
the	DT	O
normal	JJ	O
men	NNS	O
,	,	O
insulin	NN	O
administration	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
significant	JJ	O
decline	NN	O
of	IN	O
basal	NN	O
plasma	NN	O
glucagon	NN	O
and	CC	O
C-peptide	JJ	O
levels	NNS	O
and	CC	O
in	IN	O
a	DT	O
clear-cut	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
arginine-induced	JJ	O
glucagon	NN	O
response	NN	O
.	.	O

These	DT	O
effects	NNS	O
of	IN	O
insulin	NN	O
were	VBD	O
significantly	RB	O
more	RBR	O
marked	JJ	O
when	WRB	O
insulin	NN	O
was	VBD	O
delivered	VBN	O
in	IN	O
a	DT	O
pulsatile	NN	O
rather	RB	O
than	IN	O
a	DT	O
continuous	JJ	O
manner	NN	O
.	.	O

In	IN	O
the	DT	O
insulin-dependent	JJ	O
diabetic	JJ	O
patients	NNS	O
,	,	O
the	DT	O
lower	JJR	O
dose	NN	O
of	IN	O
insulin	NN	O
infused	VBN	O
continuously	RB	O
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
basal	NN	O
or	CC	O
arginine-stimulated	JJ	O
glucagon	NN	O
response	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
when	WRB	O
the	DT	O
same	JJ	O
amount	NN	O
of	IN	O
insulin	NN	O
was	VBD	O
delivered	VBN	O
intermittently	RB	O
,	,	O
arginine-induced	JJ	O
glucagon	NN	O
release	NN	O
was	VBD	O
greatly	RB	O
reduced	VBN	O
.	.	O

Thus	RB	O
,	,	O
these	DT	O
data	NNS	O
support	NN	O
the	DT	O
concept	NN	O
that	WDT	O
insulin	VBZ	O
per	IN	O
se	NN	O
is	VBZ	O
a	DT	O
potent	JJ	O
physiological	JJ	O
modulator	NN	O
of	IN	O
islet	NN	O
A-	NNP	O
and	CC	O
B-cell	NNP	O
function	NN	O
.	.	O

Furthermore	RB	O
,	,	O
they	PRP	O
suggest	VBP	O
that	IN	O
these	DT	O
effects	NNS	O
of	IN	O
insulin	NN	O
are	VBP	O
reinforced	VBN	O
when	WRB	O
the	DT	O
hormone	NN	O
is	VBZ	O
administered	VBN	O
in	IN	O
an	DT	O
intermittent	JJ	O
manner	NN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reproduce	VB	O
the	DT	O
pulsatile	NN	O
physiological	JJ	O
release	NN	O
of	IN	O
insulin	NN	O
.	.	O

Diclofenac	NNP	Pharmacological
,	,	O
a	DT	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	O
,	,	O
decreases	VBZ	O
proteinuria	NN	O
in	IN	O
some	DT	O
glomerular	JJ	O
diseases	NNS	O
:	:	O
a	DT	O
controlled	VBN	O
study	NN	O
.	.	O

Treatment	NN	O
with	IN	O
nonsteroidal	JJ	Pharmacological
anti-inflammatory	JJ	Pharmacological
drugs	NNS	Pharmacological
(	(	Pharmacological
NSAIDs	NNP	Pharmacological
)	)	Pharmacological
was	VBD	O
first	RB	O
used	VBN	O
in	IN	O
glomerulonephritis	NN	O
(	(	O
GN	NNP	O
)	)	O
in	IN	O
1966	CD	O
but	CC	O
its	PRP$	O
efficiency	NN	O
is	VBZ	O
still	RB	O
debated	VBN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
antiproteinuric	JJ	O
effect	NN	O
of	IN	O
such	JJ	O
a	DT	O
treatment	NN	O
in	IN	O
a	DT	O
double-blind	NN	O
study	NN	O
.	.	O

29	CD	O
GN	NNP	O
patients	NNS	O
with	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
(	(	O
17	CD	O
membranoproliferative	NN	O
GN	NNP	O
,	,	O
12	CD	O
IgA	NNP	O
GN	NNP	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
100	CD	O
mg/day	NN	O
of	IN	O
diclofenac	NN	Pharmacological
or	CC	Pharmacological
placebo	NN	Control
for	IN	O
at	IN	O
least	JJS	O
2	CD	O
months	NNS	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
antiproteinuric	JJ	O
effect	NN	O
of	IN	O
diclofenac	NN	Pharmacological
versus	NN	O
placebo	NN	Control
with	IN	O
a	DT	O
fall	NN	O
of	IN	O
70	CD	O
%	NN	O
in	IN	O
the	DT	O
diclofenac	NN	O
group	NN	O
versus	VBD	O
6	CD	O
%	NN	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.001	CD	O
with	IN	O
the	DT	O
Mann-Whitney	NNP	O
test	NN	O
)	)	O
.	.	O

The	DT	O
median	NN	O
was	VBD	O
3	CD	O
mg/min	NN	O
at	IN	O
onset	NN	O
and	CC	O
2.45	CD	O
mg/min	NN	O
after	IN	O
2	CD	O
months	NNS	O
treatment	NN	O
with	IN	O
the	DT	O
placebo	NN	O
.	.	O

In	IN	O
the	DT	O
diclofenac	NN	Pharmacological
group	NN	O
,	,	O
it	PRP	O
was	VBD	O
2.2	CD	O
and	CC	O
0.95	CD	O
mg/min	NN	O
,	,	O
respectively	RB	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.01	CD	O
)	)	O
.	.	O

Diclofenac	NNP	Pharmacological
did	VBD	O
not	RB	O
significantly	RB	O
increase	VB	O
creatinine	NN	O
levels	NNS	O
.	.	O

Gastric	NNP	O
irritation	NN	O
was	VBD	O
noted	VBN	O
only	RB	O
once	RB	O
.	.	O

This	DT	O
study	NN	O
establishes	VBZ	O
the	DT	O
short-term	JJ	O
antiproteinuric	JJ	O
action	NN	O
of	IN	O
diclofenac	NN	O
.	.	O

Whether	IN	O
this	DT	O
action	NN	O
affects	VBZ	O
the	DT	O
final	JJ	O
outcome	NN	O
is	VBZ	O
not	RB	O
yet	RB	O
determined	VBN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
health	NN	Educational
care	NN	Educational
program	NN	Educational
for	IN	Educational
first-time	JJ	Educational
adolescent	NN	Educational
mothers	NNS	Educational
and	CC	Educational
their	PRP$	Educational
infants	NNS	Educational
.	.	O

To	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
special	JJ	Educational
health	NN	Educational
care	NN	Educational
program	NN	Educational
for	IN	O
adolescent	JJ	O
mothers	NNS	O
(	(	O
17	CD	O
years	NNS	O
old	JJ	O
or	CC	O
younger	JJR	O
)	)	O
and	CC	O
their	PRP$	O
infants	NNS	O
,	,	O
243	CD	O
mother-infant	JJ	O
pairs	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
.	.	O

All	DT	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
unwed	JJ	O
,	,	O
on	IN	O
Medicaid	NNP	O
,	,	O
and	CC	O
black	JJ	O
.	.	O

The	DT	O
control	NN	Educational
group	NN	Educational
received	VBD	Educational
routine	JJ	Educational
well-baby	NN	Educational
care	NN	Educational
.	.	O

The	DT	O
experimental	JJ	O
group	NN	O
received	VBD	O
routine	JJ	Educational
care	NN	Educational
and	CC	Educational
services	NNS	Educational
that	WDT	Educational
included	VBD	Educational
rigorous	JJ	Educational
follow-up	NN	Educational
,	,	O
discussions	NNS	Educational
with	IN	Educational
the	DT	Educational
mother	NN	Educational
about	IN	Educational
her	PRP$	Educational
plans	NNS	Educational
for	IN	Educational
return	NN	Educational
to	TO	Educational
school	NN	Educational
and	CC	Educational
use	NN	Educational
of	IN	Educational
family	NN	Educational
planning	NN	Educational
methods	NNS	Educational
,	,	O
and	CC	O
extra	JJ	Educational
health	NN	Educational
teaching	NN	Educational
.	.	O

The	DT	O
dropout	NN	O
rate	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
(	(	O
60	CD	O
%	NN	O
)	)	O
was	VBD	O
significantly	RB	O
less	JJR	O
after	IN	O
18	CD	O
months	NNS	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
82	CD	O
%	NN	O
)	)	O
.	.	O

In	IN	O
spite	NN	O
of	IN	O
the	DT	O
high	JJ	O
dropout	NN	O
rate	NN	O
,	,	O
91	CD	O
%	NN	O
of	IN	O
the	DT	O
mothers	NNS	O
were	VBD	O
located	VBN	O
for	IN	O
the	DT	O
18	CD	O
month	NN	O
follow-up	JJ	O
interview	NN	O
.	.	O

The	DT	O
repeat	JJ	O
pregnancy	NN	O
rate	NN	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
was	VBD	O
12	CD	O
%	NN	O
after	IN	O
18	CD	O
months	NNS	O
,	,	O
and	CC	O
28	CD	O
%	NN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
percentage	NN	O
returning	VBG	O
to	TO	O
school	NN	O
.	.	O

After	IN	O
12	CD	O
months	NNS	O
,	,	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
experimental	JJ	O
group	NN	O
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
fully	RB	O
immunized	VBN	O
(	(	O
33	CD	O
%	NN	O
)	)	O
than	IN	O
the	DT	O
infants	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
18	CD	O
%	NN	O
)	)	O
.	.	O

Mothers	NNS	O
in	IN	O
the	DT	O
special	JJ	Educational
care	NN	Educational
program	NN	Educational
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
clinic	NN	O
used	VBN	O
the	DT	O
emergency	NN	O
room	NN	O
less	JJR	O
than	IN	O
the	DT	O
mothers	NNS	O
who	WP	O
continued	VBD	O
to	TO	O
attend	VB	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
a	DT	O
comprehensive	JJ	Educational
health	NN	Educational
care	NN	Educational
program	NN	Educational
is	VBZ	O
one	CD	O
way	NN	O
to	TO	O
bring	VB	O
about	RP	O
better	JJR	O
outcomes	NNS	O
for	IN	O
both	DT	O
adolescent	JJ	O
mothers	NNS	O
and	CC	O
their	PRP$	O
infants	NNS	O
.	.	O

Further	JJ	O
validation	NN	O
of	IN	O
the	DT	O
alcohol	NN	O
dependence	NN	O
scale	NN	O
as	IN	O
an	DT	O
index	NN	O
of	IN	O
severity	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
Alcohol	NNP	Educational
Dependence	NNP	Educational
Scale	NNP	Educational
(	(	O
ADS	NNP	O
)	)	O
yields	VBZ	O
continuous	JJ	O
scores	NNS	O
purported	VBN	O
to	TO	O
reflect	VB	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
dependence	NN	O
syndrome	NN	O
.	.	O

We	PRP	O
evaluated	VBD	O
the	DT	O
concurrent	JJ	O
validity	NN	O
of	IN	O
the	DT	O
ADS	NNP	O
as	IN	O
a	DT	O
general	JJ	O
measure	NN	O
of	IN	O
severity	NN	O
and	CC	O
the	DT	O
screening	VBG	O
accuracy	NN	O
of	IN	O
the	DT	O
total	JJ	O
score	NN	O
and	CC	O
subscales	NNS	O
to	TO	O
detect	VB	O
Diagnostic	NNP	O
and	CC	O
Statistical	NNP	O
Manual	NNP	O
of	IN	O
Mental	NNP	O
Disorders	NNP	O
,	,	O
Fourth	NNP	O
Edition	NNP	O
(	(	O
DSM-IV	NNP	O
)	)	O
,	,	O
physiological	JJ	O
dependence	NN	O
.	.	O

METHOD	NNP	O
Treatment-seeking	JJ	O
,	,	O
alcohol-dependent	JJ	O
individuals	NNS	O
entering	VBG	O
the	DT	O
Combining	NNP	O
Pharmacotherapies	NNPS	O
and	CC	O
Behavioral	NNP	O
Interventions	NNP	O
for	IN	O
Alcohol	NNP	O
Dependence	NNP	O
(	(	O
COMBINE	NNP	O
)	)	O
Study	NNP	O
(	(	O
N	NNP	O
=	NNP	O
1,372	CD	O
;	:	O
69	CD	O
%	NN	O
men	NNS	O
)	)	O
completed	VBD	O
the	DT	O
ADS	NNP	O
,	,	O
diagnostic	JJ	O
interviews	NNS	O
,	,	O
and	CC	O
other	JJ	O
measures	NNS	O
before	IN	O
randomization	NN	O
.	.	O

Analyses	NNS	O
of	IN	O
variance	NN	O
tested	VBN	O
differences	NNS	O
between	IN	O
ADS	NNP	Educational
quartiles	NNS	O
on	IN	O
alcohol-	JJ	O
related	JJ	O
measures	NNS	O
.	.	O

Areas	NNP	O
under	IN	O
the	DT	O
receiver	NN	O
operating	VBG	O
characteristic	JJ	O
(	(	O
AUROC	NNP	O
)	)	O
curve	NN	O
assessed	VBD	O
screening	VBG	O
accuracy	NN	O
for	IN	O
DSM-IV	NNP	O
physiological	JJ	O
dependence	NN	O
(	(	O
tolerance	NN	O
or	CC	O
withdrawal	NN	O
)	)	O
or	CC	O
withdrawal	VB	O
alone	RB	O
.	.	O

RESULTS	NNP	O
ADS	NNP	O
quartiles	VBZ	O
differed	VBN	O
on	IN	O
age	NN	O
,	,	O
other	JJ	O
demographics	NNS	O
,	,	O
and	CC	O
prior	RB	O
treatment	NN	O
episodes	NNS	O
.	.	O

Linear	JJ	O
correlation	NN	O
showed	VBD	O
moderate	JJ	O
to	TO	O
large	JJ	O
magnitude	NN	O
associations	NNS	O
with	IN	O
alcohol-related	JJ	O
self-report	JJ	O
measures	NNS	O
and	CC	O
most	JJS	O
indices	NNS	O
of	IN	O
consumption	NN	O
.	.	O

ADS	NNP	O
quartiles	NNS	O
differed	VBD	O
significantly	RB	O
on	IN	O
proportion	NN	O
with	IN	O
DSM-IV	NNP	O
physiological	JJ	O
dependence	NN	O
,	,	O
but	CC	O
AUROC	NNP	O
curves	NNS	O
indicated	VBD	O
that	IN	O
the	DT	O
ADS	NNP	O
had	VBD	O
limited	VBN	O
accuracy	NN	O
as	IN	O
a	DT	O
continuous	JJ	O
measure	NN	O
to	TO	O
detect	VB	O
DSMIV	NNP	O
physiological	JJ	O
dependence	NN	O
(	(	O
AUROC	NNP	O
=	NNP	O
.75	NNP	O
[	VBD	O
95	CD	O
%	NN	O
confidence	NN	O
interval	NN	O
{	(	O
CI	NNP	O
}	)	O
:	:	O
.70-.79	JJ	O
]	NN	O
and	CC	O
.67	NNP	O
[	VBP	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
.60-.74	JJ	O
]	NN	O
for	IN	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
respectively	RB	O
;	:	O
p	CC	O
=	NNP	O
.08	NNP	O
)	)	O
or	CC	O
withdrawal	VB	O
alone	RB	O
(	(	O
AUROC	NNP	O
=	NNP	O
.77	NNP	O
[	VBD	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
.74-.80	JJ	O
]	NN	O
and	CC	O
.74	NNP	O
[	VBP	O
95	CD	O
%	NN	O
CI	NNP	O
:	:	O
.69-.79	JJ	O
]	NN	O
for	IN	O
men	NNS	O
and	CC	O
women	NNS	O
,	,	O
respectively	RB	O
;	:	O
p	CC	O
=	NNP	O
.30	NNP	O
)	)	O
.	.	O

Screening	VBG	O
accuracy	NN	O
was	VBD	O
comparably	RB	O
limited	VBN	O
based	VBN	O
on	IN	O
ADS	NNP	O
subscales	NNS	O
reflecting	VBG	O
psychoperceptual	JJ	O
or	CC	O
psychophysical	JJ	O
withdrawal	NN	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
ADS	NNP	O
reflected	VBD	O
variation	NN	O
in	IN	O
symptom	JJ	O
severity	NN	O
but	CC	O
did	VBD	O
not	RB	O
adequately	RB	O
identify	VB	O
physiological	JJ	O
dependence	NN	O
or	CC	O
withdrawal	NN	O
in	IN	O
treatment-seeking	JJ	O
individuals	NNS	O
with	IN	O
DSM-IV	NNP	O
alcohol	NN	O
dependence	NN	O
.	.	O

Partial-area	JJ	O
method	NN	O
in	IN	O
bioequivalence	NN	O
assessment	NN	O
:	:	O
naproxen	NN	Pharmacological
.	.	O

Regulatory	NNP	O
authorities	NNS	O
require	VBP	O
demonstration	NN	O
of	IN	O
bioequivalence	NN	O
through	IN	O
comparisons	NNS	O
of	IN	O
different	JJ	O
pharmacokinetic	JJ	O
parameters	NNS	O
,	,	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
plasma	JJ	O
concentration-time	JJ	O
curve	NN	O
(	(	O
AUC	NNP	O
)	)	O
,	,	O
the	DT	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
(	(	O
Cmax	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
reach	VB	O
peak	JJ	O
concentration	NN	O
(	(	O
Tmax	NNP	O
)	)	O
.	.	O

The	DT	O
applicability	NN	O
and	CC	O
validity	NN	O
of	IN	O
regulatory	JJ	O
requirements	NNS	O
have	VBP	O
been	VBN	O
widely	RB	O
criticized	VBN	O
on	IN	O
statistical	JJ	O
and	CC	O
clinical	JJ	O
relevance	NN	O
grounds	NNS	O
.	.	O

For	IN	O
most	JJS	O
noncomplicated	JJ	O
absorption	NN	O
models	NNS	O
,	,	O
the	DT	O
AUC	NNP	O
correlates	VBZ	O
well	RB	O
with	IN	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
nonlinear	JJ	O
models	NNS	O
of	IN	O
absorption	NN	O
,	,	O
in	IN	O
mechanisms	NN	O
involving	VBG	O
recycling	NN	O
of	IN	O
drugs	NNS	O
,	,	O
and	CC	O
for	IN	O
drugs	NNS	O
with	IN	O
long	JJ	O
half-life	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
(	(	O
from	IN	O
zero	CD	O
to	TO	O
infinity	NN	O
)	)	O
can	MD	O
give	VB	O
erroneous	JJ	O
and	CC	O
clinically	RB	O
irrelevant	JJ	O
results	NNS	O
since	IN	O
the	DT	O
area	NN	O
is	VBZ	O
mostly	RB	O
determined	VBN	O
by	IN	O
elimination	NN	O
phase	NN	O
or	CC	O
by	IN	O
recycling	VBG	O
.	.	O

The	DT	O
calculation	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
also	RB	O
involves	VBZ	O
prolonged	JJ	O
sampling	NN	O
,	,	O
adding	VBG	O
to	TO	O
the	DT	O
cost	NN	O
and	CC	O
risks	NNS	O
associated	VBN	O
with	IN	O
bioequivalence	NN	O
studies	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
Cmax	NNP	O
or	CC	O
Tmax	NNP	O
as	IN	O
a	DT	O
measure	NN	O
of	IN	O
rate	NN	O
of	IN	O
absorption	NN	O
,	,	O
to	TO	O
correlate	VB	O
with	IN	O
clinical	JJ	O
relevance	NN	O
,	,	O
is	VBZ	O
widely	RB	O
criticized	VBN	O
on	IN	O
logical	JJ	O
,	,	O
technical	JJ	O
,	,	O
and	CC	O
statistical	JJ	O
grounds	NNS	O
.	.	O

For	IN	O
drugs	NNS	O
used	VBN	O
on	IN	O
a	DT	O
multiple-dose	JJ	O
basis	NN	O
,	,	O
Cmax	NNP	O
and	CC	O
Tmax	NNP	O
evaluations	NNS	O
become	VBP	O
redundant	JJ	O
since	IN	O
the	DT	O
average	JJ	O
plateau	NN	O
concentration	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
by	IN	O
these	DT	O
parameters	NNS	O
.	.	O

To	TO	O
resolve	VB	O
the	DT	O
drawbacks	NNS	O
in	IN	O
the	DT	O
traditional	JJ	O
methodology	NN	O
of	IN	O
bioequivalence	NN	O
evaluation	NN	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
partial	JJ	O
areas	NNS	O
in	IN	O
lieu	NN	O
of	IN	O
total	JJ	O
AUC	NNP	O
,	,	O
Tmax	NNP	O
,	,	O
and	CC	O
Cmax	NNP	O
is	VBZ	O
suggested	VBN	O
.	.	O

This	DT	O
study	NN	O
investigates	VBZ	O
the	DT	O
logic	NN	O
and	CC	O
robustness	NN	O
of	IN	O
the	DT	O
partial-area	JJ	O
method	NN	O
in	IN	O
establishing	VBG	O
bioequivalence	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
the	DT	O
5h	CD	O
AUC	NNP	O
is	VBZ	O
a	DT	O
more	RBR	O
relevant	JJ	O
parameter	NN	O
to	TO	O
establish	VB	O
naproxen	NNS	Pharmacological
bioequivalence	NN	O
than	IN	O
AUCinf	NNP	O
.	.	O

We	PRP	O
recommend	VBP	O
against	IN	O
using	VBG	O
symmetrical	JJ	O
confidence	NN	O
intervals	NNS	O
and	CC	O
report	NN	O
excellent	JJ	O
agreement	NN	O
among	IN	O
several	JJ	O
methods	NNS	O
of	IN	O
calculating	VBG	O
confidence	NN	O
intervals	NNS	O
,	,	O
probability	NN	O
values	NNS	O
,	,	O
and	CC	O
nonparametric	JJ	O
tests	NNS	O
.	.	O

We	PRP	O
suggest	VBP	O
that	IN	O
a	DT	O
single-point	JJ	O
short-term	JJ	O
AUC	NNP	O
is	VBZ	O
a	DT	O
better	JJR	O
indicator	NN	O
of	IN	O
the	DT	O
bioequivalence	NN	O
of	IN	O
generic	JJ	O
products	NNS	O
than	IN	O
the	DT	O
total	JJ	O
AUC	NNP	O
,	,	O
Cmax	NNP	O
,	,	O
and	CC	O
Tmax	NNP	O
as	IN	O
required	VBN	O
currently	RB	O
by	IN	O
the	DT	O
regulatory	JJ	O
authorities	NNS	O
.	.	O

Effect	NN	O
of	IN	O
secretin	NN	Pharmacological
on	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
effect	NN	O
of	IN	O
intravenous	JJ	Pharmacological
porcine	NN	Pharmacological
secretin	NN	Pharmacological
on	IN	O
autistic	JJ	O
behaviours	NNS	O
in	IN	O
children	NNS	O
aged	VBD	O
2	CD	O
to	TO	O
7	CD	O
years	NNS	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
secretin	NN	O
on	IN	O
(	(	O
1	CD	O
)	)	O
performance	NN	O
on	IN	O
a	DT	O
standardized	JJ	O
language	NN	O
measure	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
autistic	JJ	O
behaviours	NN	O
,	,	O
as	IN	O
rated	VBN	O
by	IN	O
parents	NNS	O
and	CC	O
child	NN	O
development	NN	O
professionals	NNS	O
was	VBD	O
examined	VBN	O
.	.	O

Employing	VBG	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
design	NN	O
,	,	O
95	CD	O
participants	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
one	CD	O
of	IN	O
two	CD	O
groups	NNS	O
and	CC	O
administered	VBD	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
either	DT	O
secretin	NN	Pharmacological
or	CC	O
placebo	NN	Control
.	.	O

A	DT	O
follow-up	JJ	O
assessment	NN	O
was	VBD	O
conducted	VBN	O
3	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
injection	NN	O
.	.	O

No	DT	O
significant	JJ	O
differences	NNS	O
in	IN	O
language	NN	O
or	CC	O
autistic	JJ	O
behaviour	NN	O
measures	NNS	O
were	VBD	O
observed	VBN	O
at	IN	O
the	DT	O
3-week	JJ	O
follow-up	NN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

Also	RB	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
individuals	NNS	O
who	WP	O
improved	VBN	O
by	IN	O
>	NN	O
or	CC	O
=	$	O
6	CD	O
points	NNS	O
on	IN	O
the	DT	O
language	NN	O
measure	NN	O
at	IN	O
follow-up	NN	O
.	.	O

This	DT	O
study	NN	O
showed	VBD	O
no	DT	O
significant	JJ	O
effects	NNS	O
of	IN	O
secretin	NN	O
on	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Our	PRP$	O
results	NNS	O
are	VBP	O
consistent	JJ	O
with	IN	O
a	DT	O
systematic	JJ	O
review	NN	O
of	IN	O
randomized	VBN	O
controlled	JJ	O
trials	NNS	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
secretin	NN	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

5	CD	O
%	NN	O
imiquimod	JJ	Pharmacological
cream	NN	O
and	CC	O
reflectance-mode	JJ	Physical
confocal	JJ	Physical
microscopy	NN	Physical
as	IN	O
adjunct	JJ	O
modalities	NNS	O
to	TO	O
Mohs	NNP	Surgical
micrographic	JJ	Surgical
surgery	NN	Surgical
for	IN	O
treatment	NN	O
of	IN	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
.	.	O

BACKGROUND	NNP	O
Imiquimod	NNP	Pharmacological
is	VBZ	O
an	DT	O
immune	JJ	O
response	NN	O
modifier	NN	O
that	IN	O
up-regulates	JJ	O
cytokines	NNS	O
and	CC	O
has	VBZ	O
been	VBN	O
shown	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
to	TO	O
reduce	VB	O
or	CC	O
clear	VB	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
tumors	NNS	O
when	WRB	O
applied	VBN	O
topically	RB	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objectives	NNS	O
were	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
5	CD	O
%	NN	O
imiquimod	JJ	Pharmacological
cream	NN	O
in	IN	O
treating	VBG	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
preceding	VBG	O
excision	NN	O
by	IN	O
Mohs	NNP	O
micrographic	JJ	O
surgery	NN	O
and	CC	O
to	TO	O
determine	VB	O
if	IN	O
reflectance-mode	JJ	Physical
confocal	JJ	Physical
microscopy	NN	Physical
is	VBZ	O
useful	JJ	O
to	TO	O
establish	VB	O
the	DT	O
need	NN	O
for	IN	O
surgical	JJ	O
intervention	NN	O
after	IN	O
imiquimod	JJ	Pharmacological
treatment	NN	O
.	.	O

METHODS	NNP	O
Subjects	NNP	O
applied	VBD	O
study	NN	O
cream	NN	O
to	TO	O
one	CD	O
biopsy-confirmed	JJ	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
tumor	NN	O
5	CD	O
x/week	NN	O
for	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
or	CC	O
6	CD	O
weeks	NNS	O
in	IN	O
this	DT	O
vehicle-controlled	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
.	.	O

Confocal	NNP	Physical
microscopy	NN	Physical
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
6-week	JJ	O
treatment	NN	O
group	NN	O
to	TO	O
examine	VB	O
the	DT	O
target	NN	O
tumor	NN	O
area	NN	O
at	IN	O
each	DT	O
interval	JJ	O
visit	NN	O
and	CC	O
immediately	RB	O
before	IN	O
Mohs	NNP	Surgical
micrographic	JJ	Surgical
surgery	NN	Surgical
.	.	O

After	IN	O
the	DT	O
Mohs	NNP	Surgical
micrographic	JJ	Surgical
surgery	NN	Surgical
excision	NN	Surgical
,	,	O
the	DT	O
tissue	NN	O
was	VBD	O
evaluated	VBN	O
histologically	RB	O
,	,	O
and	CC	O
the	DT	O
excision	NN	O
area	NN	O
was	VBD	O
measured	VBN	O
.	.	O

Confocal	JJ	Physical
microscopy	NN	Physical
readings	NNS	O
were	VBD	O
correlated	VBN	O
to	TO	O
the	DT	O
histologic	JJ	O
diagnosis	NN	O
.	.	O

RESULTS	NNP	O
Tumors	NNPS	O
cleared	VBD	O
or	CC	O
the	DT	O
target	NN	O
tumor	NN	O
area	NN	O
was	VBD	O
reduced	VBN	O
in	IN	O
subjects	NNS	O
in	IN	O
the	DT	O
4-	JJ	O
and	CC	O
6-week	JJ	O
dosing	NN	O
regimens	NNS	O
.	.	O

Confocal	JJ	Physical
microscopy	NN	Physical
assessments	NNS	O
correlated	VBN	O
well	RB	O
with	IN	O
the	DT	O
histologic	JJ	O
diagnosis	NN	O
.	.	O

CONCLUSION	NNP	O
Imiquimod	NNP	Pharmacological
improved	VBD	O
excision	NN	O
results	NNS	O
relative	JJ	O
to	TO	O
vehicle	NN	O
when	WRB	O
used	VBN	O
for	IN	O
treating	VBG	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
before	IN	O
Mohs	NNP	Surgical
micrographic	JJ	Surgical
surgery	NN	Surgical
.	.	Surgical

Confocal	JJ	O
microscopy	NN	O
assessments	NNS	O
correlated	VBN	O
well	RB	O
with	IN	O
tumor	NN	O
response	NN	O
to	TO	O
therapy	VB	O
,	,	O
suggesting	VBG	O
that	IN	O
confocal	JJ	O
microscopy	NN	O
may	MD	O
help	VB	O
determine	VB	O
the	DT	O
need	NN	O
for	IN	O
surgery	NN	O
.	.	O

Efficacy	NN	O
of	IN	O
dose-intensified	JJ	O
MEC	NNP	Pharmacological
(	(	O
methotrexate	NN	Pharmacological
,	,	O
epirubicin	NN	Pharmacological
and	CC	O
cisplatin	NN	Pharmacological
)	)	O
chemotherapy	NN	O
for	IN	O
advanced	JJ	O
urothelial	JJ	O
carcinoma	NN	O
:	:	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
trial	NN	O
comparing	VBG	O
MEC	NNP	Pharmacological
and	CC	O
M-VAC	NNP	Pharmacological
(	(	O
methotrexate	NN	Pharmacological
,	,	O
vinblastine	NN	Pharmacological
,	,	O
doxorubicin	NN	Pharmacological
and	CC	O
cisplatin	NN	Pharmacological
)	)	O
.	.	O

Japanese	JJ	O
Urothelial	JJ	O
Cancer	NNP	O
Research	NNP	O
Group	NNP	O
.	.	O

BACKGROUND	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
antitumor	NN	O
activity	NN	O
in	IN	O
patients	NNS	O
with	IN	O
T3b	NNP	O
,	,	O
T4	NNP	O
or	CC	O
metastatic	JJ	O
urothelial	JJ	O
carcinoma	NN	O
treated	VBN	O
with	IN	O
MEC	NNP	Pharmacological
or	CC	O
M-VAC	NNP	Pharmacological
chemotherapy	NN	O
,	,	O
by	IN	O
performing	VBG	O
a	DT	O
multi-center	JJ	O
randomized	JJ	O
prospective	JJ	O
study	NN	O
.	.	O

METHODS	NNP	O
From	IN	O
1991	CD	O
to	TO	O
1995	CD	O
,	,	O
89	CD	O
patients	NNS	O
with	IN	O
T3b	NNP	O
,	,	O
T4	NNP	O
or	CC	O
metastatic	JJ	O
urothelial	JJ	O
carcinoma	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
a	DT	O
methotrexate	NN	Pharmacological
,	,	O
epirubicin	NN	Pharmacological
and	CC	O
cisplatin	NN	Pharmacological
chemotherapy	NN	O
group	NN	O
(	(	O
arm	JJ	O
1	CD	O
:	:	O
S-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
29	CD	O
)	)	O
,	,	O
a	DT	O
dose-intensified	JJ	O
MEC	NNP	Pharmacological
therapy	NN	Pharmacological
combined	VBN	O
with	IN	O
G-CSF	NNP	Pharmacological
group	NN	O
(	(	O
arm	JJ	O
2	CD	O
:	:	O
I-MEC	JJ	O
therapy	NN	O
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
or	CC	O
a	DT	O
methotrexate	NN	Pharmacological
,	,	O
vinblastine	NN	Pharmacological
,	,	O
doxorubicin	NN	Pharmacological
and	CC	O
cisplatin	NN	Pharmacological
chemotherapy	NN	O
(	(	O
arm	JJ	O
3	CD	O
:	:	O
M-VAC	JJ	Pharmacological
therapy	NN	Pharmacological
;	:	O
n	CC	O
=	VB	O
30	CD	O
)	)	O
.	.	O

At	IN	O
the	DT	O
registration	NN	O
center	NN	O
,	,	O
the	DT	O
patients	NNS	O
were	VBD	O
stratified	VBN	O
into	IN	O
previously	RB	O
untreated	JJ	O
patients	NNS	O
and	CC	O
patients	NNS	O
with	IN	O
recurrence	NN	O
after	IN	O
radical	JJ	O
operation	NN	O
and	CC	O
then	RB	O
randomly	RB	O
allocated	VBN	O
to	TO	O
the	DT	O
treatment	NN	O
groups	NNS	O
.	.	O

In	IN	O
each	DT	O
arm	NN	O
,	,	O
two	CD	O
or	CC	O
more	JJR	O
courses	NNS	O
of	IN	O
chemotherapy	NN	O
(	(	O
4-week	JJ	O
cycles	NNS	O
)	)	O
were	VBD	O
performed	VBN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
88	CD	O
eligible	JJ	O
patients	NNS	O
,	,	O
four	CD	O
treated	VBN	O
with	IN	O
S-MEC	NNP	Pharmacological
therapy	NN	Pharmacological
and	CC	O
two	CD	O
treated	VBN	O
with	IN	O
I-MEC	NNP	Pharmacological
therapy	NN	O
showed	VBD	O
CR	NNP	O
.	.	O

The	DT	O
response	NN	O
rates	NNS	O
(	(	O
CR	NNP	O
+	NNP	O
PR	NNP	O
)	)	O
were	VBD	O
52	CD	O
%	NN	O
(	(	O
15/29	CD	O
)	)	O
with	IN	O
S-MEC	NNP	Pharmacological
therapy	NN	Pharmacological
,	,	O
76	CD	O
%	NN	O
(	(	O
22/29	CD	O
)	)	O
with	IN	O
I-MEC	NNP	Pharmacological
therapy	NN	O
and	CC	O
47	CD	O
%	NN	O
(	(	O
14/30	CD	O
)	)	O
with	IN	O
M-VAC	NNP	Pharmacological
therapy	NN	O
.	.	O

The	DT	O
response	NN	O
rate	NN	O
with	IN	O
I-MEC	NNP	Pharmacological
therapy	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
that	DT	O
with	IN	O
M-VAC	NNP	Pharmacological
therapy	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.02	CD	O
)	)	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
leukopenia	NN	O
was	VBD	O
low	JJ	O
with	IN	O
I-MEC	NNP	Pharmacological
therapy	NN	O
,	,	O
the	DT	O
incidence	NN	O
of	IN	O
thrombocytopenia	NN	O
was	VBD	O
high	JJ	O
with	IN	O
this	DT	O
therapy	NN	O
.	.	O

CONCLUSION	NNP	O
MEC	NNP	Pharmacological
therapy	NN	Pharmacological
used	VBN	O
in	IN	O
this	DT	O
study	NN	O
is	VBZ	O
promising	VBG	O
in	IN	O
terms	NNS	O
of	IN	O
the	DT	O
antitumor	NN	O
effects	NNS	O
.	.	O

Low-fluence	JJ	Physical
photodynamic	JJ	Physical
therapy	NN	Physical
versus	NN	O
ranibizumab	NN	Pharmacological
for	IN	O
chronic	JJ	O
central	JJ	O
serous	JJ	O
chorioretinopathy	NN	O
:	:	O
one-year	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
.	.	O

PURPOSE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
between	IN	O
low-fluence	JJ	O
photodynamic	JJ	O
therapy	NN	O
(	(	O
PDT	NNP	O
)	)	O
and	CC	O
the	DT	O
intravitreal	JJ	O
ranibizumab	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
central	JJ	O
serous	JJ	O
chorioretinopathy	NN	O
(	(	O
CSC	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
Prospective	NNP	O
,	,	O
randomized	VBD	O
,	,	O
single-center	JJ	O
,	,	O
parallel-arm	JJ	O
,	,	O
controlled	JJ	O
trial	NN	O
.	.	O

PARTICIPANTS	CC	O
Thirty-four	JJ	O
eyes	NNS	O
of	IN	O
32	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
CSC	NNP	O
with	IN	O
>	NNP	O
6	CD	O
months	NNS	O
'	POS	O
duration	NN	O
of	IN	O
symptoms	NNS	O
or	CC	O
recurrent	JJ	O
CSC	NNP	O
were	VBD	O
randomly	RB	O
placed	VBN	O
into	IN	O
the	DT	O
low-fluence	JJ	O
PDT	NNP	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
18	CD	O
)	)	O
or	CC	O
the	DT	O
ranibizumab	NN	O
group	NN	O
(	(	O
n	JJ	O
=	NNP	O
16	CD	O
)	)	O
.	.	O

INTERVENTION	NNP	O
The	DT	O
patients	NNS	O
underwent	VBP	O
a	DT	O
single	JJ	O
session	NN	O
of	IN	O
low-fluence	NN	Physical
PDT	NNP	Physical
or	CC	O
3	CD	Pharmacological
consecutive	JJ	Pharmacological
monthly	JJ	Pharmacological
injections	NNS	Pharmacological
of	IN	Pharmacological
ranibizumab	NN	Pharmacological
.	.	O

Rescue	NNP	Control
treatment	NN	Control
was	VBD	O
available	JJ	O
from	IN	O
month	NN	O
3	CD	O
if	IN	O
the	DT	O
subretinal	JJ	O
fluid	NN	O
(	(	O
SRF	NNP	O
)	)	O
persisted	VBD	O
or	CC	O
recurred	VBN	O
after	IN	O
primary	JJ	O
treatment	NN	O
;	:	O
low-fluence	JJ	O
PDT	NNP	O
was	VBD	O
given	VBN	O
to	TO	O
the	DT	O
ranibizumab	NN	O
group	NN	O
and	CC	O
intravitreal	NN	O
ranibizumab	NN	O
to	TO	O
the	DT	O
low-fluence	NN	O
PDT	NNP	O
group	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
the	DT	O
proportion	NN	O
of	IN	O
eyes	NNS	O
with	IN	O
complete	JJ	O
resolution	NN	O
of	IN	O
SRF	NNP	O
without	IN	O
rescue	NN	O
treatment	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
the	DT	O
mean	NN	O
changes	NNS	O
in	IN	O
logarithm	NN	O
of	IN	O
the	DT	O
minimum	JJ	O
angle	NN	O
of	IN	O
resolution	NN	O
best-corrected	JJ	O
visual	JJ	O
acuity	NN	O
(	(	O
BCVA	NNP	O
)	)	O
,	,	O
central	JJ	O
retinal	JJ	O
thickness	NN	O
(	(	O
CRT	NNP	O
)	)	O
,	,	O
and	CC	O
angiographic	JJ	O
findings	NNS	O
from	IN	O
baseline	NN	O
to	TO	O
12	CD	O
months	NNS	O
.	.	O

RESULTS	NNP	O
At	IN	O
month	NN	O
12	CD	O
,	,	O
16	CD	O
eyes	NNS	O
(	(	O
88.9	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
low-fluence	JJ	O
PDT	NNP	O
group	NN	O
maintained	VBD	O
complete	JJ	O
resolution	NN	O
of	IN	O
SRF	NNP	O
without	IN	O
rescue	NN	O
treatment	NN	O
versus	IN	O
2	CD	O
eyes	NNS	O
(	(	O
12.5	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
ranibizumab	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

Two	CD	O
eyes	NNS	O
(	(	O
11.1	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
low-fluence	NN	O
PDT	NNP	O
group	NN	O
and	CC	O
11	CD	O
eyes	NNS	O
(	(	O
68.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
ranibizumab	NN	O
group	NN	O
met	VBD	O
the	DT	O
criteria	NNS	O
for	IN	O
rescue	NN	O
treatment	NN	O
(	(	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
low-fluence	NN	O
PDT	NNP	O
group	NN	O
,	,	O
the	DT	O
mean	JJ	O
decrease	NN	O
in	IN	O
CRT	NNP	O
from	IN	O
baseline	NN	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
that	DT	O
in	IN	O
the	DT	O
ranibizumab	NN	O
group	NN	O
until	IN	O
month	NN	O
6	CD	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
became	VBD	O
insignificant	JJ	O
thereafter	NN	O
.	.	O

The	DT	O
improvement	NN	O
in	IN	O
BCVA	NNP	O
from	IN	O
baseline	NN	O
was	VBD	O
superior	JJ	O
in	IN	O
the	DT	O
low-fluence	NN	O
PDT	NNP	O
group	NN	O
to	TO	O
that	DT	O
in	IN	O
the	DT	O
ranibizumab	NN	O
group	NN	O
,	,	O
but	CC	O
the	DT	O
differences	NNS	O
were	VBD	O
not	RB	O
statistically	RB	O
significant	JJ	O
except	IN	O
at	IN	O
month	NN	O
3	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.025	CD	O
)	)	O
.	.	O

On	IN	O
indocyanine	NN	O
green	JJ	O
angiography	NN	O
,	,	O
a	DT	O
significantly	RB	O
greater	JJR	O
proportion	NN	O
of	IN	O
the	DT	O
low-fluence	JJ	O
PDT	NNP	O
group	NN	O
(	(	O
16	CD	O
eyes	NNS	O
;	:	O
88.9	CD	O
%	NN	O
)	)	O
showed	VBD	O
a	DT	O
marked	JJ	O
reduction	NN	O
in	IN	O
choroidal	JJ	O
hyperpermeability	NN	O
after	IN	O
primary	JJ	O
treatment	NN	O
than	IN	O
that	DT	O
of	IN	O
the	DT	O
ranibizumab	NN	O
group	NN	O
(	(	O
0	CD	O
eyes	NNS	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

No	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
related	VBN	O
to	TO	O
the	DT	O
drugs	NNS	O
or	CC	O
procedures	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

CONCLUSIONS	VB	O
This	DT	O
study	NN	O
represents	VBZ	O
the	DT	O
overall	JJ	O
superiority	NN	O
of	IN	O
low-fluence	NN	O
PDT	NNP	O
compared	VBN	O
with	IN	O
intravitreal	JJ	O
ranibizumab	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
CSC	NNP	O
.	.	O

The	DT	O
European	JJ	O
Myocardial	NNP	O
Infarction	NNP	O
Project	NNP	O
:	:	O
an	DT	O
assessment	NN	O
of	IN	O
pre-hospital	JJ	O
thrombolysis	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
thrombolytic	JJ	Pharmacological
agents	NNS	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
early	JJ	O
and	CC	O
long-term	JJ	O
mortality	NN	O
by	IN	O
about	IN	O
20	CD	O
%	NN	O
,	,	O
and	CC	O
it	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
since	IN	O
time	NN	O
is	VBZ	O
an	DT	O
important	JJ	O
factor	NN	O
,	,	O
pre-hospital	JJ	O
treatment	NN	O
would	MD	O
give	VB	O
better	JJR	O
results	NNS	O
.	.	O

However	RB	O
,	,	O
health	NN	O
deciders	NNS	O
need	VBP	O
reliable	JJ	O
data	NNS	O
on	IN	O
which	WDT	O
to	TO	O
base	VB	O
future	JJ	O
policies	NNS	O
concerning	VBG	O
this	DT	O
.	.	O

The	DT	O
European	JJ	O
Myocardial	NNP	O
Infarction	NNP	O
Project	NNP	O
was	VBD	O
a	DT	O
European	JJ	O
Economic	NNP	O
Community-supported	NNP	O
double-blind	NN	O
study	NN	O
designed	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
pre-hospital	JJ	Pharmacological
early	JJ	Pharmacological
thrombolytic	JJ	Pharmacological
treatment	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
compared	VBN	O
with	IN	O
the	DT	O
same	JJ	O
treatment	NN	O
given	VBN	O
later	RB	O
in	IN	O
a	DT	O
hospital	NN	O
setting	NN	O
.	.	O

A	DT	O
total	NN	O
of	IN	O
5469	CD	O
patients	NNS	O
in	IN	O
16	CD	O
countries	NNS	O
were	VBD	O
randomised	VBN	O
by	IN	O
198	CD	O
mobile	JJ	O
emergency	NN	O
units	NNS	O
to	TO	O
receive	VB	O
either	DT	O
pre-hospital	JJ	O
treatment	NN	O
with	IN	O
anistreplase	NN	Pharmacological
,	,	O
the	DT	O
thrombolytic	JJ	O
agent	NN	O
used	VBN	O
,	,	O
followed	VBN	Control
by	IN	Control
placebo	NN	Control
after	IN	O
hospital	JJ	O
admission	NN	O
(	(	O
pre-hospital	JJ	O
group	NN	O
;	:	O
2750	CD	O
patients	NNS	O
)	)	O
,	,	O
or	CC	O
placebo	NN	Control
followed	VBN	Control
by	IN	Control
anistreplase	NN	Control
(	(	O
hospital	JJ	O
group	NN	O
;	:	O
2719	CD	O
patients	NNS	O
)	)	O
.	.	O

The	DT	O
median	JJ	O
time	NN	O
delay	NN	O
between	IN	O
the	DT	O
injections	NNS	O
was	VBD	O
55	CD	O
min	NN	O
.	.	O

A	DT	O
non-significant	JJ	O
decrease	NN	O
in	IN	O
30-day	JJ	O
mortality	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
pre-hospital	JJ	O
group	NN	O
(	(	O
13	CD	O
%	NN	O
:	:	O
P	NNP	O
=	NNP	O
0.08	CD	O
)	)	O
,	,	O
whereas	IN	O
the	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
death	NN	O
observed	VBD	O
,	,	O
also	RB	O
in	IN	O
favour	NN	O
of	IN	O
the	DT	O
pre-hospital	JJ	O
group	NN	O
,	,	O
was	VBD	O
on	IN	O
the	DT	O
borderline	NN	O
of	IN	O
significance	NN	O
(	(	O
16	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.049	CD	O
)	)	O
.	.	O

Although	IN	O
some	DT	O
complications	NNS	O
occurred	VBD	O
more	RBR	O
frequently	RB	O
in	IN	O
the	DT	O
pre-hospital	JJ	O
group	NN	O
in	IN	O
the	DT	O
pre-hospital	JJ	O
period	NN	O
,	,	O
the	DT	O
overall	JJ	O
incidence	NN	O
for	IN	O
serious	JJ	O
complications	NNS	O
was	VBD	O
similar	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

These	DT	O
results	NNS	O
show	VBP	O
that	IN	O
the	DT	O
pre-hospital	JJ	Pharmacological
thrombolytic	JJ	Pharmacological
strategy	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
suspected	JJ	O
myocardial	JJ	O
infarction	NN	O
is	VBZ	O
both	DT	O
effective	JJ	O
and	CC	O
safe	JJ	O
when	WRB	O
performed	VBN	O
by	IN	O
well-equipped	JJ	O
well-staffed	JJ	O
mobile	JJ	O
emergency	NN	O
units	NNS	O
.	.	O

Language	NNP	O
outcome	NN	O
in	IN	O
autism	NN	O
:	:	O
randomized	JJ	O
comparison	NN	O
of	IN	O
joint	JJ	Physical
attention	NN	Physical
and	CC	Physical
play	NN	Physical
interventions	NNS	Physical
.	.	O

This	DT	O
study	NN	O
reports	VBZ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
aimed	VBN	O
at	IN	O
joint	JJ	Physical
attention	NN	Physical
(	(	Physical
JA	NNP	Physical
)	)	Physical
and	CC	Physical
symbolic	JJ	Physical
play	NN	Physical
(	(	Physical
SP	NNP	Physical
)	)	Physical
in	IN	O
preschool	NN	O
children	NNS	O
with	IN	O
autism	NN	O
,	,	O
with	IN	O
prediction	NN	O
to	TO	O
language	NN	O
outcome	RB	O
12	CD	O
months	NNS	O
later	RB	O
.	.	O

Participants	NNS	O
were	VBD	O
58	CD	O
children	NNS	O
(	(	O
46	CD	O
boys	NNS	O
)	)	O
with	IN	O
autism	NN	O
between	IN	O
3	CD	O
and	CC	O
4	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

Children	NNP	O
were	VBD	O
randomized	VBN	O
to	TO	O
a	DT	O
JA	NNP	Educational
intervention	NN	Educational
,	,	Educational
an	DT	Educational
SP	NNP	Educational
intervention	NN	Educational
,	,	O
or	CC	O
control	NN	Control
group	NN	O
.	.	O

Interventions	NNS	O
were	VBD	O
conducted	VBN	O
30	CD	O
min	JJ	O
daily	JJ	O
for	IN	O
5-6	JJ	O
weeks	NNS	O
.	.	O

Assessments	NNS	O
of	IN	O
JA	NNP	Educational
skills	NNS	O
,	,	O
SP	NNP	Physical
skills	NNS	O
,	,	O
mother-child	JJ	O
interactions	NNS	O
,	,	O
and	CC	O
language	NN	O
development	NN	O
were	VBD	O
collected	VBN	O
at	IN	O
4	CD	O
time	NN	O
points	NNS	O
:	:	O
pre-	NN	O
and	CC	O
postintervention	NN	O
and	CC	O
6	CD	O
and	CC	O
12	CD	O
months	NNS	O
postintervention	NN	O
by	IN	O
independent	JJ	O
testers	NNS	O
.	.	O

Results	NNS	O
indicate	VBP	O
that	IN	O
expressive	JJ	O
language	NN	O
gains	NNS	O
were	VBD	O
greater	JJR	O
for	IN	O
both	DT	O
treatment	NN	O
groups	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
,	,	O
and	CC	O
results	NNS	O
could	MD	O
not	RB	O
be	VB	O
explained	VBN	O
by	IN	O
differences	NNS	O
in	IN	O
other	JJ	O
interventions	NNS	O
in	IN	O
which	WDT	O
children	NNS	O
participated	VBD	O
.	.	O

For	IN	O
children	NNS	O
beginning	VBG	O
treatment	NN	O
with	IN	O
the	DT	O
lowest	JJS	O
language	NN	O
levels	NNS	O
,	,	O
the	DT	O
JA	NNP	Educational
intervention	NN	Educational
improved	VBD	O
language	NN	O
outcome	NN	O
significantly	RB	O
more	RBR	O
than	IN	O
did	VBD	O
the	DT	O
SP	NNP	Physical
or	CC	O
control	VB	O
interventions	NNS	O
.	.	O

These	DT	O
findings	NNS	O
suggest	VBP	O
clinically	RB	O
significant	JJ	O
benefits	NNS	O
of	IN	O
actively	RB	O
treating	VBG	O
JA	NNP	Educational
and	CC	O
SP	NNP	Physical
skills	NNS	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

A	DT	O
randomized	VBN	O
controlled	JJ	O
trial	NN	O
of	IN	O
COMPASS	NNP	Other
web-based	JJ	Other
and	CC	O
face-to-face	JJ	Educational
teacher	NN	Educational
coaching	NN	Educational
in	IN	O
autism	NN	O
.	.	O

OBJECTIVE	CC	O
Most	JJS	O
children	NNS	O
with	IN	O
autism	NN	O
rely	RB	O
on	IN	O
schools	NNS	O
as	IN	O
their	PRP$	O
primary	JJ	O
source	NN	O
of	IN	O
intervention	NN	O
,	,	O
yet	RB	O
research	NN	O
has	VBZ	O
suggested	VBN	O
that	IN	O
teachers	NNS	O
rarely	RB	O
use	VBP	O
evidence-based	JJ	O
practices	NNS	O
.	.	O

To	TO	O
address	VB	O
the	DT	O
need	NN	O
for	IN	O
improved	JJ	O
educational	JJ	O
outcomes	NNS	O
,	,	O
a	DT	O
previously	RB	O
tested	VBN	O
consultation	NN	O
intervention	NN	O
called	VBD	O
the	DT	O
Collaborative	NNP	Educational
Model	NNP	Educational
for	IN	Educational
Promoting	VBG	Educational
Competence	NNP	Educational
and	CC	Educational
Success	NNP	Educational
(	(	Educational
COMPASS	NNP	Educational
;	:	O
Ruble	NNP	O
,	,	O
Dalrymple	NNP	O
,	,	O
&	CC	O
McGrew	NNP	O
,	,	O
2010	CD	O
;	:	O
Ruble	NNP	O
,	,	O
Dalrymple	NNP	O
,	,	O
&	CC	O
McGrew	NNP	O
,	,	O
2012	CD	O
)	)	O
was	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
2nd	CD	O
randomized	VBN	O
controlled	VBN	O
trial	NN	O
,	,	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
a	DT	O
web-based	JJ	O
group	NN	O
.	.	O

METHOD	NNP	O
Forty-nine	JJ	O
teacher-child	JJ	O
dyads	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
1	CD	O
of	IN	O
3	CD	O
groups	NNS	O
:	:	O
(	(	O
1	CD	O
)	)	O
a	DT	O
placebo	NN	Control
control	NN	O
(	(	O
PBO	NNP	O
)	)	O
group	NN	O
,	,	O
(	(	O
2	CD	O
)	)	O
COMPASS	NN	Educational
followed	VBN	Educational
by	IN	Educational
face-to-face	NN	Educational
(	(	Educational
FF	NNP	Educational
)	)	Educational
coaching	NN	Educational
sessions	NNS	Educational
,	,	O
and	CC	O
(	(	O
3	CD	O
)	)	O
COMPASS	NN	Educational
followed	VBN	Educational
by	IN	Educational
web-based	JJ	Educational
(	(	Educational
WEB	NNP	Educational
)	)	Educational
coaching	NN	Educational
sessions	NNS	Educational
.	.	O

Three	CD	O
individualized	JJ	O
goals	NNS	O
(	(	O
social	JJ	Educational
,	,	Educational
communication	NN	Educational
,	,	Educational
and	CC	Educational
independence	NN	Educational
skills	NNS	Educational
)	)	O
were	VBD	O
selected	VBN	O
for	IN	O
intervention	NN	O
for	IN	O
each	DT	O
child	NN	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
of	IN	O
independent	JJ	O
ratings	NNS	O
of	IN	O
child	NN	O
goal	NN	O
attainment	NN	O
and	CC	O
several	JJ	O
process	NN	O
measures	NNS	O
(	(	O
e.g.	NN	O
,	,	O
consultant	NN	O
and	CC	O
teacher	NN	O
fidelity	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
.	.	O

RESULTS	NNP	O
Using	VBG	O
an	DT	O
intent-to-treat	JJ	O
approach	NN	O
,	,	O
findings	NNS	O
replicated	VBD	O
earlier	RBR	O
results	NNS	O
with	IN	O
a	DT	O
very	RB	O
large	JJ	O
effect	NN	O
size	NN	O
(	(	O
d	JJ	O
=	NNP	O
1.41	CD	O
)	)	O
for	IN	O
the	DT	O
FF	NNP	O
group	NN	O
and	CC	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
(	(	O
d	JJ	O
=	NNP	O
1.12	CD	O
)	)	O
for	IN	O
the	DT	O
WEB	NNP	O
group	NN	O
relative	NN	O
to	TO	O
the	DT	O
PBO	NNP	O
group	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
overall	JJ	O
change	NN	O
across	IN	O
goal	NN	O
domains	NNS	O
between	IN	O
the	DT	O
FF	NNP	O
and	CC	O
WEB	NNP	O
groups	NNS	O
,	,	O
suggesting	VBG	O
the	DT	O
efficacy	NN	O
of	IN	O
videoconferencing	VBG	O
technology	NN	O
.	.	O

CONCLUSIONS	NNP	O
COMPASS	NNP	Other
is	VBZ	O
effective	JJ	O
and	CC	O
results	NNS	O
in	IN	O
improved	JJ	O
educational	JJ	O
outcomes	NNS	O
for	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Videoconferencing	NNP	O
technology	NN	O
,	,	O
as	IN	O
a	DT	O
scalable	JJ	O
tool	NN	O
,	,	O
has	VBZ	O
promise	NN	O
for	IN	O
facilitating	VBG	O
access	NN	O
to	TO	O
autism	NN	O
specialists	NNS	O
and	CC	O
bridging	VBG	O
the	DT	O
research-to-practice	JJ	O
gap	NN	O
.	.	O

Use	NNP	O
of	IN	O
EORTC	NNP	O
target	NN	O
definition	NN	O
guidelines	NNS	O
for	IN	O
dose-intensified	JJ	O
salvage	NN	O
radiation	NN	O
therapy	NN	O
for	IN	O
recurrent	JJ	O
prostate	NN	O
cancer	NN	O
:	:	O
results	NNS	O
of	IN	O
the	DT	O
quality	NN	O
assurance	NN	O
program	NN	O
of	IN	O
the	DT	O
randomized	JJ	O
trial	NN	O
SAKK	NNP	O
09/10	CD	O
.	.	O

PURPOSE	NNP	O
Different	NNP	O
international	JJ	O
target	NN	O
volume	NN	O
delineation	NN	O
guidelines	NNS	O
exist	VBP	O
and	CC	O
different	JJ	O
treatment	NN	O
techniques	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
salvage	NN	O
radiation	NN	O
therapy	NN	O
(	(	O
RT	NNP	O
)	)	O
for	IN	O
recurrent	NN	O
prostate	NN	O
cancer	NN	O
,	,	O
but	CC	O
less	JJR	O
is	VBZ	O
known	VBN	O
regarding	VBG	O
their	PRP$	O
respective	JJ	O
applicability	NN	O
in	IN	O
clinical	JJ	O
practice	NN	O
.	.	O

METHODS	NNP	O
AND	NNP	O
MATERIALS	NNP	O
A	NNP	O
randomized	JJ	O
phase	NN	O
III	NNP	O
trial	NN	O
testing	VBG	O
64	CD	Pharmacological
Gy	NNP	Pharmacological
vs	NN	Pharmacological
70	CD	Pharmacological
Gy	NNP	Pharmacological
salvage	NN	Pharmacological
RT	NNP	Pharmacological
was	VBD	O
accompanied	VBN	O
by	IN	O
an	DT	O
intense	JJ	Educational
quality	NN	Educational
assurance	NN	Educational
program	NN	Educational
including	VBG	O
a	DT	O
site-specific	JJ	O
and	CC	O
study-specific	JJ	O
questionnaire	NN	O
and	CC	O
a	DT	O
dummy	JJ	Physical
run	NN	Physical
(	(	Physical
DR	NNP	Physical
)	)	Physical
.	.	O

Target	NN	O
volume	NN	O
delineation	NN	O
was	VBD	O
performed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
European	JJ	O
Organisation	NN	O
for	IN	O
the	DT	O
Research	NNP	O
and	CC	O
Treatment	NNP	O
of	IN	O
Cancer	NNP	O
guidelines	NNS	O
,	,	O
and	CC	O
a	DT	O
DR-based	JJ	O
treatment	NN	O
plan	NN	O
was	VBD	O
established	VBN	O
for	IN	O
70	CD	O
Gy	NNP	O
.	.	O

Major	NNP	O
and	CC	O
minor	JJ	O
protocol	NN	O
deviations	NNS	O
were	VBD	O
noted	VBN	O
,	,	O
interobserver	JJ	O
agreement	NN	O
of	IN	O
delineated	JJ	O
target	NN	O
contours	NN	O
was	VBD	O
assessed	VBN	O
,	,	O
and	CC	O
dose-volume	JJ	O
histogram	NN	O
(	(	O
DVH	NNP	O
)	)	O
parameters	NNS	O
of	IN	O
different	JJ	O
treatment	NN	O
techniques	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
Thirty	NNP	O
European	JJ	O
centers	NNS	O
participated	VBD	O
,	,	O
43	CD	O
%	NN	O
of	IN	O
which	WDT	O
were	VBD	O
using	VBG	O
3-dimensional	JJ	Physical
conformal	JJ	Physical
RT	NNP	Physical
(	(	Physical
3D-CRT	JJ	Physical
)	)	Physical
,	,	O
with	IN	O
the	DT	O
remaining	VBG	O
centers	NNS	O
using	VBG	O
intensity	NN	Physical
modulated	VBN	Physical
RT	NNP	Physical
(	(	Physical
IMRT	NNP	Physical
)	)	Physical
or	CC	O
volumetric	JJ	Physical
modulated	VBN	Physical
arc	NN	Physical
technique	NN	Physical
(	(	Physical
VMAT	NNP	Physical
)	)	Physical
.	.	O

The	DT	O
first	JJ	O
submitted	VBN	O
version	NN	O
of	IN	O
the	DT	O
DR	NNP	O
contained	VBD	O
major	JJ	O
deviations	NNS	O
in	IN	O
21	CD	O
of	IN	O
30	CD	O
(	(	O
70	CD	O
%	NN	O
)	)	O
centers	NNS	O
,	,	O
mostly	RB	O
caused	VBN	O
by	IN	O
inappropriately	RB	O
defined	VBN	O
or	CC	O
lack	NN	O
of	IN	O
prostate	NN	O
bed	NN	O
(	(	O
PB	NNP	O
)	)	O
.	.	O

All	DT	O
but	CC	O
5	CD	O
centers	NNS	O
completed	VBD	O
the	DT	O
DR	NNP	O
successfully	RB	O
with	IN	O
their	PRP$	O
second	JJ	O
submitted	VBN	O
version	NN	O
.	.	O

The	DT	O
interobserver	JJ	O
agreement	NN	O
of	IN	O
the	DT	O
PB	NNP	O
was	VBD	O
moderate	JJ	O
and	CC	O
was	VBD	O
improved	VBN	O
by	IN	O
the	DT	O
DR	NNP	O
review	NN	O
,	,	O
as	IN	O
indicated	VBN	O
by	IN	O
an	DT	O
increased	VBN	O
?	.	O
value	NN	O
(	(	O
0.59	CD	O
vs	RB	O
0.55	CD	O
)	)	O
,	,	O
mean	JJ	O
sensitivity	NN	O
(	(	O
0.64	CD	O
vs	RB	O
0.58	CD	O
)	)	O
,	,	O
volume	NN	O
of	IN	O
total	JJ	O
agreement	NN	O
(	(	O
3.9	CD	O
vs	RB	O
3.3	CD	O
cm	NN	O
(	(	O
3	CD	O
)	)	O
)	)	O
,	,	O
and	CC	O
decrease	NN	O
in	IN	O
the	DT	O
union	NN	O
volume	NN	O
(	(	O
79.3	CD	O
vs	RB	O
84.2	CD	O
cm	NN	O
(	(	O
3	CD	O
)	)	O
)	)	O
.	.	O

Rectal	JJ	O
and	CC	O
bladder	VB	O
wall	NN	O
DVH	NNP	O
parameters	NNS	O
of	IN	O
IMRT	NNP	O
and	CC	O
VMAT	NNP	O
vs	VBP	O
3D-CRT	JJ	O
plans	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
interobserver	JJ	O
agreement	NN	O
of	IN	O
PB	NNP	O
delineation	NN	O
was	VBD	O
moderate	JJ	O
but	CC	O
was	VBD	O
improved	VBN	O
by	IN	O
the	DT	O
DR.	NNP	O
Major	NNP	O
deviations	NNS	O
could	MD	O
be	VB	O
identified	VBN	O
for	IN	O
the	DT	O
majority	NN	O
of	IN	O
centers	NNS	O
.	.	O

The	DT	O
DR	NNP	O
has	VBZ	O
improved	VBN	O
the	DT	O
acquaintance	NN	O
of	IN	O
the	DT	O
participating	VBG	O
centers	NNS	O
with	IN	O
the	DT	O
trial	NN	O
protocol	NN	O
.	.	O

Ciprofloxacin	NNP	Pharmacological
and	CC	Pharmacological
rifampicin	VB	Pharmacological
versus	NN	O
doxycycline	NN	Pharmacological
and	CC	Pharmacological
rifampicin	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
brucellosis	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
evaluate	VB	O
the	DT	O
efficacy	NN	O
,	,	O
safety	NN	O
,	,	O
and	CC	O
patient	JJ	O
tolerability	NN	O
of	IN	O
two	CD	O
antibiotic	JJ	O
regimens	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
brucellosis	NN	O
:	:	O
rifampicin	NN	Pharmacological
600	CD	Pharmacological
mg/day	NN	Pharmacological
and	CC	Pharmacological
doxycycline	VB	Pharmacological
200	CD	Pharmacological
mg/day	NN	Pharmacological
for	IN	O
45	CD	O
days	NNS	O
(	(	O
group	NN	O
1	CD	O
)	)	O
,	,	O
versus	FW	O
rifampicin	VBZ	Pharmacological
600	CD	Pharmacological
mg/day	NN	Pharmacological
and	CC	Pharmacological
ciprofloxacin	NN	Pharmacological
1	CD	Pharmacological
g/day	NN	Pharmacological
for	IN	Pharmacological
30	CD	Pharmacological
days	NNS	Pharmacological
(	(	O
group	NN	O
2	CD	O
)	)	O
.	.	O

Forty	JJ	O
patients	NNS	O
were	VBD	O
diagnosed	VBN	O
with	IN	O
brucellosis	NN	O
based	VBN	O
on	IN	O
clinical	JJ	O
and	CC	O
microbiological	JJ	O
findings	NNS	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
comparable	JJ	O
regarding	VBG	O
age	NN	O
and	CC	O
sex	NN	O
distribution	NN	O
.	.	O

The	DT	O
average	JJ	O
number	NN	O
of	IN	O
days	NNS	O
without	IN	O
fever	NN	O
and	CC	O
symptoms	NNS	O
was	VBD	O
lower	JJR	O
in	IN	O
group	NN	O
2	CD	O
patients	NNS	O
than	IN	O
in	IN	O
group	NN	O
1	CD	O
patients	NNS	O
(	(	O
mean+/-SD	JJ	O
:	:	O
3.85+/-1.98	JJ	O
for	IN	O
group	NN	O
1	CD	O
vs.	IN	O
2.78+/-1.03	JJ	O
for	IN	O
group	NN	O
2	CD	O
,	,	O
P=0.044	NNP	O
)	)	O
.	.	O

During	IN	O
the	DT	O
1-year	JJ	O
follow-up	JJ	O
period	NN	O
,	,	O
three	CD	O
(	(	O
15	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
group	NN	O
2	CD	O
and	CC	O
two	CD	O
(	(	O
10	CD	O
%	NN	O
)	)	O
patients	NNS	O
in	IN	O
group	NN	O
1	CD	O
had	VBD	O
clinical	JJ	O
relapses	NNS	O
;	:	O
these	DT	O
rates	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
.	.	O

Ciprofloxacin	NNP	Pharmacological
and	CC	Pharmacological
rifampicin	VB	Pharmacological
treatment	NN	O
for	IN	O
brucellosis	NN	O
is	VBZ	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
standard	JJ	O
regimen	NNS	O
of	IN	O
doxycycline	NN	Pharmacological
and	CC	Pharmacological
rifampicin	NN	Pharmacological
and	CC	O
offers	VBZ	O
the	DT	O
advantage	NN	O
of	IN	O
a	DT	O
shorter	JJR	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

[	JJ	O
Carbohydrate	NNP	O
substitutes	NNS	O
:	:	O
comparative	JJ	O
study	NN	O
of	IN	O
intestinal	JJ	O
absorption	NN	O
of	IN	O
fructose	NN	Pharmacological
,	,	O
sorbitol	NN	Pharmacological
and	CC	O
xylitol	NNP	Pharmacological
]	NNP	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
carbohydrate	NN	O
substitutes	NNS	O
fructose	VBP	Pharmacological
,	,	O
sorbitol	JJ	Pharmacological
and	CC	O
xylitol	NNS	Pharmacological
are	VBP	O
gaining	VBG	O
more	JJR	O
and	CC	O
more	JJR	O
importance	NN	O
in	IN	O
the	DT	O
production	NN	O
of	IN	O
dietary	JJ	O
food	NN	O
.	.	O

But	CC	O
they	PRP	O
can	MD	O
provoke	VB	O
gastrointestinal	JJ	O
side-effects	NNS	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
double	JJ	O
blind	NN	O
study	VBD	O
the	DT	O
rate	NN	O
of	IN	O
malabsorption	NN	O
of	IN	O
these	DT	O
sugars	NNS	O
was	VBD	O
compared	VBN	O
and	CC	O
the	DT	O
concomitant	NN	O
symptoms	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

SUBJECTS	NNP	O
AND	NNP	O
METHODS	NNP	O
25	CD	O
healthy	JJ	O
controls	NNS	O
received	VBD	O
25	CD	Pharmacological
g	NN	Pharmacological
of	IN	Pharmacological
each	DT	Pharmacological
sugar	NN	Pharmacological
within	IN	O
3	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

The	DT	O
intestinal	JJ	O
absorption	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
H2-exhalation	NNP	O
tests	NNS	O
and	CC	O
the	DT	O
clinical	JJ	O
symptoms	NNS	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
rate	NN	O
of	IN	O
malabsorption	NN	O
was	VBD	O
84	CD	O
%	NN	O
for	IN	O
sorbitol	NN	Pharmacological
,	,	O
36	CD	O
%	NN	O
for	IN	O
fructose	JJ	Pharmacological
and	CC	O
12	CD	O
%	NN	O
for	IN	O
xylitol	NNP	Pharmacological
(	(	O
p	JJ	O
<	VBP	O
0.01	CD	O
for	IN	O
sorbitol	NN	Pharmacological
versus	NN	O
fructose	NN	Pharmacological
and	CC	O
xylitol	NN	Pharmacological
)	)	O
.	.	O

57	CD	O
%	NN	O
of	IN	O
the	DT	O
participants	NNS	O
with	IN	O
pathological	JJ	O
H2-test	NNP	O
after	IN	O
sorbitol	NN	Pharmacological
and	CC	O
56	CD	O
%	NN	O
after	IN	O
fructose	JJ	Pharmacological
reported	VBD	O
symptoms	NNS	O
,	,	O
while	IN	O
all	DT	O
of	IN	O
the	DT	O
3	CD	O
malabsorbers	NNS	O
of	IN	O
xylitol	NN	Pharmacological
were	VBD	O
symptomatic	JJ	O
.	.	O

CONCLUSIONS	NNP	O
There	EX	O
is	VBZ	O
an	DT	O
advantage	NN	O
to	TO	O
administering	VBG	O
xylitol	NN	Pharmacological
and	CC	O
fructose	JJ	Pharmacological
with	IN	O
regard	NN	O
to	TO	O
the	DT	O
intestinal	JJ	O
absorption	NN	O
and	CC	O
concomitant	NN	O
symptoms	NNS	O
as	IN	O
compared	VBN	O
with	IN	O
sorbitol	NN	Pharmacological
.	.	O

H2-exhalation	NN	O
tests	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
a	DT	O
reliable	JJ	O
diagnostic	JJ	O
tool	NN	O
to	TO	O
detect	VB	O
carbohydrate	JJ	O
malabsorption	NN	O
and	CC	O
should	MD	O
find	VB	O
broader	JJR	O
application	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
non-specific	JJ	O
abdominal	JJ	O
complaints	NNS	O
.	.	O

Non-pharmacological	JJ	O
care	NN	O
for	IN	O
patients	NNS	O
with	IN	O
generalized	JJ	O
osteoarthritis	NN	O
:	:	O
design	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Non-pharmacological	JJ	Educational
treatment	NN	Educational
(	(	Educational
NPT	NNP	Educational
)	)	Educational
is	VBZ	O
a	DT	O
useful	JJ	O
treatment	NN	O
option	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
hip	NN	O
or	CC	O
knee	NN	O
osteoarthritis	NN	O
.	.	O

To	TO	O
our	PRP$	O
knowledge	NN	O
however	RB	O
,	,	O
no	DT	O
studies	NNS	O
have	VBP	O
investigated	VBN	O
the	DT	O
effect	NN	O
of	IN	O
NPT	NNP	Educational
in	IN	O
patients	NNS	O
with	IN	O
generalized	JJ	O
osteoarthritis	NN	O
(	(	O
GOA	NNP	O
)	)	O
.	.	O

The	DT	O
primary	JJ	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
two	CD	O
currently	RB	O
existing	VBG	O
health	NN	O
care	NN	O
programs	NNS	O
with	IN	O
different	JJ	O
intensity	NN	O
and	CC	O
mode	NN	O
of	IN	O
delivery	NN	O
on	IN	O
daily	JJ	O
functioning	NN	O
in	IN	O
patients	NNS	O
with	IN	O
GOA	NNP	O
.	.	O

The	DT	O
secondary	JJ	O
objective	NN	O
is	VBZ	O
to	TO	O
compare	VB	O
the	DT	O
cost-effectiveness	NN	O
of	IN	O
both	DT	O
interventions	NNS	O
.	.	O

METHODS/DESIGN	NNP	O
In	IN	O
this	DT	O
randomized	VBN	O
,	,	O
single	JJ	O
blind	NN	O
,	,	O
clinical	JJ	O
trial	NN	O
with	IN	O
active	JJ	O
controls	NNS	O
,	,	O
we	PRP	O
aim	VBP	O
to	TO	O
include	VB	O
170	CD	O
patients	NNS	O
with	IN	O
GOA	NNP	O
.	.	O

The	DT	O
experimental	JJ	O
intervention	NN	O
consist	NN	O
of	IN	O
six	CD	Educational
self-management	JJ	Educational
group	NN	Educational
sessions	NNS	Educational
provided	VBN	Educational
by	IN	Educational
a	DT	Educational
multi-disciplinary	JJ	Educational
team	NN	Educational
(	(	O
occupational	JJ	O
therapist	NN	O
,	,	O
physiotherapist	NN	O
,	,	O
dietician	JJ	O
and	CC	O
specialized	JJ	O
nurse	NN	O
)	)	O
.	.	O

The	DT	O
active	JJ	O
control	NN	O
group	NN	O
consists	VBZ	O
of	IN	O
two	CD	Control
group	NN	Control
sessions	NNS	Control
and	CC	Control
four	CD	Control
sessions	NNS	Control
by	IN	Control
telephone	NN	Control
,	,	O
provided	VBN	O
by	IN	O
a	DT	O
specialized	JJ	O
nurse	NN	O
and	CC	O
physiotherapist	NN	O
.	.	O

Both	DT	O
therapies	NNS	O
last	JJ	O
six	CD	O
weeks	NNS	O
.	.	O

Main	NNP	O
study	NN	O
outcome	NN	O
is	VBZ	O
daily	JJ	O
functioning	VBG	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
after	IN	O
the	DT	O
treatment	NN	O
,	,	O
assessed	VBN	O
on	IN	O
the	DT	O
Health	NNP	O
Assessment	NNP	O
Questionnaire	NNP	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
are	VBP	O
health	NN	O
related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
specific	JJ	O
complaints	NNS	O
,	,	O
fatigue	NN	O
,	,	O
and	CC	O
costs	NNS	O
.	.	O

Illness	NNP	O
cognitions	NNS	O
,	,	O
global	JJ	O
perceived	VBN	O
effect	NN	O
and	CC	O
self-efficacy	NN	O
,	,	O
will	MD	O
also	RB	O
be	VB	O
assessed	VBN	O
for	IN	O
a	DT	O
responder	NN	O
analysis	NN	O
.	.	O

Outcome	CC	O
assessments	NNS	O
are	VBP	O
performed	VBN	O
directly	RB	O
after	IN	O
the	DT	O
intervention	NN	O
,	,	O
after	IN	O
26	CD	O
weeks	NNS	O
and	CC	O
after	IN	O
52	CD	O
weeks	NNS	O
.	.	O

DISCUSSION	NN	O
This	DT	O
article	NN	O
describes	VBZ	O
the	DT	O
design	NN	O
of	IN	O
a	DT	O
randomized	VBN	O
,	,	O
single	JJ	O
blind	NN	O
,	,	O
clinical	JJ	O
trial	NN	O
with	IN	O
a	DT	O
one	CD	O
year	NN	O
follow	VB	O
up	IN	O
to	TO	O
compare	VB	O
the	DT	O
costs	NNS	O
and	CC	O
effectiveness	NN	O
of	IN	O
two	CD	O
non-pharmacological	JJ	Educational
interventions	NNS	Educational
with	IN	O
different	JJ	O
modes	NNS	O
of	IN	O
delivery	NN	O
for	IN	O
patients	NNS	O
with	IN	O
GOA	NNP	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
Dutch	NNP	O
Trial	NNP	O
Register	NNP	O
NTR2137	NNP	O
.	.	O

Comparison	NNP	O
of	IN	O
ketanserin	NN	Pharmacological
and	CC	O
pindolol	NN	Pharmacological
in	IN	O
hypertension	NN	O
.	.	O

The	DT	O
antihypertensive	JJ	O
effects	NNS	O
of	IN	O
ketanserin	NN	Pharmacological
(	(	O
40	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
and	CC	O
pindolol	NN	Pharmacological
(	(	O
5	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
)	)	O
as	IN	O
monotherapy	NN	O
were	VBD	O
compared	VBN	O
in	IN	O
a	DT	O
crossover	NN	O
,	,	O
double-blind	JJ	O
trial	NN	O
in	IN	O
17	CD	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Both	DT	O
ketanserin	NN	Pharmacological
and	CC	O
pindolol	NN	Pharmacological
decreased	VBN	O
supine	JJ	O
systolic	NN	O
and	CC	O
diastolic	JJ	O
blood	NN	O
pressure	NN	O
significantly	RB	O
(	(	O
P	NNP	O
less	JJR	O
than	IN	O
0.01	CD	O
for	IN	O
systolic	JJ	O
and	CC	O
P	NNP	O
less	JJR	O
than	IN	O
0.001	CD	O
for	IN	O
diastolic	NN	O
)	)	O
when	WRB	O
evaluated	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
2-month	JJ	O
treatment	NN	O
periods	NNS	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
drugs	NNS	O
.	.	O

No	DT	O
significant	JJ	O
changes	NNS	O
in	IN	O
heart	NN	O
rate	NN	O
were	VBD	O
observed	VBN	O
on	IN	O
either	DT	O
drug	NN	O
.	.	O

Both	DT	O
drugs	NNS	O
were	VBD	O
well	RB	O
tolerated	VBN	O
.	.	O

Gene	NNP	O
expression	NN	O
of	IN	O
endothelin-1	JJ	O
and	CC	O
its	PRP$	O
receptors	NNS	O
in	IN	O
the	DT	O
heart	NN	O
of	IN	O
broiler	NN	O
chickens	NNS	O
with	IN	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
-induced	VBD	O
pulmonary	JJ	O
hypertension	NN	O
.	.	O

To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
-induced	VBD	O
pulmonary	JJ	O
hypertension	NN	O
on	IN	O
endothelin	NN	O
(	(	O
ET	NNP	O
)	)	O
production	NN	O
and	CC	O
genes	NNS	O
expression	NN	O
of	IN	O
ET-1	NNP	O
,	,	O
ET	NNP	O
(	(	O
A	NNP	O
)	)	O
and	CC	O
ET	NNP	O
(	(	O
B	NNP	O
)	)	O
receptors	NNS	O
(	(	O
ET	NNP	O
(	(	O
A	NNP	O
)	)	O
R	NNP	O
and	CC	O
ET	NNP	O
(	(	O
B	NNP	O
)	)	O
R	NNP	O
)	)	O
during	IN	O
rearing	NN	O
,	,	O
semiquantitative	JJ	Physical
RT-PCR	NNP	Physical
and	CC	O
enzyme	VB	Physical
immunometric	JJ	Physical
assay	NN	Physical
were	VBD	O
performed	VBN	O
in	IN	O
the	DT	O
heart	NN	O
ventricles	NNS	O
and	CC	O
serum	NN	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
ET-1	JJ	O
and	CC	O
its	PRP$	O
receptor	NN	O
genes	NNS	O
were	VBD	O
expressed	VBN	O
in	IN	O
the	DT	O
right	NN	O
and	CC	O
left	VBD	O
ventricles	NNS	O
of	IN	O
control	NN	O
and	CC	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
-treated	VBD	O
broilers	NNS	O
at	IN	O
12	CD	O
,	,	O
28	CD	O
and	CC	O
49	CD	O
days	NNS	O
of	IN	O
age	NN	O
.	.	O

There	EX	O
were	VBD	O
significant	JJ	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
reductions	NNS	O
of	IN	O
the	DT	O
relative	JJ	O
amounts	NNS	O
of	IN	O
ET-1	NNP	O
(	(	O
in	IN	O
both	DT	O
ventricles	NNS	O
)	)	O
and	CC	O
ET	NNP	O
(	(	O
A	NNP	O
)	)	O
R	NNP	O
(	(	O
in	IN	O
the	DT	O
right	JJ	O
ventricle	NN	O
)	)	O
mRNAs	NN	O
at	IN	O
28	CD	O
and	CC	O
49	CD	O
days	NNS	O
of	IN	O
age	NN	O
,	,	O
in	IN	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
-treated	VBD	O
broilers	NNS	O
compared	VBN	O
to	TO	O
controls	NNS	O
.	.	O

The	DT	O
relative	JJ	O
amounts	NNS	O
of	IN	O
ET	NNP	O
(	(	O
B	NNP	O
)	)	O
R	NNP	O
mRNA	NN	O
in	IN	O
the	DT	O
right	NN	O
and	CC	O
left	VBD	O
ventricles	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
differ	VBP	O
between	IN	O
control	NN	O
and	CC	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
-treated	VBD	O
broilers	NNS	O
at	IN	O
any	DT	O
age	NN	O
.	.	O

The	DT	O
serum	JJ	O
level	NN	O
of	IN	O
ET	NNP	O
was	VBD	O
significantly	RB	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
increased	VBN	O
in	IN	O
T	NNP	O
(	(	O
3	CD	O
)	)	O
-treated	VBD	O
chickens	NNS	O
at	IN	O
28	CD	O
and	CC	O
49	CD	O
days	NNS	O
of	IN	O
age	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
the	DT	O
control	NN	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
ET-1	NNP	O
,	,	O
ET	NNP	O
(	(	O
A	NNP	O
)	)	O
R	NNP	O
and	CC	O
ET	NNP	O
(	(	O
B	NNP	O
)	)	O
R	NNP	O
genes	NNS	O
are	VBP	O
normally	RB	O
expressed	VBN	O
in	IN	O
the	DT	O
heart	NN	O
ventricles	NNS	O
of	IN	O
broilers	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
likely	JJ	O
that	IN	O
increased	VBD	O
serum	JJ	O
level	NN	O
of	IN	O
ET	NNP	O
and	CC	O
decreased	VBN	O
ET-1/ET	NNP	O
(	(	O
A	NNP	O
)	)	O
R	NNP	O
genes	NNS	O
expression	NN	O
in	IN	O
the	DT	O
ventricles	NNS	O
are	VBP	O
involved	VBN	O
in	IN	O
the	DT	O
heart	NN	O
dysfunction	NN	O
of	IN	O
broiler	NN	O
chickens	NNS	O
with	IN	O
developmental	JJ	O
pulmonary	JJ	O
hypertension	NN	O
.	.	O

Primary	JJ	Physical
stenting	NN	Physical
of	IN	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
final	JJ	O
results	NNS	O
of	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
(	(	O
PRISON	NNP	O
)	)	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
Primary	NNP	Surgical
intracoronary	JJ	Surgical
stent	NN	Surgical
placement	NN	Surgical
after	IN	O
successfully	RB	O
crossing	VBG	O
chronic	JJ	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
high	JJ	O
restenosis	NN	O
rate	NN	O
at	IN	O
long-term	JJ	O
follow-up	JJ	O
compared	VBN	O
with	IN	O
conventional	JJ	Physical
balloon	NN	Physical
angioplasty	NN	Physical
.	.	Physical

METHODS	NNP	O
In	IN	O
a	DT	O
prospective	JJ	O
,	,	O
randomized	JJ	O
trial	NN	O
,	,	O
balloon	NN	Physical
angioplasty	NN	Physical
was	VBD	O
compared	VBN	O
with	IN	O
stent	JJ	Surgical
implantation	NN	Surgical
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
12	CD	O
months	NNS	O
with	IN	O
angiographic	JJ	O
follow-up	NN	O
at	IN	O
6	CD	O
months	NNS	O
.	.	O

Quantitative	JJ	O
coronary	JJ	O
analysis	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
core	NN	O
lab	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
200	CD	O
patients	NNS	O
were	VBD	O
enrolled	VBN	O
.	.	O

Baseline	JJ	O
characteristics	NNS	O
were	VBD	O
evenly	RB	O
distributed	VBN	O
.	.	O

After	IN	O
the	DT	O
procedure	NN	O
the	DT	O
mean	NN	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
in	IN	O
the	DT	O
conventional	JJ	Physical
group	NN	O
was	VBD	O
2.34	CD	O
+/-	JJ	O
0.46	CD	O
mm	NN	O
versus	NN	O
2.90	CD	O
+/-	JJ	O
0.41	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	Surgical
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

The	DT	O
6-month	JJ	O
angiographic	JJ	O
follow-up	NN	O
showed	VBD	O
a	DT	O
mean	JJ	O
minimal	JJ	O
luminal	JJ	O
diameter	NN	O
of	IN	O
1.57	CD	O
+/-	JJ	O
0.74	CD	O
mm	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
1.93	CD	O
+/-	JJ	O
0.85	CD	O
mm	NN	O
in	IN	O
the	DT	O
stented	VBN	O
group	NN	O
(	(	O
P	NNP	O
=.009	NNP	O
)	)	O
and	CC	O
a	DT	O
mean	JJ	O
diameter	NN	O
stenosis	NN	O
of	IN	O
44.7	CD	O
%	NN	O
+/-	JJ	O
25.0	CD	O
%	NN	O
versus	IN	O
35.5	CD	O
%	NN	O
+/-	JJ	O
26.5	CD	O
%	NN	O
(	(	O
P	NNP	O
=.036	NNP	O
)	)	O
.	.	O

Binary	JJ	O
angiographic	JJ	O
restenosis	NN	O
(	(	O
>	JJ	O
50	CD	O
%	NN	O
diameter	JJ	O
stenosis	NN	O
)	)	O
was	VBD	O
seen	VBN	O
in	IN	O
33	CD	O
%	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
group	NN	O
versus	VBD	O
22	CD	O
%	NN	O
in	IN	O
the	DT	O
stented	VBN	Surgical
group	NN	O
(	(	O
P	NNP	O
=.137	NNP	O
)	)	O
.	.	O

The	DT	O
reocclusion	NN	O
rates	NNS	O
were	VBD	O
7.3	CD	O
%	NN	O
and	CC	O
8.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
(	(	O
P	NNP	O
=	NNP	O
1.00	CD	O
)	)	O
.	.	O

At	IN	O
12	CD	O
month	NN	O
follow-up	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
conventional	JJ	Pharmacological
group	NN	O
(	(	O
29	CD	O
%	NN	O
versus	IN	O
13	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
.0001	NNP	O
)	)	O
.	.	O

CONCLUSION	NNP	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
stenting	VBG	Surgical
of	IN	O
chronic	JJ	O
total	JJ	O
occlusions	NNS	O
is	VBZ	O
superior	JJ	O
to	TO	O
balloon	VB	Physical
angioplasty	JJ	Physical
alone	RB	Physical
with	IN	O
a	DT	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
need	NN	O
for	IN	O
target	NN	O
lesion	NN	O
revascularization	NN	O
and	CC	O
a	DT	O
lower	JJR	O
,	,	O
but	CC	O
not	RB	O
significant	JJ	O
,	,	O
restenosis	NN	O
rate	NN	O
.	.	O

Breast	NNP	Surgical
reduction	NN	Surgical
alleviates	VBZ	O
depression	NN	O
and	CC	O
anxiety	NN	O
and	CC	O
restores	VBZ	O
self-esteem	NNS	O
:	:	O
a	DT	O
prospective	JJ	O
randomised	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

Of	IN	O
women	NNS	O
who	WP	O
seek	VBP	O
reduction	NN	O
mammaplasty	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
third	JJ	O
have	VBP	O
pathological	JJ	O
degrees	NNS	O
of	IN	O
anxiety	NN	O
or	CC	O
depression	NN	O
,	,	O
or	CC	O
both	DT	O
.	.	O

The	DT	O
psychological	JJ	O
aspect	NN	O
of	IN	O
reduction	NN	Surgical
mammaplasty	NN	Surgical
is	VBZ	O
therefore	RB	O
an	DT	O
important	JJ	O
consideration	NN	O
.	.	O

We	PRP	O
did	VBD	O
a	DT	O
prospective	NN	O
randomised	VBN	O
clinical	JJ	O
trial	NN	O
to	TO	O
see	VB	O
how	WRB	O
reduction	NN	Surgical
mammaplasty	RB	Surgical
affected	VBD	O
macromastia	JJ	O
patients	NNS	O
'	POS	O
depression	NN	O
,	,	O
anxiety	NN	O
,	,	O
and	CC	O
self-esteem	JJ	O
.	.	O

Eighty-two	JJ	O
patients	NNS	O
were	VBD	O
randomised	VBN	O
,	,	O
40	CD	O
to	TO	O
have	VB	O
the	DT	O
operation	NN	O
,	,	O
and	CC	O
42	CD	O
patients	NNS	O
to	TO	O
conservative	JJ	O
treatment	NN	O
.	.	O

Both	DT	O
groups	NNS	O
were	VBD	O
followed	VBN	O
for	IN	O
six	CD	O
months	NNS	O
.	.	O

The	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
RBDI	NNP	O
questionnaire	NN	O
(	(	O
Raitasalo	NNP	O
's	POS	O
modification	NN	O
of	IN	O
the	DT	O
short	JJ	O
form	NN	O
of	IN	O
the	DT	O
Beck	NNP	O
Depression	NNP	O
Inventory	NNP	O
)	)	O
.	.	O

Twenty-nine	JJ	O
patients	NNS	O
in	IN	O
the	DT	O
operated	JJ	O
group	NN	O
and	CC	O
35	CD	O
patients	NNS	O
in	IN	O
the	DT	O
conservative	JJ	O
group	NN	O
completed	VBD	O
the	DT	O
study	NN	O
.	.	O

At	IN	O
the	DT	O
second	JJ	O
examination	NN	O
,	,	O
the	DT	O
patients	NNS	O
who	WP	O
had	VBD	O
been	VBN	O
operated	VBN	O
on	IN	O
,	,	O
had	VBD	O
significantly	RB	O
less	JJR	O
depression	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
better	JJR	O
self-esteem	NN	O
(	(	O
p=0.03	NN	O
)	)	O
than	IN	O
the	DT	O
conservative	JJ	O
group	NN	O
.	.	O

The	DT	O
proportions	NNS	O
of	IN	O
depressed	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
anxious	JJ	O
(	(	O
p=0.04	NN	O
)	)	O
patients	NNS	O
were	VBD	O
also	RB	O
smaller	JJR	O
in	IN	O
the	DT	O
group	NN	O
who	WP	O
were	VBD	O
operated	VBN	O
on	IN	O
.	.	O

There	EX	O
is	VBZ	O
significantly	RB	O
less	JJR	O
depression	NN	O
and	CC	O
anxiety	NN	O
after	IN	O
reduction	NN	O
mammaplasty	NN	Surgical
,	,	O
and	CC	O
patients	NNS	O
'	POS	O
self-esteem	NN	O
is	VBZ	O
restored	VBN	O
.	.	O

Analysis	NN	O
of	IN	O
face	NN	Other
gaze	NN	Other
in	IN	O
autism	NN	O
using	VBG	O
Bubbles	NNP	O
.	.	O

One	CD	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
abnormal	JJ	O
social	JJ	O
functioning	NN	O
in	IN	O
autism	NN	O
is	VBZ	O
an	DT	O
impaired	JJ	O
ability	NN	O
to	TO	O
direct	VB	O
eye	NN	O
gaze	NN	O
onto	IN	O
other	JJ	O
people	NNS	O
's	POS	O
faces	VBZ	O
in	IN	O
social	JJ	O
situations	NNS	O
.	.	O

Here	RB	O
,	,	O
we	PRP	O
investigated	VBD	O
the	DT	O
relationship	NN	O
between	IN	O
gaze	NN	O
onto	IN	O
the	DT	O
eye	NN	O
and	CC	O
mouth	JJ	O
regions	NNS	O
of	IN	O
faces	VBZ	O
,	,	O
and	CC	O
the	DT	O
visual	JJ	O
information	NN	O
that	WDT	O
was	VBD	O
present	JJ	O
within	IN	O
those	DT	O
regions	NNS	O
.	.	O

We	PRP	O
used	VBD	O
the	DT	O
Bubbles	NNP	Other
method	NN	Other
to	TO	O
vary	VB	O
the	DT	O
facial	JJ	O
information	NN	O
available	JJ	O
on	IN	O
any	DT	O
given	VBN	O
trial	NN	O
by	IN	O
revealing	VBG	O
only	RB	O
small	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
and	CC	O
measured	VBD	O
the	DT	O
eye	NN	O
movements	NNS	O
made	VBN	O
as	IN	O
participants	NNS	O
viewed	IN	O
these	DT	O
stimuli	NNS	O
.	.	O

Compared	VBN	O
to	TO	O
ten	VB	O
IQ-	NNP	O
and	CC	O
age-matched	JJ	O
healthy	JJ	O
controls	NNS	O
,	,	O
eight	CD	O
participants	NNS	O
with	IN	O
autism	NN	O
showed	VBD	O
less	JJR	O
fixation	JJ	O
specificity	NN	O
to	TO	O
the	DT	O
eyes	NNS	O
and	CC	O
mouth	NN	O
,	,	O
a	DT	O
greater	JJR	O
tendency	NN	O
to	TO	O
saccade	VB	O
away	RB	O
from	IN	O
the	DT	O
eyes	NNS	O
when	WRB	O
information	NN	O
was	VBD	O
present	JJ	O
in	IN	O
those	DT	O
regions	NNS	O
,	,	O
and	CC	O
abnormal	JJ	O
directionality	NN	O
of	IN	O
saccades	NNS	O
.	.	O

The	DT	O
findings	NNS	O
provide	VBP	O
novel	JJ	O
detail	NN	O
to	TO	O
the	DT	O
abnormal	JJ	O
way	NN	O
in	IN	O
which	WDT	O
people	NNS	O
with	IN	O
autism	NN	O
look	NN	O
at	IN	O
faces	VBZ	O
,	,	O
an	DT	O
impairment	NN	O
that	WDT	O
likely	JJ	O
influences	VBZ	O
all	DT	O
subsequent	JJ	O
face	NN	O
processing	NN	O
.	.	O

BCG	NNP	Pharmacological
(	(	Pharmacological
RIVM	NNP	Pharmacological
)	)	Pharmacological
versus	NN	O
mitomycin	JJ	Pharmacological
intravesical	JJ	Pharmacological
therapy	NN	Pharmacological
in	IN	O
superficial	JJ	O
bladder	NN	O
cancer	NN	O
.	.	O

First	JJ	O
results	NNS	O
of	IN	O
randomized	JJ	O
prospective	JJ	O
trial	NN	O
.	.	O

This	DT	O
study	NN	O
presents	VBZ	O
the	DT	O
preliminary	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
prospective	JJ	O
two-arm	NN	O
study	NN	O
in	IN	O
which	WDT	O
bacillus	JJ	O
Calmette-Gu?rin	NNP	O
(	(	O
BCG	NNP	O
)	)	O
RIVM	NNP	O
,	,	O
a	DT	O
Dutch	JJ	O
BCG	NNP	O
preparation	NN	O
,	,	O
is	VBZ	O
compared	VBN	O
with	IN	O
mitomycin	JJ	O
C	NNP	O
(	(	O
MMC	NNP	O
)	)	O
in	IN	O
patients	NNS	O
with	IN	O
primary	JJ	O
or	CC	O
recurrent	JJ	O
superficial	JJ	O
bladder	NN	O
tumors	NNS	O
,	,	O
including	VBG	O
carcinoma	NN	O
in	IN	O
situ	NN	O
(	(	O
CIS	NNP	O
)	)	O
.	.	O

Therapeutic	JJ	O
regimens	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
after	IN	O
complete	JJ	O
transurethral	JJ	O
resection	NN	O
of	IN	O
all	DT	O
visible	JJ	O
tumors	NNS	O
,	,	O
BCG	NNP	O
RIVM	NNP	O
(	(	O
1	CD	O
x	RB	O
10	CD	O
(	(	O
9	CD	O
)	)	O
bacilli	NN	O
in	IN	O
50	CD	O
mL	NNS	O
saline	NN	O
)	)	O
was	VBD	O
instilled	VBN	O
once	RB	O
a	DT	O
week	NN	O
for	IN	O
six	CD	O
consecutive	JJ	O
weeks	NNS	O
,	,	O
and	CC	O
mitomycin	VB	O
C	NNP	O
(	(	O
30	CD	O
mg	NN	O
in	IN	O
50	CD	O
mL	NNS	O
saline	NN	O
)	)	O
was	VBD	O
administered	VBN	O
once	RB	O
a	DT	O
week	NN	O
for	IN	O
one	CD	O
month	NN	O
(	(	O
weeks	NNS	O
1	CD	O
to	TO	O
4	CD	O
)	)	O
and	CC	O
thereafter	RB	O
once	RB	O
a	DT	O
month	NN	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
six	CD	O
months	NNS	O
.	.	O

Reported	VBN	O
are	VBP	O
the	DT	O
incidence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
in	IN	O
165	CD	O
patients	NNS	O
and	CC	O
the	DT	O
recurrence	NN	O
rate	NN	O
of	IN	O
tumors	NNS	O
in	IN	O
308	CD	O
patients	NNS	O
after	IN	O
a	DT	O
follow-up	JJ	O
period	NN	O
of	IN	O
twelve	JJ	O
months	NNS	O
.	.	O

Drug-induced	NNP	O
,	,	O
or	CC	O
chemical	NN	O
cystitis	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
13	CD	O
(	(	O
16.7	CD	O
%	NN	O
)	)	O
of	IN	O
78	CD	O
BCG-treated	JJ	O
patients	NNS	O
and	CC	O
in	IN	O
12	CD	O
(	(	O
13.8	CD	O
%	NN	O
)	)	O
of	IN	O
87	CD	O
MMC-treated	JJ	O
patients	NNS	O
.	.	O

In	IN	O
the	DT	O
same	JJ	O
groups	NNS	O
bacterial	JJ	O
cystitis	NN	O
occurred	VBD	O
in	IN	O
17	CD	O
(	(	O
21.8	CD	O
%	NN	O
)	)	O
patients	NNS	O
and	CC	O
in	IN	O
16	CD	O
(	(	O
18.4	CD	O
%	NN	O
)	)	O
patients	NNS	O
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
BCG-treated	JJ	O
group	NN	O
(	(	O
N	NNP	O
=	NNP	O
148	CD	O
)	)	O
,	,	O
44	CD	O
(	(	O
29.8	CD	O
%	NN	O
)	)	O
had	VBD	O
recurrent	JJ	O
tumors	NNS	O
,	,	O
while	IN	O
in	IN	O
the	DT	O
MMC-treated	JJ	O
group	NN	O
(	(	O
N	NNP	O
=	NNP	O
160	CD	O
)	)	O
,	,	O
40	CD	O
(	(	O
25.0	CD	O
%	NN	O
)	)	O
had	VBD	O
a	DT	O
recurrence	NN	O
.	.	O

The	DT	O
recurrence	NN	O
rate	NN	O
for	IN	O
BCG-treated	JJ	O
patients	NNS	O
was	VBD	O
0.33	CD	O
;	:	O
the	DT	O
recurrence	NN	O
rate	NN	O
for	IN	O
MMC-treated	JJ	O
patients	NNS	O
was	VBD	O
0.29	CD	O
(	(	O
P	NNP	O
=	NNP	O
0.560	CD	O
,	,	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

These	DT	O
preliminary	JJ	O
data	NNS	O
demonstrated	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
arms	NNS	O
with	IN	O
regard	NN	O
to	TO	O
toxicity	NN	O
and	CC	O
recurrence	NN	O
of	IN	O
tumors	NNS	O
.	.	O

Incidence	NN	O
of	IN	O
infectious	JJ	O
symptoms	NNS	O
after	IN	O
radiation	NN	Physical
therapy	NN	Physical
for	IN	O
breast	NN	O
cancer	NN	O
.	.	O

Long-term	JJ	O
effects	NNS	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
symptoms	NNS	O
generally	RB	O
associated	VBN	O
with	IN	O
infectious	JJ	O
disease	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
a	DT	O
questionnaire	NN	O
sent	VBD	O
out	RB	O
to	TO	O
519	CD	O
disease-free	JJ	O
breast	NN	O
cancer	NN	O
patients	NNS	O
7	CD	O
to	TO	O
12	CD	O
years	NNS	O
after	IN	O
primary	JJ	O
treatment	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
where	WRB	O
pre-	NN	Physical
and	CC	Physical
postoperative	JJ	Physical
radiation	NN	Physical
(	(	Physical
45	CD	Physical
Gy	NNP	Physical
)	)	Physical
was	VBD	O
evaluated	VBN	O
versus	NN	O
surgery	NN	Surgical
only	RB	Surgical
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
a	DT	O
significantly	RB	O
higher	JJR	O
morbidity	NN	O
among	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
preoperative	JJ	Physical
irradiation	NN	Physical
compared	VBN	O
with	IN	O
those	DT	O
irradiated	JJ	Physical
postoperative	JJ	Physical
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

This	DT	O
increased	JJ	O
morbidity	NN	O
mainly	RB	O
seemed	VBD	O
to	TO	O
be	VB	O
caused	VBN	O
by	IN	O
symptoms	NNS	O
usually	RB	O
associated	VBN	O
with	IN	O
respiratory	JJ	O
tract	JJ	O
infection	NN	O
(	(	O
p	NN	O
less	JJR	O
than	IN	O
0.05	CD	O
)	)	O
.	.	O

Although	IN	O
statistically	RB	O
not	RB	O
significant	JJ	O
the	DT	O
preoperatively	RB	Physical
irradiated	JJ	Physical
patients	NNS	O
also	RB	O
had	VBD	O
a	DT	O
higher	JJR	O
morbidity	NN	O
than	IN	O
those	DT	O
treated	VBN	O
with	IN	O
surgery	NN	Surgical
alone	RB	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
postoperatively	RB	Physical
irradiated	JJ	Physical
patients	NNS	O
and	CC	O
patients	NNS	O
treated	VBN	O
with	IN	O
surgery	NN	Surgical
only	RB	O
.	.	O

A	DT	O
significantly	RB	O
higher	JJR	O
integral	JJ	O
dose	NN	O
(	(	O
absorbed	JJ	O
energy	NN	O
within	IN	O
the	DT	O
body	NN	O
)	)	O
of	IN	O
the	DT	O
pre-	JJ	O
compared	VBN	O
with	IN	O
the	DT	O
postoperative	JJ	O
group	NN	O
(	(	O
p	VBZ	O
less	JJR	O
than	IN	O
0.025	CD	O
)	)	O
is	VBZ	O
associated	VBN	O
with	IN	O
the	DT	O
differences	NNS	O
in	IN	O
morbidity	NN	O
between	IN	O
the	DT	O
two	CD	O
irradiated	JJ	O
groups	NNS	O
.	.	O

An	DT	O
explanation	NN	O
for	IN	O
the	DT	O
increased	JJ	O
morbidity	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
that	IN	O
the	DT	O
volume	NN	O
of	IN	O
lung	NN	O
tissue	NN	O
,	,	O
encompassed	VBD	O
within	IN	O
the	DT	O
full-dose	JJ	O
target	NN	O
volume	NN	O
,	,	O
is	VBZ	O
the	DT	O
crucial	JJ	O
factor	NN	O
.	.	O

This	DT	O
volume	NN	O
was	VBD	O
considerable	JJ	O
in	IN	O
the	DT	O
preoperatively	RB	Physical
treated	JJ	Physical
patients	NNS	O
but	CC	O
kept	VBD	O
at	IN	O
a	DT	O
minimum	NN	O
in	IN	O
the	DT	O
postoperative	JJ	Physical
group	NN	O
.	.	O

Side	NNP	O
branch	NN	O
occlusion	NN	O
with	IN	O
everolimus-eluting	JJ	Surgical
and	CC	Surgical
paclitaxel-eluting	JJ	Surgical
stents	NNS	Surgical
:	:	O
three-year	JJ	O
results	NNS	O
from	IN	O
the	DT	O
SPIRIT	NNP	O
III	NNP	O
randomised	VBD	O
trial	NN	O
.	.	O

AIMS	NNP	O
AND	CC	O
METHODS	NNP	O
The	DT	O
rates	NNS	O
of	IN	O
side	NN	O
branch	NN	O
occlusion	NN	O
and	CC	O
subsequent	JJ	O
periprocedural	JJ	O
MI	NNP	O
during	IN	O
everolimus-eluting	JJ	Surgical
stent	NN	Surgical
(	(	Surgical
EES	NNP	Surgical
)	)	Surgical
and	CC	O
paclitaxel-eluting	JJ	Surgical
stent	NN	Surgical
(	(	Surgical
PES	NNP	Surgical
)	)	Surgical
placement	NN	O
were	VBD	O
examined	VBN	O
in	IN	O
the	DT	O
randomised	JJ	O
SPIRIT	NNP	O
III	NNP	O
trial	NN	O
.	.	O

Periprocedural	JJ	O
myocardial	JJ	O
infarction	NN	O
(	(	O
MI	NNP	O
)	)	O
following	VBG	O
drug-eluting	JJ	O
stent	JJ	O
placement	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
long-term	JJ	O
adverse	JJ	O
outcomes	NNS	O
.	.	O

Occlusion	NN	O
of	IN	O
side	NN	O
branches	NNS	O
may	MD	O
be	VB	O
an	DT	O
important	JJ	O
factor	NN	O
contributing	VBG	O
to	TO	O
periprocedural	JJ	O
MIs	NNP	O
.	.	O

Consecutive	JJ	O
procedural	JJ	O
angiograms	NNS	O
of	IN	O
patients	NNS	O
randomly	RB	O
assigned	VBN	O
to	TO	O
EES	NNP	Surgical
(	(	O
n=669	NN	O
)	)	O
or	CC	O
PES	NNP	Surgical
(	(	O
n=333	RB	O
)	)	O
were	VBD	O
analysed	VBN	O
by	IN	O
an	DT	O
independent	JJ	O
angiographic	JJ	O
core	NN	O
laboratory	NN	O
.	.	O

Side	NNP	O
branch	NN	O
occlusion	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
Thrombolysis	NN	O
In	IN	O
Myocardial	NNP	O
Infarction	NNP	O
(	(	O
TIMI	NNP	O
)	)	O
flow	NN	O
grade	VBD	O
0	CD	O
or	CC	O
1	CD	O
.	.	O

Clinical	JJ	O
outcomes	NNS	O
through	IN	O
three	CD	O
years	NNS	O
were	VBD	O
compared	VBN	O
by	IN	O
stent	NN	O
type	NN	O
and	CC	O
presence	NN	O
of	IN	O
side	NN	O
branch	NN	O
occlusion	NN	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
total	NN	O
of	IN	O
2,048	CD	O
side	NN	O
branches	NNS	O
were	VBD	O
evaluated	VBN	O
(	(	O
EES	NNP	O
N=1,345	NNP	O
side	NN	O
branches	NNS	O
in	IN	O
688	CD	O
stented	JJ	O
lesions	NNS	O
,	,	O
PES	NNP	O
N=703	NNP	O
side	NN	O
branches	NNS	O
in	IN	O
346	CD	O
stented	JJ	O
lesions	NNS	O
)	)	O
.	.	O

Patients	NNS	O
with	IN	O
compared	VBN	O
to	TO	O
those	DT	O
without	IN	O
transient	NN	O
or	CC	O
final	JJ	O
side	NN	O
branch	NN	O
occlusion	NN	O
had	VBD	O
significantly	RB	O
higher	JJR	O
non-Q-wave	JJ	O
MI	NNP	O
(	(	O
NQMI	NNP	O
)	)	O
rates	NNS	O
in-hospital	JJ	O
(	(	O
9.0	CD	O
%	NN	O
vs.	FW	O
0.5	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.0001	CD	O
)	)	O
.	.	O

By	IN	O
multivariable	JJ	O
analysis	NN	O
side	NN	O
branch	NN	O
occlusion	NN	O
was	VBD	O
an	DT	O
independent	JJ	O
predictor	NN	O
of	IN	O
NQMI	NNP	O
(	(	O
OR	NNP	O
4.45	CD	O
;	:	O
95	CD	O
%	NN	O
CI	NNP	O
[	NNP	O
1.82	CD	O
,	,	O
10.85	CD	O
]	NN	O
)	)	O
.	.	O

Transient	NN	O
or	CC	O
final	JJ	O
side	NN	O
branch	NN	O
occlusion	NN	O
occurred	VBD	O
less	RBR	O
frequently	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
EES	NNP	O
compared	VBN	O
to	TO	O
PES	NNP	O
(	(	O
2.8	CD	O
%	NN	O
vs.	FW	O
5.2	CD	O
%	NN	O
,	,	O
p=0.009	NN	O
)	)	O
,	,	O
contributing	VBG	O
to	TO	O
the	DT	O
numerically	RB	O
lower	JJR	O
rates	NNS	O
of	IN	O
in-hospital	JJ	O
NQMI	NNP	O
with	IN	O
EES	NNP	O
arm	NN	O
compared	VBN	O
to	TO	O
PES	NNP	O
(	(	O
0.7	CD	O
%	NN	O
vs.	FW	O
2.3	CD	O
%	NN	O
,	,	O
p=0.05	NN	O
)	)	O
.	.	O

Patients	NNS	O
treated	VBD	O
with	IN	O
EES	NNP	Surgical
rather	RB	O
than	IN	O
PES	NNP	Surgical
were	VBD	O
less	RBR	O
likely	JJ	O
to	TO	O
develop	VB	O
side	JJ	O
branch	NN	O
occlusion	NN	O
during	IN	O
stent	JJ	O
placement	NN	O
,	,	O
contributing	VBG	O
to	TO	O
lower	VB	O
rates	NNS	O
of	IN	O
periprocedural	JJ	O
MI	NNP	O
with	IN	O
EES	NNP	Surgical
compared	VBN	O
to	TO	O
PES	NNP	Surgical
.	.	O

Effectiveness	NN	O
of	IN	O
the	DT	O
school	NN	Educational
dental	JJ	Educational
screening	VBG	Educational
programme	NN	Educational
in	IN	O
stimulating	VBG	O
dental	JJ	O
attendance	NN	O
for	IN	O
children	NNS	O
in	IN	O
need	NN	O
of	IN	O
treatment	NN	O
in	IN	O
Northern	NNP	O
Ireland	NNP	O
.	.	O

UNLABELLED	IN	O
The	DT	O
school	NN	O
dental	JJ	O
screening	NN	O
programme	NN	O
has	VBZ	O
been	VBN	O
in	IN	O
existence	NN	O
from	IN	O
the	DT	O
beginning	NN	O
of	IN	O
the	DT	O
20th	JJ	O
century	NN	O
yet	RB	O
its	PRP$	O
value	NN	O
in	IN	O
encouraging	JJ	O
attendance	NN	O
among	IN	O
children	NNS	O
with	IN	O
a	DT	O
dental	JJ	O
health	NN	O
need	NN	O
is	VBZ	O
not	RB	O
fully	RB	O
established	VBN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
school	NN	Educational
dental	JJ	Educational
screening	NN	Educational
in	IN	O
promoting	VBG	O
dental	JJ	O
attendance	NN	O
among	IN	O
children	NNS	O
with	IN	O
a	DT	O
treatment	NN	O
need	NN	O
and	CC	O
to	TO	O
examine	VB	O
the	DT	O
relative	JJ	O
importance	NN	O
of	IN	O
screening	NN	O
,	,	O
social	JJ	O
class	NN	O
and	CC	O
other	JJ	O
factors	NNS	O
in	IN	O
dental	JJ	O
attendance	NN	O
.	.	O

METHODS	NNP	O
Sixty-four	JJ	O
participating	NN	O
schools	NNS	O
were	VBD	O
assigned	VBN	O
to	TO	O
study	VB	O
and	CC	O
control	VB	O
groups	NNS	O
using	VBG	O
a	DT	O
stratified	JJ	O
,	,	O
blocked	JJ	O
randomisation	NN	O
technique	NN	O
.	.	O

The	DT	O
study	NN	O
group	NN	O
children	NNS	O
received	VBD	O
the	DT	O
standard	JJ	Educational
school	NN	Educational
dental	JJ	Educational
screening	NN	Educational
and	CC	O
the	DT	O
dental	JJ	O
attendance	NN	O
of	IN	O
those	DT	O
with	IN	O
a	DT	O
positive	JJ	O
screening	NN	O
result	NN	O
was	VBD	O
assessed	VBN	O
after	IN	O
2	CD	O
months	NNS	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
questionnaire	NN	O
issued	VBN	O
to	TO	O
the	DT	O
children	NNS	O
's	POS	O
parents	NNS	O
.	.	O

The	DT	O
control	NN	O
group	NN	Educational
children	NNS	Educational
were	VBD	Educational
not	RB	Educational
,	,	Educational
at	IN	Educational
this	DT	Educational
stage	NN	Educational
,	,	Educational
screened	VBD	Educational
,	,	O
yet	CC	O
their	PRP$	O
parents	NNS	O
received	VBD	O
the	DT	O
same	JJ	O
questionnaire	NN	O
assessing	VBG	O
dental	JJ	O
attendance	NN	O
over	IN	O
the	DT	O
2-month	JJ	O
period	NN	O
.	.	O

However	RB	O
,	,	O
only	RB	O
questionnaires	VBZ	O
from	IN	O
control	NN	O
group	NN	O
children	NNS	O
who	WP	O
had	VBD	O
a	DT	O
positive	JJ	O
result	NN	O
at	IN	O
a	DT	O
subsequent	JJ	O
screening	NN	O
were	VBD	O
retained	VBN	O
for	IN	O
analysis	NN	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
2,321	CD	O
children	NNS	O
were	VBD	O
screened	VBN	O
,	,	O
with	IN	O
980	CD	O
having	VBG	O
a	DT	O
positive	JJ	O
result	NN	O
.	.	O

The	DT	O
mean	JJ	O
dmft	NN	O
of	IN	O
those	DT	O
screening	VBG	O
positive	JJ	O
was	VBD	O
4.85	CD	O
.	.	O

In	IN	O
all	DT	O
,	,	O
664	CD	O
completed	VBN	O
questionnaires	NNS	O
were	VBD	O
returned	VBN	O
,	,	O
giving	VBG	O
a	DT	O
response	NN	O
rate	NN	O
of	IN	O
67.8	CD	O
%	NN	O
.	.	O

Dental	JJ	O
attendance	NN	O
was	VBD	O
reported	VBN	O
among	IN	O
45.5	CD	O
%	NN	O
of	IN	O
the	DT	O
study	NN	O
group	NN	O
(	(	O
n=352	NN	O
)	)	O
in	IN	O
the	DT	O
2	CD	O
months	NNS	O
following	VBG	O
screening	NN	O
.	.	O

In	IN	O
the	DT	O
same	JJ	O
period	NN	O
,	,	O
27.6	CD	O
%	NN	O
of	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
n=312	RB	O
)	)	O
claimed	VBD	O
attendance	NN	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
significant	JJ	O
among	IN	O
the	DT	O
high	JJ	O
employed	VBN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
the	DT	O
unemployed	JJ	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSION	NNP	O
School	NNP	O
dental	JJ	O
screening	NN	O
was	VBD	O
capable	JJ	O
of	IN	O
stimulating	VBG	O
dental	JJ	O
attendance	NN	O
.	.	O

The	DT	O
strong	JJ	O
effect	NN	O
among	IN	O
the	DT	O
lowest	JJS	O
socio-economic	JJ	O
group	NN	O
shows	VBZ	O
that	IN	O
school	NN	O
dental	JJ	O
screening	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
decrease	VB	O
dental	JJ	O
health	NN	O
inequalities	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
intravenous	JJ	O
and	CC	O
intra-arterial	JJ	O
urokinase	JJ	O
thrombolysis	NN	O
for	IN	O
acute	JJ	O
ischaemic	JJ	O
stroke	NN	O
.	.	O

Intravenous	JJ	Pharmacological
fibrinolysis	NN	Pharmacological
(	(	Pharmacological
IVF	NNP	Pharmacological
)	)	Pharmacological
with	IN	Pharmacological
rt-PA	NN	Pharmacological
(	(	Pharmacological
alteplase	NN	Pharmacological
)	)	Pharmacological
provides	VBZ	O
significant	JJ	O
benefits	NNS	O
in	IN	O
acute	JJ	O
ischaemic	JJ	O
stroke	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
given	VBN	O
within	IN	O
the	DT	O
first	JJ	O
three	CD	O
hours	NNS	O
following	VBG	O
stroke	NN	O
onset	VBN	O
.	.	O

Intra-arterial	JJ	Pharmacological
fibrinolysis	NN	Pharmacological
(	(	Pharmacological
IAF	NNP	Pharmacological
)	)	Pharmacological
with	IN	Pharmacological
pro-urokinase	NN	Pharmacological
in	IN	O
PROACT	NNP	O
II	NNP	O
study	NN	O
provides	VBZ	O
quite	RB	O
the	DT	O
same	JJ	O
benefit	NN	O
in	IN	O
the	DT	O
first	JJ	O
6	CD	O
hours	NNS	O
.	.	O

IVF	NNP	Pharmacological
and	CC	O
IAF	NNP	Pharmacological
have	VBP	O
never	RB	O
been	VBN	O
compared	VBN	O
.	.	O

To	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
IVF	NNP	Pharmacological
and	CC	O
IAF	NNP	Pharmacological
with	IN	O
urokinase	JJ	O
given	VBN	O
within	IN	O
the	DT	O
first	JJ	O
6	CD	O
hours	NNS	O
of	IN	O
acute	JJ	O
ischaemic	JJ	O
stroke	NN	O
.	.	O

Patients	NNS	O
fulfilling	VBG	O
the	DT	O
selection	NN	O
criteria	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
urokinase	JJ	Pharmacological
900,000	CD	O
units	NNS	O
via	IN	O
intravenous	JJ	O
or	CC	O
intra-arterial	JJ	O
routes	NNS	O
.	.	O

This	DT	O
randomised	VBD	O
monocentre	NN	O
study	NN	O
was	VBD	O
done	VBN	O
between	IN	O
December	NNP	O
1995	CD	O
and	CC	O
August	NNP	O
1997	CD	O
.	.	O

The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
the	DT	O
number	NN	O
of	IN	O
patients	NNS	O
with	IN	O
a	DT	O
modified	JJ	O
Rankin	NNP	O
score	NN	O
of	IN	O
2	CD	O
or	CC	O
less	JJR	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
mortality	NN	O
,	,	O
frequency	NN	O
of	IN	O
symptomatic	JJ	O
intracranial	JJ	O
haemorrhage	NN	O
(	(	O
SIH	NNP	O
)	)	O
,	,	O
neurological	JJ	O
and	CC	O
functional	JJ	O
scores	NNS	O
.	.	O

Fourteen	CD	O
patients	NNS	O
were	VBD	O
given	VBN	O
IVF	NNP	Pharmacological
and	CC	O
13	CD	O
IAF	NNP	Pharmacological
.	.	O

The	DT	O
study	NN	O
was	VBD	O
terminated	VBN	O
by	IN	O
the	DT	O
National	NNP	O
Health	NNP	O
Authorities	NNP	O
when	WRB	O
27	CD	O
patients	NNS	O
had	VBD	O
been	VBN	O
included	VBN	O
because	IN	O
of	IN	O
the	DT	O
mortality	NN	O
rate	NN	O
.	.	O

Seven	CD	O
patients	NNS	O
(	(	O
26	CD	O
%	NN	O
)	)	O
died	VBD	O
,	,	O
4	CD	O
in	IN	O
the	DT	O
IV	NNP	O
group	NN	O
(	(	O
oedematous	JJ	O
infarct	NN	O
in	IN	O
3	CD	O
and	CC	O
recurrence	NN	O
in	IN	O
1	CD	O
)	)	O
,	,	O
3	CD	O
in	IN	O
the	DT	O
IA	NNP	O
group	NN	O
(	(	O
SIH	NNP	O
in	IN	O
2	CD	O
,	,	O
and	CC	O
oedematous	JJ	O
infarct	NN	O
in	IN	O
1	CD	O
)	)	O
.	.	O

Patients	NNS	O
given	VBN	O
IVF	NNP	Pharmacological
were	VBD	O
treated	VBN	O
significantly	RB	O
earlier	RBR	O
(	(	O
4:16	CD	O
h	NN	O
vs	NN	O
5:24	CD	O
h	NN	O
;	:	O
p=.007	NN	O
)	)	O
.	.	O

Although	IN	O
IA	NNP	O
patients	NNS	O
showed	VBD	O
greater	JJR	O
and	CC	O
earlier	RBR	O
improvement	NN	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
primary	JJ	O
and	CC	O
secondary	JJ	O
outcomes	NNS	O
.	.	O

Because	IN	O
of	IN	O
premature	NN	O
termination	NN	O
,	,	O
the	DT	O
trial	NN	O
was	VBD	O
too	RB	O
small	JJ	O
to	TO	O
provide	VB	O
any	DT	O
reliable	JJ	O
and	CC	O
conclusive	JJ	O
results	NNS	O
.	.	O

Intra-arterial	JJ	O
fibrinolysis	NN	O
began	VBD	O
significantly	RB	O
later	RBR	O
than	IN	O
IV	NNP	O
fibrinolysis	NN	O
but	CC	O
it	PRP	O
gave	VBD	O
non-significantly	RB	O
better	JJ	O
results	NNS	O
in	IN	O
this	DT	O
prematurely	RB	O
terminated	VBN	O
study	NN	O
.	.	O

Antipyrine	NNP	O
clearance	NN	O
and	CC	O
response	NN	O
to	TO	O
interferon	VB	Pharmacological
treatment	NN	O
in	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
C.	NNP	O
To	TO	O
determine	VB	O
whether	IN	O
hepatic	JJ	O
metabolic	JJ	O
function	NN	O
affects	VBZ	O
the	DT	O
response	NN	O
to	TO	O
interferon	VB	Pharmacological
treatment	NN	O
,	,	O
we	PRP	O
measured	VBD	O
antipyrine	JJ	O
clearance	NN	O
(	(	O
APC	NNP	O
)	)	O
in	IN	O
85	CD	O
patients	NNS	O
with	IN	O
chronic	JJ	O
active	JJ	O
hepatitis	NN	O
C	NNP	O
and	CC	O
compared	VBN	O
the	DT	O
results	NNS	O
with	IN	O
treatment	NN	O
outcome	NN	O
.	.	O

Among	IN	O
55	CD	O
patients	NNS	O
who	WP	O
responded	VBD	O
to	TO	O
interferon	VB	Physical
by	IN	O
normalization	NN	O
of	IN	O
alanine	JJ	O
transaminase	NN	O
(	(	O
ALT	NNP	O
)	)	O
,	,	O
median	JJ	O
APC	NNP	O
before	IN	O
treatment	NN	O
was	VBD	O
0.47	CD	O
(	(	O
range	NN	O
,	,	O
0.12	CD	O
to	TO	O
0.98	CD	O
;	:	O
normal	JJ	O
range	NN	O
,	,	O
0.34	CD	O
to	TO	O
1.02	CD	O
mL/min/kg	NNS	O
body	NN	O
wt	NN	O
)	)	O
,	,	O
a	DT	O
value	NN	O
that	WDT	O
was	VBD	O
significantly	RB	O
greater	JJR	O
than	IN	O
in	IN	O
30	CD	O
nonresponders	NNS	O
(	(	O
0.23	CD	O
;	:	O
0.08	CD	O
to	TO	O
0.67	CD	O
mL/min/kg	NNS	O
body	NN	O
wt	NN	O
,	,	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

APC	NNP	O
was	VBD	O
closely	RB	O
associated	VBN	O
with	IN	O
response	NN	O
to	TO	O
interferon	VB	Physical
.	.	O

The	DT	O
response	NN	O
rate	NN	O
among	IN	O
cases	NNS	O
with	IN	O
values	NNS	O
>	VBP	O
0.25	CD	O
mL/min/kg	NN	O
body	NN	O
weight	NN	O
was	VBD	O
79	CD	O
%	NN	O
,	,	O
the	DT	O
same	JJ	O
as	IN	O
in	IN	O
cases	NNS	O
without	IN	O
cirrhosis	NN	O
.	.	O

Cases	NNS	O
without	IN	O
cirrhosis	NN	O
and	CC	O
with	IN	O
APC	NNP	O
of	IN	O
>	NNP	O
0.25	CD	O
mL/min/kg	NN	O
body	NN	O
weight	NN	O
had	VBD	O
an	DT	O
85	CD	O
%	NN	O
chance	NN	O
of	IN	O
responding	VBG	O
to	TO	O
interferon	VB	Physical
;	:	O
this	DT	O
was	VBD	O
unlikely	JJ	O
a	DT	O
simple	JJ	O
reflection	NN	O
of	IN	O
histological	JJ	O
activity	NN	O
,	,	O
because	IN	O
the	DT	O
correlation	NN	O
with	IN	O
Scheuer	NNP	O
score	NN	O
was	VBD	O
poor	JJ	O
in	IN	O
this	DT	O
subgroup	NN	O
(	(	O
r	JJ	O
=	NNP	O
-.31	NNP	O
,	,	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

A	DT	O
second	JJ	O
,	,	O
independent	JJ	O
group	NN	O
of	IN	O
43	CD	O
patients	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
test	VB	O
the	DT	O
predictive	JJ	O
value	NN	O
of	IN	O
APC	NNP	O
(	(	O
using	VBG	O
0.25	CD	O
mL/min/kg	NN	O
body	NN	O
wt	VBD	O
as	IN	O
a	DT	O
cut-off	NN	O
)	)	O
for	IN	O
response	NN	O
to	TO	O
interferon	VB	Pharmacological
treatment	NN	O
.	.	O

In	IN	O
this	DT	O
group	NN	O
,	,	O
APC	NNP	O
correctly	RB	O
predicted	VBD	O
positive	JJ	O
response	NN	O
to	TO	O
interferon	VB	Pharmacological
in	IN	O
75	CD	O
%	NN	O
of	IN	O
cases	NNS	O
.	.	O

APC	NNP	O
was	VBD	O
also	RB	O
used	VBN	O
to	TO	O
measure	VB	O
the	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
on	IN	O
hepatic	JJ	O
metabolic	JJ	O
function	NN	O
.	.	O

Regardless	NNP	O
of	IN	O
outcome	NN	O
,	,	O
there	EX	O
was	VBD	O
no	DT	O
change	NN	O
in	IN	O
APC	NNP	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
6-month	JJ	O
course	NN	O
of	IN	O
interferon	NN	Pharmacological
treatment	NN	O
.	.	O

Six	CD	O
months	NNS	O
later	RB	O
,	,	O
however	RB	O
,	,	O
improvement	NN	O
in	IN	O
APC	NNP	O
(	(	O
14	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
was	VBD	O
evident	JJ	O
among	IN	O
responders	NNS	O
but	CC	O
not	RB	O
in	IN	O
those	DT	O
who	WP	O
had	VBD	O
failed	VBN	O
to	TO	O
respond	VB	O
to	TO	O
interferon	VB	O
.	.	O

(	(	O
ABSTRACT	NNP	O
TRUNCATED	NNP	O
AT	NNP	O
250	CD	O
WORDS	NNP	O
)	)	O
Evaluation	NN	O
of	IN	O
a	DT	O
preventive	JJ	Psychological
intervention	NN	Psychological
for	IN	O
child	JJ	O
anxiety	NN	O
in	IN	O
two	CD	O
randomized	JJ	O
attention-control	JJ	O
school	NN	O
trials	NNS	O
.	.	O

The	DT	O
present	JJ	O
research	NN	O
examined	VBD	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
cognitive-behavioral	JJ	Psychological
therapy	NN	Psychological
(	(	Psychological
CBT	NNP	Psychological
)	)	Psychological
based	VBN	Psychological
intervention	NN	Psychological
program	NN	Psychological
,	,	Psychological
FRIENDS	NNP	Psychological
,	,	O
for	IN	O
children	NNS	O
from	IN	O
grades	NNS	O
4	CD	O
to	TO	O
6	CD	O
,	,	O
using	VBG	O
random	JJ	O
assignment	NN	O
at	IN	O
the	DT	O
school-level	NN	O
and	CC	O
an	DT	O
attention-control	JJ	O
design	NN	O
in	IN	O
two	CD	O
longitudinal	JJ	O
studies	NNS	O
.	.	O

The	DT	O
first	JJ	O
study	NN	O
targeted	VBD	O
children	NNS	O
with	IN	O
anxiety	NN	O
symptoms	NNS	O
(	(	O
N=191	NNP	O
,	,	O
mean	JJ	O
age=10.1	NN	O
)	)	O
as	IN	O
screened	VBN	O
with	IN	O
self	NN	O
,	,	O
parent	NN	O
,	,	O
and	CC	O
teacher-reports	NNS	O
;	:	O
the	DT	O
second	JJ	O
study	NN	O
took	VBD	O
a	DT	O
universal	JJ	O
approach	NN	O
with	IN	O
full	JJ	O
classrooms	NNS	O
of	IN	O
children	NNS	O
participating	VBG	O
(	(	O
N=253	NNP	O
,	,	O
mean	JJ	O
age=9.8	NN	O
)	)	O
.	.	O

The	DT	O
results	NNS	O
showed	VBD	O
no	DT	O
intervention	NN	O
effect	NN	O
in	IN	O
both	DT	O
studies	NNS	O
,	,	O
with	IN	O
children	NNS	O
's	POS	O
anxiety	NN	O
symptoms	NNS	O
decreasing	VBG	O
over	IN	O
time	NN	O
regardless	NN	O
of	IN	O
whether	IN	O
they	PRP	O
were	VBD	O
in	IN	O
the	DT	O
story-reading	NN	O
(	(	O
attention	NN	O
control	NN	O
)	)	O
or	CC	O
FRIENDS	JJ	O
condition	NN	O
.	.	O

The	DT	O
findings	NNS	O
also	RB	O
indicated	VBD	O
that	IN	O
girls	NNS	O
reported	VBD	O
a	DT	O
higher	JJR	O
level	NN	O
of	IN	O
anxiety	NN	O
than	IN	O
boys	NNS	O
and	CC	O
children	NNS	O
in	IN	O
higher	JJR	O
grades	NNS	O
reported	VBD	O
lower	JJR	O
anxiety	NN	O
relative	NN	O
to	TO	O
younger	JJR	O
children	NNS	O
in	IN	O
both	DT	O
studies	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
similar	JJ	O
patterns	NNS	O
were	VBD	O
found	VBN	O
using	VBG	O
a	DT	O
subgroup	NN	O
of	IN	O
children	NNS	O
with	IN	O
high-anxiety	NN	O
symptoms	NNS	O
from	IN	O
both	DT	O
studies	NNS	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
single-dose	JJ	Pharmacological
versus	NN	O
conventional-dose	JJ	Control
antibiotic	JJ	Control
treatment	NN	Control
of	IN	O
bacteriuria	NN	O
in	IN	O
elderly	JJ	O
women	NNS	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
single-dose	JJ	Pharmacological
antibiotic	JJ	Pharmacological
therapy	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bacteriuria	NN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
non-catheterized	JJ	O
elderly	JJ	O
women	NNS	O
was	VBD	O
compared	VBN	O
with	IN	O
that	DT	O
of	IN	O
conventional	JJ	Pharmacological
7-10	JJ	Pharmacological
day	NN	Pharmacological
courses	NNS	Pharmacological
of	IN	Pharmacological
antibiotic	JJ	Pharmacological
therapy	NN	Pharmacological
.	.	O

Thirty-one	JJ	O
women	NNS	O
received	VBD	O
single-dose	JJ	Control
treatment	NN	Control
and	CC	O
22	CD	O
conventional-dose	JJ	Control
treatment	NN	Control
.	.	O

The	DT	O
cure	NN	O
rates	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
for	IN	O
the	DT	O
single-dose	JJ	O
treatments	NNS	O
were	VBD	O
52	CD	O
%	NN	O
and	CC	O
38	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
the	DT	O
cure	NN	O
rates	NNS	O
for	IN	O
the	DT	O
conventional-dose	JJ	O
treatments	NNS	O
at	IN	O
1	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
were	VBD	O
59	CD	O
%	NN	O
and	CC	O
52	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

It	PRP	O
is	VBZ	O
concluded	VBN	O
that	IN	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
place	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
single-dose	JJ	Pharmacological
antibiotic	JJ	Pharmacological
therapy	NN	Pharmacological
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
selected	VBN	O
elderly	JJ	O
women	NNS	O
with	IN	O
bacteriuria	NN	O
,	,	O
but	CC	O
larger	JJR	O
studies	NNS	O
are	VBP	O
needed	VBN	O
.	.	O

Clinical	JJ	O
benefits	NNS	O
of	IN	O
concurrent	JJ	O
capecitabine	NN	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
versus	NN	O
concurrent	NN	Pharmacological
cisplatin	NN	Pharmacological
and	CC	Pharmacological
5-flurouracil	JJ	Pharmacological
in	IN	O
locally	RB	O
advanced	JJ	O
squamous	JJ	O
cell	NN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
.	.	O

We	PRP	O
aimed	VBD	O
to	TO	O
assess	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
concurrent	JJ	O
capecitabine	NN	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
over	IN	O
concurrent	JJ	Pharmacological
cisplatin	NN	Pharmacological
and	CC	Pharmacological
5-flurouracil	JJ	Pharmacological
(	(	Pharmacological
5-FU	JJ	Pharmacological
)	)	Pharmacological
in	IN	O
locally	RB	O
advanced	JJ	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
of	IN	O
the	DT	O
head	NN	O
and	CC	O
neck	NN	O
.	.	O

One	CD	O
hundred	CD	O
and	CC	O
fifty-three	JJ	O
patients	NNS	O
(	(	O
all	DT	O
of	IN	O
whom	WP	O
had	VBD	O
stage	NN	O
III	NNP	O
or	CC	O
IV	NNP	O
unresectable	JJ	O
disease	NN	O
with	IN	O
no	DT	O
distant	JJ	O
metastases	NNS	O
and	CC	O
who	WP	O
had	VBD	O
received	VBN	O
two	CD	O
cycles	NNS	O
of	IN	O
taxol	NN	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
chemotherapy	NN	Pharmacological
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
concurrent	NN	Pharmacological
cisplatin	NN	Pharmacological
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
day	NN	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
and	CC	Pharmacological
5-FU	JJ	Pharmacological
(	(	O
750	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
day	NN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
)	)	O
from	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
radiotherapy	NN	O
at	IN	O
an	DT	O
interval	NN	O
of	IN	O
3	CD	O
weeks	NNS	O
(	(	O
Arm	NNP	O
I	PRP	O
)	)	O
or	CC	O
cisplatin	NN	Pharmacological
(	(	O
75	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
day	NN	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
and	CC	O
capecitabine	NN	Pharmacological
(	(	O
750	CD	O
mg/m	NN	O
(	(	O
2	CD	O
)	)	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
from	IN	O
day	NN	O
1-14	CD	O
)	)	O
from	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
radiotherapy	NN	O
at	IN	O
a	DT	O
3-week	JJ	O
interval	NN	O
(	(	O
Arm	NNP	O
II	NNP	O
)	)	O
.	.	O

Results	CC	O
showed	VBD	O
that	IN	O
patients	NNS	O
in	IN	O
Arm	NNP	O
II	NNP	O
had	VBD	O
a	DT	O
significantly	RB	O
better	RBR	O
rate	NN	O
of	IN	O
complete	JJ	O
response	NN	O
,	,	O
fewer	JJR	O
nodes	NNS	O
,	,	O
and	CC	O
better	JJR	O
overall	JJ	O
response	NN	O
compared	VBN	O
to	TO	O
those	DT	O
in	IN	O
Arm	NNP	O
I	PRP	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
had	VBD	O
a	DT	O
similar	JJ	O
3-year	JJ	O
disease-free	JJ	O
survival	NN	O
,	,	O
progression	NN	O
free	JJ	O
survival	NN	O
,	,	O
and	CC	O
overall	JJ	O
survival	NN	O
,	,	O
i.e	NN	O
.	.	O

they	PRP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
.	.	O

Variables	NNS	O
indicating	VBG	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
of	IN	O
the	DT	O
two	CD	O
groups	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

Patients	NNS	O
in	IN	O
Arm	NNP	O
II	NNP	O
had	VBD	O
a	DT	O
significantly	RB	O
higher	JJR	O
quality	NN	O
of	IN	O
life	NN	O
compared	VBN	O
to	TO	O
those	DT	O
in	IN	O
Arm	NNP	O
I	PRP	O
.	.	O

The	DT	O
two	CD	O
groups	NNS	O
had	VBD	O
similar	JJ	O
treatment-related	JJ	O
acute	NN	O
and	CC	O
late	JJ	O
toxicity	NN	O
,	,	O
i.e	NN	O
.	.	O

they	PRP	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
.	.	O

These	DT	O
results	NNS	O
have	VBP	O
thoroughly	RB	O
substantiated	VBN	O
the	DT	O
contention	NN	O
that	WDT	O
concurrent	JJ	O
chemoradiation	NN	O
with	IN	O
capecitabine	NN	Pharmacological
and	CC	Pharmacological
cisplatin	NN	Pharmacological
may	MD	O
be	VB	O
regarded	VBN	O
as	IN	O
an	DT	O
effective	JJ	O
and	CC	O
well-tolerated	JJ	O
regimen	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
locally	RB	O
advanced	VBN	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
external	JJ	Physical
beam	NN	Physical
radiotherapy	NN	Physical
versus	NN	O
cryoablation	NN	Physical
in	IN	O
patients	NNS	O
with	IN	O
localized	JJ	O
prostate	NN	O
cancer	NN	O
:	:	O
quality	NN	O
of	IN	O
life	NN	O
outcomes	NNS	O
.	.	O

BACKGROUND	VB	O
A	DT	O
recent	JJ	O
randomized	JJ	O
trial	NN	O
to	TO	O
compare	VB	O
external	JJ	Physical
beam	NN	Physical
radiation	NN	Physical
therapy	NN	Physical
(	(	Physical
EBRT	NNP	Physical
)	)	Physical
to	TO	O
cryoablation	NN	O
for	IN	O
localized	JJ	O
disease	NN	O
showed	VBD	O
cryoablation	NN	O
to	TO	O
be	VB	O
noninferior	JJ	O
to	TO	O
external	JJ	Physical
beam	NN	Physical
EBRT	NNP	Physical
in	IN	O
disease	NN	O
progression	NN	O
and	CC	O
overall	JJ	O
and	CC	O
disease-specific	JJ	O
survival	NN	O
.	.	O

We	PRP	O
report	VBP	O
on	IN	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QOL	NNP	O
)	)	O
outcomes	VBZ	O
for	IN	O
this	DT	O
trial	NN	O
.	.	O

METHODS	NN	O
From	IN	O
December	NNP	O
1997	CD	O
through	IN	O
February	NNP	O
2003	CD	O
,	,	O
244	CD	O
men	NNS	O
with	IN	O
newly	RB	O
diagnosed	VBN	O
localized	JJ	O
prostate	NN	O
cancer	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
cryoablation	NN	Physical
or	CC	O
EBRT	NNP	Physical
(	(	O
median	JJ	O
dose	NN	O
68	CD	O
Gy	NNP	O
)	)	O
.	.	O

All	DT	O
patients	NNS	O
received	VBD	O
neoadjuvant	JJ	Pharmacological
antiandrogen	NN	Pharmacological
therapy	NN	O
.	.	O

Patients	NNS	O
completed	VBD	O
the	DT	O
EORTC	NNP	O
QLQ	NNP	O
C30	NNP	O
and	CC	O
the	DT	O
Prostate	NNP	O
Cancer	NNP	O
Index	NNP	O
(	(	O
PCI	NNP	O
)	)	O
before	IN	O
treatment	NN	O
and	CC	O
at	IN	O
1.5	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
18	CD	O
,	,	O
24	CD	O
,	,	O
and	CC	O
36	CD	O
months	NNS	O
post-treatment	JJ	O
.	.	O

RESULTS	NNP	O
Regardless	NNP	O
of	IN	O
treatment	NN	O
arm	NN	O
,	,	O
participants	NNS	O
reported	VBD	O
high	JJ	O
levels	NNS	O
of	IN	O
QOL	NNP	O
with	IN	O
few	JJ	O
exceptions	NNS	O
.	.	O

cryoablation	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
more	RBR	O
acute	JJ	O
urinary	JJ	O
dysfunction	NN	O
(	(	O
mean	JJ	O
PCI	NNP	O
urinary	JJ	O
function	NN	O
cryoablation=69.4	NN	O
;	:	O
mean	JJ	O
EBRT=90.7	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
,	,	O
which	WDT	O
resolved	VBD	O
over	IN	O
time	NN	O
.	.	O

No	DT	O
late	JJ	O
arising	NN	O
QOL	NNP	O
issues	NNS	O
were	VBD	O
observed	VBN	O
.	.	O

Both	DT	O
EBRT	NNP	Physical
and	CC	O
cryoablation	NN	Physical
participants	NNS	O
reported	VBD	O
decreases	NNS	O
in	IN	O
sexual	JJ	O
function	NN	O
at	IN	O
3	CD	O
months	NNS	O
with	IN	O
the	DT	O
cryoablation	NN	O
patients	NNS	O
reporting	VBG	O
poorer	NN	O
functioning	NN	O
(	(	O
mean	JJ	O
cryoablation=7.2	NN	O
:	:	O
mean	JJ	O
EBRT=32.9	NNP	O
;	:	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

Mean	JJ	O
sexual	JJ	O
function	NN	O
score	NN	O
was	VBD	O
15	CD	O
points	NNS	O
lower	JJR	O
at	IN	O
3	CD	O
years	NNS	O
for	IN	O
the	DT	O
cryoablation	NN	Physical
group	NN	O
and	CC	O
13	CD	O
%	NN	O
more	JJR	O
of	IN	O
the	DT	O
cryoablation	NN	Physical
men	NNS	O
said	VBD	O
that	IN	O
sexuality	NN	O
was	VBD	O
a	DT	O
moderate	JJ	O
or	CC	O
big	JJ	O
problem	NN	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
this	DT	O
randomized	JJ	O
trial	NN	O
,	,	O
no	DT	O
long-term	JJ	O
QOL	NNP	O
advantage	NN	O
for	IN	O
either	DT	O
treatment	NN	O
was	VBD	O
apparent	JJ	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
poorer	JJR	O
sexual	JJ	O
function	NN	O
reported	VBN	O
by	IN	O
those	DT	O
treated	VBN	O
with	IN	O
cryoablation	NN	Physical
.	.	O

Men	NN	O
who	WP	O
wish	VBZ	O
to	TO	O
increase	VB	O
their	PRP$	O
odds	NNS	O
of	IN	O
retaining	VBG	O
sexual	JJ	O
function	NN	O
might	MD	O
be	VB	O
counseled	VBN	O
to	TO	O
choose	VB	O
EBRT	NNP	Physical
over	IN	O
cryoablation	NN	Physical
.	.	O

Effect	NN	O
of	IN	O
device-guided	JJ	Educational
breathing	NN	Educational
exercises	NNS	Educational
on	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
.	.	O

OBJECTIVE	NNP	O
Hypertension	NNP	O
is	VBZ	O
a	DT	O
chronic	JJ	O
disorder	NN	O
with	IN	O
a	DT	O
high	JJ	O
prevalence	NN	O
worldwide	NN	O
.	.	O

Despite	IN	O
considerable	JJ	O
efforts	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
sometimes	RB	O
hard	JJ	O
to	TO	O
reach	VB	O
treatment	NN	O
goals	NNS	O
for	IN	O
blood	NN	O
pressure	NN	O
(	(	O
BP	NNP	O
)	)	O
with	IN	O
classical	JJ	O
treatment	NN	O
options	NNS	O
.	.	O

Reducing	VBG	O
breathing	VBG	O
frequency	NN	O
has	VBZ	O
been	VBN	O
advocated	VBN	O
as	IN	O
a	DT	O
method	NN	O
to	TO	O
reduce	VB	O
BP	NNP	O
.	.	O

METHODS	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
single-blind	JJ	O
,	,	O
controlled	VBD	O
trial	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
30	CD	O
non-diabetic	JJ	O
patients	NNS	O
with	IN	O
hypertension	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
9	CD	O
weeks	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
device	NN	Educational
that	WDT	Educational
helps	VBZ	Educational
to	TO	Educational
slow	VB	Educational
breathing	NN	Educational
(	(	Educational
Resperate	NNP	Educational
)	)	Educational
on	IN	O
BP	NNP	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
QoL	NNP	O
)	)	O
.	.	O

The	DT	O
control	NN	O
group	NN	O
listened	VBD	Educational
to	TO	Educational
music	NN	Educational
and	CC	Educational
used	VBN	Educational
no	DT	Educational
other	JJ	Educational
therapeutic	JJ	Educational
device	NN	Educational
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
change	NN	O
in	IN	O
BP	NNP	O
between	IN	O
intervention	NN	O
and	CC	O
control	NN	O
;	:	O
BP	NNP	O
-4.2	NNP	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-12.4	NNP	O
to	TO	O
3.9	CD	O
)	)	O
/-2.6	NN	O
mmHg	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
-8.4	NNP	O
to	TO	O
3.3	CD	O
)	)	O
.	.	O

This	DT	O
result	NN	O
did	VBD	O
not	RB	O
alter	VB	O
in	IN	O
post	NN	O
hoc	NN	O
analyses	NNS	O
,	,	O
when	WRB	O
patients	NNS	O
not	RB	O
achieving	VBG	O
target	NN	O
breathing	NN	O
frequency	NN	O
(	(	O
<	JJ	O
10	CD	O
breaths/min	NN	O
)	)	O
or	CC	O
non-compliant	JJ	O
patients	NNS	O
were	VBD	O
excluded	VBN	O
.	.	O

QoL	NNP	O
did	VBD	O
not	RB	O
change	VB	O
over	IN	O
time	NN	O
.	.	O

CONCLUSIONS	NNP	O
We	PRP	O
found	VBD	O
no	DT	O
effect	NN	O
of	IN	O
the	DT	O
Resperate	NNP	O
on	IN	O
BP	NNP	O
or	CC	O
QoL	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

We	PRP	O
conclude	VBP	O
that	IN	O
,	,	O
at	IN	O
this	DT	O
moment	NN	O
,	,	O
this	DT	O
device	NN	O
has	VBZ	O
no	DT	O
added	VBN	O
value	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypertension	NN	O
.	.	O

Chronopharmacology	NN	O
of	IN	O
enalapril	NN	Pharmacological
in	IN	O
hypertensive	JJ	O
patients	NNS	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
enalapril	NN	Pharmacological
,	,	O
an	DT	O
angiotensin	NN	O
converting	VBG	O
enzyme	JJ	O
inhibitor	NN	O
,	,	O
are	VBP	O
reported	VBN	O
to	TO	O
vary	VB	O
with	IN	O
the	DT	O
time	NN	O
of	IN	O
administration	NN	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
was	VBD	O
undertaken	VBN	O
to	TO	O
examine	VB	O
whether	IN	O
the	DT	O
effect	NN	O
of	IN	O
enalapril	NN	Pharmacological
on	IN	O
plasma	NN	O
bradykinin	NN	O
(	(	O
BK	NNP	O
)	)	O
,	,	O
substance	NN	O
P	NNP	O
and	CC	O
prostaglandin	VB	O
E2	NNP	O
(	(	O
PGE2	NNP	O
)	)	O
,	,	O
which	WDT	O
are	VBP	O
likely	JJ	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
the	DT	O
mechanism	NN	O
of	IN	O
enalapril-induced	JJ	O
cough	NN	O
,	,	O
might	MD	O
also	RB	O
be	VB	O
affected	VBN	O
by	IN	O
its	PRP$	O
time	NN	O
of	IN	O
administration	NN	O
.	.	O

Enalapril	NNP	Pharmacological
5	CD	O
mg	NN	O
or	CC	O
placebo	NN	Control
was	VBD	O
given	VBN	O
orally	RB	O
at	IN	O
10:00	CD	O
h	NN	O
(	(	O
day	NN	O
trial	NN	O
)	)	O
or	CC	O
22:00	CD	O
h	NN	O
(	(	O
night	NN	O
trial	NN	O
)	)	O
to	TO	O
12	CD	O
patients	NNS	O
with	IN	O
essential	JJ	O
hypertension	NN	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
total	JJ	O
drug	NN	O
(	(	O
enalapril	JJ	Pharmacological
+	NNP	O
enalaprilat	NN	Control
,	,	O
its	PRP$	O
active	JJ	O
metabolite	NN	O
)	)	O
during	IN	O
the	DT	O
day	NN	O
and	CC	O
night	NN	O
trials	NNS	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
at	IN	O
any	DT	O
time	NN	O
.	.	O

However	RB	O
,	,	O
serum	JJ	Pharmacological
enalaprilat	NN	Pharmacological
tended	VBD	O
to	TO	O
be	VB	O
higher	JJR	O
and	CC	O
its	PRP$	O
maximum	JJ	O
concentration	NN	O
greater	JJR	O
in	IN	O
the	DT	O
day	NN	O
trial	NN	O
than	IN	O
in	IN	O
the	DT	O
night	NN	O
trial	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
24	CD	O
h	NN	O
after	IN	O
administration	NN	O
of	IN	O
enalapril	NN	Pharmacological
was	VBD	O
reduced	VBN	O
at	IN	O
22:00	CD	O
h	NN	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
10:00	CD	O
h.	NN	O
Plasma	NNP	O
BK	NNP	O
tended	VBD	O
to	TO	O
increase	VB	O
following	VBG	O
enalapril	JJ	Pharmacological
administration	NN	O
at	IN	O
10:00	CD	O
h	NN	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
22:00	CD	O
h.	NN	O
Remarkable	JJ	O
increases	NNS	O
in	IN	O
plasma	NN	O
BK	NNP	O
were	VBD	O
observed	VBN	O
in	IN	O
two	CD	O
patients	NNS	O
in	IN	O
the	DT	O
day	NN	O
trial	NN	O
and	CC	O
one	CD	O
of	IN	O
them	PRP	O
also	RB	O
complained	VBD	O
of	IN	O
cough	NN	O
.	.	O

However	RB	O
,	,	O
no	DT	O
such	JJ	O
increase	NN	O
in	IN	O
plasma	JJ	O
BK	NNP	O
or	CC	O
subsequent	JJ	O
adverse	JJ	O
effect	NN	O
were	VBD	O
recorded	VBN	O
in	IN	O
the	DT	O
night	NN	O
trial	NN	O
.	.	O

Plasma	NNP	O
substance	NN	O
P	NNP	O
and	CC	O
PGE2	NNP	O
did	VBD	O
not	RB	O
change	VB	O
significantly	RB	O
following	VBG	O
enalapril	JJ	Pharmacological
administration	NN	O
either	RB	O
in	IN	O
the	DT	O
day	NN	O
or	CC	O
night	NN	O
trial	NN	O
.	.	O

The	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
response	NN	O
of	IN	O
BK	NNP	O
to	TO	O
enalapril	VB	Pharmacological
is	VBZ	O
affected	VBN	O
by	IN	O
the	DT	O
time	NN	O
of	IN	O
administration	NN	O
.	.	O

In	IN	O
patients	NNS	O
who	WP	O
complain	VBP	O
of	IN	O
cough	NN	O
during	IN	O
treatment	NN	O
with	IN	O
enalapril	NN	Pharmacological
during	IN	O
the	DT	O
daytime	NN	O
,	,	O
this	DT	O
adverse	JJ	O
effect	NN	O
might	MD	O
be	VB	O
diminished	VBN	O
or	CC	O
eliminated	VBN	O
by	IN	O
a	DT	O
switch	NN	O
to	TO	O
night-time	JJ	O
administration	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
Villalta-Prandoni	NNP	Other
scale	NN	Other
and	CC	O
venous	JJ	Other
clinical	JJ	Other
severity	NN	Other
score	NN	Other
in	IN	O
the	DT	O
assessment	NN	O
of	IN	O
post	NN	O
thrombotic	JJ	O
syndrome	NN	O
.	.	O

BACKGROUND	NNP	O
Post-thrombotic	JJ	O
syndrome	NN	O
(	(	O
PTS	NNP	O
)	)	O
is	VBZ	O
the	DT	O
most	RBS	O
important	JJ	O
late	JJ	O
complication	NN	O
of	IN	O
acute	JJ	O
deep	JJ	O
venous	JJ	O
thrombosis	NN	O
(	(	O
DVT	NNP	O
)	)	O
,	,	O
with	IN	O
as	RB	O
many	JJ	O
as	IN	O
two-thirds	NNS	O
of	IN	O
patients	NNS	O
developing	VBG	O
symptoms	NNS	O
of	IN	O
pain	NN	O
,	,	O
edema	NN	O
,	,	O
hyperpigmentation	NN	O
,	,	O
or	CC	O
ulceration	NN	O
.	.	O

Although	IN	O
several	JJ	O
instruments	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
evaluation	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
PTS	NNP	O
,	,	O
including	VBG	O
the	DT	O
Villalta-Prandoni	NNP	Other
scale	NN	Other
(	(	Other
VPS	NNP	Other
)	)	Other
and	CC	O
Venous	JJ	Other
Clinical	NNP	Other
Severity	NNP	Other
Score	NNP	Other
(	(	Other
VCSS	NNP	Other
)	)	Other
,	,	O
no	DT	O
studies	NNS	O
have	VBP	O
yet	RB	O
compared	VBN	O
the	DT	O
2	CD	O
instruments	NNS	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
is	VBZ	O
to	TO	O
compare	VB	O
the	DT	O
2	CD	O
instruments	NNS	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
larger	JJR	O
randomized	VBN	O
controlled	VBD	O
study	NN	O
that	WDT	O
assessed	VBD	O
the	DT	O
impact	NN	O
of	IN	O
graduated	JJ	Physical
compressive	JJ	Physical
stockings	NNS	Physical
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
PTS	NNP	O
.	.	O

METHODS	NNP	O
Sixty-nine	JJ	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
acute	JJ	O
DVT	NNP	O
documented	VBN	O
by	IN	O
duplex	JJ	O
ultrasonography	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
treatment	NN	O
with	IN	O
30-40	JJ	Physical
mm	NN	Physical
Hg	NNP	Physical
graduated	VBD	Physical
compressive	JJ	Physical
stockings	NNS	Physical
(	(	Physical
GCS	NNP	Physical
)	)	Physical
or	CC	O
no	DT	Control
stockings	NNS	Control
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
clinically	RB	O
at	IN	O
months	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
,	,	O
18	CD	O
,	,	O
and	CC	O
24	CD	O
after	IN	O
the	DT	O
diagnosis	NN	O
of	IN	O
DVT	NNP	O
.	.	O

PTS	NNP	O
as	IN	O
defined	VBN	O
by	IN	O
the	DT	O
VPS	NNP	O
and	CC	O
VCSS	NNP	O
were	VBD	O
assessed	VBN	O
at	IN	O
these	DT	O
follow-up	JJ	O
visits	NNS	O
.	.	O

Based	VBN	O
upon	IN	O
the	DT	O
VPS	NNP	O
,	,	O
PTS	NNP	O
was	VBD	O
scored	VBN	O
as	IN	O
absent	NN	O
(	(	O
score	NN	O
<	VBZ	O
3	CD	O
or	CC	O
3	CD	O
without	IN	O
objective	JJ	O
criteria	NNS	O
)	)	O
,	,	O
mild	FW	O
to	TO	O
moderate	VB	O
(	(	O
score	NN	O
?3	NN	O
with	IN	O
1	CD	O
objective	JJ	O
criteria	NNS	O
)	)	O
,	,	O
or	CC	O
severe	RB	O
(	(	O
score	VB	O
?4	NN	O
)	)	O
.	.	O

For	IN	O
the	DT	O
VCSS	NNP	O
,	,	O
PTS	NNP	O
was	VBD	O
considered	VBN	O
to	TO	O
be	VB	O
absent	JJ	O
(	(	O
score	VB	O
?3	NN	O
)	)	O
,	,	O
mild	FW	O
to	TO	O
moderate	VB	O
(	(	O
score	VB	O
4-7	NN	O
)	)	O
,	,	O
or	CC	O
severe	RB	O
(	(	O
score	VB	O
?8	NN	O
)	)	O
.	.	O

The	DT	O
2	CD	O
instruments	NNS	O
were	VBD	O
compared	VBN	O
for	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
and	CC	O
severe	JJ	O
disease	NN	O
using	VBG	O
the	DT	O
Pearson	NNP	O
chi-squared	JJ	O
test	NN	O
and	CC	O
gamma	NN	O
statistic	NN	O
.	.	O

RESULTS	NNP	O
Good	JJ	O
correlation	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
ability	NN	O
of	IN	O
VPS	NNP	O
and	CC	O
VCSS	NNP	O
instruments	NNS	O
to	TO	O
detect	VB	O
mild	NN	O
to	TO	O
moderate	VB	O
disease	NN	O
(	(	O
gamma	JJ	O
statistic	JJ	O
=	NNP	O
0.71-0.98	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

For	IN	O
severe	JJ	O
disease	NN	O
,	,	O
a	DT	O
statistically	RB	O
significant	JJ	O
correlation	NN	O
was	VBD	O
not	RB	O
found	VBN	O
in	IN	O
the	DT	O
ability	NN	O
of	IN	O
the	DT	O
2	CD	O
instruments	NNS	O
to	TO	O
detect	VB	O
disease	NN	O
(	(	O
gamma	JJ	O
statistic	JJ	O
=	NNP	O
0.5-0.98	NN	O
;	:	O
P	NNP	O
>	NNP	O
0.05	CD	O
)	)	O
,	,	O
especially	RB	O
at	IN	O
12	CD	O
and	CC	O
24	CD	O
months	NNS	O
.	.	O

CONCLUSION	NNP	O
Both	NNP	O
VPS	NNP	O
and	CC	O
the	DT	O
VCSS	NNP	O
scoring	VBG	O
systems	NNS	O
are	VBP	O
important	JJ	O
tools	NNS	O
in	IN	O
the	DT	O
identification	NN	O
and	CC	O
follow-up	NN	O
of	IN	O
PTS	NNP	O
.	.	O

There	EX	O
exists	VBZ	O
agreement	NN	O
between	IN	O
the	DT	O
2	CD	O
instruments	NNS	O
for	IN	O
detecting	VBG	O
mild	NN	O
to	TO	O
moderate	VB	O
disease	NN	O
.	.	O

For	IN	O
severe	JJ	O
disease	NN	O
however	RB	O
,	,	O
VCSS	NNP	O
may	MD	O
possibly	RB	O
be	VB	O
a	DT	O
more	RBR	O
sensitive	JJ	O
instrument	NN	O
.	.	O

Mastication	NN	O
and	CC	O
late	JJ	O
mandibular	NN	O
fracture	NN	O
after	IN	O
surgery	NN	Surgical
of	IN	O
impacted	JJ	O
third	JJ	O
molars	NNS	O
associated	VBN	O
with	IN	O
no	DT	O
gross	JJ	O
pathology	NN	O
.	.	O

PURPOSE	VB	O
This	DT	O
study	NN	O
was	VBD	O
undertaken	VBN	O
with	IN	O
the	DT	O
null	JJ	O
hypothesis	NN	O
that	IN	O
in	IN	O
patients	NNS	O
,	,	O
fully	RB	O
denate	VB	O
or	CC	O
with	IN	O
1	CD	O
or	CC	O
2	CD	O
teeth	NNS	O
missing	VBG	O
and	CC	O
older	JJR	O
than	IN	O
25	CD	O
years	NNS	O
,	,	O
mastication	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
late	JJ	O
mandibular	JJ	O
fracture	NN	O
after	IN	O
surgical	JJ	Surgical
removal	NN	Surgical
of	IN	O
impacted	JJ	O
third	JJ	O
molars	NNS	O
(	(	O
M3s	NNP	O
)	)	O
associated	VBN	O
with	IN	O
no	DT	O
gross	JJ	O
pathology	NN	O
.	.	O

MATERIALS	NNP	O
AND	CC	O
METHODS	NNP	O
Five	NNP	O
hundred	VBD	O
sixty	NN	O
patients	NNS	O
,	,	O
fully	RB	O
dentate	VB	O
or	CC	O
with	IN	O
1	CD	O
or	CC	O
2	CD	O
teeth	NNS	O
missing	VBG	O
and	CC	O
older	JJR	O
than	IN	O
25	CD	O
years	NNS	O
who	WP	O
had	VBD	O
no	DT	O
gross	JJ	O
pathology	NN	O
associated	VBN	O
with	IN	O
their	PRP$	O
impacted	VBN	O
lower	JJR	O
M3s	NNP	O
,	,	O
were	VBD	O
recruited	VBN	O
in	IN	O
this	DT	O
study	NN	O
.	.	O

They	PRP	O
were	VBD	O
operated	VBN	Surgical
on	IN	O
under	IN	O
local	JJ	Pharmacological
anesthesia	NN	Pharmacological
using	VBG	O
a	DT	O
standard	NN	O
technique	NN	O
and	CC	O
randomly	RB	O
assigned	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
for	IN	O
nonroutine	NN	O
(	(	O
NR	NNP	O
group	NN	O
)	)	O
and	CC	O
routine	JJ	O
(	(	O
R	NNP	O
group	NN	O
)	)	O
postoperative	NN	O
instructions	NNS	O
.	.	O

In	IN	O
the	DT	O
NR	NNP	O
group	NN	O
,	,	O
patients	NNS	O
were	VBD	O
postoperatively	RB	O
educated	VBN	O
in	IN	O
the	DT	O
possibility	NN	O
of	IN	O
mandibular	JJ	O
fracture	NN	O
and	CC	O
were	VBD	O
given	VBN	O
an	DT	O
emphasis	NN	O
on	IN	O
the	DT	O
necessity	NN	O
of	IN	O
limiting	VBG	O
mastication	NN	O
to	TO	O
a	DT	O
soft	JJ	O
diet	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

In	IN	O
the	DT	O
R	NNP	O
group	NN	O
,	,	O
patients	NNS	O
were	VBD	O
given	VBN	O
no	DT	O
such	JJ	O
education	NN	O
or	CC	O
emphasis	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
followed	VBN	O
up	RP	O
for	IN	O
2	CD	O
months	NNS	O
,	,	O
and	CC	O
data	NNS	O
concerning	VBG	O
patients	NNS	O
'	POS	O
age	NN	O
and	CC	O
gender	NN	O
;	:	O
tooth	CC	O
position	NN	O
,	,	O
angulation	NN	O
,	,	O
and	CC	O
depth	NN	O
;	:	O
date	NN	O
and	CC	O
site	NN	O
of	IN	O
surgery	NN	Surgical
;	:	O
and	CC	O
occurrence	NN	O
of	IN	O
late	JJ	O
mandibular	JJ	O
fracture	NN	O
were	VBD	O
recorded	VBN	O
and	CC	O
statistically	RB	O
analyzed	VBN	O
.	.	O

A	DT	O
value	NN	O
of	IN	O
P	NNP	O
less	JJR	O
than	IN	O
.05	NN	O
was	VBD	O
considered	VBN	O
statistically	RB	O
significant	JJ	O
.	.	O

RESULTS	NNP	O
In	IN	O
no	DT	O
patient	NN	O
group	NN	O
was	VBD	O
there	RB	O
a	DT	O
late	JJ	O
mandibular	JJ	O
fracture	NN	O
recorded	VBN	O
.	.	O

All	DT	O
patients	NNS	O
completed	VBD	O
the	DT	O
follow-up	JJ	O
period	NN	O
,	,	O
and	CC	O
most	JJS	O
of	IN	O
the	DT	O
R	NNP	O
group	NN	O
patients	NNS	O
had	VBD	O
normal	JJ	O
eating	JJ	O
habits	NNS	O
10	CD	O
to	TO	O
14	CD	O
days	NNS	O
after	IN	O
surgery	NN	O
.	.	O

In	IN	O
no	DT	O
patient	NN	O
group	NN	O
was	VBD	O
there	RB	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
in	IN	O
relation	NN	O
to	TO	O
gender	VB	O
(	(	O
P	NNP	O
=	NNP	O
.735	NNP	O
)	)	O
,	,	O
site	NN	O
of	IN	O
surgery	NN	O
(	(	O
P	NNP	O
=	NNP	O
.552	NNP	O
)	)	O
,	,	O
class	NN	O
horizontal	JJ	O
space	NN	O
available	JJ	O
(	(	O
P	NNP	O
=	NNP	O
.427	NNP	O
)	)	O
,	,	O
class	NN	O
highest	JJS	O
portion	NN	O
of	IN	O
the	DT	O
M3	NNP	O
crown	NN	O
(	(	O
P	NNP	O
=	NNP	O
.424	NNP	O
)	)	O
,	,	O
angulations	NNS	O
of	IN	O
the	DT	O
teeth	NN	O
(	(	O
P	NNP	O
=	NNP	O
.925	NNP	O
)	)	O
,	,	O
and	CC	O
severity	NN	O
of	IN	O
impaction	NN	O
(	(	O
P	NNP	O
=	NNP	O
.445	NNP	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
,	,	O
fully	RB	O
dentate	VB	O
or	CC	O
with	IN	O
1	CD	O
or	CC	O
2	CD	O
teeth	NNS	O
missing	VBG	O
and	CC	O
older	JJR	O
than	IN	O
25	CD	O
years	NNS	O
who	WP	O
have	VBP	O
no	DT	O
jawbone	NN	O
atrophy	NN	O
and	CC	O
no	DT	O
systemic	JJ	O
problems	NNS	O
that	WDT	O
may	MD	O
impair	VB	O
bone	NN	O
strength	NN	O
,	,	O
mastication	NN	O
seems	VBZ	O
not	RB	O
to	TO	O
affect	VB	O
late	JJ	O
mandibular	JJ	O
fracture	NN	O
after	IN	O
surgical	JJ	O
removal	NN	O
of	IN	O
impacted	JJ	O
M3s	NNP	O
associated	VBN	O
with	IN	O
no	DT	O
gross	JJ	O
pathology	NN	O
.	.	O

The	DT	O
remote	JJ	O
possible	JJ	O
risk	NN	O
of	IN	O
the	DT	O
late	JJ	O
fracture	NN	O
shown	VBN	O
in	IN	O
our	PRP$	O
patients	NNS	O
indicates	VBZ	O
the	DT	O
need	NN	O
for	IN	O
no	DT	O
special	JJ	O
precautions	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
a	DT	O
culture-specific	JJ	Educational
education	NN	Educational
program	NN	Educational
to	TO	Educational
promote	VB	Educational
breastfeeding	NN	Educational
among	IN	O
Vietnamese	JJ	O
women	NNS	O
in	IN	O
Sydney	NNP	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
breastfeeding	VBG	O
among	IN	O
immigrant	JJ	O
Vietnamese	JJ	O
women	NNS	O
in	IN	O
Western	JJ	O
countries	NNS	O
is	VBZ	O
low	JJ	O
compared	VBN	O
to	TO	O
those	DT	O
in	IN	O
Vietnam	NNP	O
.	.	O

To	TO	O
counteract	VB	O
this	DT	O
trend	NN	O
,	,	O
a	DT	O
language	NN	Educational
and	CC	Educational
culture	NN	Educational
specific	JJ	Educational
education	NN	Educational
program	NN	O
was	VBD	O
developed	VBN	O
.	.	O

An	DT	O
experimental	JJ	O
design	NN	O
was	VBD	O
used	VBN	O
to	TO	O
test	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
this	DT	O
program	NN	O
.	.	O

The	DT	O
sample	NN	O
consisted	VBD	O
of	IN	O
182	CD	O
prenatal	JJ	O
Vietnamese	JJ	O
women	NNS	O
.	.	O

Data	NNP	O
collection	NN	O
included	VBD	O
questionnaires	NNS	O
and	CC	O
interviews	NNS	O
.	.	O

Results	NNS	O
suggested	VBD	O
that	IN	O
the	DT	O
education	NN	O
program	NN	O
had	VBD	O
significant	JJ	O
effects	NNS	O
on	IN	O
knowledge	NN	O
,	,	O
attitudes	NNS	O
,	,	O
planned	VBD	O
and	CC	O
actual	JJ	O
behaviour	NN	O
towards	NNS	O
breastfeeding	VBG	O
.	.	O

However	RB	O
,	,	O
the	DT	O
effect	NN	O
did	VBD	O
not	RB	O
sustain	VB	O
until	IN	O
6	CD	O
months	NNS	O
postpartum	NN	O
.	.	O

Implications	NNS	O
for	IN	O
nursing	NN	O
practice	NN	O
and	CC	O
further	JJ	O
research	NN	O
are	VBP	O
discussed	VBN	O
.	.	O

Dexamethasone	NNP	Pharmacological
therapy	NN	Pharmacological
and	CC	O
cortisol	JJ	O
excretion	NN	O
in	IN	O
severe	JJ	O
pediatric	JJ	O
head	NN	O
injury	NN	O
.	.	O

Glucocorticoids	NNS	Pharmacological
are	VBP	O
used	VBN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
reduce	VB	O
brain	NN	O
edema	NN	O
secondary	JJ	O
to	TO	O
head	VB	O
injury	NN	O
.	.	O

Nevertheless	RB	O
,	,	O
their	PRP$	O
usefulness	JJ	O
remains	NNS	O
uncertain	JJ	O
and	CC	O
contradictory	NN	O
.	.	O

In	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
of	IN	O
24	CD	O
children	NNS	O
with	IN	O
severe	JJ	O
head	NN	O
injury	NN	O
,	,	O
urinary	JJ	O
free	JJ	O
cortisol	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
radioimmunoassay	NN	O
.	.	O

Twelve	CD	O
patients	NNS	O
(	(	O
group	NN	O
1	CD	O
)	)	O
received	VBD	O
dexamethasone	NN	Pharmacological
and	CC	O
12	CD	O
(	(	O
group	NN	O
2	CD	O
)	)	O
did	VBD	O
not	RB	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
standardized	JJ	O
regimen	NN	O
.	.	O

In	IN	O
group	NN	O
1	CD	O
there	EX	O
was	VBD	O
complete	JJ	O
suppression	NN	O
of	IN	O
endogenous	JJ	O
cortisol	NN	O
production	NN	O
.	.	O

In	IN	O
group	NN	O
2	CD	O
free	JJ	O
cortisol	NN	O
was	VBD	O
up	RB	O
to	TO	O
20-fold	CD	O
higher	JJR	O
than	IN	O
under	IN	O
basal	JJ	O
conditions	NNS	O
and	CC	O
reached	VBN	O
maximum	JJ	O
values	NNS	O
on	IN	O
days	NNS	O
1-3	RB	O
.	.	O

Since	IN	O
the	DT	O
excretion	NN	O
of	IN	O
cortisol	NN	O
in	IN	O
urine	JJ	O
reflects	VBZ	O
the	DT	O
production	NN	O
rate	NN	O
closely	RB	O
and	CC	O
is	VBZ	O
not	RB	O
influenced	VBN	O
by	IN	O
liver	NN	O
function	NN	O
and	CC	O
barbiturates	NNS	O
,	,	O
the	DT	O
results	NNS	O
in	IN	O
group	NN	O
2	CD	O
show	NN	O
that	IN	O
the	DT	O
endogenous	JJ	O
production	NN	O
of	IN	O
steroids	NNS	O
is	VBZ	O
an	DT	O
adequate	JJ	O
reaction	NN	O
to	TO	O
severe	VB	O
head	JJ	O
injury	NN	O
.	.	O

Exogenous	JJ	O
glucocorticoids	NNS	Pharmacological
are	VBP	O
thus	RB	O
unlikely	JJ	O
to	TO	O
have	VB	O
any	DT	O
more	JJR	O
beneficial	JJ	O
effects	NNS	O
than	IN	O
endogenous	JJ	O
cortisol	NN	Pharmacological
.	.	O

Efficacy	NN	O
of	IN	O
rofecoxib	NN	Pharmacological
,	,	O
celecoxib	NN	Pharmacological
,	,	O
and	CC	O
acetaminophen	NN	Pharmacological
in	IN	O
patients	NNS	O
with	IN	O
osteoarthritis	NN	O
of	IN	O
the	DT	O
knee	NN	O
.	.	O

A	DT	O
combined	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
VACT	NNP	O
studies	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
efficacy	NN	O
among	IN	O
1578	CD	O
patients	NNS	O
with	IN	O
osteoarthritis	JJ	O
randomized	VBN	O
to	TO	O
take	VB	O
acetaminophen	NN	Pharmacological
4000	CD	O
mg	NN	O
(	(	O
n=269	JJ	O
)	)	O
,	,	O
celecoxib	$	Pharmacological
200	CD	O
mg	NN	O
(	(	O
n=523	JJ	O
)	)	O
,	,	O
rofecoxib	VBZ	Pharmacological
12.5	CD	O
mg	NN	O
(	(	O
n=259	JJ	O
)	)	O
,	,	O
or	CC	O
rofecoxib	VB	Pharmacological
25	CD	O
mg	NN	O
(	(	O
n=527	JJ	O
)	)	O
in	IN	O
a	DT	O
double	JJ	O
blind	NN	O
trial	NN	O
[	NNP	O
Vioxx	NNP	Pharmacological
,	,	O
Acetaminophen	NNP	Pharmacological
,	,	O
Celecoxib	NNP	Pharmacological
Trial	NNP	O
(	(	O
VACT2	NNP	O
)	)	O
]	NN	O
.	.	O

Results	NNS	O
were	VBD	O
also	RB	O
pooled	VBN	O
with	IN	O
the	DT	O
similarly	RB	O
designed	VBN	O
VACT1	NNP	O
trial	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
evaluated	VBD	O
over	IN	O
Days	NNP	O
1	CD	O
to	TO	O
6	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
with	IN	O
Patient	NNP	O
Global	NNP	O
Assessment	NNP	O
of	IN	O
Response	NNP	O
to	TO	O
Therapy	NNP	O
(	(	O
PGART	NNP	O
)	)	O
and	CC	O
Western	JJ	O
Ontario	NNP	O
and	CC	O
McMaster	NNP	O
Universities	NNP	O
(	(	O
WOMAC	NNP	O
)	)	O
Osteoarthritis	NNP	O
Index	NNP	O
.	.	O

RESULTS	NNP	O
For	IN	O
VACT2	NNP	O
,	,	O
median	JJ	O
time	NN	O
to	TO	O
good	JJ	O
or	CC	O
excellent	JJ	O
PGART	NNP	O
response	NN	O
was	VBD	O
6	CD	O
,	,	O
5	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
3	CD	O
days	NNS	O
for	IN	O
acetaminophen	NN	Pharmacological
,	,	O
celecoxib	NN	Pharmacological
,	,	O
rofecoxib	VBZ	Pharmacological
12.5	CD	O
mg	NN	O
,	,	O
and	CC	O
rofecoxib	VBZ	Pharmacological
25	CD	O
mg	NN	O
(	(	O
COX-2	JJ	O
inhibitors	NNS	O
vs	VBP	O
acetaminophen	NN	Pharmacological
,	,	O
p	NN	O
<	NNP	O
or=0.035	NN	O
;	:	O
rofecoxib	CC	Pharmacological
25	CD	O
mg	NN	O
vs	NN	O
celecoxib	NN	Pharmacological
,	,	O
p=0.01	NN	O
)	)	O
.	.	O

WOMAC	NNP	O
response	NN	O
over	IN	O
the	DT	O
first	JJ	O
6	CD	O
days	NNS	O
was	VBD	O
greater	JJR	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
both	DT	O
rofecoxib	NN	Pharmacological
doses	VBZ	O
than	IN	O
acetaminophen	NN	O
and	CC	O
celecoxib	NN	O
.	.	O

At	IN	O
Week	JJ	O
6	CD	O
,	,	O
all	DT	O
COX-2	NNP	O
inhibitors	NNS	O
provided	VBD	O
significantly	RB	O
greater	JJR	O
efficacy	NN	O
than	IN	O
acetaminophen	NN	O
.	.	O

Good	JJ	O
or	CC	O
excellent	JJ	O
PGART	NNP	O
was	VBD	O
numerically	RB	O
,	,	O
but	CC	O
not	RB	O
significantly	RB	O
,	,	O
greater	JJR	O
with	IN	O
rofecoxib	NN	Pharmacological
25	CD	O
mg	NN	O
(	(	O
55.4	CD	O
%	NN	O
)	)	O
than	IN	O
celecoxib	NN	Pharmacological
(	(	O
50.6	CD	O
%	NN	O
)	)	O
at	IN	O
Week	NNP	O
6	CD	O
;	:	O
a	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
seen	VBN	O
at	IN	O
Weeks	NNP	O
2	CD	O
(	(	O
6.9	CD	O
,	,	O
p=0.022	NN	O
)	)	O
and	CC	O
4	CD	O
(	(	O
6.7	CD	O
,	,	O
p=0.027	NN	O
)	)	O
and	CC	O
over	IN	O
6	CD	O
weeks	NNS	O
with	IN	O
analysis	NN	O
of	IN	O
all	DT	O
5	CD	O
PGART	NNP	O
categories	NNS	O
of	IN	O
response	NN	O
(	(	O
p=0.035	NN	O
)	)	O
.	.	O

Rofecoxib	$	Pharmacological
25	CD	O
mg	NN	O
provided	VBD	O
greater	JJR	O
response	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
than	IN	O
celecoxib	NN	Pharmacological
on	IN	O
WOMAC	NNP	O
subscales	NNS	O
.	.	O

Pooled	VBD	O
analysis	NN	O
of	IN	O
VACT1/VACT2	NNP	O
demonstrated	VBD	O
greater	JJR	O
PGART	NNP	O
(	(	O
p=0.023	NN	O
)	)	O
with	IN	O
rofecoxib	NN	Pharmacological
25	CD	O
mg	NN	O
(	(	O
56.1	CD	O
%	NN	O
)	)	O
than	IN	O
celecoxib	NN	Pharmacological
(	(	O
49.8	CD	O
%	NN	O
)	)	O
at	IN	O
6	CD	O
weeks	NNS	O
and	CC	O
greater	JJR	O
response	NN	O
to	TO	O
all	DT	O
other	JJ	O
PGART	NNP	O
and	CC	O
WOMAC	NNP	O
endpoints	NNS	O
,	,	O
and	CC	O
confirmed	VBD	O
superiority	NN	O
of	IN	O
COX-2	NNP	O
inhibitors	NNS	O
to	TO	O
acetaminophen	VB	Pharmacological
.	.	O

Overall	NNP	O
,	,	O
tolerability	NN	O
of	IN	O
the	DT	O
study	NN	O
medications	NNS	O
was	VBD	O
generally	RB	O
good	JJ	O
and	CC	O
similar	JJ	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
treatment	NN	O
groups	NNS	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
patients	NNS	O
who	WP	O
experienced	VBD	O
a	DT	O
clinical	JJ	O
adverse	JJ	O
experience	NN	O
(	(	O
AE	NNP	O
)	)	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
discontinuations	NNS	O
due	JJ	O
to	TO	O
an	DT	O
AE	NNP	O
was	VBD	O
significantly	RB	O
lower	JJR	O
with	IN	O
celecoxib	NN	Pharmacological
(	(	O
2.5	CD	O
%	NN	O
)	)	O
compared	VBN	O
to	TO	O
rofecoxib	VB	Pharmacological
25	CD	O
mg	NN	O
(	(	O
6.3	CD	O
%	NN	O
,	,	O
p=0.004	NN	O
)	)	O
or	CC	O
acetaminophen	NN	Pharmacological
(	(	O
7.8	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
and	CC	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
from	IN	O
rofecoxib	JJ	O
12.5	CD	O
mg	NN	O
(	(	O
4.6	CD	O
%	NN	O
)	)	O
.	.	O

Discontinuation	NN	O
rates	NNS	O
due	JJ	O
to	TO	O
edema	VB	O
and	CC	O
hypertension	NN	O
related	VBN	O
AE	NNP	O
were	VBD	O
similar	JJ	O
among	IN	O
all	DT	O
COX-2	NNP	O
inhibitors	NNS	O
.	.	O

CONCLUSION	NNP	O
Rofecoxib	NNP	Pharmacological
and	CC	O
celecoxib	NN	Pharmacological
provided	VBD	O
superior	JJ	O
efficacy	NN	O
to	TO	O
acetaminophen	VB	Pharmacological
.	.	O

There	EX	O
was	VBD	O
a	DT	O
more	RBR	O
rapid	JJ	O
and	CC	O
greater	JJR	O
response	NN	O
with	IN	O
rofecoxib	JJ	O
25	CD	O
mg	NN	O
than	IN	O
celecoxib	$	Pharmacological
200	CD	O
mg.	NN	O
Rofecoxib	NNP	Pharmacological
12.5	CD	O
mg	NN	O
demonstrated	VBD	O
greater	JJR	O
efficacy	NN	O
than	IN	O
celecoxib	$	Pharmacological
200	CD	O
mg	NN	O
over	IN	O
the	DT	O
first	JJ	O
6	CD	O
days	NNS	O
,	,	O
and	CC	O
was	VBD	O
similar	JJ	O
over	IN	O
6	CD	O
weeks	NNS	O
.	.	O

All	DT	O
study	NN	O
medications	NNS	O
were	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

Utilization	NN	O
patterns	NNS	O
of	IN	O
conventional	JJ	Control
and	CC	O
complementary/alternative	JJ	Other
treatments	NNS	Other
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
and	CC	O
developmental	JJ	O
disabilities	NNS	O
in	IN	O
a	DT	O
population-based	JJ	O
study	NN	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
compare	VB	O
the	DT	O
utilization	NN	O
of	IN	O
conventional	JJ	Control
treatments	NNS	Control
and	CC	O
utilization	NN	O
of	IN	O
complementary	JJ	Pharmacological
and	CC	Pharmacological
alternative	JJ	Pharmacological
medicine	NN	Pharmacological
in	IN	O
preschoolers	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
and	CC	O
other	JJ	O
developmental	JJ	O
disabilities	NNS	O
(	(	O
DD	NNP	O
)	)	O
.	.	O

METHODS	JJ	O
Participants	NNS	O
were	VBD	O
578	CD	O
children	NNS	O
who	WP	O
were	VBD	O
part	NN	O
of	IN	O
an	DT	O
ongoing	JJ	O
population-based	JJ	O
,	,	O
case-control	JJ	O
study	NN	O
of	IN	O
2-	JJ	O
to	TO	O
5-year	JJ	O
olds	NNS	O
with	IN	O
ASD	NNP	O
,	,	O
DD	NNP	O
,	,	O
and	CC	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

Parents	NNS	O
completed	VBD	O
an	DT	O
interview	NN	O
on	IN	O
past	JJ	O
and	CC	O
current	JJ	O
services	NNS	O
.	.	O

RESULTS	NNP	O
Four	CD	O
hundred	VBD	O
fifty-three	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
125	CD	O
DD	NNP	O
children	NNS	O
were	VBD	O
included	VBN	O
.	.	O

ASD	NNP	O
families	NNS	O
received	VBD	O
more	RBR	O
hours	NNS	O
of	IN	O
conventional	JJ	Physical
services	NNS	Physical
compared	VBN	O
with	IN	O
DD	NNP	O
families	NNS	O
(	(	O
17.8	CD	O
vs	RB	O
11	CD	O
;	:	O
p	NN	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
psychotropic	NN	O
medications	NNS	O
was	VBD	O
low	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
(	(	O
approximately	RB	O
3	CD	O
%	NN	O
)	)	O
.	.	O

Overall	JJ	O
,	,	O
complementary	JJ	Pharmacological
and	CC	Pharmacological
alternative	JJ	Pharmacological
medicine	NN	Pharmacological
(	(	Pharmacological
CAM	NNP	Pharmacological
)	)	Pharmacological
use	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
in	IN	O
ASD	NNP	O
(	(	O
39	CD	O
%	NN	O
)	)	O
versus	NN	O
DD	NNP	O
(	(	O
30	CD	O
%	NN	O
)	)	O
.	.	O

Hispanic	JJ	O
families	NNS	O
in	IN	O
both	DT	O
groups	NNS	O
used	VBD	O
CAM	NNP	Pharmacological
less	RBR	O
often	RB	O
than	IN	O
non-Hispanic	JJ	O
families	NNS	O
.	.	O

Variables	NNS	O
such	JJ	O
as	IN	O
level	NN	O
of	IN	O
function	NN	O
,	,	O
immunization	NN	O
status	NN	O
,	,	O
and	CC	O
the	DT	O
presence	NN	O
of	IN	O
an	DT	O
identified	VBN	O
neurogenetic	JJ	O
disorder	NN	O
were	VBD	O
not	RB	O
predictive	JJ	O
of	IN	O
CAM	NNP	Pharmacological
use	NN	O
.	.	O

A	DT	O
higher	JJR	O
level	NN	O
of	IN	O
parental	JJ	O
education	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increased	VBN	O
CAM	NNP	Pharmacological
use	NN	O
in	IN	O
ASD	NNP	O
and	CC	O
DD	NNP	O
.	.	O

Families	NNS	O
who	WP	O
used	VBD	O
>	$	O
20	CD	O
hours	NNS	O
per	IN	O
week	NN	O
of	IN	O
conventional	JJ	Physical
services	NNS	Physical
were	VBD	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	Pharmacological
,	,	O
including	VBG	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	Pharmacological
.	.	O

Underimmunized	VBN	O
children	NNS	O
were	VBD	O
marginally	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
use	VB	O
CAM	NNP	Pharmacological
but	CC	O
not	RB	O
more	RBR	O
likely	JJ	O
to	TO	O
have	VB	O
received	VBN	O
potentially	RB	O
unsafe	JJ	O
or	CC	O
disproven	JJ	O
CAM	NNP	Pharmacological
.	.	O

CONCLUSION	NNP	O
Use	NNP	O
of	IN	O
CAM	NNP	Pharmacological
is	VBZ	O
common	JJ	O
in	IN	O
families	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
neurodevelopmental	JJ	O
disorders	NNS	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
predicted	VBN	O
by	IN	O
higher	JJR	O
parental	JJ	O
education	NN	O
and	CC	O
non-Hispanic	JJ	O
ethnicity	NN	O
but	CC	O
not	RB	O
developmental	JJ	O
characteristics	NNS	O
.	.	O

Further	NNP	O
research	NN	O
should	MD	O
address	VB	O
how	WRB	O
health	NN	O
care	NN	O
providers	NNS	O
can	MD	O
support	VB	O
families	NNS	O
in	IN	O
making	VBG	O
decisions	NNS	O
about	IN	O
CAM	NNP	Pharmacological
use	NN	O
.	.	O

Effect	NN	O
of	IN	O
intestinal	JJ	O
production	NN	O
of	IN	O
equol	NN	O
on	IN	O
menopausal	NN	O
symptoms	NNS	O
in	IN	O
women	NNS	O
treated	VBN	O
with	IN	O
soy	JJ	Pharmacological
isoflavones	NNS	Pharmacological
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
effect	NN	O
of	IN	O
soy	NN	Pharmacological
isoflavones	NNS	Pharmacological
on	IN	O
menopausal	NN	O
symptoms	NNS	O
in	IN	O
women	NNS	O
who	WP	O
do	VBP	O
and	CC	O
who	WP	O
do	VBP	O
not	RB	O
produce	VB	O
equol	NN	O
,	,	O
a	DT	O
daidzein	NN	O
metabolite	NN	O
.	.	O

METHOD	NNP	O
A	NNP	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
clinical	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
over	IN	O
6	CD	O
months	NNS	O
with	IN	O
96	CD	O
healthy	JJ	O
menopausal	NN	O
women	NNS	O
.	.	O

After	IN	O
taking	VBG	O
take	VB	O
135	CD	O
mg	NN	O
of	IN	O
isoflavones	NNS	Pharmacological
daily	RB	O
for	IN	O
1	CD	O
week	NN	O
,	,	O
the	DT	O
women	NNS	O
in	IN	O
the	DT	O
study	NN	O
group	NN	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
equol-producing	NN	O
(	(	O
EP	NNP	O
)	)	O
or	CC	O
the	DT	O
non-EP	JJ	O
group	NN	O
according	VBG	O
to	TO	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
equol	NN	O
in	IN	O
their	PRP$	O
urine	NN	O
.	.	O

Menopausal	NNP	O
symptoms	NNS	O
were	VBD	O
evaluated	VBN	O
using	VBG	O
a	DT	O
modified	VBN	O
Kupperman	NNP	O
Index	NNP	O
.	.	O

RESULT	NNP	O
Compared	NNP	O
with	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
,	,	O
the	DT	O
scores	NNS	O
for	IN	O
hot	JJ	O
flashes	NNS	O
and	CC	O
excessive	JJ	O
sweating	NN	O
were	VBD	O
significantly	RB	O
reduced	VBN	O
after	IN	O
3	CD	O
months	NNS	O
,	,	O
and	CC	O
the	DT	O
scores	NNS	O
for	IN	O
weakness	NN	O
,	,	O
palpitations	NNS	O
,	,	O
limb	NN	O
paresthesia	NN	O
,	,	O
and	CC	O
total	JJ	O
symptoms	NNS	O
after	IN	O
6	CD	O
months	NNS	O
,	,	O
in	IN	O
the	DT	O
EP	NNP	O
group	NN	O
only	RB	O
.	.	O

CONCLUSIONS	NNP	O
Isoflavone	NNP	Pharmacological
supplementation	NN	Pharmacological
improves	VBZ	O
menopausal	NN	O
symptoms	NNS	O
only	RB	O
in	IN	O
women	NNS	O
with	IN	O
the	DT	O
ability	NN	O
to	TO	O
produce	VB	O
equol	NN	O
.	.	O

A	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
the	DT	O
canalith	NN	Surgical
repositioning	NN	Surgical
procedure	NN	Surgical
.	.	O

OBJECTIVE	UH	O
To	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
and	CC	O
complications	NNS	O
of	IN	O
our	PRP$	O
adaptation	NN	O
of	IN	O
the	DT	O
canalith	NN	Surgical
repositioning	NN	Surgical
procedure	NN	Surgical
(	(	Surgical
CRP	NNP	Surgical
)	)	Surgical
with	IN	O
the	DT	O
expectation	NN	O
treatment	NN	O
for	IN	O
benign	JJ	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
A	NNP	O
randomized	NN	O
,	,	O
controlled	VBN	O
trial	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
a	DT	O
neurotological	JJ	O
clinic	NN	O
in	IN	O
Thailand	NNP	O
.	.	O

METHODS	NNP	O
Fifty-eight	JJ	O
patients	NNS	O
with	IN	O
posterior	JJ	O
benign	NN	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
and	CC	O
control	NN	O
groups	NNS	O
using	VBG	O
a	DT	O
block	NN	O
of	IN	O
four	CD	O
.	.	O

The	DT	O
treatment	NN	O
group	NN	O
was	VBD	O
treated	VBN	O
with	IN	O
the	DT	O
modified	JJ	Surgical
CRP	NNP	Surgical
technique	NN	Surgical
until	IN	O
the	DT	O
nystagmus	NN	O
disappeared	VBD	O
.	.	O

A	DT	O
mastoid	JJ	O
oscillator	NN	O
was	VBD	O
not	RB	O
used	VBN	O
,	,	O
nor	CC	O
were	VBD	O
any	DT	O
instructions	NNS	O
given	VBN	O
for	IN	O
patients	NNS	O
after	IN	O
the	DT	O
maneuver	NN	O
.	.	O

Both	DT	O
groups	NNS	O
recorded	VBD	O
the	DT	O
daily	JJ	O
grading	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
the	DT	O
amount	NN	O
of	IN	O
anti-vertiginous	JJ	O
drugs	NNS	O
(	(	O
cinnarizine	NN	Pharmacological
)	)	O
taken	VBN	O
.	.	O

Objective	JJ	O
and	CC	O
subjective	JJ	O
assessments	NNS	O
were	VBD	O
made	VBN	O
weekly	RB	O
until	IN	O
the	DT	O
nystagmus	NN	O
disappeared	VBD	O
or	CC	O
until	IN	O
4	CD	O
weeks	NNS	O
had	VBD	O
passed	VBN	O
since	IN	O
treatment	NN	O
began	VBD	O
.	.	O

RESULTS	VB	O
The	DT	O
rates	NNS	O
of	IN	O
effectiveness	NN	O
of	IN	O
CRP	NNP	Surgical
treatment	NN	Surgical
and	CC	O
the	DT	O
control	NN	O
treatment	NN	O
for	IN	O
benign	JJ	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
were	VBD	O
75.9	CD	O
%	NN	O
and	CC	O
48.2	CD	O
%	NN	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
treatment	NN	O
outcomes	NNS	O
of	IN	O
the	DT	O
CRP	NNP	Surgical
and	CC	O
control	NN	O
groups	NNS	O
(	(	O
P	NNP	O
=.03	NNP	O
)	)	O
.	.	O

The	DT	O
CRP	NNP	Surgical
group	NN	O
used	VBD	O
significantly	RB	O
fewer	JJR	O
drugs	NNS	O
than	IN	O
the	DT	O
control	NN	O
group	NN	O
(	(	O
P	NNP	O
=.001	NNP	O
)	)	O
.	.	O

Complications	NNS	O
in	IN	O
the	DT	O
CRP	NNP	Surgical
group	NN	O
,	,	O
such	JJ	O
as	IN	O
lateral	JJ	O
canalithiasis	NN	O
and	CC	O
fainting	NN	O
,	,	O
were	VBD	O
observed	VBN	O
in	IN	O
13.8	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
CRP	NNP	Surgical
was	VBD	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
expectation	NN	O
treatment	NN	O
for	IN	O
benign	JJ	O
paroxysmal	JJ	O
positional	JJ	O
vertigo	NN	O
insofar	NN	O
as	IN	O
it	PRP	O
provided	VBD	O
faster	RBR	O
recovery	NN	O
and	CC	O
required	VBD	O
less	JJR	O
dependence	NN	O
on	IN	O
medication	NN	O
.	.	O

Complications	NNS	O
of	IN	O
CRP	NNP	Surgical
were	VBD	O
limited	VBN	O
to	TO	O
13.8	CD	O
%	NN	O
of	IN	O
patients	NNS	O
.	.	O

Injection	NN	O
pain	NN	O
with	IN	O
propofol	NN	Pharmacological
.	.	Pharmacological

Reduction	NN	O
with	IN	O
aspiration	NN	O
of	IN	O
blood	NN	O
.	.	O

A	DT	O
randomised	JJ	O
,	,	O
controlled	VBN	O
,	,	O
single-blind	NN	O
study	NN	O
was	VBD	O
performed	VBN	O
on	IN	O
100	CD	O
patients	NNS	O
to	TO	O
investigate	VB	O
a	DT	O
new	JJ	O
method	NN	O
of	IN	O
reducing	VBG	O
pain	NN	O
on	IN	O
propofol	NN	Pharmacological
injection	NN	O
.	.	O

Aspiration	NNP	O
of	IN	O
2	CD	O
ml	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
blood	NN	O
into	IN	O
a	DT	O
syringe	NN	O
of	IN	O
propofol	NN	Pharmacological
immediately	RB	O
before	IN	O
injection	NN	O
was	VBD	O
compared	VBN	O
with	IN	O
the	DT	O
addition	NN	O
of	IN	O
lignocaine	NN	Pharmacological
20	CD	Pharmacological
mg	NN	Pharmacological
or	CC	O
normal	JJ	Control
saline	JJ	Control
2	CD	Pharmacological
ml	NN	Pharmacological
to	TO	Pharmacological
the	DT	Pharmacological
propofol	NN	Pharmacological
before	IN	Pharmacological
injection	NN	Pharmacological
.	.	O

The	DT	O
addition	NN	O
of	IN	O
blood	NN	O
was	VBD	O
significantly	RB	O
more	RBR	O
effective	JJ	O
in	IN	O
reducing	VBG	O
pain	NN	O
on	IN	O
injection	NN	O
than	IN	O
the	DT	O
addition	NN	O
of	IN	O
saline	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
but	CC	O
was	VBD	O
not	RB	O
significantly	RB	O
more	RBR	O
effective	JJ	O
than	IN	O
the	DT	O
addition	NN	O
of	IN	O
lignocaine	NN	O
.	.	O

Loss	NNP	O
of	IN	O
tooth	JJ	O
substance	NN	O
during	IN	O
root	NN	Physical
planing	VBG	Physical
with	IN	O
various	JJ	O
periodontal	JJ	O
instruments	NNS	O
:	:	O
an	DT	O
in	IN	O
vitro	NN	O
study	NN	O
.	.	O

Ultrasonic	JJ	Physical
and	CC	Physical
power-driven	JJ	Physical
instrumentation	NN	Physical
is	VBZ	O
gaining	VBG	O
in	IN	O
significance	NN	O
as	IN	O
an	DT	O
acceptable	JJ	O
alternative	NN	O
to	TO	O
manual	JJ	O
periodontal	JJ	O
root	NN	O
treatment	NN	O
.	.	O

Some	DT	O
question	NN	O
whether	IN	O
they	PRP	O
do	VBP	O
not	RB	O
remove	VB	O
too	RB	O
much	JJ	O
tooth	DT	O
substance	NN	O
.	.	O

Various	JJ	Educational
ultrasonic	JJ	Physical
scalers	NNS	Physical
,	,	Educational
hand	NN	Physical
instruments	NNS	Physical
and	CC	Educational
two	CD	Physical
power-driven	JJ	Physical
systems	NNS	Physical
were	VBD	O
compared	VBN	O
by	IN	O
assessing	VBG	O
the	DT	O
loss	NN	O
of	IN	O
tooth	JJ	O
substance	NN	O
due	JJ	O
to	TO	O
root	VB	O
instrumentation	NN	O
.	.	O

Quantitative	JJ	O
analysis	NN	O
of	IN	O
this	DT	O
effect	NN	O
of	IN	O
the	DT	O
instruments	NNS	O
used	VBN	O
was	VBD	O
performed	VBN	O
on	IN	O
20	CD	O
freshly	RB	O
extracted	VBN	O
,	,	O
non-periodontally	RB	O
involved	VBN	O
,	,	O
large	JJ	O
human	JJ	O
molars	NNS	O
.	.	O

In	IN	O
the	DT	O
first	JJ	O
study	NN	O
,	,	O
40	CD	O
specimens	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
four	CD	O
groups	NNS	O
of	IN	O
treatment	NN	O
:	:	O
combined	VBN	O
use	NN	O
of	IN	O
ultrasonic	JJ	Physical
scaler	NN	Physical
and	CC	Physical
Periopolisher	NNP	Physical
diamond-coated	JJ	Physical
inserts	NNS	Physical
(	(	Physical
US-POL	NNP	Physical
)	)	Physical
,	,	Educational
hand	NN	Physical
instruments	NNS	Physical
(	(	Physical
MANUAL	NNP	Physical
)	)	Physical
,	,	Educational
Perioplaner-Periopolisher	NNP	Physical
system	NN	Physical
(	(	Physical
PPL-POL	NNP	Physical
)	)	Physical
and	CC	Educational
Periokit	NNP	Physical
ultrasonic-designed	JJ	Physical
scalers	NNS	Physical
(	(	Physical
PERIOKIT	NNP	Physical
)	)	Physical
.	.	Educational

The	DT	O
second	JJ	O
study	NN	O
involved	VBN	O
two	CD	O
treatment	NN	O
groups	NNS	O
,	,	O
ultrasonic	JJ	Physical
scaler	NN	Physical
alone	RB	Other
and	CC	Other
hand	NN	Physical
instruments	NNS	Physical
,	,	O
each	DT	O
allocated	VBN	O
with	IN	O
20	CD	O
teeth	NNS	O
(	(	O
small	JJ	O
root	NN	O
fragments	NNS	O
)	)	O
.	.	O

An	DT	O
unpaired	JJ	O
two-tailed	JJ	O
t	NN	O
test	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
for	IN	O
both	DT	O
studies	NNS	O
to	TO	O
compare	VB	O
the	DT	O
average	JJ	O
weight	JJ	O
loss	NN	O
of	IN	O
root	JJ	O
substance	NN	O
with	IN	O
the	DT	O
modes	NNS	O
of	IN	O
instrumentation	NN	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
significance	NN	O
was	VBD	O
set	VBN	O
at	IN	O
p	JJ	O
<	NNP	O
or=0.05	NN	O
.	.	O

The	DT	O
overall	JJ	O
results	NNS	O
of	IN	O
the	DT	O
first	JJ	O
and	CC	O
second	JJ	O
experimental	JJ	O
trials	NNS	O
did	VBD	O
not	RB	O
reveal	VB	O
obvious	JJ	O
differences	NNS	O
in	IN	O
weight	JJ	O
loss	NN	O
between	IN	O
the	DT	O
manual	JJ	O
,	,	O
ultrasonic	JJ	O
or	CC	O
power-driven	JJ	O
root	NN	O
treatments	NNS	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
of	IN	O
these	DT	O
two	CD	O
comparative	NN	O
studies	NNS	O
,	,	O
the	DT	O
power-driven	JJ	O
inserts	NNS	O
or	CC	O
the	DT	O
various	JJ	O
ultrasonic	JJ	O
scalers	NNS	O
tested	VBD	O
did	VBD	O
not	RB	O
remove	VB	O
more	RBR	O
tooth	JJ	O
substance	NN	O
than	IN	O
conventional	JJ	O
hand	NN	O
instruments	NNS	O
.	.	O

They	PRP	O
may	MD	O
thus	RB	O
be	VB	O
a	DT	O
useful	JJ	O
alternative	NN	O
for	IN	O
the	DT	O
debridement	NN	O
of	IN	O
root	NN	O
surfaces	NNS	O
.	.	O

Plasma	NNP	O
antioxidant	NN	O
status	NN	O
after	IN	O
high-dose	JJ	Pharmacological
chemotherapy	NN	Pharmacological
:	:	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
parenteral	JJ	O
nutrition	NN	O
in	IN	O
bone	NN	O
marrow	NN	O
transplantation	NN	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Chemotherapy	NNP	Pharmacological
and	CC	Pharmacological
radiation	NN	Pharmacological
therapy	NN	Pharmacological
result	NN	O
in	IN	O
increased	JJ	O
free	JJ	O
radical	JJ	O
formation	NN	O
and	CC	O
depletion	NN	O
of	IN	O
tissue	NN	O
antioxidants	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
parenteral	JJ	Pharmacological
nutrition	NN	Pharmacological
(	(	Pharmacological
PN	NNP	Pharmacological
)	)	Pharmacological
administered	VBD	O
during	IN	O
bone	NN	Surgical
marrow	NN	Surgical
transplantation	NN	Surgical
(	(	Surgical
BMT	NNP	Surgical
)	)	Surgical
supports	VBZ	O
systemic	JJ	O
antioxidant	NN	O
status	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
aims	NNS	O
of	IN	O
the	DT	O
study	NN	O
were	VBD	O
to	TO	O
determine	VB	O
1	CD	O
)	)	O
whether	IN	O
high-dose	JJ	Pharmacological
chemotherapy	NN	Pharmacological
decreases	VBZ	O
concentrations	NNS	O
of	IN	O
major	JJ	O
circulating	VBG	O
antioxidants	NNS	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
BMT	NNP	Surgical
and	CC	O
2	CD	O
)	)	O
whether	IN	O
administration	NN	O
of	IN	O
standard	JJ	O
PN	NNP	Pharmacological
maintains	VBZ	O
systemic	JJ	O
antioxidant	JJ	O
concentrations	NNS	O
compared	VBN	O
with	IN	O
PN	NNP	Pharmacological
containing	VBG	O
micronutrients	NNS	O
and	CC	O
minimal	JJ	O
lipids	NNS	O
alone	RB	O
.	.	O

DESIGN	NNP	O
Twenty-four	JJ	O
BMT	NNP	Surgical
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
either	DT	O
standard	JJ	Pharmacological
PN	NNP	Pharmacological
containing	VBG	Pharmacological
conventional	JJ	Pharmacological
amounts	NNS	Pharmacological
of	IN	Pharmacological
dextrose	NN	Pharmacological
,	,	Pharmacological
amino	JJ	Pharmacological
acids	NNS	Pharmacological
,	,	Pharmacological
micronutrients	NNS	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
lipid	JJ	Pharmacological
(	(	O
120	CD	O
kJ/d	NN	O
)	)	O
or	CC	O
a	DT	O
solution	NN	Physical
containing	VBG	Physical
only	JJ	Physical
micronutrients	NNS	Physical
(	(	O
identical	JJ	O
to	TO	O
those	DT	O
in	IN	O
standard	JJ	O
PN	NNP	O
)	)	O
and	CC	O
a	DT	O
small	JJ	O
amount	NN	O
of	IN	O
lipid	JJ	O
(	(	O
12	CD	O
kJ/d	NN	O
)	)	O
.	.	O

Plasma	NNP	O
antioxidant	JJ	O
status	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
conditioning	VBG	O
therapy	NN	O
and	CC	O
serially	RB	O
at	IN	O
days	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
7	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
14	CD	O
after	IN	O
BMT	NNP	O
.	.	O

RESULTS	NNP	O
Plasma	NNP	O
glutathione	NN	O
(	(	O
GSH	NNP	O
)	)	O
and	CC	O
alpha-	JJ	O
and	CC	O
gamma-tocopherol	JJ	O
concentrations	NNS	O
decreased	VBN	O
and	CC	O
the	DT	O
GSH	NNP	O
redox	NN	O
state	NN	O
became	VBD	O
more	RBR	O
oxidized	JJ	O
after	IN	O
conditioning	VBG	O
chemotherapy	NN	O
.	.	O

Plasma	NNP	O
cysteine	JJ	O
concentrations	NNS	O
were	VBD	O
unchanged	JJ	O
,	,	O
whereas	JJ	O
cystine	NN	O
concentrations	NNS	O
increased	VBD	O
.	.	O

Plasma	NNP	O
vitamin	JJ	O
C	NNP	O
and	CC	O
zinc	NNP	O
concentrations	NNS	O
and	CC	O
GSH	NNP	O
peroxidase	NN	O
activity	NN	O
increased	VBD	O
over	IN	O
time	NN	O
.	.	O

Plasma	VB	O
alpha-tocopherol	JJ	O
concentrations	NNS	O
were	VBD	O
lower	JJR	O
in	IN	O
patients	NNS	O
given	VBN	O
standard	JJ	O
PN	NNP	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
differences	NNS	O
in	IN	O
other	JJ	O
plasma	JJ	O
antioxidants	NNS	O
between	IN	O
groups	NNS	O
.	.	O

CONCLUSIONS	VB	O
A	DT	O
significant	JJ	O
decline	NN	O
in	IN	O
GSH-glutathione	NNP	O
disulfide	NN	O
,	,	O
cysteine-cystine	NN	O
,	,	O
and	CC	O
vitamin	FW	O
E	NNP	O
status	NN	O
occurs	VBZ	O
after	IN	O
chemotherapy	NN	Pharmacological
and	CC	O
BMT	NNP	Surgical
.	.	O

Standard	NNP	O
PN	NNP	O
does	VBZ	O
not	RB	O
improve	VB	O
antioxidant	NN	O
status	NN	O
compared	VBN	O
with	IN	O
administration	NN	O
of	IN	O
micronutrients	NNS	O
alone	RB	O
.	.	O

Further	JJ	O
evaluation	NN	O
of	IN	O
PN	NNP	O
formulations	NNS	O
to	TO	O
support	VB	O
patients	NNS	O
undergoing	VBG	O
high-dose	JJ	Pharmacological
chemotherapy	NN	Pharmacological
and	CC	O
BMT	NNP	Surgical
are	VBP	O
needed	VBN	O
.	.	O

The	DT	O
influence	NN	O
of	IN	O
sequential	JJ	O
annual	JJ	O
vaccination	NN	Pharmacological
and	CC	O
of	IN	O
DHEA	NNP	Pharmacological
administration	NN	Pharmacological
on	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	O
vaccine	NN	O
in	IN	O
the	DT	O
elderly	JJ	O
.	.	O

The	DT	O
present	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
effect	NN	O
of	IN	O
repeated	VBN	O
vaccination	NN	Pharmacological
and	CC	O
of	IN	O
dehydroepiandrosterone	NN	Pharmacological
(	(	Pharmacological
DHEA	NNP	Pharmacological
)	)	Pharmacological
treatment	NN	O
on	IN	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
influenza	VB	Pharmacological
vaccine	NN	Pharmacological
in	IN	O
elderly	JJ	O
subjects	NNS	O
.	.	O

Seventy-one	CD	O
elderly	JJ	O
volunteers	NNS	O
,	,	O
aged	VBN	O
61-89	CD	O
years	NNS	O
,	,	O
enrolled	VBD	O
in	IN	O
a	DT	O
prospective	JJ	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
to	TO	O
receive	VB	O
either	DT	O
DHEA	NNP	Pharmacological
(	(	O
50	CD	O
mg	NN	O
qd	NN	O
p.o	NN	O
.	.	O

for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
starting	VBG	O
2	CD	O
days	NNS	O
before	IN	O
immunization	NN	O
)	)	O
or	CC	O
placebo	NN	Control
.	.	Control

Antibody	NNP	O
response	NN	O
against	IN	O
the	DT	O
three	CD	O
strains	NNS	O
of	IN	O
vaccine	NN	O
was	VBD	O
measured	VBN	O
before	IN	O
and	CC	O
28	CD	O
days	NNS	O
after	IN	O
vaccination	NN	O
,	,	O
and	CC	O
compared	VBN	O
between	IN	O
previously	RB	O
vaccinated	VBN	O
and	CC	O
non-vaccinated	JJ	O
subjects	NNS	O
.	.	O

DHEA	NNP	Pharmacological
treatment	NN	Pharmacological
did	VBD	O
not	RB	O
enhance	VB	O
established	VBN	O
immunity	NN	O
.	.	O

A	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
attainment	NN	O
of	IN	O
protective	JJ	O
antibody	NN	O
titer	NN	O
(	(	O
titer	NN	O
of	IN	O
1:40	CD	O
or	CC	O
greater	JJR	O
)	)	O
against	IN	O
A/Texas	NNP	O
in	IN	O
subjects	NNS	O
with	IN	O
non-protective	JJ	O
baseline	NN	O
antibody	NN	O
titer	NN	O
was	VBD	O
recorded	VBN	O
following	VBG	O
DHEA	NNP	Pharmacological
treatment	NN	Pharmacological
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
52	CD	O
vs.	FW	O
84	CD	O
%	NN	O
,	,	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

Post-immunization	NN	O
titers	NNS	O
against	IN	O
influenza	VBP	O
A	DT	O
strains	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
immunized	VBN	O
before	RB	O
.	.	O

Additionally	RB	O
,	,	O
post-vaccination	JJ	O
protective	JJ	O
titers	NNS	O
against	IN	O
the	DT	O
A/Johannesburg	NNP	O
strain	NN	O
were	VBD	O
more	RBR	O
prevalent	JJ	O
in	IN	O
those	DT	O
subjects	NNS	O
who	WP	O
were	VBD	O
never	RB	O
vaccinated	VBN	O
before	RB	O
.	.	O

The	DT	O
results	NNS	O
were	VBD	O
not	RB	O
the	DT	O
same	JJ	O
for	IN	O
anti-B/Harbin	JJ	O
antibodies-repeated	JJ	O
vaccination	NN	O
caused	VBD	O
a	DT	O
non-significant	JJ	O
increase	NN	O
in	IN	O
HI	NNP	O
titer	NN	O
in	IN	O
previously	RB	O
vaccinated	VBN	O
subjects	NNS	O
.	.	O

Divergence	NN	O
in	IN	O
student	NN	O
and	CC	O
educator	NN	O
conceptual	JJ	O
structures	NNS	O
during	IN	O
auscultation	NN	O
training	NN	O
.	.	O

CONTEXT	NNP	O
Simulation-based	JJ	O
medical	JJ	O
education	NN	O
allows	VBZ	O
trainees	NNS	O
to	TO	O
engage	VB	O
in	IN	O
self-regulated	JJ	O
learning	NN	O
(	(	O
SRL	NNP	O
)	)	O
,	,	O
yet	RB	O
research	NN	O
aimed	VBN	O
at	IN	O
elucidating	VBG	O
the	DT	O
mechanisms	NN	O
of	IN	O
SRL	NNP	O
in	IN	O
this	DT	O
context	NN	O
is	VBZ	O
relatively	RB	O
absent	JJ	O
.	.	O

We	PRP	O
compared	VBN	O
'unguided	VBD	Educational
'	POS	Educational
SRL	NNP	Educational
with	IN	O
'directed	NNP	Educational
'	POS	Educational
SRL	NNP	Educational
(	(	O
DSRL	NNP	O
)	)	O
,	,	O
wherein	JJ	O
learners	NNS	O
followed	VBD	O
an	DT	O
expert-designed	JJ	O
booklet	NN	O
.	.	O

METHODS	NNP	O
Year	$	O
1	CD	O
medical	JJ	O
students	NNS	O
(	(	O
n	JJ	O
=	NNP	O
37	CD	O
)	)	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
practise	VB	O
identifying	VBG	O
seven	CD	O
cardiac	JJ	O
murmurs	NNS	O
using	VBG	O
a	DT	O
simulator	NN	Educational
and	CC	Educational
video	NN	Educational
only	RB	Educational
(	(	Educational
SRL	NNP	Educational
group	NN	Educational
)	)	Educational
or	CC	O
a	DT	O
simulator	NN	Educational
and	CC	Educational
video	NN	Educational
plus	CC	Educational
the	DT	Educational
booklet	NN	Educational
(	(	O
DSRL	NNP	O
group	NN	O
)	)	O
.	.	O

All	DT	O
participants	NNS	O
completed	VBD	O
a	DT	O
22-item	JJ	O
test	NN	O
3	CD	O
weeks	NNS	O
later	RB	O
.	.	O

To	TO	O
compare	VB	O
interventions	NNS	O
,	,	O
we	PRP	O
analysed	VBD	O
students	NNS	O
'	POS	O
diagnostic	JJ	O
accuracy	NN	O
.	.	O

As	IN	O
a	DT	O
novel	JJ	O
source	NN	O
of	IN	O
evidence	NN	O
,	,	O
we	PRP	O
documented	VBD	O
how	WRB	O
participants	NNS	O
autonomously	RB	O
sequenced	VBD	O
the	DT	O
seven	CD	O
murmurs	NNS	O
during	IN	O
initial	JJ	O
and	CC	O
delayed	JJ	O
practice	NN	O
sessions	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
we	PRP	O
surveyed	VBD	O
clinical	JJ	O
educators	NNS	O
(	(	O
n	JJ	O
=	NNP	O
17	CD	O
)	)	O
to	TO	O
find	VB	O
out	RP	O
how	WRB	O
they	PRP	O
would	MD	O
sequence	VB	O
their	PRP$	O
teaching	NN	O
of	IN	O
these	DT	O
murmurs	NNS	O
.	.	O

RESULTS	VB	O
The	DT	O
DSRL	NNP	O
group	NN	O
used	VBD	O
50	CD	O
%	NN	O
more	JJR	O
training	NN	O
time	NN	O
than	IN	O
the	DT	O
SRL	NNP	O
group	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
groups	NNS	O
'	POS	O
diagnostic	JJ	O
accuracy	NN	O
,	,	O
however	RB	O
,	,	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
on	IN	O
the	DT	O
post-test	NN	O
,	,	O
retention	NN	O
test	NN	O
or	CC	O
transfer	VB	O
test	NN	O
items	NNS	O
(	(	O
p	VB	O
>	RB	O
0.12	CD	O
)	)	O
.	.	O

Despite	IN	O
practising	VBG	O
with	IN	O
the	DT	O
expert-defined	JJ	O
'timing-based	JJ	O
'	POS	O
approach	NN	O
to	TO	O
murmur	VB	O
diagnosis	NN	O
(	(	O
i.e	JJ	O
.	.	O

systolic	JJ	O
versus	IN	O
diastolic	NN	O
)	)	O
,	,	O
84	CD	O
%	NN	O
of	IN	O
DSRL	NNP	O
participants	NNS	O
implemented	VBD	O
a	DT	O
location-based	JJ	O
approach	NN	O
(	(	O
i.e	JJ	O
.	.	O

practising	VBG	O
aortic	JJ	O
murmurs	NNS	O
separately	RB	O
from	IN	O
mitral	JJ	O
murmurs	NNS	O
)	)	O
during	IN	O
a	DT	O
second	JJ	O
,	,	O
unguided	JJ	O
practice	NN	O
session	NN	O
.	.	O

Notably	RB	O
,	,	O
most	JJS	O
SRL	JJ	O
participants	NNS	O
used	VBD	O
that	IN	O
same	JJ	O
approach	NN	O
spontaneously	RB	O
.	.	O

By	IN	O
contrast	NN	O
,	,	O
clinical	JJ	O
educators	NNS	O
were	VBD	O
split	VBN	O
in	IN	O
their	PRP$	O
use	NN	O
of	IN	O
the	DT	O
timing-based	JJ	O
(	(	O
n	JJ	O
=	NNP	O
10	CD	O
)	)	O
and	CC	O
the	DT	O
location-based	JJ	O
(	(	O
n	JJ	O
=	NNP	O
6	CD	O
)	)	O
approaches	NNS	O
.	.	O

Chi-squared	JJ	O
analyses	NNS	O
suggested	VBD	O
educators	NNS	O
'	POS	O
conceptions	NNS	O
for	IN	O
organising	VBG	O
murmurs	NNS	O
differed	VBN	O
significantly	RB	O
from	IN	O
students	NNS	O
'	POS	O
conceptions	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Contrary	NNP	O
to	TO	O
our	PRP$	O
predictions	NNS	O
,	,	O
directing	VBG	O
students	NNS	O
'	POS	O
SRL	NNP	O
produced	VBD	O
no	DT	O
additional	JJ	O
benefit	NN	O
and	CC	O
increased	VBD	O
their	PRP$	O
practice	NN	O
time	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
one	CD	O
potential	JJ	O
source	NN	O
of	IN	O
these	DT	O
results	NNS	O
was	VBD	O
a	DT	O
divergence	NN	O
between	IN	O
student	NN	O
and	CC	O
educator	NN	O
conceptions	NNS	O
for	IN	O
structuring	VBG	O
the	DT	O
practice	NN	O
of	IN	O
cardiac	JJ	O
auscultation	NN	O
skills	NNS	O
.	.	O

This	DT	O
phenomenon	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
well	RB	O
articulated	VBN	O
in	IN	O
the	DT	O
medical	JJ	O
education	NN	O
literature	NN	O
,	,	O
and	CC	O
may	MD	O
have	VB	O
important	JJ	O
implications	NNS	O
in	IN	O
many	JJ	O
(	(	O
especially	RB	O
technology-mediated	VBN	O
)	)	O
educational	JJ	O
contexts	NN	O
.	.	O

Theory-driven	JJ	Educational
intervention	NN	Educational
improves	VBZ	O
calcium	JJ	O
intake	NN	O
,	,	O
osteoporosis	NN	O
knowledge	NN	O
,	,	O
and	CC	O
self-efficacy	NN	O
in	IN	O
community-dwelling	JJ	O
older	JJR	O
Black	NNP	O
adults	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
assess	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
an	DT	O
osteoporosis	JJ	Educational
education	NN	Educational
program	NN	Educational
to	TO	O
improve	VB	O
calcium	NN	O
intake	NN	O
,	,	O
knowledge	NN	O
,	,	O
and	CC	O
self-efficacy	NN	O
in	IN	O
community-dwelling	JJ	O
older	JJR	O
Black	NNP	O
adults	NNS	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
repeated	VBD	O
measures	NNS	O
experimental	JJ	O
design	NN	O
.	.	O

SETTING	NN	O
Churches	NNP	O
and	CC	O
community-based	JJ	O
organizations	NNS	O
.	.	O

PARTICIPANTS	NNP	O
Men	NNP	O
and	CC	O
women	NNS	O
(	(	O
n	JJ	O
=	NNP	O
110	CD	O
)	)	O
50	CD	O
years	NNS	O
old	JJ	O
and	CC	O
older	JJR	O
from	IN	O
3	CD	O
south	JJ	O
Florida	NNP	O
counties	NNS	O
.	.	O

INTERVENTION	NNP	O
Participants	NNP	O
randomly	RB	O
assigned	VBD	O
to	TO	O
either	DT	O
of	IN	O
2	CD	O
groups	NNS	O
:	:	O
Group	NNP	O
1	CD	O
(	(	O
experimental	JJ	O
group	NN	O
)	)	O
or	CC	O
Group	NNP	O
2	CD	O
(	(	O
wait-list	JJ	Educational
control	NN	Educational
group	NN	Educational
)	)	O
.	.	O

Group	NNP	O
1	CD	O
participated	VBD	O
in	IN	O
6	CD	Educational
weekly	JJ	Educational
education	NN	Educational
program	NN	Educational
sessions	NNS	Educational
immediately	RB	O
following	VBG	O
baseline	NN	Educational
assessment	NN	Educational
,	,	O
and	CC	O
Group	NNP	O
2	CD	O
started	VBD	O
the	DT	O
program	NN	O
following	VBG	O
Group	NNP	O
1	CD	O
's	POS	O
program	NN	O
completion	NN	O
.	.	O

A	DT	O
tested	JJ	O
curriculum	NN	O
was	VBD	O
adapted	VBN	O
to	TO	O
meet	VB	O
the	DT	O
needs	NNS	O
of	IN	O
the	DT	O
target	NN	O
population	NN	O
.	.	O

MAIN	NNP	O
OUTCOME	NNP	O
MEASURES	NNP	O
Dietary	NNP	O
calcium	NN	O
intake	NN	O
,	,	O
osteoporosis	NN	O
knowledge	NN	O
,	,	O
health	NN	O
beliefs	NNS	O
,	,	O
and	CC	O
self-efficacy	NN	O
.	.	O

ANALYSIS	NNP	O
Descriptive	NNP	O
and	CC	O
summary	JJ	O
statistics	NNS	O
,	,	O
repeated	VBD	O
measures	NNS	O
analysis	NN	O
of	IN	O
variance	NN	O
,	,	O
and	CC	O
regression	NN	O
analysis	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
total	JJ	O
participants	NNS	O
,	,	O
84.6	CD	O
%	NN	O
completed	VBD	O
the	DT	O
study	NN	O
(	(	O
mean	JJ	O
age	NN	O
=	VBD	O
70.2	CD	O
years	NNS	O
)	)	O
.	.	O

Overall	UH	O
,	,	O
an	DT	O
educational	JJ	Educational
program	NN	Educational
developed	VBN	O
with	IN	O
a	DT	O
theoretical	JJ	O
background	NN	O
was	VBD	O
associated	VBN	O
with	IN	O
improvement	NN	O
in	IN	O
calcium	NN	O
intake	NN	O
,	,	O
knowledge	NN	O
,	,	O
and	CC	O
self-efficacy	NN	O
,	,	O
with	IN	O
no	DT	O
effect	NN	O
on	IN	O
most	JJS	O
health	NN	O
belief	NN	O
subscales	NNS	O
.	.	O

Assigned	VBN	O
group	NN	O
was	VBD	O
the	DT	O
major	JJ	O
predictor	NN	O
of	IN	O
change	NN	O
in	IN	O
calcium	NN	O
intake	NN	O
.	.	O

CONCLUSIONS	NNP	O
AND	NNP	O
IMPLICATIONS	NNP	O
A	NNP	O
theory-driven	JJ	O
approach	NN	O
is	VBZ	O
valuable	JJ	O
in	IN	O
improving	VBG	O
behavior	NN	O
to	TO	O
promote	VB	O
bone	NN	O
health	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Health	NNP	O
professionals	NNS	O
should	MD	O
consider	VB	O
using	VBG	O
more	JJR	O
theory-driven	JJ	O
approaches	NNS	O
in	IN	O
intervention	NN	O
studies	NNS	O
.	.	O

[	JJ	O
Evaluation	NNP	O
of	IN	O
Stepping	NNP	O
Stones	NNP	O
Triple	NNP	O
P	NNP	O
:	:	O
Interims	NNP	O
analysis	NN	O
of	IN	O
the	DT	O
Stepping-Stones-SPC-Multicentric	NNP	O
Study	NNP	O
]	NNP	O
.	.	O

Stepping	VBG	Educational
Stones	JJ	Educational
Triple	NNP	Educational
P	NNP	Educational
is	VBZ	O
a	DT	O
behavioural	JJ	O
parenting	NN	O
training	NN	O
for	IN	O
families	NNS	O
with	IN	O
a	DT	O
handicapped	JJ	O
child	NN	O
,	,	O
which	WDT	O
has	VBZ	O
already	RB	O
been	VBN	O
successfully	RB	O
evaluated	VBN	O
in	IN	O
its	PRP$	O
country	NN	O
of	IN	O
origin	NN	O
,	,	O
Australia	NNP	O
.	.	O

Within	IN	O
a	DT	O
multicentric	JJ	O
study	NN	O
of	IN	O
several	JJ	O
Social	NNP	O
Pediatric	NNP	O
Centers	NNP	O
(	(	O
SPCs	NNP	O
)	)	O
and	CC	O
further	JJ	O
clinics/institutions	NNS	O
in	IN	O
Germany	NNP	O
,	,	O
it	PRP	O
has	VBZ	O
been	VBN	O
established	VBN	O
as	IN	O
a	DT	O
group	NN	Educational
parenting	VBG	Educational
training	NN	Educational
(	(	O
3-7	JJ	O
families	NNS	O
per	IN	O
training	NN	O
)	)	O
.	.	O

Statistical	JJ	O
analysis	NN	O
proved	VBD	O
significant	JJ	O
effects	NNS	O
concerning	VBG	O
dysfunctional	JJ	O
parenting	NN	O
,	,	O
parental	JJ	O
stress	NN	O
and	CC	O
child	VB	O
behaviour	NN	O
problems	NNS	O
as	RB	O
well	RB	O
as	IN	O
little	JJ	O
side	NN	O
effects	NNS	O
and	CC	O
a	DT	O
positive	JJ	O
acceptance	NN	O
of	IN	O
stepping	VBG	O
stones	NNS	O
by	IN	O
the	DT	O
families	NNS	O
.	.	O

Comparison	NNP	O
of	IN	O
percutaneous	JJ	O
transmitral	JJ	O
commissurotomy	NN	O
with	IN	O
Inoue	NNP	O
balloon	NN	O
technique	NN	O
and	CC	O
metallic	JJ	O
commissurotomy	NN	O
:	:	O
immediate	JJ	O
and	CC	O
short-term	JJ	O
follow-up	JJ	O
results	NNS	O
of	IN	O
a	DT	O
randomized	JJ	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
The	DT	O
Inoue	NNP	O
balloon	NN	O
technique	NN	O
for	IN	O
mitral	JJ	O
commissurotomy	NN	O
is	VBZ	O
well	RB	O
established	VBN	O
and	CC	O
carried	VBN	O
out	RP	O
worldwide	NN	O
.	.	O

Metallic	NNP	O
commissurotomy	NN	O
is	VBZ	O
reported	VBN	O
to	TO	O
be	VB	O
a	DT	O
cheaper	JJR	O
and	CC	O
effective	JJ	O
alternative	NN	O
to	TO	O
balloon	VB	O
mitral	JJ	O
commissurotomy	NN	O
.	.	O

METHODS	NNP	O
One	CD	O
hundred	VBD	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
2	CD	O
groups	NNS	O
to	TO	O
undergo	VB	O
percutaneous	JJ	Surgical
transmitral	JJ	Surgical
commissurotomy	NN	Surgical
(	(	Surgical
PTMC	NNP	Surgical
)	)	Surgical
by	IN	O
means	NNS	Surgical
of	IN	Surgical
the	DT	Surgical
Inoue	NNP	Surgical
balloon	NN	Surgical
technique	NN	Surgical
(	(	Surgical
IBMC	NNP	Surgical
,	,	O
n	JJ	O
=	NNP	O
49	CD	O
)	)	O
or	CC	O
metallic	JJ	Surgical
commissurotomy	NN	Surgical
(	(	Surgical
PMMC	NNP	Surgical
,	,	Physical
n	JJ	Physical
=	NNP	Physical
51	CD	Physical
)	)	Physical
.	.	O

Patients	NNS	O
were	VBD	O
crossed	VBN	O
over	IN	O
to	TO	O
the	DT	O
other	JJ	O
technique	NN	Physical
when	WRB	O
the	DT	O
initial	JJ	O
technique	NN	O
was	VBD	O
a	DT	O
failure	NN	O
.	.	O

Success	NN	O
of	IN	O
valvotomy	NN	O
,	,	O
procedure-related	JJ	O
complications	NNS	O
,	,	O
and	CC	O
follow-up	JJ	O
events	NNS	O
of	IN	O
the	DT	O
2	CD	O
techniques	NNS	O
were	VBD	O
compared	VBN	O
.	.	O

RESULTS	NNP	O
Basal	NNP	O
echocardiographic	JJ	O
and	CC	O
hemodynamic	JJ	O
data	NNS	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Procedural	NNP	O
success	NN	O
was	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
:	:	O
45	CD	O
of	IN	O
49	CD	O
procedures	NNS	O
(	(	O
91.8	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
IBMC	NNP	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
46	CD	O
of	IN	O
51	CD	O
procedures	NNS	O
(	(	O
90.18	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
PMMC	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
1.0	CD	O
)	)	O
.	.	O

Crossover	NNP	O
was	VBD	O
also	RB	O
comparable	JJ	O
,	,	O
with	IN	O
1	CD	O
occurring	VBG	O
in	IN	O
the	DT	O
IBMC	NNP	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
3	CD	O
in	IN	O
the	DT	O
PMMC	NNP	O
group	NN	O
.	.	O

Complications	NNS	O
such	JJ	O
as	IN	O
cardiac	JJ	O
tamponade	NN	O
and	CC	O
mitral	JJ	O
regurgitation	NN	O
(	(	O
requiring	VBG	O
or	CC	O
not	RB	O
requiring	VBG	O
mitral	JJ	O
valve	FW	O
replacement	NN	O
)	)	O
were	VBD	O
similar	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
with	IN	O
3	CD	O
complications	NNS	O
in	IN	O
the	DT	O
IBMC	NNP	O
group	NN	O
,	,	O
compared	VBN	O
with	IN	O
4	CD	O
complications	NNS	O
in	IN	O
the	DT	O
PMMC	NNP	O
group	NN	O
(	(	O
P	NNP	O
=.29	NNP	O
)	)	O
.	.	O

After	IN	O
a	DT	O
follow-up	JJ	O
period	NN	O
of	IN	O
approximately	RB	O
4	CD	O
months	NNS	O
,	,	O
both	DT	O
groups	NNS	O
had	VBD	O
similar	JJ	O
event	NN	O
rates	NNS	O
and	CC	O
comparable	JJ	O
hemodynamic	JJ	O
parameters	NNS	O
(	(	O
P	NNP	O
=	NNP	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
IBMC	NNP	O
and	CC	O
PMMC	NNP	O
are	VBP	O
successful	JJ	O
means	NNS	O
of	IN	O
providing	VBG	O
relief	NN	O
from	IN	O
severe	JJ	O
mitral	JJ	O
stenosis	NN	O
with	IN	O
a	DT	O
gain	NN	O
in	IN	O
valve	JJ	O
area	NN	O
and	CC	O
reduction	NN	O
in	IN	O
transmitral	JJ	O
gradient	NN	O
.	.	O

Both	DT	O
techniques	NNS	O
have	VBP	O
similar	JJ	O
procedural	JJ	O
success	NN	O
,	,	O
complication	NN	O
rates	NNS	O
,	,	O
and	CC	O
follow-up	JJ	O
events	NNS	O
.	.	O

Short-term	JJ	O
metabolic	JJ	O
effects	NNS	O
of	IN	O
prednisone	NN	Pharmacological
administration	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
.	.	O

AIMS	NNP	O
Supraphysiologic	NNP	O
glucocorticoid	NN	O
activity	NN	O
is	VBZ	O
well	RB	O
established	VBN	O
to	TO	O
cause	VB	O
impaired	JJ	O
glucose	JJ	O
tolerance	NN	O
and	CC	O
insulin	NN	O
resistance	NN	O
,	,	O
yet	RB	O
no	DT	O
study	NN	O
has	VBZ	O
evaluated	VBN	O
dose-dependent	JJ	O
effects	NNS	O
of	IN	O
low-dose	JJ	O
prednisone	NN	Pharmacological
during	IN	O
short-term	JJ	O
oral	JJ	O
administration	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
quantify	VB	O
the	DT	O
effects	NNS	O
of	IN	O
daily	JJ	O
10	CD	Pharmacological
or	CC	Pharmacological
25	CD	Pharmacological
mg	NNS	Pharmacological
prednisone	JJ	Pharmacological
administration	NN	O
for	IN	O
one	CD	O
week	NN	O
on	IN	O
insulin	NN	O
sensitivity	NN	O
by	IN	O
employing	VBG	O
a	DT	O
two-step	JJ	Pharmacological
hyperinsulinemic	JJ	Pharmacological
euglycemic	JJ	Pharmacological
glucose	NN	Pharmacological
clamp	NN	Pharmacological
(	(	O
Step	JJ	O
1	CD	O
:	:	O
insulin	NN	O
infusion	NN	O
=	VBD	O
20	CD	O
mU/m?/min	NN	O
;	:	O
Step	CC	O
2	CD	O
:	:	O
insulin	NN	O
infusion	NN	O
=	VBD	O
80	CD	O
mU/m?/min	NN	O
)	)	O
in	IN	O
healthy	JJ	O
,	,	O
lean	JJ	O
males	NNS	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
glucose	NN	O
infused	VBN	O
at	IN	O
steady-state	JJ	O
to	TO	O
maintain	VB	O
stable	JJ	O
blood	NN	O
glucose	JJ	O
[	$	O
90	CD	O
mg/dl	NN	O
(	(	O
4.95	CD	O
mmol/l	NN	O
)	)	O
]	NN	O
was	VBD	O
used	VBN	O
to	TO	O
calculate	VB	O
several	JJ	O
indices	NNS	O
of	IN	O
insulin	NN	O
sensitivity	NN	O
.	.	O

RESULTS	NNP	O
During	IN	O
Step	NNP	O
1	CD	O
of	IN	O
the	DT	O
clamp	NN	O
,	,	O
whole	JJ	O
body	NN	O
glucose	JJ	O
disposal	NN	O
(	(	O
M	NNP	O
)	)	O
was	VBD	O
reduced	VBN	O
by	IN	O
35	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.003	CD	O
)	)	O
and	CC	O
M/I	NNP	O
was	VBD	O
reduced	VBN	O
by	IN	O
29	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.025	CD	O
)	)	O
for	IN	O
25	CD	O
mg	NN	O
prednisone	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
appreciable	JJ	O
effect	NN	O
of	IN	O
10	CD	O
mg	NN	O
prednisone	NN	O
was	VBD	O
observed	VBN	O
.	.	O

During	IN	O
Step	NNP	O
2	CD	O
,	,	O
M	NNP	O
was	VBD	O
reduced	VBN	O
by	IN	O
33	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.001	CD	O
)	)	O
and	CC	O
15	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
for	IN	O
25	CD	O
and	CC	O
10	CD	O
mg	NN	O
prednisone	NN	O
compared	VBN	O
to	TO	O
placebo	VB	O
;	:	O
and	CC	O
M/I	NNP	O
ratio	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
31	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.001	CD	O
)	)	O
and	CC	O
13	CD	O
%	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.026	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O

The	DT	O
insulin	NN	O
sensitivity	NN	O
index	NN	O
,	,	O
Si	NNP	O
,	,	O
calculated	VBD	O
as	IN	O
the	DT	O
quotient	NN	O
of	IN	O
augmentation	NN	O
of	IN	O
M/I	NNP	O
between	IN	O
Step	NNP	O
1	CD	O
and	CC	O
2	CD	O
,	,	O
was	VBD	O
reduced	VBN	O
by	IN	O
35.3	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
23.5	CD	O
%	NN	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
for	IN	O
25	CD	O
and	CC	O
10	CD	O
mg	NN	O
prednisone	NN	O
,	,	O
respectively	RB	O
.	.	O

CONCLUSION	NNP	O
Administration	NNP	O
of	IN	O
relatively	RB	O
low	JJ	O
pharmacological	JJ	O
doses	NNS	O
of	IN	O
prednisone	NN	O
for	IN	O
one	CD	O
week	NN	O
impaired	JJ	O
insulin	NN	O
sensitivity	NN	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
in	IN	O
healthy	JJ	O
males	NNS	O
.	.	O

These	DT	O
observed	JJ	O
changes	NNS	O
in	IN	O
insulin	NN	O
sensitivity	NN	O
are	VBP	O
likely	JJ	O
to	TO	O
be	VB	O
clinically	RB	O
relevant	JJ	O
,	,	O
especially	RB	O
in	IN	O
individuals	NNS	O
predisposed	VBN	O
to	TO	O
develop	VB	O
glucose	JJ	O
intolerance	NN	O
.	.	O

Improvement	NN	O
of	IN	O
pain	NN	O
related	VBN	O
self	JJ	O
management	NN	O
for	IN	O
oncologic	JJ	O
patients	NNS	O
through	IN	O
a	DT	O
trans	JJ	O
institutional	JJ	O
modular	JJ	O
nursing	NN	O
intervention	NN	O
:	:	O
protocol	NN	O
of	IN	O
a	DT	O
cluster	NN	O
randomized	VBN	O
multicenter	RB	O
trial	NN	O
.	.	O

BACKGROUND	NNP	O
Pain	NNP	O
is	VBZ	O
one	CD	O
of	IN	O
the	DT	O
most	RBS	O
frequent	JJ	O
and	CC	O
distressing	VBG	O
symptoms	NNS	O
in	IN	O
cancer	NN	O
patients	NNS	O
.	.	O

For	IN	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
patients	NNS	O
,	,	O
sufficient	JJ	O
pain	NN	O
relief	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
if	IN	O
adequate	JJ	O
treatment	NN	O
is	VBZ	O
provided	VBN	O
.	.	O

However	RB	O
,	,	O
pain	NN	O
remains	NNS	O
often	RB	O
undertreated	VBD	O
due	JJ	O
to	TO	O
institutional	JJ	O
,	,	O
health	NN	O
care	NN	O
professional	JJ	O
and	CC	O
patient	JJ	O
related	JJ	O
barriers	NNS	O
.	.	O

Patients	NNS	O
self	JJ	O
management	NN	O
skills	NNS	O
are	VBP	O
affected	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
'	POS	O
knowledge	NN	O
,	,	O
activities	NNS	O
and	CC	O
attitude	NN	O
to	TO	O
pain	VB	O
management	NN	O
.	.	O

This	DT	O
trial	NN	O
protocol	NN	O
is	VBZ	O
aimed	VBN	O
to	TO	O
test	VB	O
the	DT	O
SCION-PAIN	JJ	O
program	NN	O
,	,	O
a	DT	O
multi	NN	O
modular	NN	O
structured	VBD	O
intervention	NN	O
to	TO	O
improve	VB	O
self	NN	O
management	NN	O
in	IN	O
cancer	NN	O
patients	NNS	O
with	IN	O
pain	NN	O
.	.	O

METHODS	NNP	O
240	CD	O
patients	NNS	O
with	IN	O
diagnosed	JJ	O
malignancy	NN	O
and	CC	O
pain	NN	O
>	VBP	O
3	CD	O
days	NNS	O
and	CC	O
average	JJ	O
pain	NN	O
>	JJ	O
or=	NN	O
3/10	CD	O
will	MD	O
participate	VB	O
in	IN	O
a	DT	O
cluster	NN	O
randomized	VBN	O
trial	NN	O
on	IN	O
18	CD	O
wards	NNS	O
in	IN	O
2	CD	O
German	JJ	O
university	NN	O
hospitals	NNS	O
.	.	O

Patients	NNS	O
from	IN	O
the	DT	O
intervention	NN	O
wards	NNS	O
will	MD	O
receive	VB	O
,	,	O
additionally	RB	O
to	TO	O
standard	VB	Control
pain	NN	Control
treatment	NN	Control
,	,	O
the	DT	Physical
SCION-PAIN	JJ	Physical
program	NN	Physical
consisting	NN	Physical
of	IN	Physical
3	CD	Physical
modules	NNS	Physical
:	:	Physical
pharmacologic	NN	Physical
pain	NN	Physical
management	NN	Physical
,	,	Physical
nonpharmacologic	RB	Physical
pain	JJ	Physical
management	NN	Physical
and	CC	Physical
discharge	NN	Physical
management	NN	Physical
.	.	O

The	DT	O
intervention	NN	O
will	MD	O
be	VB	O
conducted	VBN	O
by	IN	O
specially	RB	O
trained	JJ	O
oncology	NN	O
nurses	NNS	O
and	CC	O
includes	VBZ	O
components	NNS	O
of	IN	O
patient	JJ	Educational
education	NN	Educational
,	,	Educational
skills	NNS	Educational
training	NN	Educational
and	CC	Educational
counseling	NN	Educational
to	TO	Educational
improve	VB	Educational
self	PRP	Educational
care	VB	Educational
regarding	VBG	Educational
pain	JJ	Educational
management	NN	Educational
beginning	VBG	Educational
with	IN	Educational
admission	NN	Educational
followed	VBN	Educational
by	IN	Educational
booster	NN	Educational
session	NN	Educational
every	DT	Educational
3rd	CD	Educational
day	NN	Educational
and	CC	Educational
one	CD	Educational
follow	VBP	Educational
up	RP	Educational
telephone	NN	Educational
counseling	NN	Educational
within	IN	Educational
2	CD	Educational
to	TO	Educational
3	CD	Educational
days	NNS	Educational
after	IN	Educational
discharge	NN	Educational
.	.	O

Patients	NNS	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
will	MD	O
receive	VB	O
standard	NN	O
care	NN	O
.	.	O

Primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
group	NN	O
difference	NN	O
in	IN	O
patient	NN	O
related	JJ	O
barriers	NNS	O
to	TO	O
management	NN	O
of	IN	O
cancer	NN	O
pain	NN	O
(	(	O
BQII	NNP	O
)	)	O
,	,	O
7	CD	O
days	NNS	O
after	IN	O
discharge	NN	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
are	VBP	O
:	:	O
pain	NN	O
intensity	NN	O
&	CC	O
interference	NN	O
,	,	O
adherence	NN	O
,	,	O
coping	VBG	O
and	CC	O
HRQoL	NNP	O
.	.	O

DISCUSSION	NNP	O
The	DT	O
study	NN	O
will	MD	O
determine	VB	O
if	IN	O
the	DT	O
acquired	VBN	O
self	NN	O
management	NN	O
skills	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
continue	VBP	O
to	TO	O
be	VB	O
used	VBN	O
after	IN	O
discharge	NN	O
from	IN	O
hospital	NN	O
.	.	O

It	PRP	O
is	VBZ	O
hypothesized	VBN	O
that	IN	O
patients	NNS	O
who	WP	O
receive	VBP	O
the	DT	O
multi	NN	O
modular	NN	O
structured	VBN	O
intervention	NN	O
will	MD	O
have	VB	O
less	RBR	O
patient	JJ	O
related	JJ	O
barriers	NNS	O
and	CC	O
a	DT	O
better	JJR	O
self	JJ	O
management	NN	O
of	IN	O
cancer	NN	O
pain	NN	O
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
ClinicalTrials	NNP	O
NCT00779597	NNP	O
.	.	O

[	JJ	O
Pharmacological	NNP	O
correction	NN	O
of	IN	O
free	JJ	O
radical	JJ	O
disturbances	NNS	O
and	CC	O
endotoxicosis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
diffuse	NN	O
peritonitis	NN	O
at	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
]	NNP	O
.	.	O

The	DT	O
examination	NN	O
and	CC	O
treatment	NN	O
of	IN	O
64	CD	O
patients	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
inclusion	NN	O
of	IN	O
complex	JJ	Pharmacological
antioxidant	NN	Pharmacological
cytoflavin	NN	Pharmacological
in	IN	O
intensive	JJ	O
therapy	NN	O
at	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
diffuse	NN	O
peritonitis	NN	O
allows	VBZ	O
the	DT	O
hypoxia	NN	O
degree	NN	O
to	TO	O
be	VB	O
decreased	VBN	O
that	IN	O
in	IN	O
its	PRP$	O
turn	NN	O
results	NNS	O
in	IN	O
quicker	JJ	O
recovery	NN	O
of	IN	O
the	DT	O
antioxidant	JJ	O
system	NN	O
and	CC	O
decreased	JJ	O
activity	NN	O
of	IN	O
peroxidation	NN	O
and	CC	O
endotoxicosis	NN	O
level	NN	O
.	.	O

The	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
of	IN	O
diffuse	NN	O
peritonitis	NN	O
with	IN	O
cytoflavin	NN	Pharmacological
included	VBN	O
in	IN	O
intensive	JJ	O
therapy	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
shorter	JJR	O
terms	NNS	O
of	IN	O
artificial	JJ	O
lung	NN	O
ventilation	NN	O
,	,	O
shorter	JJR	O
time	NN	O
of	IN	O
staying	VBG	O
in	IN	O
critical	JJ	O
condition	NN	O
,	,	O
more	RBR	O
favorable	JJ	O
course	NN	O
of	IN	O
complications	NNS	O
.	.	O

Single-use	NNP	O
plaque	NN	O
removal	NN	O
efficacy	NN	O
of	IN	O
three	CD	O
power	NN	Other
toothbrushes	NNS	Other
.	.	O

OBJECTIVES	NNP	O
To	TO	O
compare	VB	O
the	DT	O
safety	NN	O
and	CC	O
plaque	NN	O
removal	NN	O
efficacy	NN	O
of	IN	O
two	CD	Other
oscillating/rotating/pulsating	VBG	Other
toothbrushes	NNS	Other
(	(	O
Oral-B	NNP	Other
ProfessionalCare	NNP	Other
7000	CD	Other
[	NNP	Other
PC	NN	Other
7000	CD	Other
]	NN	O
and	CC	O
Oral-B	JJ	Other
3D	CD	Other
Excel	NNP	Other
[	VBD	Other
3DE	CD	Other
]	NN	O
)	)	O
and	CC	O
a	DT	O
high-frequency	NN	O
toothbrush	NN	O
(	(	O
Sonicare	NNP	O
Advance	NNP	O
,	,	O
Philips	NNP	O
Oral	NNP	O
Healthcare	NNP	O
;	:	O
SA	NNP	O
)	)	O
in	IN	O
a	DT	O
single-use	NN	O
,	,	O
examiner-blind	NN	O
,	,	O
three	CD	O
period	NN	O
crossover	NN	O
study	NN	O
.	.	O

METHODS	NNP	O
After	IN	O
refraining	VBG	O
from	IN	O
all	DT	O
oral	JJ	O
hygiene	NN	O
procedures	NNS	O
for	IN	O
23-25	JJ	O
hours	NNS	O
,	,	O
subjects	NNS	O
received	VBD	O
an	DT	O
oral	JJ	O
tissue	NN	O
examination	NN	O
and	CC	O
those	DT	O
with	IN	O
pre-brushing	JJ	O
whole	JJ	O
mouth	NN	O
mean	JJ	O
plaque	NN	O
scores	NNS	O
>	VBP	O
or	CC	O
=	VBP	O
0.6	CD	O
based	VBN	O
on	IN	O
the	DT	O
Rustogi	NNP	O
et	CC	O
al	NN	O
.	.	O

Modified	NNP	O
Navy	NNP	O
Plaque	NNP	O
Index	NNP	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
treatment	NN	O
sequence	NN	O
.	.	O

After	IN	O
brushing	VBG	O
with	IN	O
the	DT	O
assigned	JJ	O
toothbrush	NN	O
and	CC	O
a	DT	O
commercially	RB	O
available	JJ	O
dentifrice	NN	O
for	IN	O
2	CD	O
minutes	NNS	O
,	,	O
oral	JJ	O
tissues	NNS	O
were	VBD	O
then	RB	O
re-examined	JJ	O
and	CC	O
post-brushing	JJ	O
plaque	NN	O
scores	NNS	O
recorded	VBN	O
.	.	O

Following	VBG	O
a	DT	O
brief	JJ	O
washout	JJ	O
period	NN	O
between	IN	O
two	CD	O
additional	JJ	O
visits	NNS	O
,	,	O
the	DT	O
above	NN	O
procedures	NNS	O
were	VBD	O
repeated	VBN	O
with	IN	O
the	DT	O
two	CD	O
alternate	NN	O
toothbrushes	NNS	O
.	.	O

One	CD	O
examiner	NN	O
,	,	O
blinded	VBD	O
to	TO	O
the	DT	O
treatment	NN	O
sequence	NN	O
,	,	O
performed	VBD	O
all	DT	O
clinical	JJ	O
measurements	NNS	O
.	.	O

RESULTS	VB	O
A	DT	O
total	NN	O
of	IN	O
79	CD	O
subjects	NNS	O
(	(	O
28	CD	O
males	NNS	O
and	CC	O
51	CD	O
females	NNS	O
)	)	O
were	VBD	O
enrolled	VBN	O
and	CC	O
completed	VBN	O
the	DT	O
study	NN	O
.	.	O

Each	DT	O
toothbrush	NN	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
significantly	RB	O
reduced	VBN	O
plaque	NN	O
levels	NNS	O
after	IN	O
a	DT	O
single	JJ	O
brushing	NN	O
.	.	O

The	DT	O
PC	NN	O
7000	CD	O
and	CC	O
3DE	CD	O
were	VBD	O
equally	RB	O
more	RBR	O
effective	JJ	O
in	IN	O
plaque	NN	O
removal	NN	O
than	IN	O
the	DT	O
SA	NNP	O
,	,	O
at	IN	O
all	DT	O
tooth	DT	O
areas	NNS	O
,	,	O
reducing	VBG	O
plaque	NN	O
by	IN	O
59.0	CD	O
%	NN	O
,	,	O
59.7	CD	O
%	NN	O
and	CC	O
51.8	CD	O
%	NN	O
,	,	O
respectively	RB	O
on	IN	O
whole	JJ	O
mouth	NN	O
surfaces	NNS	O
,	,	O
and	CC	O
by	IN	O
67.5	CD	O
%	NN	O
,	,	O
67.8	CD	O
%	NN	O
and	CC	O
59.4	CD	O
%	NN	O
,	,	O
respectively	RB	O
on	IN	O
approximal	JJ	O
surfaces	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
action	NN	O
of	IN	O
the	DT	O
oscillating/rotating/pulsating	NN	O
toothbrushes	NNS	O
(	(	O
Oral-B	NNP	O
ProfessionalCare	NNP	O
7000	CD	O
and	CC	O
Oral-B	NNP	O
3D	CD	O
Excel	NNP	O
)	)	O
was	VBD	O
more	RBR	O
effective	JJ	O
in	IN	O
plaque	NN	O
removal	NN	O
than	IN	O
the	DT	O
high-frequency	NN	O
toothbrush	NN	O
(	(	O
Sonicare	NNP	O
Advance	NNP	O
)	)	O
.	.	O

Enhancing	VBG	O
caregiver	NN	O
health	NN	O
:	:	O
findings	NNS	O
from	IN	O
the	DT	O
resources	NNS	O
for	IN	O
enhancing	VBG	O
Alzheimer	NNP	O
's	POS	O
caregiver	NN	O
health	NN	O
II	NNP	O
intervention	NN	O
.	.	O

OBJECTIVES	NNP	O
To	TO	O
examine	VB	O
the	DT	O
relationships	NNS	O
between	IN	O
changes	NNS	O
from	IN	O
baseline	NN	O
to	TO	O
post-Resources	NNS	Other
for	IN	Other
Enhancing	VBG	Other
Alzheimer	NNP	Other
's	POS	Other
Caregiver	NNP	Other
Health	NNP	Other
(	(	Other
REACH	NNP	Other
)	)	Other
intervention	NN	Other
in	IN	O
caregiver	NN	O
(	(	O
CG	NNP	O
)	)	O
self-reported	JJ	O
health	NN	O
,	,	O
burden	NN	O
,	,	O
and	CC	O
bother	RB	O
.	.	O

DESIGN	NNP	O
Randomized	NNP	O
,	,	O
multisite	RB	O
clinical	JJ	O
trial	NN	O
.	.	O

SETTING	NN	O
CG	NNP	O
and	CC	O
care	VB	O
recipient	NN	O
(	(	O
CR	NNP	O
)	)	O
homes	NNS	O
in	IN	O
five	CD	O
U.S.	NNP	O
cities	NNS	O
.	.	O

PARTICIPANTS	VB	O
Four	CD	O
hundred	CD	O
ninety-five	JJ	O
dementia	NN	O
CG	NNP	O
and	CC	O
CR	NNP	O
dyads	NNS	O
(	(	O
169	CD	O
Hispanic	NNP	O
,	,	O
160	CD	O
white	JJ	O
,	,	O
and	CC	O
166	CD	O
African	JJ	O
American	NNP	O
)	)	O
receiving	VBG	O
intervention	NN	O
and	CC	O
their	PRP$	O
controls	NNS	O
.	.	O

INTERVENTION	NNP	O
CGs	NNP	O
were	VBD	O
assigned	VBN	O
to	TO	O
the	DT	O
REACH	NNP	Control
intervention	NN	Control
or	CC	O
a	DT	O
no-treatment	JJ	Control
control	NN	Control
group	NN	Control
.	.	O

Intervention	NNP	O
subjects	VBZ	O
received	VBN	O
individual	JJ	O
risk	NN	O
profiles	NNS	O
and	CC	O
the	DT	O
REACH	NNP	O
intervention	NN	O
through	IN	O
nine	CD	O
in-home	JJ	O
and	CC	O
three	CD	O
telephone	NN	Educational
sessions	NNS	Educational
over	IN	O
6	CD	O
months	NNS	O
.	.	O

Control	NNP	O
subjects	VBZ	O
received	VBN	O
two	CD	O
brief	JJ	O
check-in	JJ	Control
telephone	NN	Control
calls	VBZ	Control
during	IN	O
this	DT	O
6-month	JJ	O
period	NN	O
.	.	O

MEASUREMENTS	PDT	O
The	DT	O
primary	JJ	O
outcome	NN	O
was	VBD	O
change	NN	O
in	IN	O
CG	NNP	O
health	NN	O
status	NN	O
from	IN	O
baseline	NN	O
to	TO	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
were	VBD	O
CG	NNP	O
burden	NN	O
and	CC	O
bother	NN	O
after	IN	O
the	DT	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
After	IN	O
the	DT	O
intervention	NN	O
,	,	O
CGs	NNP	O
reported	VBD	O
better	RBR	O
self-rated	JJ	O
health	NN	O
,	,	O
sleep	VBP	O
quality	NN	O
,	,	O
physical	JJ	O
health	NN	O
,	,	O
and	CC	O
emotional	JJ	O
health	NN	O
,	,	O
which	WDT	O
was	VBD	O
related	VBN	O
to	TO	O
less	JJR	O
burden	JJ	O
and	CC	O
bother	NN	O
with	IN	O
their	PRP$	O
caregiving	NN	O
role	NN	O
than	IN	O
for	IN	O
CGs	NNP	O
not	RB	O
receiving	VBG	O
the	DT	O
intervention	NN	O
.	.	O

Changes	NNS	O
in	IN	O
depression	NN	O
appeared	VBD	O
to	TO	O
mediate	VB	O
these	DT	O
relationships	NNS	O
.	.	O

Several	JJ	O
racial	JJ	O
and	CC	O
ethnic	JJ	O
group	NN	O
differences	NNS	O
existed	VBD	O
in	IN	O
physical	JJ	O
and	CC	O
emotional	JJ	O
health	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
total	JJ	O
frustration	NN	O
with	IN	O
caregiving	NN	O
,	,	O
emotional	JJ	O
burden	NN	O
,	,	O
and	CC	O
CG-rated	JJ	O
bother	NN	O
with	IN	O
CR	NNP	O
's	POS	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
and	CC	O
instrumental	JJ	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
follow-up	JJ	O
,	,	O
although	IN	O
differences	NNS	O
between	IN	O
baseline	NN	O
and	CC	O
posttest	NN	O
did	VBD	O
not	RB	O
vary	JJ	O
according	VBG	O
to	TO	O
race	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
structured	JJ	O
,	,	O
multicomponent	JJ	O
skills	NNS	O
training	VBG	O
intervention	NN	O
that	WDT	O
targeted	VBD	O
CG	NNP	O
self-care	JJ	O
behaviors	NNS	O
as	IN	O
one	CD	O
of	IN	O
five	CD	O
target	NN	O
areas	NNS	O
,	,	O
improved	VBN	O
self-reported	JJ	O
health	NN	O
status	NN	O
,	,	O
and	CC	O
decreased	VBD	O
burden	NN	O
and	CC	O
bother	NN	O
in	IN	O
racially	RB	O
and	CC	O
ethnically	RB	O
diverse	JJ	O
CGs	NNP	O
of	IN	O
people	NNS	O
with	IN	O
dementia	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
alfentanil	NN	Pharmacological
,	,	O
fentanyl	NN	Pharmacological
and	CC	O
sufentanil	NN	Pharmacological
for	IN	O
total	JJ	O
intravenous	JJ	O
anaesthesia	NN	O
with	IN	O
propofol	NN	Pharmacological
in	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
surgery	NN	O
.	.	O

We	PRP	O
have	VBP	O
studied	VBN	O
the	DT	O
pharmacokinetics	NNS	O
and	CC	O
pharmacodynamics	NNS	O
of	IN	O
alfentanil	NN	Pharmacological
,	,	O
fentanyl	NN	Pharmacological
and	CC	O
sufentanil	VB	Pharmacological
together	RB	O
with	IN	O
propofol	NN	Pharmacological
in	IN	O
patients	NNS	O
undergoing	VBG	O
coronary	JJ	O
artery	NN	O
bypass	NN	O
graft	NN	O
surgery	NN	O
(	(	O
CABG	NNP	O
)	)	O
.	.	O

Sixty	JJ	O
patients	NNS	O
(	(	O
age	NN	O
40-73	CD	O
yr	NN	O
,	,	O
56	CD	O
male	NN	O
)	)	O
were	VBD	O
assigned	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
alfentanil	NN	Pharmacological
,	,	O
fentanyl	NN	Pharmacological
or	CC	O
sufentanil	NN	Pharmacological
and	CC	O
propofol	NN	Pharmacological
.	.	O

Plasma	NNP	O
concentrations	NNS	O
of	IN	O
these	DT	O
drugs	NNS	O
and	CC	O
times	NNS	O
for	IN	O
the	DT	O
plasma	NN	O
concentration	NN	O
to	TO	O
decrease	VB	O
by	IN	O
50	CD	O
%	NN	O
(	(	O
t50	NN	O
)	)	O
and	CC	O
80	CD	O
%	NN	O
(	(	O
t80	NN	O
)	)	O
after	IN	O
cessation	NN	O
of	IN	O
the	DT	O
infusion	NN	O
were	VBD	O
determined	VBN	O
.	.	O

Times	NNS	O
were	VBD	O
recorded	VBN	O
to	TO	O
awakening	VBG	O
and	CC	O
tracheal	JJ	O
extubation	NN	O
.	.	O

Total	JJ	O
dose	NN	O
and	CC	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
propofol	NN	O
were	VBD	O
similar	JJ	O
in	IN	O
all	DT	O
groups	NNS	O
.	.	O

Mean	NNP	O
total	JJ	O
doses	NNS	O
of	IN	O
alfentanil	NN	Pharmacological
,	,	O
fentanyl	NN	Pharmacological
and	CC	O
sufentanil	NN	Pharmacological
were	VBD	O
443	CD	O
,	,	O
45	CD	O
and	CC	O
4.4	CD	O
micrograms	NNS	O
kg-1	JJ	O
,	,	O
respectively	RB	O
.	.	O

Time	NN	O
to	TO	O
awakening	VBG	O
did	VBD	O
not	RB	O
differ	VB	O
significantly	RB	O
.	.	O

In	IN	O
patients	NNS	O
receiving	VBG	O
fentanyl	NN	Pharmacological
,	,	O
the	DT	O
trachea	NN	O
was	VBD	O
extubated	VBN	O
on	IN	O
average	JJ	O
2	CD	O
h	NN	O
later	RB	O
than	IN	O
in	IN	O
those	DT	O
receiving	VBG	O
sufentanil	NN	Pharmacological
and	CC	O
3	CD	O
h	NN	O
later	RB	O
than	IN	O
in	IN	O
those	DT	O
receiving	VBG	O
alfentanil	NN	Pharmacological
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

The	DT	O
t80	NN	O
of	IN	O
fentanyl	NN	Pharmacological
was	VBD	O
longer	JJR	O
(	(	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
than	IN	O
that	DT	O
of	IN	O
alfentanil	NN	Pharmacological
or	CC	O
sufentanil	NN	Pharmacological
,	,	O
and	CC	O
there	RB	O
was	VBD	O
a	DT	O
linear	JJ	O
correlation	NN	O
between	IN	O
the	DT	O
t80	NN	O
of	IN	O
the	DT	O
opioid	NN	O
and	CC	O
the	DT	O
time	NN	O
to	TO	O
tracheal	VB	O
extubation	NN	O
(	(	O
r	JJ	O
=	VBZ	O
0.51	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
t50	NN	O
values	NNS	O
for	IN	O
these	DT	O
opioids	NNS	O
were	VBD	O
similar	JJ	O
and	CC	O
did	VBD	O
not	RB	O
correlate	VB	O
with	IN	O
recovery	NN	O
time	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
patients	NNS	O
undergoing	VBG	O
CABG	NNP	O
and	CC	O
who	WP	O
were	VBD	O
anaesthetized	VBN	O
with	IN	O
fentanyl	NN	Pharmacological
and	CC	O
propofol	NN	Pharmacological
needed	VBN	O
mechanical	JJ	O
ventilatory	NN	O
support	NN	O
for	IN	O
a	DT	O
significantly	RB	O
longer	JJR	O
time	NN	O
than	IN	O
those	DT	O
receiving	VBG	O
alfentanil	NN	Pharmacological
or	CC	O
sufentanil	NN	Pharmacological
and	CC	O
propofol	NN	Pharmacological
.	.	O

On	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
interindividual	JJ	O
variation	NN	O
observed	VBD	O
,	,	O
the	DT	O
time	NN	O
to	TO	O
tracheal	VB	O
extubation	NN	O
was	VBD	O
most	RBS	O
predictable	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
alfentanil	NN	Pharmacological
and	CC	O
most	RBS	O
variable	JJ	O
in	IN	O
patients	NNS	O
receiving	VBG	O
fentanyl	NN	Pharmacological
,	,	O
a	DT	O
finding	NN	O
which	WDT	O
may	MD	O
be	VB	O
important	JJ	O
if	IN	O
the	DT	O
patients	NNS	O
are	VBP	O
transferred	VBN	O
to	TO	O
a	DT	O
step-down	JJ	O
unit	NN	O
on	IN	O
the	DT	O
evening	NN	O
of	IN	O
the	DT	O
operation	NN	O
.	.	O

Liposome-entrapped	JJ	Pharmacological
D.	NNP	Pharmacological
pteronyssinus	NN	Pharmacological
vaccination	NN	Pharmacological
in	IN	O
mild	JJ	O
asthma	JJ	O
patients	NNS	O
:	:	O
effect	NN	O
of	IN	O
1-year	JJ	O
double-blind	NN	O
,	,	O
placebo-controlled	JJ	Control
trial	NN	O
on	IN	O
inflammation	NN	O
,	,	O
bronchial	JJ	O
hyperresponsiveness	NN	O
and	CC	O
immediate	JJ	O
and	CC	O
late	JJ	O
bronchial	NN	O
responses	NNS	O
to	TO	O
the	DT	O
allergen	NN	O
.	.	O

BACKGROUND	NNP	O
Allergen	NNP	O
vaccination	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
mite-allergic	JJ	O
asthma	NN	O
.	.	O

Liposomes	NNS	O
are	VBP	O
immunological	JJ	O
adjuvants	NNS	O
that	WDT	O
can	MD	O
act	VB	O
as	IN	O
allergen	NN	O
carriers	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
immunological	JJ	O
and	CC	O
functional	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
liposome-entrapped	JJ	Pharmacological
D.	NNP	Pharmacological
pteronyssinus	NN	Pharmacological
vaccine	NN	Pharmacological
on	IN	O
mite	JJ	O
monosensitive	NN	O
,	,	O
mild	JJ	O
asthma	NN	O
patients	NNS	O
.	.	O

METHODS	VB	O
A	DT	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
trial	NN	O
was	VBD	O
conducted	VBN	O
on	IN	O
26	CD	O
asthma	JJ	O
patients	NNS	O
who	WP	O
randomly	VBP	O
received	VBN	O
vaccination	NN	O
or	CC	O
placebo	NN	Control
for	IN	O
1	CD	O
year	NN	O
.	.	O

The	DT	O
levels	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
Der	NNP	O
p	NN	O
1	CD	O
allergen	NN	O
were	VBD	O
constant	JJ	O
during	IN	O
the	DT	O
study	NN	O
.	.	O

Allergen	NNP	O
bronchial	JJ	O
challenge	NN	O
was	VBD	O
made	VBN	O
at	IN	O
the	DT	O
beginning	NN	O
(	(	O
T0	NNP	O
)	)	O
and	CC	O
after	IN	O
1	CD	O
year	NN	O
of	IN	O
treatment	NN	O
(	(	O
T12	NNP	O
)	)	O
.	.	O

The	DT	O
day	NN	O
before	IN	O
and	CC	O
24	CD	O
h	NN	O
after	IN	O
the	DT	O
allergen	NN	O
provocation	NN	O
,	,	O
patients	NNS	O
were	VBD	O
challenged	VBN	O
with	IN	O
methacholine	NN	Pharmacological
(	(	O
Mth	NNP	O
)	)	O
(	(	O
until	IN	O
FEV1	NNP	O
fell	VBD	O
by	IN	O
40	CD	O
%	NN	O
)	)	O
and	CC	O
blood	NN	O
and	CC	O
sputum	NN	O
samples	NNS	O
were	VBD	O
obtained	VBN	O
.	.	O

Dose-response	JJ	O
curves	NNS	O
to	TO	O
Mth	NNP	O
were	VBD	O
evaluated	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
Mth-PD20	NNP	O
(	(	O
dose	NN	O
of	IN	O
Mth	NNP	O
that	WDT	O
induced	VBD	O
20	CD	O
%	NN	O
drop	NN	O
in	IN	O
FEV1	NNP	O
)	)	O
,	,	O
slope	NN	O
(	(	O
Mth-DRS	NNP	O
)	)	O
and	CC	O
level	NN	O
of	IN	O
plateau	NN	O
.	.	O

Blood	NNP	O
and	CC	O
sputum	NN	O
eosinophils	NNS	O
and	CC	O
serum	NN	O
levels	NNS	O
of	IN	O
eosinophil	NN	O
cationic	JJ	O
protein	NN	O
(	(	O
ECP	NNP	O
)	)	O
and	CC	O
intercellular	JJ	O
adhesion	NN	O
molecule-1	NN	O
(	(	O
ICAM-1	NNP	O
)	)	O
were	VBD	O
measured	VBN	O
.	.	O

RESULTS	NNP	O
Groups	NNP	O
were	VBD	O
comparable	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
trial	NN	O
.	.	O

At	IN	O
TI2	NNP	O
,	,	O
previous	JJ	O
to	TO	O
the	DT	O
allergen	NN	O
challenge	NN	O
,	,	O
the	DT	O
active	JJ	O
group	NN	O
showed	VBD	O
higher	JJR	O
values	NNS	O
of	IN	O
both	DT	O
FEV1	NNP	O
and	CC	O
Mth-PD20	NNP	O
and	CC	O
lower	JJR	O
values	NNS	O
of	IN	O
Mth-DRS	NNP	O
.	.	O

The	DT	O
number	NN	O
of	IN	O
patients	NNS	O
presenting	VBG	O
a	DT	O
level	NN	O
of	IN	O
plateau	NN	O
increased	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
(	(	O
from	IN	O
two	CD	O
to	TO	O
four	CD	O
)	)	O
and	CC	O
decreased	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
(	(	O
from	IN	O
two	CD	O
to	TO	O
one	CD	O
)	)	O
.	.	O

At	IN	O
T12	NNP	O
,	,	O
before	IN	O
the	DT	O
allergen	NN	O
challenge	NN	O
,	,	O
serum	NN	O
ECP	NNP	O
levels	NNS	O
increased	VBN	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
and	CC	O
blood	NN	O
eosinophils	NNS	O
showed	VBD	O
a	DT	O
trend	NN	O
towards	NNS	O
lower	JJR	O
numbers	NNS	O
in	IN	O
the	DT	O
active	JJ	O
one	NN	O
.	.	O

The	DT	O
immediate	JJ	O
response	NN	O
and	CC	O
the	DT	O
changes	NNS	O
in	IN	O
Mth-DRS	NNP	O
values	NNS	O
,	,	O
sputum	NN	O
eosinophils	NNS	O
and	CC	O
serum	VB	O
ECP	NNP	O
levels	NNS	O
following	VBG	O
the	DT	O
allergen	NN	O
challenge	NN	O
were	VBD	O
attenuated	VBN	O
in	IN	O
the	DT	O
active	JJ	O
group	NN	O
.	.	O

CONCLUSION	NNP	O
Liposome-entrapped	NNP	O
D.	NNP	O
Pteronyssinus	NNP	O
vaccination	NN	O
:	:	O
(	(	O
i	NN	O
)	)	O
protects	VBZ	O
mild	JJ	O
asthma	JJ	O
patients	NNS	O
from	IN	O
the	DT	O
worsening	NN	O
of	IN	O
asthma	NNS	O
due	JJ	O
to	TO	O
sustained	VBN	O
mite	JJ	O
exposure	NN	O
;	:	O
and	CC	O
(	(	O
ii	NN	O
)	)	O
reduces	VBZ	O
the	DT	O
functional	JJ	O
and	CC	O
inflammatory	JJ	O
changes	NNS	O
induced	VBN	O
by	IN	O
allergen	NN	O
bronchial	JJ	O
provocation	NN	O
.	.	O

The	DT	O
memory	NN	O
support	NN	O
system	NN	O
for	IN	O
mild	JJ	O
cognitive	JJ	O
impairment	NN	O
:	:	O
randomized	JJ	O
trial	NN	O
of	IN	O
a	DT	O
cognitive	JJ	Pharmacological
rehabilitation	NN	Pharmacological
intervention	NN	Pharmacological
.	.	O

OBJECTIVE	JJ	O
Individuals	NNS	O
with	IN	O
amnestic	JJ	O
mild	NNS	O
cognitive	JJ	O
impairment	NN	O
(	(	O
MCI	NNP	O
)	)	O
have	VBP	O
few	JJ	O
empirically	RB	O
based	VBN	O
treatment	NN	O
options	NNS	O
for	IN	O
combating	VBG	O
their	PRP$	O
memory	NN	O
loss	NN	O
.	.	O

This	DT	O
study	NN	O
sought	VBD	O
to	TO	O
examine	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
calendar/notebook	NN	Physical
rehabilitation	NN	Physical
intervention	NN	Physical
,	,	O
the	DT	O
memory	NN	Educational
support	NN	Educational
system	NN	Educational
(	(	Educational
MSS	NNP	Educational
)	)	Educational
,	,	O
for	IN	O
individuals	NNS	O
with	IN	O
amnestic	JJ	O
MCI	NNP	O
.	.	O

METHODS	NNP	O
Forty	NNP	O
individuals	NNS	O
with	IN	O
single	JJ	O
domain	NN	O
amnestic	JJ	Educational
MCI	NNP	Educational
and	CC	O
their	PRP$	O
program	NN	O
partners	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
the	DT	O
MSS	NNP	O
,	,	O
either	RB	O
with	IN	O
training	NN	O
or	CC	O
without	IN	O
(	(	O
controls	NNS	O
)	)	O
.	.	O

Measures	NNS	O
of	IN	O
adherence	NN	O
,	,	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
,	,	O
and	CC	O
emotional	JJ	O
impact	NN	O
were	VBD	O
completed	VBN	O
at	IN	O
the	DT	O
first	JJ	O
and	CC	O
last	JJ	O
intervention	NN	O
sessions	NNS	O
and	CC	O
again	RB	O
at	IN	O
8	CD	O
weeks	NNS	O
and	CC	O
6	CD	O
months	NNS	O
post	VBN	O
intervention	NN	O
.	.	O

RESULTS	NNP	O
Training	NNP	O
in	IN	O
use	NN	O
of	IN	O
a	DT	O
notebook/calendar	NN	O
system	NN	O
significantly	RB	O
improved	VBN	O
adherence	NN	O
over	IN	O
those	DT	O
who	WP	O
received	VBD	O
the	DT	O
calendars	NNS	O
but	CC	O
no	DT	O
training	NN	O
.	.	O

Functional	NNP	O
ability	NN	O
and	CC	O
memory	NN	O
self-efficacy	NN	O
significantly	RB	O
improved	VBN	O
for	IN	O
those	DT	O
who	WP	O
received	VBD	O
MSS	NNP	O
training	NN	O
.	.	O

Change	NN	O
in	IN	O
functional	JJ	O
ability	NN	O
remained	VBD	O
significantly	RB	O
better	RBR	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
control	NN	O
group	NN	O
out	IN	O
to	TO	O
8-week	JJ	O
follow-up	NN	O
.	.	O

Care	NNP	O
partners	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
demonstrated	VBD	O
improved	VBN	O
mood	NN	O
by	IN	O
8-week	JJ	O
and	CC	O
6-month	JJ	O
follow-ups	NNS	O
,	,	O
whereas	NNS	O
control	VBP	O
care	NN	O
partners	NNS	O
reported	VBD	O
worse	JJR	O
caregiver	NN	O
burden	NN	O
by	IN	O
6-month	JJ	O
follow-up	NN	O
.	.	O

CONCLUSIONS	NNP	O
Memory	NNP	Educational
support	NN	Educational
system	NN	Educational
training	NN	Educational
resulted	VBD	O
in	IN	O
improvement	NN	O
in	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	NN	O
and	CC	O
sense	NN	O
of	IN	O
memory	NN	O
self-efficacy	NN	O
for	IN	O
individuals	NNS	O
with	IN	O
MCI	NNP	O
.	.	O

Although	IN	O
activities	NNS	O
of	IN	O
daily	JJ	O
living	VBG	O
benefits	NNS	O
were	VBD	O
maintained	VBN	O
out	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
post	NN	O
intervention	NN	O
,	,	O
future	JJ	O
inclusion	NN	O
of	IN	O
booster	NN	O
sessions	NNS	O
may	MD	O
help	VB	O
extend	VB	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
out	IN	O
even	RB	O
further	RBR	O
.	.	O

Improved	VBN	O
mood	NN	O
of	IN	O
care	NN	O
partners	NNS	O
of	IN	O
trained	JJ	O
individuals	NNS	O
and	CC	O
worsening	VBG	O
sense	NN	O
of	IN	O
caregiver	NN	O
burden	NN	O
over	IN	O
time	NN	O
for	IN	O
partners	NNS	O
of	IN	O
untrained	JJ	O
individuals	NNS	O
further	RBR	O
support	NN	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
MSS	NNP	O
for	IN	O
MCI	NNP	O
.	.	O

Tramadol	NNP	Pharmacological
suppository	NN	Pharmacological
versus	NN	O
placebo	NN	Control
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
perineal	NN	O
pain	NN	O
after	IN	O
perineorrhaphy	NN	O
:	:	O
a	DT	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
in	IN	O
Thailand	NNP	O
.	.	O

OBJECTIVE	NNP	O
This	DT	O
randomized	JJ	O
double-blinded	JJ	O
control	NN	O
trial	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
compare	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
tramodol	NN	Pharmacological
and	CC	O
placebo	NN	Control
rectal	JJ	O
suppository	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
postpartum	NN	O
perineal	NN	O
pain	NN	O
after	IN	O
perineorrhaphy	NN	O
.	.	O

MATERIAL	NNP	O
AND	CC	O
METHOD	NNP	O
One	NNP	O
hundred	VBD	O
women	NNS	O
who	WP	O
gave	VBD	O
birth	NN	O
vaginally	RB	O
with	IN	O
episiotomy	NN	O
and	CC	O
a	DT	O
second-	JJ	O
or	CC	O
third-degree	JJ	O
tear	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assign	VBN	O
to	TO	O
receive	VB	O
two	CD	O
tablets	NNS	O
oftramadol	VBP	Pharmacological
50	CD	Pharmacological
mg	NNS	Pharmacological
or	CC	O
two	CD	Control
tablets	NNS	Control
ofplacebo	RB	Control
,	,	O
the	DT	O
pill	NN	O
were	VBD	O
physically	RB	O
similar	JJ	O
to	TO	O
the	DT	O
real	JJ	O
drug	NN	O
.	.	O

Pain	VB	O
ratings	NNS	O
were	VBD	O
recorded	VBN	O
immediately	RB	O
after	IN	O
perineorrhaphy	NN	O
,	,	O
30	CD	O
minutes	NNS	O
,	,	O
and	CC	O
1	CD	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
12	CD	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
first	JJ	O
dose	NN	O
on	IN	O
a	DT	O
10-cm	JJ	O
visual	JJ	O
analogue	NN	O
scale	NN	O
.	.	O

Side	JJ	O
effects	NNS	O
and	CC	O
overall	JJ	O
opinion	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
Tramadol	NNP	Pharmacological
and	CC	O
placebo	NN	Control
had	VBD	O
no	DT	O
statistical	JJ	O
significances	NNS	O
in	IN	O
analgesic	JJ	O
properties	NNS	O
,	,	O
assessed	VBN	O
by	IN	O
the	DT	O
means	NNS	O
of	IN	O
pain	NN	O
rating	NN	O
at	IN	O
the	DT	O
different	JJ	O
time	NN	O
intervals	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
reported	VBN	O
.	.	O

CONCLUSION	NNP	O
No	NNP	O
differences	NNS	O
were	VBD	O
found	VBN	O
in	IN	O
between	IN	O
Tramadol	NNP	O
and	CC	O
placebo	NN	O
in	IN	O
relief	NN	O
perineal	NN	O
pain	NN	O
after	IN	O
perineorrhaphy	NN	O
Efficacy	NN	O
of	IN	O
Contractubex	NNP	O
gel	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
fresh	JJ	O
scars	NNS	O
after	IN	O
thoracic	NN	O
surgery	NN	O
in	IN	O
children	NNS	O
and	CC	O
adolescents	NNS	O
.	.	O

Scar	NNP	O
development	NN	O
was	VBD	O
investigated	VBN	O
in	IN	O
45	CD	O
young	JJ	O
patients	NNS	O
who	WP	O
had	VBD	O
undergone	JJ	O
thoracic	NN	O
surgery	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
either	RB	O
to	TO	O
a	DT	O
group	NN	O
which	WDT	O
was	VBD	O
treated	VBN	Pharmacological
topically	RB	Pharmacological
with	IN	Pharmacological
Contractubex	NNP	Pharmacological
gel	NN	Pharmacological
(	(	Pharmacological
Merz	NNP	Pharmacological
+	NNP	Pharmacological
Co.	NNP	Pharmacological
,	,	O
D-Frankfurt/Main	NNP	Pharmacological
)	)	Pharmacological
,	,	Pharmacological
containing	VBG	Pharmacological
10	CD	Pharmacological
%	NN	Pharmacological
onion	NN	Pharmacological
extract	NN	Pharmacological
,	,	Pharmacological
50/U	CD	Pharmacological
of	IN	Pharmacological
sodium	NN	Pharmacological
heparin	NN	Pharmacological
per	IN	Pharmacological
one	CD	Pharmacological
g	NN	Pharmacological
of	IN	Pharmacological
gel	NN	Pharmacological
and	CC	Pharmacological
1	CD	Pharmacological
%	NN	Pharmacological
allantoin	NN	Pharmacological
,	,	O
or	CC	O
to	TO	O
a	DT	O
group	NN	O
receiving	VBG	O
no	DT	O
treatment	NN	O
.	.	O

The	DT	O
treatment	NN	O
began	VBD	O
on	IN	O
average	JJ	O
26	CD	O
days	NNS	O
after	IN	O
the	DT	O
operation	NN	O
and	CC	O
was	VBD	O
continued	VBN	O
for	IN	O
one	CD	O
year	NN	O
.	.	O

The	DT	O
scars	NNS	O
of	IN	O
all	DT	O
treated	VBN	O
and	CC	O
untreated	JJ	O
patients	NNS	O
were	VBD	O
evaluated	VBN	O
at	IN	O
monthly	JJ	O
intervals	NNS	O
.	.	O

The	DT	O
appearance	NN	O
of	IN	O
the	DT	O
scar	NN	O
,	,	O
including	VBG	O
scar	NN	O
type	NN	O
and	CC	O
scar	NN	O
size	NN	O
as	RB	O
well	RB	O
as	IN	O
scar	NN	O
colour	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
by	IN	O
the	DT	O
physician	NN	O
.	.	O

A	DT	O
reduction	NN	O
of	IN	O
the	DT	O
increase	NN	O
of	IN	O
scar	NN	O
width	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
the	DT	O
Contractubex-treated	JJ	O
group	NN	O
as	IN	O
compared	VBN	O
with	IN	O
the	DT	O
untreated	JJ	O
group	NN	O
.	.	O

Further	NNP	O
,	,	O
physiological	JJ	O
scars	NNS	O
and	CC	O
skin-coloured	JJ	O
scars	NNS	O
were	VBD	O
more	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
untreated	JJ	O
group	NN	O
.	.	O

Hypertrophic	NNP	O
or	CC	O
keloidal	VB	O
scars	NNS	O
were	VBD	O
less	RBR	O
frequent	JJ	O
in	IN	O
the	DT	O
treated	JJ	O
group	NN	O
.	.	O

No	DT	O
differences	NNS	O
in	IN	O
scar	NN	O
length	NN	O
and	CC	O
scar	NN	O
height	NN	O
were	VBD	O
seen	VBN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
observation	NN	O
period	NN	O
,	,	O
the	DT	O
clinical	JJ	O
course	NN	O
of	IN	O
scar	NN	O
development	NN	O
was	VBD	O
rated	VBN	O
as	IN	O
very	RB	O
good	JJ	O
or	CC	O
good	JJ	O
in	IN	O
more	JJR	O
than	IN	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
treated	JJ	O
patients	NNS	O
,	,	O
good	JJ	O
in	IN	O
less	JJR	O
than	IN	O
40	CD	O
%	NN	O
and	CC	O
moderate	JJ	O
or	CC	O
bad	JJ	O
in	IN	O
more	JJR	O
than	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
untreated	JJ	O
cases	NNS	O
.	.	O

The	DT	O
tolerability	NN	O
of	IN	O
the	DT	O
drug	NN	O
was	VBD	O
good	JJ	O
or	CC	O
very	RB	O
good	JJ	O
in	IN	O
all	DT	O
cases	NNS	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
Contractubex	NNP	O
gel	NN	O
is	VBZ	O
useful	JJ	O
in	IN	O
scar	NN	O
treatment	NN	O
after	IN	O
thoracic	NN	O
surgery	NN	O
.	.	O

Injection	NN	O
pain	NN	O
and	CC	O
postinjection	NN	O
pain	NN	O
of	IN	O
the	DT	O
palatal-anterior	JJ	O
superior	JJ	O
alveolar	JJ	O
injection	NN	O
,	,	O
administered	VBN	O
with	IN	O
the	DT	O
Wand	NNP	O
Plus	NNP	O
system	NN	O
,	,	O
comparing	VBG	O
2	CD	O
%	NN	O
lidocaine	NN	Pharmacological
with	IN	O
1:100,000	CD	O
epinephrine	NN	Pharmacological
to	TO	O
3	CD	O
%	NN	O
mepivacaine	NN	Pharmacological
.	.	O

PURPOSE	VB	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
prospective	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
injection	NN	O
pain	NN	O
and	CC	O
postinjection	NN	O
pain	NN	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	NN	O
with	IN	O
1:100,000	CD	O
epinephrine	NN	O
and	CC	O
3	CD	O
%	NN	O
mepivacaine	NN	O
using	VBG	O
the	DT	O
computer-assisted	JJ	O
Wand	NNP	O
Plus	NNP	O
injection	NN	O
system	NN	O
to	TO	O
administer	VB	O
the	DT	O
palatal-anterior	JJ	O
superior	JJ	O
alveolar	NN	O
(	(	O
P-ASA	NNP	O
)	)	O
injection	NN	O
.	.	O

Additionally	RB	O
study	NN	O
was	VBD	O
done	VBN	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
use	NN	O
of	IN	O
topical	JJ	Pharmacological
anesthetic	NN	Pharmacological
decreased	VBD	O
the	DT	O
pain	NN	O
of	IN	O
needle	JJ	O
insertion	NN	O
with	IN	O
the	DT	O
P-ASA	NNP	O
injection	NN	O
.	.	O

STUDY	NNP	O
DESIGN	NNP	O
Using	VBG	O
a	DT	O
crossover	NN	O
design	NN	O
,	,	O
40	CD	O
subjects	NNS	O
randomly	RB	O
received	VBD	O
,	,	O
in	IN	O
a	DT	O
double-blind	JJ	O
manner	NN	O
,	,	O
P-ASA	NNP	Pharmacological
injections	NNS	Pharmacological
of	IN	Pharmacological
1.4	CD	Pharmacological
mL	NN	Pharmacological
of	IN	Pharmacological
2	CD	Pharmacological
%	NN	Pharmacological
lidocaine	NN	Pharmacological
with	IN	O
1:100,000	CD	O
epinephrine	NN	Pharmacological
and	CC	O
1.4	CD	O
mL	NN	O
of	IN	O
3	CD	O
%	NN	O
mepivacaine	NN	Pharmacological
,	,	O
at	IN	O
2	CD	O
separate	JJ	O
appointments	NNS	O
.	.	O

The	DT	O
P-ASA	JJ	O
injection	NN	O
was	VBD	O
administered	VBN	O
,	,	O
utilizing	VBG	O
the	DT	O
Wand	NNP	O
Plus	NNP	O
system	NN	O
,	,	O
6	CD	O
to	TO	O
10	CD	O
mm	NN	O
into	IN	O
the	DT	O
incisive	JJ	O
canal	NN	O
located	VBN	O
lingual	JJ	O
to	TO	O
the	DT	O
central	JJ	O
incisors	NNS	O
.	.	O

The	DT	O
pain	NN	O
of	IN	O
needle	JJ	O
insertion	NN	O
,	,	O
needle	JJ	O
placement	NN	O
,	,	O
solution	NN	O
deposition	NN	O
and	CC	O
postinjection	NN	O
pain	NN	O
were	VBD	O
recorded	VBN	O
on	IN	O
a	DT	O
Heft-Parker	NNP	O
visual	JJ	O
analog	NN	O
scale	NN	O
for	IN	O
the	DT	O
2	CD	O
P-ASA	JJ	O
injections	NNS	O
.	.	O

Eighty	JJ	O
injections	NNS	O
were	VBD	O
randomly	RB	O
administered	VBN	O
in	IN	O
the	DT	O
study	NN	O
,	,	O
40	CD	O
using	VBG	O
topical	JJ	Pharmacological
anesthetic	JJ	Pharmacological
gel	NN	Pharmacological
and	CC	O
40	CD	O
using	VBG	O
a	DT	O
placebo	NN	Control
gel	NN	Control
.	.	O

RESULTS	NNP	O
For	IN	O
needle	JJ	O
insertion	NN	O
,	,	O
30	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
reported	VBN	O
moderate/severe	RB	O
pain	NN	O
with	IN	O
the	DT	O
lidocaine	JJ	O
solution	NN	O
and	CC	O
43	CD	O
%	NN	O
reported	VBN	O
moderate/severe	RB	O
pain	NN	O
with	IN	O
the	DT	O
mepivacaine	JJ	Pharmacological
solution	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
(	(	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
between	IN	O
the	DT	O
topical	JJ	O
and	CC	O
placebo	JJ	Control
groups	NNS	O
.	.	O

For	IN	O
needle	JJ	O
placement	NN	O
into	IN	O
the	DT	O
incisive	JJ	O
canal	NN	O
,	,	O
54	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
reported	VBN	O
moderate/severe	RB	O
pain	NN	O
with	IN	O
the	DT	O
lidocaine	JJ	Pharmacological
solution	NN	O
and	CC	O
58	CD	O
%	NN	O
reported	VBN	O
moderate/severe	RB	O
pain	NN	O
with	IN	O
the	DT	O
mepivacaine	JJ	O
solution	NN	O
.	.	O

For	IN	O
anesthetic	JJ	O
solution	NN	O
deposition	NN	O
,	,	O
8	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
reported	VBN	O
moderate	JJ	O
pain	NN	O
with	IN	O
the	DT	O
lidocaine	JJ	Pharmacological
solution	NN	O
and	CC	O
12	CD	O
%	NN	O
reported	VBN	O
moderate	JJ	O
pain	NN	O
with	IN	O
the	DT	O
mepivacaine	JJ	Pharmacological
solution	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
between	IN	O
the	DT	O
lidocaine	NN	Pharmacological
and	CC	O
mepivacaine	JJ	Pharmacological
solutions	NNS	O
.	.	O

Regarding	VBG	O
postinjection	NN	O
pain	NN	O
,	,	O
when	WRB	O
anesthesia	NN	O
wore	VBD	O
off	RP	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
the	DT	O
injection	NN	O
,	,	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
reported	VBN	O
moderate/severe	RB	O
pain	NN	O
with	IN	O
the	DT	O
lidocaine	JJ	Pharmacological
solution	NN	O
and	CC	O
14	CD	O
%	NN	O
reported	VBN	O
moderate/severe	RB	O
pain	NN	O
with	IN	O
the	DT	O
mepivacaine	JJ	Pharmacological
solution	NN	O
.	.	O

Pain	NNP	O
ratings	NNS	O
decreased	VBD	O
over	IN	O
the	DT	O
next	JJ	O
3	CD	O
days	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
between	IN	O
the	DT	O
lidocaine	NN	Pharmacological
and	CC	O
mepivacaine	JJ	Pharmacological
solutions	NNS	O
.	.	O

Postinjection	NNP	O
,	,	O
12	CD	O
%	NN	O
and	CC	O
18	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
experienced	VBD	O
temporary	JJ	O
numbness/paresthesia	NN	O
of	IN	O
the	DT	O
incisive	JJ	O
papilla	NN	O
with	IN	O
the	DT	O
lidocaine	NN	Pharmacological
and	CC	O
mepivacaine	JJ	Pharmacological
solutions	NNS	O
,	,	O
respectively	RB	O
.	.	O

Twenty	CD	O
percent	NN	O
and	CC	O
28	CD	O
%	NN	O
of	IN	O
the	DT	O
subjects	NNS	O
had	VBD	O
incisive	JJ	O
papilla	NN	O
swelling	VBG	O
or	CC	O
soreness	NN	O
with	IN	O
the	DT	O
lidocaine	NN	Pharmacological
and	CC	O
mepivacaine	JJ	Pharmacological
solutions	NNS	O
,	,	O
respectively	RB	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
(	(	O
P	NNP	O
>	NNP	O
.05	NNP	O
)	)	O
between	IN	O
the	DT	O
lidocaine	NN	Pharmacological
and	CC	O
mepivacaine	JJ	Pharmacological
solutions	NNS	O
.	.	O

CONCLUSIONS	VB	O
The	DT	O
P-ASA	NNP	O
injection	NN	O
of	IN	O
1.4	CD	O
mL	NN	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	NN	Pharmacological
with	IN	O
1:100,000	CD	O
epinephrine	NN	Pharmacological
or	CC	O
3	CD	O
%	NN	O
mepivacaine	NN	Pharmacological
,	,	O
administered	VBN	O
with	IN	O
the	DT	O
Wand	NNP	O
Plus	NNP	O
,	,	O
has	VBZ	O
the	DT	O
potential	JJ	O
to	TO	O
be	VB	O
a	DT	O
painful	JJ	O
injection	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
topical	JJ	O
anesthetic	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
reduce	VB	O
pain	NN	O
of	IN	O
needle	JJ	O
insertion	NN	O
when	WRB	O
compared	VBN	O
to	TO	O
a	DT	O
placebo	NN	Control
.	.	Control

The	DT	O
incidence	NN	O
of	IN	O
postinjection	NN	O
pain	NN	O
,	,	O
temporary	JJ	O
numbness/paresthesia	NN	O
,	,	O
and	CC	O
incisive	JJ	O
papilla	NN	O
swelling	VBG	O
or	CC	O
soreness	NN	O
would	MD	O
indicate	VB	O
that	IN	O
some	DT	O
pain	NN	O
and	CC	O
problems	NNS	O
occur	VBP	O
with	IN	O
the	DT	O
P-ASA	NNP	O
technique	NN	O
,	,	O
regardless	RB	O
of	IN	O
whether	IN	O
2	CD	O
%	NN	O
lidocaine	NN	Pharmacological
with	IN	O
1:100,000	CD	O
epinephrine	NN	Pharmacological
or	CC	O
3	CD	O
%	NN	O
mepivacaine	NN	Pharmacological
is	VBZ	O
used	VBN	O
.	.	O

[	JJ	O
Treatment	NNP	O
of	IN	O
essential	JJ	O
headache	NN	O
in	IN	O
developmental	JJ	O
age	NN	O
with	IN	O
L-5-HTP	NNP	Physical
(	(	O
cross	NN	O
over	IN	O
double-blind	JJ	O
study	NN	O
versus	IN	O
placebo	NN	Control
)	)	O
]	NN	O
.	.	O

Thirty	NN	O
patients	NNS	O
(	(	O
mean	JJ	O
age	NN	O
:	:	O
10.38	CD	O
years	NNS	O
)	)	O
affected	VBN	O
by	IN	O
primary	JJ	O
headache	NN	O
were	VBD	O
selected	VBN	O
for	IN	O
a	DT	O
double-blind	JJ	O
cross-over	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomized	VBN	O
into	IN	O
2	CD	O
homogeneous	JJ	O
groups	NNS	O
of	IN	O
15	CD	O
and	CC	O
treated	VBD	O
for	IN	O
12	CD	O
weeks	NNS	O
with	IN	O
L-5-HTP	NNP	Physical
(	(	O
100	CD	O
mg/day	NN	O
)	)	O
and	CC	O
placebo	NN	Control
as	IN	O
per	IN	O
the	DT	O
following	JJ	O
design	NN	O
:	:	O
placebo	NN	Control
-	:	O
L-5-HTP	NNP	Pharmacological
(	(	O
group	NN	O
A	NNP	O
)	)	O
and	CC	O
L-5-HTP	NNP	Pharmacological
-	:	O
placebo	NN	Control
(	(	O
group	NN	O
B	NNP	O
)	)	O
.	.	O

Evaluation	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
every	DT	O
3	CD	O
weeks	NNS	O
by	IN	O
the	DT	O
Migraine	NNP	O
Index	NNP	O
supplying	VBG	O
a	DT	O
general	JJ	O
assessment	NN	O
of	IN	O
the	DT	O
attacks	NNS	O
,	,	O
i.e	NN	O
.	.	O

severity	NN	O
,	,	O
duration	NN	O
and	CC	O
frequency	NN	O
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
mean	JJ	O
score	NN	O
values	NNS	O
was	VBD	O
directly	RB	O
proportional	JJ	O
to	TO	O
L-5-HTP	NNP	Physical
treatment	NN	O
,	,	O
and	CC	O
statistical	JJ	O
significance	NN	O
(	(	O
Wilcoxon	NNP	O
's	POS	O
test	NN	O
)	)	O
was	VBD	O
observed	VBN	O
only	RB	O
for	IN	O
L-5-HTP	NNP	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
from	IN	O
0.05	CD	O
to	TO	O
0.01	CD	O
.	.	O

Improvement	NN	O
,	,	O
as	IN	O
evaluated	VBN	O
by	IN	O
CGI	NNP	O
on	IN	O
percentage	NN	O
distribution	NN	O
of	IN	O
the	DT	O
patients	NNS	O
,	,	O
was	VBD	O
homogeneous	JJ	O
in	IN	O
both	DT	O
groups	NNS	O
.	.	O

Retrograde	NNP	O
tracing	NN	O
and	CC	O
electrophysiological	JJ	O
findings	NNS	O
of	IN	O
collateral	NN	O
sprouting	NN	O
after	IN	O
end-to-side	JJ	O
neurorrhaphy	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
seek	VB	O
more	RBR	O
potent	JJ	O
evidences	NNS	O
of	IN	O
collateral	NN	O
sprouting	NN	O
for	IN	O
both	DT	O
motor	NN	O
and	CC	O
sensory	JJ	O
nerve	NN	O
fibres	NNS	O
after	IN	O
end-to-side	JJ	O
neurorrhaphy	NN	O
using	VBG	O
a	DT	O
modified	VBN	O
double-labelling	NN	O
retrograde	NN	O
tracing	VBG	O
method	NN	O
and	CC	O
to	TO	O
investigate	VB	O
the	DT	O
function	NN	O
of	IN	O
regenerated	JJ	O
motor	NN	O
axons	NNS	O
with	IN	O
electrophysiological	JJ	O
evaluation	NN	O
.	.	O

Four	CD	O
groups	NNS	O
(	(	O
n=4	JJ	O
for	IN	O
each	DT	O
group	NN	O
)	)	O
were	VBD	O
used	VBN	O
:	:	O
end-to-end	JJ	Pharmacological
coaptation	NN	Pharmacological
(	(	O
six	CD	O
months	NNS	O
postoperatively	RB	O
)	)	O
,	,	O
end-to-side	JJ	O
coaptation	NN	O
(	(	O
four	CD	O
months	NNS	O
and	CC	O
six	CD	O
months	NNS	O
postoperatively	RB	O
)	)	O
and	CC	O
normal	JJ	Control
control	NN	Control
.	.	Control

Two	CD	O
fluorescent	JJ	Pharmacological
tracers	NNS	Pharmacological
(	(	O
true	JJ	O
blue	NN	O
and	CC	O
diamidino	NN	O
yellow	NN	O
)	)	O
were	VBD	O
applied	VBN	O
to	TO	O
the	DT	O
proximal	JJ	O
ends	NNS	O
of	IN	O
tibial	JJ	O
and	CC	O
common	JJ	O
peroneal	NN	O
nerves	NNS	O
,	,	O
respectively	RB	O
after	IN	O
four	CD	O
or	CC	O
six	CD	O
months	NNS	O
of	IN	O
nerve	DT	O
coaptation	NN	O
.	.	O

Five	CD	O
days	NNS	O
later	RB	O
,	,	O
we	PRP	O
only	RB	O
found	VBD	O
single-labelled	JJ	O
motor	NN	O
and	CC	O
sensory	JJ	O
neurons	NNS	O
in	IN	O
the	DT	O
normal	JJ	O
and	CC	O
end-to-end	JJ	O
coaptation	NN	O
groups	NNS	O
,	,	O
while	IN	O
some	DT	O
dual-labelled	JJ	O
neurons	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
in	IN	O
end-to-side	JJ	O
coaptation	NN	O
groups	NNS	O
.	.	O

Four	CD	O
months	NNS	O
after	IN	O
surgery	NN	O
,	,	O
the	DT	O
motor	NN	O
nerve	NN	O
conduction	NN	O
velocity	NN	O
in	IN	O
end-to-side	JJ	O
coaptation	NN	O
was	VBD	O
significantly	RB	O
slower	JJR	O
than	IN	O
in	IN	O
the	DT	O
normal	JJ	O
control	NN	O
.	.	O

But	CC	O
no	DT	O
difference	NN	O
was	VBD	O
found	VBN	O
in	IN	O
the	DT	O
sixth	JJ	O
month	NN	O
.	.	O

These	DT	O
results	NNS	O
suggest	VBP	O
that	IN	O
end-to-side	JJ	Physical
neurorrhaphy	NN	Physical
can	MD	O
induce	VB	O
the	DT	O
functional	JJ	O
collateral	NN	O
sprouting	NN	O
of	IN	O
both	DT	O
motor	NN	O
and	CC	O
sensory	JJ	O
axons	NNS	O
in	IN	O
the	DT	O
peripheral	JJ	O
nerve	NN	O
.	.	O

Effect	NN	O
of	IN	O
thermal	JJ	O
stress	NN	O
,	,	O
restricted	VBD	Other
feeding	NN	Other
and	CC	O
combined	VBN	Other
stresses	NNS	Other
(	(	Other
thermal	JJ	Physical
stress	NN	Physical
and	CC	Other
restricted	VBD	Other
feeding	VBG	Other
)	)	Other
on	IN	O
growth	NN	O
and	CC	O
plasma	VB	O
reproductive	JJ	O
hormone	NN	O
levels	NNS	O
of	IN	O
Malpura	NNP	O
ewes	FW	O
under	IN	O
semi-arid	JJ	O
tropical	JJ	O
environment	NN	O
.	.	O

A	DT	O
study	NN	O
was	VBD	O
conducted	VBN	O
to	TO	O
assess	VB	O
the	DT	O
effect	NN	O
of	IN	O
thermal	NN	O
,	,	O
nutritional	JJ	O
and	CC	O
combined	JJ	O
stresses	NNS	O
(	(	O
thermal	JJ	O
and	CC	O
nutritional	JJ	O
)	)	O
on	IN	O
the	DT	O
growth	NN	O
,	,	O
oestradiol	NN	O
and	CC	O
progesterone	NN	O
levels	NNS	O
during	IN	O
oestrus	NN	O
cycles	NNS	O
in	IN	O
Malpura	NNP	O
ewes	NN	O
.	.	O

Twenty-eight	JJ	O
adult	NN	O
Malpura	NNP	O
ewes	NN	O
were	VBD	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
study	NN	O
.	.	O

The	DT	O
ewes	NN	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
into	IN	O
four	CD	O
groups	NNS	O
,	,	O
viz.	NN	O
,	,	O
GI	NNP	O
(	(	O
n=7	RB	O
;	:	O
control	NN	Control
)	)	Control
,	,	O
GII	NNP	O
(	(	O
n=7	RB	O
;	:	O
thermal	JJ	Physical
stress	NN	Physical
)	)	Physical
,	,	O
GIII	NNP	O
(	(	O
n=7	RB	O
;	:	O
restricted	VBN	Educational
feeding	NN	Educational
)	)	Educational
and	CC	O
GIV	NNP	O
(	(	O
n=7	RB	O
;	:	O
combined	VBN	Educational
stress	NN	Educational
)	)	Educational
.	.	O

The	DT	O
animals	NNS	O
were	VBD	O
stall	JJ	Other
fed	VBN	Other
with	IN	Other
a	DT	Other
diet	JJ	Other
consisting	NN	Other
of	IN	Other
60	CD	Other
%	NN	Other
roughage	NN	Other
and	CC	Other
40	CD	Other
%	NN	Other
concentrate	NN	Other
.	.	Other

GI	NNP	O
and	CC	O
GII	NNP	O
ewes	NN	O
were	VBD	O
provided	VBN	O
with	IN	O
ad	NN	O
libitum	NN	O
feeding	VBG	O
while	IN	O
GIII	NNP	O
and	CC	O
GIV	NNP	O
ewes	NN	O
were	VBD	O
provided	VBN	O
with	IN	O
restricted	JJ	O
feed	NN	O
(	(	O
30	CD	O
%	NN	O
intake	NN	O
of	IN	O
GI	NNP	O
and	CC	O
GII	NNP	O
ewes	NN	O
)	)	O
to	TO	O
induce	VB	O
nutritional	JJ	O
insufficiency	NN	O
.	.	O

GII	NNP	O
and	CC	O
GIV	NNP	O
ewes	NN	O
were	VBD	O
kept	VBN	O
in	IN	O
climatic	JJ	O
chamber	NN	O
at	IN	O
40?C	CD	O
and	CC	O
55	CD	O
%	NN	O
RH	NNP	O
for	IN	O
6	CD	O
h	NNS	O
a	DT	O
day	NN	O
between	IN	O
10:00	CD	O
and	CC	O
16:00	CD	O
hours	NNS	O
to	TO	O
induce	VB	O
thermal	JJ	O
stress	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
two	CD	O
oestrous	JJ	O
cycles	NNS	O
.	.	O

Parameters	NNS	O
studied	VBD	O
were	VBD	O
body	JJ	O
weight	NN	O
,	,	O
oestrus	NN	O
incidences	NNS	O
,	,	O
plasma	JJ	O
oestradiol	IN	O
17-?	JJ	O
,	,	O
plasma	JJ	O
progesterone	NN	O
,	,	O
conception	NN	O
rate	NN	O
,	,	O
gestation	NN	O
period	NN	O
,	,	O
lambing	VBG	O
rate	NN	O
,	,	O
and	CC	O
birth	NN	O
weight	NN	O
of	IN	O
lambs	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
combined	VBD	O
stress	NN	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
reduced	VBN	O
body	NN	O
weight	NN	O
,	,	O
oestrus	JJ	O
duration	NN	O
,	,	O
birth	NN	O
weight	NN	O
of	IN	O
lambs	NN	O
,	,	O
and	CC	O
oestradiol	JJ	O
17-?	JJ	O
whereas	NNS	O
significantly	RB	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
increased	VBD	O
oestrus	JJ	O
cycle	NN	O
length	NN	O
and	CC	O
progesterone	NN	O
.	.	O

Furthermore	RB	O
,	,	O
the	DT	O
results	NNS	O
reveal	VBP	O
that	IN	O
on	IN	O
comparative	JJ	O
basis	NN	O
,	,	O
ewes	NN	O
were	VBD	O
able	JJ	O
to	TO	O
better	VB	O
adapt	NN	O
in	IN	O
terms	NNS	O
of	IN	O
growth	NN	O
and	CC	O
reproduction	NN	O
to	TO	O
restricted	VB	O
feeding	NN	O
than	IN	O
thermal	JJ	O
stress	NN	O
.	.	O

However	RB	O
,	,	O
when	WRB	O
restricted	VBD	O
feeding	NN	O
was	VBD	O
coupled	VBN	O
with	IN	O
thermal	JJ	O
stress	NN	O
it	PRP	O
had	VBD	O
significant	JJ	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
influence	NN	O
on	IN	O
body	NN	O
weight	NN	O
,	,	O
average	JJ	O
daily	JJ	O
gain	NN	O
,	,	O
oestradiol	JJ	O
17-?	JJ	O
and	CC	O
progesterone	JJ	O
concentrations	NNS	O
.	.	O

This	DT	O
showed	VBD	O
that	IN	O
combined	JJ	O
stress	NN	O
were	VBD	O
more	JJR	O
detrimental	JJ	O
for	IN	O
these	DT	O
reproductive	JJ	O
hormones	NNS	O
in	IN	O
Malpura	NNP	O
ewes	NN	O
under	IN	O
a	DT	O
hot	JJ	O
semi-arid	JJ	O
environment	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
prophylactic	JJ	O
ondansetron	NN	Pharmacological
,	,	Pharmacological
droperidol	NN	Pharmacological
,	,	Pharmacological
perphenazine	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
metoclopramide	RB	Pharmacological
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
after	IN	O
major	JJ	O
gynecologic	NN	O
surgery	NN	O
.	.	O

The	DT	O
prophylactic	JJ	O
antiemetic	JJ	O
efficacy	NN	O
of	IN	O
intravenous	JJ	Pharmacological
(	(	Pharmacological
i.v	JJ	Pharmacological
.	.	Pharmacological

)	)	Pharmacological
ondansetron	NN	Pharmacological
,	,	Pharmacological
droperidol	NN	Pharmacological
,	,	Pharmacological
perphenazine	NN	Pharmacological
,	,	Pharmacological
and	CC	Pharmacological
metoclopramide	NN	Pharmacological
was	VBD	O
evaluated	VBN	O
in	IN	O
a	DT	O
prospective	JJ	O
,	,	O
double-blind	JJ	O
study	NN	O
of	IN	O
360	CD	O
ASA	NNP	O
physical	JJ	O
status	NN	O
I-III	NNP	O
patients	NNS	O
undergoing	VBG	O
total	JJ	O
abdominal	JJ	O
hysterectomy	NN	O
(	(	O
TAH	NNP	O
)	)	O
.	.	O

Subjects	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
i.v.	NN	O
,	,	O
one	CD	O
of	IN	O
ondansetron	NN	Pharmacological
4	CD	O
mg	NN	O
,	,	O
droperidol	VBZ	Pharmacological
1.25	CD	O
mg	NN	O
,	,	O
perphenazine	VBP	Pharmacological
5	CD	O
mg	NN	O
,	,	O
metoclopramide	RB	Pharmacological
10	CD	O
mg	NN	O
,	,	O
or	CC	O
placebo	RB	Control
prior	JJ	O
to	TO	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

Hypotension	NNP	O
immediately	RB	O
after	IN	O
administration	NN	O
of	IN	O
metoclopramide	NN	Pharmacological
was	VBD	O
observed	VBN	O
in	IN	O
two	CD	O
patients	NNS	O
and	CC	O
four	CD	O
patients	NNS	O
given	VBN	O
ondansetron	RP	O
developed	JJ	O
profound	NN	O
systolic	JJ	O
hypotension	NN	O
at	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

Twenty-two	JJ	O
percent	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
droperidol	NN	O
became	VBD	O
sedated	JJ	O
.	.	O

Postoperatively	RB	O
,	,	O
patients	NNS	O
developing	VBG	O
severe	JJ	O
nausea	NN	O
,	,	O
retching	NN	O
,	,	O
or	CC	O
vomiting	NN	O
,	,	O
defined	VBD	O
as	IN	O
severe	JJ	O
emetic	JJ	O
sequelae	NN	O
(	(	O
SES	NNP	O
)	)	O
,	,	O
were	VBD	O
deemed	VBN	O
to	TO	O
have	VB	O
failed	VBN	O
antiemetic	JJ	O
prophylaxis	NN	O
and	CC	O
received	VBN	O
antiemetic	JJ	O
rescue	NN	O
.	.	O

A	DT	O
significantly	RB	O
larger	JJR	O
number	NN	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
i.v	NN	O
.	.	O

ondansetron	NN	O
(	(	O
63	CD	O
%	NN	O
)	)	O
,	,	O
droperidol	NN	O
(	(	O
76	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
perphenazine	NN	O
(	(	O
70	CD	O
%	NN	O
)	)	O
were	VBD	O
free	JJ	O
of	IN	O
SES	NNP	O
when	WRB	O
compared	VBN	O
to	TO	O
placebo	VB	O
(	(	O
43	CD	O
%	NN	O
)	)	O
;	:	O
P	NNP	O
<	VBD	O
0.05	CD	O
.	.	O

Metoclopramide	NNP	O
was	VBD	O
ineffective	JJ	O
.	.	O

Although	IN	O
ondansetron	NN	O
,	,	O
droperidol	NN	O
,	,	O
and	CC	O
perphenazine	NN	O
were	VBD	O
effective	JJ	O
in	IN	O
providing	VBG	O
antiemetic	JJ	O
prophylaxis	NN	O
,	,	O
only	RB	O
i.v	NN	O
.	.	O

perphenazine	NN	O
was	VBD	O
free	JJ	O
of	IN	O
side	JJ	O
effects	NNS	O
.	.	O

Hence	NNP	O
,	,	O
we	PRP	O
conclude	VBP	O
that	DT	O
perphenazine	NN	O
is	VBZ	O
the	DT	O
best	JJS	O
choice	NN	O
for	IN	O
antiemetic	JJ	O
prophylaxis	NN	O
after	IN	O
TAH	NNP	O
.	.	O

In	IN	O
vitro	JJ	O
biocompatibility	NN	O
tests	NNS	O
of	IN	O
glass	NN	O
ionomer	NN	O
cements	NNS	O
impregnated	VBN	O
with	IN	O
collagen	NN	O
or	CC	O
bioactive	JJ	O
glass	NN	O
to	TO	O
fibroblasts	NNS	O
.	.	O

AIM	NNP	O
AND	CC	O
DESIGN	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
biocompatibility	NN	O
of	IN	O
glass	NN	O
ionomer	NN	O
cement	NN	O
(	(	O
GIC	NNP	O
)	)	O
impregnated	VBD	O
with	IN	O
collagen	NN	O
or	CC	O
bioactive	JJ	O
glass	NN	O
to	TO	O
BHK-21	NNP	O
fibroblasts	NNS	O
in	IN	O
vitro	NN	O
.	.	O

Mineral	NNP	O
Trioxide	NNP	O
Aggregate	NNP	O
was	VBD	O
used	VBN	O
as	IN	O
the	DT	O
standard	NN	O
for	IN	O
comparison	NN	O
.	.	O

Human	NNP	O
maxillary	JJ	O
central	JJ	O
incisors	NNS	O
(	(	O
n	JJ	O
=	NNP	O
70	CD	O
)	)	O
were	VBD	O
instrumented	VBN	O
with	IN	O
a	DT	O
rotary	JJ	O
NiTi	NNP	O
system	NN	O
and	CC	O
filled	VBN	O
.	.	O

Following	VBG	O
resection	NN	O
of	IN	O
the	DT	O
apical	JJ	O
3mm	CD	O
,	,	O
root	JJ	O
end	NN	O
cavities	NNS	O
were	VBD	O
prepared	JJ	O
and	CC	O
restored	VBN	O
with	IN	O
conventional	JJ	Pharmacological
GIC	NNP	Pharmacological
(	(	Pharmacological
group	NN	Pharmacological
1	CD	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
GIC	NNP	Pharmacological
with	IN	Pharmacological
0.01	CD	Pharmacological
%	NN	Pharmacological
,	,	Pharmacological
0.1	CD	Pharmacological
%	NN	Pharmacological
or	CC	Pharmacological
1	CD	Pharmacological
%	NN	Pharmacological
collagen	NN	Pharmacological
(	(	Pharmacological
groups	NNS	Pharmacological
2	CD	Pharmacological
,	,	Pharmacological
3	CD	Pharmacological
,	,	Pharmacological
4	CD	Pharmacological
respectively	RB	Pharmacological
)	)	Pharmacological
or	CC	Pharmacological
,	,	Pharmacological
10	CD	Pharmacological
%	NN	Pharmacological
,	,	Pharmacological
30	CD	Pharmacological
%	NN	Pharmacological
or	CC	Pharmacological
50	CD	Pharmacological
%	NN	Pharmacological
bioactive	JJ	Pharmacological
glass	NN	Pharmacological
(	(	Pharmacological
groups	NNS	Pharmacological
5	CD	Pharmacological
,	,	Pharmacological
6	CD	Pharmacological
,	,	Pharmacological
7	CD	Pharmacological
respectively	RB	Pharmacological
)	)	Pharmacological
,	,	Pharmacological
or	CC	Pharmacological
Mineral	NNP	Pharmacological
Trioxide	NNP	Pharmacological
Aggregate	NNP	Pharmacological
(	(	Pharmacological
group	NN	Pharmacological
8	CD	Pharmacological
)	)	Pharmacological
.	.	Pharmacological

The	DT	O
root	NN	O
slices	NNS	O
were	VBD	O
incubated	VBN	O
in	IN	O
tissue	NN	O
culture	NN	O
plates	VBZ	O
with	IN	O
BHK-21	NNP	O
fibroblast	NN	O
cell	NN	O
line	NN	O
.	.	O

Phase	NNP	O
contrast	NN	O
and	CC	O
scanning	VBG	O
electron	NN	O
microscopes	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
score	VB	O
cell	NN	O
quantity	NN	O
,	,	O
morphology	NN	O
and	CC	O
cell	NN	O
attachment	NN	O
.	.	O

The	DT	O
data	NNS	O
were	VBD	O
statistically	RB	O
analyzed	VBN	O
by	IN	O
one	CD	O
way	NN	O
ANOVA	NNP	O
with	IN	O
Post	NNP	O
Hoc	NNP	O
Tukey	NNP	O
HSD	NNP	O
test	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.05	CD	O
)	)	O
.	.	O

RESULTS	NNP	O
AND	NNP	O
CONCLUSIONS	NNP	O
Group	NNP	O
5	CD	O
showed	VBD	O
the	DT	O
highest	JJS	O
scores	NNS	O
which	WDT	O
was	VBD	O
significantly	RB	O
higher	JJR	O
than	IN	O
all	DT	O
other	JJ	O
groups	NNS	O
(	(	O
p	JJ	O
<	NNP	O
0.05	CD	O
)	)	O
except	IN	O
group	NN	O
8	CD	O
,	,	O
with	IN	O
which	WDT	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
(	(	O
p	JJ	O
>	NNP	O
0.05	CD	O
)	)	O
.	.	O

Glass	NNP	O
ionomer	JJ	O
cement	NN	O
with	IN	O
10	CD	O
%	NN	O
bioactive	JJ	O
glass	NN	O
showed	VBD	O
better	JJR	O
adhesion	NN	O
and	CC	O
spreading	NN	O
of	IN	O
cells	NNS	O
than	IN	O
glass	NN	O
ionomer	NN	O
cement	NN	O
with	IN	O
0.01	CD	O
%	NN	O
collagen	NN	O
.	.	O

The	DT	O
biocompatibility	NN	O
of	IN	O
collagen	NN	O
and	CC	O
bioactive	JJ	O
glass	NN	O
was	VBD	O
concentration	NN	O
dependent	NN	O
.	.	O

The	DT	O
addition	NN	O
of	IN	O
bioactive	JJ	O
glass	NN	O
improved	VBD	O
the	DT	O
biocompatibility	NN	O
of	IN	O
glass	NN	O
ionomer	NN	O
cement	NN	O
to	TO	O
fibroblasts	NNS	O
better	JJR	O
than	IN	O
addition	NN	O
of	IN	O
collagen	NN	O
.	.	O

[	IN	O
The	DT	O
equipotency	NN	O
of	IN	O
ropivacaine	NN	Pharmacological
,	,	O
bupivacaine	NN	Pharmacological
and	CC	O
etidocaine	NN	Pharmacological
]	NN	O
.	.	O

Ropivacaine	NNP	Pharmacological
,	,	O
congenerate	NN	O
to	TO	O
bupivacaine	VB	O
and	CC	O
mepivacaine	VB	O
has	VBZ	O
been	VBN	O
widely	RB	O
studied	VBN	O
in	IN	O
laboratory	NN	O
animals	NNS	O
,	,	O
but	CC	O
there	RB	O
have	VBP	O
been	VBN	O
few	JJ	O
investigations	NNS	O
of	IN	O
its	PRP$	O
efficacy	NN	O
in	IN	O
human	JJ	O
epidural	JJ	O
anesthesia	NN	O
and	CC	O
peripheral	JJ	O
nerve	NN	O
blocks	NNS	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
three	CD	O
long-acting	JJ	O
local	JJ	O
anesthetics	NNS	O
(	(	O
bupivacaine	VB	Pharmacological
0.75	CD	O
%	NN	O
,	,	O
ropivacaine	VB	Pharmacological
1	CD	O
%	NN	O
and	CC	O
etidocaine	VB	Pharmacological
1	CD	O
%	NN	O
)	)	O
and	CC	O
to	TO	O
try	VB	O
,	,	O
with	IN	O
reference	NN	O
to	TO	O
previous	JJ	O
studies	NNS	O
,	,	O
to	TO	O
make	VB	O
some	DT	O
statement	NN	O
about	IN	O
the	DT	O
equipotency	NN	O
of	IN	O
ropivacaine	JJ	Pharmacological
relative	NN	O
to	TO	O
bupivacaine	VB	Pharmacological
and	CC	O
etidocaine	VB	Pharmacological
.	.	O

METHODS	NNP	O
.	.	O

In	IN	O
a	DT	O
double	JJ	O
blind	NN	O
randomized	VBN	O
study	NN	O
,	,	O
epidural	JJ	O
anesthesia	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
with	IN	O
20	CD	O
ml	NNS	O
bupivacaine	VBP	Pharmacological
0.75	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
24	CD	O
)	)	O
and	CC	O
ropivacaine	VB	Pharmacological
1	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
21	CD	O
)	)	O
.	.	O

Following	VBG	O
this	DT	O
study	NN	O
epidural	JJ	O
anesthesia	NN	O
was	VBD	O
carried	VBN	O
out	IN	O
with	IN	O
20	CD	O
ml	NNS	O
etidocaine	VBP	Pharmacological
1	CD	O
%	NN	O
(	(	O
n	JJ	O
=	NNP	O
20	CD	O
)	)	O
in	IN	O
an	DT	O
open	JJ	O
study	NN	O
.	.	O

Patients	NNS	O
with	IN	O
ASA	NNP	O
I	PRP	O
or	CC	O
II	NNP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

All	DT	O
patients	NNS	O
were	VBD	O
scheduled	VBN	O
for	IN	O
varicose	JJ	O
vein	NN	O
stripping	VBG	O
.	.	O

Male	NNP	O
and	CC	O
female	JJ	O
patients	NNS	O
aged	VBN	O
18-70	JJ	O
years	NNS	O
and	CC	O
weighing	VBG	O
50-100	JJ	O
kg	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O

Patients	NNS	O
were	VBD	O
all	DT	O
placed	VBN	O
in	IN	O
a	DT	O
sitting	JJ	O
position	NN	O
,	,	O
after	IN	O
which	WDT	O
the	DT	O
epidural	JJ	O
space	NN	O
was	VBD	O
identified	VBN	O
by	IN	O
the	DT	O
loss	NN	O
of	IN	O
resistance	NN	O
technique	NN	O
and	CC	O
a	DT	O
midline	NN	O
approach	NN	O
,	,	O
at	IN	O
the	DT	O
L-3/4	JJ	O
interspace	NN	O
.	.	O

Injections	NNS	Pharmacological
of	IN	Pharmacological
3	CD	Pharmacological
ml	NN	Pharmacological
of	IN	Pharmacological
the	DT	Pharmacological
local	JJ	Pharmacological
anesthetic	NN	Pharmacological
were	VBD	O
given	VBN	O
,	,	O
followed	VBN	Pharmacological
by	IN	Pharmacological
the	DT	Pharmacological
remainder	NN	Pharmacological
of	IN	Pharmacological
the	DT	Pharmacological
local	JJ	Pharmacological
anesthetic	NN	Pharmacological
at	IN	Pharmacological
10	CD	Pharmacological
ml/min	NN	Pharmacological
1	CD	Pharmacological
min	NN	Pharmacological
later	RB	Pharmacological
.	.	O

Following	VBG	O
injection	NN	O
patients	NNS	O
were	VBD	O
immediately	RB	O
positioned	VBN	O
supine	NN	O
.	.	O

Analgesia	NNP	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
pin-prick	JJ	O
method	NN	O
and	CC	O
motor	NN	O
blockade	NN	O
was	VBD	O
assessed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
Bromage	NNP	O
scale	NN	O
.	.	O

Heart	NNP	O
rate	NN	O
and	CC	O
blood	NN	O
pressure	NN	O
were	VBD	O
monitored	VBN	O
until	IN	O
3	CD	O
h	NNS	O
after	IN	O
injection	NN	O
.	.	O

RESULTS	NNP	O
.	.	O

The	DT	O
latency	NN	O
of	IN	O
analgesia	NN	O
for	IN	O
the	DT	O
first	JJ	O
blocked	VBN	O
segment	NN	O
(	(	O
T	NNP	O
12	CD	O
for	IN	O
bupivacaine	NN	O
and	CC	O
ropivacaine	NN	O
and	CC	O
L-1	NNP	O
for	IN	O
etidocaine	NN	O
)	)	O
was	VBD	O
6.0	CD	O
min	NN	O
for	IN	O
bupivacaine	NN	Pharmacological
0.75	CD	O
,	,	O
5.5	CD	O
min	NN	O
for	IN	O
ropivacaine	JJ	Pharmacological
1	CD	O
%	NN	O
,	,	O
and	CC	O
5.2	CD	O
min	NN	O
for	IN	O
etidocaine	JJ	Pharmacological
1	CD	O
%	NN	O
,	,	O
and	CC	O
the	DT	O
highest	JJS	O
thoracic	JJ	O
dermatome	NN	O
(	(	O
T	NNP	O
5	CD	O
for	IN	O
bupivacaine	NN	Pharmacological
,	,	O
T	NNP	O
4	CD	O
for	IN	O
ropivacaine	NN	Pharmacological
and	CC	O
T	NNP	O
7	CD	O
for	IN	O
etidocaine	NN	Pharmacological
)	)	O
was	VBD	O
reached	VBN	O
after	IN	O
24	CD	O
+/-	JJ	O
10	CD	O
,	,	O
26	CD	O
+/-	JJ	O
9	CD	O
,	,	O
and	CC	O
30	CD	O
+/-	JJ	O
18	CD	O
min	NN	O
for	IN	O
bupivacaine	NN	Pharmacological
,	,	O
ropivacaine	NN	Pharmacological
,	,	O
and	CC	O
etidocaine	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
sensory	JJ	O
anesthesia	NN	O
at	IN	O
the	DT	O
T	NNP	O
10	CD	O
dermatomal	JJ	O
level	NN	O
was	VBD	O
257	CD	O
+/-	JJ	O
102	CD	O
,	,	O
278	CD	O
+/-	JJ	O
67	CD	O
,	,	O
and	CC	O
191	CD	O
+/-	JJ	O
86	CD	O
min	NN	O
for	IN	O
bupivacaine	NN	Pharmacological
,	,	O
ropivacaine	NN	Pharmacological
,	,	O
and	CC	O
etidocaine	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

The	DT	O
two-segment	JJ	O
regression	NN	O
time	NN	O
was	VBD	O
199	CD	O
+/-	JJ	O
80	CD	O
min	NN	O
for	IN	O
bupivacaine	NN	Pharmacological
,	,	O
201	CD	O
+/-	JJ	O
52	CD	O
min	NN	O
for	IN	O
ropivacaine	NN	Pharmacological
,	,	O
and	CC	O
174	CD	O
+/-	JJ	O
81	CD	O
min	NN	O
for	IN	O
etidocaine	NN	Pharmacological
.	.	O

The	DT	O
total	JJ	O
duration	NN	O
of	IN	O
sensory	JJ	O
block	NN	O
was	VBD	O
340	CD	O
+/-	JJ	O
103	CD	O
min	NN	O
for	IN	O
bupivacaine	NN	Pharmacological
,	,	O
428	CD	O
+/-	JJ	O
65	CD	O
min	NN	O
for	IN	O
ropivacaine	NN	Pharmacological
and	CC	O
223	CD	O
+/-	JJ	O
62	CD	O
min	NN	O
for	IN	O
etidocaine	NN	Pharmacological
,	,	O
respectively	RB	O
.	.	O

In	IN	O
the	DT	O
ropivacaine	NN	Pharmacological
and	CC	O
bupivacaine	NN	Pharmacological
groups	NNS	O
sensory	JJ	O
anesthesia	NN	O
was	VBD	O
considered	VBN	O
adequate	NN	O
for	IN	O
surgery	NN	O
in	IN	O
all	DT	O
cases	NNS	O
but	CC	O
one	CD	O
in	IN	O
each	DT	O
group	NN	O
;	:	O
in	IN	O
the	DT	O
etidocaine	NN	Pharmacological
group	NN	O
,	,	O
however	RB	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
showed	VBD	O
inadequate	JJ	O
analgesia	NN	O
and	CC	O
all	PDT	O
these	DT	O
patients	NNS	O
(	(	O
12/20	CD	O
)	)	O
required	VBN	O
additional	JJ	O
analgesics	NNS	O
.	.	O

Bupivacaine	NNP	Pharmacological
achieved	VBD	O
an	DT	O
average	NN	O
of	IN	O
motor	NN	O
block	NN	O
2.1	CD	O
,	,	O
ropivacaine	NN	Pharmacological
2.3	CD	O
,	,	O
and	CC	O
etidocaine	VB	Pharmacological
2.4	CD	O
.	.	O

CONCLUSION	NNP	O
.	.	O

The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
indicate	VBP	O
that	IN	O
ropivacaine	NN	Pharmacological
is	VBZ	O
an	DT	O
effective	JJ	O
local	JJ	O
anesthetic	JJ	O
agent	NN	O
.	.	O

Its	PRP$	O
potency	NN	O
is	VBZ	O
about	RB	O
equal	JJ	O
to	TO	O
that	DT	O
of	IN	O
bupivacaine	NN	Pharmacological
and	CC	O
much	RB	O
higher	JJR	O
than	IN	O
that	DT	O
of	IN	O
etidocaine	NN	Pharmacological
...	:	O
Effect	NN	O
of	IN	O
simvastatin	NN	Pharmacological
on	IN	O
hemostasis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
.	.	O

BACKGROUNDS/AIMS	NNP	O
Elevated	NNP	O
triglyceride	NN	O
levels	NNS	O
seem	VBP	O
to	TO	O
predispose	VB	O
to	TO	O
the	DT	O
earlier	JJR	O
development	NN	O
and	CC	O
accelerated	JJ	O
progression	NN	O
of	IN	O
coronary	JJ	O
artery	NN	O
disease	NN	O
.	.	O

In	IN	O
our	PRP$	O
study	NN	O
,	,	O
we	PRP	O
assessed	VBD	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
whether	IN	O
simvastatin	JJ	Pharmacological
treatment	NN	O
affects	NNS	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
included	VBD	O
39	CD	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
and	CC	O
peripheral	JJ	O
artery	NN	O
sclerosis	NN	O
,	,	O
treated	VBD	O
for	IN	O
90	CD	O
days	NNS	O
with	IN	O
either	DT	O
simvastatin	NN	Pharmacological
(	(	O
40	CD	O
mg	NNS	O
daily	RB	O
)	)	O
or	CC	O
placebo	NN	Control
.	.	O

Plasma	NNP	O
lipids	NNS	O
,	,	O
glucose	JJ	O
homeostasis	NN	O
markers	NNS	O
and	CC	O
hemostasic	JJ	O
variables	NNS	O
were	VBD	O
assessed	VBN	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
.	.	O

RESULTS	NNP	O
Simvastatin	NNP	Pharmacological
,	,	O
but	CC	O
not	RB	O
placebo	VB	Control
,	,	O
administered	VBN	O
to	TO	O
these	DT	O
patients	NNS	O
reduced	VBD	O
plasma	JJ	O
levels/activity	NN	O
of	IN	O
fibrinogen	NN	O
(	(	O
from	IN	O
3.5	CD	O
?	.	O
0.4	CD	O
to	TO	O
2.8	CD	O
?	.	O
0.3	CD	O
g/l	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
,	,	O
factor	NN	O
VII	NNP	O
(	(	O
from	IN	O
144.2	CD	O
?	.	O
16.9	CD	O
to	TO	O
112.5	CD	O
?	.	O
14.0	CD	O
%	NN	O
,	,	O
p	NN	O
<	NNP	O
0.01	CD	O
)	)	O
and	CC	O
plasminogen	JJ	O
activator	NN	O
inhibitor-1	NN	O
(	(	O
from	IN	O
76.9	CD	O
?	.	O
13.5	CD	O
to	TO	O
50.2	CD	O
?	.	O
9.2	CD	O
ng/ml	NN	O
,	,	O
p	NN	O
<	NNP	O
0.001	CD	O
)	)	O
,	,	O
without	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
von	NN	O
Willebrand	NNP	O
factor	NN	O
levels	NNS	O
,	,	O
and	CC	O
tended	VBD	O
to	TO	O
prolong	VB	O
the	DT	O
prothrombin	NN	O
and	CC	O
partial	JJ	O
thromboplastin	NN	O
times	NNS	O
.	.	O

CONCLUSION	NNP	O
Our	PRP$	O
results	NNS	O
suggest	VBP	O
that	IN	O
statin	NN	O
treatment	NN	O
produces	VBZ	O
a	DT	O
multidirectional	JJ	O
effect	NN	O
on	IN	O
coagulation	NN	O
and	CC	O
fibrinolysis	NN	O
in	IN	O
patients	NNS	O
with	IN	O
isolated	JJ	O
hypertriglyceridemia	NN	O
and	CC	O
that	IN	O
this	DT	O
treatment	NN	O
may	MD	O
bring	VB	O
some	DT	O
benefits	NNS	O
to	TO	O
patients	NNS	O
with	IN	O
elevated	JJ	O
triglyceride	NN	O
levels	NNS	O
.	.	O

Zinc	NNP	Pharmacological
supplementation	NN	Pharmacological
in	IN	O
alcoholic	JJ	O
cirrhosis	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
.	.	O

A	DT	O
double-blind	JJ	O
clinical	JJ	O
trial	NN	O
with	IN	O
zinc	NN	Pharmacological
sulfate	NN	Pharmacological
,	,	O
0.2	CD	O
g	NN	O
three	CD	O
times	NNS	O
daily	RB	O
,	,	O
and	CC	O
a	DT	O
placebo	NN	Control
was	VBD	O
performed	VBN	O
in	IN	O
30	CD	O
patients	NNS	O
with	IN	O
biopsy-proven	JJ	O
alcoholic	JJ	O
liver	NN	O
cirrhosis	NN	O
.	.	O

The	DT	O
disease	NN	O
was	VBD	O
in	IN	O
a	DT	O
stable	JJ	O
phase	NN	O
,	,	O
and	CC	O
none	NN	O
of	IN	O
the	DT	O
patients	NNS	O
showed	VBD	O
evidence	NN	O
of	IN	O
a	DT	O
decompensated	VBN	O
liver	NN	O
function	NN	O
.	.	O

Parameters	NNS	O
of	IN	O
liver	NN	O
function	NN	O
,	,	O
taste	NN	O
acuity	NN	O
,	,	O
dark	JJ	O
adaptation	NN	O
and	CC	O
of	IN	O
zinc	NN	Pharmacological
and	CC	O
vitamin	VB	Pharmacological
A	DT	Pharmacological
metabolism	NN	Pharmacological
were	VBD	O
followed	VBN	O
for	IN	O
six	CD	O
weeks	NNS	O
.	.	O

In	IN	O
the	DT	O
zinc-treated	JJ	O
group	NN	O
of	IN	O
16	CD	O
patients	NNS	O
,	,	O
serum	JJ	O
zinc	NN	O
rose	VBD	O
from	IN	O
a	DT	O
normal	JJ	O
mean	JJ	O
value	NN	O
of	IN	O
13.3	CD	O
to	TO	O
17.4	CD	O
mumol/l	NNS	O
,	,	O
whereas	IN	O
the	DT	O
mean	JJ	O
serum	NN	O
vitamin	VBZ	O
A	DT	O
level	NN	O
remained	VBD	O
practically	RB	O
unaltered	JJ	O
within	IN	O
the	DT	O
normal	JJ	O
range	NN	O
,	,	O
1.89	CD	O
at	IN	O
the	DT	O
entry	NN	O
and	CC	O
1.83	CD	O
mumol/l	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

Plasma	NNP	O
prothrombin	NN	O
and	CC	O
serum	JJ	O
alkaline	JJ	O
phosphatase	NN	O
levels	NNS	O
of	IN	O
the	DT	O
zinc	NNP	O
group	NN	O
increased	VBD	O
and	CC	O
serum	JJ	O
bilirubin	NN	O
and	CC	O
serum	JJ	O
carotene	NN	O
decreased	VBN	O
significantly	RB	O
.	.	O

The	DT	O
dark	JJ	O
adaptation	NN	O
did	VBD	O
not	RB	O
change	NN	O
,	,	O
but	CC	O
the	DT	O
taste	NN	O
function	NN	O
was	VBD	O
significantly	RB	O
improved	VBN	O
during	IN	O
zinc	NN	O
treatment	NN	O
.	.	O

The	DT	O
results	NNS	O
indicate	VBP	O
that	IN	O
zinc	NN	Pharmacological
supplementation	NN	Pharmacological
causes	VBZ	O
alleviation	NN	O
of	IN	O
certain	JJ	O
abnormalities	NNS	O
of	IN	O
cirrhotics	NNS	O
,	,	O
which	WDT	O
deserves	VBZ	O
further	JJ	O
attention	NN	O
.	.	O

Cognitive	JJ	O
effects	NNS	O
of	IN	O
risperidone	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
irritable	JJ	O
behavior	NN	O
.	.	O

OBJECTIVE	CC	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
research	NN	O
was	VBD	O
to	TO	O
explore	VB	O
the	DT	O
effects	NNS	O
of	IN	O
risperidone	NN	Pharmacological
on	IN	O
cognitive	JJ	O
processes	NNS	O
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
and	CC	O
irritable	JJ	O
behavior	NN	O
.	.	O

METHOD	NNP	O
Thirty-eight	JJ	O
children	NNS	O
,	,	O
ages	VBZ	O
5-17	CD	O
years	NNS	O
with	IN	O
autism	NN	O
and	CC	O
severe	JJ	O
behavioral	JJ	O
disturbance	NN	O
,	,	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
risperidone	VB	Pharmacological
(	(	O
0.5	CD	O
to	TO	O
3.5	CD	O
mg/day	NN	O
)	)	O
or	CC	O
placebo	NN	Control
for	IN	O
8	CD	O
weeks	NNS	O
.	.	O

This	DT	O
sample	NN	O
of	IN	O
38	CD	O
was	VBD	O
a	DT	O
subset	NN	O
of	IN	O
101	CD	O
subjects	NNS	O
who	WP	O
participated	VBD	O
in	IN	O
the	DT	O
clinical	JJ	O
trial	NN	O
;	:	O
63	CD	O
were	VBD	O
unable	JJ	O
to	TO	O
perform	VB	O
the	DT	O
cognitive	JJ	O
tasks	NNS	O
.	.	O

A	DT	O
double-blind	JJ	O
placebo-controlled	JJ	O
parallel	NN	O
groups	NNS	O
design	NN	O
was	VBD	O
used	VBN	O
.	.	O

Dependent	JJ	O
measures	NNS	O
included	VBD	O
tests	NNS	O
of	IN	O
sustained	JJ	O
attention	NN	O
,	,	O
verbal	JJ	O
learning	NN	O
,	,	O
hand-eye	JJ	O
coordination	NN	O
,	,	O
and	CC	O
spatial	JJ	O
memory	NN	O
assessed	VBN	O
before	IN	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
the	DT	O
8-week	JJ	O
treatment	NN	O
.	.	O

Changes	NNS	O
in	IN	O
performance	NN	O
were	VBD	O
compared	VBN	O
by	IN	O
repeated	JJ	O
measures	NNS	O
ANOVA	NNP	O
.	.	O

RESULTS	NNP	O
Twenty-nine	JJ	O
boys	NNS	O
and	CC	O
9	CD	O
girls	NNS	O
with	IN	O
autism	NN	O
and	CC	O
severe	JJ	O
behavioral	JJ	O
disturbance	NN	O
and	CC	O
a	DT	O
mental	JJ	O
age	NN	O
>	NNP	O
or=18	JJ	O
months	NNS	O
completed	VBN	O
the	DT	O
cognitive	JJ	O
part	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O

No	DT	O
decline	NN	O
in	IN	O
performance	NN	O
occurred	VBD	O
with	IN	O
risperidone	NN	O
.	.	O

Performance	NN	O
on	IN	O
a	DT	O
cancellation	NN	O
task	NN	O
(	(	O
number	NN	O
of	IN	O
correct	JJ	O
detections	NNS	O
)	)	O
and	CC	O
a	DT	O
verbal	JJ	O
learning	NN	O
task	NN	O
(	(	O
word	NN	O
recognition	NN	O
)	)	O
was	VBD	O
better	RBR	O
on	IN	O
risperidone	NN	Pharmacological
than	IN	O
on	IN	O
placebo	NN	Control
(	(	O
without	IN	O
correction	NN	O
for	IN	O
multiplicity	NN	O
)	)	O
.	.	O

Equivocal	JJ	O
improvement	NN	O
also	RB	O
occurred	VBD	O
on	IN	O
a	DT	O
spatial	JJ	O
memory	NN	O
task	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
treatment	NN	O
conditions	NNS	O
on	IN	O
the	DT	O
Purdue	NNP	O
Pegboard	NNP	O
(	(	O
hand-eye	JJ	O
coordination	NN	O
)	)	O
task	NN	O
or	CC	O
the	DT	O
Analog	NNP	O
Classroom	NNP	O
Task	NNP	O
(	(	O
timed	VBN	O
math	RB	O
test	NN	O
)	)	O
.	.	O

CONCLUSION	NNP	O
Risperidone	NNP	Pharmacological
given	VBN	O
to	TO	O
children	NNS	O
with	IN	O
autism	NN	O
at	IN	O
doses	VBZ	O
up	RB	O
to	TO	O
3.5	CD	O
mg	NN	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
appears	VBZ	O
to	TO	O
have	VB	O
no	DT	O
detrimental	JJ	O
effect	NN	O
on	IN	O
cognitive	JJ	O
performance	NN	O
.	.	O

Effect	NN	O
of	IN	O
micronutrient	NN	Pharmacological
supplement	NN	Pharmacological
on	IN	O
health	NN	O
and	CC	O
nutritional	JJ	O
status	NN	O
of	IN	O
schoolchildren	NNS	O
:	:	O
study	NN	O
design	NN	O
.	.	O

OBJECTIVE	IN	O
We	PRP	O
tested	VBD	O
the	DT	O
hypothesis	NN	O
that	WDT	O
supplementation	NN	O
with	IN	O
a	DT	O
micronutrient-fortified	JJ	Pharmacological
beverage	NN	Pharmacological
improves	VBZ	O
micronutrient	JJ	O
status	NN	O
and	CC	O
physical	JJ	O
and	CC	O
mental	JJ	O
development	NN	O
in	IN	O
apparently	RB	O
healthy	JJ	O
schoolchildren	NNS	O
.	.	O

METHODS	NNP	O
The	DT	O
study	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
in	IN	O
middle-income	JJ	O
students	NNS	O
in	IN	O
two	CD	O
residential	JJ	O
schools	NNS	O
that	WDT	O
catered	VBD	O
to	TO	O
children	NNS	O
from	IN	O
a	DT	O
semi-urban	JJ	O
population	NN	O
near	IN	O
Hyderabad	NNP	O
,	,	O
India	NNP	O
.	.	O

Included	NNP	O
were	VBD	O
869	CD	O
children	NNS	O
who	WP	O
were	VBD	O
6	CD	O
to	TO	O
16	CD	O
y	NN	O
of	IN	O
age	NN	O
in	IN	O
grades	NNS	O
1	CD	O
to	TO	O
10	CD	O
.	.	O

Because	IN	O
children	NNS	O
at	IN	O
each	DT	O
grade	NN	O
were	VBD	O
distributed	VBN	O
across	IN	O
two	CD	O
classrooms	NNS	O
(	(	O
clusters	NNS	O
)	)	O
and	CC	O
were	VBD	O
homogeneous	JJ	O
,	,	O
each	DT	O
grade	NN	O
was	VBD	O
considered	VBN	O
to	TO	O
consist	VB	O
of	IN	O
a	DT	O
matched	JJ	O
pair	NN	O
.	.	O

There	EX	O
were	VBD	O
thus	RB	O
10	CD	O
pairs	NNS	O
available	JJ	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Classes	NNS	O
in	IN	O
each	DT	O
grade	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
a	DT	O
micronutrient-enriched	JJ	Pharmacological
beverage	NN	Pharmacological
or	CC	O
a	DT	O
placebo	NN	Control
without	IN	Control
added	JJ	Control
micronutrients	NNS	Control
.	.	O

The	DT	O
study	NN	O
was	VBD	O
double	RB	O
blinded	VBN	O
and	CC	O
the	DT	O
duration	NN	O
was	VBD	O
14	CD	O
mo	NN	O
,	,	O
with	IN	O
supervised	JJ	O
feeding	NN	O
of	IN	O
the	DT	O
micronutrient-enriched	JJ	Pharmacological
beverage	NN	Pharmacological
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
micronutrients	NNS	Pharmacological
on	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
growth	NN	O
,	,	O
biochemical	JJ	O
status	NN	O
,	,	O
mental	JJ	O
function	NN	O
,	,	O
and	CC	O
bone	NN	O
health	NN	O
were	VBD	O
assessed	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
number	NN	O
of	IN	O
matched	JJ	O
pairs	NNS	O
varied	VBD	O
between	IN	O
seven	CD	O
and	CC	O
eight	CD	O
,	,	O
and	CC	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
children	NNS	O
per	IN	O
treatment	NN	O
group	NN	O
ranged	VBD	O
from	IN	O
32	CD	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
bone	NN	O
heath	NN	O
to	TO	O
177	CD	O
for	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
power	NN	O
of	IN	O
the	DT	O
outcome	NN	O
variables	NNS	O
ranged	VBD	O
from	IN	O
74	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
and	CC	O
was	VBD	O
adequate	NN	O
for	IN	O
successful	JJ	O
pairing	NN	O
.	.	O

The	DT	O
effect	NN	O
assessed	VBD	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
supplementation	NN	Pharmacological
showed	VBD	O
that	IN	O
the	DT	O
intervention	NN	O
was	VBD	O
beneficial	JJ	O
.	.	O

CONCLUSIONS	NNP	O
Designing	VBG	O
an	DT	O
intervention	NN	O
,	,	O
choosing	VBG	O
outcome	NN	O
variables	NNS	O
,	,	O
and	CC	O
implementing	VBG	O
the	DT	O
protocol	NN	O
in	IN	O
a	DT	O
typical	JJ	O
Indian	JJ	O
school	NN	O
setting	VBG	O
were	VBD	O
achieved	VBN	O
.	.	O

Gonadotropin-releasing	VBG	Pharmacological
hormone	NN	Pharmacological
agonist	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
premenstrual	JJ	O
symptoms	NNS	O
with	IN	O
and	CC	O
without	IN	O
ongoing	VBG	O
dysphoria	NN	O
:	:	O
a	DT	O
controlled	VBN	O
study	NN	O
.	.	O

Gonadotropin-releasing	VBG	Pharmacological
hormone	NN	Pharmacological
(	(	Pharmacological
GnRH	NNP	Pharmacological
)	)	Pharmacological
agonists	NNS	Pharmacological
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
symptoms	NNS	O
of	IN	O
premenstrual	JJ	O
syndrome	NN	O
(	(	O
PMS	NNP	O
)	)	O
.	.	O

This	DT	O
randomized	JJ	O
,	,	O
placebo-controlled	JJ	O
study	NN	O
examined	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
the	DT	O
GnRH	NNP	Pharmacological
agonist	NN	Pharmacological
,	,	O
leuprolide	JJ	O
acetate	NN	O
depot	NN	O
,	,	O
in	IN	O
a	DT	O
clearly	RB	O
defined	VBN	O
PMS	NNP	O
sample	JJ	O
versus	NNS	O
women	NNS	O
with	IN	O
premenstrual	JJ	O
symptoms	NNS	O
in	IN	O
combination	NN	O
with	IN	O
dysphoric	NN	O
symptoms	NNS	O
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
termed	VBD	O
the	DT	O
premenstrual	JJ	O
exacerbation	NN	O
(	(	O
PME	NNP	O
)	)	O
group	NN	O
.	.	O

Evaluation	NN	O
included	VBD	O
the	DT	O
Structured	NNP	O
Clinical	NNP	O
Interview	NNP	O
for	IN	O
DSM-III-R	NNP	O
,	,	O
administered	VBN	O
in	IN	O
the	DT	O
follicular	JJ	O
phase	NN	O
,	,	O
and	CC	O
the	DT	O
subject	NN	O
Penn	NNP	O
Dally	NNP	O
Symptoms	NNP	O
Report	NNP	O
(	(	O
DSR	NNP	O
)	)	O
maintained	VBD	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O

Thirty-three	NNP	O
eligible	JJ	O
women	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
double-blind	VB	O
treatment	NN	O
and	CC	O
administered	VBD	O
3.75	CD	Pharmacological
mg	NN	Pharmacological
of	IN	Pharmacological
depot	NN	Pharmacological
leuprolide	NN	Pharmacological
or	CC	O
a	DT	O
placebo	NN	Control
once	RB	O
a	DT	O
month	NN	O
for	IN	O
3	CD	O
months	NNS	O
.	.	O

The	DT	O
subjects	NNS	O
were	VBD	O
seen	VBN	O
for	IN	O
efficacy	NN	O
evaluations	NNS	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
each	DT	O
cycle	NN	O
.	.	O

Outcome	CC	O
measures	NNS	O
were	VBD	O
the	DT	O
DSRs	NNP	O
and	CC	O
the	DT	O
17-item	JJ	O
Hamilton	NNP	O
Depression	NNP	O
Rating	NNP	O
Scale	NNP	O
(	(	O
HAM-D17	NNP	O
)	)	O
.	.	O

The	DT	O
PMS	NNP	O
leuprolide	JJ	Pharmacological
subjects	NNS	O
improved	VBN	O
significantly	RB	O
compared	VBN	O
with	IN	O
the	DT	O
PMS	NNP	O
placebo	NN	O
and	CC	O
PME	NNP	O
leuprolide	RB	O
groups	NNS	O
.	.	O

The	DT	O
PME	NNP	O
leuprolide	NN	Pharmacological
group	NN	O
,	,	O
who	WP	O
had	VBD	O
dysphoric	NN	O
symptoms	NNS	O
throughout	IN	O
the	DT	O
cycle	NN	O
,	,	O
did	VBD	O
not	RB	O
improve	VB	O
.	.	O

Depression	NNP	O
symptoms	NNS	O
were	VBD	O
at	IN	O
clinical	JJ	O
levels	NNS	O
premenstrually	RB	O
in	IN	O
the	DT	O
PMS	NNP	O
and	CC	O
PME	NNP	O
groups	NNS	O
;	:	O
following	VBG	O
treatment	NN	O
they	PRP	O
remitted	VBD	O
in	IN	O
the	DT	O
PMS	NNP	O
group	NN	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
PME	NNP	O
leuprolide	JJ	Pharmacological
subjects	NNS	O
.	.	O

Efficacy	NN	O
did	VBD	O
not	RB	O
occur	VB	O
until	IN	O
after	IN	O
several	JJ	O
months	NNS	O
of	IN	O
leuprolide	JJ	Pharmacological
treatment	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
that	IN	O
PMS	NNP	O
symptoms	NNS	O
worsened	VBD	O
with	IN	O
the	DT	O
onset	NN	O
of	IN	O
treatment	NN	O
.	.	O

These	DT	O
results	NNS	O
replicate	VBP	O
the	DT	O
findings	NNS	O
in	IN	O
our	PRP$	O
preliminary	JJ	O
open-label	NN	O
study	NN	O
.	.	O

Leuprolide	NNP	Pharmacological
reduced	VBD	O
PMS	NNP	O
symptoms	NNS	O
to	TO	O
minimal	JJ	O
levels	NNS	O
where	WRB	O
symptoms	NNS	O
were	VBD	O
limited	VBN	O
to	TO	O
the	DT	O
luteal	JJ	O
phase	NN	O
.	.	O

Leuprolide	NNP	Pharmacological
was	VBD	O
not	RB	O
effective	JJ	O
for	IN	O
women	NNS	O
with	IN	O
ongoing	VBG	O
dysphoric	NN	O
symptoms	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
premenstrual	JJ	O
depression	NN	O
may	MD	O
have	VB	O
mechanisms	NNS	O
different	JJ	O
from	IN	O
those	DT	O
of	IN	O
other	JJ	O
dysphoric	JJ	O
mood	NN	O
disorders	NNS	O
.	.	O

Temporal	JJ	O
expectation	NN	O
in	IN	O
focal	JJ	O
hand	NN	O
dystonia	NN	O
.	.	O

Patients	NNS	O
with	IN	O
writer	NN	O
's	POS	O
cramp	NN	O
present	JJ	O
sensory	NN	O
and	CC	O
representational	JJ	O
abnormalities	NNS	O
relevant	VBP	O
to	TO	O
motor	VB	O
control	NN	O
,	,	O
such	JJ	O
as	IN	O
impairment	NN	O
in	IN	O
the	DT	O
temporal	JJ	O
discrimination	NN	O
between	IN	O
tactile	JJ	O
stimuli	NNS	O
and	CC	O
in	IN	O
pure	JJ	O
motor	NN	O
imagery	NN	O
tasks	NNS	O
,	,	O
like	IN	O
the	DT	O
mental	JJ	O
rotation	NN	O
of	IN	O
corporeal	NN	O
and	CC	O
inanimate	JJ	O
objects	NNS	O
.	.	O

However	RB	O
,	,	O
only	RB	O
limited	JJ	O
information	NN	O
is	VBZ	O
available	JJ	O
on	IN	O
the	DT	O
ability	NN	O
of	IN	O
patients	NNS	O
with	IN	O
dystonia	NN	O
to	TO	O
process	VB	O
the	DT	O
time-dependent	JJ	O
features	NNS	O
(	(	O
e.g	NN	O
.	.	O

speed	NN	O
)	)	O
of	IN	O
movement	NN	O
in	IN	O
real	JJ	O
time	NN	O
.	.	O

The	DT	O
processing	NN	O
of	IN	O
time-dependent	JJ	O
features	NNS	O
of	IN	O
movement	NN	O
has	VBZ	O
a	DT	O
crucial	JJ	O
role	NN	O
in	IN	O
predicting	VBG	O
whether	IN	O
the	DT	O
outcome	NN	O
of	IN	O
a	DT	O
complex	JJ	O
motor	NN	O
sequence	NN	O
,	,	O
such	JJ	O
as	IN	O
handwriting	NN	O
or	CC	O
playing	VBG	O
a	DT	O
musical	JJ	O
passage	NN	O
,	,	O
will	MD	O
be	VB	O
consistent	JJ	O
with	IN	O
its	PRP$	O
ultimate	JJ	O
goal	NN	O
,	,	O
or	CC	O
results	NNS	O
instead	RB	O
in	IN	O
an	DT	O
execution	NN	O
error	NN	O
.	.	O

In	IN	O
this	DT	O
study	NN	O
,	,	O
we	PRP	O
sought	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
implicit	JJ	O
ability	NN	O
to	TO	O
perceive	VB	O
the	DT	O
temporal	JJ	Educational
outcome	NN	Educational
of	IN	O
different	JJ	O
movements	NNS	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
patients	NNS	O
with	IN	O
writer	NN	O
's	POS	O
cramp	NN	O
.	.	O

Fourteen	JJ	O
patients	NNS	O
affected	VBN	O
by	IN	O
writer	NN	O
's	POS	O
cramp	NN	O
in	IN	O
the	DT	O
right	JJ	O
hand	NN	O
and	CC	O
17	CD	O
age-	JJ	O
and	CC	O
gender-matched	JJ	O
healthy	JJ	O
subjects	NNS	O
were	VBD	O
recruited	VBN	O
for	IN	O
the	DT	O
study	NN	O
.	.	O

Subjects	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
perform	VB	O
a	DT	O
temporal	JJ	Psychological
expectation	NN	Psychological
task	NN	Psychological
by	IN	O
predicting	VBG	O
the	DT	O
end	NN	O
of	IN	O
visually	RB	O
perceived	VBN	O
human	JJ	O
body	NN	O
motion	NN	O
(	(	O
handwriting	VBG	O
,	,	O
i.e	NN	O
.	.	O

the	DT	O
action	NN	O
performed	VBN	O
by	IN	O
the	DT	O
human	JJ	O
body	NN	O
segment	NN	O
specifically	RB	O
affected	VBN	O
by	IN	O
writer	NN	O
's	POS	O
cramp	NN	O
)	)	O
or	CC	O
inanimate	JJ	O
object	JJ	O
motion	NN	O
(	(	O
a	DT	O
moving	VBG	O
circle	NN	O
reaching	VBG	O
a	DT	O
spatial	JJ	O
target	NN	O
)	)	O
.	.	O

Videos	NNP	Psychological
representing	VBG	Psychological
movements	NNS	Psychological
were	VBD	O
shown	VBN	O
in	IN	O
full	JJ	O
before	IN	O
experimental	JJ	O
trials	NNS	O
;	:	O
the	DT	O
actual	JJ	O
tasks	NNS	O
consisted	VBN	O
of	IN	O
watching	VBG	O
the	DT	O
same	JJ	O
videos	NN	O
,	,	O
but	CC	O
interrupted	VBD	O
after	IN	O
a	DT	O
variable	JJ	O
interval	NN	O
(	(	O
'pre-dark	NNP	O
'	POS	O
)	)	O
from	IN	O
its	PRP$	O
onset	VBN	O
by	IN	O
a	DT	O
dark	JJ	O
interval	NN	O
of	IN	O
variable	JJ	O
duration	NN	O
.	.	O

During	IN	O
the	DT	O
'dark	NNP	O
'	POS	O
interval	NN	O
,	,	O
subjects	NNS	O
were	VBD	O
asked	VBN	O
to	TO	O
indicate	VB	O
when	WRB	O
the	DT	O
movement	NN	O
represented	VBN	O
in	IN	O
the	DT	O
video	NN	O
reached	VBD	O
its	PRP$	O
end	NN	O
by	IN	O
clicking	VBG	O
on	IN	O
the	DT	O
space	NN	O
bar	NN	O
of	IN	O
the	DT	O
keyboard	NN	O
.	.	O

We	PRP	O
also	RB	O
included	VBD	O
a	DT	O
visual	JJ	O
working	JJ	O
memory	NN	O
task	NN	O
.	.	O

Performance	NN	O
on	IN	O
the	DT	O
timing	NN	O
task	NN	O
was	VBD	O
analysed	VBN	O
measuring	VBG	O
the	DT	O
absolute	JJ	O
value	NN	O
of	IN	O
timing	VBG	O
error	NN	O
,	,	O
the	DT	O
coefficient	NN	O
of	IN	O
variability	NN	O
and	CC	O
the	DT	O
percentage	NN	O
of	IN	O
anticipation	NN	O
responses	NNS	O
.	.	O

Patients	NNS	O
with	IN	O
writer	NN	O
's	POS	O
cramp	NN	O
exhibited	VBD	O
greater	JJR	O
absolute	JJ	O
timing	NN	O
error	NN	O
compared	VBN	O
with	IN	O
control	NN	O
subjects	NNS	O
in	IN	O
the	DT	O
human	JJ	O
body	NN	O
motion	NN	O
task	NN	O
(	(	O
whereas	IN	O
no	DT	O
difference	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
inanimate	NN	O
object	JJ	O
motion	NN	O
task	NN	O
)	)	O
.	.	O

No	DT	O
effect	NN	O
of	IN	O
group	NN	O
was	VBD	O
documented	VBN	O
on	IN	O
the	DT	O
visual	JJ	O
working	JJ	O
memory	NN	O
tasks	NNS	O
.	.	O

Absolute	NNP	O
timing	VBG	O
error	NN	O
on	IN	O
the	DT	O
human	JJ	O
body	NN	O
motion	NN	O
task	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
correlate	VB	O
with	IN	O
symptom	JJ	O
severity	NN	O
,	,	O
disease	VB	O
duration	NN	O
or	CC	O
writing	VBG	O
speed	NN	O
.	.	O

Our	PRP$	O
findings	NNS	O
suggest	VBP	O
an	DT	O
alteration	NN	O
of	IN	O
the	DT	O
writing	VBG	O
movement	NN	O
representation	NN	O
at	IN	O
a	DT	O
central	JJ	O
level	NN	O
and	CC	O
are	VBP	O
consistent	JJ	O
with	IN	O
the	DT	O
view	NN	O
that	IN	O
dystonia	NN	O
is	VBZ	O
not	RB	O
a	DT	O
purely	RB	O
motor	NN	O
disorder	NN	O
,	,	O
but	CC	O
it	PRP	O
also	RB	O
involves	VBZ	O
non-motor	NN	O
(	(	O
sensory	JJ	O
,	,	O
cognitive	JJ	O
)	)	O
aspects	NNS	O
related	VBN	O
to	TO	O
movement	NN	O
processing	NN	O
and	CC	O
planning	NN	O
.	.	O

Topical	JJ	Physical
anesthesia	NN	Physical
during	IN	O
infant	JJ	O
eye	NN	O
examinations	NNS	O
:	:	O
does	VBZ	O
it	PRP	O
reduce	VB	O
stress	NN	O
?	.	O
We	PRP	O
studied	VBD	O
the	DT	O
effect	NN	O
of	IN	O
topical	JJ	Physical
anesthesia	NN	Physical
on	IN	O
infant	JJ	O
stress	NN	O
and	CC	O
corneal	NN	O
haze	NN	O
during	IN	O
the	DT	O
routine	JJ	O
eye	NN	O
examination	NN	O
for	IN	O
retinopathy	NN	O
of	IN	O
prematurity	NN	O
.	.	O

Using	VBG	O
a	DT	O
double-blind	JJ	O
protocol	NN	O
,	,	O
55	CD	O
premature	NN	O
infants	NNS	O
weighing	VBG	O
less	JJR	O
than	IN	O
1501	CD	O
g	NN	O
at	IN	O
birth	NN	O
were	VBD	O
selected	VBN	O
randomly	RB	O
to	TO	O
receive	VB	O
normal	JJ	Pharmacological
saline	NN	Pharmacological
or	CC	Pharmacological
proparacaine	NN	Pharmacological
HCl	NNP	Pharmacological
0.5	CD	Pharmacological
%	NN	Pharmacological
eye	NN	Pharmacological
drops	VBZ	Pharmacological
as	IN	O
a	DT	O
corneal	NN	O
wetting	VBG	O
agent	NN	O
at	IN	O
their	PRP$	O
initial	JJ	O
eye	NN	O
examination	NN	O
.	.	O

Before	IN	O
,	,	O
during	IN	O
,	,	O
and	CC	O
after	IN	O
the	DT	O
procedure	NN	O
,	,	O
infant	JJ	O
stress	NN	O
was	VBD	O
evaluated	VBN	O
by	IN	O
heart	NN	O
rate	NN	O
,	,	O
respiration	NN	O
rate	NN	O
,	,	O
blood	NN	O
pressure	NN	O
,	,	O
and	CC	O
transcutaneous	JJ	O
oxygen	NN	O
saturation	NN	O
.	.	O

Subjective	JJ	O
assessment	NN	O
of	IN	O
the	DT	O
infant	NN	O
's	POS	O
cry	NN	O
intensity	NN	O
and	CC	O
corneal	NN	O
haze	NN	O
also	RB	O
were	VBD	O
recorded	VBN	O
.	.	O

Adequate	NNP	O
data	NNS	O
were	VBD	O
collected	VBN	O
on	IN	O
42	CD	O
patients	NNS	O
.	.	O

Using	VBG	O
analysis	NN	O
of	IN	O
variance	NN	O
and	CC	O
chi-square	NN	O
tests	NNS	O
,	,	O
we	PRP	O
found	VBD	O
no	DT	O
difference	NN	O
in	IN	O
any	DT	O
of	IN	O
these	DT	O
parameters	NNS	O
between	IN	O
the	DT	O
two	CD	O
patients	NNS	O
groups	NNS	O
.	.	O

These	DT	O
data	NNS	O
suggest	VBP	O
that	IN	O
topical	JJ	O
anesthetic	JJ	Pharmacological
agents	NNS	O
offer	VBP	O
no	DT	O
advantage	NN	O
over	IN	O
normal	JJ	O
saline	JJ	O
eye	NN	O
drops	NNS	O
during	IN	O
the	DT	O
examination	NN	O
of	IN	O
premature	JJ	O
infants	NNS	O
.	.	O

Three-year	JJ	O
clinical	JJ	O
outcome	NN	O
after	IN	O
primary	JJ	O
stenting	NN	O
of	IN	O
totally	RB	O
occluded	JJ	O
native	JJ	O
coronary	JJ	O
arteries	NNS	O
:	:	O
a	DT	O
randomized	JJ	O
comparison	NN	O
of	IN	O
bare-metal	JJ	Physical
stent	JJ	Physical
implantation	NN	Physical
with	IN	Physical
sirolimus-eluting	JJ	Physical
stent	NN	Physical
implantation	NN	Physical
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
(	(	O
Primary	JJ	O
Stenting	NNP	O
of	IN	O
Totally	NNP	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
[	NNP	O
PRISON	NNP	O
]	NNP	O
II	NNP	O
study	NN	O
)	)	O
.	.	O

BACKGROUND	IN	O
The	DT	O
purpose	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
examine	VB	O
the	DT	O
3-year	JJ	O
clinical	JJ	O
outcome	NN	O
in	IN	O
patients	NNS	O
enrolled	VBN	O
in	IN	O
the	DT	O
Primary	NNP	O
Stenting	NNP	O
of	IN	O
Totally	NNP	O
Occluded	NNP	O
Native	NNP	O
Coronary	NNP	O
Arteries	NNP	O
II	NNP	O
study	NN	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
totally	RB	O
occluded	JJ	O
coronary	JJ	O
arteries	NNS	O
randomized	VBN	O
to	TO	O
either	DT	O
sirolimus-eluting	JJ	Surgical
Cypher	NNP	Surgical
stents	NNS	Surgical
(	(	Surgical
SESs	NNP	Surgical
)	)	Surgical
(	(	O
Cordis	NNP	O
,	,	O
a	DT	O
Johnson	NNP	O
&	CC	O
Joshson	NNP	O
Company	NNP	O
,	,	O
Miami	NNP	O
Lakes	NNP	O
,	,	O
FL	NNP	O
)	)	O
(	(	O
100	CD	O
patients	NNS	O
)	)	O
or	CC	O
bare-metal	JJ	Surgical
BxVelocity	NNP	Surgical
stents	NNS	Surgical
(	(	Surgical
BMSs	NNP	Surgical
)	)	Surgical
(	(	O
Cordis	NNP	O
)	)	O
(	(	O
100	CD	O
patients	NNS	O
)	)	O
were	VBD	O
followed	VBN	O
clinically	RB	O
for	IN	O
3	CD	O
years	NNS	O
.	.	O

RESULTS	NNP	O
Between	NNP	O
1	CD	O
and	CC	O
3	CD	O
years	NNS	O
,	,	O
there	EX	O
were	VBD	O
infrequent	JJ	O
additional	JJ	O
clinical	JJ	O
events	NNS	O
that	WDT	O
were	VBD	O
equally	RB	O
distributed	VBN	O
between	IN	O
the	DT	O
SES	NNP	O
and	CC	O
the	DT	O
BMS	NNP	O
group	NN	O
.	.	O

After	IN	O
3	CD	O
years	NNS	O
,	,	O
target	NN	O
lesion	NN	O
revascularization	NN	O
was	VBD	O
7	CD	O
%	NN	O
in	IN	O
the	DT	O
SES	NNP	O
group	NN	O
versus	VBD	O
27	CD	O
%	NN	O
in	IN	O
the	DT	O
BMS	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
;	:	O
and	CC	O
target	VB	O
vessel	JJ	O
revascularization	NN	O
was	VBD	O
seen	VBN	O
in	IN	O
11	CD	O
%	NN	O
in	IN	O
the	DT	O
SES	NNP	O
group	NN	O
versus	VBD	O
30	CD	O
%	NN	O
in	IN	O
the	DT	O
BMS	NNP	O
group	NN	O
(	(	O
P	NNP	O
=	NNP	O
.002	NNP	O
)	)	O
.	.	O

Major	JJ	O
adverse	JJ	O
cardiac	NN	O
events	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
10	CD	O
%	NN	O
of	IN	O
the	DT	O
SES	NNP	O
group	NN	O
versus	VBD	O
34	CD	O
%	NN	O
in	IN	O
the	DT	O
BMS	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.001	NNP	O
)	)	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
differences	NNS	O
in	IN	O
death	NN	O
,	,	O
myocardial	JJ	O
infarction	NN	O
,	,	O
and	CC	O
stent	JJ	O
thrombosis	NN	O
according	VBG	O
to	TO	O
the	DT	O
Academic	NNP	O
Research	NNP	O
Consortium	NNP	O
criteria	NNS	O
between	IN	O
the	DT	O
2	CD	O
groups	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Clinical	NNP	O
outcome	VBD	O
up	RB	O
to	TO	O
3	CD	O
years	NNS	O
after	IN	O
implantation	NN	O
of	IN	O
SESs	NNP	O
for	IN	O
total	JJ	O
coronary	JJ	O
occlusions	NNS	O
continues	VBZ	O
to	TO	O
demonstrate	VB	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
adverse	JJ	O
clinical	JJ	O
events	NNS	O
compared	VBN	O
with	IN	O
BMSs	NNP	O
without	IN	O
the	DT	O
evidence	NN	O
for	IN	O
either	DT	O
disproportionate	NN	O
late	JJ	O
restenosis	NN	O
or	CC	O
late	JJ	O
stent	JJ	O
thrombosis	NN	O
.	.	O

Conduit	NNP	O
artery	NN	O
structure	NN	O
and	CC	O
function	NN	O
in	IN	O
lowlanders	NNS	O
and	CC	O
native	JJ	O
highlanders	NNS	O
:	:	O
relationships	NNS	O
with	IN	O
oxidative	JJ	O
stress	NN	O
and	CC	O
role	NN	O
of	IN	O
sympathoexcitation	NN	O
.	.	O

Research	NNP	O
detailing	VBG	O
the	DT	O
normal	JJ	O
vascular	JJ	O
adaptions	NNS	O
to	TO	O
high	JJ	O
altitude	NN	O
is	VBZ	O
minimal	JJ	O
and	CC	O
often	RB	O
confounded	VBN	O
by	IN	O
pathology	NN	O
(	(	O
e.g.	JJ	O
,	,	O
chronic	JJ	O
mountain	NN	O
sickness	NN	O
)	)	O
and	CC	O
methodological	JJ	O
issues	NNS	O
.	.	O

We	PRP	O
examined	VBD	O
vascular	JJ	O
function	NN	O
and	CC	O
structure	NN	O
in	IN	O
:	:	O
(	(	O
1	CD	O
)	)	O
healthy	JJ	O
lowlanders	NNS	O
during	IN	O
acute	JJ	O
hypoxia	NN	O
and	CC	O
prolonged	JJ	O
(	(	O
?2	JJ	O
weeks	NNS	O
)	)	O
exposure	NN	O
to	TO	O
high	JJ	O
altitude	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
high-altitude	NN	O
natives	NNS	O
at	IN	O
5050	CD	O
m	NN	O
(	(	O
highlanders	NNS	O
)	)	O
.	.	O

In	IN	O
12	CD	O
healthy	JJ	O
lowlanders	NNS	O
(	(	O
aged	VBN	O
32	CD	O
?	.	O
7	CD	O
years	NNS	O
)	)	O
and	CC	O
12	CD	O
highlanders	NNS	O
(	(	O
Sherpa	NNP	O
;	:	O
33	CD	O
?	.	O
14	CD	O
years	NNS	O
)	)	O
we	PRP	O
assessed	VBD	O
brachial	JJ	O
endothelium-dependent	JJ	O
flow-mediated	JJ	O
dilatation	NN	O
(	(	O
FMD	NNP	O
)	)	O
,	,	O
endothelium-independent	JJ	O
dilatation	NN	O
(	(	O
via	IN	O
glyceryl	NN	O
trinitrate	NN	O
;	:	O
GTN	NNP	O
)	)	O
,	,	O
common	JJ	O
carotid	NN	O
intima-media	JJ	O
thickness	NN	O
(	(	O
CIMT	NNP	O
)	)	O
and	CC	O
diameter	NN	O
(	(	O
ultrasound	JJ	O
)	)	O
,	,	O
and	CC	O
arterial	JJ	O
stiffness	NN	O
via	IN	O
pulse	JJ	O
wave	VBP	O
velocity	NN	O
(	(	O
PWV	NNP	O
;	:	O
applanation	NN	O
tonometry	NN	O
)	)	O
.	.	O

Cephalic	NNP	O
venous	JJ	O
biomarkers	NNS	O
of	IN	O
free	JJ	O
radical-mediated	JJ	O
lipid	JJ	O
peroxidation	NN	O
(	(	O
lipid	JJ	O
hydroperoxides	NNS	O
,	,	O
LOOH	NNP	O
)	)	O
,	,	O
nitrite	JJ	O
(	(	O
NO2-	NNP	O
)	)	O
and	CC	O
lipid	JJ	O
soluble	JJ	O
antioxidants	NNS	O
were	VBD	O
also	RB	O
obtained	VBN	O
at	IN	O
rest	NN	O
.	.	O

In	IN	O
lowlanders	NNS	O
,	,	O
measurements	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
sea	NN	O
level	NN	O
(	(	O
334	CD	O
m	NN	O
)	)	O
and	CC	O
between	IN	O
days	NNS	O
3-4	NNP	O
(	(	O
acute	JJ	O
high	JJ	O
altitude	NN	O
)	)	O
and	CC	O
12-14	JJ	O
(	(	O
chronic	JJ	O
high	JJ	O
altitude	NN	O
)	)	O
following	VBG	O
arrival	NN	O
to	TO	O
5050	CD	O
m.	NN	O
Highlanders	NNP	O
were	VBD	O
assessed	VBN	O
once	RB	O
at	IN	O
5050	CD	O
m.	NN	O
Compared	NNP	O
with	IN	O
sea	NN	O
level	NN	O
,	,	O
acute	JJ	O
high	JJ	O
altitude	NN	O
reduced	VBD	O
lowlanders	NNS	O
'	POS	O
FMD	NNP	O
(	(	O
7.9	CD	O
?	.	O
0.4	CD	O
vs.	IN	O
6.8	CD	O
?	.	O
0.4	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.004	CD	O
)	)	O
and	CC	O
GTN-induced	JJ	O
dilatation	NN	O
(	(	O
16.6	CD	O
?	.	O
0.9	CD	O
vs.	IN	O
14.5	CD	O
?	.	O
0.8	CD	O
%	NN	O
;	:	O
P	NNP	O
=	NNP	O
0.006	CD	O
)	)	O
,	,	O
and	CC	O
raised	VBD	O
central	JJ	O
PWV	NNP	O
(	(	O
6.0	CD	O
?	.	O
0.2	CD	O
vs.	IN	O
6.6	CD	O
?	.	O
0.3	CD	O
m	NN	O
s	NN	O
(	(	O
-1	NNP	O
)	)	O
;	:	O
P	NNP	O
=	NNP	O
0.001	CD	O
)	)	O
.	.	O

These	DT	O
changes	NNS	O
persisted	VBD	O
at	IN	O
days	NNS	O
12-14	CD	O
,	,	O
and	CC	O
after	IN	O
allometrically	RB	O
scaling	VBG	O
FMD	NNP	O
to	TO	O
adjust	VB	O
for	IN	O
altered	JJ	O
baseline	NN	O
diameter	NN	O
.	.	O

Compared	VBN	O
to	TO	O
lowlanders	NNS	O
at	IN	O
sea	NN	O
level	NN	O
and	CC	O
high	JJ	O
altitude	NN	O
,	,	O
highlanders	NNS	O
had	VBD	O
a	DT	O
lower	JJR	O
carotid	NN	O
wall	NN	O
:	:	O
lumen	NNS	O
ratio	VBP	O
(	(	O
?19	CD	O
%	NN	O
,	,	O
P	NNP	O
?	.	O
0.04	CD	O
)	)	O
,	,	O
attributable	JJ	O
to	TO	O
a	DT	O
narrower	JJR	O
CIMT	NNP	O
and	CC	O
wider	JJR	O
lumen	NNS	O
.	.	O

Although	IN	O
both	DT	O
LOOH	NNP	O
and	CC	O
NO2-	NNP	O
increased	VBD	O
with	IN	O
high	JJ	O
altitude	NN	O
in	IN	O
lowlanders	NNS	O
,	,	O
only	RB	O
LOOH	NNP	O
correlated	VBD	O
with	IN	O
the	DT	O
reduction	NN	O
in	IN	O
GTN-induced	NNP	O
dilatation	NN	O
evident	NN	O
during	IN	O
acute	NN	O
(	(	O
n	JJ	O
=	NN	O
11	CD	O
,	,	O
r	NN	O
=	NNP	O
-0.53	NNP	O
)	)	O
and	CC	O
chronic	JJ	O
(	(	O
n	JJ	O
=	NN	O
7	CD	O
,	,	O
r	NN	O
=	NNP	O
-0.69	NNP	O
;	:	O
P	NNP	O
?	.	O
0.01	CD	O
)	)	O
exposure	NN	O
to	TO	O
5050	CD	O
m.	NN	O
In	IN	O
a	DT	O
follow-up	JJ	O
,	,	O
placebo-controlled	JJ	O
experiment	NN	O
(	(	O
n	JJ	O
=	$	O
11	CD	O
healthy	JJ	O
lowlanders	NNS	O
)	)	O
conducted	VBN	O
in	IN	O
a	DT	O
normobaric	JJ	O
hypoxic	NN	O
chamber	NN	O
(	(	O
inspired	JJ	O
O2	NNP	O
fraction	NN	O
(	(	O
F	NNP	O
IO	NNP	O
2	CD	O
)	)	O
=	NN	O
0.11	CD	O
;	:	O
6	CD	O
h	NN	O
)	)	O
,	,	O
a	DT	O
sustained	JJ	O
reduction	NN	O
in	IN	O
FMD	NNP	O
was	VBD	O
evident	JJ	O
within	IN	O
1	CD	O
h	NN	O
of	IN	O
hypoxic	NN	O
exposure	NN	O
when	WRB	O
compared	VBN	O
to	TO	O
normoxic	VB	O
baseline	NN	O
(	(	O
5.7	CD	O
?	.	O
1.6	CD	O
vs.	IN	O
8.0	CD	O
?1.3	CD	O
%	NN	O
;	:	O
P	NNP	O
<	NNP	O
0.01	CD	O
)	)	O
;	:	O
this	DT	O
decline	NN	O
in	IN	O
FMD	NNP	O
was	VBD	O
largely	RB	O
reversed	JJ	O
following	VBG	O
?1-adrenoreceptor	NN	O
blockade	NN	O
.	.	O

In	IN	O
conclusion	NN	O
,	,	O
high-altitude	JJ	O
exposure	NN	O
in	IN	O
lowlanders	NNS	O
caused	VBD	O
persistent	JJ	O
impairment	NN	O
in	IN	O
vascular	JJ	O
function	NN	O
,	,	O
which	WDT	O
was	VBD	O
mediated	VBN	O
partially	RB	O
via	IN	O
oxidative	JJ	O
stress	NN	O
and	CC	O
sympathoexcitation	NN	O
.	.	O

Although	IN	O
a	DT	O
lifetime	NN	O
of	IN	O
high-altitude	JJ	O
exposure	NN	O
neither	CC	O
intensifies	NNS	O
nor	CC	O
attenuates	VBZ	O
the	DT	O
impairments	NNS	O
seen	VBN	O
with	IN	O
short-term	JJ	O
exposure	NN	O
,	,	O
chronic	JJ	O
high-altitude	NN	O
exposure	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
arterial	JJ	O
remodelling	NN	O
.	.	O

Central	NNP	O
nervous	JJ	O
system	NN	O
serotonin	JJ	O
function	NN	O
and	CC	O
cardiovascular	JJ	O
responses	NNS	O
to	TO	O
stress	VB	O
.	.	O

OBJECTIVE	VB	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
evaluate	VB	O
the	DT	O
impact	NN	O
of	IN	O
indices	NNS	O
of	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
(	(	O
CNS	NNP	O
)	)	O
serotonin	NN	O
function	NN	O
on	IN	O
cardiovascular	JJ	O
reactivity	NN	O
to	TO	O
mental	JJ	O
stress	NN	O
.	.	O

METHODS	NNP	O
Lumbar	NNP	Physical
puncture	NN	Physical
was	VBD	O
performed	VBN	O
on	IN	O
54	CD	O
healthy	JJ	O
volunteers	NNS	O
to	TO	O
obtain	VB	O
cerebrospinal	JJ	O
fluid	NN	O
(	(	O
CSF	NNP	O
)	)	O
for	IN	O
determination	NN	O
of	IN	O
5-hydroxyindoleacetic	JJ	O
acid	NN	O
(	(	O
5HIAA	CD	O
)	)	O
levels	NNS	O
.	.	O

Genotypes	NNS	O
were	VBD	O
determined	VBN	O
with	IN	O
respect	NN	O
to	TO	O
a	DT	O
functional	JJ	O
polymorphism	NN	O
of	IN	O
the	DT	O
serotonin	NN	O
transporter	NN	O
gene	NN	O
promoter	NN	O
region	NN	O
(	(	O
5HTTLPR	CD	O
)	)	O
.	.	O

Subjects	NNS	O
then	RB	O
underwent	JJ	O
mental	JJ	O
stress	NN	O
testing	VBG	O
.	.	O

RESULTS	JJ	O
Persons	NNPS	O
with	IN	O
one	CD	O
or	CC	O
two	CD	O
long	JJ	O
(	(	O
l	NN	O
)	)	O
5HTTLPR	CD	O
alleles	NNS	O
had	VBD	O
CSF	NNP	O
levels	NNS	O
of	IN	O
the	DT	O
major	JJ	O
serotonin	NN	O
metabolite	NN	O
,	,	O
5HIAA	CD	O
,	,	O
that	WDT	O
were	VBD	O
50	CD	O
%	NN	O
higher	JJR	O
than	IN	O
those	DT	O
of	IN	O
persons	NNS	O
with	IN	O
the	DT	O
s/s	NN	O
5HTTLPR	CD	O
genotype	NN	O
.	.	O

Persons	NNS	O
with	IN	O
one	CD	O
or	CC	O
two	CD	O
l	JJ	O
alleles	NNS	O
or	CC	O
higher	JJR	O
CSF	NNP	O
5HIAA	CD	O
levels	NNS	O
also	RB	O
exhibited	VBD	O
greater	JJR	O
blood	NN	O
pressure	NN	O
and	CC	O
heart	NN	O
rate	NN	O
responses	NNS	O
to	TO	O
a	DT	O
mental	JJ	O
stress	NN	O
protocol	NN	O
.	.	O

CONCLUSIONS	NNP	O
These	DT	O
findings	NNS	O
suggest	VBP	O
the	DT	O
5HTTLPR	CD	O
polymorphism	NN	O
affects	NNS	O
CNS	NNP	O
serotonin	NN	O
function	NN	O
,	,	O
and	CC	O
they	PRP	O
are	VBP	O
consistent	JJ	O
with	IN	O
the	DT	O
general	JJ	O
hypothesis	NN	O
that	WDT	O
CNS	NNP	O
serotonin	NN	O
function	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
the	DT	O
regulation	NN	O
of	IN	O
potentially	RB	O
health-damaging	JJ	O
biobehavioral	JJ	O
characteristics	NNS	O
.	.	O

In	IN	O
particular	JJ	O
,	,	O
the	DT	O
l	NN	O
allele	NN	O
could	MD	O
contribute	VB	O
,	,	O
through	IN	O
its	PRP$	O
association	NN	O
with	IN	O
increased	JJ	O
cardiovascular	JJ	O
reactivity	NN	O
to	TO	O
stress	VB	O
,	,	O
to	TO	O
increased	VBN	O
risk	NN	O
of	IN	O
cardiovascular	JJ	O
disease	NN	O
.	.	O

PTK2	NNP	O
expression	NN	O
and	CC	O
immunochemotherapy	JJ	O
outcome	NN	O
in	IN	O
chronic	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
.	.	O

Addition	NN	O
of	IN	O
rituximab	NN	Pharmacological
(	(	Pharmacological
R	NNP	Pharmacological
)	)	Pharmacological
to	TO	Pharmacological
fludarabine	VB	Pharmacological
and	CC	Pharmacological
cyclophosphamide	VB	Pharmacological
(	(	O
FC	NNP	O
)	)	O
has	VBZ	O
significantly	RB	O
improved	VBN	O
patient	JJ	O
outcomes	NNS	O
in	IN	O
chronic	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
(	(	O
CLL	NNP	O
)	)	O
.	.	O

Whether	NNP	O
baseline	NN	O
gene	NN	O
expression	NN	O
can	MD	O
identify	VB	O
patients	NNS	O
who	WP	O
will	MD	O
benefit	VB	O
from	IN	O
immunochemotherapy	NN	O
over	IN	O
chemotherapy	NN	O
alone	RB	O
has	VBZ	O
not	RB	O
been	VBN	O
determined	VBN	O
.	.	O

We	PRP	O
assessed	VBD	O
genome-wide	JJ	O
expression	NN	O
of	IN	O
300	CD	O
pretreatment	NN	O
specimens	NNS	O
from	IN	O
a	DT	O
subset	NN	O
of	IN	O
552	CD	O
patients	NNS	O
in	IN	O
REACH	NNP	O
,	,	O
a	DT	O
study	NN	O
of	IN	O
FC	NNP	Pharmacological
or	CC	O
R-FC	NNP	Pharmacological
in	IN	O
relapsed	JJ	O
CLL	NNP	O
.	.	O

An	DT	O
independent	JJ	O
test	NN	O
set	NN	O
was	VBD	O
derived	VBN	O
from	IN	O
282	CD	O
pretreatment	NN	O
specimens	NNS	O
from	IN	O
CLL8	NNP	O
,	,	O
a	DT	O
study	NN	O
of	IN	O
FC	NNP	O
or	CC	O
R-FC	NNP	O
in	IN	O
treatment-na?ve	JJ	O
patients	NNS	O
.	.	O

Genes	NNP	O
specific	JJ	O
for	IN	O
benefit	NN	O
from	IN	O
R-FC	NNP	O
were	VBD	O
determined	VBN	O
by	IN	O
assessing	VBG	O
treatment-gene	JJ	O
interactions	NNS	O
in	IN	O
Cox	NNP	O
proportional	JJ	O
hazards	NNS	O
models	NNS	O
.	.	O

REACH	JJ	O
patients	NNS	O
with	IN	O
higher	JJR	O
pretreatment	NN	O
protein	NN	O
tyrosine	JJ	O
kinase	NN	O
2	CD	O
(	(	O
PTK2	NNP	O
)	)	O
messenger	NN	O
RNA	NNP	O
levels	NNS	O
derived	VBN	O
greater	JJR	O
benefit	NN	O
from	IN	O
R-FC	NNP	O
,	,	O
with	IN	O
significant	JJ	O
improvements	NNS	O
in	IN	O
progression-free	JJ	O
survival	NN	O
,	,	O
independent	JJ	O
of	IN	O
known	JJ	O
prognostic	JJ	O
factors	NNS	O
in	IN	O
a	DT	O
multivariate	NN	O
model	NN	O
.	.	O

Examination	NN	O
of	IN	O
PTK2	NNP	O
gene	NN	O
expression	NN	O
in	IN	O
CLL8	NNP	O
patients	NNS	O
yielded	VBD	O
similar	JJ	O
results	NNS	O
.	.	O

Furthermore	NNP	O
,	,	O
PTK2	NNP	O
inhibition	NN	O
blunted	VBD	O
R-dependent	NNP	O
cell	NN	O
death	NN	O
in	IN	O
vitro	NN	O
.	.	O

This	DT	O
retrospective	JJ	O
analysis	NN	O
from	IN	O
2	CD	O
independent	JJ	O
trials	NNS	O
revealed	VBD	O
that	IN	O
increased	VBD	O
PTK2	NNP	O
expression	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
improved	JJ	O
outcomes	NNS	O
for	IN	O
CLL	NNP	O
patients	NNS	O
treated	VBD	O
with	IN	O
R-FC	NNP	O
vs	NN	O
FC	NNP	O
.	.	O

PTK2	NNP	O
expression	NN	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
biomarker	NN	O
for	IN	O
patient	JJ	O
selection	NN	O
in	IN	O
future	JJ	O
trials	NNS	O
.	.	O

These	DT	O
trials	NNS	O
were	VBD	O
registered	VBN	O
at	IN	O
www.clinicaltrials.gov	NN	O
as	IN	O
#	#	O
NCT00090051	NNP	O
(	(	O
REACH	NNP	O
)	)	O
and	CC	O
#	#	O
NCT00281918	NNP	O
(	(	O
CLL8	NNP	O
)	)	O
.	.	O

Effect	NN	O
of	IN	O
aliskiren	NN	Pharmacological
on	IN	O
proteinuria	NNS	O
in	IN	O
non-diabetic	JJ	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
:	:	O
a	DT	O
double-blind	NN	O
,	,	O
crossover	NN	O
,	,	O
randomised	VBN	O
,	,	O
controlled	VBN	O
trial	NN	O
.	.	O

AIM	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
proteinuria-lowering	JJ	O
effect	NN	O
of	IN	O
a	DT	O
renin	NN	Pharmacological
inhibitor	NN	Pharmacological
(	(	O
aliskiren	NN	Pharmacological
)	)	O
,	,	O
compared	VBN	O
to	TO	O
placebo	VB	Control
and	CC	O
to	TO	O
an	DT	O
angiotensin-converting	JJ	Pharmacological
enzyme	NN	Pharmacological
inhibitor	NN	Pharmacological
(	(	O
perindopril	NN	Pharmacological
)	)	O
,	,	O
in	IN	O
patients	NNS	O
with	IN	O
non-diabetic	JJ	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
.	.	O

METHODS	NNP	O
A	DT	O
randomised	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
crossover	JJ	O
trial	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
14	CD	O
patients	NNS	O
with	IN	O
nondiabetic	JJ	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
with	IN	O
24-h	JJ	O
mean	JJ	O
proteinuria	NN	O
of	IN	O
2.01	CD	O
g	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
1.36?2.66	CD	O
)	)	O
and	CC	O
estimated	VBN	O
creatinine	JJ	O
clearance	NN	O
of	IN	O
93?6.8	CD	O
ml/min	NN	O
.	.	O

The	DT	O
study	NN	O
consisted	VBD	O
of	IN	O
five	CD	O
treatment	NN	O
periods	NNS	O
.	.	O

The	DT	O
patients	NNS	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
aliskiren	NNS	O
(	(	O
150	CD	O
mg	NN	O
)	)	O
,	,	O
aliskiren	RB	O
(	(	O
300	CD	O
mg	NN	O
)	)	O
,	,	O
perindopril	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
,	,	O
perindopril	NN	O
(	(	O
10	CD	O
mg	NN	O
)	)	O
or	CC	O
placebo	NN	O
.	.	O

RESULTS	NNP	O
Aliskiren	NNP	O
and	CC	O
perindopril	NN	O
reduced	VBN	O
proteinuria	NN	O
.	.	O

These	DT	O
effects	NNS	O
were	VBD	O
dose-dependent	JJ	O
.	.	O

Furthermore	CD	O
,	,	O
24-h	JJ	O
proteinuria	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
23	CD	O
%	NN	O
(	(	O
mean	JJ	O
95	CD	O
%	NN	O
CI	NNP	O
;	:	O
2?44	CD	O
)	)	O
by	IN	O
treatment	NN	O
with	IN	O
aliskiren	NNS	O
(	(	O
150	CD	O
mg	NN	O
)	)	O
,	,	O
by	IN	O
36	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
17?55	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
with	IN	O
aliskiren	NN	O
(	(	O
300	CD	O
mg	NN	O
)	)	O
,	,	O
by	IN	O
7.1	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
11?26	CD	O
)	)	O
with	IN	O
perindopril	NN	O
(	(	O
5	CD	O
mg	NN	O
)	)	O
and	CC	O
by	IN	O
25	CD	O
%	NN	O
(	(	O
95	CD	O
%	NN	O
CI	NNP	O
,	,	O
11?39	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
with	IN	O
perindopril	NN	O
(	(	O
10	CD	O
mg	NN	O
)	)	O
,	,	O
compared	VBN	O
to	TO	O
placebo	VB	O
.	.	O

No	DT	O
significant	JJ	O
difference	NN	O
was	VBD	O
found	VBN	O
between	IN	O
the	DT	O
effects	NNS	O
of	IN	O
aliskiren	NNS	O
and	CC	O
perindopril	NN	O
.	.	O

CONCLUSIONS	NNP	O
Aliskiren	NNP	O
significantly	RB	O
reduced	VBD	O
proteinuria	NNS	O
.	.	O

The	DT	O
antiproteinuric	JJ	O
effect	NN	O
is	VBZ	O
probably	RB	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
perindopril	NN	O
,	,	O
for	IN	O
equivalent	JJ	O
hypotensive	JJ	O
dosages	NNS	O
.	.	O

The	DT	O
renin	JJ	O
inhibitor	NN	O
provides	VBZ	O
a	DT	O
promising	JJ	O
alternative	JJ	O
approach	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
proteinuric	JJ	O
non-diabetic	JJ	O
kidney	NN	O
disease	NN	O
.	.	O

Effect	NN	O
of	IN	O
the	DT	O
motilin	NN	O
agonist	NN	O
KC	NNP	Pharmacological
11458	CD	Pharmacological
on	IN	O
gastric	JJ	O
emptying	VBG	O
in	IN	O
diabetic	JJ	O
gastroparesis	NN	O
.	.	O

BACKGROUND	NNP	O
KC	NNP	Pharmacological
11458	CD	Pharmacological
,	,	O
a	DT	O
motilin	JJ	O
agonist	NN	O
without	IN	O
antibiotic	JJ	O
properties	NNS	O
,	,	O
accelerates	VBZ	O
gastric	JJ	O
emptying	VBG	O
in	IN	O
animals	NNS	O
and	CC	O
healthy	JJ	O
humans	NNS	O
.	.	O

AIM	NNP	O
To	TO	O
evaluate	VB	O
the	DT	O
acute	JJ	O
effects	NNS	O
of	IN	O
KC	NNP	Pharmacological
11458	CD	Pharmacological
on	IN	O
gastric	JJ	O
emptying	VBG	O
in	IN	O
diabetic	JJ	O
gastroparesis	NN	O
.	.	O

METHODS	NNP	O
Twenty-nine	JJ	O
patients	NNS	O
(	(	O
6	CD	O
type	NN	O
1	CD	O
and	CC	O
23	CD	O
type	NN	O
2	CD	O
)	)	O
with	IN	O
gastroparesis	NN	O
underwent	JJ	O
assessments	NNS	O
of	IN	O
:	:	O
(	(	O
i	NN	O
)	)	O
gastric	NN	O
emptying	NN	O
of	IN	O
a	DT	O
solid/liquid	JJ	O
meal	NN	O
using	VBG	O
scintigraphy	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
glycaemic	FW	O
control	NN	O
(	(	O
blood	NN	O
glucose	NN	O
at	IN	O
0	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
and	CC	O
120	CD	O
min	NN	O
during	IN	O
the	DT	O
gastric	JJ	O
emptying	VBG	O
measurement	NN	O
)	)	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
upper	IN	O
gastrointestinal	JJ	O
and	CC	O
'meal-related	JJ	O
'	''	O
symptoms	NNS	O
(	(	O
questionnaire	NN	O
)	)	O
,	,	O
at	IN	O
baseline	NN	O
and	CC	O
after	IN	O
treatment	NN	O
with	IN	O
KC	NNP	Pharmacological
11458	CD	Pharmacological
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
8	CD	O
mg	NNS	O
t.d.s.	NN	O
,	,	O
or	CC	O
placebo	NN	Control
for	IN	O
8	CD	O
days	NNS	O
.	.	O

RESULTS	NNP	O
KC	NNP	Pharmacological
11458	CD	Pharmacological
had	VBD	O
no	DT	O
statistically	RB	O
significant	JJ	O
or	CC	O
clinically	RB	O
relevant	JJ	O
effect	NN	O
on	IN	O
gastric	JJ	O
emptying	NN	O
of	IN	O
either	CC	O
the	DT	O
solid	JJ	O
intragastric	JJ	O
retention	NN	O
at	IN	O
100	CD	O
min	NN	O
(	(	O
T100	NNP	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.87	CD	O
)	)	O
or	CC	O
liquid	$	O
50	CD	O
%	NN	O
emptying	JJ	O
time	NN	O
(	(	O
T50	NNP	O
)	)	O
(	(	O
P	NNP	O
=	NNP	O
0.17	CD	O
)	)	O
components	NNS	O
of	IN	O
the	DT	O
meal	NN	O
.	.	O

KC	NNP	Pharmacological
11458	CD	Pharmacological
slightly	RB	O
worsened	VBN	O
(	(	O
P	NNP	O
=	NNP	O
0.04	CD	O
)	)	O
upper	JJ	O
gastrointestinal	NN	O
symptoms	NNS	O
when	WRB	O
compared	VBN	O
with	IN	O
placebo	NN	Control
.	.	O

The	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
change	NN	O
in	IN	O
solid	JJ	O
gastric	JJ	O
emptying	VBG	O
correlated	VBN	O
with	IN	O
the	DT	O
change	NN	O
in	IN	O
the	DT	O
blood	NN	O
glucose	JJ	O
concentration	NN	O
(	(	O
r	JJ	O
=	VBZ	O
0.49	CD	O
;	:	O
P	NNP	O
<	NNP	O
0.05	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
KC	NNP	Pharmacological
11458	CD	Pharmacological
,	,	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
8	CD	O
mg	NN	O
t.d.s	NN	O
.	.	O

for	IN	O
8	CD	O
days	NNS	O
,	,	O
does	VBZ	O
not	RB	O
accelerate	VB	O
gastric	JJ	O
emptying	VBG	O
in	IN	O
patients	NNS	O
with	IN	O
diabetic	JJ	O
gastroparesis	NN	O
.	.	O

The	DT	O
absence	NN	O
of	IN	O
efficacy	NN	O
may	MD	O
relate	VB	O
to	TO	O
an	DT	O
effect	NN	O
of	IN	O
hyperglycaemia	NN	O
.	.	O

The	DT	O
impact	NN	O
of	IN	O
a	DT	O
psychological	JJ	Educational
intervention	NN	Educational
on	IN	O
quality	NN	O
of	IN	O
life	NN	O
in	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
.	.	O

The	DT	O
aim	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
determine	VB	O
whether	IN	O
psychological	JJ	Psychological
intervention	NN	Psychological
had	VBD	O
a	DT	O
beneficial	JJ	O
effect	NN	O
on	IN	O
the	DT	O
quality	NN	O
of	IN	O
life	NN	O
and	CC	O
behaviour	NN	O
of	IN	O
women	NNS	O
diagnosed	VBN	O
with	IN	O
breast	NN	O
cancer	NN	O
.	.	O

36	CD	O
consecutive	JJ	O
patients	NNS	O
with	IN	O
non-metastatic	JJ	O
breast	NN	O
cancer	NN	O
assigned	VBD	O
to	TO	O
surgery	VB	O
and	CC	O
systemic	VB	O
chemotherapy	NN	O
were	VBD	O
randomised	VBN	O
to	TO	O
receive	VB	O
either	DT	O
psychological	JJ	Psychological
intervention	NN	Psychological
(	(	Psychological
weekly	JJ	Psychological
cognitive	VBP	Psychological
individual	JJ	Psychological
psychotherapy	NN	Psychological
and	CC	Psychological
bimonthly	JJ	Psychological
family	NN	Psychological
counselling	VBG	Psychological
)	)	Psychological
or	CC	O
standard	JJ	Control
follow-up	NN	Control
.	.	O

Personality	NNP	O
(	(	O
16-PF	JJ	O
and	CC	O
IIQ	NNP	O
)	)	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
(	(	O
FLIC	NNP	O
)	)	O
,	,	O
and	CC	O
depression	NN	O
(	(	O
BDI	NNP	O
)	)	O
scores	NNS	O
were	VBD	O
the	DT	O
endpoints	NNS	O
for	IN	O
this	DT	O
study	NN	O
,	,	O
and	CC	O
the	DT	O
questionnaires	NNS	O
were	VBD	O
completed	VBN	O
by	IN	O
the	DT	O
patients	NNS	O
at	IN	O
diagnosis	NN	O
,	,	O
and	CC	O
up	RB	O
to	TO	O
9	CD	O
months	NNS	O
after	IN	O
diagnosis	NN	O
.	.	O

Cognitive	JJ	O
psychotherapy	NN	O
and	CC	O
family	NN	O
counselling	NN	O
improved	VBD	O
both	DT	O
depression	NN	O
and	CC	O
quality	NN	O
of	IN	O
life	NN	O
indexes	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
control	NN	O
group	NN	O
.	.	O

Better	NNP	O
emotional	JJ	O
coping	NN	O
behaviours	NNS	O
were	VBD	O
also	RB	O
revealed	VBN	O
by	IN	O
some	DT	O
changes	NNS	O
in	IN	O
personality	NN	O
traits	NNS	O
in	IN	O
the	DT	O
intervention	NN	O
group	NN	O
.	.	O

A	DT	O
prospective	JJ	O
multicenter	NN	O
randomized	VBD	O
comparative	JJ	O
study	NN	O
between	IN	O
the	DT	O
U-	NNP	Surgical
and	CC	Surgical
H-type	NNP	Surgical
methods	NNS	Surgical
of	IN	Surgical
the	DT	Surgical
TVT	NNP	Surgical
SECUR	NNP	Surgical
procedure	NN	Surgical
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
female	JJ	O
stress	NN	O
urinary	JJ	O
incontinence	NN	O
:	:	O
1-year	JJ	O
follow-up	NN	O
.	.	O

BACKGROUND	NNP	O
No	NNP	O
studies	NNS	O
have	VBP	O
been	VBN	O
published	VBN	O
comparing	VBG	O
the	DT	O
U-	JJ	Surgical
and	CC	Surgical
H-type	JJ	Surgical
methods	NNS	Surgical
of	IN	Surgical
the	DT	Surgical
TVT	NNP	Surgical
SECUR	NNP	Surgical
(	(	Surgical
TVT-S	NNP	Surgical
)	)	Surgical
procedure	NN	Surgical
.	.	Surgical

OBJECTIVE	CC	O
Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
two	CD	O
types	NNS	O
of	IN	O
TVT-S	NNP	O
for	IN	O
female	JJ	O
stress	NN	O
urinary	JJ	O
incontinence	NN	O
(	(	O
SUI	NNP	O
)	)	O
.	.	O

DESIGN	NNP	O
,	,	O
SETTING	NNP	O
,	,	O
AND	NNP	O
PARTICIPANTS	NNP	O
Women	NNP	O
with	IN	O
urodynamic	JJ	O
SUI	NNP	O
were	VBD	O
enrolled	VBN	O
in	IN	O
this	DT	O
12-mo	JJ	O
multicenter	NN	O
randomized	VBN	O
study	NN	O
.	.	O

INTERVENTION	NNP	O
Subjects	NNPS	O
were	VBD	O
randomly	RB	O
allocated	VBN	O
to	TO	O
either	VB	O
the	DT	O
U-	JJ	Surgical
or	CC	Surgical
H-type	JJ	Surgical
method	NN	Surgical
of	IN	Surgical
TVT-S.	JJ	Surgical
MEASUREMENTS	NNP	O
Pre-	NNP	O
and	CC	O
postoperative	JJ	O
evaluations	NNS	O
included	VBD	O
a	DT	O
standing	VBG	O
stress	NN	O
test	NN	O
,	,	O
the	DT	O
Sandvik	NNP	O
questionnaire	NN	O
,	,	O
the	DT	O
Incontinence	NNP	O
Quality	NNP	O
of	IN	O
Life	NNP	O
(	(	O
I-QOL	NNP	O
)	)	O
questionnaire	NN	O
,	,	O
and	CC	O
the	DT	O
International	NNP	O
Consultation	NNP	O
on	IN	O
Incontinence	NNP	O
Questionnaire-Female	NNP	O
Lower	NNP	O
Urinary	NNP	O
Tract	NNP	O
Symptoms	NNP	O
(	(	O
ICIQ-FLUTS	NNP	O
)	)	O
.	.	O

Patients	NNS	O
'	POS	O
satisfaction	NN	O
and	CC	O
complications	NNS	O
were	VBD	O
evaluated	VBN	O
.	.	O

Objective	NNP	O
and	CC	O
subjective	JJ	O
cures	NNS	O
were	VBD	O
defined	VBN	O
as	IN	O
no	DT	O
leakage	NN	O
on	IN	O
the	DT	O
stress	JJ	O
test	NN	O
and	CC	O
responses	NNS	O
on	IN	O
the	DT	O
Sandvik	NNP	O
questionnaire	NN	O
,	,	O
respectively	RB	O
.	.	O

We	PRP	O
compared	VBN	O
the	DT	O
surgical	JJ	O
outcomes	NNS	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
.	.	O

RESULTS	NNP	O
AND	NNP	O
LIMITATIONS	NNP	O
Of	IN	O
285	CD	O
women	NNS	O
,	,	O
144	CD	O
had	VBD	O
the	DT	O
U-type	JJ	O
method	NN	O
and	CC	O
141	CD	O
had	VBD	O
the	DT	O
H-type	JJ	O
method	NN	O
.	.	O

Objective	JJ	O
cure	NN	O
rates	NNS	O
were	VBD	O
87.5	CD	O
%	NN	O
for	IN	O
the	DT	O
U-type	JJ	O
method	NN	O
and	CC	O
80.1	CD	O
%	NN	O
for	IN	O
the	DT	O
H-type	NNP	O
method	NN	O
(	(	O
p=0.091	NN	O
)	)	O
.	.	O

Subjective	JJ	O
cure	NN	O
rates	NNS	O
were	VBD	O
77.1	CD	O
%	NN	O
for	IN	O
the	DT	O
U-type	JJ	O
method	NN	O
and	CC	O
75.7	CD	O
%	NN	O
for	IN	O
the	DT	O
H-type	NNP	O
method	NN	O
(	(	O
p=0.786	NN	O
)	)	O
.	.	O

Improvement	NN	O
in	IN	O
I-QOL	NNP	O
and	CC	O
domain	NN	O
scores	NNS	O
of	IN	O
the	DT	O
ICIQ-FLUTS	NNP	O
(	(	O
filling	VBG	O
and	CC	O
incontinence	NN	O
sum	NN	O
,	,	O
QOL	NNP	O
score	NN	O
)	)	O
,	,	O
and	CC	O
patients	NNS	O
'	POS	O
satisfaction	NN	O
favored	VBD	O
the	DT	O
U-type	JJ	O
method	NN	O
.	.	O

There	EX	O
were	VBD	O
three	CD	O
cases	NNS	O
of	IN	O
intraoperative	JJ	O
vaginal	JJ	O
wall	NN	O
perforation	NN	O
,	,	O
one	CD	O
case	NN	O
of	IN	O
increased	VBN	O
bleeding	NN	O
,	,	O
and	CC	O
three	CD	O
cases	NNS	O
of	IN	O
temporary	JJ	O
postoperative	JJ	O
retention	NN	O
.	.	O

A	DT	O
power	NN	O
calculation	NN	O
was	VBD	O
not	RB	O
performed	VBN	O
,	,	O
and	CC	O
some	DT	O
baseline	NN	O
characteristics	NNS	O
were	VBD	O
not	RB	O
balanced	VBN	O
between	IN	O
the	DT	O
two	CD	O
methods	NNS	O
.	.	O

CONCLUSIONS	NNP	O
Both	NNP	O
methods	NNS	Surgical
of	IN	Surgical
TVT-S	NNP	Surgical
provided	VBD	O
comparable	JJ	O
cure	NN	O
rates	NNS	O
for	IN	O
female	JJ	O
SUI	NNP	O
.	.	O

However	RB	O
,	,	O
QOL	NNP	O
and	CC	O
treatment	NN	O
satisfaction	NN	O
favored	VBD	O
the	DT	O
U-type	JJ	Surgical
method	NN	Surgical
.	.	O

TRIAL	NNP	O
REGISTRATION	NNP	O
The	DT	O
protocol	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
not	RB	O
registered	VBN	O
.	.	O

Study	NNP	O
design	NN	O
and	CC	O
rationale	NN	O
of	IN	O
a	DT	O
dose-ranging	JJ	O
trial	NN	O
of	IN	O
LX4211	NNP	Pharmacological
,	,	O
a	DT	O
dual	JJ	O
inhibitor	NN	O
of	IN	O
SGLT1	NNP	O
and	CC	O
SGLT2	NNP	O
,	,	O
in	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
inadequately	RB	O
controlled	VBN	O
on	IN	O
metformin	NN	O
monotherapy	NN	O
.	.	O

Sodium-glucose	JJ	O
cotransporters	NNS	O
1	CD	O
(	(	O
SGLT1	NNP	O
)	)	O
and	CC	O
2	CD	O
(	(	O
SGLT2	NNP	O
)	)	O
are	VBP	O
the	DT	O
major	JJ	O
cellular	JJ	O
transporters	NNS	O
responsible	JJ	O
for	IN	O
gastrointestinal	JJ	O
(	(	O
GI	NNP	O
)	)	O
glucose	VBP	O
absorption	NN	O
and	CC	O
renal	JJ	O
glucose	NN	O
reabsorption	NN	O
,	,	O
respectively	RB	O
.	.	O

LX4211	NNP	Pharmacological
,	,	O
a	DT	O
dual	JJ	O
inhibitor	NN	O
of	IN	O
SGLT1	NNP	O
and	CC	O
SGLT2	NNP	O
,	,	O
reduces	VBZ	O
glucose	JJ	O
absorption	NN	O
from	IN	O
the	DT	O
GI	NNP	O
tract	NN	O
and	CC	O
enhances	NNS	O
urinary	JJ	O
glucose	JJ	O
excretion	NN	O
.	.	O

Although	IN	O
several	JJ	O
SGLT2-selective	JJ	O
inhibitors	NNS	O
have	VBP	O
been	VBN	O
tested	VBN	O
in	IN	O
large	JJ	O
phase	NN	O
2	CD	O
studies	NNS	O
,	,	O
dual	JJ	O
inhibition	NN	O
of	IN	O
SGLT1	NNP	O
and	CC	O
SGLT2	NNP	O
is	VBZ	O
novel	JJ	O
at	IN	O
this	DT	O
stage	NN	O
of	IN	O
drug	NN	O
development	NN	O
,	,	O
and	CC	O
it	PRP	O
has	VBZ	O
implications	NNS	O
for	IN	O
clinical-trial	JJ	O
design	NN	O
.	.	O

In	IN	O
this	DT	O
article	NN	O
,	,	O
we	PRP	O
describe	VBP	O
the	DT	O
design	NN	O
and	CC	O
rationale	NN	O
of	IN	O
a	DT	O
phase	NN	O
2	CD	O
,	,	O
multicenter	NN	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
parallel	JJ	O
group	NN	O
study	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
LX4211	NNP	Pharmacological
in	IN	O
subjects	NNS	O
with	IN	O
type	JJ	O
2	CD	O
diabetes	NNS	O
mellitus	NN	O
who	WP	O
have	VBP	O
inadequate	JJ	O
glycemic	NNS	O
control	NN	O
on	IN	O
metformin	NN	O
monotherapy	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
is	VBZ	O
the	DT	O
change	NN	O
in	IN	O
glycated	JJ	O
hemoglobin	NN	O
A1c	NNP	O
from	IN	O
baseline	NN	O
to	TO	O
week	NN	O
12	CD	O
.	.	O

Secondary	JJ	O
endpoints	NNS	O
include	VBP	O
the	DT	O
proportion	NN	O
of	IN	O
subjects	NNS	O
achieving	VBG	O
a	DT	O
glycated	JJ	O
hemoglobin	NN	O
A1c	NNP	O
value	NN	O
of	IN	O
<	$	O
7	CD	O
%	NN	O
,	,	O
change	NN	O
from	IN	O
baseline	NN	O
in	IN	O
fasting	VBG	O
plasma	NN	O
glucose	NN	O
and	CC	O
postprandial	JJ	O
glucose	NN	O
(	(	O
as	IN	O
part	NN	O
of	IN	O
an	DT	O
oral	JJ	O
glucose	NN	O
tolerance	NN	O
test	NN	O
)	)	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
blood	NN	O
pressure	NN	O
.	.	O

Safety	NN	O
is	VBZ	O
evaluated	VBN	O
with	IN	O
particular	JJ	O
focus	NN	O
on	IN	O
hypoglycemia	NN	O
,	,	O
GI	NNP	O
symptoms	NNS	O
,	,	O
and	CC	O
incidence	NN	O
of	IN	O
genitourinary	JJ	O
tract	NN	O
infections	NNS	O
.	.	O

Effect	NN	O
of	IN	O
sport-tinted	JJ	Physical
contact	NN	Physical
lenses	NNS	Physical
for	IN	O
contrast	NN	O
enhancement	NN	O
on	IN	O
retinal	JJ	O
straylight	NN	O
measurements	NNS	O
.	.	O

PURPOSE	NNP	O
To	TO	O
investigate	VB	O
the	DT	O
effect	NN	O
of	IN	O
two	CD	O
tinted	JJ	Physical
contact	NN	Physical
lenses	NNS	Physical
(	(	Physical
CL	NNP	Physical
)	)	Physical
designed	VBN	O
for	IN	O
outdoor	JJ	O
sports	NNS	O
activity	NN	O
on	IN	O
the	DT	O
psychometric	JJ	O
determination	NN	O
of	IN	O
retinal	JJ	O
straylight	NN	O
using	VBG	O
the	DT	O
compensation	NN	O
comparison	NN	O
method	NN	O
.	.	O

METHODS	NNP	O
Thirteen	NNP	O
emmetropic	JJ	O
subjects	NNS	O
were	VBD	O
randomly	RB	O
fitted	VBN	O
with	IN	O
two	CD	Physical
different	JJ	Physical
tinted	VBN	Physical
Nike	NNP	Physical
Maxsight	NNP	Physical
(	(	Physical
Bausch	NNP	Physical
&	CC	Physical
Lomb	NNP	Physical
,	,	Physical
Rochester	NNP	Physical
,	,	Physical
NY	NNP	Physical
,	,	Physical
USA	NNP	Physical
)	)	Physical
CL	NNP	Physical
in	IN	Physical
one	CD	Physical
eye	NN	Physical
,	,	O
while	IN	O
the	DT	O
contralateral	JJ	Control
eye	NN	Control
was	VBD	Control
fitted	VBN	Control
with	IN	Control
a	DT	Control
clear	JJ	Control
lens	NNS	Control
made	VBN	Control
of	IN	Control
the	DT	Control
same	JJ	Control
material	NN	Control
(	(	O
Optima	NNP	O
38	CD	O
,	,	O
Bausch	NNP	O
&	CC	O
Lomb	NNP	O
)	)	O
.	.	O

Three	CD	O
valid	JJ	O
straylight	NN	O
measurements	NNS	O
were	VBD	O
taken	VBN	O
on	IN	O
each	DT	O
eye	NN	O
before	IN	O
and	CC	O
a	DT	O
few	JJ	O
minutes	NNS	O
after	IN	O
lens	JJ	O
insertion	NN	O
,	,	O
when	WRB	O
lens	VBZ	O
stabilization	NN	O
had	VBD	O
occurred	VBN	O
.	.	O

RESULTS	VB	O
The	DT	O
subjects	NNS	O
'	POS	O
mean	NN	O
straylight	NN	O
values	NNS	O
were	VBD	O
0.90	CD	O
+/-	JJ	O
0.09	CD	O
at	IN	O
baseline	NN	O
and	CC	O
0.95	CD	O
+/-	JJ	O
0.10	CD	O
with	IN	O
the	DT	O
clear	JJ	O
Optima	NNP	O
38	CD	O
CL	NNP	O
.	.	O

Straylight	NNP	O
values	NNS	O
were	VBD	O
0.97	CD	O
+/-	JJ	O
0.10	CD	O
and	CC	O
1.0	CD	O
+/-	JJ	O
0.10	CD	O
log	JJ	O
units	NNS	O
with	IN	O
the	DT	O
amber	NN	O
and	CC	O
grey-green	JJ	O
tinted	JJ	O
CL	NNP	O
,	,	O
respectively	RB	O
.	.	O

Differences	NNS	O
in	IN	O
straylight	NN	O
between	IN	O
baseline	NN	O
(	(	O
without	IN	O
CL	NNP	O
)	)	O
and	CC	O
with	IN	O
the	DT	O
clear	JJ	O
CL	NNP	O
in	IN	O
place	NN	O
were	VBD	O
neither	RB	O
statistically	RB	O
significant	JJ	O
(	(	O
p	JJ	O
=	NNP	O
0.066	CD	O
)	)	O
nor	CC	O
was	VBD	O
there	EX	O
a	DT	O
significant	JJ	O
difference	NN	O
between	IN	O
baseline	NN	O
and	CC	O
the	DT	O
amber	NN	O
CL	NNP	O
(	(	O
p	JJ	O
=	NNP	O
0.052	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
showed	VBD	O
a	DT	O
statistically	RB	O
significant	JJ	O
difference	NN	O
from	IN	O
baseline	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.006	CD	O
)	)	O
.	.	O

Differences	NNS	O
in	IN	O
straylight	NN	O
with	IN	O
the	DT	O
clear	JJ	O
CL	NNP	O
compared	VBN	O
with	IN	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
were	VBD	O
also	RB	O
statistically	RB	O
different	JJ	O
from	IN	O
zero	NN	O
(	(	O
p	JJ	O
=	NNP	O
0.002	CD	O
)	)	O
showing	VBG	O
an	DT	O
increased	VBN	O
straylight	NN	O
value	NN	O
for	IN	O
the	DT	O
tinted	JJ	O
CL	NNP	O
.	.	O

These	DT	O
differences	NNS	O
were	VBD	O
variable	JJ	O
,	,	O
but	CC	O
consistent	JJ	O
for	IN	O
each	DT	O
subject	NN	O
,	,	O
thus	RB	O
those	DT	O
showing	VBG	O
higher	JJR	O
or	CC	O
lower	JJR	O
changes	NNS	O
with	IN	O
one	CD	O
tinted	JJ	O
lens	VBZ	O
tended	VBN	O
to	TO	O
show	VB	O
the	DT	O
same	JJ	O
trend	NN	O
with	IN	O
the	DT	O
second	JJ	O
lens	NNS	O
(	(	O
r	NN	O
(	(	O
2	CD	O
)	)	O
=	FW	O
0.736	CD	O
)	)	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
increases	NNS	O
having	VBG	O
been	VBN	O
found	VBN	O
in	IN	O
straylight	JJ	O
values	NNS	O
with	IN	O
tinted	VBN	O
contact	NN	O
lenses	NNS	O
,	,	O
those	DT	O
changes	NNS	O
are	VBP	O
not	RB	O
likely	JJ	O
to	TO	O
induce	VB	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
visual	JJ	O
function	NN	O
under	IN	O
photopic	NN	O
conditions	NNS	O
,	,	O
even	RB	O
for	IN	O
the	DT	O
grey-green	JJ	O
CL	NNP	O
,	,	O
which	WDT	O
seems	VBZ	O
to	TO	O
increase	VB	O
straylight	JJ	O
values	NNS	O
more	RBR	O
significantly	RB	O
than	IN	O
the	DT	O
amber	JJ	O
CL	NNP	O
.	.	O

This	DT	O
difference	NN	O
between	IN	O
the	DT	O
tinted	JJ	O
CL	NNP	O
could	MD	O
suggest	VB	O
a	DT	O
wavelength	JJ	O
dependence	NN	O
of	IN	O
straylight	NN	O
values	NNS	O
,	,	O
although	IN	O
this	DT	O
should	MD	O
be	VB	O
investigated	VBN	O
further	JJ	O
by	IN	O
controlling	VBG	O
for	IN	O
pupil	NN	O
size	NN	O
and	CC	O
subjects	NNS	O
'	POS	O
pigmentation	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
using	VBG	O
neutral	JJ	O
density	NN	O
filters	NNS	O
.	.	O

[	JJ	O
Potentiation	NNP	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
non-depolarizing	JJ	O
muscle	NN	O
relaxants	NNS	O
by	IN	O
acylaminopenicillins	NNS	Pharmacological
.	.	O

Studies	NNS	O
on	IN	O
the	DT	O
example	NN	O
of	IN	O
vecuronium	NN	O
]	NN	O
.	.	O

In	IN	O
a	DT	O
prospective	JJ	O
controlled	VBN	O
clinical	JJ	O
study	NN	O
interactions	NNS	O
between	IN	O
nondepolarizing	VBG	Pharmacological
muscle	NN	Pharmacological
relaxants	NNS	Pharmacological
and	CC	O
acylaminopenicillins	NNS	Pharmacological
were	VBD	O
investigated	VBN	O
electromyographically	RB	O
.	.	O

Six	CD	O
patients	NNS	O
in	IN	O
each	DT	O
group	NN	O
received	VBD	O
either	RB	O
apalcillin	JJ	Pharmacological
,	,	Pharmacological
azlocillin	NN	Pharmacological
,	,	Pharmacological
mezlocillin	NN	Pharmacological
or	CC	Pharmacological
piperacillin	NN	Pharmacological
during	IN	O
the	DT	O
operation	NN	O
.	.	O

Muscle	NNP	O
relaxation	NN	O
was	VBD	O
maintained	VBN	O
using	VBG	O
the	DT	O
short	JJ	O
acting	VBG	O
nondepolarizing	VBG	O
relaxant	JJ	O
vecuronium	NN	O
,	,	O
which	WDT	O
shows	VBZ	O
no	DT	O
cumulative	JJ	O
effect	NN	O
within	IN	O
clinical	JJ	O
dosages	NNS	O
.	.	O

The	DT	O
intra-individual	JJ	O
comparison	NN	O
with	IN	O
the	DT	O
control	NN	O
period	NN	O
(	(	O
100	CD	O
%	NN	O
)	)	O
showed	VBD	O
a	DT	O
significant	JJ	O
prolongation	NN	O
of	IN	O
the	DT	O
duration	NN	O
of	IN	O
action	NN	O
after	IN	O
a	DT	O
fixed	JJ	O
dose	NN	O
of	IN	O
vecuronium	NN	O
.	.	O

The	DT	O
mean	JJ	O
increase	NN	O
was	VBD	O
+26	JJ	O
%	NN	O
following	VBG	O
apalcillin	NN	O
,	,	O
+46	CD	O
%	NN	O
after	IN	O
piperacillin	NN	O
,	,	O
+38	CD	O
%	NN	O
following	VBG	O
mezlocillin	NN	O
and	CC	O
+55	CD	O
%	NN	O
following	VBG	O
azlocillin	NN	O
.	.	O

The	DT	O
shortest	JJ	O
time	NN	O
of	IN	O
the	DT	O
control	NN	O
periods	NNS	O
was	VBD	O
8.6	CD	O
min	NN	O
and	CC	O
the	DT	O
maximum	JJ	O
time	NN	O
was	VBD	O
32.6	CD	O
min	NN	O
.	.	O

We	PRP	O
also	RB	O
found	VBD	O
a	DT	O
significant	JJ	O
depression	NN	O
of	IN	O
the	DT	O
EMG-response	NNP	O
.	.	O

No	NNP	O
significant	JJ	O
differences	NNS	O
could	MD	O
be	VB	O
detected	VBN	O
between	IN	O
the	DT	O
four	CD	O
antibiotics	NNS	O
.	.	O

The	DT	O
method	NN	O
described	VBN	O
here	RB	O
has	VBZ	O
proven	VBN	O
to	TO	O
be	VB	O
sensitive	JJ	O
enough	RB	O
to	TO	O
detect	VB	O
clinically	RB	O
relevant	JJ	O
interactions	NNS	O
with	IN	O
muscle	NN	O
relaxants	NNS	O
.	.	O

As	IN	O
a	DT	O
result	NN	O
of	IN	O
our	PRP$	O
study	NN	O
,	,	O
caution	NN	O
seems	VBZ	O
to	TO	O
be	VB	O
necessary	JJ	O
if	IN	O
acylaminopenicillins	NNS	Pharmacological
are	VBP	O
administered	VBN	O
in	IN	O
the	DT	O
early	JJ	O
postoperative	JJ	O
period	NN	O
.	.	O

Combining	VBG	O
afferent	JJ	Physical
stimulation	NN	Physical
and	CC	O
mirror	NN	Physical
therapy	NN	Physical
for	IN	O
rehabilitating	VBG	O
motor	NN	O
function	NN	O
,	,	O
motor	NN	O
control	NN	O
,	,	O
ambulation	NN	O
,	,	O
and	CC	O
daily	JJ	O
functions	NNS	O
after	IN	O
stroke	NN	O
.	.	O

BACKGROUND	NNP	O
Mirror	NNP	Physical
therapy	NN	Physical
(	(	Physical
MT	NNP	Physical
)	)	Physical
and	CC	O
mesh	JJ	Physical
glove	NN	Physical
(	(	Physical
MG	NNP	Physical
)	)	Physical
afferent	NN	Physical
stimulation	NN	Physical
may	MD	O
be	VB	O
effective	JJ	O
in	IN	O
reducing	VBG	O
motor	NN	O
impairment	NN	O
after	IN	O
stroke	NN	O
.	.	O

A	DT	O
hybrid	JJ	O
intervention	NN	O
of	IN	O
MT	NNP	Physical
combined	VBD	Physical
with	IN	Physical
MG	NNP	Physical
(	(	Physical
MT	NNP	Physical
+	NNP	Physical
MG	NNP	Physical
)	)	Physical
may	MD	O
broaden	VB	O
aspects	NNS	O
of	IN	O
treatment	NN	O
benefits	NNS	O
.	.	O

OBJECTIVE	NNP	O
To	TO	O
demonstrate	VB	O
the	DT	O
comparative	JJ	O
effects	NNS	O
of	IN	O
MG	NNP	Physical
+	NNP	Physical
MT	NNP	Physical
,	,	Physical
MT	NNP	Physical
,	,	O
and	CC	O
a	DT	O
control	NN	Control
treatment	NN	Control
(	(	Control
CT	NNP	Control
)	)	Control
on	IN	O
the	DT	O
outcomes	NNS	O
of	IN	O
motor	NN	O
impairments	NNS	O
,	,	O
manual	JJ	O
dexterity	NN	O
,	,	O
ambulation	NN	O
function	NN	O
,	,	O
motor	NN	O
control	NN	O
,	,	O
and	CC	O
daily	JJ	O
function	NN	O
.	.	O

METHODS	NNP	O
Forty-three	JJ	O
chronic	JJ	O
stroke	NN	O
patients	NNS	O
with	IN	O
mild	JJ	O
to	TO	O
moderate	VB	O
upper	JJ	O
extremity	NN	O
impairment	NN	O
were	VBD	O
randomly	RB	O
assigned	VBN	O
to	TO	O
receive	VB	O
MT	NNP	Physical
+	NNP	Physical
MG	NNP	Physical
,	,	O
MT	NNP	Physical
,	,	O
or	CC	O
CT	NNP	Control
for	IN	O
1.5	CD	O
hours/day	NN	O
,	,	O
5	CD	O
days/week	NN	O
for	IN	O
4	CD	O
weeks	NNS	O
.	.	O

Outcome	NNP	O
measures	NNS	O
were	VBD	O
the	DT	O
Fugl-Meyer	NNP	O
Assessment	NNP	O
(	(	O
FMA	NNP	O
)	)	O
and	CC	O
muscle	NN	O
tone	NN	O
measured	VBN	O
by	IN	O
Myoton-3	NNP	O
for	IN	O
motor	NN	O
impairment	NN	O
and	CC	O
the	DT	O
Box	NNP	O
and	CC	O
Block	NNP	O
Test	NNP	O
(	(	O
BBT	NNP	O
)	)	O
and	CC	O
10-Meter	JJ	O
Walk	NNP	O
Test	NNP	O
(	(	O
10	CD	O
MWT	NNP	O
)	)	O
for	IN	O
motor	NN	O
function	NN	O
.	.	O

Secondary	JJ	O
outcomes	NNS	O
included	VBD	O
kinematic	JJ	O
parameters	NNS	O
for	IN	O
motor	NN	O
control	NN	O
and	CC	O
the	DT	O
Motor	NNP	O
Activity	NNP	O
Log	NNP	O
and	CC	O
ABILHAND	NNP	O
Questionnaire	NNP	O
for	IN	O
daily	JJ	O
function	NN	O
.	.	O

RESULTS	NNP	O
FMA	NNP	O
total	JJ	O
scores	NNS	O
were	VBD	O
significantly	RB	O
higher	JJR	O
and	CC	O
synergistic	JJ	O
shoulder	NN	O
abduction	NN	O
during	IN	O
reach	NN	O
was	VBD	O
less	RBR	O
in	IN	O
the	DT	O
MT	NNP	Physical
+	NNP	Physical
MG	NNP	Physical
and	CC	O
MT	NNP	Physical
groups	NNS	O
compared	VBN	O
with	IN	O
the	DT	O
CT	NNP	Control
group	NN	O
.	.	O

Performance	NN	O
on	IN	O
the	DT	O
BBT	NNP	O
and	CC	O
the	DT	O
10	CD	O
MWT	NNP	O
(	(	O
velocity	NN	O
and	CC	O
stride	JJ	O
length	NN	O
in	IN	O
self-paced	JJ	O
task	NN	O
and	CC	O
velocity	NN	O
in	IN	O
as-quickly-as-possible	JJ	O
task	NN	O
)	)	O
were	VBD	O
improved	VBN	O
after	IN	O
MT	NNP	Physical
+	NNP	Physical
MG	NNP	Physical
compared	VBN	O
with	IN	O
MT	NNP	Physical
.	.	O

CONCLUSIONS	NNP	O
MT	NNP	Physical
+	NNP	Physical
MG	NNP	Physical
improved	VBD	O
manual	JJ	O
dexterity	NN	O
and	CC	O
ambulation	NN	O
.	.	O

MT	NNP	Physical
+	NNP	Physical
MG	NNP	Physical
and	CC	O
MT	NNP	Physical
reduced	VBD	O
motor	NN	O
impairment	NN	O
and	CC	O
synergistic	JJ	O
shoulder	NN	O
abduction	NN	O
more	JJR	O
than	IN	O
CT.	NNP	Control
Future	NNP	O
studies	NNS	O
may	MD	O
integrate	VB	O
functional	JJ	O
task	NN	O
practice	NN	O
into	IN	O
treatments	NNS	O
to	TO	O
enhance	VB	O
functional	JJ	O
outcomes	NNS	O
in	IN	O
patients	NNS	O
with	IN	O
various	JJ	O
levels	NNS	O
of	IN	O
motor	NN	O
severity	NN	O
.	.	O

The	DT	O
long-term	JJ	O
effects	NNS	O
of	IN	O
MG	NNP	Physical
+	NNP	Physical
MT	NNP	Physical
remain	VBP	O
to	TO	O
be	VB	O
evaluated	VBN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
haloperidol	NN	Pharmacological
on	IN	O
discrimination	NN	O
learning	NN	O
and	CC	O
behavioral	JJ	O
symptoms	NNS	O
in	IN	O
autistic	JJ	O
children	NNS	O
.	.	O

This	DT	O
double-blind	JJ	O
and	CC	O
placebo-controlled	JJ	Control
clinical	JJ	O
trial	NN	O
in	IN	O
autistic	JJ	O
children	NNS	O
had	VBD	O
three	CD	O
objectives	NNS	O
:	:	O
(	(	O
a	DT	O
)	)	O
to	TO	O
replicate	VB	O
earlier	JJR	O
findings	NNS	O
that	IN	O
haloperidol	JJ	Pharmacological
administration	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
significant	JJ	O
reduction	NN	O
of	IN	O
behavioral	JJ	O
symptoms	NNS	O
;	:	O
(	(	O
b	NN	O
)	)	O
to	TO	O
further	JJ	O
assess	NN	O
its	PRP$	O
safety	NN	O
when	WRB	O
given	VBN	O
on	IN	O
a	DT	O
short-term	JJ	O
basis	NN	O
;	:	O
and	CC	O
(	(	O
c	NN	O
)	)	O
to	TO	O
assess	VB	O
whether	IN	O
it	PRP	O
has	VBZ	O
an	DT	O
effect	NN	O
on	IN	O
discrimination	NN	O
learning	NN	O
.	.	O

Forty-five	JJ	O
children	NNS	O
,	,	O
2.02	CD	O
to	TO	O
7.58	CD	O
years	NNS	O
old	JJ	O
(	(	O
M	NNP	O
=	NNP	O
4.49	CD	O
)	)	O
,	,	O
completed	VBD	O
this	DT	O
crossover	NN	O
design	NN	O
,	,	O
with	IN	O
random	JJ	O
assignment	NN	O
to	TO	O
treatment	NN	O
sequences	NNS	O
.	.	O

Haloperidol	NNP	Pharmacological
was	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
a	DT	O
powerful	JJ	O
therapeutic	JJ	O
agent	NN	O
when	WRB	O
administered	VBN	O
for	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
free	JJ	O
of	IN	O
side	JJ	O
effects	NNS	O
;	:	O
at	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
0.25	CD	O
to	TO	O
4.0	CD	O
mg/day	NN	O
(	(	O
M	NNP	O
=	NNP	O
0.844	CD	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
clinically	RB	O
and	CC	O
statistically	RB	O
significant	JJ	O
reduction	NN	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

Under	IN	O
the	DT	O
given	VBN	O
conditions	NNS	O
,	,	O
the	DT	O
children	NNS	O
failed	VBD	O
to	TO	O
learn	VB	O
on	IN	O
either	DT	O
haloperidol	NN	Pharmacological
or	CC	O
placebo	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
a	DT	O
herbal-based	JJ	Pharmacological
toothpaste	NN	Pharmacological
on	IN	O
the	DT	O
control	NN	O
of	IN	O
plaque	NN	O
and	CC	O
gingivitis	NN	O
.	.	O

A	DT	O
double-blind	NN	O
controlled	VBD	O
clinical	JJ	O
trial	NN	O
with	IN	O
parallel	JJ	O
groups	NNS	O
was	VBD	O
designed	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
a	DT	O
herbal-based	JJ	Pharmacological
toothpaste	NN	Pharmacological
in	IN	O
the	DT	O
control	NN	O
of	IN	O
plaque	NN	O
and	CC	O
gingivitis	NN	O
as	IN	O
compared	VBN	O
with	IN	O
a	DT	O
conventional	JJ	O
dentifrice	NN	O
.	.	O

70	CD	O
subjects	NNS	O
with	IN	O
gingivitis	NN	O
completed	VBN	O
the	DT	O
6-week	JJ	O
study	NN	O
.	.	O

All	DT	O
participants	NNS	O
had	VBD	O
at	IN	O
least	JJS	O
20	CD	O
natural	JJ	O
teeth	NNS	O
with	IN	O
no	DT	O
probing	VBG	O
depths	NNS	O
greater	JJR	O
than	IN	O
3	CD	O
mm	NNS	O
and	CC	O
a	DT	O
plaque	JJ	O
index	NN	O
of	IN	O
2	CD	O
or	CC	O
more	JJR	O
at	IN	O
baseline	NN	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
both	DT	O
groups	NNS	O
were	VBD	O
balanced	VBN	O
for	IN	O
the	DT	O
parameters	NNS	O
measured	VBD	O
:	:	O
plaque	NN	O
index	NN	O
,	,	O
plaque	NN	O
vitality	NN	O
,	,	O
gingival	JJ	O
index	NN	O
,	,	O
bleeding	VBG	O
on	IN	O
probing	VBG	O
and	CC	O
gingival	JJ	O
crevicular	JJ	O
fluid	NN	O
flow	NN	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
trial	NN	O
,	,	O
there	EX	O
were	VBD	O
reductions	NNS	O
within	IN	O
both	DT	O
groups	NNS	O
,	,	O
however	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

It	PRP	O
was	VBD	O
concluded	VBN	O
that	IN	O
the	DT	O
herbal	NN	Pharmacological
based	VBN	Pharmacological
toothpaste	NN	Pharmacological
was	VBD	O
as	RB	O
effective	JJ	O
as	IN	O
the	DT	O
conventionally	RB	Control
formulated	VBN	Control
dentifrice	NN	Control
in	IN	O
the	DT	O
control	NN	O
of	IN	O
plaque	NN	O
and	CC	O
gingivitis	NN	O
.	.	O

Utilization	NN	O
of	IN	O
health	NN	O
care	NN	O
services	NNS	O
by	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
identify	VB	O
healthcare	NN	O
resource	NN	O
use	NN	O
patterns	NNS	O
associated	VBN	O
with	IN	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
(	(	O
COPD	NNP	O
)	)	O
,	,	O
resource	JJ	O
utilization	NN	O
(	(	O
RU	NNP	O
)	)	O
data	NNS	O
collection	NN	O
was	VBD	O
integrated	VBN	O
into	IN	O
a	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
placebo-controlled	JJ	Control
study	NN	O
of	IN	O
Viozan	NNP	O
(	(	O
sibenadet	JJ	O
HCl	NNP	O
)	)	O
.	.	O

This	DT	O
study	NN	O
enrolled	VBD	O
patients	NNS	O
with	IN	O
symptomatic	JJ	O
,	,	O
smoking-related	JJ	O
COPD	NNP	O
,	,	O
randomized	VBN	O
to	TO	O
receive	VB	O
sibenadet	NN	Pharmacological
or	CC	O
placebo	NN	Control
for	IN	O
a	DT	O
52-week	JJ	O
treatment	NN	O
period	NN	O
.	.	O

A	DT	O
questionnaire	NN	O
establishing	VBG	O
typical	JJ	O
pre-trial	JJ	O
,	,	O
COPD-related	JJ	O
RU	NNP	O
was	VBD	O
completed	VBN	O
by	IN	O
each	DT	O
patient	NN	O
.	.	O

Subsequent	JJ	O
data	NNS	O
were	VBD	O
collected	VBN	O
by	IN	O
means	NNS	O
of	IN	O
an	DT	O
Interactive	JJ	Educational
Voice	NNP	Educational
Response	NNP	Educational
System	NNP	Educational
(	(	O
IVRS	NNP	O
)	)	O
at	IN	O
30-day	JJ	O
intervals	NNS	O
(	(	O
14	CD	O
time	NN	O
points	NNS	O
)	)	O
during	IN	O
the	DT	O
study	NN	O
and	CC	O
in	IN	O
the	DT	O
follow-up	JJ	O
period	NN	O
.	.	O

The	DT	O
IVRS	NNP	O
system	NN	O
facilitated	VBD	O
data	NNS	O
collection	NN	O
and	CC	O
minimized	VBD	O
inconvenience	NN	O
to	TO	O
the	DT	O
patient	NN	O
.	.	O

Compliance	NN	O
with	IN	O
the	DT	O
requirement	NN	O
to	TO	O
record	VB	O
details	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
services	NNS	O
during	IN	O
the	DT	O
year-long	JJ	O
study	NN	O
was	VBD	O
high	JJ	O
.	.	O

No	DT	O
overall	JJ	O
trend	NN	O
for	IN	O
lower	JJR	O
RU	NNP	O
was	VBD	O
associated	VBN	O
with	IN	O
sibenadet	JJ	O
therapy	NN	O
,	,	O
which	WDT	O
correlates	VBZ	O
with	IN	O
the	DT	O
lack	NN	O
of	IN	O
sustained	JJ	O
clinical	JJ	O
effect	NN	O
seen	VBN	O
in	IN	O
studies	NNS	O
conducted	VBN	O
concurrently	RB	O
.	.	O

These	DT	O
data	NNS	O
do	VBP	O
,	,	O
however	RB	O
,	,	O
provide	VBP	O
valuable	JJ	O
information	NN	O
on	IN	O
RU	NNP	O
associated	VBN	O
with	IN	O
COPD	NNP	O
and	CC	O
insights	NNS	O
into	IN	O
adjustments	NNS	O
associated	VBN	O
with	IN	O
changes	NNS	O
in	IN	O
disease	NN	O
course	NN	O
.	.	O

Physicians	NNPS	O
were	VBD	O
seen	VBN	O
to	TO	O
be	VB	O
the	DT	O
most	RBS	O
common	JJ	O
source	NN	O
of	IN	O
care	NN	O
for	IN	O
patients	NNS	O
with	IN	O
COPD	NNP	O
and	CC	O
more	JJR	O
of	IN	O
the	DT	O
patients	NNS	O
with	IN	O
severe	JJ	O
COPD	NNP	O
(	(	O
stage	NN	O
III	NNP	O
)	)	O
than	IN	O
mild	NN	O
(	(	O
stage	NN	O
I	PRP	O
)	)	O
were	VBD	O
seen	VBN	O
to	TO	O
utilize	VB	O
the	DT	O
most	RBS	O
expensive	JJ	O
resources	NNS	O
(	(	O
e.g	NN	O
.	.	O

inpatient	JJ	O
hospital	NN	O
care	NN	O
)	)	O
.	.	O

For	IN	O
those	DT	O
patients	NNS	O
who	WP	O
experienced	VBD	O
an	DT	O
exacerbation	NN	O
during	IN	O
the	DT	O
trial	NN	O
(	(	O
irrespective	JJ	O
of	IN	O
treatment	NN	O
group	NN	O
)	)	O
,	,	O
resource	NN	O
use	NN	O
was	VBD	O
increased	VBN	O
during	IN	O
the	DT	O
periods	NNS	O
when	WRB	O
an	DT	O
exacerbation	NN	O
was	VBD	O
reported	VBN	O
when	WRB	O
compared	VBN	O
with	IN	O
the	DT	O
periods	NNS	O
before	IN	O
or	CC	O
after	IN	O
an	DT	O
exacerbation	NN	O
.	.	O

The	DT	O
proportion	NN	O
of	IN	O
cases	NNS	O
attending	VBG	O
the	DT	O
physician	NN	O
doubled	VBD	O
and	CC	O
with	IN	O
a	DT	O
trip	NN	O
to	TO	O
the	DT	O
Emergency	NNP	O
Room	NNP	O
(	(	O
ER	NNP	O
)	)	O
increased	VBD	O
approximately	RB	O
ninefold	JJ	O
during	IN	O
the	DT	O
reporting	NN	O
period	NN	O
in	IN	O
which	WDT	O
the	DT	O
exacerbation	NN	O
occurred	VBD	O
compared	VBN	O
with	IN	O
the	DT	O
previous	JJ	O
month	NN	O
.	.	O

This	DT	O
study	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
use	NN	O
of	IN	O
an	DT	O
IVRS	NNP	O
,	,	O
even	RB	O
in	IN	O
elderly	JJ	O
patients	NNS	O
,	,	O
is	VBZ	O
an	DT	O
effective	JJ	O
means	NNS	O
of	IN	O
gathering	VBG	O
RU	NNP	O
data	NNS	O
over	IN	O
long	JJ	O
periods	NNS	O
.	.	O

The	DT	O
study	NN	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
advent	NN	O
of	IN	O
effective	JJ	O
therapeutic	JJ	O
interventions	NNS	O
,	,	O
particularly	RB	O
any	DT	O
with	IN	O
the	DT	O
ability	NN	O
to	TO	O
minimize	VB	O
exacerbations	NNS	O
and	CC	O
limit	NN	O
disease	NN	O
progression	NN	O
,	,	O
could	MD	O
impact	VB	O
on	IN	O
the	DT	O
health	NN	O
care	NN	O
services	NNS	O
used	VBN	O
and	CC	O
potentially	RB	O
reduce	VB	O
associated	JJ	O
costs	NNS	O
.	.	O

Effect	NN	O
of	IN	O
phenylephrine	NN	Pharmacological
on	IN	O
the	DT	O
haemodynamic	JJ	O
state	NN	O
and	CC	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
during	IN	O
anaesthesia	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

BACKGROUND	IN	O
The	DT	O
upright	JJ	O
sitting	NN	O
or	CC	O
beachchair	NN	O
position	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
hypotension	NN	O
,	,	O
risk	NN	O
of	IN	O
cerebral	JJ	O
hypoperfusion	NN	O
,	,	O
and	CC	O
cerebral	JJ	O
injury	NN	O
.	.	O

We	PRP	O
hypothesized	VBD	O
that	IN	O
by	IN	O
increasing	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	JJ	Pharmacological
administration	NN	O
,	,	O
cerebral	JJ	O
perfusion	NN	O
,	,	O
and	CC	O
postoperative	JJ	O
recovery	NN	O
would	MD	O
be	VB	O
improved	VBN	O
.	.	O

METHODS	NNP	O
Thirty-four	JJ	O
patients	NNS	O
undergoing	VBG	O
elective	JJ	O
shoulder	NN	O
surgery	NN	O
were	VBD	O
randomized	VBN	O
to	TO	O
receive	VB	O
either	DT	O
saline	NN	Pharmacological
or	CC	Pharmacological
phenylephrine	NN	Pharmacological
infusion	NN	Pharmacological
(	(	Pharmacological
PE	NNP	Pharmacological
)	)	Pharmacological
5	CD	O
min	NN	O
before	IN	O
being	VBG	O
placed	VBN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
.	.	O

Simultaneous	JJ	O
measurements	NNS	O
of	IN	O
mean	JJ	O
arterial	JJ	O
pressure	NN	O
,	,	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
,	,	O
middle	JJ	O
cerebral	JJ	O
artery	NN	O
velocity	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
function	NN	O
using	VBG	O
transthoracic	JJ	O
echocardiography	NN	O
were	VBD	O
made	VBN	O
.	.	O

Postoperative	JJ	O
neurocognitive	JJ	O
function	NN	O
was	VBD	O
assessed	VBN	O
.	.	O

RESULTS	NNP	O
At	IN	O
the	DT	O
commencement	NN	O
of	IN	O
PE	NNP	O
,	,	O
mean	NN	O
(	(	O
SD	NNP	O
)	)	O
cerebral	JJ	O
oxygen	NN	O
saturation	NN	O
significantly	RB	O
decreased	VBN	O
from	IN	O
77	CD	O
(	(	O
10	CD	O
)	)	O
to	TO	O
67	CD	O
(	(	O
13	CD	O
)	)	O
%	NN	O
(	(	O
P=0.02	NNP	O
)	)	O
,	,	O
and	CC	O
further	RB	O
to	TO	O
59	CD	O
(	(	O
11	CD	O
)	)	O
%	NN	O
on	IN	O
upright	JJ	O
positioning	NN	O
.	.	O

The	DT	O
level	NN	O
of	IN	O
cerebral	JJ	O
saturation	NN	O
upright	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
different	JJ	O
to	TO	O
patients	NNS	O
receiving	VBG	O
saline	NN	O
(	(	O
P=0.07	NNP	O
)	)	O
,	,	O
with	IN	O
values	NNS	O
remaining	VBG	O
at	IN	O
room-air	JJ	O
levels	NNS	O
.	.	O

Middle	NNP	O
cerebral	JJ	O
artery	RB	O
blood	NN	O
velocity	NN	O
increased	VBN	O
by	IN	O
20	CD	O
%	NN	O
(	(	O
P=0.04	NNP	O
)	)	O
.	.	O

Phenylephrine	NNP	O
prevented	VBD	O
hypotension	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
primarily	RB	O
by	IN	O
maintaining	VBG	O
preload	NN	O
and	CC	O
increasing	VBG	O
systemic	JJ	O
vascular	NN	O
resistance	NN	O
(	(	O
P=0.01	NNP	O
)	)	O
,	,	O
and	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
cardiac	JJ	O
output	NN	O
.	.	O

No	DT	O
postoperative	JJ	O
neurocognitive	JJ	O
dysfunction	NN	O
was	VBD	O
identified	VBN	O
.	.	O

CONCLUSIONS	NNP	O
Despite	IN	O
maintaining	VBG	O
arterial	JJ	O
pressure	NN	O
with	IN	O
phenylephrine	NN	Pharmacological
,	,	O
cerebral	JJ	O
desaturation	NN	O
occurred	VBD	O
with	IN	O
upright	JJ	O
positioning	VBG	O
.	.	O

Cerebral	NNP	O
oxygen	IN	O
saturation	NN	O
can	MD	O
provide	VB	O
a	DT	O
valuable	JJ	O
endpoint	NN	O
when	WRB	O
evaluating	VBG	O
the	DT	O
effect	NN	O
of	IN	O
vasopressor	NN	O
therapy	NN	O
on	IN	O
cerebral	JJ	O
perfusion	NN	O
.	.	O

Comparison	NNP	O
of	IN	O
analgesic	JJ	O
effect	NN	O
of	IN	O
locally	RB	O
and	CC	O
systemically	RB	O
administered	VBN	O
ketorolac	NN	Pharmacological
in	IN	O
mastectomy	JJ	O
patients	NNS	O
.	.	O

BACKGROUND	NNP	O
Ketorolac	NNP	Pharmacological
is	VBZ	O
a	DT	O
parenteral	JJ	O
nonsteroidal	JJ	O
antiinflammatory	JJ	O
drug	NN	O
(	(	O
NSAID	NNP	O
)	)	O
.	.	O

Two	CD	O
features	NNS	O
have	VBP	O
limited	VBN	O
its	PRP$	O
clinical	JJ	O
utility	NN	O
:	:	O
tendency	NN	O
to	TO	O
elicit	VB	O
kidney	NN	O
failure	NN	O
and	CC	O
inability	NN	O
to	TO	O
produce	VB	O
complete	JJ	O
analgesia	NN	O
.	.	O

Because	IN	O
most	JJS	O
NSAIDs	NNP	Pharmacological
are	VBP	O
weak	JJ	O
acids	NNS	O
(	(	O
pKa	IN	O
3-5	NNP	O
)	)	O
and	CC	O
become	VBN	O
concentrated	JJ	O
in	IN	O
acidic	JJ	O
tissues	NNS	O
,	,	O
such	JJ	O
as	IN	O
injured	JJ	O
and	CC	O
inflamed	JJ	O
tissues	NNS	O
,	,	O
we	PRP	O
hypothesized	VBD	O
that	IN	O
local	JJ	O
administration	NN	O
may	MD	O
enhance	VB	O
its	PRP$	O
analgesic	JJ	O
efficacy	NN	O
while	IN	O
lowering	VBG	O
the	DT	O
potential	NN	O
for	IN	O
systemic	JJ	O
complications	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
placebo-controlled	JJ	Control
study	NN	O
of	IN	O
60	CD	O
group	NN	O
I-II	NNP	O
(	(	O
American	JJ	O
Society	NNP	O
of	IN	O
Anesthesiology	NNP	O
criteria	NNS	O
)	)	O
mastectomy	NN	O
patients	NNS	O
,	,	O
20	CD	O
in	IN	O
each	DT	O
group	NN	O
.	.	O

Near	IN	O
the	DT	O
end	NN	O
of	IN	O
surgery	NN	O
and	CC	O
every	DT	O
6	CD	O
h	NN	O
postoperatively	RB	O
,	,	O
20	CD	O
ml	NN	O
of	IN	O
the	DT	O
study	NN	O
solution	NN	O
containing	VBG	O
normal	JJ	Pharmacological
saline	NN	Pharmacological
with	IN	Pharmacological
or	CC	Pharmacological
without	IN	Pharmacological
30	CD	Pharmacological
mg	NN	Pharmacological
of	IN	Pharmacological
ketorolac	NN	Pharmacological
were	VBD	O
administered	VBN	O
simultaneously	RB	O
either	CC	O
via	IN	O
a	DT	O
Jackson-Pratt	JJ	O
drain	NN	O
or	CC	O
intravenously	RB	O
in	IN	O
a	DT	O
double-blind	JJ	O
fashion	NN	O
.	.	O

The	DT	O
quality	NN	O
of	IN	O
pain	NN	O
control	NN	O
,	,	O
the	DT	O
amount	NN	O
and	CC	O
character	NN	O
of	IN	O
the	DT	O
drain	NN	O
fluid	NN	O
,	,	O
incidence	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
the	DT	O
postoperative	JJ	O
care	NN	O
unit	NN	O
,	,	O
and	CC	O
amount	NN	O
of	IN	O
morphine	NN	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
break-through	JJ	O
pain	NN	O
were	VBD	O
recorded	VBN	O
.	.	O

RESULTS	NNP	O
Intraoperative	NNP	O
administration	NN	O
of	IN	O
ketorolac	NN	Pharmacological
resulted	VBD	O
in	IN	O
better	JJR	O
quality	NN	O
of	IN	O
pain	NN	O
control	NN	O
in	IN	O
the	DT	O
immediate	JJ	O
postoperative	JJ	O
period	NN	O
regardless	NN	O
of	IN	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
nausea	NN	O
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
placebo	NN	O
group	NN	O
,	,	O
and	CC	O
drain	NN	O
output	NN	O
in	IN	O
the	DT	O
ketorolac	NN	Pharmacological
groups	NNS	O
did	VBD	O
not	RB	O
exceed	VB	O
the	DT	O
output	NN	O
in	IN	O
the	DT	O
placebo	NN	Control
group	NN	O
.	.	O

CONCLUSION	NNP	O
Analgesic	NNP	O
of	IN	O
the	DT	O
locally	RB	O
administered	VBN	O
ketorolac	NN	Pharmacological
is	VBZ	O
equally	RB	O
effective	JJ	O
to	TO	O
the	DT	O
efficacy	NN	O
of	IN	O
ketorolac	NN	Pharmacological
administered	VBN	O
intravenously	RB	O
.	.	O

Bismuth	NNP	Pharmacological
subsalicylate	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gastritis	NN	O
due	JJ	O
to	TO	O
Campylobacter	NNP	O
pylori	NN	O
.	.	O

Fifty	JJ	O
patients	NNS	O
completed	VBD	O
an	DT	O
investigator-blind	JJ	O
trial	NN	O
comparing	VBG	O
bismuth	NN	Pharmacological
subsalicylate	NN	Pharmacological
,	,	O
erythromycin	JJ	Pharmacological
ethylsuccinate	NN	Pharmacological
,	,	O
and	CC	O
placebo	RB	Control
matched	VBN	O
to	TO	O
the	DT	O
bismuth	NN	Pharmacological
salt	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gastritis	NN	O
associated	VBN	O
with	IN	O
Campylobacter	NNP	O
pylori	NN	O
.	.	O

C.	NNP	O
pylori	NN	O
was	VBD	O
cleared	VBN	O
from	IN	O
14	CD	O
(	(	O
77.8	CD	O
%	NN	O
)	)	O
of	IN	O
18	CD	O
patients	NNS	O
given	VBN	O
locally	RB	O
active	JJ	Pharmacological
bismuth	NN	Pharmacological
,	,	O
from	IN	O
one	CD	O
(	(	O
6.7	CD	O
%	NN	O
)	)	O
of	IN	O
15	CD	O
patients	NNS	O
given	VBN	O
erythromycin	NNS	Pharmacological
,	,	O
and	CC	O
from	IN	O
none	NN	O
of	IN	O
17	CD	O
patients	NNS	O
given	VBN	O
placebo	NNS	Control
.	.	O

Gastritis	NNP	O
resolved	VBD	O
in	IN	O
13	CD	O
(	(	O
81	CD	O
%	NN	O
)	)	O
of	IN	O
16	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
bismuth	NN	Pharmacological
but	CC	O
in	IN	O
only	RB	O
three	CD	O
of	IN	O
13	CD	O
receiving	VBG	O
erythromycin	NN	Pharmacological
and	CC	O
in	IN	O
none	NN	O
of	IN	O
16	CD	O
patients	NNS	O
given	VBN	O
placebo	NNS	Control
.	.	O

Results	NNS	O
of	IN	O
endoscopic	JJ	O
examination	NN	O
showed	VBD	O
greater	JJR	O
improvement	NN	O
in	IN	O
patients	NNS	O
cleared	VBN	O
of	IN	O
C.	NNP	O
pylori	NN	O
than	IN	O
in	IN	O
those	DT	O
with	IN	O
persistent	JJ	O
infection	NN	O
.	.	O

Heartburn	NNP	O
improved	VBD	O
in	IN	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
who	WP	O
received	VBD	O
bismuth	RB	Pharmacological
compared	VBN	O
with	IN	O
17	CD	O
%	NN	O
of	IN	O
those	DT	O
given	VBN	O
placebo	NN	Control
.	.	O

The	DT	O
success	NN	O
of	IN	O
bismuth	NN	Pharmacological
is	VBZ	O
probably	RB	O
due	JJ	O
to	TO	O
its	PRP$	O
local	JJ	O
antimicrobial	JJ	O
activity	NN	O
.	.	O

Erythromycin	NN	Pharmacological
may	MD	O
have	VB	O
been	VBN	O
inactivated	VBN	O
by	IN	O
the	DT	O
low	JJ	O
pH	NN	O
in	IN	O
the	DT	O
areas	NNS	O
colonized	VBN	O
with	IN	O
C.	NNP	O
pylori	NN	O
.	.	O

Relapse	NNP	O
is	VBZ	O
less	RBR	O
frequent	JJ	O
when	WRB	O
a	DT	O
combination	NN	O
of	IN	O
bismuth	NN	Pharmacological
and	CC	O
an	DT	O
antimicrobial	JJ	O
agent	NN	O
is	VBZ	O
used	VBN	O
;	:	O
such	JJ	O
a	DT	O
combination	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
local	JJ	O
and	CC	O
systemic	JJ	O
activity	NN	O
,	,	O
stability	NN	O
at	IN	O
low	JJ	O
pH	NN	O
,	,	O
and	CC	O
good	JJ	O
penetration	NN	O
into	IN	O
gastric	JJ	O
mucus	NN	O
.	.	O

Omega-3	JJ	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
supplementation	NN	Pharmacological
in	IN	O
children	NNS	O
with	IN	O
autism	NN	O
:	:	O
a	DT	O
double-blind	JJ	O
randomized	NN	O
,	,	O
placebo-controlled	JJ	Control
pilot	NN	O
study	NN	O
.	.	O

BACKGROUND	NNP	O
There	EX	O
is	VBZ	O
increasing	VBG	O
evidence	NN	O
that	IN	O
fatty	JJ	O
acid	JJ	O
deficiencies	NNS	O
or	CC	O
imbalances	NNS	O
may	MD	O
contribute	VB	O
to	TO	O
childhood	VB	O
neurodevelopmental	JJ	O
disorders	NNS	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
a	DT	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	O
6-week	JJ	O
pilot	NN	O
trial	NN	O
investigating	VBG	O
the	DT	O
effects	NNS	O
of	IN	O
1.5	CD	Pharmacological
g/d	NN	Pharmacological
of	IN	Pharmacological
omega-3	JJ	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
(	(	Pharmacological
.84	JJ	Pharmacological
g/d	NN	Pharmacological
eicosapentaenoic	NN	Pharmacological
acid	NN	Pharmacological
,	,	Pharmacological
.7	NNP	Pharmacological
g/d	NN	Pharmacological
docosahexaenoic	NN	Pharmacological
acid	NN	Pharmacological
)	)	Pharmacological
supplementation	NN	Pharmacological
in	IN	O
13	CD	O
children	NNS	O
(	(	O
aged	VBN	O
5	CD	O
to	TO	O
17	CD	O
years	NNS	O
)	)	O
with	IN	O
autistic	JJ	O
disorders	NNS	O
accompanied	VBN	O
by	IN	O
severe	JJ	O
tantrums	NNS	O
,	,	O
aggression	NN	O
,	,	O
or	CC	O
self-injurious	JJ	O
behavior	NN	O
.	.	O

The	DT	O
outcome	NN	O
measure	NN	O
was	VBD	O
the	DT	O
Aberrant	NNP	O
Behavior	NNP	O
Checklist	NNP	O
(	(	O
ABC	NNP	O
)	)	O
at	IN	O
6	CD	O
weeks	NNS	O
.	.	O

RESULTS	NNP	O
We	PRP	O
observed	VBD	O
an	DT	O
advantage	NN	O
of	IN	O
omega-3	JJ	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
compared	VBN	O
with	IN	O
placebo	NN	Pharmacological
for	IN	O
hyperactivity	NN	O
and	CC	O
stereotypy	NN	O
,	,	O
each	DT	O
with	IN	O
a	DT	O
large	JJ	O
effect	NN	O
size	NN	O
.	.	O

Repeated-measures	NNS	O
ANOVA	NNP	O
indicated	VBD	O
a	DT	O
trend	NN	O
toward	IN	O
superiority	NN	O
of	IN	O
omega-3	JJ	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
over	IN	O
placebo	NN	O
for	IN	O
hyperactivity	NN	O
.	.	O

No	DT	O
clinically	RB	O
relevant	JJ	O
adverse	JJ	O
effects	NNS	O
were	VBD	O
elicited	VBN	O
in	IN	O
either	DT	O
group	NN	O
.	.	O

CONCLUSIONS	VBZ	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
provide	VBP	O
preliminary	JJ	O
evidence	NN	O
that	IN	O
omega-3	JJ	Pharmacological
fatty	JJ	Pharmacological
acids	NNS	Pharmacological
may	MD	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
children	NNS	O
with	IN	O
autism	NN	O
.	.	O

Behavioral	JJ	Educational
parent	NN	Educational
training	NN	Educational
to	TO	O
address	VB	O
sleep	JJ	O
disturbances	NNS	O
in	IN	O
young	JJ	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorder	NN	O
:	:	O
a	DT	O
pilot	NN	O
trial	NN	O
.	.	O

OBJECTIVES	CC	O
A	DT	O
large	JJ	O
percentage	NN	O
of	IN	O
children	NNS	O
with	IN	O
autism	NN	O
spectrum	NN	O
disorders	NNS	O
(	(	O
ASD	NNP	O
)	)	O
have	VBP	O
bedtime	VBN	O
and	CC	O
sleep	JJ	O
disturbances	NNS	O
.	.	O

However	RB	O
,	,	O
the	DT	O
treatment	NN	O
of	IN	O
these	DT	O
disturbances	NNS	O
has	VBZ	O
been	VBN	O
understudied	VBN	O
.	.	O

The	DT	O
purpose	NN	O
of	IN	O
our	PRP$	O
study	NN	O
was	VBD	O
to	TO	O
develop	VB	O
a	DT	O
manualized	JJ	Educational
behavioral	JJ	Educational
parent	NN	Educational
training	NN	Educational
(	(	O
BPT	NNP	O
)	)	O
program	NN	O
for	IN	O
parents	NNS	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
sleep	JJ	O
disturbances	NNS	O
and	CC	O
to	TO	O
test	VB	O
the	DT	O
feasibility	NN	O
,	,	O
fidelity	NN	O
,	,	O
and	CC	O
initial	JJ	O
efficacy	NN	O
of	IN	O
the	DT	O
treatment	NN	O
in	IN	O
a	DT	O
small	JJ	O
randomized	NN	O
controlled	VBN	O
trial	NN	O
(	(	O
RCT	NNP	O
)	)	O
.	.	O

PARTICIPANTS	NNP	O
AND	CC	O
METHODS	NNP	O
Parents	NNP	O
of	IN	O
a	DT	O
sample	NN	O
of	IN	O
40	CD	O
young	JJ	O
children	NNS	O
diagnosed	VBN	O
with	IN	O
ASD	NNP	O
with	IN	O
an	DT	O
average	JJ	O
age	NN	O
of	IN	O
3.5years	CD	O
were	VBD	O
enrolled	VBN	O
in	IN	O
our	PRP$	O
study	NN	O
.	.	O

Participants	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	CC	O
the	DT	O
BPT	NNP	Educational
program	NN	Educational
group	NN	O
or	CC	O
a	DT	O
comparison	NN	O
group	NN	O
who	WP	O
were	VBD	O
given	VBN	O
nonsleep-related	JJ	Educational
parent	NN	Educational
education	NN	Educational
.	.	O

Each	DT	O
participant	NN	O
was	VBD	O
individually	RB	O
administered	VBN	O
a	DT	O
5-session	JJ	O
program	NN	O
delivered	VBN	O
over	IN	O
the	DT	O
8-week	JJ	O
study	NN	O
.	.	O

Outcome	NNP	O
measures	NNS	O
of	IN	O
feasibility	NN	O
,	,	O
fidelity	NN	O
,	,	O
and	CC	O
efficacy	NN	O
were	VBD	O
collected	VBN	O
at	IN	O
weeks	NNS	O
4	CD	O
and	CC	O
8	CD	O
after	IN	O
the	DT	O
baseline	NN	O
time	NN	O
point	NN	O
.	.	O

Children	NNP	O
's	POS	O
sleep	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
parent	NN	O
report	NN	O
and	CC	O
objectively	RB	O
by	IN	O
actigraphy	NN	O
.	.	O

RESULTS	NNP	O
Of	IN	O
the	DT	O
20	CD	O
participants	NNS	O
in	IN	O
each	DT	O
group	NN	O
,	,	O
data	NNS	O
were	VBD	O
available	JJ	O
for	IN	O
15	CD	O
participants	NNS	O
randomized	VBN	O
to	TO	O
BPT	NNP	O
and	CC	O
18	CD	O
participants	NNS	O
randomized	VBN	O
to	TO	O
the	DT	O
comparison	NN	O
condition	NN	O
.	.	O

Results	NNP	O
supported	VBD	O
the	DT	O
feasibility	NN	O
of	IN	O
the	DT	O
manualized	JJ	O
parent	NN	O
training	NN	O
program	NN	O
and	CC	O
the	DT	O
comparison	NN	O
program	NN	O
.	.	O

Treatment	NNP	O
fidelity	NN	O
was	VBD	O
high	JJ	O
for	IN	O
both	DT	O
groups	NNS	O
.	.	O

The	DT	O
BPT	NNP	O
program	NN	O
group	NN	O
significantly	RB	O
improved	VBD	O
more	JJR	O
than	IN	O
the	DT	O
comparison	NN	O
group	NN	O
based	VBN	O
on	IN	O
the	DT	O
primary	JJ	O
sleep	JJ	O
outcome	NN	O
of	IN	O
parent	NN	O
report	NN	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
objective	JJ	O
changes	NNS	O
in	IN	O
sleep	NN	O
detected	VBN	O
by	IN	O
actigraphy	NN	O
.	.	O

CONCLUSIONS	NNP	O
Our	PRP$	O
study	NN	O
is	VBZ	O
one	CD	O
of	IN	O
few	JJ	O
RCTs	NNP	O
of	IN	O
a	DT	O
BPT	NNP	O
program	NN	O
to	TO	O
specifically	RB	O
target	VB	O
sleep	JJ	O
disturbances	NNS	O
in	IN	O
a	DT	O
well-characterized	JJ	O
sample	NN	O
of	IN	O
young	JJ	O
children	NNS	O
with	IN	O
ASD	NNP	O
and	CC	O
to	TO	O
demonstrate	VB	O
the	DT	O
feasibility	NN	O
of	IN	O
the	DT	O
approach	NN	O
.	.	O

Initial	JJ	O
efficacy	NN	O
favored	VBD	O
the	DT	O
BPT	NNP	O
program	NN	O
over	IN	O
the	DT	O
comparison	NN	O
group	NN	O
and	CC	O
suggested	VBD	O
that	IN	O
this	DT	O
manualized	JJ	O
parent	NN	O
training	NN	O
approach	NN	O
is	VBZ	O
worthy	JJ	O
of	IN	O
further	JJ	O
examination	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
within	IN	O
a	DT	O
larger	JJR	O
RCT	NNP	O
.	.	O

Granulocyte-macrophage	JJ	Pharmacological
colony-stimulating	JJ	Pharmacological
factor	NN	Pharmacological
as	IN	O
immunomodulating	VBG	O
factor	NN	O
together	RB	O
with	IN	O
influenza	JJ	Pharmacological
vaccination	NN	Pharmacological
in	IN	O
stem	NN	O
cell	NN	O
transplant	NN	O
patients	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
granulocyte-macrophage	JJ	Physical
colony-stimulating	JJ	Physical
factor	NN	Physical
(	(	Physical
GM-CSF	NNP	Physical
)	)	Physical
on	IN	O
the	DT	O
serological	JJ	O
response	NN	O
at	IN	O
influenza	JJ	Pharmacological
vaccination	NN	Pharmacological
was	VBD	O
studied	VBN	O
in	IN	O
117	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
undergone	JJ	O
stem	NN	O
cell	NN	O
transplantation	NN	O
(	(	O
SCT	NNP	O
)	)	O
.	.	O

The	DT	O
vaccine	NN	O
response	NN	O
was	VBD	O
evaluated	VBN	O
as	IN	O
significant	JJ	O
increases	NNS	O
in	IN	O
levels	NNS	O
of	IN	O
influenza	JJ	O
hemagglutination-inhibition	NN	O
(	(	O
HAI	NNP	O
)	)	O
antibodies	NNS	O
and	CC	O
of	IN	O
IgG	NNP	O
antibodies	NNS	O
measured	VBN	O
by	IN	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
antibody	NN	O
response	NN	O
to	TO	O
either	DT	O
influenza	VB	O
A	NNP	O
or	CC	O
B	NNP	O
in	IN	O
64	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
GM-CSF	NNP	Physical
at	IN	O
vaccination	NN	O
,	,	O
compared	VBN	O
with	IN	O
the	DT	O
53	NNS	O
who	WP	O
did	VBD	O
not	RB	O
.	.	O

In	IN	O
the	DT	O
subgroup	NN	O
of	IN	O
allogeneic	JJ	O
SCT	NNP	O
patients	NNS	O
,	,	O
HAI	NNP	O
showed	VBD	O
that	IN	O
the	DT	O
response	NN	O
rate	NN	O
to	TO	O
the	DT	O
influenza	NN	Pharmacological
B	NNP	Pharmacological
vaccine	NN	Pharmacological
was	VBD	O
significantly	RB	O
higher	JJR	O
in	IN	O
the	DT	O
treatment	NN	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
.	.	O

ELISA	NN	O
showed	VBD	O
that	IN	O
autologous	JJ	O
SCT	NNP	O
patients	NNS	O
with	IN	O
breast	JJ	O
cancer	NN	O
who	WP	O
received	VBD	O
GM-CSF	NNP	O
had	VBD	O
a	DT	O
better	JJR	O
response	NN	O
to	TO	O
influenza	VB	O
A	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.05	NNP	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
P	NNP	O
<	NNP	O
.01	NNP	O
)	)	O
.	.	O

At	IN	O
early	JJ	O
vaccination	NN	O
,	,	O
4-12	JJ	O
months	NNS	O
after	IN	O
stem	NN	O
cell	NN	O
transplantation	NN	O
,	,	O
these	DT	O
responses	NNS	O
were	VBD	O
more	RBR	O
pronounced	JJ	O
.	.	O

GM-CSF	JJ	Pharmacological
appears	VBZ	O
to	TO	O
improve	VB	O
the	DT	O
response	NN	O
to	TO	O
influenza	VB	O
vaccination	NN	O
in	IN	O
some	DT	O
groups	NNS	O
of	IN	O
SCT	NNP	O
patients	NNS	O
,	,	O
but	CC	O
only	RB	O
to	TO	O
a	DT	O
limited	JJ	O
extent	NN	O
.	.	O

A	DT	O
comparison	NN	O
of	IN	O
a	DT	O
short	JJ	Educational
nurse-based	JJ	Educational
and	CC	Educational
a	DT	Educational
long	JJ	Educational
multidisciplinary	JJ	Educational
version	NN	Educational
of	IN	Educational
structured	JJ	Educational
patient	JJ	Educational
education	NN	Educational
in	IN	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
.	.	O

OBJECTIVE	CC	O
Structured	NNP	Educational
multidisciplinary	JJ	Educational
patient	NN	Educational
group	NN	Educational
education	NN	Educational
has	VBZ	O
positive	JJ	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
,	,	O
health-related	JJ	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
disease-related	JJ	O
knowledge	NN	O
in	IN	O
patients	NNS	O
with	IN	O
irritable	JJ	O
bowel	NN	O
syndrome	NN	O
(	(	O
IBS	NNP	O
)	)	O
,	,	O
but	CC	O
few	JJ	O
studies	NNS	O
comparing	VBG	O
different	JJ	O
forms	NNS	O
of	IN	O
educational	JJ	O
interventions	NNS	O
are	VBP	O
available	JJ	O
.	.	O

Our	PRP$	O
aim	NN	O
was	VBD	O
to	TO	O
compare	VB	O
the	DT	O
effects	NNS	O
of	IN	O
long	JJ	Educational
multidisciplinary	JJ	Educational
group	NN	Educational
education	NN	Educational
with	IN	O
a	DT	O
short	JJ	Educational
nurse-based	JJ	Educational
group	NN	Educational
education	NN	Educational
with	IN	O
regard	NN	O
to	TO	O
symptoms	NNS	O
,	,	O
knowledge	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
satisfaction	NN	O
with	IN	O
the	DT	O
intervention	NN	O
in	IN	O
IBS	NNP	O
patients	NNS	O
.	.	O

METHODS	NNP	O
Patients	NNPS	O
with	IN	O
IBS	NNP	O
according	VBG	O
to	TO	O
the	DT	O
Rome	NNP	O
II	NNP	O
criteria	NNS	O
were	VBD	O
randomized	VBN	O
to	TO	O
either	DT	O
short	JJ	Educational
nurse-based	JJ	Educational
or	CC	Educational
a	DT	Educational
long	JJ	Educational
multidisciplinary-based	JJ	Educational
education	NN	Educational
.	.	Educational

The	DT	O
effects	NNS	O
were	VBD	O
evaluated	VBN	O
by	IN	O
self-administered	JJ	Educational
questionnaires	NNS	Educational
at	IN	O
3	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
after	IN	O
baseline	NN	O
,	,	O
and	CC	O
compared	VBN	O
between	IN	O
the	DT	O
groups	NNS	O
.	.	O

RESULTS	NNP	O
No	NNP	O
differences	NNS	O
in	IN	O
effects	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
between-group	JJ	O
comparisons	NNS	O
at	IN	O
any	DT	O
of	IN	O
the	DT	O
follow-up	JJ	O
assessments	NNS	O
.	.	O

However	RB	O
,	,	O
positive	JJ	O
effects	NNS	O
on	IN	O
symptoms	NNS	O
,	,	O
knowledge	NN	O
,	,	O
quality	NN	O
of	IN	O
life	NN	O
,	,	O
and	CC	O
satisfaction	NN	O
with	IN	O
the	DT	O
intervention	NN	O
were	VBD	O
found	VBN	O
in	IN	O
both	CC	O
the	DT	O
short	JJ	O
and	CC	O
the	DT	O
long	JJ	O
version	NN	O
.	.	O

CONCLUSION	VB	O
A	DT	O
short	JJ	Educational
,	,	Educational
nurse-based	JJ	Educational
educational	JJ	Educational
intervention	NN	Educational
seems	VBZ	O
to	TO	O
be	VB	O
as	RB	O
efficacious	JJ	O
as	IN	O
a	DT	O
longer	RBR	Educational
multidisciplinary	JJ	Educational
version	NN	O
.	.	O

In	IN	O
both	DT	O
groups	NNS	O
,	,	O
positive	JJ	O
effects	NNS	O
on	IN	O
patients	NNS	O
'	POS	O
well-being	NN	O
were	VBD	O
found	VBN	O
to	TO	O
a	DT	O
similar	JJ	O
extent	NN	O
.	.	O

This	DT	O
is	VBZ	O
an	DT	O
important	JJ	O
finding	NN	O
that	IN	O
,	,	O
from	IN	O
a	DT	O
cost-effective	JJ	O
perspective	NN	O
,	,	O
could	MD	O
contribute	VB	O
toward	IN	O
an	DT	O
optimized	JJ	O
management	NN	O
of	IN	O
patients	NNS	O
with	IN	O
IBS	NNP	O
.	.	O

A	DT	O
randomized	JJ	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
phase	NN	O
I	PRP	O
study	VBP	O
of	IN	O
MEDI-545	NNP	Pharmacological
,	,	O
an	DT	O
anti-interferon-alfa	JJ	O
monoclonal	NN	O
antibody	NN	O
,	,	O
in	IN	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
psoriasis	NN	O
.	.	O

BACKGROUND	NNP	O
Interferon-alfa	NNP	O
(	(	O
IFN-alpha	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
implicated	VBN	O
in	IN	O
the	DT	O
pathogenesis	NN	O
of	IN	O
psoriasis	NN	O
.	.	O

OBJECTIVE	UH	O
To	TO	O
evaluate	VB	O
the	DT	O
safety	NN	O
profile	NN	O
of	IN	O
MEDI-545	NNP	Pharmacological
,	,	O
a	DT	O
fully	RB	O
human	JJ	O
anti-IFN-alpha	JJ	O
monoclonal	NN	O
antibody	NN	O
and	CC	O
to	TO	O
explore	VB	O
its	PRP$	O
effect	NN	O
on	IN	O
the	DT	O
involvement	NN	O
of	IN	O
type	NN	O
I	PRP	O
IFN-alpha	VBP	O
activity	NN	O
in	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
established	VBN	O
plaque	NN	O
psoriasis	NN	O
.	.	O

METHODS	NNP	O
We	PRP	O
conducted	VBD	O
an	DT	O
18-week	JJ	O
,	,	O
randomized	VBN	O
,	,	O
double-blind	JJ	O
,	,	O
placebo-controlled	JJ	Control
,	,	O
dose-escalating	JJ	O
study	NN	O
in	IN	O
36	CD	O
subjects	NNS	O
with	IN	O
chronic	JJ	O
plaque	NN	O
psoriasis	NN	O
.	.	O

Subjects	VBZ	O
received	VBD	O
one	CD	O
intravenous	JJ	O
dose	NN	O
of	IN	O
MEDI-545	NNP	Pharmacological
(	(	O
0.3-30.0	JJ	O
mg/kg	NN	O
)	)	O
or	CC	O
placebo	NN	Control
.	.	O

Study	NNP	O
outcomes	NNS	O
were	VBD	O
safety	NN	O
profile	NN	O
,	,	O
pharmacokinetics	NNS	O
,	,	O
immunogenicity	NN	O
,	,	O
and	CC	O
clinical	JJ	O
effects	NNS	O
.	.	O

RESULTS	NNP	O
There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
in	IN	O
adverse	JJ	O
events	NNS	O
between	IN	O
MEDI-545	NNP	Pharmacological
and	CC	O
placebo	NN	Control
.	.	O

Two	CD	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
were	VBD	O
reported	VBN	O
;	:	O
one	CD	O
drug-related	JJ	O
hypotensive	JJ	O
infusion	NN	O
reaction	NN	O
occurred	VBD	O
in	IN	O
one	CD	O
subject	NN	O
in	IN	O
the	DT	O
30.0	CD	O
mg/kg	JJ	O
MEDI-545	NNP	Pharmacological
dose	NN	O
group	NN	O
,	,	O
causing	VBG	O
discontinuation	NN	O
of	IN	O
study	JJ	O
drug	NN	O
in	IN	O
that	DT	O
subject	NN	O
and	CC	O
study	NN	O
dismissal	NN	O
of	IN	O
the	DT	O
other	JJ	O
subjects	NNS	O
in	IN	O
the	DT	O
same	JJ	O
cohort	NN	O
;	:	O
and	CC	O
a	DT	O
myocardial	JJ	O
infarction	NN	O
occurred	VBD	O
in	IN	O
one	CD	O
subject	NN	O
in	IN	O
the	DT	O
10	CD	O
mg/kg	JJ	O
MEDI-545	NNP	Pharmacological
dose	NN	O
group	NN	O
,	,	O
which	WDT	O
was	VBD	O
considered	VBN	O
to	TO	O
be	VB	O
unrelated	JJ	O
to	TO	O
treatment	NN	O
.	.	O

MEDI-545	NNP	Pharmacological
was	VBD	O
nonimmunogenic	JJ	O
,	,	O
had	VBD	O
a	DT	O
half-life	NN	O
of	IN	O
21	CD	O
days	NNS	O
,	,	O
showed	VBD	O
no	DT	O
significant	JJ	O
inhibition	NN	O
of	IN	O
the	DT	O
type	NN	O
I	PRP	O
IFN	NNP	O
gene	NN	O
signature	NN	O
,	,	O
and	CC	O
had	VBD	O
no	DT	O
clinical	JJ	O
activity	NN	O
.	.	O

LIMITATIONS	VB	O
The	DT	O
study	NN	O
addressed	VBD	O
only	RB	O
IFN-alpha	NNP	O
and	CC	O
chronic	JJ	O
psoriatic	JJ	O
lesions	NNS	O
.	.	O

CONCLUSION	VB	O
The	DT	O
safety	NN	O
profile	NN	O
of	IN	O
MEDI-545	NNP	Pharmacological
supports	NNS	O
further	RBR	O
clinical	JJ	O
development	NN	O
.	.	O

IFN-alpha	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
significantly	RB	O
involved	VBN	O
in	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
established	VBN	O
plaque	NN	O
psoriasis	NN	O
.	.	O

Transcutaneous	JJ	Physical
electrical	JJ	Physical
nerve	NN	Physical
stimulation	NN	Physical
after	IN	O
thoracotomy	NN	O
.	.	O

Pain	NNP	O
relief	NN	O
and	CC	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
rate	NN	O
--	:	O
a	DT	O
trial	NN	O
of	IN	O
transcutaneous	JJ	Physical
electrical	JJ	Physical
nerve	NN	Physical
stimulation	NN	Physical
.	.	O

Forty	NNP	O
patients	NNS	O
scheduled	VBN	O
to	TO	O
undergo	VB	O
thoracotomy	NN	O
were	VBD	O
randomly	RB	Physical
allocated	VBN	Physical
to	TO	Physical
receive	VB	Physical
either	RB	Physical
transcutaneous	JJ	Physical
electrical	JJ	Physical
nerve	NN	Physical
stimulation	NN	Physical
with	IN	Physical
intramuscular	JJ	Physical
papaveretum	NN	Physical
(	(	Physical
20	CD	Physical
patients	NNS	Physical
)	)	Physical
or	CC	O
intramuscular	JJ	Physical
papaveretum	NN	Physical
alone	RB	Physical
(	(	Physical
20	CD	Physical
patients	NNS	Physical
)	)	Physical
for	IN	Physical
postoperative	JJ	Physical
pain	NN	Physical
relief	NN	Physical
.	.	Physical

Total	JJ	O
intramuscular	JJ	O
analgesic	NN	O
requirements	NNS	O
in	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
,	,	O
time	NN	O
to	TO	O
satisfactory	VB	O
transfer	NN	O
to	TO	O
oral	JJ	O
analgesia	NN	O
,	,	O
antiemetic	JJ	O
requirements	NNS	O
and	CC	O
length	NN	O
of	IN	O
stay	NN	O
in	IN	O
hospital	NN	O
postoperatively	RB	O
were	VBD	O
noted	VBN	O
.	.	O

Peak	NNP	O
expiratory	JJ	O
flow	NN	O
rate	NN	O
was	VBD	O
compared	VBN	O
pre-	JJ	O
and	CC	O
postoperatively	RB	O
in	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

Use	NNP	O
of	IN	O
nerve	NN	O
stimulation	NN	O
did	VBD	O
not	RB	O
significantly	RB	O
alter	VB	O
the	DT	O
requirements	NNS	O
for	IN	O
analgesia	JJ	O
although	IN	O
there	EX	O
was	VBD	O
a	DT	O
reduction	NN	O
in	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
the	DT	O
nerve	NN	O
stimulation	NN	O
group	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
difference	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
with	IN	O
respect	NN	O
to	TO	O
changes	NNS	O
in	IN	O
peak	NN	O
expiratory	NN	O
flow	NN	O
rate	NN	O
.	.	O

Randomized	VBN	O
trial	NN	O
of	IN	O
angiotensin	JJ	Pharmacological
II-receptor	NNP	Pharmacological
blocker	NN	Pharmacological
vs.	FW	O
dihydropiridine	NN	Pharmacological
calcium	NN	Pharmacological
channel	NN	Pharmacological
blocker	NN	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
paroxysmal	JJ	O
atrial	JJ	O
fibrillation	NN	O
with	IN	O
hypertension	NN	O
(	(	O
J-RHYTHM	NNP	O
II	NNP	O
study	NN	O
)	)	O
.	.	O

AIMS	NNP	O
Atrial	NNP	O
fibrillation	NN	O
(	(	O
AF	NNP	O
)	)	O
is	VBZ	O
a	DT	O
common	JJ	O
arrhythmia	NN	O
frequently	RB	O
associated	VBN	O
with	IN	O
hypertension	NN	O
.	.	O

This	DT	O
study	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
test	VB	O
the	DT	O
hypothesis	NN	O
that	IN	O
lowering	VBG	O
blood	NN	O
pressure	NN	O
by	IN	O
angiotensin	JJ	Pharmacological
II-receptor	NNP	Pharmacological
blockers	NNS	Pharmacological
(	(	Pharmacological
ARB	NNP	Pharmacological
)	)	Pharmacological
has	VBZ	O
more	JJR	O
beneficial	JJ	O
effects	NNS	O
than	IN	O
by	IN	O
conventional	JJ	Pharmacological
calcium	NN	Pharmacological
channel	NN	Pharmacological
blockers	NNS	Pharmacological
(	(	Pharmacological
CCB	NNP	Pharmacological
)	)	Pharmacological
on	IN	O
the	DT	O
frequency	NN	O
of	IN	O
paroxysmal	JJ	O
AF	NNP	O
with	IN	O
hypertension	NN	O
.	.	O

METHODS	NNP	O
AND	CC	O
RESULTS	NNP	O
The	DT	O
Japanese	JJ	O
Rhythm	NNP	O
Management	NNP	O
Trial	NNP	O
II	NNP	O
for	IN	O
Atrial	NNP	O
Fibrillation	NNP	O
(	(	O
J-RHYTHM	NNP	O
II	NNP	O
study	NN	O
)	)	O
is	VBZ	O
an	DT	O
open-label	JJ	O
randomized	JJ	O
comparison	NN	O
between	IN	O
an	DT	O
ARB	NNP	Pharmacological
(	(	Pharmacological
candesartan	NN	Pharmacological
)	)	Pharmacological
and	CC	O
a	DT	O
CCB	NNP	Pharmacological
(	(	Pharmacological
amlodipine	NN	Pharmacological
)	)	Pharmacological
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
paroxysmal	JJ	O
AF	NNP	O
associated	VBN	O
with	IN	O
hypertension	NN	O
.	.	O

Using	VBG	O
daily	JJ	O
transtelephonic	JJ	O
monitoring	NN	O
,	,	O
we	PRP	O
examined	VBD	O
asymptomatic	JJ	O
and	CC	O
symptomatic	JJ	O
paroxysmal	NN	O
AF	NNP	O
episodes	VBZ	O
during	IN	O
a	DT	O
maximum	JJ	O
1	CD	O
year	NN	O
treatment	NN	O
.	.	O

The	DT	O
primary	JJ	O
endpoint	NN	O
was	VBD	O
the	DT	O
difference	NN	O
in	IN	O
AF	NNP	O
frequency	NN	O
between	IN	O
the	DT	O
pre-treatment	JJ	O
period	NN	O
and	CC	O
the	DT	O
final	JJ	O
month	NN	O
of	IN	O
the	DT	O
follow-up	NN	O
.	.	O

The	DT	O
secondary	JJ	O
endpoints	NNS	O
included	VBD	O
cardiovascular	JJ	O
events	NNS	O
,	,	O
development	NN	O
of	IN	O
persistent	JJ	O
AF	NNP	O
,	,	O
left	VBD	O
atrial	JJ	O
dimension	NN	O
,	,	O
and	CC	O
quality-of-life	NN	O
(	(	O
QOL	NNP	O
)	)	O
.	.	O

The	DT	O
study	NN	O
enrolled	VBD	O
318	CD	O
patients	NNS	O
(	(	O
66	CD	O
years	NNS	O
,	,	O
male/female	JJ	O
219/99	CD	O
,	,	O
158	CD	O
in	IN	O
the	DT	O
ARB	NNP	Pharmacological
group	NN	O
and	CC	O
160	CD	O
in	IN	O
the	DT	O
CCB	NNP	Pharmacological
group	NN	O
)	)	O
treated	VBD	O
at	IN	O
48	CD	O
sites	NNS	O
throughout	IN	O
Japan	NNP	O
.	.	O

At	IN	O
baseline	NN	O
,	,	O
the	DT	O
frequency	NN	O
of	IN	O
AF	NNP	O
episodes	NNS	O
(	(	O
days/month	NN	O
)	)	O
was	VBD	O
3.8	CD	O
?	.	O
5.0	CD	O
in	IN	O
the	DT	O
ARB	NNP	O
group	NN	O
vs.	FW	O
4.8	CD	O
?	.	O
6.3	CD	O
in	IN	O
the	DT	O
CCB	NNP	O
group	NN	O
(	(	O
not	RB	O
significant	JJ	O
)	)	O
.	.	O

During	IN	O
the	DT	O
follow-up	JJ	O
,	,	O
blood	NN	O
pressure	NN	O
was	VBD	O
significantly	RB	O
lower	JJR	O
in	IN	O
the	DT	O
CCB	NNP	O
group	NN	O
than	IN	O
in	IN	O
the	DT	O
ARB	NNP	O
group	NN	O
(	(	O
P	NNP	O
<	NNP	O
0.001	CD	O
)	)	O
.	.	O

The	DT	O
AF	NNP	O
frequency	NN	O
decreased	VBD	O
similarly	RB	O
in	IN	O
both	DT	O
groups	NNS	O
,	,	O
and	CC	O
there	EX	O
was	VBD	O
no	DT	O
significant	JJ	O
difference	NN	O
in	IN	O
the	DT	O
primary	JJ	O
endpoint	NN	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
.	.	O

There	EX	O
were	VBD	O
no	DT	O
significant	JJ	O
differences	NNS	O
between	IN	O
the	DT	O
two	CD	O
groups	NNS	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
persistent	JJ	O
AF	NNP	O
,	,	O
changes	NNS	O
in	IN	O
left	JJ	O
atrial	JJ	O
dimension	NN	O
,	,	O
occurrence	NN	O
of	IN	O
cardiovascular	JJ	O
events	NNS	O
,	,	O
or	CC	O
changes	NNS	O
in	IN	O
QOL	NNP	O
.	.	O

CONCLUSIONS	NNP	O
In	IN	O
patients	NNS	O
with	IN	O
paroxysmal	JJ	O
AF	NNP	O
and	CC	O
hypertension	NN	O
,	,	O
treatment	NN	O
of	IN	O
hypertension	NN	O
by	IN	O
candesartan	NN	O
did	VBD	O
not	RB	O
have	VB	O
an	DT	O
advantage	NN	O
over	RP	O
amlodipine	NN	O
in	IN	O
the	DT	O
reduction	NN	O
in	IN	O
the	DT	O
frequency	NN	O
of	IN	O
paroxysmal	JJ	O
AF	NNP	O
(	(	O
umin	JJ	O
CTR	NNP	O
C000000427	NNP	O
)	)	O
.	.	O

Multimodal	NNP	O
evaluation	NN	O
of	IN	O
risperidone	NN	Pharmacological
for	IN	O
destructive	JJ	O
behavior	NN	O
:	:	O
functional	JJ	O
analysis	NN	O
,	,	O
direct	JJ	O
observations	NNS	O
,	,	O
rating	NN	O
scales	NNS	O
,	,	O
and	CC	O
psychiatric	JJ	O
impressions	NNS	O
.	.	O

Risperidone	NNP	Pharmacological
,	,	O
an	DT	O
atypical	JJ	O
neuroleptic	NN	O
,	,	O
has	VBZ	O
become	VBN	O
a	DT	O
popular	JJ	O
option	NN	O
for	IN	O
treating	VBG	O
destructive	JJ	O
behaviors	NNS	O
of	IN	O
persons	NNS	O
with	IN	O
developmental	JJ	O
disabilities	NNS	O
.	.	O

A	DT	O
few	JJ	O
studies	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
that	IN	O
evaluate	VBP	O
the	DT	O
effects	NNS	O
of	IN	O
risperidone	NN	Pharmacological
on	IN	O
destructive	JJ	O
behavior	NN	O
;	:	O
however	RB	O
,	,	O
none	NN	O
of	IN	O
these	DT	O
studies	NNS	O
have	VBP	O
combined	VBN	O
objective	JJ	O
measures	NNS	O
with	IN	O
rating	NN	O
scales	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
risperidone	NN	Pharmacological
on	IN	O
destructive	JJ	O
behavior	NN	O
across	IN	O
home	NN	O
and	CC	O
clinical	JJ	O
settings	NNS	O
.	.	O

This	DT	O
study	NN	O
evaluated	VBD	O
the	DT	O
wide	JJ	O
range	NN	O
of	IN	O
effects	NNS	O
of	IN	O
risperidone	NN	Pharmacological
on	IN	O
destructive	JJ	O
behavior	NN	O
of	IN	O
2	CD	O
persons	NNS	O
with	IN	O
developmental	JJ	O
disabilities	NNS	O
using	VBG	O
weekly	JJ	O
functional	JJ	O
analysis	NN	O
sessions	NNS	O
,	,	O
daily	JJ	O
observations	NNS	O
,	,	O
hourly	RB	O
home	NN	O
data	NNS	O
,	,	O
weekly	JJ	O
rating	NN	O
scales	NNS	O
,	,	O
and	CC	O
monthly	JJ	O
psychiatric	JJ	O
impressions	NNS	O
.	.	O

Results	NNS	O
indicate	VBP	O
that	IN	O
risperidone	NN	O
does	VBZ	O
decrease	VB	O
destructive	JJ	O
behavior	NN	O
and	CC	O
that	IN	O
,	,	O
for	IN	O
the	DT	O
most	JJS	O
part	NN	O
,	,	O
all	DT	O
of	IN	O
the	DT	O
various	JJ	O
measures	NNS	O
yielded	VBD	O
similar	JJ	O
results	NNS	O
.	.	O

Dose	NNP	O
dependent	JJ	O
response	NN	O
of	IN	O
symptoms	NNS	O
,	,	O
pituitary	JJ	O
,	,	O
and	CC	O
bone	NN	O
to	TO	O
transdermal	VB	O
oestrogen	NN	O
in	IN	O
postmenopausal	JJ	O
women	NNS	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
the	DT	O
plasma	NN	O
oestradiol	JJ	O
concentration	NN	O
on	IN	O
climacteric	NN	O
symptoms	NNS	O
,	,	O
gonadotrophin	JJ	O
release	NN	O
,	,	O
and	CC	O
bone	NN	O
resorption	NN	O
was	VBD	O
studied	VBN	O
in	IN	O
three	CD	O
groups	NNS	O
of	IN	O
postmenopausal	JJ	O
women	NNS	O
given	VBN	O
0.025	CD	O
mg	NNS	O
,	,	O
0.05	CD	O
mg	NN	O
,	,	O
or	CC	O
0.1	CD	O
mg	NNS	O
transdermal	JJ	Pharmacological
oestradiol	JJ	Pharmacological
daily	RB	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
dose	JJ	O
related	JJ	O
reduction	NN	O
in	IN	O
symptoms	NNS	O
,	,	O
plasma	JJ	O
follicle	NN	O
stimulating	VBG	O
hormone	NN	O
concentration	NN	O
,	,	O
and	CC	O
urinary	JJ	O
calcium	NN	O
and	CC	O
hydroxyproline	JJ	O
excretion	NN	O
.	.	O

The	DT	O
relation	NN	O
of	IN	O
the	DT	O
response	NN	O
to	TO	O
plasma	VB	O
oestradiol	JJ	O
values	NNS	O
was	VBD	O
similar	JJ	O
for	IN	O
each	DT	O
variable	NN	O
with	IN	O
an	DT	O
initial	JJ	O
large	JJ	O
reduction	NN	O
and	CC	O
little	JJ	O
change	NN	O
in	IN	O
response	NN	O
to	TO	O
increases	NNS	O
in	IN	O
the	DT	O
plasma	NN	O
oestradiol	JJ	Pharmacological
concentration	NN	O
above	IN	O
150	CD	O
pmol/l	NN	O
(	(	O
41	CD	O
pg/ml	NN	O
)	)	O
.	.	O

Hormone	CD	O
replacement	NN	O
therapy	NN	O
producing	VBG	O
an	DT	O
effect	NN	O
equivalent	NN	O
to	TO	O
higher	JJR	O
oestradiol	JJ	O
concentrations	NNS	O
is	VBZ	O
likely	JJ	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
side	NN	O
effects	NNS	O
without	IN	O
conferring	VBG	O
any	DT	O
additional	JJ	O
benefit	NN	O
.	.	O

[	JJ	O
Effects	NNS	O
of	IN	O
simvastatin	NN	Pharmacological
on	IN	O
plasma	NN	O
lipids	NNS	O
,	,	O
lipoproteins	NNS	O
and	CC	O
apoproteins	NNS	O
(	(	O
A1	NNP	O
and	CC	O
B	NNP	O
)	)	O
.	.	O

24	CD	O
cases	NNS	O
of	IN	O
major	JJ	O
primary	JJ	O
hypercholesterolemia	NN	O
]	NN	O
.	.	O

We	PRP	O
studied	VBD	O
the	DT	O
effects	NNS	O
of	IN	O
simvastatin	NN	Pharmacological
(	(	Pharmacological
MK	NNP	Pharmacological
733	CD	Pharmacological
)	)	O
,	,	O
a	DT	O
new	JJ	O
competitive	JJ	O
inhibitor	NN	O
of	IN	O
HMG	NNP	O
CoA	NNP	O
reductase	NN	O
,	,	O
alone	RB	O
and	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
bile	JJ	Pharmacological
acid	NN	Pharmacological
sequestrant	NN	Pharmacological
,	,	Pharmacological
cholestyramine	NN	Pharmacological
,	,	O
on	IN	O
serum	NN	O
levels	NNS	O
of	IN	O
lipoproteins	NNS	O
and	CC	O
apoproteins	NNS	O
A1	NNP	O
and	CC	O
B	NNP	O
,	,	O
in	IN	O
24	CD	O
patients	NNS	O
with	IN	O
familial	JJ	O
hypercholesterolemia	NN	O
.	.	O

After	IN	O
simvastatin	JJ	Pharmacological
treatment	NN	Pharmacological
(	(	O
40	CD	O
mg/day	NN	O
)	)	O
alone	RB	O
for	IN	O
12	CD	O
weeks	NNS	O
,	,	O
serum	JJ	O
total	NN	O
and	CC	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
decreased	VBN	O
by	IN	O
31	CD	O
and	CC	O
36	CD	O
percent	NN	O
respectively	RB	O
.	.	O

With	IN	O
the	DT	O
addition	NN	O
of	IN	O
cholestyramine	NN	Pharmacological
,	,	O
there	EX	O
was	VBD	O
a	DT	O
41	CD	O
per	IN	O
cent	NN	O
total	JJ	O
decrease	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
from	IN	O
the	DT	O
control	NN	O
value	NN	O
and	CC	O
a	DT	O
50	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
.	.	O

After	IN	O
cholestyramine	JJ	Pharmacological
treatment	NN	Pharmacological
alone	RB	O
for	IN	O
12	CD	O
weeks	NNS	O
,	,	O
serum	JJ	O
total	NN	O
and	CC	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
decreased	VBN	O
by	IN	O
20	CD	O
percent	NN	O
and	CC	O
29	CD	O
percent	NN	O
respectively	RB	O
.	.	O

With	IN	O
the	DT	O
addition	NN	O
of	IN	O
simvastatin	NN	Pharmacological
(	(	O
20	CD	O
mg	NNS	O
per	IN	O
day	NN	O
)	)	O
,	,	O
there	EX	O
was	VBD	O
a	DT	O
32	CD	O
percent	NN	O
total	JJ	O
decrease	NN	O
in	IN	O
serum	NN	O
cholesterol	NN	O
from	IN	O
the	DT	O
control	NN	O
value	NN	O
and	CC	O
a	DT	O
43	CD	O
percent	NN	O
decrease	NN	O
in	IN	O
low	JJ	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
.	.	O

High	JJ	O
density	NN	O
lipoprotein	VBP	O
cholesterol	NN	O
remained	VBD	O
unchanged	JJ	O
.	.	O

No	DT	O
major	JJ	O
adverse	JJ	O
effect	NN	O
was	VBD	O
observed	VBN	O
.	.	O

If	IN	O
long	JJ	O
term	NN	O
safety	NN	O
can	MD	O
be	VB	O
confirmed	VBN	O
,	,	O
the	DT	O
simvastatin-cholestyramine	JJ	Pharmacological
regimen	NNS	Pharmacological
may	MD	O
prove	VB	O
useful	JJ	O
in	IN	O
heterozygous	JJ	O
familial	JJ	O
hypercholesterolemia	NN	O
.	.	O

